BMP	B-Protein
-	I-Protein
6	I-Protein
inhibits	O
growth	O
of	O
mature	O
human	O
B	O
cells	O
;	O
induction	O
of	O
Smad	O
phosphorylation	O
and	O
upregulation	O
of	O
Id1	B-Protein

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
belong	O
to	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
superfamily	O
and	O
are	O
secreted	O
proteins	O
with	O
pleiotropic	O
roles	O
in	O
many	O
different	O
cell	O
types	O
.	O

A	O
potential	O
role	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
immune	O
system	O
has	O
been	O
implied	O
by	O
various	O
studies	O
of	O
malignant	O
and	O
rheumatoid	O
diseases	O
.	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
belong	B-X
to	B-X
the	B-X
TGF-beta	B-X
superfamily	B-X
and	B-X
are	B-X
secreted	B-X
proteins	B-X
with	B-X
pleiotropic	B-X
roles	B-X
in	B-X
many	B-X
different	B-X
cell	B-X
types	B-X
.	B-X
A	B-X
potential	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
has	B-X
been	B-X
implied	B-X
by	B-X
various	B-X
studies	B-X
of	B-X
malignant	B-X
and	B-X
rheumatoid	B-X
diseases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
B	B-X
cells	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
explored	O
the	O
role	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
normal	O
human	O
peripheral	O
blood	O
B	O
cells	O
.	O

Results	O

The	O
B	O
cells	O
were	O
found	O
to	O
express	O
BMP	O
type	O
I	O
and	O
type	O
II	O
receptors	O
and	O
BMP	B-Protein
-	I-Protein
6	I-Protein
rapidly	O
induced	O
phosphorylation	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
.	O

Furthermore	O
,	O
Smad	B-Protein
-	O
phosphorylation	O
was	O
followed	O
by	O
upregulation	O
of	O
Id1	B-Protein
mRNA	O
and	O
Id1	B-Protein
protein	O
,	O
whereas	O
Id2	B-Protein
and	O
Id3	B-Protein
expression	O
was	O
not	O
affected	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
had	O
an	O
antiproliferative	O
effect	O
both	O
in	O
naive	O
(	O
CD19	B-Protein
+	O
CD27	B-Protein
-	O
)	O
and	O
memory	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
CD27	B-Protein
+	O
)	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	B-Protein
.	O
<EOS>	B-X
An	B-X
EPIC	B-X
label-free	B-X
phenotypic	B-X
platform	B-X
was	B-X
developed	B-X
to	B-X
explore	B-X
B	B-X
cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
and	B-X
CD40R-mediated	B-X
B	B-X
cell	B-X
activation	B-X
.	B-X
The	B-X
phenotypic	B-X
assay	B-X
measured	B-X
the	B-X
association	B-X
of	B-X
RL	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
B	B-X
cells	B-X
expressing	B-X
lymphocyte	B-X
function-associated	B-X
antigen	B-X
1	B-X
(	B-X
LFA-1	B-X
)	B-X
to	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
1	B-X
(	B-X
ICAM-1	B-X
)	B-X
-coated	B-X
EPIC	B-X
plates	B-X
.	B-X
Anti-IgM	B-X
(	B-X
immunoglobulin	B-X
M	B-X
)	B-X
mediated	B-X
BCR	B-X
activation	B-X
elicited	B-X
a	B-X
response	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
LFA-1/ICAM-1	B-X
specific	B-X
inhibitors	B-X
and	B-X
a	B-X
panel	B-X
of	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
(	B-X
BTK	B-X
)	B-X
inhibitors	B-X
.	B-X
LFA-1/ICAM-1	B-X
association	B-X
was	B-X
further	B-X
increased	B-X
on	B-X
coapplication	B-X
of	B-X
anti-IgM	B-X
and	B-X
mega	B-X
CD40L	B-X
when	B-X
compared	B-X
to	B-X
individual	B-X
application	B-X
of	B-X
either	B-X
.	B-X
Anti-IgM	B-X
,	B-X
mega	B-X
CD40L	B-X
,	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
displayed	B-X
distinct	B-X
kinetic	B-X
profiles	B-X
that	B-X
were	B-X
inhibited	B-X
by	B-X
treatment	B-X
with	B-X
a	B-X
BTK	B-X
inhibitor	B-X
.	B-X
We	B-X
also	B-X
established	B-X
a	B-X
FLIPR-based	B-X
assay	B-X
to	B-X
measure	B-X
B	B-X
cell	B-X
activation	B-X
in	B-X
Ramos	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
B	B-X
cells	B-X
and	B-X
an	B-X
RL	B-X
cell	B-X
line	B-X
.	B-X
Anti-IgM-mediated	B-X
BCR	B-X
activation	B-X
elicited	B-X
a	B-X
robust	B-X
calcium	B-X
response	B-X
that	B-X
was	B-X
inhibited	B-X
by	B-X
a	B-X
panel	B-X
of	B-X
BTK	B-X
inhibitors	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
FLIPR	B-X
,	B-X
the	B-X
EPIC	B-X
assay	B-X
has	B-X
the	B-X
propensity	B-X
to	B-X
identify	B-X
inhibitors	B-X
of	B-X
both	B-X
BCR	B-X
and	B-X
CD40R-mediated	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
may	B-X
provide	B-X
more	B-X
pharmacological	B-X
depth	B-X
or	B-X
novel	B-X
mechanisms	B-X
of	B-X
action	B-X
for	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
.	B-X

Additionally	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
.	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
belong	B-X
to	B-X
the	B-X
TGF-beta	B-X
superfamily	B-X
and	B-X
are	B-X
secreted	B-X
proteins	B-X
with	B-X
pleiotropic	B-X
roles	B-X
in	B-X
many	B-X
different	B-X
cell	B-X
types	B-X
.	B-X
A	B-X
potential	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
has	B-X
been	B-X
implied	B-X
by	B-X
various	B-X
studies	B-X
of	B-X
malignant	B-X
and	B-X
rheumatoid	B-X
diseases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
B	B-X
cells	B-X
.	B-X

Importantly	O
,	O
the	O
antiproliferative	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
B	O
-	O
cells	O
was	O
completely	O
neutralized	O
by	O
the	O
natural	O
antagonist	O
,	O
noggin	B-Protein
.	O

Furthermore	O
,	O
B	O
cells	O
were	O
demonstrated	O
to	O
upregulate	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
upon	O
stimulation	O
with	O
anti	O
-	O
IgM	O
.	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
belong	B-X
to	B-X
the	B-X
TGF-beta	B-X
superfamily	B-X
and	B-X
are	B-X
secreted	B-X
proteins	B-X
with	B-X
pleiotropic	B-X
roles	B-X
in	B-X
many	B-X
different	B-X
cell	B-X
types	B-X
.	B-X
A	B-X
potential	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
has	B-X
been	B-X
implied	B-X
by	B-X
various	B-X
studies	B-X
of	B-X
malignant	B-X
and	B-X
rheumatoid	B-X
diseases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
B	B-X
cells	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

In	O
mature	O
human	O
B	O
cells	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
inhibited	O
cell	O
growth	O
,	O
and	O
rapidly	O
induced	O
phosphorylation	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
followed	O
by	O
an	O
upregulation	O
of	O
Id1	B-Protein
.	O

Members	O
of	O
the	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta	I-Protein
(	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
)	O
superfamily	O
play	O
central	O
roles	O
in	O
controlling	O
cellular	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
[	O
1	O
]	O
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
Pax	B-X
gene	B-X
family	B-X
encode	B-X
a	B-X
set	B-X
of	B-X
paired-domain	B-X
transcription	B-X
factors	B-X
which	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
regulating	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
apoptosis	B-X
,	B-X
cell	B-X
migration	B-X
,	B-X
and	B-X
stem-cell	B-X
maintenance	B-X
.	B-X
Auto-	B-X
and	B-X
inter-regulation	B-X
are	B-X
mechanisms	B-X
frequently	B-X
employed	B-X
to	B-X
achieve	B-X
precise	B-X
control	B-X
of	B-X
Pax	B-X
expression	B-X
domains	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
tissues	B-X
including	B-X
the	B-X
eye	B-X
,	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
kidney	B-X
,	B-X
pancreas	B-X
,	B-X
skeletal	B-X
system	B-X
,	B-X
muscle	B-X
,	B-X
tooth	B-X
,	B-X
and	B-X
thymus	B-X
.	B-X
An	B-X
increasing	B-X
number	B-X
of	B-X
studies	B-X
also	B-X
relate	B-X
patterns	B-X
of	B-X
Pax	B-X
expression	B-X
to	B-X
signaling	B-X
by	B-X
members	B-X
of	B-X
the	B-X
TGFbeta	B-X
superfamily	B-X
and	B-X
,	B-X
in	B-X
some	B-X
instances	B-X
,	B-X
this	B-X
is	B-X
due	B-X
to	B-X
disruption	B-X
of	B-X
Pax	B-X
gene	B-X
auto-regulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
evidence	B-X
highlighting	B-X
functional	B-X
and	B-X
mechanistic	B-X
overlap	B-X
between	B-X
TGFbeta	B-X
signaling	B-X
and	B-X
Pax-mediated	B-X
gene	B-X
transcription	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
self-regulation	B-X
of	B-X
Pax	B-X
gene	B-X
expression	B-X
coupled	B-X
with	B-X
modulation	B-X
by	B-X
the	B-X
TGFbeta	B-X
superfamily	B-X
represents	B-X
a	B-X
signaling	B-X
axis	B-X
that	B-X
is	B-X
frequently	B-X
employed	B-X
during	B-X
development	B-X
and	B-X
disease	B-X
to	B-X
drive	B-X
normal	B-X
tissue	B-X
growth	B-X
,	B-X
differentiation	B-X
and	B-X
homeostasis	B-X
.	B-X

These	O
cytokines	O
can	O
be	O
divided	O
into	O
three	O
subgroups	O
:	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	I-Protein
the	O
activins	O
/	O
inhibins	O
,	O
and	O
the	O
bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
,	O
of	O
which	O
the	O
latter	O
constitute	O
the	O
largest	O
family	O
.	O

BMPs	O
are	O
30	O
-	O
38	O
kDa	O
hetero	O
-	O
or	O
homodimeric	O
proteins	O
originally	O
identified	O
by	O
their	O
ability	O
to	O
induce	O
ectopic	O
cartilage	O
and	O
bone	O
formation	O
[	O
2	O
,	O
3	O
]	O
.	O

Several	O
studies	O
have	O
demonstrated	O
an	O
essential	O
role	O
of	O
these	O
proteins	O
during	O
embryogenesis	O
,	O
and	O
more	O
recently	O
,	O
also	O
in	O
adult	O
tissues	O
[	O
1	O
]	O
.	O
<EOS>	B-X
In	B-X
aging	B-X
sarcopenia	B-X
is	B-X
due	B-X
to	B-X
mild	B-X
chronic	B-X
inflammation	B-X
but	B-X
also	B-X
to	B-X
fiber-intrinsic	B-X
defects	B-X
,	B-X
such	B-X
as	B-X
mitochondrial	B-X
dysfunction	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
skeletal	B-X
muscle	B-X
,	B-X
the	B-X
nervous	B-X
tissue	B-X
is	B-X
also	B-X
affected	B-X
in	B-X
elderly	B-X
people	B-X
.	B-X
In	B-X
2013	B-X
,	B-X
a	B-X
precursor	B-X
study	B-X
in	B-X
humans	B-X
was	B-X
published	B-X
in	B-X
the	B-X
European	B-X
Journal	B-X
of	B-X
Translation	B-X
Myology	B-X
(	B-X
formerly	B-X
known	B-X
as	B-X
Basic	B-X
and	B-X
Applied	B-X
Myology	B-X
)	B-X
,	B-X
highlighting	B-X
the	B-X
occurrence	B-X
of	B-X
reinnervation	B-X
in	B-X
the	B-X
musculature	B-X
of	B-X
aged	B-X
,	B-X
exercise-trained	B-X
individuals	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
matching	B-X
control	B-X
.	B-X
The	B-X
tyrosine	B-X
kinase	B-X
receptor	B-X
erbB2	B-X
,	B-X
also	B-X
known	B-X
in	B-X
humans	B-X
as	B-X
Her2	B-X
,	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
or	B-X
erbB1	B-X
)	B-X
family	B-X
,	B-X
which	B-X
also	B-X
includes	B-X
erbB3	B-X
and	B-X
erbB4	B-X
.	B-X
The	B-X
erbBs	B-X
were	B-X
discovered	B-X
in	B-X
an	B-X
avian	B-X
erythroblastosis	B-X
tumor	B-X
virus	B-X
and	B-X
exhibited	B-X
similarities	B-X
to	B-X
human	B-X
EGFR	B-X
(	B-X
Yarden	B-X
and	B-X
Sliwkowski	B-X
,	B-X
2001	B-X
)	B-X
.	B-X
ErbB	B-X
receptors	B-X
bind	B-X
to	B-X
a	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
termed	B-X
neuregulins/heregulin	B-X
(	B-X
NRG/HRG	B-X
)	B-X
,	B-X
which	B-X
comprise	B-X
NRG-1	B-X
,	B-X
-2	B-X
,	B-X
-3	B-X
,	B-X
and	B-X
-4	B-X
and	B-X
include	B-X
multiple	B-X
isoforms	B-X
.	B-X
ErbB2	B-X
is	B-X
expressed	B-X
in	B-X
multiple	B-X
neuronal	B-X
and	B-X
non-neuronal	B-X
tissues	B-X
in	B-X
embryos	B-X
and	B-X
adult	B-X
animals	B-X
,	B-X
including	B-X
the	B-X
heart	B-X
.	B-X
Genetic	B-X
data	B-X
demonstrated	B-X
that	B-X
erbB2	B-X
is	B-X
required	B-X
for	B-X
normal	B-X
embryonic	B-X
development	B-X
of	B-X
neural	B-X
crest-derived	B-X
cranial	B-X
sensory	B-X
neurons	B-X
.	B-X
ErbB2/Her2-null	B-X
mutant	B-X
embryos	B-X
of	B-X
a	B-X
trabeculation	B-X
defect	B-X
die	B-X
before	B-X
embryonic	B-X
day	B-X
(	B-X
E	B-X
)	B-X
11	B-X
.	B-X
To	B-X
study	B-X
its	B-X
role	B-X
at	B-X
later	B-X
stages	B-X
of	B-X
development	B-X
,	B-X
we	B-X
generated	B-X
a	B-X
transgenic	B-X
mouse	B-X
line	B-X
that	B-X
specifically	B-X
expresses	B-X
the	B-X
rat	B-X
erbB2	B-X
cDNA	B-X
in	B-X
the	B-X
heart	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
cardiac-specific	B-X
alpha-myosin	B-X
heavy	B-X
chain	B-X
promoter	B-X
.	B-X
To	B-X
study	B-X
the	B-X
role	B-X
of	B-X
erbB2	B-X
in	B-X
the	B-X
adult	B-X
heart	B-X
,	B-X
we	B-X
generated	B-X
conditional	B-X
mutant	B-X
mice	B-X
carrying	B-X
a	B-X
cardiac-restricted	B-X
deletion	B-X
of	B-X
erbB2	B-X
.	B-X
The	B-X
adverse	B-X
effect	B-X
is	B-X
increased	B-X
significantly	B-X
in	B-X
those	B-X
patients	B-X
who	B-X
also	B-X
receive	B-X
the	B-X
chemotherapeutical	B-X
agent	B-X
anthracycline	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
erbB2	B-X
signaling	B-X
in	B-X
the	B-X
heart	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
prevention	B-X
of	B-X
dilated	B-X
cardiomyopathy	B-X
.	B-X
These	B-X
mice	B-X
also	B-X
will	B-X
provide	B-X
important	B-X
information	B-X
for	B-X
devising	B-X
strategies	B-X
to	B-X
mitigate	B-X
the	B-X
cardiotoxic	B-X
effects	B-X
of	B-X
Herceptin	B-X
treatment	B-X
,	B-X
allowing	B-X
for	B-X
the	B-X
potential	B-X
expanded	B-X
use	B-X
of	B-X
this	B-X
drug	B-X
to	B-X
treat	B-X
all	B-X
cancers	B-X
overexpressing	B-X
erbB2	B-X
.	B-X

TGF	B-Protein
-	I-Protein
beta	I-Protein
has	O
been	O
intensively	O
studied	O
in	O
normal	O
and	O
malignant	O
haematopoietic	O
cells	O
and	O
is	O
one	O
of	O
the	O
most	O
potent	O
endogenous	O
negative	O
regulators	O
known	O
to	O
date	O
.	O

[	O
4	O
]	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

In	O
contrast	O
,	O
the	O
effect	O
of	O
BMPs	O
in	O
the	O
immune	O
system	O
has	O
not	O
been	O
widely	O
investigated	O
.	O
<EOS>	B-X
In	B-X
recent	B-X
years	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
regulatory	B-X
T-cells	B-X
(	B-X
T	B-X
(	B-X
R	B-X
)	B-X
)	B-X
were	B-X
identified	B-X
as	B-X
the	B-X
major	B-X
obstacle	B-X
to	B-X
effective	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
removal	B-X
or	B-X
inactivation	B-X
of	B-X
T	B-X
(	B-X
R	B-X
)	B-X
cells	B-X
led	B-X
to	B-X
enhanced	B-X
anti-tumor	B-X
immune	B-X
response	B-X
and	B-X
better	B-X
efficacy	B-X
of	B-X
cancer	B-X
vaccines	B-X
.	B-X
This	B-X
study	B-X
reports	B-X
that	B-X
Bone	B-X
Morphogenic	B-X
Protein	B-X
Receptor	B-X
1α	B-X
(	B-X
BMPR1α	B-X
,	B-X
Alk-3	B-X
)	B-X
is	B-X
expressed	B-X
by	B-X
activated	B-X
effector	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
T	B-X
(	B-X
R	B-X
)	B-X
cells	B-X
and	B-X
modulates	B-X
functions	B-X
of	B-X
both	B-X
cell	B-X
types	B-X
.	B-X
Bone	B-X
Morphogenic	B-X
Proteins	B-X
(	B-X
BMPs	B-X
)	B-X
belong	B-X
to	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-β	B-X
family	B-X
of	B-X
cytokines	B-X
that	B-X
also	B-X
include	B-X
TGFβ	B-X
and	B-X
activins	B-X
.	B-X
BMPs	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
embryonic	B-X
development	B-X
,	B-X
tissue	B-X
differentiation	B-X
and	B-X
homeostasis	B-X
,	B-X
and	B-X
development	B-X
of	B-X
cancer	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
BMPs	B-X
and	B-X
activins	B-X
synergize	B-X
with	B-X
TGFβ	B-X
to	B-X
regulate	B-X
thymic	B-X
T-cell	B-X
development	B-X
,	B-X
maintain	B-X
T	B-X
(	B-X
R	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
control	B-X
peripheral	B-X
tolerance	B-X
.	B-X

In	O
that	O
respect	O
,	O
BMP	B-Protein
-	I-Protein
2	I-Protein
,	O
-	B-Protein
4	I-Protein
and	O
-	B-Protein
7	I-Protein
have	O
been	O
found	O
to	O
control	O
differentiation	O
of	O
hematopoietic	O
stem	O
cells	O
[	O
5	O
]	O
and	O
early	O
T	O
cell	O
development	O
[	O
6	O
,	O
7	O
]	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
has	O
been	O
reported	O
to	O
reduce	O
the	O
number	O
of	O
cobblestone	O
-	O
area	O
-	O
forming	O
cells	O
of	O
normal	O
human	O
haematopoietic	O
cells	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
BMP	B-Protein
-	I-Protein
2	I-Protein
,	O
-	B-Protein
4	I-Protein
,	O
6	B-Protein
and	O
-	B-Protein
7	I-Protein
had	O
an	O
antiproliferative	O
and	O
a	O
proapoptotic	O
effect	O
on	O
multiple	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

In	O
addition	O
,	O
by	O
gene	O
expression	O
profiling	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
significantly	O
increased	O
the	O
predictive	O
value	O
for	O
a	O
multi	O
-	O
gene	O
signature	O
test	O
and	O
was	O
associated	O
with	O
a	O
poor	O
outcome	O
in	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
(	O
DLBCL	O
)	O
[	O
12	O
]	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
,	O
like	O
the	O
other	O
BMP	O
members	O
,	O
signals	O
through	O
ligation	O
and	O
heterodimerzation	O
of	O
BMP	O
type	O
I	O
[	O
activin	O
-	O
like	O
-	O
kinase	O
(	O
ALK	O
)	O
]	O
and	O
type	O
II	O
serine	O
-	O
threonine	O
kinase	O
receptors	O
,	O
which	O
subsequently	O
propagates	O
the	O
signal	O
downstream	O
by	O
phosphorylating	O
Smad	O
proteins	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
can	O
signal	O
through	O
the	O
ligation	O
of	O
the	O
type	O
I	O
receptors	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
,	O
BMP	B-Protein
-	I-Protein
RIA	I-Protein
,	O
and	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
and	O
the	O
type	O
II	O
receptors	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
,	O
Act	B-Protein
-	I-Protein
RIIA	I-Protein
and	O
Act	B-Protein
-	I-Protein
RIIB	I-Protein
,	O
which	O
lead	O
to	O
the	O
phosphorylation	O
of	O
the	O
receptor	O
Smads	O
(	O
Smad	B-Protein
-	I-Protein
1	I-Protein
,	O
Smad	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
Smad	B-Protein
-	I-Protein
8	I-Protein
)	O
.	O

The	O
R	O
-	O
Smads	O
then	O
form	O
complexes	O
with	O
the	O
co	O
-	O
Smad	O
(	O
Smad4	B-Protein
)	O
and	O
are	O
translocated	O
into	O
the	O
nucleus	O
where	O
they	O
exert	O
gene	O
regulation	O
[	O
1	O
,	O
13	O
]	O
.	O

Given	O
the	O
reported	O
role	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
B	O
-	O
cell	O
malignancies	O
and	O
haematopoietic	O
progenitor	O
cells	O
,	O
we	O
wanted	O
to	O
explore	O
its	O
potential	O
role	O
in	O
normal	O
human	O
B	O
cells	O
.	O

We	O
studied	O
the	O
effects	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
proliferation	O
and	O
apoptosis	O
on	O
resting	O
and	O
stimulated	O
B	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
BMP	O
receptors	O
and	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
activation	O
of	O
the	O
Smad	O
signalling	O
pathway	O
with	O
subsequent	O
regulation	O
of	O
the	O
target	O
genes	O
Id1	B-Protein
-	O
Id4	B-Protein
,	O
were	O
resolved	O
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
B	O
cells	O
also	O
were	O
capable	O
of	O
producing	O
BMP	B-Protein
-	I-Protein
6	I-Protein
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
inhibits	O
anti	O
-	O
IgM	O
induced	O
proliferation	O
of	O
human	O
B	O
cells	O

The	O
effects	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
normal	O
and	O
neoplastic	O
hematopoietic	O
cells	O
prompted	O
us	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
normal	O
human	O
B	O
cells	O
.	O

All	O
experiments	O
in	O
this	O
study	O
were	O
performed	O
under	O
serum	O
-	O
free	O
conditions	O
as	O
FCS	O
has	O
been	O
shown	O
to	O
interfere	O
with	O
BMP	O
-	O
signalling	O
[	O
14	O
]	O
(	O
own	O
observations	O
)	O
.	O

To	O
study	O
the	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
proliferation	O
,	O
B	O
-	O
cells	O
from	O
healthy	O
volunteers	O
were	O
stimulated	O
with	O
anti	O
-	O
IgM	O
and	O
/	O
or	O
CD40L	B-Protein
in	O
the	O
presence	O
or	O
absence	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
for	O
three	O
days	O
.	O
<EOS>	B-X
Disrupting	B-X
the	B-X
CD40-CD40L	B-X
co-stimulatory	B-X
pathway	B-X
reduces	B-X
atherosclerosis	B-X
and	B-X
induces	B-X
a	B-X
stable	B-X
atherosclerotic	B-X
plaque	B-X
phenotype	B-X
that	B-X
is	B-X
low	B-X
in	B-X
inflammation	B-X
and	B-X
high	B-X
in	B-X
fibrosis	B-X
.	B-X
Therefore	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
CD40-CD40L	B-X
pathway	B-X
is	B-X
an	B-X
attractive	B-X
therapeutic	B-X
target	B-X
to	B-X
reduce	B-X
clinical	B-X
complications	B-X
of	B-X
atherosclerosis	B-X
.	B-X
The	B-X
CD40-CD40L	B-X
dyad	B-X
is	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
other	B-X
co-stimulatory	B-X
molecules	B-X
,	B-X
to	B-X
activate	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
and	B-X
to	B-X
contribute	B-X
to	B-X
T-cell	B-X
priming	B-X
and	B-X
B-cell	B-X
isotype	B-X
switching	B-X
.	B-X
Besides	B-X
their	B-X
presence	B-X
on	B-X
T-cells	B-X
and	B-X
APCs	B-X
,	B-X
CD40	B-X
and	B-X
CD40L	B-X
are	B-X
also	B-X
present	B-X
on	B-X
macrophages	B-X
,	B-X
endothelial	B-X
cells	B-X
and	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
in	B-X
the	B-X
plaque	B-X
,	B-X
where	B-X
they	B-X
can	B-X
exert	B-X
pro-atherogenic	B-X
functions	B-X
.	B-X
Moreover	B-X
,	B-X
recent	B-X
progress	B-X
indicates	B-X
the	B-X
involvement	B-X
of	B-X
neutrophil	B-X
CD40	B-X
,	B-X
platelet	B-X
CD40L	B-X
and	B-X
dendritic	B-X
cell	B-X
CD40	B-X
in	B-X
atherogenesis	B-X
.	B-X
Since	B-X
systemic	B-X
CD40-CD40L	B-X
modulation	B-X
compromises	B-X
host	B-X
defense	B-X
,	B-X
more	B-X
targeted	B-X
interventions	B-X
are	B-X
needed	B-X
to	B-X
develop	B-X
superior	B-X
treatment	B-X
strategies	B-X
for	B-X
atherosclerosis	B-X
.	B-X
We	B-X
believe	B-X
that	B-X
by	B-X
unravelling	B-X
the	B-X
cell-cell	B-X
CD40-CD40L	B-X
interactions	B-X
,	B-X
inhibition	B-X
of	B-X
cell-type	B-X
specific	B-X
(	B-X
signalling	B-X
components	B-X
of	B-X
)	B-X
CD40	B-X
(	B-X
L	B-X
)	B-X
that	B-X
do	B-X
not	B-X
compromise	B-X
the	B-X
patient	B-X
's	B-X
immune	B-X
system	B-X
,	B-X
will	B-X
become	B-X
possible	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
highlight	B-X
the	B-X
cell-type	B-X
specific	B-X
multi-functionality	B-X
of	B-X
CD40-CD40L	B-X
signalling	B-X
in	B-X
atherosclerosis	B-X
.	B-X

We	O
found	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
led	O
to	O
a	O
35	O
%	O
mean	O
reduction	O
of	O
anti	O
-	O
IgM	O
-	O
induced	O
DNA	O
synthesis	O
(	O
n	O
=	O
8	O
;	O
p	O
<	O
=	O
0	O
.	O
0002	O
,	O
Figure	O
1A	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
B	O
cells	O
treated	O
with	O
anti	O
-	O
IgM	O
and	O
CD40L	B-Protein
(	O
26	O
%	O
mean	O
reduction	O
,	O
n	O
=	O
6	O
;	O
p	O
<	O
=	O
0	O
.	O
023	O
)	O
.	O

The	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
induced	O
inhibition	O
of	O
proliferation	O
was	O
dose	O
-	O
dependent	O
in	O
both	O
peripheral	O
B	O
cells	O
(	O
Figure	O
1B	O
)	O
and	O
the	O
Burkitt	O
lymphoma	O
cell	O
line	O
Ramos	O
(	O
40	O
%	O
reduction	O
of	O
DNA	O
synthesis	O
,	O
Figure	O
1C	O
)	O
.	O

The	O
BMP	B-Protein
-	I-Protein
6	I-Protein
effects	O
could	O
be	O
reversed	O
by	O
addition	O
of	O
the	O
extracellular	O
inhibitor	O
Noggin	B-Protein
(	O
Figure	O
1D	O
)	O
.	O

Similarly	O
,	O
a	O
combination	O
of	O
the	O
soluble	O
BMP	O
receptors	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
-	O
Fc	O
and	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
-	O
Fc	O
also	O
neutralized	O
the	O
effects	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
test	O
whether	O
BMP	B-Protein
-	I-Protein
6	I-Protein
had	O
different	O
effect	O
on	O
naive	O
and	O
memory	O
B	O
cells	O
.	O

Naive	O
(	O
CD19	B-Protein
+	O
CD27	B-Protein
-	O
)	O
and	O
memory	O
(	O
CD19	B-Protein
+	O
CD27	B-Protein
+	O
)	O
B	O
cells	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
cell	O
sorting	O
of	O
immunobead	O
-	O
isolated	O
CD19	B-Protein
+	O
B	O
cells	O
[	O
15	O
]	O
,	O
and	O
tested	O
for	O
their	O
capacity	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
.	O

However	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
inhibited	O
anti	O
-	O
IgM	O
induced	O
DNA	O
synthesis	O
in	O
the	O
two	O
subpopulations	O
to	O
a	O
similar	O
extent	O
,	O
with	O
a	O
mean	O
reduction	O
of	O
DNA	O
-	O
synthesis	O
of	O
45	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
004	O
)	O
for	O
naive	O
B	O
cells	O
and	O
48	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
001	O
)	O
for	O
memory	O
B	O
cells	O
(	O
Figure	O
1E	O
)	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
induces	O
cell	O
death	O
in	O
human	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O

Next	O
,	O
we	O
wanted	O
to	O
establish	O
whether	O
BMP	B-Protein
-	I-Protein
6	I-Protein
also	O
could	O
affect	O
the	O
viability	O
of	O
normal	O
B	O
cells	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
propidium	O
iodide	O
(	O
PI	O
)	O
staining	O
after	O
culture	O
with	O
or	O
without	O
BMP	B-Protein
-	I-Protein
6	I-Protein
for	O
48	O
hours	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
an	B-X
innovative	B-X
approach	B-X
to	B-X
use	B-X
charged	B-X
fluorochromes	B-X
such	B-X
as	B-X
propidium	B-X
iodide	B-X
(	B-X
PI	B-X
)	B-X
in	B-X
the	B-X
real-time	B-X
,	B-X
dynamic	B-X
cell	B-X
viability	B-X
assays	B-X
.	B-X
Uptake	B-X
of	B-X
PI	B-X
by	B-X
live	B-X
cells	B-X
,	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
long-term	B-X
proliferation	B-X
capacity	B-X
,	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
and	B-X
pharmacologic	B-X
interactions	B-X
with	B-X
anticancer	B-X
drugs	B-X
were	B-X
studied	B-X
using	B-X
both	B-X
laser	B-X
scanning	B-X
microscopy	B-X
and	B-X
laser	B-X
scanning	B-X
cytometry	B-X
.	B-X
Exposure	B-X
of	B-X
human	B-X
carcinomic	B-X
alveolar	B-X
basal	B-X
epithelial	B-X
A549	B-X
cells	B-X
in	B-X
cultures	B-X
to	B-X
1.5	B-X
or	B-X
7.5	B-X
microM	B-X
of	B-X
PI	B-X
for	B-X
24	B-X
h	B-X
had	B-X
minimal	B-X
effect	B-X
on	B-X
cell	B-X
cycle	B-X
progression	B-X
including	B-X
DNA	B-X
replication	B-X
as	B-X
measured	B-X
by	B-X
incorporation	B-X
of	B-X
5'-ethynyl-2-deoxyuridine	B-X
(	B-X
EdU	B-X
)	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
click	B-X
chemistry	B-X
''	B-X
approach	B-X
and	B-X
measured	B-X
by	B-X
laser	B-X
scanning	B-X
cytometry	B-X
.	B-X
A	B-X
modest	B-X
reduction	B-X
,	B-X
from	B-X
44	B-X
to	B-X
40	B-X
%	B-X
or	B-X
33	B-X
%	B-X
,	B-X
in	B-X
frequency	B-X
of	B-X
DNA	B-X
replicating	B-X
cells	B-X
was	B-X
seen	B-X
after	B-X
48	B-X
h	B-X
at	B-X
1.5	B-X
or	B-X
7.5	B-X
microM	B-X
concentration	B-X
of	B-X
PI	B-X
.	B-X
There	B-X
was	B-X
no	B-X
evidence	B-X
of	B-X
increased	B-X
phosphorylation	B-X
of	B-X
histone	B-X
gammaH2AX	B-X
in	B-X
cells	B-X
growing	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1.5	B-X
or	B-X
7.5	B-X
microM	B-X
of	B-X
PI	B-X
for	B-X
up	B-X
to	B-X
48	B-X
h.	B-X
Confocal	B-X
image	B-X
analysis	B-X
of	B-X
HeLa	B-X
and	B-X
NIH	B-X
3T3	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
growing	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PI	B-X
showed	B-X
granular	B-X
distribution	B-X
in	B-X
cell	B-X
cytoplasm	B-X
suggesting	B-X
PI	B-X
accumulation	B-X
in	B-X
endosomes	B-X
and	B-X
progressive	B-X
increase	B-X
in	B-X
fluorescence	B-X
of	B-X
nucleoli	B-X
reflecting	B-X
PI	B-X
binding	B-X
to	B-X
nucleolar	B-X
RNA	B-X
.	B-X
The	B-X
overall	B-X
responses	B-X
of	B-X
cells	B-X
to	B-X
cytotoxic	B-X
agents	B-X
were	B-X
also	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
growth	B-X
in	B-X
the	B-X
presence	B-X
PI	B-X
.	B-X
Our	B-X
data	B-X
lend	B-X
further	B-X
support	B-X
to	B-X
the	B-X
notion	B-X
that	B-X
PI	B-X
can	B-X
be	B-X
effectively	B-X
used	B-X
in	B-X
real-time	B-X
,	B-X
kinetic	B-X
viability	B-X
assays	B-X
.	B-X

Interestingly	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
showed	O
a	O
small	O
,	O
but	O
reproducible	O
mean	O
increase	O
of	O
cell	O
death	O
from	O
17	O
to	O
23	O
%	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
003	O
)	O
in	O
anti	O
-	O
IgM	O
stimulated	O
CD27	B-Protein
+	O
memory	O
B	O
cells	O
.	O

Furthermore	O
,	O
Ramos	O
cells	O
showed	O
a	O
mean	O
increase	O
in	O
cell	O
death	O
from	O
20	O
to	O
50	O
%	O
(	O
n	O
=	O
3	O
,	O
p	O
<	O
0	O
,	O
001	O
,	O
figure	O
3	O
)	O
after	O
BMP	B-Protein
-	I-Protein
6	I-Protein
treatment	O
.	O

In	O
contrast	O
,	O
cell	O
death	O
of	O
total	O
CD19	B-Protein
+	O
cells	O
(	O
n	O
=	O
6	O
;	O
p	O
<	O
=	O
0	O
,	O
32	O
;	O
data	O
not	O
shown	O
)	O
or	O
CD27	B-Protein
-	O
IgG	O
-	O
naive	O
B	O
cells	O
was	O
not	O
significantly	O
affected	O
(	O
n	O
=	O
5	O
;	O
p	O
<	O
=	O
0	O
,	O
65	O
,	O
figure	O
2	O
)	O
.	O

Human	O
B	O
cells	O
express	O
BMP	B-Protein
-	I-Protein
6	I-Protein
receptors	O

Detailed	O
knowledge	O
regarding	O
expression	O
of	O
different	O
BMP	O
receptors	O
in	O
B	O
cells	O
is	O
currently	O
not	O
available	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
BMPs	O
in	O
human	O
B	O
cells	O
,	O
we	O
performed	O
western	O
blot	O
analysis	O
for	O
type	O
I	O
and	O
type	O
II	O
BMP	O
receptors	O
.	O

This	O
analysis	O
revealed	O
that	O
the	O
type	O
I	O
receptors	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
,	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
and	O
the	O
type	O
II	O
receptors	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
and	O
Act	B-Protein
-	I-Protein
RIIb	I-Protein
are	O
expressed	O
on	O
resting	O
human	O
B	O
-	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

Ramos	O
cells	O
expressed	O
the	O
type	O
I	O
receptors	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
,	O
weakly	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
and	O
the	O
type	O
II	O
receptor	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
,	O
but	O
more	O
weakly	O
than	O
normal	O
B	O
cells	O
(	O
Figure	O
4	O
)	O
.	O

HL60	O
cells	O
were	O
used	O
for	O
comparison	O
and	O
weakly	O
expressed	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
and	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
normal	O
human	O
B	O
cells	O
and	O
Ramos	O
cells	O
express	O
a	O
set	O
of	O
BMP	O
receptors	O
,	O
previously	O
shown	O
to	O
bind	O
BMP	B-Protein
-	I-Protein
6	I-Protein
[	O
16	O
]	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
induces	O
phosphorylation	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
<EOS>	B-X
Although	B-X
hepcidin	B-X
expression	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
induced	B-X
by	B-X
the	B-X
BMP/Smad	B-X
signaling	B-X
pathway	B-X
,	B-X
it	B-X
is	B-X
not	B-X
yet	B-X
known	B-X
how	B-X
iron	B-X
regulates	B-X
this	B-X
pathway	B-X
and	B-X
what	B-X
its	B-X
exact	B-X
molecular	B-X
targets	B-X
are	B-X
.	B-X
They	B-X
are	B-X
coding	B-X
for	B-X
Bmp6	B-X
,	B-X
Smad7	B-X
,	B-X
Id1	B-X
,	B-X
and	B-X
Atoh8	B-X
all	B-X
related	B-X
to	B-X
the	B-X
Bmp/Smad	B-X
pathway	B-X
.	B-X
As	B-X
shown	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
variations	B-X
in	B-X
Bmp6	B-X
expression	B-X
induced	B-X
by	B-X
the	B-X
diet	B-X
iron	B-X
content	B-X
have	B-X
for	B-X
functional	B-X
consequence	B-X
similar	B-X
changes	B-X
in	B-X
Smad1/5/8	B-X
phosphorylation	B-X
that	B-X
leads	B-X
to	B-X
formation	B-X
of	B-X
heteromeric	B-X
complexes	B-X
with	B-X
Smad4	B-X
and	B-X
their	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Iron	B-X
overload	B-X
developed	B-X
by	B-X
Smad4-	B-X
and	B-X
Hamp1-deficient	B-X
mice	B-X
also	B-X
increased	B-X
Bmp6	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
analysis	B-X
of	B-X
mice	B-X
with	B-X
liver-specific	B-X
disruption	B-X
of	B-X
Smad4	B-X
,	B-X
activation	B-X
of	B-X
Smad7	B-X
,	B-X
Id1	B-X
,	B-X
and	B-X
Atoh8	B-X
transcription	B-X
by	B-X
iron	B-X
requires	B-X
Smad4	B-X
.	B-X

Upon	O
ligand	O
binding	O
,	O
the	O
type	O
II	O
receptor	O
transphosphorylates	O
and	O
activates	O
the	O
type	O
I	O
receptor	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
beta	B-X
(	B-X
TGFbeta	B-X
)	B-X
superfamily	B-X
polypeptides	B-X
regulate	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
by	B-X
binding	B-X
to	B-X
single	B-X
pass	B-X
serine/threonine	B-X
kinases	B-X
referred	B-X
to	B-X
as	B-X
TGFbeta	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
receptors	B-X
.	B-X
Signal	B-X
propagation	B-X
is	B-X
dependent	B-X
upon	B-X
heteromeric	B-X
(	B-X
type	B-X
I-type	B-X
II	B-X
)	B-X
complex	B-X
formation	B-X
and	B-X
transphosphorylation	B-X
of	B-X
the	B-X
type	B-X
I	B-X
receptor	B-X
by	B-X
the	B-X
type	B-X
II	B-X
receptor	B-X
.	B-X
While	B-X
many	B-X
of	B-X
the	B-X
phosphorylation	B-X
events	B-X
necessary	B-X
for	B-X
receptor	B-X
signaling	B-X
have	B-X
recently	B-X
been	B-X
characterized	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TGFbeta	B-X
receptor	B-X
kinase	B-X
activity	B-X
in	B-X
modulating	B-X
receptor	B-X
endocytosis	B-X
has	B-X
not	B-X
been	B-X
addressed	B-X
.	B-X
To	B-X
that	B-X
end	B-X
,	B-X
we	B-X
have	B-X
used	B-X
chimeric	B-X
receptors	B-X
consisting	B-X
of	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
the	B-X
granulocyte/macrophage	B-X
colony-stimulating	B-X
factor	B-X
alpha	B-X
and	B-X
beta	B-X
receptors	B-X
spliced	B-X
to	B-X
the	B-X
TGFbeta	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
transmembrane	B-X
and	B-X
cytoplasmic	B-X
domains	B-X
to	B-X
address	B-X
the	B-X
specific	B-X
role	B-X
of	B-X
type	B-X
I	B-X
and/or	B-X
type	B-X
II	B-X
receptor	B-X
kinase	B-X
activity	B-X
in	B-X
TGFbeta	B-X
receptor	B-X
internalization	B-X
,	B-X
down-regulation	B-X
,	B-X
and	B-X
signaling	B-X
.	B-X
To	B-X
inactivate	B-X
chimeric	B-X
receptor	B-X
kinase	B-X
activity	B-X
,	B-X
point	B-X
mutations	B-X
in	B-X
the	B-X
ATP	B-X
binding	B-X
site	B-X
were	B-X
made	B-X
at	B-X
amino	B-X
acids	B-X
232	B-X
and	B-X
277	B-X
in	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
receptor	B-X
,	B-X
respectively	B-X
.	B-X
Either	B-X
of	B-X
these	B-X
mutations	B-X
abolished	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
1	B-X
protein	B-X
expression	B-X
stimulated	B-X
by	B-X
granulocyte/macrophage	B-X
colony-stimulating	B-X
factor	B-X
activation	B-X
of	B-X
chimeric	B-X
heteromeric	B-X
type	B-X
I-type	B-X
II	B-X
TGFbeta	B-X
receptors	B-X
.	B-X
They	B-X
did	B-X
not	B-X
,	B-X
however	B-X
,	B-X
modulate	B-X
TGFbeta	B-X
signaling	B-X
stimulated	B-X
through	B-X
the	B-X
endogenous	B-X
TGFbeta	B-X
receptor	B-X
.	B-X
Although	B-X
TGFbeta	B-X
receptor	B-X
signaling	B-X
was	B-X
dependent	B-X
upon	B-X
the	B-X
kinase	B-X
activity	B-X
of	B-X
both	B-X
chimeric	B-X
receptors	B-X
,	B-X
the	B-X
initial	B-X
endocytic	B-X
response	B-X
was	B-X
distinctly	B-X
regulated	B-X
by	B-X
type	B-X
I	B-X
and/or	B-X
type	B-X
II	B-X
receptor	B-X
kinase	B-X
activity	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
while	B-X
heteromeric	B-X
receptor	B-X
complexes	B-X
containing	B-X
a	B-X
kinase-inactive	B-X
type	B-X
I	B-X
receptor	B-X
were	B-X
endocytosed	B-X
similarly	B-X
to	B-X
wild	B-X
type	B-X
complexes	B-X
,	B-X
the	B-X
kinase	B-X
activity	B-X
of	B-X
the	B-X
type	B-X
II	B-X
TGFbeta	B-X
receptor	B-X
was	B-X
necessary	B-X
for	B-X
optimal	B-X
internalization	B-X
and	B-X
receptor	B-X
down-regulation	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
responses	B-X
were	B-X
shown	B-X
to	B-X
occur	B-X
independently	B-X
of	B-X
type	B-X
II	B-X
receptor	B-X
autophosphorylation	B-X
but	B-X
require	B-X
a	B-X
type	B-X
II	B-X
receptor	B-X
capable	B-X
of	B-X
transphosphorylation	B-X
.	B-X

Type	O
I	O
receptors	O
can	O
signal	O
via	O
several	O
pathways	O
.	O
<EOS>	B-X
Dysregulation	B-X
of	B-X
IL-6-type	B-X
cytokine	B-X
signalling	B-X
contributes	B-X
to	B-X
the	B-X
onset	B-X
and	B-X
maintenance	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
osteoporosis	B-X
,	B-X
multiple	B-X
sclerosis	B-X
and	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
(	B-X
e.g	B-X
.	B-X
IL-6-type	B-X
cytokines	B-X
exert	B-X
their	B-X
action	B-X
via	B-X
the	B-X
signal	B-X
transducers	B-X
gp	B-X
(	B-X
glycoprotein	B-X
)	B-X
130	B-X
,	B-X
LIF	B-X
receptor	B-X
and	B-X
OSM	B-X
receptor	B-X
leading	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
JAK/STAT	B-X
(	B-X
Janus	B-X
kinase/signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X
and	B-X
MAPK	B-X
(	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
)	B-X
cascades	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
recent	B-X
progress	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
IL-6-type	B-X
cytokine	B-X
signal	B-X
transduction	B-X
.	B-X
Emphasis	B-X
is	B-X
put	B-X
on	B-X
the	B-X
termination	B-X
and	B-X
modulation	B-X
of	B-X
the	B-X
JAK/STAT	B-X
signalling	B-X
pathway	B-X
mediated	B-X
by	B-X
tyrosine	B-X
phosphatases	B-X
,	B-X
the	B-X
SOCS	B-X
(	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signalling	B-X
)	B-X
feedback	B-X
inhibitors	B-X
and	B-X
PIAS	B-X
(	B-X
protein	B-X
inhibitor	B-X
of	B-X
activated	B-X
STAT	B-X
)	B-X
proteins	B-X
.	B-X
Also	B-X
the	B-X
cross-talk	B-X
between	B-X
the	B-X
JAK/STAT	B-X
pathway	B-X
with	B-X
other	B-X
signalling	B-X
cascades	B-X
is	B-X
discussed	B-X
.	B-X

We	O
examined	O
the	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
Smad	O
phosphorylation	O
,	O
as	O
the	O
activation	O
of	O
Smad	O
is	O
considered	O
to	O
be	O
a	O
major	O
signalling	O
pathway	O
for	O
BMPs	O
[	O
17	O
]	O
.	O

B	O
cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
media	O
over	O
night	O
and	O
then	O
treated	O
with	O
BMP	B-Protein
-	I-Protein
6	I-Protein
for	O
various	O
time	O
points	O
.	O

Total	O
protein	O
lysates	O
were	O
prepared	O
,	O
and	O
the	O
amounts	O
of	O
the	O
phosphorylated	O
forms	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
were	O
determined	O
by	O
western	O
blot	O
analysis	O
.	O

Interestingly	O
,	O
treatment	O
with	O
500	O
ng	O
/	O
ml	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
phosphorylation	O
of	O
Smad	O
.	O

The	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
phosphorylation	O
was	O
high	O
at	O
the	O
earliest	O
time	O
point	O
tested	O
(	O
15	O
minutes	O
)	O
,	O
and	O
remained	O
high	O
for	O
at	O
least	O
48	O
hours	O
(	O
Figure	O
5	O
)	O
.	O

A	O
similar	O
phosphorylation	O
was	O
observed	O
in	O
Ramos	O
cells	O
,	O
but	O
not	O
in	O
HL60	O
cells	O
(	O
Figure	O
6	O
)	O
.	O
<EOS>	B-X
The	B-X
polyglutamic	B-X
acid/peptoid	B-X
1	B-X
(	B-X
QM56	B-X
)	B-X
nanoconjugate	B-X
inhibits	B-X
apoptosis	B-X
by	B-X
interfering	B-X
with	B-X
Apaf-1	B-X
binding	B-X
to	B-X
procaspase-9	B-X
.	B-X
We	B-X
now	B-X
describe	B-X
anti-inflammatory	B-X
properties	B-X
of	B-X
QM56	B-X
in	B-X
mouse	B-X
kidney	B-X
and	B-X
renal	B-X
cell	B-X
models.In	B-X
cultured	B-X
murine	B-X
tubular	B-X
cells	B-X
,	B-X
QM56	B-X
inhibited	B-X
the	B-X
inflammatory	B-X
response	B-X
to	B-X
Tweak	B-X
,	B-X
a	B-X
non-apoptotic	B-X
stimulus	B-X
.	B-X
Similar	B-X
to	B-X
JAK2	B-X
kinase	B-X
inhibitors	B-X
,	B-X
QM56	B-X
inhibited	B-X
Tweak-induced	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
and	B-X
chemokine	B-X
expression	B-X
,	B-X
despite	B-X
failing	B-X
to	B-X
inhibit	B-X
NF-κB-p65	B-X
nuclear	B-X
translocation	B-X
and	B-X
NF-κB	B-X
DNA	B-X
binding	B-X
.	B-X
QM56	B-X
prevented	B-X
JAK2	B-X
activation	B-X
and	B-X
NF-κB-p65	B-X
(	B-X
Ser536	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
anti-inflammatory	B-X
effect	B-X
and	B-X
JAK2	B-X
inhibition	B-X
by	B-X
QM56	B-X
were	B-X
observed	B-X
in	B-X
Apaf-1	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
.	B-X
In	B-X
murine	B-X
acute	B-X
kidney	B-X
injury	B-X
,	B-X
QM56	B-X
decreased	B-X
tubular	B-X
cell	B-X
apoptosis	B-X
and	B-X
kidney	B-X
inflammation	B-X
as	B-X
measured	B-X
by	B-X
down-modulations	B-X
of	B-X
MCP-1	B-X
and	B-X
Rantes	B-X
mRNA	B-X
expression	B-X
,	B-X
immune	B-X
cell	B-X
infiltration	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
JAK2-dependent	B-X
inflammatory	B-X
pathway.In	B-X
conclusion	B-X
,	B-X
QM56	B-X
has	B-X
an	B-X
anti-inflammatory	B-X
activity	B-X
which	B-X
is	B-X
independent	B-X
from	B-X
its	B-X
role	B-X
as	B-X
inhibitor	B-X
of	B-X
Apaf-1	B-X
and	B-X
apoptosis	B-X
and	B-X
may	B-X
have	B-X
potential	B-X
therapeutic	B-X
relevance	B-X
.	B-X

Furthermore	O
,	O
we	O
also	O
tested	O
whether	O
other	O
known	O
downstream	O
signalling	O
pathways	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
could	O
be	O
triggered	O
by	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
human	O
B	O
cells	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
significant	O
changes	O
in	O
the	O
level	O
of	O
phospho	O
-	O
STAT3	B-Protein
or	O
phospho	O
-	O
p38	B-Protein
upon	O
BMP	B-Protein
-	I-Protein
6	I-Protein
treatment	O
of	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
induces	O
upregulation	O
of	O
Id1	B-Protein
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
are	B-X
multifunctional	B-X
cytokines	B-X
previously	B-X
found	B-X
to	B-X
regulate	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
human	B-X
B	B-X
progenitor	B-X
cells	B-X
.	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
belong	B-X
to	B-X
the	B-X
TGF-beta	B-X
superfamily	B-X
and	B-X
are	B-X
secreted	B-X
proteins	B-X
with	B-X
pleiotropic	B-X
roles	B-X
in	B-X
many	B-X
different	B-X
cell	B-X
types	B-X
.	B-X
A	B-X
potential	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
has	B-X
been	B-X
implied	B-X
by	B-X
various	B-X
studies	B-X
of	B-X
malignant	B-X
and	B-X
rheumatoid	B-X
diseases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
BMP-6	B-X
in	B-X
normal	B-X
human	B-X
peripheral	B-X
blood	B-X
B	B-X
cells	B-X
.	B-X

Next	O
,	O
we	O
wanted	O
to	O
explore	O
whether	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
phosphorylation	O
of	O
Smad	B-Protein
1	I-Protein
/	O
5	B-Protein
/	O
8	B-Protein
also	O
could	O
induce	O
transcriptional	O
changes	O
of	O
target	O
genes	O
.	O

In	O
this	O
regard	O
,	O
the	O
inhibitors	O
of	O
DNA	O
binding	O
proteins	O
(	O
Ids	O
)	O
are	O
considered	O
to	O
be	O
some	O
of	O
the	O
major	O
target	O
genes	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

Thus	O
,	O
B	O
cells	O
were	O
pre	O
-	O
incubated	O
over	O
night	O
in	O
X	O
-	O
VIVO	O
15	O
,	O
and	O
then	O
cultured	O
in	O
medium	O
alone	O
or	O
in	O
the	O
presence	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
for	O
various	O
time	O
points	O
before	O
preparation	O
of	O
total	O
RNA	O
.	O

The	O
amount	O
of	O
Id1	B-Protein
-	O
Id4	B-Protein
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	O
of	O
Id1	B-Protein
mRNA	O
in	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
treated	O
B	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
up	O
-	O
regulation	O
of	O
Id1	B-Protein
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
inducible	O
gene	O
,	O
with	O
maximal	O
upregulation	O
two	O
hours	O
after	O
the	O
addition	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
and	O
returned	O
to	O
baseline	O
after	O
24	O
hours	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
for	O
Id2	B-Protein
and	O
Id3	B-Protein
mRNA	O
,	O
whereas	O
Id4	B-Protein
-	O
transcripts	O
were	O
not	O
detectable	O
(	O
Figure	O
7	O
,	O
data	O
not	O
shown	O
)	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
induced	O
upregulation	O
of	O
Id1	B-Protein
mRNA	O
also	O
was	O
correlated	O
with	O
upregulation	O
of	O
Id1	B-Protein
protein	O
as	O
well	O
.	O

The	O
increase	O
in	O
Id1	B-Protein
protein	O
level	O
was	O
detectable	O
after	O
one	O
hour	O
and	O
increased	O
until	O
24	O
hours	O
after	O
BMP	B-Protein
-	I-Protein
6	I-Protein
addition	O
,	O
showing	O
a	O
16	O
-	O
fold	O
upregulation	O
compared	O
with	O
t0	O
(	O
p	O
<	O
=	O
0	O
.	O
020	O
,	O
n	O
=	O
4	O
)	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

In	O
line	O
with	O
the	O
mRNA	O
data	O
,	O
no	O
consistent	O
change	O
in	O
the	O
amounts	O
of	O
Id2	B-Protein
and	O
Id3	B-Protein
protein	O
could	O
be	O
observed	O
(	O
Figure	O
8	O
and	O
9	O
)	O
.	O

We	O
were	O
able	O
to	O
block	O
the	O
Id1	B-Protein
specific	O
band	O
with	O
a	O
blocking	O
peptide	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
Id1	B-Protein
could	O
be	O
a	O
possible	O
target	O
gene	O
for	O
mediating	O
the	O
effects	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
human	O
B	O
cells	O
,	O
whereas	O
Id2	B-Protein
and	O
Id3	B-Protein
not	O
seem	O
to	O
be	O
involved	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
production	O
in	O
B	O
cells	O

The	O
fact	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
has	O
been	O
reported	O
to	O
act	O
as	O
an	O
autocrine	O
stimulator	O
in	O
chondrocytes	O
[	O
18	O
]	O
and	O
ovarium	O
[	O
19	O
]	O
,	O
prompted	O
us	O
to	O
investigate	O
whether	O
normal	O
human	O
B	O
cells	O
could	O
produce	O
BMP	B-Protein
-	I-Protein
6	I-Protein
upon	O
stimulation	O
.	O

Ramos	O
cells	O
,	O
which	O
have	O
been	O
described	O
to	O
express	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
endogenously	O
[	O
20	O
]	O
,	O
and	O
the	O
T	O
cell	O
line	O
Jurkat	O
,	O
served	O
as	O
positive	O
and	O
negative	O
controls	O
,	O
respectively	O
.	O

Endogenous	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
levels	O
in	O
normal	O
B	O
cells	O
were	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
after	O
stimulation	O
with	O
anti	O
-	O
IgM	O
for	O
different	O
time	O
points	O
.	O

Interestingly	O
,	O
the	O
up	O
-	O
regulation	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
was	O
characteristic	O
of	O
an	O
early	O
-	O
to	O
intermediate	O
inducible	O
gene	O
with	O
maximal	O
upregulation	O
four	O
hours	O
after	O
the	O
addition	O
of	O
anti	O
-	O
IgM	O
.	O

The	O
level	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
was	O
back	O
to	O
baseline	O
after	O
24	O
hours	O
upon	O
stimulation	O
(	O
Figure	O
10	O
)	O
.	O

Furthermore	O
,	O
both	O
FCS	O
and	O
human	O
AB	O
-	O
serum	O
induced	O
significant	O
upregulation	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
(	O
Figure	O
11	O
)	O
.	O

Interestingly	O
,	O
in	O
a	O
separate	O
study	O
we	O
have	O
found	O
that	O
normal	O
human	O
T	O
cells	O
do	O
not	O
express	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
after	O
activation	O
(	O
Sivertsen	O
et	O
al	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

Next	O
,	O
we	O
wanted	O
to	O
detect	O
BMP	B-Protein
-	I-Protein
6	I-Protein
protein	O
in	O
normal	O
B	O
-	O
cells	O
and	O
tested	O
various	O
commercially	O
available	O
antibodies	O
.	O

However	O
,	O
in	O
our	O
hands	O
these	O
anti	O
-	O
BMP	B-Protein
-	I-Protein
6	I-Protein
antibodies	O
did	O
only	O
recognize	O
the	O
recombinant	O
BMP	B-Protein
-	I-Protein
6	I-Protein
protein	O
and	O
not	O
the	O
native	O
protein	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
an	O
important	O
role	O
for	O
BMP	O
superfamily	O
members	O
in	O
hematopoietic	O
stem	O
cells	O
,	O
early	O
thymocytes	O
[	O
6	O
,	O
7	O
]	O
and	O
B	O
-	O
cell	O
malignancies	O
[	O
8	O
,	O
11	O
,	O
12	O
]	O
,	O
but	O
a	O
role	O
for	O
BMPs	O
in	O
normal	O
human	O
B	O
cells	O
has	O
previously	O
not	O
been	O
reported	O
.	O

The	O
present	O
study	O
demonstrated	O
a	O
significant	O
antiproliferative	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
peripheral	O
blood	O
CD19	B-Protein
+	O
B	O
cells	O
.	O

Additionally	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
cell	O
death	O
in	O
CD27	B-Protein
+	O
memory	O
B	O
cells	O
as	O
well	O
as	O
in	O
a	O
Burkitt	O
lymphoma	O
cell	O
line	O
(	O
Ramos	O
)	O
.	O

Importantly	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
a	O
rapid	O
and	O
marked	O
increase	O
in	O
Smad	B-Protein
-	I-Protein
1	I-Protein
/	O
5	B-Protein
/	O
8	B-Protein
phosphorylation	O
.	O

Furthermore	O
,	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
Smad	B-Protein
phosphorylation	O
was	O
followed	O
by	O
a	O
selective	O
upregulation	O
of	O
Id1	B-Protein
mRNA	O
and	O
subsequent	O
Id1	B-Protein
protein	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
demonstrated	O
antiproliferative	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
anti	O
-	O
IgM	O
treated	O
B	O
cells	O
was	O
significant	O
and	O
dose	O
-	O
dependent	O
.	O

Importantly	O
,	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
could	O
be	O
completely	O
neutralized	O
by	O
the	O
use	O
of	O
a	O
natural	O
inhibitor	O
,	O
Noggin	B-Protein
.	O

This	O
is	O
in	O
line	O
with	O
others	O
,	O
showing	O
that	O
Noggin	B-Protein
can	O
function	O
as	O
a	O
BMP	B-Protein
-	I-Protein
6	I-Protein
antagonist	O
[	O
21	O
,	O
22	O
]	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
soluble	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
-	O
Fc	O
and	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
-	O
Fc	O
fusion	O
proteins	O
also	O
neutralized	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
human	O
B	O
cells	O
.	O

Interestingly	O
,	O
as	O
for	O
other	O
TGF	O
family	O
members	O
,	O
bifunctional	O
effects	O
have	O
also	O
been	O
demonstrated	O
for	O
BMPs	O
.	O

Whereas	O
several	O
of	O
the	O
BMPs	O
have	O
been	O
shown	O
to	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
including	O
condrocytes	O
[	O
23	O
]	O
,	O
liver	O
[	O
24	O
]	O
and	O
granulosa	O
cells	O
[	O
25	O
]	O
,	O
antiproliferative	O
effects	O
and	O
induction	O
of	O
apoptosis	O
has	O
been	O
reported	O
for	O
B	O
and	O
T	O
lineage	O
cells	O
.	O

Similar	O
effects	O
as	O
demonstrated	O
for	O
BMP	B-Protein
-	I-Protein
6	I-Protein
on	O
human	O
B	O
cells	O
in	O
the	O
present	O
study	O
,	O
were	O
demonstrated	O
for	O
BMP	B-Protein
-	I-Protein
2	I-Protein
,	O
4	B-Protein
,	O
6	B-Protein
and	O
-	B-Protein
7	I-Protein
in	O
human	O
myeloma	O
cells	O
[	O
9	O
-	O
11	O
]	O
.	O

Other	O
members	O
of	O
the	O
BMP	O
-	O
family	O
have	O
also	O
been	O
reported	O
to	O
induce	O
apoptosis	O
,	O
including	O
in	O
mouse	O
B	O
lineage	O
cells	O
[	O
26	O
]	O
.	O

Additionally	O
,	O
BMP	B-Protein
-	I-Protein
4	I-Protein
inhibits	O
thymocyte	O
proliferation	O
[	O
6	O
]	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
role	O
of	O
BMPs	O
in	O
the	O
regulation	O
of	O
proliferation	O
and	O
apoptosis	O
is	O
highly	O
cell	O
type	O
dependent	O
.	O

To	O
examine	O
how	O
BMP	B-Protein
-	I-Protein
6	I-Protein
exerts	O
its	O
functional	O
effects	O
in	O
B	O
cells	O
,	O
we	O
analysed	O
BMP	O
receptor	O
expression	O
by	O
western	O
blot	O
analysis	O
.	O

Human	O
peripheral	O
B	O
cells	O
were	O
found	O
to	O
express	O
the	O
BMP	O
type	O
I	O
receptors	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
and	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
,	O
and	O
the	O
type	O
II	O
-	O
receptors	O
BMP	B-Protein
-	I-Protein
RII	I-Protein
and	O
Act	B-Protein
-	I-Protein
RIIb	I-Protein
,	O
which	O
signal	O
after	O
binding	O
of	O
several	O
BMPs	O
,	O
including	O
BMP	B-Protein
-	I-Protein
6	I-Protein
[	O
16	O
,	O
13	O
]	O
.	O

To	O
further	O
explore	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induced	O
signalling	O
,	O
activation	O
of	O
several	O
pathways	O
is	O
possible	O
.	O
<EOS>	B-X
BMP	B-X
and	B-X
IL-6	B-X
signaling	B-X
act	B-X
via	B-X
Smad	B-X
and	B-X
Stat3	B-X
transcription	B-X
factors	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
increase	B-X
expression	B-X
of	B-X
hepcidin	B-X
,	B-X
the	B-X
master	B-X
regulator	B-X
of	B-X
iron	B-X
metabolism	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
ferristatin	B-X
II	B-X
action	B-X
on	B-X
hepcidin	B-X
production	B-X
.	B-X
Ferristatin	B-X
II	B-X
also	B-X
increased	B-X
Stat3	B-X
phosphorylation	B-X
in	B-X
the	B-X
rat	B-X
liver	B-X
without	B-X
affecting	B-X
serum	B-X
or	B-X
hepatic	B-X
IL-6	B-X
levels	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
whether	B-X
the	B-X
Stat3	B-X
activation	B-X
observed	B-X
in	B-X
vivo	B-X
is	B-X
a	B-X
cause	B-X
or	B-X
a	B-X
consequence	B-X
to	B-X
hepcidin	B-X
induction	B-X
.	B-X
Reporter	B-X
gene	B-X
expression	B-X
studies	B-X
demonstrated	B-X
that	B-X
ferristatin	B-X
II	B-X
synergized	B-X
with	B-X
BMP6	B-X
and	B-X
IL-6	B-X
to	B-X
enhance	B-X
hepcidin	B-X
expression	B-X
in	B-X
vitro	B-X
.	B-X
However	B-X
,	B-X
this	B-X
synergy	B-X
was	B-X
not	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
either	B-X
Smad	B-X
or	B-X
Stat3	B-X
signaling	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
ferristatin	B-X
II	B-X
may	B-X
activate	B-X
a	B-X
novel	B-X
pathway	B-X
for	B-X
hepcidin	B-X
regulation	B-X
.	B-X

The	O
major	O
signalling	O
pathway	O
known	O
to	O
date	O
,	O
is	O
activation	O
of	O
R	O
-	O
Smads	O
[	O
13	O
,	O
27	O
]	O
.	O

In	O
that	O
respect	O
,	O
BMPs	O
have	O
been	O
shown	O
to	O
exert	O
antiproliferative	O
effects	O
in	O
B	O
lineage	O
cells	O
via	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
[	O
11	O
,	O
28	O
]	O
.	O

Furthermore	O
,	O
BMP	B-Protein
-	I-Protein
2	I-Protein
has	O
been	O
shown	O
to	O
induce	O
activation	O
of	O
STAT3	B-Protein
in	O
myeloma	O
cells	O
[	O
9	O
]	O
.	O

However	O
,	O
phosphorylation	O
of	O
R	O
-	O
Smad	O
was	O
not	O
investigated	O
in	O
that	O
study	O
.	O
<EOS>	B-X
Signal	B-X
transduction	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
Smad1	B-X
,	B-X
5	B-X
and	B-X
8	B-X
are	B-X
the	B-X
immediate	B-X
downstream	B-X
molecules	B-X
of	B-X
BMP	B-X
receptors	B-X
and	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
BMP	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
BMPs	B-X
was	B-X
first	B-X
identified	B-X
in	B-X
the	B-X
1960s	B-X
(	B-X
Urist	B-X
,	B-X
M.R	B-X
.	B-X
Reprod	B-X
.	B-X
Three	B-X
type	B-X
I	B-X
receptors	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
bind	B-X
BMP	B-X
ligands	B-X
,	B-X
type	B-X
IA	B-X
and	B-X
IB	B-X
BMP	B-X
receptors	B-X
(	B-X
BMPR-IA	B-X
or	B-X
ALK-3	B-X
and	B-X
BMPR-IB	B-X
or	B-X
ALK-6	B-X
)	B-X
and	B-X
type	B-X
IA	B-X
activin	B-X
receptor	B-X
(	B-X
ActR-IA	B-X
or	B-X
ALK-2	B-X
)	B-X
(	B-X
Koenig	B-X
,	B-X
B.B	B-X
.	B-X
(	B-X
1998	B-X
)	B-X
``	B-X
Specific	B-X
activation	B-X
of	B-X
Smad1	B-X
signaling	B-X
pathways	B-X
by	B-X
the	B-X
BMP7	B-X
type	B-X
I	B-X
receptor	B-X
,	B-X
ALK2	B-X
''	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
Three	B-X
type	B-X
II	B-X
receptors	B-X
for	B-X
BMPs	B-X
have	B-X
also	B-X
been	B-X
identified	B-X
and	B-X
they	B-X
are	B-X
type	B-X
II	B-X
BMP	B-X
receptor	B-X
(	B-X
BMPR-II	B-X
)	B-X
and	B-X
type	B-X
II	B-X
and	B-X
IIB	B-X
activin	B-X
receptors	B-X
(	B-X
ActR-II	B-X
and	B-X
ActR-IIB	B-X
)	B-X
(	B-X
Yamashita	B-X
,	B-X
H.	B-X
et	B-X
al	B-X
.	B-X
130	B-X
,	B-X
217-226	B-X
;	B-X
Rosenzweig	B-X
,	B-X
B.L	B-X
.	B-X
Whereas	B-X
BMPR-IA	B-X
,	B-X
IB	B-X
and	B-X
II	B-X
are	B-X
specific	B-X
to	B-X
BMPs	B-X
,	B-X
ActR-IA	B-X
,	B-X
II	B-X
and	B-X
IIB	B-X
are	B-X
also	B-X
signaling	B-X
receptors	B-X
for	B-X
activins	B-X
.	B-X
Heldi	B-X
(	B-X
2002	B-X
)	B-X
``	B-X
From	B-X
mono-	B-X
to	B-X
oligo-Smads	B-X
:	B-X
the	B-X
heart	B-X
of	B-X
the	B-X
matter	B-X
in	B-X
TGFbeta	B-X
signal	B-X
transduction	B-X
''	B-X
Genes	B-X
Dev	B-X
.	B-X
The	B-X
type	B-X
I	B-X
BMP	B-X
receptor	B-X
substrates	B-X
include	B-X
a	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
Smad	B-X
proteins	B-X
,	B-X
that	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
relaying	B-X
the	B-X
BMP	B-X
signal	B-X
from	B-X
the	B-X
receptor	B-X
to	B-X
target	B-X
genes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
Smad1	B-X
,	B-X
5	B-X
and	B-X
8	B-X
are	B-X
phosphorylated	B-X
by	B-X
BMP	B-X
receptors	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
(	B-X
Hoodless	B-X
,	B-X
P.A	B-X
.	B-X
(	B-X
1996	B-X
)	B-X
``	B-X
MADR1	B-X
,	B-X
a	B-X
MAD-related	B-X
protein	B-X
that	B-X
functions	B-X
in	B-X
BMP2	B-X
signaling	B-X
pathways	B-X
''	B-X
,	B-X
Cell	B-X
85	B-X
,	B-X
489-500	B-X
;	B-X
Chen	B-X
Y.	B-X
et	B-X
al	B-X
.	B-X
(	B-X
1997	B-X
)	B-X
``	B-X
Smad8	B-X
mediates	B-X
the	B-X
signaling	B-X
of	B-X
the	B-X
receptor	B-X
serine	B-X
kinase	B-X
''	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
94	B-X
,	B-X
12938-12943	B-X
;	B-X
Nishimura	B-X
R.	B-X
et	B-X
al	B-X
.	B-X
(	B-X
1998	B-X
)	B-X
``	B-X
Smad5	B-X
and	B-X
DPC4	B-X
are	B-X
key	B-X
molecules	B-X
in	B-X
mediating	B-X
BMP-2-induced	B-X
osteoblastic	B-X
differentiation	B-X
of	B-X
the	B-X
pluripotent	B-X
mesenchymal	B-X
precursor	B-X
cell	B-X
line	B-X
C2C12	B-X
''	B-X
,	B-X
J.	B-X
Biol	B-X
.	B-X
After	B-X
release	B-X
from	B-X
the	B-X
receptor	B-X
,	B-X
the	B-X
phosphorylated	B-X
Smad	B-X
proteins	B-X
associate	B-X
with	B-X
the	B-X
related	B-X
protein	B-X
Smad4	B-X
,	B-X
which	B-X
acts	B-X
as	B-X
a	B-X
shared	B-X
partner	B-X
.	B-X

BMP	B-Protein
-	I-Protein
2	I-Protein
has	O
also	O
been	O
shown	O
to	O
induce	O
phosphorylation	O
of	O
p38	O
[	O
29	O
]	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
bone	B-X
morphogenetic	B-X
protein-2	B-X
(	B-X
BMP-2	B-X
)	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
Osterix	B-X
expression	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
homeodomain	B-X
sequence	B-X
located	B-X
in	B-X
the	B-X
proximal	B-X
region	B-X
of	B-X
the	B-X
Osterix	B-X
promoter	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
induction	B-X
of	B-X
Dlx5	B-X
by	B-X
BMP-2	B-X
mediates	B-X
Osterix	B-X
transcriptional	B-X
activation	B-X
.	B-X
First	B-X
,	B-X
BMP-2	B-X
induction	B-X
of	B-X
Dlx5	B-X
precedes	B-X
the	B-X
induction	B-X
of	B-X
Osterix	B-X
.	B-X
Second	B-X
,	B-X
Dlx5	B-X
binds	B-X
to	B-X
the	B-X
BMP-responsive	B-X
homeodomain	B-X
sequences	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Third	B-X
,	B-X
Dlx5	B-X
overexpression	B-X
and	B-X
knock-down	B-X
assays	B-X
demonstrate	B-X
its	B-X
role	B-X
in	B-X
activating	B-X
Osterix	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
BMP-2	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Dlx5	B-X
is	B-X
a	B-X
novel	B-X
substrate	B-X
for	B-X
p38	B-X
MAPK	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
and	B-X
that	B-X
Ser-34	B-X
and	B-X
Ser-217	B-X
are	B-X
the	B-X
sites	B-X
phosphorylated	B-X
by	B-X
p38	B-X
.	B-X
Phosphorylation	B-X
at	B-X
Ser-34/217	B-X
increases	B-X
the	B-X
transactivation	B-X
potential	B-X
of	B-X
Dlx5	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
BMP	B-X
activates	B-X
expression	B-X
of	B-X
Osterix	B-X
through	B-X
the	B-X
induction	B-X
of	B-X
Dlx5	B-X
and	B-X
its	B-X
further	B-X
transcriptional	B-X
activation	B-X
by	B-X
p38-mediated	B-X
phosphorylation	B-X
.	B-X

Thus	O
,	O
phosphorylation	O
of	O
p38	O
,	O
STAT3	B-Protein
and	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
represent	O
important	O
BMP	O
-	O
signalling	O
pathways	O
that	O
mediated	O
the	O
effects	O
of	O
BMPs	O
and	O
even	O
cross	O
-	O
talk	O
between	O
these	O
pathways	O
has	O
been	O
reported	O
[	O
29	O
,	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
induced	O
changes	O
in	O
the	O
phosphorylation	O
status	O
of	O
STAT3	B-Protein
or	O
p38	O
in	O
human	O
peripheral	O
B	O
cells	O
.	O
<EOS>	B-X
There	B-X
are	B-X
limited	B-X
studies	B-X
on	B-X
the	B-X
presentation	B-X
and	B-X
characteristics	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
women	B-X
under	B-X
age	B-X
40	B-X
.	B-X
Bulbourethral	B-X
syringocele	B-X
is	B-X
an	B-X
uncommon	B-X
and	B-X
under-diagnosed	B-X
condition	B-X
most	B-X
commonly	B-X
seen	B-X
in	B-X
the	B-X
paediatric	B-X
population	B-X
,	B-X
although	B-X
there	B-X
is	B-X
increasing	B-X
recognition	B-X
in	B-X
adults	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
difficulty	B-X
in	B-X
diagnosis	B-X
,	B-X
we	B-X
report	B-X
our	B-X
experience	B-X
of	B-X
urethral	B-X
syringocele	B-X
in	B-X
a	B-X
quaternary	B-X
paediatric	B-X
hospital	B-X
,	B-X
with	B-X
differing	B-X
presentations	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
.	B-X
To	B-X
estimate	B-X
the	B-X
impact	B-X
of	B-X
delayed	B-X
presentation	B-X
of	B-X
anorectal	B-X
malformation	B-X
(	B-X
ARM	B-X
)	B-X
in	B-X
neonates	B-X
and	B-X
to	B-X
compare	B-X
the	B-X
presenting	B-X
characteristics	B-X
and	B-X
outcomes	B-X
of	B-X
early	B-X
versus	B-X
delayed	B-X
presentation	B-X
.	B-X

Instead	O
,	O
a	O
rapid	O
and	O
marked	O
phosphorylation	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
was	O
revealed	O
.	O

In	O
a	O
parallel	O
study	O
,	O
we	O
have	O
found	O
that	O
other	O
BMPs	O
also	O
induced	O
phosphorylation	O
of	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
in	O
peripheral	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
are	O
currently	O
pursuing	O
microarray	O
studies	O
to	O
identify	O
the	O
signalling	O
pathways	O
and	O
target	O
genes	O
that	O
are	O
differently	O
regulated	O
by	O
the	O
various	O
BMPs	O
in	O
human	O
B	O
cells	O
.	O

Upregulation	O
of	O
Id1	B-Protein
via	O
Smad1	B-Protein
/	O
5	B-Protein
/	O
8	B-Protein
phosphorylation	O
is	O
a	O
known	O
mechanism	O
for	O
BMP	B-Protein
-	I-Protein
6	I-Protein
signalling	O
in	O
other	O
cell	O
systems	O
[	O
31	O
,	O
32	O
]	O
and	O
regulation	O
of	O
Id	O
-	O
proteins	O
is	O
thought	O
to	O
be	O
an	O
important	O
mechanism	O
for	O
Smad	O
-	O
signalling	O
[	O
17	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
experiments	O
revealed	O
a	O
specific	O
four	O
-	O
fold	O
upregulation	O
for	O
Id1	B-Protein
in	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
treated	O
B	O
cells	O
,	O
while	O
the	O
amount	O
of	O
Id2	B-Protein
-	O
Id4	B-Protein
remained	O
unchanged	O
.	O

In	O
agreement	O
with	O
this	O
,	O
western	O
blot	O
analysis	O
demonstrated	O
an	O
upregulation	O
of	O
Id1	B-Protein
protein	O
,	O
while	O
the	O
amount	O
of	O
Id2	B-Protein
and	O
Id3	B-Protein
protein	O
levels	O
remained	O
unchanged	O
.	O

Previously	O
,	O
Id1	B-Protein
has	O
been	O
considered	O
not	O
to	O
be	O
expressed	O
in	O
later	O
developmental	O
stages	O
than	O
pro	O
-	O
B	O
cells	O
[	O
33	O
,	O
34	O
]	O
,	O
and	O
its	O
constitutive	O
expression	O
has	O
been	O
reported	O
to	O
impair	O
mouse	O
B	O
cell	O
development	O
[	O
35	O
]	O
.	O
<EOS>	B-X
VAR2CSA	B-X
is	B-X
considered	B-X
as	B-X
the	B-X
main	B-X
target	B-X
of	B-X
protective	B-X
immunity	B-X
against	B-X
pregnancy-associated	B-X
malaria	B-X
.	B-X
VAR2CSA	B-X
high	B-X
molecular	B-X
weight	B-X
complicates	B-X
scaling	B-X
up	B-X
production	B-X
of	B-X
VAR2CSA	B-X
recombinant	B-X
protein	B-X
for	B-X
large-scale	B-X
vaccination	B-X
programmes	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
antibodies	B-X
induced	B-X
by	B-X
NTS-DBL1X-Id1-DBL2X	B-X
efficiently	B-X
block	B-X
parasite	B-X
binding	B-X
to	B-X
CSA	B-X
in	B-X
a	B-X
similar	B-X
manner	B-X
to	B-X
antibodies	B-X
induced	B-X
by	B-X
the	B-X
full-length	B-X
extracellular	B-X
part	B-X
of	B-X
VAR2CSA	B-X
.	B-X
In	B-X
order	B-X
to	B-X
identifying	B-X
the	B-X
shortest	B-X
fragment	B-X
of	B-X
VAR2CSA	B-X
carrying	B-X
major	B-X
protective	B-X
epitopes	B-X
able	B-X
to	B-X
elicit	B-X
inhibitory	B-X
antibodies	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
refined	B-X
antigenic	B-X
mapping	B-X
of	B-X
NTS-DBL1X-Id1-DBL2X	B-X
through	B-X
a	B-X
DNA	B-X
vaccination	B-X
technique	B-X
.	B-X

Therefore	O
,	O
our	O
demonstration	O
of	O
the	O
time	O
-	O
dependent	O
upregulation	O
of	O
Id1	B-Protein
mRNA	O
and	O
protein	O
in	O
mature	O
normal	O
human	O
B	O
cells	O
is	O
of	O
particular	O
interest	O
.	O

In	O
that	O
respect	O
,	O
it	O
is	O
noteworthy	O
that	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signalling	O
in	O
early	O
and	O
mature	O
B	O
cells	O
induces	O
both	O
Id2	B-Protein
and	O
Id3	B-Protein
expression	O
[	O
36	O
,	O
37	O
]	O
,	O
but	O
not	O
Id1	B-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

Interestingly	O
,	O
these	O
results	O
show	O
that	O
various	O
members	O
of	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
family	O
regulate	O
Id	O
proteins	O
differently	O
.	O
<EOS>	B-X
Yet	B-X
,	B-X
how	B-X
different	B-X
members	B-X
of	B-X
the	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
family	B-X
regulate	B-X
EndMT	B-X
is	B-X
not	B-X
well	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
TGF-β2	B-X
,	B-X
but	B-X
not	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
(	B-X
BMP	B-X
)	B-X
9	B-X
,	B-X
triggers	B-X
EndMT	B-X
in	B-X
murine	B-X
endothelial	B-X
MS-1	B-X
and	B-X
2H11	B-X
cells	B-X
.	B-X
TGF-β2	B-X
strongly	B-X
upregulates	B-X
the	B-X
transcription	B-X
factor	B-X
SNAIL	B-X
,	B-X
and	B-X
the	B-X
depletion	B-X
of	B-X

Id2	B-Protein
and	O
Id3	B-Protein
are	O
considered	O
to	O
be	O
the	O
Id	O
proteins	O
mainly	O
expressed	O
in	O
mature	O
B	O
cells	O
[	O
38	O
]	O
.	O

The	O
present	O
study	O
also	O
found	O
Id2	B-Protein
and	O
Id3	B-Protein
protein	O
in	O
B	O
cells	O
to	O
be	O
more	O
highly	O
expressed	O
than	O
Id1	B-Protein
in	O
resting	O
B	O
cells	O
.	O

However	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
did	O
not	O
induce	O
significant	O
changes	O
in	O
the	O
protein	O
expression	O
of	O
Id2	B-Protein
and	O
Id3	B-Protein
.	O
<EOS>	B-X
The	B-X
BMP/TGFβ-Smad	B-X
,	B-X
Notch	B-X
and	B-X
VEGF	B-X
signaling	B-X
guides	B-X
formation	B-X
of	B-X
endothelial	B-X
tip	B-X
and	B-X
stalk	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
crosstalk	B-X
of	B-X
bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
VEGFR2	B-X
)	B-X
signaling	B-X
has	B-X
remained	B-X
largely	B-X
unknown	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
BMP	B-X
family	B-X
members	B-X
regulate	B-X
VEGFR2	B-X
and	B-X
Notch	B-X
signaling	B-X
,	B-X
and	B-X
act	B-X
via	B-X
TAZ-Hippo	B-X
signaling	B-X
pathway	B-X
.	B-X
BMPs	B-X
were	B-X
found	B-X
to	B-X
be	B-X
regulated	B-X
after	B-X
VEGF	B-X
gene	B-X
transfer	B-X
in	B-X
C57/Bl6	B-X
mice	B-X
and	B-X
in	B-X
a	B-X
porcine	B-X
myocardial	B-X
ischemia	B-X
model	B-X
.	B-X
BMPs	B-X
2/4/6	B-X
were	B-X
identified	B-X
as	B-X
endothelium-specific	B-X
targets	B-X
of	B-X
VEGF	B-X
.	B-X
BMP2	B-X
modulated	B-X
VEGF-mediated	B-X
endothelial	B-X
sprouting	B-X
via	B-X
Delta	B-X
like	B-X
Canonical	B-X
Notch	B-X
Ligand	B-X
4	B-X
(	B-X
DLL4	B-X
)	B-X
.	B-X
BMP6	B-X
modulated	B-X
VEGF	B-X
signaling	B-X
by	B-X
regulating	B-X
VEGFR2	B-X
expression	B-X
and	B-X
acted	B-X
via	B-X
Hippo	B-X
signaling	B-X
effector	B-X
TAZ	B-X
,	B-X
known	B-X
to	B-X
regulate	B-X
cell	B-X
survival/proliferation	B-X
,	B-X
and	B-X
to	B-X
be	B-X
dysregulated	B-X
in	B-X
cancer	B-X
.	B-X
In	B-X
a	B-X
matrigel	B-X
plug	B-X
assay	B-X
in	B-X
nude	B-X
mice	B-X
BMP6	B-X
was	B-X
further	B-X
demonstrated	B-X
to	B-X
induce	B-X
angiogenesis	B-X
.	B-X
BMP6	B-X
is	B-X
the	B-X
first	B-X
member	B-X
of	B-X
BMP	B-X
family	B-X
found	B-X
to	B-X
directly	B-X
regulate	B-X
both	B-X
Hippo	B-X
signaling	B-X
and	B-X
neovessel	B-X
formation	B-X
.	B-X

It	O
is	O
believed	O
that	O
Id	O
proteins	O
block	O
differentiation	O
and	O
promote	O
proliferation	O
in	O
various	O
cell	O
types	O
[	O
39	O
,	O
33	O
]	O
.	O

Id	O
proteins	O
act	O
as	O
dominant	O
-	O
negative	O
inhibitors	O
of	O
E	O
-	O
proteins	O
and	O
Pax5	B-Protein
function	O
by	O
forming	O
dimers	O
with	O
these	O
proteins	O
,	O
making	O
them	O
unable	O
to	O
bind	O
DNA	O
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
balance	O
among	O
E	O
-	O
proteins	O
,	O
Pax5	B-Protein
and	O
Id	O
proteins	O
might	O
have	O
an	O
important	O
role	O
in	O
activated	O
B	O
cells	O
[	O
38	O
]	O
.	O

In	O
that	O
respect	O
,	O
E	O
-	O
proteins	O
have	O
been	O
implicated	O
in	O
both	O
the	O
promotion	O
and	O
inhibition	O
of	O
cell	O
survival	O
and	O
growth	O
at	O
different	O
points	O
in	O
lymphocyte	O
development	O
[	O
40	O
]	O
.	O

The	O
antiproliferative	O
and	O
death	O
inducing	O
effect	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
B	O
cells	O
with	O
concomitant	O
upregulation	O
of	O
Id1	B-Protein
protein	O
is	O
therefore	O
in	O
line	O
with	O
the	O
view	O
that	O
Id	O
proteins	O
are	O
required	O
for	O
the	O
induction	O
of	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
-	O
lymphocyte	O
progenitors	O
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
[	O
40	O
]	O
.	O

Furthermore	O
,	O
Id	O
proteins	O
are	O
known	O
as	O
important	O
parts	O
of	O
signalling	O
pathways	O
involved	O
in	O
development	O
,	O
cell	O
cycle	O
and	O
tumorigenesis	O
[	O
32	O
]	O
.	O

It	O
is	O
well	O
established	O
that	O
various	O
members	O
of	O
the	O
Id	O
family	O
are	O
overexpressed	O
in	O
a	O
range	O
of	O
human	O
tumours	O
and	O
generally	O
,	O
Id1	B-Protein
appears	O
to	O
be	O
the	O
family	O
member	O
most	O
widely	O
overexpressed	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
[	O
41	O
]	O
,	O
including	O
multiple	O
myeloma	O
[	O
42	O
,	O
32	O
]	O
.	O

Additionally	O
,	O
our	O
findings	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
activates	O
intracellular	O
signalling	O
pathways	O
in	O
human	O
B	O
cells	O
might	O
be	O
of	O
potential	O
pathophysiological	O
significance	O
in	O
lymphoma	O
and	O
inflammation	O
.	O

High	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
in	O
DLBCL	O
has	O
been	O
shown	O
to	O
correlate	O
to	O
unfavourable	O
outcome	O
[	O
12	O
]	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
of	O
interest	O
that	O
targeted	O
expression	O
of	O
Id1	B-Protein
to	O
B	O
-	O
lymphocytes	O
resulted	O
in	O
aberrant	O
B	O
cell	O
development	O
,	O
massive	O
apoptosis	O
,	O
and	O
subsequent	O
development	O
of	O
B	O
cell	O
lymphomas	O
[	O
35	O
]	O
.	O

Moreover	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
[	O
43	O
,	O
44	O
]	O
and	O
elevated	O
levels	O
of	O
Id1	B-Protein
and	O
Id3	B-Protein
have	O
been	O
found	O
in	O
the	O
synovia	O
of	O
RA	O
-	O
patients	O
[	O
45	O
]	O
.	O

Altogether	O
,	O
these	O
results	O
point	O
to	O
an	O
important	O
role	O
for	O
Id	O
proteins	O
in	O
the	O
regulation	O
of	O
normal	O
B	O
cell	O
homeostasis	O
and	O
in	O
diseases	O
,	O
where	O
B	O
cells	O
are	O
involved	O
.	O

It	O
will	O
therefore	O
be	O
important	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
Id	B-Protein
-	I-Protein
1	I-Protein
in	O
human	O
B	O
cells	O
by	O
selective	O
over	O
expression	O
or	O
inhibition	O
of	O
Id	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
.	O
<EOS>	B-X
Diabetic	B-X
cardiomyopathy	B-X
(	B-X
DbCM	B-X
)	B-X
is	B-X
a	B-X
major	B-X
complication	B-X
in	B-X
type-1	B-X
diabetes	B-X
,	B-X
accompanied	B-X
by	B-X
altered	B-X
cardiac	B-X
energetics	B-X
,	B-X
impaired	B-X
mitochondrial	B-X
function	B-X
,	B-X
and	B-X
oxidative	B-X
stress	B-X
.	B-X
Previous	B-X
studies	B-X
indicate	B-X
that	B-X
type-1	B-X
diabetes	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
cardiac	B-X
expression	B-X
of	B-X
KLF5	B-X
(	B-X
Krüppel-like	B-X
factor-5	B-X
)	B-X
and	B-X
PPARα	B-X
(	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
)	B-X
that	B-X
regulate	B-X
cardiac	B-X
lipid	B-X
metabolism	B-X
.	B-X
Despite	B-X
progress	B-X
in	B-X
the	B-X
discovery	B-X
of	B-X
various	B-X
genetic	B-X
risk	B-X
factors	B-X
thanks	B-X
to	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
genomics	B-X
technologies	B-X
,	B-X
the	B-X
precise	B-X
pathological	B-X
mechanisms	B-X
underlying	B-X
the	B-X
onset	B-X
of	B-X
NDDs	B-X
remain	B-X
elusive	B-X
owing	B-X
to	B-X
the	B-X
profound	B-X
genetic	B-X
and	B-X
phenotypic	B-X
heterogeneity	B-X
of	B-X
these	B-X
conditions	B-X
.	B-X
Ceramide	B-X
plays	B-X
pathogenic	B-X
roles	B-X
in	B-X
nonalcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
(	B-X
NAFLD	B-X
)	B-X
via	B-X
multiple	B-X
mechanisms	B-X
,	B-X
and	B-X
as	B-X
such	B-X
inhibition	B-X
of	B-X
ceramide	B-X
de	B-X
novo	B-X
synthesis	B-X
in	B-X
the	B-X
liver	B-X
may	B-X
be	B-X
of	B-X
therapeutically	B-X
beneficial	B-X
in	B-X
patients	B-X
with	B-X
NAFLD	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
explore	B-X
whether	B-X
inhibition	B-X
of	B-X
ceramide	B-X
signaling	B-X
by	B-X
myriocin	B-X
is	B-X
beneficial	B-X
in	B-X
animal	B-X
model	B-X
of	B-X
NAFLD	B-X
via	B-X
regulating	B-X
autophagy	B-X
.	B-X

Given	O
the	O
role	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
mature	O
human	O
B	O
cells	O
demonstrated	O
here	O
,	O
identification	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
producing	O
cells	O
in	O
vivo	O
with	O
possibility	O
of	O
interaction	O
with	O
naive	O
and	O
memory	O
B	O
cells	O
might	O
contribute	O
to	O
the	O
understanding	O
of	O
mature	O
B	O
cell	O
biology	O
.	O

High	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
expression	O
in	O
DLBCL	O
has	O
been	O
detected	O
by	O
gene	O
expression	O
profiling	O
[	O
12	O
]	O
.	O

Furthermore	O
,	O
production	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
transcripts	O
in	O
normal	O
activated	O
B	O
cells	O
was	O
detected	O
in	O
the	O
same	O
study	O
.	O

Of	O
note	O
,	O
an	O
autocrine	O
BMP	B-Protein
-	I-Protein
6	I-Protein
loop	O
has	O
been	O
reported	O
by	O
others	O
in	O
chondrocytes	O
and	O
in	O
the	O
ovarium	O
[	O
46	O
,	O
19	O
,	O
18	O
]	O
.	O

Therefore	O
,	O
we	O
wanted	O
to	O
explore	O
the	O
possibility	O
for	O
an	O
autocrine	O
BMP	B-Protein
-	I-Protein
6	I-Protein
loop	O
in	O
human	O
B	O
cells	O
.	O

We	O
analysed	O
the	O
expression	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
in	O
peripheral	O
blood	O
B	O
cells	O
by	O
real	O
-	O
time	O
PCR	O
,	O
and	O
report	O
here	O
the	O
upregulation	O
of	O
endogenous	O
BMP	B-Protein
-	I-Protein
6	I-Protein
transcripts	O
after	O
stimulation	O
with	O
FCS	O
,	O
human	O
AB	O
-	O
serum	O
and	O
,	O
most	O
importantly	O
,	O
anti	O
-	O
IgM	O
.	O

However	O
,	O
our	O
attempts	O
to	O
study	O
BMP	B-Protein
-	I-Protein
6	I-Protein
protein	O
levels	O
were	O
unsuccessful	O
due	O
to	O
problems	O
with	O
unspecific	O
binding	O
of	O
the	O
anti	O
-	O
BMP	O
-	O
6	O
antibodies	O
tested	O
,	O
and	O
lack	O
of	O
specific	O
staining	O
in	O
control	O
cells	O
known	O
to	O
express	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
.	O

In	O
contrast	O
,	O
the	O
recombinant	O
protein	O
was	O
readily	O
detected	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
the	B-X
use	B-X
of	B-X
this	B-X
antibody	B-X
for	B-X
imaging	B-X
can	B-X
be	B-X
problematic	B-X
because	B-X
it	B-X
readily	B-X
binds	B-X
to	B-X
double-stranded	B-X
RNA	B-X
(	B-X
dsRNA	B-X
)	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
nonspecific	B-X
signal	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
purified	B-X
,	B-X
catalytically	B-X
inactive	B-X
human	B-X
RNase	B-X
H1	B-X
tagged	B-X
with	B-X
GFP	B-X
(	B-X
GFP-dRNH1	B-X
)	B-X
is	B-X
a	B-X
more	B-X
specific	B-X
reagent	B-X
for	B-X
imaging	B-X
RNA-DNA	B-X
hybrids	B-X
.	B-X
Surfactant	B-X
protein	B-X
(	B-X
SP	B-X
)	B-X
D	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
collectin	B-X
family	B-X
of	B-X
innate	B-X
immune	B-X
molecules	B-X
that	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
innate	B-X
host	B-X
defense	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
GH	B-X
circulates	B-X
in	B-X
the	B-X
plasma	B-X
partially	B-X
bound	B-X
with	B-X
a	B-X
GH-binding	B-X
protein	B-X
(	B-X
GHBP	B-X
)	B-X
,	B-X
but	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
the	B-X
GHBP	B-X
and	B-X
how	B-X
it	B-X
affects	B-X
GH	B-X
bioactivity	B-X
in	B-X
vivo	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
took	B-X
advantage	B-X
of	B-X
the	B-X
known	B-X
biological	B-X
action	B-X
of	B-X
exogenous	B-X
human	B-X
(	B-X
h	B-X
)	B-X
GH	B-X
to	B-X
inhibit	B-X
endogenous	B-X
rat	B-X
(	B-X
r	B-X
)	B-X
pulsatile	B-X
GH	B-X
release	B-X
and	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
combining	B-X
hGH	B-X
with	B-X
recombinant	B-X
hGHBP	B-X
on	B-X
this	B-X
response	B-X
in	B-X
normal	B-X
rats	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
disappearance	B-X
rate	B-X
of	B-X
hGH	B-X
was	B-X
markedly	B-X
slower	B-X
in	B-X
rats	B-X
administered	B-X
the	B-X
hGH	B-X
+	B-X
hGHBP	B-X
complex	B-X
;	B-X
plasma	B-X
hGH	B-X
concentrations	B-X
at	B-X
7	B-X
h	B-X
after	B-X
injection	B-X
were	B-X
14-fold	B-X
higher	B-X
than	B-X
those	B-X
in	B-X
animals	B-X
administered	B-X
hGH	B-X
alone	B-X
,	B-X
and	B-X
hGH	B-X
was	B-X
still	B-X
readily	B-X
detectable	B-X
up	B-X
to	B-X
24	B-X
h	B-X
after	B-X
injection	B-X
.	B-X

In	O
that	O
respect	O
,	O
few	O
investigators	O
have	O
detected	O
BMP	B-Protein
-	I-Protein
6	I-Protein
protein	O
in	O
humans	O
,	O
especially	O
in	O
non	O
-	O
pathogenic	O
tissue	O
.	O

The	O
possibility	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
production	O
in	O
human	O
B	O
-	O
cells	O
is	O
in	O
line	O
with	O
a	O
recent	O
work	O
that	O
reported	O
the	O
production	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
mouse	O
B	O
cells	O
,	O
infiltrating	O
the	O
bone	O
marrow	O
of	O
mice	O
with	O
inflammatory	O
arthritis	O
[	O
43	O
]	O
.	O

In	O
this	O
study	O
,	O
a	O
role	O
for	O
BMPs	O
in	O
the	O
inflammatoric	O
process	O
of	O
arthritis	O
was	O
suggested	O
.	O

The	O
upregulation	O
of	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
transcripts	O
after	O
IgM	O
-	O
crosslinking	O
is	O
of	O
pathophysiologic	O
interest	O
[	O
12	O
]	O
.	O

A	O
loss	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
responsiveness	O
has	O
been	O
suggested	O
to	O
be	O
a	O
critical	O
contribution	O
to	O
malignant	O
transformation	O
[	O
47	O
,	O
48	O
]	O
and	O
similar	O
oncogenic	O
mechanisms	O
have	O
been	O
postulated	O
for	O
BMPs	O
.	O

Lines	O
of	O
evidence	O
suggest	O
[	O
49	O
]	O
that	O
at	O
early	O
stages	O
of	O
carcinogenesis	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
is	O
not	O
a	O
tumour	O
promoter	O
,	O
but	O
suppresses	O
benign	O
and	O
malignant	O
tumour	O
outgrowth	O
.	O

These	O
findings	O
are	O
in	O
good	O
agreement	O
with	O
previous	O
findings	O
for	O
other	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
family	O
members	O
,	O
including	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
and	O
BMP	B-Protein
-	I-Protein
4	I-Protein
[	O
50	O
]	O
,	O
indicating	O
that	O
cellular	O
context	O
of	O
the	O
BMP	O
target	O
cell	O
might	O
define	O
the	O
various	O
observed	O
effects	O
.	O

In	O
contrast	O
to	O
the	O
upregulation	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
transcript	O
in	O
B	O
cells	O
,	O
we	O
were	O
not	O
able	O
to	O
detect	O
BMP	B-Protein
-	I-Protein
6	I-Protein
transcripts	O
in	O
human	O
peripheral	O
blood	O
CD4	B-Protein
+	O
or	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
resting	O
or	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
;	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
findings	O
in	O
T	O
cell	O
lines	O
[	O
20	O
]	O
and	O
T	O
cells	O
in	O
mice	O
[	O
43	O
]	O
.	O
<EOS>	B-X
Traditionally	B-X
,	B-X
mitogenic	B-X
lectins	B-X
such	B-X
as	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
have	B-X
been	B-X
used	B-X
for	B-X
polyclonal	B-X
T	B-X
cell	B-X
stimulation	B-X
.	B-X
A	B-X
more	B-X
physiologically	B-X
relevant	B-X
approach	B-X
uses	B-X
beads	B-X
coated	B-X
with	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
to	B-X
stimulate	B-X
T	B-X
cells	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
partially	B-X
mimics	B-X
stimulation	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
the	B-X
steps	B-X
involved	B-X
in	B-X
T	B-X
cell	B-X
stimulation	B-X
and	B-X
their	B-X
subsequent	B-X
in	B-X
vitro	B-X
expansion	B-X
using	B-X
anti-CD3/CD28	B-X
beads	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
peripheral	B-X
blood	B-X
mononucleated	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
with	B-X
anti-CD3/CD28-coated	B-X
magnetic	B-X
beads	B-X
promotes	B-X
intrinsic	B-X
resistance	B-X
to	B-X
HIV	B-X
as	B-X
well	B-X
as	B-X
cell	B-X
expansion	B-X
.	B-X

Other	O
potential	O
BMP	B-Protein
-	I-Protein
6	I-Protein
sources	O
for	O
mature	O
B	O
cells	O
in	O
vivo	O
might	O
be	O
other	O
cells	O
of	O
the	O
immune	O
system	O
or	O
tissue	O
with	O
contact	O
to	O
the	O
hematopoietic	O
system	O
.	O

One	O
well	O
recognized	O
source	O
for	O
BMP	B-Protein
-	I-Protein
6	I-Protein
production	O
is	O
the	O
human	O
bone	O
and	O
bone	O
marrow	O
stroma	O
[	O
51	O
,	O
8	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
noteworthy	O
that	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
highly	O
express	O
BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
[	O
52	O
]	O
,	O
and	O
vascular	O
endothelium	O
has	O
been	O
reported	O
to	O
produce	O
BMP	B-Protein
-	I-Protein
6	I-Protein
[	O
53	O
]	O
.	O

These	O
studies	O
might	O
imply	O
a	O
role	O
for	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
transendothelial	O
migration	O
of	O
B	O
cells	O
.	O

BMP	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
has	O
been	O
demonstrated	O
in	O
murine	O
macrophage	O
cell	O
lines	O
,	O
but	O
not	O
in	O
humans	O
[	O
54	O
]	O
.	O

In	O
accordance	O
with	O
these	O
findings	O
,	O
other	O
human	O
cell	O
lines	O
of	O
neutrophil	O
and	O
monocytic	O
origin	O
have	O
been	O
described	O
to	O
be	O
negative	O
for	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
transcript	O
[	O
20	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
currently	O
no	O
report	O
about	O
BMP	B-Protein
-	I-Protein
6	I-Protein
production	O
of	O
human	O
dendritic	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induces	O
activation	O
of	O
intracellular	O
Smad	O
signalling	O
in	O
mature	O
human	O
B	O
-	O
cells	O
with	O
consecutive	O
production	O
of	O
Id1	B-Protein
protein	O
.	O

Furthermore	O
,	O
we	O
report	O
that	O
BMP	B-Protein
-	I-Protein
6	I-Protein
has	O
an	O
antiproliferative	O
effect	O
in	O
B	O
cells	O
stimulated	O
with	O
anti	O
-	O
IgM	O
alone	O
or	O
the	O
combined	O
action	O
of	O
anti	O
-	O
IgM	O
and	O
CD40L	B-Protein
.	O
<EOS>	B-X
An	B-X
EPIC	B-X
label-free	B-X
phenotypic	B-X
platform	B-X
was	B-X
developed	B-X
to	B-X
explore	B-X
B	B-X
cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
and	B-X
CD40R-mediated	B-X
B	B-X
cell	B-X
activation	B-X
.	B-X
The	B-X
phenotypic	B-X
assay	B-X
measured	B-X
the	B-X
association	B-X
of	B-X
RL	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
B	B-X
cells	B-X
expressing	B-X
lymphocyte	B-X
function-associated	B-X
antigen	B-X
1	B-X
(	B-X
LFA-1	B-X
)	B-X
to	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
1	B-X
(	B-X
ICAM-1	B-X
)	B-X
-coated	B-X
EPIC	B-X
plates	B-X
.	B-X
Anti-IgM	B-X
(	B-X
immunoglobulin	B-X
M	B-X
)	B-X
mediated	B-X
BCR	B-X
activation	B-X
elicited	B-X
a	B-X
response	B-X
that	B-X
was	B-X
blocked	B-X
by	B-X
LFA-1/ICAM-1	B-X
specific	B-X
inhibitors	B-X
and	B-X
a	B-X
panel	B-X
of	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
(	B-X
BTK	B-X
)	B-X
inhibitors	B-X
.	B-X
LFA-1/ICAM-1	B-X
association	B-X
was	B-X
further	B-X
increased	B-X
on	B-X
coapplication	B-X
of	B-X
anti-IgM	B-X
and	B-X
mega	B-X
CD40L	B-X
when	B-X
compared	B-X
to	B-X
individual	B-X
application	B-X
of	B-X
either	B-X
.	B-X
Anti-IgM	B-X
,	B-X
mega	B-X
CD40L	B-X
,	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
both	B-X
displayed	B-X
distinct	B-X
kinetic	B-X
profiles	B-X
that	B-X
were	B-X
inhibited	B-X
by	B-X
treatment	B-X
with	B-X
a	B-X
BTK	B-X
inhibitor	B-X
.	B-X
We	B-X
also	B-X
established	B-X
a	B-X
FLIPR-based	B-X
assay	B-X
to	B-X
measure	B-X
B	B-X
cell	B-X
activation	B-X
in	B-X
Ramos	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
B	B-X
cells	B-X
and	B-X
an	B-X
RL	B-X
cell	B-X
line	B-X
.	B-X
Anti-IgM-mediated	B-X
BCR	B-X
activation	B-X
elicited	B-X
a	B-X
robust	B-X
calcium	B-X
response	B-X
that	B-X
was	B-X
inhibited	B-X
by	B-X
a	B-X
panel	B-X
of	B-X
BTK	B-X
inhibitors	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
FLIPR	B-X
,	B-X
the	B-X
EPIC	B-X
assay	B-X
has	B-X
the	B-X
propensity	B-X
to	B-X
identify	B-X
inhibitors	B-X
of	B-X
both	B-X
BCR	B-X
and	B-X
CD40R-mediated	B-X
B	B-X
cell	B-X
activation	B-X
and	B-X
may	B-X
provide	B-X
more	B-X
pharmacological	B-X
depth	B-X
or	B-X
novel	B-X
mechanisms	B-X
of	B-X
action	B-X
for	B-X
inhibition	B-X
of	B-X
B	B-X
cell	B-X
activation	B-X
.	B-X

Additionally	O
,	O
BMP	B-Protein
-	I-Protein
6	I-Protein
induces	O
cell	O
death	O
in	O
activated	O
memory	O
B	O
cells	O
and	O
Ramos	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
rationale	O
to	O
further	O
examine	O
the	O
role	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
signalling	O
in	O
normal	O
B	O
cell	O
biology	O
as	O
well	O
as	O
in	O
pathologic	O
conditions	O
like	O
B	O
cell	O
malignancies	O
and	O
autoimmune	O
disorders	O
.	O

Cell	O
culture	O
<EOS>	B-X
This	B-X
overview	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
to	B-X
provide	B-X
an	B-X
unmet	B-X
need	B-X
for	B-X
information	B-X
on	B-X
best	B-X
practices	B-X
in	B-X
animal	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
target	B-X
audience	B-X
primarily	B-X
consists	B-X
of	B-X
entry-level	B-X
scientists	B-X
with	B-X
minimal	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
It	B-X
also	B-X
include	B-X
scientists	B-X
,	B-X
journalists	B-X
,	B-X
and	B-X
educators	B-X
with	B-X
some	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
,	B-X
but	B-X
in	B-X
need	B-X
of	B-X
a	B-X
refresher	B-X
in	B-X
best	B-X
practices	B-X
.	B-X
The	B-X
articles	B-X
will	B-X
be	B-X
published	B-X
in	B-X
this	B-X
journal	B-X
over	B-X
a	B-X
six-month	B-X
period	B-X
and	B-X
will	B-X
emphasize	B-X
best	B-X
practices	B-X
in	B-X
:	B-X
(	B-X
1	B-X
)	B-X
media	B-X
selection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
use	B-X
and	B-X
evaluation	B-X
of	B-X
animal	B-X
serum	B-X
as	B-X
a	B-X
component	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
;	B-X
(	B-X
3	B-X
)	B-X
receipt	B-X
of	B-X
new	B-X
cells	B-X
into	B-X
the	B-X
laboratory	B-X
;	B-X
(	B-X
4	B-X
)	B-X
naming	B-X
cell	B-X
lines	B-X
;	B-X
(	B-X
5	B-X
)	B-X
authenticating	B-X
cell	B-X
line	B-X
identity	B-X
;	B-X
(	B-X
6	B-X
)	B-X
detecting	B-X
and	B-X
mitigating	B-X
risk	B-X
of	B-X
cell	B-X
culture	B-X
contamination	B-X
;	B-X
(	B-X
7	B-X
)	B-X
cryopreservation	B-X
and	B-X
thawing	B-X
of	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
8	B-X
)	B-X
storing	B-X
and	B-X
shipping	B-X
viable	B-X
cells	B-X
.	B-X

If	O
not	O
specified	O
,	O
all	O
cells	O
were	O
cultured	O
in	O
X	O
-	O
VIVO	O
15	O
(	O
TM	O
)	O
(	O
BioWhittaker	O
,	O
Verviers	O
,	O
Belgium	O
)	O
serum	O
-	O
free	O
medium	O
at	O
37degreesC	O
and	O
5	O
%	O
CO2	O
in	O
air	O
.	O

Peripheral	O
blood	O
was	O
provided	O
by	O
the	O
Blood	O
Bank	O
at	O
Buskerud	O
Regional	O
Hospital	O
with	O
formal	O
agreement	O
by	O
the	O
patients	O
,	O
and	O
approval	O
by	O
the	O
regional	O
ethics	O
committee	O
.	O

Highly	O
purified	O
resting	O
human	O
B	O
-	O
lymphocytes	O
(	O
CD19	B-Protein
+	O
cells	O
)	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
by	O
rosetting	O
with	O
immunomagnetic	O
beads	O
(	O
Dynabeads	O
M450	O
;	O
Dynal	O
,	O
Oslo	O
,	O
Norway	O
)	O
as	O
described	O
[	O
55	O
]	O
.	O

This	O
procedure	O
yields	O
less	O
than	O
0	O
.	O
5	O
%	O
T	O
cells	O
,	O
0	O
.	O
1	O
%	O
NK	O
cells	O
,	O
and	O
0	O
.	O
5	O
%	O
monocytes	O
as	O
judged	O
by	O
indirect	O
immunofluorescence	O
staining	O
.	O

The	O
following	O
cell	O
lines	O
from	O
human	O
lymphoid	O
malignancies	O
were	O
maintained	O
in	O
RPMI	O
1640	O
(	O
PAA	O
Laboratories	O
GmbH	O
,	O
Pasching	O
,	O
Austria	O
)	O
supplemented	O
with	O
10	O
%	O
foetal	O
bovine	O
serum	O
(	O
FCS	O
)	O
,	O
100	O
units	O
/	O
ml	O
penicillin	O
G	O
,	O
and	O
100	O
units	O
/	O
ml	O
of	O
streptomycin	O
sulphate	O
,	O
but	O
serum	O
-	O
starved	O
for	O
at	O
least	O
four	O
hours	O
and	O
cultured	O
in	O
X	O
-	O
VIVO	O
15	O
(	O
TM	O
)	O
when	O
included	O
in	O
experiments	O
:	O
EBV	O
-	O
negative	O
BL	O
cell	O
lines	O
Ramos	O
(	O
ECACC	O
85030802	O
)	O
,	O
HL60	O
(	O
JCRB0085	O
)	O
.	O

Growth	O
factors	O
/	O
supplements	O
<EOS>	B-X
Colostrum	B-X
is	B-X
the	B-X
milk	B-X
produced	B-X
during	B-X
the	B-X
first	B-X
few	B-X
days	B-X
after	B-X
birth	B-X
and	B-X
contains	B-X
high	B-X
levels	B-X
of	B-X
immunoglobulins	B-X
,	B-X
antimicrobial	B-X
peptides	B-X
,	B-X
and	B-X
growth	B-X
factors	B-X
.	B-X
However	B-X
,	B-X
oocyte-GC/CC	B-X
communication	B-X
is	B-X
bidirectional	B-X
with	B-X
the	B-X
oocyte	B-X
secreting	B-X
potent	B-X
growth	B-X
factors	B-X
that	B-X
act	B-X
locally	B-X
to	B-X
direct	B-X
the	B-X
differentiation	B-X
and	B-X
function	B-X
of	B-X
CCs	B-X
.	B-X
Two	B-X
important	B-X
oocyte-secreted	B-X
factors	B-X
(	B-X
OSFs	B-X
)	B-X
are	B-X
growth-differentiation	B-X
factor	B-X
9	B-X
and	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
15	B-X
,	B-X
which	B-X
activate	B-X
signaling	B-X
pathways	B-X
in	B-X
CCs	B-X
to	B-X
regulate	B-X
key	B-X
genes	B-X
and	B-X
cellular	B-X
processes	B-X
required	B-X
for	B-X
CC	B-X
differentiation	B-X
and	B-X
for	B-X
CCs	B-X
to	B-X
maintain	B-X
their	B-X
distinctive	B-X
phenotype	B-X
.	B-X
Apart	B-X
from	B-X
the	B-X
basal	B-X
media	B-X
,	B-X
supplements	B-X
in	B-X
the	B-X
medium	B-X
and	B-X
various	B-X
physical	B-X
factors	B-X
promote	B-X
the	B-X
cell	B-X
growth	B-X
.	B-X
With	B-X
this	B-X
context	B-X
,	B-X
the	B-X
study	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
optimize	B-X
the	B-X
culture	B-X
medium	B-X
using	B-X
various	B-X
supplements	B-X
and	B-X
physical	B-X
factors	B-X
for	B-X
the	B-X
growth	B-X
of	B-X
hemocytes	B-X
culture	B-X
from	B-X
Penaeus	B-X
vannamei	B-X
.	B-X

The	O
following	O
reagents	O
were	O
used	O
at	O
indicated	O
concentrations	O
:	O
recombinant	O
human	O
(	O
rhu	O
)	O
BMP	B-Protein
-	I-Protein
6	I-Protein
(	O
1	O
mug	O
/	O
ml	O
,	O
if	O
not	O
specified	O
otherwise	O
)	O
,	O
rhu	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
/	O
ALK	B-Protein
-	I-Protein
6	I-Protein
/	O
Fc	O
Chimera	O
(	O
5	O
mug	O
/	O
ml	O
)	O
,	O
rhu	O
BMPR	B-Protein
-	I-Protein
II	I-Protein
/	O
Fc	O
Chimera	O
(	O
5	O
mug	O
/	O
ml	O
)	O
,	O
and	O
recombinant	O
mouse	O
Noggin	B-Protein
(	O
5	O
mug	O
/	O
ml	O
)	O
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
;	O
Anti	O
-	O
IgM	O
F	O
(	O
ab	O
)	O
2	O
fragments	O
of	O
rabbit	O
polyclonal	O
antibodies	O
to	O
human	O
IgM	O
heavy	O
chain	O
(	O
37	O
.	O
5	O
mug	O
/	O
ml	O
)	O
was	O
obtained	O
from	O
Dako	O
,	O
Copenhagen	O
,	O
Denmark	O
and	O
rhu	O
CD40	B-Protein
ligand	I-Protein
(	O
CD40L	B-Protein
,	O
10	O
ng	O
/	O
ml	O
)	O
was	O
a	O
gift	O
from	O
Immunex	O
Corp	O
.	O

(	O
Seattle	O
,	O
WA	O
)	O
.	O

Antibodies	O
used	O
for	O
flow	O
cytometric	O
analysis	O
and	O
immunoblot	O
analysis	O
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
intracellular	B-X
staining	B-X
techniques	B-X
,	B-X
cytometer	B-X
technology	B-X
,	B-X
fluorescent	B-X
reagents	B-X
,	B-X
and	B-X
antibody	B-X
production	B-X
have	B-X
expanded	B-X
the	B-X
number	B-X
of	B-X
intracellular	B-X
antigens	B-X
that	B-X
can	B-X
be	B-X
analyzed	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
convenient	B-X
flow-cytometric	B-X
and	B-X
immunoblot	B-X
assays	B-X
for	B-X
monitoring	B-X
ADP-ribosylation	B-X
of	B-X
cell	B-X
surface	B-X
proteins	B-X
on	B-X
living	B-X
cells	B-X
by	B-X
exploiting	B-X
the	B-X
capacity	B-X
of	B-X
ARTs	B-X
to	B-X
utilize	B-X
etheno-NAD	B-X
as	B-X
substrate	B-X
.	B-X
Etheno-ADP-ribosylation	B-X
of	B-X
cell	B-X
surface	B-X
proteins	B-X
can	B-X
be	B-X
detected	B-X
by	B-X
flow	B-X
cytometry	B-X
with	B-X
1G4	B-X
,	B-X
a	B-X
monoclonal	B-X
antibody	B-X
specific	B-X
for	B-X
ethenoadenosine	B-X
.	B-X
The	B-X
flow-cytometric	B-X
1G4	B-X
staining	B-X
assay	B-X
can	B-X
be	B-X
used	B-X
to	B-X
identify	B-X
subpopulations	B-X
of	B-X
cells	B-X
expressing	B-X
cell	B-X
surface	B-X
ART	B-X
activity	B-X
and	B-X
to	B-X
select	B-X
ART	B-X
(	B-X
hi	B-X
)	B-X
cell	B-X
variants	B-X
.	B-X
The	B-X
immunoblot	B-X
1G4	B-X
staining	B-X
assay	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
identify	B-X
etheno-ADP-ribosylated	B-X
target	B-X
proteins	B-X
.	B-X

Antibodies	O
against	O
the	O
human	O
BMP	O
-	O
receptors	O
Act	B-Protein
-	I-Protein
RIA	I-Protein
,	O
BMP	B-Protein
-	I-Protein
RIB	I-Protein
,	O
BMPR	B-Protein
-	I-Protein
II	I-Protein
,	O
Act	B-Protein
-	I-Protein
RIIA	I-Protein
and	O
Act	B-Protein
-	I-Protein
RIIb	I-Protein
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
.	O

Detection	O
of	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
-	O
protein	O
has	O
been	O
tried	O
with	O
the	O
following	O
antibodies	O
:	O
goat	O
polyclonal	O
anti	O
-	O
BMP	B-Protein
-	I-Protein
6	I-Protein
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
,	O
monoclonal	O
mouse	O
anti	O
-	O
BMP	B-Protein
-	I-Protein
6	I-Protein
and	O
polyclonal	O
goat	O
anti	O
-	O
BMP	B-Protein
-	I-Protein
6	I-Protein
from	O
R	O
&	O
D	O
Systems	O
(	O
Abingdon	O
,	O
UK	O
)	O
,	O
and	O
mouse	O
monoclonal	O
anti	O
-	O
BMP	B-Protein
-	I-Protein
6	I-Protein
(	O
Chemicon	O
International	O
Inc	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Characterisation	O
of	O
BMP	O
-	O
signalling	O
pathways	O
was	O
done	O
by	O
use	O
of	O
anti	O
-	O
phospho	O
-	O
Smad1	B-Protein
,	O
-	B-Protein
5	I-Protein
,	O
-	O
and	O
8	B-Protein
polyclonal	O
antibody	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Expression	O
levels	O
of	O
Id1	B-Protein
-	O
3	B-Protein
proteins	O
were	O
detected	O
with	O
polyclonal	O
rabbit	O
antibody	O
and	O
detection	O
was	O
blocked	O
with	O
blocking	O
peptide	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

As	O
secondary	O
antibodies	O
served	O
anti	O
-	O
mouse	O
,	O
anti	O
-	O
goat	O
or	O
anti	O
-	O
rabbit	O
IgG	O
-	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
from	O
Dakocytomation	O
AS	O
(	O
Copenhagen	O
,	O
Denmark	O
)	O
for	O
immunoblot	O
analysis	O
.	O

Anti	O
-	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
from	O
Santa	O
-	O
Cruz	O
.	O

From	O
Becton	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
)	O
,	O
we	O
purchased	O
anti	O
-	O
CD19	B-Protein
-	O
PE	O
,	O
anti	O
-	O
CD19	B-Protein
-	O
FITC	O
.	O

The	O
antibodies	O
used	O
for	O
cell	O
sorting	O
were	O
anti	O
-	O
CD19	B-Protein
PC5	O
from	O
Immunotech	O
SA	O
(	O
Marseille	O
,	O
France	O
)	O
and	O
anti	O
-	O
CD27	B-Protein
PE	O
from	O
Becton	O
Dickinson	O
,	O
Biosciences	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cell	O
sorting	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
and	B-X
cell	B-X
sorting	B-X
are	B-X
well-established	B-X
technologies	B-X
in	B-X
clinical	B-X
diagnostics	B-X
and	B-X
biomedical	B-X
research	B-X
.	B-X
This	B-X
chapter	B-X
will	B-X
begin	B-X
with	B-X
a	B-X
discussion	B-X
of	B-X
basic	B-X
principles	B-X
of	B-X
flow	B-X
cytometry	B-X
and	B-X
cell	B-X
sorting	B-X
,	B-X
including	B-X
a	B-X
technical	B-X
description	B-X
of	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
the	B-X
performance	B-X
of	B-X
these	B-X
instruments	B-X
.	B-X
The	B-X
remaining	B-X
sections	B-X
will	B-X
then	B-X
be	B-X
divided	B-X
into	B-X
clinical-	B-X
and	B-X
research-based	B-X
applications	B-X
of	B-X
flow	B-X
cytometry	B-X
and	B-X
cell	B-X
sorting	B-X
,	B-X
highlighting	B-X
salient	B-X
studies	B-X
that	B-X
illustrate	B-X
the	B-X
versatility	B-X
of	B-X
this	B-X
indispensable	B-X
technology	B-X
.	B-X
Image-based	B-X
cell	B-X
sorting	B-X
(	B-X
IBCS	B-X
)	B-X
systems	B-X
utilize	B-X
microfluidic	B-X
or	B-X
microarray	B-X
platforms	B-X
,	B-X
each	B-X
having	B-X
unique	B-X
characteristics	B-X
and	B-X
applications	B-X
.	B-X
Cell	B-X
sorting	B-X
guided	B-X
by	B-X
high-content	B-X
image	B-X
information	B-X
has	B-X
far-reaching	B-X
implications	B-X
in	B-X
biomedical	B-X
research	B-X
,	B-X
clinical	B-X
medicine	B-X
,	B-X
and	B-X
pharmaceutical	B-X
development	B-X
.	B-X

Highly	O
purified	O
CD19	B-Protein
+	O
CD27	B-Protein
-	O
or	O
CD19	B-Protein
+	O
CD27	B-Protein
+	O
cells	O
were	O
obtained	O
by	O
staining	O
CD19	B-Protein
+	O
cells	O
with	O
anti	O
-	O
CD27	B-Protein
PE	O
and	O
CD19	B-Protein
PC5	O
mAbs	O
for	O
30	O
minutes	O
at	O
4degreesC	O
,	O
followed	O
by	O
washing	O
with	O
PBS	O
and	O
sorting	O
on	O
FACS	O
DiVa	O
from	O
Becton	O
Dickinson	O
.	O
<EOS>	B-X
Correspondingly	B-X
,	B-X
most	B-X
CVID	B-X
patients	B-X
exhibit	B-X
a	B-X
severely	B-X
decreased	B-X
proportion	B-X
of	B-X
class	B-X
switched	B-X
memory	B-X
B	B-X
cells	B-X
(	B-X
CD19+CD27+IgD-IgM-IgG+	B-X
or	B-X
IgA+	B-X
)	B-X
in	B-X
their	B-X
peripheral	B-X
blood	B-X
(	B-X
CVID	B-X
type	B-X
I	B-X
)	B-X
.	B-X
We	B-X
previously	B-X
identified	B-X
a	B-X
subgroup	B-X
of	B-X
CVID	B-X
patients	B-X
showing	B-X
a	B-X
significantly	B-X
reduced	B-X
expression	B-X
of	B-X
CD86	B-X
and	B-X
CD137	B-X
following	B-X
activation	B-X
in	B-X
vitro	B-X
of	B-X
PBMC	B-X
or	B-X
purified	B-X
B	B-X
cells	B-X
(	B-X
CD19+	B-X
)	B-X
with	B-X
anti-IgM	B-X
plus	B-X
IL-2	B-X
.	B-X
Here	B-X
we	B-X
extend	B-X
our	B-X
previous	B-X
studies	B-X
by	B-X
asking	B-X
whether	B-X
highly	B-X
purified	B-X
,	B-X
cell-sorted	B-X
naive	B-X
B	B-X
cells	B-X
show	B-X
already	B-X
an	B-X
expression	B-X
defect	B-X
of	B-X
B	B-X
cell	B-X
surface	B-X
molecules	B-X
relevant	B-X
in	B-X
activation	B-X
(	B-X
CD39	B-X
,	B-X
CD69	B-X
)	B-X
,	B-X
differentiation	B-X
(	B-X
CD24	B-X
,	B-X
CD27	B-X
,	B-X
CD38	B-X
)	B-X
or	B-X
T-B	B-X
interaction	B-X
(	B-X
CD25	B-X
,	B-X
CD70	B-X
,	B-X
CD86	B-X
)	B-X
.	B-X
We	B-X
stimulated	B-X
cell-sorted	B-X
,	B-X
naive	B-X
B	B-X
cells	B-X
(	B-X
CD19+CD27-IgM+IgDhighIgG-IgA-	B-X
)	B-X
from	B-X
10	B-X
CVID	B-X
patients	B-X
and	B-X
10	B-X
healthy	B-X
controls	B-X
for	B-X
4	B-X
days	B-X
with	B-X
anti-IgM	B-X
plus	B-X
IL-2	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
autologous	B-X
CD4+	B-X
T	B-X
cells	B-X
and	B-X
measured	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
referred	B-X
surface	B-X
molecules	B-X
.	B-X
Based	B-X
on	B-X
reduced	B-X
or	B-X
normal	B-X
numbers	B-X
of	B-X
switched	B-X
memory	B-X
B	B-X
cells	B-X
the	B-X
CVID	B-X
patients	B-X
had	B-X
previously	B-X
been	B-X
classified	B-X
into	B-X
eight	B-X
type	B-X
I	B-X
patients	B-X
and	B-X
two	B-X
type	B-X
II	B-X
patients	B-X
,	B-X
respectively	B-X
.	B-X
Interestingly	B-X
,	B-X
only	B-X
the	B-X
molecules	B-X
CD25	B-X
,	B-X
CD70	B-X
and	B-X
CD86	B-X
,	B-X
all	B-X
relevant	B-X
in	B-X
cognate	B-X
T-B	B-X
interaction	B-X
,	B-X
showed	B-X
a	B-X
significantly	B-X
lower	B-X
expression	B-X
in	B-X
naive	B-X
B	B-X
cells	B-X
from	B-X
CVID	B-X
patients	B-X
compared	B-X
to	B-X
controls	B-X
.	B-X
While	B-X
coculture	B-X
with	B-X
autologous	B-X
CD4+	B-X
T	B-X
cells	B-X
normalized	B-X
the	B-X
CD25	B-X
expression	B-X
,	B-X
CD70	B-X
and	B-X
CD86	B-X
expression	B-X
remained	B-X
subnormal	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
eight	B-X
CVID	B-X
patients	B-X
of	B-X
type	B-X
I	B-X
.	B-X
These	B-X
findings	B-X
strongly	B-X
suggest	B-X
an	B-X
intrinsic	B-X
signalling	B-X
or	B-X
expression	B-X
defect	B-X
for	B-X
CD70/CD86	B-X
at	B-X
the	B-X
level	B-X
of	B-X
naive	B-X
B	B-X
cells	B-X
in	B-X
type	B-X
I	B-X
CVID	B-X
patients	B-X
.	B-X

Western	O
-	O
blot	O
analysis	O
<EOS>	B-X
Appropriate	B-X
protein	B-X
extraction	B-X
method	B-X
,	B-X
electrophoresis	B-X
,	B-X
and	B-X
transfer	B-X
of	B-X
proteins	B-X
,	B-X
immunodetection	B-X
of	B-X
blotted	B-X
protein	B-X
by	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
ultimate	B-X
step	B-X
of	B-X
imaging	B-X
and	B-X
analyzing	B-X
the	B-X
data	B-X
is	B-X
nothing	B-X
short	B-X
of	B-X
a	B-X
symphony	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Electrophoresis	B-X
and	B-X
the	B-X
following	B-X
western	B-X
blot	B-X
analysis	B-X
are	B-X
indispensable	B-X
to	B-X
investigate	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
exposed	B-X
to	B-X
nanoparticles	B-X
or	B-X
nanomaterials	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
select	B-X
a	B-X
good	B-X
blocking	B-X
agent	B-X
and	B-X
an	B-X
appropriate	B-X
pair	B-X
of	B-X
primary	B-X
and	B-X
peroxidase-tagged	B-X
secondary	B-X
antibodies	B-X
to	B-X
obtain	B-X
good	B-X
results	B-X
in	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
the	B-X
whole	B-X
process	B-X
of	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
from	B-X
sample	B-X
preparation	B-X
to	B-X
quantitative	B-X
measurement	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
described	B-X
.	B-X

B	O
cells	O
from	O
peripheral	O
blood	O
or	O
cultured	O
cell	O
-	O
lines	O
were	O
lysed	O
in	O
lysis	O
buffer	O
(	O
glycerol	O
10	O
%	O
,	O
beta	O
-	O
mercaptoethanol	O
5	O
%	O
,	O
0	O
.	O
0625	O
M	O
Tris	O
-	O
HCL	O
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
sodium	O
dodecyl	O
sulphate	O
[	O
SDS	O
]	O
2	O
.	O
5	O
%	O
w	O
/	O
vol	O
)	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
identification	B-X
of	B-X
B	B-X
cells	B-X
in	B-X
1965	B-X
(	B-X
Cooper	B-X
et	B-X
al	B-X
.	B-X
1965	B-X
)	B-X
,	B-X
three	B-X
has	B-X
been	B-X
tremendous	B-X
progress	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
B	B-X
cell	B-X
development	B-X
,	B-X
maturation	B-X
and	B-X
function	B-X
.	B-X
A	B-X
number	B-X
of	B-X
B	B-X
cell	B-X
subpopulations	B-X
,	B-X
including	B-X
B-1	B-X
,	B-X
B-2	B-X
and	B-X
regulatory	B-X
B	B-X
cells	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
B-1	B-X
cells	B-X
mainly	B-X
originate	B-X
from	B-X
the	B-X
fetal	B-X
liver	B-X
and	B-X
contain	B-X
B-1a	B-X
and	B-X
B-1b	B-X
subsets	B-X
.	B-X
B-2	B-X
cells	B-X
are	B-X
derived	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
and	B-X
can	B-X
be	B-X
further	B-X
classified	B-X
into	B-X
follicular	B-X
B	B-X
(	B-X
FOB	B-X
)	B-X
and	B-X
marginal	B-X
zone	B-X
B	B-X
(	B-X
MZB	B-X
)	B-X
cells	B-X
.	B-X
Regulatory	B-X
B	B-X
cells	B-X
(	B-X
Bregs	B-X
)	B-X
function	B-X
to	B-X
suppress	B-X
immune	B-X
responses	B-X
,	B-X
primarily	B-X
by	B-X
production	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokine	B-X
IL-10	B-X
.	B-X
B	B-X
cell	B-X
tolerance	B-X
is	B-X
established	B-X
at	B-X
several	B-X
checkpoints	B-X
,	B-X
during	B-X
B	B-X
cell	B-X
development	B-X
in	B-X
the	B-X
BM	B-X
(	B-X
central	B-X
tolerance	B-X
)	B-X
as	B-X
well	B-X
as	B-X
during	B-X
B	B-X
cell	B-X
maturation	B-X
and	B-X
activation	B-X
in	B-X
the	B-X
periphery	B-X
(	B-X
peripheral	B-X
tolerance	B-X
)	B-X
.	B-X
This	B-X
chapter	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
important	B-X
processes	B-X
during	B-X
the	B-X
development	B-X
and	B-X
maturation	B-X
of	B-X
B-1	B-X
and	B-X
B-2	B-X
cells	B-X
.	B-X

Total	O
protein	O
(	O
30	O
-	O
100	O
mug	O
)	O
from	O
each	O
sample	O
was	O
run	O
on	O
10	O
%	O
or	O
12	O
%	O
SDS	O
/	O
polyacrylamide	O
(	O
SDS	O
/	O
PAGE	O
)	O
gels	O
and	O
blotted	O
onto	O
nitrocellulose	O
filters	O
(	O
Protran	O
;	O
Schleicher	O
&	O
Schuell	O
GmbH	O
,	O
Dassel	O
,	O
Germany	O
)	O
.	O

Blocking	O
,	O
washing	O
and	O
incubation	O
of	O
the	O
filters	O
with	O
primary	O
antibodies	O
were	O
done	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocols	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
.	O

After	O
washing	O
with	O
TBS	O
/	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
(	O
TBS	O
-	O
T	O
)	O
,	O
the	O
filters	O
were	O
incubated	O
with	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
coupled	O
to	O
relevant	O
secondary	O
antibodies	O
(	O
see	O
above	O
)	O
for	O
60	O
minutes	O
at	O
RT	O
.	O

Enzyme	O
activity	O
was	O
visualised	O
by	O
the	O
enhanced	O
chemiluminescence	O
system	O
,	O
ECL	O
+	O
PLUS	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Densitometric	O
analysis	O
was	O
performed	O
by	O
scanning	O
hyperfilms	O
on	O
a	O
Personal	O
Densitometer	O
SI	O
(	O
Molecular	O
Dynamics	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Quantification	O
of	O
Id1	B-Protein
,	O
Id2	B-Protein
and	O
Id3	B-Protein
protein	O
was	O
calculated	O
by	O
normalizing	O
the	O
specific	O
protein	O
bands	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
using	O
Image	O
Quant	O
5	O
.	O
5	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Analysis	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
which	B-X
induce	B-X
bone	B-X
formation	B-X
from	B-X
mesenchymal	B-X
cells	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
BMPs	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
as	B-X
well	B-X
as	B-X
in	B-X
bone	B-X
tissue	B-X
has	B-X
recently	B-X
been	B-X
reported	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
BMP-6	B-X
is	B-X
neuron-specific	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
temporal	B-X
and	B-X
spatial	B-X
expression	B-X
patterns	B-X
of	B-X
BMP-6	B-X
mRNA	B-X
in	B-X
the	B-X
developing	B-X
rat	B-X
and	B-X
gerbil	B-X
brain	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
BMP-6	B-X
transcript	B-X
level	B-X
was	B-X
specifically	B-X
high	B-X
from	B-X
newborn	B-X
to	B-X
3	B-X
weeks	B-X
after	B-X
birth	B-X
compared	B-X
with	B-X
those	B-X
in	B-X
fetal	B-X
and	B-X
adult	B-X
rats	B-X
.	B-X
In	B-X
situ	B-X
hybridization	B-X
showed	B-X
that	B-X
most	B-X
of	B-X
the	B-X
neurons	B-X
possessed	B-X
high	B-X
levels	B-X
of	B-X
BMP-6	B-X
mRNA	B-X
in	B-X
the	B-X
neonatal	B-X
brain	B-X
,	B-X
while	B-X
in	B-X
the	B-X
adult	B-X
brain	B-X
,	B-X
BMP-6	B-X
mRNA	B-X
level	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
most	B-X
of	B-X
the	B-X
neurons	B-X
except	B-X
those	B-X
in	B-X
hippocampus	B-X
which	B-X
retained	B-X
high	B-X
levels	B-X
.	B-X
Furthermore	B-X
,	B-X
to	B-X
show	B-X
that	B-X
the	B-X
BMP-6	B-X
expression	B-X
was	B-X
specific	B-X
to	B-X
neurons	B-X
,	B-X
we	B-X
induced	B-X
delayed	B-X
neuronal	B-X
cell	B-X
death	B-X
and	B-X
compensative	B-X
glial	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
gerbil	B-X
hippocampus	B-X
by	B-X
transient	B-X
ischemia	B-X
.	B-X
Our	B-X
findings	B-X
collectively	B-X
suggest	B-X
that	B-X
BMP-6	B-X
is	B-X
neuron-specific	B-X
and	B-X
may	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
neuronal	B-X
maturation	B-X
and	B-X
synapse	B-X
formation	B-X
.	B-X

Endogenous	O
expression	O
of	O
the	O
BMP	B-Protein
-	I-Protein
6	I-Protein
gene	O
was	O
examined	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
protein-6	B-X
(	B-X
BMP-6	B-X
)	B-X
is	B-X
critically	B-X
involved	B-X
in	B-X
many	B-X
developmental	B-X
processes	B-X
.	B-X
Recent	B-X
studies	B-X
indicate	B-X
that	B-X
BMP-6	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
tumor	B-X
differentiation	B-X
and	B-X
metastasis	B-X
.	B-X
Although	B-X
accumulated	B-X
evidence	B-X
has	B-X
shown	B-X
the	B-X
bone	B-X
anabolic	B-X
effects	B-X
of	B-X
bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
that	B-X
were	B-X
exogenously	B-X
applied	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
roles	B-X
of	B-X
endogenous	B-X
BMPs	B-X
during	B-X
bone	B-X
formation	B-X
remain	B-X
to	B-X
be	B-X
clarified	B-X
.	B-X
This	B-X
study	B-X
initially	B-X
investigated	B-X
expression	B-X
patterns	B-X
of	B-X
BMPs	B-X
in	B-X
the	B-X
mouse	B-X
long	B-X
bone	B-X
and	B-X
found	B-X
that	B-X
BMP2	B-X
and	B-X
BMP6	B-X
were	B-X
the	B-X
main	B-X
subtypes	B-X
expressed	B-X
in	B-X
hypertrophic	B-X
chondrocytes	B-X
that	B-X
induce	B-X
endochondral	B-X
bone	B-X
formation	B-X
.	B-X
We	B-X
then	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
combination	B-X
of	B-X
these	B-X
BMPs	B-X
in	B-X
bone	B-X
formation	B-X
in	B-X
vivo	B-X
by	B-X
generating	B-X
the	B-X
compound-deficient	B-X
mice	B-X
(	B-X
Bmp2+/-	B-X
;	B-X
Bmp6-/-	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
fetal	B-X
and	B-X
adult	B-X
compound-deficient	B-X
mice	B-X
showed	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
trabecular	B-X
bone	B-X
volume	B-X
with	B-X
suppressed	B-X
bone	B-X
formation	B-X
,	B-X
but	B-X
normal	B-X
bone	B-X
resorption	B-X
,	B-X
whereas	B-X
the	B-X
single	B-X
deficient	B-X
mice	B-X
(	B-X
Bmp2+/-	B-X
or	B-X
Bmp6-/-	B-X
)	B-X
did	B-X
not	B-X
.	B-X
In	B-X
the	B-X
cultures	B-X
of	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
however	B-X
,	B-X
there	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
osteogenic	B-X
differentiation	B-X
between	B-X
WT	B-X
and	B-X
compound-deficient	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
the	B-X
exogenous	B-X
BMP2	B-X
.	B-X
We	B-X
thus	B-X
concluded	B-X
that	B-X
endogenous	B-X
BMP2	B-X
and	B-X
BMP6	B-X
cooperatively	B-X
play	B-X
pivotal	B-X
roles	B-X
in	B-X
bone	B-X
formation	B-X
under	B-X
both	B-X
physiological	B-X
and	B-X
pathological	B-X
conditions	B-X
.	B-X

Total	O
RNA	O
was	O
isolated	O
using	O
Absolutely	O
RNA	O
(	O
TM	O
)	O
RT	O
-	O
PCR	O
Miniprep	O
Kit	O
(	O
Stratagene	O
Europe	O
,	O
Amsterdam	O
,	O
Netherland	O
)	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Quantification	O
of	O
the	O
isolated	O
total	O
RNA	O
was	O
achieved	O
by	O
using	O
spectrophotometric	O
OD260	O
measurements	O
.	O

Equal	O
amounts	O
of	O
RNA	O
were	O
then	O
reverse	O
transcribed	O
to	O
cDNA	O
with	O
TaqMan	O
(	O
R	O
)	O
Reverse	O
Transcription	O
Reagents	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
U	O
.	O
S	O
.	O
A	O
)	O
.	O

To	O
measure	O
mRNA	O
expression	O
of	O
BMP6	B-Protein
,	O
Id1	B-Protein
-	O
Id4	B-Protein
and	O
PGK1	B-Protein
PCR	O
were	O
carried	O
out	O
with	O
TaqMan	O
(	O
R	O
)	O
universal	O
master	O
mix	O
.	O

Primers	O
and	O
probes	O
were	O
provided	O
by	O
Assay	O
-	O
on	O
-	O
Demand	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
final	O
volume	O
of	O
25	O
mul	O
(	O
BMP	B-Protein
-	I-Protein
6	I-Protein
)	O
or	O
20	O
mul	O
(	O
ID1	O
)	O
.	O

The	O
cDNA	O
added	O
to	O
each	O
reaction	O
was	O
equivalent	O
to	O
the	O
input	O
of	O
20	O
ng	O
of	O
total	O
RNA	O
.	O

The	O
gene	O
expression	O
was	O
quantified	O
using	O
the	O
standard	O
curve	O
method	O
(	O
BMP6	B-Protein
)	O
,	O
or	O
the	O
comparative	O
CT	O
method	O
(	O
Id1	B-Protein
)	O
as	O
described	O
in	O
ABI7700	O
User	O
Bulletin	O
2	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
expression	O
was	O
then	O
normalized	O
to	O
the	O
expression	O
level	O
of	O
PGK1	B-Protein
.	O

PGK1	B-Protein
was	O
chosen	O
,	O
because	O
it	O
has	O
been	O
shown	O
to	O
have	O
low	O
expression	O
variability	O
among	O
lymphocyte	O
specimens	O
[	O
56	O
]	O
.	O

Expression	O
levels	O
in	O
B	O
cells	O
were	O
then	O
related	O
to	O
the	O
expression	O
levels	O
in	O
Ramos	O
cells	O
.	O

Cell	O
proliferation	O
<EOS>	B-X
Cell	B-X
viability	B-X
is	B-X
defined	B-X
as	B-X
the	B-X
number	B-X
of	B-X
healthy	B-X
cells	B-X
in	B-X
a	B-X
sample	B-X
and	B-X
proliferation	B-X
of	B-X
cells	B-X
is	B-X
a	B-X
vital	B-X
indicator	B-X
for	B-X
understanding	B-X
the	B-X
mechanisms	B-X
in	B-X
action	B-X
of	B-X
certain	B-X
genes	B-X
,	B-X
proteins	B-X
and	B-X
pathways	B-X
involved	B-X
cell	B-X
survival	B-X
or	B-X
death	B-X
after	B-X
exposing	B-X
to	B-X
toxic	B-X
agents	B-X
.	B-X
Generally	B-X
,	B-X
methods	B-X
used	B-X
to	B-X
determine	B-X
viability	B-X
are	B-X
also	B-X
common	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
cell	B-X
proliferation	B-X
.	B-X
Cell	B-X
cytotoxicity	B-X
and	B-X
proliferation	B-X
assays	B-X
are	B-X
generally	B-X
used	B-X
for	B-X
drug	B-X
screening	B-X
to	B-X
detect	B-X
whether	B-X
the	B-X
test	B-X
molecules	B-X
have	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
or	B-X
display	B-X
direct	B-X
cytotoxic	B-X
effects	B-X
.	B-X
These	B-X
methods	B-X
could	B-X
be	B-X
basically	B-X
classified	B-X
into	B-X
different	B-X
categories	B-X
:	B-X
(	B-X
I	B-X
)	B-X
dye	B-X
exclusion	B-X
methods	B-X
such	B-X
as	B-X
trypan	B-X
blue	B-X
dye	B-X
exclusion	B-X
assay	B-X
,	B-X
(	B-X
II	B-X
)	B-X
methods	B-X
based	B-X
on	B-X
metabolic	B-X
activity	B-X
,	B-X
(	B-X
III	B-X
)	B-X
ATP	B-X
assay	B-X
,	B-X
(	B-X
IV	B-X
)	B-X
sulforhodamine	B-X
B	B-X
assay	B-X
,	B-X
(	B-X
V	B-X
)	B-X
protease	B-X
viability	B-X
marker	B-X
assay	B-X
,	B-X
(	B-X
VI	B-X
)	B-X
clonogenic	B-X
cell	B-X
survival	B-X
assay	B-X
,	B-X
(	B-X
VII	B-X
)	B-X
DNA	B-X
synthesis	B-X
cell	B-X
proliferation	B-X
assays	B-X
and	B-X
(	B-X
V	B-X
)	B-X
raman	B-X
micro-spectroscopy	B-X
.	B-X
This	B-X
particular	B-X
review	B-X
aims	B-X
to	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
common	B-X
cell	B-X
proliferation	B-X
and	B-X
cytotoxicity	B-X
assays	B-X
together	B-X
with	B-X
their	B-X
own	B-X
advantages	B-X
and	B-X
disadvantages	B-X
,	B-X
their	B-X
methodologies	B-X
,	B-X
comparisons	B-X
and	B-X
intended	B-X
purposes	B-X
.	B-X

For	O
estimation	O
of	O
DNA	O
synthesis	O
,	O
CD19	B-Protein
+	O
cells	O
(	O
7	O
.	O
5	O
x	O
104	O
cells	O
/	O
0	O
.	O
2	O
ml	O
)	O
or	O
Ramos	O
cells	O
(	O
1	O
x	O
104	O
cells	O
/	O
0	O
.	O
2	O
ml	O
)	O
were	O
cultured	O
in	O
triplicate	O
in	O
microtiter	O
wells	O
.	O

The	O
cells	O
were	O
pulsed	O
with	O
3	O
.	O
7	O
x	O
104Bq	O
[	O
3H	O
]	O
thymidine	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
for	O
the	O
last	O
16	O
h	O
of	O
a	O
72	O
-	O
h	O
incubation	O
.	O

The	O
cells	O
were	O
harvested	O
using	O
an	O
automated	O
cell	O
harvester	O
(	O
Packard	O
Instrument	O
Company	O
,	O
Meriden	O
,	O
CT	O
,	O
USA	O
)	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
determined	O
in	O
a	O
scintillation	O
counter	O
(	O
TopCount	O
,	O
Packard	O
Instrument	O
Company	O
Inc	O
.	O
,	O
Meriden	O
,	O
CT	O
)	O
.	O

Determination	O
of	O
cell	O
death	O
<EOS>	B-X
Depending	B-X
on	B-X
the	B-X
initiating	B-X
stimulus	B-X
,	B-X
cancer	B-X
cell	B-X
death	B-X
can	B-X
be	B-X
immunogenic	B-X
or	B-X
nonimmunogenic	B-X
.	B-X
Immunogenic	B-X
cell	B-X
death	B-X
(	B-X
ICD	B-X
)	B-X
involves	B-X
changes	B-X
in	B-X
the	B-X
composition	B-X
of	B-X
the	B-X
cell	B-X
surface	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
soluble	B-X
mediators	B-X
,	B-X
occurring	B-X
in	B-X
a	B-X
defined	B-X
temporal	B-X
sequence	B-X
.	B-X
Such	B-X
signals	B-X
operate	B-X
on	B-X
a	B-X
series	B-X
of	B-X
receptors	B-X
expressed	B-X
by	B-X
dendritic	B-X
cells	B-X
to	B-X
stimulate	B-X
the	B-X
presentation	B-X
of	B-X
tumor	B-X
antigens	B-X
to	B-X
T	B-X
cells	B-X
.	B-X
Hence	B-X
,	B-X
suboptimal	B-X
regimens	B-X
(	B-X
failing	B-X
to	B-X
induce	B-X
ICD	B-X
)	B-X
,	B-X
selective	B-X
alterations	B-X
in	B-X
cancer	B-X
cells	B-X
(	B-X
preventing	B-X
the	B-X
emission	B-X
of	B-X
immunogenic	B-X
signals	B-X
during	B-X
ICD	B-X
)	B-X
,	B-X
or	B-X
defects	B-X
in	B-X
immune	B-X
effectors	B-X
(	B-X
abolishing	B-X
the	B-X
perception	B-X
of	B-X
ICD	B-X
by	B-X
the	B-X
immune	B-X
system	B-X
)	B-X
can	B-X
all	B-X
contribute	B-X
to	B-X
therapeutic	B-X
failure	B-X
.	B-X

Cell	O
death	O
was	O
measured	O
by	O
vital	O
dye	O
exclusion	O
test	O
by	O
staining	O
cells	O
with	O
5	O
mug	O
/	O
ml	O
propidium	O
iodide	O
(	O
[	O
PI	O
]	O
;	O
Calbiochem	O
Corp	O
.	O
;	O
La	O
Jolla	O
,	O
CA	O
;	O
5	O
mg	O
/	O
ml	O
)	O
for	O
one	O
minute	O
on	O
ice	O
.	O

At	O
least	O
1	O
,	O
000	O
cells	O
per	O
sample	O
were	O
run	O
on	O
a	O
BD	O
FACSCalibur	O
flow	O
cytometer	O
.	O

Statistical	O
analysis	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
groups	O
was	O
determined	O
using	O
the	O
paired	O
two	O
-	O
tailed	O
Wilcoxon	O
nonparametric	O
test	O
,	O
by	O
applying	O
SPSS10	O
.	O
1	O
software	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

Sp1	B-Protein
and	O
Sp3	B-Protein
regulate	O
basal	O
transcription	O
of	O
the	O
human	O
APOBEC3G	B-Protein
gene	O
<EOS>	B-X
APOBEC3G	B-X
(	B-X
A3G	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
recently	B-X
discovered	B-X
family	B-X
of	B-X
human	B-X
cytidine	B-X
deaminases	B-X
,	B-X
is	B-X
expressed	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
active	B-X
against	B-X
HIV-1	B-X
and	B-X
other	B-X
retroviruses	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
.	B-X
Luciferase	B-X
reporter	B-X
assays	B-X
demonstrated	B-X
that	B-X
a	B-X
1025	B-X
bp	B-X
A3G	B-X
promoter	B-X
sequence	B-X
(	B-X
from	B-X
-959	B-X
to	B-X
+66	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
displayed	B-X
constitutive	B-X
promoter	B-X
activity	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
this	B-X
A3G	B-X
core	B-X
promoter	B-X
was	B-X
dependent	B-X
on	B-X
a	B-X
GC-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-87/-78	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
assays	B-X
demonstrated	B-X
that	B-X
the	B-X
identified	B-X
GC-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
ubiquitous	B-X
transcription	B-X
factors	B-X
specificity	B-X
protein	B-X
(	B-X
Sp	B-X
)	B-X
1	B-X
and	B-X
Sp3	B-X
.	B-X

APOBEC3G	B-Protein
(	O
A3G	B-Protein
)	O
,	O
a	O
member	O
of	O
the	O
recently	O
discovered	O
family	O
of	O
human	O
cytidine	O
deaminases	O
,	O
is	O
expressed	O
in	O
peripheral	O
blood	O
lymphocytes	O
and	O
has	O
been	O
shown	O
to	O
be	O
active	O
against	O
HIV	O
-	O
1	O
and	O
other	O
retroviruses	O
.	O
<EOS>	B-X
APOBEC3G	B-X
(	B-X
A3G	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
recently	B-X
discovered	B-X
family	B-X
of	B-X
human	B-X
cytidine	B-X
deaminases	B-X
,	B-X
is	B-X
expressed	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
active	B-X
against	B-X
HIV-1	B-X
and	B-X
other	B-X
retroviruses	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
.	B-X
Luciferase	B-X
reporter	B-X
assays	B-X
demonstrated	B-X
that	B-X
a	B-X
1025	B-X
bp	B-X
A3G	B-X
promoter	B-X
sequence	B-X
(	B-X
from	B-X
-959	B-X
to	B-X
+66	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
displayed	B-X
constitutive	B-X
promoter	B-X
activity	B-X
.	B-X
In	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
A3G	B-X
promoter	B-X
was	B-X
not	B-X
inducible	B-X
by	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
interferon	B-X
treatment	B-X
or	B-X
expression	B-X
of	B-X
HIV-1	B-X
proteins	B-X
.	B-X
Using	B-X
a	B-X
series	B-X
of	B-X
5	B-X
'	B-X
deletion	B-X
promoter	B-X
constructs	B-X
in	B-X
luciferase	B-X
reporter	B-X
assays	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
180	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
this	B-X
A3G	B-X
core	B-X
promoter	B-X
was	B-X
dependent	B-X
on	B-X
a	B-X
GC-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-87/-78	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
assays	B-X
demonstrated	B-X
that	B-X
the	B-X
identified	B-X
GC-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
ubiquitous	B-X
transcription	B-X
factors	B-X
specificity	B-X
protein	B-X
(	B-X
Sp	B-X
)	B-X
1	B-X
and	B-X
Sp3	B-X
.	B-X

To	O
gain	O
new	O
insights	O
into	O
the	O
transcriptional	O
regulation	O
of	O
this	O
restriction	O
factor	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
promoter	O
region	O
of	O
A3G	B-Protein
.	O
<EOS>	B-X
Apolipoprotein	B-X
B	B-X
mRNA-editing	B-X
enzyme	B-X
catalytic	B-X
polypeptide-like	B-X
3G	B-X
(	B-X
APOBEC3G	B-X
,	B-X
A3G	B-X
)	B-X
exert	B-X
antiviral	B-X
defense	B-X
as	B-X
an	B-X
important	B-X
factor	B-X
of	B-X
innate	B-X
immunity	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFN-γ、IL2、IL15、IL7	B-X
could	B-X
induce	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
However	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
nuclear	B-X
factor	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
have	B-X
not	B-X
been	B-X
reported	B-X
at	B-X
the	B-X
present	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
and	B-X
investigate	B-X
the	B-X
modulation	B-X
of	B-X
USF1	B-X
gene	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
232	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
to	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
full	B-X
promoter	B-X
.	B-X
Transcriptional	B-X
start	B-X
sites	B-X
(	B-X
TSS	B-X
)	B-X
were	B-X
identified	B-X
by	B-X
the	B-X
luciferase	B-X
reporter	B-X
assays	B-X
of	B-X
plasmids	B-X
containing	B-X
full	B-X
or	B-X
shorter	B-X
fragments	B-X
of	B-X
the	B-X
A3G	B-X
promoter	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
of	B-X
A3G	B-X
is	B-X
located	B-X
within	B-X
the	B-X
region	B-X
-159/-84	B-X
relative	B-X
to	B-X
the	B-X
TSS	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
A3G	B-X
core	B-X
promoter	B-X
regulated	B-X
by	B-X
USF1	B-X
was	B-X
dependent	B-X
on	B-X
an	B-X
E-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-91/-86	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
TSS	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
USF1	B-X
gene	B-X
can	B-X
take	B-X
part	B-X
in	B-X
basal	B-X
transcription	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
A3G	B-X
gene	B-X
in	B-X
hepatocyte	B-X
,	B-X
and	B-X
the	B-X
identified	B-X
E-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
USF1	B-X
.	B-X

Transcriptional	O
start	O
sites	O
were	O
identified	O
by	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
miRNA	B-X
genes	B-X
has	B-X
not	B-X
been	B-X
studied	B-X
extensively	B-X
owing	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
sufficient	B-X
information	B-X
about	B-X
the	B-X
promoters	B-X
and	B-X
transcription	B-X
start	B-X
sites	B-X
of	B-X
most	B-X
miRNAs	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
sequenced	B-X
and	B-X
compared	B-X
800	B-X
bp	B-X
of	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
nine	B-X
Ly49	B-X
genes	B-X
from	B-X
C57B1/6	B-X
mice	B-X
.	B-X
This	B-X
analysis	B-X
also	B-X
found	B-X
that	B-X
Ly49B	B-X
and	B-X
H	B-X
differ	B-X
from	B-X
the	B-X
other	B-X
genes	B-X
in	B-X
having	B-X
long	B-X
interspersed	B-X
repetitive	B-X
sequence	B-X
in	B-X
their	B-X
promoter	B-X
region	B-X
which	B-X
suggests	B-X
a	B-X
gene	B-X
conversion	B-X
or	B-X
rearrangement	B-X
involving	B-X
these	B-X
two	B-X
genes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
performed	B-X
5	B-X
'	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
on	B-X
four	B-X
Ly49	B-X
genes	B-X
to	B-X
localize	B-X
transcriptional	B-X
start	B-X
sites	B-X
.	B-X
These	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
transcriptional	B-X
initiation	B-X
sites	B-X
are	B-X
heterogeneous	B-X
for	B-X
all	B-X
of	B-X
the	B-X
genes	B-X
examined	B-X
,	B-X
and	B-X
that	B-X
a	B-X
large	B-X
majority	B-X
of	B-X
Ly49G	B-X
transcripts	B-X
originate	B-X
from	B-X
the	B-X
second	B-X
exon	B-X
as	B-X
well	B-X
as	B-X
its	B-X
first	B-X
intron	B-X
.	B-X
Although	B-X
potential	B-X
TATA	B-X
boxes	B-X
have	B-X
been	B-X
previously	B-X
identified	B-X
for	B-X
some	B-X
of	B-X
the	B-X
genes	B-X
,	B-X
we	B-X
did	B-X
not	B-X
find	B-X
evidence	B-X
that	B-X
a	B-X
majority	B-X
of	B-X
transcripts	B-X
initiate	B-X
at	B-X
the	B-X
expected	B-X
distance	B-X
downstream	B-X
of	B-X
these	B-X
boxes	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differences	B-X
in	B-X
the	B-X
location	B-X
of	B-X
transcriptional	B-X
start	B-X
sites	B-X
contribute	B-X
to	B-X
the	B-X
observed	B-X
complexity	B-X
in	B-X
receptor	B-X
repertoire	B-X
patterns	B-X
.	B-X

Luciferase	B-Protein
reporter	O
assays	O
demonstrated	O
that	O
a	O
1025	O
bp	O
A3G	O
promoter	O
sequence	O
(	O
from	O
-	O
959	O
to	O
+	O
66	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
displayed	O
constitutive	O
promoter	O
activity	O
.	O

In	O
T	O
cells	O
,	O
the	O
A3G	B-Protein
promoter	O
was	O
not	O
inducible	O
by	O
mitogenic	O
stimulation	O
,	O
interferon	O
treatment	O
or	O
expression	O
of	O
HIV	O
-	O
1	O
proteins	O
.	O
<EOS>	B-X
More	B-X
than	B-X
two	B-X
decades	B-X
have	B-X
passed	B-X
since	B-X
genetically	B-X
modified	B-X
HIV	B-X
was	B-X
used	B-X
for	B-X
gene	B-X
delivery	B-X
.	B-X
Through	B-X
continuous	B-X
improvements	B-X
these	B-X
early	B-X
marker	B-X
gene-carrying	B-X
HIVs	B-X
have	B-X
evolved	B-X
into	B-X
safer	B-X
and	B-X
more	B-X
effective	B-X
lentiviral	B-X
vectors	B-X
.	B-X
Lentiviral	B-X
vectors	B-X
offer	B-X
several	B-X
attractive	B-X
properties	B-X
as	B-X
gene-delivery	B-X
vehicles	B-X
,	B-X
including	B-X
:	B-X
(	B-X
i	B-X
)	B-X
sustained	B-X
gene	B-X
delivery	B-X
through	B-X
stable	B-X
vector	B-X
integration	B-X
into	B-X
host	B-X
genome	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
capability	B-X
of	B-X
infecting	B-X
both	B-X
dividing	B-X
and	B-X
non-dividing	B-X
cells	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
broad	B-X
tissue	B-X
tropisms	B-X
,	B-X
including	B-X
important	B-X
gene-	B-X
and	B-X
cell-therapy-target	B-X
cell	B-X
types	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
no	B-X
expression	B-X
of	B-X
viral	B-X
proteins	B-X
after	B-X
vector	B-X
transduction	B-X
;	B-X
(	B-X
v	B-X
)	B-X
the	B-X
ability	B-X
to	B-X
deliver	B-X
complex	B-X
genetic	B-X
elements	B-X
,	B-X
such	B-X
as	B-X
polycistronic	B-X
or	B-X
intron-containing	B-X
sequences	B-X
;	B-X
(	B-X
vi	B-X
)	B-X
potentially	B-X
safer	B-X
integration	B-X
site	B-X
profile	B-X
;	B-X
and	B-X
(	B-X
vii	B-X
)	B-X
a	B-X
relatively	B-X
easy	B-X
system	B-X
for	B-X
vector	B-X
manipulation	B-X
and	B-X
production	B-X
.	B-X
Accordingly	B-X
,	B-X
lentivector	B-X
technologies	B-X
now	B-X
have	B-X
widespread	B-X
use	B-X
in	B-X
basic	B-X
biology	B-X
and	B-X
translational	B-X
studies	B-X
for	B-X
stable	B-X
transgene	B-X
overexpression	B-X
,	B-X
persistent	B-X
gene	B-X
silencing	B-X
,	B-X
immunization	B-X
,	B-X
in	B-X
vivo	B-X
imaging	B-X
,	B-X
generating	B-X
transgenic	B-X
animals	B-X
,	B-X
induction	B-X
of	B-X
pluripotent	B-X
cells	B-X
,	B-X
stem	B-X
cell	B-X
modification	B-X
and	B-X
lineage	B-X
tracking	B-X
,	B-X
or	B-X
site-directed	B-X
gene	B-X
editing	B-X
.	B-X

Using	O
a	O
series	O
of	O
5	O
'	O
deletion	O
promoter	O
constructs	O
in	O
luciferase	B-Protein
reporter	O
assays	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
was	O
sufficient	O
for	O
full	O
promoter	O
activity	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
.	B-X
Transcriptional	B-X
start	B-X
sites	B-X
were	B-X
identified	B-X
by	B-X
5'-rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
analysis	B-X
.	B-X
Luciferase	B-X
reporter	B-X
assays	B-X
demonstrated	B-X
that	B-X
a	B-X
1025	B-X
bp	B-X
A3G	B-X
promoter	B-X
sequence	B-X
(	B-X
from	B-X
-959	B-X
to	B-X
+66	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
displayed	B-X
constitutive	B-X
promoter	B-X
activity	B-X
.	B-X
In	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
A3G	B-X
promoter	B-X
was	B-X
not	B-X
inducible	B-X
by	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
interferon	B-X
treatment	B-X
or	B-X
expression	B-X
of	B-X
HIV-1	B-X
proteins	B-X
.	B-X
Using	B-X
a	B-X
series	B-X
of	B-X
5	B-X
'	B-X
deletion	B-X
promoter	B-X
constructs	B-X
in	B-X
luciferase	B-X
reporter	B-X
assays	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
180	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
this	B-X
A3G	B-X
core	B-X
promoter	B-X
was	B-X
dependent	B-X
on	B-X
a	B-X
GC-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-87/-78	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
assays	B-X
demonstrated	B-X
that	B-X
the	B-X
identified	B-X
GC-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
ubiquitous	B-X
transcription	B-X
factors	B-X
specificity	B-X
protein	B-X
(	B-X
Sp	B-X
)	B-X
1	B-X
and	B-X
Sp3	B-X
.	B-X

Transcriptional	O
activity	O
of	O
this	O
A3G	O
core	O
promoter	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
(	O
located	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
)	O
and	O
was	O
abolished	O
after	O
mutation	O
of	O
this	O
DNA	O
element	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
the	O
identified	O
GC	O
-	O
box	O
represented	O
a	O
binding	O
site	O
for	O
the	O
ubiquitous	O
transcription	O
factors	O
specificity	B-Protein
protein	I-Protein
(	I-Protein
Sp	I-Protein
)	I-Protein
1	I-Protein
and	O
Sp3	B-Protein
.	O
<EOS>	B-X
APOBEC3G	B-X
(	B-X
A3G	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
recently	B-X
discovered	B-X
family	B-X
of	B-X
human	B-X
cytidine	B-X
deaminases	B-X
,	B-X
is	B-X
expressed	B-X
in	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
active	B-X
against	B-X
HIV-1	B-X
and	B-X
other	B-X
retroviruses	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
.	B-X
Transcriptional	B-X
start	B-X
sites	B-X
were	B-X
identified	B-X
by	B-X
5'-rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
analysis	B-X
.	B-X
Luciferase	B-X
reporter	B-X
assays	B-X
demonstrated	B-X
that	B-X
a	B-X
1025	B-X
bp	B-X
A3G	B-X
promoter	B-X
sequence	B-X
(	B-X
from	B-X
-959	B-X
to	B-X
+66	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
displayed	B-X
constitutive	B-X
promoter	B-X
activity	B-X
.	B-X
In	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
A3G	B-X
promoter	B-X
was	B-X
not	B-X
inducible	B-X
by	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
interferon	B-X
treatment	B-X
or	B-X
expression	B-X
of	B-X
HIV-1	B-X
proteins	B-X
.	B-X
Using	B-X
a	B-X
series	B-X
of	B-X
5	B-X
'	B-X
deletion	B-X
promoter	B-X
constructs	B-X
in	B-X
luciferase	B-X
reporter	B-X
assays	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
180	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
this	B-X
A3G	B-X
core	B-X
promoter	B-X
was	B-X
dependent	B-X
on	B-X
a	B-X
GC-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-87/-78	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
start	B-X
site	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
assays	B-X
demonstrated	B-X
that	B-X
the	B-X
identified	B-X
GC-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
ubiquitous	B-X
transcription	B-X
factors	B-X
specificity	B-X
protein	B-X
(	B-X
Sp	B-X
)	B-X
1	B-X
and	B-X
Sp3	B-X
.	B-X

The	O
recently	O
discovered	O
APOBEC3	O
family	O
of	O
cytidine	O
deaminases	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
antiviral	O
intrinsic	O
immunity	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
primates	O
,	O
the	O
seven	O
paralogs	O
APOBEC3A	B-Protein
,	O
B	B-Protein
,	O
C	B-Protein
,	O
DE	B-Protein
,	O
F	B-Protein
,	O
G	B-Protein
,	O
H	B-Protein
(	O
A3A	O
-	O
H	O
)	O
have	O
been	O
described	O
(	O
3	O
)	O
,	O
and	O
they	O
appear	O
to	O
fulfill	O
individual	O
functions	O
.	O

Human	O
APOBEC3G	B-Protein
(	O
A3G	B-Protein
)	O
,	O
the	O
most	O
prominent	O
member	O
of	O
the	O
APOBEC3	O
family	O
has	O
been	O
identified	O
as	O
the	O
cellular	O
restriction	O
factor	O
that	O
is	O
responsible	O
for	O
inhibition	O
of	O
virion	B-Protein
infectivity	I-Protein
factor	I-Protein
(	O
Vif	B-Protein
)	O
-	O
deleted	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
in	O
non	O
-	O
permissive	O
cells	O
(	O
4	O
)	O
.	O

A3G	B-Protein
is	O
packaged	O
into	O
HIV	O
-	O
1deltavif	B-Protein
particles	O
and	O
causes	O
C	O
-	O
to	O
-	O
U	O
deaminations	O
on	O
the	O
single	O
-	O
stranded	O
viral	O
DNA	O
during	O
reverse	O
transcription	O
(	O
5	O
-	O
8	O
)	O
.	O

This	O
leads	O
to	O
degradation	O
of	O
the	O
uracile	O
-	O
containing	O
DNA	O
by	O
cellular	O
repair	O
mechanisms	O
or	O
to	O
hypermutation	O
of	O
the	O
viral	O
genome	O
(	O
5	O
,	O
6	O
)	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
131	B-X
human	B-X
brains	B-X
(	B-X
44	B-X
neurotypical	B-X
,	B-X
19	B-X
with	B-X
Tourette	B-X
syndrome	B-X
,	B-X
9	B-X
with	B-X
schizophrenia	B-X
,	B-X
and	B-X
59	B-X
with	B-X
autism	B-X
)	B-X
for	B-X
somatic	B-X
mutations	B-X
after	B-X
whole	B-X
genome	B-X
sequencing	B-X
to	B-X
a	B-X
depth	B-X
of	B-X
more	B-X
than	B-X
200×	B-X
.	B-X
Typically	B-X
,	B-X
brains	B-X
had	B-X
20	B-X
to	B-X
60	B-X
detectable	B-X
single-nucleotide	B-X
mutations	B-X
,	B-X
but	B-X
~6	B-X
%	B-X
of	B-X
brains	B-X
harbored	B-X
hundreds	B-X
of	B-X
somatic	B-X
mutations	B-X
.	B-X
Somatic	B-X
duplications	B-X
,	B-X
likely	B-X
arising	B-X
during	B-X
development	B-X
,	B-X
were	B-X
found	B-X
in	B-X
~5	B-X
%	B-X
of	B-X
normal	B-X
and	B-X
diseased	B-X
brains	B-X
,	B-X
reflecting	B-X
background	B-X
mutagenesis	B-X
.	B-X
The	B-X
top-ranked	B-X
affected	B-X
motifs	B-X
corresponded	B-X
to	B-X
MEIS	B-X
(	B-X
myeloid	B-X
ectopic	B-X
viral	B-X
integration	B-X
site	B-X
)	B-X
transcription	B-X
factors	B-X
,	B-X
suggesting	B-X
a	B-X
potential	B-X
link	B-X
between	B-X
their	B-X
involvement	B-X
in	B-X
gene	B-X
regulation	B-X
and	B-X
autism	B-X
.	B-X

As	O
a	O
result	O
,	O
only	O
a	O
marginal	O
fraction	O
of	O
the	O
A3G	B-Protein
-	O
containing	O
HIV	O
-	O
1	O
particles	O
is	O
able	O
to	O
complete	O
the	O
replication	O
cycle	O
.	O

In	O
addition	O
to	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
,	O
A3G	B-Protein
restricts	O
replication	O
of	O
other	O
lentiviruses	O
,	O
gammaretroviruses	O
,	O
deltaretroviruses	O
,	O
spumaviruses	O
,	O
long	O
-	O
terminal	O
-	O
repeat	O
(	O
LTR	O
)	O
-	O
retrotransposons	O
,	O
orthohepadnaviruses	O
and	O
avihepadnaviruses	O
(	O
9	O
-	O
21	O
)	O
.	O

Interestingly	O
,	O
deamination	O
seems	O
not	O
to	O
be	O
the	O
only	O
A3G	B-Protein
-	O
mediated	O
antiviral	O
mechanism	O
;	O
in	O
the	O
case	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
,	O
A3G	B-Protein
was	O
shown	O
to	O
restrict	O
virus	O
replication	O
by	O
deamination	O
-	O
independent	O
mechanisms	O
(	O
12	O
,	O
13	O
,	O
19	O
,	O
22	O
-	O
25	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
species-specific	B-X
ammonium	B-X
toxicity	B-X
,	B-X
intraspecific	B-X
variability	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
.	B-X
Plants	B-X
were	B-X
grown	B-X
with	B-X
either	B-X
1mM	B-X
NO₃	B-X
(	B-X
-	B-X
)	B-X
or	B-X
NH₄	B-X
(	B-X
+	B-X
)	B-X
as	B-X
the	B-X
N	B-X
source	B-X
,	B-X
and	B-X
several	B-X
parameters	B-X
related	B-X
to	B-X
ammonium	B-X
tolerance	B-X
and	B-X
assimilation	B-X
were	B-X
determined	B-X
.	B-X
From	B-X
the	B-X
parameters	B-X
determined	B-X
,	B-X
tissue	B-X
ammonium	B-X
content	B-X
was	B-X
the	B-X
one	B-X
with	B-X
the	B-X
highest	B-X
impact	B-X
on	B-X
shoot	B-X
biomass	B-X
,	B-X
and	B-X
interestingly	B-X
this	B-X
was	B-X
also	B-X
the	B-X
case	B-X
when	B-X
N	B-X
was	B-X
supplied	B-X
as	B-X
NO₃	B-X
(	B-X
-	B-X
)	B-X
.	B-X
Overall	B-X
,	B-X
NH4	B-X
(	B-X
+	B-X
)	B-X
accumulation	B-X
seems	B-X
to	B-X
be	B-X
an	B-X
important	B-X
player	B-X
in	B-X
Arabidopsis	B-X
natural	B-X
variability	B-X
in	B-X
ammonium	B-X
tolerance	B-X
rather	B-X
than	B-X
the	B-X
cell	B-X
NH₄	B-X
(	B-X
+	B-X
)	B-X
assimilation	B-X
capacity	B-X
.	B-X

Another	O
member	O
of	O
the	O
APOBEC3	O
family	O
,	O
APOBEC3F	B-Protein
(	O
A3F	B-Protein
)	O
,	O
appears	O
to	O
have	O
similar	O
activities	O
like	O
A3G	B-Protein
(	O
26	O
,	O
27	O
)	O
.	O

A3F	B-Protein
is	O
also	O
packaged	O
into	O
HIV	O
-	O
1deltavif	B-Protein
particles	O
and	O
induces	O
similar	O
C	O
-	O
to	O
-	O
U	O
deaminations	O
,	O
although	O
the	O
proteins	O
differ	O
in	O
their	O
target	O
sequences	O
specificity	O
(	O
26	O
,	O
28	O
)	O
.	O

Furthermore	O
,	O
A3F	B-Protein
proteins	O
were	O
detected	O
in	O
many	O
tissues	O
that	O
express	O
A3G	B-Protein
and	O
are	O
able	O
to	O
form	O
heteromultimers	O
with	O
A3G	B-Protein
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

Both	O
proteins	O
localize	O
to	O
mRNA	O
processing	O
(	O
P	O
)	O
bodies	O
,	O
cytoplasmic	O
compartments	O
involved	O
in	O
the	O
degradation	O
and	O
storage	O
of	O
non	O
-	O
translating	O
mRNAs	O
(	O
30	O
,	O
31	O
)	O
.	O

A3G	B-Protein
has	O
been	O
shown	O
to	O
be	O
expressed	O
in	O
T	O
cells	O
,	O
a	O
relevant	O
cell	O
target	O
for	O
HIV	O
-	O
1	O
in	O
vivo	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
regulation	O
(	O
4	O
,	O
29	O
,	O
32	O
)	O
.	O

There	O
is	O
a	O
report	O
describing	O
that	O
mitogenic	O
stimulation	O
of	O
T	O
cells	O
upregulates	O
A3G	B-Protein
mRNA	O
levels	O
,	O
but	O
this	O
was	O
not	O
analyzed	O
on	O
the	O
transcriptional	O
level	O
(	O
33	O
)	O
.	O

Since	O
the	O
A3G	B-Protein
promoter	O
has	O
not	O
been	O
systematically	O
analyzed	O
so	O
far	O
,	O
our	O
aim	O
was	O
to	O
clone	O
the	O
A3G	B-Protein
promoter	O
and	O
characterize	O
its	O
regulation	O
in	O
T	O
cells	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
decipher	B-X
the	B-X
signalling	B-X
pathway	B-X
(	B-X
s	B-X
)	B-X
and	B-X
regulatory	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
involved	B-X
in	B-X
A3B	B-X
induction	B-X
and	B-X
related	B-X
HBV	B-X
control	B-X
.	B-X
We	B-X
found	B-X
that	B-X
UC	B-X
cell	B-X
lines	B-X
highly	B-X
express	B-X
A3B	B-X
and	B-X
in	B-X
some	B-X
cases	B-X
A3G	B-X
,	B-X
but	B-X
not	B-X
A3A	B-X
,	B-X
and	B-X
exhibit	B-X
corresponding	B-X
cytidine	B-X
deamination	B-X
activity	B-X
Recent	B-X
findings	B-X
introduced	B-X
APOBEC3G	B-X
(	B-X
A3G	B-X
)	B-X
as	B-X
a	B-X
host	B-X
factor	B-X
that	B-X
blocks	B-X
viral	B-X
replication	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
expression	B-X
of	B-X
liver	B-X
A3G	B-X
protein	B-X
in	B-X
association	B-X
with	B-X
both	B-X
replication	B-X
of	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
and	B-X
frequency	B-X
of	B-X
G	B-X
to	B-X
A	B-X
mutations	B-X
in	B-X
BCP	B-X
(	B-X
basal	B-X
core	B-X
promoter	B-X
)	B-X
-PC	B-X
(	B-X
pre-core	B-X
)	B-X
region	B-X
.	B-X

In	O
our	O
study	O
,	O
we	O
observed	O
that	O
A3G	B-Protein
uses	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
of	O
the	O
A3G	B-Protein
promoter	O
,	O
we	O
identified	O
a	O
180	O
bp	O
region	O
that	O
mediated	O
basal	O
transcription	O
.	O

In	O
T	O
cells	O
,	O
transcriptional	O
activity	O
of	O
this	O
core	O
promoter	O
was	O
not	O
inducible	O
by	O
mitogenic	O
stimulation	O
or	O
interferon	B-Protein
treatment	O
,	O
but	O
was	O
dependent	O
on	O
a	O
GC	O
-	O
box	O
which	O
was	O
recognized	O
by	O
Sp	B-Protein
(	I-Protein
specificity	I-Protein
protein	I-Protein
)	I-Protein
1	I-Protein
and	O
Sp3	B-Protein
transcription	O
factors	O
.	O

Cell	O
culture	O
<EOS>	B-X
This	B-X
overview	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
to	B-X
provide	B-X
an	B-X
unmet	B-X
need	B-X
for	B-X
information	B-X
on	B-X
best	B-X
practices	B-X
in	B-X
animal	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
target	B-X
audience	B-X
primarily	B-X
consists	B-X
of	B-X
entry-level	B-X
scientists	B-X
with	B-X
minimal	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
It	B-X
also	B-X
include	B-X
scientists	B-X
,	B-X
journalists	B-X
,	B-X
and	B-X
educators	B-X
with	B-X
some	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
,	B-X
but	B-X
in	B-X
need	B-X
of	B-X
a	B-X
refresher	B-X
in	B-X
best	B-X
practices	B-X
.	B-X
The	B-X
articles	B-X
will	B-X
be	B-X
published	B-X
in	B-X
this	B-X
journal	B-X
over	B-X
a	B-X
six-month	B-X
period	B-X
and	B-X
will	B-X
emphasize	B-X
best	B-X
practices	B-X
in	B-X
:	B-X
(	B-X
1	B-X
)	B-X
media	B-X
selection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
use	B-X
and	B-X
evaluation	B-X
of	B-X
animal	B-X
serum	B-X
as	B-X
a	B-X
component	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
;	B-X
(	B-X
3	B-X
)	B-X
receipt	B-X
of	B-X
new	B-X
cells	B-X
into	B-X
the	B-X
laboratory	B-X
;	B-X
(	B-X
4	B-X
)	B-X
naming	B-X
cell	B-X
lines	B-X
;	B-X
(	B-X
5	B-X
)	B-X
authenticating	B-X
cell	B-X
line	B-X
identity	B-X
;	B-X
(	B-X
6	B-X
)	B-X
detecting	B-X
and	B-X
mitigating	B-X
risk	B-X
of	B-X
cell	B-X
culture	B-X
contamination	B-X
;	B-X
(	B-X
7	B-X
)	B-X
cryopreservation	B-X
and	B-X
thawing	B-X
of	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
8	B-X
)	B-X
storing	B-X
and	B-X
shipping	B-X
viable	B-X
cells	B-X
.	B-X

The	O
human	O
T	O
cell	O
lines	O
A3	O
.	O
01	O
and	O
PM1	O
(	O
NIBSC	O
,	O
UK	O
)	O
and	O
the	O
human	O
myeloid	O
cell	O
line	O
U937	O
(	O
NIBSC	O
,	O
UK	O
)	O
were	O
grown	O
in	O
complete	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U	O
/	O
ml	O
penicillin	O
-	O
streptomycin	O
.	O

The	O
human	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
kindly	O
provided	O
by	O
Dr	O
Thomas	O
Pietschmann	O
,	O
Department	O
of	O
Molecular	O
Virology	O
,	O
University	O
of	O
Heidelberg	O
)	O
as	O
well	O
as	O
HeLa	O
cells	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
high	O
glucose	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
100	O
U	O
/	O
ml	O
penicillin	O
-	O
streptomycin	O
.	O

Cells	O
lines	O
were	O
incubated	O
at	O
37degreesC	O
with	O
100	O
%	O
humidity	O
in	O
5	O
-	O
7	O
%	O
CO2	O
and	O
passaged	O
using	O
standard	O
cell	O
culture	O
techniques	O
.	O

Plasmids	O
<EOS>	B-X
Plasmids	B-X
mediate	B-X
the	B-X
horizontal	B-X
transmission	B-X
of	B-X
genetic	B-X
information	B-X
between	B-X
bacteria	B-X
,	B-X
facilitating	B-X
their	B-X
adaptation	B-X
to	B-X
multiple	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
bacteria	B-X
with	B-X
new	B-X
adaptive	B-X
tools	B-X
,	B-X
but	B-X
they	B-X
also	B-X
entail	B-X
a	B-X
metabolic	B-X
burden	B-X
that	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
selection	B-X
for	B-X
plasmid-encoded	B-X
traits	B-X
,	B-X
reduces	B-X
the	B-X
competitiveness	B-X
of	B-X
the	B-X
plasmid-carrying	B-X
clone	B-X
.	B-X
Plasmids	B-X
are	B-X
important	B-X
vehicles	B-X
for	B-X
rapid	B-X
adaptation	B-X
of	B-X
bacterial	B-X
populations	B-X
to	B-X
changing	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
various	B-X
accessory	B-X
traits	B-X
which	B-X
might	B-X
be	B-X
beneficial	B-X
under	B-X
particular	B-X
conditions	B-X
.	B-X

For	O
cloning	O
of	O
an	O
APOBEC3G	B-Protein
promoter	O
-	O
driven	O
reporter	O
plasmid	O
,	O
genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
T	O
cell	O
line	O
PM1	O
using	O
the	O
DNeasy	O
Kit	O
(	O
Qiagen	O
)	O
.	O

The	O
DNA	O
sequence	O
ranging	O
from	O
positions	O
-	O
959	O
to	O
+	O
66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
was	O
amplified	O
via	O
PCR	O
using	O
the	O
primers	O
3Gprom1025	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTGCTGCAGGCCATCTGGATGTATATG	O
-	O
3	O
'	O
)	O
and	O
3Gpromreverse	O
(	O
5	O
'	O
-	O
ACAGCAGATCTAGGGACCTCTGATAAAGACAGG	O
-	O
3	O
'	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pwo	B-Protein
DNA	O
Polymerase	O
(	O
Roche	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
58degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

The	O
amplicon	O
was	O
ligated	O
into	O
the	O
promoterless	O
luciferase	B-Protein
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
,	O
which	O
were	O
introduced	O
by	O
the	O
primers	O
.	O

The	O
resulting	O
construct	O
contained	O
1025	O
bp	O
of	O
the	O
A3G	B-Protein
promoter	O
and	O
was	O
designated	O
pGL3	O
-	O
APOprom1025	O
.	O

Reporter	O
plasmids	O
containing	O
shorter	O
fragments	O
of	O
the	O
APOBEC3G	B-Protein
promoter	O
were	O
constructed	O
using	O
pGL3	O
-	O
APOprom1025	O
as	O
template	O
and	O
the	O
following	O
forward	O
primers	O
:	O
for	O
plasmid	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436	O
/	O
+	O
66	O
)	O
:	O
3Gprom502	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCCATAACATGGGGACAAGA	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159	O
/	O
+	O
66	O
)	O
:	O
3Gprom225	O
(	O
5	O
'	O
-	O
TGTGAACGCGTCGAGGGCAGGATCCGGGAGT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom180	O
(	O
containing	O
sequence	O
-	O
114	O
/	O
+	O
66	O
)	O
:	O
3Gprom180	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCTTGATGGTGGAGAGGAGG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom150	O
(	O
containing	O
sequence	O
-	O
84	O
/	O
+	O
66	O
)	O
:	O
3Gprom150	O
(	O
5	O
'	O
-	O
TGTGAACGCGTGCGGGACCACCAGGGGAGGGGCTT	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom120	O
(	O
containing	O
sequence	O
-	O
54	O
/	O
+	O
66	O
)	O
:	O
3Gprom120	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTGCTGGCTCAGCCTGGTGTG	O
-	O
3	O
'	O
)	O
;	O
for	O
plasmid	O
pGL3	O
-	O
APOprom60	O
(	O
containing	O
sequence	O
+	O
7	O
/	O
+	O
66	O
)	O
:	O
3Gprom60	O
(	O
5	O
'	O
-	O
TGTGAACGCGTCCCTTTGCAATTGCCTTG	O
-	O
3	O
'	O
)	O
;	O
each	O
in	O
combination	O
with	O
the	O
reverse	O
primer	O
3Gpromreverse	O
(	O
described	O
above	O
)	O
.	O

PCR	O
reactions	O
were	O
performed	O
with	O
Pfu	B-Protein
Ultra	O
Hotstart	O
(	O
Stratagene	O
)	O
using	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
72degreesC	O
for	O
60	O
s	O
;	O
one	O
cycle	O
72degreesC	O
for	O
7	O
min	O
.	O

As	O
for	O
pGL3	O
-	O
APOprom1025	O
,	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
and	O
PCR	O
products	O
were	O
ligated	O
into	O
pGL3	O
-	O
Basic	O
(	O
Promega	O
)	O
via	O
these	O
restriction	O
sites	O
.	O

pGL3	O
-	O
APOprom180mut	O
carries	O
two	O
point	O
mutations	O
(	O
bold	O
)	O
and	O
was	O
generated	O
using	O
the	O
primer	O
3GProm180mut	O
(	O
5	O
'	O
-	O
TGTGAACGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGTTCGGGACCACCAG	O
-	O
3	O
'	O
)	O
in	O
combination	O
with	O
primer	O
3Gpromreverse	O
.	O

This	O
PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
65degreesC	O
.	O

pGL3promE1	O
(	O
containing	O
nucleotides	O
-	O
114	O
/	O
-	O
85	O
)	O
and	O
pGL3promE2	O
(	O
containing	O
nucleotides	O
-	O
92	O
/	O
-	O
63	O
)	O
were	O
constructed	O
by	O
annealing	O
the	O
following	O
single	O
-	O
stranded	O
oligonucleotides	O
:	O
114	O
_	O
85Plus	O
(	O
5	O
'	O
-	O
CGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGGA	O
-	O
3	O
'	O
)	O
and	O
114	O
_	O
85Minus	O
(	O
5	O
'	O
-	O
GATCTCCAGCTGGAGCCTCCTCTCCACCATCAAGAA	O
-	O
3	O
'	O
)	O
or	O
92	O
-	O
63Plus	O
(	O
5	O
'	O
-	O
CGCGTCCAGCTGGGCGGGACCACCAGGGGAGGGGCA	O
-	O
3	O
'	O
)	O
and	O
92	O
_	O
63Minus	O
(	O
5	O
'	O
-	O
GATCTGCCCCTCCCCTGGTGGTCCCGCCCAGCTGGA	O
-	O
3	O
'	O
)	O
.	O
<EOS>	B-X
Cuban	B-X
protein	B-X
subunit	B-X
vaccine	B-X
Abdala	B-X
has	B-X
shown	B-X
safety	B-X
,	B-X
tolerability	B-X
and	B-X
efficacy	B-X
(	B-X
92·3	B-X
%	B-X
[	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
85·7‒95·8	B-X
]	B-X
)	B-X
against	B-X
SARS-CoV-2	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
An	B-X
efficient	B-X
protocol	B-X
has	B-X
been	B-X
developed	B-X
for	B-X
the	B-X
synthesis	B-X
of	B-X
a	B-X
small	B-X
library	B-X
of	B-X
3'-deoxy-3'-	B-X
(	B-X
4-substituted-triazol-1-yl	B-X
)	B-X
-5-methyluridine	B-X
using	B-X
Cu	B-X
(	B-X
I	B-X
)	B-X
-catalyzed	B-X
Huisgen-Sharpless-Meldal	B-X
1,3-dipolar	B-X
cycloaddition	B-X
reaction	B-X
of	B-X
3'-azido-3'-deoxy-5-methyluridine	B-X
with	B-X
different	B-X
alkynes	B-X
under	B-X
optimized	B-X
condition	B-X
in	B-X
an	B-X
overall	B-X
yields	B-X
of	B-X
76	B-X
%	B-X
-92	B-X
%	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
azido	B-X
precursor	B-X
compound	B-X
,	B-X
i.e.	B-X
,	B-X
3'-azido-3'-deoxy-5-methyluridine	B-X
was	B-X
chemoenzymatically	B-X
synthesized	B-X
from	B-X
D-xylose	B-X
in	B-X
good	B-X
yield	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
alkynes	B-X
used	B-X
in	B-X
cycloaddition	B-X
reaction	B-X
were	B-X
synthesized	B-X
by	B-X
the	B-X
reaction	B-X
of	B-X
hydroxycoumarins	B-X
or	B-X
naphthols	B-X
with	B-X
propargyl	B-X
bromide	B-X
in	B-X
acetone	B-X
using	B-X
K2CO3in	B-X
excellent	B-X
yields	B-X
.	B-X
All	B-X
synthesized	B-X
compounds	B-X
were	B-X
unambiguously	B-X
identified	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
their	B-X
spectral	B-X
(	B-X
IR	B-X
,	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
,	B-X
(	B-X
13	B-X
)	B-X
C	B-X
NMR	B-X
spectra	B-X
,	B-X
and	B-X
high-resolution	B-X
mass	B-X
spectra	B-X
)	B-X
data	B-X
analysis	B-X
.	B-X

After	O
annealing	O
,	O
the	O
double	O
-	O
stranded	O
oligonucleotides	O
which	O
contained	O
the	O
respective	O
30	O
bp	O
of	O
the	O
APOBEC3G	B-Protein
promoter	O
and	O
sticky	O
ends	O
compatible	O
with	O
MluI	O
and	O
BglII	O
restriction	O
sites	O
were	O
ligated	O
into	O
the	O
pGL3	O
-	O
Promoter	O
(	O
Promega	O
)	O
vector	O
.	O

The	O
sequences	O
of	O
all	O
constructed	O
plasmids	O
were	O
verified	O
by	O
sequence	O
analysis	O
.	O
<EOS>	B-X
Whether	B-X
the	B-X
technique	B-X
is	B-X
used	B-X
to	B-X
verify	B-X
that	B-X
a	B-X
clone	B-X
is	B-X
constructed	B-X
properly	B-X
or	B-X
to	B-X
validate	B-X
an	B-X
interesting	B-X
variant	B-X
found	B-X
by	B-X
next-generation	B-X
whole-genome	B-X
sequencing	B-X
,	B-X
capillary	B-X
sequencing	B-X
is	B-X
an	B-X
extremely	B-X
versatile	B-X
tool	B-X
.	B-X
This	B-X
method	B-X
for	B-X
cycle	B-X
sequencing	B-X
relies	B-X
on	B-X
the	B-X
use	B-X
of	B-X
the	B-X
ABI3730xl	B-X
capillary	B-X
sequencer	B-X
.	B-X
The	B-X
template	B-X
can	B-X
be	B-X
prepared	B-X
from	B-X
plasmid	B-X
minipreps	B-X
for	B-X
direct	B-X
sequencing	B-X
of	B-X
clones	B-X
to	B-X
identify	B-X
a	B-X
mutation	B-X
or	B-X
structure	B-X
of	B-X
interest	B-X
,	B-X
or	B-X
amplified	B-X
products	B-X
can	B-X
be	B-X
sequenced	B-X
individually	B-X
with	B-X
each	B-X
of	B-X
the	B-X
two	B-X
primers	B-X
used	B-X
in	B-X
LongAmp	B-X
amplification	B-X
reactions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
bioinformatics	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
and	B-X
clone	B-X
the	B-X
extracellular	B-X
region	B-X
of	B-X
Xinjiang	B-X
sheep	B-X
CTLA-4	B-X
(	B-X
NM_001009214	B-X
)	B-X
.	B-X
The	B-X
correctly	B-X
sequenced	B-X
CTLA-4	B-X
IgV	B-X
was	B-X
digested	B-X
and	B-X
then	B-X
ligated	B-X
into	B-X
the	B-X
prokaryotic	B-X
expression	B-X
vector	B-X
pET-30a	B-X
(	B-X
+	B-X
)	B-X
.	B-X
The	B-X
plasmid	B-X
pET30a-CTLA-4	B-X
IgV	B-X
was	B-X
constructed	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
recombinant	B-X
protein	B-X
CTLA-4	B-X
IgV	B-X
.	B-X
Clustal	B-X
X	B-X
multiple	B-X
sequence	B-X
alignment	B-X
revealed	B-X
that	B-X
the	B-X
protein	B-X
sequence	B-X
of	B-X
Xinjiang	B-X
sheep	B-X
CTLA-4	B-X
IgV	B-X
was	B-X
different	B-X
from	B-X
that	B-X
of	B-X
the	B-X
known	B-X
CTLA-4	B-X
extracellular	B-X
region	B-X
.	B-X
The	B-X
3D	B-X
protein	B-X
structure	B-X
of	B-X
Xinjiang	B-X
sheep	B-X
CTLA-4	B-X
IgV	B-X
was	B-X
constructed	B-X
via	B-X
the	B-X
bioinformatics	B-X
method	B-X
.	B-X
The	B-X
functionality	B-X
of	B-X
the	B-X
Xinjiang	B-X
sheep	B-X
CTLA-4	B-X
IgV	B-X
protein	B-X
was	B-X
further	B-X
verified	B-X
by	B-X
fusing	B-X
the	B-X
CTLA-4	B-X
extracellular	B-X
V	B-X
region	B-X
with	B-X
EgG1Y162	B-X
,	B-X
a	B-X
protective	B-X
protein	B-X
from	B-X

Nucleotide	O
-	O
219	O
of	O
the	O
cloned	O
APOBEC3G	B-Protein
promoter	O
differs	O
from	O
the	O
sequence	O
in	O
the	O
database	O
(	O
GenBank	O
(	O
TM	O
)	O
accession	O
number	O
DQ147772	O
)	O
.	O

An	O
A	O
-	O
to	O
-	O
C	O
substitution	O
is	O
present	O
at	O
this	O
position	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
transcriptional	O
start	O
site	O
we	O
identified	O
.	O

The	O
reporter	O
plasmids	O
pGL3	O
-	O
Control	O
and	O
phRG	O
-	O
TK	O
were	O
purchased	O
from	O
Promega	O
.	O

pGL2	O
-	O
CVX	O
contains	O
two	O
repeats	O
of	O
the	O
IFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
(	O
GATCTGGATTTAGAGTAATATGAAACTGAAAGTACTTCG	O
)	O
of	O
the	O
guanylate	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
GBP	B-Protein
)	O
gene	O
in	O
front	O
of	O
a	O
CMV	O
minimal	O
promoter	O
and	O
was	O
kindly	O
provided	O
by	O
Ute	O
Pagelow	O
and	O
Mario	O
Koster	O
from	O
the	O
Helmholtz	O
-	O
Zentrum	O
fur	O
Infektionsforschung	O
.	O

Plasmid	O
pNL4	O
-	O
3	O
(	O
NIBSC	O
,	O
UK	O
)	O
contains	O
the	O
full	O
-	O
length	O
HIV	O
-	O
1NL4	O
-	O
3	O
genome	O
and	O
has	O
been	O
described	O
previously	O
(	O
34	O
)	O
.	O

pcDNA3	O
.	O
1Vif	O
was	O
generously	O
provided	O
by	O
Nathaniel	O
R	O
.	O
Landau	O
from	O
the	O
Salk	O
Institute	O
,	O
La	O
Jolla	O
.	O

It	O
was	O
generated	O
by	O
amplifying	O
the	O
Vif	B-Protein
gene	O
from	O
pNL4	O
-	O
3	O
and	O
ligating	O
it	O
into	O
the	O
pcDNA3	O
.	O
1	O
vector	O
via	O
BamHI	O
and	O
XhoI	O
restriction	O
sites	O
.	O

A	O
3	O
'	O
-	O
WPRE	O
element	O
was	O
included	O
into	O
the	O
XhoI	O
site	O
.	O

pBS	O
-	O
kRSPA	O
-	O
TatHIV	B-Protein
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
was	O
constructed	O
by	O
amplifying	O
the	O
two	O
exons	O
of	O
Tat	B-Protein
via	O
PCR	O
reaction	O
using	O
the	O
molecular	O
clone	O
pNL4	O
-	O
3	O
as	O
template	O
and	O
the	O
following	O
primer	O
sets	O
:	O
exon1	O
,	O
5UXho1HIV	O
-	O
Tat1Plus	B-Protein
(	O
5	O
'	O
-	O
GCATGCTCGAGATGGAGCCAGTAGATCCTAG	O
-	O
3	O
'	O
)	O
and	O
HIV	O
-	O
Tat1Minus	B-Protein
(	O
5	O
'	O
-	O
TGCTTTGATAGAGAAGCTTGATG	O
-	O
3	O
'	O
)	O
;	O
exon2	O
,	O
15FHIV	O
-	O
Tat2Plus	B-Protein
(	O
5	O
'	O
-	O
TTCTCTATCAAAGCAACCCACCTCCCAATCCCG	O
-	O
3	O
'	O
)	O
and	O
5USpe1HIV	O
-	O
Tat2Minus	B-Protein
(	O
5	O
'	O
-	O
GACGTACTAGTCTATTCCTTCGGGCCTGTC	O
-	O
3	O
'	O
)	O
.	O

XhoI	O
and	O
SpeI	O
restriction	O
sites	O
were	O
introduced	O
via	O
the	O
primers	O
.	O

The	O
sense	O
-	O
primer	O
of	O
exon2	O
starts	O
with	O
a	O
15	O
-	O
mer	O
which	O
is	O
homologous	O
to	O
the	O
3	O
'	O
end	O
of	O
exon1	O
and	O
necessary	O
for	O
fusion	O
of	O
both	O
exons	O
.	O

PCRs	O
were	O
performed	O
with	O
Expand	O
High	O
Fidelity	O
PCR	O
System	O
(	O
Roche	O
)	O
using	O
the	O
following	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
55degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
45	O
s	O
;	O
one	O
cycle	O
68degreesC	O
for	O
7	O
min	O
.	O

For	O
fusion	O
of	O
both	O
exons	O
,	O
the	O
following	O
PCR	O
conditions	O
were	O
applied	O
:	O
one	O
cycle	O
94degreesC	O
for	O
3	O
min	O
;	O
35	O
cycles	O
94degreesC	O
for	O
45	O
s	O
,	O
58degreesC	O
for	O
45	O
s	O
,	O
68degreesC	O
for	O
60	O
s	O
.	O

After	O
10	O
cycles	O
without	O
primers	O
,	O
the	O
sense	O
-	O
primer	O
of	O
exon1	O
and	O
the	O
antisense	O
-	O
primer	O
of	O
exon2	O
were	O
added	O
for	O
the	O
remaining	O
cycles	O
.	O

The	O
resulting	O
amplicon	O
was	O
ligated	O
into	O
the	O
pBS	O
-	O
kRSPA	O
vector	O
(	O
35	O
)	O
via	O
XhoI	O
and	O
SpeI	O
restriction	O
sites	O
.	O

5	O
'	O
-	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O
<EOS>	B-X
A	B-X
promising	B-X
alternative	B-X
is	B-X
5'-RACE	B-X
,	B-X
which	B-X
avoids	B-X
primer	B-X
bias	B-X
by	B-X
applying	B-X
only	B-X
one	B-X
primer	B-X
pair	B-X
.	B-X
In	B-X
5'-RACE	B-X
data	B-X
,	B-X
however	B-X
,	B-X
non-regular	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombination	B-X
(	B-X
e.g.	B-X
,	B-X
TCR	B-X
sequences	B-X
without	B-X
a	B-X
V	B-X
gene	B-X
segment	B-X
)	B-X
has	B-X
been	B-X
observed	B-X
and	B-X
the	B-X
frequency	B-X
varies	B-X
(	B-X
30-80	B-X
%	B-X
)	B-X
between	B-X
studies	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
speculate	B-X
the	B-X
cause	B-X
by	B-X
comparing	B-X
the	B-X
5'-RACE	B-X
protocols	B-X
,	B-X
careful	B-X
experimental	B-X
confirmation	B-X
is	B-X
needed	B-X
and	B-X
such	B-X
a	B-X
systematic	B-X
study	B-X
is	B-X
still	B-X
not	B-X
available	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
5'-RACE	B-X
protocol	B-X
of	B-X
a	B-X
commercial	B-X
kit	B-X
and	B-X
demonstrated	B-X
how	B-X
a	B-X
modification	B-X
increased	B-X
the	B-X
fraction	B-X
of	B-X
regular	B-X
TCR-β	B-X
sequences	B-X
to	B-X
>	B-X
85	B-X
%	B-X
.	B-X
Therefore	B-X
,	B-X
thorough	B-X
removal	B-X
of	B-X
short	B-X
DNA	B-X
fragments	B-X
from	B-X
a	B-X
5'-RACE	B-X
library	B-X
is	B-X
the	B-X
key	B-X
to	B-X
high	B-X
data	B-X
efficiency	B-X
.	B-X
We	B-X
highly	B-X
recommend	B-X
conducting	B-X
a	B-X
fragment	B-X
length	B-X
analysis	B-X
before	B-X
sequencing	B-X
,	B-X
and	B-X
the	B-X
fraction	B-X
of	B-X
short	B-X
DNA	B-X
fragments	B-X
can	B-X
be	B-X
used	B-X
to	B-X
estimate	B-X
the	B-X
percentage	B-X
of	B-X
non-regular	B-X
TCR	B-X
sequences	B-X
.	B-X

Total	O
RNA	O
was	O
isolated	O
from	O
A3	O
.	O
01	O
T	O
cells	O
using	O
RNeasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
.	O

The	O
transcriptional	O
start	O
sites	O
of	O
A3G	B-Protein
were	O
identified	O
using	O
the	O
5	O
'	O
/	O
3	O
'	O
RACE	O
Kit	O
,	O
2nd	O
Generation	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
following	O
primers	O
were	O
used	O
:	O
RACE	O
-	O
APO3G1	O
(	O
5	O
'	O
-	O
TATCCCTTGTACACTTTGT	O
-	O
3	O
'	O
)	O
for	O
cDNA	O
synthesis	O
,	O
RACE	O
-	O
APO3G2	O
(	O
5	O
'	O
-	O
CATACTCCTGGTCACGAT	O
-	O
3	O
'	O
)	O
for	O
the	O
first	O
PCR	O
and	O
RACE	O
-	O
APO3Gnest	O
(	O
5	O
'	O
-	O
GAATACACCTGGCCTCGAA	O
-	O
3	O
'	O
)	O
for	O
the	O
nested	O
PCR	O
.	O
<EOS>	B-X
cDNAs	B-X
whose	B-X
first-strand	B-X
synthesis	B-X
has	B-X
been	B-X
primed	B-X
by	B-X
oligo	B-X
(	B-X
dT	B-X
)	B-X
generally	B-X
contain	B-X
the	B-X
3	B-X
'	B-X
sequences	B-X
of	B-X
the	B-X
RNA	B-X
.	B-X
However	B-X
,	B-X
cDNAs	B-X
generated	B-X
by	B-X
internal	B-X
gene-specific	B-X
primers	B-X
will	B-X
usually	B-X
lack	B-X
one	B-X
or	B-X
both	B-X
terminal	B-X
regions	B-X
of	B-X
the	B-X
parental	B-X
mRNA	B-X
.	B-X
And	B-X
alternate	B-X
splicing	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
internal	B-X
A-rich	B-X
tract	B-X
can	B-X
generate	B-X
cDNA	B-X
clones	B-X
that	B-X
lack	B-X
3	B-X
'	B-X
sequences	B-X
.	B-X
These	B-X
sequences	B-X
can	B-X
be	B-X
recovered	B-X
using	B-X
3'-RACE	B-X
(	B-X
rapid	B-X
amplification	B-X
of	B-X
cDNA	B-X
ends	B-X
)	B-X
,	B-X
which	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
map	B-X
the	B-X
3	B-X
'	B-X
termini	B-X
of	B-X
families	B-X
of	B-X
mRNAs	B-X
with	B-X
alternative	B-X
polyadenylation	B-X
sites	B-X
.	B-X
Briefly	B-X
,	B-X
a	B-X
population	B-X
of	B-X
mRNAs	B-X
is	B-X
transcribed	B-X
into	B-X
cDNA	B-X
using	B-X
an	B-X
adaptor-primer	B-X
with	B-X
a	B-X
poly	B-X
(	B-X
T	B-X
)	B-X
at	B-X
its	B-X
3	B-X
'	B-X
end	B-X
and	B-X
30-40	B-X
nt	B-X
containing	B-X
the	B-X
recognition	B-X
sites	B-X
for	B-X
two	B-X
or	B-X
three	B-X
restriction	B-X
enzymes	B-X
at	B-X
its	B-X
5	B-X
'	B-X
end	B-X
.	B-X
Reverse	B-X
transcription	B-X
is	B-X
usually	B-X
followed	B-X
by	B-X
two	B-X
successive	B-X
rounds	B-X
of	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
The	B-X
first	B-X
is	B-X
primed	B-X
by	B-X
a	B-X
gene-specific	B-X
sense	B-X
oligonucleotide	B-X
and	B-X
the	B-X
antisense	B-X
(	B-X
dT	B-X
)	B-X
adaptor-primer	B-X
.	B-X
The	B-X
products	B-X
of	B-X
the	B-X
first	B-X
PCR	B-X
can	B-X
be	B-X
used	B-X
as	B-X
templates	B-X
for	B-X
a	B-X
second	B-X
,	B-X
nested	B-X
PCR	B-X
,	B-X
which	B-X
is	B-X
primed	B-X
by	B-X
a	B-X
gene-specific	B-X
sense	B-X
oligonucleotide	B-X
internal	B-X
to	B-X
the	B-X
first	B-X
,	B-X
and	B-X
a	B-X
second	B-X
antisense	B-X
oligonucleotide	B-X
whose	B-X
sequence	B-X
is	B-X
identical	B-X
to	B-X
the	B-X
central	B-X
region	B-X
of	B-X
the	B-X
(	B-X
dT	B-X
)	B-X
adaptor-primer	B-X
.	B-X
The	B-X
products	B-X
amplified	B-X
in	B-X
the	B-X
second	B-X
PCR	B-X
are	B-X
isolated	B-X
,	B-X
cleaved	B-X
with	B-X
a	B-X
suitable	B-X
restriction	B-X
enzyme	B-X
,	B-X
cloned	B-X
,	B-X
and	B-X
characterized	B-X
.	B-X

Reaction	O
products	O
were	O
analyzed	O
by	O
agarose	O
gel	O
electrophoresis	O
,	O
purified	O
using	O
QIAquick	O
gel	O
extraction	O
kit	O
(	O
Qiagen	O
)	O
,	O
T	O
/	O
A	O
-	O
cloned	O
into	O
vector	O
pCR4	O
-	O
TOPO	O
(	O
Invitrogen	O
)	O
and	O
sequenced	O
.	O

Luciferase	B-Protein
assay	O
<EOS>	B-X
The	B-X
split-luciferase	B-X
complementation	B-X
assay	B-X
makes	B-X
the	B-X
study	B-X
of	B-X
two	B-X
or	B-X
more	B-X
interacting	B-X
proteins	B-X
possible	B-X
.	B-X
Split	B-X
luciferase	B-X
is	B-X
an	B-X
effective	B-X
tool	B-X
for	B-X
assaying	B-X
biochemical	B-X
metabolites	B-X
,	B-X
where	B-X
a	B-X
domain	B-X
or	B-X
an	B-X
intact	B-X
protein	B-X
is	B-X
inserted	B-X
into	B-X
an	B-X
internally	B-X
fragmented	B-X
luciferase	B-X
,	B-X
resulting	B-X
in	B-X
ligand	B-X
binding	B-X
,	B-X
which	B-X
causes	B-X
a	B-X
change	B-X
in	B-X
the	B-X
emitted	B-X
signals	B-X
.	B-X
We	B-X
review	B-X
the	B-X
various	B-X
applications	B-X
of	B-X
this	B-X
novel	B-X
luminescent	B-X
biosensor	B-X
in	B-X
studying	B-X
protein-protein	B-X
interactions	B-X
and	B-X
assaying	B-X
metabolites	B-X
involved	B-X
in	B-X
analytical	B-X
biochemistry	B-X
,	B-X
cell	B-X
communication	B-X
and	B-X
cell	B-X
signaling	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
and	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
whole	B-X
cell	B-X
,	B-X
and	B-X
show	B-X
that	B-X
luciferase-based	B-X
biosensors	B-X
are	B-X
powerful	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
applied	B-X
for	B-X
diagnostic	B-X
and	B-X
therapeutic	B-X
purposes	B-X
.	B-X
Luciferase	B-X
assays	B-X
are	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
identifying	B-X
and	B-X
characterizing	B-X
functional	B-X
variants	B-X
,	B-X
allowing	B-X
investigations	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
intracellular	B-X
signaling	B-X
,	B-X
transcription	B-X
factors	B-X
,	B-X
receptor	B-X
activity	B-X
,	B-X
and	B-X
protein	B-X
folding	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
different	B-X
ways	B-X
that	B-X
luciferase	B-X
assays	B-X
can	B-X
be	B-X
used	B-X
to	B-X
validate	B-X
functionality	B-X
of	B-X
a	B-X
variant	B-X
.	B-X

For	O
transient	O
transfection	O
of	O
A3	O
.	O
01	O
and	O
U937	O
cells	O
,	O
DMRIE	O
-	O
C	O
transfection	O
reagent	O
(	O
Life	O
Technologies	O
)	O
was	O
used	O
(	O
36	O
)	O
.	O

Cells	O
were	O
seeded	O
in	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
(	O
5	O
x	O
105	O
cells	O
per	O
well	O
)	O
in	O
1	O
.	O
5	O
ml	O
Opti	O
-	O
MEM	O
(	O
Life	O
Technologies	O
)	O
containing	O
0	O
.	O
5	O
microg	O
firefly	O
luciferase	B-Protein
reporter	O
plasmid	O
and	O
3	O
.	O
5	O
microl	O
DMRIE	O
-	O
C	O
.	O

After	O
4	O
-	O
5	O
h	O
of	O
incubation	O
,	O
1	O
.	O
5	O
ml	O
complete	O
RPMI	O
medium	O
were	O
added	O
.	O
<EOS>	B-X
Measurement	B-X
of	B-X
frequencies	B-X
of	B-X
6-thioguanine-resistant	B-X
(	B-X
TGr	B-X
)	B-X
human	B-X
peripheral	B-X
lymphocytes	B-X
may	B-X
contribute	B-X
to	B-X
quantitative	B-X
genetic	B-X
risk	B-X
assessment	B-X
in	B-X
occupationally	B-X
or	B-X
environmentally	B-X
exposed	B-X
human	B-X
populations	B-X
.	B-X
A	B-X
simple	B-X
procedure	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
TGr	B-X
human	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
was	B-X
developed	B-X
in	B-X
our	B-X
laboratory	B-X
,	B-X
using	B-X
whole	B-X
blood	B-X
culturing	B-X
and	B-X
5-bromodeoxyuridine	B-X
(	B-X
BrdU	B-X
)	B-X
labeling	B-X
in	B-X
combination	B-X
with	B-X
immunocytochemical	B-X
staining	B-X
.	B-X
Modifications	B-X
of	B-X
the	B-X
procedure	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
false	B-X
positive	B-X
effects	B-X
of	B-X
spontaneously	B-X
cycling	B-X
lymphocytes	B-X
(	B-X
phenocopies	B-X
)	B-X
,	B-X
and	B-X
to	B-X
optimize	B-X
duration	B-X
of	B-X
BrdU	B-X
labeling	B-X
and	B-X
the	B-X
culturing	B-X
period	B-X
,	B-X
were	B-X
evaluated	B-X
.	B-X
A	B-X
standard	B-X
procedure	B-X
was	B-X
developed	B-X
which	B-X
applied	B-X
24	B-X
h	B-X
cold	B-X
storage	B-X
of	B-X
the	B-X
diluted	B-X
heparinized	B-X
blood	B-X
(	B-X
1:10	B-X
,	B-X
v	B-X
:	B-X
v	B-X
in	B-X
RPMI	B-X
1640	B-X
medium	B-X
)	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
to	B-X
reduce	B-X
the	B-X
effect	B-X
of	B-X
spontaneously	B-X
cycling	B-X
lymphocytes	B-X
,	B-X
and	B-X
whole	B-X
blood	B-X
culturing	B-X
in	B-X
RPMI	B-X
1640	B-X
complete	B-X
medium	B-X
with	B-X
stimulation	B-X
of	B-X
T	B-X
lymphocytes	B-X
using	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
,	B-X
selection	B-X
of	B-X
TGr	B-X
lymphocytes	B-X
by	B-X
adding	B-X
TG	B-X
to	B-X
a	B-X
final	B-X
concentration	B-X
of	B-X
2	B-X
x	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
M	B-X
and	B-X
,	B-X
after	B-X
24	B-X
h	B-X
of	B-X
incubation	B-X
,	B-X
labeling	B-X
of	B-X
TGr	B-X
lymphocytes	B-X
with	B-X
2.5	B-X
x	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
BrdU	B-X
during	B-X
16	B-X
h.	B-X
Using	B-X
this	B-X
standard	B-X
procedure	B-X
,	B-X
frequencies	B-X
of	B-X
TGr	B-X
cells	B-X
in	B-X
45	B-X
healthy	B-X
individuals	B-X
(	B-X
aged	B-X
21-64	B-X
)	B-X
were	B-X
observed	B-X
to	B-X
range	B-X
from	B-X
0.3	B-X
to	B-X
229.8	B-X
x	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
,	B-X
with	B-X
a	B-X
mean	B-X
variant	B-X
frequency	B-X
(	B-X
VF	B-X
)	B-X
(	B-X
+/-	B-X
SD	B-X
)	B-X
of	B-X
136	B-X
x	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
(	B-X
+/-	B-X
35.8	B-X
)	B-X
.	B-X
After	B-X
exclusion	B-X
of	B-X
the	B-X
one	B-X
extremely	B-X
high	B-X
value	B-X
of	B-X
229.8	B-X
x	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
,	B-X
mean	B-X
VF	B-X
was	B-X
8.7	B-X
x	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
(	B-X
+/-	B-X
14.1	B-X
)	B-X
.	B-X
A	B-X
significant	B-X
inverse	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
logVF	B-X
and	B-X
the	B-X
labeling	B-X
index	B-X
of	B-X
control	B-X
cultures	B-X
(	B-X
LIc	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
cultures	B-X
with	B-X
low	B-X
LIc	B-X
tend	B-X
to	B-X
yield	B-X
higher	B-X
VF	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

HepG2	O
and	O
Huh7	O
cell	O
lines	O
were	O
transfected	O
using	O
LipofectAMINE	O
Plus	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Life	O
Technologies	O
)	O
.	O

Briefly	O
,	O
exponential	O
growing	O
cells	O
(	O
1	O
.	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
5	O
microl	O
LipofectAMINE	O
,	O
6	O
microl	O
PLUS	O
reagent	O
and	O
the	O
required	O
amount	O
of	O
plasmid	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
Opti	O
-	O
MEM	O
.	O

Following	O
4	O
h	O
of	O
incubation	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
and	O
3	O
ml	O
of	O
complete	O
DMEM	O
medium	O
were	O
added	O
.	O

For	O
cotransfection	O
of	O
reporter	O
plasmids	O
and	O
siRNA	O
into	O
HeLa	O
cells	O
,	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
cotransfection	O
of	O
adherent	O
cells	O
with	O
siRNA	O
and	O
plasmid	O
DNA	O
.	O

Two	O
days	O
after	O
transfection	O
of	O
the	O
respective	O
cell	O
lines	O
,	O
cells	O
were	O
harvested	O
in	O
100	O
microl	O
(	O
suspension	O
cells	O
)	O
or	O
300	O
microl	O
(	O
adherent	O
cells	O
)	O
of	O
Passive	O
Lysis	O
Buffer	O
(	O
Promega	O
)	O
and	O
luciferase	B-Protein
assay	O
was	O
performed	O
using	O
the	O
Dual	O
Luciferase	O
Assay	O
System	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

As	O
an	O
internal	O
control	O
,	O
50	O
ng	O
(	O
adherent	O
cells	O
)	O
or	O
100	O
ng	O
(	O
suspension	O
cells	O
)	O
of	O
ph	O
-	O
RG	O
-	O
TK	O
plasmid	O
(	O
Promega	O
)	O
,	O
which	O
constitutively	O
expresses	O
renilla	O
luciferase	B-Protein
was	O
cotransfected	O
in	O
every	O
sample	O
and	O
firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
renilla	O
luciferase	B-Protein
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
in	O
the	O
figures	O
.	O

For	O
stimulation	O
of	O
cells	O
,	O
final	O
concentrations	O
of	O
20	O
ng	O
/	O
ml	O
TPA	O
(	O
Sigma	O
)	O
or	O
30	O
ng	O
/	O
ml	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
30	O
ng	O
/	O
ml	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Tebu	O
-	O
Bio	O
)	O
were	O
applied	O
approximately	O
15	O
h	O
before	O
harvesting	O
for	O
luciferase	B-Protein
assay	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
classical	B-X
assay	B-X
,	B-X
solutions	B-X
of	B-X
protein	B-X
and	B-X
nucleic	B-X
acid	B-X
are	B-X
combined	B-X
and	B-X
the	B-X
resulting	B-X
mixtures	B-X
are	B-X
subjected	B-X
to	B-X
electrophoresis	B-X
under	B-X
native	B-X
conditions	B-X
through	B-X
polyacrylamide	B-X
or	B-X
agarose	B-X
gel	B-X
.	B-X
In	B-X
this	B-X
protocol	B-X
,	B-X
we	B-X
identify	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
that	B-X
determine	B-X
the	B-X
stabilities	B-X
and	B-X
electrophoretic	B-X
mobilities	B-X
of	B-X
complexes	B-X
under	B-X
assay	B-X
conditions	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
to	B-X
detect	B-X
formation	B-X
of	B-X
complexes	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
and	B-X
to	B-X
determine	B-X
,	B-X
among	B-X
other	B-X
parameters	B-X
,	B-X
equilibrium	B-X
constants	B-X
for	B-X
the	B-X
interaction	B-X
.	B-X

For	O
preparation	O
of	O
nuclear	O
extracts	O
,	O
5	O
x	O
106	O
A3	O
.	O
01	O
T	O
cells	O
were	O
washed	O
in	O
cold	O
PBS	O
and	O
resuspended	O
in	O
500	O
microl	O
buffer	O
A	O
(	O
10	O
mM	O
HEPES	O
pH7	O
.	O
9	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
1	O
mM	O
EGTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
)	O
.	O

After	O
incubation	O
for	O
15	O
min	O
on	O
ice	O
,	O
swollen	O
cells	O
were	O
pressed	O
10	O
times	O
through	O
a	O
syringe	O
with	O
a	O
26G	O
needle	O
and	O
centrifuged	O
at	O
5000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
5	O
min	O
.	O

Pellets	O
contained	O
the	O
nuclei	O
and	O
were	O
washed	O
in	O
buffer	O
A	O
for	O
two	O
times	O
and	O
resuspended	O
in	O
50	O
microl	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
400	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
)	O
.	O

After	O
shaking	O
for	O
30	O
min	O
at	O
4degreesC	O
and	O
centrifugation	O
for	O
10	O
min	O
at	O
13	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
,	O
supernatants	O
were	O
used	O
as	O
nuclear	O
extracts	O
.	O

EMSA	O
probes	O
were	O
generated	O
by	O
annealing	O
the	O
following	O
complementary	O
oligonucleotides	O
:	O
APO	O
-	O
Sp1	B-Protein
/	O
3	O
,	O
5	O
'	O
-	O
CCAGCTGGGCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCCCCTCCCCTGGTGGTCCCGCCCAGCTGG	O
-	O
3	O
'	O
;	O
APO	O
-	O
Sp1	B-Protein
/	O
3mut	O
,	O
5	O
'	O
-	O
CCAGCTGTTCGGGACCACCAGGGGAGGGGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCCCCTCCCCTGGTGGTCCCGAACAGCTGG	O
-	O
3	O
'	O
according	O
to	O
standard	O
procedures	O
.	O

Nucleotides	O
differing	O
from	O
the	O
original	O
promoter	O
sequence	O
are	O
shown	O
in	O
bold	O
type	O
.	O

A	O
commercially	O
available	O
Sp1	B-Protein
probe	O
(	O
sc	O
-	O
2502	O
,	O
referred	O
to	O
as	O
Sp1cons	O
)	O
was	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

The	O
double	O
-	O
stranded	O
oligonucleotides	O
were	O
5	O
'	O
end	O
-	O
labeled	O
using	O
T4	B-Protein
polynucleotide	I-Protein
kinase	I-Protein
(	O
New	O
England	O
Biolabs	O
)	O
and	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
(	O
3000	O
Ci	O
/	O
mmol	O
,	O
Amersham	O
)	O
and	O
purified	O
by	O
using	O
Nick	O
G50	O
columns	O
(	O
Amersham	O
)	O
.	O

For	O
EMSA	O
,	O
5	O
microg	O
of	O
nuclear	O
proteins	O
were	O
preincubated	O
on	O
ice	O
with	O
2	O
microg	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Roche	O
)	O
as	O
an	O
unspecific	O
competitor	O
and	O
1	O
microg	O
of	O
bovine	B-Protein
serum	I-Protein
albumin	I-Protein
in	O
band	O
shift	O
buffer	O
(	O
50	O
mM	O
Tris	O
,	O
150	O
mM	O
KCl	O
,	O
5	O
mM	O
EDTA	O
,	O
2	O
.	O
5	O
mM	O
dithiothreitol	O
,	O
20	O
%	O
Ficoll	O
)	O
for	O
15	O
min	O
.	O

32P	O
-	O
labeled	O
oligonucleotides	O
(	O
50	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
)	O
were	O
added	O
in	O
a	O
total	O
volume	O
of	O
20	O
microl	O
,	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
5	O
%	O
native	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5xTris	O
-	O
borate	O
-	O
EDTA	O
buffer	O
.	O

Upon	O
fractionation	O
,	O
gels	O
were	O
dried	O
and	O
exposed	O
for	O
autoradiography	O
.	O
<EOS>	B-X
Collagenase-treated	B-X
isolated	B-X
cells	B-X
,	B-X
prepared	B-X
from	B-X
epididymal	B-X
fat	B-X
pads	B-X
of	B-X
Sprague-Dawley	B-X
rats	B-X
exposed	B-X
to	B-X
32Pi	B-X
or	B-X
(	B-X
gamma-32P	B-X
)	B-X
-ATP	B-X
,	B-X
result	B-X
in	B-X
differences	B-X
in	B-X
label	B-X
incorporation	B-X
into	B-X
peptides	B-X
as	B-X
determined	B-X
by	B-X
autoradiography	B-X
of	B-X
dried	B-X
SDS	B-X
polyacrylamide	B-X
gels	B-X
.	B-X
(	B-X
gamma-32P	B-X
)	B-X
-ATP	B-X
exposed	B-X
cells	B-X
gave	B-X
a	B-X
dose-dependent	B-X
increase	B-X
in	B-X
a	B-X
53,000-dalton	B-X
band	B-X
,	B-X
a	B-X
finding	B-X
shared	B-X
by	B-X
cells	B-X
exposed	B-X
to	B-X
cAMP	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
epinephrine	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
the	B-X
53,000-	B-X
and	B-X
the	B-X
18,000-dalton	B-X
peptides	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
that	B-X
catalyze	B-X
their	B-X
phosphorylation	B-X
on	B-X
the	B-X
external	B-X
surface	B-X
of	B-X
the	B-X
fat	B-X
cell	B-X
is	B-X
supported	B-X
by	B-X
studies	B-X
using	B-X
a	B-X
number	B-X
of	B-X
macromolecular	B-X
probes	B-X
as	B-X
well	B-X
as	B-X
by	B-X
subcellular	B-X
fractionation	B-X
studies	B-X
.	B-X

For	O
competition	O
experiments	O
,	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1	B-Protein
/	O
3	O
or	O
APO	O
-	O
Sp1	B-Protein
/	O
3mut	O
oligonucleotides	O
was	O
added	O
to	O
the	O
preincubation	O
mixture	O
.	O
<EOS>	B-X
The	B-X
TAZ1	B-X
domain	B-X
of	B-X
CREB	B-X
binding	B-X
protein	B-X
is	B-X
crucial	B-X
for	B-X
transcriptional	B-X
regulation	B-X
and	B-X
recognizes	B-X
multiple	B-X
targets	B-X
.	B-X
The	B-X
interactions	B-X
between	B-X
TAZ1	B-X
and	B-X
its	B-X
specific	B-X
targets	B-X
are	B-X
related	B-X
to	B-X
the	B-X
cellular	B-X
hypoxic	B-X
negative	B-X
feedback	B-X
regulation	B-X
.	B-X
Previous	B-X
experiments	B-X
reported	B-X
that	B-X
one	B-X
of	B-X
the	B-X
TAZ1	B-X
targets	B-X
,	B-X
CITED2	B-X
,	B-X
is	B-X
an	B-X
efficient	B-X
competitor	B-X
of	B-X
another	B-X
target	B-X
,	B-X
HIF-1α	B-X
.	B-X
Here	B-X
,	B-X
by	B-X
developing	B-X
the	B-X
structure-based	B-X
models	B-X
of	B-X
TAZ1	B-X
complexes	B-X
,	B-X
we	B-X
have	B-X
uncovered	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
the	B-X
competitions	B-X
between	B-X
the	B-X
two	B-X
intrinsic	B-X
disordered	B-X
proteins	B-X
(	B-X
IDPs	B-X
)	B-X
HIF-1α	B-X
and	B-X
CITED2	B-X
binding	B-X
to	B-X
TAZ1	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
the	B-X
experimental	B-X
hypothesis	B-X
on	B-X
the	B-X
competition	B-X
mechanisms	B-X
and	B-X
the	B-X
apparent	B-X
affinity	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
simulations	B-X
locate	B-X
the	B-X
dominant	B-X
position	B-X
of	B-X
forming	B-X
TAZ1-CITED2	B-X
complex	B-X
in	B-X
both	B-X
thermodynamics	B-X
and	B-X
kinetics	B-X
.	B-X
For	B-X
thermodynamics	B-X
,	B-X
TAZ1-CITED2	B-X
is	B-X
the	B-X
lowest	B-X
basin	B-X
located	B-X
on	B-X
the	B-X
free	B-X
energy	B-X
surface	B-X
of	B-X
binding	B-X
in	B-X
the	B-X
ternary	B-X
system	B-X
.	B-X
For	B-X
kinetics	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
CITED2	B-X
binds	B-X
to	B-X
TAZ1	B-X
faster	B-X
than	B-X
HIF-1α	B-X
.	B-X

For	O
supershift	O
experiments	O
,	O
2	O
microg	O
Sp1	B-Protein
antibody	O
(	O
sc	O
-	O
59x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
Sp3	B-Protein
antibody	O
(	O
sc	O
-	O
644x	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
added	O
to	O
the	O
preincubation	O
mixture	O
and	O
preincubation	O
time	O
was	O
extended	O
to	O
30	O
min	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
an	B-X
important	B-X
technique	B-X
in	B-X
the	B-X
study	B-X
of	B-X
protein-gene	B-X
interactions	B-X
.	B-X
Using	B-X
ChIP	B-X
,	B-X
DNA-protein	B-X
interactions	B-X
are	B-X
studied	B-X
within	B-X
the	B-X
context	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
The	B-X
basic	B-X
steps	B-X
in	B-X
this	B-X
technique	B-X
are	B-X
fixation	B-X
,	B-X
sonication	B-X
,	B-X
immunoprecipitation	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
the	B-X
immunoprecipitated	B-X
DNA	B-X
.	B-X
Although	B-X
ChIP	B-X
is	B-X
a	B-X
very	B-X
versatile	B-X
tool	B-X
,	B-X
the	B-X
procedure	B-X
requires	B-X
the	B-X
optimization	B-X
of	B-X
reaction	B-X
conditions	B-X
.	B-X
Several	B-X
modifications	B-X
to	B-X
the	B-X
original	B-X
ChIP	B-X
technique	B-X
have	B-X
been	B-X
published	B-X
to	B-X
improve	B-X
the	B-X
success	B-X
and	B-X
to	B-X
enhance	B-X
the	B-X
utility	B-X
of	B-X
this	B-X
procedure	B-X
.	B-X
This	B-X
review	B-X
addresses	B-X
the	B-X
critical	B-X
parameters	B-X
and	B-X
the	B-X
variants	B-X
of	B-X
ChiP	B-X
as	B-X
well	B-X
as	B-X
the	B-X
different	B-X
analytical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
combined	B-X
with	B-X
ChIP	B-X
to	B-X
enable	B-X
better	B-X
understanding	B-X
of	B-X
DNA-protein	B-X
interactions	B-X
in	B-X
vivo	B-X
.	B-X

A3	O
.	O
01	O
cells	O
were	O
treated	O
with	O
RPMI	O
culture	O
medium	O
containing	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
.	O
at	O
37degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
incubated	O
for	O
10	O
min	O
.	O
on	O
ice	O
after	O
resuspension	O
in	O
SDS	O
lysis	O
buffer	O
(	O
ChIP	O
Assay	O
Kit	O
,	O
Upstate	O
)	O
.	O

After	O
centrifugation	O
,	O
pellets	O
were	O
resuspended	O
in	O
MNase	O
reaction	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
10	O
mM	O
NaCl	O
,	O
3	O
mM	O
MgCl2	O
,	O
1	O
mM	O
CaCl2	O
,	O
4	O
%	O
NP	O
-	O
40	O
)	O
.	O

DNA	O
digestion	O
was	O
performed	O
using	O
50	O
U	O
Micrococcal	B-Protein
Nuclease	I-Protein
(	O
Fermentas	O
)	O
and	O
1	O
x	O
107	O
cells	O
per	O
tube	O
in	O
a	O
volume	O
of	O
1	O
.	O
5	O
ml	O
.	O

After	O
2	O
min	O
,	O
reaction	O
was	O
stopped	O
by	O
adding	O
30	O
microl	O
200	O
mM	O
EGTA	O
.	O

Further	O
steps	O
were	O
performed	O
using	O
the	O
Chromatin	O
Immunoprecipitation	O
Assay	O
Kit	O
(	O
Upstate	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

1	O
x	O
107	O
cells	O
and	O
2	O
microg	O
antibody	O
(	O
Sp1	B-Protein
(	O
Pep2	O
)	O
sc	O
-	O
59	O
,	O
Sp3	B-Protein
(	O
D	O
-	O
20	O
)	O
sc	O
-	O
644	O
or	O
actin	B-Protein
(	O
H	O
-	O
196	O
)	O
sc	O
-	O
7210	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
were	O
used	O
for	O
each	O
immunoprecipitation	O
.	O

All	O
buffers	O
were	O
freshly	O
supplied	O
with	O
protease	O
inhibitors	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
freshly	B-X
isolated	B-X
,	B-X
nontransformed	B-X
lacrimal	B-X
gland	B-X
acini	B-X
express	B-X
two	B-X
of	B-X
the	B-X
three	B-X
known	B-X
alpha	B-X
(	B-X
1	B-X
)	B-X
-adrenergic	B-X
receptors	B-X
(	B-X
ARs	B-X
)	B-X
,	B-X
namely	B-X
,	B-X
alpha	B-X
(	B-X
1B	B-X
)	B-X
-	B-X
and	B-X
alpha	B-X
(	B-X
1D	B-X
)	B-X
-ARs	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
phenylephrine	B-X
caused	B-X
the	B-X
shedding	B-X
of	B-X
EGF	B-X
from	B-X
freshly	B-X
isolated	B-X
acini	B-X
into	B-X
the	B-X
buffer	B-X
.	B-X
Incubation	B-X
of	B-X
freshly	B-X
isolated	B-X
cells	B-X
with	B-X
conditioned	B-X
buffer	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
phenylephrine	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
EGF	B-X
receptor	B-X
and	B-X
p42/p44	B-X
MAPK	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
in	B-X
freshly	B-X
isolated	B-X
lacrimal	B-X
gland	B-X
acini	B-X
,	B-X
alpha	B-X
(	B-X
1	B-X
)	B-X
-adrenergic	B-X
agonists	B-X
activate	B-X
the	B-X
alpha	B-X
(	B-X
1D	B-X
)	B-X
-AR	B-X
to	B-X
stimulate	B-X
protein	B-X
secretion	B-X
and	B-X
the	B-X
ectodomain	B-X
shedding	B-X
of	B-X
EGF	B-X
to	B-X
transactivate	B-X
the	B-X
EGF	B-X
receptor	B-X
,	B-X
potentially	B-X
via	B-X
ADAM17	B-X
,	B-X
which	B-X
activates	B-X
p42/p44	B-X
MAPK	B-X
to	B-X
negatively	B-X
modulate	B-X
protein	B-X
secretion	B-X
.	B-X

After	O
phenol	O
/	O
chloroform	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
DNA	O
was	O
resolved	O
in	O
16	O
microl	O
H2O	O
.	O

Immunoprecipitated	O
DNA	O
was	O
detected	O
by	O
nested	O
PCR	O
using	O
4	O
microl	O
of	O
the	O
resolved	O
DNA	O
in	O
the	O
first	O
PCR	O
,	O
and	O
1	O
microl	O
for	O
the	O
nested	O
PCR	O
.	O

For	O
amplification	O
of	O
the	O
A3G	B-Protein
promoter	O
,	O
the	O
following	O
primers	O
were	O
used	O
:	O
ChIP3Gplus	O
5	O
'	O
-	O
ccacggtggcctccgagggtga	O
-	O
3	O
'	O
and	O
ChIP3Gminus	O
:	O
5	O
'	O
-	O
ctctccaccatcaagacagac	O
-	O
3	O
'	O
(	O
1	O
.	O
PCR	O
)	O
;	O
ChIP3G2plus	O
:	O
5	O
'	O
-	O
tactctccctccctgtcccca	O
-	O
3	O
'	O
and	O
ChIP3G	O
nested	O
minus	O
:	O
5	O
'	O
-	O
aggctgatgcctccgcag	O
-	O
3	O
'	O
(	O
nested	O
PCR	O
)	O
.	O

Taq	B-Protein
polymerase	I-Protein
(	O
Qiagen	O
)	O
was	O
used	O
together	O
with	O
the	O
following	O
cycle	O
conditions	O
:	O
one	O
cycle	O
94degreesC	O
for	O
2	O
min	O
;	O
30	O
cycles	O
94degreesC	O
for	O
30	O
s	O
,	O
60degreesC	O
for	O
60	O
s	O
,	O
72degreesC	O
for	O
2	O
min	O
;	O
one	O
cycle	O
72degreesC	O
for	O
10	O
min	O
.	O

As	O
a	O
negative	O
control	O
,	O
a	O
region	O
in	O
the	O
A3G	B-Protein
gene	O
was	O
targeted	O
using	O
the	O
primers	O
ChIP3Gneg	O
_	O
plus	O
:	O
5	O
'	O
-	O
taagtaccacccagagatgag	O
-	O
3	O
'	O
and	O
ChIP3Gneg	O
_	O
minus	O
:	O
5	O
'	O
-	O
catgatcttcatggtggcacg	O
-	O
3	O
'	O
for	O
both	O
PCR	O
steps	O
.	O

PCR	O
conditions	O
were	O
the	O
same	O
as	O
for	O
the	O
A3G	B-Protein
promoter	O
sequence	O
,	O
with	O
the	O
exception	O
that	O
annealing	O
temperature	O
was	O
decreased	O
to	O
55degreesC	O
.	O

RNA	O
interference	O
and	O
western	O
blot	O
analysis	O
<EOS>	B-X
The	B-X
complete	B-X
mRNA	B-X
sequence	B-X
was	B-X
6174	B-X
bp	B-X
in	B-X
length	B-X
with	B-X
an	B-X
open	B-X
reading	B-X
frame	B-X
(	B-X
ORF	B-X
)	B-X
of	B-X
5796	B-X
bp	B-X
encoding	B-X
1931	B-X
amino	B-X
acid	B-X
residues	B-X
.	B-X
NlVgR	B-X
was	B-X
specifically	B-X
expressed	B-X
in	B-X
the	B-X
ovary	B-X
,	B-X
and	B-X
the	B-X
mRNA	B-X
level	B-X
started	B-X
to	B-X
increase	B-X
after	B-X
adult	B-X
female	B-X
emergence	B-X
,	B-X
with	B-X
a	B-X
peak	B-X
on	B-X
day	B-X
7	B-X
in	B-X
the	B-X
adult	B-X
stage	B-X
,	B-X
and	B-X
then	B-X
declined	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
NlVgR	B-X
protein	B-X
revealed	B-X
an	B-X
ovary-specific	B-X
expression	B-X
pattern	B-X
,	B-X
which	B-X
was	B-X
consistent	B-X
with	B-X
NlVgR	B-X
transcript	B-X
detection	B-X
.	B-X
Injection	B-X
with	B-X
NlVgR	B-X
double-stranded	B-X
RNA	B-X
(	B-X
dsRNA	B-X
)	B-X
significantly	B-X
disturbed	B-X
NlVgR	B-X
,	B-X
which	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
NlVg	B-X
protein	B-X
content	B-X
in	B-X
the	B-X
ovaries	B-X
,	B-X
an	B-X
accumulation	B-X
of	B-X
NlVg	B-X
protein	B-X
in	B-X
the	B-X
hemolymph	B-X
,	B-X
the	B-X
arrested	B-X
development	B-X
of	B-X
ovaries	B-X
,	B-X
and	B-X
the	B-X
failure	B-X
of	B-X
insects	B-X
to	B-X
reproduce	B-X
.	B-X

Sp1	B-Protein
and	O
Sp3	B-Protein
translation	O
was	O
silenced	O
in	O
HeLa	O
cells	O
using	O
the	O
siRNA	O
duplexes	O
Hs	O
_	O
SP1	O
_	O
1	O
_	O
HP	O
and	O
Hs	O
_	O
SP3	O
_	O
1	O
_	O
HP	O
(	O
Qiagen	O
)	O
.	O

A	O
nonspecific	O
siRNA	O
(	O
Qiagen	O
)	O
was	O
used	O
as	O
control	O
.	O

HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
or	O
300	O
ng	O
siRNA	O
per	O
6	O
-	O
well	O
,	O
using	O
the	O
HiPerfect	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
reverse	O
transfection	O
of	O
adherent	O
cells	O
in	O
6	O
-	O
well	O
plates	O
.	O
<EOS>	B-X
293	B-X
cell	B-X
line	B-X
(	B-X
widely	B-X
known	B-X
as	B-X
the	B-X
Human	B-X
Embryonic	B-X
Kidney	B-X
293	B-X
cells	B-X
)	B-X
and	B-X
its	B-X
derivatives	B-X
were	B-X
the	B-X
most	B-X
used	B-X
cells	B-X
after	B-X
HeLa	B-X
in	B-X
cell	B-X
biology	B-X
studies	B-X
and	B-X
after	B-X
CHO	B-X
in	B-X
biotechnology	B-X
as	B-X
a	B-X
vehicle	B-X
for	B-X
the	B-X
production	B-X
of	B-X
adenoviral	B-X
vaccines	B-X
and	B-X
recombinant	B-X
proteins	B-X
,	B-X
for	B-X
analysis	B-X
of	B-X
the	B-X
neuronal	B-X
synapse	B-X
formation	B-X
,	B-X
in	B-X
electrophysiology	B-X
and	B-X
neuropharmacology	B-X
.	B-X
Despite	B-X
the	B-X
historically	B-X
long-term	B-X
productive	B-X
exploitation	B-X
,	B-X
the	B-X
origin	B-X
,	B-X
phenotype	B-X
,	B-X
karyotype	B-X
,	B-X
and	B-X
tumorigenicity	B-X
of	B-X
293	B-X
cells	B-X
are	B-X
still	B-X
debated	B-X
.	B-X
293	B-X
cells	B-X
were	B-X
considered	B-X
the	B-X
kidney	B-X
epithelial	B-X
cells	B-X
or	B-X
even	B-X
fibroblasts	B-X
.	B-X
However	B-X
,	B-X
293	B-X
cells	B-X
demonstrate	B-X
no	B-X
evident	B-X
tissue-specific	B-X
gene	B-X
expression	B-X
signature	B-X
and	B-X
express	B-X
the	B-X
markers	B-X
of	B-X
renal	B-X
progenitor	B-X
cells	B-X
,	B-X
neuronal	B-X
cells	B-X
and	B-X
adrenal	B-X
gland	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
potential	B-X
to	B-X
propagate	B-X
the	B-X
highly	B-X
neurotropic	B-X
viruses	B-X
,	B-X
inducible	B-X
synaptogenesis	B-X
,	B-X
functionality	B-X
of	B-X
the	B-X
endogenous	B-X
neuron-specific	B-X
voltage-gated	B-X
channels	B-X
,	B-X
and	B-X
response	B-X
to	B-X
the	B-X
diverse	B-X
agonists	B-X
implicated	B-X
in	B-X
neuronal	B-X
signaling	B-X
give	B-X
credibility	B-X
to	B-X
consider	B-X
293	B-X
cells	B-X
of	B-X
neuronal	B-X
lineage	B-X
phenotype	B-X
.	B-X
The	B-X
compound	B-X
phenotype	B-X
of	B-X
293	B-X
cells	B-X
can	B-X
be	B-X
due	B-X
to	B-X
heterogeneous	B-X
,	B-X
unstable	B-X
karyotype	B-X
.	B-X
The	B-X
mean	B-X
chromosome	B-X
number	B-X
and	B-X
chromosome	B-X
aberrations	B-X
differ	B-X
between	B-X
293	B-X
cells	B-X
and	B-X
derivatives	B-X
as	B-X
well	B-X
as	B-X
between	B-X
293	B-X
cells	B-X
from	B-X
the	B-X
different	B-X
cell	B-X
banks/labs	B-X
.	B-X
293	B-X
cells	B-X
are	B-X
tumorigenic	B-X
,	B-X
whereas	B-X
acute	B-X
changes	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
cancer-associated	B-X
genes	B-X
aggravate	B-X
tumorigenicity	B-X
by	B-X
promoting	B-X
chromosome	B-X
instability	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
procedure	B-X
of	B-X
a	B-X
stable	B-X
empty	B-X
vector	B-X
transfection	B-X
can	B-X
also	B-X
impact	B-X
karyotype	B-X
and	B-X
phenotype	B-X
.	B-X
The	B-X
discussed	B-X
issues	B-X
caution	B-X
against	B-X
misinterpretations	B-X
and	B-X
pitfalls	B-X
during	B-X
the	B-X
different	B-X
experimental	B-X
manipulations	B-X
with	B-X
293	B-X
cells	B-X
.	B-X

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
HeLa	O
cells	O
were	O
harvested	O
for	O
detection	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
proteins	O
.	O

Cells	O
were	O
washed	O
in	O
PBS	O
,	O
lysed	O
in	O
RIPA	O
(	O
25	O
mM	O
Tris	O
pH	O
8	O
.	O
0	O
,	O
137	O
mM	O
NaCl	O
,	O
1	O
%	O
Glycerol	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
2	O
mM	O
EDTA	O
pH	O
8	O
,	O
0	O
.	O
1	O
%	O
SDS	O
and	O
protease	O
inhibitors	O
)	O
and	O
lysates	O
were	O
cleared	O
by	O
centrifugation	O
.	O

After	O
boiling	O
with	O
Laemmli	O
'	O
s	O
buffer	O
,	O
samples	O
were	O
subjected	O
to	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
transfer	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Sp1	B-Protein
and	O
Sp3	B-Protein
proteins	O
were	O
detected	O
using	O
alpha	O
-	O
Sp1	B-Protein
(	O
Pep2	O
)	O
antibody	O
(	O
sc	O
-	O
59	O
,	O
Santa	O
Cruz	O
)	O
or	O
alpha	O
-	O
Sp3	B-Protein
(	O
D	O
-	O
20	O
)	O
antibody	O
(	O
sc	O
-	O
644	O
,	O
Santa	O
Cruz	O
)	O
followed	O
by	O
incubation	O
with	O
alpha	O
-	O
rabbit	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

For	O
detection	O
of	O
tubulin	B-Protein
,	O
alpha	O
-	O
tubulin	B-Protein
(	O
B5	O
-	O
1	O
-	O
2	O
,	O
Sigma	O
)	O
and	O
alpha	O
-	O
mouse	O
-	O
HRP	O
(	O
Amersham	O
Biosciences	O
)	O
antibodies	O
were	O
used	O
.	O

Signals	O
were	O
visualized	O
by	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
,	O
Amersham	O
Biosciences	O
)	O
.	O

Characterization	O
of	O
the	O
transcriptional	O
start	O
sites	O
of	O
APOBEC3G	B-Protein
by	O
5	O
'	O
-	O
RACE	O

To	O
identify	O
the	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
of	O
APOBEC3G	B-Protein
(	O
A3G	B-Protein
)	O
in	O
A3	O
.	O
01	O
T	O
cells	O
,	O
we	O
performed	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
analysis	O
(	O
RACE	O
)	O
with	O
A3G	B-Protein
-	O
specific	O
primers	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Agarose	O
gel	O
electrophoresis	O
resolved	O
the	O
nested	O
PCR	O
products	O
into	O
three	O
bands	O
of	O
different	O
electrophoretic	O
mobility	O
with	O
a	O
dominant	O
middle	O
band	O
(	O
Figure	O
2	O
)	O
.	O

For	O
each	O
band	O
,	O
the	O
DNA	O
was	O
cloned	O
and	O
sequence	O
analysis	O
of	O
six	O
or	O
seven	O
individual	O
transformants	O
was	O
performed	O
.	O
<EOS>	B-X
Three	B-X
patients	B-X
died	B-X
within	B-X
six	B-X
months	B-X
of	B-X
lung	B-X
resection	B-X
and	B-X
in	B-X
each	B-X
case	B-X
a	B-X
postmortem	B-X
examination	B-X
was	B-X
performed	B-X
.	B-X
In	B-X
seven	B-X
the	B-X
carcinomatous	B-X
component	B-X
was	B-X
a	B-X
squamous-celled	B-X
growth	B-X
,	B-X
and	B-X
in	B-X
one	B-X
columnar-celled	B-X
;	B-X
the	B-X
histology	B-X
of	B-X
the	B-X
sarcomatous	B-X
element	B-X
varied	B-X
.	B-X
To	B-X
conduct	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
on	B-X
the	B-X
prevalence	B-X
of	B-X
tooth	B-X
grinding	B-X
and/or	B-X
clenching	B-X
(	B-X
TGC	B-X
)	B-X
in	B-X
children	B-X
and	B-X
adolescents	B-X
with	B-X
a	B-X
neurodevelopmental	B-X
disorder	B-X
or	B-X
other	B-X
developmental	B-X
condition	B-X
.	B-X
Seven	B-X
fitness	B-X
subtests	B-X
covering	B-X
a	B-X
variety	B-X
of	B-X
motor	B-X
dimensions	B-X
(	B-X
6-minute	B-X
run	B-X
,	B-X
pushups	B-X
,	B-X
sit-ups	B-X
,	B-X
standing	B-X
broad	B-X
jump	B-X
,	B-X
20	B-X
m	B-X
sprint	B-X
,	B-X
jumping	B-X
sideways	B-X
,	B-X
and	B-X
balancing	B-X
backwards	B-X
)	B-X
were	B-X
conducted	B-X
to	B-X
a	B-X
total	B-X
of	B-X
790	B-X
six-year-olds	B-X
,	B-X
1371	B-X
seven-year-olds	B-X
,	B-X
1331	B-X
eight-year-olds	B-X
,	B-X
and	B-X
925	B-X
nine-year-olds	B-X
(	B-X
48.2	B-X
%	B-X
females	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
for	B-X
6-	B-X
and	B-X
7-year-olds	B-X
,	B-X
all	B-X
seven	B-X
items	B-X
including	B-X
balancing	B-X
backwards	B-X
can	B-X
be	B-X
accumulated	B-X
to	B-X
one	B-X
factor	B-X
.	B-X

We	O
observed	O
that	O
the	O
transcriptional	O
start	O
sites	O
of	O
the	O
A3G	B-Protein
gene	O
were	O
located	O
between	O
58	O
and	O
361	O
nt	O
upstream	O
of	O
the	O
ATG	O
start	O
codon	O
(	O
Figure	O
1	O
)	O
.	O

Although	O
TSS	O
were	O
variable	O
and	O
most	O
sites	O
were	O
only	O
detected	O
once	O
among	O
the	O
19	O
clones	O
analyzed	O
,	O
one	O
TSS	O
was	O
identified	O
in	O
six	O
individual	O
clones	O
.	O

This	O
TSS	O
was	O
located	O
66	O
nt	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
A3G	B-Protein
mRNA	O
sequence	O
(	O
GenBank	O
(	O
TM	O
)	O
accession	O
number	O
NM021822	O
)	O
and	O
we	O
defined	O
this	O
position	O
as	O
the	O
major	O
transcriptional	O
start	O
site	O
of	O
the	O
A3G	B-Protein
gene	O
.	O

The	O
core	O
promoter	O
of	O
A3G	B-Protein
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O

For	O
characterization	O
of	O
the	O
A3G	B-Protein
promoter	O
,	O
we	O
cloned	O
the	O
1025	O
bp	O
located	O
at	O
position	O
-	O
959	O
/	O
+	O
66	O
relative	O
to	O
the	O
identified	O
transcription	O
start	O
into	O
the	O
promoterless	O
pGL3	O
-	O
Basic	O
luciferase	B-Protein
reporter	O
plasmid	O
and	O
designated	O
the	O
plasmid	O
pGL3	O
-	O
Basic	O
-	O
APOprom1025	O
.	O

Similarly	O
,	O
pGL3	O
-	O
APOprom502	O
(	O
containing	O
sequence	O
-	O
436	O
/	O
+	O
66	O
)	O
,	O
pGL3	O
-	O
APOprom225	O
(	O
containing	O
sequence	O
-	O
159	O
/	O
+	O
66	O
)	O
and	O
further	O
5	O
'	O
deletion	O
reporter	O
constructs	O
containing	O
180	O
,	O
150	O
,	O
120	O
or	O
60	O
bp	O
upstream	O
of	O
position	O
+	O
65	O
were	O
generated	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
order	O
to	O
analyze	O
transcriptional	O
activity	O
,	O
the	O
luciferase	B-Protein
reporter	O
plasmids	O
were	O
transiently	O
transfected	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Luciferase	B-Protein
assays	O
revealed	O
a	O
~	O
20	O
-	O
fold	O
increased	O
transcriptional	O
activity	O
of	O
the	O
1025	O
bp	O
sequence	O
as	O
compared	O
to	O
the	O
empty	O
vector	O
,	O
indicating	O
that	O
we	O
had	O
identified	O
an	O
active	O
A3G	B-Protein
promoter	O
sequence	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
transcription	O
rate	O
was	O
not	O
significantly	O
altered	O
by	O
the	O
5	O
'	O
deletions	O
leading	O
to	O
the	O
502	O
,	O
225	O
and	O
180	O
bp	O
fragments	O
(	O
Figure	O
3B	O
)	O
.	O
<EOS>	B-X
In	B-X
many	B-X
eukaryotes	B-X
,	B-X
including	B-X
mammals	B-X
,	B-X
plants	B-X
,	B-X
yeast	B-X
,	B-X
and	B-X
insects	B-X
,	B-X
introns	B-X
can	B-X
increase	B-X
gene	B-X
expression	B-X
without	B-X
functioning	B-X
as	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
transcription	B-X
factors	B-X
.	B-X
Introns	B-X
can	B-X
increase	B-X
transcript	B-X
levels	B-X
by	B-X
affecting	B-X
the	B-X
rate	B-X
of	B-X
transcription	B-X
,	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
transcript	B-X
stability	B-X
.	B-X
The	B-X
role	B-X
of	B-X
splicing	B-X
in	B-X
IME	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
intron	B-X
position	B-X
relative	B-X
to	B-X
the	B-X
sites	B-X
of	B-X
transcription	B-X
and	B-X
translation	B-X
initiation	B-X
are	B-X
elaborated	B-X
.	B-X
It	B-X
is	B-X
well	B-X
established	B-X
that	B-X
illicit	B-X
drugs	B-X
users	B-X
are	B-X
a	B-X
high	B-X
risk	B-X
population	B-X
for	B-X
infection	B-X
with	B-X
HIV	B-X
with	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
HIV	B-X
transmission	B-X
and	B-X
replication	B-X
.	B-X
Several	B-X
studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
drugs	B-X
of	B-X
abuse	B-X
increase	B-X
viral	B-X
RNA	B-X
concentrations	B-X
by	B-X
enhancing	B-X
HIV	B-X
replication	B-X
,	B-X
in	B-X
particular	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
.	B-X
The	B-X
CNS	B-X
is	B-X
a	B-X
common	B-X
target	B-X
for	B-X
both	B-X
drugs	B-X
of	B-X
abuse	B-X
and	B-X
HIV	B-X
,	B-X
and	B-X
their	B-X
synergistic	B-X
action	B-X
accelerates	B-X
neuronal	B-X
injury	B-X
and	B-X
cognitive	B-X
impairment	B-X
.	B-X
In	B-X
order	B-X
to	B-X
generate	B-X
complete	B-X
genomic	B-X
transcripts	B-X
,	B-X
HIV	B-X
gene	B-X
expression	B-X
has	B-X
to	B-X
progress	B-X
through	B-X
both	B-X
the	B-X
initiation	B-X
and	B-X
elongation	B-X
phases	B-X
of	B-X
transcription	B-X
,	B-X
which	B-X
requires	B-X
coordinated	B-X
action	B-X
of	B-X
different	B-X
transcription	B-X
factors	B-X
.	B-X

In	O
contrast	O
,	O
a	O
drop	O
in	O
luciferase	B-Protein
activity	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
150	O
bp	O
fragment	O
.	O

This	O
construct	O
only	O
retained	O
28	O
%	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
promoter	O
in	O
A3	O
.	O
01	O
T	O
cells	O
and	O
activity	O
of	O
the	O
120	O
bp	O
fragment	O
was	O
further	O
reduced	O
.	O

Comparable	O
reductions	O
relative	O
to	O
the	O
activity	O
of	O
180	O
bp	O
fragment	O
were	O
observed	O
in	O
the	O
myeloid	O
cell	O
line	O
U937	O
and	O
the	O
hepatic	O
cell	O
lines	O
HepG2	O
and	O
Huh7	O
(	O
Figure	O
3C	O
)	O
,	O
indicating	O
that	O
the	O
core	O
promoter	O
of	O
A3G	B-Protein
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

The	O
A3G	B-Protein
promoter	O
is	O
not	O
inducible	O
in	O
T	O
cells	O
<EOS>	B-X
We	B-X
found	B-X
that	B-X
UC	B-X
cell	B-X
lines	B-X
highly	B-X
express	B-X
A3B	B-X
and	B-X
in	B-X
some	B-X
cases	B-X
A3G	B-X
,	B-X
but	B-X
not	B-X
A3A	B-X
,	B-X
and	B-X
exhibit	B-X
corresponding	B-X
cytidine	B-X
deamination	B-X
activity	B-X
Apolipoprotein	B-X
B	B-X
mRNA-editing	B-X
enzyme	B-X
catalytic	B-X
polypeptide-like	B-X
3G	B-X
(	B-X
APOBEC3G	B-X
,	B-X
A3G	B-X
)	B-X
exert	B-X
antiviral	B-X
defense	B-X
as	B-X
an	B-X
important	B-X
factor	B-X
of	B-X
innate	B-X
immunity	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFN-γ、IL2、IL15、IL7	B-X
could	B-X
induce	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
However	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
nuclear	B-X
factor	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
have	B-X
not	B-X
been	B-X
reported	B-X
at	B-X
the	B-X
present	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
and	B-X
investigate	B-X
the	B-X
modulation	B-X
of	B-X
USF1	B-X
gene	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
232	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
to	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
full	B-X
promoter	B-X
.	B-X
Transcriptional	B-X
start	B-X
sites	B-X
(	B-X
TSS	B-X
)	B-X
were	B-X
identified	B-X
by	B-X
the	B-X
luciferase	B-X
reporter	B-X
assays	B-X
of	B-X
plasmids	B-X
containing	B-X
full	B-X
or	B-X
shorter	B-X
fragments	B-X
of	B-X
the	B-X
A3G	B-X
promoter	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
of	B-X
A3G	B-X
is	B-X
located	B-X
within	B-X
the	B-X
region	B-X
-159/-84	B-X
relative	B-X
to	B-X
the	B-X
TSS	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
A3G	B-X
core	B-X
promoter	B-X
regulated	B-X
by	B-X
USF1	B-X
was	B-X
dependent	B-X
on	B-X
an	B-X
E-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-91/-86	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
TSS	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
USF1	B-X
gene	B-X
can	B-X
take	B-X
part	B-X
in	B-X
basal	B-X
transcription	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
A3G	B-X
gene	B-X
in	B-X
hepatocyte	B-X
,	B-X
and	B-X
the	B-X
identified	B-X
E-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
USF1	B-X
.	B-X

According	O
to	O
the	O
current	O
knowledge	O
,	O
APOBEC3G	B-Protein
plays	O
a	O
role	O
in	O
the	O
innate	O
defence	O
against	O
pathogens	O
like	O
HIV	O
-	O
1	O
.	O

The	O
latter	O
has	O
evolved	O
a	O
mechanism	O
to	O
counteract	O
A3G	B-Protein
activity	O
by	O
expressing	O
the	O
regulatory	O
protein	O
Vif	B-Protein
(	O
4	O
)	O
.	O

Vif	B-Protein
induces	O
proteasomal	O
degradation	O
of	O
A3G	B-Protein
and	O
additionally	O
inhibits	O
A3G	B-Protein
activity	O
by	O
further	O
mechanisms	O
(	O
8	O
,	O
37	O
-	O
43	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
overexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
also	O
influences	O
A3G	B-Protein
promoter	O
activity	O
,	O
we	O
either	O
expressed	O
HIV	O
-	O
1	O
Vif	B-Protein
or	O
the	O
HIV	O
-	O
1	O
Tat	B-Protein
protein	O
,	O
the	O
latter	O
has	O
been	O
shown	O
to	O
activate	O
different	O
viral	O
and	O
cellular	O
promoters	O
(	O
44	O
,	O
45	O
)	O
.	O

In	O
addition	O
,	O
increasing	O
amounts	O
of	O
the	O
plasmid	O
pNL4	O
-	O
3	O
,	O
containing	O
the	O
full	O
-	O
length	O
genome	O
of	O
HIV	O
-	O
1	O
,	O
were	O
transfected	O
.	O

These	O
constructs	O
or	O
the	O
empty	O
vector	O
pcDNA3	O
.	O
1	O
were	O
cotransfected	O
with	O
the	O
1025	O
bp	O
construct	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O
<EOS>	B-X
A	B-X
novel	B-X
archetype	B-X
might	B-X
materialize	B-X
in	B-X
the	B-X
near	B-X
future	B-X
with	B-X
synthetic	B-X
biology	B-X
techniques	B-X
that	B-X
will	B-X
facilitate	B-X
quicker	B-X
assembly	B-X
and	B-X
iteration	B-X
of	B-X
DNA	B-X
clones	B-X
,	B-X
accelerating	B-X
the	B-X
progress	B-X
of	B-X
gene	B-X
therapy	B-X
vectors	B-X
,	B-X
recombinant	B-X
protein	B-X
production	B-X
processes	B-X
and	B-X
new	B-X
vaccines	B-X
by	B-X
in	B-X
vitro	B-X
chemical	B-X
synthesis	B-X
of	B-X
any	B-X
in	B-X
silico-specified	B-X
DNA	B-X
construct	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
examine	B-X
the	B-X
major	B-X
breakthroughs	B-X
in	B-X
cloning	B-X
techniques	B-X
and	B-X
their	B-X
applications	B-X
in	B-X
various	B-X
areas	B-X
of	B-X
biological	B-X
research	B-X
that	B-X
have	B-X
evolved	B-X
mainly	B-X
due	B-X
to	B-X
easy	B-X
construction	B-X
of	B-X
novel	B-X
expression	B-X
systems	B-X
.	B-X
We	B-X
describe	B-X
the	B-X
construction	B-X
and	B-X
characterization	B-X
of	B-X
retroviral	B-X
vectors	B-X
and	B-X
packaging	B-X
plasmids	B-X
that	B-X
produce	B-X
helper-free	B-X
retrovirus	B-X
with	B-X
titers	B-X
of	B-X
1	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
to	B-X
5	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
within	B-X
48	B-X
h.	B-X
These	B-X
vectors	B-X
contain	B-X
the	B-X
immediate	B-X
early	B-X
region	B-X
of	B-X
the	B-X
human	B-X
cytomegalovirus	B-X
enhancer-promoter	B-X
fused	B-X
to	B-X
the	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
at	B-X
the	B-X
TATA	B-X
box	B-X
in	B-X
the	B-X
5	B-X
'	B-X
U3	B-X
region	B-X
,	B-X
yielding	B-X
the	B-X
pCL	B-X
promoter	B-X
.	B-X
By	B-X
selecting	B-X
vectors	B-X
designed	B-X
to	B-X
express	B-X
genes	B-X
from	B-X
one	B-X
of	B-X
four	B-X
promoters	B-X
(	B-X
dihydrofolate	B-X
reductase	B-X
,	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
long	B-X
terminal	B-X
repeat	B-X
,	B-X
or	B-X
cytomegalovirus	B-X
)	B-X
,	B-X
the	B-X
pCL	B-X
system	B-X
permits	B-X
the	B-X
investigator	B-X
to	B-X
control	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
target	B-X
cells	B-X
over	B-X
a	B-X
100-fold	B-X
range	B-X
,	B-X
while	B-X
maintaining	B-X
uniformly	B-X
high	B-X
titers	B-X
of	B-X
virus	B-X
from	B-X
transiently	B-X
transfected	B-X
producer	B-X
cells	B-X
.	B-X
Ecotropic	B-X
,	B-X
amphotropic	B-X
(	B-X
4070A	B-X
)	B-X
,	B-X
and	B-X
amphotropic-mink	B-X
cell	B-X
focus-forming	B-X
hybrid	B-X
(	B-X
10A1	B-X
)	B-X
envelope	B-X
constructions	B-X
have	B-X
been	B-X
prepared	B-X
and	B-X
tested	B-X
,	B-X
permitting	B-X
flexible	B-X
selection	B-X
of	B-X
vector	B-X
pseudotype	B-X
in	B-X
accordance	B-X
with	B-X
experimental	B-X
needs	B-X
.	B-X
Vector	B-X
supernatants	B-X
are	B-X
free	B-X
of	B-X
helper	B-X
virus	B-X
and	B-X
are	B-X
of	B-X
sufficiently	B-X
high	B-X
titer	B-X
within	B-X
2	B-X
days	B-X
of	B-X
transient	B-X
transfection	B-X
in	B-X
293	B-X
cells	B-X
to	B-X
permit	B-X
infection	B-X
of	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
randomly	B-X
cycling	B-X
target	B-X
cells	B-X
in	B-X
culture	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
efficacy	B-X
of	B-X
these	B-X
vectors	B-X
by	B-X
using	B-X
them	B-X
to	B-X
transfer	B-X
three	B-X
potent	B-X
cell	B-X
cycle	B-X
control	B-X
genes	B-X
(	B-X
the	B-X
p16	B-X
(	B-X
INK4A	B-X
)	B-X
,	B-X
p53	B-X
,	B-X
and	B-X
Rb1	B-X
genes	B-X
)	B-X
into	B-X
human	B-X
glioblastoma	B-X
cells	B-X
.	B-X

Luciferase	B-Protein
assays	O
showed	O
that	O
the	O
transcriptional	O
activity	O
of	O
the	O
A3G	B-Protein
promoter	O
was	O
not	O
significantly	O
altered	O
in	O
the	O
presence	O
of	O
Vif	B-Protein
,	O
Tat	B-Protein
or	O
HIV	O
-	O
1NL4	O
-	O
3	O
(	O
Figure	O
4A	O
)	O
,	O
suggesting	O
that	O
HIV	O
-	O
1	O
is	O
not	O
modulating	O
A3G	B-Protein
expression	O
on	O
the	O
transcriptional	O
level	O
.	O
<EOS>	B-X
Apolipoprotein	B-X
B	B-X
mRNA-editing	B-X
enzyme	B-X
catalytic	B-X
polypeptide-like	B-X
3G	B-X
(	B-X
APOBEC3G	B-X
,	B-X
A3G	B-X
)	B-X
exert	B-X
antiviral	B-X
defense	B-X
as	B-X
an	B-X
important	B-X
factor	B-X
of	B-X
innate	B-X
immunity	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
IFN-γ、IL2、IL15、IL7	B-X
could	B-X
induce	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
However	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
other	B-X
nuclear	B-X
factor	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
have	B-X
not	B-X
been	B-X
reported	B-X
at	B-X
the	B-X
present	B-X
.	B-X
To	B-X
gain	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
this	B-X
restriction	B-X
factor	B-X
,	B-X
we	B-X
cloned	B-X
and	B-X
characterized	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
A3G	B-X
and	B-X
investigate	B-X
the	B-X
modulation	B-X
of	B-X
USF1	B-X
gene	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
A3G	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
232	B-X
bp	B-X
region	B-X
that	B-X
was	B-X
sufficient	B-X
to	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
full	B-X
promoter	B-X
.	B-X
Transcriptional	B-X
start	B-X
sites	B-X
(	B-X
TSS	B-X
)	B-X
were	B-X
identified	B-X
by	B-X
the	B-X
luciferase	B-X
reporter	B-X
assays	B-X
of	B-X
plasmids	B-X
containing	B-X
full	B-X
or	B-X
shorter	B-X
fragments	B-X
of	B-X
the	B-X
A3G	B-X
promoter	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
core	B-X
promoter	B-X
of	B-X
A3G	B-X
is	B-X
located	B-X
within	B-X
the	B-X
region	B-X
-159/-84	B-X
relative	B-X
to	B-X
the	B-X
TSS	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
A3G	B-X
core	B-X
promoter	B-X
regulated	B-X
by	B-X
USF1	B-X
was	B-X
dependent	B-X
on	B-X
an	B-X
E-box	B-X
(	B-X
located	B-X
at	B-X
position	B-X
-91/-86	B-X
relative	B-X
to	B-X
the	B-X
major	B-X
TSS	B-X
)	B-X
and	B-X
was	B-X
abolished	B-X
after	B-X
mutation	B-X
of	B-X
this	B-X
DNA	B-X
element	B-X
.	B-X
USF1	B-X
gene	B-X
can	B-X
take	B-X
part	B-X
in	B-X
basal	B-X
transcription	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
A3G	B-X
gene	B-X
in	B-X
hepatocyte	B-X
,	B-X
and	B-X
the	B-X
identified	B-X
E-box	B-X
represented	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
USF1	B-X
.	B-X

It	O
has	O
been	O
shown	O
that	O
the	O
amount	O
of	O
A3G	B-Protein
mRNA	O
in	O
T	O
cells	O
is	O
increased	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phorbol	O
ester	O
(	O
46	O
-	O
48	O
)	O
.	O

In	O
addition	O
,	O
interferons	O
have	O
been	O
described	O
to	O
upregulate	O
A3G	B-Protein
expression	O
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
,	O
48	O
)	O
.	O

To	O
investigate	O
whether	O
these	O
stimuli	O
interfere	O
with	O
A3G	B-Protein
promoter	O
activity	O
in	O
T	O
cells	O
,	O
we	O
transfected	O
A3	O
.	O
01	O
T	O
cells	O
with	O
the	O
1025	O
bp	O
promoter	O
or	O
the	O
empty	O
vector	O
pGL3	O
-	O
Basic	O
(	O
vector	O
)	O
and	O
treated	O
the	O
cells	O
with	O
phorbol	O
ester	O
(	O
TPA	O
)	O
.	O

The	O
luciferase	B-Protein
assay	O
showed	O
that	O
the	O
~	O
15	O
-	O
fold	O
increased	O
transcriptional	O
activity	O
of	O
the	O
1025	O
bp	O
promoter	O
relative	O
to	O
the	O
empty	O
vector	O
was	O
not	O
further	O
enhanced	O
by	O
TPA	O
treatment	O
(	O
Figure	O
4B	O
)	O
,	O
although	O
the	O
functional	O
activity	O
of	O
TPA	O
was	O
confirmed	O
by	O
induction	O
of	O
the	O
SV40	O
promoter	O
-	O
containing	O
reporter	O
plasmid	O
pGL3	O
-	O
Control	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similarly	O
,	O
treatment	O
of	O
A3	O
.	O
01	O
T	O
cells	O
transfected	O
with	O
the	O
A3G	B-Protein
promoter	O
deletion	O
constructs	O
with	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
showed	O
no	O
effect	O
(	O
Figure	O
4C	O
)	O
.	O

Interestingly	O
,	O
a	O
control	O
plasmid	O
(	O
pGL2	O
-	O
CVX	O
)	O
containing	O
two	O
IFN	O
-	O
responsive	O
GAS	O
(	O
gamma	O
activated	O
sequence	O
)	O
elements	O
upstream	O
of	O
the	O
luciferase	B-Protein
reporter	O
gene	O
was	O
only	O
induced	O
by	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
in	O
these	O
cells	O
(	O
Figure	O
4C	O
)	O
.	O

Since	O
two	O
reports	O
describe	O
A3G	B-Protein
upregulation	O
by	O
interferons	O
in	O
hepatocytes	O
(	O
47	O
,	O
48	O
)	O
,	O
we	O
additionally	O
performed	O
the	O
experiment	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
.	O

In	O
line	O
with	O
these	O
publications	O
,	O
we	O
observed	O
an	O
induction	O
of	O
the	O
A3G	B-Protein
promoter	O
by	O
approximately	O
2	O
-	O
fold	O
after	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
stimulation	O
(	O
Figure	O
4D	O
)	O
with	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
being	O
slightly	O
more	O
potent	O
.	O

For	O
both	O
interferon	O
types	O
,	O
induction	O
of	O
A3G	B-Protein
promoter	O
activity	O
was	O
observed	O
for	O
all	O
deletion	O
constructs	O
except	O
for	O
the	O
60	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
responsible	O
region	O
is	O
located	O
within	O
the	O
60	O
nt	O
present	O
in	O
the	O
120	O
bp	O
,	O
but	O
not	O
in	O
the	O
60	O
bp	O
fragment	O
.	O

A	O
GC	O
-	O
box	O
located	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	B-Protein
promoter	O
is	O
important	O
for	O
transcriptional	O
activity	O

The	O
reporter	O
studies	O
shown	O
in	O
Figure	O
3	O
had	O
demonstrated	O
a	O
drop	O
in	O
luciferase	B-Protein
activity	O
after	O
deletion	O
of	O
the	O
30	O
nt	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

We	O
therefore	O
inspected	O
the	O
30	O
bp	O
sequence	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
and	O
identified	O
a	O
GC	O
-	O
box	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
(	O
see	O
Figure	O
1	O
)	O
.	O

The	O
sequence	O
TGGGCGGGAC	O
,	O
which	O
is	O
interrupted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
represents	O
a	O
variant	O
of	O
the	O
(	O
G	O
/	O
T	O
)	O
GGGCGG	O
(	O
G	O
/	O
A	O
)	O
(	O
G	O
/	O
A	O
)	O
(	O
C	O
/	O
T	O
)	O
consensus	O
motif	O
recognized	O
by	O
Sp1	B-Protein
and	O
Sp3	B-Protein
transcription	O
factors	O
.	O

To	O
analyze	O
whether	O
this	O
putative	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
site	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
,	O
we	O
introduced	O
two	O
point	O
mutations	O
which	O
changed	O
the	O
sequence	O
from	O
TGGGCGGGAC	O
to	O
TGTTCGGGAC	O
(	O
mutations	O
shown	O
in	O
bold	O
)	O
.	O

This	O
resulted	O
in	O
a	O
71	O
%	O
reduction	O
of	O
the	O
transcriptional	O
activity	O
compared	O
to	O
the	O
unmodified	O
180	O
bp	O
promoter	O
(	O
Figure	O
5A	O
)	O
and	O
this	O
value	O
was	O
only	O
marginally	O
higher	O
than	O
the	O
luciferase	B-Protein
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
indicating	O
that	O
the	O
identified	O
motif	O
is	O
essential	O
for	O
basal	O
activity	O
of	O
the	O
A3G	B-Protein
core	O
promoter	O
.	O

To	O
further	O
examine	O
the	O
transcriptional	O
potency	O
of	O
the	O
30	O
nt	O
present	O
in	O
the	O
180	O
bp	O
promoter	O
,	O
we	O
cloned	O
the	O
region	O
-	O
114	O
/	O
-	O
85	O
(	O
containing	O
all	O
nucleotides	O
which	O
are	O
deleted	O
in	O
the	O
150	O
bp	O
fragment	O
,	O
designated	O
E1	O
)	O
or	O
the	O
region	O
-	O
92	O
/	O
-	O
63	O
(	O
containing	O
the	O
putative	O
Sp1	O
/	O
Sp3	O
motif	O
,	O
designated	O
E2	O
)	O
into	O
the	O
vector	O
pGL3	O
-	O
Promoter	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
vector	O
contains	O
a	O
luciferase	B-Protein
reporter	O
gene	O
under	O
the	O
control	O
of	O
an	O
SV40	O
promoter	O
without	O
enhancer	O
sequences	O
,	O
and	O
putative	O
transcriptionally	O
active	O
sequences	O
can	O
be	O
cloned	O
upstream	O
of	O
the	O
SV40	O
promoter	O
.	O

Luciferase	B-Protein
assays	O
showed	O
that	O
the	O
E1	O
element	O
increased	O
SV40	O
promoter	O
activity	O
only	O
by	O
~	O
2	O
-	O
fold	O
(	O
Figure	O
5B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
30	O
nt	O
of	O
E2	O
enhanced	O
the	O
transcriptional	O
activity	O
of	O
the	O
SV40	O
promoter	O
by	O
~	O
4	O
.	O
3	O
-	O
fold	O
,	O
indicating	O
that	O
the	O
intact	O
GC	O
-	O
box	O
present	O
in	O
the	O
E2	O
element	O
was	O
responsible	O
for	O
the	O
strongly	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
SV40	O
promoter	O
.	O

Sp1	B-Protein
and	O
Sp3	B-Protein
transcription	O
factors	O
bind	O
to	O
the	O
GC	O
-	O
box	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	B-Protein
promoter	O

To	O
investigate	O
whether	O
the	O
GC	O
-	O
box	O
represents	O
a	O
binding	O
site	O
for	O
the	O
transcription	O
factors	O
Sp1	B-Protein
and	O
Sp3	B-Protein
,	O
we	O
performed	O
EMSA	O
analyses	O
with	O
nuclear	O
extracts	O
isolated	O
from	O
A3	O
.	O
01	O
T	O
cells	O
.	O

As	O
probes	O
,	O
we	O
radioactively	O
labeled	O
the	O
unmodified	O
E2	O
sequence	O
(	O
nucleotides	O
-	O
92	O
/	O
-	O
63	O
of	O
the	O
A3G	B-Protein
promoter	O
,	O
probe	O
designated	O
APO	O
-	O
Sp1	O
/	O
3	O
)	O
or	O
the	O
same	O
region	O
carrying	O
the	O
two	O
point	O
mutations	O
described	O
above	O
(	O
probe	O
designated	O
APO	O
-	O
Sp1	O
/	O
3mut	O
)	O
.	O

As	O
control	O
,	O
we	O
used	O
a	O
commercially	O
available	O
Sp1	O
consensus	O
oligonucleotide	O
(	O
Sp1cons	O
)	O
,	O
which	O
is	O
known	O
to	O
be	O
recognized	O
by	O
Sp1	B-Protein
transcription	O
factors	O
.	O

Four	O
DNA	O
-	O
protein	O
complexes	O
were	O
observed	O
in	O
the	O
presence	O
of	O
the	O
APO	O
-	O
Sp1	O
/	O
3	O
probe	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
upper	O
two	O
complexes	O
were	O
specific	O
since	O
they	O
disappeared	O
in	O
the	O
presence	O
of	O
a	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1	O
/	O
3	O
probe	O
(	O
Figure	O
6A	O
,	O
lane	O
7	O
)	O
.	O

Further	O
confirmation	O
of	O
the	O
specificity	O
of	O
these	O
DNA	O
-	O
protein	O
complexes	O
was	O
demonstrated	O
by	O
the	O
inability	O
of	O
the	O
unlabeled	O
APO	O
-	O
Sp1	O
/	O
3mut	O
probe	O
to	O
abolish	O
binding	O
(	O
Figure	O
6A	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

As	O
expected	O
,	O
the	O
two	O
specific	O
complexes	O
were	O
also	O
present	O
in	O
the	O
case	O
of	O
the	O
Sp1cons	O
control	O
probe	O
(	O
Figure	O
6A	O
,	O
lanes	O
2	O
and	O
3	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
these	O
specific	O
complexes	O
was	O
observed	O
when	O
the	O
mutated	O
probe	O
was	O
used	O
(	O
Figure	O
6A	O
,	O
lanes	O
10	O
and	O
11	O
)	O
,	O
confirming	O
that	O
protein	O
binding	O
was	O
dependent	O
on	O
the	O
identified	O
GC	O
-	O
box	O
.	O

In	O
order	O
to	O
characterize	O
the	O
complexes	O
,	O
we	O
performed	O
supershift	O
experiments	O
using	O
Sp1	B-Protein
-	O
and	O
Sp3	B-Protein
-	O
specific	O
antibodies	O
.	O

The	O
upper	O
of	O
the	O
complexes	O
that	O
appeared	O
in	O
combination	O
with	O
the	O
Sp1cons	O
or	O
APO	O
-	O
Sp1	O
/	O
3	O
probes	O
,	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp1	B-Protein
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
3	O
and	O
7	O
)	O
,	O
whereas	O
the	O
lower	O
complex	O
shifted	O
in	O
the	O
presence	O
of	O
the	O
Sp3	B-Protein
antibody	O
(	O
Figure	O
6B	O
,	O
lanes	O
4	O
and	O
8	O
)	O
.	O

Taken	O
together	O
,	O
the	O
EMSA	O
demonstrated	O
that	O
the	O
GC	O
-	O
box	O
located	O
on	O
the	O
A3G	B-Protein
core	O
promoter	O
serves	O
as	O
a	O
binding	O
site	O
for	O
Sp1	B-Protein
and	O
Sp3	B-Protein
.	O

To	O
show	O
binding	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
factors	O
also	O
in	O
the	O
context	O
of	O
the	O
endogenous	O
A3G	B-Protein
promoter	O
,	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
was	O
performed	O
.	O

Sp1	B-Protein
and	O
Sp3	B-Protein
antibodies	O
,	O
but	O
not	O
an	O
actin	B-Protein
antibody	O
,	O
immunoprecipitated	O
the	O
A3G	B-Protein
promoter	O
in	O
A3	O
.	O
01	O
T	O
cells	O
(	O
Figure	O
6C	O
,	O
upper	O
panel	O
)	O
.	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
CENP-W	B-X
,	B-X
we	B-X
analyzed	B-X
its	B-X
TATA-less	B-X
promoter	B-X
and	B-X
identified	B-X
a	B-X
GC-rich	B-X
putative	B-X
Sp1	B-X
binding	B-X
site	B-X
located	B-X
at	B-X
-46	B-X
to	B-X
-36	B-X
that	B-X
was	B-X
critical	B-X
in	B-X
CENP-W	B-X
expression	B-X
.	B-X
Competitive	B-X
electrophoretic	B-X
gel	B-X
mobility	B-X
shift	B-X
assay	B-X
using	B-X
mutated	B-X
oligos	B-X
and	B-X
supershift	B-X
assays	B-X
with	B-X
Sp1	B-X
and	B-X
Sp3	B-X
antibodies	B-X
demonstrated	B-X
that	B-X
both	B-X
proteins	B-X
specifically	B-X
bound	B-X
to	B-X
this	B-X
promoter	B-X
region	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CENP-W	B-X
was	B-X
highly	B-X
induced	B-X
by	B-X
serum	B-X
stimulation	B-X
followed	B-X
by	B-X
serum	B-X
deprivation	B-X
,	B-X
with	B-X
Sp1	B-X
and	B-X
Sp3	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
this	B-X
transactivation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
Sp1	B-X
together	B-X
with	B-X
Sp3	B-X
may	B-X
function	B-X
as	B-X
the	B-X
main	B-X
regulator	B-X
of	B-X
the	B-X
basal	B-X
and	B-X
serum-induced	B-X
transcription	B-X
of	B-X
CENP-W	B-X
.	B-X

In	O
contrast	O
,	O
no	O
PCR	O
signal	O
was	O
received	O
with	O
a	O
primer	O
pair	O
recognizing	O
a	O
region	O
in	O
the	O
A3G	B-Protein
gene	O
~	O
4000	O
bp	O
downstream	O
of	O
the	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
site	O
(	O
Figure	O
6C	O
,	O
lower	O
panel	O
)	O
.	O

Only	O
the	O
positive	O
controls	O
showed	O
a	O
DNA	O
band	O
,	O
with	O
an	O
A3G	B-Protein
expression	O
plasmid	O
or	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
input	O
DNA	O
used	O
as	O
template	O
.	O

This	O
demonstrates	O
the	O
binding	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
transcription	O
factors	O
to	O
the	O
endogenous	O
A3G	B-Protein
promoter	O
.	O

Silencing	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
reduces	O
A3G	B-Protein
promoter	O
activity	O

To	O
confirm	O
the	O
role	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
in	O
regulation	O
of	O
A3G	B-Protein
promoter	O
activity	O
,	O
we	O
silenced	O
their	O
translation	O
via	O
RNA	O
interference	O
.	O

Functionality	O
of	O
the	O
siRNAs	O
directed	O
against	O
Sp1	B-Protein
or	O
Sp3	B-Protein
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
:	O
protein	O
levels	O
of	O
Sp1	B-Protein
as	O
well	O
as	O
the	O
long	O
and	O
short	O
isoforms	O
of	O
Sp3	B-Protein
were	O
strongly	O
reduced	O
in	O
the	O
presence	O
of	O
150	O
or	O
300	O
ng	O
specific	O
siRNA	O
(	O
Figure	O
7A	O
)	O
.	O
<EOS>	B-X
Sp1	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
regulating	B-X
many	B-X
genes	B-X
through	B-X
its	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
containing	B-X
three	B-X
zinc	B-X
fingers	B-X
.	B-X
We	B-X
were	B-X
interested	B-X
in	B-X
identifying	B-X
target	B-X
genes	B-X
regulated	B-X
by	B-X
Sp1	B-X
,	B-X
particularly	B-X
those	B-X
involved	B-X
in	B-X
proliferation	B-X
and	B-X
cancer	B-X
.	B-X
Our	B-X
approach	B-X
was	B-X
to	B-X
treat	B-X
HeLa	B-X
cells	B-X
with	B-X
a	B-X
siRNA	B-X
directed	B-X
against	B-X
Sp1	B-X
mRNA	B-X
to	B-X
decrease	B-X
the	B-X
expression	B-X
of	B-X
Sp1	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
the	B-X
genes	B-X
activated	B-X
by	B-X
this	B-X
transcription	B-X
factor	B-X
.	B-X
Sp1-siRNA	B-X
treatment	B-X
led	B-X
to	B-X
a	B-X
great	B-X
number	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
as	B-X
determined	B-X
by	B-X
whole	B-X
genome	B-X
cDNA	B-X
microarray	B-X
analysis	B-X
.	B-X
Underexpressed	B-X
genes	B-X
were	B-X
selected	B-X
since	B-X
they	B-X
represent	B-X
putative	B-X
genes	B-X
activated	B-X
by	B-X
Sp1	B-X
and	B-X
classified	B-X
in	B-X
six	B-X
Gene	B-X
Onthology	B-X
categories	B-X
,	B-X
namely	B-X
proliferation	B-X
and	B-X
cancer	B-X
,	B-X
mRNA	B-X
processing	B-X
,	B-X
lipid	B-X
metabolism	B-X
,	B-X
glucidic	B-X
metabolism	B-X
,	B-X
transcription	B-X
and	B-X
translation	B-X
.	B-X
Putative	B-X
Sp1	B-X
binding	B-X
sites	B-X
were	B-X
found	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
the	B-X
selected	B-X
genes	B-X
using	B-X
the	B-X
Match™	B-X
software	B-X
.	B-X
After	B-X
literature	B-X
mining	B-X
,	B-X
11	B-X
genes	B-X
were	B-X
selected	B-X
for	B-X
further	B-X
validation	B-X
.	B-X
Underexpression	B-X
by	B-X
qRT-PCR	B-X
was	B-X
confirmed	B-X
for	B-X
the	B-X
11	B-X
genes	B-X
plus	B-X
Sp1	B-X
in	B-X
HeLa	B-X
cells	B-X
after	B-X
Sp1-siRNA	B-X
treatment	B-X
.	B-X
EMSA	B-X
and	B-X
ChIP	B-X
assays	B-X
were	B-X
performed	B-X
to	B-X
test	B-X
for	B-X
binding	B-X
of	B-X
Sp1	B-X
to	B-X
the	B-X
promoters	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
We	B-X
observed	B-X
binding	B-X
of	B-X
Sp1	B-X
to	B-X
the	B-X
promoters	B-X
of	B-X
RAB20	B-X
,	B-X
FGF21	B-X
,	B-X
IHPK2	B-X
,	B-X
ARHGAP18	B-X
,	B-X
NPM3	B-X
,	B-X
SRSF7	B-X
,	B-X
CALM3	B-X
,	B-X
PGD	B-X
and	B-X
Sp1	B-X
itself	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
RAB20	B-X
,	B-X
FGF21	B-X
and	B-X
IHPK2	B-X
and	B-X
luciferase	B-X
activity	B-X
for	B-X
these	B-X
three	B-X
genes	B-X
related	B-X
to	B-X
proliferation	B-X
and	B-X
cancer	B-X
,	B-X
were	B-X
determined	B-X
after	B-X
overexpression	B-X
of	B-X
Sp1	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
to	B-X
confirm	B-X
their	B-X
regulation	B-X
by	B-X
Sp1	B-X
.	B-X
Involvement	B-X
of	B-X
these	B-X
three	B-X
genes	B-X
in	B-X
proliferation	B-X
was	B-X
validated	B-X
by	B-X
gene	B-X
silencing	B-X
using	B-X
polypurine	B-X
reverse	B-X
hoogsteen	B-X
hairpins	B-X
.	B-X

An	O
unspecific	O
control	O
siRNA	O
had	O
no	O
influence	O
(	O
Figure	O
7A	O
)	O
.	O

We	O
then	O
cotransfected	O
the	O
luciferase	B-Protein
reporter	I-Protein
plasmid	I-Protein
containing	I-Protein
the	I-Protein
180	I-Protein
bp	I-Protein
A3G	I-Protein
promoter	I-Protein
together	O
with	O
100	O
ng	O
siRNA	O
using	O
an	O
optimized	O
protocol	O
for	O
the	O
cotransfection	O
of	O
plasmid	O
plus	O
siRNA	O
.	O

This	O
resulted	O
in	O
a	O
31	O
-	O
43	O
%	O
reduction	O
of	O
luciferase	O
activity	O
in	O
the	O
presence	O
of	O
Sp1	B-Protein
-	O
or	O
Sp3	B-Protein
-	O
specific	O
siRNA	O
compared	O
to	O
the	O
control	O
siRNA	O
.	O

In	O
contrast	O
,	O
no	O
influence	O
on	O
transcriptional	O
activity	O
of	O
the	O
150	O
bp	O
fragment	O
,	O
which	O
does	O
not	O
contain	O
the	O
Sp1	O
/	O
Sp3	O
-	O
binding	O
motif	O
,	O
was	O
observed	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
latter	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
HSPA2	B-X
gene	B-X
is	B-X
not	B-X
limited	B-X
to	B-X
the	B-X
testis	B-X
,	B-X
and	B-X
recent	B-X
data	B-X
show	B-X
that	B-X
human	B-X
tumor	B-X
cells	B-X
can	B-X
express	B-X
this	B-X
gene	B-X
at	B-X
significant	B-X
levels	B-X
.	B-X
The	B-X
characteristics	B-X
of	B-X
HSPA2	B-X
expression	B-X
suggests	B-X
that	B-X
it	B-X
can	B-X
influence	B-X
the	B-X
phenotype	B-X
and	B-X
survival	B-X
of	B-X
cancer	B-X
cells	B-X
similarly	B-X
as	B-X
overexpression	B-X
of	B-X
major	B-X
members	B-X
of	B-X
the	B-X
HSP70	B-X
gene	B-X
family	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
established	B-X
that	B-X
the	B-X
human	B-X
HSPA2	B-X
gene	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
its	B-X
rodent	B-X
counterparts	B-X
,	B-X
is	B-X
intronless	B-X
and	B-X
has	B-X
a	B-X
single	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
In	B-X
order	B-X
to	B-X
perform	B-X
a	B-X
functional	B-X
study	B-X
of	B-X
the	B-X
HSPA2	B-X
promoter	B-X
,	B-X
we	B-X
used	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
and	B-X
found	B-X
that	B-X
the	B-X
392	B-X
bp	B-X
fragment	B-X
upstream	B-X
of	B-X
the	B-X
ATG	B-X
codon	B-X
was	B-X
a	B-X
minimal	B-X
region	B-X
required	B-X
for	B-X
efficient	B-X
transcription	B-X
,	B-X
while	B-X
a	B-X
150	B-X
bp	B-X
deletion	B-X
from	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
this	B-X
region	B-X
dramatically	B-X
reduced	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

Thus	O
,	O
both	O
Sp1	B-Protein
and	O
Sp3	B-Protein
factors	O
are	O
mediating	O
transcriptional	O
activity	O
of	O
the	O
A3G	B-Protein
promoter	O
.	O

Shortly	O
after	O
the	O
discovery	O
of	O
APOBEC3G	B-Protein
,	O
it	O
became	O
clear	O
that	O
this	O
human	O
gene	O
plays	O
an	O
important	O
role	O
in	O
antiretroviral	O
defense	O
(	O
4	O
)	O
.	O

Originally	O
identified	O
as	O
a	O
restriction	O
factor	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
expression	O
of	O
APOBEC3G	B-Protein
was	O
found	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
,	O
which	O
represent	O
the	O
main	O
target	O
cells	O
for	O
HIV	O
-	O
1	O
(	O
32	O
)	O
.	O

In	O
addition	O
,	O
the	O
protein	O
was	O
detected	O
in	O
lung	O
,	O
liver	O
,	O
spleen	O
,	O
testis	O
and	O
ovary	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
transcriptional	O
regulation	O
(	O
29	O
,	O
32	O
,	O
47	O
)	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
cloned	O
the	O
human	O
APOBEC3G	B-Protein
promoter	O
and	O
analyzed	O
its	O
regulation	O
in	O
T	O
cells	O
.	O

Applying	O
5	O
'	O
-	O
RACE	O
,	O
we	O
identified	O
multiple	O
start	O
sites	O
for	O
transcription	O
of	O
the	O
A3G	B-Protein
gene	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
gene	O
appears	O
to	O
lack	O
canonical	O
CCAAT	O
and	O
TATA	O
boxes	O
(	O
32	O
)	O
,	O
a	O
condition	O
often	O
associated	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
(	O
49	O
-	O
51	O
)	O
.	O

However	O
,	O
one	O
single	O
start	O
site	O
was	O
detected	O
in	O
6	O
of	O
19	O
clones	O
and	O
was	O
designated	O
as	O
+	O
1	O
.	O

This	O
TSS	O
is	O
located	O
66	O
bp	O
upstream	O
of	O
the	O
start	O
of	O
the	O
published	O
mRNA	O
sequence	O
(	O
GenBank	O
(	O
TM	O
)	O
NM021822	O
)	O
.	O

We	O
cloned	O
a	O
1025	O
bp	O
promoter	O
,	O
which	O
ranges	O
from	O
position	O
-	O
959	O
/	O
+	O
66	O
relative	O
to	O
the	O
identified	O
TSS	O
.	O

Luciferase	B-Protein
reporter	O
assays	O
showed	O
that	O
this	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Treatment	O
with	O
the	O
phorbol	O
ester	O
TPA	O
did	O
not	O
further	O
enhance	O
transcriptional	O
activity	O
,	O
although	O
upregulation	O
of	O
A3G	B-Protein
mRNA	O
levels	O
in	O
T	O
cells	O
by	O
TPA	O
has	O
been	O
described	O
(	O
33	O
)	O
.	O
<EOS>	B-X
In	B-X
1988	B-X
,	B-X
we	B-X
first	B-X
reported	B-X
the	B-X
complete	B-X
chemical	B-X
structure	B-X
of	B-X
a	B-X
new	B-X
type	B-X
of	B-X
phorbol	B-X
ester	B-X
,	B-X
abbreviated	B-X
to	B-X
DHPB	B-X
,	B-X
found	B-X
in	B-X
seed	B-X
oil	B-X
of	B-X
Jatropha	B-X
curcas	B-X
L.	B-X
(	B-X
Saboodam	B-X
in	B-X
Thai	B-X
)	B-X
and	B-X
its	B-X
tumor-promoting	B-X
activity	B-X
on	B-X
mouse	B-X
skin	B-X
.	B-X
Although	B-X
this	B-X
seed	B-X
oil	B-X
contains	B-X
toxic	B-X
phorbol	B-X
ester	B-X
,	B-X
it	B-X
was	B-X
planned	B-X
to	B-X
use	B-X
it	B-X
as	B-X
a	B-X
feasible	B-X
renewable	B-X
oil	B-X
and	B-X
the	B-X
extracted	B-X
seed	B-X
cake	B-X
as	B-X
fertilizer	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
increases	B-X
in	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
stimulation	B-X
of	B-X
Na+/H+	B-X
exchange	B-X
,	B-X
and	B-X
turnover	B-X
of	B-X
membrane	B-X
phospholipids	B-X
as	B-X
signals	B-X
for	B-X
mitogen-induced	B-X
activation	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
reviewed	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
optimal	B-X
concentrations	B-X
of	B-X
lectin	B-X
and	B-X
appropriately	B-X
presented	B-X
antigen	B-X
,	B-X
T	B-X
cells	B-X
increase	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
secrete	B-X
IL2	B-X
,	B-X
express	B-X
IL2	B-X
receptors	B-X
and	B-X
later	B-X
divide	B-X
.	B-X
Treatment	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
TPA	B-X
appears	B-X
to	B-X
bypass	B-X
the	B-X
requirement	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
for	B-X
IL2	B-X
secretion	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
various	B-X
mitogens	B-X
can	B-X
trigger	B-X
T	B-X
cells	B-X
through	B-X
both	B-X
[	B-X
Ca2+	B-X
]	B-X
i-dependent	B-X
and	B-X
[	B-X
Ca2+	B-X
]	B-X
i-independent	B-X
pathways	B-X
.	B-X
It	B-X
is	B-X
clear	B-X
that	B-X
lymphoid	B-X
cells	B-X
of	B-X
both	B-X
T	B-X
and	B-X
B	B-X
lineage	B-X
possess	B-X
a	B-X
functional	B-X
Na+/H+	B-X
antiport	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
pHi	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
third	B-X
possible	B-X
reason	B-X
for	B-X
the	B-X
stimulation	B-X
of	B-X
Na+/H+	B-X
exchange	B-X
could	B-X
be	B-X
to	B-X
increase	B-X
the	B-X
osmotic	B-X
content	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
inducing	B-X
cell	B-X
swelling	B-X
that	B-X
may	B-X
be	B-X
an	B-X
early	B-X
requirement	B-X
for	B-X
cellular	B-X
growth	B-X
.	B-X
Indeed	B-X
,	B-X
amiloride-sensitive	B-X
cellular	B-X
swelling	B-X
has	B-X
been	B-X
detected	B-X
electronically	B-X
following	B-X
treatment	B-X
of	B-X
T	B-X
lymphocytes	B-X
with	B-X
TPA	B-X
(	B-X
Grinstein	B-X
et	B-X
al	B-X
.	B-X

Rose	O
et	O
al	O
.	O
used	O
actinomycin	O
D	O
to	O
block	O
further	O
transcription	O
and	O
did	O
not	O
find	O
evidence	O
for	O
enhanced	O
mRNA	O
stability	O
.	O

Therefore	O
,	O
the	O
authors	O
suggested	O
that	O
an	O
enhanced	O
transcription	O
rate	O
could	O
be	O
responsible	O
for	O
the	O
increased	O
amount	O
of	O
A3G	B-Protein
mRNA	O
after	O
TPA	O
treatment	O
.	O

However	O
,	O
the	O
promoter	O
analysis	O
we	O
performed	O
indicates	O
a	O
different	O
mechanism	O
that	O
is	O
independent	O
of	O
transcriptional	O
regulation	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
the	B-X
unique	B-X
features	B-X
of	B-X
RBf2	B-X
contribute	B-X
to	B-X
diverse	B-X
roles	B-X
in	B-X
gene	B-X
regulation	B-X
,	B-X
we	B-X
performed	B-X
chromatin	B-X
immunoprecipitation	B-X
sequencing	B-X
for	B-X
both	B-X
RBf2	B-X
and	B-X
RBf1	B-X
in	B-X
embryos	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
this	B-X
finding	B-X
by	B-X
assessing	B-X
RBf	B-X
activity	B-X
on	B-X
ribosomal	B-X
protein	B-X
promoters	B-X
and	B-X
the	B-X
endogenous	B-X
genes	B-X
.	B-X
RBf1	B-X
and	B-X
RBf2	B-X
significantly	B-X
repressed	B-X
expression	B-X
of	B-X
some	B-X
ribosomal	B-X
protein	B-X
genes	B-X
,	B-X
although	B-X
not	B-X
all	B-X
bound	B-X
genes	B-X
showed	B-X
transcriptional	B-X
effects	B-X
.	B-X
We	B-X
carried	B-X
out	B-X
bioinformatic	B-X
analysis	B-X
to	B-X
investigate	B-X
the	B-X
basis	B-X
for	B-X
differential	B-X
targeting	B-X
by	B-X
these	B-X
two	B-X
proteins	B-X
and	B-X
found	B-X
that	B-X
RBf2-specific	B-X
promoters	B-X
have	B-X
distinct	B-X
sequence	B-X
motifs	B-X
,	B-X
suggesting	B-X
unique	B-X
targeting	B-X
mechanisms	B-X
.	B-X
Association	B-X
of	B-X
RBf2	B-X
with	B-X
these	B-X
promoters	B-X
appears	B-X
to	B-X
be	B-X
independent	B-X
of	B-X
dE2F2/dDP	B-X
,	B-X
although	B-X
promoters	B-X
bound	B-X
by	B-X
both	B-X
RBf1	B-X
and	B-X
RBf2	B-X
require	B-X
dE2F2/dDP	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
unique	B-X
RBf2	B-X
targets	B-X
suggest	B-X
that	B-X
evolutionary	B-X
appearance	B-X
of	B-X
this	B-X
corepressor	B-X
represents	B-X
the	B-X
acquisition	B-X
of	B-X
potentially	B-X
novel	B-X
roles	B-X
in	B-X
gene	B-X
regulation	B-X
for	B-X
the	B-X
RB	B-X
family	B-X
.	B-X

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
A3G	B-Protein
promoter	O
was	O
not	O
inducible	O
by	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
A3	O
.	O
01	O
T	O
cells	O
,	O
whereas	O
in	O
the	O
hepatic	O
cell	O
line	O
HepG2	O
,	O
a	O
moderate	O
induction	O
was	O
measured	O
.	O

It	O
has	O
been	O
described	O
previously	O
that	O
A3G	B-Protein
gene	O
expression	O
is	O
upregulated	O
by	O
interferons	O
in	O
hepatocytes	O
and	O
macrophages	O
(	O
46	O
-	O
48	O
,	O
52	O
)	O
.	O

In	O
this	O
context	O
,	O
two	O
interferon	O
-	O
responsive	O
elements	O
have	O
been	O
identified	O
at	O
the	O
positions	O
-	O
6	O
/	O
+	O
9	O
and	O
+	O
1	O
/	O
+	O
15	O
relative	O
to	O
the	O
TSS	O
(	O
48	O
)	O
.	O

Consistent	O
with	O
this	O
data	O
,	O
we	O
observed	O
an	O
interferon	O
induction	O
in	O
hepatocytes	O
for	O
the	O
fragments	O
ranging	O
between	O
1025	O
and	O
120	O
bp	O
length	O
.	O

The	O
activity	O
of	O
the	O
60	O
bp	O
fragment	O
that	O
does	O
not	O
contain	O
these	O
motifs	O
was	O
not	O
affected	O
.	O
<EOS>	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
15,652	B-X
bp	B-X
Echis	B-X
ocellatus	B-X
pre-pro	B-X
EOC00089-like	B-X
PIII-SVMP	B-X
gene	B-X
was	B-X
assembled	B-X
from	B-X
PCR-amplified	B-X
sequences	B-X
of	B-X
overlapping	B-X
genomic	B-X
fragments	B-X
.	B-X
However	B-X
,	B-X
the	B-X
lizard	B-X
and	B-X
the	B-X
human	B-X
ADAM28	B-X
genes	B-X
contain	B-X
5	B-X
introns	B-X
not	B-X
present	B-X
in	B-X
the	B-X
E.	B-X
ocellatus	B-X
gene	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
Ang1-7	B-X
supplementation	B-X
on	B-X
blood	B-X
pressure	B-X
,	B-X
renal	B-X
circulation	B-X
and	B-X
intrarenal	B-X
reactivity	B-X
(	B-X
IVR	B-X
)	B-X
to	B-X
vasoactive	B-X
agents	B-X
in	B-X
normoglycaemic	B-X
(	B-X
NG	B-X
)	B-X
and	B-X
streptozotocin	B-X
diabetic	B-X
rats	B-X
(	B-X
DM	B-X
)	B-X
.	B-X
In	B-X
Sprague	B-X
Dawley	B-X
DM	B-X
and	B-X
NG	B-X
rats	B-X
,	B-X
3	B-X
weeks	B-X
after	B-X
streptozotocin	B-X
(	B-X
60	B-X
mg/kg	B-X
i.p	B-X
.	B-X
)	B-X

Thus	O
,	O
the	O
induction	O
we	O
observed	O
was	O
most	O
likely	O
mediated	O
by	O
the	O
described	O
interferon	O
-	O
responsive	O
elements	O
.	O

However	O
,	O
according	O
to	O
our	O
results	O
,	O
these	O
motifs	O
can	O
enhance	O
transcription	O
in	O
hepatic	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
whether	B-X
cavins	B-X
are	B-X
involved	B-X
in	B-X
hepatic	B-X
sinusoidal	B-X
angiogenesis	B-X
and	B-X
remodeling	B-X
during	B-X
progression	B-X
to	B-X
cirrhosis	B-X
,	B-X
normal	B-X
control	B-X
liver	B-X
specimens	B-X
and	B-X
early	B-X
and	B-X
late	B-X
cirrhotic	B-X
liver	B-X
specimens	B-X
were	B-X
studied	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
current	B-X
study	B-X
is	B-X
to	B-X
elucidate	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
Nck1	B-X
depletion	B-X
regulates	B-X
hepatic	B-X
insulin	B-X
signaling	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
miR-135a	B-X
in	B-X
regulating	B-X
HCV	B-X
life	B-X
cycle	B-X
and	B-X
showed	B-X
that	B-X
it	B-X
preferentially	B-X
enhances	B-X
viral	B-X
genome	B-X
replication	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
miR-135a	B-X
hepatic	B-X
abundance	B-X
is	B-X
upregulated	B-X
by	B-X
HCV	B-X
infection	B-X
in	B-X
both	B-X
cultured	B-X
hepatocytes	B-X
and	B-X
human	B-X
liver	B-X
,	B-X
likely	B-X
mediating	B-X
a	B-X
more	B-X
favorable	B-X
environment	B-X
for	B-X
viral	B-X
replication	B-X
and	B-X
possibly	B-X
contributing	B-X
to	B-X
HCV-induced	B-X
liver	B-X
malignancy	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
novel	B-X
insights	B-X
into	B-X
HCV-host	B-X
interactions	B-X
and	B-X
unveil	B-X
molecular	B-X
pathways	B-X
linking	B-X
miRNA	B-X
biology	B-X
to	B-X
HCV	B-X
pathogenesis	B-X
.	B-X

This	O
is	O
surprising	O
,	O
since	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
-	O
inducible	O
signaling	O
cascades	O
are	O
present	O
in	O
A3	O
.	O
01	O
T	O
cells	O
:	O
we	O
showed	O
that	O
the	O
control	O
plasmid	O
harboring	O
interferon	O
-	O
responsive	O
GAS	O
elements	O
was	O
markedly	O
induced	O
by	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
treatment	O
.	O

In	O
contrast	O
,	O
the	O
GAS	O
element	O
was	O
not	O
responsive	O
to	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
treatment	O
in	O
these	O
cells	O
,	O
suggesting	O
that	O
our	O
T	O
cell	O
line	O
was	O
not	O
able	O
to	O
mediate	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
induced	O
signals	O
.	O
<EOS>	B-X
Machine	B-X
learning	B-X
analysis	B-X
of	B-X
high-resolution	B-X
computed	B-X
tomographic	B-X
lung	B-X
scans	B-X
permits	B-X
quantitative	B-X
morphometry	B-X
of	B-X
the	B-X
lung	B-X
circulation	B-X
without	B-X
intravenous	B-X
contrast	B-X
.	B-X
The	B-X
present	B-X
paper	B-X
outlines	B-X
characteristics	B-X
of	B-X
thoron	B-X
and	B-X
its	B-X
progeny	B-X
in	B-X
the	B-X
indoor	B-X
environment	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
state-of-the-art	B-X
of	B-X
the	B-X
three	B-X
major	B-X
classes	B-X
of	B-X
gas	B-X
contrast	B-X
agents	B-X
used	B-X
in	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
-hyperpolarized	B-X
(	B-X
HP	B-X
)	B-X
gas	B-X
,	B-X
molecular	B-X
oxygen	B-X
,	B-X
and	B-X
fluorinated	B-X
gas	B-X
--	B-X
and	B-X
their	B-X
application	B-X
to	B-X
clinical	B-X
pulmonary	B-X
research	B-X
.	B-X
Oganesson	B-X
(	B-X
Og	B-X
)	B-X
is	B-X
the	B-X
last	B-X
entry	B-X
into	B-X
the	B-X
Periodic	B-X
Table	B-X
completing	B-X
the	B-X
seventh	B-X
period	B-X
of	B-X
elements	B-X
and	B-X
group	B-X
18	B-X
of	B-X
the	B-X
noble	B-X
gases	B-X
.	B-X

So	O
far	O
,	O
enhanced	O
A3G	B-Protein
promoter	O
activity	O
by	O
interferons	O
is	O
clearly	O
described	O
in	O
hepatocytes	O
and	O
macrophages	O
,	O
whereas	O
the	O
situation	O
in	O
T	O
cells	O
is	O
still	O
unclear	O
.	O

A	O
recent	O
study	O
found	O
no	O
influence	O
of	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
on	O
A3G	B-Protein
expression	O
in	O
resting	O
primary	O
blood	O
lymphocytes	O
(	O
52	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
have	B-X
revealed	B-X
a	B-X
complex	B-X
involvement	B-X
of	B-X
epigenetic	B-X
mechanisms	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
including	B-X
methylation	B-X
,	B-X
chromatin	B-X
modification	B-X
and	B-X
remodeling	B-X
,	B-X
and	B-X
the	B-X
diverse	B-X
activities	B-X
of	B-X
non-coding	B-X
RNAs	B-X
.	B-X
The	B-X
roles	B-X
of	B-X
gene	B-X
methylation	B-X
and	B-X
miRNAs	B-X
have	B-X
been	B-X
relatively	B-X
well	B-X
studied	B-X
in	B-X
melanoma	B-X
,	B-X
but	B-X
other	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
changes	B-X
in	B-X
chromatin	B-X
status	B-X
and	B-X
in	B-X
the	B-X
differential	B-X
expression	B-X
of	B-X
long	B-X
non-coding	B-X
RNAs	B-X
can	B-X
lead	B-X
to	B-X
altered	B-X
regulation	B-X
of	B-X
key	B-X
genes	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
they	B-X
affect	B-X
the	B-X
functioning	B-X
of	B-X
signaling	B-X
pathways	B-X
that	B-X
influence	B-X
each	B-X
other	B-X
,	B-X
intersect	B-X
,	B-X
and	B-X
form	B-X
networks	B-X
in	B-X
which	B-X
local	B-X
perturbations	B-X
disturb	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
whole	B-X
system	B-X
.	B-X
Using	B-X
a	B-X
mouse	B-X
breast	B-X
cancer	B-X
model	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
ART	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
to	B-X
determine	B-X
how	B-X
it	B-X
influences	B-X
the	B-X
anti-tumor	B-X
immune	B-X
response	B-X
.	B-X

Another	O
publication	O
describes	O
an	O
enhanced	O
expression	O
of	O
A3G	B-Protein
after	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
treatment	O
in	O
resting	O
primary	O
CD4	B-Protein
T	O
cells	O
,	O
but	O
not	O
in	O
activated	O
T	O
cells	O
(	O
53	O
)	O
.	O

This	O
observation	O
is	O
not	O
contradictory	O
to	O
our	O
results	O
since	O
T	O
cell	O
lines	O
are	O
mitotically	O
active	O
and	O
therefore	O
rather	O
in	O
an	O
activated	O
than	O
in	O
a	O
resting	O
state	O
.	O
<EOS>	B-X
Barrett	B-X
's	B-X
esophagus	B-X
:	B-X
diagnosis	B-X
and	B-X
management	B-X
.	B-X
It	B-X
is	B-X
worth	B-X
distinguishing	B-X
between	B-X
the	B-X
two	B-X
strategies	B-X
of	B-X
expectant	B-X
management	B-X
for	B-X
prostate	B-X
cancer	B-X
.	B-X
Watchful	B-X
waiting	B-X
entails	B-X
administering	B-X
non-curative	B-X
androgen	B-X
deprivation	B-X
therapy	B-X
to	B-X
patients	B-X
on	B-X
development	B-X
of	B-X
symptomatic	B-X
progression	B-X
,	B-X
whereas	B-X
active	B-X
surveillance	B-X
entails	B-X
delivering	B-X
curative	B-X
treatment	B-X
on	B-X
signs	B-X
of	B-X
disease	B-X
progression	B-X
.	B-X
The	B-X
objectives	B-X
of	B-X
the	B-X
two	B-X
management	B-X
strategies	B-X
and	B-X
the	B-X
patients	B-X
enrolled	B-X
in	B-X
either	B-X
are	B-X
different	B-X
:	B-X
(	B-X
i	B-X
)	B-X
to	B-X
review	B-X
the	B-X
role	B-X
of	B-X
active	B-X
surveillance	B-X
as	B-X
a	B-X
management	B-X
strategy	B-X
for	B-X
patients	B-X
with	B-X
low-risk	B-X
prostate	B-X
cancer	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
review	B-X
the	B-X
benefits	B-X
and	B-X
pitfalls	B-X
of	B-X
active	B-X
surveillance	B-X
.	B-X
We	B-X
carried	B-X
out	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
active	B-X
surveillance	B-X
for	B-X
prostate	B-X
cancer	B-X
in	B-X
the	B-X
literature	B-X
using	B-X
the	B-X
National	B-X
Center	B-X
for	B-X
Biotechnology	B-X
Information	B-X
's	B-X
electronic	B-X
database	B-X
,	B-X
PubMed	B-X
.	B-X
We	B-X
carried	B-X
out	B-X
a	B-X
search	B-X
in	B-X
English	B-X
using	B-X
the	B-X
terms	B-X
:	B-X
active	B-X
surveillance	B-X
,	B-X
prostate	B-X
cancer	B-X
,	B-X
watchful	B-X
waiting	B-X
and	B-X
conservative	B-X
management	B-X
.	B-X
Active	B-X
surveillance	B-X
appears	B-X
to	B-X
reduce	B-X
overtreatment	B-X
in	B-X
patients	B-X
with	B-X
low-risk	B-X
prostate	B-X
cancer	B-X
without	B-X
compromising	B-X
cancer-specific	B-X
survival	B-X
at	B-X
10	B-X
years	B-X
.	B-X
Therefore	B-X
,	B-X
active	B-X
surveillance	B-X
is	B-X
an	B-X
option	B-X
for	B-X
select	B-X
patients	B-X
who	B-X
want	B-X
to	B-X
avoid	B-X
the	B-X
side-effects	B-X
inherent	B-X
to	B-X
the	B-X
different	B-X
types	B-X
of	B-X
immediate	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
inclusion	B-X
criteria	B-X
for	B-X
active	B-X
surveillance	B-X
and	B-X
the	B-X
most	B-X
appropriate	B-X
method	B-X
of	B-X
monitoring	B-X
patients	B-X
on	B-X
active	B-X
surveillance	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
standardized	B-X
.	B-X

In	O
conclusion	O
,	O
the	O
current	O
data	O
suggests	O
that	O
regulation	O
of	O
the	O
A3G	B-Protein
promoter	O
activity	O
by	O
interferons	O
is	O
dependent	O
on	O
the	O
cell	O
type	O
and	O
possibly	O
also	O
from	O
the	O
cellular	O
activation	O
status	O
.	O

We	O
additionally	O
analyzed	O
the	O
influence	O
of	O
HIV	O
-	O
1	O
proteins	O
on	O
A3G	B-Protein
promoter	O
activity	O
.	O

The	O
HIV	O
-	O
1	O
Vif	B-Protein
protein	O
is	O
neutralizing	O
the	O
antiviral	O
function	O
of	O
A3G	B-Protein
by	O
a	O
multitude	O
of	O
ways	O
.	O

Targeting	O
the	O
A3G	B-Protein
protein	O
for	O
proteasomal	O
degradation	O
is	O
considered	O
to	O
be	O
the	O
main	O
mode	O
of	O
action	O
(	O
37	O
-	O
41	O
)	O
,	O
but	O
it	O
becomes	O
more	O
and	O
more	O
clear	O
that	O
other	O
mechanisms	O
are	O
also	O
involved	O
.	O

There	O
is	O
evidence	O
that	O
Vif	B-Protein
also	O
promotes	O
exclusion	O
of	O
A3G	B-Protein
from	O
the	O
virus	O
particles	O
and	O
an	O
influence	O
on	O
the	O
A3G	B-Protein
translation	O
process	O
is	O
discussed	O
(	O
8	O
,	O
42	O
,	O
43	O
)	O
.	O

The	O
question	O
whether	O
Vif	B-Protein
alters	O
transcription	O
controlled	O
by	O
the	O
A3G	B-Protein
promoter	O
has	O
not	O
been	O
analyzed	O
so	O
far	O
.	O

Our	O
analysis	O
indicates	O
that	O
transcription	O
from	O
the	O
A3G	B-Protein
promoter	O
is	O
unaffected	O
by	O
Vif	B-Protein
or	O
other	O
HIV	O
-	O
1	O
proteins	O
.	O
<EOS>	B-X
The	B-X
HIV-1	B-X
is	B-X
a	B-X
formidable	B-X
pathogen	B-X
with	B-X
establishment	B-X
of	B-X
a	B-X
persistent	B-X
infection	B-X
based	B-X
on	B-X
the	B-X
ability	B-X
to	B-X
integrate	B-X
the	B-X
proviral	B-X
genome	B-X
into	B-X
chronically	B-X
infected	B-X
cells	B-X
,	B-X
and	B-X
by	B-X
the	B-X
rapid	B-X
evolution	B-X
made	B-X
possible	B-X
by	B-X
a	B-X
high	B-X
mutation	B-X
rate	B-X
and	B-X
frequent	B-X
recombination	B-X
during	B-X
the	B-X
viral	B-X
replication	B-X
.	B-X
HIV-1	B-X
has	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
genes	B-X
that	B-X
facilitate	B-X
viral	B-X
persistence	B-X
and	B-X
regulation	B-X
of	B-X
HIV	B-X
replication	B-X
,	B-X
but	B-X
this	B-X
virus	B-X
also	B-X
usurps	B-X
cellular	B-X
machinery	B-X
for	B-X
HIV	B-X
replication	B-X
,	B-X
particularly	B-X
during	B-X
gene	B-X
expression	B-X
and	B-X
virion	B-X
assembly	B-X
and	B-X
budding	B-X
.	B-X
Recent	B-X
success	B-X
with	B-X
antiretroviral	B-X
therapy	B-X
may	B-X
be	B-X
limited	B-X
by	B-X
the	B-X
emergence	B-X
HIV	B-X
drug	B-X
resistance	B-X
and	B-X
by	B-X
toxicities	B-X
and	B-X
other	B-X
requirements	B-X
for	B-X
successful	B-X
long-term	B-X
therapy	B-X
.	B-X
Further	B-X
investigation	B-X
of	B-X
HIV-1	B-X
replication	B-X
may	B-X
allow	B-X
identification	B-X
of	B-X
novel	B-X
targets	B-X
of	B-X
antiretroviral	B-X
therapy	B-X
that	B-X
may	B-X
allow	B-X
continued	B-X
virus	B-X
suppression	B-X
in	B-X
patients	B-X
of	B-X
failing	B-X
current	B-X
regiments	B-X
,	B-X
particularly	B-X
drugs	B-X
that	B-X
target	B-X
HIV-1	B-X
entry	B-X
and	B-X
HIV-1	B-X
integration	B-X
.	B-X

Taken	O
together	O
,	O
in	O
T	O
cell	O
lines	O
,	O
the	O
A3G	B-Protein
promoter	O
appears	O
constitutively	O
active	O
.	O

By	O
generating	O
a	O
series	O
of	O
5	O
'	O
deletions	O
,	O
we	O
showed	O
that	O
the	O
core	O
promoter	O
is	O
located	O
within	O
the	O
region	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

This	O
180	O
bp	O
promoter	O
was	O
transcriptionally	O
active	O
in	O
the	O
lymphoid	O
,	O
myeloid	O
and	O
hepatic	O
cell	O
lines	O
we	O
tested	O
,	O
indicating	O
that	O
ubiquitous	O
transcription	O
factors	O
are	O
involved	O
in	O
regulation	O
of	O
A3G	B-Protein
gene	O
transcription	O
.	O

A	O
GC	O
-	O
box	O
with	O
the	O
sequence	O
TGGGCGGGAC	O
was	O
identified	O
at	O
position	O
-	O
87	O
/	O
-	O
78	O
of	O
the	O
A3G	B-Protein
promoter	O
.	O

This	O
GC	O
-	O
box	O
is	O
essential	O
for	O
basal	O
promoter	O
activity	O
,	O
since	O
changing	O
the	O
motif	O
to	O
TGTTCGGGAC	B-Protein
by	O
introducing	O
two	O
point	O
mutations	O
strongly	O
reduced	O
A3G	B-Protein
promoter	O
activity	O
.	O

The	O
transcriptional	O
potency	O
of	O
the	O
GC	O
-	O
box	O
was	O
further	O
demonstrated	O
by	O
cloning	O
it	O
upstream	O
of	O
an	O
SV40	O
promoter	O
.	O

This	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
enhanced	O
transcription	O
rate	O
.	O

The	O
hypothesis	O
that	O
a	O
general	O
transcription	O
factor	O
is	O
involved	O
in	O
regulation	O
of	O
A3G	B-Protein
transcription	O
was	O
confirmed	O
by	O
EMSA	O
.	O

Supershift	O
analysis	O
showed	O
that	O
the	O
transcription	O
factors	O
Sp1	B-Protein
and	O
Sp3	B-Protein
which	O
are	O
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
,	O
bind	O
specifically	O
to	O
the	O
identified	O
motif	O
.	O

In	O
addition	O
,	O
the	O
binding	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
to	O
the	O
endogenous	O
A3G	B-Protein
promoter	O
was	O
demonstrated	O
by	O
a	O
chromatin	O
immunoprecipitation	O
assay	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
the	O
5	O
'	O
-	O
RACE	O
,	O
since	O
Sp1	B-Protein
is	O
known	O
to	O
play	O
an	O
important	O
role	O
for	O
RNA	B-Protein
polymerase	I-Protein
II	I-Protein
to	O
bind	O
to	O
the	O
transcription	O
initiation	O
site	O
in	O
TATA	O
-	O
boxless	O
promoters	O
and	O
is	O
associated	O
with	O
multiple	O
transcription	O
initiation	O
sites	O
(	O
54	O
-	O
56	O
)	O
.	O

We	O
also	O
tested	O
whether	O
overexpression	O
of	O
Sp1	B-Protein
or	O
Sp3	B-Protein
proteins	O
had	O
an	O
influence	O
on	O
A3G	B-Protein
promoter	O
activity	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
Sp1	B-X
transcription	B-X
factor	B-X
to	B-X
DNA	B-X
is	B-X
considered	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
small	B-X
ligands	B-X
designed	B-X
to	B-X
interfere	B-X
with	B-X
gene	B-X
transcription	B-X
.	B-X
We	B-X
attempted	B-X
to	B-X
distinguish	B-X
the	B-X
direct	B-X
inhibition	B-X
of	B-X
the	B-X
Sp1-binding	B-X
to	B-X
DNA	B-X
in	B-X
vivo	B-X
(	B-X
cell	B-X
culture	B-X
)	B-X
from	B-X
more	B-X
indirect	B-X
effects	B-X
due	B-X
to	B-X
the	B-X
network	B-X
of	B-X
pathways	B-X
that	B-X
modulate	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
which	B-X
may	B-X
decrease	B-X
transcription	B-X
without	B-X
direct	B-X
interference	B-X
with	B-X
Sp1-DNA	B-X
interactions	B-X
.	B-X
We	B-X
tested	B-X
whether	B-X
the	B-X
Sp3	B-X
protein	B-X
,	B-X
whose	B-X
putative	B-X
binding	B-X
sequence	B-X
overlaps	B-X
the	B-X
Sp1	B-X
site	B-X
,	B-X
can	B-X
inhibit	B-X
Sp1-activated	B-X
transcription	B-X
and	B-X
interfere	B-X
with	B-X
drug-DNA	B-X
interactions	B-X
.	B-X
A	B-X
well-characterized	B-X
model	B-X
system	B-X
consisting	B-X
of	B-X
a	B-X
wtGLUT1	B-X
(	B-X
wild-type	B-X
glucose	B-X
transporter	B-X
1	B-X
)	B-X
gene	B-X
promoter	B-X
,	B-X
or	B-X
a	B-X
mutated	B-X
mut2GLUT1	B-X
promoter	B-X
,	B-X
linked	B-X
to	B-X
a	B-X
CAT	B-X
(	B-X
chloramphenicol	B-X
acetyltransferase	B-X
)	B-X
reporter	B-X
gene	B-X
,	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
the	B-X
effects	B-X
of	B-X
overexpressed	B-X
Sp1	B-X
and	B-X
Sp3	B-X
transcription	B-X
factors	B-X
in	B-X
transiently	B-X
transfected	B-X
Jurkat	B-X
T	B-X
lymphocytes	B-X
.	B-X
Bisanthracycline	B-X
WP631	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
Sp1-activated	B-X
transcription	B-X
in	B-X
vitro	B-X
,	B-X
was	B-X
assayed	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
specifically	B-X
inhibit	B-X
transcription	B-X
in	B-X
transfected	B-X
Jurkat	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
mut2GLUT1	B-X
promoter	B-X
was	B-X
used	B-X
to	B-X
further	B-X
discriminate	B-X
between	B-X
the	B-X
WP631	B-X
interference	B-X
with	B-X
Sp1-DNA	B-X
complexes	B-X
and	B-X
Sp3-induced	B-X
inhibition	B-X
,	B-X
since	B-X
the	B-X
Sp3-binding	B-X
site	B-X
is	B-X
canceled	B-X
in	B-X
this	B-X
promoter	B-X
and	B-X
replaced	B-X
by	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
for	B-X
WP631	B-X
.	B-X

Luciferase	B-Protein
assays	O
revealed	O
that	O
A3G	B-Protein
promoter	O
activities	O
remained	O
unchanged	O
(	O
data	O
not	O
shown	O
)	O
,	O
most	O
probably	O
due	O
to	O
the	O
high	O
basal	O
expression	O
level	O
of	O
the	O
endogenous	O
Sp1	B-Protein
and	O
/	O
or	O
Sp3	B-Protein
proteins	O
.	O
<EOS>	B-X
Sp1	B-X
and	B-X
Sp3	B-X
are	B-X
transcription	B-X
factors	B-X
expressed	B-X
in	B-X
all	B-X
mammalian	B-X
cells	B-X
.	B-X
Dysregulation	B-X
of	B-X
Sp1	B-X
and	B-X
Sp3	B-X
is	B-X
observed	B-X
in	B-X
many	B-X
cancers	B-X
and	B-X
diseases	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
similarity	B-X
of	B-X
the	B-X
DNA	B-X
binding	B-X
domains	B-X
,	B-X
Sp1	B-X
and	B-X
Sp3	B-X
recognize	B-X
and	B-X
associate	B-X
with	B-X
the	B-X
same	B-X
DNA	B-X
element	B-X
with	B-X
similar	B-X
affinity	B-X
.	B-X
Both	B-X
Sp1	B-X
and	B-X
Sp3	B-X
can	B-X
interact	B-X
with	B-X
and	B-X
recruit	B-X
a	B-X
large	B-X
number	B-X
of	B-X
proteins	B-X
including	B-X
the	B-X
transcription	B-X
initiation	B-X
complex	B-X
,	B-X
histone	B-X
modifying	B-X
enzymes	B-X
and	B-X
chromatin	B-X
remodeling	B-X
complexes	B-X
,	B-X
which	B-X
strongly	B-X
suggest	B-X
that	B-X
Sp1	B-X
and	B-X
Sp3	B-X
are	B-X
important	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
remodeling	B-X
chromatin	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
role	B-X
of	B-X
Sp1	B-X
and	B-X
Sp3	B-X
in	B-X
normal	B-X
and	B-X
cancer	B-X
cell	B-X
biology	B-X
and	B-X
the	B-X
multiple	B-X
mechanisms	B-X
deciding	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
Sp1	B-X
and	B-X
Sp3	B-X
will	B-X
be	B-X
presented	B-X
.	B-X

The	O
Sp	O
family	O
of	O
transcription	O
factors	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
many	O
housekeeping	O
,	O
tissue	O
-	O
specific	O
,	O
viral	O
and	O
inducible	O
genes	O
(	O
57	O
)	O
.	O

Whereas	O
Sp1	B-Protein
typically	O
acts	O
as	O
an	O
activator	O
,	O
Sp3	B-Protein
can	O
serve	O
as	O
a	O
repressor	O
or	O
activator	O
(	O
57	O
)	O
.	O
<EOS>	B-X
Inverse	B-X
associations	B-X
were	B-X
also	B-X
observed	B-X
for	B-X
increasing	B-X
activity	B-X
over	B-X
time	B-X
,	B-X
resistance	B-X
exercise	B-X
,	B-X
occupational	B-X
activity	B-X
and	B-X
for	B-X
cardiorespiratory	B-X
fitness	B-X
.	B-X
Nonlinear	B-X
relations	B-X
were	B-X
observed	B-X
for	B-X
leisure-time	B-X
activity	B-X
,	B-X
vigorous	B-X
activity	B-X
,	B-X
walking	B-X
and	B-X
resistance	B-X
exercise	B-X
(	B-X
p	B-X
nonlinearity	B-X
<	B-X
0.0001	B-X
for	B-X
all	B-X
)	B-X
,	B-X
with	B-X
steeper	B-X
reductions	B-X
in	B-X
type	B-X
2	B-X
diabetes	B-X
risk	B-X
at	B-X
low	B-X
activity	B-X
levels	B-X
than	B-X
high	B-X
activity	B-X
levels	B-X
.	B-X
Reductions	B-X
in	B-X
risk	B-X
are	B-X
observed	B-X
up	B-X
to	B-X
5-7	B-X
h	B-X
of	B-X
leisure-time	B-X
,	B-X
vigorous	B-X
or	B-X
low	B-X
intensity	B-X
physical	B-X
activity	B-X
per	B-X
week	B-X
,	B-X
but	B-X
further	B-X
reductions	B-X
can	B-X
not	B-X
be	B-X
excluded	B-X
beyond	B-X
this	B-X
range	B-X
.	B-X
This	B-X
paper	B-X
focuses	B-X
on	B-X
the	B-X
key	B-X
function	B-X
of	B-X
imitation	B-X
in	B-X
motor	B-X
and	B-X
social	B-X
development	B-X
of	B-X
typically	B-X
developing	B-X
infants	B-X
and	B-X
low-functioning	B-X
children	B-X
with	B-X
autism	B-X
spectrum	B-X
disorder	B-X
(	B-X
ASD	B-X
)	B-X
.	B-X

However	O
,	O
in	O
the	O
context	O
of	O
the	O
A3G	B-Protein
promoter	O
,	O
both	O
transcription	O
factors	O
serve	O
as	O
activators	O
,	O
as	O
shown	O
by	O
siRNA	O
-	O
mediated	O
silencing	O
of	O
the	O
single	O
factors	O
.	O

Although	O
siRNAs	O
directed	O
against	O
Sp1	B-Protein
or	O
Sp3	B-Protein
significantly	O
reduced	O
transcription	O
controlled	O
by	O
the	O
180	O
bp	O
promoter	O
,	O
transcriptional	O
activity	O
was	O
not	O
reduced	O
to	O
the	O
level	O
of	O
the	O
150	O
bp	O
fragment	O
.	O
<EOS>	B-X
Bromodomain	B-X
is	B-X
an	B-X
evolutionally	B-X
conserved	B-X
domain	B-X
that	B-X
is	B-X
found	B-X
in	B-X
proteins	B-X
strongly	B-X
implicated	B-X
in	B-X
signal-dependent	B-X
transcriptional	B-X
regulation	B-X
.	B-X
Previous	B-X
studies	B-X
showed	B-X
that	B-X
BRD7	B-X
gene	B-X
exhibited	B-X
much	B-X
higher-level	B-X
of	B-X
mRNA	B-X
expression	B-X
in	B-X
normal	B-X
nasopharyngeal	B-X
epithelia	B-X
than	B-X
in	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
biopsies	B-X
and	B-X
cell	B-X
lines	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
its	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
BRD7	B-X
gene	B-X
.	B-X

This	O
can	O
be	O
explained	O
by	O
the	O
remaining	O
low	O
amounts	O
of	O
Sp1	B-Protein
/	O
Sp3	B-Protein
proteins	O
which	O
can	O
be	O
seen	O
in	O
the	O
western	O
blot	O
analysis	O
.	O

Alternatively	O
,	O
other	O
transcription	O
factors	O
could	O
be	O
involved	O
in	O
A3G	B-Protein
regulation	O
.	O

Our	O
results	O
also	O
provide	O
information	O
about	O
the	O
regulation	O
of	O
APOBEC3F	B-Protein
(	O
A3F	B-Protein
)	O
,	O
another	O
member	O
of	O
the	O
human	O
APOBEC3	O
family	O
.	O

A3F	B-Protein
is	O
expressed	O
in	O
many	O
human	O
tissues	O
that	O
also	O
express	O
A3G	B-Protein
and	O
both	O
proteins	O
have	O
been	O
shown	O
to	O
form	O
heteromultimers	O
,	O
which	O
are	O
most	O
likely	O
generated	O
through	O
binding	O
to	O
an	O
RNA	O
intermediate	O
(	O
26	O
,	O
29	O
,	O
30	O
)	O
.	O

A3F	B-Protein
only	O
differs	O
in	O
16	O
nt	O
from	O
the	O
560	O
nt	O
upstream	O
of	O
the	O
TSS	O
of	O
A3G	B-Protein
(	O
GenBank	O
(	O
TM	O
)	O
DQ146365	O
and	O
DQ147772	O
)	O
.	O

The	O
180	O
-	O
bp	O
core	O
promoter	O
region	O
,	O
which	O
we	O
identified	O
for	O
A3G	B-Protein
has	O
100	O
%	O
identity	O
with	O
the	O
A3F	B-Protein
sequence	O
.	O

Therefore	O
,	O
Sp1	B-Protein
/	O
Sp3	B-Protein
transcription	O
factors	O
are	O
most	O
likely	O
also	O
mediating	O
basal	O
transcription	O
of	O
the	O
A3F	B-Protein
gene	O
.	O

Our	O
study	O
revealed	O
that	O
the	O
human	O
A3G	B-Protein
gene	O
is	O
controlled	O
by	O
a	O
promoter	O
with	O
multiple	O
transcriptional	O
start	O
sites	O
.	O

In	O
A3	O
.	O
01	O
T	O
cells	O
,	O
the	O
A3G	B-Protein
promoter	O
appears	O
constitutively	O
active	O
and	O
is	O
not	O
inducible	O
by	O
TPA	O
,	O
type	O
I	O
or	O
II	O
interferons	O
or	O
by	O
HIV	O
-	O
1	O
proteins	O
.	O
<EOS>	B-X
The	B-X
interferon	B-X
γ-inducible	B-X
protein	B-X
16	B-X
(	B-X
IFI16	B-X
)	B-X
is	B-X
known	B-X
as	B-X
immune	B-X
sensor	B-X
of	B-X
retroviral	B-X
DNA	B-X
intermediates	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IFI16	B-X
restricts	B-X
HIV-1	B-X
independently	B-X
of	B-X
immune	B-X
sensing	B-X
by	B-X
binding	B-X
and	B-X
inhibiting	B-X
the	B-X
host	B-X
transcription	B-X
factor	B-X
Sp1	B-X
that	B-X
drives	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X
This	B-X
antiretroviral	B-X
activity	B-X
and	B-X
ability	B-X
to	B-X
bind	B-X
Sp1	B-X
require	B-X
the	B-X
N-terminal	B-X
pyrin	B-X
domain	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
IFI16	B-X
,	B-X
but	B-X
not	B-X
the	B-X
HIN	B-X
domains	B-X
involved	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
Highly	B-X
prevalent	B-X
clade	B-X
C	B-X
HIV-1	B-X
strains	B-X
are	B-X
more	B-X
resistant	B-X
to	B-X
IFI16	B-X
and	B-X
less	B-X
dependent	B-X
on	B-X
Sp1	B-X
than	B-X
other	B-X
HIV-1	B-X
subtypes	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
Sp1	B-X
by	B-X
IFI16	B-X
or	B-X
pharmacologically	B-X
by	B-X
Mithramycin	B-X
A	B-X
suppresses	B-X
reactivation	B-X
of	B-X
latent	B-X
HIV-1	B-X
in	B-X
CD4	B-X

The	O
core	O
promoter	O
is	O
located	O
within	O
a	O
region	O
of	O
180	O
bp	O
at	O
position	O
-	O
114	O
/	O
+	O
66	O
relative	O
to	O
the	O
TSS	O
.	O

A	O
GC	O
-	O
box	O
is	O
crucial	O
to	O
the	O
function	O
of	O
the	O
core	O
promoter	O
and	O
represents	O
a	O
binding	O
site	O
for	O
Sp1	B-Protein
and	O
Sp3	B-Protein
transcription	O
factors	O
.	O

Our	O
results	O
can	O
serve	O
as	O
a	O
basis	O
for	O
future	O
studies	O
aimed	O
at	O
understanding	O
how	O
A3G	B-Protein
and	O
A3F	B-Protein
expression	O
is	O
controlled	O
in	O
different	O
tissues	O
and	O
how	O
these	O
restriction	O
factors	O
can	O
be	O
used	O
to	O
develop	O
novel	O
therapeutic	O
strategies	O
against	O
HIV	O
-	O
1	O
infection	O
.	O

Sequence	O
of	O
the	O
A3G	B-Protein
promoter	O
and	O
the	O
downstream	O
region	O
.	O

The	O
first	O
1000	O
bp	O
upstream	O
of	O
the	O
major	O
TSS	O
are	O
shown	O
in	O
lower	O
case	O
,	O
the	O
first	O
800	O
bp	O
of	O
the	O
transcribed	O
sequence	O
are	O
shown	O
in	O
upper	O
case	O
.	O

Introns	O
are	O
removed	O
,	O
but	O
their	O
positions	O
are	O
indicated	O
.	O
<EOS>	B-X
Introns	B-X
are	B-X
transcribed	B-X
as	B-X
part	B-X
of	B-X
a	B-X
precursor	B-X
RNA	B-X
that	B-X
is	B-X
subsequently	B-X
removed	B-X
by	B-X
splicing	B-X
,	B-X
giving	B-X
rise	B-X
to	B-X
mature	B-X
mRNA	B-X
.	B-X
Two	B-X
exon-intron	B-X
boundaries	B-X
,	B-X
or	B-X
splice	B-X
sites	B-X
,	B-X
were	B-X
identified	B-X
at	B-X
positions	B-X
863	B-X
to	B-X
868	B-X
and	B-X
1553	B-X
to	B-X
1558	B-X
of	B-X
RTA1	B-X
.	B-X
Site-directed	B-X
and	B-X
deletion	B-X
mutation	B-X
studies	B-X
of	B-X
the	B-X
splice	B-X
site	B-X
sequence	B-X
indicated	B-X
that	B-X
sequence	B-X
conservation	B-X
was	B-X
important	B-X
in	B-X
order	B-X
for	B-X
accurate	B-X
splicing	B-X
to	B-X
occur	B-X
.	B-X
lincRNAs	B-X
seem	B-X
to	B-X
be	B-X
poorly	B-X
conserved	B-X
at	B-X
the	B-X
sequence	B-X
level	B-X
but	B-X
at	B-X
least	B-X
some	B-X
lincRNAs	B-X
have	B-X
conserved	B-X
structural	B-X
elements	B-X
and	B-X
syntenic	B-X
genomic	B-X
positions	B-X
.	B-X

Arrows	O
refer	O
to	O
transcriptional	B-Protein
start	I-Protein
sites	I-Protein
and	O
their	O
observed	O
frequency	O
is	O
given	O
by	O
the	O
numbers	O
above	O
.	O

The	O
primer	O
binding	O
sites	O
for	O
5	O
'	O
-	O
RACE	O
analysis	O
and	O
cloning	O
of	O
the	O
luciferase	B-Protein
reporter	O
constructs	O
are	O
underlined	O
and	O
the	O
names	O
of	O
the	O
primers	O
are	O
annotated	O
.	O

Gray	O
and	O
black	O
arrowheads	O
define	O
the	O
regions	O
designated	O
E1	O
and	O
E2	O
which	O
were	O
cloned	O
into	O
vector	O
pGL3	O
-	O
Promoter	O
and	O
used	O
as	O
EMSA	O
probes	O
.	O

The	O
ATG	O
start	O
codon	O
and	O
the	O
identified	O
Sp1	O
/	O
Sp3	O
transcription	O
factor	O
binding	O
site	O
are	O
shown	O
in	O
bold	O
.	O

5	O
'	O
-	O
RACE	O
analysis	O
of	O
the	O
A3G	B-Protein
cDNA	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
size	O
marker	O
and	O
A3G	B-Protein
5	O
'	O
-	O
RACE	O
products	O
after	O
nested	O
PCR	O
with	O
primer	O
RACE	O
-	O
APO3Gnest	O
(	O
see	O
Figure	O
1	O
for	O
primer	O
details	O
)	O
.	O

Arrowheads	O
indicate	O
the	O
three	O
resulting	O
DNA	O
bands	O
which	O
were	O
cloned	O
and	O
sequenced	O
.	O

Luciferase	B-Protein
activities	O
of	O
A3G	B-Protein
promoter	O
constructs	O
in	O
different	O
cell	O
lines	O
.	O

(	O
A	O
)	O
A3G	B-Protein
promoter	O
5	O
'	O
deletion	O
constructs	O
of	O
different	O
sizes	O
were	O
cloned	O
into	O
pGL3	O
-	O
Basic	O
luciferase	B-Protein
reporter	O
plasmids	O
.	O

Numbering	O
is	O
relative	O
to	O
the	O
major	O
TSS	O
.	O

A	O
putative	O
Sp1	O
/	O
Sp3	O
consensus	O
site	O
(	O
gray	O
square	O
)	O
is	O
depicted	O
.	O

(	O
B	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	B-Protein
promoter	O
deletion	O
constructs	O
.	O

Numbers	O
on	O
the	O
x	O
-	O
axis	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	B-Protein
promoter	O
fragments	O
in	O
bp	O
.	O

(	O
C	O
)	O
A3G	B-Protein
promoter	O
plasmids	O
were	O
transfected	O
into	O
U937	O
,	O
HepG2	O
and	O
Huh7	O
cell	O
lines	O
.	O

Numbers	O
in	O
the	O
legends	O
refer	O
to	O
the	O
length	O
of	O
the	O
A3G	B-Protein
promoter	O
fragments	O
in	O
bp	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	B-Protein
assay	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
tumorigenesis	B-X
of	B-X
mutant	B-X
[	B-X
12Asp	B-X
]	B-X
-K-ras	B-X
in	B-X
endometrial	B-X
carcinoma	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
ER	B-X
.	B-X
Susceptibility	B-X
to	B-X
transmissible	B-X
spongiform	B-X
encephalopathy	B-X
and	B-X
different	B-X
alleles	B-X
of	B-X
the	B-X
prion	B-X
protein	B-X
gene	B-X
(	B-X
PRNP	B-X
)	B-X
of	B-X
humans	B-X
and	B-X
sheep	B-X
are	B-X
associated	B-X
.	B-X
A	B-X
tentative	B-X
association	B-X
between	B-X
PRNP	B-X
promoter	B-X
polymorphisms	B-X
and	B-X
bovine	B-X
spongiform	B-X
encephalopathy	B-X
(	B-X
BSE	B-X
)	B-X
susceptibility	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
German	B-X
cattle	B-X
,	B-X
whereas	B-X
none	B-X
of	B-X
the	B-X
known	B-X
polymorphisms	B-X
within	B-X
the	B-X
bovine	B-X
PRNP-coding	B-X
sequence	B-X
affect	B-X
BSE	B-X
susceptibility	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
novel	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
located	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
bovine	B-X
PRNP	B-X
affecting	B-X
its	B-X
expression	B-X
were	B-X
demonstrated	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
.	B-X
We	B-X
sequenced	B-X
exon	B-X
1	B-X
,	B-X
and	B-X
the	B-X
approximately	B-X
200-bp	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
PRNP	B-X
translation	B-X
initiation	B-X
site	B-X
containing	B-X
the	B-X
proximal	B-X
promoter	B-X
of	B-X
PRNP	B-X
was	B-X
harvested	B-X
.	B-X
We	B-X
identified	B-X
7	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
:	B-X
-184A	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
,	B-X
-85T	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-47C	B-X
--	B-X
>	B-X
A	B-X
,	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
,	B-X
+17C	B-X
--	B-X
>	B-X
T	B-X
and	B-X
+43C	B-X
--	B-X
>	B-X
T	B-X
.	B-X
Six	B-X
segregated	B-X
haplotypes	B-X
in	B-X
the	B-X
population	B-X
were	B-X
cloned	B-X
into	B-X
luciferase-expressing	B-X
plasmids	B-X
,	B-X
transfected	B-X
into	B-X
N2a	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
reporter	B-X
activities	B-X
were	B-X
measured	B-X
48	B-X
h	B-X
after	B-X
transfection	B-X
.	B-X
Six	B-X
haplotypes	B-X
showed	B-X
a	B-X
decreased	B-X
expression	B-X
level	B-X
including	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
in	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
or	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
at	B-X
48	B-X
h	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
haplotype	B-X
.	B-X
These	B-X
results	B-X
advocate	B-X
that	B-X
certain	B-X
polymorphisms	B-X
such	B-X
as	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
polymorphisms	B-X
in	B-X
the	B-X
bovine	B-X
PRNP	B-X
promoter	B-X
region	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
could	B-X
influence	B-X
promoter	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
breeding	B-X
cattle	B-X
with	B-X
such	B-X
substitutions	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
approach	B-X
in	B-X
reducing	B-X
BSE	B-X
risk	B-X
.	B-X

Firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
transiently	B-X
transfected	B-X
primary	B-X
monolayer	B-X
cultures	B-X
of	B-X
porcine	B-X
granulosa-luteal	B-X
cells	B-X
with	B-X
a	B-X
reporter	B-X
vector	B-X
containing	B-X
the	B-X
putative	B-X
5'-upstream	B-X
full-length	B-X
(	B-X
pLDLR1076/luc	B-X
)	B-X
regulatory	B-X
region	B-X
(	B-X
-1076	B-X
to	B-X
+11	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
homologous	B-X
LDL	B-X
receptor	B-X
gene	B-X
driving	B-X
firefly	B-X
luciferase	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
and/or	B-X
LH	B-X
(	B-X
each	B-X
100	B-X
ng/ml	B-X
)	B-X
.	B-X
Combined	B-X
exposure	B-X
to	B-X
LH	B-X
and	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
stimulated	B-X
LDL	B-X
receptor	B-X
transcriptional	B-X
activity	B-X
maximally	B-X
at	B-X
4	B-X
h	B-X
by	B-X
8-	B-X
to	B-X
20-fold	B-X
,	B-X
as	B-X
normalized	B-X
by	B-X
coexpression	B-X
of	B-X
Renilla	B-X
luciferase	B-X
.	B-X

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A3G	B-Protein
promoter	O
activities	O
after	O
coexpression	O
of	O
HIV	O
-	O
1	O
proteins	O
or	O
treatment	O
with	O
TPA	O
or	O
interferons	O
.	O
<EOS>	B-X
Recombinant	B-X
interferon-alpha	B-X
(	B-X
IFN-alpha	B-X
)	B-X
was	B-X
approved	B-X
by	B-X
regulatory	B-X
agencies	B-X
in	B-X
many	B-X
countries	B-X
in	B-X
1986	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
history	B-X
of	B-X
the	B-X
purification	B-X
of	B-X
human	B-X
IFNs	B-X
and	B-X
the	B-X
key	B-X
aspects	B-X
of	B-X
our	B-X
current	B-X
state	B-X
of	B-X
knowledge	B-X
of	B-X
human	B-X
IFN	B-X
genes	B-X
,	B-X
proteins	B-X
,	B-X
and	B-X
receptors	B-X
.	B-X
The	B-X
biological	B-X
activities	B-X
and	B-X
clinical	B-X
applications	B-X
of	B-X
the	B-X
proteins	B-X
are	B-X
discussed	B-X
.	B-X
An	B-X
extensive	B-X
section	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
these	B-X
molecules	B-X
provides	B-X
some	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
development	B-X
of	B-X
these	B-X
proteins	B-X
as	B-X
major	B-X
elements	B-X
of	B-X
innate	B-X
immunity	B-X
.	B-X

(	O
A	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
cotransfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	B-Protein
promoter	O
and	O
1	O
microg	O
of	O
Vif	B-Protein
expression	O
plasmid	O
,	O
1	O
microg	O
Tat	B-Protein
expression	O
plasmid	O
or	O
increasing	O
amounts	O
of	O
HIV	O
-	O
1NL4	O
-	O
3	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
microg	O
)	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	B-Protein
assay	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
tumorigenesis	B-X
of	B-X
mutant	B-X
[	B-X
12Asp	B-X
]	B-X
-K-ras	B-X
in	B-X
endometrial	B-X
carcinoma	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
ER	B-X
.	B-X
Susceptibility	B-X
to	B-X
transmissible	B-X
spongiform	B-X
encephalopathy	B-X
and	B-X
different	B-X
alleles	B-X
of	B-X
the	B-X
prion	B-X
protein	B-X
gene	B-X
(	B-X
PRNP	B-X
)	B-X
of	B-X
humans	B-X
and	B-X
sheep	B-X
are	B-X
associated	B-X
.	B-X
A	B-X
tentative	B-X
association	B-X
between	B-X
PRNP	B-X
promoter	B-X
polymorphisms	B-X
and	B-X
bovine	B-X
spongiform	B-X
encephalopathy	B-X
(	B-X
BSE	B-X
)	B-X
susceptibility	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
German	B-X
cattle	B-X
,	B-X
whereas	B-X
none	B-X
of	B-X
the	B-X
known	B-X
polymorphisms	B-X
within	B-X
the	B-X
bovine	B-X
PRNP-coding	B-X
sequence	B-X
affect	B-X
BSE	B-X
susceptibility	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
novel	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
located	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
bovine	B-X
PRNP	B-X
affecting	B-X
its	B-X
expression	B-X
were	B-X
demonstrated	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
.	B-X
We	B-X
sequenced	B-X
exon	B-X
1	B-X
,	B-X
and	B-X
the	B-X
approximately	B-X
200-bp	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
PRNP	B-X
translation	B-X
initiation	B-X
site	B-X
containing	B-X
the	B-X
proximal	B-X
promoter	B-X
of	B-X
PRNP	B-X
was	B-X
harvested	B-X
.	B-X
We	B-X
identified	B-X
7	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
:	B-X
-184A	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
,	B-X
-85T	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-47C	B-X
--	B-X
>	B-X
A	B-X
,	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
,	B-X
+17C	B-X
--	B-X
>	B-X
T	B-X
and	B-X
+43C	B-X
--	B-X
>	B-X
T	B-X
.	B-X
Six	B-X
segregated	B-X
haplotypes	B-X
in	B-X
the	B-X
population	B-X
were	B-X
cloned	B-X
into	B-X
luciferase-expressing	B-X
plasmids	B-X
,	B-X
transfected	B-X
into	B-X
N2a	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
reporter	B-X
activities	B-X
were	B-X
measured	B-X
48	B-X
h	B-X
after	B-X
transfection	B-X
.	B-X
Six	B-X
haplotypes	B-X
showed	B-X
a	B-X
decreased	B-X
expression	B-X
level	B-X
including	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
in	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
or	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
at	B-X
48	B-X
h	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
haplotype	B-X
.	B-X
These	B-X
results	B-X
advocate	B-X
that	B-X
certain	B-X
polymorphisms	B-X
such	B-X
as	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
polymorphisms	B-X
in	B-X
the	B-X
bovine	B-X
PRNP	B-X
promoter	B-X
region	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
could	B-X
influence	B-X
promoter	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
breeding	B-X
cattle	B-X
with	B-X
such	B-X
substitutions	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
approach	B-X
in	B-X
reducing	B-X
BSE	B-X
risk	B-X
.	B-X

Firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
transiently	B-X
transfected	B-X
primary	B-X
monolayer	B-X
cultures	B-X
of	B-X
porcine	B-X
granulosa-luteal	B-X
cells	B-X
with	B-X
a	B-X
reporter	B-X
vector	B-X
containing	B-X
the	B-X
putative	B-X
5'-upstream	B-X
full-length	B-X
(	B-X
pLDLR1076/luc	B-X
)	B-X
regulatory	B-X
region	B-X
(	B-X
-1076	B-X
to	B-X
+11	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
homologous	B-X
LDL	B-X
receptor	B-X
gene	B-X
driving	B-X
firefly	B-X
luciferase	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
and/or	B-X
LH	B-X
(	B-X
each	B-X
100	B-X
ng/ml	B-X
)	B-X
.	B-X
Combined	B-X
exposure	B-X
to	B-X
LH	B-X
and	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
stimulated	B-X
LDL	B-X
receptor	B-X
transcriptional	B-X
activity	B-X
maximally	B-X
at	B-X
4	B-X
h	B-X
by	B-X
8-	B-X
to	B-X
20-fold	B-X
,	B-X
as	B-X
normalized	B-X
by	B-X
coexpression	B-X
of	B-X
Renilla	B-X
luciferase	B-X
.	B-X

(	O
B	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
pGL3	O
-	O
Basic	O
reporter	O
plasmid	O
containing	O
the	O
1025	O
bp	O
A3G	B-Protein
promoter	O
or	O
with	O
empty	O
vector	O
.	O
<EOS>	B-X
Adeno-associated	B-X
virus	B-X
(	B-X
AAV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
viral	B-X
gene	B-X
delivery	B-X
vectors	B-X
with	B-X
long-term	B-X
gene	B-X
expression	B-X
and	B-X
disease	B-X
correction	B-X
,	B-X
featuring	B-X
high	B-X
efficiency	B-X
and	B-X
excellent	B-X
safety	B-X
in	B-X
human	B-X
clinical	B-X
trials	B-X
.	B-X
During	B-X
the	B-X
production	B-X
of	B-X
AAV	B-X
vectors	B-X
,	B-X
there	B-X
are	B-X
several	B-X
quality	B-X
control	B-X
(	B-X
QC	B-X
)	B-X
parameters	B-X
that	B-X
should	B-X
be	B-X
rigorously	B-X
monitored	B-X
to	B-X
comply	B-X
with	B-X
clinical	B-X
safety	B-X
and	B-X
efficacy	B-X
.	B-X
This	B-X
review	B-X
gives	B-X
a	B-X
short	B-X
summary	B-X
of	B-X
the	B-X
most	B-X
frequently	B-X
used	B-X
AVV	B-X
production	B-X
and	B-X
purification	B-X
methods	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
analytical	B-X
techniques	B-X
applied	B-X
to	B-X
determine	B-X
the	B-X
full/empty	B-X
capsid	B-X
ratio	B-X
and	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
encapsidated	B-X
therapeutic	B-X
DNA	B-X
of	B-X
the	B-X
products	B-X
.	B-X
Transient	B-X
and	B-X
stable	B-X
vector	B-X
transfections	B-X
have	B-X
played	B-X
important	B-X
roles	B-X
in	B-X
illustrating	B-X
the	B-X
function	B-X
of	B-X
specific	B-X
genes/proteins	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
an	B-X
assumption	B-X
that	B-X
empty	B-X
vector-transfected	B-X
cells	B-X
preserve	B-X
the	B-X
cytogenetic	B-X
and	B-X
phenotypic	B-X
characteristics	B-X
,	B-X
and	B-X
represent	B-X
the	B-X
adequate	B-X
control	B-X
in	B-X
transfection	B-X
experiments	B-X
is	B-X
not	B-X
universally	B-X
valid	B-X
.	B-X
A	B-X
DNA	B-X
vector	B-X
,	B-X
a	B-X
transfection	B-X
reagent	B-X
,	B-X
expression	B-X
of	B-X
an	B-X
antibiotic	B-X
resistance	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
reporter	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
selection	B-X
by	B-X
acute/chronic	B-X
antibiotic	B-X
treatment	B-X
may	B-X
evoke	B-X
cellular	B-X
responses	B-X
that	B-X
affect	B-X
the	B-X
biochemical	B-X
processes	B-X
under	B-X
investigation	B-X
.	B-X
We	B-X
exemplify	B-X
a	B-X
number	B-X
of	B-X
studies	B-X
,	B-X
which	B-X
reported	B-X
obvious	B-X
genomic	B-X
,	B-X
transcriptomic	B-X
and	B-X
phenotypic	B-X
changes	B-X
of	B-X
tumor	B-X
cells	B-X
after	B-X
transient/stable	B-X
transfection	B-X
of	B-X
an	B-X
empty	B-X
vector	B-X
.	B-X

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	B-Protein
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
20	O
ng	O
/	O
ml	O
TPA	O
.	O

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	B-Protein
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
and	O
the	O
values	O
for	O
the	O
empty	O
vectors	O
(	O
untreated	O
and	O
TPA	O
-	O
stimulated	O
)	O
were	O
set	O
as	O
1	O
.	O

(	O
C	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
the	O
A3G	B-Protein
promoter	O
constructs	O
or	O
with	O
the	O
interferon	B-Protein
-	O
responsive	O
reporter	O
plasmid	O
pGL2	O
-	O
CVX	O
(	O
GAS	O
)	O
.	O

Fifteen	O
hour	O
before	O
harvesting	O
for	O
luciferase	B-Protein
assay	O
,	O
a	O
subset	O
of	O
the	O
cell	O
culture	O
was	O
stimulated	O
with	O
30	O
ng	O
/	O
ml	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
With	B-X
continued	B-X
understanding	B-X
of	B-X
this	B-X
disease	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
SLE	B-X
is	B-X
related	B-X
to	B-X
the	B-X
interferon	B-X
gene	B-X
signature	B-X
.	B-X
Most	B-X
studies	B-X
have	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
IFN-α	B-X
in	B-X
SLE	B-X
,	B-X
but	B-X
our	B-X
previous	B-X
study	B-X
suggested	B-X
a	B-X
nonnegligible	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
.	B-X
Some	B-X
scholars	B-X
previously	B-X
found	B-X
that	B-X
IFN-γ	B-X
is	B-X
abnormally	B-X
elevated	B-X
as	B-X
early	B-X
as	B-X
before	B-X
the	B-X
classification	B-X
of	B-X
SLE	B-X
and	B-X
before	B-X
the	B-X
emergence	B-X
of	B-X
autoantibodies	B-X
and	B-X
IFN-α	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
large	B-X
overlap	B-X
between	B-X
IFN-α	B-X
and	B-X
IFN-γ	B-X
,	B-X
SLE	B-X
is	B-X
mostly	B-X
characterized	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
IFN-α	B-X
gene	B-X
after	B-X
onset	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
may	B-X
be	B-X
underestimated	B-X
.	B-X
This	B-X
article	B-X
mainly	B-X
reviews	B-X
the	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
and	B-X
focuses	B-X
on	B-X
the	B-X
nonnegligible	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
to	B-X
gain	B-X
a	B-X
more	B-X
comprehensive	B-X
understanding	B-X
of	B-X
the	B-X
disease	B-X
.	B-X

Forty	O
-	O
eight	O
hour	O
after	O
transfection	O
,	O
luciferase	B-Protein
assay	O
was	O
performed	O
.	O

Firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
transiently	B-X
transfected	B-X
primary	B-X
monolayer	B-X
cultures	B-X
of	B-X
porcine	B-X
granulosa-luteal	B-X
cells	B-X
with	B-X
a	B-X
reporter	B-X
vector	B-X
containing	B-X
the	B-X
putative	B-X
5'-upstream	B-X
full-length	B-X
(	B-X
pLDLR1076/luc	B-X
)	B-X
regulatory	B-X
region	B-X
(	B-X
-1076	B-X
to	B-X
+11	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
homologous	B-X
LDL	B-X
receptor	B-X
gene	B-X
driving	B-X
firefly	B-X
luciferase	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
and/or	B-X
LH	B-X
(	B-X
each	B-X
100	B-X
ng/ml	B-X
)	B-X
.	B-X
Combined	B-X
exposure	B-X
to	B-X
LH	B-X
and	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
stimulated	B-X
LDL	B-X
receptor	B-X
transcriptional	B-X
activity	B-X
maximally	B-X
at	B-X
4	B-X
h	B-X
by	B-X
8-	B-X
to	B-X
20-fold	B-X
,	B-X
as	B-X
normalized	B-X
by	B-X
coexpression	B-X
of	B-X
Renilla	B-X
luciferase	B-X
.	B-X

(	O
D	O
)	O
HepG2	O
cells	O
were	O
used	O
for	O
transfection	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
detected	B-X
miR-200a	B-X
down-regulation	B-X
,	B-X
Keap1	B-X
up-regulation	B-X
,	B-X
Nrf2	B-X
antioxidant	B-X
pathway	B-X
inactivation	B-X
,	B-X
ROS-driven	B-X
thioredoxin-interacting	B-X
protein	B-X
(	B-X
TXNIP	B-X
)	B-X
over-expression	B-X
,	B-X
NOD-like	B-X
receptor	B-X
(	B-X
NLR	B-X
)	B-X
family	B-X
,	B-X
pyrin	B-X
domain	B-X
containing	B-X
3	B-X
(	B-X
NLRP3	B-X
)	B-X
inflammasome	B-X
activation	B-X
and	B-X
dysregulation	B-X
of	B-X
peroxisome	B-X
proliferator	B-X
activated	B-X
receptor-α	B-X
(	B-X
PPAR-α	B-X
)	B-X
,	B-X
carnitine	B-X
palmitoyl	B-X
transferase-1	B-X
(	B-X
CPT-1	B-X
)	B-X
,	B-X
sterol	B-X
regulatory	B-X
element	B-X
binging	B-X
protein	B-X
1	B-X
(	B-X
SREBP-1	B-X
)	B-X
and	B-X
stearoyl-CoA	B-X
desaturase-1	B-X
(	B-X
SCD-1	B-X
)	B-X
in	B-X
rat	B-X
livers	B-X
,	B-X
BRL-3A	B-X
and	B-X
HepG2	B-X
cells	B-X
under	B-X
high	B-X
fructose	B-X
induction	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
data	B-X
from	B-X
the	B-X
treatment	B-X
or	B-X
transfection	B-X
of	B-X
miR-200a	B-X
minic	B-X
,	B-X
Keap1	B-X
and	B-X
TXNIP	B-X
siRNA	B-X
,	B-X
Nrf2	B-X
activator	B-X
and	B-X
ROS	B-X
inhibitor	B-X
demonstrated	B-X
that	B-X
fructose-induced	B-X
miR-200a	B-X
low-expression	B-X
increased	B-X
Keap1	B-X
to	B-X
block	B-X
Nrf2	B-X
antioxidant	B-X
pathway	B-X
,	B-X
and	B-X
then	B-X
enhanced	B-X
ROS-driven	B-X
TXNIP	B-X
to	B-X
activate	B-X
NLRP3	B-X
inflammasome	B-X
and	B-X
disturb	B-X
lipid	B-X
metabolism-related	B-X
proteins	B-X
,	B-X
causing	B-X
inflammation	B-X
and	B-X
lipid	B-X
deposition	B-X
in	B-X
BRL-3A	B-X
cells	B-X
.	B-X
Fructose	B-X
is	B-X
an	B-X
abundant	B-X
source	B-X
of	B-X
carbon	B-X
and	B-X
energy	B-X
for	B-X
cells	B-X
to	B-X
use	B-X
for	B-X
metabolism	B-X
,	B-X
but	B-X
only	B-X
certain	B-X
cell	B-X
types	B-X
use	B-X
fructose	B-X
to	B-X
proliferate	B-X
.	B-X
Tumor	B-X
cells	B-X
that	B-X
acquire	B-X
the	B-X
ability	B-X
to	B-X
metabolize	B-X
fructose	B-X
have	B-X
a	B-X
fitness	B-X
advantage	B-X
over	B-X
their	B-X
neighboring	B-X
cells	B-X
,	B-X
but	B-X
the	B-X
proteins	B-X
that	B-X
mediate	B-X
fructose	B-X
metabolism	B-X
in	B-X
this	B-X
context	B-X
are	B-X
unknown	B-X
.	B-X

The	O
experiment	O
was	O
performed	O
as	O
described	O
in	O
(	O
C	O
)	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
representative	O
experiments	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

A	O
GC	O
-	O
box	O
mediates	O
transcriptional	O
activity	O
of	O
the	O
180	O
bp	O
core	O
promoter	O
.	O

(	O
A	O
)	O
A3	O
.	O
01	O
T	O
cells	O
were	O
transfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
,	O
150	O
or	O
120	O
bp	O
of	O
the	O
A3G	B-Protein
promoter	O
.	O

The	O
two	O
G	O
-	O
to	O
-	O
T	O
substitutions	O
introduced	O
into	O
the	O
GC	O
-	O
box	O
of	O
the	O
180	O
bp	O
fragment	O
(	O
180mut	O
)	O
are	O
specified	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
for	O
luciferase	B-Protein
assay	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
tumorigenesis	B-X
of	B-X
mutant	B-X
[	B-X
12Asp	B-X
]	B-X
-K-ras	B-X
in	B-X
endometrial	B-X
carcinoma	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
ER	B-X
.	B-X
Susceptibility	B-X
to	B-X
transmissible	B-X
spongiform	B-X
encephalopathy	B-X
and	B-X
different	B-X
alleles	B-X
of	B-X
the	B-X
prion	B-X
protein	B-X
gene	B-X
(	B-X
PRNP	B-X
)	B-X
of	B-X
humans	B-X
and	B-X
sheep	B-X
are	B-X
associated	B-X
.	B-X
A	B-X
tentative	B-X
association	B-X
between	B-X
PRNP	B-X
promoter	B-X
polymorphisms	B-X
and	B-X
bovine	B-X
spongiform	B-X
encephalopathy	B-X
(	B-X
BSE	B-X
)	B-X
susceptibility	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
German	B-X
cattle	B-X
,	B-X
whereas	B-X
none	B-X
of	B-X
the	B-X
known	B-X
polymorphisms	B-X
within	B-X
the	B-X
bovine	B-X
PRNP-coding	B-X
sequence	B-X
affect	B-X
BSE	B-X
susceptibility	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
novel	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
located	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
bovine	B-X
PRNP	B-X
affecting	B-X
its	B-X
expression	B-X
were	B-X
demonstrated	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
.	B-X
We	B-X
sequenced	B-X
exon	B-X
1	B-X
,	B-X
and	B-X
the	B-X
approximately	B-X
200-bp	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
PRNP	B-X
translation	B-X
initiation	B-X
site	B-X
containing	B-X
the	B-X
proximal	B-X
promoter	B-X
of	B-X
PRNP	B-X
was	B-X
harvested	B-X
.	B-X
We	B-X
identified	B-X
7	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
:	B-X
-184A	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
,	B-X
-85T	B-X
--	B-X
>	B-X
G	B-X
,	B-X
-47C	B-X
--	B-X
>	B-X
A	B-X
,	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
,	B-X
+17C	B-X
--	B-X
>	B-X
T	B-X
and	B-X
+43C	B-X
--	B-X
>	B-X
T	B-X
.	B-X
Six	B-X
segregated	B-X
haplotypes	B-X
in	B-X
the	B-X
population	B-X
were	B-X
cloned	B-X
into	B-X
luciferase-expressing	B-X
plasmids	B-X
,	B-X
transfected	B-X
into	B-X
N2a	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
reporter	B-X
activities	B-X
were	B-X
measured	B-X
48	B-X
h	B-X
after	B-X
transfection	B-X
.	B-X
Six	B-X
haplotypes	B-X
showed	B-X
a	B-X
decreased	B-X
expression	B-X
level	B-X
including	B-X
-6C	B-X
--	B-X
>	B-X
T	B-X
in	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
or	B-X
-141T	B-X
--	B-X
>	B-X
C	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
at	B-X
48	B-X
h	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
haplotype	B-X
.	B-X
These	B-X
results	B-X
advocate	B-X
that	B-X
certain	B-X
polymorphisms	B-X
such	B-X
as	B-X
specific	B-X
protein	B-X
1	B-X
binding	B-X
site	B-X
polymorphisms	B-X
in	B-X
the	B-X
bovine	B-X
PRNP	B-X
promoter	B-X
region	B-X
in	B-X
Japanese	B-X
Black	B-X
cattle	B-X
could	B-X
influence	B-X
promoter	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
breeding	B-X
cattle	B-X
with	B-X
such	B-X
substitutions	B-X
may	B-X
be	B-X
a	B-X
useful	B-X
approach	B-X
in	B-X
reducing	B-X
BSE	B-X
risk	B-X
.	B-X

Firefly	O
luciferase	B-Protein
activities	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O
<EOS>	B-X
To	B-X
this	B-X
end	B-X
,	B-X
we	B-X
transiently	B-X
transfected	B-X
primary	B-X
monolayer	B-X
cultures	B-X
of	B-X
porcine	B-X
granulosa-luteal	B-X
cells	B-X
with	B-X
a	B-X
reporter	B-X
vector	B-X
containing	B-X
the	B-X
putative	B-X
5'-upstream	B-X
full-length	B-X
(	B-X
pLDLR1076/luc	B-X
)	B-X
regulatory	B-X
region	B-X
(	B-X
-1076	B-X
to	B-X
+11	B-X
bp	B-X
)	B-X
of	B-X
the	B-X
homologous	B-X
LDL	B-X
receptor	B-X
gene	B-X
driving	B-X
firefly	B-X
luciferase	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
and/or	B-X
LH	B-X
(	B-X
each	B-X
100	B-X
ng/ml	B-X
)	B-X
.	B-X
Combined	B-X
exposure	B-X
to	B-X
LH	B-X
and	B-X
insulin	B-X
(	B-X
or	B-X
IGF-I	B-X
)	B-X
stimulated	B-X
LDL	B-X
receptor	B-X
transcriptional	B-X
activity	B-X
maximally	B-X
at	B-X
4	B-X
h	B-X
by	B-X
8-	B-X
to	B-X
20-fold	B-X
,	B-X
as	B-X
normalized	B-X
by	B-X
coexpression	B-X
of	B-X
Renilla	B-X
luciferase	B-X
.	B-X

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

(	O
B	O
)	O
pGL3	O
-	O
Promoter	O
reporter	O
plasmids	O
containing	O
the	O
regions	O
E1	O
or	O
E2	O
(	O
see	O
Figure	O
1	O
)	O
upstream	O
of	O
the	O
SV40	O
promoter	O
were	O
transfected	O
into	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Firefly	O
luciferase	B-Protein
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Sp1	B-Protein
and	O
Sp3	B-Protein
bind	O
to	O
the	O
GC	O
-	O
box	O
present	O
in	O
the	O
A3G	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Nuclear	O
extracts	O
of	O
A3	O
.	O
01	O
T	O
cells	O
were	O
incubated	O
with	O
a	O
32P	O
-	O
labeled	O
commercial	O
Sp1	B-Protein
oligonucleotide	O
probe	O
(	O
Sp1cons	O
)	O
or	O
labeled	O
probes	O
homologous	O
to	O
the	O
unmodified	O
or	O
mutated	O
E2	O
region	O
(	O
see	O
Figure	O
1	O
)	O
of	O
the	O
A3G	B-Protein
promoter	O
(	O
APO	O
-	O
Sp1	B-Protein
/	O
3	B-Protein
and	O
APO	O
-	O
Sp1	B-Protein
/	O
3mut	B-Protein
)	O
.	O

Protein	O
-	O
DNA	O
complexes	O
were	O
separated	O
by	O
polyacrylamide	O
electrophoresis	O
and	O
detected	O
by	O
autoradiography	O
.	O
<EOS>	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
sensitive	B-X
and	B-X
relatively	B-X
straightforward	B-X
methodology	B-X
used	B-X
to	B-X
detect	B-X
sequence-specific	B-X
DNA-protein	B-X
interactions	B-X
.	B-X
It	B-X
is	B-X
the	B-X
fundamental	B-X
procedure	B-X
of	B-X
several	B-X
variants	B-X
that	B-X
allow	B-X
qualitative	B-X
and	B-X
quantitative	B-X
assessments	B-X
of	B-X
protein-nucleic	B-X
acid	B-X
complexes	B-X
.	B-X
Classically	B-X
,	B-X
nuclear	B-X
proteins	B-X
and	B-X
DNA	B-X
are	B-X
combined	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
mixture	B-X
is	B-X
electrophoretically	B-X
separated	B-X
in	B-X
polyacrylamide	B-X
or	B-X
agarose	B-X
gel	B-X
under	B-X
native	B-X
conditions	B-X
.	B-X
The	B-X
distribution	B-X
within	B-X
the	B-X
gel	B-X
is	B-X
generally	B-X
detected	B-X
with	B-X
autoradiography	B-X
of	B-X
the	B-X

EMSA	O
was	O
performed	O
with	O
a	O
1	O
-	O
or	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
APO	O
-	O
Sp1	B-Protein
/	O
3	B-Protein
probe	O
(	O
competitor	O
,	O
lanes	O
6	O
and	O
7	O
)	O
or	O
APO	O
-	O
Sp1	B-Protein
/	O
3mut	B-Protein
probe	O
(	O
competitor	O
mut	O
.	O
,	O
lanes	O
12	O
and	O
13	O
)	O
.	O

(	O
B	O
)	O
Sp1	B-Protein
-	O
and	O
Sp3	B-Protein
-	O
specific	O
antibodies	O
were	O
added	O
to	O
the	O
EMSA	O
reactions	O
resulting	O
in	O
a	O
supershift	O
(	O
ss	O
)	O
of	O
the	O
respective	O
antibody	O
-	O
protein	O
-	O
oligo	O
complexes	O
(	O
lanes	O
3	O
,	O
4	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
12	O
)	O
.	O

(	O
C	O
)	O
ChIP	O
assay	O
was	O
performed	O
with	O
DNA	O
from	O
A3	O
.	O
01	O
T	O
cells	O
.	O

Immunoprecipitation	O
was	O
performed	O
with	O
antibodies	O
against	O
Sp1	B-Protein
,	O
Sp3	B-Protein
or	O
actin	B-Protein
.	O
<EOS>	B-X
These	B-X
properties	B-X
,	B-X
along	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
transition	B-X
between	B-X
monomeric	B-X
(	B-X
G-actin	B-X
)	B-X
and	B-X
filamentous	B-X
(	B-X
F-actin	B-X
)	B-X
states	B-X
under	B-X
the	B-X
control	B-X
of	B-X
nucleotide	B-X
hydrolysis	B-X
,	B-X
ions	B-X
,	B-X
and	B-X
a	B-X
large	B-X
number	B-X
of	B-X
actin-binding	B-X
proteins	B-X
,	B-X
make	B-X
actin	B-X
a	B-X
critical	B-X
player	B-X
in	B-X
many	B-X
cellular	B-X
functions	B-X
,	B-X
ranging	B-X
from	B-X
cell	B-X
motility	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cell	B-X
shape	B-X
and	B-X
polarity	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
transcription	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
interaction	B-X
of	B-X
filamentous	B-X
actin	B-X
with	B-X
myosin	B-X
forms	B-X
the	B-X
basis	B-X
of	B-X
muscle	B-X
contraction	B-X
.	B-X
Owing	B-X
to	B-X
its	B-X
central	B-X
role	B-X
in	B-X
the	B-X
cell	B-X
,	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
is	B-X
also	B-X
disrupted	B-X
or	B-X
taken	B-X
over	B-X
by	B-X
numerous	B-X
pathogens	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
structures	B-X
of	B-X
G-actin	B-X
and	B-X
F-actin	B-X
and	B-X
discuss	B-X
some	B-X
of	B-X
the	B-X
interactions	B-X
that	B-X
control	B-X
the	B-X
polymerization	B-X
and	B-X
disassembly	B-X
of	B-X
actin	B-X
.	B-X

PCR	O
primer	O
pairs	O
specific	O
for	O
the	O
A3G	B-Protein
promoter	O
(	O
upper	O
panel	O
)	O
or	O
the	O
A3G	B-Protein
gene	O
(	O
lower	O
panel	O
)	O
were	O
used	O
.	O

As	O
positive	O
controls	O
,	O
the	O
sheared	O
and	O
cross	O
-	O
linked	O
DNA	O
before	O
the	O
immunoprecipitation	O
step	O
(	O
input	O
)	O
or	O
a	O
plasmid	O
carrying	O
the	O
target	O
sequence	O
(	O
plasmid	O
)	O
was	O
used	O
as	O
template	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
single-plasmid	B-X
system	B-X
which	B-X
allows	B-X
efficient	B-X
genome	B-X
editing	B-X
of	B-X
Bacillus	B-X
subtilis	B-X
The	B-X
plasmid	B-X
pJOE8999	B-X
is	B-X
a	B-X
shuttle	B-X
vector	B-X
that	B-X
has	B-X
a	B-X
pUC	B-X
minimal	B-X
origin	B-X
of	B-X
replication	B-X
for	B-X
Escherichia	B-X
coli	B-X
,	B-X
the	B-X
temperature-sensitive	B-X
replication	B-X
origin	B-X
of	B-X
plasmid	B-X
pE194	B-X
(	B-X
ts	B-X
)	B-X
for	B-X
B.	B-X
subtilis	B-X
,	B-X
and	B-X
a	B-X
kanamycin	B-X
resistance	B-X
gene	B-X
working	B-X
in	B-X
both	B-X
organisms	B-X
.	B-X
For	B-X
genome	B-X
editing	B-X
,	B-X
it	B-X
carries	B-X
the	B-X
cas9	B-X
gene	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
B.	B-X
subtilis	B-X
mannose-inducible	B-X
promoter	B-X
PmanP	B-X
and	B-X
a	B-X
single	B-X
guide	B-X
RNA	B-X
(	B-X
sgRNA	B-X
)	B-X
-encoding	B-X
sequence	B-X
transcribed	B-X
via	B-X
a	B-X
strong	B-X
promoter	B-X
.	B-X
This	B-X
sgRNA	B-X
guides	B-X
the	B-X
Cas9	B-X
nuclease	B-X
to	B-X
its	B-X
target	B-X
.	B-X
The	B-X
20-nucleotide	B-X
spacer	B-X
sequence	B-X
at	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
sgRNA	B-X
sequence	B-X
,	B-X
responsible	B-X
for	B-X
target	B-X
specificity	B-X
,	B-X
is	B-X
located	B-X
between	B-X
BsaI	B-X
sites	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
target	B-X
specificity	B-X
is	B-X
altered	B-X
by	B-X
changing	B-X
the	B-X
spacer	B-X
sequences	B-X
via	B-X
oligonucleotides	B-X
fitted	B-X
between	B-X
the	B-X
BsaI	B-X
sites	B-X
.	B-X
Cas9	B-X
in	B-X
complex	B-X
with	B-X
the	B-X
sgRNA	B-X
induces	B-X
double-strand	B-X
breaks	B-X
(	B-X
DSBs	B-X
)	B-X
at	B-X
its	B-X
target	B-X
site	B-X
.	B-X
Repair	B-X
of	B-X
the	B-X
DSBs	B-X
and	B-X
the	B-X
required	B-X
modification	B-X
of	B-X
the	B-X
genome	B-X
are	B-X
achieved	B-X
by	B-X
adding	B-X
homology	B-X
templates	B-X
,	B-X
usually	B-X
two	B-X
PCR	B-X
fragments	B-X
obtained	B-X
from	B-X
both	B-X
sides	B-X
of	B-X
the	B-X
target	B-X
sequence	B-X
.	B-X
Two	B-X
adjacent	B-X
SfiI	B-X
sites	B-X
enable	B-X
the	B-X
ordered	B-X
integration	B-X
of	B-X
these	B-X
homology	B-X
templates	B-X
into	B-X
the	B-X
vector	B-X
.	B-X

Silencing	O
of	O
Sp1	B-Protein
and	O
Sp3	B-Protein
reduces	O
A3G	B-Protein
promoter	O
activity	O
.	O

(	O
A	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
150	O
and	O
300	O
ng	O
of	O
unspecific	O
,	O
Sp1	B-Protein
-	O
specific	O
or	O
Sp3	B-Protein
-	O
specific	O
siRNA	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
-inducing	B-X
anticancer	B-X
agents	B-X
such	B-X
as	B-X
phenethylisothiocyanate	B-X
(	B-X
PEITC	B-X
)	B-X
activate	B-X
stress	B-X
pathways	B-X
for	B-X
killing	B-X
cancer	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
PEITC-induced	B-X
ROS	B-X
decreased	B-X
expression	B-X
of	B-X
microRNA	B-X
27a	B-X
(	B-X
miR-27a	B-X
)	B-X
/miR-20a	B-X
:	B-X
miR-17-5p	B-X
and	B-X
induced	B-X
miR-regulated	B-X
ZBTB10/ZBTB4	B-X
and	B-X
ZBTB34	B-X
transcriptional	B-X
repressors	B-X
,	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
downregulate	B-X
specificity	B-X
protein	B-X
(	B-X
Sp	B-X
)	B-X
transcription	B-X
factors	B-X
(	B-X
TFs	B-X
)	B-X
Sp1	B-X
,	B-X
Sp3	B-X
,	B-X
and	B-X
Sp4	B-X
in	B-X
pancreatic	B-X
cancer	B-X
cells	B-X
.	B-X
Decreased	B-X
expression	B-X
of	B-X
miR-27a/miR-20a	B-X
:	B-X
miR-17-5p	B-X
by	B-X
PEITC-induced	B-X
ROS	B-X
is	B-X
a	B-X
key	B-X
step	B-X
in	B-X
triggering	B-X
the	B-X
miR-ZBTB	B-X
Sp	B-X
cascade	B-X
leading	B-X
to	B-X
downregulation	B-X
of	B-X
Sp	B-X
TFs	B-X
,	B-X
and	B-X
this	B-X
is	B-X
due	B-X
to	B-X
ROS-dependent	B-X
epigenetic	B-X
effects	B-X
associated	B-X
with	B-X
genome-wide	B-X
shifts	B-X
in	B-X
repressor	B-X
complexes	B-X
,	B-X
resulting	B-X
in	B-X
decreased	B-X
expression	B-X
of	B-X
Myc	B-X
and	B-X
the	B-X
Myc-regulated	B-X
miRs	B-X
.	B-X
Knockdown	B-X
of	B-X
Sp1	B-X
alone	B-X
by	B-X
RNA	B-X
interference	B-X
also	B-X
induced	B-X
apoptosis	B-X
and	B-X
decreased	B-X
pancreatic	B-X
cancer	B-X
cell	B-X
growth	B-X
and	B-X
invasion	B-X
,	B-X
indicating	B-X
that	B-X
downregulation	B-X
of	B-X
Sp	B-X
transcription	B-X
factors	B-X
is	B-X
an	B-X
important	B-X
common	B-X
mechanism	B-X
of	B-X
action	B-X
for	B-X
PEITC	B-X
and	B-X
other	B-X
ROS-inducing	B-X
anticancer	B-X
agents	B-X
.	B-X

After	O
48	O
h	O
,	O
cells	O
were	O
harvested	O
and	O
Sp1	B-Protein
and	O
Sp3	B-Protein
proteins	O
were	O
detected	O
by	O
western	O
blot	O
analysis	O
.	O

As	O
loading	O
control	O
,	O
protein	O
levels	O
of	O
tubulin	B-Protein
are	O
shown	O
.	O
<EOS>	B-X
Western	B-X
blot	B-X
is	B-X
routinely	B-X
used	B-X
to	B-X
quantify	B-X
differences	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
target	B-X
proteins	B-X
in	B-X
tissues	B-X
.	B-X
Standard	B-X
methods	B-X
typically	B-X
use	B-X
measurements	B-X
of	B-X
housekeeping	B-X
proteins	B-X
to	B-X
control	B-X
for	B-X
variations	B-X
in	B-X
loading	B-X
and	B-X
protein	B-X
transfer	B-X
.	B-X
This	B-X
is	B-X
problematic	B-X
,	B-X
however	B-X
,	B-X
when	B-X
housekeeping	B-X
proteins	B-X
also	B-X
are	B-X
affected	B-X
by	B-X
experimental	B-X
conditions	B-X
such	B-X
as	B-X
injury	B-X
,	B-X
disease	B-X
,	B-X
and/or	B-X
gonadal	B-X
hormone	B-X
manipulations	B-X
.	B-X
Tissues	B-X
also	B-X
were	B-X
collected	B-X
from	B-X
rats	B-X
with	B-X
a	B-X
normal	B-X
estrous	B-X
cycle	B-X
killed	B-X
at	B-X
proestrus	B-X
when	B-X
estradiol	B-X
levels	B-X
are	B-X
high	B-X
,	B-X
and	B-X
at	B-X
diestrus	B-X
when	B-X
estradiol	B-X
levels	B-X
are	B-X
low	B-X
.	B-X
Western	B-X
blot	B-X
detection	B-X
of	B-X
α-tubulin	B-X
,	B-X
β-actin	B-X
,	B-X
and	B-X
GAPDH	B-X
was	B-X
performed	B-X
and	B-X
were	B-X
compared	B-X
for	B-X
sensitivity	B-X
and	B-X
reliability	B-X
with	B-X
a	B-X
fluorescent	B-X
total	B-X
protein	B-X
stain	B-X
(	B-X
REVERT	B-X

(	O
B	O
)	O
HeLa	O
cells	O
were	O
cotransfected	O
with	O
reporter	O
plasmid	O
pGL3	O
-	O
Basic	O
containing	O
180	O
or	O
150	O
bp	O
of	O
the	O
A3G	B-Protein
promoter	O
and	O
siRNA	O
.	O

Hundred	O
nanogram	O
of	O
unspecific	O
siRNA	O
(	O
control	O
)	O
,	O
Sp1	B-Protein
-	O
specific	O
siRNA	O
(	O
Sp1	B-Protein
)	O
,	O
Sp3	B-Protein
-	O
specific	O
siRNA	O
(	O
Sp3	B-Protein
)	O
or	O
a	O
mixture	O
of	O
50	O
ng	O
Sp1	B-Protein
-	O
specific	O
plus	O
50	O
ng	O
Sp3	B-Protein
-	O
specific	O
siRNA	O
(	O
Sp1	B-Protein
+	O
Sp3	B-Protein
)	O
were	O
used	O
.	O

Firefly	O
luciferase	B-Protein
activities	O
after	O
48	O
h	O
were	O
normalized	O
to	O
coexpressed	O
renilla	O
luciferase	B-Protein
activities	O
.	O

Mean	O
values	O
(	O
+	O
/	O
-	O
SD	O
)	O
of	O
a	O
representative	O
experiment	O
performed	O
in	O
triplicate	O
are	O
shown	O
.	O

Protein	O
kinase	O
D	O
enzymes	O
are	O
dispensable	O
for	O
proliferation	O
,	O
survival	O
and	O
antigen	O
receptor	O
-	O
regulated	O
NFkappaB	O
activity	O
in	O
vertebrate	O
B	O
-	O
cells	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
kinase	B-X
D	B-X
(	B-X
PKD	B-X
)	B-X
enzymes	B-X
we	B-X
generated	B-X
a	B-X
PKD-null	B-X
DT40	B-X
B-lymphocyte	B-X
cell	B-X
line	B-X
.	B-X
Previously	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
PKDs	B-X
have	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
regulating	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
DT40	B-X
B-cells	B-X
[	B-X
Matthews	B-X
,	B-X
S.A.	B-X
,	B-X
Liu	B-X
,	B-X
P.	B-X
,	B-X
Spitaler	B-X
,	B-X
M.	B-X
,	B-X
Olson	B-X
,	B-X
E.N.	B-X
,	B-X
McKinsey	B-X
,	B-X
T.A.	B-X
,	B-X
Cantrell	B-X
,	B-X
D.A	B-X
.	B-X
and	B-X
Scharenberg	B-X
,	B-X
A.M.	B-X
(	B-X
2006	B-X
)	B-X
Essential	B-X
role	B-X
for	B-X
protein	B-X
kinase	B-X
D	B-X
family	B-X
kinases	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
Cell	B-X
Biol	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
PKDs	B-X
are	B-X
also	B-X
required	B-X
to	B-X
regulate	B-X
HSP27	B-X
phosphorylation	B-X
in	B-X
DT40	B-X
B-cells	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
previous	B-X
observations	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
PKD	B-X
enzymes	B-X
do	B-X
not	B-X
regulate	B-X
basic	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
proliferation	B-X
or	B-X
survival	B-X
responses	B-X
,	B-X
nor	B-X
NFkappaB	B-X
transcriptional	B-X
activity	B-X
downstream	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
PKDs	B-X
have	B-X
a	B-X
selective	B-X
role	B-X
in	B-X
DT40	B-X
B-cell	B-X
biology	B-X
.	B-X

To	O
investigate	O
the	O
importance	O
of	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
enzymes	O
we	O
generated	O
a	O
PKD	O
-	O
null	O
DT40	O
B	O
-	O
lymphocyte	O
cell	O
line	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
kinase	B-X
D	B-X
(	B-X
PKD	B-X
)	B-X
enzymes	B-X
we	B-X
generated	B-X
a	B-X
PKD-null	B-X
DT40	B-X
B-lymphocyte	B-X
cell	B-X
line	B-X
.	B-X
Previously	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
PKDs	B-X
have	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
regulating	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
DT40	B-X
B-cells	B-X
[	B-X
Matthews	B-X
,	B-X
S.A.	B-X
,	B-X
Liu	B-X
,	B-X
P.	B-X
,	B-X
Spitaler	B-X
,	B-X
M.	B-X
,	B-X
Olson	B-X
,	B-X
E.N.	B-X
,	B-X
McKinsey	B-X
,	B-X
T.A.	B-X
,	B-X
Cantrell	B-X
,	B-X
D.A	B-X
.	B-X
and	B-X
Scharenberg	B-X
,	B-X
A.M.	B-X
(	B-X
2006	B-X
)	B-X
Essential	B-X
role	B-X
for	B-X
protein	B-X
kinase	B-X
D	B-X
family	B-X
kinases	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
Cell	B-X
Biol	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
PKDs	B-X
are	B-X
also	B-X
required	B-X
to	B-X
regulate	B-X
HSP27	B-X
phosphorylation	B-X
in	B-X
DT40	B-X
B-cells	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
previous	B-X
observations	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
PKD	B-X
enzymes	B-X
do	B-X
not	B-X
regulate	B-X
basic	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
proliferation	B-X
or	B-X
survival	B-X
responses	B-X
,	B-X
nor	B-X
NFkappaB	B-X
transcriptional	B-X
activity	B-X
downstream	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
PKDs	B-X
have	B-X
a	B-X
selective	B-X
role	B-X
in	B-X
DT40	B-X
B-cell	B-X
biology	B-X
.	B-X

Previously	O
we	O
have	O
shown	O
that	O
PKDs	O
have	O
an	O
essential	O
role	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
in	O
DT40	O
B	O
-	O
cells	O
[	O
Matthews	O
,	O
S	O
.	O
A	O
.	O
,	O
Liu	O
,	O
P	O
.	O
,	O
Spitaler	O
,	O
M	O
.	O
,	O
Olson	O
,	O
E	O
.	O
N	O
.	O
,	O
McKinsey	O
,	O
T	O
.	O
A	O
.	O
,	O
Cantrell	O
,	O
D	O
.	O
A	O
.	O
and	O
Scharenberg	O
,	O
A	O
.	O
M	O
.	O
(	O
2006	O
)	O
Essential	O
role	O
for	O
protein	O
kinase	O
D	O
family	O
kinases	O
in	O
the	O
regulation	O
of	O
class	O
II	O
histone	O
deacetylases	O
in	O
B	O
lymphocytes	O
.	O
Mol	O
.	O
Cell	O
Biol	O
.	O
26	O
,	O
1569	O
-	O
1577	O
]	O
.	O

We	O
now	O
show	O
that	O
PKDs	O
are	O
also	O
required	O
to	O
regulate	O
HSP27	B-Protein
phosphorylation	O
in	O
DT40	O
B	O
-	O
cells	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
kinase	B-X
D	B-X
(	B-X
PKD	B-X
)	B-X
enzymes	B-X
we	B-X
generated	B-X
a	B-X
PKD-null	B-X
DT40	B-X
B-lymphocyte	B-X
cell	B-X
line	B-X
.	B-X
Previously	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
PKDs	B-X
have	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
regulating	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
DT40	B-X
B-cells	B-X
[	B-X
Matthews	B-X
,	B-X
S.A.	B-X
,	B-X
Liu	B-X
,	B-X
P.	B-X
,	B-X
Spitaler	B-X
,	B-X
M.	B-X
,	B-X
Olson	B-X
,	B-X
E.N.	B-X
,	B-X
McKinsey	B-X
,	B-X
T.A.	B-X
,	B-X
Cantrell	B-X
,	B-X
D.A	B-X
.	B-X
and	B-X
Scharenberg	B-X
,	B-X
A.M.	B-X
(	B-X
2006	B-X
)	B-X
Essential	B-X
role	B-X
for	B-X
protein	B-X
kinase	B-X
D	B-X
family	B-X
kinases	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
Cell	B-X
Biol	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
PKDs	B-X
are	B-X
also	B-X
required	B-X
to	B-X
regulate	B-X
HSP27	B-X
phosphorylation	B-X
in	B-X
DT40	B-X
B-cells	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
previous	B-X
observations	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
PKD	B-X
enzymes	B-X
do	B-X
not	B-X
regulate	B-X
basic	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
proliferation	B-X
or	B-X
survival	B-X
responses	B-X
,	B-X
nor	B-X
NFkappaB	B-X
transcriptional	B-X
activity	B-X
downstream	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
PKDs	B-X
have	B-X
a	B-X
selective	B-X
role	B-X
in	B-X
DT40	B-X
B-cell	B-X
biology	B-X
.	B-X

However	O
,	O
in	O
contrast	O
to	O
previous	O
observations	O
in	O
other	O
cell	O
types	O
,	O
PKD	O
enzymes	O
do	O
not	O
regulate	O
basic	O
cellular	O
processes	O
such	O
as	O
proliferation	O
or	O
survival	O
responses	O
,	O
nor	O
NFkappaB	O
transcriptional	O
activity	O
downstream	O
of	O
the	O
B	O
cell	O
antigen	O
receptor	O
.	O

Thus	O
,	O
PKDs	O
have	O
a	O
selective	O
role	O
in	O
DT40	O
B	O
-	O
cell	O
biology	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
kinase	B-X
D	B-X
(	B-X
PKD	B-X
)	B-X
enzymes	B-X
we	B-X
generated	B-X
a	B-X
PKD-null	B-X
DT40	B-X
B-lymphocyte	B-X
cell	B-X
line	B-X
.	B-X
Previously	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
PKDs	B-X
have	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
regulating	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
DT40	B-X
B-cells	B-X
[	B-X
Matthews	B-X
,	B-X
S.A.	B-X
,	B-X
Liu	B-X
,	B-X
P.	B-X
,	B-X
Spitaler	B-X
,	B-X
M.	B-X
,	B-X
Olson	B-X
,	B-X
E.N.	B-X
,	B-X
McKinsey	B-X
,	B-X
T.A.	B-X
,	B-X
Cantrell	B-X
,	B-X
D.A	B-X
.	B-X
and	B-X
Scharenberg	B-X
,	B-X
A.M.	B-X
(	B-X
2006	B-X
)	B-X
Essential	B-X
role	B-X
for	B-X
protein	B-X
kinase	B-X
D	B-X
family	B-X
kinases	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
class	B-X
II	B-X
histone	B-X
deacetylases	B-X
in	B-X
B	B-X
lymphocytes	B-X
.	B-X
Cell	B-X
Biol	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
PKDs	B-X
are	B-X
also	B-X
required	B-X
to	B-X
regulate	B-X
HSP27	B-X
phosphorylation	B-X
in	B-X
DT40	B-X
B-cells	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
previous	B-X
observations	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
PKD	B-X
enzymes	B-X
do	B-X
not	B-X
regulate	B-X
basic	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
proliferation	B-X
or	B-X
survival	B-X
responses	B-X
,	B-X
nor	B-X
NFkappaB	B-X
transcriptional	B-X
activity	B-X
downstream	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
Thus	B-X
,	B-X
PKDs	B-X
have	B-X
a	B-X
selective	B-X
role	B-X
in	B-X
DT40	B-X
B-cell	B-X
biology	B-X
.	B-X

1The	O
protein	O
kinase	O
D	O
(	O
PKD	O
)	O
serine	O
/	O
threonine	O
kinase	O
family	O
has	O
three	O
members	O
:	O
PKD1	B-Protein
,	O
PKD2	B-Protein
and	O
PKD3	B-Protein
.	O

Most	O
cell	O
types	O
express	O
at	O
least	O
two	O
PKD	O
isoforms	O
but	O
PKD	O
enzymes	O
are	O
especially	O
highly	O
expressed	O
in	O
haematopoietic	O
cells	O
,	O
where	O
they	O
are	O
activated	O
in	O
response	O
to	O
antigen	O
receptors	O
stimulation	O
[	O
2	O
,	O
3	O
]	O
.	O

A	O
conserved	O
signalling	O
pathway	O
linking	O
antigen	O
receptors	O
to	O
PKDs	O
involves	O
the	O
activation	O
of	O
PLCgamma	O
and	O
the	O
subsequent	O
production	O
of	O
diacylglycerol	O
(	O
DAG	O
)	O
which	O
stimulates	O
classical	O
and	O
/	O
or	O
novel	O
protein	O
kinase	O
Cs	O
(	O
PKC	O
)	O
that	O
phosphorylate	O
two	O
key	O
regulatory	O
serine	O
residues	O
in	O
the	O
activation	O
loop	O
of	O
PKD	O
kinases	O
[	O
3	O
-	O
6	O
]	O
.	O

The	O
N	O
-	O
terminal	O
regulatory	O
region	O
of	O
PKD	O
enzymes	O
contains	O
a	O
DAG	O
binding	O
domain	O
and	O
direct	O
binding	O
of	O
DAG	O
also	O
contributes	O
to	O
PKD1	B-Protein
activation	O
[	O
7	O
]	O
as	O
well	O
as	O
regulating	O
the	O
spatial	O
location	O
of	O
PKD	O
enzymes	O
within	O
cells	O
[	O
8	O
-	O
12	O
]	O
.	O

PKD	O
enzymes	O
have	O
been	O
proposed	O
to	O
regulate	O
numerous	O
cellular	O
functions	O
,	O
including	O
cell	O
proliferation	O
[	O
13	O
-	O
16	O
]	O
,	O
anti	O
-	O
apoptotic	O
signals	O
[	O
17	O
,	O
18	O
]	O
and	O
thymocyte	O
development	O
[	O
19	O
]	O
.	O

Expression	O
of	O
mutant	O
catalytically	O
inactive	O
and	O
constitutively	O
activated	O
PKDs	O
can	O
also	O
modify	O
Golgi	O
function	O
,	O
cell	O
adhesion	O
and	O
cell	O
motility	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

In	O
particular	O
,	O
PKDs	O
have	O
been	O
widely	O
linked	O
to	O
the	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
and	O
in	O
regulating	O
cell	O
survival	O
during	O
oxidative	O
stress	O
[	O
17	O
,	O
21	O
-	O
23	O
]	O
.	O

Another	O
recently	O
proposed	O
PKD1	B-Protein
substrate	O
is	O
HSP27	B-Protein
[	O
24	O
]	O
,	O
a	O
small	O
heat	O
shock	O
protein	O
involved	O
in	O
regulating	O
cell	O
migration	O
and	O
cell	O
survival	O
[	O
25	O
]	O
.	O

An	O
essential	O
role	O
for	O
PKD	O
enzymes	O
in	O
regulating	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
,	O
enzymes	O
that	O
repress	O
MEF2	B-Protein
-	O
dependent	O
gene	O
transcription	O
,	O
has	O
also	O
been	O
demonstrated	O
[	O
1	O
,	O
26	O
-	O
28	O
]	O
.	O

To	O
investigate	O
the	O
biological	O
role	O
of	O
PKDs	O
we	O
have	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	O
expression	O
of	O
one	O
or	O
more	O
members	O
of	O
the	O
PKD	O
family	O
[	O
1	O
]	O
,	O
allowing	O
us	O
to	O
investigate	O
the	O
function	O
(	O
s	O
)	O
of	O
PKD	O
isoforms	O
following	O
B	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
stimulation	O
,	O
as	O
well	O
addressing	O
the	O
issue	O
of	O
functional	O
redundancy	O
between	O
the	O
different	O
PKD	O
family	O
members	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
PKDs	O
are	O
indispensable	O
for	O
HDAC	O
regulation	O
in	O
B	O
cells	O
[	O
1	O
]	O
.	O

Herein	O
we	O
show	O
that	O
PKDs	O
are	O
also	O
indispensable	O
for	O
HSP27	B-Protein
phosphorylation	O
in	O
B	O
cells	O
.	O

However	O
,	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O
are	O
viable	O
and	O
proliferate	O
normally	O
.	O

Moreover	O
,	O
loss	O
of	O
the	O
entire	O
cellular	O
pool	O
of	O
PKD	O
does	O
not	O
critically	O
affect	O
oxidative	O
stress	O
responses	O
in	O
B	O
cells	O
nor	O
do	O
PKD	O
kinases	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
NFkappaB	O
transcriptional	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
that	O
in	O
B	O
lymphocytes	O
,	O
PKD	O
kinases	O
are	O
not	O
critical	O
regulators	O
of	O
many	O
of	O
the	O
cellular	O
processes	O
previously	O
ascribed	O
to	O
them	O
in	O
other	O
cellular	O
systems	O
.	O

2	O
.	O
1Cell	O
culture	O
,	O
transient	O
transfections	O
and	O
cell	O
stimulation	O

The	O
generation	O
,	O
culture	O
and	O
activation	O
of	O
PKD1	B-Protein
-	O
/	O
-	O
,	O
PKD3	B-Protein
-	O
/	O
-	O
and	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
knockout	O
DT40	O
B	O
cell	O
lines	O
have	O
been	O
described	O
previously	O
[	O
1	O
]	O
.	O

Cells	O
were	O
lysed	O
and	O
protein	O
extracts	O
were	O
analysed	O
in	O
Western	O
blotting	O
experiments	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
assays	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O
<EOS>	B-X
The	B-X
system	B-X
described	B-X
here	B-X
combines	B-X
both	B-X
mechanisms	B-X
,	B-X
since	B-X
a	B-X
unique	B-X
transcription	B-X
factor	B-X
can	B-X
be	B-X
shifted	B-X
from	B-X
a	B-X
repression	B-X
to	B-X
a	B-X
stimulation	B-X
activity	B-X
by	B-X
simply	B-X
changing	B-X
its	B-X
ligand	B-X
.	B-X
The	B-X
principle	B-X
of	B-X
this	B-X
method	B-X
is	B-X
based	B-X
on	B-X
the	B-X
unexpected	B-X
ability	B-X
of	B-X
the	B-X
chimeric	B-X
protein	B-X
containing	B-X
the	B-X
DNA-binding	B-X
domain	B-X
of	B-X
the	B-X
yeast	B-X
Gal4	B-X
transcription	B-X
factor	B-X
fused	B-X
to	B-X
the	B-X
COOH	B-X
half	B-X
of	B-X
the	B-X
estradiol	B-X
receptor	B-X
(	B-X
GalER	B-X
)	B-X
,	B-X
to	B-X
act	B-X
as	B-X
a	B-X
repressor	B-X
when	B-X
bound	B-X
to	B-X
the	B-X
drug	B-X
4OH-tamoxifen	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
previously	B-X
described	B-X
optimized	B-X
Gal4-responsive	B-X
promoter	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
this	B-X
system	B-X
has	B-X
been	B-X
assessed	B-X
in	B-X
transient	B-X
expression	B-X
assays	B-X
using	B-X
the	B-X
chloramphenicol	B-X
acetyl	B-X
transferase	B-X
(	B-X
CAT	B-X
)	B-X
,	B-X
and	B-X
in	B-X
situ	B-X
,	B-X
through	B-X
the	B-X
activity	B-X
of	B-X
a	B-X
Gal4	B-X
responsive	B-X
beta-galactosidase	B-X
gene	B-X
.	B-X
Bacteroides	B-X
uniformis	B-X
RYC3373	B-X
resistant	B-X
to	B-X
64	B-X
micrograms	B-X
of	B-X
chloramphenicol	B-X
per	B-X
ml	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
peritoneal	B-X
pelvic	B-X
abscess	B-X
of	B-X
a	B-X
patient	B-X
not	B-X
previously	B-X
treated	B-X
with	B-X
this	B-X
drug	B-X
.	B-X
Chloramphenicol	B-X
resistance	B-X
was	B-X
transferable	B-X
at	B-X
low	B-X
frequency	B-X
to	B-X
a	B-X
suitable	B-X
Bacteroides	B-X
fragilis	B-X
recipient	B-X
.	B-X
Donor	B-X
and	B-X
transconjugant	B-X
strains	B-X
produced	B-X
chloramphenicol	B-X
acetyltransferase	B-X
constitutively	B-X
.	B-X
The	B-X
Km	B-X
for	B-X
chloramphenicol	B-X
was	B-X
40	B-X
microM	B-X
,	B-X
and	B-X
its	B-X
inactivation	B-X
by	B-X
5-5'-dithiobis	B-X
(	B-X
2-nitrobenzoic	B-X
acid	B-X
)	B-X
suggested	B-X
its	B-X
similarity	B-X
to	B-X
the	B-X
type	B-X
II	B-X
enterobacterial	B-X
enzymes	B-X
encoded	B-X
by	B-X
different	B-X
conjugative	B-X
plasmids	B-X
and	B-X
also	B-X
to	B-X
a	B-X
previously	B-X
described	B-X
enzyme	B-X
of	B-X
B.	B-X
fragilis	B-X
F47	B-X
and	B-X
F48	B-X
.	B-X
The	B-X
genetic	B-X
basis	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
synthesis	B-X
in	B-X
Bacteroides	B-X
spp	B-X
.	B-X
had	B-X
not	B-X
been	B-X
previously	B-X
established	B-X
.	B-X

2	O
.	O
2sIgM	O
staining	O
<EOS>	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
and	B-X
commercial	B-X
websites	B-X
suggest	B-X
a	B-X
multitude	B-X
of	B-X
Ponceau	B-X
S	B-X
staining	B-X
protocols	B-X
for	B-X
total	B-X
protein	B-X
staining	B-X
of	B-X
blots	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
which	B-X
Ponceau	B-X
S	B-X
staining	B-X
protocol	B-X
would	B-X
result	B-X
in	B-X
the	B-X
highest	B-X
sensitivity	B-X
of	B-X
protein	B-X
band	B-X
detection	B-X
.	B-X
Unexpectedly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
irrespective	B-X
of	B-X
the	B-X
Ponceau	B-X
S	B-X
concentration	B-X
(	B-X
between	B-X
0.001	B-X
and	B-X
2	B-X
%	B-X
(	B-X
w/v	B-X
)	B-X
)	B-X
,	B-X
acid	B-X
concentration	B-X
,	B-X
and	B-X
acid	B-X
type	B-X
(	B-X
acetic	B-X
acid	B-X
,	B-X
trichloroacetic	B-X
acid	B-X
and/or	B-X
sulfosalicylic	B-X
acid	B-X
)	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
protein	B-X
detection	B-X
remained	B-X
constant	B-X
.	B-X
In	B-X
various	B-X
contexts	B-X
,	B-X
for	B-X
example	B-X
to	B-X
determine	B-X
the	B-X
extents	B-X
of	B-X
cerebral	B-X
insults	B-X
or	B-X
of	B-X
myocardial	B-X
infarctions	B-X
in	B-X
experimental	B-X
studies	B-X
,	B-X
tetrazolium	B-X
based	B-X
staining	B-X
procedures	B-X
of	B-X
vital	B-X
cells	B-X
are	B-X
widely	B-X
used	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
set	B-X
out	B-X
to	B-X
test	B-X
the	B-X
applicability	B-X
of	B-X
tetrazolium	B-X
based	B-X
staining	B-X
on	B-X
bone	B-X
samples	B-X
.	B-X
8	B-X
brains	B-X
and	B-X
26	B-X
femoral	B-X
heads	B-X
from	B-X
sheep	B-X
were	B-X
used	B-X
to	B-X
prepare	B-X
tissue	B-X
slices	B-X
,	B-X
which	B-X
were	B-X
stained	B-X
with	B-X
2,3,5-triphenyltetrazolium	B-X
chloride	B-X
(	B-X
TTC	B-X
)	B-X
at	B-X
various	B-X
times	B-X
(	B-X
1	B-X
to	B-X
12h	B-X
)	B-X
after	B-X
explantation	B-X
.	B-X
TTC-staining	B-X
of	B-X
tissue	B-X
slices	B-X
indicated	B-X
detectability	B-X
of	B-X
vital	B-X
cells	B-X
in	B-X
slices	B-X
from	B-X
both	B-X
tissues	B-X
up	B-X
to	B-X
4h	B-X
after	B-X
explantation	B-X
.	B-X
Staining	B-X
intensity	B-X
at	B-X
later	B-X
time-points	B-X
was	B-X
indistinguishable	B-X
from	B-X
the	B-X
staining	B-X
of	B-X
untreated	B-X
samples	B-X
or	B-X
sodium	B-X
azide	B-X
treated	B-X
(	B-X
necrotic	B-X
cells	B-X
)	B-X
controls	B-X
.	B-X
We	B-X
provide	B-X
experimental	B-X
evidence	B-X
that	B-X
the	B-X
choice	B-X
of	B-X
the	B-X
optimal	B-X
surgical	B-X
approach	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
fractures	B-X
involving	B-X
cancellous	B-X
bone	B-X
could	B-X
be	B-X
aided	B-X
by	B-X
a	B-X
simple	B-X
staining	B-X
procedure	B-X
for	B-X
vital	B-X
bone	B-X
.	B-X

DT40	O
B	O
cells	O
(	O
2	O
x	O
106	O
cells	O
per	O
point	O
)	O
were	O
resuspended	O
in	O
200	O
mul	O
buffer	O
(	O
RPMI	O
1640	O
media	O
,	O
1	O
%	O
foetal	O
calf	O
serum	O
)	O
containing	O
anti	O
-	O
chicken	O
M1	O
monoclonal	O
antibody	O
conjugated	O
to	O
FITC	O
for	O
20	O
min	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
and	O
fluorescent	O
intensity	O
was	O
analysed	O
by	O
flow	O
cytometry	O
.	O

All	O
results	O
shown	O
are	O
representative	O
of	O
at	O
two	O
to	O
four	O
independent	O
experiments	O
unless	O
otherwise	O
indicated	O
.	O

3	O
.	O
1Loss	O
of	O
HSP27	B-Protein
phosphorylation	O
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

DT40	O
B	O
cells	O
express	O
two	O
PKD	O
isoforms	O
,	O
PKD1	B-Protein
and	O
PKD3	B-Protein
,	O
and	O
as	O
previously	O
described	O
we	O
have	O
recently	O
generated	O
DT40	O
B	O
cell	O
lines	O
that	O
lack	O
expression	O
of	O
either	O
PKD1	B-Protein
or	O
PKD3	B-Protein
or	O
both	O
enzymes	O
[	O
1	O
]	O
.	O
<EOS>	B-X
It	B-X
is	B-X
becoming	B-X
increasingly	B-X
apparent	B-X
that	B-X
many	B-X
well-known	B-X
enzymes	B-X
have	B-X
alternative	B-X
non-enzymic	B-X
functions	B-X
.	B-X
The	B-X
semicarbazide-sensitive	B-X
amine	B-X
oxidase	B-X
(	B-X
EC	B-X
1.4.3.6	B-X
)	B-X
is	B-X
considered	B-X
in	B-X
more	B-X
depth	B-X
as	B-X
an	B-X
example	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
computational	B-X
studies	B-X
about	B-X
the	B-X
migration	B-X
of	B-X
substrates	B-X
and	B-X
products	B-X
through	B-X
the	B-X
enzyme	B-X
's	B-X
structure	B-X
and	B-X
the	B-X
phylogenetic	B-X
distribution	B-X
of	B-X
VAO	B-X
and	B-X
related	B-X
enzymes	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
enzymes	B-X
for	B-X
their	B-X
respective	B-X
substrates	B-X
has	B-X
been	B-X
a	B-X
focal	B-X
point	B-X
of	B-X
enzyme	B-X
kinetics	B-X
since	B-X
the	B-X
initial	B-X
characterization	B-X
of	B-X
metabolic	B-X
chemistry	B-X
.	B-X
Fersht	B-X
's	B-X
definition	B-X
of	B-X
the	B-X
ratio	B-X
kcat/Km	B-X
for	B-X
two	B-X
different	B-X
substrates	B-X
as	B-X
the	B-X
``	B-X
specificity	B-X
constant	B-X
''	B-X
(	B-X
ref	B-X
[	B-X
7	B-X
]	B-X
)	B-X
,	B-X
based	B-X
on	B-X
the	B-X
premise	B-X
that	B-X
the	B-X
important	B-X
specificity	B-X
existed	B-X
when	B-X
the	B-X
substrates	B-X
were	B-X
competing	B-X
in	B-X
the	B-X
same	B-X
reaction	B-X
,	B-X
has	B-X
become	B-X
a	B-X
consensus	B-X
standard	B-X
for	B-X
enzymes	B-X
obeying	B-X
Michaelis-Menten	B-X
kinetics	B-X
.	B-X

In	O
generating	O
the	O
double	O
knockout	O
cell	O
lines	O
we	O
targeted	O
the	O
PKD1	B-Protein
loci	O
in	O
a	O
PKD3	B-Protein
-	O
/	O
-	O
cell	O
line	O
that	O
expressed	O
a	O
Flag	O
-	O
PKD3	B-Protein
transgene	O
under	O
the	O
control	O
of	O
a	O
doxycycline	O
-	O
inducible	O
promoter	O
.	O

Hence	O
,	O
in	O
the	O
presence	O
of	O
doxycycline	O
,	O
Flag	O
-	O
PKD3	B-Protein
expression	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
double	O
knockout	O
cells	O
is	O
comparable	O
to	O
endogenous	O
PKD3	B-Protein
present	O
in	O
wild	O
-	O
type	O
DT40	O
cells	O
and	O
removal	O
of	O
doxycycline	O
from	O
the	O
culture	O
media	O
for	O
5	O
days	O
results	O
in	O
a	O
completely	O
null	O
PKD	O
phenotype	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Previously	O
,	O
we	O
have	O
demonstrated	O
that	O
phosphorylation	O
and	O
nuclear	O
exclusion	O
of	O
class	O
II	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
during	O
BCR	O
engagement	O
is	O
defective	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
B	O
cells	O
and	O
can	O
restored	O
upon	O
re	O
-	O
expression	O
of	O
a	O
single	O
PKD	O
isoform	O
[	O
1	O
]	O
.	O

The	O
small	O
heat	O
shock	O
protein	O
HSP27	B-Protein
has	O
recently	O
been	O
proposed	O
as	O
a	O
PKD1	B-Protein
substrate	O
[	O
24	O
]	O
and	O
we	O
accordingly	O
assessed	O
whether	O
PKD	O
-	O
null	O
DT40	O
cells	O
have	O
defective	O
phosphorylation	O
of	O
HSP27	B-Protein
on	O
serine	O
82	O
,	O
the	O
proposed	O
PKD1	B-Protein
substrate	O
sequence	O
.	O

We	O
initially	O
investigated	O
the	O
regulation	O
of	O
HSP27	B-Protein
phosphorylation	O
in	O
single	O
knockout	O
DT40	O
B	O
cells	O
lacking	O
either	O
PKD1	B-Protein
or	O
PKD3	B-Protein
.	O
<EOS>	B-X
The	B-X
Protein	B-X
kinase	B-X
D3	B-X
(	B-X
PKD3	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
signal	B-X
transduction	B-X
downstream	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
.	B-X
Protein	B-X
kinase	B-X
D3	B-X
(	B-X
PKD3	B-X
)	B-X
is	B-X
upregulated	B-X
in	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
and	B-X
associated	B-X
with	B-X
cell	B-X
proliferation	B-X
and	B-X
metastasis	B-X
development	B-X
but	B-X
its	B-X
precise	B-X
pro-oncogenic	B-X
function	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
PKD3	B-X
is	B-X
required	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
the	B-X
TNBC	B-X
stem	B-X
cell	B-X
population	B-X
.	B-X
The	B-X
depletion	B-X
of	B-X
PKD3	B-X
in	B-X
MDA-MB-231	B-X
cells	B-X
reduced	B-X
the	B-X
cancer	B-X
stem	B-X
cell	B-X
frequency	B-X
in	B-X
vitro	B-X
and	B-X
tumor	B-X
initiation	B-X
potential	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
further	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
RhoGEF	B-X
GEF-H1	B-X
is	B-X
upstream	B-X
of	B-X
PKD3	B-X
activation	B-X
in	B-X
TNBC	B-X
stem	B-X
cells	B-X
.	B-X
Based	B-X
on	B-X
our	B-X
results	B-X
we	B-X
propose	B-X
that	B-X
targeting	B-X
the	B-X
GEF-H1/PKD3	B-X
signaling	B-X
pathway	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
might	B-X
provide	B-X
an	B-X
effective	B-X
therapeutic	B-X
option	B-X
for	B-X
TNBC	B-X
.	B-X

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

1B	O
,	O
activation	O
of	O
the	O
BCR	O
or	O
treatment	O
with	O
the	O
DAG	O
-	O
mimetic	O
PdBu	O
increased	O
the	O
levels	O
of	O
HSP27	B-Protein
phosphorylation	O
at	O
S82	O
in	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
.	O
<EOS>	B-X
As	B-X
a	B-X
consequence	B-X
of	B-X
the	B-X
translocation	B-X
,	B-X
the	B-X
dysregulated	B-X
BCR-Abl	B-X
fusion	B-X
oncoprotein	B-X
is	B-X
formed	B-X
and	B-X
it	B-X
produces	B-X
the	B-X
abnormal	B-X
proliferation	B-X
of	B-X
white	B-X
blood	B-X
cells	B-X
.	B-X
The	B-X
treatment	B-X
of	B-X
CML	B-X
with	B-X
imatinib	B-X
revolutionized	B-X
the	B-X
treatment	B-X
of	B-X
this	B-X
disorder	B-X
and	B-X
led	B-X
to	B-X
the	B-X
discovery	B-X
and	B-X
development	B-X
of	B-X
dozens	B-X
of	B-X
effective	B-X
targeted	B-X
protein	B-X
kinase	B-X
inhibitors	B-X
.	B-X
The	B-X
BCR-Abl	B-X
fusion	B-X
protein	B-X
lacks	B-X
the	B-X
physiological	B-X
N-terminal	B-X
myristoyl	B-X
group	B-X
that	B-X
binds	B-X
to	B-X
a	B-X
hydrophobic	B-X
pocket	B-X
in	B-X
the	B-X
large	B-X
protein	B-X
kinase	B-X
lobe	B-X
and	B-X
inhibits	B-X
enzyme	B-X
activity	B-X
.	B-X
Asciminib	B-X
is	B-X
orally	B-X
effective	B-X
and	B-X
was	B-X
FDA-approved	B-X
as	B-X
a	B-X
third-line	B-X
treatment	B-X
for	B-X
CML	B-X
and	B-X
a	B-X
first-line	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
the	B-X
T315I	B-X
mutation	B-X
.	B-X
It	B-X
blocks	B-X
the	B-X
activity	B-X
of	B-X
BCR-Abl	B-X
by	B-X
interacting	B-X
with	B-X
the	B-X
myristate-binding	B-X
site	B-X
located	B-X
23	B-X
Å	B-X
from	B-X
the	B-X
ATP-binding	B-X
site	B-X
and	B-X
is	B-X
the	B-X
prototype	B-X
of	B-X
a	B-X
type	B-X
IV	B-X
inhibitor	B-X
.	B-X

BCR	O
and	O
phorbol	O
ester	O
signals	O
were	O
also	O
able	O
to	O
increase	O
HSP27	B-Protein
phosphorylation	O
in	O
PKD1	B-Protein
or	O
PKD3	B-Protein
single	O
knockout	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

However	O
,	O
BCR	O
-	O
and	O
phorbol	O
ester	O
-	O
induced	O
phosphorylation	O
of	O
HSP27	B-Protein
on	O
S82	O
was	O
abolished	O
in	O
B	O
cells	O
that	O
lacked	O
both	O
PKD1	B-Protein
and	O
PKD3	B-Protein
(	O
Fig	O
.	O
1C	O
)	O
.	O

Significantly	O
,	O
doxycycline	O
-	O
induced	O
expression	O
of	O
the	O
Flag	O
-	O
PKD3	B-Protein
transgene	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
sufficient	O
to	O
restore	O
normal	O
regulation	O
of	O
HSP27	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
a	O
kinase	O
-	O
deficient	O
PKD3	B-Protein
mutant	O
protein	O
in	O
the	O
double	O
knockout	O
cells	O
was	O
not	O
able	O
to	O
restore	O
BCR	O
-	O
or	O
phorbol	O
ester	O
-	O
induced	O
HSP27	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

Hence	O
,	O
PKD3	B-Protein
as	O
well	O
as	O
PKD1	B-Protein
can	O
regulate	O
HSP27	B-Protein
phosphorylation	O
and	O
in	O
DT40	O
B	O
cells	O
they	O
are	O
functionally	O
redundant	O
as	O
HSP27	B-Protein
kinases	O
.	O

3	O
.	O
2Cellular	O
proliferation	O
and	O
survival	O
in	O
DT40	O
B	O
cells	O
lacking	O
expression	O
of	O
PKD	O
family	O
kinases	O

PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
survival	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
.	O

To	O
investigate	O
the	O
effect	O
that	O
loss	O
of	O
PKD	O
kinases	O
had	O
on	O
B	O
cell	O
survival	O
and	O
/	O
or	O
proliferation	O
we	O
cultured	O
wild	O
-	O
type	O
and	O
PKD	O
-	O
null	O
cells	O
in	O
the	O
presence	O
(	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
:	O
Flag	O
-	O
PKD3	B-Protein
+	O
ve	O
)	O
or	O
absence	O
(	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
)	O
of	O
doxycycline	O
and	O
monitored	O
exponential	O
growth	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

2A	O
,	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
cells	O
proliferated	O
exponentially	O
and	O
re	O
-	O
expression	O
of	O
Flag	O
-	O
PKD3	B-Protein
in	O
these	O
cells	O
had	O
no	O
impact	O
on	O
the	O
rate	O
of	O
proliferation	O
.	O

Furthermore	O
,	O
the	O
viability	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
B	O
cells	O
during	O
routine	O
culturing	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
was	O
noted	O
that	O
the	O
population	O
doubling	O
time	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
cells	O
was	O
slightly	O
slower	O
than	O
that	O
of	O
wild	O
type	O
DT40	O
cells	O
(	O
12	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
8	O
h	O
versus	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
h	O
)	O
but	O
the	O
failure	O
of	O
PKD3	B-Protein
re	O
-	O
expression	O
to	O
modify	O
the	O
proliferation	O
rate	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
cells	O
suggests	O
that	O
these	O
small	O
differences	O
were	O
most	O
likely	O
the	O
result	O
of	O
clonal	O
variation	O
and	O
were	O
not	O
caused	O
specifically	O
by	O
loss	O
of	O
PKD	O
enzymes	O
.	O

Thus	O
,	O
PKD	O
family	O
enzymes	O
are	O
not	O
essential	O
for	O
regulating	O
basal	O
survival	O
and	O
proliferation	O
of	O
DT40	O
B	O
cells	O
.	O
<EOS>	B-X
Direct	B-X
thiol	B-X
oxidation	B-X
of	B-X
key	B-X
proteins	B-X
such	B-X
as	B-X
ATG4	B-X
,	B-X
ATM	B-X
and	B-X
TFEB	B-X
are	B-X
responsible	B-X
for	B-X
specific	B-X
regulations	B-X
in	B-X
phagophore	B-X
expansion	B-X
,	B-X
cargo	B-X
recognition	B-X
and	B-X
autophagy	B-X
gene	B-X
transcription	B-X
,	B-X
respectively	B-X
.	B-X
Beclin	B-X
1	B-X
is	B-X
a	B-X
molecular	B-X
platform	B-X
assembling	B-X
an	B-X
interactome	B-X
with	B-X
stimulating	B-X
and	B-X
suppressive	B-X
components	B-X
which	B-X
regulate	B-X
the	B-X
initiation	B-X
of	B-X
the	B-X
autophagosome	B-X
formation	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
expression	B-X
Beclin	B-X
1	B-X
is	B-X
reduced	B-X
in	B-X
AD	B-X
brain	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
deficiency	B-X
of	B-X
Beclin	B-X
1	B-X
in	B-X
cultured	B-X
neurons	B-X
and	B-X
transgenic	B-X
mice	B-X
provokes	B-X
the	B-X
deposition	B-X
of	B-X
amyloid-β	B-X
peptides	B-X
whereas	B-X
its	B-X
overexpression	B-X
reduces	B-X
the	B-X
accumulation	B-X
of	B-X
amyloid-β	B-X
.	B-X
There	B-X
are	B-X
several	B-X
potential	B-X
mechanisms	B-X
,	B-X
which	B-X
could	B-X
inhibit	B-X
the	B-X
function	B-X
of	B-X
Beclin	B-X
1	B-X
interactome	B-X
and	B-X
thus	B-X
impair	B-X
autophagy	B-X
and	B-X
promote	B-X
AD	B-X
pathology	B-X
.	B-X
The	B-X
mechanisms	B-X
include	B-X
(	B-X
i	B-X
)	B-X
reduction	B-X
of	B-X
Beclin	B-X
1	B-X
expression	B-X
or	B-X
its	B-X
increased	B-X
proteolytic	B-X
cleavage	B-X
by	B-X
caspases	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
sequestration	B-X
of	B-X
Beclin	B-X
1	B-X
to	B-X
non-functional	B-X
locations	B-X
,	B-X
such	B-X
as	B-X
tau	B-X
tangles	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
formation	B-X
of	B-X
inhibitory	B-X
complexes	B-X
between	B-X
Beclin	B-X
1	B-X
and	B-X
antiapoptotic	B-X
Bcl-2	B-X
proteins	B-X
or	B-X
inflammasomes	B-X
,	B-X
(	B-X
iv	B-X
)	B-X
interaction	B-X
of	B-X
Beclin	B-X
1	B-X
with	B-X
inhibitory	B-X
neurovirulent	B-X
proteins	B-X
,	B-X
e.g	B-X
.	B-X
herpex	B-X
simplex	B-X
ICP34.5	B-X
,	B-X
or	B-X
(	B-X
v	B-X
)	B-X
inhibition	B-X
of	B-X
the	B-X
Beclin	B-X
1/Vps34	B-X
complex	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
CDK1	B-X
and	B-X
CDK5	B-X
.	B-X
We	B-X
will	B-X
shortly	B-X
introduce	B-X
the	B-X
function	B-X
of	B-X
Beclin	B-X
1	B-X
interactome	B-X
in	B-X
autophagy	B-X
and	B-X
phagocytosis	B-X
,	B-X
review	B-X
the	B-X
recent	B-X
evidence	B-X
indicating	B-X
that	B-X
Beclin	B-X
1	B-X
regulates	B-X
autophagy	B-X
and	B-X
APP	B-X
processing	B-X
in	B-X
AD	B-X
,	B-X
and	B-X
finally	B-X
examine	B-X
the	B-X
potential	B-X
mechanisms	B-X
through	B-X
which	B-X
Beclin	B-X
1	B-X
dysfunction	B-X
could	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
AD	B-X
.	B-X

PKD	O
enzymes	O
,	O
specifically	O
PKD1	B-Protein
and	O
PKD2	B-Protein
,	O
have	O
previously	O
been	O
linked	O
to	O
a	O
protective	O
role	O
against	O
oxidative	O
stress	O
-	O
induced	O
injury	O
in	O
3T3	O
fibroblast	O
,	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
[	O
17	O
,	O
30	O
-	O
32	O
]	O
.	O

We	O
therefore	O
addressed	O
the	O
role	O
of	O
PKD	O
family	O
kinases	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
other	O
stress	O
stimuli	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

2B	O
,	O
loss	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
expression	O
had	O
no	O
significant	O
impact	O
on	O
the	O
survival	O
of	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
mitochondrial	O
stress	O
stimuli	O
(	O
H2O2	O
or	O
serum	O
deprivation	O
)	O
;	O
DNA	O
damaging	O
agents	O
(	O
etoposide	O
or	O
doxorubicin	O
)	O
;	O
ER	O
pathway	O
stress	O
due	O
to	O
calcium	O
overload	O
(	O
thapsigargin	O
)	O
or	O
following	O
prolonged	O
treatment	O
with	O
phorbol	O
esters	O
or	O
Trichostatin	O
A	O
,	O
an	O
inhibitor	O
of	O
class	O
I	O
/	O
II	O
HDACs	O
.	O

Thus	O
,	O
PKD	O
kinases	O
do	O
not	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
B	O
cell	O
survival	O
in	O
response	O
to	O
a	O
range	O
of	O
different	O
stress	O
stimuli	O
.	O
<EOS>	B-X
Inflammation	B-X
,	B-X
inappropriate	B-X
intracellular	B-X
activation	B-X
of	B-X
digestive	B-X
enzymes	B-X
,	B-X
and	B-X
parenchymal	B-X
acinar	B-X
cell	B-X
death	B-X
by	B-X
necrosis	B-X
are	B-X
the	B-X
critical	B-X
pathophysiologic	B-X
processes	B-X
of	B-X
acute	B-X
pancreatitis	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
elucidate	B-X
the	B-X
key	B-X
molecular	B-X
signals	B-X
that	B-X
mediate	B-X
these	B-X
pathobiologic	B-X
processes	B-X
and	B-X
develop	B-X
new	B-X
therapeutic	B-X
strategies	B-X
to	B-X
attenuate	B-X
the	B-X
appropriate	B-X
signaling	B-X
pathways	B-X
in	B-X
order	B-X
to	B-X
improve	B-X
outcomes	B-X
for	B-X
this	B-X
disease	B-X
.	B-X
A	B-X
novel	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
D	B-X
(	B-X
PKD	B-X
)	B-X
family	B-X
has	B-X
emerged	B-X
as	B-X
key	B-X
participants	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
and	B-X
this	B-X
family	B-X
is	B-X
increasingly	B-X
being	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
multiple	B-X
cellular	B-X
functions	B-X
and	B-X
diseases	B-X
.	B-X
The	B-X
Hippo	B-X
pathway	B-X
nuclear	B-X
effector	B-X
Yes-associated	B-X
protein	B-X
(	B-X
YAP	B-X
)	B-X
potentiates	B-X
the	B-X
progression	B-X
of	B-X
polycystic	B-X
kidney	B-X
disease	B-X
(	B-X
PKD	B-X
)	B-X
arising	B-X
from	B-X
ciliopathies	B-X
.	B-X
The	B-X
mechanisms	B-X
underlying	B-X
the	B-X
increase	B-X
in	B-X
YAP	B-X
expression	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
PKD	B-X
remain	B-X
obscure	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
in	B-X
kidneys	B-X
from	B-X
mice	B-X
with	B-X
juvenile	B-X
cystic	B-X
kidney	B-X
(	B-X
jck	B-X
)	B-X
ciliopathy	B-X
,	B-X
the	B-X
aberrant	B-X
hyperactivity	B-X
of	B-X
mechanistic	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
,	B-X
driven	B-X
by	B-X
ERK1/2	B-X
and	B-X
PI3K/AKT	B-X
cascades	B-X
,	B-X
induced	B-X
ER	B-X
proteotoxic	B-X
stress	B-X
.	B-X
To	B-X
reduce	B-X
this	B-X
stress	B-X
by	B-X
reprogramming	B-X
translation	B-X
,	B-X
the	B-X
protein	B-X
kinase	B-X
R-like	B-X
ER	B-X
kinase-eukaryotic	B-X
initiation	B-X
factor	B-X
2α	B-X
(	B-X
PERK/eIF2α	B-X
)	B-X
arm	B-X
of	B-X
the	B-X
integrated	B-X
stress	B-X
response	B-X
(	B-X
ISR	B-X
)	B-X
was	B-X
activated	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
YAP	B-X
underwent	B-X
K63-linked	B-X
polyubiquitination	B-X
by	B-X
SCF	B-X
S-phase	B-X
kinase-associated	B-X
protein	B-X
2	B-X
(	B-X
SKP2	B-X
)	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
a	B-X
Hippo-independent	B-X
,	B-X
nonproteolytic	B-X
ubiquitination	B-X
that	B-X
enhances	B-X
YAP	B-X
nuclear	B-X
trafficking	B-X
and	B-X
transcriptional	B-X
activity	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Defective	B-X
ISR	B-X
cellular	B-X
adaptation	B-X
to	B-X
ER	B-X
stress	B-X
in	B-X
eIF2α	B-X
phosphorylation-deficient	B-X
jck	B-X
mice	B-X
further	B-X
augmented	B-X
YAP-mediated	B-X
transcriptional	B-X
activity	B-X
and	B-X
renal	B-X
cyst	B-X
growth	B-X
.	B-X
Conversely	B-X
,	B-X
pharmacological	B-X
tuning	B-X
down	B-X
of	B-X
ER	B-X
stress/ISR	B-X
activity	B-X
and	B-X
SKP2	B-X
expression	B-X
in	B-X
jck	B-X
mice	B-X
by	B-X
administration	B-X
of	B-X
tauroursodeoxycholic	B-X
acid	B-X
(	B-X
TUDCA	B-X
)	B-X
or	B-X
tolvaptan	B-X
impeded	B-X
these	B-X
processes	B-X
.	B-X

3	O
.	O
3Antigen	O
receptor	O
regulated	O
signalling	O
pathways	O
in	O
PKD	O
-	O
null	O
DT40	O
B	O
cells	O

To	O
further	O
explore	O
the	O
contribution	O
of	O
PKD	O
kinases	O
to	O
DT40	O
B	O
cell	O
biology	O
we	O
investigated	O
whether	O
specific	O
BCR	O
-	O
regulated	O
signalling	O
events	O
were	O
defective	O
in	O
the	O
PKD	O
-	O
null	O
B	O
cells	O
.	O

Initial	O
experiments	O
revealed	O
that	O
surface	O
expression	O
of	O
the	O
BCR	O
was	O
reduced	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
(	O
and	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
:	O
Flag	O
-	O
PKD3	B-Protein
+	O
ve	O
)	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
3A	O
and	O
data	O
not	O
shown	O
)	O
.	O

Nevertheless	O
,	O
BCR	O
-	O
crosslinking	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
cells	O
was	O
sufficient	O
to	O
induce	O
the	O
activation	O
of	O
a	O
number	O
of	O
signalling	O
cascades	O
,	O
similar	O
to	O
that	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Hence	O
,	O
BCR	O
-	O
induced	O
activation	O
of	O
the	O
Akt	B-Protein
,	O
mTOR	B-Protein
/	O
p70	O
S6	O
kinase	O
(	O
as	O
shown	O
by	O
S6	B-Protein
ribosomal	I-Protein
protein	I-Protein
phosphorylation	O
)	O
and	O
MAPK	O
signalling	O
pathways	O
was	O
clearly	O
detectable	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
null	O
B	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Furthermore	O
,	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
cellular	O
proteins	O
as	O
well	O
as	O
an	O
increase	O
in	O
intracellular	O
calcium	O
levels	O
was	O
also	O
observed	O
following	O
BCR	O
stimulation	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
null	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
did	O
observe	O
that	O
the	O
strength	O
of	O
BCR	O
(	O
but	O
not	O
phorbol	O
ester	O
)	O
-	O
induced	O
regulation	O
of	O
the	O
Erk1	B-Protein
-	O
RSK1	B-Protein
signalling	O
pathway	O
was	O
reduced	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
B	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
B	O
cells	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

One	O
interpretation	O
of	O
this	O
data	O
is	O
that	O
PKD	O
enzymes	O
may	O
modulate	O
Erk	O
activation	O
.	O

Indeed	O
,	O
PKD	O
enzymes	O
have	O
previously	O
been	O
linked	O
to	O
the	O
growth	O
factor	O
-	O
regulated	O
Erk	O
signalling	O
in	O
fibroblast	O
and	O
endothelial	O
cell	O
lines	O
[	O
33	O
-	O
35	O
]	O
.	O

However	O
,	O
BCR	O
-	O
induced	O
Erk	O
phosphorylation	O
was	O
also	O
reduced	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3	B-Protein
+	O
B	O
cells	O
(	O
data	O
not	O
shown	O
)	O
suggesting	O
that	O
reduced	O
BCR	O
levels	O
on	O
the	O
surface	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
(	O
and	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
-	O
Flag	O
-	O
PKD3	B-Protein
+	O
)	O
B	O
cells	O
may	O
itself	O
impact	O
on	O
the	O
strength	O
of	O
activation	O
of	O
this	O
specific	O
intracellular	O
signalling	O
pathway	O
.	O

To	O
search	O
for	O
other	O
potential	O
PKD	O
targets	O
that	O
may	O
show	O
defective	O
regulation	O
in	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
DT40	O
B	O
cells	O
,	O
we	O
used	O
a	O
PKD	O
substrate	O
phospho	O
-	O
antibody	O
that	O
recognises	O
consensus	O
phosphorylation	O
sequences	O
targeted	O
by	O
PKD	O
enzymes	O
(	O
LxRxxpS	O
/	O
T	O
)	O
[	O
36	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

3C	O
,	O
phorbol	O
ester	O
-	O
and	O
BCR	O
-	O
induced	O
phosphorylation	O
of	O
cellular	O
substrates	O
detected	O
by	O
this	O
phospho	O
-	O
antibody	O
was	O
similar	O
in	O
wild	O
-	O
type	O
and	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
cells	O
and	O
is	O
therefore	O
independent	O
of	O
PKD	O
enzymes	O
.	O

However	O
,	O
pretreatment	O
of	O
both	O
wild	O
-	O
type	O
and	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
DT40	O
B	O
cells	O
with	O
GF109203X	O
,	O
a	O
bisindoylmaleimide	O
derivative	O
that	O
inhibits	O
PKCs	O
prevented	O
the	O
induction	O
of	O
proteins	O
that	O
contain	O
phosphorylated	O
LxRxxS	O
/	O
T	O
motifs	O
.	O

Thus	O
loss	O
of	O
PKD1	B-Protein
/	O
3	B-Protein
enzymes	O
does	O
not	O
globally	O
disrupt	O
the	O
phosphorylation	O
of	O
cellular	O
proteins	O
that	O
contain	O
LxRxxpS	O
/	O
T	O
motifs	O
.	O
<EOS>	B-X
Additional	B-X
ultra-deep	B-X
sequencing	B-X
identified	B-X
recurrent	B-X
mutations	B-X
in	B-X
PKD1	B-X
,	B-X
PPARGC1B	B-X
,	B-X
KMT2D	B-X
,	B-X
and	B-X
ARID1A	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
sequencing	B-X
results	B-X
,	B-X
examination	B-X
of	B-X
147	B-X
genes	B-X
again	B-X
revealed	B-X
that	B-X
loss	B-X
of	B-X
Pkd1	B-X
,	B-X
Kmt2d	B-X
,	B-X
and	B-X
Arid1a	B-X
promoted	B-X
clonal	B-X
expansion	B-X
.	B-X
The	B-X
three	B-X
family	B-X
members	B-X
,	B-X
PKD1	B-X
,	B-X
PKD2	B-X
,	B-X
and	B-X
PKD3	B-X
,	B-X
are	B-X
activated	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
extracellular	B-X
stimuli	B-X
and	B-X
transduce	B-X
cell	B-X
signals	B-X
affecting	B-X
many	B-X
aspects	B-X
of	B-X
basic	B-X
cell	B-X
functions	B-X
including	B-X
secretion	B-X
,	B-X
migration	B-X
,	B-X
proliferation	B-X
,	B-X
survival	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
immune	B-X
response	B-X
.	B-X
Further	B-X
loss-	B-X
or	B-X
gain-of-function	B-X
studies	B-X
at	B-X
cellular	B-X
levels	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
provide	B-X
strong	B-X
support	B-X
for	B-X
crucial	B-X
roles	B-X
of	B-X
PKD	B-X
in	B-X
many	B-X
pathological	B-X
conditions	B-X
,	B-X
including	B-X
cancer	B-X
,	B-X
metabolic	B-X
disorders	B-X
,	B-X
cardiac	B-X
diseases	B-X
,	B-X
central	B-X
nervous	B-X
system	B-X
disorders	B-X
,	B-X
inflammatory	B-X
diseases	B-X
,	B-X
and	B-X
immune	B-X
dysregulation	B-X
.	B-X

This	O
result	O
is	O
perhaps	O
not	O
surprising	O
as	O
LxRxxS	O
/	O
T	O
motifs	O
also	O
act	O
as	O
good	O
substrates	O
for	O
other	O
serine	O
/	O
threonine	O
kinases	O
such	O
as	O
MAPKAPK2	B-Protein
.	O
<EOS>	B-X
Cell	B-X
death	B-X
was	B-X
once	B-X
believed	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
one	B-X
of	B-X
two	B-X
distinct	B-X
processes	B-X
,	B-X
apoptosis	B-X
(	B-X
also	B-X
known	B-X
as	B-X
programmed	B-X
cell	B-X
death	B-X
)	B-X
or	B-X
necrosis	B-X
(	B-X
uncontrolled	B-X
cell	B-X
death	B-X
)	B-X
;	B-X
in	B-X
recent	B-X
years	B-X
,	B-X
however	B-X
,	B-X
several	B-X
other	B-X
forms	B-X
of	B-X
cell	B-X
death	B-X
have	B-X
been	B-X
discovered	B-X
highlighting	B-X
that	B-X
a	B-X
cell	B-X
can	B-X
die	B-X
via	B-X
a	B-X
number	B-X
of	B-X
differing	B-X
pathways	B-X
.	B-X
Apoptosis	B-X
is	B-X
characterised	B-X
by	B-X
a	B-X
number	B-X
of	B-X
characteristic	B-X
morphological	B-X
changes	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
cell	B-X
,	B-X
together	B-X
with	B-X
a	B-X
number	B-X
of	B-X
enzyme-dependent	B-X
biochemical	B-X
processes	B-X
.	B-X
The	B-X
result	B-X
being	B-X
the	B-X
clearance	B-X
of	B-X
cells	B-X
from	B-X
the	B-X
body	B-X
,	B-X
with	B-X
minimal	B-X
damage	B-X
to	B-X
surrounding	B-X
tissues	B-X
.	B-X
Necrosis	B-X
,	B-X
however	B-X
,	B-X
is	B-X
generally	B-X
characterised	B-X
to	B-X
be	B-X
the	B-X
uncontrolled	B-X
death	B-X
of	B-X
the	B-X
cell	B-X
,	B-X
usually	B-X
following	B-X
a	B-X
severe	B-X
insult	B-X
,	B-X
resulting	B-X
in	B-X
spillage	B-X
of	B-X
the	B-X
contents	B-X
of	B-X
the	B-X
cell	B-X
into	B-X
surrounding	B-X
tissues	B-X
and	B-X
subsequent	B-X
damage	B-X
thereof	B-X
.	B-X
Failure	B-X
of	B-X
apoptosis	B-X
and	B-X
the	B-X
resultant	B-X
accumulation	B-X
of	B-X
damaged	B-X
cells	B-X
in	B-X
the	B-X
body	B-X
can	B-X
result	B-X
in	B-X
various	B-X
forms	B-X
of	B-X
cancer	B-X
.	B-X

However	O
these	O
experiments	O
do	O
provide	O
further	O
evidence	O
that	O
phosphospecific	O
antisera	O
are	O
not	O
sufficiently	O
selective	O
to	O
be	O
designated	O
kinase	O
specific	O
substrate	O
antisera	O
.	O

BCR	O
-	O
induced	O
signalling	O
pathways	O
culminate	O
in	O
the	O
activation	O
of	O
gene	O
transcription	O
events	O
that	O
control	O
B	O
cell	O
survival	O
,	O
proliferation	O
and	O
function	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
proposed	O
that	O
PKD	O
family	O
members	O
control	O
of	O
gene	O
transcription	O
through	O
activation	O
of	O
the	O
NFkappaB	O
transcription	O
factor	O
.	O

Thus	O
,	O
PKD	O
-	O
mediated	O
activation	O
of	O
NFkappaB	O
occurs	O
downstream	O
of	O
a	O
variety	O
of	O
different	O
signals	O
,	O
including	O
mROS	O
/	O
oxidative	O
stress	O
,	O
lysophosphatidic	O
acid	O
and	O
the	O
Bcr	B-Protein
-	I-Protein
Abl	I-Protein
oncogene	I-Protein
[	O
17	O
,	O
21	O
,	O
23	O
,	O
30	O
,	O
37	O
]	O
.	O

Furthermore	O
,	O
expression	O
of	O
an	O
activated	O
PKD1	B-Protein
mutant	O
enhances	O
HPK1	B-Protein
-	O
mediated	O
NFkappaB	O
activation	O
[	O
38	O
]	O
.	O

In	O
B	O
cells	O
,	O
NFkappaB	O
is	O
known	O
to	O
be	O
regulated	O
via	O
DAG	O
and	O
PKCbeta	B-Protein
[	O
39	O
,	O
40	O
]	O
but	O
whether	O
PKDs	O
are	O
key	O
intermediaries	O
for	O
NFkappaB	O
regulation	O
has	O
not	O
been	O
explored	O
.	O

The	O
data	O
(	O
Fig	O
.	O
4A	O
)	O
show	O
that	O
NFkappaB	O
transcriptional	O
activity	O
was	O
strongly	O
induced	O
in	O
both	O
wild	O
-	O
type	O
and	O
PKD1	B-Protein
/	O
3	B-Protein
-	O
/	O
-	O
DT40	O
B	O
cells	O
in	O
response	O
to	O
either	O
phorbol	O
ester	O
or	O
BCR	O
stimulation	O
.	O
<EOS>	B-X
Bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
maintain	B-X
epithelial	B-X
integrity	B-X
and	B-X
to	B-X
antagonize	B-X
the	B-X
transforming	B-X
growth	B-X
factor	B-X
β	B-X
(	B-X
TGFβ	B-X
)	B-X
-induced	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
soluble	B-X
BMP	B-X
antagonists	B-X
is	B-X
dysregulated	B-X
in	B-X
cancers	B-X
and	B-X
interrupts	B-X
proper	B-X
BMP	B-X
signaling	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
cells	B-X
circulate	B-X
between	B-X
peripheral	B-X
blood	B-X
(	B-X
PB	B-X
)	B-X
and	B-X
lymph	B-X
nodes	B-X
(	B-X
LNs	B-X
)	B-X
,	B-X
where	B-X
they	B-X
receive	B-X
proliferative	B-X
and	B-X
prosurvival	B-X
signals	B-X
from	B-X
surrounding	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
insight	B-X
into	B-X
the	B-X
metabolism	B-X
of	B-X
LN	B-X
CLL	B-X
and	B-X
how	B-X
this	B-X
may	B-X
relate	B-X
to	B-X
therapeutic	B-X
response	B-X
is	B-X
lacking	B-X
.	B-X
First	B-X
,	B-X
we	B-X
sampled	B-X
PB	B-X
from	B-X
8	B-X
patients	B-X
at	B-X
baseline	B-X
and	B-X
after	B-X
3-month	B-X
ibrutinib	B-X
(	B-X
IBR	B-X
)	B-X
treatment	B-X
,	B-X
which	B-X
forces	B-X
egress	B-X
of	B-X
CLL	B-X
cells	B-X
from	B-X
LNs	B-X
.	B-X
Second	B-X
,	B-X
we	B-X
applied	B-X
in	B-X
vitro	B-X
B-cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
or	B-X
CD40	B-X
stimulation	B-X
to	B-X
mimic	B-X
the	B-X
LN	B-X
microenvironment	B-X
and	B-X
performed	B-X
metabolomic	B-X
and	B-X
transcriptomic	B-X
analyses	B-X
.	B-X
BCR	B-X
signaling	B-X
preferably	B-X
engaged	B-X
glucose	B-X
and	B-X
glycerol	B-X
metabolism	B-X
and	B-X
several	B-X
biosynthesis	B-X
routes	B-X
.	B-X
Pathway	B-X
analyses	B-X
demonstrated	B-X
opposite	B-X
effects	B-X
of	B-X
in	B-X
vitro	B-X
stimulation	B-X
vs	B-X
IBR	B-X
treatment	B-X
.	B-X
In	B-X
agreement	B-X
,	B-X
the	B-X
metabolic	B-X
regulator	B-X
MYC	B-X
and	B-X
its	B-X
target	B-X
genes	B-X
were	B-X
induced	B-X
after	B-X
BCR/CD40	B-X
stimulation	B-X
and	B-X
suppressed	B-X
by	B-X
IBR	B-X
.	B-X
Next	B-X
,	B-X
13C	B-X
fluxomics	B-X
performed	B-X
on	B-X
CD40/BCR-stimulated	B-X
cells	B-X
confirmed	B-X
a	B-X
strong	B-X
contribution	B-X
of	B-X
glutamine	B-X
as	B-X
fuel	B-X
for	B-X
the	B-X
TCA	B-X
cycle	B-X
,	B-X
whereas	B-X
glucose	B-X
was	B-X
mainly	B-X
converted	B-X
into	B-X
lactate	B-X
and	B-X
ribose-5-phosphate	B-X
.	B-X
Finally	B-X
,	B-X
inhibition	B-X
of	B-X
glutamine	B-X
import	B-X
with	B-X
V9302	B-X
attenuated	B-X
CD40/BCR-induced	B-X
resistance	B-X
to	B-X
venetoclax	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
insight	B-X
into	B-X
crucial	B-X
metabolic	B-X
changes	B-X
driven	B-X
by	B-X
the	B-X
CLL	B-X
LN	B-X
microenvironment	B-X
.	B-X

In	O
contrast	O
,	O
BCR	O
and	O
phorbol	O
ester	O
-	O
induced	O
NFkappaB	O
transcriptional	O
activity	O
was	O
abolished	O
in	O
PKCbeta	B-Protein
-	O
/	O
-	O
DT40	O
B	O
cells	O
(	O
Fig	O
.	O
4A	O
)	O
,	O
although	O
strong	O
activation	O
of	O
PKD	O
kinases	O
(	O
as	O
assessed	O
by	O
autophosphorylation	O
of	O
PKD1	B-Protein
at	O
S916	O
)	O
was	O
observed	O
in	O
the	O
PKCbeta	B-Protein
-	O
/	O
-	O
cells	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Thus	O
,	O
PKD	O
kinases	O
are	O
neither	O
essential	O
nor	O
sufficient	O
to	O
mediate	O
BCR	O
-	O
induced	O
NFkappaB	O
activation	O
in	O
DT40	O
B	O
cells	O
and	O
hence	O
do	O
not	O
participate	O
in	O
DAG	O
/	O
PKC	O
mediated	O
control	O
of	O
NFkappaB	O
.	O

4Protein	O
kinase	O
D	O
serine	O
kinases	O
have	O
been	O
proposed	O
to	O
regulate	O
diverse	O
cellular	O
functions	O
including	O
the	O
phosphorylation	O
and	O
nuclear	O
localisation	O
of	O
class	O
II	O
HDACs	O
and	O
the	O
phosphorylation	O
of	O
HSP27	B-Protein
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
PKDs	O
act	O
as	O
mitochondrial	O
sensors	O
for	O
oxidative	O
stress	O
and	O
play	O
a	O
role	O
in	O
regulating	O
NFkappaB	O
transcription	O
factors	O
[	O
41	O
]	O
.	O

Most	O
of	O
the	O
data	O
about	O
the	O
function	O
of	O
PKDs	O
has	O
come	O
from	O
experiments	O
that	O
ectopically	O
express	O
active	O
or	O
inhibitory	O
PKD	O
mutants	O
or	O
that	O
use	O
RNAi	O
to	O
reduce	O
PKD	O
expression	O
.	O
<EOS>	B-X
Hepatocyte	B-X
growth	B-X
factor	B-X
activator	B-X
inhibitor-1	B-X
(	B-X
HAI-1	B-X
,	B-X
also	B-X
known	B-X
as	B-X
SPINT1	B-X
)	B-X
is	B-X
an	B-X
inhibitor	B-X
of	B-X
matriptase	B-X
,	B-X
a	B-X
type-2	B-X
transmembrane	B-X
protease	B-X
widely	B-X
expressed	B-X
in	B-X
epithelial	B-X
cells	B-X
.	B-X
HAI-1	B-X
also	B-X
functions	B-X
as	B-X
a	B-X
chaperone	B-X
to	B-X
maintain	B-X
the	B-X
processing	B-X
and	B-X
localization	B-X
of	B-X
matriptase	B-X
required	B-X
for	B-X
epithelial	B-X
integrity	B-X
.	B-X
However	B-X
,	B-X
mechanisms	B-X
underpinning	B-X
the	B-X
chaperone	B-X
function	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
first	B-X
Kunitz	B-X
domain	B-X
(	B-X
KD1	B-X
)	B-X
and	B-X
the	B-X
adjacent	B-X
polycystic	B-X
kidney	B-X
disease	B-X
(	B-X
PKD	B-X
)	B-X
domain-like	B-X
internal	B-X
domain	B-X
of	B-X
HAI-1	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
chaperone	B-X
function	B-X
.	B-X
In	B-X
HEK293T	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
express	B-X
endogenous	B-X
HAI-1	B-X
or	B-X
matriptase	B-X
,	B-X
forced	B-X
matriptase	B-X
overexpression	B-X
was	B-X
unsuccessful	B-X
unless	B-X
sufficient	B-X
HAI-1	B-X
was	B-X
co-expressed	B-X
.	B-X
Among	B-X
mutant	B-X
HAI-1	B-X
constructs	B-X
,	B-X
HAI-1	B-X
with	B-X
inactivation	B-X
mutation	B-X
in	B-X
KD1	B-X
(	B-X
HAI-1mKD1	B-X
)	B-X
or	B-X
HAI-1	B-X
lacking	B-X
the	B-X
PKD	B-X
domain	B-X
(	B-X
HAI-1dPKD	B-X
)	B-X
was	B-X
unable	B-X
to	B-X
support	B-X
matriptase	B-X
expression	B-X
,	B-X
and	B-X
neither	B-X
mutant	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
activated	B-X
matriptase	B-X
.	B-X
Matriptase	B-X
did	B-X
not	B-X
localize	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
when	B-X
co-expressed	B-X
with	B-X
HAI-1dPKD	B-X
.	B-X
Moreover	B-X
,	B-X
HAI-1dPKD	B-X
accumulated	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
HEK293T	B-X
and	B-X
HaCaT	B-X
cells	B-X
rather	B-X
than	B-X
localizing	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
misfolding	B-X
as	B-X
judged	B-X
by	B-X
altered	B-X
antibody	B-X
recognition	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
activationlocked	B-X
and	B-X
activity-incompetent	B-X
matriptase	B-X
were	B-X
stable	B-X
and	B-X
readily	B-X
overexpressed	B-X
and	B-X
localized	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
without	B-X
HAI-1	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
observed	B-X
matriptase	B-X
instability	B-X
was	B-X
caused	B-X
by	B-X
its	B-X
own	B-X
catalytic	B-X
activity	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
inhibitory	B-X
HAI-1	B-X
.	B-X
The	B-X
matriptase	B-X
chaperone	B-X
function	B-X
of	B-X
HAI-1	B-X
is	B-X
thus	B-X
mediated	B-X
primarily	B-X
by	B-X
the	B-X
inhibition	B-X
of	B-X
undesired	B-X
intracellular	B-X
matriptase	B-X
activity	B-X
,	B-X
and	B-X
the	B-X
PKD	B-X
domain	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
proper	B-X
folding	B-X
and	B-X
trafficking	B-X
of	B-X
inhibitory	B-X
HAI-1	B-X
and	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X

We	O
have	O
used	O
gene	O
targeting	O
to	O
specifically	O
delete	O
PKD	O
alleles	O
in	O
DT40	O
chicken	O
B	O
cells	O
and	O
can	O
thus	O
use	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
individual	O
PKD	O
isoforms	O
in	O
class	O
II	O
HDAC	O
control	O
versus	O
oxidative	O
stress	O
responses	O
and	O
NFkappaB	O
regulation	O
in	O
lymphocytes	O
.	O

We	O
have	O
previously	O
used	O
these	O
PKD	O
-	O
null	O
DT40	O
cells	O
to	O
define	O
an	O
essential	O
role	O
for	O
PKDs	O
in	O
regulation	O
of	O
class	O
II	O
HDACs	O
,	O
the	O
present	O
report	O
now	O
describes	O
an	O
indispensable	O
role	O
for	O
PKDs	O
in	O
regulating	O
the	O
phosphorylation	O
of	O
HSP27	B-Protein
on	O
serine	O
82	O
,	O
a	O
site	O
previously	O
identified	O
as	O
a	O
target	O
for	O
the	O
p38	O
-	O
MAPKAPK2	B-Protein
signalling	O
cascade	O
[	O
42	O
]	O
.	O

However	O
,	O
studies	O
of	O
PKD	O
-	O
null	O
DT40	O
cells	O
reveal	O
that	O
PKD	O
family	O
kinases	O
are	O
not	O
essential	O
for	O
oxidative	O
stress	O
survival	O
responses	O
nor	O
are	O
they	O
required	O
for	O
activation	O
of	O
NFkappaB	O
transcription	O
factors	O
.	O

These	O
latter	O
findings	O
are	O
in	O
striking	O
contrast	O
to	O
previous	O
observations	O
in	O
HeLa	O
and	O
epithelial	O
cell	O
lines	O
where	O
overexpression	O
/	O
RNAi	O
approaches	O
have	O
implicated	O
PKD1	B-Protein
/	O
2	B-Protein
in	O
the	O
control	O
of	O
proliferation	O
,	O
survival	O
and	O
NFkappaB	O
activation	O
[	O
20	O
,	O
23	O
]	O
.	O

Hence	O
,	O
the	O
present	O
report	O
shows	O
that	O
the	O
proposed	O
roles	O
for	O
PKDs	O
as	O
key	O
sensors	O
that	O
modulate	O
survival	O
pathways	O
in	O
response	O
to	O
oxidative	O
stress	O
and	O
regulate	O
cell	O
survival	O
and	O
proliferation	O
are	O
not	O
ubiquitous	O
and	O
may	O
be	O
restricted	O
to	O
certain	O
cell	O
lineages	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
loss	O
of	O
expression	O
of	O
PKD	O
family	O
members	O
does	O
not	O
globally	O
impact	O
on	O
early	O
BCR	O
-	O
regulated	O
signalling	O
pathways	O
.	O

GATA3	B-Protein
-	O
Driven	O
Th2	O
Responses	O
Inhibit	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
-	O
Induced	O
FOXP3	B-Protein
Expression	O
and	O
the	O
Formation	O
of	O
Regulatory	O
T	O
Cells	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

Transcription	O
factors	O
act	O
in	O
concert	O
to	O
induce	O
lineage	O
commitment	O
towards	O
Th1	O
,	O
Th2	O
,	O
or	O
T	O
regulatory	O
(	O
Treg	O
)	O
cells	O
,	O
and	O
their	O
counter	O
-	O
regulatory	O
mechanisms	O
were	O
shown	O
to	O
be	O
critical	O
for	O
polarization	O
between	O
Th1	O
and	O
Th2	O
phenotypes	O
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

FOXP3	B-Protein
is	O
an	O
essential	O
transcription	O
factor	O
for	O
natural	O
,	O
thymus	O
-	O
derived	O
(	O
nTreg	O
)	O
and	O
inducible	O
Treg	O
(	O
iTreg	O
)	O
commitment	O
;	O
however	O
,	O
the	O
mechanisms	O
regulating	O
its	O
expression	O
are	O
as	O
yet	O
unknown	O
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

We	O
describe	O
a	O
mechanism	O
controlling	O
iTreg	O
polarization	O
,	O
which	O
is	O
overruled	O
by	O
the	O
Th2	O
differentiation	O
pathway	O
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

We	O
demonstrated	O
that	O
interleukin	B-Protein
4	I-Protein
(	O
IL	B-Protein
-	I-Protein
4	I-Protein
)	O
present	O
at	O
the	O
time	O
of	O
T	O
cell	O
priming	O
inhibits	O
FOXP3	B-Protein
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

This	O
inhibitory	O
mechanism	O
was	O
also	O
confirmed	O
in	O
Th2	O
cells	O
and	O
in	O
T	O
cells	O
of	O
transgenic	O
mice	O
overexpressing	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
T	O
cells	O
,	O
which	O
are	O
shown	O
to	O
be	O
deficient	O
in	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TGF	I-Protein
)	I-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
FOXP3	B-Protein
induction	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
direct	O
binding	O
of	O
GATA3	B-Protein
to	O
the	O
FOXP3	B-Protein
promoter	O
,	O
which	O
represses	O
its	O
transactivation	O
process	O
.	O

Therefore	O
,	O
this	O
study	O
provides	O
a	O
new	O
understanding	O
of	O
tolerance	O
development	O
,	O
controlled	O
by	O
a	O
type	O
2	O
immune	O
response	O
.	O
<EOS>	B-X
Atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
inflammatory	B-X
skin	B-X
disease	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
complex	B-X
pathophysiology	B-X
involving	B-X
both	B-X
skin	B-X
barrier	B-X
dysfunction	B-X
and	B-X
aberrant	B-X
type	B-X
2	B-X
inflammation/immune	B-X
responses	B-X
.	B-X
Currently	B-X
,	B-X
topical	B-X
therapies	B-X
such	B-X
as	B-X
corticosteroids	B-X
and	B-X
non-steroidal	B-X
immunomodulatory	B-X
therapy	B-X
provide	B-X
limited	B-X
efficacy	B-X
for	B-X
patients	B-X
with	B-X
moderate-to-severe	B-X
AD	B-X
;	B-X
limitations	B-X
include	B-X
inadequate	B-X
response	B-X
,	B-X
cutaneous	B-X
toxicity	B-X
from	B-X
overuse	B-X
,	B-X
and	B-X
poor	B-X
tolerance	B-X
due	B-X
to	B-X
stinging	B-X
and	B-X
burning	B-X
.	B-X
Historically	B-X
,	B-X
the	B-X
development	B-X
of	B-X
targeted	B-X
therapies	B-X
has	B-X
been	B-X
challenging	B-X
due	B-X
to	B-X
the	B-X
complex	B-X
and	B-X
multifaceted	B-X
etiology	B-X
of	B-X
AD	B-X
.	B-X
Recent	B-X
progress	B-X
in	B-X
understanding	B-X
the	B-X
immunopathology	B-X
of	B-X
AD	B-X
reinforces	B-X
the	B-X
development	B-X
of	B-X
newly	B-X
targeted	B-X
therapeutics	B-X
.	B-X
The	B-X
successful	B-X
launch	B-X
of	B-X
dupilumab	B-X
,	B-X
a	B-X
monoclonal	B-X
antibody	B-X
targeting	B-X
the	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4α	B-X
receptor	B-X
subunit	B-X
,	B-X
for	B-X
AD	B-X
in	B-X
2017	B-X
spurred	B-X
the	B-X
development	B-X
of	B-X
a	B-X
number	B-X
of	B-X
biologics	B-X
targeting	B-X
novel	B-X
cytokine	B-X
and	B-X
receptor	B-X
targets	B-X
that	B-X
are	B-X
now	B-X
in	B-X
phase	B-X
II	B-X
and	B-X
III	B-X
of	B-X
development	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
treatment	O
in	O
mice	O
reduces	O
iTreg	O
cell	O
frequency	O
,	O
highlighting	O
that	O
therapeutic	O
approaches	O
that	O
target	O
IL	B-Protein
-	I-Protein
4	I-Protein
or	O
GATA3	B-Protein
might	O
provide	O
new	O
preventive	O
strategies	O
facilitating	O
tolerance	O
induction	O
particularly	O
in	O
Th2	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
allergy	O
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
induce	B-X
lineage	B-X
commitment	B-X
towards	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
or	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
their	B-X
counter-regulatory	B-X
mechanisms	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
critical	B-X
for	B-X
polarization	B-X
between	B-X
Th1	B-X
and	B-X
Th2	B-X
phenotypes	B-X
.	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
provides	B-X
a	B-X
new	B-X
understanding	B-X
of	B-X
tolerance	B-X
development	B-X
,	B-X
controlled	B-X
by	B-X
a	B-X
type	B-X
2	B-X
immune	B-X
response	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

Effective	O
immune	O
responses	O
are	O
characterized	O
by	O
T	O
cell	O
activation	O
,	O
which	O
directs	O
adaptive	O
and	O
innate	O
immune	O
responses	O
to	O
kill	O
pathogens	O
efficiently	O
.	O

Dependent	O
on	O
the	O
pathogen	O
,	O
T	O
cells	O
differentiate	O
into	O
different	O
subtypes	O
,	O
such	O
as	O
Th1	O
or	O
Th2	O
cells	O
,	O
which	O
are	O
most	O
efficient	O
in	O
defeating	O
microbial	O
or	O
parasitic	O
invaders	O
respectively	O
.	O
<EOS>	B-X
Advances	B-X
and	B-X
Challenges	B-X
in	B-X
Understanding	B-X
Cerebral	B-X
Toxoplasmosis	B-X
.	B-X
Cytokines	B-X
are	B-X
key	B-X
mediators	B-X
of	B-X
immune	B-X
responses	B-X
to	B-X
autoantigens	B-X
,	B-X
tumor	B-X
antigens	B-X
and	B-X
foreign	B-X
antigens	B-X
including	B-X
pathogens	B-X
and	B-X
transplant	B-X
antigens	B-X
.	B-X
The	B-X
cytokines	B-X
are	B-X
produced	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
immune	B-X
and	B-X
non-immune	B-X
cells	B-X
and	B-X
are	B-X
dynamically	B-X
regulated	B-X
.	B-X
However	B-X
,	B-X
Leishmania	B-X
infection	B-X
is	B-X
a	B-X
chronic	B-X
parasitic	B-X
infection	B-X
with	B-X
alternate	B-X
outcomes-	B-X
healing	B-X
or	B-X
non-healing	B-X
.	B-X
The	B-X
operational	B-X
frameworks	B-X
for	B-X
different	B-X
cytokines	B-X
have	B-X
been	B-X
laid	B-X
to	B-X
discuss	B-X
how	B-X
these	B-X
immune	B-X
mediators	B-X
control	B-X
each	B-X
of	B-X
these	B-X
forms	B-X
of	B-X
leishmaniases	B-X
.	B-X
Macrophage	B-X
metabolism	B-X
is	B-X
linked	B-X
to	B-X
different	B-X
cytokines	B-X
and	B-X
is	B-X
thereby	B-X
associated	B-X
with	B-X
the	B-X
manifestation	B-X
of	B-X
the	B-X
resistance	B-X
or	B-X
susceptibility	B-X
to	B-X
Leishmania	B-X
infection	B-X
and	B-X
of	B-X
drug	B-X
resistance	B-X
.	B-X
The	B-X
chemokine-regulated	B-X
immune	B-X
cell	B-X
movements	B-X
present	B-X
the	B-X
landscape	B-X
of	B-X
infection	B-X
and	B-X
pathogenesis	B-X
.	B-X
T	B-X
cells	B-X
subsets-	B-X
the	B-X
IFN-γ-secreting	B-X
Ly6C	B-X
+	B-X
T	B-X
cells	B-X
and	B-X
the	B-X
regulatory	B-X
T	B-X
cell	B-X
subsets-	B-X
provide	B-X
the	B-X
initial	B-X
skewing	B-X
of	B-X
Th	B-X
cell	B-X
subset	B-X
and	B-X
regulation	B-X
of	B-X
effector	B-X
Th	B-X
subsets	B-X
,	B-X
respectively	B-X
,	B-X
eventually	B-X
deciding	B-X
the	B-X
outcome	B-X
of	B-X
infection	B-X
.	B-X

A	O
hallmark	O
of	O
Th1	O
and	O
Th2	O
differentiation	O
pathways	O
is	O
the	O
exclusiveness	O
of	O
the	O
individual	O
phenotype	O
leading	O
to	O
either	O
Th1	O
or	O
Th2	O
,	O
but	O
not	O
to	O
mixed	O
populations	O
.	O
<EOS>	B-X
For	B-X
over	B-X
35	B-X
years	B-X
since	B-X
Mosmann	B-X
and	B-X
Coffman	B-X
proposed	B-X
the	B-X
seminal	B-X
``	B-X
type	B-X
1	B-X
T	B-X
helper	B-X
(	B-X
Th1	B-X
)	B-X
/type	B-X
2	B-X
T	B-X
helper	B-X
(	B-X
Th2	B-X
)	B-X
''	B-X
hypothesis	B-X
in	B-X
1986	B-X
,	B-X
the	B-X
immunological	B-X
community	B-X
has	B-X
appreciated	B-X
that	B-X
naïve	B-X
CD4	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
make	B-X
important	B-X
decisions	B-X
upon	B-X
their	B-X
activation	B-X
,	B-X
namely	B-X
to	B-X
differentiate	B-X
towards	B-X
a	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
Th17	B-X
(	B-X
interleukin-17-producing	B-X
T	B-X
helper	B-X
)	B-X
,	B-X
follicular	B-X
T	B-X
helper	B-X
(	B-X
Tfh	B-X
)	B-X
,	B-X
or	B-X
regulatory	B-X
T	B-X
cell	B-X
(	B-X
Treg	B-X
)	B-X
fate	B-X
to	B-X
orchestrate	B-X
a	B-X
variety	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
The	B-X
major	B-X
molecular	B-X
underpinnings	B-X
of	B-X
the	B-X
Th1/Th2	B-X
effector	B-X
fate	B-X
choice	B-X
had	B-X
been	B-X
initially	B-X
characterized	B-X
using	B-X
excellent	B-X
reductionist	B-X
Systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
characterized	B-X
by	B-X
the	B-X
breakdown	B-X
of	B-X
immune	B-X
tolerance	B-X
leading	B-X
to	B-X
excessive	B-X
inflammation	B-X
and	B-X
tissue	B-X
damage	B-X
.	B-X
Deregulated	B-X
levels	B-X
of	B-X
T	B-X
helper	B-X
type	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
,	B-X
type	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
,	B-X
and	B-X
type	B-X
17	B-X
(	B-X
Th17	B-X
)	B-X
cytokines	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
autoimmune	B-X
inflammation	B-X
.	B-X
Growing	B-X
evidence	B-X
has	B-X
shown	B-X
deregulated	B-X
levels	B-X
of	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cytokines	B-X
in	B-X
SLE	B-X
patients	B-X
compared	B-X
to	B-X
healthy	B-X
controls	B-X
associated	B-X
with	B-X
disease	B-X
activity	B-X
and	B-X
severity	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
describe	B-X
and	B-X
discuss	B-X
the	B-X
levels	B-X
of	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cytokines	B-X
in	B-X
SLE	B-X
patients	B-X
,	B-X
and	B-X
clinical	B-X
trials	B-X
involving	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cytokines	B-X
in	B-X
SLE	B-X
patients	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
and	B-X
TGF-β1	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cytokines	B-X
are	B-X
increased	B-X
in	B-X
SLE	B-X
patients	B-X
associated	B-X
with	B-X
disease	B-X
severity	B-X
.	B-X

The	O
exclusiveness	O
of	O
this	O
mechanism	O
is	O
provided	O
by	O
a	O
polarization	O
process	O
,	O
where	O
Th2	O
differentiation	O
inhibits	O
Th1	O
commitment	O
and	O
vice	O
versa	O
.	O

Specifically	O
interleukin	B-Protein
4	I-Protein
(	O
IL	B-Protein
-	I-Protein
4	I-Protein
)	O
-	O
induced	O
STAT6	B-Protein
and	O
GATA3	B-Protein
inhibit	O
differentiation	O
into	O
Th1	O
cells	O
in	O
the	O
early	O
phase	O
of	O
commitment	O
[	O
1	O
,	O
2	O
]	O
.	O

GATA3	B-Protein
is	O
sufficient	O
to	O
induce	O
a	O
Th2	O
phenotype	O
[	O
3	O
]	O
and	O
acts	O
not	O
only	O
through	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
the	O
Th2	O
cytokines	O
,	O
but	O
also	O
through	O
the	O
inhibition	O
of	O
Th1	O
cell	O
-	O
specific	O
factors	O
[	O
3	O
]	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
T	B-Protein
-	I-Protein
bet	I-Protein
directly	O
modulates	O
GATA3	B-Protein
function	O
,	O
suggesting	O
that	O
transcription	O
factors	O
compete	O
in	O
the	O
early	O
differentiation	O
phase	O
of	O
T	O
cells	O
,	O
potentially	O
integrating	O
environmental	O
signals	O
to	O
finally	O
imprint	O
the	O
T	O
cell	O
phenotype	O
[	O
4	O
,	O
5	O
]	O
.	O

A	O
GATA3	B-Protein
-	O
dominated	O
immune	O
response	O
has	O
been	O
shown	O
to	O
be	O
essential	O
in	O
airway	O
hyperresonsiveness	O
[	O
6	O
]	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
dominated	O
responses	O
can	O
break	O
antigen	O
-	O
specific	O
immune	O
tolerance	O
[	O
7	O
]	O
.	O

Overexpression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
GATA3	B-Protein
[	O
8	O
]	O
or	O
treatment	O
with	O
antisense	O
-	O
mediated	O
GATA3	B-Protein
blockade	O
[	O
9	O
]	O
decreased	O
the	O
severity	O
of	O
the	O
allergic	O
airway	O
hyper	O
-	O
responsiveness	O
.	O
<EOS>	B-X
Although	B-X
previous	B-X
studies	B-X
suggest	B-X
that	B-X
TPH2	B-X
neuron-restrictive	B-X
silencer	B-X
element	B-X
(	B-X
NRSE	B-X
)	B-X
functions	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
dependent	B-X
on	B-X
neuron-restrictive	B-X
silencer	B-X
factor	B-X
(	B-X
NRSF	B-X
)	B-X
activity	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
yet	B-X
to	B-X
be	B-X
fully	B-X
elucidated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
a	B-X
detailed	B-X
analysis	B-X
of	B-X
the	B-X
NRSE-mediated	B-X
repression	B-X
of	B-X
the	B-X
human	B-X
TPH2	B-X
(	B-X
hTPH2	B-X
)	B-X
promoter	B-X
activity	B-X
in	B-X
RN46A	B-X
cells	B-X
,	B-X
a	B-X
cell	B-X
line	B-X
derived	B-X
from	B-X
rat	B-X
raphe	B-X
neurons	B-X
.	B-X
Tph1	B-X
mRNA	B-X
is	B-X
the	B-X
prevalent	B-X
form	B-X
expressed	B-X
in	B-X
RN46A	B-X
cells	B-X
;	B-X
Tph2	B-X
mRNA	B-X
is	B-X
also	B-X
expressed	B-X
but	B-X
at	B-X
a	B-X
lower	B-X
level	B-X
.	B-X
The	B-X
hTPH2	B-X
promoter	B-X
activity	B-X
was	B-X
increased	B-X
by	B-X
knockdown	B-X
of	B-X
NRSF	B-X
,	B-X
or	B-X
over-expression	B-X
of	B-X
the	B-X
engineered	B-X
NRSF	B-X
(	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
or	B-X
a	B-X
DNA-binding	B-X
domain	B-X
and	B-X
activation	B-X
domain	B-X
fusion	B-X
protein	B-X
)	B-X
.	B-X
MS-275	B-X
,	B-X
a	B-X
class	B-X
I	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitor	B-X
,	B-X
was	B-X
found	B-X
to	B-X
be	B-X
more	B-X
potent	B-X
than	B-X
MC-1568	B-X
,	B-X
a	B-X
class	B-X
II	B-X
HDAC	B-X
inhibitor	B-X
,	B-X
in	B-X
enhancing	B-X
the	B-X
hTPH2	B-X
promoter	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
with	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
7	B-X
deubiquitinase	B-X
inhibitors	B-X
,	B-X
P-22077	B-X
or	B-X
HBX	B-X
41108	B-X
,	B-X
increased	B-X
the	B-X
hTPH2	B-X
promoter	B-X
activity	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
hTPH2	B-X
NRSE-mediated	B-X
promoter	B-X
repression	B-X
via	B-X
NRSF	B-X
involves	B-X
class	B-X
I	B-X
HDACs	B-X
and	B-X
is	B-X
modulated	B-X
by	B-X
the	B-X
ubiquitin-specific	B-X
protease	B-X
7-mediated	B-X
deubiquitination	B-X
and	B-X
stabilization	B-X
of	B-X
NRSF	B-X
.	B-X

The	O
discovery	O
of	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
highlights	O
another	O
phenotype	O
of	O
T	O
cells	O
,	O
which	O
is	O
essential	O
for	O
tolerance	O
against	O
self	O
-	O
antigens	O
.	O

Naturally	O
occurring	O
,	O
thymus	O
-	O
derived	O
Treg	O
(	O
nTreg	O
)	O
cells	O
are	O
generated	O
in	O
the	O
thymus	O
and	O
are	O
assumed	O
to	O
protect	O
against	O
the	O
activity	O
of	O
autoreactive	O
T	O
cells	O
in	O
the	O
periphery	O
.	O

These	O
cells	O
express	O
the	O
forkhead	O
transcription	O
factor	O
FOXP3	B-Protein
and	O
constitutively	O
express	O
CD25	B-Protein
on	O
their	O
surface	O
,	O
but	O
they	O
lack	O
expression	O
of	O
Th1	O
or	O
Th2	O
cytokines	O
.	O
<EOS>	B-X
CD4	B-X
T	B-X
cells	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
mediating	B-X
adaptive	B-X
immunity	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
pathogens	B-X
.	B-X
During	B-X
TCR	B-X
activation	B-X
in	B-X
a	B-X
particular	B-X
cytokine	B-X
milieu	B-X
,	B-X
naive	B-X
CD4	B-X
T	B-X
cells	B-X
may	B-X
differentiate	B-X
into	B-X
one	B-X
of	B-X
several	B-X
lineages	B-X
of	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
cells	B-X
,	B-X
including	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
Th17	B-X
,	B-X
and	B-X
iTreg	B-X
,	B-X
as	B-X
defined	B-X
by	B-X
their	B-X
pattern	B-X
of	B-X
cytokine	B-X
production	B-X
and	B-X
function	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
discovery	B-X
,	B-X
functions	B-X
,	B-X
and	B-X
relationships	B-X
among	B-X
Th	B-X
cells	B-X
;	B-X
the	B-X
cytokine	B-X
and	B-X
signaling	B-X
requirements	B-X
for	B-X
their	B-X
development	B-X
;	B-X
the	B-X
networks	B-X
of	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
their	B-X
differentiation	B-X
;	B-X
the	B-X
epigenetic	B-X
regulation	B-X
of	B-X
their	B-X
key	B-X
cytokines	B-X
and	B-X
transcription	B-X
factors	B-X
;	B-X
and	B-X
human	B-X
diseases	B-X
involving	B-X
defective	B-X
CD4	B-X
T	B-X
cell	B-X
differentiation	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-18	B-X
,	B-X
structurally	B-X
similar	B-X
to	B-X
IL-1β	B-X
,	B-X
is	B-X
a	B-X
member	B-X
of	B-X
IL-1	B-X
superfamily	B-X
of	B-X
cytokines	B-X
.	B-X
This	B-X
cytokine	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
by	B-X
many	B-X
human	B-X
lymphoid	B-X
and	B-X
nonlymphoid	B-X
cells	B-X
,	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inflammatory	B-X
processes	B-X
.	B-X
The	B-X
main	B-X
function	B-X
of	B-X
IL-18	B-X
is	B-X
mediated	B-X
through	B-X
induction	B-X
of	B-X
interferon-γ	B-X
(	B-X
IFN-γ	B-X
)	B-X
secretion	B-X
from	B-X
T	B-X
helper	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
.	B-X
This	B-X
cytokine	B-X
synergistically	B-X
with	B-X
IL-12	B-X
contributes	B-X
to	B-X
Th1	B-X
differentiation	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
is	B-X
important	B-X
in	B-X
host	B-X
defense	B-X
mechanisms	B-X
against	B-X
intracellular	B-X
bacteria	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
fungi	B-X
.	B-X
Recent	B-X
evidences	B-X
showing	B-X
the	B-X
involvement	B-X
of	B-X
IL-18	B-X
in	B-X
Th2	B-X
differentiation	B-X
and	B-X
ultimately	B-X
IgE	B-X
production	B-X
from	B-X
B	B-X
cells	B-X
have	B-X
shed	B-X
a	B-X
new	B-X
insight	B-X
on	B-X
the	B-X
dual	B-X
effects	B-X
of	B-X
IL-18	B-X
on	B-X
Th1	B-X
and	B-X
Th2	B-X
inflammatory	B-X
responses	B-X
.	B-X
IL-18	B-X
in	B-X
combination	B-X
with	B-X
IL-12	B-X
can	B-X
activate	B-X
cytotoxic	B-X
T	B-X
cells	B-X
(	B-X
CTLs	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
,	B-X
to	B-X
produce	B-X
IFN-γ	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
tumor	B-X
immunity	B-X
.	B-X
The	B-X
biological	B-X
activity	B-X
of	B-X
IL-18	B-X
is	B-X
not	B-X
limited	B-X
to	B-X
these	B-X
cells	B-X
,	B-X
but	B-X
it	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
development	B-X
of	B-X
Th17	B-X
cell	B-X
responses	B-X
.	B-X
IL-18	B-X
synergistically	B-X
with	B-X
IL-23	B-X
can	B-X
induce	B-X
IL-17	B-X
secretion	B-X
from	B-X
Th17	B-X
cells	B-X
.	B-X
The	B-X
diverse	B-X
biological	B-X
activity	B-X
of	B-X
IL-18	B-X
on	B-X
T-cell	B-X
subsets	B-X
and	B-X
other	B-X
immune	B-X
cells	B-X
has	B-X
made	B-X
this	B-X
cytokine	B-X
a	B-X
good	B-X
target	B-X
for	B-X
investigating	B-X
its	B-X
role	B-X
in	B-X
various	B-X
inflammatory-based	B-X
diseases	B-X
.	B-X

Particularly	O
interesting	O
are	O
those	O
Treg	O
cells	O
that	O
are	O
generated	O
in	O
the	O
periphery	O
and	O
thus	O
are	O
potential	O
targets	O
for	O
therapeutic	O
interventions	O
.	O

These	O
induced	O
Treg	O
(	O
iTreg	O
)	O
cells	O
were	O
reported	O
to	O
express	O
FOXP3	B-Protein
[	O
10	O
]	O
.	O
<EOS>	B-X
These	B-X
microorganisms	B-X
,	B-X
including	B-X
the	B-X
Helicobacter	B-X
species	B-X
,	B-X
can	B-X
induce	B-X
pathogenic	B-X
T	B-X
cells	B-X
and	B-X
are	B-X
collectively	B-X
referred	B-X
to	B-X
as	B-X
pathobionts	B-X
.	B-X
However	B-X
,	B-X
how	B-X
such	B-X
T	B-X
cells	B-X
are	B-X
constrained	B-X
in	B-X
healthy	B-X
individuals	B-X
is	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
maintain	B-X
immune	B-X
homeostasis	B-X
and	B-X
prevent	B-X
autoimmune	B-X
disease	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
Treg	B-X
knowledge	B-X
relevant	B-X
to	B-X
type	B-X
1	B-X
diabetes	B-X
,	B-X
focusing	B-X
on	B-X
Treg	B-X
signature	B-X
,	B-X
antigen	B-X
specificity	B-X
and	B-X
development	B-X
and	B-X
function	B-X
in	B-X
the	B-X
face	B-X
of	B-X
inflammation	B-X
.	B-X

The	O
exact	O
mechanisms	O
of	O
iTreg	O
generation	O
are	O
unclear	O
,	O
but	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
triggering	O
has	O
been	O
shown	O
to	O
induce	O
FOXP3	B-Protein
expression	O
and	O
suppressive	O
cells	O
in	O
human	O
[	O
11	O
,	O
12	O
]	O
,	O
however	O
the	O
phenotype	O
appears	O
to	O
be	O
of	O
transient	O
nature	O
[	O
13	O
,	O
14	O
]	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
has	O
been	O
demonstrated	O
to	O
be	O
important	O
for	O
the	O
persistent	O
induction	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
since	O
animals	O
lacking	O
the	O
TGF	B-Protein
-	I-Protein
betaRII	I-Protein
on	O
T	O
cells	O
have	O
fewer	O
peripherally	O
iTreg	O
cells	O
[	O
15	O
]	O
and	O
suffer	O
from	O
a	O
T	O
cell	O
-	O
dependent	O
multiorgan	O
inflammatory	O
disease	O
[	O
16	O
]	O
.	O

Although	O
the	O
effect	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
on	O
natural	O
and	O
inducible	O
Treg	O
cell	O
induction	O
has	O
been	O
demonstrated	O
repeatedly	O
[	O
15	O
,	O
17	O
]	O
,	O
its	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
identified	O
.	O

The	O
current	O
study	O
provides	O
evidence	O
that	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
play	O
a	O
competitive	O
role	O
in	O
iTreg	O
cell	O
commitment	O
as	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
GATA3	B-Protein
for	O
Th1	O
and	O
Th2	O
differentiation	O
,	O
respectively	O
.	O

We	O
show	O
that	O
GATA3	B-Protein
inhibits	O
FOXP3	B-Protein
induction	O
and	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
limits	O
FOXP3	B-Protein
expression	O
in	O
a	O
GATA3	B-Protein
-	O
mediated	O
way	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
show	O
that	O
GATA3	B-Protein
directly	O
binds	O
to	O
the	O
FOXP3	B-Protein
promoter	O
and	O
thereby	O
prevents	O
the	O
induction	O
of	O
this	O
gene	O
,	O
demonstrating	O
that	O
Th2	O
differentiation	O
overrules	O
iTreg	O
induction	O
.	O

FOXP3	B-Protein
Induction	O
in	O
T	O
Cell	O
Subsets	O

It	O
is	O
assumed	O
that	O
FOXP3	B-Protein
expression	O
can	O
be	O
induced	O
in	O
nonregulatory	O
T	O
cells	O
,	O
which	O
is	O
an	O
important	O
step	O
in	O
iTreg	O
cell	O
differentiation	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
all	O
CD4	B-Protein
+	O
T	O
cells	O
have	O
the	O
same	O
capacity	O
to	O
express	O
FOXP3	B-Protein
.	O

To	O
investigate	O
whether	O
FOXP3	B-Protein
can	O
be	O
expressed	O
by	O
any	O
T	O
cell	O
subset	O
or	O
if	O
expression	O
is	O
restricted	O
to	O
a	O
distinct	O
lineage	O
,	O
FOXP3	B-Protein
mRNA	O
expression	O
was	O
analyzed	O
in	O
freshly	O
isolated	O
T	O
cells	O
such	O
as	O
CD25	B-Protein
-	O
depleted	O
CD4	B-Protein
+	O
cells	O
,	O
CD45RA	B-Protein
+	O
naive	O
or	O
CD45RO	B-Protein
+	O
memory	O
T	O
cells	O
(	O
Figure	O
1A	O
)	O
,	O
as	O
well	O
as	O
T	O
cells	O
driven	O
in	O
vitro	O
toward	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
phenotypes	O
(	O
Figure	O
1B	O
;	O
phenotype	O
on	O
Figure	O
S1	O
)	O
.	O
<EOS>	B-X
In	B-X
T	B-X
cells	B-X
,	B-X
mTOR	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
lineage	B-X
specification	B-X
,	B-X
including	B-X
development	B-X
of	B-X
regulatory	B-X
cells	B-X
(	B-X
Treg	B-X
cells	B-X
)	B-X
.	B-X
This	B-X
study	B-X
sought	B-X
to	B-X
investigate	B-X
whether	B-X
mTOR	B-X
is	B-X
activated	B-X
within	B-X
Treg	B-X
cells	B-X
and	B-X
whether	B-X
this	B-X
contributes	B-X
to	B-X
the	B-X
depletion	B-X
and	B-X
dysfunction	B-X
of	B-X
Treg	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
SLE	B-X
.	B-X
An	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
-induced	B-X
allergic	B-X
rhinitis	B-X
(	B-X
AR	B-X
)	B-X
mouse	B-X
model	B-X
was	B-X
established	B-X
to	B-X
investigate	B-X
whether	B-X
α-Lipoic	B-X
acid	B-X
(	B-X
LA	B-X
)	B-X
has	B-X
a	B-X
protective	B-X
effect	B-X
against	B-X
upper	B-X
respiratory	B-X
tract	B-X
inflammation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
it	B-X
showed	B-X
down-regulated	B-X
levels	B-X
of	B-X
the	B-X
Th17	B-X
cytokine	B-X
IL-17	B-X
and	B-X
the	B-X
Th17	B-X
transcription	B-X
factor	B-X
STAT3	B-X
,	B-X
and	B-X
RORγ	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
results	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
LA	B-X
could	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
agent	B-X
in	B-X
OVA-induced	B-X
AR	B-X
by	B-X
virtue	B-X
of	B-X
its	B-X
role	B-X
in	B-X
controlling	B-X
the	B-X
Th17/Treg	B-X
balance	B-X
and	B-X
enhancing	B-X
Nrf2/HO-1	B-X
pathway	B-X
signaling	B-X
.	B-X

The	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
,	O
CD45RA	B-Protein
+	O
,	O
CD45RO	B-Protein
+	O
,	O
and	O
CD4	B-Protein
+	O
CD45RO	B-Protein
+	O
CD25	B-Protein
-	O
were	O
able	O
to	O
significantly	O
induce	O
FOXP3	B-Protein
mRNA	O
up	O
to	O
30	O
-	O
fold	O
upon	O
TCR	O
activation	O
and	O
addition	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

Th1	O
cells	O
showed	O
only	O
a	O
10	O
-	O
fold	O
increase	O
.	O

In	O
contrast	O
,	O
Th2	O
cells	O
stimulated	O
under	O
the	O
same	O
conditions	O
did	O
not	O
increase	O
FOXP3	B-Protein
expression	O
.	O
<EOS>	B-X
Out	B-X
of	B-X
50	B-X
and	B-X
61	B-X
CD4+	B-X
TCC	B-X
derived	B-X
from	B-X
the	B-X
bronchial	B-X
mucosa	B-X
of	B-X
the	B-X
two	B-X
patient	B-X
with	B-X
atopic	B-X
asthma	B-X
11	B-X
(	B-X
22	B-X
%	B-X
)	B-X
and	B-X
19	B-X
(	B-X
31	B-X
%	B-X
)	B-X
,	B-X
respectively	B-X
,	B-X
showed	B-X
both	B-X
proliferation	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
response	B-X
to	B-X
grass	B-X
pollen	B-X
allergens	B-X
under	B-X
major	B-X
histocompatibility	B-X
complex-restricted	B-X
conditions	B-X
.	B-X
Of	B-X
these	B-X
21	B-X
(	B-X
70	B-X
%	B-X
)	B-X
exhibited	B-X
a	B-X
clear-cut	B-X
type	B-X
2	B-X
T	B-X
helper	B-X
(	B-X
Th2	B-X
)	B-X
profile	B-X
and	B-X
induced	B-X
IgE	B-X
synthesis	B-X
in	B-X
autologous	B-X
peripheral	B-X
blood	B-X
B	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
grass	B-X
allergens	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
TCC	B-X
,	B-X
derived	B-X
under	B-X
the	B-X
same	B-X
experimental	B-X
conditions	B-X
from	B-X
the	B-X
bronchial	B-X
mucosa	B-X
of	B-X
two	B-X
nonatopic	B-X
patients	B-X
with	B-X
toluene	B-X
diisocyanate-induced	B-X
asthma	B-X
,	B-X
were	B-X
CD8+	B-X
and	B-X
most	B-X
of	B-X
them	B-X
produced	B-X
interferon-gamma	B-X
or	B-X
interferon-gamma	B-X
and	B-X
interleukin-5	B-X
,	B-X
but	B-X
not	B-X
interleukin-4	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nonspecific	B-X
stimulation	B-X
.	B-X
Of	B-X
22	B-X
CD4+	B-X
TCC3	B-X
(	B-X
14	B-X
%	B-X
)	B-X
derived	B-X
from	B-X
the	B-X
grass-stimulated	B-X
mucosa	B-X
of	B-X
the	B-X
patient	B-X
with	B-X
allergic	B-X
rhinitis	B-X
,	B-X
but	B-X
none	B-X
of	B-X
those	B-X
derived	B-X
from	B-X
the	B-X
unstimulated	B-X
nostril	B-X
of	B-X
the	B-X
same	B-X
patient	B-X
,	B-X
exhibited	B-X
proliferation	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
response	B-X
to	B-X
grass	B-X
allergens	B-X
.	B-X
All	B-X
had	B-X
a	B-X
clear-cut	B-X
Th2	B-X
profile	B-X
and	B-X
provided	B-X
help	B-X
for	B-X
IgE	B-X
synthesis	B-X
by	B-X
autologous	B-X
B	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
inhalation	B-X
of	B-X
the	B-X
relevant	B-X
allergen	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
allergen-specific	B-X
Th2	B-X
lymphocytes	B-X
in	B-X
the	B-X
airway	B-X
mucosa	B-X
of	B-X
patients	B-X
with	B-X
allergic	B-X
respiratory	B-X
disorders	B-X
.	B-X
These	B-X
cells	B-X
may	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
the	B-X
airways	B-X
of	B-X
atopic	B-X
patients	B-X
.	B-X

The	O
in	O
vitro	O
generated	O
iTreg	O
cells	O
were	O
unable	O
to	O
further	O
up	O
-	O
regulate	O
FOXP3	B-Protein
,	O
which	O
was	O
already	O
at	O
high	O
levels	O
under	O
the	O
resting	O
conditions	O
(	O
Figure	O
1B	O
,	O
right	O
panel	O
)	O
.	O

Th2	O
cells	O
are	O
known	O
to	O
produce	O
IL	B-Protein
-	I-Protein
4	I-Protein
upon	O
activation	O
,	O
which	O
may	O
interact	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signaling	O
and	O
thus	O
prevent	O
FOXP3	B-Protein
induction	O
.	O

However	O
,	O
the	O
neutralization	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
with	O
a	O
blocking	O
IL	B-Protein
-	I-Protein
4	I-Protein
antibody	O
did	O
not	O
rescue	O
FOXP3	B-Protein
expression	O
in	O
the	O
differentiated	O
Th2	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O
<EOS>	B-X
Cancer	B-X
arises	B-X
from	B-X
malignant	B-X
cells	B-X
that	B-X
exist	B-X
in	B-X
dynamic	B-X
multilevel	B-X
interactions	B-X
with	B-X
the	B-X
host	B-X
tissue	B-X
.	B-X
Cancer	B-X
therapies	B-X
aiming	B-X
to	B-X
directly	B-X
kill	B-X
cancer	B-X
cells	B-X
,	B-X
including	B-X
oncogene-targeted	B-X
therapy	B-X
and	B-X
immune-checkpoint	B-X
therapy	B-X
that	B-X
revives	B-X
tumour-reactive	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
,	B-X
are	B-X
effective	B-X
in	B-X
some	B-X
patients	B-X
Passive	B-X
Prophylactic	B-X
Administration	B-X
with	B-X
a	B-X
Single	B-X
Dose	B-X
of	B-X
Anti-Fel	B-X
d	B-X
1	B-X
Monoclonal	B-X
Antibodies	B-X
REGN1908-1909	B-X
in	B-X
Cat	B-X
Allergen-induced	B-X
Allergic	B-X
Rhinitis	B-X
:	B-X
A	B-X
Randomized	B-X
,	B-X
Double-Blind	B-X
,	B-X
Placebo-controlled	B-X
Clinical	B-X
Trial	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
M2‑like	B-X
TAMs	B-X
in	B-X
ATC	B-X
remains	B-X
unclear	B-X
.	B-X
M2‑like	B-X
TAMs	B-X
were	B-X
induced	B-X
by	B-X
treatment	B-X
with	B-X
PMA	B-X
,	B-X
plus	B-X
IL‑4	B-X
and	B-X
IL‑13	B-X
,	B-X
and	B-X
identified	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Transwell	B-X
and	B-X
sphere	B-X
formation	B-X
assays	B-X
were	B-X
applied	B-X
to	B-X
assess	B-X
the	B-X
invasion	B-X
and	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
insulin‑like	B-X
growth	B-X
factor	B-X
(	B-X
IGF	B-X
)	B-X
‑1	B-X
and	B-X
IGF‑2	B-X
were	B-X
examined	B-X
by	B-X
ELISA	B-X
and	B-X
reverse	B-X
transcription‑quantitative	B-X
PCR	B-X
.	B-X
Immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
M2‑like	B-X
TAM	B-X
markers	B-X
CD68	B-X
and	B-X
CD206	B-X
in	B-X
ATC	B-X
tissues	B-X
and	B-X
thyroid	B-X
adenoma	B-X
tissues	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
treatment	B-X
with	B-X
PMA	B-X
plus	B-X
IL‑4	B-X
and	B-X
IL‑13	B-X
successfully	B-X
induced	B-X
M2‑like	B-X
TAMs	B-X
.	B-X
Following	B-X
co‑culture	B-X
with	B-X
M2‑like	B-X
TAMs	B-X
,	B-X
the	B-X
invasive	B-X
ability	B-X
and	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
were	B-X
significantly	B-X
increased	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
the	B-X
EMT‑related	B-X
markers	B-X
N‑cadherin	B-X
and	B-X
Vimentin	B-X
,	B-X
the	B-X
stemness‑related	B-X
markers	B-X
Oct4	B-X
,	B-X
Sox2	B-X
and	B-X
CD133	B-X
,	B-X
and	B-X
the	B-X
insulin	B-X
receptor	B-X
(	B-X
IR	B-X
)	B-X
‑A/IGF1	B-X
receptor	B-X
(	B-X
IGF1R	B-X
)	B-X
were	B-X
markedly	B-X
upregulated	B-X
,	B-X
whereas	B-X
E‑cadherin	B-X
expression	B-X
was	B-X
significantly	B-X
decreased	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
exogenous	B-X
IGF‑1/IGF‑2	B-X
promoted	B-X
the	B-X
invasion	B-X
and	B-X
stemness	B-X
of	B-X
C643	B-X
cells	B-X
,	B-X
whereas	B-X
blocking	B-X
IGF‑1	B-X
and	B-X
IGF‑2	B-X
inhibited	B-X
metastasis	B-X
and	B-X
stemness	B-X
by	B-X
repressing	B-X
IR‑A/IGF‑1R‑mediated	B-X
PI3K/AKT/mTOR	B-X
signalling	B-X
in	B-X
the	B-X
co‑culture	B-X
system	B-X
.	B-X
IHC	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CD68	B-X
and	B-X
CD206	B-X
was	B-X
obviously	B-X
increased	B-X
in	B-X
ATC	B-X
tissues	B-X
.	B-X
To	B-X
conclude	B-X
,	B-X
M2‑like	B-X
TAMs	B-X
accelerated	B-X
the	B-X
metastasis	B-X
and	B-X
increased	B-X
the	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
underlying	B-X
mechanism	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
section	B-X
of	B-X
IGF	B-X
by	B-X
M2‑like	B-X
TAMs	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
IR‑A/IGF1R‑mediated	B-X
PI3K/AKT/mTOR	B-X
signalling	B-X
pathway	B-X
.	B-X

These	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
a	O
limited	O
capacity	O
to	O
express	O
FOXP3	B-Protein
(	O
Figure	O
1B	O
)	O
.	O

The	O
inability	O
of	O
Th2	O
cells	O
to	O
express	O
FOXP3	B-Protein
was	O
also	O
documented	O
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
confirming	O
that	O
Th2	O
cells	O
lack	O
FOXP3	B-Protein
expression	O
(	O
Figure	O
2A	O
)	O
.	O

Only	O
iTreg	O
cells	O
expressed	O
FOXP3	B-Protein
in	O
resting	O
conditions	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
resting	O
iTreg	O
cells	O
express	O
FOXP3	B-Protein
but	O
show	O
low	O
CD25	B-Protein
surface	O
expression	O
.	O

Repeated	O
exposure	O
to	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
did	O
not	O
further	O
increase	O
the	O
FOXP3	B-Protein
expression	O
in	O
the	O
iTreg	O
lineage	O
but	O
transiently	O
induced	O
FOXP3	B-Protein
expression	O
in	O
Th1	O
cells	O
.	O
<EOS>	B-X
Microglia	B-X
are	B-X
the	B-X
predominant	B-X
immune	B-X
cells	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
that	B-X
exert	B-X
key	B-X
physiological	B-X
roles	B-X
required	B-X
for	B-X
maintaining	B-X
CNS	B-X
homeostasis	B-X
,	B-X
notably	B-X
in	B-X
response	B-X
to	B-X
chronic	B-X
stress	B-X
,	B-X
as	B-X
well	B-X
as	B-X
mediating	B-X
synaptic	B-X
plasticity	B-X
,	B-X
learning	B-X
and	B-X
memory	B-X
.	B-X
The	B-X
repeated	B-X
exposure	B-X
to	B-X
stress	B-X
confers	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
developing	B-X
neurodegenerative	B-X
diseases	B-X
including	B-X
sporadic	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
While	B-X
microglia	B-X
have	B-X
been	B-X
causally	B-X
linked	B-X
to	B-X
amyloid	B-X
beta	B-X
(	B-X
Aβ	B-X
)	B-X
accumulation	B-X
,	B-X
tau	B-X
pathology	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
synaptic	B-X
loss	B-X
in	B-X
AD	B-X
,	B-X
they	B-X
were	B-X
also	B-X
attributed	B-X
beneficial	B-X
roles	B-X
,	B-X
notably	B-X
in	B-X
the	B-X
phagocytic	B-X
elimination	B-X
of	B-X
Aβ	B-X
.	B-X
CAFs	B-X
promote	B-X
cancer	B-X
cell	B-X
differentiation	B-X
and	B-X
invasion	B-X
by	B-X
releasing	B-X
various	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
growth	B-X
factors	B-X
,	B-X
chemokines	B-X
,	B-X
and	B-X
matrix-degrading	B-X
proteases	B-X
,	B-X
into	B-X
neighboring	B-X
tumor	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
microenvironment	B-X
in	B-X
case	B-X
of	B-X
radiation-induced	B-X
carcinogenesis	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
We	B-X
recently	B-X
revealed	B-X
that	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
causes	B-X
tumor	B-X
microenvironment	B-X
formation	B-X
associated	B-X
with	B-X
radiation-induced	B-X
cancer	B-X
.	B-X
Repeated	B-X
low-dose	B-X
fractionated	B-X
radiation	B-X
progressively	B-X
damages	B-X
fibroblast	B-X
mitochondria	B-X
and	B-X
elevates	B-X
mitochondrial	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
levels	B-X
.	B-X
Excessive	B-X
mitochondrial	B-X
ROS	B-X
activate	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-β	B-X
)	B-X
signaling	B-X
,	B-X
thereby	B-X
inducing	B-X
fibroblasts	B-X
activation	B-X
and	B-X
facilitating	B-X
tumor	B-X
microenvironment	B-X
formation	B-X
.	B-X
Consequently	B-X
,	B-X
radiation	B-X
affects	B-X
malignant	B-X
cancer	B-X
cells	B-X
directly	B-X
and	B-X
indirectly	B-X
via	B-X
molecular	B-X
alterations	B-X
in	B-X
stromal	B-X
fibroblasts	B-X
,	B-X
such	B-X
as	B-X
the	B-X
activation	B-X
of	B-X
TGF-β	B-X
and	B-X
angiogenic	B-X
signaling	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
for	B-X
the	B-X
first	B-X
time	B-X
the	B-X
roles	B-X
of	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
in	B-X
microenvironment	B-X
formation	B-X
associated	B-X
with	B-X
radiation-induced	B-X
cancer	B-X
.	B-X
This	B-X
review	B-X
may	B-X
help	B-X
us	B-X
understand	B-X
the	B-X
risks	B-X
of	B-X
exposure	B-X
to	B-X
low-dose	B-X
radiation	B-X
.	B-X
The	B-X
cross	B-X
talk	B-X
between	B-X
cancer	B-X
cells	B-X
and	B-X
stromal	B-X
fibroblasts	B-X
contributes	B-X
to	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
radiation-induced	B-X
cancer	B-X
.	B-X

Naturally	O
occurring	O
Th2	O
cells	O
such	O
as	O
CRTH2	B-Protein
+	O
T	O
cells	O
,	O
T	O
cells	O
isolated	O
according	O
to	O
their	O
IL	B-Protein
-	I-Protein
4	I-Protein
secretion	O
,	O
or	O
an	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
producing	O
T	O
cell	O
clone	O
(	O
BR8	O
)	O
were	O
also	O
lacking	O
FOXP3	B-Protein
expression	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
FOXP3	B-Protein
induction	O
failed	O
in	O
these	O
cells	O
in	O
contrast	O
to	O
the	O
naive	O
T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O

Because	O
IL	B-Protein
-	I-Protein
4	I-Protein
is	O
the	O
key	O
Th2	O
cytokine	O
,	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
FOXP3	B-Protein
in	O
freshly	O
isolated	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
analyzed	O
by	O
fluorescence	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
-	O
expressing	O
cells	O
were	O
most	O
abundant	O
among	O
CD45RO	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
,	O
which	O
did	O
not	O
co	O
-	O
express	O
FOXP3	B-Protein
(	O
Figure	O
3A	O
,	O
left	O
panel	O
)	O
.	O
<EOS>	B-X
Radiation-attenuated	B-X
(	B-X
RA	B-X
)	B-X
schistosomes	B-X
penetrate	B-X
the	B-X
host	B-X
via	B-X
the	B-X
skin	B-X
where	B-X
they	B-X
stimulate	B-X
intense	B-X
inflammatory	B-X
reactions	B-X
and	B-X
the	B-X
release	B-X
of	B-X
pro-inflammatory	B-X
IL-12	B-X
,	B-X
important	B-X
for	B-X
T	B-X
(	B-X
h	B-X
)	B-X
1-type	B-X
immune	B-X
responses	B-X
which	B-X
are	B-X
partially	B-X
host	B-X
protective	B-X
.	B-X
However	B-X
,	B-X
RA	B-X
larvae	B-X
also	B-X
induce	B-X
the	B-X
secretion	B-X
of	B-X
regulatory	B-X
IL-10	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
following	B-X
vaccination	B-X
of	B-X
IL-12p40	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
abundant	B-X
IL-10	B-X
was	B-X
produced	B-X
by	B-X
in	B-X
vitro	B-X
cultured	B-X
skin	B-X
biopsies	B-X
between	B-X
days	B-X
4	B-X
and	B-X
14	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
down-regulation	B-X
of	B-X
MHC	B-X
II	B-X
expression	B-X
by	B-X
cells	B-X
in	B-X
the	B-X
dermis	B-X
and	B-X
cells	B-X
that	B-X
emigrate	B-X
from	B-X
the	B-X
skin	B-X
.	B-X
In	B-X
IL-10	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
inflammation	B-X
of	B-X
the	B-X
vaccination	B-X
site	B-X
was	B-X
increased	B-X
with	B-X
larger	B-X
numbers	B-X
of	B-X
IL-12p40	B-X
(	B-X
+	B-X
)	B-X
,	B-X
MHC	B-X
II	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD86	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
in	B-X
the	B-X
dermal	B-X
exudate	B-X
,	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
elevated	B-X
levels	B-X
of	B-X
skin-derived	B-X
IL-12p40	B-X
and	B-X
IL-1beta	B-X
.	B-X
These	B-X
changes	B-X
in	B-X
IL-10	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
were	B-X
also	B-X
reflected	B-X
by	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
skin-draining	B-X
lymph	B-X
nodes	B-X
(	B-X
sdLN	B-X
)	B-X
and	B-X
greater	B-X
levels	B-X
of	B-X
lymphocyte	B-X
proliferation	B-X
.	B-X
Moreover	B-X
,	B-X
such	B-X
mice	B-X
had	B-X
increased	B-X
numbers	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
sdLN	B-X
cells	B-X
that	B-X
were	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD28	B-X
(	B-X
+	B-X
)	B-X
or	B-X
CD152	B-X
(	B-X
+	B-X
)	B-X
and	B-X
accessory	B-X
cells	B-X
that	B-X
were	B-X
CD40	B-X
(	B-X
+	B-X
)	B-X
or	B-X
MHC	B-X
II	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
secretion	B-X
of	B-X
IFN-gamma	B-X
(	B-X
and	B-X
IL-12p40	B-X
)	B-X
by	B-X
in	B-X
vitro	B-X
cultured	B-X
sdLN	B-X
cells	B-X
was	B-X
substantially	B-X
raised	B-X
in	B-X
IL-10	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
but	B-X
much	B-X
reduced	B-X
in	B-X
IL-12p40	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
development	B-X
of	B-X
highly	B-X
polarized	B-X
T	B-X
(	B-X
h	B-X
)	B-X
1	B-X
and	B-X
T	B-X
(	B-X
h	B-X
)	B-X
2	B-X
cytokine	B-X
profiles	B-X
in	B-X
the	B-X
two	B-X
groups	B-X
of	B-X
mice	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
IL-10	B-X
has	B-X
an	B-X
important	B-X
role	B-X
early	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-12-mediated	B-X
priming	B-X
of	B-X
acquired	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
effectively	B-X
contains	B-X
excessive	B-X
dermal	B-X
inflammation	B-X
and	B-X
prevents	B-X
the	B-X
development	B-X
of	B-X
highly	B-X
polarized	B-X
T	B-X
(	B-X
h	B-X
)	B-X
1-type	B-X
responses	B-X
.	B-X

In	O
contrast	O
,	O
CD45RO	B-Protein
+	O
CD25	B-Protein
+	O
cells	O
abundantly	O
expressed	O
FOXP3	B-Protein
,	O
while	O
lacking	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
Figure	O
3A	O
,	O
right	O
panel	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
frequency	O
of	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
+	O
cells	O
was	O
always	O
below	O
1	O
%	O
in	O
the	O
FOXP3	B-Protein
+	O
cells	O
close	O
to	O
the	O
background	O
.	O

The	O
IL	B-Protein
-	I-Protein
4	I-Protein
+	O
cells	O
were	O
confined	O
to	O
the	O
FOXP3	B-Protein
-	O
cells	O
,	O
as	O
shown	O
for	O
the	O
CD45RO	B-Protein
+	O
CD25	B-Protein
-	O
,	O
CD45RO	B-Protein
+	O
CD25	B-Protein
+	O
,	O
and	O
CD45RO	B-Protein
+	O
CD25	B-Protein
+	O
high	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

In	O
addition	O
,	O
neither	O
the	O
Th2	O
clone	O
(	O
BR8	O
)	O
nor	O
CRTH2	B-Protein
cells	O
significantly	O
expressed	O
FOXP3	B-Protein
(	O
Figure	O
3C	O
)	O
.	O

Cells	O
enriched	O
for	O
their	O
IL	B-Protein
-	I-Protein
4	I-Protein
secretion	O
using	O
the	O
magnetic	O
cell	O
isolation	O
technology	O
contained	O
some	O
FOXP3	B-Protein
-	O
expressing	O
cells	O
,	O
but	O
importantly	O
,	O
the	O
expression	O
did	O
not	O
overlap	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
FOXP3	B-Protein
was	O
not	O
expressed	O
by	O
Th2	O
cells	O
and	O
was	O
not	O
inducible	O
in	O
those	O
cells	O
.	O

FOXP3	B-Protein
and	O
GATA3	B-Protein
Kinetics	O
in	O
Differentiating	O
Cells	O
<EOS>	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

The	O
limited	O
capacity	O
of	O
differentiated	O
effector	O
cells	O
to	O
induce	O
FOXP3	B-Protein
expression	O
suggests	O
that	O
iTreg	O
induction	O
has	O
to	O
occur	O
before	O
effector	O
T	O
cell	O
differentiation	O
occurs	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
FOXP3	B-Protein
and	O
GATA3	B-Protein
during	O
the	O
differentiation	O
of	O
naive	O
CD4	B-Protein
T	O
cells	O
into	O
Th0	O
(	O
neutral	O
,	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
anti	O
IL	B-Protein
-	I-Protein
12	I-Protein
)	O
,	O
Th2	O
,	O
and	O
iTreg	O
phenotypes	O
.	O

After	O
initiation	O
of	O
the	O
differentiation	O
process	O
,	O
FOXP3	B-Protein
and	O
GATA3	B-Protein
showed	O
a	O
similar	O
expression	O
kinetic	O
within	O
the	O
first	O
3	O
d	O
,	O
which	O
are	O
considered	O
to	O
be	O
critical	O
in	O
T	O
cell	O
commitment	O
[	O
18	O
]	O
.	O

Under	O
Th2	O
differentiation	O
conditions	O
,	O
FOXP3	B-Protein
mRNA	O
expression	O
increased	O
only	O
marginally	O
(	O
Figure	O
4A	O
,	O
left	O
panel	O
)	O
.	O

Thus	O
,	O
although	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
showed	O
similar	O
kinetics	O
,	O
their	O
expression	O
polarizes	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
when	O
cells	O
were	O
cultured	O
towards	O
Th2	O
or	O
iTreg	O
cells	O
,	O
respectively	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Interestingly	O
,	O
the	O
Th0	O
cells	O
were	O
expressing	O
more	O
FOXP3	B-Protein
than	O
the	O
Th2	O
cells	O
,	O
but	O
expressed	O
low	O
levels	O
of	O
GATA3	B-Protein
;	O
however	O
,	O
the	O
protein	O
expression	O
slightly	O
differed	O
from	O
mRNA	O
expression	O
,	O
suggesting	O
also	O
posttranslational	O
regulation	O
and	O
degradation	O
as	O
potential	O
additional	O
mechanisms	O
in	O
the	O
differentiation	O
process	O
.	O

The	O
phenotype	O
of	O
iTreg	O
cells	O
included	O
an	O
anergic	O
phenotype	O
upon	O
anti	O
-	O
CD3	B-Protein
re	O
-	O
stimulation	O
(	O
Figure	O
S1A	O
)	O
,	O
CD103	B-Protein
,	O
CTLA	B-Protein
-	I-Protein
4	I-Protein
,	O
GITR	B-Protein
,	O
and	O
PD	B-Protein
-	I-Protein
1	I-Protein
surface	O
expression	O
(	O
Figure	O
S1B	O
)	O
.	O

On	O
the	O
single	O
-	O
cell	O
level	O
,	O
it	O
can	O
be	O
seen	O
that	O
cells	O
progress	O
through	O
a	O
transition	O
phase	O
,	O
where	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
expression	O
coexist	O
to	O
some	O
degree	O
in	O
the	O
same	O
cells	O
,	O
which	O
is	O
resolved	O
in	O
iTreg	O
cells	O
after	O
7	O
d	O
(	O
Figure	O
4B	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
Th2	O
cells	O
have	O
lost	O
their	O
capacity	O
to	O
express	O
FOXP3	B-Protein
and	O
showed	O
that	O
Th2	O
and	O
iTreg	O
cells	O
arise	O
from	O
two	O
different	O
differentiation	O
pathways	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
Inhibits	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
Mediated	O
iTreg	O
Commitment	O
<EOS>	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
induces	O
differentiation	O
of	O
naive	O
T	O
cells	O
,	O
upon	O
antigen	O
encounter	O
,	O
into	O
the	O
Th2	O
cell	O
lineage	O
.	O
<EOS>	B-X
Naive	B-X
CD4	B-X
T	B-X
cells	B-X
differentiate	B-X
into	B-X
functionally	B-X
distinct	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
cells	B-X
subsets	B-X
or	B-X
into	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
the	B-X
cytokine	B-X
milieu	B-X
in	B-X
which	B-X
they	B-X
encounter	B-X
antigen	B-X
.	B-X
A	B-X
recurring	B-X
theme	B-X
in	B-X
post-thymic	B-X
CD4	B-X
T	B-X
cell	B-X
differentiation	B-X
is	B-X
the	B-X
cross-regulation	B-X
of	B-X
lineage	B-X
choice	B-X
by	B-X
cytokines	B-X
and	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
alternative	B-X
lineages	B-X
.	B-X
For	B-X
example	B-X
,	B-X
TGFbeta	B-X
induces	B-X
the	B-X
de	B-X
novo	B-X
expression	B-X
of	B-X
the	B-X
Treg	B-X
cell	B-X
signature	B-X
transcription	B-X
factor	B-X
Foxp3	B-X
,	B-X
but	B-X
iTreg	B-X
differentiation	B-X
is	B-X
blocked	B-X
by	B-X
high	B-X
concentrations	B-X
of	B-X
the	B-X
Th2	B-X
cytokine	B-X
IL4	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
IL4	B-X
can	B-X
antagonise	B-X
Foxp3	B-X
induction	B-X
in	B-X
more	B-X
physiological	B-X
settings	B-X
remains	B-X
to	B-X
be	B-X
addressed	B-X
.	B-X
Here	B-X
we	B-X
use	B-X
a	B-X
co-culture	B-X
system	B-X
to	B-X
demonstrate	B-X
that	B-X
IL4	B-X
provided	B-X
by	B-X
Th2	B-X
cells	B-X
in	B-X
vitro	B-X
is	B-X
sufficient	B-X
to	B-X
block	B-X
Foxp3	B-X
induction	B-X
in	B-X
naive	B-X
CD4	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
Foxp3	B-X
induction	B-X
is	B-X
efficiently	B-X
blocked	B-X
not	B-X
only	B-X
by	B-X
the	B-X
Th2	B-X
transcription	B-X
factor	B-X
Gata3	B-X
,	B-X
but	B-X
also	B-X
by	B-X
PU.1	B-X
,	B-X
which	B-X
is	B-X
transiently	B-X
induced	B-X
during	B-X
Th2	B-X
differentiation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
iTreg	B-X
differentiation	B-X
may	B-X
be	B-X
affected	B-X
by	B-X
the	B-X
polarity	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

We	O
therefore	O
asked	O
whether	O
IL	B-Protein
-	I-Protein
4	I-Protein
is	O
able	O
to	O
inhibit	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
induction	O
of	O
FOXP3	B-Protein
during	O
the	O
priming	O
of	O
naive	O
T	O
cells	O
.	O

Human	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
in	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
/	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
harvested	O
after	O
5	O
d	O
.	O
<EOS>	B-X
Asthma	B-X
is	B-X
an	B-X
inflammatory	B-X
disease	B-X
caused	B-X
by	B-X
an	B-X
imbalance	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
.	B-X
2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside	B-X
(	B-X
TSG	B-X
)	B-X
,	B-X
the	B-X
main	B-X
compound	B-X
of	B-X
Agents	B-X
that	B-X
destroy	B-X
tumor	B-X
cells	B-X
and	B-X
simultaneously	B-X
boost	B-X
host	B-X
anti-tumor	B-X
immunity	B-X
are	B-X
of	B-X
keen	B-X
interest	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
carnosol	B-X
on	B-X
anti-tumor	B-X
immunity	B-X
in	B-X
a	B-X
Balb/c	B-X
mouse	B-X
model	B-X
of	B-X
fibrosarcoma	B-X
was	B-X
evaluated	B-X
.	B-X
Carnosol	B-X
was	B-X
administered	B-X
intraperitoneally	B-X
daily	B-X
(	B-X
at	B-X
5	B-X
or	B-X
10	B-X
mg/kg/day	B-X
,	B-X
for	B-X
7	B-X
days	B-X
)	B-X
to	B-X
tumor-bearing	B-X
mice	B-X
(	B-X
i.e	B-X
.	B-X
7	B-X
days	B-X
after	B-X
initial	B-X
injection	B-X
of	B-X
tumor	B-X
cells	B-X
)	B-X
.	B-X
Day	B-X
7	B-X
)	B-X
,	B-X
the	B-X
mice	B-X
had	B-X
their	B-X
tumors	B-X
measured	B-X
and	B-X
then	B-X
were	B-X
euthanized	B-X
to	B-X
permit	B-X
their	B-X
spleen	B-X
and	B-X
tumor	B-X
to	B-X
be	B-X
harvested	B-X
for	B-X
isolation	B-X
of	B-X
,	B-X
respectively	B-X
,	B-X
splenocytes	B-X
and	B-X
tumor-associated	B-X
lymphocytes	B-X
.	B-X
Using	B-X
these	B-X
materials	B-X
,	B-X
spontaneous	B-X
and	B-X
mitogen-induced	B-X
release	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
,	B-X
lymphocyte	B-X
proliferation	B-X
,	B-X
and	B-X
the	B-X
absolute	B-X
numbers/relative	B-X
percentages	B-X
of	B-X
splenic	B-X
and	B-X
tumor-associated	B-X
T-regulatory	B-X
(	B-X
Treg	B-X
)	B-X
and	B-X
other	B-X
T-lymphocyte	B-X
sub-sets	B-X
were	B-X
evaluated	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
carnosol	B-X
at	B-X
both	B-X
doses	B-X
significantly	B-X
suppressed	B-X
tumor	B-X
growth	B-X
and	B-X
caused	B-X
depletion	B-X
of	B-X
splenic	B-X
and	B-X
tumor-associated	B-X
Treg	B-X
cells	B-X
.	B-X
It	B-X
also	B-X
caused	B-X
relative	B-X
(	B-X
vs	B-X
control	B-X
mouse	B-X
cell	B-X
values	B-X
)	B-X
decreases	B-X
in	B-X
splenocyte	B-X
spontaneous/inducible	B-X
production	B-X
of	B-X
IL-4	B-X
and	B-X
IL-10	B-X
and	B-X
increases	B-X
in	B-X
IFNγ	B-X
and	B-X
cell	B-X
proliferation	B-X
.	B-X
Carnosol	B-X
at	B-X
either	B-X
dose	B-X
did	B-X
not	B-X
cause	B-X
changes	B-X
in	B-X
the	B-X
percentages	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
or	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
in	B-X
the	B-X
spleen	B-X
or	B-X
in	B-X
tumor-associated	B-X
lymphocyte	B-X
populations	B-X
.	B-X
The	B-X
observed	B-X
increases	B-X
in	B-X
IFNγ	B-X
,	B-X
decreases	B-X
in	B-X
IL-10	B-X
and	B-X
IL-4	B-X
production	B-X
,	B-X
and	B-X
reductions	B-X
in	B-X
splenic/tumor-associated	B-X
Treg	B-X
cell	B-X
levels	B-X
might	B-X
be	B-X
signs	B-X
reflecting	B-X
the	B-X
potential	B-X
anti-tumor	B-X
activity	B-X
of	B-X
carnosol	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
findings	B-X
here	B-X
,	B-X
it	B-X
is	B-X
asserted	B-X
that	B-X
carnosol	B-X
is	B-X
a	B-X
likely	B-X
candidate	B-X
-	B-X
after	B-X
more	B-X
complete	B-X
toxicologic	B-X
evaluation	B-X
-	B-X
for	B-X
eventual	B-X
use	B-X
as	B-X
an	B-X
anti-cancer	B-X
therapeutic	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
efficiently	O
repressed	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
induction	O
of	O
FOXP3	B-Protein
expression	O
(	O
Figure	O
5A	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
5B	O
)	O
.	O

Low	O
levels	O
of	O
GATA3	B-Protein
were	O
induced	O
also	O
in	O
the	O
absence	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
as	O
it	O
was	O
previously	O
observed	O
[	O
3	O
]	O
.	O

However	O
,	O
at	O
low	O
concentration	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
was	O
able	O
to	O
marginally	O
induce	O
FOXP3	B-Protein
expression	O
.	O

Of	O
note	O
,	O
GATA3	B-Protein
was	O
also	O
induced	O
in	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
at	O
high	O
IL	B-Protein
-	I-Protein
4	I-Protein
concentration	O
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

The	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
mediated	O
prevention	O
of	O
FOXP3	B-Protein
expression	O
was	O
not	O
caused	O
by	O
interferences	O
of	O
the	O
receptor	O
signaling	O
,	O
because	O
the	O
phosphorylation	O
of	O
SMAD2	B-Protein
or	O
STAT6	B-Protein
was	O
not	O
affected	O
by	O
the	O
addition	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
/	O
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
which	O
demonstrates	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
well	O
as	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signaling	O
were	O
functional	O
under	O
these	O
conditions	O
(	O
Figure	O
5C	O
)	O
.	O
<EOS>	B-X
The	B-X
M2	B-X
phenotype	B-X
is	B-X
controlled	B-X
by	B-X
key	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
6	B-X
(	B-X
STAT6	B-X
)	B-X
,	B-X
which	B-X
have	B-X
been	B-X
``	B-X
undruggable	B-X
''	B-X
selectively	B-X
in	B-X
TAMs	B-X
.	B-X
We	B-X
describe	B-X
an	B-X
engineered	B-X
exosome	B-X
therapeutic	B-X
candidate	B-X
delivering	B-X
an	B-X
antisense	B-X
oligonucleotide	B-X
(	B-X
ASO	B-X
)	B-X
targeting	B-X
STAT6	B-X
(	B-X
exoASO-STAT6	B-X
)	B-X
,	B-X
which	B-X
selectively	B-X
silences	B-X
STAT6	B-X
expression	B-X
in	B-X
TAMs	B-X
.	B-X
In	B-X
syngeneic	B-X
models	B-X
of	B-X
colorectal	B-X
cancer	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
,	B-X
exoASO-STAT6	B-X
monotherapy	B-X
results	B-X
in	B-X
>	B-X
90	B-X
%	B-X
tumor	B-X
growth	B-X
inhibition	B-X
and	B-X
50	B-X
to	B-X
80	B-X
%	B-X
complete	B-X
remissions	B-X
.	B-X
Administration	B-X
of	B-X
exoASO-STAT6	B-X
leads	B-X
to	B-X
induction	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
2	B-X
(	B-X

Increasing	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
increase	O
intracellular	O
GATA3	B-Protein
,	O
whereas	O
FOXP3	B-Protein
decreased	O
,	O
which	O
is	O
consistent	O
with	O
the	O
mRNA	O
analysis	O
(	O
Figure	O
5D	O
)	O
.	O

Furthermore	O
,	O
injection	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
into	O
wild	O
-	O
type	O
B6	O
mice	O
decreased	O
the	O
inducible	O
or	O
natural	O
Treg	O
number	O
in	O
vivo	O
.	O
<EOS>	B-X
Gut	B-X
commensal	B-X
microbes	B-X
shape	B-X
the	B-X
mucosal	B-X
immune	B-X
system	B-X
by	B-X
regulating	B-X
the	B-X
differentiation	B-X
and	B-X
expansion	B-X
of	B-X
several	B-X
types	B-X
of	B-X
T	B-X
cell	B-X
.	B-X
Clostridia	B-X
,	B-X
a	B-X
dominant	B-X
class	B-X
of	B-X
commensal	B-X
microbe	B-X
,	B-X
can	B-X
induce	B-X
colonic	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
have	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
of	B-X
inflammatory	B-X
and	B-X
allergic	B-X
responses	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
commensal	B-X
microbes	B-X
induce	B-X
colonic	B-X
Treg	B-X
cells	B-X
have	B-X
been	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
a	B-X
large	B-X
bowel	B-X
microbial	B-X
fermentation	B-X
product	B-X
,	B-X
butyrate	B-X
,	B-X
induces	B-X
the	B-X
differentiation	B-X
of	B-X
colonic	B-X
Treg	B-X
cells	B-X
in	B-X
mice	B-X
.	B-X
A	B-X
comparative	B-X
NMR-based	B-X
metabolome	B-X
analysis	B-X
suggests	B-X
that	B-X
the	B-X
luminal	B-X
concentrations	B-X
of	B-X
short-chain	B-X
fatty	B-X
acids	B-X
positively	B-X
correlates	B-X
with	B-X
the	B-X
number	B-X
of	B-X
Treg	B-X
cells	B-X
in	B-X
the	B-X
colon	B-X
.	B-X
Among	B-X
short-chain	B-X
fatty	B-X
acids	B-X
,	B-X
butyrate	B-X
induced	B-X
the	B-X
differentiation	B-X
of	B-X
Treg	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
ameliorated	B-X
the	B-X
development	B-X
of	B-X
colitis	B-X
induced	B-X
by	B-X
adoptive	B-X
transfer	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD45RB	B-X
(	B-X
hi	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
Rag1	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Treatment	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
under	B-X
the	B-X
Treg-cell-polarizing	B-X
conditions	B-X
with	B-X
butyrate	B-X
enhanced	B-X
histone	B-X
H3	B-X
acetylation	B-X
in	B-X
the	B-X
promoter	B-X
and	B-X
conserved	B-X
non-coding	B-X
sequence	B-X
regions	B-X
of	B-X
the	B-X
Foxp3	B-X
locus	B-X
,	B-X
suggesting	B-X
a	B-X
possible	B-X
mechanism	B-X
for	B-X
how	B-X
microbial-derived	B-X
butyrate	B-X
regulates	B-X
the	B-X
differentiation	B-X
of	B-X
Treg	B-X
cells	B-X
.	B-X

A	O
distinction	O
of	O
the	O
Treg	O
subsets	O
is	O
not	O
possible	O
,	O
because	O
recently	O
activated	O
iTreg	O
cells	O
also	O
express	O
surface	O
CD25	B-Protein
.	O
<EOS>	B-X
As	B-X
the	B-X
professional	B-X
antigen-presenting	B-X
cells	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
sense	B-X
the	B-X
microenvironment	B-X
and	B-X
shape	B-X
the	B-X
ensuing	B-X
adaptive	B-X
immune	B-X
response	B-X
.	B-X
Recent	B-X
work	B-X
has	B-X
established	B-X
that	B-X
DCs	B-X
comprise	B-X
several	B-X
phenotypically	B-X
and	B-X
functionally	B-X
heterogeneous	B-X
subsets	B-X
that	B-X
differentially	B-X
regulate	B-X
T	B-X
lymphocyte	B-X
differentiation	B-X
.	B-X
We	B-X
focus	B-X
on	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
how	B-X
different	B-X
DC	B-X
subsets	B-X
regulate	B-X
distinct	B-X
CD4	B-X
Although	B-X
the	B-X
roles	B-X
of	B-X
macrophages	B-X
in	B-X
fibrogenesis	B-X
have	B-X
been	B-X
studied	B-X
for	B-X
many	B-X
years	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
concerning	B-X
the	B-X
manner	B-X
in	B-X
which	B-X
T	B-X
cells	B-X
regulate	B-X
fibrosis	B-X
are	B-X
not	B-X
completely	B-X
understood	B-X
.	B-X
The	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
engages	B-X
the	B-X
antigen	B-X
and	B-X
shapes	B-X
the	B-X
repertoire	B-X
of	B-X
antigen-specific	B-X
T	B-X
cells	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
divergent	B-X
expression	B-X
of	B-X
surface	B-X
molecules	B-X
and	B-X
cell	B-X
functions	B-X
,	B-X
T	B-X
cells	B-X
are	B-X
subdivided	B-X
into	B-X
natural	B-X
killer	B-X
T	B-X
(	B-X
NKT	B-X
)	B-X
cells	B-X
,	B-X
γδ	B-X
T	B-X
cells	B-X
,	B-X
CD8	B-X

We	O
used	O
complexes	O
of	O
recombinant	O
mouse	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
rmIL	B-Protein
-	I-Protein
4	I-Protein
)	O
plus	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
which	O
have	O
been	O
shown	O
to	O
dramatically	O
increase	O
the	O
potency	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O

In	O
these	O
mice	O
,	O
the	O
percentage	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
and	O
FOXP3	B-Protein
+	O
T	O
cells	O
dramatically	O
decreased	O
when	O
the	O
antibody	O
-	O
cytokine	O
immune	O
complexes	O
were	O
injected	O
(	O
Figure	O
S2	O
)	O
.	O

Upon	O
administration	O
of	O
rmIL	B-Protein
-	I-Protein
4	I-Protein
plus	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
complexes	O
,	O
the	O
total	O
number	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cell	O
,	O
as	O
well	O
as	O
the	O
Foxp3	B-Protein
+	O
T	O
cells	O
diminished	O
by	O
half	O
(	O
Figure	O
S2G	O
and	O
S2H	O
)	O
,	O
confirming	O
that	O
the	O
lower	O
percentage	O
was	O
not	O
due	O
to	O
an	O
increase	O
in	O
the	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
,	O
but	O
a	O
real	O
decrease	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
.	O

In	O
conclusion	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
negatively	O
regulates	O
the	O
natural	O
or	O
inducible	O
Treg	O
cell	O
turnover	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O
<EOS>	B-X
Myeloid-derived	B-X
suppressor	B-X
cells	B-X
(	B-X
MDSCs	B-X
)	B-X
contribute	B-X
to	B-X
tumor-mediated	B-X
immune	B-X
escape	B-X
and	B-X
negatively	B-X
correlate	B-X
with	B-X
overall	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
intervention	B-X
stage	B-X
of	B-X
MDSCs	B-X
,	B-X
namely	B-X
development	B-X
,	B-X
expansion	B-X
and	B-X
activation	B-X
,	B-X
function	B-X
and	B-X
turnover	B-X
,	B-X
these	B-X
methods	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
:	B-X
(	B-X
I	B-X
)	B-X
prevention	B-X
or	B-X
differentiation	B-X
to	B-X
mature	B-X
cells	B-X
,	B-X
(	B-X
II	B-X
)	B-X
blockade	B-X
of	B-X
MDSC	B-X
expansion	B-X
and	B-X
activation	B-X
,	B-X
(	B-X
III	B-X
)	B-X
inhibition	B-X
of	B-X
MDSC	B-X
suppressive	B-X
activity	B-X
or	B-X
(	B-X
IV	B-X
)	B-X
depletion	B-X
of	B-X
intratumoral	B-X
MDSCs	B-X
.	B-X
An	B-X
imbalance	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
resulting	B-X
in	B-X
inflammatory	B-X
stimuli	B-X
may	B-X
induce	B-X
an	B-X
imbalance	B-X
in	B-X
bone	B-X
turnover	B-X
via	B-X
induction	B-X
of	B-X
osteoclast	B-X
differentiation	B-X
and	B-X
inhibition	B-X
of	B-X
osteoblast	B-X
differentiation	B-X
,	B-X
leading	B-X
to	B-X
various	B-X
pathological	B-X
conditions	B-X
including	B-X
osteoporosis	B-X
.	B-X
T-cell	B-X
subsets	B-X
,	B-X
helper	B-X
T	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
and	B-X
Th17	B-X
,	B-X
which	B-X
activate	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
induce	B-X
osteoclasts	B-X
,	B-X
whereas	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
,	B-X
responsible	B-X
for	B-X
immunosuppression	B-X
,	B-X
inhibit	B-X
osteoclastic	B-X
differentiation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
,	B-X
also	B-X
cause	B-X
an	B-X
imbalance	B-X
in	B-X
bone	B-X
turnover	B-X
,	B-X
induction	B-X
of	B-X
osteoclasts	B-X
and	B-X
inhibition	B-X
of	B-X
osteoblasts	B-X
.	B-X
Treatments	B-X
targeting	B-X
the	B-X
immune	B-X
system	B-X
may	B-X
regulate	B-X
abnormalities	B-X
in	B-X
bone	B-X
metabolism	B-X
,	B-X
while	B-X
also	B-X
controlling	B-X
immune	B-X
abnormalities	B-X
.	B-X
Stimulation	B-X
by	B-X
inflammatory	B-X
cytokines	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
receptor	B-X
activator	B-X
for	B-X
nuclear	B-X
factor-κB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
synovial	B-X
cells	B-X
,	B-X
thereby	B-X
inducing	B-X
bone	B-X
destruction	B-X
due	B-X
to	B-X
osteoblast-independent	B-X
osteoclast	B-X
maturation	B-X
.	B-X
However	B-X
,	B-X
biological	B-X
products	B-X
targeting	B-X
TNF	B-X
or	B-X
interleukin-6	B-X
not	B-X
only	B-X
control	B-X
disease	B-X
activity	B-X
,	B-X
but	B-X
also	B-X
inhibit	B-X
joint	B-X
destruction	B-X
.	B-X

To	O
study	O
the	O
effects	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
on	O
already	O
-	O
existing	O
human	O
natural	O
or	O
inducible	O
Treg	O
cells	O
,	O
we	O
exposed	O
sorted	O
CD25	B-Protein
+	O
T	O
cells	O
(	O
nTreg	O
cells	O
)	O
to	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
analyzed	O
FOXP3	B-Protein
expression	O
and	O
suppressive	O
capacity	O
.	O

In	O
already	O
-	O
existing	O
Treg	O
cells	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
failed	O
to	O
inhibit	O
FOXP3	B-Protein
expression	O
(	O
Figure	O
S3A	O
)	O
,	O
and	O
the	O
suppressive	O
capacity	O
was	O
not	O
altered	O
(	O
Figure	O
S3C	O
)	O
.	O

Similarly	O
pre	O
-	O
existing	O
iTreg	O
cells	O
did	O
not	O
decrease	O
FOXP3	B-Protein
expression	O
upon	O
IL	B-Protein
-	I-Protein
4	I-Protein
exposure	O
(	O
Figure	O
S3B	O
)	O
.	O

The	O
Role	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
in	O
T	O
Cell	O
Differentiation	O

Although	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
reduced	O
CD25	B-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
and	O
CD25	B-Protein
expression	O
(	O
Figure	O
6B	O
)	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
significantly	O
inhibited	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
induction	O
of	O
FOXP3	B-Protein
in	O
naive	O
T	O
cells	O
driven	O
toward	O
FOXP3	B-Protein
+	O
T	O
cells	O
,	O
as	O
shown	O
by	O
FACS	O
analysis	O
(	O
Figure	O
6A	O
)	O
.	O

It	O
is	O
known	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
is	O
a	O
potent	O
growth	O
factor	O
and	O
may	O
therefore	O
favor	O
the	O
proliferation	O
of	O
FOXP3	B-Protein
-	O
cells	O
and	O
thus	O
decrease	O
the	O
relative	O
percentage	O
of	O
FOXP3	B-Protein
+	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
cell	O
division	O
kinetics	O
by	O
CFSE	O
-	O
labeling	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
did	O
not	O
differentially	O
promote	O
cell	O
growth	O
of	O
FOXP3	B-Protein
+	O
over	O
that	O
of	O
FOXP3	B-Protein
-	O
.	O

In	O
fact	O
both	O
populations	O
showed	O
similarly	O
enhanced	O
proliferation	O
(	O
Figure	O
6A	O
)	O
.	O

Furthermore	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
induction	O
of	O
FOXP3	B-Protein
expression	O
was	O
not	O
caused	O
by	O
overgrowth	O
of	O
a	O
CD25	B-Protein
-	O
FOXP3	B-Protein
+	O
minority	O
,	O
since	O
the	O
number	O
of	O
FOXP3	B-Protein
+	O
cells	O
was	O
low	O
/	O
absent	O
in	O
the	O
purified	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
(	O
between	O
0	O
%	O
and	O
1	O
%	O
)	O
,	O
and	O
the	O
FOXP3	B-Protein
+	O
cells	O
were	O
not	O
confined	O
to	O
the	O
highly	O
divided	O
cells	O
.	O
<EOS>	B-X
A	B-X
promising	B-X
way	B-X
to	B-X
restrain	B-X
hazardous	B-X
immune	B-X
responses	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
disease	B-X
and	B-X
allergy	B-X
,	B-X
is	B-X
to	B-X
convert	B-X
disease-mediating	B-X
T	B-X
cells	B-X
into	B-X
immunosuppressive	B-X
regulatory	B-X
T	B-X
(	B-X
T	B-X
Differentiated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
preserve	B-X
plasticity	B-X
under	B-X
various	B-X
conditions	B-X
.	B-X
However	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
Th1	B-X
cells	B-X
is	B-X
unclear	B-X
,	B-X
as	B-X
is	B-X
whether	B-X
Th1	B-X
cells	B-X
can	B-X
convert	B-X
into	B-X
Th17	B-X
cells	B-X
and	B-X
thereby	B-X
contribute	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
IFN-γ	B-X
(	B-X
+	B-X
)	B-X
IL-17	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
number	B-X
of	B-X
which	B-X
correlates	B-X
with	B-X
severity	B-X
of	B-X
colitis	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
IFN-γ	B-X
(	B-X
+	B-X
)	B-X
Th1	B-X
cells	B-X
can	B-X
convert	B-X
into	B-X
Th17	B-X
cells	B-X
under	B-X
intestinal	B-X
inflammation	B-X
and	B-X
the	B-X
mechanisms	B-X
involved	B-X
.	B-X
IFN-γ	B-X
(	B-X
Thy1.1+	B-X
)	B-X
Th1	B-X
cells	B-X
were	B-X
generated	B-X
by	B-X
culturing	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
IFN-γ	B-X
(	B-X
Thy1.1	B-X
)	B-X
CBir1	B-X
TCR-Tg	B-X
reporter	B-X
mice	B-X
,	B-X
whose	B-X
TCR	B-X
is	B-X
specific	B-X
for	B-X
an	B-X
immunodominant	B-X
microbiota	B-X
antigen	B-X
,	B-X
CBir1	B-X
flagellin	B-X
,	B-X
under	B-X
Th1	B-X
polarizing	B-X
conditions	B-X
.	B-X
IFN-γ	B-X
(	B-X
Thy1.1+	B-X
)	B-X
Th1	B-X
cells	B-X
induced	B-X
colitis	B-X
in	B-X
Rag	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
after	B-X
adoptive	B-X
transfer	B-X
and	B-X
converted	B-X
into	B-X
IL-17	B-X
(	B-X
+	B-X
)	B-X
Th17	B-X
,	B-X
but	B-X
not	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Treg	B-X
cells	B-X
in	B-X
the	B-X
inflamed	B-X
intestines	B-X
.	B-X
TGF-β	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
IL-1β	B-X
and	B-X
IL-23	B-X
,	B-X
regulated	B-X
Th1	B-X
conversion	B-X
into	B-X
Th17	B-X
cells	B-X
.	B-X
TGF-β	B-X
induction	B-X
of	B-X
transcriptional	B-X
factor	B-X
Runx1	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
conversion	B-X
,	B-X
since	B-X
silencing	B-X
Runx1	B-X
by	B-X
siRNA	B-X
inhibited	B-X
Th1	B-X
conversion	B-X
into	B-X
Th17	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
TGF-β	B-X
enhanced	B-X
histone	B-X
H3K9	B-X
acetylation	B-X
but	B-X
inhibited	B-X
H3K9	B-X
trimethylation	B-X
of	B-X
Runx1-	B-X
and	B-X
ROR-γt-binding	B-X
sites	B-X
on	B-X
il-17	B-X
or	B-X
rorc	B-X
gene	B-X
in	B-X
Th1	B-X
cells	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
Th1	B-X
cells	B-X
convert	B-X
into	B-X
Th17	B-X
cells	B-X
under	B-X
inflammatory	B-X
conditions	B-X
in	B-X
intestines	B-X
,	B-X
which	B-X
is	B-X
possibly	B-X
mediated	B-X
by	B-X
TGF-β	B-X
induction	B-X
of	B-X
Runx1	B-X
.	B-X

CD25	B-Protein
was	O
down	O
-	O
regulated	O
in	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
treated	O
cells	O
compare	O
to	O
activated	O
T	O
cells	O
,	O
which	O
was	O
even	O
more	O
pronounced	O
in	O
cells	O
cultured	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

The	O
addition	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
to	O
iTreg	O
-	O
driving	O
conditions	O
decreased	O
the	O
number	O
of	O
FOXP3	B-Protein
+	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

In	O
line	O
with	O
the	O
previous	O
findings	O
,	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
producing	O
cells	O
and	O
the	O
FOXP3	B-Protein
expressing	O
cells	O
are	O
nonoverlapping	O
populations	O
.	O

Since	O
FOXP3	B-Protein
is	O
known	O
to	O
act	O
as	O
a	O
repressor	O
of	O
cytokine	O
expression	O
[	O
20	O
]	O
,	O
we	O
therefore	O
analyzed	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
expression	O
.	O

The	O
expression	O
kinetic	O
of	O
naive	O
T	O
cells	O
exposed	O
to	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
demonstrated	O
that	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
are	O
initially	O
found	O
in	O
separate	O
populations	O
(	O
day	O
2	O
)	O
,	O
but	O
transiently	O
co	O
-	O
express	O
both	O
factors	O
(	O
days	O
4	O
-	O
8	O
)	O
,	O
before	O
establishing	O
separate	O
populations	O
at	O
the	O
end	O
of	O
the	O
differentiation	O
process	O
(	O
day	O
10	O
;	O
Figure	O
6C	O
)	O
,	O
suggesting	O
that	O
GATA3	B-Protein
inhibits	O
the	O
development	O
of	O
iTreg	O
cells	O
by	O
repressing	O
FOXP3	B-Protein
.	O

These	O
results	O
showed	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
acts	O
in	O
vitro	O
as	O
an	O
inhibitor	O
of	O
FOXP3	B-Protein
expression	O
,	O
without	O
interfering	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signaling	O
,	O
probably	O
acting	O
at	O
the	O
level	O
of	O
transcription	O
factors	O
,	O
and	O
possibly	O
by	O
a	O
GATA3	B-Protein
-	O
dependent	O
mechanism	O
.	O

GATA3	B-Protein
Is	O
a	O
Negative	O
Regulator	O
of	O
FOXP3	B-Protein
Expression	O
<EOS>	B-X
Total	B-X
RNA	B-X
was	B-X
extracted	B-X
from	B-X
the	B-X
SNs	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
T-BET	B-X
,	B-X
GATA-3	B-X
,	B-X
and	B-X
FOXP3	B-X
were	B-X
evaluated	B-X
using	B-X
quantitative	B-X
real-time	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
Although	B-X
T-BET	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
pN0	B-X
(	B-X
mol+	B-X
)	B-X
than	B-X
pN0	B-X
,	B-X
FOXP3	B-X
expression	B-X
was	B-X
also	B-X
higher	B-X
in	B-X
pN0	B-X
(	B-X
mol+	B-X
)	B-X
than	B-X
pN0	B-X
.	B-X
In	B-X
pN1-2	B-X
,	B-X
T-BET	B-X
expression	B-X
decreased	B-X
compared	B-X
with	B-X
pN0	B-X
(	B-X
mol+	B-X
)	B-X
,	B-X
but	B-X
FOXP3	B-X
expression	B-X
did	B-X
not	B-X
.	B-X
In-depth	B-X
cellular	B-X
typing	B-X
by	B-X
flow	B-X
cytometry	B-X
revealed	B-X
that	B-X
the	B-X
impairment	B-X
of	B-X
IL-4Rα-mediated	B-X
signaling	B-X
during	B-X
helminth	B-X
infections	B-X
decreased	B-X
the	B-X
ability	B-X
of	B-X
central	B-X
Treg	B-X
cells	B-X
to	B-X
convert	B-X
into	B-X
effector	B-X
Treg	B-X
(	B-X
eTreg	B-X
)	B-X
cells	B-X
and	B-X
caused	B-X
a	B-X
significant	B-X
down-regulation	B-X
of	B-X
markers	B-X
associated	B-X
with	B-X
Treg	B-X
cell	B-X
migration	B-X
(	B-X
C-X-C	B-X
motif	B-X
chemokine	B-X
receptor	B-X
3	B-X
[	B-X
CXCR3	B-X
]	B-X
)	B-X
and	B-X
accumulation	B-X
in	B-X
inflamed	B-X
tissues	B-X
(	B-X
GATA	B-X
binding	B-X
protein	B-X
3	B-X
[	B-X
GATA3	B-X
]	B-X
)	B-X
as	B-X
well	B-X
as	B-X
survival	B-X
(	B-X
B	B-X
cell	B-X
lymphoma	B-X
2	B-X
[	B-X
Bcl-2	B-X
]	B-X
)	B-X
.	B-X

FOXP3	B-Protein
expression	O
decreased	O
once	O
GATA3	B-Protein
expression	O
is	O
high	O
;	O
therefore	O
,	O
we	O
hypothesized	O
a	O
potential	O
role	O
for	O
GATA3	B-Protein
in	O
repressing	O
FOXP3	B-Protein
.	O
<EOS>	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
the	B-X
immunopathology	B-X
of	B-X
toxoplasmosis	B-X
is	B-X
not	B-X
clearly	B-X
defined	B-X
yet	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
were	B-X
extremely	B-X
susceptible	B-X
to	B-X
infection	B-X
,	B-X
presenting	B-X
higher	B-X
parasite	B-X
load	B-X
and	B-X
lower	B-X
tissue	B-X
expression	B-X
of	B-X
IL-12p40	B-X
,	B-X
IFN-γ	B-X
,	B-X
TNF	B-X
,	B-X
IL-6	B-X
,	B-X
iNOS	B-X
,	B-X
Foxp3	B-X
,	B-X
T-bet	B-X
,	B-X
GATA-3	B-X
and	B-X
PPARα	B-X
.	B-X
PPARα	B-X
agonist	B-X
Gemfibrozil	B-X
improved	B-X
the	B-X
vacuolization	B-X
but	B-X
did	B-X
not	B-X
rescue	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
infected	B-X
mice	B-X
from	B-X
high	B-X
serum	B-X
triglycerides	B-X
levels	B-X
and	B-X
enhanced	B-X
mortality	B-X
.	B-X
We	B-X
also	B-X
found	B-X
intense	B-X
inflammation	B-X
in	B-X
the	B-X
ileum	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
infected	B-X
mice	B-X
,	B-X
with	B-X
epithelial	B-X
ulceration	B-X
,	B-X
augmented	B-X
CD4	B-X
and	B-X
decreased	B-X
frequency	B-X
of	B-X
NK	B-X
cells	B-X
in	B-X
the	B-X
gut	B-X
lamina	B-X
propria	B-X
.	B-X

Besides	O
GATA3	B-Protein
'	O
s	O
well	O
-	O
known	O
positive	O
effect	O
on	O
gene	O
regulation	O
,	O
GATA3	B-Protein
'	O
s	O
repressive	O
capabilities	O
were	O
previously	O
shown	O
to	O
restrict	O
Th1	O
commitment	O
by	O
inhibiting	O
STAT4	B-Protein
expression	O
[	O
2	O
,	O
21	O
]	O
,	O
and	O
therefore	O
GATA3	B-Protein
prevents	O
differentiation	O
into	O
Th1	O
cells	O
.	O

To	O
investigate	O
whether	O
GATA3	B-Protein
can	O
directly	O
inhibit	O
FOXP3	B-Protein
induction	O
,	O
we	O
transduced	O
GATA3	B-Protein
or	O
a	O
truncated	O
GATA3	B-Protein
lacking	O
the	O
DNA	O
-	O
binding	O
domain	O
in	O
human	O
primary	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
using	O
a	O
TAT	B-Protein
-	I-Protein
fused	I-Protein
,	I-Protein
recombinantly	I-Protein
expressed	I-Protein
GATA3	I-Protein
.	O

After	O
transduction	O
,	O
the	O
cells	O
were	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapeutic	B-X
approaches	B-X
targeting	B-X
TGF-β	B-X
mediated	B-X
cascade	B-X
of	B-X
fibrotic	B-X
events	B-X
is	B-X
urgently	B-X
needed	B-X
to	B-X
improve	B-X
the	B-X
survival	B-X
of	B-X
the	B-X
patients	B-X
suffering	B-X
from	B-X
devastating	B-X
disease	B-X
.	B-X
The	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
family	B-X
of	B-X
cytokines	B-X
exerts	B-X
pleiotropic	B-X
functions	B-X
during	B-X
embryonic	B-X
development	B-X
,	B-X
tissue	B-X
homeostasis	B-X
and	B-X
repair	B-X
as	B-X
well	B-X
as	B-X
within	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Single	B-X
gene	B-X
defects	B-X
in	B-X
individual	B-X
component	B-X
of	B-X
this	B-X
signaling	B-X
machinery	B-X
cause	B-X
defined	B-X
Mendelian	B-X
diseases	B-X
associated	B-X
with	B-X
aberrant	B-X
activation	B-X
of	B-X
TGF-β	B-X
signaling	B-X
,	B-X
ultimately	B-X
leading	B-X
to	B-X
impaired	B-X
development	B-X
,	B-X
immune	B-X
responses	B-X
or	B-X
both	B-X
.	B-X
Gene	B-X
defects	B-X
that	B-X
affect	B-X
members	B-X
of	B-X
the	B-X
TGF-β	B-X
cytokine	B-X
family	B-X
result	B-X
in	B-X
more	B-X
restricted	B-X
phenotypes	B-X
,	B-X
while	B-X
those	B-X
affecting	B-X
downstream	B-X
components	B-X
of	B-X
the	B-X
signaling	B-X
machinery	B-X
induce	B-X
broader	B-X
defects	B-X
.	B-X
These	B-X
rare	B-X
disorders	B-X
,	B-X
also	B-X
known	B-X
as	B-X
TGF-β	B-X
signalopathies	B-X
,	B-X
provide	B-X
the	B-X
unique	B-X
opportunity	B-X
to	B-X
improve	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
and	B-X
the	B-X
relevance	B-X
of	B-X
the	B-X
TGF-β	B-X
signaling	B-X
in	B-X
the	B-X
human	B-X
immune	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
this	B-X
elaborate	B-X
signaling	B-X
pathway	B-X
,	B-X
review	B-X
the	B-X
diverse	B-X
clinical	B-X
presentations	B-X
and	B-X
immunological	B-X
phenotypes	B-X
observed	B-X
in	B-X
these	B-X
patients	B-X
and	B-X
discuss	B-X
the	B-X
phenotypic	B-X
overlap	B-X
between	B-X
humans	B-X
and	B-X
mice	B-X
genetically	B-X
deficient	B-X
for	B-X
individual	B-X
components	B-X
of	B-X
the	B-X
TGF-β	B-X
signaling	B-X
cascade	B-X
.	B-X

TAT	B-Protein
-	I-Protein
GATA3	I-Protein
was	O
successfully	O
transduced	O
in	O
a	O
homogeneous	O
and	O
dose	O
-	O
dependent	O
manner	O
into	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
7A	O
,	O
upper	O
panel	O
)	O
.	O

TAT	B-Protein
-	I-Protein
GATA3	I-Protein
reduced	O
FOXP3	B-Protein
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
a	O
DNA	O
-	O
binding	O
domain	O
truncated	O
version	O
(	O
TAT	O
-	O
deltaDBD	O
-	O
GATA3	B-Protein
)	O
did	O
not	O
affect	O
FOXP3	B-Protein
expression	O
as	O
compared	O
with	O
expression	O
in	O
untransduced	O
cells	O
(	O
Figure	O
7A	O
)	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
inhibitory	O
effect	O
of	O
GATA3	B-Protein
on	O
FOXP3	B-Protein
in	O
transgenic	O
DO11	O
.	O
10	O
mice	O
,	O
constitutively	O
overexpressing	O
GATA3	B-Protein
under	O
the	O
control	O
of	O
the	O
CD2	B-Protein
locus	O
control	O
region	O
(	O
DO11	O
.	O
10xCD2	B-Protein
-	O
GATA3	B-Protein
)	O
.	O

The	O
thymic	O
selection	O
into	O
the	O
CD4	B-Protein
lineage	O
is	O
largely	O
intact	O
in	O
DO11	O
.	O
10xCD2	B-Protein
-	O
GATA3	B-Protein
(	O
RW	O
Hendriks	O
,	O
unpublished	O
data	O
)	O
.	O

These	O
mice	O
develop	O
lymphomas	O
at	O
an	O
older	O
age	O
,	O
but	O
signs	O
of	O
autoimmune	O
disease	O
were	O
not	O
described	O
[	O
22	O
]	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
GATA3	B-Protein
on	O
iTreg	O
,	O
CD4	B-Protein
+	O
CD62L	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
were	O
isolated	O
,	O
activated	O
with	O
OVA	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
Foxp3	B-Protein
expression	O
was	O
analyzed	O
after	O
4	O
d	O
.	O

The	O
naive	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
were	O
Foxp3	B-Protein
-	O
(	O
unpublished	O
data	O
)	O
.	O

As	O
described	O
for	O
the	O
human	O
cells	O
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
dramatically	O
up	O
-	O
regulated	O
Foxp3	B-Protein
in	O
the	O
DO11	O
.	O
10	O
littermate	O
control	O
mice	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
the	O
CD2	B-Protein
-	O
GATA3xDO11	B-Protein
.	O
10	O
mice	O
showed	O
dramatically	O
reduced	O
Foxp3	B-Protein
expression	O
when	O
activated	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
OVA	O
(	O
Figure	O
7B	O
)	O
.	O

All	O
mice	O
produced	O
similar	O
amounts	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
;	O
in	O
addition	O
,	O
Smad7	B-Protein
was	O
equally	O
expressed	O
[	O
23	O
]	O
in	O
T	O
cells	O
of	O
both	O
mice	O
strains	O
(	O
Figure	O
7C	O
)	O
,	O
indicating	O
intact	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signaling	O
.	O
<EOS>	B-X
The	B-X
findings	B-X
in	B-X
the	B-X
present	B-X
and	B-X
other	B-X
similar	B-X
studies	B-X
suggest	B-X
that	B-X
this	B-X
reduction	B-X
in	B-X
osteoblast	B-X
number	B-X
and	B-X
activity	B-X
is	B-X
due	B-X
to	B-X
an	B-X
age-related	B-X
diminution	B-X
in	B-X
the	B-X
size	B-X
and	B-X
osteogenic	B-X
potential	B-X
of	B-X
the	B-X
bone	B-X
marrow	B-X
osteoblast	B-X
progenitor	B-X
cell	B-X
(	B-X
OPC	B-X
or	B-X
CFU-f	B-X
)	B-X
compartment	B-X
.	B-X
We	B-X
previously	B-X
postulated	B-X
that	B-X
these	B-X
regressive	B-X
changes	B-X
in	B-X
the	B-X
OPC/CFU-f	B-X
compartment	B-X
occurred	B-X
in	B-X
old	B-X
animals	B-X
because	B-X
of	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
amount	B-X
and/or	B-X
activity	B-X
of	B-X
TGF-beta1	B-X
,	B-X
an	B-X
autocrine	B-X
growth	B-X
factor	B-X
important	B-X
in	B-X
the	B-X
promotion	B-X
of	B-X
OPC/CFU-f	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
In	B-X
support	B-X
of	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
now	B-X
report	B-X
that	B-X
(	B-X
1	B-X
)	B-X
the	B-X
osteogenic	B-X
capacity	B-X
of	B-X
the	B-X
bone	B-X
marrow	B-X
of	B-X
24-month-old	B-X
BALB/c	B-X
mice	B-X
,	B-X
as	B-X
assessed	B-X
in	B-X
vivo	B-X
,	B-X
is	B-X
markedly	B-X
reduced	B-X
relative	B-X
to	B-X
that	B-X
of	B-X
3-4-month-old	B-X
animals	B-X
,	B-X
(	B-X
2	B-X
)	B-X
that	B-X
the	B-X
matrix	B-X
of	B-X
the	B-X
long	B-X
bones	B-X
of	B-X
old	B-X
mice	B-X
contains	B-X
significantly	B-X
less	B-X
TGF-beta	B-X
than	B-X
that	B-X
of	B-X
young	B-X
mice	B-X
,	B-X
(	B-X
3	B-X
)	B-X
that	B-X
OPC's/CFU-f	B-X
's	B-X
isolated	B-X
from	B-X
old	B-X
mice	B-X
produce	B-X
less	B-X
TGF-beta	B-X
in	B-X
vitro	B-X
than	B-X
those	B-X
recovered	B-X
from	B-X
young	B-X
mice	B-X
,	B-X
and	B-X
(	B-X
4	B-X
)	B-X
that	B-X
OPC's/CFU-f	B-X
's	B-X
from	B-X
old	B-X
mice	B-X
express	B-X
significantly	B-X
more	B-X
TGF-beta	B-X
receptor	B-X
(	B-X
Types	B-X
I	B-X
,	B-X
II	B-X
,	B-X
and	B-X
III	B-X
)	B-X
than	B-X
those	B-X
of	B-X
young	B-X
animals	B-X
and	B-X
that	B-X
such	B-X
cells	B-X
are	B-X
more	B-X
responsive	B-X
in	B-X
vitro	B-X
to	B-X
exogenous	B-X
recombinant	B-X
TGF-beta1	B-X
.	B-X
We	B-X
also	B-X
find	B-X
that	B-X
colony	B-X
number	B-X
and	B-X
proliferative	B-X
activity	B-X
of	B-X
OPC's/CFU-f	B-X
's	B-X
of	B-X
young	B-X
mice	B-X
and	B-X
old	B-X
mice	B-X
,	B-X
respectively	B-X
,	B-X
are	B-X
significantly	B-X
reduced	B-X
when	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
neutralizing	B-X
TGF-beta1	B-X
antibody	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
in	B-X
old	B-X
male	B-X
mice	B-X
the	B-X
reduction	B-X
in	B-X
the	B-X
synthesis	B-X
and	B-X
,	B-X
perhaps	B-X
,	B-X
availability	B-X
from	B-X
the	B-X
bone	B-X
matrix	B-X
of	B-X
TGF-beta1	B-X
contributes	B-X
to	B-X
a	B-X
diminution	B-X
in	B-X
the	B-X
size	B-X
and	B-X
development	B-X
potential	B-X
of	B-X
the	B-X
bone	B-X
marrow	B-X
osteoprogenitor	B-X
pool	B-X
.	B-X

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
a	O
repressive	O
role	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
GATA3	B-Protein
transcription	O
factor	O
in	O
the	O
generation	O
of	O
iTreg	O
cells	O
.	O

GATA3	B-Protein
Represses	O
the	O
FOXP3	B-Protein
Promoter	O
<EOS>	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
GATA3	B-Protein
-	O
mediated	O
repression	O
of	O
human	O
FOXP3	B-Protein
,	O
the	O
human	O
FOXP3	B-Protein
promoter	O
was	O
studied	O
and	O
a	O
palindromic	O
binding	O
site	O
for	O
GATA3	B-Protein
was	O
discovered	O
.	O

The	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
[	O
24	O
]	O
.	O

This	O
site	O
is	O
highly	O
conserved	O
between	O
humans	O
,	O
mice	O
,	O
and	O
rats	O
(	O
Figure	O
S4	O
)	O
and	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
FOXP3	B-Protein
regulation	O
.	O

The	O
functional	O
relevance	O
of	O
this	O
site	O
was	O
studied	O
using	O
a	O
FOXP3	B-Protein
-	O
promoter	O
construct	O
[	O
24	O
]	O
.	O

We	O
transfected	O
human	O
primary	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
in	O
vitro	O
differentiated	O
Th2	O
cells	O
,	O
and	O
Jurkat	O
cells	O
(	O
Jurkat	O
cells	O
are	O
known	O
to	O
constitutively	O
express	O
GATA3	B-Protein
[	O
25	O
,	O
26	O
]	O
)	O
,	O
and	O
we	O
measured	O
FOXP3	B-Protein
promoter	O
activity	O
.	O

The	O
promoter	O
was	O
not	O
active	O
in	O
the	O
GATA3	B-Protein
-	O
expressing	O
cell	O
line	O
Jurkat	O
or	O
in	O
the	O
in	O
vitro	O
-	O
differentiated	O
Th2	O
cells	O
,	O
whereas	O
the	O
construct	O
was	O
active	O
in	O
the	O
CD4	B-Protein
cells	O
,	O
which	O
express	O
a	O
lower	O
amount	O
of	O
GATA3	B-Protein
(	O
Figure	O
8A	O
)	O
.	O
<EOS>	B-X
Several	B-X
pathogen-sensitive	B-X
gene	B-X
activities	B-X
,	B-X
promoters	B-X
of	B-X
such	B-X
genes	B-X
,	B-X
associated	B-X
transcription	B-X
factors	B-X
,	B-X
and	B-X
promoter	B-X
elements	B-X
responsible	B-X
for	B-X
crosstalk	B-X
between	B-X
the	B-X
defense	B-X
signaling	B-X
pathways	B-X
are	B-X
involved	B-X
in	B-X
plant	B-X
resistance	B-X
towards	B-X
a	B-X
pathogen	B-X
.	B-X
Still	B-X
,	B-X
only	B-X
a	B-X
handful	B-X
of	B-X
genes	B-X
and	B-X
their	B-X
promoters	B-X
related	B-X
to	B-X
plant	B-X
resistance	B-X
have	B-X
been	B-X
identified	B-X
to	B-X
date	B-X
.	B-X
Such	B-X
pathogen-sensitive	B-X
promoters	B-X
are	B-X
accountable	B-X
for	B-X
elevating	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
certain	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
infection	B-X
.	B-X
Also	B-X
,	B-X
a	B-X
suitable	B-X
promoter	B-X
is	B-X
a	B-X
key	B-X
to	B-X
devising	B-X
successful	B-X
crop	B-X
improvement	B-X
strategies	B-X
as	B-X
it	B-X
ensures	B-X
the	B-X
optimum	B-X
expression	B-X
of	B-X
the	B-X
required	B-X
transgene	B-X
.	B-X
The	B-X
study	B-X
of	B-X
the	B-X
promoters	B-X
also	B-X
helps	B-X
in	B-X
mining	B-X
more	B-X
details	B-X
about	B-X
the	B-X
transcription	B-X
factors	B-X
controlling	B-X
their	B-X
activities	B-X
and	B-X
helps	B-X
to	B-X
unveil	B-X
the	B-X
involvement	B-X
of	B-X
new	B-X
genes	B-X
in	B-X
the	B-X
pathogen	B-X
response	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
only	B-X
way	B-X
out	B-X
to	B-X
formulate	B-X
new	B-X
solutions	B-X
is	B-X
by	B-X
analyzing	B-X
the	B-X
molecular	B-X
aspects	B-X
of	B-X
these	B-X
promoters	B-X
in	B-X
detail	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provided	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
promoter	B-X
motifs	B-X
and	B-X
cis-regulatory	B-X
elements	B-X
having	B-X
specific	B-X
roles	B-X
in	B-X
pathogen	B-X
attack	B-X
response	B-X
.	B-X
To	B-X
elaborate	B-X
on	B-X
the	B-X
importance	B-X
and	B-X
get	B-X
a	B-X
vivid	B-X
picture	B-X
of	B-X
the	B-X
pathogen-sensitive	B-X
promoter	B-X
sequences	B-X
,	B-X
the	B-X
key	B-X
motifs	B-X
and	B-X
promoter	B-X
elements	B-X
were	B-X
analyzed	B-X
with	B-X
the	B-X
help	B-X
of	B-X
PlantCare	B-X
and	B-X
interpreted	B-X
with	B-X
available	B-X
literature	B-X
.	B-X
This	B-X
review	B-X
intends	B-X
to	B-X
provide	B-X
useful	B-X
information	B-X
for	B-X
reconstructing	B-X
the	B-X
gene	B-X
networks	B-X
underlying	B-X
the	B-X
resistance	B-X
of	B-X
plants	B-X
against	B-X
pathogens	B-X
.	B-X

Overexpression	O
of	O
GATA3	B-Protein
in	O
naive	O
T	O
cells	O
diminished	O
luciferase	O
activity	O
of	O
the	O
FOXP3	B-Protein
promoter	O
compared	O
with	O
the	O
control	O
vector	O
(	O
Figure	O
8B	O
)	O
.	O

To	O
further	O
address	O
the	O
function	O
of	O
the	O
GATA3	O
site	O
,	O
we	O
inserted	O
a	O
site	O
-	O
specific	O
mutation	O
deleting	O
the	O
GATA3	O
-	O
binding	O
site	O
.	O

This	O
mutation	O
increased	O
luciferase	O
activity	O
by	O
3	O
-	O
fold	O
in	O
memory	O
CD4	B-Protein
+	O
CD45RO	B-Protein
+	O
T	O
cells	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
naive	O
(	O
GATA3	B-Protein
-	O
)	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
,	O
revealing	O
a	O
repressor	O
activity	O
of	O
GATA3	B-Protein
on	O
the	O
FOXP3	B-Protein
promoter	O
(	O
Figure	O
8C	O
)	O
.	O

Furthermore	O
GATA3	B-Protein
binds	O
directly	O
to	O
the	O
FOXP3	B-Protein
promoter	O
as	O
investigated	O
by	O
pull	O
-	O
down	O
assay	O
.	O

HEK	O
cells	O
were	O
transiently	O
transfected	O
with	O
GATA3	B-Protein
or	O
a	O
control	O
vector	O
,	O
and	O
increasing	O
amounts	O
of	O
lysates	O
were	O
incubated	O
with	O
oligonucleotides	O
containing	O
the	O
GATA3	O
site	O
of	O
the	O
FOXP3	B-Protein
promoter	O
or	O
a	O
control	O
oligonucleotide	O
with	O
a	O
mutated	O
GATA3	O
-	O
binding	O
site	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
the	B-X
isolation	B-X
of	B-X
human	B-X
GnRHR	B-X
full-length	B-X
complementary	B-X
DNA	B-X
from	B-X
the	B-X
human	B-X
placental	B-X
cells	B-X
including	B-X
choriocarcinoma	B-X
JEG-3	B-X
cells	B-X
,	B-X
immortalized	B-X
extravillous	B-X
trophoblasts	B-X
,	B-X
and	B-X
primary	B-X
cultures	B-X
of	B-X
trophoblasts	B-X
.	B-X
Despite	B-X
these	B-X
observations	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
that	B-X
controls	B-X
the	B-X
transcription	B-X
regulation	B-X
of	B-X
the	B-X
GnRHR	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
placenta	B-X
remains	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
described	B-X
the	B-X
identification	B-X
of	B-X
an	B-X
upstream	B-X
placenta-specific	B-X
promoter	B-X
located	B-X
between	B-X
nucleotide	B-X
(	B-X
nt	B-X
)	B-X
-1737	B-X
and	B-X
-1346	B-X
(	B-X
relative	B-X
to	B-X
the	B-X
translation	B-X
start	B-X
site	B-X
)	B-X
for	B-X
the	B-X
human	B-X
GnRHR	B-X
gene	B-X
.	B-X
Using	B-X
transient	B-X
transfection	B-X
studies	B-X
,	B-X
this	B-X
upstream	B-X
promoter	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
determine	B-X
the	B-X
placental	B-X
cell-specific	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
.	B-X
Primer	B-X
extension	B-X
studies	B-X
further	B-X
confirmed	B-X
the	B-X
utilization	B-X
of	B-X
this	B-X
promoter	B-X
in	B-X
JEG-3	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
By	B-X
mutagenesis	B-X
coupled	B-X
to	B-X
functional	B-X
studies	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
four	B-X
putative	B-X
transcription	B-X
factor-binding	B-X
sites	B-X
,	B-X
namely	B-X
human	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
hGR	B-X
)	B-X
-Oct-1	B-X
(	B-X
nt	B-X
-1718	B-X
to	B-X
-1710	B-X
)	B-X
,	B-X
hGR-cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
;	B-X
nt	B-X
-1649	B-X
to	B-X
-1641	B-X
)	B-X
,	B-X
hGR-GATA	B-X
(	B-X
nt	B-X
-1602	B-X
to	B-X
-1597	B-X
)	B-X
,	B-X
and	B-X
hGR-activating	B-X
protein-1	B-X
(	B-X
nt	B-X
-1518	B-X
to	B-X
-1511	B-X
)	B-X
,	B-X
that	B-X
are	B-X
essential	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
these	B-X
cis-acting	B-X
motifs	B-X
reduced	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
GATA	B-X
motifs	B-X
were	B-X
subsequently	B-X
shown	B-X
to	B-X
be	B-X
placenta	B-X
specific	B-X
,	B-X
as	B-X
mutations	B-X
of	B-X
these	B-X
motifs	B-X
caused	B-X
a	B-X
dramatic	B-X
loss	B-X
in	B-X
promoter	B-X
activities	B-X
in	B-X
the	B-X
placental	B-X
JEG-3	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
ovarian	B-X
carcinoma	B-X
OVCAR-3	B-X
,	B-X
monkey	B-X
kidney	B-X
COS-1	B-X
,	B-X
and	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
.	B-X
Gel	B-X
mobility	B-X
assays	B-X
confirmed	B-X
the	B-X
binding	B-X
of	B-X
nuclear	B-X
proteins	B-X
Oct-1	B-X
,	B-X
CRE-binding	B-X
protein	B-X
,	B-X
GATA-2	B-X
,	B-X
GATA-3	B-X
,	B-X
c-Fos	B-X
,	B-X
and	B-X
c-Jun	B-X
from	B-X
JEG-3	B-X
cells	B-X
to	B-X
these	B-X
four	B-X
elements	B-X
.	B-X

After	O
the	O
pull	O
-	O
down	O
,	O
GATA3	B-Protein
binding	O
was	O
detected	O
by	O
Western	O
blot	O
.	O

Similarly	O
,	O
GATA3	B-Protein
-	O
expressing	O
Th2	O
cells	O
and	O
iTreg	O
cells	O
were	O
subjected	O
to	O
this	O
approach	O
.	O

Only	O
HEK	O
cells	O
overexpressing	O
GATA3	B-Protein
and	O
Th2	O
cells	O
showed	O
GATA3	B-Protein
-	O
binding	O
activity	O
(	O
Figure	O
8D	O
and	O
8E	O
)	O
.	O

These	O
experiments	O
demonstrated	O
that	O
GATA3	B-Protein
binds	O
the	O
palindromic	O
FOXP3	B-Protein
promoter	O
.	O

To	O
gain	O
insights	O
into	O
the	O
in	O
vivo	O
situation	O
,	O
we	O
performed	O
a	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
using	O
an	O
anti	O
-	O
GATA3	B-Protein
antibody	O
and	O
showed	O
that	O
GATA3	B-Protein
binds	O
to	O
the	O
FOXP3	B-Protein
promoter	O
region	O
in	O
Th2	O
cells	O
,	O
but	O
not	O
in	O
iTreg	O
cells	O
(	O
Figure	O
7F	O
)	O
.	O

Taken	O
together	O
these	O
data	O
demonstrate	O
that	O
the	O
GATA3	B-Protein
-	O
binding	O
to	O
the	O
FOXP3	B-Protein
promoter	O
is	O
repressing	O
FOXP3	B-Protein
expression	O
.	O

The	O
current	O
study	O
reveals	O
that	O
FOXP3	B-Protein
induction	O
,	O
an	O
important	O
step	O
in	O
iTreg	O
commitment	O
,	O
is	O
inhibited	O
by	O
GATA3	B-Protein
,	O
which	O
is	O
the	O
key	O
regulator	O
for	O
polarization	O
toward	O
Th2	O
cells	O
.	O

After	O
differentiation	O
,	O
the	O
effector	O
Th2	O
cells	O
become	O
refractory	O
to	O
conversion	O
into	O
a	O
FOXP3	B-Protein
+	O
phenotype	O
.	O

In	O
accordance	O
with	O
other	O
studies	O
,	O
we	O
found	O
that	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
were	O
able	O
to	O
up	O
-	O
regulate	O
FOXP3	B-Protein
[	O
12	O
,	O
27	O
]	O
.	O

Already	O
-	O
committed	O
cells	O
such	O
as	O
memory	O
T	O
cells	O
and	O
Th1	O
cells	O
showed	O
only	O
moderate	O
and	O
transient	O
FOXP3	B-Protein
induction	O
,	O
which	O
is	O
not	O
sufficient	O
to	O
change	O
the	O
phenotype	O
toward	O
a	O
regulatory	O
T	O
cell	O
profile	O
.	O

In	O
contrast	O
,	O
naive	O
T	O
cells	O
could	O
efficiently	O
up	O
-	O
regulate	O
FOXP3	B-Protein
when	O
treated	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
to	O
induce	O
iTreg	O
cells	O
[	O
10	O
,	O
28	O
-	O
34	O
]	O
,	O
suggesting	O
that	O
FOXP3	B-Protein
plays	O
an	O
important	O
role	O
in	O
the	O
early	O
differentiation	O
process	O
and	O
may	O
act	O
in	O
a	O
way	O
similar	O
to	O
that	O
known	O
for	O
the	O
Th1	O
/	O
Th2	O
decision	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
GATA3	B-Protein
.	O

This	O
commitment	O
is	O
characterized	O
by	O
competitive	O
expression	O
of	O
these	O
factors	O
[	O
35	O
,	O
36	O
]	O
,	O
which	O
we	O
also	O
observed	O
in	O
differentiating	O
FOXP3	B-Protein
+	O
iTreg	O
cells	O
including	O
a	O
phase	O
of	O
co	O
-	O
expression	O
,	O
which	O
turns	O
into	O
nonoverlapping	O
expression	O
upon	O
completed	O
differentiation	O
.	O

In	O
this	O
competitive	O
process	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
appeared	O
to	O
be	O
mandatory	O
for	O
the	O
induction	O
of	O
FOXP3	B-Protein
,	O
possibly	O
by	O
keeping	O
the	O
expression	O
of	O
GATA3	B-Protein
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
low	O
[	O
37	O
,	O
38	O
]	O
.	O

In	O
contrast	O
,	O
differentiating	O
naive	O
T	O
cells	O
in	O
the	O
absence	O
of	O
polarization	O
factors	O
(	O
Th0	O
)	O
such	O
as	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
showed	O
only	O
a	O
transient	O
FOXP3	B-Protein
expression	O
and	O
failed	O
to	O
generate	O
a	O
population	O
of	O
FOXP3	B-Protein
-	O
expressing	O
cells	O
,	O
but	O
GATA3	B-Protein
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
were	O
up	O
-	O
regulated	O
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
as	O
we	O
and	O
others	O
previously	O
described	O
,	O
FOXP3	B-Protein
-	O
promoting	O
factors	O
,	O
such	O
as	O
dexamethasone	O
[	O
39	O
]	O
,	O
CTLA	B-Protein
-	I-Protein
4	I-Protein
[	O
40	O
]	O
,	O
and	O
estrogens	O
[	O
41	O
]	O
,	O
are	O
also	O
known	O
as	O
inhibitors	O
of	O
GATA3	B-Protein
expression	O
[	O
42	O
-	O
45	O
]	O
.	O

Therefore	O
GATA3	B-Protein
not	O
only	O
induces	O
differentiation	O
into	O
Th2	O
cells	O
but	O
also	O
inhibits	O
FOXP3	B-Protein
expression	O
and	O
commitment	O
into	O
iTreg	O
cells	O
.	O
<EOS>	B-X
A	B-X
diagnostic	B-X
dilemma	B-X
can	B-X
be	B-X
encountered	B-X
when	B-X
primary	B-X
triple-negative	B-X
breast	B-X
carcinoma	B-X
(	B-X
TNBC	B-X
)	B-X
without	B-X
an	B-X
in	B-X
situ	B-X
component	B-X
or	B-X
metastatic	B-X
TNBCs	B-X
lose	B-X
the	B-X
currently	B-X
used	B-X
organ-specific	B-X
marker	B-X
such	B-X
as	B-X
GATA3	B-X
,	B-X
raising	B-X
concerns	B-X
about	B-X
metastatic	B-X
carcinoma	B-X
from	B-X
other	B-X
sites	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
newly	B-X
identified	B-X
breast	B-X
marker	B-X
TRPS1	B-X
with	B-X
currently	B-X
used	B-X
breast	B-X
markers	B-X
GATA3	B-X
and	B-X
SOX10	B-X
in	B-X
whole-tissue	B-X
sections	B-X
from	B-X
315	B-X
cases	B-X
of	B-X
various	B-X
subtypes	B-X
of	B-X
TNBC	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
GATA3	B-X
and	B-X
SOX10	B-X
were	B-X
expressed	B-X
in	B-X
94	B-X
%	B-X
and	B-X
0	B-X
%	B-X
of	B-X
invasive	B-X
lobular	B-X
carcinomas	B-X
,	B-X
63	B-X
%	B-X
and	B-X
74	B-X
%	B-X
of	B-X
IBC-NST	B-X
,	B-X
and	B-X
50	B-X
%	B-X
and	B-X
49	B-X
%	B-X
of	B-X
metaplastic	B-X
breast	B-X
carcinomas	B-X
,	B-X
respectively	B-X
.	B-X
For	B-X
special-type	B-X
TNBCs	B-X
,	B-X
both	B-X
TRPS1	B-X
and	B-X
GATA3	B-X
were	B-X
negative	B-X
in	B-X
acinic	B-X
cell	B-X
carcinomas	B-X
,	B-X
most	B-X
cribriform	B-X
adenoid	B-X
cystic	B-X
carcinomas	B-X
,	B-X
and	B-X
neuroendocrine	B-X
carcinomas	B-X
,	B-X
but	B-X
positive	B-X
in	B-X
secretory	B-X
carcinomas	B-X
.	B-X
Triple-negative	B-X
apocrine	B-X
carcinoma	B-X
was	B-X
the	B-X
only	B-X
subtype	B-X
of	B-X
TNBC	B-X
with	B-X
positive	B-X
GATA3	B-X
but	B-X
negative	B-X
TRPS1	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
TRPS1	B-X
is	B-X
a	B-X
highly	B-X
sensitive	B-X
marker	B-X
for	B-X
TNBCs	B-X
with	B-X
positivity	B-X
not	B-X
only	B-X
in	B-X
GATA3/SOX10-positive	B-X
TNBCs	B-X
but	B-X
also	B-X
in	B-X
almost	B-X
all	B-X
GATA3/SOX10-negative	B-X
TNBCs	B-X
.	B-X

The	O
Th2	O
cytokine	O
IL	B-Protein
-	I-Protein
4	I-Protein
but	O
not	O
IL	B-Protein
-	I-Protein
13	I-Protein
(	O
unpublished	O
data	O
)	O
was	O
able	O
to	O
inhibit	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
FOXP3	B-Protein
induction	O
and	O
therefore	O
prevented	O
conversion	O
into	O
the	O
regulatory	O
phenotype	O
.	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
belong	B-X
to	B-X
the	B-X
T	B-X
helper	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
cytokine	B-X
family	B-X
,	B-X
along	B-X
with	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-9	B-X
.	B-X
These	B-X
cytokines	B-X
are	B-X
key	B-X
mediators	B-X
of	B-X
allergic	B-X
inflammation	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
implicated	B-X
IL-4	B-X
and	B-X
IL-13	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Additionally	B-X
,	B-X
these	B-X
cytokines	B-X
have	B-X
emerged	B-X
as	B-X
potential	B-X
players	B-X
in	B-X
pathogenesis	B-X
of	B-X
inflammatory	B-X
arthritis	B-X
.	B-X
Recent	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
might	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
downregulation	B-X
of	B-X
inflammatory	B-X
processes	B-X
underlying	B-X
RA	B-X
pathology	B-X
,	B-X
and	B-X
beneficially	B-X
modulate	B-X
the	B-X
course	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
biological	B-X
features	B-X
of	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
and	B-X
provides	B-X
current	B-X
knowledge	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
these	B-X
cytokines	B-X
in	B-X
inflammatory	B-X
arthritis	B-X
.	B-X

To	O
prove	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
on	O
inducible	O
or	O
natural	O
Treg	O
commitment	O
in	O
vivo	O
,	O
we	O
treated	O
mice	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O
<EOS>	B-X
This	B-X
study	B-X
investigated	B-X
a	B-X
salutary	B-X
effect	B-X
of	B-X
atractylone	B-X
(	B-X
Atr	B-X
)	B-X
which	B-X
is	B-X
an	B-X
active	B-X
constituent	B-X
of	B-X
Pyeongwee-San	B-X
(	B-X
KMP6	B-X
)	B-X
on	B-X
mast	B-X
cell-mediated	B-X
allergic	B-X
reactions	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
study	B-X
sought	B-X
to	B-X
determine	B-X
the	B-X
potential	B-X
of	B-X
Atr	B-X
in	B-X
vitro	B-X
models	B-X
,	B-X
compound	B-X
48/80-stimulated	B-X
rat	B-X
peritoneal	B-X
mast	B-X
cells	B-X
(	B-X
RPMCs	B-X
)	B-X
,	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
plus	B-X
A23187-stimulated	B-X
human	B-X
mast	B-X
cell	B-X
line	B-X
(	B-X
HMC-1	B-X
)	B-X
cells	B-X
,	B-X
and	B-X
stem	B-X
cell	B-X
factor	B-X
(	B-X
SCF	B-X
)	B-X
-stimulated	B-X
RPMCs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
vivo	B-X
models	B-X
,	B-X
IgE-mediated	B-X
passive	B-X
cutaneous	B-X
anaphylaxis	B-X
(	B-X
PCA	B-X
)	B-X
,	B-X
compound	B-X
48/80-induced	B-X
systemic	B-X
anaphylaxis	B-X
,	B-X
and	B-X
compound	B-X
48/80-induced	B-X
ear	B-X
swelling	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
Atr	B-X
inhibited	B-X
compound	B-X
48/80-induced	B-X
RPMCs	B-X
degranulation	B-X
,	B-X
intracellular	B-X
calcium	B-X
level	B-X
,	B-X
tryptase	B-X
release	B-X
,	B-X
and	B-X
histamine	B-X
release	B-X
.	B-X
Atr	B-X
inhibited	B-X
the	B-X
up-regulation	B-X
of	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
tyrosine	B-X
kinase	B-X
activity	B-X
by	B-X
compound	B-X
48/80	B-X
.	B-X
Atr	B-X
improved	B-X
IgE-induced	B-X
PCA	B-X
reaction	B-X
by	B-X
decreasing	B-X
the	B-X
levels	B-X
of	B-X
histamine	B-X
,	B-X
IgE	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
IL-6	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
,	B-X
and	B-X
IL-13	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
PCA-induced	B-X
mice	B-X
.	B-X
Furthermore	B-X
,	B-X
Atr	B-X
mitigated	B-X
compound	B-X
48/80-induced	B-X
systemic	B-X
anaphylaxis	B-X
and	B-X
ear	B-X
swelling	B-X
.	B-X

This	O
has	O
been	O
shown	O
to	O
increase	O
the	O
effect	O
of	O
the	O
cytokine	O
in	O
vivo	O
[	O
19	O
]	O
.	O
<EOS>	B-X
The	B-X
Effects	B-X
of	B-X
Cannabinoids	B-X
on	B-X
Pro-	B-X
and	B-X
Anti-Inflammatory	B-X
Cytokines	B-X
:	B-X
A	B-X
Systematic	B-X
Review	B-X
of	B-X
Sambucol	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
vitro	B-X
against	B-X
10	B-X
strains	B-X
of	B-X
influenza	B-X
virus	B-X
.	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
Sambucol	B-X
products	B-X
on	B-X
the	B-X
healthy	B-X
immune	B-X
system	B-X
-	B-X
namely	B-X
,	B-X
its	B-X
effect	B-X
on	B-X
cytokine	B-X
production	B-X
.	B-X
The	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
was	B-X
tested	B-X
using	B-X
blood	B-X
-	B-X
derived	B-X
monocytes	B-X
from	B-X
12	B-X
healthy	B-X
human	B-X
donors	B-X
.	B-X
Production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
(	B-X
IL-1	B-X
beta	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
)	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
mostly	B-X
by	B-X
the	B-X
Sambucol	B-X
Black	B-X
Elderberry	B-X
Extract	B-X
(	B-X
2-45	B-X
fold	B-X
)	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
LPS	B-X
,	B-X
a	B-X
known	B-X
monocyte	B-X
activator	B-X
(	B-X
3.6-10.7	B-X
fold	B-X
)	B-X
.	B-X
The	B-X
most	B-X
striking	B-X
increase	B-X
was	B-X
noted	B-X
in	B-X
TNF-alpha	B-X
production	B-X
(	B-X
44.9	B-X
fold	B-X
)	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
this	B-X
study	B-X
that	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
its	B-X
antiviral	B-X
properties	B-X
,	B-X
Sambucol	B-X
Elderberry	B-X
Extract	B-X
and	B-X
its	B-X
formulations	B-X
activate	B-X
the	B-X
healthy	B-X
immune	B-X
system	B-X
by	B-X
increasing	B-X
inflammatory	B-X
cytokine	B-X
production	B-X
.	B-X
Sambucol	B-X
could	B-X
also	B-X
have	B-X
an	B-X
immunoprotective	B-X
or	B-X
immunostimulatory	B-X
effect	B-X
when	B-X
administered	B-X
to	B-X
cancer	B-X
or	B-X
AIDS	B-X
patients	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
chemotherapeutic	B-X
or	B-X
other	B-X
treatments	B-X
.	B-X
In	B-X
view	B-X
of	B-X
the	B-X
increasing	B-X
popularity	B-X
of	B-X
botanical	B-X
supplements	B-X
,	B-X
such	B-X
studies	B-X
and	B-X
investigations	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
clinical	B-X
trials	B-X
need	B-X
to	B-X
be	B-X
developed	B-X
.	B-X

Only	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
/	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
complex	O
resulted	O
in	O
a	O
decrease	O
of	O
the	O
amount	O
of	O
natural	O
or	O
inducible	O
Treg	O
(	O
CD25	B-Protein
+	O
and	O
Foxp3	B-Protein
+	O
)	O
cells	O
7	O
d	O
after	O
treatment	O
.	O
<EOS>	B-X
Foxp3-expressing	B-X
CD25	B-X
To	B-X
study	B-X
the	B-X
percentage	B-X
,	B-X
suppressive	B-X
function	B-X
and	B-X
plasticity	B-X
of	B-X
Treg	B-X
in	B-X
giant	B-X
cell	B-X
arteritis	B-X
(	B-X
GCA	B-X
)	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
and	B-X
tocilizumab	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
probable	B-X
pathway	B-X
by	B-X
which	B-X
curcumin	B-X
(	B-X
Cur	B-X
)	B-X
regulates	B-X
the	B-X
function	B-X
of	B-X
Treg	B-X
cells	B-X
by	B-X
observing	B-X
the	B-X
expression	B-X
of	B-X
costimulatory	B-X
molecules	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
Immature	B-X
dendritic	B-X
cells	B-X
(	B-X
imDCs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
donor-specific	B-X
transplant	B-X
immunotolerance	B-X
.	B-X
However	B-X
,	B-X
these	B-X
cells	B-X
have	B-X
limitations	B-X
,	B-X
such	B-X
as	B-X
rapid	B-X
maturation	B-X
and	B-X
a	B-X
short	B-X
lifespan	B-X

Our	O
results	O
suggest	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
is	O
only	O
interfering	O
with	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
into	O
iTreg	O
cells	O
.	O

But	O
since	O
a	O
distinction	O
of	O
nTreg	O
and	O
iTreg	O
cells	O
is	O
currently	O
not	O
possible	O
,	O
because	O
iTreg	O
cells	O
also	O
transiently	O
express	O
CD25	B-Protein
after	O
activation	O
,	O
we	O
cannot	O
exclude	O
that	O
IL	B-Protein
-	I-Protein
4	I-Protein
may	O
also	O
inhibit	O
Foxp3	B-Protein
expression	O
in	O
nTreg	O
cells	O
in	O
vivo	O
or	O
that	O
additional	O
effects	O
may	O
contribute	O
to	O
the	O
observed	O
drop	O
in	O
Foxp3	B-Protein
expression	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
immunosuppressive	B-X
drugs	B-X
are	B-X
currently	B-X
used	B-X
in	B-X
patients	B-X
with	B-X
allo-grafts	B-X
or	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Though	B-X
the	B-X
effects	B-X
of	B-X
rapamycin	B-X
(	B-X
RPM	B-X
)	B-X
and	B-X
other	B-X
immunosuppressant	B-X
on	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
regulatory	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
were	B-X
studied	B-X
,	B-X
their	B-X
impact	B-X
on	B-X
Ag-specific	B-X
Tregs	B-X
during	B-X
immune	B-X
response	B-X
was	B-X
not	B-X
well	B-X
defined	B-X
.	B-X
In	B-X
our	B-X
studies	B-X
,	B-X
we	B-X
adoptively	B-X
transferred	B-X
TCR-transgenic	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
naïve	B-X
T	B-X
cells	B-X
or	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
into	B-X
syngeneic	B-X
BALB/c	B-X
mice	B-X
.	B-X
24h	B-X
later	B-X
,	B-X
we	B-X
treated	B-X
the	B-X
recipients	B-X
with	B-X
OVA	B-X
immunization	B-X
and	B-X
immunosuppressant	B-X
including	B-X
rapamycin	B-X
(	B-X
RPM	B-X
)	B-X
,	B-X
fingolimod	B-X
(	B-X
FTY720	B-X
)	B-X
,	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
,	B-X
mycophenolate	B-X
mofetil	B-X
(	B-X
MMF	B-X
)	B-X
,	B-X
leflunomide	B-X
(	B-X
LEF	B-X
)	B-X
,	B-X
cyclophosphamide	B-X
(	B-X
Cy	B-X
)	B-X
or	B-X
none	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
levels	B-X
and	B-X
function	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
in	B-X
draining	B-X
lymph	B-X
nodes	B-X
(	B-X
dLNs	B-X
)	B-X
and	B-X
spleens	B-X
were	B-X
determined	B-X
at	B-X
different	B-X
time	B-X
points	B-X
.	B-X
Significantly	B-X
higher	B-X
percentage	B-X
and	B-X
cell	B-X
number	B-X
of	B-X
Ag-specific	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
were	B-X
observed	B-X
in	B-X
OVA	B-X
immunized	B-X
mice	B-X
treated	B-X
with	B-X
RPM	B-X
or	B-X
FTY720	B-X
compared	B-X
with	B-X
mice	B-X
that	B-X
received	B-X
OVA	B-X
immunization	B-X
alone	B-X
.	B-X
Furthermore	B-X
,	B-X
RPM	B-X
augmented	B-X
the	B-X
population	B-X
of	B-X
functional	B-X
iTregs	B-X
in	B-X
dLNs	B-X
and	B-X
spleens	B-X
whereas	B-X
inhibited	B-X
nTregs	B-X
during	B-X
immune	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
RPM	B-X
and	B-X
FTY720	B-X
,	B-X
MMF	B-X
,	B-X
LEF	B-X
,	B-X
CsA	B-X
,	B-X
and	B-X
Cy	B-X
markedly	B-X
decreased	B-X
the	B-X
levels	B-X
of	B-X
Ag-specific	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
KJ1-26	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
during	B-X
immune	B-X
response	B-X
.	B-X
Thus	B-X
,	B-X
different	B-X
immunosuppressive	B-X
drugs	B-X
have	B-X
distinct	B-X
effects	B-X
on	B-X
the	B-X
Ag-specific	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
during	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
stronger	B-X
inhibiting	B-X
effects	B-X
of	B-X
MMF	B-X
,	B-X
LEF	B-X
,	B-X
CsA	B-X
and	B-X
Cy	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
than	B-X
on	B-X
T	B-X
effectors	B-X
may	B-X
block	B-X
the	B-X
host	B-X
immune	B-X
tolerance	B-X
potentiality	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
has	O
already	O
been	O
shown	O
to	O
negatively	O
regulate	O
the	O
development	O
of	O
naive	O
T	O
cells	O
into	O
Th1	O
or	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
-	O
producing	O
T	O
cells	O
(	O
Th17	O
)	O
[	O
46	O
,	O
47	O
]	O
.	O
<EOS>	B-X
Interleukin-17	B-X
(	B-X
IL-17	B-X
)	B-X
is	B-X
a	B-X
proinflammatory	B-X
cytokine	B-X
that	B-X
is	B-X
most	B-X
prominently	B-X
produced	B-X
by	B-X
T-helper	B-X
type	B-X
17	B-X
(	B-X
Th17	B-X
)	B-X
cells	B-X
,	B-X
a	B-X
distinct	B-X
CD4+	B-X
T-helper	B-X
cell	B-X
subset	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
level	B-X
of	B-X
IL-17-producing	B-X
cells	B-X
in	B-X
the	B-X
breast	B-X
cancer	B-X
tumour	B-X
microenvironment	B-X
and	B-X
its	B-X
prognostic	B-X
role	B-X
.	B-X

Similar	O
effects	O
have	O
been	O
recently	O
described	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
which	O
,	O
combined	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
inhibits	O
the	O
generation	O
of	O
iTreg	O
cells	O
and	O
induces	O
differentiation	O
into	O
the	O
Th17	O
cells	O
by	O
an	O
unknown	O
mechanism	O
[	O
48	O
,	O
49	O
]	O
.	O

Thus	O
the	O
polarization	O
into	O
iTreg	O
cells	O
is	O
negatively	O
regulated	O
by	O
the	O
effector	O
cytokines	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
has	O
been	O
previously	O
shown	O
to	O
induce	O
the	O
generation	O
of	O
FOXP3	B-Protein
+	O
Treg	O
cells	O
out	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
[	O
50	O
]	O
.	O

In	O
those	O
experiments	O
,	O
the	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
used	O
were	O
low	O
,	O
and	O
as	O
we	O
also	O
observed	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
at	O
low	O
concentration	O
slightly	O
enhanced	O
FOXP3	B-Protein
expression	O
.	O

Importantly	O
,	O
these	O
concentrations	O
were	O
not	O
sufficient	O
to	O
induce	O
GATA3	B-Protein
expression	O
.	O
<EOS>	B-X
C-reactive	B-X
protein	B-X
(	B-X
CRP	B-X
)	B-X
is	B-X
a	B-X
positive	B-X
acute-phase	B-X
protein	B-X
,	B-X
serum	B-X
concentrations	B-X
of	B-X
which	B-X
increase	B-X
nonspecifically	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
processes	B-X
of	B-X
the	B-X
dog	B-X
.	B-X
The	B-X
diversity	B-X
of	B-X
the	B-X
assays	B-X
available	B-X
to	B-X
measure	B-X
CRP	B-X
in	B-X
dogs	B-X
is	B-X
nearly	B-X
as	B-X
numerous	B-X
as	B-X
the	B-X
diseases	B-X
in	B-X
which	B-X
serum	B-X
concentrations	B-X
of	B-X
this	B-X
protein	B-X
are	B-X
increased	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
protein	B-X
precipitation	B-X
by	B-X
alcohol	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
the	B-X
solubility	B-X
and	B-X
structural	B-X
changes	B-X
of	B-X
protein	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
alcohol	B-X
concentrations	B-X
.	B-X
Conformation	B-X
of	B-X
hen	B-X
egg-white	B-X
lysozyme	B-X
was	B-X
changed	B-X
from	B-X
native	B-X
to	B-X
α-helical	B-X
rich	B-X
structure	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ethanol	B-X
at	B-X
concentrations	B-X
above	B-X
60	B-X
%	B-X
.	B-X
The	B-X
solubility	B-X
of	B-X
lysozyme	B-X
was	B-X
reduced	B-X
with	B-X
increasing	B-X
ethanol	B-X
concentration	B-X
,	B-X
although	B-X
gel	B-X
formation	B-X
at	B-X
ethanol	B-X
concentrations	B-X
between	B-X
60	B-X
%	B-X
and	B-X
75	B-X
%	B-X
prevented	B-X
accurate	B-X
solubility	B-X
measurements	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
may	O
favor	O
proliferation	O
of	O
nTreg	O
cells	O
[	O
47	O
]	O
or	O
directly	O
regulate	O
FOXP3	B-Protein
expression	O
in	O
a	O
STAT	O
-	O
dependent	O
fashion	O
[	O
51	O
]	O
.	O

Since	O
IL	B-Protein
-	I-Protein
13	I-Protein
does	O
not	O
effectively	O
reduce	O
FOXP3	B-Protein
and	O
fails	O
to	O
induce	O
GATA3	B-Protein
,	O
we	O
hypothesized	O
that	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
dependent	O
inhibition	O
of	O
FOXP3	B-Protein
could	O
be	O
mediated	O
by	O
GATA3	B-Protein
.	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
belong	B-X
to	B-X
the	B-X
T	B-X
helper	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
cytokine	B-X
family	B-X
,	B-X
along	B-X
with	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-9	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
implicated	B-X
IL-4	B-X
and	B-X
IL-13	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Recent	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
might	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
downregulation	B-X
of	B-X
inflammatory	B-X
processes	B-X
underlying	B-X
RA	B-X
pathology	B-X
,	B-X
and	B-X
beneficially	B-X
modulate	B-X
the	B-X
course	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
biological	B-X
features	B-X
of	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
and	B-X
provides	B-X
current	B-X
knowledge	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
these	B-X
cytokines	B-X
in	B-X
inflammatory	B-X
arthritis	B-X
.	B-X

In	O
fact	O
,	O
GATA3	B-Protein
-	O
inducing	O
IL	B-Protein
-	I-Protein
4	I-Protein
concentrations	O
repressed	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
FOXP3	B-Protein
expression	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
well	O
as	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
signaling	O
were	O
intact	O
.	O

This	O
result	O
suggested	O
a	O
competitive	O
mechanism	O
between	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
transcription	O
factors	O
in	O
determining	O
lineage	O
commitment	O
during	O
the	O
early	O
phase	O
of	O
differentiation	O
.	O

Accordingly	O
,	O
we	O
investigated	O
naturally	O
high	O
GATA3	B-Protein
-	O
expressing	O
cells	O
and	O
confirmed	O
the	O
absence	O
of	O
FOXP3	B-Protein
.	O

Protein	O
transduction	O
of	O
GATA3	B-Protein
into	O
naive	O
T	O
cells	O
inhibited	O
FOXP3	B-Protein
induction	O
in	O
human	O
,	O
differentiating	O
,	O
naive	O
T	O
cells	O
.	O

This	O
inhibitory	O
effect	O
of	O
GATA3	B-Protein
was	O
further	O
confirmed	O
in	O
BALB	O
/	O
c	O
transgenic	O
mice	O
,	O
expressing	O
GATA3	B-Protein
in	O
T	O
cells	O
(	O
DO11	O
.	O
10	O
:	O
CD2	B-Protein
-	O
GATA3	B-Protein
transgenic	O
mice	O
)	O
.	O

In	O
line	O
with	O
the	O
transient	O
overexpression	O
of	O
GATA3	B-Protein
in	O
human	O
T	O
cells	O
,	O
cells	O
of	O
these	O
mice	O
failed	O
to	O
induce	O
FOXP3	B-Protein
expression	O
upon	O
exposure	O
with	O
antigen	O
in	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

Strikingly	O
,	O
the	O
DO11	O
.	O
10	O
:	O
CD2	B-Protein
-	O
GATA3	B-Protein
mice	O
do	O
have	O
peripheral	O
FOXP3	B-Protein
+	O
cells	O
,	O
which	O
however	O
displayed	O
a	O
10	O
%	O
-	O
25	O
%	O
lower	O
frequency	O
compared	O
to	O
wild	O
-	O
type	O
DO11	O
.	O
10	O
mice	O
.	O

Thus	O
GATA3	B-Protein
restrains	O
the	O
development	O
of	O
certain	O
Treg	O
subsets	O
,	O
presumably	O
the	O
inducible	O
,	O
peripheral	O
population	O
and	O
not	O
those	O
of	O
thymic	O
origin	O
.	O

Thymic	O
T	O
cells	O
undergo	O
a	O
different	O
maturation	O
process	O
,	O
which	O
may	O
explain	O
the	O
insensitivity	O
of	O
nTreg	O
to	O
GATA3	B-Protein
overexpression	O
[	O
52	O
]	O
.	O

In	O
contrast	O
to	O
the	O
Th2	O
-	O
differentiating	O
and	O
iTreg	O
-	O
inhibiting	O
function	O
of	O
GATA3	B-Protein
in	O
peripheral	O
T	O
cells	O
,	O
GATA3	B-Protein
acts	O
in	O
the	O
thymus	O
together	O
with	O
other	O
transcription	O
factors	O
such	O
as	O
the	O
Repressor	B-Protein
of	I-Protein
GATA3	I-Protein
(	O
ROG	B-Protein
)	O
in	O
the	O
differentiation	O
process	O
toward	O
CD8	B-Protein
cells	O
[	O
53	O
,	O
54	O
]	O
or	O
participates	O
in	O
complex	O
transcriptional	O
feedback	O
network	O
to	O
regulate	O
sympathoadrenal	O
differentiation	O
[	O
55	O
]	O
.	O
<EOS>	B-X
Gata3	B-X
mutant	B-X
mice	B-X
expire	B-X
of	B-X
noradrenergic	B-X
deficiency	B-X
by	B-X
embryonic	B-X
day	B-X
(	B-X
E	B-X
)	B-X
11	B-X
and	B-X
can	B-X
be	B-X
rescued	B-X
pharmacologically	B-X
or	B-X
,	B-X
as	B-X
shown	B-X
here	B-X
,	B-X
by	B-X
restoring	B-X
Gata3	B-X
function	B-X
specifically	B-X
in	B-X
sympathoadrenal	B-X
(	B-X
SA	B-X
)	B-X
lineages	B-X
using	B-X
the	B-X
human	B-X
DBH	B-X
promoter	B-X
to	B-X
direct	B-X
Gata3	B-X
transgenic	B-X
expression	B-X
.	B-X
In	B-X
Gata3-null	B-X
embryos	B-X
,	B-X
there	B-X
was	B-X
significant	B-X
impairment	B-X
of	B-X
SA	B-X
differentiation	B-X
and	B-X
increased	B-X
apoptosis	B-X
in	B-X
adrenal	B-X
chromaffin	B-X
cells	B-X
and	B-X
sympathetic	B-X
neurons	B-X
.	B-X
Additionally	B-X
,	B-X
mRNA	B-X
analyses	B-X
of	B-X
purified	B-X
chromaffin	B-X
cells	B-X
from	B-X
Gata3	B-X
mutants	B-X
show	B-X
that	B-X
levels	B-X
of	B-X
Mash1	B-X
,	B-X
Hand2	B-X
and	B-X
Phox2b	B-X
(	B-X
postulated	B-X
upstream	B-X
regulators	B-X
of	B-X
Gata3	B-X
)	B-X
as	B-X
well	B-X
as	B-X
terminally	B-X
differentiated	B-X
SA	B-X
lineage	B-X
products	B-X
(	B-X
tyrosine	B-X
hydroxylase	B-X
,	B-X
Th	B-X
,	B-X
and	B-X
dopamine	B-X
beta-hydroxylase	B-X
,	B-X
Dbh	B-X
)	B-X
are	B-X
markedly	B-X
altered	B-X
.	B-X
However	B-X
,	B-X
SA	B-X
lineage-specific	B-X
restoration	B-X
of	B-X
Gata3	B-X
function	B-X
in	B-X
the	B-X
Gata3	B-X
mutant	B-X
background	B-X
rescues	B-X
the	B-X
expression	B-X
phenotypes	B-X
of	B-X
the	B-X
downstream	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
putative	B-X
upstream	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
not	B-X
only	B-X
underscore	B-X
the	B-X
hypothesis	B-X
that	B-X
Gata3	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
differentiation	B-X
and	B-X
survival	B-X
of	B-X
SA	B-X
cells	B-X
,	B-X
but	B-X
also	B-X
suggest	B-X
that	B-X
their	B-X
differentiation	B-X
is	B-X
controlled	B-X
by	B-X
mutually	B-X
reinforcing	B-X
feedback	B-X
transcriptional	B-X
interactions	B-X
between	B-X
Gata3	B-X
,	B-X
Mash1	B-X
,	B-X
Hand2	B-X
and	B-X
Phox2b	B-X
in	B-X
the	B-X
SA	B-X
lineage	B-X
.	B-X

Therefore	O
,	O
the	O
role	O
of	O
GATA3	B-Protein
appears	O
to	O
be	O
tissue	O
specific	O
and	O
cannot	O
be	O
generalized	O
.	O

Our	O
study	O
demonstrates	O
that	O
GATA3	B-Protein
repressed	O
FOXP3	B-Protein
expression	O
directly	O
by	O
binding	O
to	O
the	O
FOXP3	B-Protein
promoter	O
region	O
.	O

A	O
palindromic	O
GATA	O
-	O
site	O
is	O
located	O
303	O
bp	O
upstream	O
of	O
the	O
TSS	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
which	O
we	O
have	O
previously	O
identified	O
as	O
the	O
FOXP3	B-Protein
promoter	O
[	O
24	O
]	O
.	O

Site	O
-	O
specific	O
mutation	O
of	O
this	O
site	O
increased	O
the	O
activity	O
of	O
the	O
promoter	O
constructs	O
,	O
thus	O
revealing	O
the	O
repressive	O
nature	O
of	O
this	O
GATA	O
element	O
in	O
memory	O
T	O
cells	O
,	O
which	O
naturally	O
express	O
GATA3	B-Protein
,	O
whereas	O
no	O
difference	O
was	O
seen	O
in	O
naive	O
T	O
cells	O
,	O
which	O
do	O
not	O
express	O
GATA3	B-Protein
.	O

This	O
palindromic	O
GATA	O
element	O
is	O
bound	O
by	O
GATA3	B-Protein
protein	O
as	O
proven	O
with	O
pull	O
-	O
down	O
experiments	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
by	O
ChIP	O
that	O
GATA3	B-Protein
binds	O
this	O
element	O
also	O
in	O
intact	O
cells	O
.	O

It	O
is	O
known	O
that	O
GATA3	B-Protein
can	O
induce	O
transcription	O
by	O
chromatin	O
remodeling	O
[	O
56	O
]	O
,	O
by	O
directly	O
transactivating	O
promoters	O
[	O
36	O
]	O
,	O
or	O
,	O
as	O
shown	O
in	O
the	O
current	O
study	O
,	O
acts	O
as	O
a	O
repressor	O
of	O
gene	O
expression	O
[	O
21	O
,	O
57	O
-	O
59	O
]	O
.	O
<EOS>	B-X
Translational	B-X
control	B-X
regulates	B-X
the	B-X
levels	B-X
of	B-X
protein	B-X
synthesized	B-X
from	B-X
its	B-X
transcript	B-X
and	B-X
is	B-X
key	B-X
for	B-X
the	B-X
rapid	B-X
adjustment	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
environmental	B-X
stimuli	B-X
.	B-X
Three	B-X
control	B-X
mechanisms	B-X
are	B-X
currently	B-X
proposed	B-X
in	B-X
Plasmodium	B-X
,	B-X
(	B-X
1	B-X
)	B-X
global	B-X
regulation	B-X
that	B-X
acts	B-X
on	B-X
the	B-X
translation	B-X
initiation	B-X
complex	B-X
;	B-X
(	B-X
2	B-X
)	B-X
mRNA-specific	B-X
regulation	B-X
,	B-X
involving	B-X
cis	B-X
control	B-X
elements	B-X
,	B-X
mRNA-binding	B-X
proteins	B-X
and	B-X
translational	B-X
repressors	B-X
;	B-X
and	B-X
(	B-X
3	B-X
)	B-X
induced	B-X
mRNA	B-X
decay	B-X
by	B-X
the	B-X
Ccr4-Not	B-X
and	B-X
the	B-X
RNA	B-X
exosome	B-X
complex	B-X
.	B-X
Prostate	B-X
cancer	B-X
is	B-X
the	B-X
most	B-X
frequently	B-X
diagnosed	B-X
cancer	B-X
in	B-X
males	B-X
and	B-X
its	B-X
development	B-X
and	B-X
progression	B-X
remains	B-X
an	B-X
important	B-X
area	B-X
of	B-X
study	B-X
.	B-X
Recently	B-X
,	B-X
long	B-X
non-coding	B-X
RNAs	B-X
(	B-X
lncRNAs	B-X
)	B-X
have	B-X
been	B-X
evidenced	B-X
as	B-X
key	B-X
players	B-X
in	B-X
cancer	B-X
pathogenesis	B-X
.	B-X
Specifically	B-X
,	B-X
dysregulation	B-X
of	B-X
long	B-X
non-coding	B-X
RNA	B-X
(	B-X
lncRNA	B-X
)	B-X
expression	B-X
has	B-X
shown	B-X
to	B-X
affect	B-X
tumor	B-X
proliferation	B-X
and	B-X
metastasis	B-X
,	B-X
acting	B-X
as	B-X
either	B-X
tumor	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
currently	B-X
available	B-X
information	B-X
on	B-X
prostate	B-X
cancer-related	B-X
lncRNAs	B-X
,	B-X
including	B-X

Therefore	O
keeping	O
GATA3	B-Protein
expression	O
low	O
might	O
be	O
required	O
to	O
induce	O
efficient	O
FOXP3	B-Protein
+	O
iTreg	O
cell	O
generation	O
.	O

The	O
molecular	O
interactions	O
enabling	O
GATA3	B-Protein
to	O
inhibit	O
FOXP3	B-Protein
are	O
not	O
identified	O
yet	O
,	O
but	O
the	O
GATA	O
-	O
binding	O
site	O
is	O
located	O
adjacent	O
to	O
positive	O
,	O
inducing	O
sites	O
,	O
composed	O
of	O
AP	O
-	O
1	O
-	O
NFATc2	O
sites	O
[	O
24	O
]	O
,	O
and	O
GATA3	B-Protein
may	O
compete	O
with	O
the	O
binding	O
of	O
AP	B-Protein
-	I-Protein
1	I-Protein
/	O
NFAT	B-Protein
to	O
the	O
promoter	O
(	O
unpublished	O
observations	O
)	O
.	O

In	O
summary	O
,	O
we	O
demonstrated	O
that	O
FOXP3	B-Protein
is	O
negatively	O
regulated	O
by	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

GATA3	B-Protein
acts	O
as	O
an	O
inhibitor	O
of	O
FOXP3	B-Protein
expression	O
in	O
early	O
T	O
cell	O
differentiation	O
,	O
as	O
well	O
as	O
in	O
differentiated	O
Th2	O
cells	O
by	O
directly	O
binding	O
and	O
repressing	O
the	O
FOXP3	B-Protein
promoter	O
.	O

We	O
therefore	O
describe	O
a	O
new	O
mechanism	O
of	O
how	O
Il	B-Protein
-	I-Protein
4	I-Protein
avoids	O
tolerance	O
induction	O
by	O
repressing	O
FOXP3	B-Protein
expression	O
.	O

These	O
findings	O
will	O
give	O
new	O
perspectives	O
toward	O
understanding	O
molecular	O
mechanisms	O
of	O
iTreg	O
induction	O
and	O
thus	O
pathways	O
of	O
peripheral	O
tolerance	O
induction	O
,	O
particularly	O
in	O
allergy	O
and	O
asthma	O
.	O

Mice	O
.	O
<EOS>	B-X
The	B-X
problem	B-X
of	B-X
passenger	B-X
genes	B-X
in	B-X
transgenic	B-X
mice	B-X
.	B-X
Studies	B-X
on	B-X
cryopreservation	B-X
of	B-X
embryos	B-X
and	B-X
gametes	B-X
in	B-X
mice	B-X
.	B-X
Mice	B-X
may	B-X
become	B-X
caught	B-X
in	B-X
nesting	B-X
material	B-X
.	B-X
Mice	B-X
cloned	B-X
from	B-X
cultured	B-X
stem	B-X
cells	B-X
.	B-X

Normal	O
B6	O
mice	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Transgenic	O
DO11	O
.	O
10	O
mice	O
,	O
expressing	O
a	O
T	O
cell	O
receptor	O
for	O
OVA323	O
-	O
339	O
peptide	O
in	O
the	O
context	O
of	O
H	O
-	O
2d	O
,	O
were	O
backcrossed	O
with	O
mice	O
expressing	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
driven	O
by	O
the	O
human	O
CD2	B-Protein
locus	O
control	O
region	O
(	O
CD2	B-Protein
-	O
GATA3	B-Protein
)	O
[	O
22	O
]	O
,	O
resulting	O
in	O
DO11	O
.	O
10xCD2	B-Protein
-	O
GATA3	B-Protein
mice	O
.	O

Mice	O
used	O
for	O
experiments	O
were	O
backcrossed	O
on	O
a	O
BALB	O
/	O
c	O
background	O
for	O
a	O
minimum	O
of	O
eight	O
generations	O
and	O
used	O
at	O
an	O
age	O
of	O
8	O
-	O
12	O
wk	O
.	O

Mice	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
and	O
all	O
animal	O
studies	O
were	O
performed	O
according	O
to	O
institutional	O
and	O
state	O
guidelines	O
.	O

Isolation	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
.	O
<EOS>	B-X
Once	B-X
regarded	B-X
as	B-X
an	B-X
experimental	B-X
artefact	B-X
,	B-X
cytotoxic	B-X
CD4	B-X
The	B-X
pathogenic	B-X
immune	B-X
response	B-X
in	B-X
celiac	B-X
disease	B-X
(	B-X
CeD	B-X
)	B-X
is	B-X
orchestrated	B-X
by	B-X
phenotypically	B-X
distinct	B-X
CD4	B-X
Humoral	B-X
adaptive	B-X
immune	B-X
responses	B-X
trigger	B-X
the	B-X
establishment	B-X
of	B-X
plasma	B-X
B	B-X
cells	B-X
secreting	B-X
antibodies	B-X
of	B-X
various	B-X
isotypes	B-X
that	B-X
bind	B-X
antigen	B-X
specifically	B-X
and	B-X
with	B-X
high	B-X
affinity	B-X
.	B-X
Moreover	B-X
,	B-X
memory	B-X
B	B-X
cells	B-X
will	B-X
be	B-X
generated	B-X
.	B-X
To	B-X
accomplish	B-X
this	B-X
,	B-X
B	B-X
cells	B-X
need	B-X
assistance	B-X
from	B-X
a	B-X
special	B-X
subset	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
so	B-X
called	B-X
follicular	B-X
T	B-X
cells	B-X
that	B-X
differentiate	B-X
from	B-X
naïve	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
course	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
study	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
is	B-X
of	B-X
primordial	B-X
interest	B-X
when	B-X
investigating	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
determinants	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
This	B-X
is	B-X
done	B-X
by	B-X
direct	B-X
analysis	B-X
of	B-X
the	B-X
cells	B-X
isolated	B-X
from	B-X
mice	B-X
following	B-X
an	B-X
immunological	B-X
challenge	B-X
but	B-X
in	B-X
many	B-X
instances	B-X
such	B-X
analyses	B-X
must	B-X
involve	B-X
follow-up	B-X
studies	B-X
in	B-X
cell	B-X
culture	B-X
requiring	B-X
living	B-X
cells	B-X
.	B-X
Especially	B-X
,	B-X
in	B-X
vitro	B-X
experimentation	B-X
necessitates	B-X
isolation	B-X
and	B-X
sorting	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
follicular	B-X
T	B-X
cells	B-X
are	B-X
generally	B-X
difficult	B-X
to	B-X
handle	B-X
because	B-X
they	B-X
are	B-X
prone	B-X
to	B-X
apoptosis	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
evident	B-X
when	B-X
dealing	B-X
with	B-X
follicular	B-X
T	B-X
cells	B-X
residing	B-X
in	B-X
the	B-X
gut	B-X
since	B-X
we	B-X
observed	B-X
that	B-X
isolation	B-X
and	B-X
processing	B-X
from	B-X
murine	B-X
gut	B-X
notoriously	B-X
results	B-X
in	B-X
very	B-X
high	B-X
loss	B-X
rates	B-X
when	B-X
compared	B-X
for	B-X
example	B-X
to	B-X
cells	B-X
obtained	B-X
from	B-X
immunized	B-X
peripheral	B-X
lymph	B-X
nodes	B-X
.	B-X
To	B-X
bypass	B-X
these	B-X
limitations	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
protocol	B-X
that	B-X
allows	B-X
for	B-X
efficient	B-X
isolation	B-X
of	B-X
intact	B-X
follicular	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
protocol	B-X
introduced	B-X
here	B-X
illustrates	B-X
isolation	B-X
and	B-X
handling	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
using	B-X
murine	B-X
Peyer	B-X
's	B-X
Patches	B-X
as	B-X
an	B-X
example	B-X
because	B-X
they	B-X
constantly	B-X
harbor	B-X
significant	B-X
amounts	B-X
of	B-X
these	B-X
cells	B-X
.	B-X

CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
from	O
blood	O
of	O
healthy	O
human	O
volunteers	O
using	O
the	O
anti	O
-	O
CD4	B-Protein
magnetic	O
beads	O
(	O
Dynal	O
,	O
Hamburg	O
,	O
Germany	O
)	O
as	O
previously	O
described	O
[	O
60	O
]	O
.	O

The	O
purity	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
FACS	O
and	O
was	O
>	O
=	O
95	O
%	O
.	O

Monoclonality	O
of	O
T	O
cell	O
clones	O
was	O
confirmed	O
by	O
TCR	O
-	O
chain	O
mapping	O
and	O
was	O
identified	O
to	O
be	O
Vbeta8	O
positive	O
.	O

The	O
clones	O
were	O
characterized	O
by	O
high	O
IL	B-Protein
-	I-Protein
4	I-Protein
secretion	O
.	O
<EOS>	B-X
Invariant	B-X
NKT	B-X
(	B-X
iNKT	B-X
)	B-X
cells	B-X
in	B-X
healthy	B-X
people	B-X
express	B-X
iNKT-TCRs	B-X
with	B-X
widely	B-X
varying	B-X
affinities	B-X
for	B-X
CD1d	B-X
,	B-X
suggesting	B-X
different	B-X
roles	B-X
for	B-X
high-	B-X
and	B-X
low-affinity	B-X
iNKT	B-X
clones	B-X
in	B-X
immune	B-X
regulation	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
a	B-X
selective	B-X
loss	B-X
of	B-X
clones	B-X
expressing	B-X
high-affinity	B-X
iNKT-TCRs	B-X
from	B-X
the	B-X
iNKT	B-X
repertoire	B-X
of	B-X
people	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
Furthermore	B-X
,	B-X
this	B-X
bias	B-X
in	B-X
the	B-X
clonal	B-X
iNKT	B-X
repertoire	B-X
in	B-X
type	B-X
1	B-X
diabetes	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
GM-CSF	B-X
,	B-X
IL-4	B-X
,	B-X
and	B-X
IL-13	B-X
cytokine	B-X
secretion	B-X
among	B-X
Ag-stimulated	B-X
low-affinity	B-X
iNKT	B-X
clones	B-X
.	B-X
Thus	B-X
,	B-X
qualitative	B-X
changes	B-X
of	B-X
the	B-X
clonal	B-X
iNKT	B-X
repertoire	B-X
with	B-X
the	B-X
potential	B-X
to	B-X
affect	B-X
the	B-X
regulatory	B-X
function	B-X
of	B-X
this	B-X
highly	B-X
conserved	B-X
T	B-X
cell	B-X
population	B-X
are	B-X
already	B-X
established	B-X
at	B-X
the	B-X
early	B-X
stages	B-X
in	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X

Quantitative	O
real	O
-	O
time	O
PCR	O
.	O
<EOS>	B-X
Quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
a	B-X
routinely	B-X
used	B-X
method	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantitation	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
real	B-X
time	B-X
.	B-X
Multiplex	B-X
qPCR	B-X
requires	B-X
the	B-X
use	B-X
of	B-X
probe-based	B-X
assays	B-X
,	B-X
in	B-X
which	B-X
each	B-X
probe	B-X
is	B-X
labeled	B-X
with	B-X
a	B-X
unique	B-X
fluorescent	B-X
dye	B-X
,	B-X
resulting	B-X
in	B-X
different	B-X
observed	B-X
colors	B-X
for	B-X
each	B-X
assay	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
method	B-X
using	B-X
the	B-X
SensiFAST	B-X
and	B-X
SensiFAST	B-X
One-Step	B-X
probe	B-X
kits	B-X
which	B-X
allows	B-X
simultaneous	B-X
real-time	B-X
quantitation	B-X
of	B-X
up	B-X
to	B-X
5	B-X
amplicons	B-X
.	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
is	B-X
a	B-X
technique	B-X
for	B-X
simultaneous	B-X
amplification	B-X
and	B-X
product	B-X
quantification	B-X
of	B-X
a	B-X
target	B-X
DNA	B-X
as	B-X
the	B-X
process	B-X
takes	B-X
place	B-X
in	B-X
real	B-X
time	B-X
in	B-X
a	B-X
``	B-X
closed-tube	B-X
''	B-X
system	B-X
.	B-X
The	B-X
quantification	B-X
process	B-X
employs	B-X
melting	B-X
curve	B-X
analysis	B-X
and/or	B-X
fluorescent	B-X
detection	B-X
systems	B-X
and	B-X
can	B-X
provide	B-X
amplification	B-X
and	B-X
genotyping	B-X
in	B-X
a	B-X
relatively	B-X
short	B-X
time	B-X
.	B-X

The	O
PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	B-Protein
forward	O
primer	O
5	O
'	O
-	O
GAA	O
ACA	O
GCA	O
CAT	O
TCC	O
CAG	O
AGT	O
TC	O
-	O
3	O
'	O
;	O
FOXP3	B-Protein
reverse	O
primer	O
5	O
'	O
-	O
ATG	O
GCC	O
CAG	O
CGG	O
ATG	O
AG	O
-	O
3	O
'	O
;	O
EF	B-Protein
-	I-Protein
1alpha	I-Protein
forward	O
primer	O
and	O
reverse	O
primer	O
as	O
described	O
[	O
61	O
]	O
;	O
GATA3	B-Protein
forward	O
primer	O
5	O
'	O
-	O
GCG	O
GGC	O
TCT	O
ATC	O
ACA	O
AAA	O
TGA	O
-	O
3	O
'	O
and	O
rwd	O
5	O
'	O
-	O
GCT	O
CTC	O
CTG	O
GCT	O
GCA	O
GAC	O
AGC	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
-	O
PCR	O
mastermix	O
(	O
Biorad	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Quantitative	O
PCR	O
of	O
murine	O
samples	O
was	O
performed	O
with	O
Brilliant	O
SYBR	O
Green	O
QPCR	O
master	O
mix	O
(	O
Stratagene	O
)	O
and	O
the	O
following	O
primers	O
:	O
Ubiquitin	B-Protein
C	I-Protein
,	O
5	O
'	O
-	O
AGG	O
TCA	O
AAC	O
AGG	O
AAG	O
ACA	O
GAC	O
GTA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TCACACCCAAGAACAAGCACA	O
-	O
3	O
'	O
;	O
Smad	B-Protein
-	I-Protein
7	I-Protein
,	O
5	O
'	O
-	O
GAA	O
ACC	O
GGG	O
GGA	O
ACG	O
AAT	O
TAT	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CGC	O
GAG	O
TCT	O
TCT	O
CCT	O
CCC	O
A	O
-	O
3	O
'	O
;	O
TGF	B-Protein
-	I-Protein
ss1	I-Protein
,	O
5	O
'	O
-	O
TGA	O
CGT	O
CAC	O
TGG	O
AGT	O
TGT	O
ACG	O
G	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GGT	O
TCA	O
TGT	O
CAT	O
GGA	O
TGG	O
TGC	O
-	O
3	O
'	O
.	O

Primer	O
pairs	O
were	O
evaluated	O
for	O
integrity	O
by	O
analysis	O
of	O
the	O
amplification	O
plot	O
,	O
dissociation	O
curves	O
,	O
and	O
efficiency	O
of	O
PCR	O
amplification	O
.	O

PCR	O
conditions	O
were	O
10	O
min	O
at	O
95	O
degreesC	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
15	O
s	O
at	O
95	O
degreesC	O
and	O
60	O
degreesC	O
for	O
1	O
min	O
using	O
an	O
7300	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
ubiquitin	B-Protein
C	I-Protein
was	O
performed	O
during	O
each	O
run	O
for	O
each	O
sample	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
deltadeltaCT	O
method	O
.	O

Inducible	O
murine	O
Treg	O
culture	O
.	O
<EOS>	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
regulate	B-X
immune	B-X
responses	B-X
and	B-X
maintain	B-X
self-tolerance	B-X
.	B-X
Recent	B-X
work	B-X
shows	B-X
that	B-X
Treg	B-X
cells	B-X
are	B-X
comprised	B-X
of	B-X
many	B-X
subpopulations	B-X
with	B-X
specialized	B-X
regulatory	B-X
functions	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressing	B-X
the	B-X
coinhibitory	B-X
molecule	B-X
TIGIT	B-X
as	B-X
a	B-X
distinct	B-X
Treg	B-X
cell	B-X
subset	B-X
that	B-X
specifically	B-X
suppresses	B-X
proinflammatory	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th17	B-X
cell	B-X
,	B-X
but	B-X
not	B-X
Th2	B-X
cell	B-X
responses	B-X
.	B-X
Transcriptional	B-X
profiling	B-X
characterized	B-X
TIGIT	B-X
(	B-X
+	B-X
)	B-X
Treg	B-X
cells	B-X
as	B-X
an	B-X
activated	B-X
Treg	B-X
cell	B-X
subset	B-X
with	B-X
high	B-X
expression	B-X
of	B-X
Treg	B-X
signature	B-X
genes	B-X
.	B-X
Ligation	B-X
of	B-X
TIGIT	B-X
on	B-X
Treg	B-X
cells	B-X
induced	B-X
expression	B-X
of	B-X
the	B-X
effector	B-X
molecule	B-X
fibrinogen-like	B-X
protein	B-X
2	B-X
(	B-X
Fgl2	B-X
)	B-X
,	B-X
which	B-X
promoted	B-X
Treg-cell-mediated	B-X
suppression	B-X
of	B-X
T	B-X
effector	B-X
cell	B-X
proliferation	B-X
.	B-X
TIGIT	B-X
expression	B-X
therefore	B-X
identifies	B-X
a	B-X
Treg	B-X
cell	B-X
subset	B-X
that	B-X
demonstrates	B-X
selectivity	B-X
for	B-X
suppression	B-X
of	B-X
Th1	B-X
and	B-X
Th17	B-X
cell	B-X
but	B-X
not	B-X
Th2	B-X
cell	B-X
responses	B-X
.	B-X

Naive	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
CD4	B-Protein
+	O
,	O
CD62L	B-Protein
+	O
,	O
and	O
CD25	B-Protein
-	O
)	O
were	O
isolated	O
from	O
pooled	O
lymph	O
nodes	O
and	O
spleens	O
by	O
FACS	O
(	O
FACS	O
Aria	O
,	O
BD	O
Biosciences	O
)	O
.	O

5	O
x	O
105	O
T	O
cells	O
were	O
co	O
-	O
cultured	O
with	O
2	O
.	O
5	O
x	O
104	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
[	O
62	O
]	O
and	O
0	O
.	O
01	O
mug	O
/	O
ml	O
OVA323	O
-	O
339	O
peptide	O
(	O
Ansynth	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
-	O
ng	O
/	O
mul	O
rhTGF	B-Protein
-	I-Protein
ss1	I-Protein
(	O
Peprotech	O
)	O
in	O
48	O
-	O
well	O
plates	O
.	O

After	O
4	O
d	O
,	O
cells	O
were	O
harvested	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	B-Protein
expression	O
by	O
FACS	O
or	O
gene	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O
<EOS>	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-qPCR	B-X
)	B-X
addresses	B-X
the	B-X
evident	B-X
requirement	B-X
for	B-X
quantitative	B-X
data	B-X
analysis	B-X
in	B-X
molecular	B-X
medicine	B-X
,	B-X
biotechnology	B-X
,	B-X
microbiology	B-X
and	B-X
diagnostics	B-X
and	B-X
has	B-X
become	B-X
the	B-X
method	B-X
of	B-X
choice	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
mRNA	B-X
.	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
standardization	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
series	B-X
of	B-X
RT-qPCR	B-X
protocols	B-X
that	B-X
illustrate	B-X
the	B-X
essential	B-X
technical	B-X
steps	B-X
required	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
that	B-X
are	B-X
reliable	B-X
and	B-X
reproducible	B-X
.	B-X
We	B-X
would	B-X
like	B-X
to	B-X
emphasize	B-X
,	B-X
however	B-X
,	B-X
that	B-X
RT-qPCR	B-X
data	B-X
constitute	B-X
only	B-X
a	B-X
snapshot	B-X
of	B-X
information	B-X
regarding	B-X
the	B-X
quantity	B-X
of	B-X
a	B-X
given	B-X
transcript	B-X
in	B-X
a	B-X
cell	B-X
or	B-X
tissue	B-X
.	B-X
The	B-X
entire	B-X
protocol	B-X
described	B-X
here	B-X
,	B-X
encompassing	B-X
all	B-X
stages	B-X
from	B-X
initial	B-X
assay	B-X
design	B-X
to	B-X
reliable	B-X
qPCR	B-X
data	B-X
analysis	B-X
,	B-X
requires	B-X
approximately	B-X
15	B-X
h	B-X
.	B-X

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
play	B-X
central	B-X
roles	B-X
in	B-X
adaptive	B-X
immunity	B-X
,	B-X
driving	B-X
appropriate	B-X
immune	B-X
responses	B-X
to	B-X
invading	B-X
pathogens	B-X
of	B-X
diverse	B-X
types	B-X
.	B-X
Four	B-X
major	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
subsets	B-X
,	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
Th17	B-X
,	B-X
and	B-X
Treg	B-X
cells	B-X
are	B-X
differentiated	B-X
from	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
upon	B-X
ligation	B-X
of	B-X
their	B-X
T	B-X
cell	B-X
receptors	B-X
with	B-X
antigens	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
cytokines	B-X
they	B-X
receive	B-X
.	B-X
Th1	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
IL-12	B-X
and	B-X
IFN-γ	B-X
,	B-X
mediate	B-X
host	B-X
defense	B-X
against	B-X
intracellular	B-X
pathogens	B-X
by	B-X
exclusively	B-X
expressing	B-X
IFN-γ	B-X
.	B-X
Th2	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
IL4	B-X
,	B-X
secrete	B-X
IL-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
,	B-X
and	B-X
protect	B-X
hosts	B-X
from	B-X
helminths	B-X
.	B-X
IL-6	B-X
plus	B-X
TGF-β	B-X
induces	B-X
Th17	B-X
cells	B-X
,	B-X
another	B-X
Th	B-X
subset	B-X
identified	B-X
relatively	B-X
recently	B-X
,	B-X
express	B-X
IL-17	B-X
and	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
eradication	B-X
of	B-X
extracellular	B-X
bacteria	B-X
and	B-X
fungi	B-X
.	B-X
Treg	B-X
cells	B-X
,	B-X
which	B-X
play	B-X
central	B-X
roles	B-X
in	B-X
immune	B-X
suppression	B-X
,	B-X
are	B-X
composed	B-X
of	B-X
either	B-X
thymus-derived	B-X
Treg	B-X
cells	B-X
(	B-X
tTreg	B-X
cells	B-X
)	B-X
,	B-X
which	B-X
are	B-X
directly	B-X
developed	B-X
from	B-X
CD4-single	B-X
positive	B-X
(	B-X
CD4-SP	B-X
)	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
,	B-X
or	B-X
peripherally	B-X
derived	B-X
Treg	B-X
cells	B-X
(	B-X
pTreg	B-X
cells	B-X
)	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
TGF-β	B-X
plus	B-X
IL-2	B-X
from	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
Although	B-X
the	B-X
regulated	B-X
induction	B-X
of	B-X
Th	B-X
cells	B-X
results	B-X
in	B-X
proper	B-X
eradication	B-X
of	B-X
pathogens	B-X
,	B-X
their	B-X
excess	B-X
activation	B-X
results	B-X
in	B-X
various	B-X
immune-associated	B-X
diseases	B-X
.	B-X
For	B-X
example	B-X
,	B-X
aberrant	B-X
activation	B-X
of	B-X
Th1	B-X
and	B-X
Th17	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
autoimmune	B-X
diseases	B-X
,	B-X
excess	B-X
Th2	B-X
activity	B-X
causes	B-X
atopic	B-X
diseases	B-X
,	B-X
and	B-X
impaired	B-X
function	B-X
of	B-X
Treg	B-X
cells	B-X
due	B-X
to	B-X
abrogation	B-X
of	B-X
Foxp3	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
cause	B-X
fatal	B-X
inflammatory	B-X
disorders	B-X
both	B-X
in	B-X
human	B-X
and	B-X
in	B-X
mouse	B-X
.	B-X
The	B-X
methods	B-X
for	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
each	B-X
Th	B-X
subset	B-X
described	B-X
above	B-X
are	B-X
presented	B-X
here	B-X
.	B-X
We	B-X
hope	B-X
these	B-X
methods	B-X
will	B-X
facilitate	B-X
understanding	B-X
of	B-X
differentiation	B-X
and	B-X
function	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
pathogenesis	B-X
of	B-X
various	B-X
inflammatory	B-X
diseases	B-X
.	B-X

CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
magnetically	O
-	O
sorted	O
(	O
CD45RO	B-Protein
depletion	O
,	O
MACS	O
,	O
according	O
to	O
the	O
protocol	O
of	O
the	O
manufacturer	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
(	O
1	O
mug	O
/	O
ml	O
,	O
Okt3	O
,	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
in	O
Th1	O
conditions	O
:	O
25	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
in	O
Th2	O
conditions	O
:	O
25	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
R	O
&	O
D	O
systems	O
)	O
;	O
or	O
in	O
Treg	O
conditions	O
:	O
10	O
ng	O
/	O
ml	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
5	O
mug	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
30	O
ng	O
/	O
ml	O
)	O
.	O

Cloning	O
of	O
the	O
FOXP3	B-Protein
promoter	O
and	O
construction	O
of	O
mutant	O
constructs	O
.	O

The	O
FOXP3	B-Protein
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
the	O
pGL3	O
FOXP3	B-Protein
-	O
511	O
/	O
+	O
176	O
[	O
24	O
]	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
in	O
the	O
FOXP3	B-Protein
promoter	O
region	O
were	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
following	O
primer	O
and	O
its	O
complementary	O
strand	O
were	O
used	O
:	O
GTT	O
TCT	O
CAT	O
GAG	O
CCC	O
TAT	O
TAA	O
GTC	O
ATT	O
CTT	O
ACC	O
TCT	O
CAC	O
CTC	O
TGT	O
GGT	O
GA	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O
<EOS>	B-X
Because	B-X
transfection	B-X
efficiency	B-X
in	B-X
such	B-X
assays	B-X
can	B-X
be	B-X
low	B-X
,	B-X
promoters	B-X
are	B-X
commonly	B-X
fused	B-X
to	B-X
heterologous	B-X
reporter	B-X
genes	B-X
that	B-X
encode	B-X
enzymes	B-X
that	B-X
can	B-X
be	B-X
quantified	B-X
using	B-X
highly	B-X
sensitive	B-X
assays	B-X
.	B-X
The	B-X
reporter	B-X
protein	B-X
's	B-X
activity	B-X
or	B-X
fluorescence	B-X
within	B-X
a	B-X
transfected	B-X
cell	B-X
population	B-X
is	B-X
approximately	B-X
proportional	B-X
to	B-X
the	B-X
steady-state	B-X
mRNA	B-X
level	B-X
.	B-X
Although	B-X
the	B-X
Escherichia	B-X
coli	B-X
lacZ	B-X
gene	B-X
,	B-X
encoding	B-X
beta-galactosidase	B-X
(	B-X
beta-gal	B-X
)	B-X
,	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
standard	B-X
reporter	B-X
for	B-X
monitoring	B-X
the	B-X
strength	B-X
of	B-X
a	B-X
promoter	B-X
or	B-X
enhancer	B-X
in	B-X
a	B-X
transient	B-X
or	B-X
stable	B-X
transfection	B-X
assay	B-X
,	B-X
it	B-X
is	B-X
predominantly	B-X
used	B-X
as	B-X
an	B-X
internal	B-X
control	B-X
during	B-X
transient	B-X
transfection	B-X
experiments	B-X
.	B-X
When	B-X
used	B-X
in	B-X
this	B-X
manner	B-X
,	B-X
cells	B-X
are	B-X
usually	B-X
transfected	B-X
with	B-X
the	B-X
control	B-X
plasmid	B-X
(	B-X
containing	B-X
a	B-X
ubiquitously	B-X
active	B-X
viral	B-X
promoter	B-X
fused	B-X
to	B-X
the	B-X
E.	B-X
coli	B-X
lacZ	B-X
gene	B-X
)	B-X
and	B-X
an	B-X
experimental	B-X
plasmid	B-X
containing	B-X
another	B-X
reporter	B-X
gene	B-X
(	B-X
e.g.	B-X
,	B-X
luciferase	B-X
or	B-X
chloramphenicol	B-X
acetyltransferase	B-X
[	B-X
CAT	B-X
]	B-X
)	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
promoter	B-X
or	B-X
enhancer	B-X
of	B-X
interest	B-X
.	B-X

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
overnight	O
.	O

3	O
.	O
5	O
mug	O
of	O
the	O
FOXP3	B-Protein
promoter	O
luciferase	B-Protein
reporter	O
vector	O
and	O
0	O
.	O
5	O
mug	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4	B-Protein
+	O
T	O
cells	O
resuspended	O
in	O
100	O
muL	O
of	O
Nucleofector	O
solution	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
electroporated	O
using	O
the	O
U	O
-	O
15	O
program	O
of	O
the	O
Nucleofector	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	B-Protein
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	B-Protein
assay	O
system	O
(	O
Promega	O
Biotech	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Data	O
were	O
normalized	O
by	O
the	O
activity	O
of	O
renilla	O
luciferase	B-Protein
.	O
<EOS>	B-X
The	B-X
renilla	B-X
luciferase	B-X
reporter	B-X
gene	B-X
assay	B-X
was	B-X
used	B-X
to	B-X
verify	B-X
the	B-X
activation	B-X
function	B-X
of	B-X
CD38	B-X
on	B-X
downstream	B-X
factors	B-X
.	B-X
The	B-X
luminescence	B-X
of	B-X
the	B-X
group	B-X
transfected	B-X
with	B-X
both	B-X
CD38	B-X
expression	B-X
plasmid	B-X
and	B-X
TLR9	B-X
promoter	B-X
renilla	B-X
luciferase	B-X
reporter	B-X
plasmid	B-X
was	B-X
significantly	B-X
up-regulated	B-X
compared	B-X
with	B-X
the	B-X
control	B-X
,	B-X
suggesting	B-X
that	B-X
CD38	B-X
may	B-X
activate	B-X
the	B-X
promoter	B-X
of	B-X
TLR9	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
simple	B-X
and	B-X
highly	B-X
accurate	B-X
KE-2	B-X
test	B-X
method	B-X
named	B-X
α-Sens	B-X
that	B-X
uses	B-X
the	B-X
dual	B-X
luciferase	B-X
assay	B-X
system	B-X
and	B-X
attempted	B-X
a	B-X
further	B-X
application	B-X
of	B-X
luciferase-based	B-X
determination	B-X
of	B-X
cell	B-X
viability	B-X
to	B-X
calculate	B-X
the	B-X
normalized	B-X
Antioxidant	B-X
response	B-X
element	B-X
(	B-X
ARE	B-X
)	B-X
-mediated	B-X
transcriptional	B-X
activity	B-X
,	B-X
named	B-X
normalized	B-X
ARE	B-X
Activity	B-X
(	B-X
nAA	B-X
)	B-X
,	B-X
to	B-X
evaluate	B-X
the	B-X
sensitizing	B-X
potential	B-X
of	B-X
chemicals	B-X
.	B-X
A	B-X
cell	B-X
line	B-X
carrying	B-X
the	B-X
ARE-inducible	B-X
Firefly	B-X
luciferase	B-X
reporter	B-X
gene	B-X
and	B-X
Thymidine	B-X
kinase	B-X
(	B-X
TK	B-X
)	B-X
promoter-driven	B-X
Renilla	B-X
luciferase	B-X
gene	B-X
was	B-X
established	B-X
and	B-X
used	B-X
for	B-X
the	B-X
α-Sens	B-X
.	B-X

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
scalable	B-X
method	B-X
for	B-X
measuring	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
following	B-X
RNAi	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
outlines	B-X
methods	B-X
to	B-X
transfect	B-X
cells	B-X
,	B-X
isolate	B-X
total	B-X
RNA	B-X
,	B-X
perform	B-X
cDNA	B-X
synthesis	B-X
,	B-X
run	B-X
qPCR	B-X
reactions	B-X
with	B-X
multiplexed	B-X
TaqMan	B-X
dual	B-X
hydrolysis	B-X
probes	B-X
,	B-X
and	B-X
analyze	B-X
the	B-X
results	B-X
from	B-X
qPCR	B-X
using	B-X
relative	B-X
quantification	B-X
(	B-X
Fleige	B-X
et	B-X
al.	B-X
,	B-X
2006	B-X
)	B-X
.	B-X
These	B-X
methods	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
relative	B-X
knockdown	B-X
of	B-X
a	B-X
set	B-X
of	B-X
siRNAs	B-X
against	B-X
a	B-X
target	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
the	B-X
most	B-X
effective	B-X
molecule	B-X
and	B-X
they	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
potency	B-X
of	B-X
a	B-X
siRNA	B-X
or	B-X
group	B-X
of	B-X
siRNAs	B-X
when	B-X
performed	B-X
over	B-X
a	B-X
range	B-X
of	B-X
doses	B-X
.	B-X
When	B-X
screening	B-X
panels	B-X
of	B-X
siRNAs	B-X
targeting	B-X
a	B-X
given	B-X
gene	B-X
,	B-X
knockdown	B-X
can	B-X
be	B-X
assessed	B-X
in	B-X
two	B-X
phases	B-X
.	B-X

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
TaqMan	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Applied	O
Biosystems	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Recombinant	O
TAT	B-Protein
proteins	O
.	O
<EOS>	B-X
The	B-X
inherent	B-X
ability	B-X
of	B-X
certain	B-X
peptides	B-X
or	B-X
proteins	B-X
of	B-X
viral	B-X
,	B-X
prokaryotic	B-X
and	B-X
eukaryotic	B-X
origin	B-X
to	B-X
bind	B-X
DNA	B-X
was	B-X
used	B-X
to	B-X
generate	B-X
novel	B-X
peptide-based	B-X
DNA	B-X
delivery	B-X
protocols	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
recombinant	B-X
approach	B-X
to	B-X
make	B-X
fusion	B-X
proteins	B-X
with	B-X
motifs	B-X
for	B-X
DNA-binding	B-X
ability	B-X
,	B-X
Mu	B-X
and	B-X
membrane	B-X
transduction	B-X
domains	B-X
,	B-X
TAT	B-X
,	B-X
and	B-X
tested	B-X
them	B-X
for	B-X
their	B-X
DNA-binding	B-X
,	B-X
uptake	B-X
and	B-X
transfection	B-X
efficiencies	B-X
.	B-X
In	B-X
one	B-X
of	B-X
the	B-X
constructs	B-X
,	B-X
the	B-X
recombinant	B-X
plasmid	B-X
was	B-X
designed	B-X
to	B-X
encode	B-X
the	B-X
Mu	B-X
moiety	B-X
of	B-X
sequence	B-X
MRRAHHRRRRASHRRMRGG	B-X
in-frame	B-X
with	B-X
TAT	B-X
of	B-X
sequence	B-X
YGRKKRRQRRR	B-X
to	B-X
generate	B-X
TAT-Mu	B-X
,	B-X
while	B-X
the	B-X
other	B-X
two	B-X
constructs	B-X
,	B-X
Mu	B-X
and	B-X
Mu-Mu	B-X
,	B-X
harbor	B-X
a	B-X
single	B-X
copy	B-X
or	B-X
two	B-X
copies	B-X
of	B-X
the	B-X
Mu	B-X
moiety	B-X
.	B-X
We	B-X
therefore	B-X
produced	B-X
recombinant	B-X
transcription	B-X
factor	B-X
proteins	B-X
in	B-X
E.	B-X
coli	B-X
(	B-X
OCT4	B-X
,	B-X
SOX2	B-X
,	B-X
c-MYC	B-X
and	B-X
KLF4	B-X
)	B-X
carrying	B-X
the	B-X
cell	B-X
penetrating	B-X
TAT	B-X
domain	B-X
from	B-X
HIV1	B-X
.	B-X
The	B-X
purified	B-X
proteins	B-X
were	B-X
able	B-X
to	B-X
enter	B-X
into	B-X
mammalian	B-X
cells	B-X
when	B-X
added	B-X
to	B-X
tissue	B-X
culture	B-X
medium	B-X
but	B-X
appeared	B-X
not	B-X
to	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X

The	O
cDNAs	O
encoding	O
GATA3	B-Protein
protein	O
or	O
the	O
truncated	O
GATA3	B-Protein
(	O
lacking	O
the	O
two	O
zinc	O
fingers	O
)	O
were	O
cloned	O
in	O
frame	O
into	O
an	O
expression	O
vector	O
along	O
with	O
the	O
TAT	B-Protein
sequence	O
as	O
previously	O
described	O
[	O
63	O
]	O
.	O
<EOS>	B-X
We	B-X
screened	B-X
a	B-X
panel	B-X
of	B-X
1,920	B-X
randomly	B-X
selected	B-X
cDNAs	B-X
to	B-X
discover	B-X
genes	B-X
that	B-X
are	B-X
differentially	B-X
expressed	B-X
in	B-X
HL60	B-X
cells	B-X
exposed	B-X
to	B-X
60	B-X
Hz	B-X
magnetic	B-X
fields	B-X
(	B-X
2	B-X
mT	B-X
)	B-X
or	B-X
X	B-X
rays	B-X
(	B-X
5	B-X
Gy	B-X
)	B-X
compared	B-X
to	B-X
unexposed	B-X
cells	B-X
.	B-X
Identification	B-X
of	B-X
these	B-X
clones	B-X
was	B-X
accomplished	B-X
using	B-X
our	B-X
two-gel	B-X
cDNA	B-X
library	B-X
screening	B-X
method	B-X
(	B-X
BIGEL	B-X
)	B-X
.	B-X
Eighteen	B-X
cDNAs	B-X
differentially	B-X
expressed	B-X
in	B-X
X-irradiated	B-X
compared	B-X
to	B-X
control	B-X
HL60	B-X
cells	B-X
were	B-X
recovered	B-X
from	B-X
a	B-X
panel	B-X
of	B-X
1,920	B-X
clones	B-X
.	B-X
Differential	B-X
expression	B-X
in	B-X
experimental	B-X
compared	B-X
to	B-X
control	B-X
cells	B-X
was	B-X
confirmed	B-X
independently	B-X
by	B-X
Northern	B-X
blotting	B-X
of	B-X
paired	B-X
total	B-X
RNA	B-X
samples	B-X
hybridized	B-X
to	B-X
each	B-X
of	B-X
the	B-X
18	B-X
clone-specific	B-X
cDNA	B-X
probes	B-X
.	B-X
DNA	B-X
sequencing	B-X
revealed	B-X
that	B-X
15	B-X
of	B-X
the	B-X
18	B-X
cDNA	B-X
clones	B-X
produced	B-X
matches	B-X
with	B-X
the	B-X
database	B-X
for	B-X
genes	B-X
related	B-X
to	B-X
cell	B-X
growth	B-X
,	B-X
protein	B-X
synthesis	B-X
,	B-X
energy	B-X
metabolism	B-X
,	B-X
oxidative	B-X
stress	B-X
or	B-X
apoptosis	B-X
(	B-X
including	B-X
MYC	B-X
,	B-X
neuroleukin	B-X
,	B-X
copper	B-X
zinc-dependent	B-X
superoxide	B-X
dismutase	B-X
,	B-X
TC4	B-X
RAS-like	B-X
protein	B-X
,	B-X
peptide	B-X
elongation	B-X
factor	B-X
1alpha	B-X
,	B-X
BNIP3	B-X
,	B-X
GATA3	B-X
,	B-X
NF45	B-X
,	B-X
cytochrome	B-X
c	B-X
oxidase	B-X
II	B-X
and	B-X
triosephosphate	B-X
isomerase	B-X
mRNAs	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
BIGEL	B-X
analysis	B-X
of	B-X
the	B-X
same	B-X
1,920	B-X
cDNAs	B-X
revealed	B-X
no	B-X
differences	B-X
greater	B-X
than	B-X
1.5-fold	B-X
in	B-X
expression	B-X
levels	B-X
in	B-X
magnetic-field	B-X
compared	B-X
to	B-X
sham-exposed	B-X
cells	B-X
.	B-X
Magnetic-field-exposed	B-X
and	B-X
control	B-X
samples	B-X
were	B-X
analyzed	B-X
further	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
mRNA	B-X
encoding	B-X
X-ray-responsive	B-X
genes	B-X
by	B-X
hybridization	B-X
of	B-X
the	B-X
18	B-X
specific	B-X
cDNA	B-X
probes	B-X
to	B-X
RNA	B-X
from	B-X
exposed	B-X
and	B-X
control	B-X
HL60	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
differential	B-X
gene	B-X
expression	B-X
is	B-X
induced	B-X
in	B-X
approximately	B-X
1	B-X
%	B-X
of	B-X
a	B-X
random	B-X
pool	B-X
of	B-X
cDNAs	B-X
by	B-X
ionizing	B-X
radiation	B-X
but	B-X
not	B-X
by	B-X
60	B-X
Hz	B-X
magnetic	B-X
fields	B-X
under	B-X
the	B-X
present	B-X
experimental	B-X
conditions	B-X
.	B-X

Proteins	O
were	O
expressed	O
in	O
BL21	O
Star	O
(	O
DE3	O
)	O
pLysS	O
(	O
Invitrogen	O
)	O
and	O
lysates	O
were	O
purified	O
by	O
Ni2	O
+	O
-	O
chelate	O
column	O
chromatography	O
.	O

Both	O
TAT	B-Protein
-	O
linked	O
proteins	O
were	O
more	O
than	O
95	O
%	O
pure	O
,	O
based	O
on	O
Coomassie	O
blue	O
staining	O
of	O
sodium	O
disulfate	O
acrylamide	O
gels	O
.	O

TAT	B-Protein
-	O
GATA3	B-Protein
transduction	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
measure	B-X
markers	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
inflammatory	B-X
cytokines	B-X
(	B-X
such	B-X
as	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IL-4	B-X
,	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
)	B-X
as	B-X
well	B-X
as	B-X
the	B-X
expression	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
regulatory	B-X
genes	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
4	B-X
,	B-X
STAT6	B-X
,	B-X
GATA	B-X
binding	B-X
protein	B-X
3	B-X
(	B-X
GATA3	B-X
)	B-X
,	B-X
and	B-X
T-box	B-X
expressed	B-X
in	B-X
T	B-X
cell	B-X
(	B-X
T-bet	B-X
)	B-X
)	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
taken	B-X
from	B-X
patients	B-X
at	B-X
the	B-X
beginning	B-X
and	B-X
end	B-X
of	B-X
the	B-X
treatment	B-X
.	B-X

CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
cells	O
were	O
cultured	O
in	O
AIMV	O
medium	O
and	O
transduced	O
with	O
20	O
nM	O
,	O
10	O
nM	O
,	O
or	O
500	O
nM	O
of	O
full	O
-	O
length	O
or	O
truncated	O
GATA3	B-Protein
over	O
the	O
course	O
of	O
4	O
h	O
.	O
<EOS>	B-X
Preterm-labour-associated	B-X
preterm	B-X
birth	B-X
is	B-X
a	B-X
common	B-X
cause	B-X
of	B-X
perinatal	B-X
mortality	B-X
and	B-X
morbidity	B-X
in	B-X
twin	B-X
pregnancy	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
test	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
Arabin	B-X
pessary	B-X
would	B-X
reduce	B-X
preterm-labour-associated	B-X
preterm	B-X
birth	B-X
by	B-X
40	B-X
%	B-X
or	B-X
greater	B-X
in	B-X
women	B-X
with	B-X
a	B-X
twin	B-X
pregnancy	B-X
and	B-X
a	B-X
short	B-X
cervix	B-X
.	B-X
These	B-X
ingredients	B-X
are	B-X
used	B-X
in	B-X
19	B-X
cosmetic	B-X
products	B-X
at	B-X
concentrations	B-X
as	B-X
high	B-X
as	B-X
5	B-X
%	B-X
.	B-X
Cosmetic-grade	B-X
material	B-X
may	B-X
be	B-X
extracted	B-X
using	B-X
hexane	B-X
,	B-X
ethanol	B-X
,	B-X
or	B-X
vegetable	B-X
oil	B-X
and	B-X
contain	B-X
the	B-X
full	B-X
range	B-X
of	B-X
phytocompounds	B-X
that	B-X
are	B-X
found	B-X
in	B-X
the	B-X
Capsicum	B-X
annuum	B-X
or	B-X
Capsicum	B-X
frutescens	B-X
plant	B-X
(	B-X
aka	B-X
red	B-X
chiles	B-X
)	B-X
,	B-X
including	B-X
Capsaicin	B-X
.	B-X
Aflatoxin	B-X
and	B-X
N-nitroso	B-X
compounds	B-X
(	B-X
N-nitrosodimethylamine	B-X
and	B-X
N-nitrosopyrrolidine	B-X
)	B-X
have	B-X
been	B-X
detected	B-X
as	B-X
contaminants	B-X
.	B-X
The	B-X
ultraviolet	B-X
(	B-X
UV	B-X
)	B-X
absorption	B-X
spectrum	B-X
for	B-X
Capsicum	B-X
Annuum	B-X
Fruit	B-X
Extract	B-X
indicates	B-X
a	B-X
small	B-X
peak	B-X
at	B-X
approximately	B-X
275	B-X
nm	B-X
,	B-X
and	B-X
a	B-X
gradual	B-X
increase	B-X
in	B-X
absorbance	B-X
,	B-X
beginning	B-X
at	B-X
approximately	B-X
400	B-X
nm	B-X
.	B-X
Capsicum	B-X
and	B-X
paprika	B-X
are	B-X
generally	B-X
recognized	B-X
as	B-X
safe	B-X
by	B-X
the	B-X
U.S.	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
for	B-X
use	B-X
in	B-X
food	B-X
.	B-X
Hexane	B-X
,	B-X
chloroform	B-X
,	B-X
and	B-X
ethyl	B-X
acetate	B-X
extracts	B-X
of	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
at	B-X
200	B-X
mg/kg	B-X
resulted	B-X
in	B-X
death	B-X
of	B-X
all	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
short-term	B-X
inhalation	B-X
toxicity	B-X
study	B-X
using	B-X
rats	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
found	B-X
between	B-X
vehicle	B-X
control	B-X
and	B-X
a	B-X
7	B-X
%	B-X
Capsicum	B-X
Oleoresin	B-X
solution	B-X
.	B-X
In	B-X
a	B-X
4-week	B-X
feeding	B-X
study	B-X
,	B-X
red	B-X
chilli	B-X
(	B-X
Capsicum	B-X
annuum	B-X
)	B-X
in	B-X
the	B-X
diet	B-X
at	B-X
concentrations	B-X
up	B-X
to	B-X
10	B-X
%	B-X
was	B-X
relatively	B-X
nontoxic	B-X
in	B-X
groups	B-X
of	B-X
male	B-X
mice	B-X
.	B-X
In	B-X
an	B-X
8-week	B-X
feeding	B-X
study	B-X
using	B-X
rats	B-X
,	B-X
intestinal	B-X
exfoliation	B-X
,	B-X
cytoplasmic	B-X
fatty	B-X
vacuolation	B-X
and	B-X
centrilobular	B-X
necrosis	B-X
of	B-X
hepatocytes	B-X
,	B-X
and	B-X
aggregation	B-X
of	B-X
lymphocytes	B-X
in	B-X
the	B-X
portal	B-X
areas	B-X
were	B-X
seen	B-X
at	B-X
10	B-X
%	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
,	B-X
but	B-X
not	B-X
2	B-X
%	B-X
.	B-X
Rats	B-X
fed	B-X
0.5	B-X
g/kg	B-X
day-1	B-X
crude	B-X
Capsicum	B-X
Fruit	B-X
Extract	B-X
for	B-X
60	B-X
days	B-X
exhibited	B-X
no	B-X
significant	B-X
gross	B-X
pathology	B-X
at	B-X
necropsy	B-X
,	B-X
but	B-X
slight	B-X
hyperemia	B-X
of	B-X
the	B-X
liver	B-X
and	B-X
reddening	B-X
of	B-X
the	B-X
gastric	B-X
mucosa	B-X
were	B-X
observed	B-X
.	B-X
Weanling	B-X
rats	B-X
fed	B-X
basal	B-X
diets	B-X
supplemented	B-X
with	B-X
whole	B-X
red	B-X
pepper	B-X
at	B-X
concentrations	B-X
up	B-X
to	B-X
5.0	B-X
%	B-X
for	B-X
up	B-X
to	B-X
8	B-X
weeks	B-X
had	B-X
no	B-X
pathology	B-X
of	B-X
the	B-X
large	B-X
intestines	B-X
,	B-X
livers	B-X
,	B-X
and	B-X
kidneys	B-X
,	B-X
but	B-X
destruction	B-X
of	B-X
the	B-X
taste	B-X
buds	B-X
and	B-X
keratinization	B-X
and	B-X
erosion	B-X
of	B-X
the	B-X
gastrointestinal	B-X
(	B-X
GI	B-X
)	B-X
tract	B-X
were	B-X
noted	B-X
in	B-X
groups	B-X
fed	B-X
0.5	B-X
%	B-X
to	B-X
5.0	B-X
%	B-X
red	B-X
pepper	B-X
.	B-X
The	B-X
results	B-X
of	B-X
9-and	B-X
12-month	B-X
extension	B-X
of	B-X
this	B-X
study	B-X
showed	B-X
normal	B-X
large	B-X
intestines	B-X
and	B-X
kidneys	B-X
.	B-X
In	B-X
rabbits	B-X
fed	B-X
Capsicum	B-X
Annuum	B-X
Powder	B-X
at	B-X
5	B-X
mg/kg	B-X
day-1	B-X
in	B-X
the	B-X
diet	B-X
daily	B-X
for	B-X
12	B-X
months	B-X
damage	B-X
to	B-X
the	B-X
liver	B-X
and	B-X
spleen	B-X
was	B-X
noted	B-X
.	B-X
A	B-X
rabbit	B-X
skin	B-X
irritation	B-X
test	B-X
of	B-X
Capsicum	B-X
Annuum	B-X
Fruit	B-X
Extract	B-X
at	B-X
concentrations	B-X
ranging	B-X
from	B-X
0.1	B-X
%	B-X
to	B-X
1.0	B-X
%	B-X
produced	B-X
no	B-X
irritation	B-X
,	B-X
but	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
Extract	B-X
induced	B-X
concentration-dependent	B-X
(	B-X
at	B-X
25	B-X
to	B-X
500	B-X
microg/ml	B-X
)	B-X
cytotoxicity	B-X
in	B-X
a	B-X
human	B-X
buccal	B-X
mucosa	B-X
fibroblast	B-X
cell	B-X
line	B-X
.	B-X
An	B-X
ethanol	B-X
extract	B-X
of	B-X
red	B-X
chili	B-X
was	B-X
mutagenic	B-X
in	B-X
Salmonella	B-X
typhimurium	B-X
TA98	B-X
,	B-X
but	B-X
not	B-X
in	B-X
TA100	B-X
,	B-X
or	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Other	B-X
genotoxicity	B-X
assays	B-X
gave	B-X
a	B-X
similar	B-X
pattern	B-X
of	B-X
mixed	B-X
results	B-X
.	B-X
Adenocarcinoma	B-X
of	B-X
the	B-X
abdomen	B-X
was	B-X
observed	B-X
in	B-X
7/20	B-X
mice	B-X
fed	B-X
100	B-X
mg	B-X
red	B-X
chilies	B-X
per	B-X
day	B-X
for	B-X
12	B-X
months	B-X
;	B-X
no	B-X
tumors	B-X
were	B-X
seen	B-X
in	B-X
control	B-X
animals	B-X
.	B-X
Neoplastic	B-X
changes	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
intestinal	B-X
tumors	B-X
were	B-X
observed	B-X
in	B-X
rats	B-X
fed	B-X
red	B-X
chili	B-X
powder	B-X
at	B-X
80	B-X
mg/kg	B-X
day-1	B-X
for	B-X
30	B-X
days	B-X
,	B-X
intestinal	B-X
and	B-X
colon	B-X
tumors	B-X
were	B-X
seen	B-X
in	B-X
rats	B-X
fed	B-X
red	B-X
chili	B-X
powder	B-X
and	B-X
1,2-dimethyl	B-X
hydrazine	B-X
,	B-X
but	B-X
no	B-X
tumors	B-X
were	B-X
observed	B-X
in	B-X
controls	B-X
.	B-X
In	B-X
another	B-X
study	B-X
in	B-X
rats	B-X
,	B-X
however	B-X
,	B-X
red	B-X
chile	B-X
pepper	B-X
in	B-X
the	B-X
diet	B-X
at	B-X
the	B-X
same	B-X
dose	B-X
decreased	B-X
the	B-X
number	B-X
of	B-X
tumors	B-X
seen	B-X
with	B-X
1,2-dimethylhydrazine	B-X
.	B-X
Other	B-X
feeding	B-X
studies	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
red	B-X
chili	B-X
peppers	B-X
on	B-X
the	B-X
incidence	B-X
of	B-X
stomach	B-X
tumors	B-X
produced	B-X
by	B-X
N-methyl-N'-nitro-N-nitrosoguanidine	B-X
,	B-X
finding	B-X
that	B-X
red	B-X
pepper	B-X
had	B-X
a	B-X
promoting	B-X
effect	B-X
.	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
Extract	B-X
promoted	B-X
the	B-X
carcinogenic	B-X
effect	B-X
of	B-X
methyl	B-X
(	B-X
acetoxymethyl	B-X
)	B-X
nitrosamine	B-X
(	B-X
carcinogen	B-X
)	B-X
or	B-X
benzene	B-X
hexachloride	B-X
(	B-X
hepatocarcinogen	B-X
)	B-X
in	B-X
inbred	B-X
male	B-X
and	B-X
female	B-X
Balb/c	B-X
mice	B-X
dosed	B-X
orally	B-X
(	B-X
tongue	B-X
application	B-X
)	B-X
.	B-X
Clinical	B-X
findings	B-X
include	B-X
symptoms	B-X
of	B-X
cough	B-X
,	B-X
sneezing	B-X
,	B-X
and	B-X
runny	B-X
nose	B-X
in	B-X
chili	B-X
factory	B-X
workers	B-X
.	B-X
Human	B-X
respiratory	B-X
responses	B-X
to	B-X
Capsicum	B-X
Oleoresin	B-X
spray	B-X
include	B-X
burning	B-X
of	B-X
the	B-X
throat	B-X
,	B-X
wheezing	B-X
,	B-X
dry	B-X
cough	B-X
,	B-X
shortness	B-X
of	B-X
breath	B-X
,	B-X
gagging	B-X
,	B-X
gasping	B-X
,	B-X
inability	B-X
to	B-X
breathe	B-X
or	B-X
speak	B-X
,	B-X
and	B-X
,	B-X
rarely	B-X
,	B-X
cyanosis	B-X
,	B-X
apnea	B-X
,	B-X
and	B-X
respiratory	B-X
arrest	B-X
.	B-X
A	B-X
trade	B-X
name	B-X
mixture	B-X
containing	B-X
1	B-X
%	B-X
to	B-X
5	B-X
%	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
Extract	B-X
induced	B-X
very	B-X
slight	B-X
erythema	B-X
in	B-X
1	B-X
of	B-X
10	B-X
volunteers	B-X
patch	B-X
tested	B-X
for	B-X
48	B-X
h.	B-X
Capsicum	B-X
Frutescens	B-X
Fruit	B-X
Extract	B-X
at	B-X
0.025	B-X
%	B-X
in	B-X
a	B-X
repeated-insult	B-X
patch	B-X
test	B-X
using	B-X
103	B-X
subjects	B-X
resulted	B-X
in	B-X
no	B-X
clinically	B-X
meaningful	B-X
irritation	B-X
or	B-X
allergic	B-X
contact	B-X
dermatitis	B-X
.	B-X
One	B-X
epidemiological	B-X
study	B-X
indicated	B-X
that	B-X
chili	B-X
pepper	B-X
consumption	B-X
may	B-X
be	B-X
a	B-X
strong	B-X
risk	B-X
factor	B-X
for	B-X
gastric	B-X
cancer	B-X
in	B-X
populations	B-X
with	B-X
high	B-X
intakes	B-X
of	B-X
chili	B-X
pepper	B-X
;	B-X
however	B-X
,	B-X
other	B-X
studies	B-X
did	B-X
not	B-X
find	B-X
this	B-X
association	B-X
.	B-X
Capsaicin	B-X
is	B-X
not	B-X
generally	B-X
recognized	B-X
as	B-X
safe	B-X
and	B-X
effective	B-X
by	B-X
the	B-X
U.S.	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
for	B-X
fever	B-X
blister	B-X
and	B-X
cold	B-X
sore	B-X
treatment	B-X
,	B-X
but	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
safe	B-X
and	B-X
effective	B-X
as	B-X
an	B-X
external	B-X
analgesic	B-X
counterirritant	B-X
.	B-X
Ingested	B-X
Capsaicin	B-X
is	B-X
rapidly	B-X
absorbed	B-X
from	B-X
the	B-X
stomach	B-X
and	B-X
small	B-X
intestine	B-X
in	B-X
animal	B-X
studies	B-X
.	B-X
Subcutaneous	B-X
injection	B-X
of	B-X
Capsaicin	B-X
in	B-X
rats	B-X
resulted	B-X
in	B-X
a	B-X
rise	B-X
in	B-X
the	B-X
blood	B-X
concentration	B-X
,	B-X
reaching	B-X
a	B-X
maximum	B-X
at	B-X
5	B-X
h	B-X
;	B-X
the	B-X
highest	B-X
tissue	B-X
concentrations	B-X
were	B-X
in	B-X
the	B-X
kidney	B-X
and	B-X
lowest	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
In	B-X
vitro	B-X
percutaneous	B-X
absorption	B-X
of	B-X
Capsaicin	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
human	B-X
,	B-X
rat	B-X
,	B-X
mouse	B-X
,	B-X
rabbit	B-X
,	B-X
and	B-X
pig	B-X
skin	B-X
.	B-X
Enhancement	B-X
of	B-X
the	B-X
skin	B-X
permeation	B-X
of	B-X
naproxen	B-X
(	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
agent	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Capsaicin	B-X
has	B-X
also	B-X
been	B-X
demonstrated	B-X
.	B-X
Pharmacological	B-X
and	B-X
physiological	B-X
studies	B-X
demonstrated	B-X
that	B-X
Capsaicin	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
vanillyl	B-X
moiety	B-X
,	B-X
produces	B-X
its	B-X
sensory	B-X
effects	B-X
by	B-X
activating	B-X
a	B-X
Ca2	B-X
+-permeable	B-X
ion	B-X
channel	B-X
on	B-X
sensory	B-X
neurons	B-X
.	B-X
Capsaicin-induced	B-X
stimulation	B-X
of	B-X
prostaglandin	B-X
biosynthesis	B-X
has	B-X
been	B-X
shown	B-X
using	B-X
bull	B-X
seminal	B-X
vesicles	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
synoviocytes	B-X
.	B-X
Capsaicin	B-X
inhibits	B-X
protein	B-X
synthesis	B-X
in	B-X
Vero	B-X
kidney	B-X
cells	B-X
and	B-X
human	B-X
neuroblastoma	B-X
SHSY-5Y	B-X
cells	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
inhibits	B-X
growth	B-X
of	B-X
E.	B-X
coli	B-X
,	B-X
Pseudomonas	B-X
solanacearum	B-X
,	B-X
and	B-X
Bacillus	B-X
subtilis	B-X
bacterial	B-X
cultures	B-X
,	B-X
but	B-X
not	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
Oral	B-X
LD50	B-X
values	B-X
as	B-X
low	B-X
as	B-X
161.2	B-X
mg/kg	B-X
(	B-X
rats	B-X
)	B-X
and	B-X
118.8	B-X
mg/kg	B-X
(	B-X
mice	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
for	B-X
Capsaicin	B-X
in	B-X
acute	B-X
oral	B-X
toxicity	B-X
studies	B-X
,	B-X
with	B-X
hemorrhage	B-X
of	B-X
the	B-X
gastric	B-X
fundus	B-X
observed	B-X
in	B-X
some	B-X
of	B-X
the	B-X
animals	B-X
that	B-X
died	B-X
.	B-X
In	B-X
subchronic	B-X
oral	B-X
toxicity	B-X
studies	B-X
using	B-X
mice	B-X
,	B-X
Capsaicin	B-X
produced	B-X
statistically	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
growth	B-X
rate	B-X
and	B-X
liver/body	B-X
weight	B-X
increases	B-X
.	B-X
Dose-related	B-X
edema	B-X
was	B-X
observed	B-X
in	B-X
animals	B-X
receiving	B-X
Capsaicin	B-X
injections	B-X
into	B-X
the	B-X
hindpaw	B-X
(	B-X
rats	B-X
)	B-X
or	B-X
application	B-X
to	B-X
the	B-X
ear	B-X
(	B-X
mice	B-X
)	B-X
.	B-X
In	B-X
guinea	B-X
pigs	B-X
,	B-X
dinitrochlorobenzene	B-X
contact	B-X
dermatitis	B-X
was	B-X
enhanced	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Capsaicin	B-X
,	B-X
injected	B-X
subcutaneously	B-X
,	B-X
whereas	B-X
dermal	B-X
application	B-X
inhibited	B-X
sensitization	B-X
in	B-X
mice	B-X
.	B-X
Immune	B-X
system	B-X
effects	B-X
have	B-X
been	B-X
observed	B-X
in	B-X
neonatal	B-X
rats	B-X
injected	B-X
subcutaneously	B-X
with	B-X
Capsaicin	B-X
.	B-X
Capsaicin	B-X
produced	B-X
mixed	B-X
results	B-X
in	B-X
S.	B-X
typhimurium	B-X
micronucleus	B-X
and	B-X
sister-chromatid	B-X
exchange	B-X
genotoxicity	B-X
assays	B-X
.	B-X
Carcinogenic	B-X
,	B-X
cocarcinogenic	B-X
,	B-X
anticarcinogenic	B-X
,	B-X
antitumorigenic	B-X
,	B-X
tumor	B-X
promotion	B-X
,	B-X
and	B-X
anti-tumor	B-X
promotion	B-X
effects	B-X
of	B-X
Capsaicin	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
animal	B-X
studies	B-X
.	B-X
Except	B-X
for	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
crown-rump	B-X
length	B-X
in	B-X
day	B-X
18	B-X
rats	B-X
injected	B-X
subcutaneously	B-X
with	B-X
Capsaicin	B-X
(	B-X
50	B-X
mg/kg	B-X
)	B-X
on	B-X
gestation	B-X
days	B-X
14	B-X
,	B-X
16	B-X
,	B-X
18	B-X
,	B-X
or	B-X
20	B-X
,	B-X
no	B-X
reproductive	B-X
or	B-X
developmental	B-X
toxicity	B-X
was	B-X
noted	B-X
.	B-X
In	B-X
pregnant	B-X
mice	B-X
dosed	B-X
subcutaneously	B-X
with	B-X
Capsaicin	B-X
,	B-X
depletion	B-X
of	B-X
substance	B-X
P	B-X
in	B-X
the	B-X
spinal	B-X
cord	B-X
and	B-X
peripheral	B-X
nerves	B-X
of	B-X
pregnant	B-X
females	B-X
and	B-X
fetuses	B-X
was	B-X
noted	B-X
.	B-X
In	B-X
clinical	B-X
tests	B-X
,	B-X
nerve	B-X
degeneration	B-X
of	B-X
intracutaneous	B-X
nerve	B-X
fibers	B-X
and	B-X
a	B-X
decrease	B-X
in	B-X
pain	B-X
sensation	B-X
induced	B-X
by	B-X
heat	B-X
and	B-X
mechanical	B-X
stimuli	B-X
were	B-X
evident	B-X
in	B-X
subjects	B-X
injected	B-X
intradermally	B-X
with	B-X
Capsaicin	B-X
.	B-X
An	B-X
increase	B-X
in	B-X
mean	B-X
inspiratory	B-X
flow	B-X
was	B-X
reported	B-X
for	B-X
eight	B-X
normal	B-X
subjects	B-X
who	B-X
inhaled	B-X
nebulized	B-X
10	B-X
(	B-X
-7	B-X
)	B-X
M	B-X
Capsaicin	B-X
.	B-X
The	B-X
results	B-X
of	B-X
provocative	B-X
and	B-X
predictive	B-X
tests	B-X
involving	B-X
human	B-X
subjects	B-X
indicated	B-X
that	B-X
Capsaicin	B-X
is	B-X
a	B-X
skin	B-X
irritant	B-X
.	B-X
Overall	B-X
,	B-X
studies	B-X
suggested	B-X
that	B-X
these	B-X
ingredients	B-X
can	B-X
be	B-X
irritating	B-X
at	B-X
low	B-X
concentrations	B-X
.	B-X
Although	B-X
the	B-X
genotoxicity	B-X
,	B-X
carcinogenicity	B-X
,	B-X
and	B-X
tumor	B-X
promotion	B-X
potential	B-X
of	B-X
Capsaicin	B-X
have	B-X
been	B-X
demonstrated	B-X
,	B-X
so	B-X
have	B-X
opposite	B-X
effects	B-X
.	B-X
Skin	B-X
irritation	B-X
and	B-X
other	B-X
tumor-promoting	B-X
effects	B-X
of	B-X
Capsaicin	B-X
appear	B-X
to	B-X
be	B-X
mediated	B-X
through	B-X
interaction	B-X
with	B-X
the	B-X
same	B-X
vanilloid	B-X
receptor	B-X
.	B-X
Given	B-X
this	B-X
mechanism	B-X
of	B-X
action	B-X
and	B-X
the	B-X
observation	B-X
that	B-X
many	B-X
tumor	B-X
promoters	B-X
are	B-X
irritating	B-X
to	B-X
the	B-X
skin	B-X
,	B-X
the	B-X
Panel	B-X
considered	B-X
it	B-X
likely	B-X
that	B-X
a	B-X
potent	B-X
tumor	B-X
promoter	B-X
may	B-X
also	B-X
be	B-X
a	B-X
moderate	B-X
to	B-X
severe	B-X
skin	B-X
irritant	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
limitation	B-X
on	B-X
Capsaicin	B-X
content	B-X
that	B-X
would	B-X
significantly	B-X
reduce	B-X
its	B-X
skin	B-X
irritation	B-X
potential	B-X
is	B-X
expected	B-X
to	B-X
,	B-X
in	B-X
effect	B-X
,	B-X
lessen	B-X
any	B-X
concerns	B-X
relating	B-X
to	B-X
tumor	B-X
promotion	B-X
potential	B-X
.	B-X
Because	B-X
Capsaicin	B-X
enhanced	B-X
the	B-X
penetration	B-X
of	B-X
an	B-X
anti-inflammatory	B-X
agent	B-X
through	B-X
human	B-X
skin	B-X
,	B-X
the	B-X
Panel	B-X
recommends	B-X
that	B-X
care	B-X
should	B-X
be	B-X
exercised	B-X
in	B-X
using	B-X
ingredients	B-X
that	B-X
contain	B-X
Capsaicin	B-X
in	B-X
cosmetic	B-X
products	B-X
.	B-X
The	B-X
Panel	B-X
advised	B-X
industry	B-X
that	B-X
the	B-X
total	B-X
polychlorinated	B-X
biphenyl	B-X
(	B-X
PCB	B-X
)	B-X
/pesticide	B-X
contamination	B-X
should	B-X
be	B-X
limited	B-X
to	B-X
not	B-X
more	B-X
than	B-X
40	B-X
ppm	B-X
,	B-X
with	B-X
not	B-X
more	B-X
than	B-X
10	B-X
ppm	B-X
for	B-X
any	B-X
specific	B-X
residue	B-X
,	B-X
and	B-X
agreed	B-X
on	B-X
the	B-X
following	B-X
limitations	B-X
for	B-X
other	B-X
impurities	B-X
:	B-X
arsenic	B-X
(	B-X
3	B-X
mg/kg	B-X
max	B-X
)	B-X
,	B-X
heavy	B-X
metals	B-X
(	B-X
0.002	B-X
%	B-X
max	B-X
)	B-X
,	B-X
and	B-X
lead	B-X
(	B-X
5	B-X
mg/kg	B-X
max	B-X
)	B-X
.	B-X
Industry	B-X
was	B-X
also	B-X
advised	B-X
that	B-X
aflatoxin	B-X
should	B-X
not	B-X
be	B-X
present	B-X
in	B-X
these	B-X
ingredients	B-X
(	B-X
the	B-X
Panel	B-X
adopted	B-X
<	B-X
or	B-X
=15	B-X
ppb	B-X
as	B-X
corresponding	B-X
to	B-X
``	B-X
negative	B-X
''	B-X
aflatoxin	B-X
content	B-X
)	B-X
,	B-X
and	B-X
that	B-X
ingredients	B-X
derived	B-X
from	B-X
Capsicum	B-X
annuum	B-X
and	B-X
Capsicum	B-X
Frutescens	B-X
Plant	B-X
species	B-X
should	B-X
not	B-X
be	B-X
used	B-X
in	B-X
products	B-X
where	B-X
N-nitroso	B-X
compounds	B-X
may	B-X
be	B-X
formed	B-X
.	B-X

After	O
4	O
h	O
,	O
the	O
cells	O
were	O
washed	O
and	O
activated	O
with	O
soluble	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

Each	O
day	O
,	O
the	O
TAT	B-Protein
proteins	O
were	O
freshly	O
added	O
to	O
the	O
medium	O
.	O

FOXP3	B-Protein
expression	O
was	O
measured	O
after	O
5	O
d	O
by	O
intracellular	O
staining	O
.	O
<EOS>	B-X
However	B-X
,	B-X
because	B-X
this	B-X
technique	B-X
may	B-X
be	B-X
time-consuming	B-X
,	B-X
particularly	B-X
for	B-X
intracellular	B-X
staining	B-X
,	B-X
it	B-X
could	B-X
be	B-X
problematic	B-X
for	B-X
its	B-X
use	B-X
in	B-X
daily	B-X
routine	B-X
or	B-X
in	B-X
large	B-X
cohorts	B-X
.	B-X
Recently	B-X
,	B-X
a	B-X
novel	B-X
reagent	B-X
has	B-X
been	B-X
developed	B-X
to	B-X
perform	B-X
intracellular	B-X
staining	B-X
in	B-X
one	B-X
step	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
our	B-X
study	B-X
was	B-X
thus	B-X
to	B-X
assess	B-X
this	B-X
new	B-X
method	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
reference	B-X
technique	B-X
by	B-X
focusing	B-X
on	B-X
FOXP3	B-X
staining	B-X
in	B-X
clinical	B-X
samples	B-X
.	B-X

Intracellular	O
cytokine	O
staining	O
.	O
<EOS>	B-X
Intracellular	B-X
cytokine	B-X
staining	B-X
is	B-X
a	B-X
popular	B-X
method	B-X
for	B-X
visualizing	B-X
cellular	B-X
responses	B-X
,	B-X
most	B-X
often	B-X
T-cell	B-X
responses	B-X
to	B-X
antigenic	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
It	B-X
can	B-X
be	B-X
coupled	B-X
with	B-X
staining	B-X
for	B-X
other	B-X
functional	B-X
markers	B-X
,	B-X
such	B-X
as	B-X
upregulation	B-X
of	B-X
CD107	B-X
or	B-X
CD154	B-X
,	B-X
as	B-X
well	B-X
as	B-X
phenotypic	B-X
markers	B-X
that	B-X
define	B-X
specific	B-X
cellular	B-X
subsets	B-X
,	B-X
e.g.	B-X
,	B-X
effector	B-X
and	B-X
memory	B-X
T-cell	B-X
compartments	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
or	B-X
monocytes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
review	B-X
best	B-X
practices	B-X
for	B-X
antibody	B-X
panel	B-X
design	B-X
and	B-X
procedural	B-X
variables	B-X
for	B-X
multicolor	B-X
intracellular	B-X
cytokine	B-X
staining	B-X
,	B-X
and	B-X
present	B-X
an	B-X
optimized	B-X
protocol	B-X
with	B-X
variations	B-X
designed	B-X
for	B-X
use	B-X
with	B-X
specific	B-X
markers	B-X
and	B-X
sample	B-X
types	B-X
.	B-X
Cellular	B-X
immune	B-X
responses	B-X
to	B-X
vaccination	B-X
that	B-X
define	B-X
vaccine	B-X
immunogenicity	B-X
and/or	B-X
immune	B-X
correlates	B-X
of	B-X
protection	B-X
can	B-X
be	B-X
measured	B-X
using	B-X
multiparameter	B-X
intracellular	B-X
cytokine	B-X
staining	B-X
(	B-X
ICS	B-X
)	B-X
assays	B-X
.	B-X

T	O
cells	O
were	O
stimulated	O
with	O
2	O
x	O
10	O
-	O
7	O
M	O
PMA	O
and	O
1	O
mug	O
/	O
ml	O
of	O
ionomycin	O
(	O
Sigma	O
Chemicals	O
)	O
for	O
4	O
h	O
.	O

The	O
following	O
mAb	O
was	O
used	O
:	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
PE	O
(	O
8D4	O
-	O
8	O
,	O
BD	O
)	O
.	O

Matched	O
isotype	O
controls	O
were	O
used	O
at	O
the	O
same	O
protein	O
concentration	O
as	O
the	O
respective	O
antibodies	O
.	O
<EOS>	B-X
Knowledge	B-X
of	B-X
what	B-X
constitute	B-X
normal	B-X
serum	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
concentrations	B-X
are	B-X
important	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
immunologic	B-X
disorders	B-X
.	B-X
Statistical	B-X
analyses	B-X
were	B-X
used	B-X
to	B-X
compare	B-X
Igs	B-X
between	B-X
sexes	B-X
and	B-X
age	B-X
groups	B-X
,	B-X
and	B-X
to	B-X
compare	B-X
IgG	B-X
in	B-X
this	B-X
study	B-X
with	B-X
data	B-X
from	B-X
other	B-X
published	B-X
studies	B-X
.	B-X
IgG	B-X
,	B-X
IgA	B-X
,	B-X
IgG2	B-X
,	B-X
and	B-X
IgG3	B-X
concentrations	B-X
showed	B-X
a	B-X
gradual	B-X
increase	B-X
with	B-X
increasing	B-X
age	B-X
.	B-X
There	B-X
were	B-X
no	B-X
significant	B-X
sex	B-X
differences	B-X
for	B-X
any	B-X
immunoglobulin	B-X
isotype	B-X
(	B-X
P=	B-X
0.971	B-X
)	B-X
.	B-X
Our	B-X
mean	B-X
IgG	B-X
concentration	B-X
was	B-X
lower	B-X
than	B-X
that	B-X
measured	B-X
by	B-X
the	B-X
radial	B-X
diffusion	B-X
method	B-X
in	B-X
healthy	B-X
Thai	B-X
children	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
all	B-X
age	B-X
groups	B-X
,	B-X
the	B-X
mean	B-X
IgG	B-X
concentration	B-X
in	B-X
our	B-X
study	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
that	B-X
reported	B-X
in	B-X
Turkish	B-X
and	B-X
USA	B-X
children	B-X
,	B-X
evaluated	B-X
by	B-X
the	B-X
nephelometric	B-X
and	B-X
radial	B-X
diffusion	B-X
techniques	B-X
,	B-X
respectively	B-X
(	B-X
both	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
information	B-X
about	B-X
normal	B-X
Ig	B-X
concentrations	B-X
measured	B-X
by	B-X
nephelometry	B-X
in	B-X
healthy	B-X
Asian	B-X
children	B-X
and	B-X
illustrates	B-X
the	B-X
importance	B-X
of	B-X
ascertaining	B-X
normal	B-X
Ig	B-X
values	B-X
for	B-X
age-	B-X
and	B-X
ethnic-matched	B-X
controls	B-X
using	B-X
the	B-X
same	B-X
assay	B-X
to	B-X
diagnose	B-X
immunologic	B-X
disorders	B-X
correctly	B-X
.	B-X

Four	O
-	O
color	O
FACS	O
was	O
performed	O
using	O
an	O
EPICS	O
XL	O
-	O
MCL	O
(	O
Beckman	O
Coulter	O
)	O
using	O
the	O
software	O
Expo32	O
version	O
for	O
data	O
acquisition	O
and	O
evaluation	O
.	O

Flow	O
cytometry	O
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
technology	B-X
that	B-X
provides	B-X
rapid	B-X
multi-parametric	B-X
analysis	B-X
of	B-X
single	B-X
cells	B-X
in	B-X
solution	B-X
.	B-X
Flow	B-X
cytometers	B-X
utilize	B-X
lasers	B-X
as	B-X
light	B-X
sources	B-X
to	B-X
produce	B-X
both	B-X
scattered	B-X
and	B-X
fluorescent	B-X
light	B-X
signals	B-X
that	B-X
are	B-X
read	B-X
by	B-X
detectors	B-X
such	B-X
as	B-X
photodiodes	B-X
or	B-X
photomultiplier	B-X
tubes	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
fluorescent	B-X
reagents	B-X
are	B-X
utilized	B-X
in	B-X
flow	B-X
cytometry	B-X
.	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
that	B-X
has	B-X
applications	B-X
in	B-X
immunology	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
bacteriology	B-X
,	B-X
virology	B-X
,	B-X
cancer	B-X
biology	B-X
,	B-X
and	B-X
infectious	B-X
disease	B-X
monitoring	B-X
.	B-X

For	O
analysis	O
of	O
FOXP3	B-Protein
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
antibody	O
CD25	B-Protein
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
cells	O
were	O
incubated	O
with	O
PE	O
-	O
conjugated	O
monoclonal	O
antibody	O
PCH101	O
(	O
anti	O
-	O
human	O
FOXP3	B-Protein
;	O
eBioscience	O
)	O
based	O
on	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
)	O
.	O

For	O
cell	O
surface	O
marker	O
staining	O
,	O
cells	O
were	O
incubated	O
for	O
20	O
min	O
at	O
4degreesC	O
in	O
staining	O
buffer	O
with	O
the	O
following	O
antibodies	O
:	O
anti	O
-	O
CD152	B-Protein
-	O
PE	O
(	O
CTLA	O
-	O
4	O
;	O
BD	O
)	O
,	O
anti	O
-	O
PD	B-Protein
-	I-Protein
1	I-Protein
(	O
eBiosciences	O
)	O
,	O
anti	O
-	O
GITR	B-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
,	O
anti	O
-	O
CD69	B-Protein
(	O
Beckman	O
Coulter	O
)	O
,	O
anti	O
-	O
CD103	B-Protein
(	O
DakoCytomation	O
)	O
,	O
anti	O
-	O
CD62L	B-Protein
(	O
Beckman	O
Coulter	O
)	O
,	O
or	O
anti	O
-	O
HLA	O
-	O
DR	O
(	O
Beckman	O
Coulter	O
)	O
.	O

The	O
controls	O
were	O
FITC	O
,	O
PE	O
,	O
or	O
ECD	O
-	O
conjugated	O
mouse	O
IgG1	O
or	O
rat	O
IgG2a	O
.	O
<EOS>	B-X
IgE	B-X
and	B-X
IgG2a	B-X
isotypes	B-X
in	B-X
the	B-X
rat	B-X
.	B-X
CD3-FITC	B-X
,	B-X
CD14-PE	B-X
,	B-X
7-AAD	B-X
,	B-X
CD11b-PECy7	B-X
,	B-X
CD235a-APC	B-X
,	B-X
CD19-APCeF780	B-X
;	B-X
and	B-X
2	B-X
.	B-X
7-AAD	B-X
,	B-X
CD105-PECy7	B-X
,	B-X
CD45/CD31/CD235a-APC	B-X
,	B-X
and	B-X
CD200-APCeF780	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
three	B-X
murine	B-X
receptors	B-X
,	B-X
each	B-X
was	B-X
expressed	B-X
by	B-X
stable	B-X
transfection	B-X
of	B-X
corresponding	B-X
cDNAs	B-X
in	B-X
two	B-X
model	B-X
cells	B-X
:	B-X
the	B-X
murine	B-X
lymphoma	B-X
B	B-X
cell	B-X
IIA1.6	B-X
and	B-X
the	B-X
rat	B-X
basophilic	B-X
leukemia	B-X
cell	B-X
RBL-2H3	B-X
.	B-X
Biological	B-X
activities	B-X
of	B-X
recombinant	B-X
receptors	B-X
were	B-X
triggered	B-X
with	B-X
soluble	B-X
immune	B-X
complexes	B-X
or	B-X
2.4G2	B-X
IgG	B-X
in	B-X
IIA1.6	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
no	B-X
Fc	B-X
gamma	B-X
R	B-X
,	B-X
and	B-X
with	B-X
2.4G2	B-X
Fab	B-X
or	B-X
F	B-X
(	B-X
ab	B-X
'	B-X
)	B-X
2	B-X
,	B-X
cross-linked	B-X
with	B-X
mouse	B-X
anti-rat	B-X
F	B-X
(	B-X
ab	B-X
'	B-X
)	B-X
2	B-X
in	B-X
RBL	B-X
,	B-X
which	B-X
express	B-X
rat	B-X
Fc	B-X
gamma	B-X
R.	B-X
Conditions	B-X
for	B-X
studying	B-X
cell	B-X
activation	B-X
and	B-X
endocytosis	B-X
in	B-X
both	B-X
cell	B-X
models	B-X
are	B-X
described	B-X
,	B-X
as	B-X
are	B-X
conditions	B-X
for	B-X
studying	B-X
phagocytosis	B-X
in	B-X
RBL	B-X
cells	B-X
and	B-X
antigen	B-X
presentation	B-X
or	B-X
regulation	B-X
of	B-X
cell	B-X
activation	B-X
in	B-X
IIA1.6	B-X
cells	B-X
.	B-X

For	O
staining	O
of	O
mouse	O
cells	O
,	O
the	O
following	O
mAbs	O
from	O
BD	O
Biosciences	O
were	O
used	O
following	O
standard	O
techniques	O
as	O
described	O
above	O
:	O
anti	O
-	O
CD3	B-Protein
,	O
anti	O
-	O
CD4	B-Protein
,	O
and	O
anti	O
-	O
CD25	B-Protein
.	O

Anti	O
-	O
FcgammaRII	O
/	O
III	O
antibody	O
(	O
2	O
.	O
4G2	O
,	O
ATCC	O
)	O
was	O
included	O
in	O
all	O
stainings	O
to	O
reduce	O
nonspecific	O
antibody	O
binding	O
.	O

To	O
isolate	O
naive	O
murine	O
CD4	B-Protein
T	O
cells	O
from	O
murine	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10xCD2	B-Protein
-	O
GATA3	B-Protein
T	O
cells	O
,	O
cells	O
were	O
stained	O
with	O
anti	O
-	O
CD25	B-Protein
-	O
FITC	O
,	O
anti	O
-	O
CD62L	B-Protein
-	O
PE	O
,	O
and	O
anti	O
-	O
CD4	B-Protein
-	O
APC	O
prior	O
to	O
sorting	O
.	O
<EOS>	B-X
This	B-X
chapter	B-X
shows	B-X
protocols	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
peripheral	B-X
Treg	B-X
(	B-X
pTreg	B-X
)	B-X
from	B-X
polyclonal	B-X
and	B-X
monoclonal	B-X
CD4	B-X
Dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
play	B-X
the	B-X
dual	B-X
task	B-X
of	B-X
initiating	B-X
cellular	B-X
immunity	B-X
against	B-X
potentially	B-X
harmful	B-X
foreign	B-X
antigens	B-X
(	B-X
Ag	B-X
)	B-X
,	B-X
while	B-X
maintaining	B-X
immunological	B-X
tolerance	B-X
to	B-X
self-Ag	B-X
and	B-X
environmental	B-X
Ag	B-X
.	B-X
The	B-X
resulting	B-X
``	B-X
killer	B-X
''	B-X
DC	B-X
delivered	B-X
apoptotic	B-X
signals	B-X
,	B-X
instead	B-X
of	B-X
activation	B-X
signals	B-X
,	B-X
to	B-X
primed	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
induced	B-X
Ag-specific	B-X
immunosuppression	B-X
in	B-X
vivo	B-X
.	B-X
To	B-X
study	B-X
the	B-X
impact	B-X
of	B-X
killer	B-X
DC	B-X
on	B-X
naive	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
fate	B-X
of	B-X
Ag-reactive	B-X
T	B-X
cells	B-X
and	B-X
the	B-X
extent	B-X
of	B-X
their	B-X
depletion	B-X
after	B-X
killer	B-X
DC	B-X
treatment	B-X
,	B-X
we	B-X
performed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
reconstitution	B-X
experiments	B-X
using	B-X
:	B-X
(	B-X
a	B-X
)	B-X
killer	B-X
DC-DC	B-X
hybrids	B-X
created	B-X
between	B-X
CD95L-transduced	B-X
XS106	B-X
DC	B-X
clone	B-X
(	B-X
A/J	B-X
origin	B-X
)	B-X
and	B-X
splenic	B-X
DC	B-X
from	B-X
BALB/c	B-X
mice	B-X
,	B-X
(	B-X
b	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
isolated	B-X
from	B-X
DO11.10	B-X
transgenic	B-X
mice	B-X
(	B-X
BALB/c	B-X
background	B-X
)	B-X
,	B-X
and	B-X
(	B-X
c	B-X
)	B-X
OVA	B-X
(	B-X
323-339	B-X
)	B-X
peptide	B-X
as	B-X
relevant	B-X
Ag	B-X
.	B-X
Ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
-pulsed	B-X
killer	B-X
DC-DC	B-X
hybrids	B-X
inhibited	B-X
DO11.10	B-X
T	B-X
cell	B-X
activation	B-X
triggered	B-X
by	B-X
conventional	B-X
DC	B-X
,	B-X
instead	B-X
of	B-X
inducing	B-X
their	B-X
activation	B-X
.	B-X
Rapid	B-X
apoptosis	B-X
of	B-X
T	B-X
cells	B-X
was	B-X
observed	B-X
after	B-X
co-culture	B-X
with	B-X
OVA-pulsed	B-X
killer	B-X
DC-DC	B-X
hybrids	B-X
,	B-X
but	B-X
not	B-X
with	B-X
non-pulsed	B-X
killer	B-X
DC-DC	B-X
hybrids	B-X
or	B-X
OVA-pulsed	B-X
control	B-X
DC-DC	B-X
hybrids	B-X
.	B-X
For	B-X
in	B-X
vivo	B-X
reconstitution	B-X
,	B-X
(	B-X
BALB/cxA/J	B-X
)	B-X
F1	B-X
mice	B-X
received	B-X
subcutaneous	B-X
administration	B-X
of	B-X
killer	B-X
DC-DC	B-X
hybrids	B-X
,	B-X
followed	B-X
by	B-X
intravenous	B-X
inoculation	B-X
of	B-X
DO11.10	B-X
T	B-X
cells	B-X
.	B-X
Killer	B-X
DC-DC	B-X
hybrids	B-X
migrated	B-X
preferentially	B-X
to	B-X
draining	B-X
lymph	B-X
nodes	B-X
albeit	B-X
with	B-X
relatively	B-X
low	B-X
efficiency	B-X
(	B-X
0.5-1	B-X
%	B-X
recovery	B-X
)	B-X
and	B-X
they	B-X
induced	B-X
significant	B-X
,	B-X
but	B-X
incomplete	B-X
(	B-X
30-40	B-X
%	B-X
)	B-X
killing	B-X
of	B-X
DO11.10	B-X
T	B-X
cells	B-X
in	B-X
this	B-X
location	B-X
.	B-X
These	B-X
results	B-X
document	B-X
the	B-X
abilities	B-X
of	B-X
CD95L-transduced	B-X
DC	B-X
to	B-X
trigger	B-X
apoptosis	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
in	B-X
an	B-X
Ag-specific	B-X
manner	B-X
,	B-X
to	B-X
overrule	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
delivered	B-X
by	B-X
conventional	B-X
DC	B-X
,	B-X
and	B-X
to	B-X
reduce	B-X
local	B-X
frequencies	B-X
of	B-X
Ag-reactive	B-X
T	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
Our	B-X
data	B-X
also	B-X
uncover	B-X
two	B-X
major	B-X
limitations	B-X
(	B-X
relatively	B-X
low	B-X
homing	B-X
efficiency	B-X
and	B-X
incomplete	B-X
elimination	B-X
of	B-X
Ag-reactive	B-X
T	B-X
cells	B-X
)	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
overcome	B-X
for	B-X
clinical	B-X
application	B-X
of	B-X
CD95L-transduced	B-X
DC	B-X
strategy	B-X
.	B-X

Dead	O
cells	O
were	O
excluded	O
with	O
4	O
'	O
'	O
,	O
6	O
-	O
Diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
.	O
<EOS>	B-X
Cellular	B-X
viability	B-X
is	B-X
usually	B-X
determined	B-X
by	B-X
measuring	B-X
the	B-X
capacity	B-X
of	B-X
cells	B-X
to	B-X
exclude	B-X
vital	B-X
dyes	B-X
such	B-X
as	B-X
4',6-diamidino-2-phenylindole	B-X
(	B-X
DAPI	B-X
)	B-X
,	B-X
or	B-X
by	B-X
assessing	B-X
nuclear	B-X
morphology	B-X
with	B-X
chromatinophilic	B-X
plasma	B-X
membrane-permeant	B-X
dyes	B-X
,	B-X
such	B-X
as	B-X
Hoechst	B-X
33342	B-X
.	B-X
However	B-X
,	B-X
a	B-X
fraction	B-X
of	B-X
cells	B-X
that	B-X
exclude	B-X
DAPI	B-X
or	B-X
exhibit	B-X
normal	B-X
nuclear	B-X
morphology	B-X
have	B-X
already	B-X
lost	B-X
mitochondrial	B-X
functions	B-X
and/or	B-X
manifest	B-X
massive	B-X
activation	B-X
of	B-X
apoptotic	B-X
caspases	B-X
,	B-X
and	B-X
hence	B-X
are	B-X
irremediably	B-X
committed	B-X
to	B-X
death	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
protocol	B-X
for	B-X
the	B-X
simultaneous	B-X
detection	B-X
of	B-X
plasma	B-X
membrane	B-X
integrity	B-X
(	B-X
based	B-X
on	B-X
DAPI	B-X
)	B-X
or	B-X
nuclear	B-X
morphology	B-X
(	B-X
based	B-X
on	B-X
Hoechst	B-X
33342	B-X
)	B-X
,	B-X
mitochondrial	B-X
functions	B-X
(	B-X
based	B-X
on	B-X
the	B-X
mitochondrial	B-X
transmembrane	B-X
potential	B-X
probe	B-X
DiOC6	B-X
(	B-X
3	B-X
)	B-X
)	B-X
and	B-X
caspase	B-X
activation	B-X
(	B-X
based	B-X
on	B-X
YO-PRO®-3	B-X
,	B-X
which	B-X
can	B-X
enter	B-X
cells	B-X
exclusively	B-X
upon	B-X
the	B-X
caspase-mediated	B-X
activation	B-X
of	B-X
pannexin	B-X
1	B-X
channels	B-X
)	B-X
.	B-X
This	B-X
method	B-X
,	B-X
which	B-X
allows	B-X
for	B-X
the	B-X
precise	B-X
quantification	B-X
of	B-X
dead	B-X
,	B-X
dying	B-X
and	B-X
healthy	B-X
cells	B-X
,	B-X
can	B-X
be	B-X
implemented	B-X
on	B-X
epifluorescence	B-X
microscopy	B-X
or	B-X
flow	B-X
cytometry	B-X
platforms	B-X
and	B-X
is	B-X
compatible	B-X
with	B-X
a	B-X
robotized	B-X
,	B-X
high-throughput	B-X
workflow	B-X
.	B-X

To	O
analyze	O
murine	O
Foxp3	B-Protein
expression	O
in	O
inducible	O
Treg	O
cultures	O
,	O
cells	O
were	O
stained	O
intracellularly	O
with	O
anti	O
-	O
Foxp3	B-Protein
-	O
PE	O
according	O
to	O
manufacturer	O
'	O
s	O
instruction	O
,	O
in	O
conjunction	O
with	O
anti	O
-	O
CD4	B-Protein
-	O
APC	O
and	O
LIVE	O
/	O
DEAD	O
fixable	O
dead	O
cell	O
stain	O
kit	O
(	O
Invitrogen	O
)	O
to	O
discriminate	O
live	O
cells	O
.	O

All	O
monoclonal	O
antibodies	O
for	O
murine	O
cell	O
stainings	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
Biosciences	O
.	O
<EOS>	B-X
Fast	B-X
and	B-X
selective	B-X
isolation	B-X
of	B-X
single	B-X
cells	B-X
with	B-X
unique	B-X
spatial	B-X
and	B-X
morphological	B-X
traits	B-X
remains	B-X
a	B-X
technical	B-X
challenge	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
address	B-X
this	B-X
by	B-X
establishing	B-X
high-speed	B-X
image-enabled	B-X
cell	B-X
sorting	B-X
(	B-X
ICS	B-X
)	B-X
,	B-X
which	B-X
records	B-X
multicolor	B-X
fluorescence	B-X
images	B-X
and	B-X
sorts	B-X
cells	B-X
based	B-X
on	B-X
measurements	B-X
from	B-X
image	B-X
data	B-X
at	B-X
speeds	B-X
up	B-X
to	B-X
15,000	B-X
events	B-X
per	B-X
second	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ICS	B-X
quantifies	B-X
cell	B-X
morphology	B-X
and	B-X
localization	B-X
of	B-X
labeled	B-X
proteins	B-X
and	B-X
increases	B-X
the	B-X
resolution	B-X
of	B-X
cell	B-X
cycle	B-X
analyses	B-X
by	B-X
separating	B-X
mitotic	B-X
stages	B-X
.	B-X
By	B-X
assessing	B-X
complex	B-X
cellular	B-X
phenotypes	B-X
,	B-X
ICS	B-X
substantially	B-X
expands	B-X
the	B-X
phenotypic	B-X
space	B-X
accessible	B-X
to	B-X
cell-sorting	B-X
applications	B-X
and	B-X
pooled	B-X
genetic	B-X
screening	B-X
.	B-X

Western	O
blotting	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
techniques	B-X
in	B-X
molecular	B-X
biology	B-X
and	B-X
proteomics	B-X
.	B-X
Since	B-X
western	B-X
blotting	B-X
is	B-X
a	B-X
multistep	B-X
protocol	B-X
,	B-X
variations	B-X
and	B-X
errors	B-X
can	B-X
occur	B-X
at	B-X
any	B-X
step	B-X
reducing	B-X
the	B-X
reliability	B-X
and	B-X
reproducibility	B-X
of	B-X
this	B-X
technique	B-X
.	B-X
Areas	B-X
covered	B-X
:	B-X
In	B-X
this	B-X
review	B-X
,	B-X
improvements	B-X
in	B-X
different	B-X
areas	B-X
of	B-X
western	B-X
blotting	B-X
,	B-X
including	B-X
protein	B-X
transfer	B-X
and	B-X
antibody	B-X
validation	B-X
,	B-X
are	B-X
summarized	B-X
.	B-X
The	B-X
review	B-X
discusses	B-X
the	B-X
most	B-X
advanced	B-X
western	B-X
blotting	B-X
techniques	B-X
available	B-X
and	B-X
highlights	B-X
the	B-X
relationship	B-X
between	B-X
next	B-X
generation	B-X
western	B-X
blotting	B-X
techniques	B-X
and	B-X
its	B-X
clinical	B-X
relevance	B-X
.	B-X
New	B-X
methods	B-X
such	B-X
as	B-X
single	B-X
cell-resolution	B-X
western	B-X
blot	B-X
,	B-X
capillary	B-X
electrophoresis	B-X
,	B-X
DigiWest	B-X
,	B-X
automated	B-X
microfluid	B-X
western	B-X
blotting	B-X
and	B-X
microchip	B-X
electrophoresis	B-X
have	B-X
all	B-X
been	B-X
developed	B-X
to	B-X
reduce	B-X
potential	B-X
problems	B-X
associated	B-X
with	B-X
the	B-X
western	B-X
blotting	B-X
technique	B-X
.	B-X

For	O
FOXP3	B-Protein
analysis	O
on	O
the	O
protein	O
level	O
,	O
1	O
x	O
106	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Magicmark	O
,	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Life	O
Science	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
BSA	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
an	O
1	O
:	O
200	O
dilution	O
of	O
goat	O
anti	O
-	O
FOXP3	B-Protein
in	O
blocking	O
buffer	O
(	O
Abcam	O
)	O
overnight	O
at	O
4	O
degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
goat	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
1000	O
camera	O
(	O
Fuji	O
)	O
.	O

Membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
re	O
-	O
blocked	O
for	O
1	O
h	O
.	O

The	O
membranes	O
were	O
re	O
-	O
probed	O
using	O
anti	O
-	O
GATA3	B-Protein
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
T	B-Protein
-	I-Protein
bet	I-Protein
(	O
4B10	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
GAPDH	B-Protein
(	O
6C5	O
,	O
Ambion	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
SMAD2	B-Protein
(	O
138D4	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
STAT6	B-Protein
(	O
5A4	O
)	O
,	O
and	O
anti	O
-	O
STAT6	B-Protein
(	O
Cell	O
Signaling	O
Technology	O
)	O
,	O

Administration	O
of	O
cytokines	O
and	O
antibodies	O
in	O
vivo	O
.	O
<EOS>	B-X
Systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
is	B-X
a	B-X
life-threatening	B-X
autoimmune	B-X
disease	B-X
characterized	B-X
by	B-X
adaptive	B-X
immune	B-X
system	B-X
activation	B-X
,	B-X
formation	B-X
of	B-X
double-stranded	B-X
DNA	B-X
autoantibodies	B-X
and	B-X
organ	B-X
inflammation	B-X
.	B-X
In	B-X
adoptive	B-X
cell	B-X
therapy	B-X
(	B-X
ACT	B-X
)	B-X
,	B-X
autologous	B-X
tumor-specific	B-X
T-cells	B-X
isolated	B-X
from	B-X
cancer	B-X
patients	B-X
are	B-X
activated	B-X
and	B-X
expanded	B-X
ex	B-X
vivo	B-X
,	B-X
then	B-X
infused	B-X
back	B-X
into	B-X
the	B-X
individual	B-X
to	B-X
eliminate	B-X
metastatic	B-X
tumors	B-X
.	B-X
A	B-X
major	B-X
limitation	B-X
of	B-X
this	B-X
promising	B-X
approach	B-X
is	B-X
the	B-X
rapid	B-X
loss	B-X
of	B-X
ACT	B-X
T-cell	B-X
effector	B-X
function	B-X
in	B-X
vivo	B-X
due	B-X
to	B-X
the	B-X
highly	B-X
immunosuppressive	B-X
environment	B-X
in	B-X
tumors	B-X
.	B-X
Here	B-X
we	B-X
propose	B-X
a	B-X
novel	B-X
strategy	B-X
to	B-X
repeatedly	B-X
stimulate	B-X
or	B-X
track	B-X
ACT	B-X
T-cells	B-X
,	B-X
using	B-X
cytokines	B-X
or	B-X
ACT-cell-specific	B-X
antibodies	B-X
as	B-X
ligands	B-X
to	B-X
target	B-X
PEGylated	B-X
liposomes	B-X
to	B-X
transferred	B-X
T-cells	B-X
in	B-X
vivo	B-X
.	B-X
Using	B-X
F	B-X
(	B-X
ab	B-X
'	B-X
)	B-X
2	B-X
fragments	B-X
against	B-X
a	B-X
unique	B-X
cell	B-X
surface	B-X
antigen	B-X
on	B-X
ACT	B-X
cells	B-X
(	B-X
Thy1.1	B-X
)	B-X
or	B-X
an	B-X
engineered	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
molecule	B-X
on	B-X
an	B-X
Fc	B-X
framework	B-X
as	B-X
targeting	B-X
ligands	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
>	B-X
95	B-X
%	B-X
of	B-X
ACT	B-X
cells	B-X
can	B-X
be	B-X
conjugated	B-X
with	B-X
liposomes	B-X
following	B-X
a	B-X
single	B-X
injection	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
feasibility	B-X
of	B-X
repeated	B-X
functional	B-X
targeting	B-X
of	B-X
T-cells	B-X
in	B-X
vivo	B-X
,	B-X
which	B-X
will	B-X
enable	B-X
delivery	B-X
of	B-X
imaging	B-X
contrast	B-X
agents	B-X
,	B-X
immunomodulators	B-X
,	B-X
or	B-X
chemotherapy	B-X
agents	B-X
in	B-X
adoptive	B-X
cell	B-X
therapy	B-X
regimens	B-X
.	B-X

Age	O
-	O
and	O
gender	O
-	O
matched	O
normal	O
B6	O
mice	O
received	O
every	O
other	O
day	O
intraperitoneal	O
(	O
ip	O
)	O
injections	O
of	O
PBS	O
,	O
1	O
.	O
5	O
mug	O
rmIL	O
-	O
4	O
,	O
50	O
mug	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
,	O
or	O
a	O
mixture	O
of	O
1	O
.	O
5	O
mug	O
rmIL	B-Protein
-	I-Protein
4	I-Protein
plus	O
50	O
mug	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
(	O
11B11	O
or	O
MAB404	O
)	O
for	O
7	O
d	O
.	O

Thereafter	O
,	O
spleen	O
and	O
lymph	O
node	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
for	O
CD3	B-Protein
,	O
CD4	B-Protein
,	O
and	O
CD25	B-Protein
expression	O
.	O

The	O
anti	O
-	O
mouse	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
MAB404	O
was	O
obtained	O
from	O
R	O
&	O
D	O
Systems	O
,	O
the	O
second	O
anti	O
-	O
mouse	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAb	O
11B11	O
was	O
purchased	O
from	O
eBioscience	O
.	O

ChIP	O
.	O
<EOS>	B-X
Owing	B-X
to	B-X
its	B-X
digital	B-X
nature	B-X
,	B-X
ChIP-seq	B-X
has	B-X
become	B-X
the	B-X
standard	B-X
method	B-X
for	B-X
genome-wide	B-X
ChIP	B-X
analysis	B-X
.	B-X
The	B-X
densities	B-X
of	B-X
recovered	B-X
ChIP	B-X
sequence	B-X
reads	B-X
along	B-X
the	B-X
genome	B-X
are	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Although	B-X
a	B-X
relatively	B-X
small	B-X
amount	B-X
of	B-X
ChIP	B-X
DNA	B-X
is	B-X
required	B-X
for	B-X
ChIP-seq	B-X
,	B-X
the	B-X
current	B-X
sequencing	B-X
platforms	B-X
still	B-X
require	B-X
amplification	B-X
of	B-X
the	B-X
ChIP	B-X
DNA	B-X
by	B-X
ligation-mediated	B-X
PCR	B-X
(	B-X
LM-PCR	B-X
)	B-X
.	B-X
This	B-X
protocol	B-X
,	B-X
which	B-X
involves	B-X
linker	B-X
ligation	B-X
followed	B-X
by	B-X
size	B-X
selection	B-X
,	B-X
is	B-X
the	B-X
standard	B-X
ChIP-seq	B-X
protocol	B-X
using	B-X
an	B-X
Illumina	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
size-selected	B-X
ChIP	B-X
DNA	B-X
is	B-X
amplified	B-X
by	B-X
LM-PCR	B-X
and	B-X
size-selected	B-X
for	B-X
the	B-X
second	B-X
time	B-X
.	B-X
The	B-X
purified	B-X
ChIP	B-X
DNA	B-X
is	B-X
then	B-X
loaded	B-X
into	B-X
the	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
ChIP	B-X
DNA	B-X
can	B-X
also	B-X
be	B-X
processed	B-X
in	B-X
parallel	B-X
for	B-X
ChIP-chip	B-X
results	B-X
.	B-X

ChIP	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Upstate	O
Biotechnology	O
)	O
with	O
the	O
following	O
modifications	O
.	O

iTreg	O
and	O
Th2	O
cells	O
were	O
fixed	O
with	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

The	O
chromatin	O
was	O
sheared	O
to	O
200	O
-	O
1000	O
bp	O
of	O
length	O
by	O
sonication	O
with	O
five	O
pulses	O
of	O
10	O
s	O
at	O
30	O
%	O
power	O
(	O
Bandelin	O
)	O
.	O

The	O
chromatin	O
was	O
pre	O
-	O
cleared	O
for	O
2	O
h	O
with	O
normal	O
mouse	O
IgG	O
beads	O
and	O
then	O
incubated	O
with	O
anti	O
-	O
GATA3	B-Protein
-	O
agarose	O
beads	O
(	O
HG3	O
-	O
31	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
2	O
h	O
.	O

Washing	O
and	O
elution	O
buffers	O
were	O
used	O
according	O
to	O
the	O
protocol	O
of	O
Upstate	O
Biotechnology	O
.	O

Crosslinks	O
were	O
reversed	O
by	O
incubation	O
at	O
65	O
degreesC	O
for	O
4	O
h	O
in	O
the	O
presence	O
of	O
0	O
.	O
2	O
M	O
NaCl	O
,	O
and	O
the	O
DNA	O
was	O
purified	O
by	O
phenol	O
/	O
chloroform	O
extraction	O
.	O

The	O
amount	O
of	O
DNA	O
was	O
determined	O
by	O
conventional	O
PCR	O
.	O
<EOS>	B-X
We	B-X
compared	B-X
a	B-X
qualitative	B-X
in-clinic	B-X
(	B-X
IC	B-X
)	B-X
-PCR	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
Mycoplasma	B-X
haemofelis	B-X
DNA	B-X
with	B-X
the	B-X
results	B-X
of	B-X
a	B-X
commercial	B-X
qualitative	B-X
laboratory-based	B-X
,	B-X
conventional	B-X
(	B-X
c	B-X
)	B-X
PCR	B-X
.	B-X
Forty-three	B-X
previously	B-X
tested	B-X
blood	B-X
samples	B-X
with	B-X
known	B-X
PCR	B-X
results	B-X
for	B-X
hemoplasmas	B-X
and	B-X
Bartonella	B-X
spp	B-X
.	B-X
At	B-X
the	B-X
first	B-X
laboratory	B-X
,	B-X
DNA	B-X
was	B-X
purified	B-X
and	B-X
run	B-X
on	B-X
2	B-X
cPCR	B-X
assays	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
hemoplasmas	B-X
and	B-X
Bartonella	B-X
spp	B-X
.	B-X
At	B-X
the	B-X
second	B-X
laboratory	B-X
,	B-X
DNA	B-X
was	B-X
purified	B-X
using	B-X
2	B-X
purification	B-X
protocols	B-X
and	B-X
both	B-X
run	B-X
in	B-X
the	B-X
IC-PCR	B-X
assay	B-X
.	B-X
The	B-X
cPCR	B-X
results	B-X
confirmed	B-X
that	B-X
18	B-X
samples	B-X
were	B-X
positive	B-X
for	B-X
M.	B-X
haemofelis	B-X
,	B-X
5	B-X
for	B-X
'	B-X
Candidatus	B-X
M.	B-X
haemominutum	B-X
'	B-X
,	B-X
8	B-X
for	B-X
Bartonella	B-X
henselae	B-X
,	B-X
2	B-X
for	B-X
Bartonella	B-X
clarridgeiae	B-X
,	B-X
and	B-X
10	B-X
were	B-X
negative	B-X
for	B-X
both	B-X
genera	B-X
.	B-X
The	B-X
IC-PCR	B-X
assay	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
M.	B-X
haemofelis	B-X
had	B-X
a	B-X
sensitivity	B-X
of	B-X
94.4	B-X
%	B-X
and	B-X
specificity	B-X
of	B-X
96	B-X
%	B-X
,	B-X
when	B-X
using	B-X
the	B-X
same	B-X
DNA	B-X
purification	B-X
method	B-X
as	B-X
the	B-X
first	B-X
laboratory	B-X
.	B-X
Using	B-X
the	B-X
second	B-X
purification	B-X
method	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
IC-PCR	B-X
assay	B-X
was	B-X
77.8	B-X
%	B-X
and	B-X
specificity	B-X
was	B-X
96	B-X
%	B-X
.	B-X
Bartonella	B-X
species	B-X
were	B-X
not	B-X
detected	B-X
by	B-X
the	B-X
IC-PCR	B-X
M.	B-X
haemofelis	B-X
assay	B-X
.	B-X
The	B-X
IC-PCR	B-X
assay	B-X
decreased	B-X
the	B-X
amount	B-X
of	B-X
time	B-X
to	B-X
final	B-X
result	B-X
compared	B-X
to	B-X
a	B-X
cPCR	B-X
assay	B-X
.	B-X

The	O
PCR	O
addressed	O
for	O
the	O
FOXP3	B-Protein
promoter	O
region	O
-	O
246	O
to	O
-	O
511	O
and	O
was	O
performed	O
using	O
the	O
following	O
primers	O
:	O
5	O
'	O
-	O
gtgccctttacgagt	O
catctg	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
gtgccctttacgagtcatctg	O
-	O
3	O
'	O
.	O

The	O
PCR	O
products	O
were	O
visualized	O
using	O
an	O
ethidium	O
bromide	O
gel	O
.	O
<EOS>	B-X
PCR-single	B-X
strand	B-X
conformation	B-X
polymorphism	B-X
analysis	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
INSL3	B-X
gene	B-X
for	B-X
genetic	B-X
variants	B-X
.	B-X
For	B-X
rapid	B-X
screening	B-X
of	B-X
a	B-X
detected	B-X
nonsilent	B-X
genetic	B-X
alteration	B-X
,	B-X
restriction	B-X
assay	B-X
using	B-X
endonuclease	B-X
Eag	B-X
I	B-X
was	B-X
further	B-X
employed	B-X
.	B-X
Products	B-X
were	B-X
analysed	B-X
on	B-X
2	B-X
%	B-X
agarose	B-X
gel	B-X
and	B-X
restriction	B-X
patterns	B-X
were	B-X
visualised	B-X
by	B-X
ethidium	B-X
bromide	B-X
.	B-X
Polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
is	B-X
used	B-X
to	B-X
estimate	B-X
the	B-X
number	B-X
of	B-X
CAG	B-X
repeats	B-X
but	B-X
may	B-X
be	B-X
inefficient	B-X
in	B-X
long	B-X
repeats	B-X
because	B-X
of	B-X
the	B-X
high	B-X
C+G	B-X
content	B-X
of	B-X
the	B-X
HD	B-X
locus	B-X
.	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
PCR	B-X
approach	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
HD	B-X
,	B-X
which	B-X
permits	B-X
direct	B-X
visualization	B-X
of	B-X
the	B-X
amplified	B-X
products	B-X
on	B-X
agarose	B-X
gel	B-X
,	B-X
using	B-X
ethidium	B-X
bromide	B-X
.	B-X
The	B-X
bisulfite	B-X
treatment	B-X
dramatically	B-X
reduces	B-X
the	B-X
C	B-X
+	B-X
G	B-X
content	B-X
of	B-X
the	B-X
region	B-X
;	B-X
thus	B-X
,	B-X
the	B-X
high	B-X
Tm	B-X
and	B-X
stable	B-X
secondary	B-X
structures	B-X
are	B-X
no	B-X
longer	B-X
obstacles	B-X
to	B-X
PCR	B-X
.	B-X
In	B-X
both	B-X
normal	B-X
and	B-X
affected	B-X
individuals	B-X
,	B-X
UAG	B-X
repeats	B-X
(	B-X
5'-	B-X
CAG-3	B-X
'	B-X
,	B-X
before	B-X
bisulfite	B-X
treatment	B-X
)	B-X
in	B-X
the	B-X
sense	B-X
strand	B-X
can	B-X
easily	B-X
be	B-X
amplified	B-X
and	B-X
visualized	B-X
on	B-X
a	B-X
gel	B-X
by	B-X
ethidium	B-X
bromide	B-X
staining	B-X
.	B-X
The	B-X
method	B-X
has	B-X
considerable	B-X
advantages	B-X
compared	B-X
with	B-X
other	B-X
described	B-X
PCR-based	B-X
diagnostic	B-X
tests	B-X
for	B-X
HD	B-X
.	B-X

Pull	O
-	O
down	O
assay	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
classic	B-X
and	B-X
widely	B-X
used	B-X
methods	B-X
to	B-X
discover	B-X
or	B-X
confirm	B-X
novel	B-X
protein	B-X
interactions	B-X
in	B-X
plant	B-X
cells	B-X
is	B-X
the	B-X
pull-down	B-X
assay	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
practical	B-X
protocol	B-X
of	B-X
the	B-X
tag-based	B-X
pull-down	B-X
assay	B-X
and	B-X
discuss	B-X
solutions	B-X
to	B-X
some	B-X
common	B-X
problems	B-X
associated	B-X
with	B-X
this	B-X
assay	B-X
.	B-X
The	B-X
GST	B-X
pull-down	B-X
assay	B-X
is	B-X
an	B-X
intuitive	B-X
and	B-X
fast	B-X
in	B-X
vitro	B-X
method	B-X
for	B-X
analyzing	B-X
protein-protein	B-X
or	B-X
protein-ligand	B-X
interactions	B-X
and	B-X
is	B-X
comprised	B-X
of	B-X
a	B-X
``	B-X
bait	B-X
''	B-X
which	B-X
is	B-X
a	B-X
GST-fused	B-X
protein	B-X
expressed	B-X
in	B-X
E.	B-X
coli	B-X
host	B-X
or	B-X
a	B-X
baculovirus	B-X
expression	B-X
system	B-X
and	B-X
a	B-X
``	B-X
prey	B-X
''	B-X
which	B-X
comprises	B-X
putative	B-X
binding	B-X
partner	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
or	B-X
other	B-X
ligand	B-X
molecule	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
pull-down	B-X
assay	B-X
is	B-X
an	B-X
in	B-X
vitro	B-X
technique	B-X
used	B-X
to	B-X
detect	B-X
physical	B-X
interactions	B-X
between	B-X
two	B-X
or	B-X
more	B-X
proteins	B-X
and	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
confirming	B-X
a	B-X
predicted	B-X
protein-protein	B-X
interaction	B-X
or	B-X
identifying	B-X
novel	B-X
interacting	B-X
partners	B-X
.	B-X

CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
2	O
h	O
at	O
37degreesC	O
.	O

The	O
cells	O
were	O
pelleted	O
,	O
resuspended	O
in	O
buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
[	O
pH	O
7	O
.	O
9	O
]	O
,	O
420	O
mM	O
NaCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
2	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
protease	O
inhibitors	O
[	O
Sigma	O
]	O
.	O
and	O
0	O
.	O
1	O
%	O
NP	O
-	O
40	O
)	O
and	O
lysed	O
on	O
ice	O
for	O
15	O
min	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
used	B-X
tangential	B-X
flow	B-X
filtration	B-X
(	B-X
TFF	B-X
)	B-X
to	B-X
isolate	B-X
polymeric	B-X
Hp	B-X
from	B-X
plasma	B-X
proteins	B-X
using	B-X
human	B-X
Fraction	B-X
IV	B-X
(	B-X
FIV	B-X
)	B-X
as	B-X
the	B-X
starting	B-X
material	B-X
.	B-X
After	B-X
removal	B-X
of	B-X
insoluble	B-X
material	B-X
from	B-X
a	B-X
suspension	B-X
of	B-X
FIV	B-X
paste	B-X
,	B-X
the	B-X
protein	B-X
mixture	B-X
was	B-X
clarified	B-X
on	B-X
a	B-X
0.2	B-X
μm	B-X
hollow	B-X
fiber	B-X
(	B-X
HF	B-X
)	B-X
TFF	B-X
filter	B-X
.	B-X
Because	B-X
the	B-X
chromophore	B-X
is	B-X
not	B-X
chemically	B-X
bound	B-X
to	B-X
the	B-X
protein	B-X
or	B-X
other	B-X
insoluble	B-X
material	B-X
,	B-X
it	B-X
is	B-X
not	B-X
lost	B-X
when	B-X
the	B-X
insoluble	B-X
substrate	B-X
is	B-X
removed	B-X
by	B-X
centrifugation	B-X
or	B-X
filtration	B-X
after	B-X
the	B-X
reaction	B-X
is	B-X
completed	B-X
.	B-X
The	B-X
temperature	B-X
of	B-X
-196	B-X
°C	B-X
achieved	B-X
with	B-X
the	B-X
use	B-X
of	B-X
LN2	B-X
protects	B-X
the	B-X
biological	B-X
material	B-X
from	B-X
degradation	B-X
by	B-X
proteases	B-X
and	B-X
nucleases	B-X
,	B-X
allowing	B-X
the	B-X
retrieval	B-X
of	B-X
intact	B-X
proteins	B-X
,	B-X
nucleic	B-X
acids	B-X
and	B-X
other	B-X
macromolecules	B-X
.	B-X
This	B-X
popcorn	B-X
is	B-X
then	B-X
pulverized	B-X
under	B-X
LN2	B-X
in	B-X
a	B-X
freezer	B-X
mill	B-X
to	B-X
generate	B-X
a	B-X
frozen	B-X
``	B-X
powdered	B-X
''	B-X
extract	B-X
which	B-X
is	B-X
thawed	B-X
slowly	B-X
and	B-X
clarified	B-X
by	B-X
centrifugation	B-X
to	B-X
remove	B-X
insoluble	B-X
debris	B-X
.	B-X

The	O
supernatant	O
was	O
diluted	O
1	O
:	O
3	O
with	O
buffer	O
D	O
(	O
as	O
buffer	O
C	O
,	O
but	O
without	O
NaCl	O
)	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
mug	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
(	O
Sigma	O
)	O
and	O
70	O
mul	O
of	O
streptavidin	O
-	O
agarose	O
(	O
Amersham	O
Biosciences	O
)	O
carrying	O
biotinylated	O
oligonucleotides	O
,	O
for	O
3	O
h	O
at	O
4	O
degreesC	O
.	O

The	O
beads	O
were	O
washed	O
twice	O
with	O
buffer	O
C	O
:	O
D	O
(	O
1	O
:	O
3	O
)	O
and	O
resuspended	O
in	O
DTT	O
-	O
containing	O
loading	O
buffer	O
(	O
NuPAGE	O
;	O
Invitrogen	O
)	O
,	O
heated	O
to	O
70	O
degreesC	O
for	O
10	O
min	O
,	O
and	O
the	O
eluants	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
bis	O
-	O
tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
detected	O
using	O
an	O
anti	O
-	O
GATA3	B-Protein
mAb	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O

Accumulated	O
signals	O
were	O
analyzed	O
using	O
AIDA	O
software	O
(	O
Raytest	O
)	O
.	O

Th2	O
Cells	O
Cannot	O
Induce	O
FOXP3	B-Protein
Expression	O
<EOS>	B-X
These	B-X
early	B-X
activated	B-X
antigen	B-X
specific	B-X
Treg	B-X
,	B-X
were	B-X
respectively	B-X
named	B-X
Ts1	B-X
and	B-X
Ts2	B-X
cells	B-X
,	B-X
as	B-X
they	B-X
depend	B-X
on	B-X
Th1	B-X
or	B-X
Th2	B-X
responses	B-X
.	B-X
Our	B-X
studies	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
nTreg	B-X
with	B-X
Th1	B-X
or	B-X
Th2	B-X
responses	B-X
induced	B-X
separate	B-X
lineages	B-X
of	B-X
antigen	B-X
specific	B-X
Treg	B-X
,	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
late	B-X
Th1	B-X
and	B-X
Th2	B-X
cytokines	B-X
,	B-X
not	B-X
the	B-X
early	B-X
cytokines	B-X
IL-2	B-X
and	B-X
IL-4	B-X
.	B-X
KLF10	B-X
overexpressing	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
T	B-X
cells	B-X
induced	B-X
both	B-X
TGF-beta1	B-X
and	B-X
Foxp3	B-X
expression	B-X
,	B-X
an	B-X
effect	B-X
associated	B-X
with	B-X
reduced	B-X
T-Bet	B-X
(	B-X
Th1	B-X
marker	B-X
)	B-X
and	B-X
Gata3	B-X
(	B-X
Th2	B-X
marker	B-X
)	B-X
mRNA	B-X
expression	B-X
.	B-X
Consistently	B-X
,	B-X
KLF10	B-X
(	B-X
-/-	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
enhanced	B-X
differentiation	B-X
along	B-X
both	B-X
Th1	B-X
and	B-X
Th2	B-X
pathways	B-X
and	B-X
elaborate	B-X
higher	B-X
levels	B-X
of	B-X
Th1	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X

(	O
A	O
)	O
Human	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
with	O
or	O
without	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
as	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
of	O
(	O
B	O
)	O
.	O
<EOS>	B-X
The	B-X
stomach	B-X
is	B-X
a	B-X
sensitive	B-X
digestive	B-X
organ	B-X
that	B-X
is	B-X
susceptible	B-X
to	B-X
exogenous	B-X
pathogens	B-X
from	B-X
the	B-X
diet	B-X
.	B-X
In	B-X
response	B-X
to	B-X
such	B-X
pathogens	B-X
,	B-X
the	B-X
stomach	B-X
induces	B-X
oxidative	B-X
stress	B-X
,	B-X
which	B-X
might	B-X
be	B-X
related	B-X
to	B-X
the	B-X
development	B-X
of	B-X
both	B-X
gastric	B-X
organic	B-X
disorders	B-X
such	B-X
as	B-X
gastritis	B-X
,	B-X
gastric	B-X
ulcers	B-X
,	B-X
and	B-X
gastric	B-X
cancer	B-X
,	B-X
and	B-X
functional	B-X
disorders	B-X
such	B-X
as	B-X
functional	B-X
dyspepsia	B-X
.	B-X
We	B-X
performed	B-X
a	B-X
sequential	B-X
morphological	B-X
and	B-X
molecular	B-X
biological	B-X
study	B-X
of	B-X
the	B-X
development	B-X
of	B-X
the	B-X
vertebral	B-X
bodies	B-X
in	B-X
Atlantic	B-X
salmon	B-X
(	B-X
Salmo	B-X
salar	B-X
L.	B-X
)	B-X
.	B-X
The	B-X
nucleation	B-X
and	B-X
growth	B-X
of	B-X
hydroxyapatite	B-X
crystals	B-X
in	B-X
both	B-X
the	B-X
lamellar	B-X
type	B-X
II	B-X
collagen	B-X
matrix	B-X
of	B-X
the	B-X
notochord	B-X
sheath	B-X
and	B-X
the	B-X
lamellar	B-X
type	B-X
I	B-X
collagen	B-X
matrix	B-X
derived	B-X
from	B-X
the	B-X
sclerotome	B-X
,	B-X
were	B-X
highly	B-X
similar	B-X
.	B-X
In	B-X
both	B-X
matrices	B-X
the	B-X
hydroxyapatite	B-X
crystals	B-X
nucleate	B-X
and	B-X
accrete	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
collagen	B-X
fibrils	B-X
rather	B-X
than	B-X
inside	B-X
the	B-X
fibrils	B-X
,	B-X
a	B-X
process	B-X
that	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
template	B-X
imposed	B-X
by	B-X
the	B-X
collagen	B-X
fibrils	B-X
.	B-X
Apatite	B-X
crystal	B-X
growth	B-X
starts	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
small	B-X
plate-like	B-X
structures	B-X
,	B-X
about	B-X
5	B-X
nm	B-X
thick	B-X
,	B-X
that	B-X
gradually	B-X
grow	B-X
and	B-X
aggregate	B-X
to	B-X
form	B-X
extensive	B-X
multi-branched	B-X
crystal	B-X
arborizations	B-X
,	B-X
resembling	B-X
dendritic	B-X
growth	B-X
.	B-X
The	B-X
hydroxyapatite	B-X
crystals	B-X
are	B-X
always	B-X
oriented	B-X
parallel	B-X
to	B-X
the	B-X
long	B-X
axis	B-X
of	B-X
the	B-X
collagen	B-X
fibrils	B-X
,	B-X
and	B-X
the	B-X
lamellar	B-X
collagen	B-X
matrices	B-X
provide	B-X
oriented	B-X
support	B-X
for	B-X
crystal	B-X
growth	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
for	B-X
the	B-X
first	B-X
time	B-X
by	B-X
means	B-X
of	B-X
synchroton	B-X
radiation	B-X
based	B-X
on	B-X
X-ray	B-X
diffraction	B-X
that	B-X
the	B-X
chordacentra	B-X
contain	B-X
hydroxyapatite	B-X
.	B-X
We	B-X
employed	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
to	B-X
study	B-X
the	B-X
expression	B-X
of	B-X
key	B-X
signalling	B-X
molecule	B-X
transcripts	B-X
expressed	B-X
in	B-X
the	B-X
cellular	B-X
core	B-X
of	B-X
the	B-X
notochord	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
notochord	B-X
not	B-X
only	B-X
produces	B-X
and	B-X
maintains	B-X
the	B-X
notochord	B-X
sheath	B-X
but	B-X
also	B-X
expresses	B-X
factors	B-X
known	B-X
to	B-X
regulate	B-X
skeletogenesis	B-X
:	B-X
sonic	B-X
hedgehog	B-X
(	B-X
shh	B-X
)	B-X
,	B-X
indian	B-X
hedgehog	B-X
homolog	B-X
b	B-X
(	B-X
ihhb	B-X
)	B-X
,	B-X
parathyroid	B-X
hormone	B-X
1	B-X
receptor	B-X
(	B-X
pth1r	B-X
)	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
beta	B-X
1	B-X
(	B-X
tgfb1	B-X
)	B-X
.	B-X

Cells	O
were	O
harvested	O
after	O
5	O
days	O
and	O
FOXP3	B-Protein
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
4	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
In	O
vitro	O
differentiated	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
were	O
activated	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
or	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
indicated	O
.	O
<EOS>	B-X
The	B-X
M1	B-X
phenotype	B-X
exacerbates	B-X
neuroinflammation	B-X
,	B-X
whereas	B-X
the	B-X
M2	B-X
phenotype	B-X
promotes	B-X
tissue	B-X
repair	B-X
and	B-X
provides	B-X
anti-inflammatory	B-X
effects	B-X
.	B-X
First	B-X
,	B-X
we	B-X
established	B-X
a	B-X
method	B-X
for	B-X
effective	B-X
induction	B-X
of	B-X
M1	B-X
or	B-X
M2	B-X
microglia	B-X
by	B-X
exposure	B-X
to	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
or	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
be	B-X
used	B-X
for	B-X
transplantation	B-X
in	B-X
a	B-X
SCI	B-X
mouse	B-X
model	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
indicated	B-X
that	B-X
M2	B-X
microglia	B-X
obtained	B-X
by	B-X
IL-4	B-X
stimulation	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
candidate	B-X
for	B-X
cell	B-X
transplantation	B-X
therapy	B-X
for	B-X
SCI	B-X
.	B-X
M1	B-X
macrophages	B-X
are	B-X
typically	B-X
activated	B-X
by	B-X
lipopolysaccharide	B-X
and	B-X
produce	B-X
proinflammatory	B-X
cytokines	B-X
.	B-X
Conversely	B-X
,	B-X
M2	B-X
macrophages	B-X
are	B-X
activated	B-X
by	B-X
stimulation	B-X
with	B-X
interleukin	B-X
4	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
promote	B-X
tissue	B-X
remodeling	B-X
and	B-X
anti-inflammatory	B-X
reactions	B-X
.	B-X
Docosahexaenoic	B-X
acid	B-X
(	B-X
DHA	B-X
)	B-X
,	B-X
a	B-X
PUFA	B-X
,	B-X
has	B-X
anti-inflammatory	B-X
effects	B-X
on	B-X
chronic	B-X
inflammatory	B-X
disease	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
macrophage	B-X
polarization	B-X
remains	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
clarified	B-X
the	B-X
effects	B-X
of	B-X
DHA	B-X
on	B-X
macrophage	B-X
polarization	B-X
using	B-X
U937	B-X
cells	B-X
.	B-X
Treatment	B-X
with	B-X
DHA	B-X
resulted	B-X
in	B-X
upregulation	B-X
of	B-X
M2	B-X
macrophage	B-X
markers	B-X
and	B-X
increased	B-X
secretion	B-X
of	B-X
anti-inflammatory	B-X
cytokines	B-X
by	B-X
U937	B-X
cells	B-X
.	B-X
IL-4	B-X
,	B-X
but	B-X
not	B-X
DHA	B-X
,	B-X
triggered	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
6	B-X
(	B-X
STAT6	B-X
)	B-X
.	B-X
DHA	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
krüppel-like	B-X
factor-4	B-X
(	B-X
KLF4	B-X
)	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
macrophage	B-X
polarization	B-X
and	B-X
increased	B-X
the	B-X
phosphorylation	B-X
of	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
.	B-X
A	B-X
selective	B-X
inhibitor	B-X
of	B-X
p38	B-X
MAPK	B-X
downregulated	B-X
the	B-X
expression	B-X
of	B-X
CD206	B-X
in	B-X
DHA-treated	B-X
U937	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
inhibitors	B-X
of	B-X
autophagy	B-X
suppressed	B-X
the	B-X
phosphorylation	B-X
of	B-X
p38	B-X
MAPK	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
CD206	B-X
in	B-X
DHA-treated	B-X
U937	B-X
cells	B-X
.	B-X
Expression	B-X
of	B-X
microtubule-associated	B-X
protein	B-X
light	B-X
chain	B-X
3-II	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
autophagosome	B-X
formation	B-X
,	B-X
was	B-X
enhanced	B-X
in	B-X
DHA-treated	B-X
U937	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
indicated	B-X
that	B-X
DHA	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
M2	B-X
macrophage	B-X
markers	B-X
through	B-X
the	B-X
p38	B-X
MAPK	B-X
signaling	B-X
pathway	B-X
and	B-X
autophagy	B-X
,	B-X
suggesting	B-X
that	B-X
DHA	B-X
regulates	B-X
M2	B-X
macrophage	B-X
polarization	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
.	B-X

The	O
phenotype	O
of	O
these	O
cells	O
was	O
confirmed	O
by	O
FACS	O
and	O
proliferation	O
analysis	O
(	O
Figure	O
S1	O
)	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
four	O
independent	O
experiments	O
.	O

Th2	O
Cells	O
Do	O
Not	O
Express	O
FOXP3	B-Protein
<EOS>	B-X
T	B-X
helper	B-X
type	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
stably	B-X
express	B-X
IFN-gamma	B-X
,	B-X
whereas	B-X
Th2	B-X
cells	B-X
express	B-X
IL-4	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressing	B-X
the	B-X
coinhibitory	B-X
molecule	B-X
TIGIT	B-X
as	B-X
a	B-X
distinct	B-X
Treg	B-X
cell	B-X
subset	B-X
that	B-X
specifically	B-X
suppresses	B-X
proinflammatory	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th17	B-X
cell	B-X
,	B-X
but	B-X
not	B-X
Th2	B-X
cell	B-X
responses	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
Fgl2	B-X
was	B-X
necessary	B-X
to	B-X
prevent	B-X
suppression	B-X
of	B-X
Th2	B-X
cytokine	B-X
production	B-X
in	B-X
a	B-X
model	B-X
of	B-X
allergic	B-X
airway	B-X
inflammation	B-X
.	B-X
TIGIT	B-X
expression	B-X
therefore	B-X
identifies	B-X
a	B-X
Treg	B-X
cell	B-X
subset	B-X
that	B-X
demonstrates	B-X
selectivity	B-X
for	B-X
suppression	B-X
of	B-X
Th1	B-X
and	B-X
Th17	B-X
cell	B-X
but	B-X
not	B-X
Th2	B-X
cell	B-X
responses	B-X
.	B-X

(	O
A	O
)	O
Intracellular	O
FACS	O
analysis	O
of	O
FOXP3	B-Protein
expression	O
in	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
-	O
differentiated	O
cells	O
(	O
two	O
rounds	O
,	O
phenotype	O
see	O
Figure	O
S1	O
)	O
,	O
rested	O
or	O
activated	O
,	O
with	O
or	O
without	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O
<EOS>	B-X
The	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
is	B-X
the	B-X
prototype	B-X
of	B-X
the	B-X
TGF-β	B-X
family	B-X
of	B-X
growth	B-X
and	B-X
differentiation	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
encoded	B-X
by	B-X
33	B-X
genes	B-X
in	B-X
mammals	B-X
and	B-X
comprises	B-X
homo-	B-X
and	B-X
heterodimers	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
reader	B-X
to	B-X
the	B-X
TGF-β	B-X
family	B-X
with	B-X
its	B-X
complexity	B-X
of	B-X
names	B-X
and	B-X
biological	B-X
activities	B-X
.	B-X
It	B-X
also	B-X
introduces	B-X
TGF-β	B-X
as	B-X
the	B-X
best-studied	B-X
factor	B-X
among	B-X
the	B-X
TGF-β	B-X
family	B-X
proteins	B-X
,	B-X
with	B-X
its	B-X
diversity	B-X
of	B-X
roles	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
immune	B-X
system	B-X
,	B-X
and	B-X
its	B-X
key	B-X
roles	B-X
in	B-X
pathology	B-X
,	B-X
for	B-X
example	B-X
,	B-X
skeletal	B-X
diseases	B-X
,	B-X
fibrosis	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
Transforming	B-X
growth	B-X
factor-β1	B-X
(	B-X
TGF-β1	B-X
)	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
crucial	B-X
mediator	B-X
in	B-X
tissue	B-X
fibrosis	B-X
and	B-X
causes	B-X
tissue	B-X
scarring	B-X
largely	B-X
by	B-X
activating	B-X
its	B-X
downstream	B-X
small	B-X
mother	B-X
against	B-X
decapentaplegic	B-X
(	B-X
Smad	B-X
)	B-X
signaling	B-X
.	B-X
Different	B-X
TGF-β	B-X
signalings	B-X
play	B-X
different	B-X
roles	B-X
in	B-X
fibrogenesis	B-X
.	B-X
TGF-β1	B-X
directly	B-X
activates	B-X
Smad	B-X
signaling	B-X
which	B-X
triggers	B-X
pro-fibrotic	B-X
gene	B-X
overexpression	B-X
.	B-X
Excessive	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
dysregulation	B-X
of	B-X
TGF-β1/Smad	B-X
pathway	B-X
was	B-X
an	B-X
important	B-X
pathogenic	B-X
mechanism	B-X
in	B-X
tissue	B-X
fibrosis	B-X
.	B-X
Smad2	B-X
and	B-X
Smad3	B-X
are	B-X
the	B-X
two	B-X
major	B-X
downstream	B-X
regulator	B-X
that	B-X
promote	B-X
TGF-β1-mediated	B-X
tissue	B-X
fibrosis	B-X
,	B-X
while	B-X
Smad7	B-X
serves	B-X
as	B-X
a	B-X
negative	B-X
feedback	B-X
regulator	B-X
of	B-X
TGF-β1/Smad	B-X
pathway	B-X
thereby	B-X
protects	B-X
against	B-X
TGF-β1-mediated	B-X
fibrosis	B-X
.	B-X
This	B-X
review	B-X
presents	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
TGF-β/Smad	B-X
signaling	B-X
pathway	B-X
in	B-X
renal	B-X
,	B-X
hepatic	B-X
,	B-X
pulmonary	B-X
and	B-X
cardiac	B-X
fibrosis	B-X
,	B-X
followed	B-X
by	B-X
an	B-X
in-depth	B-X
discussion	B-X
of	B-X
their	B-X
molecular	B-X
mechanisms	B-X
of	B-X
intervention	B-X
effects	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
role	B-X
of	B-X
TGF-β/Smad	B-X
signaling	B-X
pathway	B-X
in	B-X
tumor	B-X
or	B-X
cancer	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
current	B-X
advances	B-X
also	B-X
highlight	B-X
targeting	B-X
TGF-β/Smad	B-X
signaling	B-X
pathway	B-X
for	B-X
the	B-X
prevention	B-X
of	B-X
tissue	B-X
fibrosis	B-X
.	B-X

FOXP3	B-Protein
expression	O
was	O
measured	O
after	O
5	O
d	O
in	O
culture	O
.	O

The	O
dot	O
blots	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Shows	O
the	O
same	O
experimental	O
setup	O
,	O
but	O
naturally	O
occurring	O
Th2	O
cells	O
were	O
analyzed	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

Th2	O
-	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
Producing	O
Cells	O
Lack	O
FOXP3	B-Protein
<EOS>	B-X
Upon	B-X
activation	B-X
,	B-X
naïve	B-X
CD4	B-X
For	B-X
over	B-X
35	B-X
years	B-X
since	B-X
Mosmann	B-X
and	B-X
Coffman	B-X
proposed	B-X
the	B-X
seminal	B-X
``	B-X
type	B-X
1	B-X
T	B-X
helper	B-X
(	B-X
Th1	B-X
)	B-X
/type	B-X
2	B-X
T	B-X
helper	B-X
(	B-X
Th2	B-X
)	B-X
''	B-X
hypothesis	B-X
in	B-X
1986	B-X
,	B-X
the	B-X
immunological	B-X
community	B-X
has	B-X
appreciated	B-X
that	B-X
naïve	B-X
CD4	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
make	B-X
important	B-X
decisions	B-X
upon	B-X
their	B-X
activation	B-X
,	B-X
namely	B-X
to	B-X
differentiate	B-X
towards	B-X
a	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
Th17	B-X
(	B-X
interleukin-17-producing	B-X
T	B-X
helper	B-X
)	B-X
,	B-X
follicular	B-X
T	B-X
helper	B-X
(	B-X
Tfh	B-X
)	B-X
,	B-X
or	B-X
regulatory	B-X
T	B-X
cell	B-X
(	B-X
Treg	B-X
)	B-X
fate	B-X
to	B-X
orchestrate	B-X
a	B-X
variety	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
The	B-X
major	B-X
molecular	B-X
underpinnings	B-X
of	B-X
the	B-X
Th1/Th2	B-X
effector	B-X
fate	B-X
choice	B-X
had	B-X
been	B-X
initially	B-X
characterized	B-X
using	B-X
excellent	B-X
reductionist	B-X
A	B-X
large	B-X
body	B-X
of	B-X
evidence	B-X
indicates	B-X
the	B-X
existence	B-X
of	B-X
functionally	B-X
polarized	B-X
CD4+	B-X
T-cell	B-X
responses	B-X
based	B-X
on	B-X
their	B-X
profile	B-X
of	B-X
cytokine	B-X
secretion	B-X
.	B-X
Type	B-X
1	B-X
T	B-X
helper	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
produce	B-X
interferon-gamma	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-beta	B-X
,	B-X
which	B-X
activate	B-X
macrophages	B-X
and	B-X
are	B-X
responsible	B-X
for	B-X
cell-mediated	B-X
immunity	B-X
and	B-X
phagocyte-dependent	B-X
protective	B-X
responses	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
type	B-X
2	B-X
Th	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
produce	B-X
IL-4	B-X
,	B-X
IL-5	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
IL-13	B-X
,	B-X
which	B-X
are	B-X
responsible	B-X
for	B-X
strong	B-X
antibody	B-X
production	B-X
,	B-X
eosinophil	B-X
activation	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
several	B-X
macrophage	B-X
functions	B-X
,	B-X
thus	B-X
providing	B-X
phagocyte-independent	B-X
protective	B-X
responses	B-X
.	B-X
Th1	B-X
cells	B-X
mainly	B-X
develop	B-X
following	B-X
infections	B-X
by	B-X
intracellular	B-X
bacteria	B-X
and	B-X
some	B-X
viruses	B-X
,	B-X
whereas	B-X
Th2	B-X
cells	B-X
predominate	B-X
in	B-X
response	B-X
to	B-X
infestations	B-X
by	B-X
gastrointestinal	B-X
nematodes	B-X
.	B-X
Polarized	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
not	B-X
only	B-X
exhibit	B-X
different	B-X
functional	B-X
properties	B-X
,	B-X
but	B-X
also	B-X
show	B-X
the	B-X
preferential	B-X
expression	B-X
of	B-X
some	B-X
activation	B-X
markers	B-X
and	B-X
distinct	B-X
transcription	B-X
factors	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
playing	B-X
different	B-X
roles	B-X
in	B-X
protection	B-X
,	B-X
polarized	B-X
Th1-type	B-X
and	B-X
Th2-type	B-X
responses	B-X
are	B-X
also	B-X
responsible	B-X
for	B-X
different	B-X
types	B-X
of	B-X
immunopathological	B-X
reactions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
allergen-specific	B-X
Th2	B-X
responses	B-X
are	B-X
responsible	B-X
for	B-X
atopic	B-X
disorders	B-X
in	B-X
genetically	B-X
susceptible	B-X
individuals	B-X
.	B-X
Moreover	B-X
,	B-X
Th2	B-X
responses	B-X
against	B-X
still	B-X
unknown	B-X
antigens	B-X
predominate	B-X
in	B-X
Omenn	B-X
's	B-X
syndrome	B-X
,	B-X
idiopathic	B-X
pulmonary	B-X
fibrosis	B-X
,	B-X
and	B-X
progressive	B-X
systemic	B-X
sclerosis	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
prevalence	B-X
of	B-X
Th2	B-X
responses	B-X
may	B-X
play	B-X
some	B-X
role	B-X
in	B-X
a	B-X
more	B-X
rapid	B-X
evolution	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
infection	B-X
to	B-X
the	B-X
full-blown	B-X
disease	B-X
.	B-X
The	B-X
Th1/Th2	B-X
paradigm	B-X
also	B-X
provides	B-X
the	B-X
rationale	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
types	B-X
of	B-X
vaccines	B-X
against	B-X
infectious	B-X
agents	B-X
and	B-X
of	B-X
novel	B-X
strategies	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
allergic	B-X
and	B-X
autoimmune	B-X
disorders	B-X
.	B-X

(	O
A	O
)	O
FACS	O
analysis	O
of	O
intracellular	O
FOXP3	B-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
expression	O
following	O
PMA	O
/	O
Ionomycin	O
stimulation	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
gated	O
on	O
the	O
basis	O
of	O
CD45RO	B-Protein
and	O
CD25	B-Protein
surface	O
expression	O
(	O
upper	O
panel	O
)	O
,	O
and	O
gated	O
cells	O
are	O
shown	O
below	O
for	O
the	O
CD45RO	B-Protein
+	O
CD25	B-Protein
-	O
(	O
A	O
,	O
left	O
panel	O
)	O
,	O
the	O
CD45RO	B-Protein
+	O
CD25	B-Protein
+	O
(	O
right	O
panel	O
)	O
,	O
and	O
the	O
CD45RO	B-Protein
-	O
CD25	B-Protein
-	O
subsets	O
(	O
central	O
panel	O
)	O
.	O

A	O
statistical	O
analysis	O
of	O
eight	O
independent	O
donors	O
after	O
subtraction	O
of	O
the	O
isotype	O
control	O
are	O
shown	O
in	O
(	O
B	O
)	O
.	O

The	O
dotted	O
gray	O
line	O
indicates	O
the	O
IC	O
background	O
level	O
.	O

The	O
error	O
bars	O
show	O
the	O
error	O
of	O
the	O
mean	O
.	O
<EOS>	B-X
Standard	B-X
deviation	B-X
and	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
have	B-X
been	B-X
applied	B-X
widely	B-X
as	B-X
error	B-X
bars	B-X
in	B-X
scientific	B-X
plots	B-X
.	B-X
Here	B-X
we	B-X
seek	B-X
to	B-X
fill	B-X
this	B-X
gap	B-X
by	B-X
outlining	B-X
the	B-X
reasoning	B-X
for	B-X
choosing	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
over	B-X
standard	B-X
deviation	B-X
and	B-X
hope	B-X
to	B-X
shed	B-X
light	B-X
on	B-X
this	B-X
unsettled	B-X
disagreement	B-X
among	B-X
the	B-X
biomedical	B-X
community	B-X
.	B-X
The	B-X
utility	B-X
of	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
and	B-X
standard	B-X
deviation	B-X
as	B-X
error	B-X
bars	B-X
is	B-X
further	B-X
discussed	B-X
by	B-X
examining	B-X
the	B-X
figures	B-X
and	B-X
plots	B-X
published	B-X
in	B-X
two	B-X
research	B-X
articles	B-X
on	B-X
pancreatic	B-X
disease	B-X
.	B-X
When	B-X
making	B-X
an	B-X
inference	B-X
or	B-X
comparison	B-X
with	B-X
uncertain	B-X
,	B-X
noisy	B-X
,	B-X
or	B-X
incomplete	B-X
data	B-X
,	B-X
measurement	B-X
error	B-X
and	B-X
confidence	B-X
intervals	B-X
can	B-X
be	B-X
as	B-X
important	B-X
for	B-X
judgment	B-X
as	B-X
the	B-X
actual	B-X
mean	B-X
values	B-X
of	B-X
different	B-X
groups	B-X
.	B-X
These	B-X
often	B-X
misunderstood	B-X
statistical	B-X
quantities	B-X
are	B-X
frequently	B-X
represented	B-X
by	B-X
bar	B-X
charts	B-X
with	B-X
error	B-X
bars	B-X
.	B-X
This	B-X
paper	B-X
investigates	B-X
drawbacks	B-X
with	B-X
this	B-X
standard	B-X
encoding	B-X
,	B-X
and	B-X
considers	B-X
a	B-X
set	B-X
of	B-X
alternatives	B-X
designed	B-X
to	B-X
more	B-X
effectively	B-X
communicate	B-X
the	B-X
implications	B-X
of	B-X
mean	B-X
and	B-X
error	B-X
data	B-X
to	B-X
a	B-X
general	B-X
audience	B-X
,	B-X
drawing	B-X
from	B-X
lessons	B-X
learned	B-X
from	B-X
the	B-X
use	B-X
of	B-X
visual	B-X
statistics	B-X
in	B-X
the	B-X
information	B-X
visualization	B-X
community	B-X
.	B-X
We	B-X
present	B-X
a	B-X
series	B-X
of	B-X
crowd-sourced	B-X
experiments	B-X
that	B-X
confirm	B-X
that	B-X
the	B-X
encoding	B-X
of	B-X
mean	B-X
and	B-X
error	B-X
significantly	B-X
changes	B-X
how	B-X
viewers	B-X
make	B-X
decisions	B-X
about	B-X
uncertain	B-X
data	B-X
.	B-X
We	B-X
suggest	B-X
the	B-X
use	B-X
of	B-X
gradient	B-X
plots	B-X
(	B-X
which	B-X
use	B-X
transparency	B-X
to	B-X
encode	B-X
uncertainty	B-X
)	B-X
and	B-X
violin	B-X
plots	B-X
(	B-X
which	B-X
use	B-X
width	B-X
)	B-X
as	B-X
better	B-X
alternatives	B-X
for	B-X
inferential	B-X
tasks	B-X
than	B-X
bar	B-X
charts	B-X
with	B-X
error	B-X
bars	B-X
.	B-X

(	O
C	O
)	O
Similarly	O
,	O
a	O
Th2	O
clone	O
(	O
BR8	O
)	O
,	O
CRTH2	B-Protein
+	O
Th2	O
cells	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
secreting	O
cells	O
,	O
and	O
memory	O
T	O
cells	O
(	O
CD45RO	B-Protein
)	O
were	O
stained	O
for	O
FOXP3	B-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

FOXP3	B-Protein
Induction	O
During	O
the	O
Differentiation	O
Process	O
<EOS>	B-X
The	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
driving	B-X
Th17	B-X
and	B-X
Treg	B-X
cell	B-X
lineages	B-X
differentiation	B-X
respectively	B-X
,	B-X
RORγt	B-X
and	B-X
FOXP3	B-X
are	B-X
tightly	B-X
regulated	B-X
under	B-X
different	B-X
tissue	B-X
microenvironment	B-X
,	B-X
especially	B-X
the	B-X
transcriptional	B-X
induction	B-X
,	B-X
posttranslational	B-X
modifications	B-X
,	B-X
and	B-X
dynamic	B-X
enzymatic	B-X
cofactors	B-X
binding	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
transcription	B-X
factor	B-X
FOXP3	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
CD4+	B-X
CD25+	B-X
Tregs	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
capacity	B-X
of	B-X
FOXP3	B-X
to	B-X
drive	B-X
the	B-X
generation	B-X
of	B-X
suppressive	B-X
CD4+	B-X
CD25+	B-X
Tregs	B-X
in	B-X
humans	B-X
.	B-X
Surprisingly	B-X
,	B-X
although	B-X
ectopic	B-X
expression	B-X
of	B-X
FOXP3	B-X
in	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
induction	B-X
of	B-X
hyporesponsiveness	B-X
and	B-X
suppression	B-X
of	B-X
IL-2	B-X
production	B-X
,	B-X
it	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
acquisition	B-X
of	B-X
significant	B-X
suppressor	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
Similarly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
FOXP3delta2	B-X
,	B-X
an	B-X
isoform	B-X
found	B-X
in	B-X
human	B-X
CD4+	B-X
CD25+	B-X
Tregs	B-X
that	B-X
lacks	B-X
exon	B-X
2	B-X
,	B-X
also	B-X
failed	B-X
to	B-X
induce	B-X
the	B-X
development	B-X
of	B-X
suppressor	B-X
T	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
when	B-X
FOXP3	B-X
and	B-X
FOXP3delta2	B-X
were	B-X
simultaneously	B-X
overexpressed	B-X
,	B-X
although	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
Treg-associated	B-X
cell	B-X
surface	B-X
markers	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
only	B-X
a	B-X
modest	B-X
suppressive	B-X
activity	B-X
was	B-X
induced	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
in	B-X
humans	B-X
,	B-X
overexpression	B-X
of	B-X
FOXP3	B-X
alone	B-X
or	B-X
together	B-X
with	B-X
FOXP3delta2	B-X
is	B-X
not	B-X
an	B-X
effective	B-X
method	B-X
to	B-X
generate	B-X
potent	B-X
suppressor	B-X
T	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
suggest	B-X
that	B-X
factors	B-X
in	B-X
addition	B-X
to	B-X
FOXP3	B-X
are	B-X
required	B-X
during	B-X
the	B-X
process	B-X
of	B-X
activation	B-X
and/or	B-X
differentiation	B-X
for	B-X
the	B-X
development	B-X
of	B-X
bona	B-X
fide	B-X
Tregs	B-X
.	B-X

(	O
A	O
)	O
Human	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
in	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
5	O
ng	O
/	O
ml	O
)	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
25	O
ng	O
/	O
ml	O
)	O
.	O

The	O
cells	O
were	O
harvested	O
at	O
different	O
time	O
points	O
,	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
FOXP3	B-Protein
and	O
GATA3	B-Protein
expression	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Intracellular	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
staining	O
is	O
shown	O
after	O
exposure	O
of	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
to	O
differentiating	O
conditions	O
as	O
in	O
part	O
A	O
of	O
the	O
figure	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

Effect	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
on	O
FOXP3	B-Protein
Induction	O
<EOS>	B-X
The	B-X
level	B-X
of	B-X
cytokines	B-X
of	B-X
interferon-γ	B-X
(	B-X
IFN-γ	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
,	B-X
interleukin-17	B-X
(	B-X
IL-17	B-X
)	B-X
,	B-X
IL-4	B-X
,	B-X
IL-12	B-X
,	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
and	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
Treg	B-X
cells	B-X
percentage	B-X
were	B-X
assayed	B-X
.	B-X
The	B-X
levels	B-X
of	B-X
IFN-γ	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-12	B-X
,	B-X
and	B-X
IL-17	B-X
were	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
level	B-X
of	B-X
TGF-β	B-X
,	B-X
IL-4	B-X
,	B-X
and	B-X
IL-10	B-X
were	B-X
increased	B-X
in	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
of	B-X
mice	B-X
treated	B-X
with	B-X
exosome	B-X
.	B-X
Percentages	B-X
of	B-X
CD4	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
produced	B-X
by	B-X
mainly	B-X
T	B-X
helper	B-X
17	B-X
(	B-X
Th17	B-X
)	B-X
cells	B-X
may	B-X
play	B-X
an	B-X
important	B-X
destructive	B-X
role	B-X
in	B-X
chronic	B-X
periodontitis	B-X
(	B-X
CP	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
IL-35	B-X
,	B-X
might	B-X
have	B-X
a	B-X
beneficial	B-X
effect	B-X
in	B-X
periodontitis	B-X
by	B-X
inhibiting	B-X
differentiation	B-X
of	B-X
Th17	B-X
cells	B-X
.	B-X

(	O
A	O
)	O
A	O
statistical	O
analysis	O
was	O
performed	O
with	O
six	O
donors	O
on	O
day	O
5	O
(	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
and	O
with	O
or	O
without	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
100	O
ng	O
/	O
ml	O
)	O
)	O
;	O
Shown	O
is	O
the	O
mean	O
,	O
and	O
error	O
bars	O
indicated	O
the	O
SD	O
of	O
six	O
donors	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Dunnett	O
test	O
.	O

Statistical	O
significance	O
is	O
indicated	O
by	O
asterisks	O
(	O
*	O
p	O
<	O
=	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
01	O
,	O
Dunnett	O
)	O
.	O

(	O
B	O
)	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
a	O
constant	O
concentration	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
5	O
ng	O
/	O
ml	O
)	O
with	O
an	O
increasing	O
concentration	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
as	O
indicated	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
quantification	O
after	O
5	O
d	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
a	B-X
simultaneous	B-X
NO2	B-X
and	B-X
particle	B-X
or	B-X
fibre	B-X
exposure	B-X
on	B-X
the	B-X
proinflammatory	B-X
specific	B-X
mRNA	B-X
expression	B-X
and	B-X
protein	B-X
secretion	B-X
of	B-X
human	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AM	B-X
)	B-X
in	B-X
comparison	B-X
to	B-X
only	B-X
particle	B-X
or	B-X
fibre	B-X
exposed	B-X
AM	B-X
.	B-X
Particle	B-X
or	B-X
fibre	B-X
exposure	B-X
of	B-X
the	B-X
AM	B-X
was	B-X
continued	B-X
in	B-X
humidified	B-X
air	B-X
at	B-X
5	B-X
%	B-X
CO2	B-X
and	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
an	B-X
additional	B-X
hour	B-X
(	B-X
harvesting	B-X
of	B-X
total	B-X
RNA	B-X
)	B-X
or	B-X
additional	B-X
7	B-X
hrs	B-X
(	B-X
harvesting	B-X
of	B-X
culture	B-X
supernatant	B-X
)	B-X
.	B-X
The	B-X
mRNA	B-X
expression	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokines	B-X
IL-1beta	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
and	B-X
TNF-alpha	B-X
of	B-X
NO2-particle/fibre	B-X
co-exposed	B-X
AM	B-X
and	B-X
only	B-X
particle	B-X
or	B-X
fibre	B-X
exposed	B-X
AM	B-X
was	B-X
detected	B-X
using	B-X
specific	B-X
RT-PCR	B-X
.	B-X
Cytotoxicity	B-X
was	B-X
detected	B-X
by	B-X
lactatedehydrogenase	B-X
quantification	B-X
in	B-X
the	B-X
culture	B-X
supernatant	B-X
.	B-X
We	B-X
observed	B-X
an	B-X
increased	B-X
IL-1beta-	B-X
,	B-X
IL-6-	B-X
,	B-X
IL-8-	B-X
and	B-X
TNF-alpha-specific	B-X
mRNA	B-X
expression	B-X
of	B-X
particle	B-X
or	B-X
fibre	B-X
exposed	B-X
AM	B-X
,	B-X
which	B-X
was	B-X
decreased	B-X
after	B-X
an	B-X
additional	B-X
NO2	B-X
exposure	B-X
.	B-X

(	O
C	O
)	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
cells	O
were	O
stimulated	O
in	O
vitro	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
10ng	O
/	O
ml	O
)	O
,	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
100	O
ng	O
/	O
ml	O
)	O
as	O
indicated	O
.	O

After	O
1	O
h	O
,	O
cell	O
lysates	O
were	O
prepared	O
and	O
analyzed	O
by	O
Western	O
blot	O
for	O
phosphorylated	O
SMAD2	B-Protein
and	O
STAT6	B-Protein
.	O

Total	O
STAT6	B-Protein
and	O
GAPDH	B-Protein
served	O
as	O
internal	O
control	O
.	O

(	O
D	O
)	O
Intracellular	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
staining	O
are	O
shown	O
after	O
exposure	O
of	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
described	O
for	O
panel	O
B	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
Inhibits	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
Mediated	O
iTreg	O
Commitment	O
<EOS>	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
mechanism	B-X
controlling	B-X
iTreg	B-X
polarization	B-X
,	B-X
which	B-X
is	B-X
overruled	B-X
by	B-X
the	B-X
Th2	B-X
differentiation	B-X
pathway	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

CFSE	O
-	O
labeled	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
cells	O
were	O
activated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
as	O
indicated	O
.	O

After	O
5	O
d	O
,	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
A	O
)	O
and	O
results	O
of	O
six	O
independent	O
experiments	O
are	O
shown	O
in	O
the	O
bar	O
graph	O
below	O
(	O
B	O
)	O
.	O

Statistical	O
significance	O
(	O
one	O
-	O
way	O
Anova	O
,	O
Newman	O
-	O
Keuls	O
)	O
is	O
indicated	O
by	O
asterisks	O
(	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
=	O
0	O
.	O
001	O
)	O
.	O

(	O
C	O
)	O
Kinetic	O
analysis	O
of	O
intracellular	O
GATA3	B-Protein
and	O
FOXP3	B-Protein
staining	O
is	O
shown	O
in	O
panel	O
C	O
following	O
exposure	O
of	O
CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
T	O
cells	O
to	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

GATA3	B-Protein
Acts	O
as	O
a	O
Negative	O
Regulator	O
of	O
FOXP3	B-Protein
Expression	O

(	O
A	O
)	O
Human	O
naive	O
CD4	B-Protein
+	O
CDRA	B-Protein
+	O
T	O
cells	O
were	O
transduced	O
with	O
0	O
,	O
20	O
,	O
100	O
,	O
and	O
500	O
nM	O
of	O
TAT	B-Protein
-	I-Protein
GATA3	I-Protein
protein	O
,	O
and	O
intracellular	O
presence	O
of	O
GATA3	B-Protein
was	O
analyzed	O
using	O
FACS	O
following	O
anti	O
-	O
CD3	B-Protein
/	O
CD28	B-Protein
activation	O
of	O
the	O
cells	O
.	O

GFP	B-Protein
-	O
positive	O
cells	O
were	O
gated	O
and	O
analyzed	O
for	O
intracellular	O
FOXP3	B-Protein
expression	O
following	O
a	O
2	O
-	O
d	O
incubation	O
period	O
(	O
lower	O
panel	O
)	O
.	O

Data	O
are	O
representative	O
of	O
four	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
cold	B-X
tumors	B-X
harbor	B-X
a	B-X
mechanism	B-X
of	B-X
immune	B-X
escape	B-X
upstream	B-X
and	B-X
independent	B-X
of	B-X
ICs	B-X
that	B-X
may	B-X
be	B-X
driven	B-X
by	B-X
tumor	B-X
biology	B-X
rather	B-X
than	B-X
differences	B-X
in	B-X
mutational	B-X
neoantigen	B-X
burden	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
cardioprotective	B-X
and	B-X
antiarrhythmic	B-X
effects	B-X
of	B-X
NC	B-X
in	B-X
animal	B-X
and	B-X
cell	B-X
experiments	B-X
.	B-X
The	B-X
method	B-X
relies	B-X
on	B-X
a	B-X
color	B-X
separation	B-X
method	B-X
that	B-X
discriminates	B-X
between	B-X
two	B-X
chromogens	B-X
expressed	B-X
as	B-X
brown	B-X
and	B-X
blue	B-X
colors	B-X
robustly	B-X
,	B-X
independent	B-X
of	B-X
color	B-X
variation	B-X
or	B-X
biomarker	B-X
expression	B-X
level	B-X
.	B-X
Experiments	B-X
for	B-X
the	B-X
semi-quantitative	B-X
scoring	B-X
of	B-X
images	B-X
in	B-X
five	B-X
categories	B-X
have	B-X
been	B-X
carried	B-X
out	B-X
by	B-X
comparing	B-X
the	B-X
results	B-X
with	B-X
the	B-X
scores	B-X
of	B-X
four	B-X
expert	B-X
researchers	B-X
yielding	B-X
accuracies	B-X
that	B-X
range	B-X
between	B-X
76.60	B-X
%	B-X
and	B-X
94.58	B-X
%	B-X
.	B-X

(	O
B	O
)	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
T	O
cells	O
were	O
isolated	O
from	O
D011	O
.	O
10	O
and	O
D011	O
.	O
10xCD2	B-Protein
-	O
GATA3	B-Protein
mice	O
and	O
treated	O
with	O
OVA	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
for	O
96	O
h	O
.	O

Surface	O
CD4	B-Protein
and	O
intracellular	O
FOXP3	B-Protein
were	O
measured	O
by	O
FACS	O
.	O
<EOS>	B-X
Since	B-X
zinc	B-X
deficiency	B-X
and	B-X
allergic	B-X
hyperresponsive	B-X
reactions	B-X
are	B-X
often	B-X
accompanied	B-X
,	B-X
the	B-X
influence	B-X
of	B-X
zinc	B-X
on	B-X
allergen-induced	B-X
cell	B-X
growth	B-X
,	B-X
CD4+	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cell	B-X
numbers	B-X
and	B-X
cytokine	B-X
expression	B-X
during	B-X
allergic	B-X
immune	B-X
reactions	B-X
was	B-X
investigated	B-X
.	B-X

These	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
propose	B-X
clustering	B-X
by	B-X
increasing	B-X
the	B-X
rand	B-X
index	B-X
via	B-X
coordinate	B-X
ascent	B-X
(	B-X
CIRCA	B-X
)	B-X
:	B-X
an	B-X
unsupervised	B-X
,	B-X
data-driven	B-X
clustering	B-X
method	B-X
for	B-X
deriving	B-X
ground-truth	B-X
scene	B-X
categories	B-X
.	B-X
In	B-X
Experiment	B-X
1	B-X
,	B-X
human	B-X
participants	B-X
organized	B-X
80	B-X
stereoscopic	B-X
images	B-X
of	B-X
outdoor	B-X
scenes	B-X
from	B-X
the	B-X
Southampton-York	B-X
Natural	B-X
Scenes	B-X
(	B-X
SYNS	B-X
)	B-X
dataset	B-X
(	B-X
Adams	B-X
et	B-X
al.	B-X
,	B-X
2016	B-X
)	B-X
into	B-X
discrete	B-X
categories	B-X
.	B-X
In	B-X
separate	B-X
tasks	B-X
,	B-X
images	B-X
were	B-X
grouped	B-X
according	B-X
to	B-X
i	B-X
)	B-X
semantic	B-X
content	B-X
,	B-X
ii	B-X
)	B-X
three-dimensional	B-X
spatial	B-X
structure	B-X
,	B-X
or	B-X
iii	B-X
)	B-X
two-dimensional	B-X
image	B-X
appearance	B-X
.	B-X
Using	B-X
the	B-X
CIRCA	B-X
method	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
most	B-X
representative	B-X
category	B-X
structure	B-X
and	B-X
then	B-X
derived	B-X
category	B-X
labels	B-X
for	B-X
each	B-X
task/dimension	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
Experiment	B-X
4	B-X
,	B-X
we	B-X
validated	B-X
CIRCA	B-X
on	B-X
a	B-X
larger	B-X
,	B-X
independent	B-X
dataset	B-X
of	B-X
same-different	B-X
category	B-X
judgements	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
believe	B-X
this	B-X
novel	B-X
categorization	B-X
method	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
datasets	B-X
to	B-X
derive	B-X
optimal	B-X
categorical	B-X
groupings	B-X
and	B-X
labels	B-X
from	B-X
psychophysical	B-X
judgements	B-X
of	B-X
stimulus	B-X
similarity	B-X
.	B-X

(	O
C	O
)	O
The	O
cells	O
treated	O
as	O
in	O
(	O
B	O
)	O
were	O
harvested	O
and	O
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
for	O
SMAD7	B-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
expression	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

GATA3	B-Protein
Represses	O
the	O
Human	O
FOXP3	B-Protein
Promoter	O
<EOS>	B-X
FOXP3	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
natural	B-X
,	B-X
thymus-derived	B-X
(	B-X
nTreg	B-X
)	B-X
and	B-X
inducible	B-X
Treg	B-X
(	B-X
iTreg	B-X
)	B-X
commitment	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanisms	B-X
regulating	B-X
its	B-X
expression	B-X
are	B-X
as	B-X
yet	B-X
unknown	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
interleukin	B-X
4	B-X
(	B-X
IL-4	B-X
)	B-X
present	B-X
at	B-X
the	B-X
time	B-X
of	B-X
T	B-X
cell	B-X
priming	B-X
inhibits	B-X
FOXP3	B-X
.	B-X
This	B-X
inhibitory	B-X
mechanism	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
Th2	B-X
cells	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
GATA-3	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
deficient	B-X
in	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-beta-mediated	B-X
FOXP3	B-X
induction	B-X
.	B-X
This	B-X
inhibition	B-X
is	B-X
mediated	B-X
by	B-X
direct	B-X
binding	B-X
of	B-X
GATA3	B-X
to	B-X
the	B-X
FOXP3	B-X
promoter	B-X
,	B-X
which	B-X
represses	B-X
its	B-X
transactivation	B-X
process	B-X
.	B-X
IL-4	B-X
treatment	B-X
in	B-X
mice	B-X
reduces	B-X
iTreg	B-X
cell	B-X
frequency	B-X
,	B-X
highlighting	B-X
that	B-X
therapeutic	B-X
approaches	B-X
that	B-X
target	B-X
IL-4	B-X
or	B-X
GATA3	B-X
might	B-X
provide	B-X
new	B-X
preventive	B-X
strategies	B-X
facilitating	B-X
tolerance	B-X
induction	B-X
particularly	B-X
in	B-X
Th2-mediated	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
allergy	B-X
.	B-X

(	O
A	O
)	O
Jurkat	O
,	O
Th2	O
cells	O
,	O
and	O
human	O
primary	O
CD4	B-Protein
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
basic	O
)	O
or	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	B-Protein
promoter	O
region	O
fused	O
to	O
the	O
luciferase	B-Protein
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	B-Protein
of	O
four	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
B	O
)	O
Naive	O
CD4	B-Protein
T	O
cells	O
were	O
transfected	O
with	O
the	O
FOXP3	B-Protein
promoter	O
reporter	O
construct	O
together	O
with	O
a	O
GATA3	B-Protein
expression	O
vector	O
or	O
an	O
empty	O
vector	O
.	O
<EOS>	B-X
Adeno-associated	B-X
virus	B-X
(	B-X
AAV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
viral	B-X
gene	B-X
delivery	B-X
vectors	B-X
with	B-X
long-term	B-X
gene	B-X
expression	B-X
and	B-X
disease	B-X
correction	B-X
,	B-X
featuring	B-X
high	B-X
efficiency	B-X
and	B-X
excellent	B-X
safety	B-X
in	B-X
human	B-X
clinical	B-X
trials	B-X
.	B-X
During	B-X
the	B-X
production	B-X
of	B-X
AAV	B-X
vectors	B-X
,	B-X
there	B-X
are	B-X
several	B-X
quality	B-X
control	B-X
(	B-X
QC	B-X
)	B-X
parameters	B-X
that	B-X
should	B-X
be	B-X
rigorously	B-X
monitored	B-X
to	B-X
comply	B-X
with	B-X
clinical	B-X
safety	B-X
and	B-X
efficacy	B-X
.	B-X
This	B-X
review	B-X
gives	B-X
a	B-X
short	B-X
summary	B-X
of	B-X
the	B-X
most	B-X
frequently	B-X
used	B-X
AVV	B-X
production	B-X
and	B-X
purification	B-X
methods	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
analytical	B-X
techniques	B-X
applied	B-X
to	B-X
determine	B-X
the	B-X
full/empty	B-X
capsid	B-X
ratio	B-X
and	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
encapsidated	B-X
therapeutic	B-X
DNA	B-X
of	B-X
the	B-X
products	B-X
.	B-X
Transient	B-X
and	B-X
stable	B-X
vector	B-X
transfections	B-X
have	B-X
played	B-X
important	B-X
roles	B-X
in	B-X
illustrating	B-X
the	B-X
function	B-X
of	B-X
specific	B-X
genes/proteins	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
an	B-X
assumption	B-X
that	B-X
empty	B-X
vector-transfected	B-X
cells	B-X
preserve	B-X
the	B-X
cytogenetic	B-X
and	B-X
phenotypic	B-X
characteristics	B-X
,	B-X
and	B-X
represent	B-X
the	B-X
adequate	B-X
control	B-X
in	B-X
transfection	B-X
experiments	B-X
is	B-X
not	B-X
universally	B-X
valid	B-X
.	B-X
A	B-X
DNA	B-X
vector	B-X
,	B-X
a	B-X
transfection	B-X
reagent	B-X
,	B-X
expression	B-X
of	B-X
an	B-X
antibiotic	B-X
resistance	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
reporter	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
selection	B-X
by	B-X
acute/chronic	B-X
antibiotic	B-X
treatment	B-X
may	B-X
evoke	B-X
cellular	B-X
responses	B-X
that	B-X
affect	B-X
the	B-X
biochemical	B-X
processes	B-X
under	B-X
investigation	B-X
.	B-X
We	B-X
exemplify	B-X
a	B-X
number	B-X
of	B-X
studies	B-X
,	B-X
which	B-X
reported	B-X
obvious	B-X
genomic	B-X
,	B-X
transcriptomic	B-X
and	B-X
phenotypic	B-X
changes	B-X
of	B-X
tumor	B-X
cells	B-X
after	B-X
transient/stable	B-X
transfection	B-X
of	B-X
an	B-X
empty	B-X
vector	B-X
.	B-X
We	B-X
conceptualize	B-X
that	B-X
the	B-X
diverse	B-X
experimental	B-X
manipulations	B-X
(	B-X
e.g.	B-X
,	B-X
transgene	B-X
overexpression	B-X
,	B-X
gene	B-X
knock	B-X
out/down	B-X
,	B-X
chemical	B-X
treatments	B-X
,	B-X
acute	B-X
changes	B-X
in	B-X
culture	B-X
conditions	B-X
,	B-X
etc	B-X
.	B-X
)	B-X

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Naive	O
(	O
left	O
panel	O
)	O
or	O
memory	O
(	O
right	O
panel	O
)	O
CD4	B-Protein
T	O
cells	O
were	O
transfected	O
with	O
wild	O
-	O
type	O
or	O
a	O
GATA3	B-Protein
mutated	O
511	O
-	O
FOXP3	B-Protein
promoter	O
reporter	O
construct	O
and	O
activated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
arbitrary	O
light	O
units	O
normalized	O
for	O
renilla	O
luciferase	B-Protein
of	O
eight	O
independent	O
experiments	O
;	O
samples	O
were	O
measured	O
in	O
triplicates	O
.	O

(	O
D	O
)	O
Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
cells	O
transfected	O
with	O
GATA3	B-Protein
or	O
an	O
empty	O
vector	O
,	O
(	O
E	O
)	O
Th1	O
,	O
Th2	O
,	O
or	O
iTreg	O
cells	O
and	O
binding	O
factors	O
precipitated	O
using	O
biotinylated	O
oligonucleotides	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
IL-27	B-X
on	B-X
Th9	B-X
differentiation	B-X
and	B-X
Th1/Th2	B-X
balance	B-X
.	B-X
The	B-X
strength	B-X
of	B-X
immune	B-X
responses	B-X
induced	B-X
by	B-X
DNA	B-X
vaccine	B-X
is	B-X
closely	B-X
associated	B-X
with	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
cloned	B-X
antigens	B-X
available	B-X
to	B-X
the	B-X
antigen	B-X
presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
.	B-X
To	B-X
acquire	B-X
a	B-X
larger	B-X
and	B-X
more	B-X
persistent	B-X
amount	B-X
of	B-X
antigen	B-X
,	B-X
a	B-X
dual-promoter	B-X
,	B-X
which	B-X
could	B-X
double	B-X
the	B-X
target	B-X
antigen	B-X
output	B-X
through	B-X
its	B-X
expression	B-X
both	B-X
in	B-X
prokaryotic	B-X
and	B-X
eukaryotic	B-X
cells	B-X
,	B-X
was	B-X
employed	B-X
in	B-X
the	B-X
constructed	B-X
anti-caries	B-X
DNA	B-X
vaccine	B-X
with	B-X
attenuated	B-X
Salmonella	B-X
as	B-X
mucosal	B-X
delivery	B-X
vector	B-X
in	B-X
this	B-X
study	B-X
.	B-X
Here	B-X
,	B-X
both	B-X
CMV	B-X
and	B-X
nirB	B-X
promoters	B-X
were	B-X
included	B-X
in	B-X
the	B-X
plasmid	B-X
that	B-X
harbors	B-X
the	B-X
genes	B-X
encoding	B-X
the	B-X
functional	B-X
epitopes	B-X
of	B-X
two	B-X
virulence	B-X
factors	B-X
of	B-X
S.	B-X
mutans	B-X
,	B-X
i.e	B-X
.	B-X
the	B-X
saliva-binding	B-X
region	B-X
(	B-X
SBR	B-X
)	B-X
of	B-X
PAc	B-X
and	B-X
the	B-X
glucan-binding	B-X
region	B-X
(	B-X
GBR	B-X
)	B-X
of	B-X
glucosyltransferase-I	B-X
(	B-X
GTF-I	B-X
)	B-X
.	B-X
The	B-X
serum	B-X
IgG	B-X
subclass	B-X
profiles	B-X
suggested	B-X
a	B-X
Th1/Th2-mixed	B-X
but	B-X
Th2	B-X
biased	B-X
immune	B-X
response	B-X
to	B-X
the	B-X
cloned	B-X
antigens	B-X
,	B-X
which	B-X
was	B-X
further	B-X
confirmed	B-X
by	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
the	B-X
Th1	B-X
(	B-X
IFN-γ	B-X
,	B-X
IL-2	B-X
)	B-X
and	B-X
Th2	B-X
(	B-X
IL-4	B-X
,	B-X
IL-10	B-X
)	B-X
cytokines	B-X
in	B-X
splenocytes	B-X
of	B-X
immunized	B-X
mice	B-X
upon	B-X
stimulation	B-X
with	B-X
SBR	B-X
or	B-X
GBR	B-X
.	B-X
Following	B-X
challenge	B-X
,	B-X
mice	B-X
immunized	B-X
with	B-X
Salmonella	B-X
expressing	B-X
SBR	B-X
and	B-X
GBR	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
CMV-nirB	B-X
promoter	B-X
showed	B-X
a	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
of	B-X
S.	B-X
mutans	B-X
in	B-X
the	B-X
dental	B-X
plaque	B-X
compared	B-X
to	B-X
the	B-X
empty	B-X
vector-immunized	B-X
or	B-X
unimmunized	B-X
mice	B-X
,	B-X
and	B-X
the	B-X
reduction	B-X
was	B-X
also	B-X
significant	B-X
at	B-X
weeks	B-X
3-8	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
post-challenge	B-X
when	B-X
compared	B-X
with	B-X
those	B-X
receiving	B-X
Salmonella	B-X
clones	B-X
with	B-X
nirB	B-X
promoter	B-X
alone	B-X
.	B-X

The	O
oligonucleotides	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
on	O
a	O
SDS	O
-	O
PAGE	O
gel	O
.	O
<EOS>	B-X
Controversy	B-X
remains	B-X
about	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
(	B-X
TFs	B-X
)	B-X
,	B-X
which	B-X
bind	B-X
to	B-X
the	B-X
two	B-X
E-box	B-X
elements	B-X
(	B-X
CACGTG	B-X
,	B-X
proximal	B-X
and	B-X
distal	B-X
)	B-X
of	B-X
the	B-X
human	B-X
telomerase	B-X
(	B-X
hTERT	B-X
)	B-X
gene	B-X
promoter	B-X
,	B-X
the	B-X
essential	B-X
elements	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
telomerase	B-X
.	B-X
The	B-X
protein	B-X
spot	B-X
was	B-X
cut	B-X
from	B-X
2-DE	B-X
and	B-X
in-gel	B-X
digested	B-X
with	B-X
trypsin	B-X
for	B-X
LC-nanospray	B-X
ESI-MS/MS	B-X
analysis	B-X
.	B-X
This	B-X
identified	B-X
upstream	B-X
stimulatory	B-X
factor	B-X
2	B-X
(	B-X
USF2	B-X
)	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
specific	B-X
antibodies	B-X
clearly	B-X
shows	B-X
USF2	B-X
present	B-X
in	B-X
the	B-X
purified	B-X
fraction	B-X
and	B-X
USF2	B-X
antibody	B-X
supershifts	B-X
the	B-X
specific	B-X
DNA-binding	B-X
complex	B-X
on	B-X
non-denaturing	B-X
gels	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
novel	B-X
method	B-X
was	B-X
developed	B-X
in	B-X
which	B-X
the	B-X
specific	B-X
DNA-TF	B-X
complex	B-X
was	B-X
separated	B-X
on	B-X
a	B-X
non-denaturing	B-X
gel	B-X
,	B-X
the	B-X
band	B-X
was	B-X
cut	B-X
and	B-X
applied	B-X
to	B-X
SDS-PAGE	B-X
for	B-X
a	B-X
second	B-X
dimension	B-X
.	B-X
Western	B-X
blots	B-X
of	B-X
this	B-X
second	B-X
gel	B-X
also	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
USF2	B-X
.	B-X

The	O
amounts	O
of	O
GATA3	B-Protein
protein	O
in	O
the	O
precipitates	O
were	O
assessed	O
by	O
immunoblotting	O
with	O
anti	O
-	O
GATA3	B-Protein
mAb	O
.	O

Total	O
nuclear	O
extracts	O
were	O
also	O
run	O
as	O
controls	O
.	O
<EOS>	B-X
Nuclear	B-X
run-off	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
quantify	B-X
the	B-X
relative	B-X
rates	B-X
of	B-X
mRNA	B-X
transcription	B-X
in	B-X
nuclear	B-X
extracts	B-X
from	B-X
hepatopancreas	B-X
of	B-X
aerobic	B-X
and	B-X
anoxic	B-X
snails	B-X
.	B-X
Total	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
-UTP	B-X
incorporation	B-X
into	B-X
RNA	B-X
by	B-X
nuclei	B-X
from	B-X
48	B-X
h	B-X
anoxic	B-X
snails	B-X
ranged	B-X
from	B-X
42	B-X
to	B-X
50	B-X
%	B-X
of	B-X
that	B-X
observed	B-X
for	B-X
nuclei	B-X
from	B-X
normoxic	B-X
snails	B-X
.	B-X
Examination	B-X
of	B-X
selected	B-X
expressed	B-X
sequence	B-X
tags	B-X
also	B-X
showed	B-X
an	B-X
overall	B-X
decrease	B-X
in	B-X
mRNA	B-X
transcription	B-X
levels	B-X
in	B-X
samples	B-X
derived	B-X
from	B-X
anoxic	B-X
nuclei	B-X
as	B-X
compared	B-X
with	B-X
normoxic	B-X
nuclei	B-X
.	B-X
Control	B-X
of	B-X
ribosomal	B-X
translation	B-X
was	B-X
also	B-X
examined	B-X
by	B-X
assessing	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
eukaryotic	B-X
initiation	B-X
factors	B-X
eIF-2alpha	B-X
and	B-X
eIF-4E	B-X
and	B-X
the	B-X
eukaryotic	B-X
elongation	B-X
factor-1gamma	B-X
(	B-X
eEF-1gamma	B-X
)	B-X
.	B-X

Data	O
are	O
representative	O
of	O
three	O
different	O
experiments	O
.	O
<EOS>	B-X
Antimony	B-X
(	B-X
Sb	B-X
)	B-X
distribution	B-X
,	B-X
solubility	B-X
and	B-X
mobility	B-X
onto	B-X
natural	B-X
soils	B-X
of	B-X
China	B-X
were	B-X
studied	B-X
in	B-X
lysimeter	B-X
and	B-X
batch	B-X
experiments	B-X
as	B-X
a	B-X
function	B-X
of	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
soil	B-X
.	B-X
Soil	B-X
solutions	B-X
were	B-X
collected	B-X
by	B-X
suction	B-X
cups	B-X
installed	B-X
at	B-X
different	B-X
depth	B-X
of	B-X
lysimeters	B-X
,	B-X
and	B-X
leachates	B-X
were	B-X
regularly	B-X
collected	B-X
and	B-X
analyzed	B-X
for	B-X
Sb	B-X
concentrations	B-X
.	B-X
Batch	B-X
experiments	B-X
were	B-X
performed	B-X
in	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
sorption	B-X
capacity	B-X
and	B-X
the	B-X
partition	B-X
coefficient	B-X
(	B-X
Kd	B-X
)	B-X
.	B-X
New	B-X
features	B-X
are	B-X
introduced	B-X
that	B-X
add	B-X
to	B-X
current	B-X
theoretical	B-X
efforts	B-X
:	B-X
(	B-X
i	B-X
)	B-X
a	B-X
unique	B-X
measure	B-X
of	B-X
bond	B-X
strength	B-X
based	B-X
on	B-X
local	B-X
mode	B-X
force	B-X
constants	B-X
ranging	B-X
from	B-X
bonding	B-X
in	B-X
single	B-X
molecules	B-X
in	B-X
different	B-X
environments	B-X
to	B-X
bonding	B-X
in	B-X
periodic	B-X
systems	B-X
and	B-X
crystals	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
a	B-X
new	B-X
way	B-X
to	B-X
interpret	B-X
vibrational	B-X
spectra	B-X
by	B-X
pinpointing	B-X
and	B-X
probing	B-X
interactions	B-X
between	B-X
particular	B-X
bond	B-X
stretching	B-X
contributions	B-X
to	B-X
the	B-X
normal	B-X
modes	B-X
.	B-X
Three	B-X
current	B-X
focus	B-X
points	B-X
of	B-X
the	B-X
local	B-X
mode	B-X
analysis	B-X
are	B-X
reported	B-X
,	B-X
demonstrating	B-X
how	B-X
the	B-X
local	B-X
mode	B-X
analysis	B-X
extracts	B-X
important	B-X
information	B-X
hidden	B-X
in	B-X
vibrational	B-X
spectroscopy	B-X
data	B-X
supporting	B-X
current	B-X
experiments	B-X
:	B-X
(	B-X
i	B-X
)	B-X
metal-ligand	B-X
bonding	B-X
in	B-X
heme	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
myoglobin	B-X
and	B-X
neuroglobin	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
disentanglement	B-X
of	B-X
DNA	B-X
normal	B-X
modes	B-X
;	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
hydrogen	B-X
bonding	B-X
in	B-X
water	B-X
clusters	B-X
and	B-X
ice	B-X
.	B-X

(	O
F	O
)	O
iTreg	O
or	O
Th2	O
cells	O
were	O
analyzed	O
by	O
ChIP	O
for	O
GATA3	B-Protein
binding	O
to	O
the	O
FOXP3	B-Protein
promoter	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
whether	B-X
FoxP3	B-X
These	B-X
microorganisms	B-X
,	B-X
including	B-X
the	B-X
Helicobacter	B-X
species	B-X
,	B-X
can	B-X
induce	B-X
pathogenic	B-X
T	B-X
cells	B-X
and	B-X
are	B-X
collectively	B-X
referred	B-X
to	B-X
as	B-X
pathobionts	B-X
.	B-X
However	B-X
,	B-X
how	B-X
such	B-X
T	B-X
cells	B-X
are	B-X
constrained	B-X
in	B-X
healthy	B-X
individuals	B-X
is	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
For	B-X
example	B-X
,	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
are	B-X
characterized	B-X
by	B-X
expression	B-X
of	B-X
FOXP3	B-X
,	B-X
which	B-X
is	B-X
either	B-X
induced	B-X
during	B-X
thymic	B-X
development	B-X
for	B-X
natural	B-X
Tregs	B-X
(	B-X
nTregs	B-X
)	B-X
,	B-X
or	B-X
in	B-X
the	B-X
periphery	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TGF-beta	B-X
and	B-X
retinoic	B-X
acid	B-X
for	B-X
induced	B-X
Tregs	B-X
(	B-X
iTreg	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
recent	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
the	B-X
signature	B-X
transcription	B-X
factor	B-X
for	B-X
Th17	B-X
cells	B-X
,	B-X
RORgammat	B-X
,	B-X
is	B-X
also	B-X
induced	B-X
by	B-X
TGF-beta	B-X
,	B-X
thus	B-X
linking	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
Treg	B-X
and	B-X
Th17	B-X
lineages	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
second	B-X
signal	B-X
from	B-X
a	B-X
proinflammatory	B-X
cytokine	B-X
,	B-X
FOXP3	B-X
can	B-X
inhibit	B-X
RORgammat	B-X
function	B-X
and	B-X
drive	B-X
Treg	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
the	B-X
cell	B-X
also	B-X
receives	B-X
a	B-X
signal	B-X
from	B-X
a	B-X
proinflammation	B-X
cytokine	B-X
(	B-X
e.g.	B-X
,	B-X
IL-6	B-X
)	B-X
,	B-X
FOXP3	B-X
function	B-X
is	B-X
inhibited	B-X
and	B-X
the	B-X
Th17	B-X
differentiation	B-X
pathway	B-X
is	B-X
induced	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
the	B-X
balance	B-X
between	B-X
FOXP3	B-X
and	B-X
RORgammat	B-X
function	B-X
that	B-X
determines	B-X
CD4	B-X
T	B-X
cell	B-X
fate	B-X
and	B-X
the	B-X
type	B-X
of	B-X
immune	B-X
response	B-X
that	B-X
will	B-X
be	B-X
generated	B-X
.	B-X

The	O
"	O
input	O
"	O
represents	O
PCR	O
amplification	O
of	O
the	O
total	O
sample	O
,	O
which	O
was	O
not	O
subjected	O
to	O
any	O
precipitation	O
.	O

Results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
the	B-X
previous	B-X
study	B-X
three	B-X
behavioural	B-X
types	B-X
of	B-X
participants	B-X
were	B-X
revealed	B-X
:	B-X
non-leaders	B-X
,	B-X
prosocial	B-X
leaders	B-X
and	B-X
leaders-cheaters	B-X
,	B-X
each	B-X
having	B-X
a	B-X
set	B-X
of	B-X
distinguishing	B-X
personality	B-X
,	B-X
communicative	B-X
,	B-X
and	B-X
cooperative	B-X
features	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
three	B-X
composite	B-X
portraits	B-X
representing	B-X
different	B-X
leadership	B-X
qualities	B-X
of	B-X
Buryat	B-X
men	B-X
from	B-X
the	B-X
prior	B-X
experiment	B-X
were	B-X
created	B-X
.	B-X
The	B-X
composites	B-X
were	B-X
then	B-X
scored	B-X
on	B-X
a	B-X
number	B-X
of	B-X
traits	B-X
by	B-X
male	B-X
and	B-X
female	B-X
Russian	B-X
and	B-X
Buryat	B-X
independent	B-X
raters	B-X
(	B-X

Suppression	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
Nuclear	O
Import	O
and	O
Phosphorylation	O
:	O
A	O
Novel	O
Mechanism	O
of	O
Corticosteroid	O
Action	O
in	O
Allergic	O
Disease	O
<EOS>	B-X
[	B-X
This	B-X
corrects	B-X
the	B-X
article	B-X
DOI	B-X
:	B-X
10.1371/journal.pmed.1000076	B-X
.	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

GATA	B-Protein
-	I-Protein
3	I-Protein
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
the	O
cytokines	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
from	O
T	O
helper	O
-	O
2	O
(	O
Th2	O
)	O
cells	O
and	O
therefore	O
is	O
a	O
key	O
mediator	O
of	O
allergic	O
diseases	O
.	O

Corticosteroids	O
are	O
highly	O
effective	O
in	O
suppressing	O
allergic	O
inflammation	O
,	O
but	O
their	O
effects	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
are	O
unknown	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

We	O
investigated	O
the	O
effect	O
of	O
the	O
corticosteroid	O
fluticasone	O
propionate	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
regulation	O
in	O
human	O
T	O
-	O
lymphocytes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Methods	O
and	O
Findings	O
<EOS>	B-X
This	B-X
glossary	B-X
was	B-X
developed	B-X
by	B-X
a	B-X
working	B-X
group	B-X
of	B-X
the	B-X
ILAE	B-X
Commission	B-X
on	B-X
Diagnostic	B-X
Methods	B-X
incorporating	B-X
the	B-X
EEG	B-X
Task	B-X
Force	B-X
.	B-X

In	O
a	O
T	O
lymphocyte	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
stimulated	O
by	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
in	O
vitro	O
we	O
demonstrated	O
that	O
fluticasone	O
inhibits	O
nuclear	O
translocation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
expression	O
of	O
Th2	O
cytokines	O
via	O
a	O
mechanism	O
independent	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
competition	O
between	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
the	O
ligand	O
-	O
activated	O
glucocorticoid	B-Protein
receptor	I-Protein
for	O
nuclear	O
transport	O
through	O
the	O
nuclear	O
importer	O
importin	O
-	O
alpha	O
.	O

In	O
addition	O
,	O
fluticasone	O
induces	O
the	O
expression	O
of	O
mitogen	B-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
(	I-Protein
MAPK	I-Protein
)	I-Protein
phosphatase	I-Protein
-	I-Protein
1	I-Protein
(	O
MKP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
the	O
endogenous	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
which	O
is	O
necessary	O
for	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
translocation	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

These	O
inhibitory	O
effects	O
of	O
fluticasone	O
are	O
rapid	O
,	O
potent	O
,	O
and	O
prolonged	O
.	O
<EOS>	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

We	O
also	O
demonstrated	O
that	O
inhaled	O
fluticasone	O
inhibits	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
translocation	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
in	O
vivo	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Conclusions	O
<EOS>	B-X
[	B-X
Conclusions	B-X
of	B-X
the	B-X
First	B-X
Workshop	B-X
of	B-X
the	B-X
oncology	B-X
societies	B-X
AIOM	B-X
,	B-X
AIRO	B-X
and	B-X
SICO	B-X
about	B-X
pancreatic	B-X
cancer	B-X
]	B-X
.	B-X

Corticosteroids	O
have	O
a	O
potent	O
inhibitory	O
effect	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
via	O
two	O
interacting	O
mechanisms	O
that	O
potently	O
suppress	O
Th2	O
cytokine	O
expression	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

This	O
novel	O
mechanism	O
of	O
action	O
of	O
corticosteroids	O
may	O
account	O
for	O
the	O
striking	O
clinical	O
efficacy	O
of	O
corticosteroids	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X

Please	O
see	O
later	O
in	O
the	O
article	O
for	O
Editors	O
'	O
Summary	O
<EOS>	B-X
Please	B-X
see	B-X
later	B-X
in	B-X
the	B-X
article	B-X
for	B-X
the	B-X
Editors	B-X
'	B-X
Summary	B-X
.	B-X
Please	B-X
see	B-X
later	B-X
in	B-X
the	B-X
article	B-X
for	B-X
the	B-X
Editors	B-X
'	B-X
Summary	B-X
.	B-X
Please	B-X
see	B-X
later	B-X
in	B-X
the	B-X
article	B-X
for	B-X
the	B-X
Editors	B-X
'	B-X
Summary	B-X
.	B-X

Inflammation	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
,	O
rhinitis	O
,	O
and	O
atopic	O
dermatitis	O
is	O
mediated	O
via	O
expression	O
of	O
the	O
cytokines	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
from	O
T	O
helper	O
-	O
2	O
(	O
Th2	O
)	O
cells	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
regulate	O
the	O
expression	O
of	O
IgE	O
from	O
B	O
lymphocytes	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
5	I-Protein
plays	O
a	O
key	O
role	O
in	O
eosinophilic	O
inflammation	O
[	O
1	O
]	O
.	O

Th2	O
cytokines	O
are	O
regulated	O
by	O
the	O
zinc	O
finger	O
transcription	O
factor	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
Th2	O
cells	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

GATA	B-Protein
-	I-Protein
3	I-Protein
determines	O
Th2	O
cell	O
differentiation	O
and	O
selectively	O
activates	O
the	O
promoters	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
through	O
chromatin	O
remodelling	O
[	O
4	O
]	O
-	O
[	O
7	O
]	O
.	O

The	O
key	O
role	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
allergic	O
airway	O
inflammation	O
has	O
been	O
demonstrated	O
in	O
mice	O
by	O
the	O
reduced	O
release	O
of	O
Th2	O
cytokines	O
in	O
animals	O
treated	O
with	O
dominant	O
-	O
negative	O
mutants	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
by	O
local	O
application	O
of	O
antisense	O
oligonucleotides	O
to	O
GATA	B-Protein
-	I-Protein
3	I-Protein
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

Furthermore	O
,	O
conditional	O
knock	O
-	O
out	O
of	O
the	O
Gata3	B-Protein
gene	O
in	O
mice	O
reduces	O
expression	O
of	O
Th2	O
cytokines	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
10	O
]	O
,	O
and	O
similar	O
results	O
have	O
been	O
reported	O
in	O
isolated	O
murine	O
CD4	B-Protein
+	O
lymphocytes	O
[	O
11	O
]	O
.	O

Finally	O
,	O
knockdown	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
expression	O
using	O
siRNA	O
in	O
human	O
T	O
cells	O
results	O
in	O
loss	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
mediated	O
Th2	O
cytokine	O
expression	O
[	O
12	O
]	O
.	O

In	O
order	O
for	O
GATA	B-Protein
-	I-Protein
3	I-Protein
to	O
regulate	O
gene	O
expression	O
,	O
it	O
must	O
translocate	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
access	O
its	O
target	O
genes	O
.	O

Enhanced	O
nuclear	O
expression	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
following	O
T	O
cell	O
receptor	O
activation	O
was	O
first	O
demonstrated	O
in	O
murine	O
T	O
cells	O
[	O
13	O
]	O
and	O
was	O
recently	O
confirmed	O
in	O
human	O
T	O
cells	O
following	O
T	O
cell	O
receptor	O
and	O
co	O
-	O
receptor	O
stimulation	O
[	O
12	O
]	O
.	O

GATA	B-Protein
-	I-Protein
3	I-Protein
contains	O
a	O
classical	O
nuclear	O
import	O
signal	O
[	O
14	O
]	O
and	O
is	O
transported	O
into	O
the	O
nucleus	O
by	O
the	O
nuclear	O
import	O
protein	O
importin	O
-	O
alpha	O
(	O
also	O
known	O
as	O
karyopherin	O
-	O
alpha	O
)	O
[	O
12	O
]	O
.	O

Deletion	O
of	O
a	O
region	O
encompassing	O
the	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localisation	O
sequence	O
(	O
NLS	O
)	O
region	O
in	O
murine	O
and	O
human	O
cells	O
prevents	O
its	O
nuclear	O
localisation	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
.	O

The	O
affinity	O
of	O
the	O
importin	O
-	O
alpha	O
-	O
NLS	O
interaction	O
is	O
regulated	O
by	O
phosphorylation	O
[	O
15	O
]	O
,	O
and	O
we	O
have	O
shown	O
that	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
plays	O
a	O
critical	O
role	O
in	O
phosphorylating	O
GATA	B-Protein
-	I-Protein
3	I-Protein
to	O
enhance	O
its	O
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
subsequent	O
transport	O
into	O
the	O
nucleus	O
[	O
12	O
]	O
.	O

Corticosteroids	O
are	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
allergic	O
inflammation	O
,	O
with	O
marked	O
suppression	O
of	O
Th2	O
cytokines	O
in	O
airways	O
of	O
patients	O
with	O
asthma	O
[	O
16	O
]	O
.	O

Corticosteroids	O
mediate	O
their	O
anti	O
-	O
inflammatory	O
effects	O
through	O
binding	O
to	O
glucocorticoid	B-Protein
receptors	I-Protein
(	O
GRs	B-Protein
)	O
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
interact	O
with	O
glucocorticoid	O
response	O
elements	O
(	O
GREs	O
)	O
in	O
the	O
promoter	O
regions	O
of	O
steroid	O
-	O
sensitive	O
genes	O
.	O

Alternatively	O
,	O
activated	O
GR	B-Protein
interacts	O
with	O
coactivator	O
molecules	O
to	O
suppress	O
the	O
expression	O
of	O
inflammatory	O
genes	O
by	O
inhibiting	O
the	O
action	O
of	O
proinflammatory	O
transcription	O
factors	O
such	O
as	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
through	O
the	O
recruitment	O
of	O
co	O
-	O
repressor	O
molecules	O
such	O
as	O
histone	B-Protein
deacetylase	I-Protein
-	I-Protein
2	I-Protein
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Nuclear	O
localisation	O
and	O
retention	O
of	O
GR	B-Protein
is	O
mediated	O
through	O
the	O
nuclear	O
localisation	O
sequences	O
NL1	O
and	O
NL2	O
[	O
19	O
]	O
,	O
by	O
nuclear	O
retention	O
signals	O
[	O
20	O
]	O
,	O
and	O
by	O
control	O
of	O
nuclear	O
export	O
via	O
a	O
chromosomal	B-Protein
region	I-Protein
maintenance	I-Protein
1	I-Protein
(	O
CRM	B-Protein
-	I-Protein
1	I-Protein
)	O
dependent	O
pathway	O
[	O
21	O
]	O
.	O

NL1	O
,	O
which	O
is	O
similar	O
to	O
the	O
SV40	O
NLS	O
,	O
binds	O
to	O
importin	O
-	O
alpha	O
[	O
22	O
]	O
.	O

NL1	O
is	O
activated	O
both	O
by	O
glucocorticoid	O
agonists	O
such	O
as	O
dexamethasone	O
and	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
and	O
by	O
glucocorticoid	O
antagonists	O
such	O
as	O
mifepristone	O
(	O
RU486	O
)	O
[	O
23	O
]	O
.	O

NL1	O
can	O
be	O
mutated	O
,	O
and	O
the	O
resulting	O
GR	B-Protein
still	O
translocates	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
ligands	O
,	O
but	O
via	O
interaction	O
with	O
importin	B-Protein
7	I-Protein
,	O
an	O
event	O
that	O
requires	O
an	O
as	O
-	O
yet	O
unknown	O
component	O
[	O
23	O
]	O
.	O

NL2	O
is	O
poorly	O
defined	O
,	O
residing	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
,	O
and	O
much	O
less	O
is	O
known	O
about	O
its	O
mechanism	O
of	O
GR	B-Protein
import	O
[	O
24	O
]	O
.	O

A	O
variety	O
of	O
other	O
factors	O
are	O
also	O
important	O
for	O
the	O
regulation	O
of	O
GR	B-Protein
activation	O
and	O
nuclear	O
import	O
including	O
chaperones	O
such	O
as	O
Hsp90	O
and	O
other	O
immunophilins	O
[	O
24	O
]	O
-	O
[	O
26	O
]	O
and	O
FK506	O
-	O
binding	O
proteins	O
that	O
may	O
be	O
linked	O
to	O
dynein	O
and	O
/	O
or	O
peptidylprolyl	O
isomerase	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
availability	B-X
of	B-X
therapeutic	B-X
options	B-X
including	B-X
temozolomide	B-X
,	B-X
radiotherapy	B-X
and	B-X
some	B-X
target	B-X
agents	B-X
following	B-X
neurosurgery	B-X
,	B-X
the	B-X
prognosis	B-X
of	B-X
glioma	B-X
patients	B-X
remains	B-X
poor	B-X
.	B-X
Cyclophilins	B-X
(	B-X
Enzyme	B-X
Commission	B-X
(	B-X
EC	B-X
)	B-X
number	B-X
5.1.2.8	B-X
)	B-X
belong	B-X
to	B-X
a	B-X
group	B-X
of	B-X
proteins	B-X
that	B-X
have	B-X
peptidyl-prolyl	B-X
cis-trans	B-X
isomerase	B-X
activity	B-X
;	B-X
such	B-X
proteins	B-X
are	B-X
collectively	B-X
known	B-X
as	B-X
immunophilins	B-X
and	B-X
also	B-X
include	B-X
the	B-X
FK-506-binding	B-X
proteins	B-X
and	B-X
the	B-X
parvulins	B-X
.	B-X
Cyclophilins	B-X
are	B-X
found	B-X
in	B-X
all	B-X
cells	B-X
of	B-X
all	B-X
organisms	B-X
studied	B-X
,	B-X
in	B-X
both	B-X
prokaryotes	B-X
and	B-X
eukaryotes	B-X
;	B-X
humans	B-X
have	B-X
a	B-X
total	B-X
of	B-X
16	B-X
cyclophilin	B-X
proteins	B-X
,	B-X
Arabidopsis	B-X
up	B-X
to	B-X
29	B-X
and	B-X
Saccharomyces	B-X
8	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
implicated	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
additional	B-X
cellular	B-X
functions	B-X
for	B-X
cyclophilins	B-X
,	B-X
including	B-X
roles	B-X
as	B-X
chaperones	B-X
and	B-X
in	B-X
cell	B-X
signaling	B-X
.	B-X

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
inhibition	O
of	O
Th2	O
cytokines	O
by	O
corticosteroids	O
is	O
not	O
well	O
understood	O
,	O
because	O
the	O
genes	O
encoding	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
do	O
not	O
have	O
any	O
recognisable	O
GRE	O
sequence	O
[	O
29	O
]	O
and	O
are	O
only	O
partly	O
regulated	O
by	O
NF	O
-	O
kappaB	O
in	O
human	O
cells	O
[	O
30	O
]	O
-	O
[	O
32	O
]	O
.	O
<EOS>	B-X
Asthma	B-X
is	B-X
an	B-X
inflammatory	B-X
disease	B-X
characterized	B-X
by	B-X
reversible	B-X
airway	B-X
obstruction	B-X
from	B-X
a	B-X
combination	B-X
of	B-X
bronchoconstriction	B-X
and	B-X
inflammatory	B-X
changes	B-X
including	B-X
airway	B-X
edema	B-X
,	B-X
infiltration	B-X
of	B-X
inflammatory	B-X
cells	B-X
such	B-X
as	B-X
eosinophils	B-X
,	B-X
mast	B-X
cells	B-X
,	B-X
CD4+	B-X
T	B-X
helper	B-X
cells	B-X
and	B-X
monocyte/macrophages	B-X
.	B-X
Inhaled	B-X
corticosteroids	B-X
are	B-X
the	B-X
sentinel	B-X
therapy	B-X
for	B-X
asthma	B-X
inflammation	B-X
but	B-X
are	B-X
not	B-X
always	B-X
totally	B-X
effective	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
reasons	B-X
.	B-X
With	B-X
the	B-X
increased	B-X
understanding	B-X
about	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
asthma	B-X
inflammation	B-X
,	B-X
new	B-X
therapies	B-X
are	B-X
emerging	B-X
to	B-X
target	B-X
specific	B-X
molecular	B-X
networks	B-X
,	B-X
including	B-X
antibodies	B-X
against	B-X
IgE	B-X
and	B-X
the	B-X
TH2	B-X
cytokine	B-X
IL-5	B-X
;	B-X
soluble	B-X
IL-4	B-X
receptors	B-X
and	B-X
recombinant	B-X
TH1	B-X
cytokines	B-X
such	B-X
as	B-X
IL-12	B-X
.	B-X
Further	B-X
,	B-X
allergen	B-X
immunotherapy	B-X
for	B-X
asthma	B-X
is	B-X
based	B-X
upon	B-X
its	B-X
ability	B-X
to	B-X
change	B-X
a	B-X
TH2	B-X
to	B-X
a	B-X
TH1	B-X
response	B-X
by	B-X
inhibiting	B-X
IL-4	B-X
and/or	B-X
stimulating	B-X
IFN	B-X
gamma	B-X
production	B-X
.	B-X

Using	O
overexpression	O
and	O
CAT	B-Protein
-	O
reporter	O
genes	O
,	O
Lavender	O
and	O
colleagues	O
[	O
33	O
]	O
have	O
shown	O
that	O
GR	B-Protein
reduced	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
mediated	O
IL	B-Protein
-	I-Protein
5	I-Protein
and	O
-	B-Protein
13	I-Protein
promoter	O
activity	O
in	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

The	O
authors	O
postulated	O
that	O
local	O
recruitment	O
of	O
GR	B-Protein
may	O
alter	O
the	O
ability	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
either	O
to	O
bind	O
to	O
its	O
target	O
site	O
,	O
to	O
cause	O
transcriptional	O
up	O
-	O
regulation	O
,	O
or	O
to	O
maintain	O
an	O
environment	O
that	O
is	O
permissive	O
for	O
transcription	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
heterogenous	B-X
population	B-X
of	B-X
cells	B-X
that	B-X
exist	B-X
alongside	B-X
the	B-X
extracellular	B-X
matrix	B-X
and	B-X
soluble	B-X
components	B-X
.	B-X
These	B-X
components	B-X
can	B-X
shape	B-X
an	B-X
environment	B-X
that	B-X
is	B-X
conducive	B-X
to	B-X
tumor	B-X
growth	B-X
and	B-X
metastatic	B-X
spread	B-X
.	B-X
It	B-X
is	B-X
well-established	B-X
that	B-X
stromal	B-X
cancer-associated	B-X
fibroblasts	B-X
(	B-X
CAFs	B-X
)	B-X
in	B-X
the	B-X
TME	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
creating	B-X
and	B-X
maintaining	B-X
a	B-X
growth-permissive	B-X
environment	B-X
for	B-X
tumor	B-X
cells	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
is	B-X
a	B-X
key	B-X
transcription	B-X
factor	B-X
that	B-X
regulates	B-X
the	B-X
function	B-X
of	B-X
CAFs	B-X
,	B-X
and	B-X
their	B-X
crosstalk	B-X
with	B-X
tumor	B-X
and	B-X
immune	B-X
cells	B-X
within	B-X
the	B-X
TME	B-X
.	B-X
CAF-intrinsic	B-X
STAT3	B-X
activity	B-X
within	B-X
the	B-X
TME	B-X
correlates	B-X
with	B-X
tumor	B-X
progression	B-X
,	B-X
immune	B-X
suppression	B-X
and	B-X
eventually	B-X
the	B-X
establishment	B-X
of	B-X
metastases	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
roles	B-X
of	B-X
STAT3	B-X
in	B-X
regulating	B-X
CAF	B-X
function	B-X
and	B-X
their	B-X
crosstalk	B-X
with	B-X
other	B-X
cells	B-X
constituting	B-X
the	B-X
TME	B-X
and	B-X
discuss	B-X
the	B-X
utility	B-X
of	B-X
targeting	B-X
STAT3	B-X
within	B-X
the	B-X
TME	B-X
for	B-X
therapeutic	B-X
benefit	B-X
.	B-X

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
a	O
synthetic	O
corticosteroid	O
,	O
FP	O
,	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
a	O
T	O
lymphocyte	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
activated	O
by	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	O
antibodies	O
in	O
vitro	O
.	O

We	O
also	O
studied	O
the	O
effects	O
of	O
inhaled	O
fluticasone	O
therapy	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
subcellular	O
localization	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
patients	O
with	O
asthma	O
.	O

Participants	O
and	O
Study	O
Design	O
<EOS>	B-X
To	B-X
present	B-X
the	B-X
study	B-X
design	B-X
,	B-X
study	B-X
population	B-X
and	B-X
questionnaire	B-X
content	B-X
of	B-X
the	B-X
Danish	B-X
National	B-X
Youth	B-X
Study	B-X
2019	B-X
,	B-X
and	B-X
to	B-X
describe	B-X
the	B-X
differences	B-X
between	B-X
participants	B-X
and	B-X
non-participants	B-X
regarding	B-X
demographic	B-X
and	B-X
socioeconomic	B-X
characteristics	B-X
.	B-X
The	B-X
Yabu	B-X
Cohort	B-X
Study	B-X
was	B-X
launched	B-X
in	B-X
2012	B-X
to	B-X
identify	B-X
the	B-X
associations	B-X
between	B-X
social	B-X
relationships	B-X
and	B-X
health	B-X
among	B-X
community-dwelling	B-X
older	B-X
Japanese	B-X
people	B-X
and	B-X
to	B-X
evaluate	B-X
population	B-X
approaches	B-X
for	B-X
preventive	B-X
long-term	B-X
care	B-X
in	B-X
the	B-X
community	B-X
.	B-X
The	B-X
Hatoyama	B-X
Cohort	B-X
Study	B-X
was	B-X
launched	B-X
in	B-X
2010	B-X
to	B-X
identify	B-X
factors	B-X
that	B-X
predict	B-X
functional	B-X
decline	B-X
and	B-X
to	B-X
establish	B-X
strategies	B-X
to	B-X
prevent	B-X
frailty	B-X
among	B-X
community-dwelling	B-X
elderly	B-X
Japanese	B-X
.	B-X
The	B-X
Danish	B-X
National	B-X
Youth	B-X
Study	B-X
2014	B-X
:	B-X
Study	B-X
design	B-X
,	B-X
population	B-X
characteristics	B-X
and	B-X
non-response	B-X
analysis	B-X
.	B-X

We	O
studied	O
patients	O
with	O
mild	O
asthma	O
who	O
were	O
not	O
treated	O
with	O
inhaled	O
corticosteroids	O
who	O
had	O
been	O
included	O
in	O
a	O
previously	O
reported	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
with	O
FP	O
[	O
34	O
]	O
.	O
<EOS>	B-X
The	B-X
goals	B-X
of	B-X
treatment	B-X
are	B-X
prevention	B-X
of	B-X
fatalities	B-X
,	B-X
hospitalizations	B-X
,	B-X
and	B-X
emergency	B-X
department	B-X
visits	B-X
,	B-X
along	B-X
with	B-X
achieving	B-X
good	B-X
long-term	B-X
control	B-X
of	B-X
asthma	B-X
,	B-X
with	B-X
reduction	B-X
of	B-X
symptoms	B-X
,	B-X
maintenance	B-X
of	B-X
normal	B-X
activity	B-X
level	B-X
,	B-X
prevention	B-X
of	B-X
exacerbations	B-X
and	B-X
accelerated	B-X
loss	B-X
of	B-X
pulmonary	B-X
function	B-X
(	B-X
forced	B-X
expiratory	B-X
volume	B-X
in	B-X
the	B-X
first	B-X
second	B-X
of	B-X
expiration	B-X
[	B-X
FEV	B-X
Comorbidities	B-X
can	B-X
influence	B-X
asthma	B-X
control	B-X
and	B-X
promote	B-X
asthma	B-X
exacerbations	B-X
(	B-X
AE	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
multimorbidity	B-X
in	B-X
AE	B-X
,	B-X
through	B-X
long-term	B-X
follow-up	B-X
in	B-X
patients	B-X
with	B-X
asthma	B-X
of	B-X
different	B-X
severity	B-X
has	B-X
been	B-X
scarcely	B-X
studied	B-X
in	B-X
real-life	B-X
conditions	B-X
.	B-X
Objective	B-X
:	B-X
To	B-X
describe	B-X
the	B-X
epidemiological	B-X
and	B-X
clinical	B-X
characteristics	B-X
and	B-X
predictive	B-X
factors	B-X
of	B-X
AE	B-X
in	B-X
patients	B-X
who	B-X
had	B-X
presented	B-X
at	B-X
least	B-X
one	B-X
AE	B-X
in	B-X
the	B-X
last	B-X
year	B-X
among	B-X
patients	B-X
recruited	B-X
in	B-X
the	B-X
MEchanism	B-X
of	B-X
Genesis	B-X
and	B-X
Evolution	B-X
of	B-X
Asthma	B-X
(	B-X
MEGA	B-X
)	B-X
project	B-X
.	B-X

Seven	O
patients	O
with	O
mild	O
asthma	O
entered	O
the	O
study	O
and	O
were	O
randomized	O
to	O
receive	O
a	O
single	O
inhalation	O
of	O
FP	O
(	O
100	O
and	O
500	O
microg	O
)	O
or	O
a	O
matched	O
placebo	O
control	O
via	O
a	O
spacer	O
chamber	O
,	O
and	O
the	O
other	O
treatment	O
was	O
given	O
after	O
a	O
wash	O
-	O
out	O
period	O
of	O
at	O
least	O
6	O
d	O
.	O

Blood	O
was	O
taken	O
for	O
preparation	O
of	O
PBMCs	O
at	O
1	O
and	O
2	O
h	O
after	O
drug	O
administration	O
.	O

All	O
patients	O
gave	O
informed	O
consent	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Royal	O
Brompton	O
and	O
Harefield	O
Hospitals	O
NHS	O
Trust	O
.	O

The	O
clinical	O
study	O
was	O
conducted	O
before	O
the	O
requirement	O
for	O
Clinical	O
Trial	O
Registration	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
describes	B-X
the	B-X
rationale	B-X
and	B-X
design	B-X
of	B-X
the	B-X
MINDUUDD	B-X
study	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
which	B-X
is	B-X
to	B-X
evaluate	B-X
the	B-X
effectiveness	B-X
of	B-X
a	B-X
mindfulness	B-X
and	B-X
self-compassion	B-X
4-session	B-X
programme	B-X
versus	B-X
the	B-X
standard	B-X
8-session	B-X
programme	B-X
to	B-X
reduce	B-X
work	B-X
stress	B-X
and	B-X
burnout	B-X
in	B-X
Family	B-X
and	B-X
Community	B-X
Medicine	B-X
and	B-X
Nursing	B-X
tutors	B-X
and	B-X
residents	B-X
.	B-X
While	B-X
guidance	B-X
on	B-X
statistical	B-X
principles	B-X
for	B-X
clinical	B-X
trials	B-X
exists	B-X
,	B-X
there	B-X
is	B-X
an	B-X
absence	B-X
of	B-X
guidance	B-X
covering	B-X
the	B-X
required	B-X
content	B-X
of	B-X
statistical	B-X
analysis	B-X
plans	B-X
(	B-X
SAPs	B-X
)	B-X
to	B-X
support	B-X
transparency	B-X
and	B-X
reproducibility	B-X
.	B-X
As	B-X
a	B-X
method	B-X
of	B-X
conservative	B-X
treatment	B-X
of	B-X
this	B-X
disease	B-X
,	B-X
manipulation	B-X
is	B-X
widely	B-X
used	B-X
in	B-X
clinical	B-X
practice	B-X
.	B-X
We	B-X
will	B-X
summarize	B-X
the	B-X
current	B-X
published	B-X
evidence	B-X
of	B-X
manipulation	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
DLS	B-X
,	B-X
and	B-X
evaluate	B-X
the	B-X
effectiveness	B-X
and	B-X
safety	B-X
of	B-X
manipulation	B-X
through	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
,	B-X
so	B-X
as	B-X
to	B-X
provide	B-X
more	B-X
reliable	B-X
evidence	B-X
for	B-X
future	B-X
clinical	B-X
practice	B-X
.	B-X

Antibodies	O
and	O
Reagents	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
Monoclonal	B-X
antibodies	B-X
as	B-X
reagents	B-X
.	B-X
Reagents	B-X
and	B-X
assay	B-X
kits	B-X
can	B-X
now	B-X
be	B-X
bought	B-X
commercially	B-X
but	B-X
not	B-X
for	B-X
the	B-X
more	B-X
esoteric	B-X
or	B-X
new	B-X
hormones	B-X
.	B-X

The	O
monoclonal	O
antibodies	O
against	O
human	O
CD3	B-Protein
,	O
CD28	B-Protein
,	O
GR	B-Protein
,	O
and	O
importin	O
-	O
alpha	O
were	O
purchased	O
from	O
BD	O
Biosciences	O
(	O
Oxford	O
,	O
United	O
Kingdom	O
)	O
.	O

Rabbit	O
antibodies	O
against	O
human	O
GATA	B-Protein
-	I-Protein
3	I-Protein
(	O
H	O
-	O
48	O
)	O
and	O
GR	B-Protein
(	O
E	O
-	O
20	O
,	O
sc	O
-	O
1003	O
)	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
polyclonal	O
rabbit	O
antibodies	O
against	O
phospho	O
-	O
p38	O
MAP	O
kinase	O
and	O
phospho	O
-	O
ATF	B-Protein
-	I-Protein
2	I-Protein
from	O
Cell	O
Signaling	O
Technology	O
(	O
New	O
England	O
Biolabs	O
,	O
Hertford	O
,	O
UK	O
)	O
,	O
monoclonal	O
antibody	O
against	O
phosphoserine	O
(	O
clone	O
4H4	O
)	O
from	O
Affiniti	O
Research	O
Products	O
(	O
Exeter	O
,	O
UK	O
)	O
,	O
and	O
antibodies	O
against	O
rabbit	O
IgG	O
-	O
conjugated	O
TRITC	O
from	O
Dako	O
Cytomation	O
(	O
Cambridge	O
,	O
UK	O
)	O
.	O

The	O
anti	O
-	O
GR	O
antibody	O
(	O
Clone	O
41	O
)	O
from	O
BD	O
Transduction	O
Laboratories	O
(	O
Oxford	O
,	O
UK	O
)	O
was	O
used	O
for	O
Western	O
blot	O
analysis	O
.	O

All	O
other	O
reagents	O
were	O
purchased	O
from	O
Sigma	O
(	O
Poole	O
,	O
UK	O
)	O
.	O

Cell	O
Culture	O
and	O
PBMC	O
Isolation	O
<EOS>	B-X
The	B-X
monocyte-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
moDCs	B-X
)	B-X
are	B-X
a	B-X
subset	B-X
of	B-X
dendritic	B-X
cells	B-X
widely	B-X
used	B-X
in	B-X
immunological	B-X
studies	B-X
as	B-X
a	B-X
convenient	B-X
and	B-X
easy	B-X
approach	B-X
after	B-X
isolation	B-X
of	B-X
mononuclear	B-X
cells	B-X
directly	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
compare	B-X
three	B-X
different	B-X
protocols	B-X
for	B-X
monocyte	B-X
isolation	B-X
from	B-X
PBMC	B-X
:	B-X
1	B-X
)	B-X
Cold-aggregation	B-X
;	B-X
2	B-X
)	B-X
Percoll	B-X
gradient	B-X
;	B-X
and	B-X
3	B-X
)	B-X
Magnetic	B-X
beads	B-X
cell-enrichment	B-X
.	B-X
Additionally	B-X
we	B-X
also	B-X
compared	B-X
four	B-X
different	B-X
monocyte	B-X
differentiation	B-X
and	B-X
culture	B-X
techniques	B-X
:	B-X
1	B-X
)	B-X
Cell	B-X
culture	B-X
media	B-X
;	B-X
2	B-X
)	B-X
Serum	B-X
sources	B-X
;	B-X
3	B-X
)	B-X
required	B-X
GM-CSF	B-X
and	B-X
IL-4	B-X
concentrations	B-X
;	B-X
4	B-X
)	B-X
Cell	B-X
culture	B-X
systems	B-X
.	B-X
Purified	B-X
PBMC	B-X
followed	B-X
by	B-X
two	B-X
steps	B-X
of	B-X
cold	B-X
aggregation	B-X
,	B-X
yielded	B-X
cell	B-X
viability	B-X
around	B-X
95	B-X
%	B-X
with	B-X
poor	B-X
monocyte	B-X
enrichment	B-X
(	B-X
monocytes	B-X
increase	B-X
vs.	B-X
lymphocytes	B-X
reduction	B-X
was	B-X
not	B-X
statistically	B-X
significant	B-X
,	B-X
p	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
Conversely	B-X
,	B-X
monocyte	B-X
isolation	B-X
from	B-X
PBMC	B-X
with	B-X
discontinuous	B-X
Percoll	B-X
gradient	B-X
generated	B-X
around	B-X
50	B-X
%	B-X
cell	B-X
viability	B-X
.	B-X

A	O
human	O
T	O
cell	O
line	O
(	O
HuT	O
-	O
78	O
)	O
was	O
purchased	O
from	O
ECACC	O
European	O
Collection	O
of	O
Cell	O
Culture	O
(	O
Wiltshire	O
,	O
UK	O
)	O
were	O
cultured	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

PBMCs	O
were	O
isolated	O
by	O
density	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
(	O
density	O
,	O
1	O
.	O
077	O
g	O
/	O
ml	O
;	O
Amersham	O
Biosciences	O
,	O
Amersham	O
,	O
UK	O
)	O
as	O
previously	O
described	O
[	O
34	O
]	O
.	O

Cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
(	O
1	O
microg	O
/	O
ml	O
each	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
to	O
stimulate	O
Th2	O
cytokine	O
release	O
in	O
the	O
presence	O
or	O
absence	O
of	O
FP	O
(	O
10	O
-	O
12	O
to	O
10	O
-	O
8M	O
)	O
.	O

Cytospins	O
were	O
prepared	O
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
localization	O
determined	O
by	O
confocal	O
microscopy	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Reverse	O
Transcription	O
PCR	O
<EOS>	B-X
RT-PCR	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
test	B-X
for	B-X
genetic	B-X
diseases	B-X
and	B-X
to	B-X
characterize	B-X
gene	B-X
expression	B-X
in	B-X
various	B-X
tissue	B-X
types	B-X
,	B-X
cell	B-X
types	B-X
,	B-X
and	B-X
over	B-X
developmental	B-X
time	B-X
courses	B-X
.	B-X
RT-PCR	B-X
is	B-X
also	B-X
commonly	B-X
used	B-X
to	B-X
clone	B-X
cDNAs	B-X
for	B-X
further	B-X
use	B-X
with	B-X
other	B-X
molecular	B-X
biology	B-X
techniques	B-X
(	B-X
e.g.	B-X
,	B-X
see	B-X
Oligo	B-X
(	B-X
dT	B-X
)	B-X
-primed	B-X
RT-PCR	B-X
isolation	B-X
of	B-X
polyadenylated	B-X
RNA	B-X
degradation	B-X
intermediates	B-X
and	B-X
Circularized	B-X
RT-PCR	B-X
(	B-X
cRT-PCR	B-X
)	B-X
:	B-X
analysis	B-X
of	B-X
RNA	B-X
5	B-X
'	B-X
ends	B-X
,	B-X
3	B-X
'	B-X
ends	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tails	B-X
)	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
a	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
assay	B-X
using	B-X
a	B-X
two-enzyme	B-X
,	B-X
two-tube	B-X
approach	B-X
,	B-X
carried	B-X
out	B-X
using	B-X
either	B-X
SYBR	B-X
Green	B-X
I	B-X
or	B-X
TaqMan	B-X
chemistries	B-X
.	B-X
The	B-X
protocol	B-X
uses	B-X
a	B-X
PCR	B-X
volume	B-X
of	B-X
20	B-X
µL	B-X
(	B-X
although	B-X
most	B-X
manufacturers	B-X
recommend	B-X
50-µL	B-X
reactions	B-X
)	B-X
.	B-X
However	B-X
,	B-X
if	B-X
the	B-X
PCR	B-X
target	B-X
is	B-X
not	B-X
very	B-X
abundant	B-X
(	B-X
i.e.	B-X
,	B-X
present	B-X
at	B-X
one	B-X
to	B-X
10	B-X
copies	B-X
per	B-X
sample	B-X
)	B-X
,	B-X
a	B-X
larger	B-X
volume	B-X
may	B-X
yield	B-X
better	B-X
reproducibility	B-X
between	B-X
samples	B-X
.	B-X

Total	O
RNA	O
was	O
extracted	O
using	O
lysis	O
buffer	O
(	O
RNeasy	O
kit	O
;	O
Qiagen	O
,	O
Crawley	O
,	O
UK	O
)	O
.	O
<EOS>	B-X
Obtaining	B-X
sufficient	B-X
RNA	B-X
yield	B-X
and	B-X
quality	B-X
for	B-X
comprehensive	B-X
transcriptomic	B-X
studies	B-X
is	B-X
cumbersome	B-X
for	B-X
clinical	B-X
samples	B-X
in	B-X
which	B-X
RNA	B-X
from	B-X
the	B-X
pathogen	B-X
is	B-X
present	B-X
in	B-X
low	B-X
numbers	B-X
relative	B-X
to	B-X
the	B-X
nucleic	B-X
acids	B-X
from	B-X
the	B-X
host	B-X
,	B-X
especially	B-X
for	B-X
pathogens	B-X
,	B-X
such	B-X
as	B-X
yeasts	B-X
,	B-X
with	B-X
a	B-X
solid	B-X
cell	B-X
wall	B-X
.	B-X
Therefore	B-X
,	B-X
yeast	B-X
cell	B-X
lysis	B-X
including	B-X
cell	B-X
wall	B-X
disruption	B-X
constitutes	B-X
an	B-X
essential	B-X
first	B-X
step	B-X
to	B-X
maximize	B-X
RNA	B-X
yield	B-X
.	B-X
Moreover	B-X
,	B-X
during	B-X
the	B-X
last	B-X
years	B-X
,	B-X
different	B-X
methods	B-X
for	B-X
RNA	B-X
extraction	B-X
from	B-X
yeasts	B-X
have	B-X
been	B-X
developed	B-X
,	B-X
ranging	B-X
from	B-X
classic	B-X
hot	B-X
phenol	B-X
methods	B-X
to	B-X
commercially	B-X
available	B-X
specific	B-X
kits	B-X
.	B-X
They	B-X
offer	B-X
different	B-X
RNA	B-X
yield	B-X
and	B-X
quality	B-X
,	B-X
also	B-X
depending	B-X
on	B-X
the	B-X
original	B-X
storage	B-X
medium	B-X
,	B-X
such	B-X
as	B-X
RNAlater	B-X
.	B-X

During	O
RNA	O
purification	O
,	O
genomic	O
DNA	O
was	O
digested	O
with	O
RNase	O
-	O
free	O
DNase	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Next	O
,	O
0	O
.	O
5	O
microg	O
of	O
total	O
RNA	O
was	O
reversed	O
transcribed	O
using	O
the	O
avian	O
myeloblastosis	O
virus	O
RT	O
(	O
Promega	O
,	O
Southampton	O
,	O
UK	O
)	O
.	O

For	O
relative	O
quantification	O
,	O
RT	O
-	O
PCR	O
was	O
carried	O
out	O
using	O
cDNA	O
probes	O
.	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
or	B-X
kinetic	B-X
RT-PCR	B-X
is	B-X
increasingly	B-X
used	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
specific	B-X
mRNA	B-X
targets	B-X
,	B-X
especially	B-X
in	B-X
clinical	B-X
applications	B-X
.	B-X
To	B-X
quantify	B-X
the	B-X
mRNA	B-X
of	B-X
cytokines	B-X
and	B-X
their	B-X
receptors	B-X
,	B-X
which	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
autoimmune	B-X
diseases	B-X
such	B-X
as	B-X
multiple	B-X
sclerosis	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
quantitative	B-X
two-step	B-X
RT-PCR	B-X
assays	B-X
for	B-X
IL-4	B-X
,	B-X
IL-4R	B-X
,	B-X
IFN-gamma	B-X
,	B-X
IFN-beta	B-X
,	B-X
and	B-X
the	B-X
housekeeping	B-X
gene	B-X
porphobilinogen	B-X
deaminase	B-X
(	B-X
PBGD	B-X
)	B-X
.	B-X
The	B-X
quantification	B-X
was	B-X
carried	B-X
out	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
standard	B-X
curves	B-X
generated	B-X
with	B-X
external	B-X
homologous	B-X
plasmids	B-X
for	B-X
each	B-X
different	B-X
parameter	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
gene	B-X
expression	B-X
of	B-X
PBGD	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
procedure	B-X
represents	B-X
a	B-X
relative	B-X
quantification	B-X
method	B-X
with	B-X
external	B-X
standards	B-X
,	B-X
as	B-X
the	B-X
standard	B-X
curves	B-X
were	B-X
used	B-X
to	B-X
obtain	B-X
an	B-X
absolute	B-X
value	B-X
for	B-X
the	B-X
copy	B-X
numbers	B-X
of	B-X
the	B-X
targets	B-X
and	B-X
the	B-X
reference	B-X
(	B-X
PBGD	B-X
)	B-X
.	B-X
The	B-X
new	B-X
software	B-X
version	B-X
3.5	B-X
of	B-X
the	B-X
LightCycler	B-X
system	B-X
allows	B-X
the	B-X
construction	B-X
of	B-X
a	B-X
single	B-X
parameter-dependent	B-X
plasmid	B-X
standard	B-X
curve	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
unknown	B-X
samples	B-X
from	B-X
different	B-X
runs	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
how	B-X
to	B-X
achieve	B-X
precise	B-X
and	B-X
reproducible	B-X
quantification	B-X
,	B-X
even	B-X
when	B-X
using	B-X
measurements	B-X
from	B-X
different	B-X
PCR	B-X
runs	B-X
.	B-X

Primers	O
for	O
IL	B-Protein
-	I-Protein
4	I-Protein
were	O
from	O
Sigma	O
-	O
Genosys	O
(	O
Cambridge	O
,	O
UK	O
)	O
.	O

Sequences	O
of	O
GADPH	O
used	O
are	O
as	O
follows	O
:	O
forward	O
5	O
'	O
-	O
CCACCCATGGCAAATTCCATGGC	O
,	O
reverse	O
3	O
'	O
-	O
TCTAGACGGCAGGTCAGGTCCAC	O
.	O

Cell	O
Fractionation	O
,	O
Immunoprecipitation	O
,	O
and	O
Western	O
Blot	O
Analysis	O
<EOS>	B-X
MYBL2	B-X
disrupts	B-X
the	B-X
Hippo-YAP	B-X
pathway	B-X
and	B-X
confers	B-X
castration	B-X
resistance	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
prostate	B-X
cancer	B-X
.	B-X
Cancer-associated	B-X
fibroblasts	B-X
facilitate	B-X
premetastatic	B-X
niche	B-X
formation	B-X
through	B-X
lncRNA	B-X
SNHG5-mediated	B-X
angiogenesis	B-X
and	B-X
vascular	B-X
permeability	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
The	B-X
viability	B-X
,	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
invasion	B-X
of	B-X
cSCC	B-X
cells	B-X
after	B-X
indicated	B-X
transfection	B-X
were	B-X
examined	B-X
by	B-X
Cell	B-X
Counting	B-X
Kit-8	B-X
assays	B-X
,	B-X
colony	B-X
formation	B-X
assays	B-X
,	B-X
TdT-mediated	B-X
dUTP	B-X
Nick-End	B-X
Labeling	B-X
assays	B-X
,	B-X
wound	B-X
healing	B-X
assays	B-X
,	B-X
and	B-X
Transwell	B-X
assays	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
quantify	B-X
the	B-X
protein	B-X
level	B-X
of	B-X
messenger	B-X
RNA	B-X
cyclin-dependent	B-X
kinase	B-X
inhibitor	B-X
1B	B-X
(	B-X
CDKN1B	B-X
)	B-X
.	B-X

Nuclear	O
and	O
cytoplasmic	O
fractions	O
were	O
prepared	O
as	O
previously	O
described	O
[	O
35	O
]	O
.	O
<EOS>	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
salt	B-X
the	B-X
cytoplasmic	B-X
glucocorticoid	B-X
receptor	B-X
of	B-X
fetal	B-X
rabbit	B-X
lung	B-X
sediments	B-X
at	B-X
7	B-X
S	B-X
while	B-X
the	B-X
nuclear	B-X
receptor	B-X
sediments	B-X
at	B-X
4	B-X
S.	B-X
However	B-X
,	B-X
if	B-X
nuclear	B-X
extracts	B-X
are	B-X
mixed	B-X
with	B-X
receptor-depleted	B-X
cytosol	B-X
preparations	B-X
in	B-X
dilute	B-X
buffer	B-X
solutions	B-X
without	B-X
added	B-X
salt	B-X
,	B-X
the	B-X
nuclear	B-X
4	B-X
S	B-X
receptor	B-X
sediments	B-X
as	B-X
a	B-X
7	B-X
S	B-X
species	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
for	B-X
the	B-X
cytoplasmic	B-X
form	B-X
under	B-X
the	B-X
same	B-X
conditions	B-X
suggesting	B-X
an	B-X
interaction	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
with	B-X
other	B-X
cytosol	B-X
proteins	B-X
rather	B-X
than	B-X
with	B-X
itself	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
both	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
receptors	B-X
sediment	B-X
at	B-X
4	B-X
S	B-X
in	B-X
0.4	B-X
M	B-X
KCl	B-X
and	B-X
a	B-X
major	B-X
fraction	B-X
of	B-X
the	B-X
nuclear	B-X
receptor	B-X
has	B-X
an	B-X
agarose	B-X
elution	B-X
profile	B-X
identical	B-X
to	B-X
that	B-X
of	B-X
the	B-X
cytoplasmic	B-X
receptor	B-X
.	B-X
Thus	B-X
a	B-X
major	B-X
fraction	B-X
of	B-X
the	B-X
nuclear	B-X
receptors	B-X
is	B-X
indistinguishable	B-X
from	B-X
the	B-X
cytoplasmic	B-X
receptors	B-X
by	B-X
the	B-X
methods	B-X
used	B-X
.	B-X
Since	B-X
the	B-X
cytoplasmic	B-X
receptor	B-X
sediments	B-X
at	B-X
4	B-X
S	B-X
in	B-X
0.15	B-X
M	B-X
KCl	B-X
,	B-X
it	B-X
is	B-X
suggested	B-X
that	B-X
in	B-X
vivo	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
may	B-X
exist	B-X
as	B-X
a	B-X
4	B-X
S	B-X
species	B-X
and	B-X
that	B-X
the	B-X
7	B-X
S	B-X
form	B-X
described	B-X
previously	B-X
may	B-X
result	B-X
from	B-X
an	B-X
interaction	B-X
of	B-X
the	B-X
4	B-X
S	B-X
component	B-X
with	B-X
other	B-X
cytosol	B-X
proteins	B-X
in	B-X
hypotonic	B-X
media	B-X
.	B-X
About	B-X
25	B-X
%	B-X
of	B-X
the	B-X
receptor	B-X
present	B-X
in	B-X
nuclear	B-X
extracts	B-X
has	B-X
an	B-X
agarose	B-X
elution	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
the	B-X
cytoplasmic	B-X
receptor	B-X
in	B-X
0.4	B-X
M	B-X
KCl	B-X
.	B-X
Earlier	B-X
observations	B-X
suggested	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
hormone	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
is	B-X
localized	B-X
exclusively	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
lung	B-X
cells	B-X
and	B-X
that	B-X
the	B-X
nuclear	B-X
receptor	B-X
is	B-X
formed	B-X
by	B-X
a	B-X
transfer	B-X
of	B-X
the	B-X
cytoplasmic	B-X
steroid-receptor	B-X
complex	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
cytoplasmic	B-X
glucocorticoid	B-X
receptor	B-X
involves	B-X
conformational	B-X
changes	B-X
which	B-X
favor	B-X
its	B-X
transfer	B-X
and/or	B-X
binding	B-X
to	B-X
nuclear	B-X
sites	B-X
rather	B-X
than	B-X
conversion	B-X
of	B-X
a	B-X
4	B-X
S	B-X
species	B-X
to	B-X
a	B-X
faster-sedimenting	B-X
form	B-X
by	B-X
dimerization	B-X
or	B-X
by	B-X
addition	B-X
of	B-X
another	B-X
protein	B-X
unit	B-X
as	B-X
has	B-X
been	B-X
proposed	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
estrogen	B-X
receptor	B-X
of	B-X
the	B-X
rat	B-X
uterus	B-X
.	B-X

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
NP	O
-	O
40	O
lysis	O
buffer	O
(	O
0	O
.	O
5	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
20	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
)	O
in	O
the	O
presence	O
of	O
complete	O
protease	O
cocktail	O
inhibitor	O
.	O

Lysates	O
were	O
centrifuged	O
at	O
4degreesC	O
for	O
10	O
min	O
at	O
12	O
,	O
000	O
rpm	O
in	O
an	O
Eppendorf	O
microcentrifuge	O
to	O
remove	O
cellular	O
debris	O
.	O

Samples	O
were	O
then	O
immunoprecipitated	O
with	O
either	O
10	O
microl	O
of	O
antibody	O
against	O
GATA	B-Protein
-	I-Protein
3	I-Protein
or	O
importin	O
-	O
alpha	O
using	O
A	O
/	O
G	O
agarose	O
slurry	O
in	O
the	O
presence	O
of	O
protease	O
inhibitor	O
using	O
the	O
Catch	O
and	O
Release	O
methodology	O
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
USA	O
)	O
.	O

Western	O
blot	O
analysis	O
was	O
performed	O
using	O
anti	O
-	O
GATA	O
-	O
3	O
,	O
anti	O
-	O
importin	O
-	O
alpha	O
,	O
anti	O
-	O
GR	O
,	O
anti	O
-	O
p	O
-	O
p38	O
MAP	O
kinase	O
,	O
anti	O
-	O
p	O
-	O
ATF	O
-	O
2	O
,	O
and	O
anti	O
-	O
p	O
-	O
serine	O
.	O

Immunoreactive	O
proteins	O
were	O
detected	O
using	O
an	O
enhanced	O
chemiluminescence	O
ECL	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
,	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
ChIP	B-X
,	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
in	B-X
vivo	B-X
interactions	B-X
of	B-X
proteins	B-X
with	B-X
specific	B-X
regions	B-X
of	B-X
genomic	B-X
DNA	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
an	B-X
important	B-X
technique	B-X
in	B-X
the	B-X
study	B-X
of	B-X
protein-gene	B-X
interactions	B-X
.	B-X
Chromatin	B-X
plays	B-X
important	B-X
functions	B-X
in	B-X
regulating	B-X
many	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
DNA	B-X
transcription	B-X
,	B-X
replication	B-X
,	B-X
and	B-X
repair	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
that	B-X
allows	B-X
the	B-X
study	B-X
of	B-X
specific	B-X
protein-DNA	B-X
interactions	B-X
in	B-X
cultured	B-X
cells	B-X
and	B-X
fresh	B-X
or	B-X
fixed	B-X
tissue	B-X
.	B-X
Chromatin	B-X
is	B-X
isolated	B-X
and	B-X
sheared	B-X
,	B-X
and	B-X
antibodies	B-X
against	B-X
the	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
interest	B-X
are	B-X
used	B-X
to	B-X
isolate	B-X
specific	B-X
protein-DNA	B-X
complexes	B-X
.	B-X

Chromatin	O
immunoprecipitation	O
(	O
IP	O
)	O
was	O
performed	O
as	O
previously	O
described	O
[	O
12	O
]	O
in	O
HuT	O
-	O
78	O
T	O
-	O
cells	O
with	O
2	O
microg	O
of	O
anti	O
-	O
GATA	O
-	O
3	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
or	O
isotypic	O
immunoglobulin	O
G	O
as	O
a	O
non	O
-	O
specific	O
control	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
overnight	O
at	O
4degreesC	O
.	O

Promoter	O
sequences	O
were	O
detected	O
with	O
PCR	O
primers	O
for	O
the	O
IL	B-Protein
-	I-Protein
5	I-Protein
promoter	O
(	O
-	O
445	O
to	O
+	O
4	O
)	O
:	O
forward	O
5	O
'	O
-	O
TTAATCTAGCCACAGTCATAG	O
-	O
3	O
'	O
and	O
reverse	O
:	O
5	O
'	O
-	O
TCATGGCTCTGAAACGTTCTG	O
-	O
3	O
'	O
.	O

PCR	O
was	O
performed	O
using	O
a	O
Hybaid	O
Omnigene	O
thermal	O
cycler	O
(	O
Hybaid	O
,	O
Ashford	O
,	O
UK	O
)	O
with	O
cycling	O
parameters	O
of	O
72degreesC	O
for	O
10	O
min	O
,	O
35	O
cycles	O
at	O
94degreesC	O
for	O
45	O
s	O
,	O
52degreesC	O
for	O
45	O
s	O
,	O
72degreesC	O
for	O
45	O
s	O
.	O

GR	B-Protein
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
In	O
Vitro	O
Competition	O
Assay	O
for	O
Importin	O
-	O
alpha	O
(	O
Far	O
-	O
Western	O
ELISA	O
)	O

Immunoprecipitated	O
importin	O
-	O
alpha	O
(	O
anti	O
-	O
importin	O
-	O
alpha	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
from	O
HuT	O
-	O
78	O
cells	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
purified	O
from	O
the	O
excised	O
gel	O
by	O
electroelution	O
[	O
36	O
]	O
.	O

Similarly	O
,	O
GATA	B-Protein
-	I-Protein
3	I-Protein
was	O
isolated	O
from	O
nonstimulated	O
HuT	O
-	O
78	O
cells	O
or	O
cells	O
stimulated	O
for	O
30	O
min	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
and	O
GR	B-Protein
was	O
isolated	O
from	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
30	O
min	O
)	O
stimulated	O
HuT	O
-	O
78	O
cells	O
.	O

These	O
proteins	O
were	O
subsequently	O
refolded	O
in	O
glycine	O
solution	O
.	O
<EOS>	B-X
The	B-X
specific	B-X
pair	B-X
of	B-X
heat	B-X
shock	B-X
protein	B-X
70	B-X
(	B-X
Hsp70	B-X
)	B-X
and	B-X
Hsp40	B-X
constitutes	B-X
an	B-X
essential	B-X
molecular	B-X
chaperone	B-X
system	B-X
involved	B-X
in	B-X
numerous	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
the	B-X
proper	B-X
folding/refolding	B-X
and	B-X
transport	B-X
of	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
performed	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
spectroscopy	B-X
to	B-X
determine	B-X
the	B-X
solution	B-X
structure	B-X
of	B-X
JD	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
glycine/phenylalaninerich	B-X
region	B-X
(	B-X
GF-motif	B-X
)	B-X
of	B-X
human	B-X
Tid1	B-X
.	B-X
Collectively	B-X
with	B-X
our	B-X
sequence	B-X
analysis	B-X
,	B-X
the	B-X
present	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
functional	B-X
and	B-X
regulatory	B-X
mode	B-X
of	B-X
Tid1	B-X
resembles	B-X
that	B-X
of	B-X
the	B-X
DNAJB1	B-X
subfamily	B-X
members	B-X
rather	B-X
than	B-X
DNAJA1	B-X
or	B-X
DNAJA2	B-X
subfamily	B-X
proteins	B-X
.	B-X
We	B-X
used	B-X
hydrogen	B-X
exchange-mass	B-X
spectrometry	B-X
(	B-X
HX	B-X
MS	B-X
)	B-X
and	B-X
fluorescence	B-X
to	B-X
compare	B-X
the	B-X
folding	B-X
of	B-X
maltose	B-X
binding	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
in	B-X
free	B-X
solution	B-X
and	B-X
in	B-X
the	B-X
GroEL/ES	B-X
cavity	B-X
.	B-X
A	B-X
single	B-X
valine	B-X
to	B-X
glycine	B-X
mutation	B-X
imposes	B-X
a	B-X
definable	B-X
folding	B-X
defect	B-X
,	B-X
slows	B-X
early	B-X
intermediate	B-X
formation	B-X
by	B-X
20-fold	B-X
,	B-X
and	B-X
therefore	B-X
subsequent	B-X
global	B-X
folding	B-X
by	B-X
approximately	B-X
twofold	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
the	B-X
preintermediate	B-X
,	B-X
its	B-X
mutational	B-X
destabilization	B-X
,	B-X
and	B-X
its	B-X
restoration	B-X
by	B-X
GroEL	B-X
encapsulation	B-X
was	B-X
made	B-X
possible	B-X
by	B-X
the	B-X
measurement	B-X
of	B-X
a	B-X
previously	B-X
unexpected	B-X
type	B-X
of	B-X
low-level	B-X
HX	B-X
protection	B-X
,	B-X
apparently	B-X
not	B-X
dependent	B-X
on	B-X
H-bonding	B-X
,	B-X
that	B-X
may	B-X
be	B-X
characteristic	B-X
of	B-X
proteins	B-X
in	B-X
confined	B-X
spaces	B-X
.	B-X

100	O
microl	O
of	O
importin	O
-	O
alpha	O
solution	O
(	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
was	O
added	O
to	O
96	O
-	O
well	O
plates	O
coated	O
with	O
goat	O
anti	O
-	O
importin	O
-	O
alpha	O
antibody	O
.	O

After	O
1	O
h	O
incubation	O
,	O
GATA	B-Protein
-	I-Protein
3	I-Protein
(	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
from	O
stimulated	O
or	O
unstimulated	O
cells	O
were	O
added	O
to	O
the	O
importin	O
-	O
alpha	O
-	O
coated	O
wells	O
.	O

GR	B-Protein
(	O
10	O
or	O
100	O
ng	O
/	O
ml	O
in	O
TBS	O
)	O
from	O
stimulated	O
or	O
unstimulated	O
cells	O
were	O
added	O
to	O
some	O
wells	O
.	O
<EOS>	B-X
Engagement	B-X
of	B-X
integrin	B-X
receptors	B-X
during	B-X
cell	B-X
adhesion	B-X
leads	B-X
to	B-X
changes	B-X
in	B-X
the	B-X
morphology	B-X
and	B-X
the	B-X
state	B-X
of	B-X
activation	B-X
of	B-X
cells	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
human	B-X
mast	B-X
cell	B-X
line	B-X
HMC-1	B-X
were	B-X
added	B-X
to	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
-	B-X
,	B-X
vitronectin	B-X
(	B-X
VN	B-X
)	B-X
-	B-X
or	B-X
,	B-X
as	B-X
a	B-X
control	B-X
,	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
BSA	B-X
)	B-X
-coated	B-X
wells	B-X
and	B-X
were	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and/or	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
(	B-X
ionophore	B-X
)	B-X
.	B-X
Cytokine	B-X
production	B-X
was	B-X
evaluated	B-X
using	B-X
semiquantitative	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
analysis	B-X
of	B-X
cell	B-X
extracts	B-X
and	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
analysis	B-X
of	B-X
cell	B-X
supernatants	B-X
.	B-X
After	B-X
a	B-X
4-hr	B-X
incubation	B-X
,	B-X
mRNA	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-8	B-X
(	B-X
and	B-X
weakly	B-X
of	B-X
IL-6	B-X
)	B-X
was	B-X
up-regulated	B-X
in	B-X
matrix-adherent	B-X
cells	B-X
,	B-X
with	B-X
further	B-X
increase	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and/or	B-X
ionophore	B-X
,	B-X
compared	B-X
with	B-X
unstimulated	B-X
cells	B-X
.	B-X
High-level	B-X
de	B-X
novo	B-X
expression	B-X
of	B-X
IL-3	B-X
and	B-X
of	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
was	B-X
observed	B-X
mainly	B-X
in	B-X
matrix-adherent	B-X
cells	B-X
.	B-X
These	B-X
changes	B-X
were	B-X
paralleled	B-X
by	B-X
the	B-X
secretory	B-X
pattern	B-X
of	B-X
HMC-1	B-X
cells	B-X
after	B-X
a	B-X
24-hr	B-X
stimulation	B-X
.	B-X
Unstimulated	B-X
cells	B-X
adherent	B-X
to	B-X
FN	B-X
or	B-X
VN	B-X
had	B-X
already	B-X
released	B-X
small	B-X
amounts	B-X
of	B-X
IL-8	B-X
,	B-X
and	B-X
both	B-X
VN-	B-X
and	B-X
FN-adherent	B-X
cells	B-X
produced	B-X
,	B-X
almost	B-X
invariably	B-X
,	B-X
a	B-X
higher	B-X
level	B-X
of	B-X
cytokines	B-X
than	B-X
BSA-exposed	B-X
cells	B-X
after	B-X
additional	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
mast	B-X
cell	B-X
adhesion	B-X
to	B-X
matrix	B-X
proteins	B-X
by	B-X
itself	B-X
has	B-X
only	B-X
selected	B-X
and	B-X
minor	B-X
effects	B-X
,	B-X
but	B-X
additional	B-X
activation	B-X
of	B-X
mast	B-X
cells	B-X
by	B-X
secretory	B-X
stimuli	B-X
causes	B-X
significantly	B-X
enhanced	B-X
cytokine	B-X
gene	B-X
expression	B-X
and	B-X
secretion	B-X
,	B-X
suggesting	B-X
that	B-X
mast	B-X
cells	B-X
are	B-X
far	B-X
more	B-X
active	B-X
in	B-X
their	B-X
natural	B-X
tissue	B-X
environment	B-X
than	B-X
hitherto	B-X
suggested	B-X
from	B-X
data	B-X
in	B-X
suspension	B-X
cultures	B-X
.	B-X

After	O
a	O
further	O
1	O
h	O
incubation	O
,	O
the	O
plate	O
was	O
washed	O
and	O
incubated	O
with	O
primary	O
antibodies	O
(	O
a	O
mixture	O
of	O
rabbit	O
anti	O
-	O
GATA	O
-	O
3	O
and	O
mouse	O
anti	O
-	O
GR	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
1	O
.	O
5	O
h	O
,	O
and	O
then	O
incubated	O
with	O
secondary	O
antibodies	O
.	O

FITC	O
swine	O
anti	O
-	O
rabbit	O
IgG	O
(	O
Dako	O
,	O
Cambridge	O
,	O
UK	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
and	O
rhodamine	O
donkey	O
anti	O
-	O
mouse	O
IgG	O
(	O
Novus	O
,	O
Littleton	O
,	O
Colorado	O
,	O
USA	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
GR	B-Protein
.	O

FITC	O
and	O
rhodamine	O
levels	O
were	O
measured	O
with	O
a	O
fluorescent	O
micro	O
-	O
plate	O
reader	O
(	O
Bioline	O
,	O
London	O
,	O
UK	O
)	O
.	O

NF	O
-	O
kappaB	O
Activation	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
transcription	B-X
factor	B-X
family	B-X
has	B-X
been	B-X
considered	B-X
the	B-X
central	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
process	B-X
and	B-X
a	B-X
key	B-X
participant	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
Coincident	B-X
with	B-X
the	B-X
molecular	B-X
cloning	B-X
of	B-X
NF-κB/RelA	B-X
and	B-X
identification	B-X
of	B-X
its	B-X
kinship	B-X
to	B-X
the	B-X
v-Rel	B-X
oncogene	B-X
,	B-X
it	B-X
was	B-X
anticipated	B-X
that	B-X
NF-κB	B-X
itself	B-X
would	B-X
be	B-X
involved	B-X
in	B-X
cancer	B-X
development	B-X
.	B-X
Oncogenic	B-X
activating	B-X
mutations	B-X
in	B-X
NF-κB	B-X
genes	B-X
are	B-X
rare	B-X
and	B-X
have	B-X
been	B-X
identified	B-X
only	B-X
in	B-X
some	B-X
lymphoid	B-X
malignancies	B-X
,	B-X
while	B-X
most	B-X
NF-κB	B-X
activating	B-X
mutations	B-X
in	B-X
lymphoid	B-X
malignancies	B-X
occur	B-X
in	B-X
upstream	B-X
signaling	B-X
components	B-X
that	B-X
feed	B-X
into	B-X
NF-κB	B-X
.	B-X
NF-κB	B-X
activation	B-X
is	B-X
also	B-X
prevalent	B-X
in	B-X
carcinomas	B-X
,	B-X
in	B-X
which	B-X
NF-κB	B-X
activation	B-X
is	B-X
mainly	B-X
driven	B-X
by	B-X
inflammatory	B-X
cytokines	B-X
within	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Importantly	B-X
,	B-X
however	B-X
,	B-X
in	B-X
all	B-X
malignancies	B-X
,	B-X
NF-κB	B-X
acts	B-X
in	B-X
a	B-X
cell	B-X
type-specific	B-X
manner	B-X
:	B-X
activating	B-X
survival	B-X
genes	B-X
within	B-X
cancer	B-X
cells	B-X
and	B-X
inflammation-promoting	B-X
genes	B-X
in	B-X
components	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
complex	B-X
biological	B-X
functions	B-X
of	B-X
NF-κB	B-X
have	B-X
made	B-X
its	B-X
therapeutic	B-X
targeting	B-X
a	B-X
challenge	B-X
.	B-X

NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
was	O
determined	O
using	O
an	O
ELISA	O
-	O
based	O
kit	O
(	O
Trans	O
-	O
AM	O
p65	B-Protein
,	O
Active	O
Motif	O
,	O
Rixensart	O
,	O
Belgium	O
)	O
.	O

In	O
brief	O
,	O
5	O
microg	O
of	O
nuclear	O
extracts	O
were	O
incubated	O
with	O
a	O
plate	O
coated	O
with	O
an	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotide	O
.	O

Plates	O
were	O
washed	O
before	O
addition	O
of	O
an	O
anti	O
-	O
p65	O
antibody	O
.	O

Antibody	O
binding	O
was	O
detected	O
with	O
a	O
secondary	O
HRP	O
-	O
conjugated	O
antibody	O
and	O
developed	O
with	O
TMB	O
substrate	O
.	O

The	O
intensity	O
of	O
the	O
reaction	O
was	O
measured	O
at	O
450	O
nm	O
.	O
<EOS>	B-X
A2E	B-X
was	B-X
irradiated	B-X
with	B-X
a	B-X
blue	B-X
light-emitting	B-X
diode	B-X
(	B-X
LED	B-X
)	B-X
source	B-X
(	B-X
450	B-X
nm	B-X
)	B-X
or	B-X
full	B-X
visible	B-X
light	B-X
(	B-X
400-700	B-X
nm	B-X
)	B-X
of	B-X
a	B-X
halogen	B-X
lamp	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
water-soluble	B-X
products	B-X
of	B-X
photooxidative	B-X
destruction	B-X
were	B-X
investigated	B-X
for	B-X
the	B-X
content	B-X
of	B-X
carbonyl	B-X
compounds	B-X
by	B-X
mass	B-X
spectrometry	B-X
and	B-X
reaction	B-X
with	B-X
thiobarbituric	B-X
acid	B-X
.	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
water-soluble	B-X
products	B-X
formed	B-X
during	B-X
A2E	B-X
photooxidation	B-X
and	B-X
containing	B-X
carbonyl	B-X
compounds	B-X
cause	B-X
modification	B-X
of	B-X
serum	B-X
albumin	B-X
and	B-X
hemoglobin	B-X
,	B-X
measured	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
fluorescence	B-X
intensity	B-X
at	B-X
440-455	B-X
nm	B-X
.	B-X
The	B-X
primary	B-X
efficacy	B-X
measurement	B-X
was	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
in	B-X
Hamilton	B-X
's	B-X
Depression	B-X
Rating	B-X
Scale	B-X
(	B-X
HAMD	B-X
)	B-X
,	B-X
while	B-X
the	B-X
primary	B-X
tolerability	B-X
measurement	B-X
was	B-X
the	B-X
Toronto	B-X
Side-Effects	B-X
Scale	B-X
(	B-X
TSES	B-X
)	B-X
intensity	B-X
scores	B-X
at	B-X
the	B-X
last	B-X
visit	B-X
.	B-X
The	B-X
TSES	B-X
intensity	B-X
score	B-X
was	B-X
increased	B-X
in	B-X
SMs	B-X
,	B-X
compared	B-X
with	B-X
NMs	B-X
,	B-X
by	B-X
43	B-X
%	B-X
for	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
by	B-X
22	B-X
%	B-X
for	B-X
gastrointestinal	B-X
adverse	B-X
drug	B-X
reactions	B-X
.	B-X
No	B-X
significant	B-X
differences	B-X
in	B-X
measured	B-X
parameters	B-X
were	B-X
observed	B-X
between	B-X
NMs	B-X
and	B-X
FMs	B-X
.	B-X

Immunofluorescence	O
Staining	O
<EOS>	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
is	B-X
an	B-X
important	B-X
immunochemical	B-X
technique	B-X
that	B-X
allows	B-X
for	B-X
detection	B-X
and	B-X
localization	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
antigens	B-X
in	B-X
different	B-X
types	B-X
of	B-X
tissues	B-X
of	B-X
various	B-X
cell	B-X
preparations	B-X
.	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
on	B-X
tissue	B-X
sections	B-X
allows	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
protein	B-X
species	B-X
subcellular	B-X
localization	B-X
.	B-X
Immunofluorescence	B-X
staining	B-X
is	B-X
the	B-X
key	B-X
technique	B-X
for	B-X
visualizing	B-X
organization	B-X
of	B-X
endogenous	B-X
cellular	B-X
structures	B-X
in	B-X
single	B-X
cells	B-X
.	B-X
Immunofluorescence	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
technique	B-X
to	B-X
visualize	B-X
the	B-X
localization	B-X
of	B-X
proteins	B-X
of	B-X
interest	B-X
.	B-X

Immunofluorescence	O
staining	O
was	O
performed	O
as	O
previously	O
described	O
[	O
34	O
]	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
three	B-X
histochemical	B-X
methods	B-X
for	B-X
the	B-X
staining	B-X
of	B-X
myelin	B-X
suitable	B-X
for	B-X
formalin-fixed	B-X
and	B-X
paraffin-embedded	B-X
materials	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
osmium	B-X
tetroxide	B-X
method	B-X
,	B-X
which	B-X
consist	B-X
in	B-X
the	B-X
osmication	B-X
of	B-X
previously	B-X
fixed	B-X
tissues	B-X
.	B-X
Osmication	B-X
is	B-X
performed	B-X
prior	B-X
the	B-X
embedding	B-X
of	B-X
tissues	B-X
in	B-X
paraffin	B-X
giving	B-X
a	B-X
permanent	B-X
positive	B-X
reaction	B-X
for	B-X
myelin	B-X
as	B-X
well	B-X
as	B-X
other	B-X
lipids	B-X
present	B-X
in	B-X
the	B-X
tissue	B-X
.	B-X
The	B-X
prognostic	B-X
value	B-X
of	B-X
tumor-infiltrating	B-X
lymphocytes	B-X
(	B-X
TILs	B-X
)	B-X
assessed	B-X
by	B-X
machine	B-X
learning	B-X
algorithms	B-X
in	B-X
melanoma	B-X
patients	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
but	B-X
has	B-X
not	B-X
been	B-X
widely	B-X
adopted	B-X
in	B-X
the	B-X
clinic	B-X
.	B-X

All	O
staining	O
was	O
performed	O
at	O
room	O
temperature	O
and	O
under	O
humidification	O
.	O

Cells	O
were	O
collected	O
and	O
cytospins	O
prepared	O
in	O
a	O
cytocentrifuge	O
(	O
Shandon	O
II	O
,	O
Shandon	O
,	O
Runcorn	O
,	O
UK	O
)	O
.	O

Cells	O
were	O
permeabilized	O
,	O
blocked	O
,	O
and	O
then	O
incubated	O
with	O
GR	B-Protein
(	O
1	O
:	O
50	O
E	O
-	O
20	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
anti	O
-	O
GATA	O
-	O
3	O
(	O
H	O
-	O
48	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
antibody	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
type	B-X
2	B-X
innate	B-X
lymphoid	B-X
cells	B-X
(	B-X
ILC2s	B-X
)	B-X
and	B-X
interleukin-33	B-X
(	B-X
IL-33	B-X
)	B-X
in	B-X
chronic	B-X
obstructive	B-X
pulmonary	B-X
disease	B-X
(	B-X
COPD	B-X
)	B-X
.	B-X
Serum	B-X
and	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
were	B-X
isolated	B-X
from	B-X
healthy	B-X
controls	B-X
and	B-X
COPD	B-X
patients	B-X
.	B-X
ILC2	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
COPD	B-X
patients	B-X
were	B-X
stimulated	B-X
with	B-X
IL-33	B-X
or	B-X
neutralizing	B-X
ST2	B-X
antibody+IL-33	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
a	B-X
relationship	B-X
exists	B-X
between	B-X
gastric	B-X
and	B-X
oral	B-X
Helicobacter	B-X
pylori	B-X
and	B-X
oral	B-X
hygiene	B-X
in	B-X
patients	B-X
with	B-X
vitamin	B-X
B12	B-X
deficiency	B-X
.	B-X

After	O
three	O
washes	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
,	O
cells	O
were	O
incubated	O
with	O
tetrarhodamine	O
isothiocyanate	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
antibody	O
(	O
Dako	O
)	O
.	O

Cytospins	O
were	O
counterstained	O
with	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
dihydrochloride	O
(	O
DAPI	O
)	O
,	O
a	O
fluorescent	O
blue	O
nuclear	O
indole	O
chromatin	O
stain	O
,	O
and	O
mounted	O
in	O
PBS	O
:	O
glycerol	O
(	O
50	O
:	O
50	O
)	O
.	O

The	O
immunopositive	O
signal	O
was	O
characterised	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
on	O
a	O
Leica	O
TCS	O
NT	O
/	O
SP	O
interactive	O
laser	O
cytometer	O
equipped	O
with	O
confocal	O
optics	O
(	O
Leica	O
Microsystems	O
,	O
Wetzlar	O
,	O
Germany	O
)	O
.	O

To	O
determine	O
the	O
specificity	O
of	O
the	O
antibodies	O
,	O
rabbit	O
serum	O
immunoglobulin	O
(	O
Dako	O
)	O
and	O
secondary	O
antibodies	O
without	O
the	O
primary	O
were	O
used	O
as	O
controls	O
.	O

Positively	O
stained	O
nuclei	O
and	O
total	O
cells	O
were	O
counted	O
(	O
500	O
)	O
on	O
each	O
slide	O
with	O
the	O
observer	O
blinded	O
to	O
the	O
treatment	O
.	O

GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
GFP	B-Protein
Construct	O
<EOS>	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
23	B-X
CHB	B-X
patients	B-X
,	B-X
8	B-X
acute	B-X
hepatitis	B-X
B	B-X
(	B-X
AHB	B-X
)	B-X
patients	B-X
and	B-X
10	B-X
healthy	B-X
controls	B-X
were	B-X
isolated	B-X
.	B-X
The	B-X
T-bet	B-X
DNA	B-X
fragment	B-X
was	B-X
subcloned	B-X
into	B-X
the	B-X
pGC-FU	B-X
vector	B-X
containing	B-X
GFP	B-X
to	B-X
generate	B-X
a	B-X
recombinant	B-X
lentiviral	B-X
vector	B-X
,	B-X
pGC-FU-T-bet	B-X
,	B-X
while	B-X
a	B-X
no-load	B-X
pGC-FU	B-X
vector	B-X
was	B-X
used	B-X
as	B-X
the	B-X
negative	B-X
control	B-X
.	B-X
After	B-X
transduction	B-X
into	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
another	B-X
22	B-X
CHB	B-X
patients	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
Th1-	B-X
and	B-X
Th2-type	B-X
cytokines	B-X
was	B-X
assayed	B-X
by	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
,	B-X
and	B-X
RT-PCR	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
were	B-X
used	B-X
to	B-X
measure	B-X
the	B-X
mRNA	B-X
and	B-X
transcription	B-X
levels	B-X
of	B-X
H2.0-like	B-X
homeobox	B-X
(	B-X
HLX1	B-X
)	B-X
,	B-X
GATA-3	B-X
and	B-X
STAT-6	B-X
.	B-X
Th1-type	B-X
cytokines	B-X
and	B-X
HLX1	B-X
expression	B-X
was	B-X
upregulated	B-X
,	B-X
while	B-X
Th2-type	B-X
cytokines	B-X
and	B-X
GATA-3	B-X
and	B-X
STAT-6	B-X
expression	B-X
was	B-X
repressed	B-X
after	B-X
lentiviral	B-X
introduction	B-X
of	B-X
T-bet	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
lentivirally	B-X
overexpressed	B-X
T-bet	B-X
regulates	B-X
Th	B-X
cell	B-X
lineage	B-X
commitment	B-X
in	B-X
CHB	B-X
patients	B-X
,	B-X
which	B-X
may	B-X
be	B-X
mediated	B-X
by	B-X
regulating	B-X
HLX1	B-X
,	B-X
GATA-3	B-X
and	B-X
STAT-6	B-X
expression	B-X
.	B-X

The	O
GATA	B-Protein
-	I-Protein
3	I-Protein
clone	O
(	O
BC003070	O
)	O
complete	O
cDNA	O
was	O
obtained	O
from	O
Invitrogen	O
Life	O
Technologies	O
as	O
a	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
XhoI	O
insert	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
the	O
pOTB7	O
vector	O
.	O

GATA	B-Protein
-	I-Protein
3	I-Protein
was	O
excised	O
from	O
pOTB7	O
using	O
XhoI	B-Protein
digestion	O
and	O
pEGFP	O
-	O
C2	O
(	O
Clontech	O
,	O
Saint	O
-	O
Germain	O
-	O
en	O
-	O
Laye	O
,	O
France	O
)	O
was	O
digested	O
with	O
BamHI	B-Protein
.	O

DNA	O
was	O
recovered	O
by	O
phenol	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
and	O
both	O
the	O
GATA	B-Protein
-	I-Protein
3	I-Protein
fragment	O
and	O
the	O
pEGFP	O
-	O
C2	O
vector	O
blunt	O
-	O
ended	O
by	O
incubation	O
with	O
Klenow	O
(	O
Bioline	O
Bio	O
-	O
27029	O
)	O
for	O
30	O
min	O
at	O
37degreesC	O
.	O

Klenow	O
was	O
inactivated	O
by	O
incubation	O
for	O
10	O
min	O
at	O
75degreesC	O
.	O

DNA	O
was	O
recovered	O
by	O
phenol	O
extraction	O
and	O
ethanol	O
precipitation	O
,	O
and	O
both	O
the	O
blunt	O
-	O
ended	O
GATA	B-Protein
-	I-Protein
3	I-Protein
fragment	O
and	O
the	O
GFP	B-Protein
vector	O
were	O
subsequently	O
digested	O
with	O
EcoRI	B-Protein
before	O
the	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
blunt	O
end	O
GATA	B-Protein
-	I-Protein
3	I-Protein
fragment	O
was	O
inserted	O
into	O
the	O
5	O
'	O
-	O
EcoRI	O
/	O
3	O
'	O
-	O
blunt	O
ended	O
GFP	B-Protein
vector	O
.	O

Positive	O
clones	O
were	O
confirmed	O
by	O
digestion	O
and	O
size	O
analysis	O
by	O
1	O
%	O
agarose	O
gel	O
electrophoresis	O
and	O
by	O
sequencing	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
efficiency	B-X
and	B-X
safety	B-X
of	B-X
transfection	B-X
of	B-X
PEGFP-IL-1ra	B-X
plasmid	B-X
via	B-X
cation	B-X
polymer	B-X
mediation	B-X
(	B-X
poly-ethylenimine	B-X
,	B-X
PEI	B-X
)	B-X
by	B-X
injection	B-X
into	B-X
the	B-X
corneal	B-X
stroma	B-X
.	B-X

Transfection	O
<EOS>	B-X
Novel	B-X
transfection	B-X
methods	B-X
in	B-X
primary	B-X
lung	B-X
cell	B-X
cultures	B-X
.	B-X
Transfection	B-X
is	B-X
defined	B-X
as	B-X
the	B-X
transfer	B-X
of	B-X
foreign	B-X
nucleic	B-X
acids	B-X
into	B-X
cells	B-X
.	B-X
Transfection	B-X
of	B-X
cultured	B-X
mammalian	B-X
cells	B-X
using	B-X
diethylaminoethyl	B-X
(	B-X
DEAE	B-X
)	B-X
-dextran/DNA	B-X
can	B-X
be	B-X
an	B-X
attractive	B-X
alternative	B-X
to	B-X
other	B-X
transfection	B-X
methods	B-X
in	B-X
many	B-X
circumstances	B-X
.	B-X
Transfection	B-X
complexes	B-X
and	B-X
other	B-X
delivery	B-X
vehicles	B-X
accumulate	B-X
in	B-X
late	B-X
endosomes	B-X
where	B-X
sEV	B-X
are	B-X
formed	B-X
and	B-X
over	B-X
50	B-X
%	B-X
of	B-X
transfection	B-X
complexes	B-X
or	B-X
delivery	B-X
vehicles	B-X
administered	B-X
to	B-X
cells	B-X
are	B-X
released	B-X
again	B-X
to	B-X
the	B-X
extracellular	B-X
space	B-X
by	B-X
exocytosis	B-X
.	B-X
Transfection	B-X
of	B-X
cells	B-X
also	B-X
impaired	B-X
the	B-X
capacity	B-X
of	B-X
sEVs	B-X
to	B-X
deliver	B-X
stably-expressed	B-X
siRNAs	B-X
,	B-X
suggesting	B-X
that	B-X
transfection	B-X
of	B-X
cells	B-X
may	B-X
alter	B-X
sEVs	B-X
and	B-X
prevent	B-X
the	B-X
study	B-X
of	B-X
their	B-X
endogenous	B-X
capacity	B-X
to	B-X
deliver	B-X
RNA	B-X
to	B-X
target	B-X
cells	B-X
.	B-X

HuT	O
-	O
78	O
cells	O
were	O
transfected	O
with	O
either	O
EP8	O
or	O
GFP	O
vector	O
only	O
DNA	O
using	O
solution	O
R	O
,	O
programme	O
V	O
-	O
001	O
at	O
a	O
ratio	O
of	O
3x106	O
cells	O
/	O
4	O
microg	O
DNA	O
for	O
7	O
-	O
8	O
h	O
in	O
complete	O
medium	O
(	O
10	O
%	O
bovine	O
serum	O
in	O
RPMI1640	O
+	O
15	O
L	O
-	O
glutamine	O
)	O
according	O
to	O
the	O
general	O
Amaxa	O
protocol	O
for	O
nucleofection	O
.	O

The	O
medium	O
was	O
subsequently	O
changed	O
to	O
1	O
%	O
RPMI	O
for	O
24	O
h	O
before	O
transfected	O
cells	O
were	O
added	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
treated	O
wells	O
and	O
live	O
cell	O
videomicroscopy	O
performed	O
.	O

Time	O
-	O
Lapse	O
Microscopy	O
<EOS>	B-X
Time-lapse	B-X
microscopy	B-X
(	B-X
TLM	B-X
)	B-X
is	B-X
an	B-X
ideal	B-X
tool	B-X
to	B-X
study	B-X
this	B-X
process	B-X
since	B-X
the	B-X
ability	B-X
to	B-X
capture	B-X
images	B-X
over	B-X
time	B-X
provides	B-X
a	B-X
combination	B-X
of	B-X
morphological	B-X
,	B-X
dynamic	B-X
and	B-X
quantitative	B-X
information	B-X
about	B-X
developmental	B-X
events	B-X
.	B-X
Time-lapse	B-X
monitoring	B-X
overcomes	B-X
this	B-X
limitation	B-X
without	B-X
exposing	B-X
the	B-X
embryos	B-X
to	B-X
environmental	B-X
changes	B-X
.	B-X
Basic	B-X
Protocol	B-X
1	B-X
:	B-X
Sample	B-X
preparation	B-X
Basic	B-X
Protocol	B-X
2	B-X
:	B-X
Time-lapse	B-X
microscopy	B-X
:	B-X
Evos	B-X
protocol	B-X
Basic	B-X
Protocol	B-X
3	B-X
:	B-X
Batch	B-X
file	B-X
renaming	B-X
Basic	B-X
Protocol	B-X
4	B-X
:	B-X
Machine	B-X
learning	B-X
analysis	B-X
of	B-X
Evos	B-X
images	B-X
with	B-X
Orbit	B-X
Basic	B-X
Protocol	B-X
5	B-X
:	B-X
Parametrization	B-X
of	B-X
Orbit	B-X
output	B-X
in	B-X
R	B-X
Basic	B-X
Protocol	B-X
6	B-X
:	B-X
Visualization	B-X
of	B-X
logistic	B-X
fits	B-X
in	B-X
R.	B-X
Time-lapse	B-X
microscopy	B-X
of	B-X
C.	B-X
elegans	B-X
post-embryonic	B-X
development	B-X
is	B-X
challenging	B-X
,	B-X
as	B-X
larvae	B-X
are	B-X
highly	B-X
motile	B-X
.	B-X

HuT	O
-	O
78	O
cells	O
expressing	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
GFP	I-Protein
were	O
maintained	O
at	O
37degreesC	O
in	O
growth	O
medium	O
in	O
a	O
closed	O
FCS2	O
perfusion	O
chamber	O
(	O
Bioptechs	O
,	O
Butler	O
,	O
Pennsylvania	O
,	O
USA	O
)	O
combined	O
with	O
an	O
objective	O
heater	O
(	O
Bioptechs	O
)	O
on	O
the	O
stage	O
a	O
Zeiss	O
Axiovert	O
200	O
microscope	O
(	O
Thornwood	O
,	O
New	O
York	O
,	O
USA	O
)	O
.	O

Observations	O
were	O
made	O
by	O
40x1	O
.	O
0	O
NA	O
oil	O
-	O
immersion	O
objective	O
lens	O
,	O
and	O
fluorescence	O
and	O
phase	O
contrast	O
images	O
were	O
gathered	O
using	O
a	O
Hamamatsu	O
ORCA	O
-	O
ER	O
charged	O
coupled	O
device	O
camera	O
(	O
Bridgewater	O
,	O
New	O
Jersey	O
,	O
USA	O
)	O
driven	O
by	O
Openlab	O
software	O
(	O
Improvision	O
,	O
Coventry	O
,	O
UK	O
)	O
.	O

Photographs	O
were	O
taken	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
240	O
min	O
.	O

Densitometric	O
Analysis	O
<EOS>	B-X
Densitometric	B-X
quantification	B-X
of	B-X
allantoin	B-X
was	B-X
carried	B-X
out	B-X
on	B-X
TLC	B-X
Si60	B-X
plates	B-X
with	B-X
butanol-50	B-X
%	B-X
methanol/formic	B-X
acid	B-X
,	B-X
66.5:33.2:0.3	B-X
(	B-X
V/V/V	B-X
)	B-X
as	B-X
developing	B-X
solvent	B-X
,	B-X
at	B-X
a	B-X
wavelength	B-X
of	B-X
190	B-X
nm	B-X
.	B-X
Densitometric	B-X
measurements	B-X
were	B-X
done	B-X
using	B-X
densitometer	B-X
TLC	B-X
Scanner	B-X
3	B-X
at	B-X
246	B-X
nm	B-X
.	B-X
DENSITOMETRIC	B-X
ANALYSIS	B-X
OF	B-X
BODY	B-X
COMPOSITION	B-X
:	B-X
REVISION	B-X
OF	B-X
SOME	B-X
QUANTITATIVE	B-X
ASSUMPTIONS	B-X
.	B-X
[	B-X
UV-densitometric	B-X
analysis	B-X
of	B-X
roquefortin	B-X
and	B-X
PR	B-X
toxin	B-X
]	B-X
.	B-X

Densitometry	O
of	O
ECL	O
immunoblots	O
was	O
performed	O
using	O
Gelworks	O
ID	O
intermediate	O
software	O
(	O
Ultraviolet	O
Products	O
,	O
Cambridgeshire	O
,	O
UK	O
)	O
.	O

Briefly	O
,	O
immunoblots	O
were	O
scanned	O
and	O
gates	O
were	O
drawn	O
tightly	O
around	O
each	O
band	O
.	O

Background	O
values	O
from	O
each	O
lane	O
were	O
subtracted	O
to	O
normalize	O
each	O
measurement	O
.	O

The	O
bands	O
were	O
quantified	O
using	O
the	O
Gelworks	O
software	O
.	O

All	O
Western	O
blots	O
were	O
exposed	O
to	O
film	O
for	O
varying	O
lengths	O
of	O
time	O
,	O
and	O
only	O
films	O
generating	O
subsaturating	O
levels	O
of	O
intensity	O
were	O
selected	O
for	O
densitometric	O
evaluation	O
.	O

Statistical	O
Analysis	O

Data	O
from	O
three	O
or	O
more	O
independent	O
experiments	O
are	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
,	O
except	O
where	O
stated	O
and	O
were	O
compared	O
using	O
GraphPad	O
Prism	O
4	O
(	O
GraphPad	O
Software	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
graphpad	O
.	O
com	O
)	O
.	O

Results	O
were	O
analysed	O
using	O
one	O
-	O
way	O
ANOVA	O
with	O
Newman	O
-	O
Keuls	O
post	O
test	O
except	O
for	O
the	O
data	O
from	O
the	O
in	O
vivo	O
inhaled	O
FP	O
study	O
,	O
which	O
was	O
analysed	O
by	O
Friedman	O
'	O
s	O
test	O
with	O
subsequent	O
Wilcoxson	O
matched	O
pair	O
signed	O
rank	O
sum	O
test	O
.	O

Data	O
from	O
this	O
analysis	O
are	O
presented	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
.	O
<EOS>	B-X
However	B-X
,	B-X
when	B-X
a	B-X
segmentation	B-X
method	B-X
is	B-X
run	B-X
on	B-X
new	B-X
data	B-X
(	B-X
for	B-X
which	B-X
no	B-X
ground	B-X
truth	B-X
exists	B-X
)	B-X
it	B-X
is	B-X
highly	B-X
desirable	B-X
to	B-X
efficiently	B-X
detect	B-X
and	B-X
assess	B-X
algorithm	B-X
failures	B-X
so	B-X
that	B-X
these	B-X
cases	B-X
can	B-X
be	B-X
excluded	B-X
from	B-X
scientific	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
two	B-X
outlier	B-X
detection	B-X
methods	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
performance	B-X
of	B-X
an	B-X
automatic	B-X
CP	B-X
segmentation	B-X
algorithm	B-X
are	B-X
presented	B-X
.	B-X
The	B-X
first	B-X
one	B-X
is	B-X
a	B-X
univariate	B-X
non-parametric	B-X
method	B-X
using	B-X
a	B-X
box-whisker	B-X
plot	B-X
.	B-X
Four	B-X
classifiers-linear	B-X
discriminant	B-X
analysis	B-X
(	B-X
LDA	B-X
)	B-X
,	B-X
logistic	B-X
regression	B-X
(	B-X
LR	B-X
)	B-X
,	B-X
support	B-X
vector	B-X
machine	B-X
(	B-X
SVM	B-X
)	B-X
,	B-X
and	B-X
random	B-X
forest	B-X
classification	B-X
(	B-X
RFC	B-X
)	B-X
-were	B-X
trained	B-X
using	B-X
the	B-X
designed	B-X
features	B-X
and	B-X
evaluated	B-X
using	B-X
a	B-X
leave-one-out	B-X
cross	B-X
validation	B-X
.	B-X

Friedman	O
'	O
s	O
test	O
was	O
used	O
as	O
three	O
matched	O
measures	O
were	O
obtained	O
using	O
placebo	O
,	O
100	O
microg	O
,	O
and	O
500	O
microg	O
of	O
inhaled	O
FP	O
,	O
which	O
had	O
variable	O
baseline	O
levels	O
.	O

We	O
did	O
not	O
assume	O
a	O
Gaussian	O
distribution	O
of	O
the	O
data	O
due	O
to	O
the	O
limited	O
numbers	O
of	O
participants	O
analysed	O
(	O
seven	O
)	O
.	O
The	O
null	O
hypothesis	O
was	O
rejected	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
Effect	O
of	O
Corticosteroids	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
Nuclear	O
Translocation	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
mRNA	O

Corticosteroids	O
are	O
effective	O
in	O
inhibiting	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
regulated	O
IL	B-Protein
-	I-Protein
4	I-Protein
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
32	O
]	O
.	O
<EOS>	B-X
GATA-3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
from	B-X
T	B-X
helper-2	B-X
(	B-X
Th2	B-X
)	B-X
cells	B-X
and	B-X
therefore	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
allergic	B-X
diseases	B-X
.	B-X
Corticosteroids	B-X
are	B-X
highly	B-X
effective	B-X
in	B-X
suppressing	B-X
allergic	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
effects	B-X
on	B-X
GATA-3	B-X
are	B-X
unknown	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
corticosteroid	B-X
fluticasone	B-X
propionate	B-X
on	B-X
GATA-3	B-X
regulation	B-X
in	B-X
human	B-X
T-lymphocytes	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

We	O
therefore	O
investigated	O
whether	O
corticosteroids	O
affect	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
nuclear	O
import	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
.	O

Stimulation	O
of	O
cells	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
resulted	O
in	O
a	O
rapid	O
cytoplasmic	O
/	O
nuclear	O
GATA	B-Protein
-	I-Protein
3	I-Protein
translocation	O
(	O
Figure	O
1A	O
)	O
,	O
confirming	O
our	O
previous	O
results	O
[	O
12	O
]	O
.	O

We	O
also	O
confirmed	O
a	O
clear	O
separation	O
of	O
nuclear	O
and	O
cytosolic	O
fractions	O
as	O
indicated	O
by	O
histone	O
H1	O
and	O
MEK	B-Protein
-	I-Protein
1	I-Protein
markers	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
potent	O
topical	O
corticosteroid	O
FP	O
caused	O
sustained	O
loss	O
of	O
nuclear	O
GATA	B-Protein
-	I-Protein
3	I-Protein
expression	O
and	O
cytoplasmic	O
retention	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
at	O
concentrations	O
ranging	O
from	O
10	O
-	O
12	O
to	O
10	O
-	O
8	O
M	O
,	O
which	O
cover	O
the	O
therapeutic	O
range	O
[	O
37	O
]	O
.	O

This	O
effect	O
was	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
,	O
with	O
a	O
peak	O
effect	O
of	O
11	O
.	O
6	O
-	O
fold	O
at	O
30	O
min	O
at	O
a	O
concentration	O
of	O
10	O
-	O
8	O
M	O
(	O
Figure	O
1C	O
)	O
and	O
was	O
associated	O
with	O
marked	O
reductions	O
in	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
mRNA	O
expression	O
(	O
Figure	O
1D	O
)	O
and	O
a	O
loss	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
binding	O
to	O
the	O
native	O
IL	B-Protein
-	I-Protein
5	I-Protein
promoter	O
(	O
Figure	O
1E	O
)	O
.	O

Ligand	O
-	O
Activated	O
GR	B-Protein
Competes	O
with	O
GATA	B-Protein
-	I-Protein
3	I-Protein
for	O
Importin	O
-	O
alpha	O

We	O
confirmed	O
and	O
extended	O
previous	O
data	O
[	O
20	O
]	O
to	O
show	O
that	O
ligand	O
-	O
activated	O
GR	B-Protein
as	O
well	O
as	O
GATA	B-Protein
-	I-Protein
3	I-Protein
uses	O
importin	O
-	O
alpha	O
for	O
its	O
nuclear	O
import	O
(	O
Figure	O
2A	O
and	O
2B	O
)	O
.	O

This	O
interaction	O
between	O
GR	B-Protein
and	O
importin	O
-	O
alpha	O
was	O
significant	O
at	O
concentrations	O
as	O
low	O
as	O
10	O
-	O
12	O
M	O
and	O
was	O
maximal	O
with	O
10	O
-	O
8	O
M	O
FP	O
.	O

Subsequent	O
GR	B-Protein
nuclear	O
translocation	O
was	O
rapid	O
and	O
sustained	O
at	O
significant	O
levels	O
for	O
at	O
least	O
14	O
h	O
(	O
Figure	O
2B	O
)	O
.	O

Using	O
IP	O
-	O
Western	O
blotting	O
we	O
showed	O
that	O
FP	O
at	O
10	O
-	O
12	O
-	O
10	O
-	O
8	O
M	O
decreased	O
the	O
association	O
between	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
importin	O
-	O
alpha	O
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2C	O
)	O
.	O

In	O
addition	O
,	O
using	O
GFP	B-Protein
-	I-Protein
labelled	I-Protein
GATA	I-Protein
-	I-Protein
3	I-Protein
and	O
confocal	O
microscopy	O
we	O
demonstrated	O
that	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
following	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
for	O
30	O
min	O
was	O
attenuated	O
by	O
pretreatment	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
(	O
Figure	O
2D	O
)	O
.	O

Effect	O
on	O
MKP	B-Protein
-	I-Protein
1	I-Protein
<EOS>	B-X
Superior	B-X
effect	B-X
of	B-X
MP-AzeFlu	B-X
compared	B-X
to	B-X
monotherapy	B-X
with	B-X
fluticasone	B-X
propionate	B-X
or	B-X
azelastine	B-X
on	B-X
GILZ	B-X
,	B-X
MKP-1	B-X
and	B-X
TTP	B-X
anti-inflammatory	B-X
gene	B-X
expression	B-X
in	B-X
healthy	B-X
and	B-X
inflamed	B-X
upper	B-X
airway	B-X
mucosa	B-X
.	B-X
Studies	B-X
suggest	B-X
that	B-X
brain-derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
exerts	B-X
effects	B-X
on	B-X
the	B-X
neuronal	B-X
function	B-X
of	B-X
hippocampal	B-X
neurons	B-X
and	B-X
increases	B-X
hippocampal	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
phosphatase-1	B-X
(	B-X
MKP-1	B-X
)	B-X
expression	B-X
,	B-X
which	B-X
causes	B-X
depressive	B-X
behaviors	B-X
in	B-X
rat	B-X
or	B-X
mouse	B-X
.	B-X
Here	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
change	B-X
of	B-X
serum	B-X
MKP-1	B-X
,	B-X
BDNF	B-X
,	B-X
testosterone	B-X
(	B-X
T	B-X
)	B-X
,	B-X
and	B-X
estradiol	B-X
(	B-X
E2	B-X
)	B-X
levels	B-X
,	B-X
in	B-X
order	B-X
to	B-X
test	B-X
the	B-X
hypothesis	B-X
that	B-X
dysregulation	B-X
of	B-X
MKP-1	B-X
,	B-X
BDNF	B-X
,	B-X
T	B-X
,	B-X
and	B-X
E2	B-X
are	B-X
associated	B-X
with	B-X
depression	B-X
in	B-X
perimenopausal	B-X
women	B-X
.	B-X
Mitogen-activated	B-X
protein	B-X
kinase	B-X
phosphatases	B-X
(	B-X
MKPs	B-X
)	B-X
are	B-X
dual	B-X
specificity	B-X
protein	B-X
phosphatases	B-X
(	B-X
DUSPs	B-X
)	B-X
that	B-X
dephosphorylate	B-X
both	B-X
phospho-tyrosine	B-X
and	B-X
phospho-threonine	B-X
residues	B-X
on	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
.	B-X
While	B-X
small	B-X
molecule	B-X
MAPK	B-X
inhibitors	B-X
have	B-X
utility	B-X
,	B-X
in	B-X
this	B-X
review	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
exploring	B-X
the	B-X
potential	B-X
of	B-X
targeting	B-X
the	B-X
endogenous	B-X
MAPK	B-X
deactivator	B-X
--	B-X
MKP-1	B-X
.	B-X
Importantly	B-X
,	B-X
there	B-X
is	B-X
a	B-X
strong	B-X
justification	B-X
for	B-X
developing	B-X
both	B-X
inhibitors	B-X
and	B-X
upregulators	B-X
of	B-X
MKP-1	B-X
because	B-X
of	B-X
the	B-X
diverse	B-X
roles	B-X
played	B-X
by	B-X
MAPKs	B-X
in	B-X
disease	B-X
:	B-X
for	B-X
example	B-X
,	B-X
in	B-X
cancer	B-X
,	B-X
MKP-1	B-X
inhibitors	B-X
may	B-X
prove	B-X
beneficial	B-X
,	B-X
as	B-X
MKP-1	B-X
is	B-X
overexpressed	B-X
and	B-X
is	B-X
considered	B-X
responsible	B-X
for	B-X
the	B-X
failure	B-X
of	B-X
JNK-driven	B-X
apoptotic	B-X
pathways	B-X
induced	B-X
by	B-X
chemotherapeutics	B-X
;	B-X
conversely	B-X
,	B-X
in	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
asthma	B-X
and	B-X
arthritis	B-X
,	B-X
MKP-1	B-X
reduces	B-X
MAPK-mediated	B-X
signalling	B-X
and	B-X
developing	B-X
novel	B-X
ligands	B-X
to	B-X
upregulate	B-X
MKP-1	B-X
levels	B-X
would	B-X
be	B-X
a	B-X
therapeutically	B-X
attractive	B-X
anti-inflammatory	B-X
strategy	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
review	B-X
we	B-X
utilise	B-X
MKP-1	B-X
homology	B-X
modeling	B-X
to	B-X
highlight	B-X
the	B-X
structural	B-X
features	B-X
of	B-X
MKP-1	B-X
inhibitors	B-X
that	B-X
permit	B-X
potent	B-X
and	B-X
selective	B-X
inhibition	B-X
,	B-X
and	B-X
to	B-X
provide	B-X
insights	B-X
into	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
selective	B-X
MKP-1	B-X
upregulators	B-X
.	B-X

Dexamethasone	O
inhibits	O
p38	O
MAPK	O
function	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
through	O
the	O
rapid	O
induction	O
of	O
the	O
dual	O
kinase	O
phosphatase	O
MKP	B-Protein
-	I-Protein
1	I-Protein
(	O
MAPK	B-Protein
phosphatase	I-Protein
-	I-Protein
1	I-Protein
)	O
,	O
and	O
this	O
effect	O
lasts	O
for	O
up	O
to	O
24	O
h	O
[	O
28	O
]	O
.	O

FP	O
(	O
10	O
-	O
8	O
M	O
)	O
treatment	O
of	O
HuT	O
-	O
78	O
cells	O
activated	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
in	O
vitro	O
significantly	O
decreased	O
p38	O
MAPK	O
phosphorylation	O
(	O
Figure	O
3A	O
)	O
and	O
activity	O
measured	O
by	O
phosphorylation	O
of	O
the	O
downstream	O
target	O
ATF	B-Protein
-	I-Protein
2	I-Protein
(	O
Figure	O
3B	O
)	O
.	O

This	O
effect	O
was	O
detected	O
at	O
30	O
min	O
and	O
lasted	O
for	O
at	O
least	O
14	O
h	O
(	O
Figure	O
3B	O
)	O
.	O

FP	O
(	O
10	O
-	O
8	O
M	O
)	O
also	O
significantly	O
reduced	O
GATA	B-Protein
-	I-Protein
3	I-Protein
serine	O
phosphorylation	O
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
stimulation	O
in	O
both	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3C	O
)	O
.	O

This	O
reduction	O
in	O
GATA	B-Protein
-	I-Protein
3	I-Protein
phosphorylation	O
was	O
also	O
seen	O
with	O
lower	O
concentrations	O
of	O
FP	O
.	O

We	O
found	O
that	O
FP	O
significantly	O
induced	O
MKP	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
in	O
both	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
reaching	O
a	O
plateau	O
at	O
10	O
-	O
8	O
M	O
after	O
10	O
min	O
(	O
Figure	O
3D	O
and	O
3E	O
)	O
.	O

However	O
,	O
the	O
effects	O
of	O
FP	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
,	O
importin	O
-	O
alpha	O
association	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
expression	O
are	O
seen	O
at	O
10	O
,	O
000	O
-	O
fold	O
lower	O
concentrations	O
(	O
10	O
-	O
12	O
M	O
,	O
see	O
Figure	O
2	O
)	O
.	O

Using	O
an	O
in	O
vitro	O
competition	O
assay	O
(	O
Figure	O
4A	O
)	O
utilizing	O
purified	O
activated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
importin	O
-	O
alpha	O
,	O
and	O
activated	O
GR	B-Protein
,	O
we	O
demonstrated	O
that	O
activated	O
GR	B-Protein
significantly	O
increased	O
GR	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
in	O
the	O
presence	O
and	O
absence	O
of	O
activated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
(	O
Figure	O
4B	O
)	O
.	O

This	O
effect	O
is	O
not	O
mutual	O
,	O
since	O
activated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
did	O
not	O
block	O
GR	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
(	O
Figure	O
4C	O
)	O
.	O
<EOS>	B-X
Initial	B-X
research	B-X
suggests	B-X
that	B-X
mindfulness	B-X
meditation	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
intervention	B-X
for	B-X
binge	B-X
eating	B-X
;	B-X
however	B-X
,	B-X
no	B-X
systematic	B-X
review	B-X
has	B-X
examined	B-X
interventions	B-X
where	B-X
mindfulness	B-X
meditation	B-X
was	B-X
the	B-X
primary	B-X
intervention	B-X
and	B-X
no	B-X
review	B-X
has	B-X
examined	B-X
its	B-X
effect	B-X
on	B-X
subclinical	B-X
disordered	B-X
eating	B-X
or	B-X
weight	B-X
.	B-X
Results	B-X
suggest	B-X
that	B-X
mindfulness	B-X
meditation	B-X
effectively	B-X
decreases	B-X
binge	B-X
eating	B-X
and	B-X
emotional	B-X
eating	B-X
in	B-X
populations	B-X
engaging	B-X
in	B-X
this	B-X
behavior	B-X
;	B-X
evidence	B-X
for	B-X
its	B-X
effect	B-X
on	B-X
weight	B-X
is	B-X
mixed	B-X
.	B-X
Additional	B-X
research	B-X
is	B-X
warranted	B-X
to	B-X
determine	B-X
comparative	B-X
effectiveness	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
mindfulness	B-X
training	B-X
.	B-X
Molecular	B-X
rapid	B-X
diagnostic	B-X
tests	B-X
(	B-X
mRDTs	B-X
)	B-X
are	B-X
a	B-X
promising	B-X
complement	B-X
to	B-X
conventional	B-X
laboratory	B-X
methods	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
bloodstream	B-X
infections	B-X
and	B-X
may	B-X
reduce	B-X
the	B-X
time	B-X
to	B-X
effective	B-X
therapy	B-X
among	B-X
patients	B-X
with	B-X
bloodstream	B-X
infections	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
cost-effectivenesses	B-X
of	B-X
competing	B-X
strategies	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
bloodstream	B-X
infection	B-X
alone	B-X
or	B-X
combined	B-X
with	B-X
an	B-X
ASP	B-X
.	B-X
To	B-X
this	B-X
effect	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
decision-analytic	B-X
model	B-X
comparing	B-X
12	B-X
strategies	B-X
for	B-X
the	B-X
diagnosis	B-X
of	B-X
bloodstream	B-X
infection	B-X
.	B-X
The	B-X
baseline	B-X
strategy	B-X
used	B-X
as	B-X
the	B-X
standard	B-X
was	B-X
the	B-X
use	B-X
of	B-X
conventional	B-X
laboratory	B-X
methods	B-X
without	B-X
an	B-X
ASP	B-X
,	B-X
and	B-X
our	B-X
decision-analytic	B-X
model	B-X
assessed	B-X
the	B-X
cost-effectivenesses	B-X
of	B-X
5	B-X
principal	B-X
strategies	B-X
:	B-X
mRDT	B-X
(	B-X
with	B-X
and	B-X
without	B-X
an	B-X
ASP	B-X
)	B-X
,	B-X
mRDT	B-X
with	B-X
an	B-X
ASP	B-X
,	B-X
mRDT	B-X
without	B-X
an	B-X
ASP	B-X
,	B-X
conventional	B-X
laboratory	B-X
methods	B-X
with	B-X
an	B-X
ASP	B-X
,	B-X
and	B-X
conventional	B-X
laboratory	B-X
methods	B-X
without	B-X
an	B-X
ASP	B-X
.	B-X
Furthermore	B-X
,	B-X
based	B-X
on	B-X
the	B-X
availability	B-X
of	B-X
data	B-X
in	B-X
the	B-X
literature	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
cost-effectivenesses	B-X
of	B-X
7	B-X
mRDT	B-X
subcategories	B-X
,	B-X
as	B-X
follows	B-X
:	B-X
PCR	B-X
with	B-X
an	B-X
ASP	B-X
,	B-X
matrix-assisted	B-X
laser	B-X
desorption	B-X
ionization-time	B-X
of	B-X
flight	B-X
(	B-X
MALDI-TOF	B-X
)	B-X
analysis	B-X
with	B-X
an	B-X
ASP	B-X
,	B-X
peptide	B-X
nucleic	B-X
acid	B-X
fluorescent	B-X

These	O
data	O
also	O
suggest	O
that	O
both	O
activated	O
GR	B-Protein
and	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
can	O
directly	O
associate	O
with	O
importin	O
-	O
alpha	O
(	O
Figure	O
4D	O
)	O
and	O
that	O
activated	O
GR	B-Protein
attenuates	O
the	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
/	O
importin	O
-	O
alpha	O
interaction	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
4E	O
)	O
.	O

Together	O
,	O
this	O
suggests	O
that	O
ligand	O
-	O
activated	O
GR	B-Protein
may	O
compete	O
with	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
for	O
importin	O
-	O
alpha	O
and	O
thereby	O
limit	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
.	O

Other	O
possible	O
interpretations	O
of	O
our	O
results	O
could	O
include	O
an	O
effect	O
of	O
FP	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
export	O
and	O
/	O
or	O
degradation	O
.	O
<EOS>	B-X
A	B-X
required	B-X
PROTAC	B-X
component	B-X
is	B-X
a	B-X
ligand	B-X
binding	B-X
to	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
which	B-X
is	B-X
then	B-X
joined	B-X
to	B-X
another	B-X
ligand	B-X
binding	B-X
to	B-X
a	B-X
protein	B-X
to	B-X
be	B-X
degraded	B-X
via	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
The	B-X
advent	B-X
of	B-X
nonpeptidic	B-X
small-molecule	B-X
E3	B-X
ligase	B-X
ligands	B-X
,	B-X
notably	B-X
for	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
and	B-X
cereblon	B-X
(	B-X
CRBN	B-X
)	B-X
,	B-X
revolutionized	B-X
the	B-X
field	B-X
and	B-X
ushered	B-X
in	B-X
the	B-X
design	B-X
of	B-X
drug-like	B-X
PROTACs	B-X
with	B-X
potent	B-X
and	B-X
selective	B-X
degradation	B-X
activity	B-X
.	B-X
A	B-X
first	B-X
wave	B-X
of	B-X
PROTAC	B-X
drugs	B-X
are	B-X
now	B-X
undergoing	B-X
clinical	B-X
development	B-X
in	B-X
cancer	B-X
,	B-X
and	B-X
the	B-X
field	B-X
is	B-X
seeking	B-X
to	B-X
extend	B-X
the	B-X
repertoire	B-X
of	B-X
chemistries	B-X
that	B-X
allow	B-X
hijacking	B-X
new	B-X
E3	B-X
ligases	B-X
to	B-X
improve	B-X
the	B-X
scope	B-X
of	B-X
targeted	B-X
protein	B-X
degradation.Here	B-X
,	B-X
we	B-X
briefly	B-X
review	B-X
how	B-X
traditional	B-X
E3	B-X
ligase	B-X
ligands	B-X
were	B-X
discovered	B-X
,	B-X
and	B-X
then	B-X
outline	B-X
approaches	B-X
and	B-X
ligands	B-X
that	B-X
have	B-X
been	B-X
recently	B-X
used	B-X
to	B-X
discover	B-X
new	B-X
E3	B-X
ligases	B-X
for	B-X
PROTACs	B-X
.	B-X
However	B-X
,	B-X
the	B-X
PROTAC	B-X
technology	B-X
has	B-X
some	B-X
limitations	B-X
,	B-X
and	B-X
emerging	B-X
new	B-X
degrader	B-X
technologies	B-X
may	B-X
greatly	B-X
broaden	B-X
the	B-X
spectrum	B-X
of	B-X
targets	B-X
that	B-X
could	B-X
be	B-X
selectively	B-X
degraded	B-X
by	B-X
harnessing	B-X
a	B-X
second	B-X
major	B-X
degradation	B-X
pathway	B-X
in	B-X
cells	B-X
.	B-X
We	B-X
review	B-X
key	B-X
emerging	B-X
technologies	B-X
that	B-X
exploit	B-X
the	B-X
lysosomal	B-X
degradation	B-X
pathway	B-X
and	B-X
discuss	B-X
their	B-X
potential	B-X
applications	B-X
and	B-X
limitations	B-X
.	B-X

Leptomycin	O
B	O
,	O
which	O
inhibits	O
nuclear	O
export	O
,	O
did	O
not	O
affect	O
the	O
ability	O
of	O
FP	O
to	O
block	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localization	O
(	O
Figure	O
5A	O
)	O
.	O
<EOS>	B-X
The	B-X
first	B-X
inhibitor	B-X
of	B-X
nuclear	B-X
transport	B-X
,	B-X
leptomycin	B-X
B	B-X
(	B-X
LMB	B-X
)	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
the	B-X
IMPβ	B-X
homologue	B-X
Exportin	B-X
1	B-X
(	B-X
EXP1	B-X
)	B-X
almost	B-X
20	B-X
years	B-X
ago	B-X
,	B-X
but	B-X
it	B-X
has	B-X
only	B-X
been	B-X
in	B-X
the	B-X
last	B-X
five	B-X
or	B-X
so	B-X
years	B-X
that	B-X
new	B-X
inhibitors	B-X
of	B-X
nuclear	B-X
export	B-X
as	B-X
well	B-X
as	B-X
import	B-X
have	B-X
been	B-X
identified	B-X
and	B-X
characterised	B-X
.	B-X
Of	B-X
utility	B-X
in	B-X
biological	B-X
research	B-X
,	B-X
these	B-X
inhibitors	B-X
include	B-X
those	B-X
that	B-X
target-specific	B-X
EXPs/IMPs	B-X
,	B-X
with	B-X
accompanying	B-X
toxicity	B-X
profiles	B-X
,	B-X
as	B-X
well	B-X
as	B-X
agents	B-X
that	B-X
specifically	B-X
target	B-X
particular	B-X
nuclear	B-X
import	B-X
cargoes	B-X
.	B-X
Both	B-X
types	B-X
of	B-X
inhibitors	B-X
have	B-X
begun	B-X
to	B-X
be	B-X
tested	B-X
in	B-X
preclinical/clinical	B-X
studies	B-X
,	B-X
with	B-X
particular	B-X
focus	B-X
on	B-X
limiting	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
or	B-X
treating	B-X
viral	B-X
infection	B-X
,	B-X
and	B-X
the	B-X
most	B-X
advanced	B-X
agent	B-X
targeting	B-X
EXP1	B-X
(	B-X
Selinexor	B-X
)	B-X
has	B-X
progressed	B-X
successfully	B-X
through	B-X
>	B-X
40	B-X
clinical	B-X
trials	B-X
for	B-X
a	B-X
range	B-X
of	B-X
high-grade	B-X
cancers	B-X
and	B-X
is	B-X
approaching	B-X
FDA	B-X
approval	B-X
for	B-X
a	B-X
number	B-X
of	B-X
indications	B-X
.	B-X
Trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
eukaryotic	B-X
cell	B-X
cycle	B-X
and	B-X
an	B-X
inducer	B-X
of	B-X
morphological	B-X
reversion	B-X
of	B-X
transformed	B-X
cells	B-X
,	B-X
inhibits	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
at	B-X
nanomolar	B-X
concentrations	B-X
.	B-X
These	B-X
inhibitors	B-X
activate	B-X
expression	B-X
of	B-X
p21Waf1	B-X
and	B-X
16INK4A	B-X
in	B-X
a	B-X
p53-independent	B-X
manner	B-X
.	B-X
The	B-X
target	B-X
molecule	B-X
of	B-X
leptomycin	B-X
B	B-X
(	B-X
LMB	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
antitumor	B-X
agent	B-X
,	B-X
was	B-X
genetically	B-X
and	B-X
biochemically	B-X
identified	B-X
as	B-X
CRM1	B-X
,	B-X
a	B-X
protein	B-X
reported	B-X
as	B-X
being	B-X
required	B-X
for	B-X
chromosome	B-X
structure	B-X
control	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
CRM1	B-X
was	B-X
a	B-X
receptor	B-X
for	B-X
the	B-X
nuclear	B-X
export	B-X
signal	B-X
(	B-X
NES	B-X
)	B-X
and	B-X
that	B-X
LMB	B-X
inhibited	B-X
nuclear	B-X
export	B-X
of	B-X
proteins	B-X
.	B-X
Using	B-X
LMB	B-X
,	B-X
we	B-X
identified	B-X
a	B-X
novel	B-X
NES	B-X
in	B-X
fission	B-X
yeast	B-X
transcription	B-X
factor	B-X
Pap1	B-X
,	B-X
the	B-X
function	B-X
of	B-X
which	B-X
is	B-X
abolished	B-X
by	B-X
oxidative	B-X
stress	B-X
in	B-X
a	B-X
manner	B-X
conserved	B-X
in	B-X
eukaryotes	B-X
.	B-X

Additionally	O
,	O
FP	O
had	O
no	O
effect	O
on	O
whole	O
cell	O
GATA	B-Protein
-	I-Protein
3	I-Protein
expression	O
during	O
the	O
time	O
course	O
of	O
these	O
experiments	O
(	O
Figure	O
5B	O
)	O
.	O

Nor	O
did	O
addition	O
of	O
FP	O
subsequent	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
nuclear	O
translocation	O
affect	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
residency	O
(	O
Figure	O
5C	O
)	O
,	O
suggesting	O
that	O
activated	O
GR	B-Protein
does	O
not	O
enhance	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
export	O
.	O

Finally	O
,	O
the	O
effect	O
of	O
FP	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
was	O
not	O
nonspecific	O
,	O
since	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
had	O
no	O
effect	O
on	O
p65	B-Protein
nuclear	O
translocation	O
measured	O
at	O
60	O
min	O
(	O
Figure	O
5D	O
)	O
.	O

The	O
Inhibitory	O
Effect	O
of	O
Corticosteroids	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
Nuclear	O
Localization	O
in	O
Primary	O
T	O
Lymphocytes	O
Ex	O
Vivo	O
and	O
In	O
Vivo	O

Treatment	O
with	O
FP	O
ex	O
vivo	O
demonstrated	O
a	O
concentration	O
-	O
dependent	O
decrease	O
in	O
the	O
direct	O
interaction	O
between	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
importin	O
-	O
alpha	O
in	O
PBMCs	O
from	O
patients	O
with	O
asthma	O
(	O
Figure	O
6A	O
and	O
6B	O
)	O
,	O
which	O
was	O
significantly	O
inhibited	O
at	O
10	O
-	O
12	O
M	O
FP	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
ANOVA	O
and	O
Newman	O
-	O
Keuls	O
test	O
)	O
and	O
completely	O
attenuated	O
by	O
10	O
-	O
8	O
M	O
FP	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
ANOVA	O
and	O
Newman	O
-	O
Keuls	O
test	O
)	O
.	O

Our	O
previous	O
T	O
cell	O
line	O
studies	O
indicated	O
that	O
10	O
-	O
12	O
M	O
FP	O
suppresses	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
-	B-Protein
5	I-Protein
gene	O
expression	O
and	O
attenuated	O
the	O
interaction	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
with	O
importin	O
-	O
alpha	O
(	O
see	O
Figures	O
1D	O
and	O
2	O
)	O
.	O

This	O
concentration	O
is	O
close	O
to	O
peak	O
plasma	O
levels	O
obtained	O
from	O
asthmatic	O
patients	O
treated	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
[	O
27	O
]	O
.	O

Inhaled	O
FP	O
(	O
500	O
microg	O
)	O
treatment	O
of	O
seven	O
steroid	O
-	O
naive	O
asthma	O
patients	O
significantly	O
reduced	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
interaction	O
in	O
vivo	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

This	O
produced	O
a	O
>	O
90	O
%	O
decrease	O
in	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
association	O
at	O
2	O
h	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
13	O
,	O
494	O
[	O
6	O
,	O
828	O
-	O
17	O
,	O
829	O
]	O
versus	O
879	O
[	O
597	O
-	O
1	O
,	O
165	O
]	O
;	O
p	O
<	O
0	O
.	O
05	O
Friedman	O
'	O
s	O
analysis	O
)	O
.	O

However	O
,	O
this	O
did	O
not	O
reach	O
significance	O
using	O
Wilcoxon	O
'	O
s	O
post	O
-	O
test	O
analysis	O
(	O
W	O
=	O
6	O
.	O
00	O
)	O
probably	O
due	O
to	O
low	O
numbers	O
of	O
participants	O
.	O

Similar	O
results	O
were	O
observed	O
when	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
association	O
was	O
measured	O
(	O
Figure	O
6C	O
and	O
6D	O
)	O
.	O

The	O
lower	O
dose	O
of	O
FP	O
(	O
100	O
microg	O
)	O
was	O
not	O
effective	O
.	O

The	O
attenuated	O
interaction	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
did	O
not	O
result	O
from	O
the	O
defective	O
recycling	O
of	O
importin	O
-	O
alpha	O
,	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
abundance	O
of	O
importin	O
-	O
alpha	O
in	O
the	O
cytoplasmic	O
pool	O
was	O
not	O
detected	O
(	O
Figure	O
6E	O
)	O
.	O
<EOS>	B-X
This	B-X
research	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
and	B-X
mechanisms	B-X
of	B-X
Danshen	B-X
on	B-X
anemia	B-X
in	B-X
a	B-X
zebrafish	B-X
model	B-X
based	B-X
on	B-X
the	B-X
results	B-X
of	B-X
a	B-X
network	B-X
pharmacology	B-X
study	B-X
.	B-X
Class	B-X
I	B-X
deacetylase	B-X
HDAC1/2	B-X
often	B-X
associates	B-X
with	B-X
repressor	B-X
complexes	B-X
,	B-X
such	B-X
as	B-X
Sin3	B-X
(	B-X
Switch	B-X
Independent	B-X
3	B-X
)	B-X
,	B-X
NuRD	B-X
(	B-X
Nucleosome	B-X
remodeling	B-X
and	B-X
deacetylase	B-X
)	B-X
and	B-X
CoREST	B-X
(	B-X
Corepressor	B-X
of	B-X
RE1	B-X
silencing	B-X
transcription	B-X
factor	B-X
)	B-X
complexes	B-X
.	B-X
The	B-X
reduction	B-X
of	B-X
HDAC	B-X
activity	B-X
not	B-X
only	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
transcription	B-X
activators	B-X
such	B-X
as	B-X
GATA-1	B-X
(	B-X
GATA-binding	B-X
factor	B-X
1	B-X
)	B-X
,	B-X
TAL1	B-X
(	B-X
TAL	B-X
BHLH	B-X
Transcription	B-X
Factor	B-X
1	B-X
)	B-X
and	B-X
KLF1	B-X
(	B-X
Krüpple-like	B-X
factor	B-X
1	B-X
)	B-X
,	B-X
but	B-X
also	B-X
represses	B-X
transcription	B-X
repressors	B-X
such	B-X
as	B-X
PU.1	B-X
(	B-X
Putative	B-X
oncogene	B-X
Spi-1	B-X
)	B-X
.	B-X
Parturition	B-X
at	B-X
both	B-X
term	B-X
and	B-X
preterm	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
abundance	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
the	B-X
fetal	B-X
membranes	B-X
regardless	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
infection	B-X
,	B-X
which	B-X
is	B-X
believed	B-X
to	B-X
induce	B-X
rupture	B-X
of	B-X
membranes	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
matrix	B-X
metalloproteinases	B-X
.	B-X
Here	B-X
we	B-X
showed	B-X
that	B-X
there	B-X
were	B-X
reciprocal	B-X
increases	B-X
in	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
and	B-X
decreases	B-X
in	B-X
lysyl	B-X
oxidase	B-X
(	B-X
LOX	B-X
)	B-X
,	B-X
a	B-X
collagen	B-X
crosslinking	B-X
enzyme	B-X
,	B-X
in	B-X
the	B-X
human	B-X
amnion	B-X
tissue	B-X
following	B-X
spontaneous	B-X
rupture	B-X
of	B-X
membrane	B-X
at	B-X
term	B-X
and	B-X
pPROM	B-X
.	B-X
Mechanistic	B-X
study	B-X
revealed	B-X
that	B-X
IL-1β	B-X
inhibited	B-X
LOX	B-X
expression	B-X
through	B-X
activation	B-X
of	B-X
p38	B-X
and	B-X
Erk1/2	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
pathways	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
kappa	B-X
light-chain	B-X
enhancer	B-X
of	B-X
activated	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
cell	B-X
subunit	B-X
p65	B-X
as	B-X
well	B-X
as	B-X
GATA	B-X
binding	B-X
protein	B-X
3	B-X
(	B-X
GATA3	B-X
)	B-X
.	B-X
Subsequently	B-X
,	B-X
activated	B-X
NF-κB	B-X
interacted	B-X
with	B-X
GATA3	B-X
at	B-X
the	B-X
NF-κB	B-X
binding	B-X
site	B-X
of	B-X
LOX	B-X
promoter	B-X
to	B-X
inhibit	B-X
its	B-X
expression	B-X
.	B-X

We	O
further	O
examined	O
whether	O
inhaled	O
FP	O
could	O
affect	O
cellular	O
localization	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

Treatment	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
for	O
2	O
h	O
significantly	O
increased	O
GR	B-Protein
nuclear	O
translocation	O
(	O
Figure	O
7A	O
)	O
and	O
concomitantly	O
decreased	O
the	O
number	O
of	O
nuclear	O
GATA	B-Protein
-	I-Protein
3	I-Protein
immunoreactive	O
peripheral	O
blood	O
T	O
cells	O
(	O
37	O
%	O
+	O
/	O
-	O
4	O
.	O
2	O
%	O
versus	O
58	O
.	O
2	O
%	O
+	O
/	O
-	O
4	O
.	O
95	O
%	O
,	O
p	O
=	O
0	O
.	O
016	O
,	O
W	O
=	O
28	O
.	O
0	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
compared	O
with	O
placebo	O
as	O
measured	O
by	O
immunocytochemistry	O
(	O
Figure	O
7A	O
and	O
7B	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
Western	O
blotting	O
,	O
which	O
also	O
indicated	O
that	O
this	O
effect	O
was	O
both	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
(	O
Figure	O
7C	O
and	O
7D	O
)	O
.	O

Thus	O
,	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
induced	O
significant	O
loss	O
in	O
nuclear	O
GATA	B-Protein
-	I-Protein
3	I-Protein
at	O
2	O
h	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
.	O
40	O
[	O
0	O
.	O
27	O
-	O
0	O
.	O
53	O
]	O
versus	O
0	O
.	O
14	O
[	O
0	O
.	O
11	O
-	O
0	O
.	O
19	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
W	O
=	O
21	O
.	O
00	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
(	O
Figure	O
7C	O
)	O
and	O
cytoplasmic	O
GATA	B-Protein
-	I-Protein
3	I-Protein
levels	O
were	O
enhanced	O
by	O
inhaled	O
FP	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
.	O
0032	O
[	O
0	O
.	O
0026	O
-	O
0	O
.	O
0039	O
]	O
versus	O
0	O
.	O
658	O
[	O
0	O
.	O
592	O
-	O
0	O
.	O
720	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
W	O
=	O
-	O
21	O
.	O
00	O
,	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
)	O
(	O
Figure	O
7D	O
)	O
.	O

In	O
addition	O
,	O
FP	O
(	O
500	O
microg	O
)	O
inhibited	O
p38	O
MAPK	O
phosphorylation	O
in	O
primary	O
T	O
cells	O
in	O
vivo	O
at	O
2	O
h	O
in	O
samples	O
from	O
two	O
patients	O
(	O
Figure	O
7E	O
)	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
inhaled	O
FP	O
reduces	O
nuclear	O
localization	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
vivo	O
by	O
acutely	O
inhibiting	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
association	O
.	O

This	O
effect	O
may	O
be	O
direct	O
,	O
through	O
competition	O
for	O
importin	O
-	O
alpha	O
or	O
associated	O
molecules	O
,	O
or	O
secondary	O
to	O
an	O
effect	O
on	O
p38	O
MAPK	O
-	O
mediated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
phosphorylation	O
via	O
rapid	O
induction	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Receptor-like	B-X
cytoplasmic	B-X
kinases	B-X
(	B-X
RLCKs	B-X
)	B-X
,	B-X
which	B-X
lack	B-X
extracellular	B-X
ligand-binding	B-X
domains	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
a	B-X
major	B-X
class	B-X
of	B-X
signaling	B-X
proteins	B-X
that	B-X
regulate	B-X
plant	B-X
cellular	B-X
activities	B-X
in	B-X
response	B-X
to	B-X
biotic/abiotic	B-X
stresses	B-X
and	B-X
endogenous	B-X
extracellular	B-X
signaling	B-X
molecules	B-X
.	B-X
The	B-X
activity	B-X
and	B-X
stability	B-X
of	B-X
RLCKs	B-X
are	B-X
dynamically	B-X
regulated	B-X
not	B-X
only	B-X
by	B-X
RKs	B-X
but	B-X
also	B-X
by	B-X
other	B-X
RLCK-associated	B-X
proteins	B-X
.	B-X
Analyses	B-X
of	B-X
RLCK-associated	B-X
components	B-X
and	B-X
substrates	B-X
have	B-X
suggested	B-X
phosphorylation	B-X
relays	B-X
as	B-X
a	B-X
major	B-X
mechanism	B-X
underlying	B-X
RK-mediated	B-X
signaling	B-X
.	B-X
Myeloperoxidase	B-X
(	B-X
MPO	B-X
)	B-X
-specific	B-X
antineutrophil	B-X
cytoplasmic	B-X
antibody	B-X
(	B-X
ANCA	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
rapidly	B-X
progressive	B-X
glomerulonephritis	B-X
(	B-X
RPGN	B-X
)	B-X
in	B-X
microscopic	B-X
polyangiitis	B-X
(	B-X
MPA	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
anti-MPO	B-X
antibody	B-X
has	B-X
been	B-X
found	B-X
to	B-X
activate	B-X
glomerular	B-X
endothelial	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
upregulation	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Interestingly	B-X
,	B-X
anti-moesin	B-X
is	B-X
observed	B-X
in	B-X
sera	B-X
of	B-X
SCG/Kj	B-X
mice	B-X
,	B-X
which	B-X
spontaneously	B-X
develop	B-X
MPO-ANCA-associated	B-X
RPGN	B-X
,	B-X
and	B-X
of	B-X
patients	B-X
with	B-X
MPO-AAV	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
glomerular	B-X
endothelial	B-X
cells	B-X
by	B-X
the	B-X
anti-MPO	B-X
antibody	B-X
appears	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
signaling	B-X
through	B-X
moesin	B-X
.	B-X

The	O
combination	O
of	O
these	O
two	O
interacting	O
effects	O
can	O
result	O
in	O
complete	O
suppression	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
and	O
thus	O
Th2	O
cytokine	O
gene	O
expression	O
.	O

Here	O
we	O
have	O
demonstrated	O
,	O
to	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
that	O
corticosteroids	O
may	O
inhibit	O
GATA	B-Protein
-	I-Protein
3	I-Protein
function	O
and	O
therefore	O
the	O
transcription	O
of	O
Th2	O
genes	O
via	O
two	O
distinct	O
but	O
interacting	O
molecular	O
mechanisms	O
.	O

Firstly	O
,	O
corticosteroid	O
-	O
activated	O
GR	B-Protein
appears	O
to	O
compete	O
with	O
activated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
for	O
nuclear	O
import	O
via	O
importin	O
-	O
alpha	O
,	O
which	O
is	O
required	O
for	O
the	O
nuclear	O
transport	O
of	O
both	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
GR	B-Protein
.	O

Secondly	O
,	O
corticosteroids	O
at	O
higher	O
concentrations	O
increase	O
the	O
expression	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
potent	O
inhibitor	O
of	O
p38	O
MAPK	O
activity	O
and	O
thereby	O
prevent	O
T	O
cell	O
receptor	O
/	O
co	O
-	O
receptor	O
activation	O
of	O
p38	O
MAPK	O
to	O
prevent	O
the	O
phosphorylation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
that	O
is	O
necessary	O
for	O
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
subsequent	O
nuclear	O
import	O
.	O

We	O
have	O
previously	O
shown	O
that	O
translocation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
involves	O
the	O
nuclear	O
transporter	O
protein	O
importin	O
-	O
alpha	O
,	O
which	O
interacts	O
with	O
phosphorylated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
[	O
12	O
]	O
.	O

We	O
have	O
also	O
previously	O
reported	O
that	O
GATA	B-Protein
-	I-Protein
3	I-Protein
knockdown	O
using	O
siRNA	O
results	O
in	O
suppression	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
IL	B-Protein
-	I-Protein
4	I-Protein
/	O
IL	B-Protein
-	I-Protein
5	I-Protein
mRNA	O
induction	O
,	O
thus	O
implicating	O
an	O
essential	O
role	O
for	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
the	O
transcription	O
of	O
these	O
genes	O
[	O
12	O
]	O
.	O

We	O
now	O
confirm	O
,	O
in	O
human	O
T	O
cells	O
,	O
that	O
GR	B-Protein
also	O
uses	O
the	O
same	O
nuclear	O
import	O
mechanism	O
as	O
GATA	B-Protein
-	I-Protein
3	I-Protein
[	O
22	O
]	O
.	O

We	O
therefore	O
propose	O
that	O
there	O
is	O
competition	O
between	O
ligand	O
-	O
activated	O
GR	B-Protein
and	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
for	O
nuclear	O
import	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
there	O
is	O
preferential	O
binding	O
of	O
importin	O
-	O
alpha	O
to	O
activated	O
GR	B-Protein
over	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
so	O
that	O
corticosteroids	O
would	O
preferentially	O
reduce	O
GATA	B-Protein
-	I-Protein
3	I-Protein
entry	O
and	O
thus	O
rapidly	O
switch	O
off	O
Th2	O
gene	O
transcription	O
without	O
any	O
need	O
for	O
any	O
intermediate	O
steps	O
.	O

Furthermore	O
,	O
there	O
was	O
some	O
degree	O
of	O
specificity	O
for	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
as	O
nuclear	O
translocation	O
of	O
the	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappaB	O
was	O
not	O
affected	O
by	O
corticosteroid	O
exposure	O
.	O

We	O
tested	O
some	O
alternative	O
explanations	O
for	O
this	O
effect	O
of	O
FP	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
exclusion	O
and	O
failed	O
to	O
show	O
that	O
FP	O
either	O
enhances	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
export	O
directly	O
or	O
induces	O
GATA	B-Protein
-	I-Protein
3	I-Protein
degradation	O
.	O
<EOS>	B-X
Hypoxia	B-X
attenuates	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
Epo	B-X
promoter	B-X
by	B-X
GATA-2	B-X
.	B-X
Three	B-X
HIF-α	B-X
prolyl	B-X
hydroxylases	B-X
(	B-X
PHD-1	B-X
,	B-X
-2	B-X
and	B-X
-3	B-X
)	B-X
initiate	B-X
proteasomal	B-X
degradation	B-X
of	B-X
HIF-α	B-X
,	B-X
while	B-X
an	B-X
asparaginyl	B-X
hydroxylase	B-X
(	B-X
'factor	B-X
inhibiting	B-X
HIF-1	B-X
'	B-X
,	B-X
FIH-1	B-X
)	B-X
inhibits	B-X
the	B-X
transactivation	B-X
potential	B-X
.	B-X
GATA	B-X
binding	B-X
protein	B-X
3	B-X
(	B-X
GATA3	B-X
)	B-X
is	B-X
indispensable	B-X
in	B-X
development	B-X
of	B-X
human	B-X
organs	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
GATA3	B-X
in	B-X
cancers	B-X
remains	B-X
elusive	B-X
.	B-X
Regulation	B-X
of	B-X
HIF-1α	B-X
degradation	B-X
is	B-X
orchestrated	B-X
through	B-X
collaboration	B-X
of	B-X
its	B-X
interacting	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
discover	B-X
that	B-X
GATA3	B-X
is	B-X
upregulated	B-X
in	B-X
head	B-X
and	B-X
neck	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
HNSCC	B-X
)	B-X
and	B-X
is	B-X
an	B-X
independent	B-X
predictor	B-X
for	B-X
poor	B-X
disease-free	B-X
survival	B-X
.	B-X
GATA3	B-X
promotes	B-X
invasive	B-X
behaviours	B-X
of	B-X
HNSCC	B-X
and	B-X
melanoma	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
immunodeficient	B-X
mice	B-X
.	B-X
Mechanistically	B-X
,	B-X
GATA3	B-X
physically	B-X
associates	B-X
with	B-X
HIF-1α	B-X
under	B-X
hypoxia	B-X
to	B-X
inhibit	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
of	B-X
HIF-1α	B-X
,	B-X
which	B-X
is	B-X
independent	B-X
of	B-X
HIF-1α	B-X
prolyl	B-X
hydroxylation	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
the	B-X
GATA3/HIF-1α	B-X
complex	B-X
binds	B-X
to	B-X
and	B-X
regulates	B-X
HIF-1	B-X
target	B-X
genes	B-X
,	B-X
which	B-X
is	B-X
also	B-X
supported	B-X
by	B-X
the	B-X
microarray	B-X
analysis	B-X
.	B-X
Notably	B-X
,	B-X
the	B-X
GATA3-mediated	B-X
invasiveness	B-X
can	B-X
be	B-X
significantly	B-X
reversed	B-X
by	B-X
HIF-1α	B-X
knockdown	B-X
,	B-X
suggesting	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
HIF-1α	B-X
in	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
GATA3-mediated	B-X
effects	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
GATA3	B-X
stabilizes	B-X
HIF-1α	B-X
to	B-X
enhance	B-X
cancer	B-X
invasiveness	B-X
under	B-X
hypoxia	B-X
and	B-X
support	B-X
the	B-X
GATA3/HIF-1α	B-X
axis	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
cancer	B-X
treatment	B-X
.	B-X

The	O
evidence	O
from	O
the	O
in	O
vitro	O
competition	O
assays	O
does	O
,	O
however	O
,	O
suggest	O
that	O
purified	O
activated	O
GR	B-Protein
can	O
clearly	O
attenuate	O
purified	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
association	O
and	O
that	O
the	O
converse	O
does	O
not	O
occur	O
.	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
only	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
can	O
associate	O
with	O
importin	O
-	O
alpha	O
.	O

This	O
mechanism	O
is	O
sensitive	O
to	O
very	O
low	O
concentrations	O
of	O
corticosteroid	O
and	O
would	O
be	O
rapid	O
in	O
onset	O
as	O
no	O
changes	O
in	O
protein	O
synthesis	O
are	O
required	O
.	O

This	O
acute	O
mechanism	O
may	O
also	O
contribute	O
to	O
the	O
reduction	O
in	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
and	O
may	O
play	O
a	O
major	O
role	O
at	O
low	O
corticosteroid	O
concentrations	O
and	O
/	O
or	O
at	O
early	O
time	O
points	O
prior	O
to	O
MKP	B-Protein
-	I-Protein
1	I-Protein
induction	O
.	O

Corticosteroids	O
can	O
modulate	O
p38	O
MAPK	O
activity	O
through	O
the	O
induction	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
potent	O
endogenous	O
inhibitor	O
of	O
MAPK	O
function	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

We	O
report	O
here	O
a	O
rapid	O
induction	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
following	O
stimulation	O
of	O
cells	O
with	O
relatively	O
high	O
concentrations	O
of	O
FP	O
.	O

We	O
hypothesize	O
that	O
this	O
rapid	O
induction	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
can	O
reduce	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
by	O
attenuating	O
p38	O
MAPK	O
activity	O
and	O
subsequent	O
GATA	B-Protein
-	I-Protein
3	I-Protein
phosphorylation	O
,	O
thus	O
preventing	O
nuclear	O
translocation	O
.	O

The	O
location	O
of	O
the	O
serine	O
residue	O
(	O
s	O
)	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
that	O
are	O
phosphorylated	O
by	O
p38	O
MAPK	O
are	O
currently	O
unknown	O
,	O
but	O
a	O
bioinformatics	O
search	O
(	O
Motif	O
Scanner	O
,	O
http	O
:	O
/	O
/	O
scansite	O
.	O
mit	O
.	O
edu	O
/	O
motifscan	O
_	O
seq	O
.	O
phtml	O
)	O
indicates	O
at	O
least	O
three	O
potential	O
p38	O
MAPK	O
-	O
sensitive	O
serine	O
residues	O
.	O

As	O
predicted	O
from	O
these	O
in	O
vitro	O
data	O
,	O
impairment	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
by	O
FP	O
may	O
,	O
at	O
least	O
in	O
part	O
,	O
underlie	O
the	O
efficacy	O
of	O
corticosteroids	O
in	O
suppressing	O
allergic	O
inflammation	O
.	O

Although	O
we	O
did	O
not	O
assess	O
the	O
acute	O
inhibitory	O
effect	O
of	O
FP	O
on	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
in	O
vivo	O
,	O
a	O
single	O
inhalation	O
of	O
FP	O
(	O
500	O
microg	O
)	O
may	O
have	O
comparable	O
effects	O
,	O
as	O
it	O
provides	O
plasma	O
levels	O
within	O
a	O
relevant	O
range	O
of	O
concentrations	O
used	O
to	O
suppress	O
IL	B-Protein
-	I-Protein
4	I-Protein
transcription	O
in	O
our	O
in	O
vitro	O
system	O
[	O
37	O
]	O
.	O

A	O
lower	O
dose	O
of	O
inhaled	O
FP	O
(	O
100	O
microg	O
)	O
was	O
not	O
effective	O
,	O
but	O
plasma	O
concentrations	O
may	O
be	O
below	O
those	O
required	O
for	O
GATA	B-Protein
-	I-Protein
3	I-Protein
inhibition	O
.	O
<EOS>	B-X
Inhaled	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X
is	B-X
a	B-X
high-potency	B-X
inhaled	B-X
corticosteroid	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
asthma	B-X
.	B-X
Inhaled	B-X
corticosteroids	B-X
(	B-X
ICSs	B-X
)	B-X
provide	B-X
important	B-X
anti-inflammatory	B-X
treatment	B-X
but	B-X
may	B-X
not	B-X
provide	B-X
optimal	B-X
control	B-X
of	B-X
asthma	B-X
when	B-X
taken	B-X
alone	B-X
.	B-X
Two	B-X
therapeutic	B-X
alternatives	B-X
for	B-X
enhanced	B-X
asthma	B-X
control	B-X
are	B-X
to	B-X
substitute	B-X
the	B-X
combination	B-X
of	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X
and	B-X
salmeterol	B-X
(	B-X
FP/Salm	B-X
Combo	B-X
)	B-X
through	B-X
the	B-X
Diskus	B-X
inhaler	B-X
or	B-X
to	B-X
add	B-X
montelukast	B-X
to	B-X
existing	B-X
ICS	B-X
therapy	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
benefit	B-X
of	B-X
adding	B-X
salmeterol	B-X
was	B-X
superior	B-X
to	B-X
doubling	B-X
the	B-X
dose	B-X
of	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X
over	B-X
6	B-X
months	B-X
,	B-X
compared	B-X
to	B-X
a	B-X
control	B-X
group	B-X
who	B-X
remained	B-X
on	B-X
a	B-X
lower	B-X
dose	B-X
of	B-X
FP	B-X
.	B-X
The	B-X
multi-centre	B-X
,	B-X
double-blind	B-X
,	B-X
parallel	B-X
group	B-X
study	B-X
involved	B-X
496	B-X
symptomatic	B-X
asthmatic	B-X
patients	B-X
with	B-X
a	B-X
history	B-X
of	B-X
exacerbations	B-X
on	B-X
500-800	B-X
micrograms	B-X
(	B-X
microg	B-X
)	B-X
inhaled	B-X
corticosteroids	B-X
(	B-X
ICS	B-X
)	B-X
twice	B-X
daily	B-X
(	B-X
b.d	B-X
.	B-X
)	B-X
in	B-X
a	B-X
broadly	B-X
representative	B-X
group	B-X
of	B-X
100	B-X
hospitals	B-X
and	B-X
general	B-X
practices	B-X
in	B-X
six	B-X
countries	B-X
.	B-X
Two	B-X
doses	B-X
of	B-X
FP	B-X
--	B-X
250	B-X
microg	B-X
b.d	B-X
.	B-X
(	B-X
FP250	B-X
)	B-X
or	B-X
500	B-X
microg	B-X
b.d	B-X
.	B-X
(	B-X
FP500	B-X
)	B-X
--	B-X
were	B-X
compared	B-X
with	B-X
the	B-X
lower	B-X
dose	B-X
of	B-X
FP	B-X
plus	B-X
a	B-X
long-acting	B-X
beta2-agonist	B-X
,	B-X
salmeterol	B-X
50	B-X
microg	B-X
b.d	B-X
.	B-X
(	B-X
SM/FP250	B-X
)	B-X
.	B-X
Patients	B-X
symptomatic	B-X
on	B-X
the	B-X
run-in	B-X
dose	B-X
of	B-X
FP250	B-X
alone	B-X
formed	B-X
the	B-X
control	B-X
group	B-X
in	B-X
the	B-X
treatment	B-X
period	B-X
.	B-X
Over	B-X
6	B-X
months	B-X
,	B-X
SM/FP250	B-X
significantly	B-X
improved	B-X
mean	B-X
morning	B-X
peak	B-X
expiratory	B-X
flow	B-X
rates	B-X
(	B-X
amPEF	B-X
)	B-X
by	B-X
42.1	B-X
l/min	B-X
,	B-X
more	B-X
than	B-X
twice	B-X
the	B-X
improvement	B-X
achieved	B-X
with	B-X
either	B-X
dose	B-X
of	B-X
FP	B-X
alone	B-X
.	B-X
SM/FP250	B-X
also	B-X
resulted	B-X
in	B-X
more	B-X
symptom-free	B-X
days	B-X
and	B-X
nights	B-X
(	B-X
P	B-X
<	B-X
0.002	B-X
)	B-X
and	B-X
days	B-X
and	B-X
nights	B-X
with	B-X
no	B-X
relief	B-X
medication	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
number	B-X
of	B-X
severe	B-X
exacerbations	B-X
was	B-X
low	B-X
:	B-X
3	B-X
,	B-X
6	B-X
and	B-X
8	B-X
%	B-X
in	B-X
the	B-X
SM/FP250	B-X
,	B-X
low-	B-X
and	B-X
high-dose	B-X
FP	B-X
groups	B-X
,	B-X
respectively	B-X
.	B-X
This	B-X
study	B-X
confirms	B-X
that	B-X
adding	B-X
salmeterol	B-X
to	B-X
low-dose	B-X
inhaled	B-X
FP	B-X
offers	B-X
greater	B-X
improvements	B-X
than	B-X
either	B-X
maintaining	B-X
or	B-X
doubling	B-X
the	B-X
dose	B-X
of	B-X
FP	B-X
.	B-X
Significant	B-X
benefit	B-X
was	B-X
gained	B-X
from	B-X
adding	B-X
salmeterol	B-X
in	B-X
a	B-X
group	B-X
of	B-X
patients	B-X
who	B-X
appeared	B-X
to	B-X
have	B-X
been	B-X
at	B-X
the	B-X
top	B-X
of	B-X
their	B-X
steroid	B-X
dose-response	B-X
curve	B-X
receiving	B-X
FP250	B-X
.	B-X

However	O
,	O
it	O
is	O
likely	O
that	O
the	O
higher	O
concentrations	O
of	O
FP	O
in	O
the	O
airways	O
after	O
inhaled	O
administration	O
would	O
be	O
effective	O
in	O
inhibiting	O
GATA	B-Protein
-	I-Protein
3	I-Protein
in	O
airway	O
T	O
cells	O
of	O
asthma	O
patients	O
.	O

The	O
study	O
of	O
PBMCs	O
from	O
asthma	O
patients	O
treated	O
with	O
inhaled	O
corticosteroid	O
therapy	O
clearly	O
demonstrates	O
that	O
these	O
molecular	O
mechanisms	O
are	O
likely	O
to	O
also	O
occur	O
in	O
patients	O
at	O
therapeutic	O
doses	O
of	O
inhaled	O
corticosteroids	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
have	O
shown	O
that	O
corticosteroids	O
can	O
suppress	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
release	O
from	O
peripheral	O
blood	O
cells	O
of	O
asthma	O
patients	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
40	O
]	O
-	O
[	O
42	O
]	O
.	O

In	O
summary	O
,	O
our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
action	O
of	O
corticosteroids	O
:	O
suppression	O
of	O
allergic	O
inflammation	O
through	O
a	O
rapid	O
inhibitory	O
effect	O
on	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
translocation	O
by	O
preferential	O
binding	O
to	O
the	O
shared	O
nuclear	O
import	O
protein	O
importin	O
-	O
alpha	O
and	O
by	O
a	O
second	O
mechanism	O
involving	O
increased	O
synthesis	O
of	O
MKP	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
inhibits	O
p38	O
MAPK	O
,	O
thus	O
preventing	O
the	O
phosphorylation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
that	O
is	O
necessary	O
for	O
nuclear	O
translocation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
.	O

These	O
two	O
mechanisms	O
are	O
likely	O
to	O
be	O
synergistic	O
,	O
accounting	O
for	O
the	O
rapid	O
and	O
potent	O
effect	O
of	O
corticosteroids	O
on	O
allergic	O
inflammation	O
.	O

This	O
is	O
exemplified	O
by	O
the	O
rapid	O
inhibitory	O
effect	O
of	O
topical	O
corticosteroids	O
on	O
nasal	O
Th2	O
cytokine	O
release	O
after	O
allergen	O
provocation	O
in	O
individuals	O
with	O
seasonal	O
allergic	O
rhinitis	O
(	O
hay	O
fever	O
)	O
[	O
43	O
]	O
.	O

Prevention	O
of	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
interaction	O
with	O
importin	O
-	O
alpha	O
may	O
provide	O
a	O
new	O
approach	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
.	O

Fluticasone	O
propionate	O
down	O
-	O
regulates	O
Th2	O
cytokine	O
gene	O
expression	O
and	O
inhibits	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
.	O

(	O
A	O
)	O
Anti	O
-	O
CD3	O
/	O
CD28	O
treatment	O
of	O
HuT	O
-	O
78	O
cells	O
results	O
in	O
translocation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
within	O
30	O
min	O
.	O

(	O
B	O
)	O
Histone	O
H1	O
and	O
MEK	B-Protein
-	I-Protein
1	I-Protein
were	O
used	O
to	O
confirm	O
distinct	O
separation	O
of	O
cytoplasmic	O
and	O
nuclear	O
extracts	O
in	O
three	O
separate	O
experiments	O
.	O

(	O
C	O
)	O
Western	O
blot	O
analysis	O
of	O
FP	O
-	O
treated	O
HuT	O
-	O
78	O
cells	O
demonstrated	O
impaired	O
nuclear	O
localization	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
induced	O
by	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
in	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
manner	O
.	O

Cells	O
were	O
pretreated	O
with	O
FP	O
for	O
30	O
min	O
prior	O
to	O
stimulation	O
.	O

MEK1	B-Protein
and	O
histone	O
H1	O
were	O
used	O
to	O
demonstrate	O
equal	O
cytoplasmic	O
and	O
nuclear	O
loading	O
respectively	O
.	O

Results	O
are	O
presented	O
graphically	O
below	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
t	O
=	O
0	O
.	O

(	O
D	O
)	O
RT	O
-	O
PCR	O
showing	O
that	O
FP	O
inhibits	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
5	I-Protein
mRNA	O
expression	O
in	O
CD3	B-Protein
/	O
CD28	B-Protein
-	O
costimulated	O
cells	O
.	O

GAPDH	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

Lower	O
panels	O
show	O
graphical	O
analysis	O
of	O
results	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
.	O

(	O
E	O
)	O
FP	O
(	O
10	O
nM	O
)	O
reduces	O
the	O
ability	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
to	O
associate	O
with	O
the	O
native	O
IL	B-Protein
-	I-Protein
5	I-Protein
promoter	O
60	O
min	O
after	O
stimulation	O
.	O

Data	O
are	O
also	O
shown	O
graphically	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O

All	O
data	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
ex	B-X
vivo	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
post	B-X
system	B-X
on	B-X
fracture	B-X
resistance	B-X
and	B-X
failure	B-X
mode	B-X
of	B-X
root	B-X
filled	B-X
incisor	B-X
,	B-X
canine	B-X
,	B-X
premolar	B-X
and	B-X
molar	B-X
teeth	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
bond	B-X
strength	B-X
of	B-X
a	B-X
composite	B-X
resin	B-X
to	B-X
glass-fiber	B-X
post	B-X
(	B-X
GFP	B-X
)	B-X
treated	B-X
or	B-X
not	B-X
with	B-X
phosphoric	B-X
acid	B-X
,	B-X
silane	B-X
coupling	B-X
agent	B-X
,	B-X
and	B-X
unfilled	B-X
resin	B-X
.	B-X
The	B-X
specimens	B-X
were	B-X
stored	B-X
in	B-X
distilled	B-X
water	B-X
at	B-X
37	B-X
°C	B-X
for	B-X
24	B-X
h.	B-X
Microtensile	B-X
bond	B-X
test	B-X
was	B-X
performed	B-X
using	B-X
a	B-X
mechanical	B-X
testing	B-X
machine	B-X
until	B-X
failure	B-X
(	B-X
n=10	B-X
)	B-X
.	B-X
The	B-X
data	B-X
were	B-X
analyzed	B-X
using	B-X
two-way	B-X
ANOVA	B-X
followed	B-X
by	B-X
Student-Newman-Keuls	B-X
'	B-X
test	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X

Fluticasone	O
propionate	O
reduces	O
GATA	B-Protein
-	I-Protein
3	I-Protein
association	O
with	O
importin	O
-	O
alpha	O
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
import	O
.	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
demonstrates	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
induction	O
of	O
FP	O
-	O
activated	O
GR	B-Protein
interaction	O
with	O
importin	O
-	O
alpha	O
(	O
Imp	O
-	O
alpha	O
)	O
.	O

A	O
positive	O
control	O
for	O
GR	B-Protein
association	O
with	O
importin	O
is	O
shown	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O
<EOS>	B-X
RT-PCR	B-X
data	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
liver	B-X
,	B-X
kidney	B-X
,	B-X
heart	B-X
,	B-X
adrenal	B-X
glands	B-X
and	B-X
adipose	B-X
tissue	B-X
,	B-X
and	B-X
allowed	B-X
the	B-X
detection	B-X
of	B-X
a	B-X
very	B-X
low	B-X
amount	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
the	B-X
stomach	B-X
,	B-X
the	B-X
duodenum	B-X
and	B-X
brain	B-X
but	B-X
not	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
B	O
)	O
Western	O
blot	O
analysis	O
demonstrated	O
a	O
time	O
-	O
(	O
at	O
10	O
-	O
8	O
M	O
FP	O
)	O
and	O
concentration	O
-	O
(	O
at	O
60	O
min	O
after	O
stimulation	O
)	O
dependent	O
induction	O
of	O
FP	O
-	O
activated	O
GR	B-Protein
nuclear	O
translocation	O
measured	O
by	O
IP	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O
<EOS>	B-X
RT-PCR	B-X
data	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
liver	B-X
,	B-X
kidney	B-X
,	B-X
heart	B-X
,	B-X
adrenal	B-X
glands	B-X
and	B-X
adipose	B-X
tissue	B-X
,	B-X
and	B-X
allowed	B-X
the	B-X
detection	B-X
of	B-X
a	B-X
very	B-X
low	B-X
amount	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
the	B-X
stomach	B-X
,	B-X
the	B-X
duodenum	B-X
and	B-X
brain	B-X
but	B-X
not	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
.	O
<EOS>	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
A	B-X
comprehensive	B-X
understanding	B-X
of	B-X
the	B-X
benefits	B-X
of	B-X
COVID-19	B-X
vaccination	B-X
requires	B-X
consideration	B-X
of	B-X
disease	B-X
attenuation	B-X
,	B-X
determined	B-X
as	B-X
whether	B-X
people	B-X
who	B-X
develop	B-X
COVID-19	B-X
despite	B-X
vaccination	B-X
have	B-X
lower	B-X
disease	B-X
severity	B-X
than	B-X
unvaccinated	B-X
people	B-X
.	B-X
The	B-X
emergence	B-X
of	B-X
the	B-X
B.1.617.2	B-X
(	B-X
delta	B-X
)	B-X
variant	B-X
of	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
and	B-X
the	B-X
reduced	B-X
effectiveness	B-X
over	B-X
time	B-X
of	B-X
the	B-X
BNT162b2	B-X
vaccine	B-X
(	B-X
Pfizer-BioNTech	B-X
)	B-X
led	B-X
to	B-X
a	B-X
resurgence	B-X
of	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
cases	B-X
in	B-X
populations	B-X
that	B-X
had	B-X
been	B-X
vaccinated	B-X
early	B-X
.	B-X
On	B-X
July	B-X
30	B-X
,	B-X
2021	B-X
,	B-X
the	B-X
Israeli	B-X
Ministry	B-X
of	B-X
Health	B-X
approved	B-X
the	B-X
use	B-X
of	B-X
a	B-X
third	B-X
dose	B-X
of	B-X
BNT162b2	B-X
(	B-X
booster	B-X
)	B-X
to	B-X
cope	B-X
with	B-X
this	B-X
resurgence	B-X
.	B-X

(	O
C	O
)	O
Western	O
blot	O
analysis	O
of	O
HuT	O
-	O
78	O
cells	O
treated	O
with	O
FP	O
and	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
demonstrated	O
a	O
concentration	O
-	O
dependent	O
decrease	O
in	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
association	O
at	O
20	O
min	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
is	O
shown	O
below	O
.	O
<EOS>	B-X
RT-PCR	B-X
data	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
liver	B-X
,	B-X
kidney	B-X
,	B-X
heart	B-X
,	B-X
adrenal	B-X
glands	B-X
and	B-X
adipose	B-X
tissue	B-X
,	B-X
and	B-X
allowed	B-X
the	B-X
detection	B-X
of	B-X
a	B-X
very	B-X
low	B-X
amount	B-X
of	B-X
glucagon	B-X
receptor	B-X
mRNA	B-X
in	B-X
the	B-X
stomach	B-X
,	B-X
the	B-X
duodenum	B-X
and	B-X
brain	B-X
but	B-X
not	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
alphaCD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
D	O
)	O
GFP	O
-	O
tagged	O
GATA	B-Protein
-	I-Protein
3	I-Protein
was	O
overexpressed	O
and	O
cells	O
stimulated	O
(	O
b	O
,	O
c	O
)	O
or	O
not	O
(	O
a	O
)	O
for	O
30	O
min	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
.	O

The	O
effect	O
of	O
30	O
min	O
pretreatment	O
of	O
cells	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
c	O
)	O
is	O
also	O
shown	O
.	O

All	O
data	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
ex	B-X
vivo	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
post	B-X
system	B-X
on	B-X
fracture	B-X
resistance	B-X
and	B-X
failure	B-X
mode	B-X
of	B-X
root	B-X
filled	B-X
incisor	B-X
,	B-X
canine	B-X
,	B-X
premolar	B-X
and	B-X
molar	B-X
teeth	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
bond	B-X
strength	B-X
of	B-X
a	B-X
composite	B-X
resin	B-X
to	B-X
glass-fiber	B-X
post	B-X
(	B-X
GFP	B-X
)	B-X
treated	B-X
or	B-X
not	B-X
with	B-X
phosphoric	B-X
acid	B-X
,	B-X
silane	B-X
coupling	B-X
agent	B-X
,	B-X
and	B-X
unfilled	B-X
resin	B-X
.	B-X
The	B-X
specimens	B-X
were	B-X
stored	B-X
in	B-X
distilled	B-X
water	B-X
at	B-X
37	B-X
°C	B-X
for	B-X
24	B-X
h.	B-X
Microtensile	B-X
bond	B-X
test	B-X
was	B-X
performed	B-X
using	B-X
a	B-X
mechanical	B-X
testing	B-X
machine	B-X
until	B-X
failure	B-X
(	B-X
n=10	B-X
)	B-X
.	B-X
The	B-X
data	B-X
were	B-X
analyzed	B-X
using	B-X
two-way	B-X
ANOVA	B-X
followed	B-X
by	B-X
Student-Newman-Keuls	B-X
'	B-X
test	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X

Fluticasone	O
propionate	O
-	O
mediated	O
inhibition	O
of	O
p38	O
MAP	O
kinase	O
phosphorylation	O
and	O
activation	O
is	O
associated	O
with	O
a	O
marked	O
down	O
-	O
regulation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
serine	O
phosphorylation	O
.	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
shows	O
that	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
30	O
min	O
)	O
treatment	O
reduced	O
dual	O
phosphorylation	O
(	O
threonine	O
-	O
180	O
and	O
tyrosine	O
-	O
182	O
)	O
of	O
p38	O
MAPK	O
in	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
co	O
-	O
stimulated	O
HuT	O
-	O
78	O
cells	O
.	O

(	O
B	O
)	O
Time	O
course	O
of	O
the	O
effect	O
of	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
on	O
phosphorylation	O
of	O
activated	B-Protein
transcription	I-Protein
factor	I-Protein
2	I-Protein
(	O
ATF	B-Protein
-	I-Protein
2	I-Protein
)	O
,	O
a	O
measure	O
of	O
p38	O
MAPK	O
activity	O
.	O

(	O
C	O
)	O
FP	O
-	O
induced	O
inhibition	O
of	O
p38	O
MAPK	O
activity	O
is	O
associated	O
with	O
the	O
decrease	O
of	O
anti	O
-	O
CD3	O
/	O
CD28	O
co	O
-	O
stimulation	O
-	O
induced	O
serine	O
phosphorylation	O
(	O
P	O
-	O
Ser	O
)	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
.	O

For	O
(	O
A	O
-	O
C	O
)	O
,	O
quantification	O
of	O
the	O
densitometry	O
data	O
is	O
also	O
shown	O
.	O

Each	O
bar	O
represents	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
control	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
alphaCD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
D	O
)	O
FP	O
induced	O
MKP	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

All	O
results	O
are	O
representative	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
where	O
appropriate	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
E	O
)	O
FP	O
induces	O
MKP	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Results	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O
<EOS>	B-X
It	B-X
turns	B-X
out	B-X
that	B-X
this	B-X
approach	B-X
can	B-X
unmix	B-X
an	B-X
unknown	B-X
number	B-X
of	B-X
independent	B-X
data	B-X
sources	B-X
by	B-X
extracting	B-X
a	B-X
minimal	B-X
number	B-X
of	B-X
low-complexity	B-X
features	B-X
necessary	B-X
for	B-X
representing	B-X
the	B-X
data	B-X
.	B-X
Although	B-X
LOCOCODE	B-X
is	B-X
not	B-X
explicitly	B-X
designed	B-X
to	B-X
enforce	B-X
sparse	B-X
or	B-X
factorial	B-X
codes	B-X
,	B-X
it	B-X
extracts	B-X
optimal	B-X
codes	B-X
for	B-X
difficult	B-X
versions	B-X
of	B-X
the	B-X
``	B-X
bars	B-X
''	B-X
benchmark	B-X
problem	B-X
,	B-X
whereas	B-X
independent	B-X
component	B-X
analysis	B-X
(	B-X
ICA	B-X
)	B-X
and	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
do	B-X
not	B-X
.	B-X
Unlike	B-X
ICA	B-X
,	B-X
it	B-X
does	B-X
not	B-X
need	B-X
to	B-X
know	B-X
the	B-X
number	B-X
of	B-X
independent	B-X
sources	B-X
.	B-X
Our	B-X
results	B-X
reveal	B-X
an	B-X
interesting	B-X
,	B-X
previously	B-X
ignored	B-X
connection	B-X
between	B-X
two	B-X
important	B-X
fields	B-X
:	B-X
regularizer	B-X
research	B-X
and	B-X
ICA-related	B-X
research	B-X
.	B-X

All	O
data	O
except	O
(	O
E	O
)	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
competes	O
with	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
for	O
importin	O
-	O
alpha	O
.	O

(	O
A	O
)	O
schematic	O
representation	O
of	O
the	O
in	O
vitro	O
binding	O
competition	O
assay	O
.	O

(	O
B	O
)	O
GR	B-Protein
isolated	O
from	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
stimulated	O
cells	O
enhances	O
GR	B-Protein
-	O
importin	O
-	O
alpha	O
binding	O
in	O
the	O
presence	O
(	O
*	O
)	O
and	O
absence	O
(	O
=	O
=	O
blacksquare	O
,	O
square	O
,	O
filled	O
=	O
=	O
)	O
of	O
activated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
no	O
activated	O
GR	B-Protein
.	O

(	O
C	O
)	O
GATA	B-Protein
-	I-Protein
3	I-Protein
isolated	O
from	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
does	O
not	O
attenuate	O
GR	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
control	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

(	O
D	O
)	O
Activated	O
GR	B-Protein
blocks	O
the	O
ability	O
of	O
purified	O
phospho	O
-	O
GATA	B-Protein
-	I-Protein
3	I-Protein
isolated	O
from	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
interacting	O
with	O
immobilised	O
importin	O
-	O
alpha	O
in	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
GATA	B-Protein
-	I-Protein
3	I-Protein
isolated	O
from	O
unstimulated	O
cells	O
.	O

#	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
stimulated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
binding	O
.	O

(	O
E	O
)	O
The	O
effect	O
of	O
activated	O
(	O
*	O
)	O
versus	O
unstimulated	O
(	O
o	O
)	O
GR	B-Protein
on	O
attenuation	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
-	O
importin	O
-	O
alpha	O
association	O
was	O
concentration	O
-	O
dependent	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
between	O
groups	O
.	O
<EOS>	B-X
Cerebral	B-X
venous	B-X
sinus	B-X
thrombosis	B-X
(	B-X
CVST	B-X
)	B-X
as	B-X
a	B-X
part	B-X
of	B-X
the	B-X
thrombosis	B-X
and	B-X
thrombocytopenia	B-X
syndrome	B-X
is	B-X
a	B-X
rare	B-X
adverse	B-X
drug	B-X
reaction	B-X
of	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
disease	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
vaccination	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
age-stratified	B-X
risk	B-X
of	B-X
CVST	B-X
with	B-X
and	B-X
without	B-X
thrombocytopenia	B-X
after	B-X
SARS-CoV-2	B-X
vaccination	B-X
.	B-X
The	B-X
immunogenicity	B-X
of	B-X
two-dose	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
vaccine	B-X
is	B-X
lower	B-X
among	B-X
heart	B-X
transplant	B-X
(	B-X
HTx	B-X
)	B-X
recipients	B-X
,	B-X
compared	B-X
with	B-X
the	B-X
general	B-X
population	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
immunogenicity	B-X
of	B-X
a	B-X
third-dose	B-X
vaccine	B-X
in	B-X
HTx	B-X
recipients	B-X
.	B-X

All	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
three	O
independent	O
experiments	O
and	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Fluticasone	O
propionate	O
does	O
not	O
affect	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
export	O
.	O
<EOS>	B-X
The	B-X
anti-inflammatory	B-X
drug	B-X
fluticasone	B-X
propionate	B-X
has	B-X
recently	B-X
emerged	B-X
as	B-X
a	B-X
potential	B-X
outpatient	B-X
treatment	B-X
option	B-X
,	B-X
especially	B-X
for	B-X
those	B-X
with	B-X
newly	B-X
diagnosed	B-X
disease	B-X
.	B-X
The	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
fluticasone	B-X
propionate/formoterol	B-X
fumarate	B-X
pressurized	B-X
metered-dose	B-X
inhaler	B-X
(	B-X
pMDI	B-X
)	B-X
(	B-X
fluticasone/formoterol	B-X
;	B-X
Flutiform	B-X
This	B-X
article	B-X
reviews	B-X
efficacy	B-X
versus	B-X
systemic	B-X
activity	B-X
profiles	B-X
for	B-X
various	B-X
dosing	B-X
regimens	B-X
of	B-X
budesonide	B-X
(	B-X
BUD	B-X
)	B-X
and	B-X
fluticasone	B-X
propionate	B-X
(	B-X
FP	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
explored	B-X
how	B-X
adherence	B-X
could	B-X
potentially	B-X
affect	B-X
the	B-X
risk-benefit	B-X
profile	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
mild	B-X
,	B-X
moderate	B-X
,	B-X
and	B-X
moderate-to-severe	B-X
asthma	B-X
.	B-X

(	O
A	O
)	O
Western	O
blot	O
analysis	O
showing	O
that	O
the	O
nuclear	O
export	O
inhibitor	O
leptomycin	O
B	O
(	O
2	O
nM	O
)	O
does	O
not	O
affect	O
the	O
ability	O
of	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
to	O
prevent	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localization	O
measured	O
at	O
60	O
min	O
.	O

*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
unstimulated	O
cells	O
,	O
#	O
#	O
#	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
cells	O
.	O

(	O
B	O
)	O
Western	O
blot	O
analysis	O
showing	O
that	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
does	O
not	O
affect	O
whole	O
-	O
cell	O
GATA	B-Protein
-	I-Protein
3	I-Protein
degradation	O
over	O
17	O
h	O
.	O

(	O
C	O
)	O
GFP	O
-	O
tagged	O
GATA	B-Protein
-	I-Protein
3	I-Protein
is	O
overexpressed	O
and	O
cells	O
stimulated	O
(	O
b	O
-	O
j	O
)	O
or	O
not	O
(	O
a	O
)	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
.	O

The	O
effect	O
of	O
treating	O
cells	O
with	O
FP	O
(	O
10	O
-	O
8	O
M	O
,	O
f	O
-	O
j	O
)	O
after	O
30	O
min	O
stimulation	O
with	O
anti	O
-	O
CD3	O
/	O
CD28	O
is	O
also	O
shown	O
.	O

(	O
D	O
)	O
FP	O
(	O
10	O
-	O
8	O
M	O
)	O
does	O
not	O
prevent	O
anti	O
-	O
CD3	O
/	O
CD28	O
-	O
stimulated	O
p65	B-Protein
nuclear	O
translocation	O
at	O
60	O
min	O
after	O
stimulation	O
.	O

*	O
*	O
p	O
<	O
0	O
.	O
01	O
compared	O
to	O
unstimulated	O
cells	O
.	O

All	O
results	O
are	O
representative	O
of	O
at	O
least	O
four	O
independent	O
experiments	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Results	O
were	O
analysed	O
by	O
ANOVA	O
followed	O
by	O
Newman	O
-	O
Keuls	O
test	O
.	O
<EOS>	B-X
Shear	B-X
bond	B-X
strength	B-X
tests	B-X
were	B-X
performed	B-X
after	B-X
adhesive	B-X
cementation	B-X
in	B-X
20	B-X
specimens	B-X
per	B-X
group	B-X
,	B-X
with	B-X
half	B-X
(	B-X
n	B-X
=	B-X
10	B-X
)	B-X
subjected	B-X
to	B-X
thermocycling	B-X
(	B-X
5,000	B-X
cycles	B-X
,	B-X
5°C	B-X
to	B-X
55°C	B-X
)	B-X
.	B-X
One-way	B-X
and	B-X
two-way	B-X
ANOVA	B-X
followed	B-X
by	B-X
Student-Newman-Keuls	B-X
test	B-X
(	B-X
α	B-X
=	B-X
.05	B-X
)	B-X
were	B-X
used	B-X
to	B-X
analyze	B-X
the	B-X
data	B-X
statistically	B-X
.	B-X
Statistical	B-X
analyses	B-X
were	B-X
performed	B-X
by	B-X
one-way	B-X
ANOVA	B-X
followed	B-X
by	B-X
the	B-X
Student-Newman-Keuls	B-X
post	B-X
hoc	B-X
test	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
intraplantar	B-X
(	B-X
i.pl	B-X
.	B-X
)	B-X
administration	B-X
of	B-X
four	B-X
additional	B-X
adenosine	B-X
receptor	B-X
drugs-8-cyclopentyl-1,3-dipropylxanthine	B-X
(	B-X
DPCPX	B-X
,	B-X
an	B-X
A1	B-X
antagonist	B-X
,	B-X
1-10	B-X
μg/paw	B-X
)	B-X
,	B-X
N	B-X
(	B-X
6	B-X
)	B-X
-	B-X
[	B-X
2-	B-X
(	B-X
3,5-dimethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
2-methylphenyl	B-X
)	B-X
-ethyl	B-X
]	B-X
adenosine	B-X
(	B-X
DPMA	B-X
,	B-X
an	B-X
A2B	B-X
agonist	B-X
,	B-X
1-100	B-X
μg/paw	B-X
)	B-X
,	B-X
alloxazine	B-X
(	B-X
an	B-X
A2B	B-X
antagonist	B-X
,	B-X
0.1-3	B-X
μg/paw	B-X
)	B-X
,	B-X
and	B-X
2-hexyn-1-yl-N	B-X
(	B-X
6	B-X
)	B-X
-methyladenosine	B-X
(	B-X
HEMADO	B-X
)	B-X
(	B-X
an	B-X
A3	B-X
agonist	B-X
,	B-X
1-100	B-X
μg/paw	B-X
)	B-X
(	B-X
p	B-X
>	B-X
0.05	B-X
vs.	B-X
vehicle	B-X
for	B-X
all	B-X
tests	B-X
)	B-X
.	B-X

Fluticasone	O
propionate	O
impairs	O
GATA	B-Protein
-	I-Protein
3	I-Protein
interaction	O
with	O
importin	O
-	O
alpha	O
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localization	O
in	O
vivo	O
and	O
ex	O
vivo	O
.	O

(	O
A	O
and	O
B	O
)	O
Co	O
-	O
immunoprecipitation	O
analysis	O
of	O
PBMCs	O
from	O
steroid	O
-	O
naive	O
asthma	O
patients	O
treated	O
with	O
FP	O
in	O
vitro	O
demonstrated	O
impaired	O
interaction	O
between	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
importin	O
-	O
alpha	O
measured	O
at	O
60	O
min	O
.	O

Each	O
bar	O
represents	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
control	O
as	O
determined	O
by	O
ANOVA	O
/	O
Newman	O
-	O
Keuls	O
analysis	O
.	O

(	O
C	O
and	O
D	O
)	O
Co	O
-	O
immunoprecipitation	O
analyses	O
of	O
PBMCs	O
from	O
steroid	O
-	O
naive	O
asthma	O
patients	O
treated	O
with	O
inhaled	O
FP	O
(	O
500	O
microg	O
via	O
a	O
spacer	O
)	O
in	O
vivo	O
demonstrated	O
decreased	O
association	O
between	O
GATA	B-Protein
-	I-Protein
3	I-Protein
and	O
importin	O
-	O
alpha	O
.	O

The	O
individual	O
values	O
for	O
each	O
treatment	O
are	O
presented	O
graphically	O
.	O
<EOS>	B-X
It	B-X
also	B-X
describes	B-X
a	B-X
new	B-X
way	B-X
of	B-X
illustrating	B-X
the	B-X
caries	B-X
risk	B-X
profile	B-X
of	B-X
an	B-X
individual	B-X
,	B-X
the	B-X
Cariogram	B-X
.	B-X
Taken	B-X
separately	B-X
,	B-X
these	B-X
biological	B-X
factors	B-X
often	B-X
have	B-X
limited	B-X
predictive	B-X
values	B-X
.	B-X
Socioeconomic	B-X
factors	B-X
often	B-X
have	B-X
a	B-X
heavy	B-X
impact	B-X
on	B-X
the	B-X
biological	B-X
factors	B-X
as	B-X
they	B-X
can	B-X
explain	B-X
why	B-X
an	B-X
individual	B-X
,	B-X
for	B-X
example	B-X
,	B-X
has	B-X
a	B-X
cariogenic	B-X
diet	B-X
or	B-X
neglects	B-X
oral	B-X
hygiene	B-X
.	B-X
The	B-X
Cariogram	B-X
identifies	B-X
the	B-X
caries	B-X
risk	B-X
factors	B-X
for	B-X
the	B-X
individual	B-X
and	B-X
provides	B-X
examples	B-X
of	B-X
preventive	B-X
and	B-X
treatment	B-X
strategies	B-X
to	B-X
the	B-X
clinician	B-X
.	B-X

(	O
E	O
)	O
Representative	O
Western	O
blot	O
showing	O
that	O
importin	O
-	O
alpha	O
expression	O
was	O
unaffected	O
by	O
inhalation	O
of	O
FP	O
.	O

Blot	O
is	O
representative	O
of	O
gels	O
from	O
three	O
participants	O
.	O

Inhaled	O
fluticasone	O
propionate	O
impairs	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localization	O
in	O
PBMCs	O
.	O

(	O
A	O
)	O
Representative	O
immunocytochemistry	O
of	O
showing	O
the	O
effect	O
of	O
inhaled	O
FP	O
(	O
500	O
microg	O
)	O
on	O
GR	B-Protein
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
nuclear	O
localisation	O
.	O

(	O
B	O
)	O
Nuclear	O
GATA	B-Protein
-	I-Protein
3	I-Protein
immunoreactivity	O
in	O
PBMCs	O
from	O
seven	O
steroid	O
-	O
naive	O
asthma	O
patients	O
2	O
h	O
following	O
inhaled	O
FP	O
treatment	O
(	O
100	O
or	O
500	O
microg	O
via	O
spacer	O
)	O
.	O

The	O
median	O
and	O
interquartile	O
ranges	O
for	O
each	O
treatment	O
are	O
presented	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
(	O
n	O
=	O
7	O
)	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
Wilcoxon	O
'	O
s	O
rank	O
test	O
compared	O
with	O
placebo	O
.	O

(	O
C	O
)	O
Immunoblotting	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
nuclear	O
expression	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
and	O
increased	O
cytoplasmic	O
GATA	B-Protein
-	I-Protein
3	I-Protein
expression	O
after	O
inhalation	O
of	O
FP	O
.	O

(	O
D	O
)	O
Immunoblotting	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
nuclear	O
expression	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
,	O
and	O
increased	O
cytoplasmic	O
GATA	B-Protein
-	I-Protein
3	I-Protein
expression	O
2	O
h	O
after	O
inhalation	O
of	O
FP	O
.	O

Histone	O
H1	O
and	O
MEK	B-Protein
-	I-Protein
1	I-Protein
immunoblotting	O
confirmed	O
equivalent	O
total	O
protein	O
loading	O
for	O
the	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
respectively	O
.	O

Quantification	O
of	O
the	O
densitometry	O
data	O
in	O
(	O
C	O
)	O
and	O
(	O
D	O
)	O
is	O
shown	O
as	O
a	O
box	O
-	O
and	O
-	O
whiskers	O
plot	O
of	O
results	O
from	O
n	O
=	O
6	O
participants	O
for	O
which	O
data	O
were	O
available	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
compared	O
to	O
control	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

(	O
E	O
)	O
Western	O
blot	O
analyses	O
of	O
PBMCs	O
demonstrated	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
dual	O
phosphorylation	O
(	O
threonine	O
-	O
180	O
and	O
tyrosine	O
-	O
182	O
)	O
of	O
p38	O
MAPK	O
after	O
inhalation	O
of	O
FP	O
(	O
500	O
microg	O
)	O
.	O

The	O
results	O
shown	O
in	O
(	O
E	O
)	O
are	O
representative	O
of	O
samples	O
from	O
two	O
participants	O
.	O

Degraded	O
Carrageenan	O
Causing	O
Colitis	O
in	O
Rats	O
Induces	O
TNF	B-Protein
Secretion	O
and	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
Upregulation	O
in	O
Monocytes	O
through	O
NF	O
-	O
kappaB	O
Activation	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
All	B-X
these	B-X
effects	B-X
were	B-X
linked	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
.	B-X

Carrageenan	O
(	O
CGN	O
)	O
is	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
derived	O
from	O
red	O
seaweeds	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

In	O
rodents	O
,	O
its	O
degraded	O
forms	O
(	O
dCGN	O
)	O
can	O
induce	O
intestinal	O
inflammation	O
associated	O
with	O
macrophage	O
recruitment	O
and	O
activation	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
All	B-X
these	B-X
effects	B-X
were	B-X
linked	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
:	O
1	O
)	O
to	O
analyze	O
the	O
size	O
-	O
dependent	O
effects	O
of	O
dCGN	O
on	O
colon	O
inflammation	O
in	O
vivo	O
,	O
and	O
2	O
)	O
to	O
correlate	O
these	O
effects	O
with	O
monocyte	O
/	O
macrophage	O
proliferation	O
,	O
cytokine	O
production	O
and	O
expression	O
of	O
various	O
cell	O
surface	O
antigens	O
including	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
adhesion	B-Protein
molecule	I-Protein
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
All	B-X
these	B-X
effects	B-X
were	B-X
linked	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
either	O
10	O
or	O
40	O
kDa	O
,	O
dCGN	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

The	O
40	O
kDa	O
,	O
but	O
not	O
the	O
10	O
kDa	O
dCGN	O
,	O
induced	O
colitis	O
in	O
in	O
vivo	O
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
this	B-X
reassembly	B-X
procedure	B-X
to	B-X
test	B-X
the	B-X
function	B-X
of	B-X
the	B-X
40-kDa	B-X
subunit	B-X
of	B-X
the	B-X
coated	B-X
vesicle	B-X
(	B-X
H+	B-X
)	B-X
-ATPase	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
V0	B-X
,	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
peripheral	B-X
subunits	B-X
reassemble	B-X
into	B-X
a	B-X
V1	B-X
subcomplex	B-X
which	B-X
contains	B-X
the	B-X
73-kDa	B-X
A	B-X
subunit	B-X
,	B-X
the	B-X
58-kDa	B-X
B	B-X
subunit	B-X
,	B-X
and	B-X
the	B-X
34-	B-X
and	B-X
33-kDa	B-X
subunits	B-X
but	B-X
lacks	B-X
the	B-X
40-kDa	B-X
subunit	B-X
.	B-X
This	B-X
subcomplex	B-X
,	B-X
which	B-X
sediments	B-X
with	B-X
a	B-X
mass	B-X
of	B-X
approximately	B-X
500	B-X
kDa	B-X
,	B-X
can	B-X
be	B-X
separated	B-X
from	B-X
the	B-X
remaining	B-X
monomeric	B-X
subunits	B-X
(	B-X
and	B-X
the	B-X
40-kDa	B-X
subunit	B-X
)	B-X
by	B-X
density	B-X
gradient	B-X
sedimentation	B-X
.	B-X
When	B-X
dissociated	B-X
with	B-X
0.36	B-X
M	B-X
KI	B-X
,	B-X
2.5	B-X
mM	B-X
ATP	B-X
,	B-X
and	B-X
2.5	B-X
mM	B-X
MgSO4	B-X
,	B-X
and	B-X
added	B-X
to	B-X
membranes	B-X
from	B-X
which	B-X
V1	B-X
has	B-X
been	B-X
dissociated	B-X
,	B-X
this	B-X
V1	B-X
(	B-X
-40	B-X
kDa	B-X
)	B-X
subcomplex	B-X
is	B-X
able	B-X
to	B-X
reassemble	B-X
with	B-X
V0	B-X
to	B-X
give	B-X
a	B-X
(	B-X
H+	B-X
)	B-X
-ATPase	B-X
with	B-X
a	B-X
proton	B-X
pumping	B-X
activity	B-X
approximately	B-X
half	B-X
that	B-X
obtained	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
40-kDa	B-X
subunit	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
monomeric	B-X
fraction	B-X
obtained	B-X
from	B-X
density	B-X
gradient	B-X
sedimentation	B-X
contains	B-X
the	B-X
40-kDa	B-X
subunit	B-X
but	B-X
lacks	B-X
the	B-X
34-kDa	B-X
subunit	B-X
.	B-X
The	B-X
V1V0	B-X
complexes	B-X
assembled	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
either	B-X
the	B-X
40-	B-X
or	B-X
34-kDa	B-X
subunits	B-X
,	B-X
while	B-X
active	B-X
,	B-X
are	B-X
not	B-X
stable	B-X
to	B-X
detergent	B-X
solubilization	B-X
and	B-X
immunoprecipitation	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
of	B-X
these	B-X
subunits	B-X
play	B-X
a	B-X
role	B-X
in	B-X
stabilization	B-X
of	B-X
the	B-X
(	B-X
H+	B-X
)	B-X
-ATPase	B-X
complex	B-X
.	B-X
Evidence	B-X
for	B-X
interaction	B-X
between	B-X
the	B-X
40-	B-X
and	B-X
33-kDa	B-X
subunits	B-X
is	B-X
also	B-X
presented	B-X
.	B-X

Degraded	O
CGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
arresting	O
the	O
cells	O
in	O
G1	O
phase	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

In	O
addition	O
,	O
dCGN	O
increased	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
with	O
a	O
major	O
effect	O
seen	O
after	O
40	O
kDa	O
dCGN	O
exposure	O
.	O

Also	O
,	O
dCGN	O
stimulated	O
monocyte	O
aggregation	O
in	O
vitro	O
that	O
was	O
prevented	O
by	O
incubation	O
with	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Finally	O
,	O
dCGN	O
stimulated	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
and	O
secretion	O
by	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X

All	O
these	O
effects	O
were	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
,	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
inflammation	B-X
and	B-X
cell	B-X
death	B-X
,	B-X
in	B-X
the	B-X
development	B-X
of	B-X
hepatocellular	B-X
injury	B-X
,	B-X
liver	B-X
fibrosis	B-X
and	B-X
HCC	B-X
,	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
of	B-X
NF-κB	B-X
in	B-X
different	B-X
cellular	B-X
compartments	B-X
of	B-X
the	B-X
liver	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
NF-κB	B-X
acts	B-X
as	B-X
a	B-X
central	B-X
link	B-X
between	B-X
hepatic	B-X
injury	B-X
,	B-X
fibrosis	B-X
and	B-X
HCC	B-X
,	B-X
and	B-X
that	B-X
it	B-X
may	B-X
represent	B-X
a	B-X
target	B-X
for	B-X
the	B-X
prevention	B-X
or	B-X
treatment	B-X
of	B-X
liver	B-X
fibrosis	B-X
and	B-X
HCC	B-X
.	B-X
However	B-X
,	B-X
NF-κB	B-X
acts	B-X
as	B-X
a	B-X
two-edged	B-X
sword	B-X
and	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
may	B-X
not	B-X
only	B-X
exert	B-X
beneficial	B-X
effects	B-X
but	B-X
also	B-X
negatively	B-X
impact	B-X
hepatocyte	B-X
viability	B-X
,	B-X
especially	B-X
when	B-X
NF-κB	B-X
inhibition	B-X
is	B-X
pronounced	B-X
.	B-X
Finding	B-X
appropriate	B-X
targets	B-X
or	B-X
identifying	B-X
drugs	B-X
that	B-X
either	B-X
exert	B-X
only	B-X
a	B-X
moderate	B-X
effect	B-X
on	B-X
NF-κB	B-X
activity	B-X
or	B-X
that	B-X
can	B-X
be	B-X
specifically	B-X
delivered	B-X
to	B-X
nonparenchymal	B-X
cells	B-X
will	B-X
be	B-X
essential	B-X
to	B-X
avoid	B-X
the	B-X
increase	B-X
in	B-X
liver	B-X
injury	B-X
associated	B-X
with	B-X
complete	B-X
NF-κB	B-X
blockade	B-X
in	B-X
hepatocytes	B-X
.	B-X

These	O
data	O
strongly	O
suggest	O
that	O
the	O
degraded	O
forms	O
of	O
CGN	O
have	O
a	O
pronounced	O
effect	O
on	O
monocytes	O
,	O
characteristic	O
of	O
an	O
inflammatory	O
phenotype	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
All	B-X
these	B-X
effects	B-X
were	B-X
linked	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Carrageenan	O
(	O
CGN	O
)	O
is	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
(	O
>	O
200	O
kDa	O
)	O
derived	O
from	O
red	O
algae	O
(	O
Rhodophyceae	O
)	O
.	O

Three	O
main	O
forms	O
of	O
CGN	O
have	O
been	O
identified	O
:	O
kappa	O
,	O
iota	O
,	O
and	O
lambda	O
.	O

They	O
differ	O
from	O
each	O
other	O
in	O
sulphation	O
degree	O
and	O
solubility	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O
<EOS>	B-X
The	B-X
two-compartment	B-X
arrangement	B-X
enlarged	B-X
the	B-X
role	B-X
of	B-X
epidermal	B-X
lipids	B-X
from	B-X
that	B-X
of	B-X
the	B-X
plasticizing	B-X
component	B-X
of	B-X
the	B-X
SC	B-X
to	B-X
that	B-X
of	B-X
the	B-X
epidermal	B-X
barrier	B-X
governing	B-X
water-holding	B-X
properties	B-X
as	B-X
well	B-X
as	B-X
take-up	B-X
of	B-X
water	B-X
,	B-X
the	B-X
differences	B-X
in	B-X
permeability	B-X
of	B-X
topically	B-X
applied	B-X
lipophilic	B-X
and	B-X
hydrophilic	B-X
agents	B-X
as	B-X
well	B-X
as	B-X
cohesion	B-X
and	B-X
desquamation	B-X
of	B-X
the	B-X
SC	B-X
.	B-X
Mammalian	B-X
differentiation	B-X
involves	B-X
characteristic	B-X
changes	B-X
in	B-X
lipid	B-X
composition	B-X
consistent	B-X
with	B-X
the	B-X
requirements	B-X
for	B-X
waterproofing	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
solid	B-X
crystal	B-X
and	B-X
liquid	B-X
crystalline	B-X
phases	B-X
in	B-X
epidermal	B-X
lipids	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
degree	B-X
of	B-X
fatty	B-X
acid	B-X
unsaturation	B-X
and	B-X
the	B-X
amount	B-X
of	B-X
water	B-X
.	B-X
We	B-X
purified	B-X
the	B-X
acetylcholinesterase	B-X
20-fold	B-X
by	B-X
differential	B-X
centrifugation	B-X
and	B-X
filtration	B-X
through	B-X
a	B-X
column	B-X
of	B-X
4	B-X
%	B-X
agarose	B-X
.	B-X
The	B-X
complex	B-X
was	B-X
unstable	B-X
below	B-X
pH	B-X
5	B-X
or	B-X
during	B-X
storage	B-X
at	B-X
7	B-X
degrees	B-X
.	B-X
Although	B-X
similar	B-X
in	B-X
specificity	B-X
,	B-X
the	B-X
cholinesterase	B-X
of	B-X
the	B-X
blood	B-X
differed	B-X
from	B-X
the	B-X
enzyme	B-X
in	B-X
Aplysia	B-X
nervous	B-X
tissue	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
membrane	B-X
.	B-X
When	B-X
negatively	B-X
stained	B-X
,	B-X
the	B-X
unit	B-X
particle	B-X
appeared	B-X
to	B-X
be	B-X
a	B-X
disc	B-X
with	B-X
a	B-X
diameter	B-X
of	B-X
280	B-X
A	B-X
and	B-X
a	B-X
width	B-X
of	B-X
45	B-X
A	B-X
.	B-X
The	B-X
purified	B-X
hemocyanin	B-X
was	B-X
found	B-X
to	B-X
contain	B-X
0.26	B-X
%	B-X
copper	B-X
(	B-X
dry	B-X
weight	B-X
)	B-X
.	B-X
Using	B-X
differential	B-X
centrifugation	B-X
and	B-X
gel	B-X
filtration	B-X
we	B-X
also	B-X
obtained	B-X
a	B-X
9-fold	B-X
purification	B-X
of	B-X
Aplysia	B-X
hemagglutinin	B-X
.	B-X
This	B-X
particle	B-X
was	B-X
120	B-X
A	B-X
in	B-X
diameter	B-X
with	B-X
a	B-X
dark	B-X
staining	B-X
central	B-X
core	B-X
of	B-X
40	B-X
A	B-X
consisting	B-X
of	B-X
6	B-X
subunits	B-X
.	B-X
The	B-X
particle	B-X
tentatively	B-X
identified	B-X
as	B-X
erythrocurorin	B-X
appeared	B-X
as	B-X
a	B-X
structure	B-X
200	B-X
A	B-X
in	B-X
diameter	B-X
consisting	B-X
of	B-X
5	B-X
V-shaped	B-X
subunits	B-X
.	B-X

Native	O
CGN	O
is	O
thought	O
to	O
be	O
harmless	O
and	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
to	O
improve	O
texture	O
.	O

It	O
is	O
also	O
used	O
in	O
cosmetics	O
and	O
pharmaceuticals	O
.	O
<EOS>	B-X
The	B-X
classification	B-X
as	B-X
bio-inert	B-X
material	B-X
has	B-X
given	B-X
the	B-X
possibility	B-X
to	B-X
normal-sized	B-X
(	B-X
>	B-X
100	B-X
nm	B-X
)	B-X
titanium	B-X
dioxide	B-X
particles	B-X
(	B-X
TiO2-NPs	B-X
)	B-X
to	B-X
be	B-X
extensively	B-X
used	B-X
in	B-X
food	B-X
products	B-X
and	B-X
as	B-X
ingredients	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
pharmaceutical	B-X
products	B-X
and	B-X
cosmetics	B-X
,	B-X
such	B-X
as	B-X
sunscreens	B-X
and	B-X
toothpastes	B-X
.	B-X
Cosmetics	B-X
,	B-X
cosmeceuticals	B-X
,	B-X
and	B-X
variable	B-X
healthcare	B-X
products	B-X
used	B-X
parabens	B-X
,	B-X
among	B-X
other	B-X
excipients	B-X
,	B-X
for	B-X
their	B-X
preservative	B-X
and	B-X
antimicrobial	B-X
activities	B-X
.	B-X
In	B-X
response	B-X
,	B-X
worldwide	B-X
authorities	B-X
set	B-X
regulations	B-X
for	B-X
the	B-X
allowance	B-X
concentrations	B-X
of	B-X
paraben	B-X
to	B-X
be	B-X
used	B-X
in	B-X
variable	B-X
cosmetic	B-X
products	B-X
.	B-X
The	B-X
recent	B-X
increase	B-X
in	B-X
the	B-X
consumption	B-X
of	B-X
modern	B-X
human	B-X
or	B-X
veterinary	B-X
drugs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
surge	B-X
of	B-X
anthropogenic	B-X
pharmaceuticals	B-X
,	B-X
frequently	B-X
introduced	B-X
into	B-X
terrestrial	B-X
environments	B-X
via	B-X
untreated/treated	B-X
wastewater	B-X
.	B-X
Details	B-X
about	B-X
adsorption	B-X
,	B-X
absorption	B-X
,	B-X
degradation	B-X
and	B-X
uptake	B-X
behaviours	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
fate	B-X
and	B-X
actual	B-X
environmental	B-X
impact	B-X
of	B-X
pharmaceuticals	B-X
are	B-X
a	B-X
prerequisite	B-X
before	B-X
the	B-X
traditional	B-X
transportation	B-X
prediction	B-X
models	B-X
originally	B-X
designed	B-X
for	B-X
the	B-X
aquatic	B-X
environment	B-X
can	B-X
be	B-X
extrapolated	B-X
to	B-X
terrestrial	B-X
systems	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
current	B-X
knowledgebase	B-X
pertaining	B-X
the	B-X
introduction	B-X
of	B-X
pharmaceuticals	B-X
to	B-X
soils	B-X
via	B-X
wastewater	B-X
irrigation	B-X
or	B-X
the	B-X
application	B-X
of	B-X
biosolids	B-X
.	B-X
The	B-X
focus	B-X
on	B-X
the	B-X
transportation	B-X
,	B-X
transformation	B-X
and	B-X
accumulation	B-X
of	B-X
pharmaceuticals	B-X
through	B-X
the	B-X
food	B-X
chain	B-X
highlights	B-X
the	B-X
urgent	B-X
need	B-X
to	B-X
strengthen	B-X
our	B-X
capabilities	B-X
concerning	B-X
their	B-X
detection	B-X
and	B-X
characterization	B-X
in	B-X
the	B-X
terrestrial	B-X
ecosystem	B-X
.	B-X

However	O
,	O
acid	O
treatment	O
at	O
high	O
temperature	O
(	O
80degreesC	O
)	O
triggers	O
CGN	O
hydrolysis	O
to	O
lower	O
molecular	O
weight	O
(	O
<	O
50	O
kDa	O
)	O
compounds	O
known	O
as	O
poligeenan	O
or	O
degraded	O
CGN	O
(	O
dCGN	O
)	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
common	B-X
food	B-X
additive	B-X
that	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
for	B-X
decades	B-X
as	B-X
a	B-X
gelling	B-X
,	B-X
thickening	B-X
and	B-X
stabilizing	B-X
agent	B-X
.	B-X
Carrageenan	B-X
has	B-X
been	B-X
proven	B-X
safe	B-X
for	B-X
human	B-X
consumption	B-X
;	B-X
however	B-X
,	B-X
there	B-X
has	B-X
been	B-X
significant	B-X
confusion	B-X
in	B-X
the	B-X
literature	B-X
between	B-X
CGN	B-X
and	B-X
the	B-X
products	B-X
of	B-X
intentional	B-X
acid-hydrolysis	B-X
of	B-X
CGN	B-X
,	B-X
which	B-X
are	B-X
degraded	B-X
CGN	B-X
(	B-X
d-CGN	B-X
)	B-X
and	B-X
poligeenan	B-X
(	B-X
PGN	B-X
)	B-X
.	B-X
In	B-X
part	B-X
,	B-X
this	B-X
confusion	B-X
was	B-X
due	B-X
to	B-X
the	B-X
nomenclature	B-X
used	B-X
in	B-X
early	B-X
studies	B-X
on	B-X
CGN	B-X
,	B-X
where	B-X
poligeenan	B-X
was	B-X
referred	B-X
to	B-X
as	B-X
``	B-X
degraded	B-X
carrageenan	B-X
''	B-X
(	B-X
d-CGN	B-X
)	B-X
and	B-X
``	B-X
degraded	B-X
carrageenan	B-X
''	B-X
was	B-X
simply	B-X
referred	B-X
to	B-X
as	B-X
carrageenan	B-X
.	B-X
Although	B-X
this	B-X
nomenclature	B-X
has	B-X
been	B-X
corrected	B-X
,	B-X
confusion	B-X
still	B-X
exists	B-X
resulting	B-X
in	B-X
misinterpretation	B-X
of	B-X
data	B-X
and	B-X
the	B-X
subsequent	B-X
dissemination	B-X
of	B-X
incorrect	B-X
information	B-X
regarding	B-X
the	B-X
safe	B-X
dietary	B-X
use	B-X
of	B-X
CGN	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
weight	B-X
distribution	B-X
of	B-X
CGN	B-X
has	B-X
further	B-X
exacerbated	B-X
the	B-X
issue	B-X
.	B-X
The	B-X
significant	B-X
differences	B-X
in	B-X
chemistry	B-X
,	B-X
manufacture	B-X
,	B-X
and	B-X
protein	B-X
reactivity	B-X
of	B-X
CGN	B-X
versus	B-X
d-CGN	B-X
and	B-X
PGN	B-X
are	B-X
reviewed	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
the	B-X

These	O
dCGNs	O
induce	O
inflammation	O
and	O
have	O
been	O
widely	O
used	O
as	O
models	O
of	O
colitis	O
in	O
several	O
species	O
,	O
including	O
rats	O
[	O
3	O
]	O
,	O
rabbits	O
[	O
4	O
]	O
and	O
guinea	O
pigs	O
[	O
5	O
]	O
.	O

The	O
role	O
of	O
dCGN	O
as	O
a	O
tumor	O
-	O
promoting	O
factor	O
remains	O
controversial	O
[	O
4	O
]	O
,	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
.	O

Although	O
the	O
native	O
form	O
is	O
thought	O
to	O
be	O
harmless	O
for	O
human	O
consumption	O
,	O
small	O
amounts	O
of	O
dCGN	O
are	O
probably	O
produced	O
by	O
acid	O
hydrolysis	O
during	O
gastric	O
digestion	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
or	O
interaction	O
with	O
intestinal	O
bacteria	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O
<EOS>	B-X
COVID-19	B-X
is	B-X
an	B-X
infectious	B-X
disease	B-X
caused	B-X
by	B-X
the	B-X
Severe	B-X
Acute	B-X
Respiratory	B-X
Syndrome	B-X
Coronavirus-2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
and	B-X
according	B-X
to	B-X
the	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
,	B-X
to	B-X
date	B-X
,	B-X
SARS-CoV-2	B-X
has	B-X
already	B-X
infected	B-X
more	B-X
than	B-X
91.8	B-X
million	B-X
people	B-X
worldwide	B-X
with	B-X
1,986,871	B-X
deaths	B-X
.	B-X
This	B-X
virus	B-X
affects	B-X
mainly	B-X
the	B-X
respiratory	B-X
system	B-X
,	B-X
but	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
(	B-X
GIT	B-X
)	B-X
is	B-X
also	B-X
a	B-X
target	B-X
,	B-X
meanwhile	B-X
SARS-CoV-2	B-X
was	B-X
already	B-X
detected	B-X
in	B-X
oesophagus	B-X
,	B-X
stomach	B-X
,	B-X
duodenum	B-X
,	B-X
rectum	B-X
,	B-X
and	B-X
in	B-X
fecal	B-X
samples	B-X
from	B-X
COVID-19	B-X
patients	B-X
.	B-X
Prolonged	B-X
GIT	B-X
manifestations	B-X
in	B-X
COVID-19	B-X
,	B-X
mainly	B-X
the	B-X
diarrhea	B-X
,	B-X
were	B-X
correlated	B-X
with	B-X
decreased	B-X
richness	B-X
and	B-X
diversity	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
,	B-X
immune	B-X
deregulation	B-X
and	B-X
delayed	B-X
SARS-CoV-2	B-X
clearance	B-X
.	B-X
So	B-X
,	B-X
the	B-X
bidirectional	B-X
interactions	B-X
between	B-X
the	B-X
respiratory	B-X
mucosa	B-X
and	B-X
the	B-X
gut	B-X
microbiota	B-X
,	B-X
known	B-X
as	B-X
gut-lung	B-X
axis	B-X
,	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
healthy	B-X
or	B-X
pathologic	B-X
immune	B-X
responses	B-X
to	B-X
SARS-CoV-2	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
the	B-X
intestinal	B-X
dysbiosis	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
mortality	B-X
in	B-X
other	B-X
respiratory	B-X
infections	B-X
,	B-X
due	B-X
to	B-X
an	B-X
exacerbated	B-X
inflammation	B-X
and	B-X
decreased	B-X
regulatory	B-X
or	B-X
anti-inflammatory	B-X
mechanisms	B-X
in	B-X
the	B-X
lungs	B-X
and	B-X
in	B-X
the	B-X
gut	B-X
,	B-X
pointing	B-X
to	B-X
this	B-X
important	B-X
relationship	B-X
between	B-X
both	B-X
mucosal	B-X
compartments	B-X
.	B-X
Therefore	B-X
,	B-X
since	B-X
the	B-X
mucous	B-X
membranes	B-X
from	B-X
the	B-X
respiratory	B-X
and	B-X
gastrointestinal	B-X
tracts	B-X
are	B-X
affected	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
dysbiosis	B-X
and	B-X
inflammation	B-X
,	B-X
it	B-X
is	B-X
plausible	B-X
to	B-X
assume	B-X
that	B-X
adjunctive	B-X
therapies	B-X
based	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
and	B-X
re-establishment	B-X
of	B-X
eubiosis	B-X
conditions	B-X
could	B-X
be	B-X
an	B-X
important	B-X
therapeutic	B-X
approach	B-X
for	B-X
constraining	B-X
the	B-X
harmful	B-X
consequences	B-X
of	B-X
COVID-19	B-X
.	B-X
Then	B-X
,	B-X
in	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarized	B-X
studies	B-X
showing	B-X
the	B-X
persistence	B-X
of	B-X
SARS-CoV-2	B-X
in	B-X
the	B-X
gastrointestinal	B-X
system	B-X
and	B-X
the	B-X
related	B-X
digestive	B-X
COVID-19	B-X
manifestations	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
literature	B-X
demonstrating	B-X
nasopharyngeal	B-X
,	B-X
pulmonary	B-X
and	B-X
intestinal	B-X
dysbiosis	B-X
in	B-X
COVID-19	B-X
patients	B-X
.	B-X

Whereas	O
the	O
effects	O
of	O
native	O
and	O
dCGN	O
on	O
intestinal	O
inflammation	O
have	O
been	O
extensively	O
analyzed	O
in	O
animal	O
models	O
,	O
only	O
few	O
studies	O
have	O
been	O
conducted	O
using	O
human	O
cell	O
lines	O
.	O

Recent	O
studies	O
have	O
shown	O
a	O
link	O
between	O
exposure	O
to	O
native	O
form	O
CGN	O
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
by	O
the	O
human	O
intestinal	O
epithelial	O
cell	O
line	O
,	O
NCM460	O
,	O
via	O
Nuclear	O
Factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
.	O

NF	O
-	O
kappaB	O
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
the	O
expression	O
of	O
genes	O
associated	O
with	O
inflammation	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O
<EOS>	B-X
Nonalcoholic	B-X
steatohepatitis	B-X
(	B-X
NASH	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
oxidative	B-X
stress	B-X
.	B-X
We	B-X
surmised	B-X
that	B-X
pharmacologic	B-X
activation	B-X
of	B-X
NF-E2	B-X
p45-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
using	B-X
the	B-X
acetylenic	B-X
tricyclic	B-X
bis	B-X
(	B-X
cyano	B-X
enone	B-X
)	B-X
TBE-31	B-X
would	B-X
suppress	B-X
NASH	B-X
because	B-X
Nrf2	B-X
is	B-X
a	B-X
transcriptional	B-X
master	B-X
regulator	B-X
of	B-X
intracellular	B-X
redox	B-X
homeostasis	B-X
.	B-X
Nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
comprises	B-X
a	B-X
family	B-X
of	B-X
proteins	B-X
that	B-X
act	B-X
as	B-X
transcription	B-X
factors	B-X
promoting	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
genes	B-X
.	B-X
Activation	B-X
of	B-X
NF-κB	B-X
biochemical	B-X
cascades	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
regulation	B-X
of	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
and	B-X
inflammation	B-X
,	B-X
among	B-X
other	B-X
physiological	B-X
responses	B-X
.	B-X
However	B-X
,	B-X
genetic	B-X
abnormalities	B-X
and	B-X
continuous	B-X
stimulation	B-X
of	B-X
the	B-X
NF-	B-X
κB-IKKβ	B-X
pathway	B-X
are	B-X
directly	B-X
related	B-X
to	B-X
many	B-X
types	B-X
of	B-X
inflammatory	B-X
and	B-X
autoimmune	B-X
diseases	B-X
,	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
genesis	B-X
and	B-X
survival	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X

Macrophage	O
infiltration	O
and	O
accumulation	O
is	O
a	O
common	O
characteristic	O
of	O
intestinal	O
diseases	O
[	O
17	O
]	O
.	O
<EOS>	B-X
We	B-X
sought	B-X
develop	B-X
and	B-X
characterize	B-X
a	B-X
diet-induced	B-X
model	B-X
of	B-X
metabolic	B-X
syndrome	B-X
and	B-X
its	B-X
related	B-X
diseases	B-X
.	B-X

Macrophages	O
represent	O
10	O
%	O
of	O
total	O
lamina	O
propria	O
cells	O
,	O
secrete	O
a	O
wide	O
range	O
of	O
biologically	O
active	O
compounds	O
and	O
express	O
cell	O
-	O
adhesion	O
molecules	O
.	O

The	O
immune	O
cell	O
response	O
to	O
an	O
inflammatory	O
stimulus	O
seems	O
to	O
be	O
amplified	O
or	O
directly	O
generated	O
by	O
cells	O
exposed	O
to	O
sulphated	O
polysaccharides	O
such	O
as	O
carrageenans	O
.	O

Indeed	O
,	O
inflammation	O
induced	O
by	O
dCGN	O
was	O
associated	O
with	O
recruitment	O
of	O
macrophages	O
to	O
inflammation	O
sites	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

Also	O
,	O
inflammation	O
induced	O
by	O
Dextran	O
Sulphate	O
Sodium	O
(	O
DSS	O
)	O
,	O
another	O
sulphated	O
compound	O
,	O
was	O
directly	O
associated	O
with	O
macrophages	O
recruitment	O
[	O
20	O
]	O
,	O
since	O
DSS	O
still	O
provoked	O
inflammation	O
after	O
T	O
-	O
lymphocyte	O
and	O
NK	O
cell	O
depletion	O
[	O
20	O
]	O
.	O

Although	O
inflammation	O
can	O
be	O
induced	O
by	O
dCGN	O
,	O
there	O
are	O
no	O
data	O
on	O
human	O
monocyte	O
responses	O
to	O
dCGN	O
exposure	O
.	O

Therefore	O
,	O
to	O
investigate	O
the	O
effects	O
of	O
dCGN	O
on	O
human	O
monocytes	O
,	O
normal	O
Peripheral	O
Blood	O
Monocytes	O
(	O
PBM	O
)	O
and	O
tumoral	O
monocyte	O
/	O
macrophage	O
THP	O
-	O
1	O
cells	O
were	O
exposed	O
to	O
10	O
kDa	O
and	O
40	O
kDa	O
dCGN	O
.	O

We	O
found	O
that	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
increased	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
stimulated	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
monocyte	O
aggregation	O
,	O
and	O
stimulated	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
and	O
secretion	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

These	O
responses	O
were	O
more	O
pronounced	O
after	O
40	O
kDa	O
dCGN	O
exposure	O
and	O
were	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
addition	O
,	O
the	O
40	O
kDa	O
dCGN	O
,	O
but	O
not	O
the	O
10	O
kDa	O
dCGN	O
induced	O
in	O
vivo	O
colitis	O
as	O
shown	O
by	O
the	O
inflammatory	O
response	O
in	O
the	O
rat	O
colon	O
.	O
<EOS>	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
degraded	O
forms	O
of	O
CGN	O
have	O
an	O
important	O
effect	O
on	O
monocytes	O
resulting	O
in	O
an	O
inflammatory	O
phenotype	O
.	O

Preparation	O
of	O
Degraded	O
Carrageenan	O
<EOS>	B-X
Carrageenans	B-X
are	B-X
sulfated	B-X
galactans	B-X
that	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
industrial	B-X
applications	B-X
for	B-X
their	B-X
thickening	B-X
and	B-X
gelling	B-X
properties	B-X
,	B-X
which	B-X
vary	B-X
according	B-X
to	B-X
the	B-X
amount	B-X
and	B-X
distribution	B-X
of	B-X
ester	B-X
sulfate	B-X
groups	B-X
along	B-X
the	B-X
galactan	B-X
backbone	B-X
.	B-X
Carrageenan	B-X
is	B-X
a	B-X
linear	B-X
sulphated	B-X
polysaccharide	B-X
extracted	B-X
from	B-X
red	B-X
seaweed	B-X
of	B-X
the	B-X
Rhodophyceae	B-X
family	B-X
.	B-X
Carrageenan	B-X
(	B-X
CRG	B-X
)	B-X
and	B-X
carrageenan/chitosan	B-X
(	B-X
CH	B-X
)	B-X
gel	B-X
beads	B-X
(	B-X
CRG/CH	B-X
)	B-X
were	B-X
prepared	B-X
as	B-X
a	B-X
release	B-X
delivery	B-X
system	B-X
for	B-X
echinochrome	B-X
A	B-X
(	B-X
Ech	B-X
)	B-X
.	B-X
Carrageenan	B-X
beads	B-X
containing	B-X
Ech	B-X
were	B-X
coated	B-X
with	B-X
CH	B-X
by	B-X
layering	B-X
.	B-X

Two	O
preparations	O
of	O
degraded	O
carrageenan	O
with	O
low	O
,	O
(	O
~	O
10	O
kDa	O
;	O
C10	O
)	O
,	O
and	O
medium	O
,	O
(	O
~	O
40	O
kDa	O
;	O
C40	O
)	O
molecular	O
weight	O
were	O
prepared	O
from	O
native	O
iota	O
-	O
carrageenan	O
extracted	O
from	O
Euchema	O
spinosum	O
(	O
generously	O
provided	O
by	O
Sanofi	O
Biosystems	O
Industry	O
,	O
Boulogne	O
-	O
Billancourt	O
,	O
France	O
)	O
.	O

Native	O
carrageenan	O
was	O
dissolved	O
in	O
distilled	O
water	O
(	O
5	O
%	O
w	O
/	O
v	O
)	O
under	O
vigorous	O
stirring	O
and	O
heated	O
to	O
60degreesC	O
.	O

Then	O
,	O
the	O
carrageenan	O
solution	O
was	O
submitted	O
to	O
two	O
different	O
treatments	O
to	O
obtain	O
both	O
low	O
and	O
medium	O
molecular	O
weight	O
fractions	O
.	O

Briefly	O
,	O
for	O
the	O
low	O
molecular	O
weight	O
fraction	O
,	O
carrageenan	O
solution	O
was	O
hydrolyzed	O
with	O
0	O
.	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
sulphuric	O
acid	O
for	O
15	O
min	O
at	O
80degreesC	O
.	O

After	O
neutralization	O
with	O
NaOH	O
4N	O
,	O
the	O
solution	O
was	O
ultra	O
filtered	O
through	O
a	O
hollow	O
fibre	O
cartridge	O
with	O
MW	O
cut	O
-	O
off	O
5	O
kDa	O
,	O
(	O
Amicon	O
Inc	O
,	O
Beverly	O
,	O
USA	O
)	O
.	O

For	O
the	O
medium	O
molecular	O
weight	O
fraction	O
,	O
the	O
carrageenan	O
solution	O
was	O
hydrolyzed	O
with	O
0	O
.	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
sulphuric	O
acid	O
for	O
30	O
min	O
at	O
60degreesC	O
.	O

After	O
neutralization	O
,	O
the	O
supernatant	O
was	O
ultra	O
filtered	O
(	O
MW	O
cut	O
-	O
off	O
100	O
kDa	O
)	O
.	O

The	O
filtrate	O
was	O
submitted	O
to	O
a	O
second	O
ultra	O
filtration	O
(	O
MW	O
cut	O
-	O
off	O
5	O
kDa	O
)	O
.	O

Both	O
preparations	O
of	O
dCGN	O
were	O
precipitated	O
with	O
4	O
volumes	O
of	O
95	O
%	O
ethanol	O
,	O
dried	O
at	O
room	O
temperature	O
and	O
ground	O
to	O
small	O
particles	O
(	O
1	O
mm	O
in	O
diameter	O
)	O
.	O

Using	O
gel	O
-	O
permeation	O
chromatography	O
in	O
combination	O
with	O
light	O
scattering	O
measurements	O
(	O
see	O
Viebke	O
et	O
al	O
.	O
[	O
21	O
]	O
)	O
,	O
it	O
was	O
confirmed	O
that	O
the	O
low	O
fraction	O
had	O
an	O
average	O
molecular	O
weight	O
of	O
10	O
kDa	O
,	O
and	O
the	O
medium	O
fraction	O
of	O
40	O
kDa	O
.	O

The	O
sulphate	O
content	O
of	O
polysaccharides	O
in	O
both	O
fractions	O
was	O
measured	O
following	O
the	O
method	O
of	O
Quemener	O
et	O
al	O
.	O

[	O
22	O
]	O
.	O

Finally	O
,	O
the	O
absence	O
of	O
polysaccharide	O
structure	O
modifications	O
in	O
the	O
two	O
fractions	O
was	O
confirmed	O
using	O
2H	O
-	O
NMR	O
spectroscopy	O
.	O

The	O
absence	O
of	O
LPS	O
contamination	O
in	O
the	O
two	O
fractions	O
was	O
confirmed	O
using	O
the	O
e	O
-	O
Toxate	O
(	O
R	O
)	O
kit	O
(	O
Sigma	O
,	O
St	O
Quentin	O
Fallavier	O
,	O
France	O
)	O
.	O

Before	O
use	O
in	O
cell	O
culture	O
,	O
the	O
two	O
fractions	O
were	O
dissolved	O
in	O
complete	O
medium	O
during	O
30	O
min	O
at	O
56degreesC	O
.	O

Animals	O
,	O
Chemicals	O
and	O
Diet	O
<EOS>	B-X
Diet	B-X
quality	B-X
and	B-X
quantity	B-X
in	B-X
conjunction	B-X
with	B-X
toxin	B-X
and	B-X
pathogen	B-X
exposure	B-X
are	B-X
key	B-X
contributors	B-X
to	B-X
microbe-host	B-X
physiology	B-X
and	B-X
malnutrition	B-X
.	B-X
Dietary	B-X
factors	B-X
can	B-X
influence	B-X
epigenetic	B-X
mechanisms	B-X
.	B-X
Diet-cancer	B-X
hypotheses	B-X
can	B-X
be	B-X
organized	B-X
according	B-X
to	B-X
this	B-X
conceptual	B-X
framework	B-X
.	B-X
Diet	B-X
offered	B-X
and	B-X
refused	B-X
was	B-X
measured	B-X
daily	B-X
,	B-X
and	B-X
DM	B-X
intakes	B-X
(	B-X
DMI	B-X
)	B-X
were	B-X
calculated	B-X
by	B-X
difference	B-X
.	B-X

Male	O
Wistar	O
rats	O
(	O
150	O
g	O
average	O
weight	O
)	O
were	O
housed	O
under	O
standard	O
conditions	O
and	O
fed	O
ad	O
libitum	O
with	O
standard	O
rodent	O
laboratory	O
chow	O
.	O

Degraded	O
iota	O
-	O
carrageenans	O
were	O
administered	O
in	O
the	O
drinking	O
water	O
(	O
5	O
%	O
w	O
/	O
v	O
)	O
for	O
55	O
days	O
to	O
2	O
groups	O
of	O
six	O
animals	O
each	O
.	O

The	O
first	O
group	O
received	O
the	O
low	O
molecular	O
weight	O
carrageenan	O
(	O
10	O
kDa	O
dCGN	O
)	O
and	O
the	O
second	O
received	O
the	O
medium	O
molecular	O
weight	O
carrageenan	O
(	O
40	O
kDa	O
dCGN	O
)	O
.	O

An	O
additional	O
group	O
of	O
four	O
rats	O
were	O
maintained	O
on	O
regular	O
tap	O
water	O
(	O
control	O
group	O
)	O
.	O

To	O
increase	O
palatability	O
0	O
.	O
2	O
%	O
sucrose	O
was	O
added	O
to	O
the	O
drinking	O
water	O
of	O
all	O
groups	O
(	O
Van	O
der	O
Waaji	O
et	O
al	O
.	O
,	O
[	O
23	O
]	O
)	O
.	O

Fresh	O
carrageenan	O
solutions	O
were	O
prepared	O
daily	O
.	O

Evaluation	O
of	O
Colitis	O
<EOS>	B-X
Select	B-X
animal	B-X
models	B-X
of	B-X
colitis	B-X
and	B-X
their	B-X
value	B-X
in	B-X
predicting	B-X
clinical	B-X
efficacy	B-X
of	B-X
biological	B-X
therapies	B-X
in	B-X
ulcerative	B-X
colitis	B-X
.	B-X

Body	O
weight	O
,	O
liquid	O
and	O
food	O
consumption	O
,	O
diarrhea	O
and	O
rectal	O
bleeding	O
(	O
detected	O
by	O
eye	O
inspection	O
)	O
were	O
recorded	O
throughout	O
the	O
feeding	O
period	O
.	O

After	O
55	O
days	O
,	O
animals	O
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
.	O

The	O
length	O
of	O
the	O
colon	O
was	O
measured	O
as	O
described	O
by	O
Okayashu	O
et	O
al	O
.	O
<EOS>	B-X
The	B-X
vertical	B-X
rectus	B-X
abdominis	B-X
flap	B-X
is	B-X
considered	B-X
the	B-X
gold	B-X
standard	B-X
in	B-X
perineal	B-X
reconstruction	B-X
after	B-X
oncological	B-X
abdominoperineal	B-X
resection	B-X
;	B-X
however	B-X
,	B-X
it	B-X
has	B-X
a	B-X
nonnegligible	B-X
donor	B-X
site	B-X
morbidity	B-X
.	B-X
The	B-X
anterolateral	B-X
thigh	B-X
flap	B-X
offers	B-X
reliable	B-X
soft	B-X
tissue	B-X
coverage	B-X
.	B-X
Bursectomy	B-X
is	B-X
regarded	B-X
as	B-X
a	B-X
standard	B-X
surgical	B-X
procedure	B-X
during	B-X
gastrectomy	B-X
for	B-X
serosa-positive	B-X
gastric	B-X
cancer	B-X
in	B-X
Japanese	B-X
gastric	B-X
cancer	B-X
treatment	B-X
guidelines	B-X
(	B-X
Japanese	B-X
Gastric	B-X
Cancer	B-X
Association	B-X
in	B-X
Gastric	B-X
Cancer	B-X
14:113-123	B-X
,	B-X
2011	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
our	B-X
previous	B-X
experience	B-X
of	B-X
laparoscopic	B-X
bursectomy	B-X
in	B-X
distal	B-X
gastrectomy	B-X
(	B-X
Zou	B-X
et	B-X
al	B-X
.	B-X
in	B-X
Oncol	B-X
Lett	B-X
10:99-102	B-X
,	B-X
2015	B-X
)	B-X
,	B-X
herein	B-X
,	B-X
we	B-X
described	B-X
the	B-X
technique	B-X
of	B-X
totally	B-X
laparoscopic	B-X
radical	B-X
total	B-X
gastrectomy	B-X
with	B-X
complete	B-X
bursectomy	B-X
using	B-X
an	B-X
outside	B-X
bursa	B-X
omentalis	B-X
approach	B-X
.	B-X

[	O
24	O
]	O
.	O

Then	O
,	O
each	O
colon	O
was	O
ligated	O
in	O
sections	O
of	O
2	O
cm	O
and	O
1	O
to	O
2	O
ml	O
of	O
10	O
%	O
formalin	O
was	O
infused	O
into	O
the	O
intestinal	O
lumen	O
.	O

The	O
moderately	O
distended	O
segment	O
was	O
sectioned	O
and	O
fixed	O
in	O
10	O
%	O
formalin	O
.	O

The	O
following	O
day	O
,	O
the	O
intestinal	O
content	O
was	O
removed	O
by	O
vortexing	O
.	O

The	O
fixed	O
segment	O
was	O
kept	O
in	O
10	O
%	O
formalin	O
at	O
4degreesC	O
until	O
the	O
paraffin	O
embedding	O
procedure	O
.	O

To	O
evaluate	O
the	O
degree	O
of	O
inflammation	O
,	O
this	O
segment	O
of	O
colon	O
was	O
opened	O
longitudinally	O
and	O
macroscopic	O
and	O
histological	O
scores	O
of	O
inflammation	O
were	O
recorded	O
as	O
previously	O
described	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
.	O

The	O
toluidine	O
blue	O
staining	O
was	O
used	O
for	O
identification	O
of	O
sulphated	O
polysaccharides	O
in	O
the	O
intestinal	O
mucosa	O
.	O

On	O
the	O
day	O
of	O
sacrifice	O
,	O
a	O
fresh	O
sample	O
of	O
each	O
colon	O
(	O
50	O
mg	O
)	O
was	O
collected	O
for	O
myeloperoxidase	B-Protein
(	O
MPO	B-Protein
)	O
assay	O
according	O
to	O
Krawisz	O
et	O
al	O
.	O
,	O
[	O
27	O
]	O
.	O

The	O
level	O
of	O
MPO	B-Protein
,	O
mainly	O
expressed	O
by	O
neutrophils	O
,	O
indicates	O
the	O
rate	O
of	O
recruitment	O
of	O
neutrophils	O
to	O
the	O
intestinal	O
mucosa	O
.	O

One	O
unit	O
of	O
MPO	O
activity	O
corresponds	O
to	O
the	O
degradation	O
of	O
1	O
micromol	O
of	O
peroxide	O
per	O
minute	O
at	O
25degreesC	O
.	O

Cell	O
Culture	O
<EOS>	B-X
Cultures	B-X
,	B-X
supposedly	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
or	B-X
mouse	B-X
,	B-X
proved	B-X
to	B-X
be	B-X
HeLa	B-X
cells	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
valuable	B-X
tools	B-X
which	B-X
is	B-X
being	B-X
applied	B-X
in	B-X
both	B-X
fundamental	B-X
and	B-X
applied	B-X
gastrointestinal	B-X
research	B-X
.	B-X
Cell	B-X
culture	B-X
-	B-X
Fact	B-X
and	B-X
fiction	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
a	B-X
well-established	B-X
standard	B-X
technique	B-X
and	B-X
a	B-X
fundamental	B-X
tool	B-X
in	B-X
biology	B-X
and	B-X
medicine	B-X
.	B-X

All	O
tissue	O
culture	O
reagents	O
were	O
from	O
Invitrogen	O
(	O
Cergy	O
Pontoise	O
,	O
France	O
)	O
.	O

THP	O
-	O
1	O
human	O
monocytic	O
cells	O
were	O
maintained	O
in	O
RPMI	O
-	O
1640	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
U	O
/	O
ml	O
penicillin	O
and	O
50	O
mg	O
/	O
ml	O
streptomycin	O
at	O
37degreesC	O
in	O
a	O
5	O
%	O
CO2	O
incubator	O
.	O

Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
obtained	O
from	O
heparinized	O
blood	O
by	O
Ficoll	O
-	O
Hypaque	O
density	O
gradient	O
.	O
<EOS>	B-X
Lymphocyte	B-X
thymidine	B-X
uptake	B-X
in	B-X
leucocytes	B-X
prepared	B-X
by	B-X
NH4Cl	B-X
induced	B-X
RBC	B-X
lysis	B-X
was	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
lymphocytes	B-X
obtained	B-X
following	B-X
Ficoll-Hypaque	B-X
centrifugation	B-X
using	B-X
polynomial	B-X
regression	B-X
dose	B-X
response	B-X
curves	B-X
which	B-X
adjusted	B-X
for	B-X
inherent	B-X
subject	B-X
variability	B-X
.	B-X
Heparinized	B-X
blood	B-X
was	B-X
either	B-X
layered	B-X
in	B-X
Ficoll-Hypaque	B-X
or	B-X
treated	B-X
with	B-X
0.87	B-X
%	B-X
NH4Cl	B-X
to	B-X
induce	B-X
RBC	B-X
lysis	B-X
.	B-X
For	B-X
each	B-X
subject	B-X
,	B-X
at	B-X
each	B-X
Pha	B-X
concentration	B-X
ranging	B-X
from	B-X
12.5	B-X
to	B-X
167micrograms/ml	B-X
,	B-X
triplicate	B-X
mean	B-X
cpm	B-X
of	B-X
Ficoll-Hypaque	B-X
treated	B-X
lymphocytes	B-X
and	B-X
NH4Cl	B-X
treated	B-X
lymphocytes	B-X
were	B-X
compared	B-X
by	B-X
the	B-X
2	B-X
tailed	B-X
Student	B-X
's	B-X
T	B-X
test	B-X
.	B-X
Responses	B-X
of	B-X
cultures	B-X
of	B-X
NH4Cl	B-X
treated	B-X
lymphocytes	B-X
were	B-X
significantly	B-X
different	B-X
(	B-X
less	B-X
than	B-X
0.05	B-X
)	B-X
from	B-X
the	B-X
responses	B-X
of	B-X
cultures	B-X
of	B-X
Ficoll-Hypaque	B-X
treated	B-X
lymphocytes	B-X
for	B-X
at	B-X
least	B-X
2	B-X
PHA	B-X
doses	B-X
in	B-X
8	B-X
of	B-X
the	B-X
11	B-X
subjects	B-X
.	B-X
For	B-X
Ficoll-Hypaque	B-X
treated	B-X
lymphocytes	B-X
,	B-X
mean	B-X
cmp=44,977+1400.4	B-X
(	B-X
PHA	B-X
concentration	B-X
)	B-X
-5.90	B-X
(	B-X
PHA	B-X
concentration	B-X
)	B-X
2+	B-X
subject	B-X
effect	B-X
;	B-X
s.e.=22,256	B-X
;	B-X
for	B-X
NH4Cl	B-X
treated	B-X
lymphocytes	B-X
,	B-X
mean	B-X
cpm=58,039+1022.8	B-X
(	B-X
Pha	B-X
concentration	B-X
)	B-X
-5.32	B-X
(	B-X
PHA	B-X
concentration	B-X
)	B-X
2+	B-X
subject	B-X
effect	B-X
;	B-X
s.e.=37,966	B-X
.	B-X
indicates	B-X
that	B-X
the	B-X
NH4Cl	B-X
treated	B-X
lymphocyte	B-X
culture	B-X
dose	B-X
response	B-X
curve	B-X
is	B-X
less	B-X
predictable	B-X
than	B-X
that	B-X
of	B-X
Ficoll-Hypaque	B-X
treated	B-X
lymphocytes	B-X
.	B-X

Monocytes	O
were	O
then	O
isolated	O
by	O
adherence	O
to	O
culture	O
flasks	O
as	O
described	O
[	O
28	O
]	O
.	O
<EOS>	B-X
The	B-X
method	B-X
described	B-X
below	B-X
,	B-X
prepared	B-X
in	B-X
accordance	B-X
with	B-X
Good	B-X
Manufacturing	B-X
Process	B-X
(	B-X
GMP	B-X
)	B-X
guidelines	B-X
,	B-X
is	B-X
an	B-X
optimization	B-X
of	B-X
the	B-X
most	B-X
common	B-X
ex	B-X
vivo	B-X
preparation	B-X
method	B-X
for	B-X
generating	B-X
large	B-X
numbers	B-X
of	B-X
DCs	B-X
for	B-X
clinical	B-X
studies	B-X
.	B-X
PBMCs	B-X
are	B-X
isolated	B-X
by	B-X
Ficoll	B-X
gradient	B-X
centrifugation	B-X
and	B-X
frozen	B-X
in	B-X
aliquots	B-X
.	B-X
On	B-X
Day	B-X
1	B-X
,	B-X
PBMCs	B-X
are	B-X
thawed	B-X
and	B-X
plated	B-X
onto	B-X
tissue	B-X
culture	B-X
flasks	B-X
to	B-X
select	B-X
for	B-X
monocytes	B-X
which	B-X
adhere	B-X
to	B-X
the	B-X
plastic	B-X
surface	B-X
after	B-X
1-2	B-X
hr	B-X
incubation	B-X
at	B-X
37	B-X
°C	B-X
in	B-X
the	B-X
tissue	B-X
culture	B-X
incubator	B-X
.	B-X
After	B-X
incubation	B-X
,	B-X
the	B-X
lymphocytes	B-X
are	B-X
washed	B-X
off	B-X
and	B-X
the	B-X
adherent	B-X
monocytes	B-X
are	B-X
cultured	B-X
for	B-X
5	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
interleukin-4	B-X
(	B-X
IL-4	B-X
)	B-X
and	B-X
granulocyte	B-X
macrophage-colony	B-X
stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
to	B-X
differentiate	B-X
to	B-X
immature	B-X
DCs	B-X
.	B-X

For	O
cell	O
aggregation	O
,	O
monocytes	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
C10	O
or	O
C40	O
for	O
72	O
h	O
.	O
<EOS>	B-X
Medium-chain	B-X
triacylglycerides	B-X
(	B-X
MCTs	B-X
)	B-X
are	B-X
dietary	B-X
supplements	B-X
that	B-X
can	B-X
induce	B-X
ketosis	B-X
without	B-X
the	B-X
need	B-X
for	B-X
a	B-X
traditional	B-X
ketogenic	B-X
diet	B-X
or	B-X
prolonged	B-X
fasting	B-X
.	B-X
They	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
marginally	B-X
delay	B-X
the	B-X
progression	B-X
of	B-X
neurodegenerative	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
Alzheimer	B-X
's	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
there	B-X
have	B-X
been	B-X
inconsistencies	B-X
in	B-X
reports	B-X
of	B-X
the	B-X
MCT	B-X
dose-response	B-X
relationship	B-X
,	B-X
which	B-X
may	B-X
be	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
MCT	B-X
composition	B-X
,	B-X
participant	B-X
characteristics	B-X
,	B-X
and	B-X
other	B-X
factors	B-X
that	B-X
can	B-X
influence	B-X
ketone	B-X
generation	B-X
.	B-X
To	B-X
resolve	B-X
these	B-X
discrepancies	B-X
,	B-X
we	B-X
reviewed	B-X
studies	B-X
that	B-X
investigated	B-X
the	B-X
ketogenic	B-X
effect	B-X
of	B-X
MCTs	B-X
in	B-X
healthy	B-X
adults	B-X
.	B-X
Aside	B-X
from	B-X
the	B-X
treatment	B-X
dose	B-X
,	B-X
other	B-X
factors	B-X
that	B-X
can	B-X
influence	B-X
the	B-X
ketogenic	B-X
response	B-X
,	B-X
such	B-X
as	B-X
accompanying	B-X
meals	B-X
,	B-X
fasting	B-X
duration	B-X
,	B-X
and	B-X
caffeine	B-X
intake	B-X
,	B-X
were	B-X
assessed	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
available	B-X
literature	B-X
,	B-X
four	B-X
practical	B-X
recommendations	B-X
are	B-X
made	B-X
to	B-X
optimize	B-X
the	B-X
ketogenic	B-X
effect	B-X
of	B-X
MCTs	B-X
and	B-X
reduce	B-X
unwanted	B-X
side	B-X
effects	B-X
(	B-X
primarily	B-X
gastrointestinal	B-X
discomfort	B-X
and	B-X
diarrhea	B-X
)	B-X
.	B-X
First	B-X
,	B-X
the	B-X
starting	B-X
dose	B-X
should	B-X
be	B-X
either	B-X
5	B-X
g	B-X
of	B-X
octanoic	B-X
acid	B-X
[	B-X
caprylic	B-X
acid	B-X
(	B-X
C8	B-X
)	B-X
;	B-X
a	B-X
component	B-X
of	B-X
MCTs	B-X
]	B-X
or	B-X
5	B-X
g	B-X
of	B-X
a	B-X
combination	B-X
of	B-X
C8	B-X
and	B-X
decanoic	B-X
or	B-X
capric	B-X
acid	B-X
(	B-X
C10	B-X
;	B-X
another	B-X
component	B-X
of	B-X
MCTs	B-X
)	B-X
,	B-X
and	B-X
the	B-X
dose	B-X
should	B-X
be	B-X
progressively	B-X
increased	B-X
to	B-X
15-20	B-X
g	B-X
of	B-X
C8	B-X
.	B-X
Second	B-X
,	B-X
MCTs	B-X
should	B-X
be	B-X
consumed	B-X
after	B-X
an	B-X
overnight	B-X
fast	B-X
,	B-X
without	B-X
an	B-X
accompanying	B-X
meal	B-X
if	B-X
tolerable	B-X
,	B-X
or	B-X
with	B-X
a	B-X
low-carbohydrate	B-X
meal	B-X
.	B-X
Third	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
caffeine	B-X
may	B-X
slightly	B-X
increase	B-X
the	B-X
ketogenic	B-X
response	B-X
.	B-X
Fourth	B-X
,	B-X
emulsifying	B-X
the	B-X
MCTs	B-X
might	B-X
increase	B-X
their	B-X
ketogenic	B-X
effect	B-X
and	B-X
alleviate	B-X
side	B-X
effects	B-X
.	B-X

Cell	O
colonies	O
were	O
monitored	O
under	O
an	O
inverted	O
phase	O
contrast	O
microscope	O
coupled	O
through	O
a	O
video	O
camera	O
to	O
a	O
computer	O
.	O

In	O
some	O
wells	O
,	O
neutralizing	O
monoclonal	O
antibody	O
to	O
ICAM	O
-	O
1	O
(	O
2	O
.	O
5	O
microg	O
/	O
ml	O
)	O
(	O
Tebu	O
,	O
Le	O
Perray	O
en	O
Yvelines	O
,	O
France	O
)	O
was	O
added	O
.	O

Cell	O
Cycle	O
Analysis	O
<EOS>	B-X
Cell	B-X
cycle	B-X
analysis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
earliest	B-X
applications	B-X
in	B-X
flow	B-X
cytometry	B-X
and	B-X
continues	B-X
to	B-X
be	B-X
highly	B-X
used	B-X
to	B-X
this	B-X
day	B-X
.	B-X
Clinical	B-X
Cell	B-X
Cycle	B-X
Analysis	B-X
Revisited	B-X
.	B-X
Cell	B-X
cycle	B-X
analysis	B-X
by	B-X
mass	B-X
cytometry	B-X
(	B-X
MC	B-X
)	B-X
is	B-X
hampered	B-X
by	B-X
the	B-X
poor	B-X
resolution	B-X
of	B-X
the	B-X
Iridium-labeled	B-X
DNA	B-X
intercalator	B-X
compared	B-X
to	B-X
DNA-specific	B-X
fluorescent	B-X
dyes	B-X
.	B-X
Cell	B-X
cycle	B-X
analysis	B-X
of	B-X
apoptosis	B-X
using	B-X
flow	B-X
cytometry	B-X
.	B-X

THP	O
-	O
1	O
cells	O
in	O
exponential	O
growth	O
phase	O
were	O
exposed	O
to	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenans	O
for	O
24	O
h	O
before	O
being	O
stained	O
with	O
propidium	O
iodide	O
using	O
the	O
DNA	O
-	O
Prep	O
Coulter	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
(	O
Beckman	O
-	O
Coulter	O
,	O
Villepinte	O
,	O
France	O
)	O
.	O

Cell	O
DNA	O
content	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
using	O
an	O
EPICS	O
XL2	O
(	O
Beckman	O
-	O
Coulter	O
)	O
.	O

Raw	O
data	O
for	O
the	O
distribution	O
of	O
DNA	O
content	O
of	O
30	O
,	O
000	O
cells	O
retrieved	O
from	O
the	O
cytometer	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
G0	O
/	O
G1	O
through	O
G2	O
/	O
M	O
populations	O
.	O

Multicycle	O
AV	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
used	O
to	O
generate	O
DNA	O
content	O
frequency	O
histograms	O
and	O
facilitate	O
data	O
analysis	O
.	O

Cell	O
Surface	O
Antigen	O
Expression	O
Analysis	O
<EOS>	B-X
Antigen	B-X
expression	B-X
plays	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
clinical	B-X
studies	B-X
,	B-X
pathology	B-X
,	B-X
biology	B-X
and	B-X
chemistry	B-X
.	B-X
Expression	B-X
ratios	B-X
matched	B-X
conventional	B-X
flow	B-X
cytometry	B-X
measurements	B-X
over	B-X
a	B-X
40-fold	B-X
difference	B-X
,	B-X
and	B-X
the	B-X
sample	B-X
enrichment	B-X
was	B-X
9.5×	B-X
.	B-X
Cell	B-X
state-	B-X
,	B-X
developmental	B-X
stage-	B-X
,	B-X
and	B-X
lineage-specific	B-X
combinatorial	B-X
expression	B-X
of	B-X
cluster	B-X
of	B-X
differentiation	B-X
(	B-X
CD	B-X
)	B-X
molecules	B-X
enables	B-X
the	B-X
identification	B-X
of	B-X
cellular	B-X
subsets	B-X
via	B-X
multicolor	B-X
flow	B-X
cytometry	B-X
.	B-X
Cell-enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
cell-ELISA	B-X
)	B-X
is	B-X
an	B-X
useful	B-X
technique	B-X
for	B-X
the	B-X
quantitative	B-X
analysis	B-X
of	B-X
cell	B-X
surface	B-X
antigen	B-X
expression	B-X
that	B-X
was	B-X
developed	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
enzyme	B-X
immunohistochemistry	B-X
(	B-X
EIH	B-X
)	B-X
and	B-X
ELISA	B-X
.	B-X

Peripheral	O
Blood	O
Monocytes	O
or	O
THP	O
-	O
1	O
cells	O
were	O
exposed	O
to	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
36	O
h	O
.	O
<EOS>	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
are	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
circulating	B-X
leukocytes	B-X
.	B-X
Using	B-X
a	B-X
murine	B-X
adoptive	B-X
transfer	B-X
system	B-X
to	B-X
probe	B-X
monocyte	B-X
homing	B-X
and	B-X
differentiation	B-X
in	B-X
vivo	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
functional	B-X
subsets	B-X
among	B-X
murine	B-X
blood	B-X
monocytes	B-X
:	B-X
a	B-X
short-lived	B-X
CX	B-X
(	B-X
3	B-X
)	B-X
CR1	B-X
(	B-X
lo	B-X
)	B-X
CCR2	B-X
(	B-X
+	B-X
)	B-X
Gr1	B-X
(	B-X
+	B-X
)	B-X
subset	B-X
that	B-X
is	B-X
actively	B-X
recruited	B-X
to	B-X
inflamed	B-X
tissues	B-X
and	B-X
a	B-X
CX	B-X
(	B-X
3	B-X
)	B-X
CR1	B-X
(	B-X
hi	B-X
)	B-X
CCR2	B-X
(	B-X
-	B-X
)	B-X
Gr1	B-X
(	B-X
-	B-X
)	B-X
subset	B-X
characterized	B-X
by	B-X
CX	B-X
(	B-X
3	B-X
)	B-X
CR1-dependent	B-X
recruitment	B-X
to	B-X
noninflamed	B-X
tissues	B-X
.	B-X
Both	B-X
subsets	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
differentiate	B-X
into	B-X
dendritic	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
level	B-X
of	B-X
CX	B-X
(	B-X
3	B-X
)	B-X
CR1	B-X
expression	B-X
also	B-X
defines	B-X
the	B-X
two	B-X
major	B-X
human	B-X
monocyte	B-X
subsets	B-X
,	B-X
the	B-X
CD14	B-X
(	B-X
+	B-X
)	B-X
CD16	B-X
(	B-X
-	B-X
)	B-X
and	B-X
CD14	B-X
(	B-X
lo	B-X
)	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
monocytes	B-X
,	B-X
which	B-X
share	B-X
phenotype	B-X
and	B-X
homing	B-X
potential	B-X
with	B-X
the	B-X
mouse	B-X
subsets	B-X
.	B-X
These	B-X
findings	B-X
raise	B-X
the	B-X
potential	B-X
for	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
in	B-X
inflammatory	B-X
diseases	B-X
.	B-X

After	O
two	O
washes	O
in	O
PBS	O
without	O
Ca2	O
+	O
and	O
Mg2	O
+	O
,	O
cells	O
were	O
incubated	O
in	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
gelatin	O
and	O
8	O
%	O
AB	O
human	O
serum	O
to	O
prevent	O
binding	O
to	O
Fc	O
receptors	O
.	O

Then	O
,	O
5x105	O
cells	O
were	O
incubated	O
with	O
primary	O
antibodies	O
at	O
4degreesC	O
for	O
30	O
min	O
.	O

Two	O
other	O
washes	O
in	O
PBS	O
preceded	O
incubation	O
with	O
FITC	O
-	O
conjugated	O
goat	O
antibody	O
anti	O
-	O
mouse	O
IgG	O
diluted	O
1	O
/	O
1000	O
at	O
4degreesC	O
for	O
30	O
min	O
(	O
Tebu	O
)	O
.	O

After	O
two	O
additional	O
washes	O
,	O
analysis	O
of	O
stained	O
cells	O
was	O
performed	O
on	O
an	O
EPICS	O
XL2	O
(	O
Beckman	O
-	O
Coulter	O
)	O
.	O

The	O
cell	O
population	O
was	O
gated	O
according	O
to	O
its	O
forward	O
and	O
wide	O
-	O
angle	O
light	O
scattering	O
.	O

Data	O
were	O
expressed	O
as	O
mean	O
relative	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
3000	O
cells	O
.	O

TNF	B-Protein
Activity	O
Bioassay	O
<EOS>	B-X
TRAF6	B-X
(	B-X
TNF	B-X
receptor	B-X
associated	B-X
factor	B-X
6	B-X
)	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
NFKB	B-X
activation	B-X
and	B-X
macroautphagy/autophagy	B-X
activation	B-X
induced	B-X
by	B-X
TLR4	B-X
(	B-X
toll	B-X
like	B-X
receptor	B-X
4	B-X
)	B-X
signaling	B-X
.	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
superfamily	B-X
(	B-X
TNFSF	B-X
)	B-X
ligands	B-X
and	B-X
receptors	B-X
have	B-X
distinctive	B-X
structural	B-X
characters	B-X
that	B-X
link	B-X
them	B-X
to	B-X
cell	B-X
growth	B-X
,	B-X
cell	B-X
survival	B-X
,	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
molecules	B-X
are	B-X
expressed	B-X
in	B-X
cells	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
which	B-X
may	B-X
be	B-X
central	B-X
to	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
as	B-X
well	B-X
as	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
the	B-X
function	B-X
of	B-X
TNFSF	B-X
members	B-X
is	B-X
not	B-X
just	B-X
restricted	B-X
to	B-X
immune	B-X
cells	B-X
.	B-X
Members	B-X
of	B-X
TNFSF	B-X
have	B-X
been	B-X
linked	B-X
to	B-X
an	B-X
array	B-X
of	B-X
pathophysiologies	B-X
,	B-X
including	B-X
cancer	B-X
,	B-X
neurologic	B-X
,	B-X
cardiovascular	B-X
,	B-X
pulmonary	B-X
,	B-X
autoimmune	B-X
,	B-X
and	B-X
metabolic	B-X
diseases	B-X
.	B-X
TNF-α	B-X
of	B-X
TNFSF	B-X
is	B-X
a	B-X
pro-inflammatory	B-X
cytokine	B-X
produced	B-X
by	B-X
macrophages/monocytes	B-X
,	B-X
widely	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
inflammatory	B-X
disorders	B-X
.	B-X
In	B-X
view	B-X
of	B-X
these	B-X
facts	B-X
,	B-X
TNF-α	B-X
has	B-X
been	B-X
recommended	B-X
as	B-X
an	B-X
important	B-X
target	B-X
for	B-X
discovering	B-X
drugs	B-X
for	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X
Various	B-X
cell-based	B-X
assays	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
TNF-α	B-X
in	B-X
inflammation	B-X
and	B-X
to	B-X
estimate	B-X
the	B-X
concentrations	B-X
of	B-X
TNF-α	B-X
levels	B-X
in	B-X
body	B-X
fluids	B-X
such	B-X
as	B-X
plasma	B-X
,	B-X
synovium	B-X
,	B-X
etc.	B-X
,	B-X
are	B-X
being	B-X
followed	B-X
by	B-X
researchers	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
methods	B-X
of	B-X
cell	B-X
viability	B-X
assay	B-X
,	B-X
ELISA	B-X
assay	B-X
,	B-X
RT-PCR	B-X
,	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
for	B-X
estimating	B-X
LPS-induced	B-X
TNF-α	B-X
protein	B-X
expressions	B-X
are	B-X
described	B-X
in	B-X
detail	B-X
.	B-X

Monocytes	O
or	O
THP	O
-	O
1	O
cells	O
were	O
cultured	O
with	O
or	O
without	O
different	O
concentrations	O
of	O
CGNs	O
or	O
LPS	O
(	O
Salmonella	O
typhosa	O
,	O
Sigma	O
)	O
for	O
24	O
h	O
or	O
the	O
indicated	O
time	O
.	O
<EOS>	B-X
Differentiated	B-X
macrophages	B-X
are	B-X
the	B-X
resident	B-X
tissue	B-X
phagocytes	B-X
and	B-X
sentinel	B-X
cells	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
phenotype	B-X
of	B-X
mature	B-X
tissue	B-X
macrophages	B-X
represents	B-X
the	B-X
composite	B-X
of	B-X
environmental	B-X
and	B-X
differentiation-dependent	B-X
imprinting	B-X
.	B-X
Phorbol-12-myristate-13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
(	B-X
3	B-X
)	B-X
)	B-X
are	B-X
stimuli	B-X
commonly	B-X
used	B-X
to	B-X
induce	B-X
macrophage	B-X
differentiation	B-X
in	B-X
monocytic	B-X
cell	B-X
lines	B-X
but	B-X
the	B-X
extent	B-X
of	B-X
differentiation	B-X
in	B-X
comparison	B-X
to	B-X
primary	B-X
tissue	B-X
macrophages	B-X
is	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
compared	B-X
the	B-X
phenotype	B-X
of	B-X
the	B-X
promonocytic	B-X
THP-1	B-X
cell	B-X
line	B-X
after	B-X
various	B-X
protocols	B-X
of	B-X
differentiation	B-X
utilising	B-X
VD	B-X
(	B-X
3	B-X
)	B-X
and	B-X
PMA	B-X
in	B-X
comparison	B-X
to	B-X
primary	B-X
human	B-X
monocytes	B-X
or	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X
.	B-X
Both	B-X
stimuli	B-X
induced	B-X
changes	B-X
in	B-X
cell	B-X
morphology	B-X
indicative	B-X
of	B-X
differentiation	B-X
but	B-X
neither	B-X
showed	B-X
differentiation	B-X
comparable	B-X
to	B-X
MDM	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
PMA	B-X
treatment	B-X
followed	B-X
by	B-X
5	B-X
days	B-X
resting	B-X
in	B-X
culture	B-X
without	B-X
PMA	B-X
(	B-X
PMAr	B-X
)	B-X
increased	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
ratio	B-X
,	B-X
increased	B-X
mitochondrial	B-X
and	B-X
lysosomal	B-X
numbers	B-X
and	B-X
altered	B-X
differentiation-dependent	B-X
cell	B-X
surface	B-X
markers	B-X
in	B-X
a	B-X
pattern	B-X
similar	B-X
to	B-X
MDM	B-X
.	B-X
Moreover	B-X
,	B-X
PMAr	B-X
cells	B-X
showed	B-X
relative	B-X
resistance	B-X
to	B-X
apoptotic	B-X
stimuli	B-X
and	B-X
maintained	B-X
levels	B-X
of	B-X
the	B-X
differentiation-dependent	B-X
anti-apoptotic	B-X
protein	B-X
Mcl-1	B-X
similar	B-X
to	B-X
MDM	B-X
.	B-X
PMAr	B-X
cells	B-X
retained	B-X
a	B-X
high	B-X
phagocytic	B-X
capacity	B-X
for	B-X
latex	B-X
beads	B-X
,	B-X
and	B-X
expressed	B-X
a	B-X
cytokine	B-X
profile	B-X
that	B-X
resembled	B-X
MDM	B-X
in	B-X
response	B-X
to	B-X
TLR	B-X
ligands	B-X
,	B-X
in	B-X
particular	B-X
with	B-X
marked	B-X
TLR2	B-X
responses	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
MDM	B-X
and	B-X
PMAr	B-X
retained	B-X
marked	B-X
plasticity	B-X
to	B-X
stimulus-directed	B-X
polarization	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
modified	B-X
PMA	B-X
differentiation	B-X
protocol	B-X
can	B-X
enhance	B-X
macrophage	B-X
differentiation	B-X
of	B-X
THP-1	B-X
cells	B-X
and	B-X
identify	B-X
increased	B-X
numbers	B-X
of	B-X
mitochondria	B-X
and	B-X
lysosomes	B-X
,	B-X
resistance	B-X
to	B-X
apoptosis	B-X
and	B-X
the	B-X
potency	B-X
of	B-X
TLR2	B-X
responses	B-X
as	B-X
important	B-X
discriminators	B-X
of	B-X
the	B-X
level	B-X
of	B-X
macrophage	B-X
differentiation	B-X
for	B-X
transformed	B-X
cells	B-X
.	B-X

Biologically	O
active	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
/	O
beta	B-Protein
in	O
tissue	O
culture	O
supernatant	O
was	O
measured	O
using	O
the	O
WEHI	O
164	O
clone	O
13	O
-	O
cell	O
killing	O
assay	O
[	O
29	O
]	O
.	O

TNF	B-Protein
concentrations	O
are	O
expressed	O
as	O
pg	O
/	O
ml	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
Pg-LPS	B-X
and	B-X
Pg-infected	B-X
EC	B-X
with	B-X
lenabasum	B-X
(	B-X
5	B-X
µM	B-X
;	B-X
6	B-X
h	B-X
)	B-X
reduced	B-X
the	B-X
gene	B-X
expression	B-X
of	B-X
TNF-α	B-X
,	B-X
COX-2	B-X
,	B-X
NF-κB	B-X
,	B-X
and	B-X
RANKL	B-X
,	B-X
whereas	B-X
it	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
IL-10	B-X
and	B-X
resolvin	B-X
E1	B-X
receptor	B-X
respectively	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
regulates	B-X
trophoblast	B-X
turnover	B-X
during	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
placental	B-X
syncytium	B-X
and	B-X
can	B-X
be	B-X
a	B-X
potentially	B-X
relevant	B-X
target	B-X
for	B-X
adverse	B-X
effects	B-X
of	B-X
xenobiotics	B-X
.	B-X
Undifferentiated	B-X
and	B-X
syncytialized	B-X
BeWo	B-X
cells	B-X
were	B-X
exposed	B-X
to	B-X
TNF	B-X
(	B-X
10	B-X
pg/mL-10	B-X
ng/mL	B-X
)	B-X
for	B-X
48	B-X
h	B-X
after	B-X
which	B-X
cell	B-X
viability	B-X
,	B-X
progesterone	B-X
release	B-X
and	B-X
gene	B-X
expression	B-X
of	B-X
a	B-X
selected	B-X
set	B-X
of	B-X
markers	B-X
representative	B-X
for	B-X
placental	B-X
function	B-X
were	B-X
assessed	B-X
.	B-X
In	B-X
undifferentiated	B-X
BeWo	B-X
cells	B-X
,	B-X
high	B-X
TNF	B-X
levels	B-X
(	B-X
1-10	B-X
ng/mL	B-X
)	B-X
increased	B-X
gene	B-X
expression	B-X
of	B-X
TNF	B-X
,	B-X
NF-κB	B-X
,	B-X
and	B-X
TNFRSF1B	B-X
to	B-X
maximally	B-X
99	B-X
±	B-X
17	B-X
,	B-X
2.2	B-X
±	B-X
0.2	B-X
,	B-X
and	B-X
3.0	B-X
±	B-X
0.4	B-X
of	B-X
control	B-X
values	B-X
,	B-X
respectively	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Additionally	B-X
,	B-X
TNF	B-X
may	B-X
induce	B-X
syncytialization	B-X
in	B-X
BeWo	B-X
cells	B-X
as	B-X
it	B-X
upregulated	B-X
ERVW-1	B-X
expression	B-X
by	B-X
1.55	B-X
±	B-X
0.14-fold	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
TNF	B-X
levels	B-X
of	B-X
10	B-X
and	B-X
100	B-X
pg/mL	B-X
did	B-X
not	B-X
affect	B-X
gene	B-X
expression	B-X
in	B-X
both	B-X
undifferentiated	B-X
and	B-X
syncytialized	B-X
BeWo	B-X
cells	B-X
,	B-X
but	B-X
did	B-X
enhance	B-X
cell	B-X
viability	B-X
in	B-X
syncytialised	B-X
BeWo	B-X
cells	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
found	B-X
that	B-X
high	B-X
TNF	B-X
levels	B-X
(	B-X
1-10	B-X
ng/mL	B-X
)	B-X
increased	B-X
gene	B-X
expression	B-X
of	B-X
TNF	B-X
,	B-X
NF-κB	B-X
,	B-X
and	B-X
TNFRSF1B	B-X
especially	B-X
in	B-X
undifferentiated	B-X
BeWo	B-X
cells	B-X
,	B-X
while	B-X
physiological	B-X
TNF	B-X
concentrations	B-X
positively	B-X
affected	B-X
cell	B-X
viability	B-X
and	B-X
while	B-X
there	B-X
was	B-X
no	B-X
effect	B-X
on	B-X
any	B-X
of	B-X
the	B-X
investigated	B-X
functional	B-X
markers	B-X
.	B-X

RT	O
-	O
PCR	O
Analysis	O
<EOS>	B-X
RT-PCR	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
test	B-X
for	B-X
genetic	B-X
diseases	B-X
and	B-X
to	B-X
characterize	B-X
gene	B-X
expression	B-X
in	B-X
various	B-X
tissue	B-X
types	B-X
,	B-X
cell	B-X
types	B-X
,	B-X
and	B-X
over	B-X
developmental	B-X
time	B-X
courses	B-X
.	B-X
RT-PCR	B-X
is	B-X
also	B-X
commonly	B-X
used	B-X
to	B-X
clone	B-X
cDNAs	B-X
for	B-X
further	B-X
use	B-X
with	B-X
other	B-X
molecular	B-X
biology	B-X
techniques	B-X
(	B-X
e.g.	B-X
,	B-X
see	B-X
Oligo	B-X
(	B-X
dT	B-X
)	B-X
-primed	B-X
RT-PCR	B-X
isolation	B-X
of	B-X
polyadenylated	B-X
RNA	B-X
degradation	B-X
intermediates	B-X
and	B-X
Circularized	B-X
RT-PCR	B-X
(	B-X
cRT-PCR	B-X
)	B-X
:	B-X
analysis	B-X
of	B-X
RNA	B-X
5	B-X
'	B-X
ends	B-X
,	B-X
3	B-X
'	B-X
ends	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tails	B-X
)	B-X
.	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
uses	B-X
fluorescent	B-X
reporter	B-X
molecules	B-X
to	B-X
monitor	B-X
the	B-X
production	B-X
of	B-X
amplification	B-X
products	B-X
during	B-X
each	B-X
cycle	B-X
of	B-X
the	B-X
PCR	B-X
reaction	B-X
.	B-X
Its	B-X
simplicity	B-X
,	B-X
specificity	B-X
and	B-X
sensitivity	B-X
,	B-X
together	B-X
with	B-X
its	B-X
potential	B-X
for	B-X
high	B-X
throughput	B-X
and	B-X
the	B-X
ongoing	B-X
introduction	B-X
of	B-X
new	B-X
chemistries	B-X
,	B-X
more	B-X
reliable	B-X
instrumentation	B-X
and	B-X
improved	B-X
protocols	B-X
,	B-X
has	B-X
made	B-X
real-time	B-X
RT-PCR	B-X
the	B-X
benchmark	B-X
technology	B-X
for	B-X
the	B-X
detection	B-X
and/or	B-X
comparison	B-X
of	B-X
RNA	B-X
levels	B-X
.	B-X

Total	O
RNA	O
from	O
monocytes	O
was	O
isolated	O
using	O
TRIzol	O
Reagent	O
(	O
TM	O
)	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
generated	O
on	O
1	O
microg	O
of	O
total	O
RNA	O
in	O
a	O
reaction	O
volume	O
of	O
20	O
microl	O
,	O
using	O
M	O
-	O
MLV	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
was	O
done	O
in	O
the	O
linear	O
range	O
of	O
amplification	O
(	O
determined	O
for	O
each	O
primer	O
pair	O
-	O
cDNA	O
combination	O
)	O
.	O

Standard	O
PCR	O
reactions	O
were	O
performed	O
with	O
1	O
microl	O
of	O
the	O
cDNA	O
solution	O
,	O
50	O
microM	O
of	O
each	O
primer	O
solution	O
,	O
10	O
mM	O
of	O
each	O
dNTP	O
,	O
25	O
mM	O
MgCl2	O
,	O
10X	O
Goldstar	O
DNA	O
polymerase	O
reaction	O
buffer	O
,	O
and	O
0	O
.	O
5	O
units	O
of	O
Goldstar	O
DNA	O
polymerase	O
(	O
Eurogentec	O
,	O
Seraing	O
,	O
Belgium	O
)	O
.	O

First	O
PCR	O
cycle	O
consisted	O
of	O
1	O
min	O
at	O
92degreesC	O
,	O
1	O
min	O
at	O
58degreesC	O
and	O
1	O
min	O
at	O
72degreesC	O
;	O
then	O
each	O
PCR	O
cycle	O
consisted	O
of	O
40	O
sec	O
at	O
92degreesC	O
,	O
40	O
sec	O
at	O
58degreesC	O
and	O
50	O
sec	O
at	O
72degreesC	O
.	O

cDNA	O
for	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
amplified	O
for	O
28	O
cycles	O
using	O
the	O
oligos	O
:	O
sense	O
5	O
'	O
-	O
GGCATCGTGATGGACTCCG	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
GCTGGAAGGTGGACAGCGA	O
-	O
3	O
'	O
.	O

cDNA	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
amplified	O
for	O
35	O
cycles	O
using	O
the	O
oligos	O
:	O
sense	O
5	O
'	O
-	O
AAGCCTGTAGCCCATGTTGT	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
-	O
CAGATAGATGGGCTCATACC	O
-	O
3	O
'	O
.	O

cDNA	O
for	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
was	O
amplified	O
for	O
35	O
cycles	O
using	O
the	O
oligos	O
sense	O
5	O
'	O
-	O
GTAGCAGCCGCAGTCATAATGG	O
-	O
3	O
'	O
and	O
antisense	O
5	O
'	O
-	O
A	O
TGCTGTTGTATCTGACTGAGG	O
-	O
3	O
'	O
.	O

NF	O
-	O
kB	O
Transcription	O
Reporter	O
Gene	O
Assay	O
<EOS>	B-X
Mutational	B-X
analysis	B-X
of	B-X
the	B-X
IL-8	B-X
promoter	B-X
revealed	B-X
that	B-X
it	B-X
was	B-X
not	B-X
the	B-X
AP-1	B-X
binding	B-X
site	B-X
,	B-X
but	B-X
rather	B-X
the	B-X
NF-κB	B-X
site	B-X
that	B-X
was	B-X
essential	B-X
to	B-X
connect	B-X
resveratrol	B-X
stimulation	B-X
with	B-X
the	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-8	B-X
gene	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
NF-κB	B-X
site	B-X
of	B-X
the	B-X
IL-8	B-X
gene	B-X
functions	B-X
as	B-X
resveratrol-responsive	B-X
element	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
an	B-X
NF-κB-responsive	B-X
reporter	B-X
gene	B-X
,	B-X
controlled	B-X
by	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
showed	B-X
that	B-X
resveratrol	B-X
stimulation	B-X
increased	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF-κB	B-X
.	B-X
These	B-X
data	B-X
were	B-X
corroborated	B-X
by	B-X
an	B-X
experiment	B-X
showing	B-X
that	B-X
incubation	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
the	B-X
NF-κB	B-X
inhibitor	B-X
JSH-23	B-X
attenuated	B-X
resveratrol-induced	B-X
activation	B-X
of	B-X
the	B-X
IL-8	B-X
promoter	B-X
and	B-X
reduced	B-X
the	B-X
cellular	B-X
NF-κB	B-X
activity	B-X
following	B-X
stimulation	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
resveratrol	B-X
.	B-X
The	B-X
protein	B-X
kinase	B-X
extracellular	B-X
signal-regulated	B-X
protein	B-X
kinase	B-X
ERK1/2	B-X
was	B-X
identified	B-X
to	B-X
function	B-X
as	B-X
signal	B-X
transducer	B-X
connecting	B-X
resveratrol	B-X
stimulation	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
IL-8	B-X
promoter-controlled	B-X
transcription	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
resveratrol	B-X
,	B-X
proposed	B-X
to	B-X
exhibit	B-X
anti-inflammatory	B-X
activity	B-X
,	B-X
stimulates	B-X
expression	B-X
of	B-X
the	B-X
pro-inflammatory	B-X
chemokine	B-X
IL-8	B-X
via	B-X
NF-κB	B-X
,	B-X
which	B-X
is	B-X
known	B-X
as	B-X
an	B-X
important	B-X
mediator	B-X
of	B-X
inflammatory	B-X
processes	B-X
.	B-X

The	O
plasmid	O
3XMHC	O
-	O
luc	O
(	O
a	O
generous	O
gift	O
from	O
Drs	O
.	O
J	O
.	O
Westwick	O
and	O
D	O
.	O
A	O
.	O
Brenner	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
)	O
contains	O
three	O
copies	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
element	O
from	O
the	O
MHC	O
class	O
I	O
locus	O
,	O
placed	O
upstream	O
of	O
the	O
luciferase	B-Protein
gene	O
.	O

Human	O
monocytic	O
THP	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
as	O
previously	O
described	O
[	O
30	O
]	O
,	O
and	O
then	O
cultured	O
for	O
4	O
h	O
alone	O
or	O
with	O
increasing	O
concentration	O
of	O
either	O
C10	O
or	O
C40	O
.	O
<EOS>	B-X
Among	B-X
isoprenoids	B-X
,	B-X
carotenoids	B-X
were	B-X
the	B-X
first	B-X
group	B-X
of	B-X
compounds	B-X
which	B-X
were	B-X
synthesized	B-X
from	B-X
foreign	B-X
genes	B-X
in	B-X
non-carotenogenic	B-X
Escherichia	B-X
coli	B-X
as	B-X
a	B-X
heterologous	B-X
host	B-X
.	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
carotenoids	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
produced	B-X
in	B-X
E.	B-X
coli	B-X
due	B-X
to	B-X
the	B-X
introduction	B-X
of	B-X
combinations	B-X
of	B-X
carotenoid	B-X
biosynthesis	B-X
genes	B-X
,	B-X
which	B-X
were	B-X
isolated	B-X
from	B-X
carotenogenic	B-X
organisms	B-X
.	B-X
Carotenoids	B-X
that	B-X
have	B-X
been	B-X
produced	B-X
in	B-X
E.	B-X
coli	B-X
are	B-X
mostly	B-X
cyclic	B-X
carotenoids	B-X
that	B-X
retain	B-X
carbon	B-X
40	B-X
(	B-X
C40	B-X
)	B-X
basic	B-X
structure	B-X
,	B-X
except	B-X
for	B-X
acyclic	B-X
carotene	B-X
lycopene	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
acyclic	B-X
carotenoids	B-X
,	B-X
which	B-X
can	B-X
also	B-X
be	B-X
produced	B-X
in	B-X
E.	B-X
coli	B-X
,	B-X
comprise	B-X
a	B-X
group	B-X
of	B-X
carotenoids	B-X
with	B-X
diverse	B-X
chain	B-X
lengths	B-X
,	B-X
i.e.	B-X
,	B-X
with	B-X
C20	B-X
,	B-X
C30	B-X
,	B-X
C40	B-X
,	B-X
or	B-X
C50	B-X
basic	B-X
skeleton	B-X
.	B-X
As	B-X
for	B-X
acyclic	B-X
C30	B-X
,	B-X
C40	B-X
,	B-X
and	B-X
C50	B-X
carotenoids	B-X
,	B-X
carotenogenic	B-X
genes	B-X
of	B-X
bacterial	B-X
origin	B-X
were	B-X
needed	B-X
,	B-X
while	B-X
a	B-X
cleavage	B-X
dioxygenase	B-X
gene	B-X
of	B-X
higher-plant	B-X
origin	B-X
was	B-X
utilized	B-X
for	B-X
the	B-X
synthesis	B-X
of	B-X
acyclic	B-X
C20	B-X
carotenoids	B-X
.	B-X
The	B-X
present	B-X
chapter	B-X
is	B-X
a	B-X
review	B-X
on	B-X
the	B-X
biosynthesis	B-X
of	B-X
such	B-X
diverse	B-X
acyclic	B-X
carotenoids	B-X
at	B-X
the	B-X
gene	B-X
level	B-X
.	B-X

Luciferase	B-Protein
activity	O
was	O
determined	O
using	O
a	O
luminometer	O
(	O
Monolight	O
2010	O
Luminometer	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

Western	O
Blot	O
Analysis	O
<EOS>	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Biochemical	B-X
approaches	B-X
,	B-X
including	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
a	B-X
powerful	B-X
tool	B-X
in	B-X
C.	B-X
elegans	B-X
biology	B-X
for	B-X
understanding	B-X
molecular	B-X
mechanisms	B-X
that	B-X
link	B-X
genotypes	B-X
to	B-X
phenotypes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
protocol	B-X
for	B-X
Western	B-X
blot	B-X
analysis	B-X
using	B-X
protein	B-X
extracts	B-X
obtained	B-X
from	B-X
C.	B-X
elegans	B-X
samples	B-X
.	B-X

THP	O
-	O
1	O
cells	O
were	O
stimulated	O
for	O
various	O
lengths	O
of	O
time	O
with	O
0	O
.	O
1	O
mg	O
/	O
ml	O
C10	O
or	O
C40	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
.	O
<EOS>	B-X
Despite	B-X
advances	B-X
in	B-X
supportive	B-X
care	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
potent	B-X
antimicrobials	B-X
,	B-X
the	B-X
mortality	B-X
exceeds	B-X
20	B-X
%	B-X
.	B-X
The	B-X
passive	B-X
infusion	B-X
of	B-X
antibodies	B-X
directed	B-X
against	B-X
a	B-X
conserved	B-X
region	B-X
of	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
was	B-X
highly	B-X
protective	B-X
in	B-X
an	B-X
early	B-X
study	B-X
(	B-X
NEJM	B-X
307	B-X
[	B-X
1982	B-X
]	B-X
1225	B-X
)	B-X
.	B-X
Our	B-X
group	B-X
found	B-X
that	B-X
a	B-X
whole	B-X
bacterial	B-X
vaccine	B-X
made	B-X
from	B-X
the	B-X
Escherichia	B-X
coli	B-X
O111	B-X
:	B-X
B4	B-X
,	B-X
J5	B-X
(	B-X
Rc	B-X
chemotype	B-X
)	B-X
mutant	B-X
induced	B-X
protective	B-X
antibodies	B-X
when	B-X
given	B-X
passively	B-X
as	B-X
treatment	B-X
for	B-X
sepsis	B-X
in	B-X
a	B-X
neutropenic	B-X
rat	B-X
model	B-X
.	B-X
A	B-X
subunit	B-X
vaccine	B-X
,	B-X
composed	B-X
of	B-X
detoxified	B-X
J5	B-X
LPS	B-X
complexed	B-X
to	B-X
group	B-X
B	B-X
meningococcal	B-X
outer	B-X
membrane	B-X
protein	B-X
(	B-X
OMP	B-X
)	B-X
,	B-X
provided	B-X
similar	B-X
protection	B-X
when	B-X
antibodies	B-X
were	B-X
given	B-X
passively	B-X
,	B-X
or	B-X
induced	B-X
actively	B-X
in	B-X
both	B-X
the	B-X
neutropenic	B-X
and	B-X
cecal	B-X
ligation/puncture	B-X
models	B-X
of	B-X
sepsis	B-X
.	B-X
A	B-X
phase	B-X
I	B-X
study	B-X
in	B-X
24	B-X
subjects	B-X
(	B-X
at	B-X
5	B-X
,	B-X
10	B-X
and	B-X
25	B-X
microg	B-X
doses	B-X
[	B-X
based	B-X
on	B-X
LPS	B-X
]	B-X
for	B-X
each	B-X
group	B-X
of	B-X
8	B-X
)	B-X
revealed	B-X
the	B-X
vaccine	B-X
to	B-X
be	B-X
well-tolerated	B-X
with	B-X
no	B-X
systemic	B-X
endotoxin-like	B-X
effects	B-X
.	B-X
Although	B-X
a	B-X
two	B-X
to	B-X
three-fold	B-X
increase	B-X
in	B-X
antibody	B-X
levels	B-X
over	B-X
baseline	B-X
(	B-X
by	B-X
ELISA	B-X
assay	B-X
)	B-X
was	B-X
observed	B-X
at	B-X
the	B-X
10	B-X
and	B-X
25	B-X
microg	B-X
doses	B-X
,	B-X
the	B-X
plasma	B-X
from	B-X
both	B-X
high	B-X
and	B-X
low	B-X
responders	B-X
reduced	B-X
LPS-induced	B-X
cytokine	B-X
generation	B-X
in	B-X
whole	B-X
blood	B-X
.	B-X
Reimmunization	B-X
of	B-X
six	B-X
subjects	B-X
at	B-X
12	B-X
months	B-X
did	B-X
not	B-X
convert	B-X
low	B-X
responders	B-X
to	B-X
high	B-X
responders	B-X
or	B-X
boost	B-X
the	B-X
still	B-X
elevated	B-X
anti-J5	B-X
LPS	B-X
levels	B-X
of	B-X
high	B-X
responders	B-X
.	B-X
If	B-X
functional	B-X
assays	B-X
of	B-X
anti-LPS	B-X
antibodies	B-X
are	B-X
better	B-X
predictors	B-X
of	B-X
vaccine	B-X
efficacy	B-X
than	B-X
ELISA	B-X
antibody	B-X
levels	B-X
,	B-X
then	B-X
it	B-X
will	B-X
be	B-X
necessary	B-X
to	B-X
determine	B-X
which	B-X
of	B-X
many	B-X
potential	B-X
assays	B-X
best	B-X
correlates	B-X
with	B-X
protection	B-X
in	B-X
animal	B-X
models	B-X
.	B-X

Cells	O
were	O
then	O
pelleted	O
,	O
washed	O
and	O
homogenised	O
in	O
lysis	O
buffer	O
(	O
10	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
9	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
6	O
%	O
NP	O
-	O
40	O
,	O
and	O
0	O
.	O
5	O
mM	O
PMSF	O
)	O
on	O
ice	O
.	O

Homogenates	O
were	O
sonicated	O
,	O
centrifuged	O
at	O
10	O
,	O
000	O
rpm	O
to	O
remove	O
cellular	O
debris	O
,	O
and	O
supernatant	O
collected	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
the	O
DC	O
Protein	O
Assay	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
transient	B-X
receptor	B-X
potential	B-X
melastatin	B-X
3	B-X
proteotypic	B-X
peptides	B-X
employing	B-X
an	B-X
efficient	B-X
membrane	B-X
protein	B-X
extraction	B-X
method	B-X
for	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X

Proteins	O
in	O
samples	O
(	O
15	O
microg	O
total	O
proteins	O
)	O
were	O
resolved	O
in	O
a	O
denaturing	O
12	O
%	O
polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
protein	O
was	O
detected	O
using	O
a	O
rabbit	O
polyclonal	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
)	O
followed	O
by	O
a	O
horseradish	O
peroxidase	O
-	O
coupled	O
goat	O
polyclonal	O
antibody	O
against	O
rabbit	O
Ig	O
(	O
Caltag	O
Laboratories	O
)	O
.	O

Finally	O
,	O
IkappaB	O
bands	O
were	O
revealed	O
using	O
the	O
ECL	O
(	O
TM	O
)	O
detection	O
system	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Les	O
Ullis	O
,	O
France	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
instruction	O
.	O

Antibody	O
to	O
alpha	O
-	O
Tubulin	O
(	O
Santa	O
Cruz	O
)	O
was	O
use	O
as	O
loading	O
control	O
.	O

For	O
nuclear	O
NF	O
-	O
kappaB	O
,	O
THP	O
-	O
1	O
cells	O
were	O
stimulated	O
with	O
1	O
mg	O
/	O
ml	O
C10	O
or	O
C40	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Cells	O
were	O
then	O
pelleted	O
and	O
nuclei	O
separated	O
as	O
described	O
[	O
31	O
]	O
.	O
<EOS>	B-X
A	B-X
rapid	B-X
isotonic	B-X
method	B-X
for	B-X
fractionation	B-X
of	B-X
nuclei	B-X
from	B-X
rat	B-X
brain	B-X
is	B-X
described	B-X
.	B-X
First	B-X
,	B-X
light	B-X
and	B-X
electron	B-X
microscopic	B-X
examination	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
the	B-X
nuclei	B-X
in	B-X
each	B-X
preparation	B-X
and	B-X
to	B-X
assess	B-X
the	B-X
purity	B-X
of	B-X
each	B-X
preparation	B-X
.	B-X
Fraction	B-X
1	B-X
was	B-X
enriched	B-X
in	B-X
neuronal	B-X
nuclei	B-X
;	B-X
fractions	B-X
2b	B-X
and	B-X
4b	B-X
in	B-X
astrocytic	B-X
nuclei	B-X
;	B-X
and	B-X
fractions	B-X
3	B-X
,	B-X
5c	B-X
,	B-X
and	B-X
6	B-X
in	B-X
nuclei	B-X
of	B-X
oligodendrocytes	B-X
.	B-X
Electron	B-X
microscopy	B-X
showed	B-X
that	B-X
the	B-X
various	B-X
classes	B-X
of	B-X
nuclei	B-X
are	B-X
congruent	B-X
to	B-X
90	B-X
%	B-X
pure	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
procedure	B-X
described	B-X
here	B-X
is	B-X
suitable	B-X
for	B-X
obtaining	B-X
highly	B-X
purified	B-X
neuronal	B-X
and	B-X
three	B-X
types	B-X
of	B-X
glial	B-X
nuclei	B-X
from	B-X
rat	B-X
brain	B-X
.	B-X

Nuclei	O
were	O
washed	O
and	O
homogenized	O
directly	O
in	O
loading	O
(	O
Laemli	O
)	O
buffer	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
100degreesC	O
.	O

Proteins	O
in	O
samples	O
were	O
resolved	O
in	O
a	O
denaturing	O
8	O
%	O
polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
polyvinylidine	O
fluoride	O
(	O
PVDF	O
)	O
membrane	O
(	O
Immobilon	O
-	O
P	O
;	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
)	O
.	O

Membranes	O
were	O
incubated	O
in	O
blocking	O
buffer	O
(	O
1	O
%	O
BSA	O
,	O
in	O
PBS	O
)	O
for	O
two	O
hours	O
at	O
room	O
temperature	O
.	O

Membranes	O
were	O
subsequently	O
probed	O
with	O
the	O
corresponding	O
antibody	O
in	O
blocking	O
buffer	O
,	O
overnight	O
.	O

Rabbit	O
polyclonal	O
antibody	O
anti	O
-	O
NF	O
-	O
kappaB	O
p50	O
subunit	O
(	O
#	O
sc	O
-	O
114	O
)	O
or	O
anti	O
-	O
NF	O
-	O
kappaB	O
p65	O
subunit	O
(	O
#	O
sc	O
-	O
109	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
were	O
used	O
.	O

Membranes	O
were	O
washed	O
six	O
times	O
in	O
PBS	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
,	O
5	O
minutes	O
each	O
time	O
,	O
and	O
incubated	O
with	O
a	O
1	O
/	O
3000	O
dilution	O
of	O
HRP	O
-	O
conjugated	O
F	O
(	O
ab	O
'	O
)	O
2	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
in	O
5	O
%	O
nonfat	O
dry	O
milk	O
and	O
0	O
.	O
05	O
%	O
Tween	O
20	O
in	O
PBS	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
six	O
more	O
times	O
in	O
PBS	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
,	O
antibody	O
-	O
reactive	O
proteins	O
were	O
detected	O
using	O
a	O
chemiluminescence	O
substrate	O
(	O
SuperSignal	O
;	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

To	O
confirm	O
that	O
equivalent	O
amounts	O
of	O
protein	O
were	O
loaded	O
in	O
each	O
line	O
,	O
membranes	O
were	O
also	O
Western	O
blotted	O
for	O
ERK	O
as	O
described	O
[	O
32	O
]	O
.	O

Analysis	O
of	O
NF	O
-	O
kappaB	O
Activation	O
by	O
Flow	O
Cytometry	O
<EOS>	B-X
The	B-X
protocol	B-X
describes	B-X
method	B-X
for	B-X
quantitative	B-X
imaging	B-X
flow	B-X
cytometry	B-X
analysis	B-X
of	B-X
intracellular	B-X
distribution	B-X
of	B-X
NF-kappaB	B-X
in	B-X
ARPE-19	B-X
cells	B-X
stained	B-X
with	B-X
specific	B-X
fluorochrome-conjugated	B-X
antibodies	B-X
.	B-X
We	B-X
focused	B-X
on	B-X
the	B-X
effects	B-X
of	B-X
PTGS2/NF-κB	B-X
signaling	B-X
pathway	B-X
on	B-X
the	B-X
radiation	B-X
resistance	B-X
of	B-X
glioma	B-X
in	B-X
the	B-X
study	B-X
.	B-X
Aberrant	B-X
activity	B-X
of	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
many	B-X
diseases	B-X
and	B-X
is	B-X
therapeutically	B-X
targeted	B-X
.	B-X
Post-translational	B-X
modifications	B-X
,	B-X
particularly	B-X
phosphorylation	B-X
of	B-X
the	B-X
RELA/p65	B-X
sub-unit	B-X
,	B-X
are	B-X
essential	B-X
for	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
localization	B-X
of	B-X
NF-κB/p65	B-X
and	B-X
initiation	B-X
of	B-X
transcription	B-X
of	B-X
downstream	B-X
target	B-X
genes	B-X
.	B-X
Immunoblot	B-X
and	B-X
phospho-flow	B-X
cytometry	B-X
have	B-X
been	B-X
used	B-X
to	B-X
study	B-X
the	B-X
relationship	B-X
between	B-X
phosphorylation	B-X
motifs	B-X
and	B-X
NF-κB	B-X
activation	B-X
and	B-X
microscopic	B-X
analysis	B-X
of	B-X
nuclear	B-X
localization	B-X
of	B-X
p65	B-X
is	B-X
also	B-X
used	B-X
as	B-X
a	B-X
parameter	B-X
for	B-X
activation	B-X
.	B-X
TNFα-	B-X
or	B-X
PMA/Ionomycin-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
serine	B-X
529	B-X
in	B-X
cell	B-X
line	B-X
models	B-X
and	B-X
healthy	B-X
donor	B-X
lymphocytes	B-X
served	B-X
as	B-X
the	B-X
experimental	B-X
model	B-X
.	B-X

Nuclear	O
activation	O
of	O
NF	O
-	O
kappabeta	O
by	O
flow	O
cytometry	O
was	O
performed	O
as	O
described	O
[	O
31	O
]	O
.	O

Statistical	O
Analysis	O

The	O
results	O
were	O
expressed	O
as	O
the	O
mean	O
value	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
of	O
individual	O
experiments	O
.	O

The	O
statistical	O
significance	O
of	O
the	O
differences	O
between	O
mean	O
values	O
was	O
assessed	O
by	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Degraded	O
CGN	O
Induce	O
Colonic	O
Inflammation	O
<EOS>	B-X
Carrageenans	B-X
(	B-X
CGNs	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
foods	B-X
and	B-X
pharmaceuticals	B-X
although	B-X
their	B-X
safety	B-X
remains	B-X
controversial	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
CGNs	B-X
and	B-X
CGN-degrading	B-X
bacteria	B-X
in	B-X
the	B-X
human	B-X
colon	B-X
,	B-X
we	B-X
screened	B-X
for	B-X
CGN	B-X
degradation	B-X
by	B-X
human	B-X
fecal	B-X
microbiota	B-X
,	B-X
and	B-X
for	B-X
inflammatory	B-X
response	B-X
to	B-X
CGNs	B-X
and/or	B-X
CGN-degrading	B-X
bacteria	B-X
in	B-X
germ	B-X
free	B-X
mice	B-X
.	B-X
Thin-layer	B-X
chromatography	B-X
indicated	B-X
that	B-X
high	B-X
molecular	B-X
weight	B-X
(	B-X
MW	B-X
)	B-X
CGNs	B-X
(	B-X
≥100	B-X
kDa	B-X
)	B-X
remained	B-X
undegraded	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
human	B-X
fecal	B-X
microbiota	B-X
,	B-X
whereas	B-X
low	B-X
MW	B-X
CGNs	B-X
,	B-X
i.e.	B-X
,	B-X
κ-carrageenan	B-X
oligosaccharides	B-X
(	B-X
KCO	B-X
,	B-X
~4.5	B-X
kDa	B-X
)	B-X
were	B-X
degraded	B-X
when	B-X
exposed	B-X
to	B-X
seven	B-X
of	B-X
eight	B-X
human	B-X
fecal	B-X
samples	B-X
,	B-X
although	B-X
sulfate	B-X
groups	B-X
were	B-X
not	B-X
removed	B-X
during	B-X
degradation	B-X
.	B-X
Our	B-X
study	B-X
shows	B-X
that	B-X
KCO-degrading	B-X
bacteria	B-X
and	B-X
the	B-X
low	B-X
MW	B-X
products	B-X
of	B-X
KCO	B-X
can	B-X
promote	B-X
proinflammatory	B-X
effects	B-X
in	B-X
mice	B-X
,	B-X
and	B-X
represent	B-X
two	B-X
key	B-X
markers	B-X
for	B-X
evaluating	B-X
CGN	B-X
safety	B-X
in	B-X
foods	B-X
or	B-X
medicines	B-X
.	B-X

All	O
rats	O
developed	O
diarrhea	O
during	O
degraded	O
carrageenan	O
administration	O
and	O
gross	O
evidence	O
of	O
blood	O
was	O
frequently	O
detected	O
in	O
the	O
stools	O
.	O

Colon	O
length	O
dramatically	O
decreased	O
in	O
all	O
treated	O
rats	O
with	O
a	O
more	O
pronounced	O
effect	O
being	O
observed	O
in	O
the	O
40	O
kDa	O
dCGN	O
treated	O
group	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Furthermore	O
,	O
prolonged	O
exposure	O
to	O
40	O
kDa	O
dCGN	O
resulted	O
in	O
high	O
macroscopic	O
and	O
histological	O
scores	O
of	O
inflammation	O
(	O
Fig	O
.	O
1B	O
,	O
C	O
)	O
.	O

Only	O
weak	O
myeloperoxidase	B-Protein
activity	O
was	O
detected	O
in	O
both	O
control	O
and	O
dCGN	O
-	O
treated	O
groups	O
(	O
Fig	O
.	O
1D	O
)	O
,	O
indicating	O
that	O
granulocytes	O
did	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
inflammation	O
at	O
that	O
stage	O
.	O

Histological	O
examination	O
revealed	O
various	O
degrees	O
of	O
mucosal	O
inflammation	O
.	O
<EOS>	B-X
Whereas	B-X
most	B-X
duodenal	B-X
biopsies	B-X
with	B-X
chronic	B-X
giardiasis	B-X
show	B-X
little	B-X
or	B-X
no	B-X
inflammatory	B-X
reaction	B-X
,	B-X
some	B-X
patients	B-X
may	B-X
develop	B-X
a	B-X
severe	B-X
disease	B-X
with	B-X
significant	B-X
mucosal	B-X
inflammation	B-X
and	B-X
various	B-X
degrees	B-X
of	B-X
villous	B-X
blunting	B-X
.	B-X
Interestingly	B-X
enough	B-X
,	B-X
all	B-X
mucosal	B-X
biopsy	B-X
specimens	B-X
from	B-X
the	B-X
duodenum	B-X
were	B-X
parasite	B-X
free	B-X
.	B-X
Therefore	B-X
,	B-X
giardiasis	B-X
could	B-X
only	B-X
be	B-X
revealed	B-X
by	B-X
the	B-X
demonstration	B-X
of	B-X
trophozoites	B-X
of	B-X
G.	B-X
lamblia	B-X
in	B-X
biopsy	B-X
specimens	B-X
from	B-X
the	B-X
terminal	B-X
ileum	B-X
,	B-X
which	B-X
had	B-X
been	B-X
taken	B-X
simultaneously	B-X
or	B-X
several	B-X
weeks	B-X
later	B-X
.	B-X
In	B-X
the	B-X
cases	B-X
described	B-X
here	B-X
infestation	B-X
with	B-X
G.	B-X
lamblia	B-X
was	B-X
only	B-X
proven	B-X
histologically	B-X
by	B-X
examination	B-X
of	B-X
mucosal	B-X
biopsy	B-X
specimens	B-X
taken	B-X
from	B-X
the	B-X
terminal	B-X
ileum	B-X
.	B-X

Rats	O
treated	O
with	O
10	O
kDa	O
dCGN	O
showed	O
edema	O
,	O
epithelium	O
atrophy	O
and	O
slight	O
lymphocyte	O
infiltration	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
symptoms	O
were	O
totally	O
absent	O
in	O
the	O
colon	O
of	O
control	O
rats	O
(	O
Fig	O
.	O
1E	O
)	O
.	O

More	O
severe	O
mucosal	O
injuries	O
including	O
ulceration	O
,	O
hyperplastic	O
epithelium	O
,	O
crypt	O
distortion	O
and	O
a	O
strong	O
macrophage	O
infiltration	O
,	O
were	O
observed	O
in	O
the	O
40	O
kDa	O
dCGN	O
-	O
treated	O
rats	O
(	O
Fig	O
.	O
1F	O
)	O
.	O

No	O
sulphated	O
polysaccharides	O
were	O
detected	O
by	O
toluidine	O
blue	O
staining	O
of	O
colon	O
mucosa	O
from	O
rats	O
treated	O
with	O
either	O
the	O
10	O
or	O
40	O
kDa	O
dCGN	O
(	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X

Although	O
we	O
cannot	O
exclude	O
that	O
dCGN	O
mat	O
not	O
have	O
retained	O
in	O
the	O
section	O
during	O
the	O
histology	O
procedure	O
,	O
this	O
indicates	O
that	O
these	O
polymers	O
may	O
not	O
have	O
been	O
phagocytosed	O
.	O

Degraded	O
CGN	O
Induced	O
-	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
Production	O
by	O
Monocytes	O
In	O
Vitro	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

In	O
order	O
to	O
study	O
the	O
capacity	O
of	O
dCGN	O
to	O
stimulate	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
peripheral	O
blood	O
monocytes	O
were	O
cultivated	O
in	O
the	O
presence	O
of	O
dCGN	O
(	O
0	O
.	O
1	O
to	O
1	O
mg	O
/	O
ml	O
)	O
.	O

Very	O
low	O
levels	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
were	O
induced	O
in	O
PBM	O
after	O
stimulation	O
with	O
native	O
CGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Addition	O
of	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
resulted	O
in	O
approximately	O
a	O
60	O
-	O
fold	O
increase	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
PBM	O
.	O

This	O
was	O
a	O
dose	O
-	O
dependent	O
effect	O
that	O
reached	O
a	O
180	O
-	O
fold	O
increase	O
when	O
cells	O
were	O
exposed	O
to	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

A	O
250	O
-	O
fold	O
increase	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
was	O
detected	O
at	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
increased	O
in	O
time	O
reaching	O
a	O
maximum	O
level	O
at	O
8	O
hours	O
of	O
culture	O
(	O
Figure	O
2B	O
)	O
.	O

After	O
24	O
h	O
,	O
the	O
amount	O
of	O
secreted	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
still	O
one	O
third	O
of	O
the	O
total	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
a	O
known	O
activator	O
of	O
immune	O
cells	O
also	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
with	O
similar	O
kinetics	O
as	O
dCGN	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

However	O
,	O
the	O
amount	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
produced	O
by	O
LPS	O
was	O
4	O
-	O
fold	O
less	O
than	O
the	O
one	O
produced	O
by	O
dCGN	O
and	O
it	O
was	O
not	O
detected	O
after	O
8	O
hours	O
of	O
culture	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Similarly	O
,	O
monocytic	O
THP	O
-	O
1	O
cells	O
cultivated	O
in	O
the	O
presence	O
of	O
variable	O
concentration	O
of	O
dCGN	O
showed	O
an	O
increase	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

This	O
increase	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
was	O
significantly	O
smaller	O
(	O
about	O
10	O
-	O
fold	O
)	O
than	O
the	O
one	O
presented	O
by	O
PBM	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

No	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
released	O
from	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
native	O
CGN	O
(	O
not	O
shown	O
)	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
THP	O
-	O
1	O
cells	O
was	O
not	O
dose	O
dependent	O
to	O
the	O
amount	O
of	O
dCGN	O
used	O
.	O
<EOS>	B-X
COVID-19	B-X
is	B-X
characterized	B-X
by	B-X
excessive	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
acute	B-X
lung	B-X
damage	B-X
associated	B-X
with	B-X
patient	B-X
mortality	B-X
.	B-X
While	B-X
multiple	B-X
inflammatory	B-X
cytokines	B-X
are	B-X
produced	B-X
by	B-X
innate	B-X
immune	B-X
cells	B-X
during	B-X
SARS-CoV-2	B-X
infection	B-X
,	B-X
we	B-X
found	B-X
that	B-X
only	B-X
the	B-X
combination	B-X
of	B-X
TNF-α	B-X
and	B-X
IFN-γ	B-X
induced	B-X
inflammatory	B-X
cell	B-X
death	B-X
characterized	B-X
by	B-X
inflammatory	B-X
cell	B-X
death	B-X
,	B-X
PANoptosis	B-X
.	B-X
Mechanistically	B-X
,	B-X
TNF-α	B-X
and	B-X
IFN-γ	B-X
co-treatment	B-X
activated	B-X
the	B-X
JAK/STAT1/IRF1	B-X
axis	B-X
,	B-X
inducing	B-X
nitric	B-X
oxide	B-X
production	B-X
and	B-X
driving	B-X
caspase-8/FADD-mediated	B-X
PANoptosis	B-X
.	B-X
TNF-α	B-X
and	B-X
IFN-γ	B-X
caused	B-X
a	B-X
lethal	B-X
cytokine	B-X
shock	B-X
in	B-X
mice	B-X
that	B-X
mirrors	B-X
the	B-X
tissue	B-X
damage	B-X
and	B-X
inflammation	B-X
of	B-X
COVID-19	B-X
,	B-X
and	B-X
inhibiting	B-X
PANoptosis	B-X
protected	B-X
mice	B-X
from	B-X
this	B-X
pathology	B-X
and	B-X
death	B-X
.	B-X
Furthermore	B-X
,	B-X
treating	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
against	B-X
TNF-α	B-X
and	B-X
IFN-γ	B-X
protected	B-X
mice	B-X
from	B-X
mortality	B-X
during	B-X
SARS-CoV-2	B-X
infection	B-X
,	B-X
sepsis	B-X
,	B-X
hemophagocytic	B-X
lymphohistiocytosis	B-X
,	B-X
and	B-X
cytokine	B-X
shock	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
blocking	B-X
the	B-X
cytokine-mediated	B-X
inflammatory	B-X
cell	B-X
death	B-X
signaling	B-X
pathway	B-X
identified	B-X
here	B-X
may	B-X
benefit	B-X
patients	B-X
with	B-X
COVID-19	B-X
or	B-X
other	B-X
infectious	B-X
and	B-X
autoinflammatory	B-X
diseases	B-X
by	B-X
limiting	B-X
tissue	B-X
damage/inflammation	B-X
.	B-X

Also	O
there	O
was	O
no	O
difference	O
between	O
the	O
two	O
forms	O
(	O
10	O
and	O
40	O
kDa	O
)	O
of	O
dCGN	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

Interestingly	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
from	O
THP	O
-	O
1	O
cells	O
stimulated	O
with	O
dCGN	O
reached	O
a	O
maximum	O
level	O
at	O
32	O
h	O
,	O
while	O
stimulation	O
with	O
LPS	O
reached	O
a	O
maximum	O
level	O
at	O
56	O
h	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

Effect	O
of	O
Native	O
and	O
Degraded	O
CGN	O
on	O
THP	O
-	O
1	O
Proliferation	O
and	O
Cell	O
Cycle	O

Preliminary	O
observations	O
by	O
enumeration	O
of	O
THP	O
-	O
1	O
cells	O
exposed	O
to	O
different	O
concentrations	O
of	O
native	O
and	O
dCGN	O
(	O
10	O
and	O
40	O
kDa	O
)	O
during	O
2	O
,	O
5	O
and	O
7	O
days	O
,	O
showed	O
a	O
decline	O
in	O
cell	O
number	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
suggested	O
that	O
dCGN	O
might	O
cause	O
an	O
alteration	O
in	O
the	O
cell	O
cycle	O
.	O

Cell	O
cycle	O
analysis	O
using	O
flow	O
cytometry	O
showed	O
an	O
accumulation	O
of	O
THP	O
-	O
1	O
cells	O
in	O
G0	O
/	O
G1	O
phase	O
,	O
which	O
was	O
associated	O
with	O
a	O
decrease	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

The	O
percentage	O
of	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
was	O
45	O
.	O
2	O
%	O
for	O
control	O
cells	O
,	O
62	O
.	O
6	O
%	O
for	O
C10	O
dCGN	O
(	O
at	O
2	O
mg	O
/	O
ml	O
)	O
,	O
and	O
64	O
.	O
2	O
%	O
for	O
C40	O
dCGN	O
-	O
treated	O
cells	O
(	O
at	O
2	O
mg	O
/	O
ml	O
)	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

The	O
effect	O
of	O
dCGN	O
on	O
cell	O
cycle	O
was	O
dose	O
-	O
dependent	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Neither	O
native	O
nor	O
dCGN	O
had	O
an	O
effect	O
on	O
the	O
number	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
phase	O
(	O
Fig	O
.	O
3	O
)	O
.	O

This	O
effect	O
is	O
not	O
due	O
to	O
cytotoxicity	O
of	O
dCGN	O
even	O
at	O
the	O
highest	O
concentration	O
(	O
i	O
.	O
e	O
.	O
2	O
mg	O
/	O
ml	O
)	O
since	O
cell	O
viability	O
was	O
not	O
affected	O
(	O
data	O
not	O
shown	O
)	O
.	O

ICAM	B-Protein
-	I-Protein
1	I-Protein
Expression	O
Is	O
Induced	O
by	O
Degraded	O
CGN	O
and	O
Is	O
Responsible	O
for	O
Monocytes	O
Aggregation	O
In	O
Vitro	O

In	O
order	O
to	O
study	O
the	O
effect	O
of	O
dCGN	O
on	O
the	O
expression	O
of	O
cell	O
surface	O
antigens	O
,	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
for	O
36	O
h	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dCGN	O
.	O

The	O
expression	O
of	O
various	O
cell	O
surface	O
molecules	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
as	O
described	O
in	O
materials	O
and	O
methods	O
.	O
<EOS>	B-X
Murine	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
negative	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
Flt-3	B-X
.	B-X
We	B-X
now	B-X
present	B-X
clear	B-X
evidence	B-X
for	B-X
the	B-X
expression	B-X
change	B-X
of	B-X
Flt-3	B-X
(	B-X
-	B-X
)	B-X
HSCs	B-X
in	B-X
an	B-X
activating	B-X
state	B-X
,	B-X
and	B-X
the	B-X
reversibility	B-X
of	B-X
Flt-3	B-X
expression	B-X
by	B-X
HSCs	B-X
in	B-X
vivo	B-X
.	B-X

Both	O
forms	O
of	O
dCGN	O
clearly	O
stimulated	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
(	O
CD54	B-Protein
)	O
on	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

The	O
increase	O
in	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
higher	O
on	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Another	O
surface	O
antigen	O
,	O
the	O
lymphocyte	B-Protein
function	I-Protein
-	I-Protein
associated	I-Protein
antigen	I-Protein
3	I-Protein
(	O
CD58	B-Protein
)	O
was	O
slightly	O
reduced	O
on	O
PBM	O
after	O
treatment	O
with	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Interestingly	O
,	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
molecules	O
of	O
class	O
I	O
(	O
HLA	O
-	O
ABC	O
)	O
and	O
of	O
class	O
II	O
(	O
HLA	O
-	O
DR	O
)	O
,	O
as	O
well	O
as	O
the	O
monocyte	B-Protein
marker	I-Protein
CD14	B-Protein
,	O
seemed	O
to	O
be	O
reduced	O
by	O
treatment	O
with	O
dCGN	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

However	O
,	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
<EOS>	B-X
Altogether	B-X
,	B-X
sex-related	B-X
differences	B-X
in	B-X
PD	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
disease	B-X
development	B-X
might	B-X
involve	B-X
distinct	B-X
pathogenic	B-X
mechanisms	B-X
(	B-X
or	B-X
the	B-X
same	B-X
mechanism	B-X
but	B-X
in	B-X
a	B-X
different	B-X
way	B-X
)	B-X
in	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
most	B-X
recent	B-X
knowledge	B-X
concerning	B-X
differences	B-X
between	B-X
women	B-X
and	B-X
men	B-X
in	B-X
PD	B-X
clinical	B-X
features	B-X
,	B-X
risk	B-X
factors	B-X
,	B-X
response	B-X
to	B-X
treatments	B-X
and	B-X
mechanisms	B-X
underlying	B-X
the	B-X
disease	B-X
pathophysiology	B-X
.	B-X
Considering	B-X
how	B-X
different	B-X
sleep-wake	B-X
behavior	B-X
can	B-X
be	B-X
between	B-X
workdays	B-X
and	B-X
work-free	B-X
days	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
sleep	B-X
quality	B-X
should	B-X
show	B-X
similar	B-X
differences	B-X
.	B-X
We	B-X
investigated	B-X
these	B-X
potential	B-X
differences	B-X
in	B-X
a	B-X
cross-sectional	B-X
online	B-X
study	B-X
using	B-X
the	B-X
original	B-X
and	B-X
two	B-X
adapted	B-X
versions	B-X
of	B-X
the	B-X
PSQI	B-X
that	B-X
replaced	B-X
``	B-X
usual	B-X
''	B-X
by	B-X
explicitly	B-X
referring	B-X
to	B-X
sleep	B-X
on	B-X
workdays	B-X
or	B-X
work-free	B-X
days	B-X
.	B-X
To	B-X
find	B-X
out	B-X
whether	B-X
PSQI	B-X
score	B-X
differences	B-X
could	B-X
be	B-X
predicted	B-X
by	B-X
chronotype	B-X
and/or	B-X
social	B-X
jetlag	B-X
a	B-X
mediation	B-X
analysis	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
The	B-X
mediation	B-X
of	B-X
social	B-X
jetlag	B-X
on	B-X
the	B-X
association	B-X
of	B-X
chronotype	B-X
and	B-X
PSQI	B-X
score	B-X
differences	B-X
could	B-X
mean	B-X
that	B-X
not	B-X
chronotype	B-X
per	B-X
se	B-X
,	B-X
but	B-X
rather	B-X
the	B-X
collision	B-X
of	B-X
an	B-X
individuals	B-X
'	B-X
chronotype	B-X
with	B-X
fixed	B-X
work	B-X
schedules	B-X
explains	B-X
the	B-X
differences	B-X
between	B-X
sleep	B-X
on	B-X
workdays	B-X
and	B-X
work-free	B-X
days	B-X
.	B-X

Treatment	O
with	O
dCGN	O
also	O
induced	O
a	O
strong	O
aggregation	O
of	O
monocytes	O
,	O
detected	O
by	O
phase	O
contrast	O
inverse	O
microscopy	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Although	O
this	O
effect	O
was	O
easily	O
observed	O
in	O
monocytes	O
incubated	O
with	O
the	O
10	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
5B	O
)	O
,	O
a	O
more	O
robust	O
cell	O
aggregation	O
was	O
observed	O
in	O
monocytes	O
incubated	O
with	O
the	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

ICAM	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
proposed	O
to	O
be	O
the	O
main	O
adhesion	O
molecule	O
responsible	O
for	O
monocyte	O
aggregation	O
.	O

To	O
confirm	O
this	O
,	O
monocytes	O
were	O
incubated	O
with	O
both	O
types	O
of	O
dCGN	O
in	O
the	O
presence	O
of	O
an	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
,	O
an	O
anti	O
-	O
CD58	O
antibody	O
and	O
an	O
isotype	O
control	O
IgG1	O
antibody	O
.	O

The	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
effectively	O
blocked	O
the	O
cell	O
aggregates	O
induced	O
by	O
dCGN	O
(	O
Fig	O
.	O
5D	O
,	O
5E	O
)	O
,	O
strongly	O
suggesting	O
that	O
indeed	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
is	O
responsible	O
for	O
monocyte	O
aggregation	O
.	O

Both	O
the	O
control	O
IgG1	O
and	O
the	O
anti	O
-	O
CD58	O
antibody	O
did	O
not	O
modify	O
monocyte	O
aggregation	O
(	O
data	O
not	O
shown	O
)	O
.	O

Degraded	O
CGN	O
Induce	O
an	O
Increase	O
in	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
Expression	O

The	O
increase	O
in	O
surface	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
monocytes	O
correlated	O
with	O
an	O
upregulation	O
of	O
mRNA	O
for	O
these	O
molecules	O
.	O
<EOS>	B-X
All	B-X
three	B-X
RSV-infected	B-X
endothelial	B-X
cell	B-X
types	B-X
showed	B-X
an	B-X
enhanced	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
ICAM-1	B-X
(	B-X
CD54	B-X
)	B-X
,	B-X
which	B-X
increased	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
RSV-dose-dependent	B-X
manner	B-X
.	B-X
By	B-X
using	B-X
noninfectious	B-X
RSV	B-X
particles	B-X
we	B-X
verified	B-X
that	B-X
replication	B-X
of	B-X
RSV	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
increase	B-X
of	B-X
ICAM-1	B-X
cell	B-X
surface	B-X
expression	B-X
.	B-X
The	B-X
up-regulated	B-X
ICAM-1	B-X
expression	B-X
pattern	B-X
correlated	B-X
with	B-X
an	B-X
increased	B-X
cellular	B-X
ICAM-1	B-X
mRNA	B-X
amount	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
ICAM-1	B-X
,	B-X
a	B-X
de	B-X
novo	B-X
expression	B-X
of	B-X
VCAM-1	B-X
(	B-X
CD106	B-X
)	B-X
was	B-X
only	B-X
observed	B-X
on	B-X
RSV-infected	B-X
HUVEC	B-X
.	B-X
Additional	B-X
experiments	B-X
performed	B-X
with	B-X
neutralizing	B-X
Abs	B-X
specific	B-X
for	B-X
IL-1alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
TNF-alpha	B-X
,	B-X
respectively	B-X
,	B-X
excluded	B-X
an	B-X
autocrine	B-X
mechanism	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
ICAM-1	B-X
up-regulation	B-X
.	B-X
The	B-X
virus-induced	B-X
ICAM-1	B-X
up-regulation	B-X
was	B-X
dependent	B-X
on	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
A	B-X
,	B-X
PI3K	B-X
,	B-X
and	B-X
p38	B-X
MAPK	B-X
activity	B-X
.	B-X
Adhesion	B-X
experiments	B-X
using	B-X
polymorphonuclear	B-X
neutrophil	B-X
granulocytes	B-X
(	B-X
PMN	B-X
)	B-X
verified	B-X
an	B-X
increased	B-X
ICAM-1-dependent	B-X
adhesion	B-X
rate	B-X
of	B-X
PMN	B-X
cocultured	B-X
with	B-X
RSV-infected	B-X
endothelial	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
increased	B-X
adhesiveness	B-X
resulted	B-X
in	B-X
an	B-X
enhanced	B-X
transmigration	B-X
rate	B-X
of	B-X
PMN	B-X
.	B-X
Our	B-X
in	B-X
vitro	B-X
data	B-X
suggest	B-X
that	B-X
human	B-X
lung	B-X
endothelial	B-X
cells	B-X
are	B-X
target	B-X
cells	B-X
for	B-X
RSV	B-X
infection	B-X
and	B-X
that	B-X
ICAM-1	B-X
up-regulated	B-X
on	B-X
RSV-infected	B-X
endothelial	B-X
cells	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
enhanced	B-X
accumulation	B-X
of	B-X
PMN	B-X
into	B-X
the	B-X
bronchoalveolar	B-X
space	B-X
.	B-X

Both	O
10	O
kDa	O
and	O
40	O
kDa	O
dCGN	O
induced	O
a	O
robust	O
increase	O
in	O
mRNA	O
for	O
both	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Fig	O
.	O
6	O
)	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
dCGN	O
treatment	O
.	O

Degraded	O
CGN	O
Induce	O
IkappaB	O
Degradation	O
and	O
NF	O
-	O
kappaB	O
Activation	O
<EOS>	B-X
Experiments	B-X
in	B-X
this	B-X
report	B-X
indicate	B-X
that	B-X
BCL10	B-X
is	B-X
required	B-X
for	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
by	B-X
both	B-X
canonical	B-X
and	B-X
noncanonical	B-X
pathways	B-X
,	B-X
following	B-X
stimulation	B-X
by	B-X
the	B-X
sulfated	B-X
polysaccharide	B-X
carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
.	B-X
In	B-X
wild	B-X
type	B-X
and	B-X
IkappaB-kinase	B-X
(	B-X
IKK	B-X
)	B-X
alpha	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
,	B-X
increases	B-X
in	B-X
phospho-IkappaBalpha	B-X
,	B-X
nuclear	B-X
NF-kappaB	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
and	B-X
p50	B-X
,	B-X
and	B-X
KC	B-X
,	B-X
the	B-X
mouse	B-X
analog	B-X
of	B-X
human	B-X
interleukin-8	B-X
,	B-X
were	B-X
markedly	B-X
reduced	B-X
by	B-X
silencing	B-X
BCL10	B-X
or	B-X
by	B-X
exposure	B-X
to	B-X
the	B-X
free	B-X
radical	B-X
scavenger	B-X
Tempol	B-X
.	B-X
In	B-X
IKKbeta	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
,	B-X
BCL10	B-X
silencing	B-X
,	B-X
but	B-X
not	B-X
Tempol	B-X
,	B-X
reduced	B-X
the	B-X
CGN-induced	B-X
increases	B-X
in	B-X
KC	B-X
,	B-X
phospho-NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
cytoplasmic	B-X
NF-kappaB	B-X
p100	B-X
,	B-X
and	B-X
nuclear	B-X
NF-kappaB	B-X
p52	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
a	B-X
BCL10	B-X
requirement	B-X
for	B-X
activation	B-X
of	B-X
the	B-X
noncanonical	B-X
pathway	B-X
.	B-X
In	B-X
NCM460	B-X
cells	B-X
,	B-X
derived	B-X
from	B-X
normal	B-X
,	B-X
human	B-X
colonic	B-X
epithelium	B-X
,	B-X
the	B-X
CGN-induced	B-X
increases	B-X
in	B-X
NF-kappaB	B-X
family	B-X
members	B-X
,	B-X
p65	B-X
,	B-X
p50	B-X
,	B-X
p52	B-X
,	B-X
and	B-X
RelB	B-X
,	B-X
were	B-X
inhibited	B-X
by	B-X
BCL10	B-X
silencing	B-X
.	B-X
Although	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
confocal	B-X
images	B-X
demonstrated	B-X
no	B-X
change	B-X
in	B-X
total	B-X
NIK	B-X
following	B-X
CGN	B-X
,	B-X
increases	B-X
in	B-X
phospho-NIK	B-X
in	B-X
the	B-X
wild	B-X
type	B-X
,	B-X
IKKbeta	B-X
(	B-X
-/-	B-X
)	B-X
and	B-X
IKKalpha	B-X
(	B-X
-/-	B-X
)	B-X
cells	B-X
were	B-X
inhibited	B-X
by	B-X
silencing	B-X
BCL10	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
an	B-X
upstream	B-X
signaling	B-X
role	B-X
for	B-X
BCL10	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
its	B-X
effects	B-X
on	B-X
IKKgamma	B-X
,	B-X
the	B-X
regulatory	B-X
component	B-X
of	B-X
the	B-X
IKK	B-X
signalosome	B-X
,	B-X
and	B-X
a	B-X
requirement	B-X
for	B-X
BCL10	B-X
in	B-X
both	B-X
canonical	B-X
and	B-X
noncanonical	B-X
pathways	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X

The	O
expression	O
of	O
genes	O
encoding	O
for	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
controlled	O
by	O
the	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
.	O

Site	O
-	O
specific	O
phosphorylation	O
of	O
the	O
inhibitor	O
IkappaB	O
leads	O
to	O
its	O
degradation	O
by	O
proteasome	O
and	O
to	O
a	O
consequential	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

Using	O
a	O
reporter	O
plasmid	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
it	O
was	O
confirmed	O
that	O
dCGN	O
induced	O
a	O
strong	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
as	O
reflected	O
by	O
an	O
increase	O
in	O
luciferase	B-Protein
activity	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

Both	O
forms	O
of	O
dCGN	O
used	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

However	O
,	O
the	O
effect	O
was	O
more	O
strongly	O
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

These	O
results	O
were	O
further	O
confirmed	O
by	O
directly	O
detecting	O
NF	O
-	O
kappaB	O
in	O
the	O
cell	O
nucleus	O
by	O
Western	O
blotting	O
(	O
Fig	O
.	O
7C	O
)	O
and	O
by	O
FACS	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

These	O
assays	O
also	O
allowed	O
us	O
to	O
determine	O
what	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
subunits	I-Protein
were	O
activated	O
by	O
dCGN	O
.	O

Both	O
forms	O
(	O
10	O
or	O
40	O
kDa	O
)	O
of	O
dCGN	O
induced	O
activation	O
of	O
the	O
p50	B-Protein
and	O
p65	B-Protein
subunits	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
nuclear	O
factor	O
was	O
present	O
in	O
low	O
levels	O
in	O
the	O
cell	O
nucleus	O
and	O
increased	O
considerably	O
after	O
treatment	O
with	O
dCGN	O
.	O

Western	O
blots	O
suggested	O
the	O
the	O
40	O
kDa	O
form	O
of	O
dCGN	O
induced	O
a	O
stronger	O
activation	O
of	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

A	O
more	O
sentive	O
assay	O
for	O
nuclear	O
factor	O
activation	O
is	O
flow	O
cytometry	O
of	O
nuclei	O
stained	O
with	O
specific	O
antibodies	O
for	O
the	O
nuclear	O
factor	O
of	O
interest	O
.	O

In	O
agreement	O
with	O
the	O
previous	O
data	O
,	O
FACS	O
analysis	O
of	O
nuclei	O
from	O
THP	O
-	O
1	O
cells	O
showed	O
that	O
there	O
was	O
a	O
basal	O
level	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

Again	O
,	O
both	O
forms	O
(	O
10	O
or	O
40	O
kDa	O
)	O
of	O
dCGN	O
induced	O
an	O
increase	O
of	O
the	O
p50	B-Protein
and	O
p65	B-Protein
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

The	O
40	O
kDa	O
degraded	O
CGN	O
gave	O
a	O
stronger	O
increase	O
of	O
NF	O
-	O
kappaB	O
(	O
Fig	O
.	O
7D	O
)	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
the	O
heterodimer	O
p50	O
/	O
p65	O
is	O
the	O
NF	O
-	O
kappaB	O
isoform	O
activated	O
by	O
degraded	O
CGN	O
in	O
monocytes	O
.	O

In	O
addition	O
,	O
degradation	O
of	O
the	O
inhibitor	B-Protein
IkappaBalpha	B-Protein
was	O
also	O
observed	O
in	O
cells	O
treated	O
with	O
dCGN	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

No	O
significant	O
IkappaBalpha	B-Protein
degradation	O
was	O
detected	O
within	O
two	O
hours	O
of	O
dCGN	O
treatment	O
,	O
but	O
IkappaBalpha	B-Protein
was	O
markedly	O
degraded	O
by	O
four	O
hours	O
of	O
dCGN	O
treatment	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

We	O
focused	O
on	O
IkappaBalpha	B-Protein
subunit	O
,	O
since	O
it	O
masks	O
the	O
nuclear	O
localisation	O
sequence	O
of	O
p65	B-Protein
,	O
it	O
is	O
the	O
most	O
rapidly	O
degraded	O
subunit	O
and	O
the	O
most	O
studied	O
one	O
.	O

Inflammation	O
of	O
the	O
intestinal	O
tract	O
is	O
usually	O
associated	O
with	O
infiltration	O
and	O
activation	O
of	O
intestinal	O
macrophages	O
[	O
17	O
]	O
.	O

These	O
macrophages	O
are	O
able	O
to	O
initiate	O
immune	O
responses	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
cells	O
that	O
either	O
exacerbate	O
or	O
inhibit	O
the	O
inflammation	O
.	O
<EOS>	B-X
Punicalagin	B-X
,	B-X
a	B-X
hydrolysable	B-X
tannin	B-X
of	B-X
pomegranate	B-X
juice	B-X
,	B-X
exhibits	B-X
multiple	B-X
biological	B-X
effects	B-X
,	B-X
including	B-X
inhibiting	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
in	B-X
macrophages	B-X
.	B-X
Autophagy	B-X
,	B-X
an	B-X
intracellular	B-X
self-digestion	B-X
process	B-X
,	B-X
has	B-X
been	B-X
recently	B-X
shown	B-X
to	B-X
regulate	B-X
inflammatory	B-X
responses	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
anti-inflammatory	B-X
potential	B-X
of	B-X
punicalagin	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induced	B-X
RAW264.7	B-X
macrophages	B-X
and	B-X
uncovered	B-X
the	B-X
underlying	B-X
mechanisms	B-X
.	B-X
Punicalagin	B-X
significantly	B-X
attenuated	B-X
,	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
LPS-induced	B-X
release	B-X
of	B-X
NO	B-X
and	B-X
decreased	B-X
pro-inflammatory	B-X
cytokines	B-X
TNF-α	B-X
and	B-X
IL-6	B-X
release	B-X
at	B-X
the	B-X
highest	B-X
concentration	B-X
.	B-X
We	B-X
found	B-X
that	B-X
punicalagin	B-X
inhibited	B-X
NF-κB	B-X
and	B-X
MAPK	B-X
activation	B-X
in	B-X
LPS-induced	B-X
RAW264.7	B-X
macrophages	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
punicalagin	B-X
pre-treatment	B-X
enhanced	B-X
LC3II	B-X
,	B-X
p62	B-X
expression	B-X
,	B-X
and	B-X
decreased	B-X
Beclin1	B-X
expression	B-X
in	B-X
LPS-induced	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
our	B-X
observations	B-X
indicated	B-X
that	B-X
LPS-induced	B-X
releases	B-X
of	B-X
NO	B-X
,	B-X
TNF-α	B-X
,	B-X
and	B-X
IL-6	B-X
were	B-X
attenuated	B-X
by	B-X
treatment	B-X
with	B-X
autophagy	B-X
inhibitor	B-X
chloroquine	B-X
,	B-X
suggesting	B-X
that	B-X
autophagy	B-X
inhibition	B-X
participated	B-X
in	B-X
anti-inflammatory	B-X
effect	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
punicalagin	B-X
downregulated	B-X
FoxO3a	B-X
expression	B-X
,	B-X
resulting	B-X
in	B-X
autophagy	B-X
inhibition	B-X
.	B-X
Overall	B-X
these	B-X
results	B-X
suggested	B-X
that	B-X
punicalagin	B-X
played	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
attenuation	B-X
of	B-X
LPS-induced	B-X
inflammatory	B-X
responses	B-X
in	B-X
RAW264.7	B-X
macrophages	B-X
and	B-X
that	B-X
the	B-X
mechanisms	B-X
involved	B-X
downregulation	B-X
of	B-X
the	B-X
FoxO3a/autophagy	B-X
signaling	B-X
pathway	B-X
.	B-X

Accumulation	O
of	O
different	O
types	O
of	O
leukocytes	O
,	O
including	O
monocytes	O
/	O
macrophages	O
,	O
neutrophils	O
,	O
and	O
lymphocytes	O
in	O
the	O
intestinal	O
mucosa	O
during	O
inflammation	O
,	O
is	O
normally	O
followed	O
by	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
[	O
33	O
]	O
.	O

Several	O
stimuli	O
can	O
induce	O
these	O
leukocytes	O
to	O
produce	O
and	O
secrete	O
cytokines	O
during	O
inflammation	O
.	O
<EOS>	B-X
Fibrosis	B-X
is	B-X
the	B-X
end	B-X
result	B-X
of	B-X
chronic	B-X
inflammatory	B-X
reactions	B-X
induced	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
stimuli	B-X
including	B-X
persistent	B-X
infections	B-X
,	B-X
autoimmune	B-X
reactions	B-X
,	B-X
allergic	B-X
responses	B-X
,	B-X
chemical	B-X
insults	B-X
,	B-X
radiation	B-X
,	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
Although	B-X
current	B-X
treatments	B-X
for	B-X
fibrotic	B-X
diseases	B-X
such	B-X
as	B-X
idiopathic	B-X
pulmonary	B-X
fibrosis	B-X
,	B-X
liver	B-X
cirrhosis	B-X
,	B-X
systemic	B-X
sclerosis	B-X
,	B-X
progressive	B-X
kidney	B-X
disease	B-X
,	B-X
and	B-X
cardiovascular	B-X
fibrosis	B-X
typically	B-X
target	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
there	B-X
is	B-X
accumulating	B-X
evidence	B-X
that	B-X
the	B-X
mechanisms	B-X
driving	B-X
fibrogenesis	B-X
are	B-X
distinct	B-X
from	B-X
those	B-X
regulating	B-X
inflammation	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
some	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
ongoing	B-X
inflammation	B-X
is	B-X
needed	B-X
to	B-X
reverse	B-X
established	B-X
and	B-X
progressive	B-X
fibrosis	B-X
.	B-X
Myofibroblasts	B-X
are	B-X
activated	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
mechanisms	B-X
,	B-X
including	B-X
paracrine	B-X
signals	B-X
derived	B-X
from	B-X
lymphocytes	B-X
and	B-X
macrophages	B-X
,	B-X
autocrine	B-X
factors	B-X
secreted	B-X
by	B-X
myofibroblasts	B-X
,	B-X
and	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
PAMPS	B-X
)	B-X
produced	B-X
by	B-X
pathogenic	B-X
organisms	B-X
that	B-X
interact	B-X
with	B-X
pattern	B-X
recognition	B-X
receptors	B-X
(	B-X
i.e	B-X
.	B-X

One	O
of	O
the	O
most	O
potent	O
and	O
known	O
stimuli	O
for	O
leukocyte	O
activation	O
is	O
LPS	O
from	O
Gram	O
-	O
negative	O
bacteria	O
[	O
34	O
]	O
.	O
<EOS>	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
from	B-X
Gram-negative	B-X
bacteria	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
innate	B-X
immune-activating	B-X
stimuli	B-X
known	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
LPS	B-X
effects	B-X
on	B-X
human	B-X
monocyte	B-X
and	B-X
macrophage	B-X
function	B-X
.	B-X
We	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
LPS	B-X
signal	B-X
transduction	B-X
with	B-X
attention	B-X
given	B-X
to	B-X
receptor	B-X
cooperativity	B-X
and	B-X
species	B-X
differences	B-X
in	B-X
LPS	B-X
responses	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
role	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
and	B-X
lysine	B-X
acetylation	B-X
in	B-X
signalling	B-X
.	B-X
We	B-X
also	B-X
review	B-X
LPS-regulated	B-X
transcription	B-X
,	B-X
with	B-X
emphasis	B-X
on	B-X
chromatin	B-X
remodeling	B-X
and	B-X
primary	B-X
versus	B-X
secondary	B-X
transcriptional	B-X
control	B-X
mechanisms	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
review	B-X
the	B-X
regulation	B-X
and	B-X
function	B-X
of	B-X
LPS-inducible	B-X
cytokines	B-X
produced	B-X
by	B-X
human	B-X
monocytes	B-X
and	B-X
macrophages	B-X
including	B-X
TNFα	B-X
,	B-X
the	B-X
IL-1	B-X
family	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
the	B-X
IL-10	B-X
family	B-X
,	B-X
the	B-X
IL-12	B-X
family	B-X
,	B-X
IL-15	B-X
and	B-X
TGFβ	B-X
.	B-X

In	O
addition	O
,	O
other	O
factors	O
are	O
also	O
able	O
to	O
stimulate	O
cytokine	O
secretion	O
from	O
various	O
leukocytes	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
.	O
<EOS>	B-X
Although	B-X
epithelial	B-X
cells	B-X
can	B-X
also	B-X
be	B-X
induced	B-X
by	B-X
Th2	B-X
cytokines	B-X
to	B-X
express	B-X
proeosinophilic	B-X
mediators	B-X
,	B-X
no	B-X
environmental	B-X
agents	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
promote	B-X
this	B-X
effect	B-X
.	B-X
Fc	B-X
epsilon	B-X
R2/CD23	B-X
induction	B-X
was	B-X
detectable	B-X
both	B-X
by	B-X
flow	B-X
cytometry	B-X
using	B-X
anti-CD23	B-X
mAbs	B-X
as	B-X
well	B-X
as	B-X
soluble	B-X
IgE	B-X
,	B-X
and	B-X
by	B-X
the	B-X
immunoprecipitation	B-X
with	B-X
CD23-specific	B-X
mAb	B-X
or	B-X
IgE	B-X
of	B-X
a	B-X
45-kD	B-X
band	B-X
from	B-X
125I-lactoperoxidase-labeled	B-X
Mo	B-X
.	B-X
Fc	B-X
epsilon	B-X
R2/CD23	B-X
was	B-X
fully	B-X
expressed	B-X
after	B-X
a	B-X
24-h	B-X
incubation	B-X
with	B-X
rIL-4	B-X
,	B-X
and	B-X
was	B-X
still	B-X
detectable	B-X
after	B-X
72	B-X
h	B-X
from	B-X
the	B-X
addition	B-X
of	B-X
IL-4	B-X
.	B-X
This	B-X
effect	B-X
was	B-X
specific	B-X
,	B-X
because	B-X
none	B-X
of	B-X
the	B-X
other	B-X
rILs	B-X
tested	B-X
(	B-X
IL-1	B-X
,	B-X
IL-2	B-X
,	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
B	B-X
cell	B-X
stimulatory	B-X
factor	B-X
2	B-X
,	B-X
granulocyte-macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
,	B-X
and	B-X
IFN-gamma	B-X
)	B-X
could	B-X
induce	B-X
FC	B-X
epsilon	B-X
R2/CD23	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
various	B-X
combinations	B-X
.	B-X
IFN-gamma	B-X
was	B-X
not	B-X
able	B-X
to	B-X
inhibit	B-X
the	B-X
IL-4-induced	B-X
expression	B-X
of	B-X
Fc	B-X
epsilon	B-X
R2/CD23	B-X
on	B-X
Mo	B-X
,	B-X
neither	B-X
when	B-X
added	B-X
to	B-X
the	B-X
culture	B-X
together	B-X
with	B-X
IL-4	B-X
,	B-X
nor	B-X
when	B-X
added	B-X
36	B-X
h	B-X
earlier	B-X
.	B-X

One	O
such	O
factor	O
is	O
CGN	O
,	O
a	O
high	O
molecular	O
weight	O
sulphated	O
polysaccharide	O
(	O
>	O
200	O
kDa	O
)	O
derived	O
from	O
red	O
algae	O
(	O
Rhodophyceae	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Native	O
CGN	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
(	O
E	O
407	O
)	O
to	O
improve	O
texture	O
.	O

It	O
is	O
also	O
used	O
in	O
cosmetics	O
and	O
pharmaceuticals	O
.	O
<EOS>	B-X
The	B-X
classification	B-X
as	B-X
bio-inert	B-X
material	B-X
has	B-X
given	B-X
the	B-X
possibility	B-X
to	B-X
normal-sized	B-X
(	B-X
>	B-X
100	B-X
nm	B-X
)	B-X
titanium	B-X
dioxide	B-X
particles	B-X
(	B-X
TiO2-NPs	B-X
)	B-X
to	B-X
be	B-X
extensively	B-X
used	B-X
in	B-X
food	B-X
products	B-X
and	B-X
as	B-X
ingredients	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
pharmaceutical	B-X
products	B-X
and	B-X
cosmetics	B-X
,	B-X
such	B-X
as	B-X
sunscreens	B-X
and	B-X
toothpastes	B-X
.	B-X
Cosmetics	B-X
,	B-X
cosmeceuticals	B-X
,	B-X
and	B-X
variable	B-X
healthcare	B-X
products	B-X
used	B-X
parabens	B-X
,	B-X
among	B-X
other	B-X
excipients	B-X
,	B-X
for	B-X
their	B-X
preservative	B-X
and	B-X
antimicrobial	B-X
activities	B-X
.	B-X
In	B-X
response	B-X
,	B-X
worldwide	B-X
authorities	B-X
set	B-X
regulations	B-X
for	B-X
the	B-X
allowance	B-X
concentrations	B-X
of	B-X
paraben	B-X
to	B-X
be	B-X
used	B-X
in	B-X
variable	B-X
cosmetic	B-X
products	B-X
.	B-X
The	B-X
recent	B-X
increase	B-X
in	B-X
the	B-X
consumption	B-X
of	B-X
modern	B-X
human	B-X
or	B-X
veterinary	B-X
drugs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
surge	B-X
of	B-X
anthropogenic	B-X
pharmaceuticals	B-X
,	B-X
frequently	B-X
introduced	B-X
into	B-X
terrestrial	B-X
environments	B-X
via	B-X
untreated/treated	B-X
wastewater	B-X
.	B-X
Details	B-X
about	B-X
adsorption	B-X
,	B-X
absorption	B-X
,	B-X
degradation	B-X
and	B-X
uptake	B-X
behaviours	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
fate	B-X
and	B-X
actual	B-X
environmental	B-X
impact	B-X
of	B-X
pharmaceuticals	B-X
are	B-X
a	B-X
prerequisite	B-X
before	B-X
the	B-X
traditional	B-X
transportation	B-X
prediction	B-X
models	B-X
originally	B-X
designed	B-X
for	B-X
the	B-X
aquatic	B-X
environment	B-X
can	B-X
be	B-X
extrapolated	B-X
to	B-X
terrestrial	B-X
systems	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
current	B-X
knowledgebase	B-X
pertaining	B-X
the	B-X
introduction	B-X
of	B-X
pharmaceuticals	B-X
to	B-X
soils	B-X
via	B-X
wastewater	B-X
irrigation	B-X
or	B-X
the	B-X
application	B-X
of	B-X
biosolids	B-X
.	B-X
The	B-X
focus	B-X
on	B-X
the	B-X
transportation	B-X
,	B-X
transformation	B-X
and	B-X
accumulation	B-X
of	B-X
pharmaceuticals	B-X
through	B-X
the	B-X
food	B-X
chain	B-X
highlights	B-X
the	B-X
urgent	B-X
need	B-X
to	B-X
strengthen	B-X
our	B-X
capabilities	B-X
concerning	B-X
their	B-X
detection	B-X
and	B-X
characterization	B-X
in	B-X
the	B-X
terrestrial	B-X
ecosystem	B-X
.	B-X

Although	O
native	O
form	O
CGN	O
(	O
200	O
-	O
800	O
kDa	O
)	O
has	O
been	O
declared	O
harmless	O
to	O
humans	O
[	O
8	O
]	O
,	O
its	O
degraded	O
forms	O
(	O
<	O
50	O
kDa	O
)	O
,	O
also	O
known	O
as	O
poligeenan	O
,	O
are	O
widely	O
used	O
to	O
induce	O
colitis	O
in	O
rodents	O
[	O
3	O
]	O
-	O
[	O
5	O
]	O
.	O

These	O
degraded	O
CGN	O
may	O
also	O
have	O
a	O
possible	O
carcinogenic	O
effect	O
[	O
4	O
]	O
,	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
;	O
however	O
this	O
is	O
still	O
controversial	O
.	O
<EOS>	B-X
The	B-X
range	B-X
of	B-X
contamination	B-X
is	B-X
between	B-X
0.7	B-X
to	B-X
7.8	B-X
ng	B-X
ml-1	B-X
for	B-X
the	B-X
general	B-X
population	B-X
and	B-X
12	B-X
to	B-X
55	B-X
ng	B-X
ml-1	B-X
for	B-X
people	B-X
suffering	B-X
from	B-X
chronic	B-X
renal	B-X
failure	B-X
.	B-X
It	B-X
appears	B-X
that	B-X
21	B-X
to	B-X
64	B-X
%	B-X
of	B-X
people	B-X
suffering	B-X
from	B-X
nephropathy	B-X
are	B-X
OTA	B-X
positive	B-X
with	B-X
a	B-X
detection	B-X
limit	B-X
of	B-X
1ng	B-X
ml-1	B-X
.	B-X
This	B-X
situation	B-X
prompted	B-X
us	B-X
to	B-X
search	B-X
for	B-X
possible	B-X
association	B-X
of	B-X
OTA	B-X
contamination	B-X
and	B-X
nephropathy	B-X
resembling	B-X
Balkan	B-X
endemic	B-X
nephropathy	B-X
.	B-X
The	B-X
classification	B-X
of	B-X
the	B-X
ill	B-X
population	B-X
into	B-X
chronic	B-X
interstitial	B-X
nephropathy	B-X
(	B-X
CIN	B-X
)	B-X
,	B-X
chronic	B-X
glomerular	B-X
nephropathy	B-X
(	B-X
CGN	B-X
)	B-X
,	B-X
chronic	B-X
vascular	B-X
nephropathy	B-X
(	B-X
CVN	B-X
)	B-X
and	B-X
others	B-X
,	B-X
indicated	B-X
that	B-X
the	B-X
largest	B-X
is	B-X
the	B-X
CIN	B-X
group	B-X
which	B-X
is	B-X
significantly	B-X
different	B-X
from	B-X
the	B-X
other	B-X
groups	B-X
,	B-X
and	B-X
from	B-X
the	B-X
control	B-X
(	B-X
P	B-X
<	B-X
0.005	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
presented	B-X
the	B-X
highest	B-X
OTA	B-X
mean	B-X
values	B-X
(	B-X
25	B-X
to	B-X
59	B-X
ng	B-X
ml-1	B-X
)	B-X
compared	B-X
with	B-X
the	B-X
control	B-X
,	B-X
CGN	B-X
,	B-X
CVN	B-X
and	B-X
other	B-X
groups	B-X
(	B-X
6	B-X
to	B-X
18	B-X
ng	B-X
ml-1	B-X
)	B-X
according	B-X
to	B-X
the	B-X
designated	B-X
region	B-X
in	B-X
Tunisia	B-X
.	B-X

Although	O
acid	O
treatment	O
at	O
high	O
temperature	O
(	O
80degreesC	O
)	O
is	O
required	O
for	O
CGN	O
hydrolysis	O
in	O
vitro	O
to	O
lower	O
molecular	O
weight	O
dCGN	O
,	O
it	O
is	O
probable	O
that	O
some	O
dCGN	O
are	O
produced	O
by	O
acid	O
hydrolysis	O
during	O
gastric	O
digestion	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
or	O
interaction	O
with	O
intestinal	O
bacteria	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O
<EOS>	B-X
A	B-X
group	B-X
of	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
that	B-X
less	B-X
than	B-X
the	B-X
genome-wide	B-X
statistical	B-X
significance	B-X
threshold	B-X
(	B-X
5	B-X
×	B-X
10	B-X
COVID-19	B-X
is	B-X
an	B-X
infectious	B-X
disease	B-X
caused	B-X
by	B-X
the	B-X
Severe	B-X
Acute	B-X
Respiratory	B-X
Syndrome	B-X
Coronavirus-2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
and	B-X
according	B-X
to	B-X
the	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
,	B-X
to	B-X
date	B-X
,	B-X
SARS-CoV-2	B-X
has	B-X
already	B-X
infected	B-X
more	B-X
than	B-X
91.8	B-X
million	B-X
people	B-X
worldwide	B-X
with	B-X
1,986,871	B-X
deaths	B-X
.	B-X
This	B-X
virus	B-X
affects	B-X
mainly	B-X
the	B-X
respiratory	B-X
system	B-X
,	B-X
but	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
(	B-X
GIT	B-X
)	B-X
is	B-X
also	B-X
a	B-X
target	B-X
,	B-X
meanwhile	B-X
SARS-CoV-2	B-X
was	B-X
already	B-X
detected	B-X
in	B-X
oesophagus	B-X
,	B-X
stomach	B-X
,	B-X
duodenum	B-X
,	B-X
rectum	B-X
,	B-X
and	B-X
in	B-X
fecal	B-X
samples	B-X
from	B-X
COVID-19	B-X
patients	B-X
.	B-X
Prolonged	B-X
GIT	B-X
manifestations	B-X
in	B-X
COVID-19	B-X
,	B-X
mainly	B-X
the	B-X
diarrhea	B-X
,	B-X
were	B-X
correlated	B-X
with	B-X
decreased	B-X
richness	B-X
and	B-X
diversity	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
,	B-X
immune	B-X
deregulation	B-X
and	B-X
delayed	B-X
SARS-CoV-2	B-X
clearance	B-X
.	B-X
So	B-X
,	B-X
the	B-X
bidirectional	B-X
interactions	B-X
between	B-X
the	B-X
respiratory	B-X
mucosa	B-X
and	B-X
the	B-X
gut	B-X
microbiota	B-X
,	B-X
known	B-X
as	B-X
gut-lung	B-X
axis	B-X
,	B-X
are	B-X
supposed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
healthy	B-X
or	B-X
pathologic	B-X
immune	B-X
responses	B-X
to	B-X
SARS-CoV-2	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
the	B-X
intestinal	B-X
dysbiosis	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
mortality	B-X
in	B-X
other	B-X
respiratory	B-X
infections	B-X
,	B-X
due	B-X
to	B-X
an	B-X
exacerbated	B-X
inflammation	B-X
and	B-X
decreased	B-X
regulatory	B-X
or	B-X
anti-inflammatory	B-X
mechanisms	B-X
in	B-X
the	B-X
lungs	B-X
and	B-X
in	B-X
the	B-X
gut	B-X
,	B-X
pointing	B-X
to	B-X
this	B-X
important	B-X
relationship	B-X
between	B-X
both	B-X
mucosal	B-X
compartments	B-X
.	B-X
Therefore	B-X
,	B-X
since	B-X
the	B-X
mucous	B-X
membranes	B-X
from	B-X
the	B-X
respiratory	B-X
and	B-X
gastrointestinal	B-X
tracts	B-X
are	B-X
affected	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
dysbiosis	B-X
and	B-X
inflammation	B-X
,	B-X
it	B-X
is	B-X
plausible	B-X
to	B-X
assume	B-X
that	B-X
adjunctive	B-X
therapies	B-X
based	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
and	B-X
re-establishment	B-X
of	B-X
eubiosis	B-X
conditions	B-X
could	B-X
be	B-X
an	B-X
important	B-X
therapeutic	B-X
approach	B-X
for	B-X
constraining	B-X
the	B-X
harmful	B-X
consequences	B-X
of	B-X
COVID-19	B-X
.	B-X
Then	B-X
,	B-X
in	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarized	B-X
studies	B-X
showing	B-X
the	B-X
persistence	B-X
of	B-X
SARS-CoV-2	B-X
in	B-X
the	B-X
gastrointestinal	B-X
system	B-X
and	B-X
the	B-X
related	B-X
digestive	B-X
COVID-19	B-X
manifestations	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
literature	B-X
demonstrating	B-X
nasopharyngeal	B-X
,	B-X
pulmonary	B-X
and	B-X
intestinal	B-X
dysbiosis	B-X
in	B-X
COVID-19	B-X
patients	B-X
.	B-X

Thus	O
,	O
understanding	O
the	O
mechanisms	O
of	O
dCGN	O
-	O
induced	O
bowel	O
inflammation	O
is	O
of	O
great	O
importance	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
role	O
of	O
human	O
monocytes	O
(	O
PBM	O
and	O
THP	O
-	O
1	O
)	O
in	O
dCGN	O
-	O
induced	O
inflammation	O
.	O

Preliminary	O
in	O
vivo	O
studies	O
in	O
rats	O
treated	O
with	O
dCGN	O
revealed	O
significant	O
shortening	O
of	O
the	O
large	O
intestine	O
associated	O
with	O
an	O
inflammatory	O
state	O
,	O
i	O
.	O
e	O
.	O
strong	O
infiltration	O
of	O
macrophages	O
to	O
the	O
intestinal	O
mucosa	O
similar	O
to	O
DSS	O
-	O
induced	O
inflammation	O
[	O
20	O
]	O
.	O

Using	O
two	O
fractions	O
of	O
dCGN	O
(	O
10	O
and	O
40	O
kDa	O
)	O
,	O
we	O
observed	O
a	O
strong	O
correlation	O
between	O
the	O
severity	O
of	O
the	O
inflammation	O
and	O
the	O
dCGN	O
molecular	O
size	O
,	O
thus	O
confirming	O
the	O
size	O
related	O
inflammation	O
in	O
vivo	O
.	O

This	O
macrophage	O
accumulation	O
was	O
not	O
due	O
to	O
cell	O
proliferation	O
because	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
monocytes	O
proliferation	O
in	O
vitro	O
.	O
<EOS>	B-X
Macrophages	B-X
exposed	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
including	B-X
LPS	B-X
undergo	B-X
metabolic	B-X
reprogramming	B-X
to	B-X
facilitate	B-X
macrophage	B-X
effector	B-X
function	B-X
.	B-X
The	B-X
Krebs	B-X
cycle	B-X
is	B-X
a	B-X
central	B-X
metabolic	B-X
pathway	B-X
within	B-X
all	B-X
mammalian	B-X
cell	B-X
types	B-X
.	B-X
In	B-X
activated	B-X
macrophages	B-X
,	B-X
distinct	B-X
breaks	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
regulate	B-X
macrophage	B-X
effector	B-X
function	B-X
through	B-X
the	B-X
accumulation	B-X
of	B-X
several	B-X
metabolites	B-X
that	B-X
were	B-X
recently	B-X
shown	B-X
to	B-X
have	B-X
signaling	B-X
roles	B-X
in	B-X
immunity	B-X
.	B-X
One	B-X
metabolite	B-X
that	B-X
accumulates	B-X
in	B-X
macrophages	B-X
because	B-X
of	B-X
the	B-X
disturbance	B-X
in	B-X
the	B-X
Krebs	B-X
cycle	B-X
is	B-X
itaconate	B-X
,	B-X
which	B-X
is	B-X
derived	B-X
from	B-X
cis-aconitate	B-X
by	B-X
the	B-X
enzyme	B-X
cis-aconitate	B-X
decarboxylase	B-X
(	B-X
ACOD1	B-X
)	B-X
,	B-X
encoded	B-X
by	B-X
immunoresponsive	B-X
gene	B-X
1	B-X
(	B-X
Irg1	B-X
)	B-X
.	B-X

These	O
results	O
are	O
similar	O
to	O
those	O
obtained	O
with	O
human	O
colonic	O
epithelial	O
cells	O
(	O
NCM460	O
cell	O
line	O
)	O
exposed	O
to	O
native	O
CGN	O
for	O
1	O
-	O
8	O
days	O
[	O
37	O
]	O
.	O

Thus	O
,	O
it	O
seems	O
that	O
dCGN	O
promote	O
macrophage	O
infiltration	O
by	O
recruiting	O
new	O
cells	O
to	O
the	O
inflamed	O
intestinal	O
mucosa	O
and	O
not	O
by	O
inducing	O
cell	O
proliferation	O
.	O

In	O
addition	O
,	O
very	O
few	O
polymorphonuclear	O
cells	O
were	O
detected	O
in	O
the	O
mucosa	O
at	O
the	O
time	O
point	O
analyzed	O
as	O
demonstrated	O
by	O
a	O
very	O
low	O
level	O
of	O
MPO	O
in	O
the	O
intestinal	O
tissue	O
.	O

These	O
results	O
suggest	O
that	O
monocytes	O
might	O
produce	O
cytokines	O
associated	O
with	O
activation	O
into	O
macrophages	O
in	O
response	O
to	O
dCGN	O
.	O

Thus	O
,	O
we	O
analyzed	O
the	O
production	O
of	O
TNF	B-Protein
by	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
in	O
response	O
to	O
dCGN	O
.	O

Degraded	O
CGN	O
induced	O
a	O
robust	O
production	O
of	O
TNF	B-Protein
by	O
monocytes	O
.	O

The	O
40	O
kDa	O
form	O
of	O
dCGN	O
was	O
more	O
potent	O
for	O
monocyte	O
stimulation	O
than	O
the	O
10	O
kDa	O
or	O
the	O
native	O
ones	O
.	O
<EOS>	B-X
Native	B-X
proteins	B-X
perform	B-X
an	B-X
amazing	B-X
variety	B-X
of	B-X
biochemical	B-X
functions	B-X
,	B-X
including	B-X
enzymatic	B-X
catalysis	B-X
,	B-X
and	B-X
can	B-X
engage	B-X
in	B-X
protein-protein	B-X
and	B-X
protein-DNA	B-X
interactions	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
life	B-X
.	B-X
Comparison	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
compact	B-X
conformations	B-X
of	B-X
artificially	B-X
generated	B-X
compact	B-X
protein	B-X
structures	B-X
selected	B-X
for	B-X
thermodynamic	B-X
stability	B-X
but	B-X
not	B-X
any	B-X
type	B-X
of	B-X
function	B-X
,	B-X
the	B-X
artificial	B-X
(	B-X
ART	B-X
)	B-X
protein	B-X
library	B-X
,	B-X
demonstrates	B-X
that	B-X
a	B-X
remarkable	B-X
number	B-X
of	B-X
the	B-X
properties	B-X
of	B-X
native-like	B-X
proteins	B-X
are	B-X
recapitulated	B-X
.	B-X
ART	B-X
structures	B-X
are	B-X
predicted	B-X
to	B-X
be	B-X
capable	B-X
of	B-X
weakly	B-X
binding	B-X
metabolites	B-X
and	B-X
cover	B-X
a	B-X
significant	B-X
fraction	B-X
of	B-X
metabolic	B-X
pathways	B-X
,	B-X
with	B-X
the	B-X
most	B-X
enriched	B-X
pathways	B-X
including	B-X
ancient	B-X
ones	B-X
such	B-X
as	B-X
glycolysis	B-X
.	B-X
Based	B-X
on	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
further	B-X
propose	B-X
a	B-X
language	B-X
generalization	B-X
effect	B-X
(	B-X
LGE	B-X
)	B-X
and	B-X
hypothesize	B-X
that	B-X
people	B-X
may	B-X
inherit	B-X
the	B-X
universal	B-X
phonological	B-X
features	B-X
from	B-X
their	B-X
native	B-X
languages	B-X
and	B-X
then	B-X
transfer	B-X
them	B-X
to	B-X
foreign	B-X
languages	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
in	B-X
two	B-X
experiments	B-X
,	B-X
participants	B-X
listened	B-X
to	B-X
a	B-X
pair	B-X
of	B-X
normal	B-X
and	B-X
syllable	B-X
reversed	B-X
recordings	B-X
(	B-X
Experiments	B-X
1a-1d	B-X
)	B-X
or	B-X
normal	B-X
and	B-X
phonemic	B-X
reversed	B-X
recordings	B-X
(	B-X
Experiments	B-X
2a-2d	B-X
)	B-X
in	B-X
unknown	B-X
and	B-X
native	B-X
languages	B-X
and	B-X
reported	B-X
their	B-X
similarities	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
participants	B-X
were	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
dissimilarities	B-X
of	B-X
normal	B-X
recordings	B-X
than	B-X
to	B-X
reversed	B-X
ones	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
participants	B-X
could	B-X
identify	B-X
the	B-X
universal	B-X
phonological	B-X
features	B-X
from	B-X
normal	B-X
recordings	B-X
,	B-X
but	B-X
not	B-X
reversed	B-X
ones	B-X
,	B-X
and	B-X
then	B-X
adopt	B-X
these	B-X
features	B-X
to	B-X
better	B-X
verify	B-X
the	B-X
dissimilarities	B-X
of	B-X
normal	B-X
recordings	B-X
.	B-X

Surprisingly	O
,	O
monocyte	O
activation	O
by	O
dCGN	O
to	O
produce	O
TNF	B-Protein
was	O
much	O
stronger	O
than	O
the	O
activation	O
induced	O
by	O
LPS	O
,	O
an	O
inflammatory	O
factor	O
considered	O
to	O
be	O
among	O
the	O
most	O
potent	O
stimuli	O
for	O
leukocyte	O
activation	O
.	O

These	O
results	O
underline	O
the	O
fact	O
that	O
partially	O
degraded	O
forms	O
of	O
CGN	O
have	O
important	O
cellular	O
effects	O
.	O

The	O
amount	O
of	O
TNF	B-Protein
secreted	O
by	O
PBM	O
induced	O
with	O
LPS	O
was	O
much	O
larger	O
than	O
the	O
one	O
secreted	O
by	O
THP	O
-	O
1	O
monocytes	O
.	O

Since	O
monocyte	O
activation	O
by	O
LPS	O
is	O
associated	O
with	O
the	O
presence	O
of	O
the	O
CD14	B-Protein
and	O
TLR4	B-Protein
receptors	I-Protein
[	O
38	O
]	O
-	O
[	O
40	O
]	O
,	O
the	O
different	O
response	O
observed	O
could	O
be	O
due	O
to	O
the	O
different	O
expression	O
of	O
these	O
receptors	O
in	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O

CD14	B-Protein
is	O
not	O
expressed	O
by	O
THP	O
-	O
1	O
monocytes	O
,	O
but	O
it	O
is	O
expressed	O
by	O
PBM	O
.	O
<EOS>	B-X
Human	B-X
monocyte	B-X
differentiation	B-X
antigen	B-X
CD14	B-X
is	B-X
a	B-X
pattern	B-X
recognition	B-X
receptor	B-X
(	B-X
PRR	B-X
)	B-X
that	B-X
enhances	B-X
innate	B-X
immune	B-X
responses	B-X
.	B-X
CD14	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
monocytes	B-X
to	B-X
signal	B-X
intracellular	B-X
responses	B-X
upon	B-X
bacterial	B-X
encounters	B-X
.	B-X
Given	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
intracellular	B-X
tail	B-X
,	B-X
CD14	B-X
was	B-X
doubted	B-X
to	B-X
have	B-X
the	B-X
signaling	B-X
capacities	B-X
.	B-X
Later	B-X
CD14	B-X
was	B-X
confirmed	B-X
as	B-X
the	B-X
TLR	B-X
co-receptor	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
.	B-X
However	B-X
,	B-X
CD14	B-X
has	B-X
been	B-X
revealed	B-X
as	B-X
a	B-X
multi-talented	B-X
receptor	B-X
.	B-X
In	B-X
last	B-X
decade	B-X
,	B-X
CD14	B-X
was	B-X
identified	B-X
to	B-X
activate	B-X
NFAT	B-X
to	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
myeloid	B-X
cells	B-X
in	B-X
a	B-X
TLR4-independent	B-X
manner	B-X
and	B-X
to	B-X
transport	B-X
inflammatory	B-X
lipids	B-X
to	B-X
induce	B-X
phagocyte	B-X
hyperactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
advancements	B-X
in	B-X
the	B-X
basic	B-X
biology	B-X
of	B-X
the	B-X
CD14	B-X
including	B-X
its	B-X
structure	B-X
,	B-X
binding	B-X
ligands	B-X
,	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
its	B-X
roles	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
inflammation	B-X
,	B-X
atherosclerosis	B-X
,	B-X
tumor	B-X
and	B-X
metabolic	B-X
diseases	B-X
.	B-X
We	B-X
also	B-X
discuss	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
targeting	B-X
the	B-X
CD14	B-X
in	B-X
related	B-X
diseases	B-X
.	B-X

This	O
fact	O
could	O
explain	O
why	O
THP	O
-	O
1	O
cells	O
produced	O
a	O
much	O
smaller	O
response	O
to	O
LPS	O
than	O
PBM	O
and	O
also	O
the	O
difference	O
of	O
kinetics	O
in	O
the	O
LPS	O
induced	O
TNF	B-Protein
secretion	O
.	O

The	O
peak	O
of	O
TNF	B-Protein
response	O
was	O
observed	O
after	O
8	O
h	O
stimulation	O
followed	O
by	O
a	O
rapid	O
decrease	O
to	O
baseline	O
at	O
10	O
h	O
,	O
whereas	O
on	O
THP	O
-	O
1	O
cells	O
the	O
peak	O
was	O
not	O
reached	O
until	O
after	O
56	O
h	O
.	O

Moreover	O
,	O
the	O
amount	O
of	O
TNF	B-Protein
secreted	O
by	O
monocytes	O
induced	O
with	O
dCGN	O
was	O
much	O
larger	O
than	O
the	O
one	O
induced	O
by	O
LPS	O
.	O

On	O
the	O
other	O
hand	O
,	O
LPS	O
and	O
dCGN	O
displayed	O
a	O
very	O
different	O
TNF	B-Protein
secretion	O
curve	O
in	O
THP	O
-	O
1	O
cells	O
.	O

These	O
differences	O
suggest	O
that	O
dCGN	O
and	O
LPS	O
could	O
use	O
different	O
activation	O
mechanisms	O
.	O

It	O
is	O
noteworthy	O
that	O
neutralizing	O
antibody	O
to	O
CD14	O
only	O
partially	O
(	O
<	O
40	O
%	O
)	O
inhibited	O
dCGN	O
-	O
induced	O
TNF	B-Protein
secretion	O
(	O
not	O
shown	O
)	O
.	O

TLR4	B-Protein
has	O
been	O
recently	O
identified	O
as	O
a	O
surface	O
membrane	O
receptor	B-Protein
for	O
CGN	O
in	O
human	O
colonic	O
epithelial	O
cells	O
[	O
41	O
]	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
TLR4	B-Protein
is	O
activated	O
by	O
dCGN	O
to	O
induce	O
cytokine	O
secretion	O
by	O
monocytes	O
.	O

We	O
can	O
only	O
speculate	O
that	O
TLR4	B-Protein
may	O
have	O
a	O
higher	O
affinity	O
-	O
binding	O
site	O
for	O
dCGN	O
than	O
for	O
LPS	O
,	O
however	O
,	O
this	O
hypothesis	O
remains	O
to	O
be	O
tested	O
.	O

Another	O
indicator	O
that	O
dCGN	O
stimulate	O
monocytes	O
leading	O
to	O
a	O
more	O
active	O
phenotype	O
is	O
the	O
fact	O
that	O
surface	O
expression	O
of	O
the	O
adhesion	B-Protein
molecule	I-Protein
ICAM	B-Protein
-	I-Protein
1	I-Protein
was	O
enhanced	O
in	O
both	O
PBM	O
and	O
THP	O
-	O
1	O
cells	O
.	O

The	O
over	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
caused	O
the	O
activated	O
monocytes	O
to	O
form	O
cell	O
aggregates	O
that	O
were	O
more	O
abundant	O
among	O
cells	O
treated	O
with	O
the	O
40	O
kDa	O
dCGN	O
.	O

This	O
correlates	O
with	O
the	O
higher	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
,	O
suggesting	O
that	O
the	O
partially	O
degraded	O
CGN	O
is	O
more	O
biologically	O
active	O
.	O

In	O
addition	O
,	O
the	O
cell	O
aggregates	O
are	O
reminiscent	O
of	O
monocyte	O
aggregates	O
,	O
which	O
form	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
42	O
]	O
.	O

These	O
giant	O
cells	O
were	O
not	O
observed	O
in	O
healthy	O
individuals	O
or	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
[	O
42	O
]	O
.	O
<EOS>	B-X
Ulcerative	B-X
colitis	B-X
is	B-X
an	B-X
idiopathic	B-X
,	B-X
chronic	B-X
inflammatory	B-X
disorder	B-X
of	B-X
the	B-X
colonic	B-X
mucosa	B-X
,	B-X
which	B-X
starts	B-X
in	B-X
the	B-X
rectum	B-X
and	B-X
generally	B-X
extends	B-X
proximally	B-X
in	B-X
a	B-X
continuous	B-X
manner	B-X
through	B-X
part	B-X
of	B-X
,	B-X
or	B-X
the	B-X
entire	B-X
,	B-X
colon	B-X
;	B-X
however	B-X
,	B-X
some	B-X
patients	B-X
with	B-X
proctitis	B-X
or	B-X
left-sided	B-X
colitis	B-X
might	B-X
have	B-X
a	B-X
caecal	B-X
patch	B-X
of	B-X
inflammation	B-X
.	B-X
In	B-X
this	B-X
Seminar	B-X
we	B-X
discuss	B-X
the	B-X
epidemiology	B-X
,	B-X
pathophysiology	B-X
,	B-X
diagnostic	B-X
approach	B-X
,	B-X
natural	B-X
history	B-X
,	B-X
medical	B-X
and	B-X
surgical	B-X
management	B-X
,	B-X
and	B-X
main	B-X
disease-related	B-X
complications	B-X
of	B-X
ulcerative	B-X
colitis	B-X
,	B-X
and	B-X
briefly	B-X
outline	B-X
novel	B-X
treatment	B-X
options	B-X
.	B-X
Ulcerative	B-X
colitis	B-X
is	B-X
a	B-X
chronic	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
with	B-X
an	B-X
estimated	B-X
150	B-X
000	B-X
patients	B-X
in	B-X
Germany	B-X
alone	B-X
.	B-X
Ulcerative	B-X
colitis	B-X
is	B-X
a	B-X
relapsing	B-X
and	B-X
remitting	B-X
disease	B-X
that	B-X
is	B-X
increasing	B-X
in	B-X
incidence	B-X
and	B-X
prevalence	B-X
.	B-X
Importantly	B-X
,	B-X
despite	B-X
best	B-X
medical	B-X
therapy	B-X
,	B-X
surgery	B-X
may	B-X
be	B-X
required	B-X
in	B-X
a	B-X
proportion	B-X
of	B-X
patients	B-X
.	B-X
The	B-X
future	B-X
will	B-X
likely	B-X
see	B-X
an	B-X
array	B-X
of	B-X
new	B-X
therapeutic	B-X
options	B-X
for	B-X
those	B-X
with	B-X
ulcerative	B-X
colitis	B-X
with	B-X
the	B-X
potential	B-X
for	B-X
a	B-X
more	B-X
personalised	B-X
treatment	B-X
approach	B-X
.	B-X

Moreover	O
,	O
increased	O
expression	O
levels	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
LFA	B-Protein
-	I-Protein
3	I-Protein
(	O
CD58	B-Protein
)	O
were	O
also	O
detected	O
in	O
monocytes	O
from	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
.	O

Thus	O
,	O
degraded	O
CGN	O
clearly	O
can	O
activate	O
monocytes	O
to	O
express	O
an	O
increased	O
number	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
adhesion	B-Protein
molecules	I-Protein
,	O
therefore	O
being	O
capable	O
of	O
creating	O
the	O
conditions	O
characteristic	O
of	O
Crohn	O
'	O
s	O
disease	O
symptomatology	O
,	O
i	O
.	O
e	O
.	O
PBM	O
accumulation	O
and	O
MGC	O
formation	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

The	O
NF	O
-	O
kappaB	O
pathway	O
regulates	O
genes	O
responsible	O
for	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
initiates	B-X
local	B-X
inflammation	B-X
by	B-X
triggering	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
to	B-X
express	B-X
adhesion	B-X
molecules	B-X
for	B-X
leukocytes	B-X
such	B-X
as	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
ICAM-1	B-X
or	B-X
CD54	B-X
)	B-X
.	B-X
A	B-X
prior	B-X
study	B-X
identified	B-X
siRNA	B-X
molecules	B-X
that	B-X
reduce	B-X
ICAM-1	B-X
expression	B-X
in	B-X
cultured	B-X
human	B-X
umbilical	B-X
vein	B-X
EC	B-X
(	B-X
HUVEC	B-X
)	B-X
.	B-X
One	B-X
of	B-X
these	B-X
,	B-X
ISIS	B-X
121736	B-X
,	B-X
unexpectedly	B-X
inhibits	B-X
TNF-mediated	B-X
up-regulation	B-X
of	B-X
additional	B-X
molecules	B-X
on	B-X
EC	B-X
,	B-X
including	B-X
E-selectin	B-X
(	B-X
CD62E	B-X
)	B-X
,	B-X
VCAM-1	B-X
(	B-X
CD106	B-X
)	B-X
and	B-X
HLA-A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
.	B-X
736	B-X
Transfection	B-X
of	B-X
EC	B-X
blocked	B-X
multiple	B-X
early	B-X
TNF-related	B-X
signaling	B-X
events	B-X
,	B-X
including	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
IL-1	B-X
activation	B-X
of	B-X
these	B-X
same	B-X
pathways	B-X
was	B-X
not	B-X
inhibited	B-X
.	B-X
A	B-X
unifying	B-X
explanation	B-X
is	B-X
that	B-X
736	B-X
siRNA	B-X
specifically	B-X
reduced	B-X
expression	B-X
of	B-X
mRNA	B-X
encoding	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
as	B-X
well	B-X
as	B-X
TNFR1	B-X
surface	B-X
expression	B-X
.	B-X
A	B-X
sequence	B-X
with	B-X
high	B-X
identity	B-X
to	B-X
the	B-X
736	B-X
antisense	B-X
strand	B-X
(	B-X
17	B-X
of	B-X
19	B-X
bases	B-X
)	B-X
is	B-X
present	B-X
within	B-X
the	B-X
3'UTR	B-X
of	B-X
human	B-X
TNFR1	B-X
mRNA	B-X
.	B-X
An	B-X
EGFP	B-X
construct	B-X
incorporating	B-X
the	B-X
3'UTR	B-X
of	B-X
TNFR1	B-X
was	B-X
silenced	B-X
by	B-X
736	B-X
siRNA	B-X
and	B-X
this	B-X
effect	B-X
was	B-X
lost	B-X
by	B-X
mutagenesis	B-X
of	B-X
this	B-X
complementary	B-X
sequence	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
an	B-X
siRNA	B-X
molecule	B-X
selected	B-X
to	B-X
target	B-X
ICAM-1	B-X
through	B-X
its	B-X
antisense	B-X
strand	B-X
exhibited	B-X
broad	B-X
anti-TNF	B-X
activities	B-X
.	B-X
We	B-X
show	B-X
that	B-X
this	B-X
off-target	B-X
effect	B-X
is	B-X
mediated	B-X
by	B-X
siRNA	B-X
knockdown	B-X
of	B-X
TNFR1	B-X
via	B-X
its	B-X
sense	B-X
strand	B-X
.	B-X
This	B-X
may	B-X
be	B-X
the	B-X
first	B-X
example	B-X
in	B-X
which	B-X
the	B-X
off-target	B-X
effect	B-X
of	B-X
an	B-X
siRNA	B-X
is	B-X
actually	B-X
responsible	B-X
for	B-X
the	B-X
anticipated	B-X
effect	B-X
by	B-X
acting	B-X
to	B-X
reduce	B-X
expression	B-X
of	B-X
a	B-X
protein	B-X
(	B-X
TNFR1	B-X
)	B-X
that	B-X
normally	B-X
regulates	B-X
expression	B-X
of	B-X
the	B-X
intended	B-X
target	B-X
(	B-X
ICAM-1	B-X
)	B-X
.	B-X

NF	O
-	O
kappaB	O
activation	O
is	O
associated	O
with	O
the	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
IkappaB	O
[	O
47	O
]	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
/REL	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
has	B-X
a	B-X
central	B-X
role	B-X
in	B-X
coordinating	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
genes	B-X
that	B-X
control	B-X
immune	B-X
responses	B-X
.	B-X
There	B-X
has	B-X
been	B-X
intense	B-X
scientific	B-X
activity	B-X
in	B-X
the	B-X
NF-kappaB	B-X
field	B-X
owing	B-X
to	B-X
the	B-X
involvement	B-X
of	B-X
these	B-X
factors	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
key	B-X
molecules	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
diseases	B-X
ranging	B-X
from	B-X
inflammation	B-X
to	B-X
cancer	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
our	B-X
current	B-X
understanding	B-X
of	B-X
NF-kappaB	B-X
regulation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
also	B-X
discuss	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
proteins	B-X
as	B-X
potential	B-X
therapeutic	B-X
targets	B-X
in	B-X
clinical	B-X
applications	B-X
.	B-X

Indeed	O
,	O
dCGN	O
induced	O
NF	O
-	O
kappaB	O
activation	O
as	O
shown	O
by	O
degradation	O
of	O
IkappaBalpha	B-Protein
,	O
translocation	O
of	O
p65	B-Protein
and	O
p50	B-Protein
sub	O
-	O
units	O
to	O
the	O
nucleus	O
and	O
by	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
responsive	O
luciferase	B-Protein
reporter	O
plasmid	O
.	O

Again	O
,	O
a	O
stronger	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
induced	O
by	O
the	O
40	O
kDa	O
dCGN	O
compared	O
to	O
10	O
kDa	O
dCGN	O
,	O
suggesting	O
that	O
the	O
partially	O
degraded	O
CGN	O
is	O
more	O
biologically	O
active	O
.	O

Our	O
data	O
are	O
in	O
agreement	O
with	O
a	O
previous	O
study	O
showing	O
that	O
native	O
CGN	O
also	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
human	O
colonic	O
epithelial	O
cells	O
[	O
48	O
]	O
.	O

NF	O
-	O
kappaB	O
pathway	O
is	O
often	O
associated	O
to	O
promote	O
cell	O
survival	O
and	O
cancer	O
cell	O
growth	O
,	O
however	O
it	O
has	O
been	O
sometimes	O
reported	O
to	O
behave	O
as	O
a	O
tumor	O
suppressor	O
,	O
arresting	O
cell	O
proliferation	O
[	O
49	O
]	O
.	O

Such	O
relationship	O
between	O
NF	O
-	O
kB	O
activation	O
and	O
cell	O
cycle	O
regulation	O
has	O
been	O
reported	O
in	O
normal	O
human	O
epidermal	O
cells	O
[	O
50	O
]	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
shown	O
that	O
NF	O
-	O
kappaB	O
activation	O
suppressed	O
cdk4	B-Protein
expression	O
,	O
which	O
is	O
necessary	O
for	O
the	O
transition	O
to	O
S	O
phase	O
.	O

Finally	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
reported	O
to	O
induce	O
growth	O
arrest	O
in	O
normal	O
human	O
keratinocytes	O
by	O
a	O
mechanims	O
involving	O
the	O
cdk	O
inhibitor	O
p21	B-Protein
[	O
51	O
]	O
.	O

The	O
effects	O
of	O
dCGN	O
on	O
p21	B-Protein
and	O
cdk4	B-Protein
expression	O
remain	O
to	O
be	O
studied	O
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
demonstrated	O
a	O
direct	O
action	O
of	O
dCGN	O
on	O
monocytes	O
.	O

Monocytes	O
exposed	O
to	O
dCGN	O
acquired	O
an	O
inflammatory	O
phenotype	O
that	O
included	O
higher	O
expression	O
of	O
the	O
adhesion	O
molecule	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
via	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

This	O
higher	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
resulted	O
in	O
formation	O
of	O
cell	O
aggregates	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
.	O

We	O
presume	O
that	O
the	O
differential	O
effects	O
of	O
10	O
and	O
40	O
kDa	O
dCGN	O
to	O
induce	O
these	O
effects	O
on	O
monocytes	O
are	O
tightly	O
linked	O
to	O
their	O
capacity	O
to	O
induce	O
inflammation	O
in	O
vivo	O
.	O

However	O
,	O
in	O
vivo	O
,	O
macrophages	O
do	O
not	O
come	O
in	O
direct	O
contact	O
with	O
the	O
intestinal	O
lumen	O
and	O
are	O
separated	O
by	O
the	O
epithelial	O
barrier	O
.	O
<EOS>	B-X
Plasticity	B-X
and	B-X
functional	B-X
polarization	B-X
are	B-X
hallmarks	B-X
of	B-X
macrophages	B-X
.	B-X
Macrophages	B-X
commonly	B-X
exist	B-X
in	B-X
two	B-X
distinct	B-X
subsets	B-X
:	B-X
classically	B-X
activated	B-X
macrophages	B-X
(	B-X
M1	B-X
)	B-X
and	B-X
alternatively	B-X
activated	B-X
macrophages	B-X
(	B-X
M2	B-X
)	B-X
.	B-X
M2b	B-X
,	B-X
a	B-X
subtype	B-X
of	B-X
M2	B-X
macrophages	B-X
,	B-X
has	B-X
attracted	B-X
increasing	B-X
attention	B-X
over	B-X
the	B-X
past	B-X
decade	B-X
due	B-X
to	B-X
its	B-X
strong	B-X
immune-regulated	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
.	B-X
A	B-X
wide	B-X
variety	B-X
of	B-X
stimuli	B-X
and	B-X
multiple	B-X
factors	B-X
modulate	B-X
M2b	B-X
macrophage	B-X
polarization	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
M2b	B-X
macrophages	B-X
possess	B-X
both	B-X
protective	B-X
and	B-X
pathogenic	B-X
roles	B-X
in	B-X
various	B-X
diseases	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
discuss	B-X
current	B-X
knowledge	B-X
of	B-X
M2b	B-X
macrophage	B-X
polarization	B-X
,	B-X
the	B-X
roles	B-X
of	B-X
M2b	B-X
macrophages	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
and	B-X
the	B-X
stimuli	B-X
to	B-X
modulate	B-X
M2b	B-X
macrophage	B-X
polarization	B-X
.	B-X

The	O
way	O
by	O
which	O
dCGN	O
may	O
leave	O
the	O
intestinal	O
lumen	O
and	O
cross	O
the	O
epithelial	O
barrier	O
to	O
reach	O
the	O
macrophages	O
is	O
an	O
intriguing	O
open	O
question	O
.	O

One	O
possible	O
explanation	O
resides	O
in	O
the	O
potential	O
of	O
dCGN	O
to	O
"	O
induce	O
"	O
cellular	O
and	O
paracellular	O
injurious	O
effects	O
at	O
the	O
intestinal	O
epithelial	O
cell	O
monolayer	O
[	O
48	O
]	O
.	O

In	O
conclusion	O
,	O
dCGN	O
inhibited	O
THP	O
-	O
1	O
cell	O
proliferation	O
in	O
vitro	O
,	O
accumulating	O
the	O
cells	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
increased	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
stimulated	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
monocyte	O
aggregation	O
in	O
vitro	O
,	O
and	O
stimulated	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
and	O
secretion	O
.	O

These	O
responses	O
were	O
more	O
pronounced	O
following	O
40	O
kDa	O
dCGN	O
,	O
and	O
were	O
all	O
linked	O
to	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
,	O
although	O
CGN	O
is	O
widely	O
used	O
as	O
a	O
food	O
additive	O
,	O
its	O
degraded	O
forms	O
have	O
an	O
important	O
effect	O
on	O
monocytes	O
characteristic	O
of	O
an	O
inflammatory	O
phenotype	O
.	O

Degraded	O
CGN	O
induced	O
colon	O
inflammation	O
in	O
rats	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Histograms	O
showing	O
the	O
effect	O
of	O
degraded	O
CGN	O
on	O
:	O
colon	O
length	O
(	O
A	O
)	O
;	O
macroscopic	O
(	O
B	O
)	O
and	O
histological	O
(	O
C	O
)	O
inflammation	O
score	O
of	O
colon	O
;	O
Myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
(	O
D	O
)	O
.	O

Control	O
rats	O
(	O
white	O
bars	O
)	O
;	O
10	O
kDa	O
degraded	O
CGN	O
-	O
treated	O
rats	O
(	O
grey	O
bars	O
)	O
;	O
40	O
kDa	O
degraded	O
CGN	O
-	O
treated	O
rats	O
(	O
black	O
bars	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
analyze	B-X
the	B-X
effect	B-X
of	B-X
Bilih	B-X
fish	B-X
bars	B-X
(	B-X
BFB	B-X
)	B-X
on	B-X
oxidative	B-X
stress	B-X
based	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
MDA	B-X
and	B-X
SOD	B-X
in	B-X
diabetic	B-X
rat	B-X
models	B-X
.	B-X
Forty	B-X
white	B-X
male	B-X
rats	B-X
of	B-X
the	B-X
Sprague-Dawley	B-X
strain	B-X
were	B-X
placed	B-X
into	B-X
the	B-X
following	B-X
five	B-X
groups	B-X
:	B-X
normal	B-X
and	B-X
diabetic	B-X
rats	B-X
that	B-X
were	B-X
fed	B-X
either	B-X
the	B-X
standard	B-X
feed	B-X
and	B-X
metformin	B-X
,	B-X
BFB	B-X
,	B-X
BFB	B-X
,	B-X
and	B-X
metformin	B-X
or	B-X
BFF	B-X
with	B-X
a	B-X
zinc	B-X
dose	B-X
of	B-X
0.54	B-X
mg.	B-X
A	B-X
single	B-X
dose	B-X
of	B-X
STZ	B-X
(	B-X
40	B-X
mg/kg	B-X
)	B-X
was	B-X
used	B-X
to	B-X
induce	B-X
diabetes	B-X
in	B-X
the	B-X
rats	B-X
.	B-X
The	B-X
levels	B-X
of	B-X
MDA	B-X
in	B-X
rats	B-X
that	B-X
received	B-X
the	B-X
intervention	B-X
with	B-X
Bilih	B-X
fish	B-X
were	B-X
8.236±0.46	B-X
μmol/L	B-X
for	B-X
the	B-X
BFB	B-X
group	B-X
and	B-X
8.266±0.66	B-X
μmol/L	B-X
for	B-X
the	B-X
BFF	B-X
group	B-X
,	B-X
which	B-X
were	B-X
both	B-X
lower	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
normal	B-X
rats	B-X
(	B-X
8.279±0.51	B-X
μmol/L	B-X
)	B-X
.	B-X
The	B-X
levels	B-X
of	B-X
SOD	B-X
in	B-X
rats	B-X
that	B-X
received	B-X
the	B-X
intervention	B-X
with	B-X
BFB	B-X
and	B-X
BFF	B-X
were	B-X
higher	B-X
compared	B-X
to	B-X
the	B-X
diabetic	B-X
rats	B-X
with	B-X
standard	B-X
feed	B-X
,	B-X
but	B-X
this	B-X
increase	B-X
was	B-X
not	B-X
significant	B-X
(	B-X
p	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X

*	O
p	O
<	O
0	O
.	O
05	O
from	O
control	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

*	O
*	O
p	O
<	O
0	O
.	O
01	O
from	O
control	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
covid-19	B-X
vaccinations	B-X
represents	B-X
a	B-X
notable	B-X
scientific	B-X
achievement	B-X
.	B-X
Nevertheless	B-X
,	B-X
concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
their	B-X
possible	B-X
detrimental	B-X
impact	B-X
on	B-X
male	B-X
fertility	B-X
OBJECTIVE	B-X
:	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
covid-19	B-X
BNT162b2	B-X
(	B-X
Pfizer	B-X
)	B-X
vaccine	B-X
on	B-X
semen	B-X
parameters	B-X
among	B-X
semen	B-X
donors	B-X
(	B-X
SD	B-X
)	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
relationship	B-X
between	B-X
COVID-19	B-X
full	B-X
vaccination	B-X
(	B-X
two	B-X
completed	B-X
doses	B-X
)	B-X
and	B-X
possible	B-X
arthritis	B-X
flare	B-X
.	B-X

Histological	O
analysis	O
of	O
colon	O
from	O
control	O
rats	O
(	O
E	O
)	O
,	O
and	O
from	O
40	O
kDa	O
dCGN	O
-	O
treated	O
rats	O
(	O
F	O
)	O
.	O

Degraded	O
CGN	O
stimulated	O
TNF	B-Protein
secretion	O
from	O
monocytes	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Levels	O
of	O
TNF	B-Protein
released	O
from	O
peripheral	O
blood	O
monocytes	O
(	O
A	O
-	O
B	O
)	O
and	O
THP	O
-	O
1	O
cells	O
(	O
C	O
-	O
D	O
)	O
after	O
stimulation	O
with	O
dCGN	O
.	O

A	O
:	O
TNF	B-Protein
release	O
induced	O
by	O
native	O
CGN	O
(	O
open	O
bars	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
grey	O
bars	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
black	O
bars	O
)	O
.	O

B	O
:	O
Kinetics	O
of	O
TNF	B-Protein
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
black	O
diamonds	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
black	O
triangles	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
black	O
squares	O
)	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
open	O
squares	O
)	O
.	O

C	O
:	O
TNF	B-Protein
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
open	O
bars	O
)	O
,	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
hatched	O
bars	O
)	O
,	O
or	O
increasing	O
concentrations	O
of	O
10	O
kDa	O
dCGN	O
(	O
grey	O
bars	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
black	O
bars	O
)	O
.	O
<EOS>	B-X
Recently	B-X
we	B-X
showed	B-X
that	B-X
RV	B-X
infects	B-X
bronchial	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
BSMCs	B-X
)	B-X
triggering	B-X
production	B-X
of	B-X
interferons	B-X
and	B-X
IL-33	B-X
.	B-X
Here	B-X
we	B-X
compared	B-X
levels	B-X
of	B-X
RV-induced	B-X
IL-33	B-X
in	B-X
BSMCs	B-X
from	B-X
healthy	B-X
and	B-X
asthmatic	B-X
subjects	B-X
,	B-X
and	B-X
explored	B-X
the	B-X
involvement	B-X
of	B-X
pattern-recognition	B-X
receptors	B-X
(	B-X
PRRs	B-X
)	B-X
and	B-X
downstream	B-X
signalling	B-X
pathways	B-X
in	B-X
IL-33	B-X
expression	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
patients	B-X
with	B-X
hepatitis	B-X
C	B-X
virus	B-X
chronically	B-X
administered	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-alpha	B-X
develop	B-X
increased	B-X
evening	B-X
plasma	B-X
cortisol	B-X
concentrations	B-X
and	B-X
a	B-X
flattened	B-X
diurnal	B-X
cortisol	B-X
slope	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
increased	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
and	B-X
its	B-X
soluble	B-X
receptor	B-X
2	B-X
(	B-X
sTNFR2	B-X
)	B-X
.	B-X
Increased	B-X
TNF	B-X
and	B-X
sTNFR2	B-X
were	B-X
further	B-X
correlated	B-X
with	B-X
depression	B-X
and	B-X
fatigue	B-X
scores	B-X
.	B-X
The	B-X
current	B-X
study	B-X
examined	B-X
whether	B-X
flattened	B-X
cortisol	B-X
slope	B-X
might	B-X
be	B-X
secondary	B-X
to	B-X
reduced	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
sensitivity	B-X
,	B-X
by	B-X
measuring	B-X
glucocorticoid	B-X
negative	B-X
feedback	B-X
to	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
administration	B-X
followed	B-X
by	B-X
corticotropin	B-X
releasing	B-X
hormone	B-X
(	B-X
CRH	B-X
)	B-X
challenge	B-X
.	B-X
In	B-X
an	B-X
exploratory	B-X
analysis	B-X
,	B-X
28	B-X
male	B-X
and	B-X
female	B-X
patients	B-X
with	B-X
hepatitis	B-X
C	B-X
virus	B-X
were	B-X
studied	B-X
at	B-X
baseline	B-X
(	B-X
Visit	B-X
1	B-X
)	B-X
and	B-X
after	B-X
12weeks	B-X
(	B-X
Visit	B-X
2	B-X
)	B-X
of	B-X
either	B-X
IFN-alpha	B-X
plus	B-X
ribavirin	B-X
(	B-X
n=17	B-X
)	B-X
or	B-X
no	B-X
treatment	B-X
(	B-X
n=11	B-X
)	B-X
.	B-X
Patients	B-X
underwent	B-X
dexamethasone	B-X
DEX-CRH	B-X
challenge	B-X
,	B-X
neuropsychiatric	B-X
assessments	B-X
,	B-X
and	B-X
measurement	B-X
of	B-X
plasma	B-X
TNF	B-X
and	B-X
sTNFR2	B-X
during	B-X
each	B-X
visit	B-X
.	B-X
IFN-alpha	B-X
did	B-X
not	B-X
affect	B-X
neuroendocrine	B-X
responses	B-X
following	B-X
CRH	B-X
but	B-X
did	B-X
increase	B-X
post-DEX	B-X
cortisol	B-X
,	B-X
which	B-X
was	B-X
correlated	B-X
with	B-X
flattening	B-X
of	B-X
the	B-X
diurnal	B-X
cortisol	B-X
slope	B-X
(	B-X
r=0.57	B-X
,	B-X
p=0.002	B-X
)	B-X
and	B-X
with	B-X
increased	B-X
depression	B-X
scores	B-X
(	B-X
r=0.38	B-X
,	B-X
p=0.047	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
change	B-X
in	B-X
post-DEX	B-X
cortisol	B-X
was	B-X
associated	B-X
with	B-X
IFN-alpha-induced	B-X
increase	B-X
in	B-X
sTNFR2	B-X
(	B-X
r=0.51	B-X
,	B-X
p=006	B-X
)	B-X
,	B-X
which	B-X
was	B-X
in	B-X
turn	B-X
correlated	B-X
with	B-X
depression	B-X
(	B-X
r=0.63	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
fatigue	B-X
(	B-X
r=0.51	B-X
,	B-X
p=0.005	B-X
)	B-X
scores	B-X
.	B-X
Whereas	B-X
the	B-X
relationship	B-X
between	B-X
sTNFR2	B-X
and	B-X
depression	B-X
scores	B-X
were	B-X
independent	B-X
of	B-X
the	B-X
change	B-X
in	B-X
post-DEX	B-X
cortisol	B-X
,	B-X
the	B-X
correlation	B-X
between	B-X
post-DEX	B-X
cortisol	B-X
and	B-X
depression	B-X
scores	B-X
was	B-X
not	B-X
significant	B-X
when	B-X
controlling	B-X
for	B-X
sTNFR2	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
inflammation	B-X
induced	B-X
in	B-X
patients	B-X
with	B-X
hepatitis	B-X
C	B-X
virus	B-X
during	B-X
IFN-alpha	B-X
therapy	B-X
precipitates	B-X
decreased	B-X
GR	B-X
sensitivity	B-X
to	B-X
lead	B-X
to	B-X
a	B-X
flattened	B-X
diurnal	B-X
cortisol	B-X
slope	B-X
.	B-X

D	O
:	O
Kinetics	O
of	O
TNF	B-Protein
release	O
induced	O
by	O
nothing	O
(	O
control	O
;	O
black	O
diamonds	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
black	O
triangles	O
)	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
black	O
squares	O
)	O
,	O
or	O
10	O
microg	O
/	O
ml	O
LPS	O
(	O
open	O
squares	O
)	O
.	O

Degraded	O
CGN	O
induced	O
THP1	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
.	O

THP	O
-	O
1	O
cells	O
in	O
exponential	O
growth	O
phase	O
were	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
24	O
h	O
before	O
being	O
stained	O
with	O
propidium	O
iodide	O
.	O

Cell	O
DNA	O
content	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
.	O
<EOS>	B-X
In	B-X
this	B-X
unit	B-X
,	B-X
two	B-X
protocols	B-X
are	B-X
described	B-X
for	B-X
analyzing	B-X
cell	B-X
cycle	B-X
status	B-X
using	B-X
flow	B-X
cytometry	B-X
.	B-X
The	B-X
first	B-X
is	B-X
based	B-X
on	B-X
the	B-X
simultaneous	B-X
analysis	B-X
of	B-X
proliferation-specific	B-X
marker	B-X
(	B-X
Ki-67	B-X
)	B-X
and	B-X
cellular	B-X
DNA	B-X
content	B-X
,	B-X
which	B-X
discriminate	B-X
resting/quiescent	B-X
cell	B-X
populations	B-X
(	B-X
G0	B-X
cell	B-X
)	B-X
and	B-X
quantify	B-X
cell	B-X
cycle	B-X
distribution	B-X
(	B-X
G1	B-X
,	B-X
S	B-X
,	B-X
or	B-X
G2/M	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
second	B-X
is	B-X
based	B-X
on	B-X
differential	B-X
staining	B-X
of	B-X
DNA	B-X
and	B-X
RNA	B-X
through	B-X
co-staining	B-X
of	B-X
Hoechst	B-X
33342	B-X
and	B-X
Pyronin	B-X
Y	B-X
,	B-X
which	B-X
is	B-X
also	B-X
useful	B-X
to	B-X
identify	B-X
G0	B-X
cells	B-X
from	B-X
G1	B-X
cells	B-X
.	B-X
Along	B-X
with	B-X
these	B-X
methods	B-X
for	B-X
analyzing	B-X
cell	B-X
cycle	B-X
status	B-X
,	B-X
two	B-X
additional	B-X
methods	B-X
for	B-X
cell	B-X
proliferation	B-X
assays	B-X
with	B-X
recent	B-X
updates	B-X
of	B-X
newly	B-X
developed	B-X
fluorophores	B-X
,	B-X
which	B-X
allow	B-X
multiplex	B-X
analysis	B-X
of	B-X
cell	B-X
cycle	B-X
status	B-X
,	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
a	B-X
gene	B-X
of	B-X
interest	B-X
using	B-X
flow	B-X
cytometry	B-X
,	B-X
are	B-X
outlined	B-X
.	B-X

A	O
:	O
Histograms	O
of	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

B	O
:	O
Percentage	O
of	O
cells	O
in	O
each	O
phase	O
of	O
the	O
cell	O
cycle	O
when	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
different	O
concentrations	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
,	O
or	O
of	O
native	O
CGN	O
(	O
Native	O
)	O
.	O
<EOS>	B-X
Over	B-X
a	B-X
hundred	B-X
different	B-X
subunits	B-X
encoding	B-X
distinct	B-X
K	B-X
channel	B-X
subtypes	B-X
have	B-X
been	B-X
identified	B-X
so	B-X
far	B-X
.	B-X
A	B-X
major	B-X
challenge	B-X
is	B-X
to	B-X
relate	B-X
these	B-X
many	B-X
different	B-X
channel	B-X
subunits	B-X
to	B-X
the	B-X
functional	B-X
K	B-X
currents	B-X
observed	B-X
in	B-X
native	B-X
neurons	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
have	B-X
concentrated	B-X
on	B-X
cerebellar	B-X
granule	B-X
neurons	B-X
(	B-X
CGNs	B-X
)	B-X
.	B-X
For	B-X
each	B-X
super	B-X
family	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
the	B-X
subunits	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
CGNs	B-X
and	B-X
related	B-X
the	B-X
properties	B-X
of	B-X
these	B-X
expressed	B-X
channel	B-X
subunits	B-X
to	B-X
the	B-X
functional	B-X
currents	B-X
seen	B-X
in	B-X
electrophysiological	B-X
recordings	B-X
from	B-X
these	B-X
neurons	B-X
.	B-X
We	B-X
show	B-X
that	B-X
at	B-X
least	B-X
26	B-X
potassium	B-X
channel	B-X
alpha	B-X
subunits	B-X
are	B-X
moderately	B-X
or	B-X
strongly	B-X
expressed	B-X
in	B-X
CGNs	B-X
.	B-X
Nevertheless	B-X
,	B-X
a	B-X
good	B-X
empirical	B-X
model	B-X
of	B-X
CGN	B-X
function	B-X
has	B-X
been	B-X
obtained	B-X
with	B-X
just	B-X
six	B-X
distinct	B-X
K	B-X
conductances	B-X
.	B-X
The	B-X
transient	B-X
KA	B-X
current	B-X
in	B-X
CGNs	B-X
,	B-X
seems	B-X
due	B-X
to	B-X
expression	B-X
of	B-X
Kv4.2	B-X
channels	B-X
or	B-X
Kv4.2/4.3	B-X
heteromers	B-X
,	B-X
while	B-X
the	B-X
KCa	B-X
current	B-X
is	B-X
due	B-X
to	B-X
expression	B-X
of	B-X
large-conductance	B-X
slo	B-X
channels	B-X
.	B-X
Lastly	B-X
,	B-X
the	B-X
delayed-rectifier	B-X
Kv	B-X
current	B-X
has	B-X
as	B-X
many	B-X
as	B-X
six	B-X
different	B-X
potential	B-X
contributors	B-X
from	B-X
the	B-X
extensive	B-X
Kv	B-X
family	B-X
of	B-X
alpha	B-X
subunits	B-X
.	B-X
Since	B-X
many	B-X
of	B-X
these	B-X
subunits	B-X
are	B-X
highly	B-X
regulated	B-X
by	B-X
neurotransmitters	B-X
,	B-X
physiological	B-X
regulators	B-X
and	B-X
,	B-X
often	B-X
,	B-X
auxiliary	B-X
subunits	B-X
,	B-X
the	B-X
resulting	B-X
electrical	B-X
properties	B-X
of	B-X
CGNs	B-X
may	B-X
be	B-X
highly	B-X
dynamic	B-X
and	B-X
subject	B-X
to	B-X
constant	B-X
fine-tuning	B-X
.	B-X

Degraded	O
CGN	O
stimulated	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
monocytes	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
or	O
THP	O
-	O
1	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
carrageenan	O
for	O
24	O
h	O
before	O
being	O
stained	O
for	O
various	O
cell	O
surface	O
antigens	O
.	O
<EOS>	B-X
Tumor	B-X
associated	B-X
macrophages	B-X
(	B-X
TAMs	B-X
)	B-X
are	B-X
present	B-X
in	B-X
high	B-X
density	B-X
in	B-X
solid	B-X
tumors	B-X
.	B-X
TAMs	B-X
share	B-X
many	B-X
characteristics	B-X
with	B-X
alternatively	B-X
activated	B-X
macrophages	B-X
,	B-X
also	B-X
called	B-X
M2	B-X
.	B-X
They	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
favor	B-X
tumor	B-X
development	B-X
and	B-X
a	B-X
role	B-X
in	B-X
chemoresistance	B-X
has	B-X
also	B-X
been	B-X
suggested	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
M2	B-X
in	B-X
comparison	B-X
to	B-X
M1	B-X
macrophages	B-X
on	B-X
cancer	B-X
cell	B-X
sensitivity	B-X
to	B-X
etoposide	B-X
.	B-X

Antigen	O
expression	O
was	O
then	O
analyzed	O
by	O
flow	O
cytometry	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
CAR	B-X
expression	B-X
was	B-X
analyzed	B-X
in	B-X
peripheral	B-X
blood	B-X
samples	B-X
from	B-X
patients	B-X
and	B-X
healthy	B-X
donors	B-X
by	B-X
flow	B-X
cytometry	B-X
with	B-X
four	B-X
commercially	B-X
available	B-X
detection	B-X
reagents	B-X
and	B-X
on	B-X
the	B-X
gene	B-X
level	B-X
by	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
.	B-X
Flow	B-X
cytometric	B-X
analysis	B-X
of	B-X
CAR	B-X
expression	B-X
showed	B-X
higher	B-X
mean	B-X
CAR	B-X
expression	B-X
values	B-X
for	B-X
CD19	B-X
CAR	B-X
detection	B-X
reagent	B-X
and	B-X
the	B-X
F	B-X
(	B-X
ab	B-X
'	B-X
)	B-X
2	B-X
antibody	B-X
than	B-X
Protein	B-X
L	B-X
and	B-X
CD19	B-X
Protein	B-X
.	B-X
Furthermore	B-X
,	B-X
flow	B-X
cytometry-based	B-X
CAR-T	B-X
cell	B-X
frequencies	B-X
by	B-X
CD19	B-X
CAR	B-X
detection	B-X
reagent	B-X
showed	B-X
a	B-X
good	B-X
correlation	B-X
with	B-X
qPCR	B-X
results	B-X
.	B-X
Perfect	B-X
isolation	B-X
of	B-X
the	B-X
malignant	B-X
B-cell	B-X
population	B-X
from	B-X
a	B-X
surgical	B-X
biopsy	B-X
is	B-X
a	B-X
significant	B-X
challenge	B-X
,	B-X
masking	B-X
important	B-X
FL	B-X
biology	B-X
,	B-X
such	B-X
as	B-X
immune	B-X
checkpoint	B-X
coexpression	B-X
patterns	B-X
.	B-X
To	B-X
resolve	B-X
the	B-X
underlying	B-X
transcriptional	B-X
networks	B-X
of	B-X
follicular	B-X
B-cell	B-X
lymphomas	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
transcriptomes	B-X
of	B-X
34	B-X
188	B-X
cells	B-X
derived	B-X
from	B-X
6	B-X
primary	B-X
FL	B-X
tumors	B-X
.	B-X
For	B-X
each	B-X
tumor	B-X
,	B-X
we	B-X
identified	B-X
normal	B-X
immune	B-X
subpopulations	B-X
and	B-X
malignant	B-X
B	B-X
cells	B-X
,	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
.	B-X
We	B-X
used	B-X
multicolor	B-X
flow	B-X
cytometry	B-X
analysis	B-X
of	B-X
the	B-X
same	B-X
tumors	B-X
to	B-X
confirm	B-X
our	B-X
assignments	B-X
of	B-X
cellular	B-X
lineages	B-X
and	B-X
validate	B-X
our	B-X
predictions	B-X
of	B-X
expressed	B-X
proteins	B-X
.	B-X
Comparison	B-X
of	B-X
gene	B-X
expression	B-X
between	B-X
matched	B-X
malignant	B-X
and	B-X
normal	B-X
B	B-X
cells	B-X
from	B-X
the	B-X
same	B-X
patient	B-X
revealed	B-X
tumor-specific	B-X
features	B-X
.	B-X
Malignant	B-X
B	B-X
cells	B-X
exhibited	B-X
restricted	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
light	B-X
chain	B-X
expression	B-X
(	B-X
either	B-X
Igκ	B-X
or	B-X
Igλ	B-X
)	B-X
,	B-X
as	B-X
well	B-X
the	B-X
expected	B-X
upregulation	B-X
of	B-X
the	B-X

A	O
:	O
Histograms	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

B	O
:	O
Fluorescence	O
intensity	O
for	O
expression	O
of	O
the	O
antigens	O
HLA	O
-	O
ABC	O
,	O
HLA	O
-	O
DR	O
,	O
CD14	B-Protein
,	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
CD58	B-Protein
in	O
cells	O
treated	O
with	O
medium	O
only	O
(	O
control	O
)	O
,	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
.	O

Data	O
are	O
mean	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
A	B-X
computer	B-X
program	B-X
tells	B-X
me	B-X
that	B-X
a	B-X
mean	B-X
value	B-X
is	B-X
12.3456789012	B-X
,	B-X
but	B-X
how	B-X
many	B-X
of	B-X
these	B-X
digits	B-X
are	B-X
significant	B-X
(	B-X
the	B-X
rest	B-X
being	B-X
random	B-X
junk	B-X
)	B-X
?	B-X
In	B-X
most	B-X
clinical	B-X
and	B-X
experimental	B-X
studies	B-X
,	B-X
the	B-X
standard	B-X
deviation	B-X
(	B-X
SD	B-X
)	B-X
and	B-X
the	B-X
estimated	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
(	B-X
SEM	B-X
)	B-X
are	B-X
used	B-X
to	B-X
present	B-X
the	B-X
characteristics	B-X
of	B-X
sample	B-X
data	B-X
and	B-X
to	B-X
explain	B-X
statistical	B-X
analysis	B-X
results	B-X
.	B-X
However	B-X
,	B-X
some	B-X
authors	B-X
occasionally	B-X
muddle	B-X
the	B-X
distinctive	B-X
usage	B-X
between	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
in	B-X
medical	B-X
literature	B-X
.	B-X
Because	B-X
the	B-X
process	B-X
of	B-X
calculating	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
includes	B-X
different	B-X
statistical	B-X
inferences	B-X
,	B-X
each	B-X
of	B-X
them	B-X
has	B-X
its	B-X
own	B-X
meaning	B-X
.	B-X
In	B-X
other	B-X
words	B-X
,	B-X
SD	B-X
indicates	B-X
how	B-X
accurately	B-X
the	B-X
mean	B-X
represents	B-X
sample	B-X
data	B-X
.	B-X
However	B-X
the	B-X
meaning	B-X
of	B-X
SEM	B-X
includes	B-X
statistical	B-X
inference	B-X
based	B-X
on	B-X
the	B-X
sampling	B-X
distribution	B-X
.	B-X
SEM	B-X
is	B-X
the	B-X
SD	B-X
of	B-X
the	B-X
theoretical	B-X
distribution	B-X
of	B-X
the	B-X
sample	B-X
means	B-X
(	B-X
the	B-X
sampling	B-X
distribution	B-X
)	B-X
.	B-X
While	B-X
either	B-X
SD	B-X
or	B-X
SEM	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
describe	B-X
data	B-X
and	B-X
statistical	B-X
results	B-X
,	B-X
one	B-X
should	B-X
be	B-X
aware	B-X
of	B-X
reasonable	B-X
methods	B-X
with	B-X
which	B-X
to	B-X
use	B-X
SD	B-X
and	B-X
SEM	B-X
.	B-X
We	B-X
aim	B-X
to	B-X
elucidate	B-X
the	B-X
distinctions	B-X
between	B-X
SD	B-X
and	B-X
SEM	B-X
and	B-X
to	B-X
provide	B-X
proper	B-X
usage	B-X
guidelines	B-X
for	B-X
both	B-X
,	B-X
which	B-X
summarize	B-X
data	B-X
and	B-X
describe	B-X
statistical	B-X
results	B-X
.	B-X

Degraded	O
CGN	O
induced	O
monocytes	O
aggregation	O
in	O
vitro	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
is	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulphated	B-X
polysaccharide	B-X
derived	B-X
from	B-X
red	B-X
seaweeds	B-X
.	B-X
In	B-X
rodents	B-X
,	B-X
its	B-X
degraded	B-X
forms	B-X
(	B-X
dCGN	B-X
)	B-X
can	B-X
induce	B-X
intestinal	B-X
inflammation	B-X
associated	B-X
with	B-X
macrophage	B-X
recruitment	B-X
and	B-X
activation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
:	B-X
1	B-X
)	B-X
to	B-X
analyze	B-X
the	B-X
size-dependent	B-X
effects	B-X
of	B-X
dCGN	B-X
on	B-X
colon	B-X
inflammation	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
2	B-X
)	B-X
to	B-X
correlate	B-X
these	B-X
effects	B-X
with	B-X
monocyte/macrophage	B-X
proliferation	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
expression	B-X
of	B-X
various	B-X
cell	B-X
surface	B-X
antigens	B-X
including	B-X
ICAM-1	B-X
adhesion	B-X
molecule	B-X
.	B-X
Peripheral	B-X
blood	B-X
monocytes	B-X
(	B-X
PBM	B-X
)	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
either	B-X
10	B-X
or	B-X
40	B-X
kDa	B-X
,	B-X
dCGN	B-X
.	B-X
The	B-X
40	B-X
kDa	B-X
,	B-X
but	B-X
not	B-X
the	B-X
10	B-X
kDa	B-X
dCGN	B-X
,	B-X
induced	B-X
colitis	B-X
in	B-X
in	B-X
vivo	B-X
.	B-X
Degraded	B-X
CGN	B-X
inhibited	B-X
THP-1	B-X
cell	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
arresting	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
phase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dCGN	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
in	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
with	B-X
a	B-X
major	B-X
effect	B-X
seen	B-X
after	B-X
40	B-X
kDa	B-X
dCGN	B-X
exposure	B-X
.	B-X
Also	B-X
,	B-X
dCGN	B-X
stimulated	B-X
monocyte	B-X
aggregation	B-X
in	B-X
vitro	B-X
that	B-X
was	B-X
prevented	B-X
by	B-X
incubation	B-X
with	B-X
anti-ICAM-1	B-X
antibody	B-X
.	B-X
Finally	B-X
,	B-X
dCGN	B-X
stimulated	B-X
TNF-alpha	B-X
expression	B-X
and	B-X
secretion	B-X
by	B-X
both	B-X
PBM	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
strongly	B-X
suggest	B-X
that	B-X
the	B-X
degraded	B-X
forms	B-X
of	B-X
CGN	B-X
have	B-X
a	B-X
pronounced	B-X
effect	B-X
on	B-X
monocytes	B-X
,	B-X
characteristic	B-X
of	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X

Monocytes	O
were	O
incubated	O
in	O
the	O
absence	O
(	O
A	O
)	O
or	O
the	O
presence	O
of	O
1	O
mg	O
/	O
ml	O
10	O
kDa	O
dCGN	O
(	O
B	O
)	O
,	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
(	O
C	O
)	O
,	O
or	O
1	O
mg	O
/	O
ml	O
40	O
kDa	O
dCGN	O
plus	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
(	O
D	O
)	O
.	O

Cells	O
were	O
observed	O
by	O
phase	O
contrast	O
inverse	O
microscopy	O
at	O
150X	O
magnification	O
.	O

Inserts	O
in	O
A	O
and	O
B	O
show	O
a	O
close	O
up	O
of	O
cells	O
at	O
300X	O
magnification	O
.	O

E	O
:	O
Number	O
of	O
monocyte	O
aggregates	O
in	O
24	O
wells	O
plate	O
of	O
PBM	O
cell	O
cultured	O
with	O
nothing	O
(	O
control	O
)	O
,	O
with	O
10	O
kDa	O
degraded	O
CGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
40	O
kDa	O
degraded	O
CGN	O
(	O
C40	O
)	O
.	O

Some	O
cultures	O
had	O
also	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
ICAM	O
-	O
1	O
antibody	O
.	O
<EOS>	B-X
Two	B-X
different	B-X
modalities	B-X
[	B-X
direct	B-X
graft	B-X
treatment	B-X
by	B-X
mitomycin	B-X
C	B-X
(	B-X
MMC	B-X
)	B-X
and	B-X
blockage	B-X
of	B-X
the	B-X
lymphocyte	B-X
function-associated	B-X
antigen-1/intracellular	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
LFA-1/ICAM-1	B-X
)	B-X
pathway	B-X
in	B-X
recipients	B-X
by	B-X
species-specific	B-X
mAbs	B-X
]	B-X
were	B-X
tested	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
produce	B-X
unresponsiveness	B-X
to	B-X
secondary	B-X
islet	B-X
xenografts	B-X
.	B-X
The	B-X
significant	B-X
reduction	B-X
of	B-X
angiographic	B-X
restenosis	B-X
rates	B-X
in	B-X
the	B-X
ISAR-SWEET	B-X
study	B-X
(	B-X
intracoronary	B-X
stenting	B-X
and	B-X
antithrombotic	B-X
regimen	B-X
:	B-X
is	B-X
abciximab	B-X
a	B-X
superior	B-X
way	B-X
to	B-X
eliminate	B-X
elevated	B-X
thrombotic	B-X
risk	B-X
in	B-X
diabetes	B-X
)	B-X
raises	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
abciximab	B-X
acts	B-X
on	B-X
clopidogrel-independent	B-X
mechanisms	B-X
in	B-X
suppressing	B-X
neointimal	B-X
hyperplasia	B-X
.	B-X
The	B-X
current	B-X
study	B-X
investigates	B-X
the	B-X
direct	B-X
effect	B-X
of	B-X
abciximab	B-X
on	B-X
ICAM-1	B-X
expression	B-X
,	B-X
migration	B-X
and	B-X
proliferation	B-X
.	B-X
It	B-X
has	B-X
been	B-X
reported	B-X
that	B-X
fibrinogen	B-X
may	B-X
act	B-X
as	B-X
a	B-X
bridging	B-X
ligand	B-X
,	B-X
binding	B-X
to	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
ICAM-1	B-X
)	B-X
on	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
and	B-X
to	B-X
Mac-1	B-X
on	B-X
THP-1	B-X
cells	B-X
(	B-X
a	B-X
monocytic	B-X
cell	B-X
line	B-X
)	B-X
to	B-X
increase	B-X
adhesion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
fibrinogen	B-X
altered	B-X
the	B-X
expression	B-X
of	B-X
ICAM-1	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
increased	B-X
the	B-X
adhesion	B-X
of	B-X
THP-1	B-X
cells	B-X
to	B-X
cultured	B-X
human	B-X
saphenous	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HSVECs	B-X
)	B-X
.	B-X
Incubation	B-X
of	B-X
HSVECs	B-X
with	B-X
0.3	B-X
to	B-X
4	B-X
micromol/L	B-X
fibrinogen	B-X
caused	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
in	B-X
ICAM-1	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
ELISA	B-X
.	B-X
The	B-X
4-	B-X
to	B-X
5-fold	B-X
increase	B-X
in	B-X
ICAM-1	B-X
protein	B-X
concentration	B-X
in	B-X
HSVECs	B-X
stimulated	B-X
by	B-X
4	B-X
micromol/L	B-X
fibrinogen	B-X
for	B-X
6	B-X
hours	B-X
was	B-X
concomitant	B-X
with	B-X
a	B-X
4-	B-X
to	B-X
5-fold	B-X
increase	B-X
in	B-X
ICAM-1	B-X
mRNA	B-X
.	B-X
This	B-X
fibrinogen-stimulated	B-X
ICAM-1	B-X
upregulation	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
2-fold	B-X
increase	B-X
in	B-X
THP-1	B-X
cell	B-X
adhesion	B-X
to	B-X
HSVECs	B-X
.	B-X
The	B-X
fibrinogen-derived	B-X
peptide	B-X
Bbeta15-42	B-X
bound	B-X
to	B-X
HSVECs	B-X
(	B-X
K	B-X
(	B-X
d	B-X
)	B-X
0.18	B-X
micromol/L	B-X
)	B-X
.	B-X
Preincubation	B-X
of	B-X
HSVECs	B-X
with	B-X
Bbeta15-42	B-X
,	B-X
a	B-X
neutralizing	B-X
antibody	B-X
to	B-X
urokinase	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
,	B-X
or	B-X
the	B-X
F	B-X
(	B-X
ab	B-X
)	B-X
(	B-X
1	B-X
)	B-X
fragment	B-X
of	B-X
a	B-X
monoclonal	B-X
antibody	B-X
to	B-X
vascular	B-X
endothelial	B-X
cadherin	B-X
significantly	B-X
attenuated	B-X
the	B-X
increase	B-X
in	B-X
ICAM-1	B-X
stimulated	B-X
by	B-X
fibrinogen	B-X
.	B-X
Capillary	B-X
electrophoretic	B-X
analysis	B-X
indicated	B-X
that	B-X
anti-uPA	B-X
prevented	B-X
the	B-X
release	B-X
of	B-X
any	B-X
fibrinopeptide	B-X
B	B-X
(	B-X
Bbeta1-14	B-X
)	B-X
in	B-X
cultures	B-X
of	B-X
HSVECs	B-X
incubated	B-X
with	B-X
4	B-X
micromol/L	B-X
fibrinogen	B-X
for	B-X
6	B-X
hours	B-X
.	B-X
Moreover	B-X
,	B-X
incubation	B-X
of	B-X
HSVECs	B-X
with	B-X
either	B-X
fibrin	B-X
monomer	B-X
(	B-X
1	B-X
micromol/L	B-X
)	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
to	B-X
vascular	B-X
endothelial	B-X
cadherin	B-X
(	B-X
25	B-X
microg/mL	B-X
)	B-X
increased	B-X
ICAM-1	B-X
protein	B-X
concentration	B-X
3-	B-X
to	B-X
4-fold	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
cleavage	B-X
of	B-X
fibrinopeptide	B-X
B	B-X
from	B-X
fibrinogen	B-X
by	B-X
endothelial	B-X
uPA	B-X
permits	B-X
the	B-X
exposed	B-X
Bbeta15-42	B-X
sequence	B-X
of	B-X
fibrinogen	B-X
to	B-X
bind	B-X
to	B-X
vascular	B-X
endothelial	B-X
cadherin	B-X
on	B-X
HSVECs	B-X
and	B-X
to	B-X
upregulate	B-X
the	B-X
expression	B-X
of	B-X
ICAM-1	B-X
.	B-X

Data	O
are	O
mean	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
A	B-X
computer	B-X
program	B-X
tells	B-X
me	B-X
that	B-X
a	B-X
mean	B-X
value	B-X
is	B-X
12.3456789012	B-X
,	B-X
but	B-X
how	B-X
many	B-X
of	B-X
these	B-X
digits	B-X
are	B-X
significant	B-X
(	B-X
the	B-X
rest	B-X
being	B-X
random	B-X
junk	B-X
)	B-X
?	B-X
In	B-X
most	B-X
clinical	B-X
and	B-X
experimental	B-X
studies	B-X
,	B-X
the	B-X
standard	B-X
deviation	B-X
(	B-X
SD	B-X
)	B-X
and	B-X
the	B-X
estimated	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
(	B-X
SEM	B-X
)	B-X
are	B-X
used	B-X
to	B-X
present	B-X
the	B-X
characteristics	B-X
of	B-X
sample	B-X
data	B-X
and	B-X
to	B-X
explain	B-X
statistical	B-X
analysis	B-X
results	B-X
.	B-X
However	B-X
,	B-X
some	B-X
authors	B-X
occasionally	B-X
muddle	B-X
the	B-X
distinctive	B-X
usage	B-X
between	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
in	B-X
medical	B-X
literature	B-X
.	B-X
Because	B-X
the	B-X
process	B-X
of	B-X
calculating	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
includes	B-X
different	B-X
statistical	B-X
inferences	B-X
,	B-X
each	B-X
of	B-X
them	B-X
has	B-X
its	B-X
own	B-X
meaning	B-X
.	B-X
In	B-X
other	B-X
words	B-X
,	B-X
SD	B-X
indicates	B-X
how	B-X
accurately	B-X
the	B-X
mean	B-X
represents	B-X
sample	B-X
data	B-X
.	B-X
However	B-X
the	B-X
meaning	B-X
of	B-X
SEM	B-X
includes	B-X
statistical	B-X
inference	B-X
based	B-X
on	B-X
the	B-X
sampling	B-X
distribution	B-X
.	B-X
SEM	B-X
is	B-X
the	B-X
SD	B-X
of	B-X
the	B-X
theoretical	B-X
distribution	B-X
of	B-X
the	B-X
sample	B-X
means	B-X
(	B-X
the	B-X
sampling	B-X
distribution	B-X
)	B-X
.	B-X
While	B-X
either	B-X
SD	B-X
or	B-X
SEM	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
describe	B-X
data	B-X
and	B-X
statistical	B-X
results	B-X
,	B-X
one	B-X
should	B-X
be	B-X
aware	B-X
of	B-X
reasonable	B-X
methods	B-X
with	B-X
which	B-X
to	B-X
use	B-X
SD	B-X
and	B-X
SEM	B-X
.	B-X
We	B-X
aim	B-X
to	B-X
elucidate	B-X
the	B-X
distinctions	B-X
between	B-X
SD	B-X
and	B-X
SEM	B-X
and	B-X
to	B-X
provide	B-X
proper	B-X
usage	B-X
guidelines	B-X
for	B-X
both	B-X
,	B-X
which	B-X
summarize	B-X
data	B-X
and	B-X
describe	B-X
statistical	B-X
results	B-X
.	B-X

Degraded	O
CGN	O
stimulated	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
expression	O
in	O
monocytes	O
.	O

Representative	O
samples	O
of	O
RT	O
-	O
PCR	O
analysis	O
showing	O
over	O
expression	O
of	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
after	O
stimulation	O
of	O
monocytes	O
with	O
1	O
g	O
/	O
l	O
of	O
degraded	O
CGN	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
expression	O
was	O
used	O
as	O
normalization	O
gene	O
.	O

Degraded	O
CGN	O
activated	O
the	O
NF	O
-	O
kB	O
pathway	O
in	O
monocytes	O
.	O

A	O
:	O
THP	O
-	O
1	O
cells	O
were	O
transfected	O
with	O
a	O
NF	O
-	O
kappaB	O
reporter	O
plasmid	O
driving	O
expression	O
of	O
luciferase	B-Protein
.	O

Cells	O
were	O
then	O
treated	O
with	O
various	O
concentrations	O
of	O
10	O
kDa	O
(	O
triangles	O
)	O
,	O
or	O
40	O
kDa	O
dCGN	O
(	O
squares	O
)	O
.	O

B	O
:	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
were	O
lysed	O
after	O
various	O
periods	O
of	O
time	O
.	O

Proteins	O
in	O
cell	O
extracts	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
then	O
Western	O
blotted	O
for	O
IkappaBalpha	B-Protein
or	O
alpha	O
-	O
tubulin	O
as	O
loading	O
control	O
.	O
<EOS>	B-X
Overloading-induced	B-X
cell	B-X
death	B-X
,	B-X
especially	B-X
endogenous	B-X
stem	B-X
cell	B-X
death	B-X
,	B-X
is	B-X
the	B-X
leading	B-X
factor	B-X
that	B-X
undermines	B-X
intrinsic	B-X
repair	B-X
and	B-X
aggravates	B-X
IDD	B-X
.	B-X
Previous	B-X
research	B-X
has	B-X
separately	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
oxygen	B-X
concentration	B-X
and	B-X
mechanical	B-X
loading	B-X
in	B-X
IDD	B-X
.	B-X
The	B-X
microtubule	B-X
network	B-X
of	B-X
cardiac	B-X
muscle	B-X
cells	B-X
has	B-X
unique	B-X
architectural	B-X
and	B-X
biophysical	B-X
features	B-X
to	B-X
accommodate	B-X
the	B-X
demands	B-X
of	B-X
the	B-X
working	B-X
heart	B-X
.	B-X
Advances	B-X
in	B-X
live-cell	B-X
imaging	B-X
and	B-X
in	B-X
deciphering	B-X
the	B-X
'tubulin	B-X
code	B-X
'	B-X
have	B-X
shone	B-X
new	B-X
light	B-X
on	B-X
this	B-X
cytoskeletal	B-X
network	B-X
and	B-X
its	B-X
role	B-X
in	B-X
heart	B-X
failure	B-X
.	B-X
Microtubule-based	B-X
transport	B-X
orchestrates	B-X
the	B-X
growth	B-X
and	B-X
maintenance	B-X
of	B-X
the	B-X
contractile	B-X
apparatus	B-X
through	B-X
spatiotemporal	B-X
control	B-X
of	B-X
translation	B-X
,	B-X
while	B-X
also	B-X
organizing	B-X
the	B-X
specialized	B-X
membrane	B-X
systems	B-X
required	B-X
for	B-X
excitation-contraction	B-X
coupling	B-X
.	B-X

C	O
:	O
Degraded	O
carrageenans	O
(	O
dCGN	O
)	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Carrageenan	B-X
(	B-X
CGN	B-X
)	B-X
,	B-X
a	B-X
high	B-X
molecular	B-X
weight	B-X
sulfated	B-X
polysaccharide	B-X
,	B-X
is	B-X
a	B-X
traditional	B-X
ingredient	B-X
used	B-X
in	B-X
food	B-X
industry	B-X
.	B-X

THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
nothing	O
(	O
control	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Nuclei	O
were	O
isolated	O
and	O
lysed	O
.	O
<EOS>	B-X
This	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
analysis	B-X
of	B-X
DNA	B-X
fragmentation	B-X
using	B-X
the	B-X
specific	B-X
DNA	B-X
Breakage	B-X
Detection-Fluorescence	B-X
In	B-X
Situ	B-X
Hybridization	B-X
(	B-X
DBD-FISH	B-X
)	B-X
assay	B-X
,	B-X
which	B-X
allows	B-X
the	B-X
detection	B-X
of	B-X
DNA	B-X
breaks	B-X
in	B-X
lysed	B-X
sperm	B-X
nuclei	B-X
.	B-X
Sperm	B-X
suspensions	B-X
either	B-X
prepared	B-X
from	B-X
semen	B-X
or	B-X
isolated	B-X
from	B-X
semen	B-X
by	B-X
gradient	B-X
centrifugation	B-X
were	B-X
embedded	B-X
in	B-X
an	B-X
agarose	B-X
microgel	B-X
on	B-X
slides	B-X
and	B-X
treated	B-X
with	B-X
0.08	B-X
N	B-X
HCl	B-X
and	B-X
lysing	B-X
solutions	B-X
containing	B-X
0.8	B-X
M	B-X
dithiothreitol	B-X
(	B-X
DTT	B-X
)	B-X
,	B-X
1	B-X
%	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
(	B-X
SDS	B-X
)	B-X
,	B-X
and	B-X
2	B-X
M	B-X
NaCl	B-X
.	B-X
Nuclei	B-X
have	B-X
been	B-X
isolated	B-X
from	B-X
plasmodia	B-X
ofPhysarum	B-X
.	B-X
Large	B-X
RNA	B-X
products	B-X
(	B-X
up	B-X
to	B-X
30	B-X
S	B-X
when	B-X
analysed	B-X
under	B-X
denaturating	B-X
conditions	B-X
)	B-X
are	B-X
transcribed	B-X
on	B-X
chromatin.The	B-X
template	B-X
activity	B-X
of	B-X
nuclei	B-X
or	B-X
chromatin	B-X
,	B-X
measured	B-X
using	B-X
saturating	B-X
amounts	B-X
of	B-X
added	B-X
RNA	B-X
polymerase	B-X
B	B-X
,	B-X
correlates	B-X
with	B-X
the	B-X
in	B-X
vivo	B-X
RNA	B-X
synthesis	B-X
in	B-X
three	B-X
well	B-X
defined	B-X
situations	B-X
.	B-X

Proteins	O
in	O
nuclear	O
extracts	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
then	O
Western	O
blotted	O
for	O
NF	O
-	O
kappaB	O
p50	B-Protein
subunit	O
(	O
p50	B-Protein
)	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
(	O
p65	B-Protein
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
genetic	B-X
or	B-X
pharmacological	B-X
targeting	B-X
of	B-X
the	B-X
oncogenic	B-X
MUC1	B-X
subunit	B-X
MUC1-C	B-X
is	B-X
sufficient	B-X
to	B-X
suppress	B-X
PD-L1	B-X
expression	B-X
in	B-X
TNBC	B-X
cells	B-X
.	B-X
The	B-X
pleiotropic	B-X
consequences	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
kappa	B-X
light	B-X
polypeptide	B-X
gene	B-X
enhancer	B-X
in	B-X
B-cells	B-X
(	B-X
NF-κB	B-X
)	B-X
pathway	B-X
activation	B-X
result	B-X
from	B-X
the	B-X
combinatorial	B-X
effects	B-X
of	B-X
the	B-X
five	B-X
subunits	B-X
that	B-X
form	B-X
the	B-X
homo-	B-X
and	B-X
heterodimeric	B-X
NF-κB	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
recent	B-X
results	B-X
that	B-X
reveal	B-X
that	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
kappa	B-X
light	B-X
polypeptide	B-X
gene	B-X
enhancer	B-X
in	B-X
B-cells	B-X
1	B-X
(	B-X
NFKB1	B-X
)	B-X
(	B-X
p105/p50	B-X
)	B-X
subunit	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
NF-κB	B-X
activity	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
effects	B-X
are	B-X
not	B-X
restricted	B-X
to	B-X
being	B-X
a	B-X
dimer	B-X
partner	B-X
for	B-X
other	B-X
NF-κB	B-X
subunits	B-X
.	B-X
Rather	B-X
p50	B-X
homodimers	B-X
have	B-X
a	B-X
critical	B-X
role	B-X
as	B-X
suppressors	B-X
of	B-X
the	B-X
NF-κB	B-X
response	B-X
,	B-X
while	B-X
the	B-X
p105	B-X
precursor	B-X
has	B-X
a	B-X
variety	B-X
of	B-X
NF-κB-independent	B-X
functions	B-X
.	B-X
In	B-X
humans	B-X
,	B-X
low	B-X
expression	B-X
of	B-X
Kip1	B-X
ubiquitination-promoting	B-X
complex	B-X
1	B-X
(	B-X
KPC1	B-X
)	B-X
,	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
required	B-X
for	B-X
p105	B-X
to	B-X
p50	B-X
processing	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
correlate	B-X
with	B-X
a	B-X
reduction	B-X
in	B-X
p50	B-X
and	B-X
glioblastoma	B-X
incidence	B-X
.	B-X
Therefore	B-X
,	B-X
while	B-X
the	B-X
majority	B-X
of	B-X
research	B-X
in	B-X
this	B-X
field	B-X
has	B-X
focused	B-X
on	B-X
the	B-X
upstream	B-X
signalling	B-X
pathways	B-X
leading	B-X
to	B-X
NF-κB	B-X
activation	B-X
or	B-X
the	B-X
function	B-X
of	B-X
other	B-X
NF-κB	B-X
subunits	B-X
,	B-X
such	B-X
as	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
NFKB1	B-X
,	B-X
potentially	B-X
revealing	B-X
new	B-X
strategies	B-X
for	B-X
targeting	B-X
this	B-X
pathway	B-X
in	B-X
inflammatory	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X

Lower	O
panels	O
show	O
Western	O
blots	O
of	O
nuclear	O
ERK	O
revealing	O
equivalent	O
amount	O
of	O
protein	O
in	O
each	O
sample	O
.	O

Data	O
are	O
representative	O
of	O
three	O
separate	O
experiments	O
.	O
<EOS>	B-X
We	B-X
delineate	B-X
three	B-X
idealised	B-X
perspectives	B-X
for	B-X
the	B-X
prediction	B-X
of	B-X
chemical	B-X
effects	B-X
:	B-X
the	B-X
suborganismal	B-X
,	B-X
organismal	B-X
and	B-X
ecological	B-X
perspective	B-X
,	B-X
which	B-X
are	B-X
currently	B-X
largely	B-X
separated	B-X
.	B-X
Synthesising	B-X
the	B-X
three	B-X
perspectives	B-X
,	B-X
some	B-X
central	B-X
aspects	B-X
and	B-X
associated	B-X
types	B-X
of	B-X
data	B-X
seem	B-X
particularly	B-X
necessary	B-X
to	B-X
improve	B-X
prediction	B-X
.	B-X
These	B-X
could	B-X
be	B-X
collected	B-X
in	B-X
nested	B-X
and	B-X
interconnected	B-X
micro-	B-X
and	B-X
mesocosm	B-X
experiments	B-X
.	B-X
Sticking	B-X
efficiencies	B-X
determined	B-X
from	B-X
field	B-X
experiments	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
determined	B-X
under	B-X
laboratory	B-X
conditions	B-X
.	B-X
Modeling	B-X
transport	B-X
of	B-X
E.	B-X
coli	B-X
can	B-X
be	B-X
separated	B-X
into	B-X
three	B-X
steps	B-X
:	B-X
(	B-X
1	B-X
)	B-X
attachment	B-X
rate	B-X
coefficients	B-X
and	B-X
straining	B-X
rate	B-X
coefficients	B-X
can	B-X
be	B-X
calculated	B-X
from	B-X
Darcy	B-X
flow	B-X
velocity	B-X
fields	B-X
or	B-X
pore	B-X
water	B-X
flow	B-X
velocity	B-X
fields	B-X
,	B-X
calculated	B-X
SCCE	B-X
fields	B-X
,	B-X
realistic	B-X
sticking	B-X
efficiency	B-X
values	B-X
and	B-X
straining	B-X
correction	B-X
parameters	B-X
,	B-X
(	B-X
2	B-X
)	B-X
together	B-X
with	B-X
the	B-X
inactivation	B-X
rate	B-X
coefficient	B-X
,	B-X
total	B-X
rate	B-X
coefficient	B-X
fields	B-X
can	B-X
be	B-X
generated	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
used	B-X
as	B-X
input	B-X
for	B-X
modeling	B-X
the	B-X
transport	B-X
of	B-X
E.	B-X
coli	B-X
in	B-X
existing	B-X
contaminant	B-X
transport	B-X
codes	B-X
.	B-X
Areas	B-X
of	B-X
future	B-X
research	B-X
are	B-X
manifold	B-X
and	B-X
include	B-X
the	B-X
effects	B-X
of	B-X
typical	B-X
wastewater	B-X
characteristics	B-X
,	B-X
including	B-X
high	B-X
concentrations	B-X
of	B-X
organic	B-X
compounds	B-X
,	B-X
on	B-X
the	B-X
transport	B-X
of	B-X
E.	B-X
coli	B-X
and	B-X
thermotolerant	B-X
coliforms	B-X
,	B-X
and	B-X
the	B-X
upscaling	B-X
of	B-X
experiments	B-X
to	B-X
represent	B-X
typical	B-X
field	B-X
conditions	B-X
,	B-X
possibly	B-X
including	B-X
preferential	B-X
flow	B-X
mechanisms	B-X
and	B-X
the	B-X
aspect	B-X
of	B-X
population	B-X
heterogeneity	B-X
of	B-X
E.	B-X
coli	B-X
.	B-X

D	O
:	O
Degraded	O
carrageenan	O
(	O
dCGN	O
)	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

Nuclei	O
isolated	O
from	O
THP	O
-	O
1	O
cells	O
were	O
fluorescence	O
-	O
stained	O
for	O
NF	O
-	O
kappaB	O
p50	B-Protein
subunit	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
before	O
(	O
filled	O
area	O
)	O
or	O
after	O
cells	O
were	O
treated	O
with	O
1	O
mg	O
/	O
ml	O
of	O
10	O
kDa	O
dCGN	O
(	O
C10	O
)	O
,	O
or	O
with	O
1	O
mg	O
/	O
ml	O
of	O
40	O
kDa	O
dCGN	O
(	O
C40	O
)	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Dashed	O
line	O
corresponds	O
to	O
nuclei	O
stained	O
only	O
with	O
secondary	O
fluorescence	O
antibody	O
.	O

Fluorescence	O
intensity	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
as	O
described	O
.	O
<EOS>	B-X
The	B-X
distribution	B-X
of	B-X
fluorescence	B-X
signals	B-X
measured	B-X
with	B-X
flow	B-X
cytometry	B-X
can	B-X
be	B-X
influenced	B-X
by	B-X
several	B-X
factors	B-X
,	B-X
including	B-X
qualitative	B-X
and	B-X
quantitative	B-X
properties	B-X
of	B-X
the	B-X
used	B-X
fluorochromes	B-X
,	B-X
optical	B-X
properties	B-X
of	B-X
the	B-X
detection	B-X
system	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
variability	B-X
within	B-X
the	B-X
analyzed	B-X
cell	B-X
population	B-X
itself	B-X
.	B-X
Cell	B-X
cycle	B-X
,	B-X
together	B-X
with	B-X
changes	B-X
in	B-X
the	B-X
cell	B-X
size	B-X
,	B-X
are	B-X
two	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
alter	B-X
the	B-X
functional	B-X
properties	B-X
of	B-X
analyzed	B-X
cells	B-X
and	B-X
thus	B-X
affect	B-X
the	B-X
interpretation	B-X
of	B-X
obtained	B-X
results	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
association	B-X
between	B-X
cell	B-X
cycle	B-X
status	B-X
and	B-X
cell	B-X
size	B-X
,	B-X
and	B-X
the	B-X
variability	B-X
in	B-X
the	B-X
distribution	B-X
of	B-X
fluorescence	B-X
intensity	B-X
as	B-X
determined	B-X
with	B-X
flow	B-X
cytometry	B-X
,	B-X
at	B-X
population	B-X
scale	B-X
.	B-X
SYBR	B-X
Green	B-X
I	B-X
(	B-X
SG	B-X
)	B-X
,	B-X
a	B-X
nucleic	B-X
acid	B-X
stain	B-X
,	B-X
its	B-X
fluorescence	B-X
intensity	B-X
is	B-X
correlated	B-X
with	B-X
the	B-X
amount	B-X
of	B-X
double-stranded	B-X
DNA	B-X
.	B-X
This	B-X
study	B-X
established	B-X
a	B-X
new	B-X
method	B-X
through	B-X
successive	B-X
SG-SG-PI	B-X
staining	B-X
(	B-X
PI	B-X
:	B-X
Propidium	B-X
Iodide	B-X
)	B-X
with	B-X
flow	B-X
cytometry	B-X
(	B-X
FCM	B-X
)	B-X
.	B-X
This	B-X
method	B-X
was	B-X
briefly	B-X
described	B-X
as	B-X
follows	B-X
:	B-X
firstly	B-X
,	B-X
(	B-X
1	B-X
)	B-X
the	B-X
fungal	B-X
spores	B-X
were	B-X
stained	B-X
with	B-X
SG	B-X
and	B-X
washed	B-X
by	B-X
centrifugation	B-X
;	B-X
and	B-X
then	B-X
,	B-X
(	B-X
2	B-X
)	B-X
the	B-X
washed	B-X
spores	B-X
were	B-X
treated	B-X
with	B-X
disinfectants	B-X
and	B-X
terminated	B-X
;	B-X
after	B-X
that	B-X
,	B-X
(	B-X
3	B-X
)	B-X
the	B-X
disinfected	B-X
spores	B-X
were	B-X
re-stained	B-X
with	B-X
SG	B-X
and	B-X
analyzed	B-X
by	B-X
FCM	B-X
;	B-X
finally	B-X
,	B-X
(	B-X
4	B-X
)	B-X
the	B-X
SG	B-X
re-stained	B-X
spores	B-X
were	B-X
stained	B-X
with	B-X
PI	B-X
and	B-X
analyzed	B-X
by	B-X
FCM	B-X
.	B-X
The	B-X
percentages	B-X
of	B-X
spores	B-X
with	B-X
DNA	B-X
damage	B-X
and	B-X
membrane	B-X
damage	B-X
were	B-X
determined	B-X
by	B-X
the	B-X
fluorescence	B-X
intensity	B-X
obtained	B-X
from	B-X
steps	B-X
(	B-X
3	B-X
)	B-X
and	B-X
(	B-X
4	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X

Transcription	O
factors	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
in	O
the	O
induction	O
and	O
suppressive	O
function	O
of	O
Foxp3	B-Protein
+	O
inducible	O
regulatory	O
T	O
cells	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

Forkhead	B-Protein
box	I-Protein
P3	I-Protein
(	O
FOXP3	B-Protein
)	O
+	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
inducible	O
regulatory	O
T	O
(	O
iT	O
reg	O
)	O
cells	O
play	O
an	O
important	O
role	O
in	O
immune	O
tolerance	O
and	O
homeostasis	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
(	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
)	O
induces	O
the	O
expression	O
of	O
the	O
Runt	O
-	O
related	O
transcription	O
factors	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
in	O
CD4	B-Protein
+	O
T	O
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

This	O
induction	O
seems	O
to	O
be	O
a	O
prerequisite	O
for	O
the	O
binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
to	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X

Inactivation	O
of	O
the	O
gene	O
encoding	O
RUNX	B-Protein
cofactor	O
core	B-Protein
-	I-Protein
binding	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
(	O
CBFbeta	B-Protein
)	O
in	O
mice	O
and	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
suppression	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
in	O
human	O
T	O
cells	O
resulted	O
in	O
reduced	O
expression	O
of	O
Foxp3	B-Protein
.	O

The	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
into	O
Foxp3	B-Protein
+	O
iT	O
reg	O
cells	O
was	O
significantly	O
decreased	O
in	O
adoptively	O
transferred	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	O
cre	B-Protein
naive	O
T	O
cells	O
into	O
Rag2	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

Both	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
silenced	O
human	O
T	O
reg	O
cells	O
and	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	O
cre	B-Protein
mouse	O
T	O
reg	O
cells	O
showed	O
diminished	O
suppressive	O
function	O
in	O
vitro	O
.	O

Circulating	O
human	O
CD4	B-Protein
+	O
CD25high	B-Protein
CD127	B-Protein
-	O
T	O
reg	O
cells	O
significantly	O
expressed	O
higher	O
levels	O
of	O
RUNX3	B-Protein
,	O
FOXP3	B-Protein
,	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
mRNA	O
compared	O
with	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

Furthermore	O
,	O
FOXP3	B-Protein
and	O
RUNX3	B-Protein
were	O
colocalized	O
in	O
human	O
tonsil	O
T	O
reg	O
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

These	O
data	O
demonstrate	O
Runx	B-Protein
transcription	O
factors	O
as	O
a	O
molecular	O
link	O
in	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
induced	O
Foxp3	B-Protein
expression	O
in	O
iT	O
reg	O
cell	O
differentiation	O
and	O
function	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

Regulatory	O
T	O
(	O
T	O
reg	O
)	O
cells	O
expressing	O
the	O
transcription	O
factor	O
forkhead	B-Protein
box	I-Protein
P3	I-Protein
(	O
FOXP3	B-Protein
,	O
human	O
;	O
Foxp3	B-Protein
,	O
mouse	O
)	O
play	O
an	O
essential	O
role	O
in	O
controlling	O
immune	O
responses	O
to	O
autoantigens	O
,	O
allergens	O
,	O
tumor	O
antigens	O
,	O
transplantation	O
antigens	O
,	O
and	O
infectious	O
agents	O
(	O
Hori	O
et	O
al	O
.	O
,	O
2003	O
;	O
Akdis	O
,	O
2006	O
)	O
.	O

Foxp3	B-Protein
is	O
a	O
member	O
of	O
the	O
forkhead	O
/	O
winged	O
-	O
helix	O
family	O
of	O
transcriptional	O
regulators	O
,	O
and	O
its	O
expression	O
in	O
T	O
reg	O
cells	O
is	O
essential	O
for	O
their	O
development	O
and	O
function	O
(	O
Fontenot	O
et	O
al	O
.	O
,	O
2003	O
;	O
Williams	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

A	O
spontaneous	O
mutation	O
of	O
the	O
X	O
-	O
linkedFoxp3gene	B-Protein
inscurfymice	O
causes	O
an	O
autoimmune	O
-	O
like	O
disease	O
,	O
whereas	O
the	O
mutation	O
in	O
humans	O
leads	O
to	O
immunodysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
and	O
X	O
-	O
linked	O
syndrome	O
that	O
is	O
also	O
a	O
severe	O
multiorgan	O
autoimmune	O
disease	O
with	O
hyper	O
-	O
IgE	O
(	O
Ziegler	O
,	O
2006	O
)	O
.	O
Although	O
the	O
essential	O
role	O
of	O
Foxp3	B-Protein
in	O
central	O
and	O
peripheral	O
tolerance	O
has	O
been	O
extensively	O
studied	O
,	O
its	O
regulation	O
,	O
cooperation	O
with	O
other	O
transcription	O
factors	O
,	O
and	O
how	O
it	O
functions	O
in	O
inducible	O
T	O
reg	O
(	O
iT	O
reg	O
)	O
cells	O
to	O
suppress	O
various	O
target	O
genes	O
is	O
mostly	O
not	O
yet	O
understood	O
.	O

It	O
is	O
known	O
that	O
Foxp3	B-Protein
cooperates	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
to	O
regulate	O
the	O
transcription	O
of	O
different	O
target	O
genes	O
(	O
Schubert	O
et	O
al	O
.	O
,	O
2001	O
;	O
Bettelli	O
et	O
al	O
.	O
,	O
2005	O
;	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

The	O
Th2	O
cytokine	O
IL	B-Protein
-	I-Protein
4	I-Protein
inhibits	O
FOXP3	B-Protein
expression	O
during	O
T	O
cell	O
priming	O
.	O

GATA3	B-Protein
binds	O
to	O
theFOXP3promoter	B-Protein
and	O
can	O
repress	O
the	O
FOXP3	B-Protein
trans	O
-	O
activation	O
process	O
directly	O
in	O
Th2	O
cells	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
was	O
further	O
demonstrated	O
that	O
both	O
Th1	O
and	O
Th2	O
transcription	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
GATA3	B-Protein
oppose	O
peripheral	O
induction	O
of	O
Foxp3	B-Protein
+	O
T	O
reg	O
cells	O
in	O
mice	O
through	O
STAT1	B-Protein
-	O
,	O
STAT4	B-Protein
-	O
,	O
and	O
STAT6	B-Protein
-	O
dependent	O
pathways	O
(	O
Wei	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Although	O
natural	O
T	O
reg	O
(	O
nT	O
reg	O
)	O
cells	O
that	O
differentiate	O
in	O
the	O
thymus	O
are	O
characterized	O
by	O
their	O
stable	O
Foxp3	B-Protein
expression	O
,	O
the	O
generation	O
of	O
iT	O
reg	O
cells	O
specific	O
for	O
allergens	O
,	O
alloantigens	O
,	O
and	O
autoantigens	O
in	O
the	O
periphery	O
has	O
been	O
associated	O
with	O
a	O
transient	O
Foxp3	B-Protein
+	O
phenotype	O
(	O
Fontenot	O
et	O
al	O
.	O
,	O
2003	O
;	O
Hori	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

The	O
crucial	O
role	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
in	O
their	O
generation	O
has	O
been	O
demonstrated	O
.	O
The	O
RUNX	B-Protein
gene	O
family	O
(	O
Runt	O
-	O
related	O
transcription	O
factor	O
,	O
acute	O
myeloid	O
leukemia	O
[	O
AML	O
]	O
,	O
core	O
-	O
binding	O
factor	O
-	O
alpha	O
[	O
CBFalpha	O
]	O
,	O
and	O
polyoma	O
enhancer	O
-	O
binding	O
protein	O
-	O
2alpha	O
[	O
PEBP2alpha	O
]	O
)	O
contains	O
three	O
members	O
,	O
RUNX1	B-Protein
(	O
AML1	B-Protein
/	O
CBFA2	B-Protein
/	O
PEBP2alphaB	B-Protein
)	O
,	O
RUNX2	B-Protein
(	O
AML3	B-Protein
/	O
CBFA1	B-Protein
/	O
PEBP2alphaA	B-Protein
)	O
,	O
and	O
RUNX3	B-Protein
(	O
AML2	O
/	O
CBFA3	O
/	O
PEBP2alphaC	O
)	O
.	O

They	O
are	O
essential	O
transcriptional	O
regulators	O
of	O
different	O
developmental	O
pathways	O
.	O
<EOS>	B-X
Circadian	B-X
rhythms	B-X
align	B-X
physiological	B-X
functions	B-X
with	B-X
the	B-X
light-dark	B-X
cycle	B-X
through	B-X
oscillatory	B-X
changes	B-X
in	B-X
the	B-X
abundance	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
clock	B-X
transcriptional	B-X
programme	B-X
.	B-X
Timely	B-X
removal	B-X
of	B-X
these	B-X
proteins	B-X
by	B-X
different	B-X
proteolytic	B-X
systems	B-X
is	B-X
essential	B-X
to	B-X
circadian	B-X
strength	B-X
and	B-X
adaptability	B-X
.	B-X
Disruption	B-X
of	B-X
this	B-X
autophagic	B-X
pathway	B-X
in	B-X
vivo	B-X
leads	B-X
to	B-X
temporal	B-X
shifts	B-X
and	B-X
amplitude	B-X
changes	B-X
of	B-X
the	B-X
clock-dependent	B-X
transcriptional	B-X
waves	B-X
and	B-X
fragmented	B-X
circadian	B-X
patterns	B-X
,	B-X
resembling	B-X
those	B-X
in	B-X
sleep	B-X
disorders	B-X
and	B-X
ageing	B-X
.	B-X
Disruption	B-X
of	B-X
this	B-X
circadian	B-X
clock/CMA	B-X
axis	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
both	B-X
pathways	B-X
malfunctioning	B-X
in	B-X
ageing	B-X
and	B-X
for	B-X
the	B-X
subsequently	B-X
pronounced	B-X
proteostasis	B-X
defect	B-X
.	B-X

RUNX2	B-Protein
is	O
mostly	O
important	O
for	O
bone	O
development	O
and	O
osteoblast	O
differentiation	O
(	O
Komori	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

RUNX1	B-Protein
plays	O
an	O
important	O
role	O
in	O
hematopoiesis	O
during	O
development	O
,	O
and	O
RUNX3	B-Protein
has	O
important	O
functions	O
in	O
thymogenesis	O
and	O
neurogenesis	O
(	O
Wang	O
et	O
al	O
.	O
,	O
1996	O
;	O
Inoue	O
et	O
al	O
.	O
,	O
2002	O
;	O
Levanon	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

RUNX1	B-Protein
and	O
RUNX3	B-Protein
also	O
work	O
together	O
in	O
the	O
establishment	O
of	O
lineage	O
specification	O
of	O
T	O
lymphocytes	O
(	O
Taniuchi	O
et	O
al	O
.	O
,	O
2002	O
;	O
Egawa	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
RUNX1is	B-Protein
a	O
frequent	O
target	O
for	O
chromosomal	O
translocations	O
associated	O
with	O
leukemias	O
(	O
Look	O
,	O
1997	O
)	O
,	O
andRUNX3methylation	B-Protein
and	O
silencing	O
is	O
observed	O
in	O
various	O
human	O
epithelial	O
cancers	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
RUNX	B-Protein
family	O
members	O
share	O
the	O
Runt	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
DNA	O
binding	O
(	O
Ito	O
,	O
1999	O
)	O
.	O

The	O
Runt	O
domain	O
-	O
containing	O
protein	O
constitutes	O
the	O
alpha	O
-	O
chain	O
partner	O
of	O
the	O
heterodimeric	O
CBF	B-Protein
complex	O
.	O

RUNX	O
proteins	O
heterodimerize	O
with	O
the	O
non	O
-	O
DNA	O
-	O
binding	O
partner	O
,	O
CBFbeta	B-Protein
,	O
which	O
increases	O
the	O
affinity	O
for	O
DNA	O
binding	O
and	O
stabilizes	O
the	O
complex	O
by	O
preventing	O
ubiquitin	B-Protein
-	O
dependent	O
degradation	O
(	O
Wang	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
CBF	B-Protein
complexes	O
regulate	O
the	O
expression	O
of	O
cellular	O
genes	O
through	O
binding	O
to	O
promoters	O
or	O
enhancer	O
elements	O
.	O
<EOS>	B-X
The	B-X
proper	B-X
activities	B-X
of	B-X
enhancers	B-X
and	B-X
gene	B-X
promoters	B-X
are	B-X
essential	B-X
for	B-X
coordinated	B-X
transcription	B-X
within	B-X
a	B-X
cell	B-X
.	B-X
Although	B-X
diverse	B-X
methodologies	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
identify	B-X
enhancers	B-X
and	B-X
promoters	B-X
,	B-X
most	B-X
have	B-X
tacitly	B-X
assumed	B-X
that	B-X
these	B-X
elements	B-X
are	B-X
distinct	B-X
.	B-X
However	B-X
,	B-X
studies	B-X
have	B-X
unexpectedly	B-X
shown	B-X
that	B-X
regulatory	B-X
elements	B-X
may	B-X
have	B-X
both	B-X
enhancer	B-X
and	B-X
promoter	B-X
functions	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
these	B-X
results	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
factors	B-X
that	B-X
determine	B-X
the	B-X
promoter	B-X
and/or	B-X
enhancer	B-X
activity	B-X
of	B-X
regulatory	B-X
elements	B-X
.	B-X
We	B-X
discuss	B-X
emerging	B-X
models	B-X
that	B-X
define	B-X
regulatory	B-X
elements	B-X
by	B-X
accessible	B-X
DNA	B-X
and	B-X
their	B-X
non-mutually-exclusive	B-X
abilities	B-X
to	B-X
drive	B-X
transcription	B-X
initiation	B-X
(	B-X
promoter	B-X
activity	B-X
)	B-X
and/or	B-X
to	B-X
enhance	B-X
transcription	B-X
at	B-X
other	B-X
such	B-X
regions	B-X
(	B-X
enhancer	B-X
activity	B-X
)	B-X
.	B-X

The	O
effects	O
of	O
the	O
RUNX	B-Protein
-	O
CBFbeta	B-Protein
complex	O
regulation	O
are	O
clearly	O
cell	O
lineage	O
and	O
stage	O
specific	O
.	O

They	O
include	O
the	O
crucial	O
choices	O
between	O
cell	O
-	O
cycle	O
exit	O
and	O
continued	O
proliferation	O
,	O
as	O
well	O
as	O
between	O
cell	O
differentiation	O
and	O
self	O
-	O
renewal	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
Because	O
of	O
the	O
involvement	O
of	O
RUNX	B-Protein
mutations	O
in	O
different	O
autoimmune	O
diseases	O
and	O
the	O
known	O
interaction	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
we	O
investigated	O
the	O
impact	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
on	O
the	O
expression	O
of	O
FOXP3	B-Protein
and	O
subsequently	O
on	O
the	O
development	O
and	O
function	O
of	O
iT	O
reg	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
induced	O
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
are	O
involved	O
in	O
the	O
development	O
and	O
suppressive	O
function	O
of	O
Foxp3	B-Protein
+	O
iT	O
reg	O
cells	O
.	O

The	O
role	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
transcription	O
factors	O
in	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
iT	O
reg	O
cell	O
generation	O

To	O
investigate	O
the	O
role	O
of	O
RUNX	B-Protein
transcription	O
factors	O
in	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
,	O
we	O
cultured	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
isolated	O
from	O
human	O
PBMCs	O
,	O
in	O
conditions	O
that	O
enable	O
the	O
development	O
of	O
iT	O
reg	O
cells	O
.	O

Stimulation	O
with	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAbs	O
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
alone	O
resulted	O
in	O
a	O
minimal	O
up	O
-	O
regulation	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
mRNA	O
(	O
Fig	O
.	O
1	O
A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
combination	O
of	O
both	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAbs	O
induced	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
mRNAs	O
,	O
as	O
well	O
as	O
FOXP3	B-Protein
mRNA	O
,	O
within	O
48	O
h	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

This	O
result	O
suggested	O
further	O
experiments	O
to	O
investigate	O
whether	O
the	O
up	O
-	O
regulation	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
might	O
be	O
a	O
feature	O
of	O
iT	O
reg	O
cells	O
during	O
their	O
development	O
or	O
even	O
a	O
prerequisite	O
for	O
their	O
induction	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
expression	O
was	O
knocked	O
down	O
in	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
by	O
transfection	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
;	O
Fig	O
.	O
1	O
B	O
)	O
.	O

Deficiency	O
of	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
resulted	O
in	O
markedly	O
reduced	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
induction	O
of	O
FOXP3	B-Protein
mRNA	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
compared	O
with	O
control	O
cells	O
transfected	O
with	O
scrambled	O
siRNA	O
.	O
<EOS>	B-X
The	B-X
inflammasome	B-X
initiates	B-X
innate	B-X
defence	B-X
and	B-X
inflammatory	B-X
responses	B-X
by	B-X
activating	B-X
caspase-1	B-X
and	B-X
pyroptotic	B-X
cell	B-X
death	B-X
in	B-X
myeloid	B-X
cells	B-X
Genetic	B-X
predispositions	B-X
to	B-X
myeloid	B-X
malignancies	B-X
can	B-X
be	B-X
classified	B-X
into	B-X
three	B-X
categories	B-X
:	B-X
familial	B-X
cancer	B-X
syndromes	B-X
associated	B-X
with	B-X
increased	B-X
risk	B-X
of	B-X
various	B-X
malignancies	B-X
including	B-X
myelodysplasia	B-X
and	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
such	B-X
as	B-X
Li-Fraumeni	B-X
syndrome	B-X
and	B-X
constitutional	B-X
mismatch	B-X
repair	B-X
deficiency	B-X
(	B-X
CMMRD	B-X
)	B-X
;	B-X
germline	B-X
mutations	B-X
conferring	B-X
a	B-X
specific	B-X
increased	B-X
risk	B-X
of	B-X
myelodysplastic	B-X
syndrome	B-X
and	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
such	B-X
as	B-X
mutations	B-X
in	B-X
ANKRD26	B-X
,	B-X
CEBPA	B-X
,	B-X
DDX41	B-X
,	B-X
ETV6	B-X
,	B-X
GATA2	B-X
,	B-X
RUNX1	B-X
,	B-X
SRP72	B-X
genes	B-X
;	B-X
and	B-X
finally	B-X
primarily	B-X
pediatric	B-X
inherited	B-X
bone	B-X
marrow	B-X
failure	B-X
syndromes	B-X
such	B-X
as	B-X
Fanconi	B-X
anemia	B-X
,	B-X
dyskeratosis	B-X
congenita	B-X
,	B-X
severe	B-X
congenital	B-X
neutropenia	B-X
,	B-X
Shwachman-Diamond	B-X
syndrome	B-X
and	B-X
Diamond	B-X
Blackfan	B-X
anemia	B-X
.	B-X
AML	B-X
carrying	B-X
the	B-X
RUNX1-RUNX1T1	B-X
or	B-X
PML-RARA	B-X
fusion	B-X
genes	B-X
or	B-X
mutations	B-X
in	B-X
signaling	B-X
genes	B-X
(	B-X
FLT3-ITD	B-X
in	B-X
combination	B-X
with	B-X
TET2	B-X
or	B-X
TET2	B-X
and	B-X
DNMT3A	B-X
deficiency	B-X
)	B-X
,	B-X
cohesin	B-X
complex	B-X
members	B-X
(	B-X
STAG2	B-X
)	B-X
,	B-X
TP53	B-X
and	B-X
BCOR	B-X
as	B-X
co-occurring	B-X
lesions	B-X
,	B-X
IDH1/2	B-X
and	B-X
ALL	B-X
cases	B-X
expressing	B-X
the	B-X
TCF3-HLF	B-X
chimera	B-X
or	B-X
TET1	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
PARPi	B-X
in	B-X
preclinical	B-X
studies	B-X
.	B-X
The	B-X
revised	B-X
2016	B-X
WHO	B-X
classification	B-X
introduced	B-X
a	B-X
novel	B-X
category	B-X
of	B-X
``	B-X
myeloid	B-X
neoplasms	B-X
with	B-X
germline	B-X
predisposition	B-X
''	B-X
with	B-X
GATA2	B-X
,	B-X
CEBPA	B-X
,	B-X
DDX41	B-X
,	B-X
RUNX1	B-X
,	B-X
ANKRD26	B-X
and	B-X
ETV6	B-X
genes	B-X
expanding	B-X
the	B-X
spectrum	B-X
of	B-X
hereditary	B-X
myeloid	B-X
neoplasms	B-X
(	B-X
MN	B-X
)	B-X
.	B-X

The	O
level	O
of	O
FOXP3	B-Protein
mRNA	O
was	O
further	O
reduced	O
when	O
both	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
were	O
knocked	O
down	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
during	O
their	O
differentiation	O
to	O
iT	O
reg	O
cells	O
(	O
Fig	O
.	O
1	O
B	O
)	O
.	O

The	O
influence	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
on	O
the	O
development	O
of	O
other	O
T	O
cell	O
subsets	O
and	O
their	O
specific	O
transcription	O
factor	O
expression	O
was	O
further	O
investigated	O
.	O

Naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
under	O
Th1	O
,	O
Th2	O
,	O
T	O
reg	O
cell	O
,	O
and	O
Th17	O
differentiation	O
conditions	O
and	O
the	O
mRNA	O
expression	O
of	O
the	O
predominant	O
transcription	O
factor	O
for	O
each	O
cell	O
type	O
was	O
subsequently	O
analyzed	O
.	O

We	O
observed	O
no	O
change	O
in	O
GATA3	B-Protein
expression	O
in	O
Th2	O
cells	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
expression	O
in	O
Th1	O
cells	O
,	O
or	O
RORC2	B-Protein
mRNA	O
expression	O
in	O
Th17	O
cells	O
in	O
which	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
were	O
knocked	O
down	O
compared	O
with	O
control	O
cells	O
.	O
<EOS>	B-X
Abnormal	B-X
immune	B-X
response	B-X
resulting	B-X
from	B-X
disordered	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
1/Th2	B-X
and	B-X
Th17/regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
cytokine	B-X
expression	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
serve	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
preeclampsia	B-X
(	B-X
PE	B-X
)	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
lineage	B-X
transcription	B-X
factor	B-X
T‑bet	B-X
can	B-X
restore	B-X
immune	B-X
balance	B-X
and	B-X
alleviate	B-X
the	B-X
systemic	B-X
inflammatory	B-X
response	B-X
present	B-X
in	B-X
PE	B-X
,	B-X
30	B-X
patients	B-X
diagnosed	B-X
with	B-X
PE	B-X
were	B-X
assessed	B-X
and	B-X
compared	B-X
with	B-X
healthy	B-X
pregnant	B-X
controls	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
T‑bet	B-X
and	B-X
retinoic	B-X
acid	B-X
receptor‑related	B-X
orphan	B-X
receptor	B-X
(	B-X
ROR	B-X
)	B-X
γt	B-X
were	B-X
increased	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
of	B-X
PE	B-X
patients	B-X
compared	B-X
with	B-X
controls	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
abnormally	B-X
high	B-X
T‑bet	B-X
:	B-X
GATA3	B-X
and	B-X
RORγt	B-X
:	B-X
forkhead	B-X
box	B-X
(	B-X
FOX	B-X
)	B-X
P3	B-X
ratios	B-X
.	B-X
The	B-X
present	B-X
study	B-X
additionally	B-X
identified	B-X
a	B-X
high‑efficiency	B-X
,	B-X
specific	B-X
small	B-X
interfering	B-X
(	B-X
si	B-X
)	B-X
RNA	B-X
that	B-X
can	B-X
downregulate	B-X
RORγt	B-X
and	B-X
T‑bet	B-X
mRNA	B-X
levels	B-X
and	B-X
inhibit	B-X
protein	B-X
expression	B-X
.	B-X
This	B-X
effective	B-X
siRNA	B-X
was	B-X
transfected	B-X
into	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
PE	B-X
to	B-X
observe	B-X
the	B-X
changes	B-X
to	B-X
transcription	B-X
factor	B-X
expression	B-X
and	B-X
attempt	B-X
to	B-X
elucidate	B-X
the	B-X
regulatory	B-X
mechanism	B-X
of	B-X
T	B-X
cell	B-X
subsets	B-X
.	B-X
It	B-X
was	B-X
identified	B-X
that	B-X
knockdown	B-X
of	B-X
RORγt	B-X
induced	B-X
increased	B-X
expression	B-X
of	B-X
FOXP3	B-X
and	B-X
that	B-X
the	B-X
ratios	B-X
of	B-X
RORγt	B-X
:	B-X
FOXP3	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
‑17A	B-X
:	B-X
IL‑10	B-X
were	B-X
subsequently	B-X
decreased	B-X
.	B-X
The	B-X
results	B-X
suggested	B-X
that	B-X
siRNA‑mediated	B-X
knockdown	B-X
of	B-X
T‑bet	B-X
regulated	B-X
the	B-X
immune	B-X
balance	B-X
of	B-X
Th17/Tregs	B-X
via	B-X
changes	B-X
to	B-X
RORγt	B-X
and	B-X
FOXP3	B-X
.	B-X
When	B-X
siRNA	B-X
against	B-X
RORγt	B-X
and	B-X
T‑bet	B-X
were	B-X
used	B-X
in	B-X
combination	B-X
,	B-X
a	B-X
stronger	B-X
ability	B-X
to	B-X
regulate	B-X
immune	B-X
balance	B-X
was	B-X
observed	B-X
.	B-X
These	B-X
results	B-X
imply	B-X
that	B-X
Th1‑	B-X
and	B-X
Th17‑type	B-X
immunity	B-X
is	B-X
dominant	B-X
in	B-X
PE	B-X
and	B-X
that	B-X
the	B-X
siRNA‑mediated	B-X
knockdown	B-X
of	B-X
certain	B-X
Th1	B-X
and	B-X
Th17	B-X
cell	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
therapeutic	B-X
target	B-X
for	B-X
promoting	B-X
immune	B-X
balance	B-X
in	B-X
CD4+	B-X
T	B-X
cell	B-X
subgroups	B-X
and	B-X
ameliorating	B-X
local	B-X
and	B-X
generalized	B-X
inflammation	B-X
in	B-X
PE	B-X
.	B-X

On	O
the	O
contrary	O
,	O
FOXP3	B-Protein
mRNA	O
was	O
significantly	O
decreased	O
in	O
RUNX1	B-Protein
-	O
and	O
RUNX3	B-Protein
-	O
deficient	O
T	O
reg	O
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O
1	O
C	O
)	O
.	O

The	O
effect	O
of	O
RUNX	B-Protein
silencing	O
on	O
the	O
expression	O
level	O
of	O
intracellular	O
FOXP3	B-Protein
during	O
naive	O
CD4	B-Protein
+	O
T	O
cell	O
differentiation	O
to	O
iT	O
reg	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
.	O

FOXP3	B-Protein
was	O
only	O
slightly	O
reduced	O
after	O
RUNX1	B-Protein
silencing	O
.	O

Transfection	O
of	O
siRNA	O
for	O
RUNX3	B-Protein
had	O
a	O
stronger	O
effect	O
.	O

The	O
most	O
striking	O
FOXP3	B-Protein
reduction	O
was	O
observed	O
when	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
were	O
silenced	O
together	O
(	O
Fig	O
.	O
1	O
D	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
total	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
S1	O
and	O
Fig	O
.	O
S2	O
)	O
.	O

The	O
increased	O
impact	O
of	O
combined	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
knockdown	O
implies	O
that	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
might	O
have	O
redundant	O
functions	O
in	O
the	O
induction	O
of	O
FOXP3	B-Protein
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
control	O
siRNA	O
-	O
transfected	O
or	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
-	O
transfected	O
CD4	B-Protein
+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
or	O
without	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAb	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
did	O
not	O
show	O
any	O
significant	O
difference	O
(	O
Fig	O
.	O
S3	O
)	O
.	O

To	O
determine	O
whether	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
are	O
also	O
expressed	O
in	O
human	O
T	O
reg	O
cells	O
in	O
vivo	O
,	O
we	O
isolated	O
peripheral	O
blood	O
CD4	B-Protein
+	O
CD127	B-Protein
-	O
CD25high	B-Protein
T	O
reg	O
cells	O
and	O
compared	O
them	O
with	O
CD4	B-Protein
+	O
CD127	B-Protein
+	O
CD25	B-Protein
-	O
T	O
cells	O
.	O

Circulating	O
T	O
reg	O
cells	O
expressed	O
significantly	O
higher	O
levels	O
of	O
RUNX3	B-Protein
mRNA	O
compared	O
with	O
CD4	B-Protein
+	O
CD25	B-Protein
-	O
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

As	O
expected	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
FOXP3	B-Protein
mRNAs	O
are	O
also	O
expressed	O
in	O
circulating	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
RUNX1	B-Protein
mRNA	O
expression	O
between	O
these	O
two	O
cell	O
subsets	O
.	O
<EOS>	B-X
Although	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNXs	B-X
(	B-X
RUNX1-3	B-X
)	B-X
have	B-X
a	B-X
high	B-X
similarity	B-X
in	B-X
their	B-X
structure	B-X
,	B-X
only	B-X
RUNX3	B-X
is	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
gastric	B-X
carcinogenesis	B-X
.	B-X
First	B-X
,	B-X
we	B-X
examined	B-X
mRNA	B-X
expression	B-X
of	B-X
these	B-X
three	B-X
RUNX	B-X
genes	B-X
in	B-X
the	B-X
gastric	B-X
mucosa	B-X
,	B-X
and	B-X
,	B-X
finding	B-X
only	B-X
RUNX2	B-X
was	B-X
not	B-X
expressed	B-X
there	B-X
,	B-X
we	B-X
further	B-X
investigated	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
expression	B-X
in	B-X
three	B-X
regions	B-X
including	B-X
the	B-X
pit	B-X
,	B-X
isthmus/neck	B-X
,	B-X
and	B-X
gland	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
normal	B-X
stomach	B-X
and	B-X
whether	B-X
RUNX1	B-X
is	B-X
involved	B-X
in	B-X
gastric	B-X
carcinogenesis	B-X
.	B-X
The	B-X
mRNA	B-X
expression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
was	B-X
examined	B-X
by	B-X
use	B-X
of	B-X
the	B-X
three	B-X
regions	B-X
isolated	B-X
by	B-X
laser-captured	B-X
microdissection	B-X
(	B-X
LCM	B-X
)	B-X
and	B-X
by	B-X
use	B-X
of	B-X
primary	B-X
gastric	B-X
cancer	B-X
tissues	B-X
.	B-X
Furthermore	B-X
,	B-X
RUNX1	B-X
mutational	B-X
analysis	B-X
was	B-X
performed	B-X
in	B-X
the	B-X
cancer	B-X
cells	B-X
,	B-X
which	B-X
also	B-X
were	B-X
isolated	B-X
from	B-X
44	B-X
paraffin-embedded	B-X
gastric	B-X
cancer	B-X
tissues	B-X
by	B-X
LCM	B-X
.	B-X
RUNX1	B-X
was	B-X
co-expressed	B-X
with	B-X
RUNX3	B-X
in	B-X
the	B-X
pit	B-X
region	B-X
,	B-X
and	B-X
has	B-X
cell	B-X
growth-inhibition	B-X
activity	B-X
similar	B-X
to	B-X
RUNX3	B-X
.	B-X
RUNX3	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
suppressed	B-X
by	B-X
DNA	B-X
methylation	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
gastric	B-X
cancers	B-X
;	B-X
however	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
RUNX1	B-X
mRNA	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
of	B-X
the	B-X
gastric	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
gastric	B-X
cancer	B-X
tissues	B-X
that	B-X
we	B-X
examined	B-X
.	B-X
No	B-X
RUNX1	B-X
mutation	B-X
was	B-X
found	B-X
in	B-X
the	B-X
44	B-X
gastric	B-X
cancer	B-X
patients	B-X
.	B-X
Although	B-X
RUNX1	B-X
is	B-X
similar	B-X
to	B-X
RUNX3	B-X
in	B-X
both	B-X
the	B-X
expression	B-X
pattern	B-X
in	B-X
the	B-X
stomach	B-X
and	B-X
its	B-X
cell	B-X
growth-inhibition	B-X
activity	B-X
,	B-X
RUNX1	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
most	B-X
cases	B-X
of	B-X
gastric	B-X
cancers	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
transcriptional	B-X
target	B-X
genes	B-X
are	B-X
different	B-X
between	B-X
these	B-X
two	B-X
family	B-X
genes	B-X
.	B-X

We	O
also	O
performed	O
an	O
analysis	O
of	O
human	O
tonsils	O
,	O
which	O
contain	O
high	O
numbers	O
of	O
FOXP3	B-Protein
+	O
T	O
reg	O
cells	O
(	O
Verhagen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Staining	O
of	O
tonsil	O
sections	O
for	O
FOXP3	B-Protein
and	O
RUNX3	B-Protein
demonstrated	O
in	O
vivo	O
coexpression	O
of	O
these	O
two	O
molecules	O
in	O
a	O
subset	O
of	O
T	O
reg	O
cells	O
,	O
whereas	O
there	O
was	O
low	O
RUNX1	B-Protein
expression	O
in	O
all	O
tonsil	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O

RUNX1	B-Protein
and	O
RUNX3	B-Protein
bind	O
to	O
the	O
FOXP3	B-Protein
promoter	O

Transcription	O
element	O
search	O
system	O
analysis	O
of	O
the	O
human	O
FOXP3	B-Protein
promoter	O
predicted	O
3	O
putative	O
RUNX	O
binding	O
sites	O
at	O
333	O
,	O
287	O
,	O
and	O
53	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
.	O

All	O
three	O
binding	O
sites	O
are	O
conserved	O
between	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
(	O
Fig	O
.	O
S4	O
)	O
.	O

To	O
verify	O
the	O
putative	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
,	O
we	O
transiently	O
transfected	O
HEK293T	O
cells	O
with	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
.	O

After	O
the	O
pull	O
-	O
down	O
with	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
binding	O
sequences	O
,	O
but	O
not	O
mutant	O
sequences	O
,	O
RUNX	B-Protein
binding	O
to	O
the	O
FOXP3	B-Protein
promoter	O
oligonucleotides	O
was	O
detected	O
by	O
Western	O
blot	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O
<EOS>	B-X
Depletion	B-X
of	B-X
CSB	B-X
protein	B-X
with	B-X
anti-CSB	B-X
antibody	B-X
reduced	B-X
the	B-X
8-OH-Gua	B-X
incision	B-X
rate	B-X
of	B-X
wild	B-X
type	B-X
cell	B-X
extracts	B-X
but	B-X
not	B-X
of	B-X
CSB	B-X
null	B-X
and	B-X
motif	B-X
VI	B-X
mutant	B-X
cell	B-X
extracts	B-X
,	B-X
suggesting	B-X
a	B-X
direct	B-X
contribution	B-X
of	B-X
CSB	B-X
to	B-X
the	B-X
catalytic	B-X
process	B-X
of	B-X
8-OH-Gua	B-X
incision	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
its	B-X
motif	B-X
VI	B-X
in	B-X
this	B-X
pathway	B-X
.	B-X
This	B-X
complementation	B-X
could	B-X
not	B-X
fully	B-X
recover	B-X
the	B-X
deficiency	B-X
of	B-X
the	B-X
incision	B-X
activity	B-X
in	B-X
WCE	B-X
from	B-X
CS-B	B-X
null	B-X
and	B-X
mutant	B-X
cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
some	B-X
additional	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
are	B-X
necessary	B-X
for	B-X
the	B-X
full	B-X
activity	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
showed	B-X
a	B-X
defect	B-X
in	B-X
binding	B-X
of	B-X
CSB	B-X
null	B-X
and	B-X
motif	B-X
VI	B-X
mutant	B-X
cell	B-X
extracts	B-X
to	B-X
8-OH-Gua-containing	B-X
oligonucleotides	B-X
.	B-X
We	B-X
detected	B-X
less	B-X
hOgg1	B-X
transcript	B-X
and	B-X
protein	B-X
in	B-X
the	B-X
cell	B-X
extracts	B-X
from	B-X
CS-B	B-X
null	B-X
and	B-X
mutant	B-X
cells	B-X
,	B-X
suggesting	B-X
hOgg1	B-X
may	B-X
be	B-X
the	B-X
missing	B-X
component	B-X
.	B-X

To	O
confirm	O
these	O
results	O
and	O
test	O
the	O
ability	O
of	O
single	O
binding	O
site	O
sequences	O
to	O
bind	O
either	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
,	O
we	O
used	O
the	O
promoter	O
enzyme	O
immunoassay	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
functional	B-X
consequences	B-X
of	B-X
the	B-X
single-nucleotide	B-X
polymorphism	B-X
rs4648889	B-X
in	B-X
a	B-X
putative	B-X
enhancer	B-X
upstream	B-X
of	B-X
the	B-X
RUNX3	B-X
promoter	B-X
associated	B-X
with	B-X
susceptibility	B-X
to	B-X
ankylosing	B-X
spondylitis	B-X
(	B-X
AS	B-X
)	B-X
.	B-X
In	B-X
gastric	B-X
cancer	B-X
,	B-X
a	B-X
new	B-X
epigenetic	B-X
mechanism	B-X
of	B-X
tumour	B-X
suppressor	B-X
loss	B-X
has	B-X
been	B-X
suggested	B-X
where	B-X
the	B-X
histone	B-X
methyltransferase	B-X
enhancer	B-X
of	B-X
zeste	B-X
homolog	B-X
2	B-X
(	B-X
EZH2	B-X
)	B-X
is	B-X
responsible	B-X
for	B-X
loss	B-X
of	B-X
expression	B-X
of	B-X
RUNX3	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
EZH2	B-X
influences	B-X
the	B-X
expression	B-X
of	B-X
RUNX3	B-X
in	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
and	B-X
whether	B-X
this	B-X
is	B-X
independent	B-X
of	B-X
methylation	B-X
.	B-X
We	B-X
determined	B-X
protein	B-X
and	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
levels	B-X
of	B-X
EZH2	B-X
and	B-X
RUNX3	B-X
and	B-X
assessed	B-X
RUNX3	B-X
methylation	B-X
with	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
using	B-X
72	B-X
human	B-X
CRCs	B-X
and	B-X
8	B-X
CRC	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
efficient	B-X
RNA	B-X
interference-mediated	B-X
knockdown	B-X
of	B-X
EZH2	B-X
on	B-X
RUNX3	B-X
levels	B-X
,	B-X
cell	B-X
viability	B-X
and	B-X
H3K27	B-X
trimethylation	B-X
of	B-X
the	B-X
RUNX3	B-X
promoter	B-X
using	B-X
chromatin	B-X
immunoprecipitation	B-X
.	B-X
Despite	B-X
higher	B-X
levels	B-X
of	B-X
EZH2	B-X
and	B-X
lower	B-X
levels	B-X
of	B-X
RUNX3	B-X
in	B-X
CRC	B-X
specimens	B-X
in	B-X
general	B-X
,	B-X
no	B-X
inverse	B-X
correlation	B-X
between	B-X
EZH2	B-X
and	B-X
RUNX3	B-X
in	B-X
paired	B-X
samples	B-X
was	B-X
found	B-X
arguing	B-X
against	B-X
a	B-X
major	B-X
role	B-X
for	B-X
histone	B-X
methylation	B-X
in	B-X
silencing	B-X
RUNX3	B-X
in	B-X
CRC	B-X
.	B-X
Conversely	B-X
,	B-X
downregulation	B-X
of	B-X
RUNX3	B-X
mRNA	B-X
in	B-X
the	B-X
same	B-X
tumours	B-X
was	B-X
associated	B-X
with	B-X
RUNX3	B-X
DNA	B-X
methylation	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
cell	B-X
lines	B-X
,	B-X
knockdown	B-X
of	B-X
EZH2	B-X
removed	B-X
the	B-X
repressive	B-X
chromatin	B-X
marks	B-X
from	B-X
RUNX3	B-X
but	B-X
did	B-X
not	B-X
result	B-X
in	B-X
RUNX3	B-X
re-expression	B-X
.	B-X
However	B-X
,	B-X
it	B-X
prevented	B-X
the	B-X
re-silencing	B-X
of	B-X
RUNX3	B-X
after	B-X
the	B-X
removal	B-X
of	B-X
demethylating	B-X
agents	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
DNA	B-X
methylation	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
the	B-X
transcriptional	B-X
silencing	B-X
of	B-X
RUNX3	B-X
in	B-X
CRC	B-X
,	B-X
but	B-X
EZH2	B-X
and	B-X
histone	B-X
methylation	B-X
are	B-X
necessary	B-X
for	B-X
its	B-X
methylation-dependent	B-X
re-silencing	B-X
after	B-X
the	B-X
removal	B-X
of	B-X
demethylating	B-X
agents	B-X
.	B-X
These	B-X
results	B-X
would	B-X
predict	B-X
that	B-X
inhibitors	B-X
of	B-X
EZH2	B-X
and	B-X
histone	B-X
methylation	B-X
would	B-X
enhance	B-X
the	B-X
effects	B-X
of	B-X
demethylating	B-X
agents	B-X
in	B-X
cancer	B-X
therapy	B-X
.	B-X

Cell	O
lysates	O
were	O
obtained	O
from	O
HEK293T	O
cells	O
that	O
had	O
been	O
transiently	O
transfected	O
with	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
expression	O
vectors	O
.	O
<EOS>	B-X
RUNX	B-X
proteins	B-X
belong	B-X
to	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
essential	B-X
for	B-X
cellular	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
with	B-X
emerging	B-X
data	B-X
implicating	B-X
RUNX3	B-X
in	B-X
haematopoiesis	B-X
and	B-X
haematological	B-X
malignancies	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
RUNX3	B-X
plays	B-X
an	B-X
important	B-X
regulatory	B-X
role	B-X
in	B-X
normal	B-X
human	B-X
erythropoiesis	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
altering	B-X
RUNX3	B-X
expression	B-X
on	B-X
erythropoiesis	B-X
was	B-X
determined	B-X
by	B-X
transducing	B-X
human	B-X
CD34	B-X
Loss	B-X
of	B-X
RUNX3	B-X
expression	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
many	B-X
other	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
no	B-X
studies	B-X
have	B-X
shown	B-X
the	B-X
relationship	B-X
between	B-X
RUNX3	B-X
expression	B-X
and	B-X
chondrosarcoma	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
detected	B-X
RUNX3	B-X
expression	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
chondrosarcoma	B-X
.	B-X
In	B-X
patient	B-X
samples	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
RUNX3	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
lower	B-X
in	B-X
cancer	B-X
tissues	B-X
than	B-X
in	B-X
normal	B-X
tissues	B-X
.	B-X
Down-regulation	B-X
of	B-X
RUNX3	B-X
mRNA	B-X
in	B-X
tumor	B-X
tissues	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
RUNX3	B-X
promoter	B-X
methylation	B-X
.	B-X
Loss	B-X
of	B-X
RUNX3	B-X
expression	B-X
was	B-X
significantly	B-X
associated	B-X
with	B-X
more	B-X
aggressive	B-X
chondrosarcoma	B-X
types	B-X
and	B-X
decreased	B-X
survival	B-X
time	B-X
of	B-X
patients	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
exogenous	B-X
expression	B-X
of	B-X
RUNX3	B-X
in	B-X
vitro	B-X
,	B-X
chondrosarcoma	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
the	B-X
pcDNA3.1-RUNX3	B-X
expression	B-X
vector	B-X
.	B-X
Relative	B-X
to	B-X
control	B-X
cells	B-X
,	B-X
RUNX3-expressing	B-X
cells	B-X
exhibited	B-X
lower	B-X
proliferation	B-X
and	B-X
higher	B-X
apoptosis	B-X
rates	B-X
as	B-X
assessed	B-X
by	B-X
colony	B-X
formation	B-X
and	B-X
Annexin	B-X
V-FITC/PI	B-X
double	B-X
staining	B-X
,	B-X
respectively	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
RUNX3	B-X
acts	B-X
a	B-X
tumor	B-X
suppressor	B-X
in	B-X
chondrosarcoma	B-X
and	B-X
that	B-X
RUNX3	B-X
promoter	B-X
methylation	B-X
may	B-X
be	B-X
the	B-X
molecular	B-X
mechanism	B-X
for	B-X
its	B-X
decreased	B-X
expression	B-X
.	B-X

The	O
biotinylated	O
FOXP3	B-Protein
promoter	O
oligonucleotides	O
were	O
linked	O
to	O
a	O
streptavidin	O
-	O
coated	O
microtiter	O
plate	O
,	O
and	O
bound	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
was	O
detected	O
by	O
using	O
anti	O
-	O
RUNX	B-Protein
antibodies	O
and	O
a	O
peroxidase	O
-	O
labeled	O
secondary	O
antibody	O
.	O

We	O
showed	O
binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
binding	O
sites	O
,	O
whereas	O
there	O
was	O
no	O
binding	O
detectable	O
when	O
a	O
combination	O
of	O
the	O
mutated	O
oligonucleotides	O
was	O
used	O
in	O
the	O
assay	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

Although	O
there	O
was	O
a	O
similar	O
and	O
high	O
degree	O
of	O
binding	O
to	O
the	O
-	O
333	O
and	O
-	O
287	O
sites	O
,	O
a	O
lower	O
degree	O
of	O
binding	O
was	O
detected	O
when	O
the	O
oligonucleotide	O
containing	O
the	O
-	O
53	O
site	O
in	O
the	O
Foxp3	B-Protein
promoter	O
was	O
used	O
.	O

This	O
effect	O
was	O
observed	O
both	O
for	O
binding	O
to	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

The	O
binding	O
to	O
the	O
two	O
single	O
binding	O
sites	O
at	O
-	O
333	O
and	O
-	O
287	O
was	O
comparable	O
to	O
the	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
results	O
confirmed	O
the	O
binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
complexes	O
containing	O
CBFbeta	B-Protein
to	O
FOXP3	B-Protein
promoter	O
during	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
toward	O
T	O
reg	O
cells	O
.	O

Here	O
,	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAb	O
,	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
as	O
a	O
Foxp3	B-Protein
-	O
inducing	O
stimulation	O
.	O

Amplification	O
of	O
PCR	O
products	O
from	O
the	O
FOXP3	B-Protein
promoter	O
region	O
with	O
the	O
predicted	O
RUNX	O
binding	O
sites	O
showed	O
that	O
RUNX1	B-Protein
,	O
RUNX3	B-Protein
,	O
and	O
CBFbeta	B-Protein
were	O
immunoprecipitated	O
together	O
with	O
the	O
FOXP3	B-Protein
promoter	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

Negative	O
control	O
primer	O
targeting	O
open	O
reading	O
frame	O
-	O
free	O
intergenic	O
DNA	O
,	O
IGX1A	O
did	O
not	O
show	O
any	O
significant	O
change	O
in	O
site	O
occupancy	O
.	O

Regulation	O
of	O
FOXP3	B-Protein
promoter	O
activity	O
and	O
FOXP3	B-Protein
protein	O
expression	O
by	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein

To	O
investigate	O
the	O
effect	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
binding	O
to	O
the	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
,	O
we	O
transfected	O
human	O
peripheral	O
blood	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
a	O
FOXP3	B-Protein
promoter	I-Protein
luciferase	I-Protein
reporter	O
vector	O
and	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
expression	O
vectors	O
.	O
<EOS>	B-X
RUNX	B-X
proteins	B-X
belong	B-X
to	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
essential	B-X
for	B-X
cellular	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
with	B-X
emerging	B-X
data	B-X
implicating	B-X
RUNX3	B-X
in	B-X
haematopoiesis	B-X
and	B-X
haematological	B-X
malignancies	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
RUNX3	B-X
plays	B-X
an	B-X
important	B-X
regulatory	B-X
role	B-X
in	B-X
normal	B-X
human	B-X
erythropoiesis	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
altering	B-X
RUNX3	B-X
expression	B-X
on	B-X
erythropoiesis	B-X
was	B-X
determined	B-X
by	B-X
transducing	B-X
human	B-X
CD34	B-X
We	B-X
now	B-X
report	B-X
the	B-X
physical	B-X
mapping	B-X
of	B-X
the	B-X
Dsi1	B-X
locus	B-X
to	B-X
a	B-X
site	B-X
30	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
distal	B-X
(	B-X
P1	B-X
)	B-X
promoter	B-X
of	B-X
the	B-X
murine	B-X
Runx3	B-X
gene	B-X
.	B-X
Comparison	B-X
with	B-X
the	B-X
syntenic	B-X
region	B-X
of	B-X
human	B-X
chromosome	B-X
1	B-X
shows	B-X
that	B-X
the	B-X
next	B-X
gene	B-X
is	B-X
over	B-X
250	B-X
kb	B-X
5	B-X
'	B-X
to	B-X
Runx3	B-X
,	B-X
suggesting	B-X
that	B-X
Runx3	B-X
may	B-X
be	B-X
the	B-X
primary	B-X
target	B-X
of	B-X
retroviral	B-X
insertions	B-X
at	B-X
Dsi1	B-X
.	B-X
Proviral	B-X
insertion	B-X
was	B-X
associated	B-X
with	B-X
very	B-X
high	B-X
levels	B-X
of	B-X
expression	B-X
of	B-X
Runx3	B-X
,	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
transcripts	B-X
arising	B-X
at	B-X
the	B-X
P1	B-X
promoter	B-X
.	B-X

An	O
increase	O
in	O
luciferase	B-Protein
activity	O
was	O
observed	O
only	O
when	O
the	O
FOXP3	B-Protein
promoter	I-Protein
(	I-Protein
-	I-Protein
511	I-Protein
to	I-Protein
+	I-Protein
176	I-Protein
)	I-Protein
luciferase	I-Protein
construct	O
was	O
cotransfected	O
with	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
expression	O
vectors	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

The	O
increase	O
in	O
promoter	O
activity	O
was	O
greater	O
upon	O
cotransfection	O
of	O
RUNX3	B-Protein
compared	O
with	O
RUNX1	B-Protein
.	O

Luciferase	B-Protein
expression	O
was	O
abrogated	O
when	O
the	O
Runx	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
(	O
-	O
511	O
to	O
+	O
176	O
)	O
luciferase	B-Protein
construct	O
were	O
mutated	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

In	O
these	O
experiments	O
,	O
the	O
overexpression	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
eliminated	O
the	O
need	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
for	O
FOXP3	B-Protein
promoter	O
activation	O
and	O
PMA	O
/	O
ionomycin	O
stimulation	O
was	O
sufficient	O
.	O

To	O
examine	O
the	O
role	O
of	O
each	O
of	O
the	O
three	O
RUNX	O
binding	O
sites	O
for	O
the	O
FOXP3	B-Protein
promoter	O
activity	O
,	O
we	O
mutated	O
each	O
individually	O
or	O
in	O
combination	O
.	O
<EOS>	B-X
Combinative	B-X
treatment	B-X
of	B-X
β-elemene	B-X
and	B-X
cetuximab	B-X
is	B-X
sensitive	B-X
to	B-X
KRAS	B-X
mutant	B-X
colorectal	B-X
cancer	B-X
cells	B-X
by	B-X
inducing	B-X
ferroptosis	B-X
and	B-X
inhibiting	B-X
epithelial-mesenchymal	B-X
transformation	B-X
.	B-X
However	B-X
,	B-X
limited	B-X
success	B-X
of	B-X
ICB	B-X
as	B-X
monotherapy	B-X
mandates	B-X
the	B-X
evaluation	B-X
of	B-X
combination	B-X
strategies	B-X
incorporating	B-X
immunotherapy	B-X
for	B-X
improved	B-X
clinical	B-X
efficacy	B-X
.	B-X
Greater	B-X
efforts	B-X
are	B-X
required	B-X
in	B-X
discovery	B-X
and	B-X
understanding	B-X
of	B-X
novel	B-X
combination	B-X
strategies	B-X
to	B-X
maximize	B-X
clinical	B-X
benefit	B-X
with	B-X
tolerable	B-X
adverse	B-X
effects	B-X
.	B-X
This	B-X
current	B-X
review	B-X
provides	B-X
a	B-X
comprehensive	B-X
assessment	B-X
of	B-X
RT	B-X
and	B-X
ICB	B-X
in	B-X
HCC	B-X
,	B-X
their	B-X
respective	B-X
impact	B-X
on	B-X
TME	B-X
,	B-X
the	B-X
rationale	B-X
for	B-X
their	B-X
synergistic	B-X
combination	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
current	B-X
potential	B-X
biomarkers	B-X
available	B-X
to	B-X
predict	B-X
clinical	B-X
response	B-X
.	B-X
We	B-X
also	B-X
speculate	B-X
on	B-X
novel	B-X
future	B-X
strategies	B-X
to	B-X
further	B-X
enhance	B-X
the	B-X
efficacy	B-X
of	B-X
this	B-X
combination	B-X
.	B-X

No	O
reduction	O
in	O
luciferase	B-Protein
activity	O
was	O
observed	O
when	O
the	O
-	O
53	O
site	O
was	O
mutated	O
and	O
only	O
a	O
slight	O
reduction	O
when	O
either	O
the	O
-	O
287	O
or	O
-	O
333	O
site	O
was	O
mutated	O
(	O
Fig	O
.	O
4	O
B	O
)	O
.	O

However	O
,	O
mutating	O
the	O
-	O
53	O
site	O
in	O
combination	O
with	O
one	O
of	O
the	O
other	O
two	O
sites	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
luciferase	B-Protein
activity	O
,	O
with	O
the	O
greatest	O
reduction	O
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
(	O
Fig	O
.	O
4	O
B	O
)	O
,	O
suggesting	O
that	O
the	O
identified	O
binding	O
sites	O
have	O
redundant	O
functions	O
and	O
RUNX	B-Protein
binding	O
to	O
more	O
than	O
one	O
site	O
is	O
necessary	O
for	O
the	O
full	O
activation	O
of	O
the	O
FOXP3	B-Protein
promoter	O
.	O

Supporting	O
these	O
findings	O
,	O
the	O
overexpression	O
of	O
RUNX1	B-Protein
in	O
human	O
primary	O
CD4	B-Protein
+	O
T	O
cells	O
resulted	O
in	O
significantly	O
elevated	O
levels	O
of	O
FOXP3	B-Protein
protein	O
measured	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
.	O

This	O
was	O
achieved	O
without	O
any	O
requirement	O
for	O
anti	O
-	O
CD3	B-Protein
,	O
anti	O
-	O
CD28	B-Protein
stimulation	O
,	O
or	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O
<EOS>	B-X
TGF-beta	B-X
:	B-X
a	B-X
master	B-X
immune	B-X
regulator	B-X
.	B-X
Regulation	B-X
of	B-X
EMT	B-X
is	B-X
mostly	B-X
initiated	B-X
by	B-X
outside	B-X
signalling	B-X
,	B-X
including	B-X
TGF-β	B-X
,	B-X
growth	B-X
factors	B-X
,	B-X
Notch	B-X
ligand	B-X
,	B-X
Wnt	B-X
,	B-X
and	B-X
hypoxia	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
epigenetic	B-X
regulation	B-X
of	B-X
two	B-X
critical	B-X
EMT	B-X
signalling	B-X
pathways	B-X
:	B-X
hypoxia	B-X
and	B-X
TGF-β	B-X
.	B-X
For	B-X
hypoxia	B-X
,	B-X
hypoxia-induced	B-X
EMT	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interplay	B-X
between	B-X
chromatin	B-X
modifiers	B-X
histone	B-X
deacetylase	B-X
3	B-X
(	B-X
HDAC3	B-X
)	B-X
and	B-X
WDR5	B-X
coupled	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
histone	B-X
3	B-X
lysine	B-X
4	B-X
acetylation	B-X
(	B-X
H3K4Ac	B-X
)	B-X
mark	B-X
that	B-X
labels	B-X
the	B-X
promoter	B-X
regions	B-X
of	B-X
various	B-X
traditional	B-X
EMT	B-X
marker	B-X
genes	B-X
(	B-X
e.g	B-X
.	B-X
For	B-X
TGF-β-induced	B-X
ΕΜΤ	B-X
,	B-X
global	B-X
chromatin	B-X
changes	B-X
,	B-X
removal	B-X
of	B-X
a	B-X
histone	B-X
variant	B-X
(	B-X
H2A.Z	B-X
)	B-X
,	B-X
and	B-X
new	B-X
chromatin	B-X
modifiers	B-X
(	B-X
e.g	B-X
.	B-X

Although	O
there	O
was	O
a	O
trend	O
,	O
the	O
transfection	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
RUNX3	B-Protein
did	O
not	O
lead	O
to	O
statistically	O
significant	O
increase	O
in	O
FOXP3	B-Protein
(	O
Fig	O
.	O
S5	O
)	O
.	O

Role	O
of	O
CBFbeta	B-Protein
in	O
the	O
induction	O
of	O
Foxp3	B-Protein
<EOS>	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

CBFbeta	B-Protein
,	O
a	O
common	O
cofactor	O
of	O
all	O
RUNX	B-Protein
proteins	O
,	O
stabilizes	O
and	O
increases	O
the	O
binding	O
of	O
the	O
runt	O
domain	O
to	O
target	O
DNA	O
sequences	O
.	O

To	O
target	O
all	O
Runx	B-Protein
proteins	O
that	O
might	O
be	O
involved	O
in	O
the	O
induction	O
of	O
Foxp3	B-Protein
,	O
we	O
used	O
mice	O
in	O
which	O
loxP	O
-	O
flanked	O
Cbfb	B-Protein
alleles	O
were	O
inactivated	O
in	O
T	O
cells	O
through	O
expression	O
of	O
a	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
transgene	O
.	O

Retinoic	O
acid	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
synergize	O
in	O
the	O
induction	O
of	O
Foxp3	B-Protein
in	O
naive	O
T	O
cells	O
(	O
Kang	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

To	O
investigate	O
whether	O
Runx	B-Protein
-	O
mediated	O
induction	O
of	O
Foxp3	B-Protein
is	O
dependent	O
on	O
the	O
expression	O
of	O
CBFbeta	B-Protein
,	O
naive	O
CD4	B-Protein
+	O
CD8	B-Protein
-	O
T	O
cells	O
from	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
control	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
mAbs	O
,	O
retinoic	O
acid	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
and	O
analyzed	O
for	O
intracellular	O
Foxp3	B-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
induced	O
Foxp3	B-Protein
in	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
cells	O
in	O
a	O
dose	O
dependent	O
manner	O
,	O
and	O
this	O
was	O
significantly	O
reduced	O
in	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
cells	O
.	O

Retinoic	O
acid	O
enhanced	O
Foxp3	B-Protein
expression	O
even	O
in	O
20	O
pg	O
/	O
ml	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
more	O
than	O
95	O
%	O
of	O
the	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
became	O
Foxp3	B-Protein
+	O
in	O
100	O
and	O
500	O
pg	O
/	O
ml	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
doses	O
.	O

The	O
induction	O
of	O
Foxp3	B-Protein
was	O
again	O
significantly	O
lower	O
in	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
CD4	B-Protein
+	O
T	O
cells	O
even	O
in	O
the	O
presence	O
of	O
retinoic	O
acid	O
,	O
demonstrating	O
that	O
deficiency	O
in	O
Runx	B-Protein
binding	O
to	O
DNA	O
affects	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
induction	O
of	O
Foxp3	B-Protein
in	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
5	O
A	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
induction	O
of	O
Foxp3	B-Protein
when	O
endogenous	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
were	O
neutralized	O
(	O
Fig	O
.	O
S6	O
)	O
.	O

The	O
importance	O
of	O
RUNX	B-Protein
transcription	O
factors	O
for	O
the	O
in	O
vivo	O
conversion	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
into	O
iT	O
reg	O
cells	O
was	O
examined	O
.	O

Control	O
CbfbF	B-Protein
/	O
F	O
or	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
naive	O
T	O
cells	O
,	O
harboring	O
a	O
Foxp3	B-Protein
-	O
IRES	O
-	O
GFP	B-Protein
allele	O
were	O
adoptively	O
transferred	O
into	O
Rag2	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
Restricted	B-X
dorsiflexion	B-X
(	B-X
DF	B-X
)	B-X
at	B-X
the	B-X
ankle	B-X
joint	B-X
can	B-X
cause	B-X
acute	B-X
and	B-X
chronic	B-X
injuries	B-X
at	B-X
the	B-X
ankle	B-X
and	B-X
knee	B-X
.	B-X
Myofascial	B-X
release	B-X
and	B-X
instrument-assisted	B-X
soft	B-X
tissue	B-X
mobilization	B-X
(	B-X
IASTM	B-X
)	B-X
techniques	B-X
have	B-X
been	B-X
used	B-X
to	B-X
increase	B-X
range	B-X
of	B-X
motion	B-X
(	B-X
ROM	B-X
)	B-X
;	B-X
however	B-X
,	B-X
evidence	B-X
directly	B-X
comparing	B-X
their	B-X
effectiveness	B-X
is	B-X
limited	B-X
.	B-X
This	B-X
study	B-X
synthesized	B-X
and	B-X
tested	B-X
experimental	B-X
gels	B-X
containing	B-X
fluoride	B-X
(	B-X
F-	B-X
)	B-X
and	B-X
stannous	B-X
(	B-X
Sn2+	B-X
)	B-X
ions	B-X
for	B-X
the	B-X
control	B-X
of	B-X
dental	B-X
erosion	B-X
.	B-X
Enamel	B-X
and	B-X
dentin	B-X
polished	B-X
specimens	B-X
were	B-X
eroded	B-X
(	B-X
1	B-X
%	B-X
citric	B-X
acid	B-X
solution	B-X
,	B-X
10	B-X
min	B-X
)	B-X
and	B-X
randomly	B-X
allocated	B-X
into	B-X
5	B-X
groups	B-X
(	B-X
n=10	B-X
)	B-X
:	B-X
Placebo	B-X
-	B-X
Hydroxypropyl	B-X
Methylcellulose	B-X
(	B-X
HMC	B-X
)	B-X
gel	B-X
;	B-X
F+Sn+HMC	B-X
-	B-X
7,500	B-X
ppm	B-X
F-	B-X
/	B-X
15,000	B-X
ppm	B-X
Sn2+	B-X
;	B-X
F+HMC	B-X
-	B-X
7,500	B-X
ppm	B-X
F-	B-X
;	B-X
Commercial	B-X
acidulated	B-X
phosphate	B-X
fluoride	B-X
gel	B-X
(	B-X
12,300	B-X
ppm	B-X
F-	B-X
)	B-X
;	B-X
and	B-X
Control	B-X
-	B-X
no	B-X
treatment	B-X
.	B-X
For	B-X
enamel	B-X
,	B-X
after	B-X
5	B-X
and	B-X
10	B-X
days	B-X
,	B-X
F+Sn+HMC	B-X
presented	B-X
the	B-X
lowest	B-X
SL	B-X
,	B-X
which	B-X
did	B-X
not	B-X
differ	B-X
from	B-X
the	B-X
commercial	B-X
gel	B-X
.	B-X
After	B-X
20	B-X
days	B-X
,	B-X
no	B-X
differences	B-X
were	B-X
found	B-X
between	B-X
commercial	B-X
,	B-X
F+HMC	B-X
,	B-X
and	B-X
F+Sn+HMC	B-X
groups	B-X
.	B-X
For	B-X
dentin	B-X
,	B-X
on	B-X
the	B-X
5th	B-X
day	B-X
,	B-X
F+Sn+HMC	B-X
,	B-X
F+HMC	B-X
and	B-X
commercial	B-X
did	B-X
not	B-X
differ	B-X
significantly	B-X
,	B-X
showing	B-X
lower	B-X
SL	B-X
than	B-X
the	B-X
control	B-X
and	B-X
the	B-X
placebo	B-X
.	B-X
On	B-X
the	B-X
10th	B-X
day	B-X
,	B-X
F+Sn+HMC	B-X
and	B-X
commercial	B-X
presented	B-X
the	B-X
lowest	B-X
SL	B-X
compared	B-X
to	B-X
control	B-X
and	B-X
placebo	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
experimental	B-X
F+Sn+HMC	B-X
gel	B-X
was	B-X
able	B-X
to	B-X
control	B-X
the	B-X
progression	B-X
of	B-X
tooth	B-X
erosion	B-X
.	B-X

6	O
wk	O
later	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
expression	O
(	O
Fig	O
.	O
5	O
B	O
)	O
.	O

There	O
was	O
a	O
consistently	O
lower	O
percentage	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
that	O
had	O
developed	O
Foxp3	B-Protein
expression	O
in	O
the	O
mesenteric	O
lymph	O
node	O
and	O
lamina	O
propria	O
of	O
mice	O
transferred	O
with	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
cells	O
compared	O
with	O
control	O
cells	O
(	O
Fig	O
.	O
5	O
,	O
B	O
and	O
C	O
)	O
.	O

These	O
data	O
affirm	O
the	O
significance	O
of	O
RUNX	B-Protein
proteins	O
for	O
the	O
in	O
vivo	O
generation	O
of	O
CD4	B-Protein
+	O
Foxp3	B-Protein
+	O
T	O
cells	O
.	O

CBFbeta	B-Protein
,	O
RUNX1	B-Protein
,	O
and	O
RUNX3	B-Protein
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
CD25	B-Protein
+	O
Foxp3	B-Protein
+	O
T	O
reg	O
cells	O

Even	O
though	O
Cbfb	B-Protein
-	O
deficient	O
CD4	B-Protein
+	O
T	O
cells	O
had	O
impaired	O
induction	O
of	O
Foxp3	B-Protein
after	O
stimulation	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
mAbs	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
sufficient	O
numbers	O
of	O
Foxp3	B-Protein
+	O
cells	O
could	O
be	O
generated	O
to	O
permit	O
analysis	O
of	O
their	O
suppressive	O
activity	O
.	O

Purified	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
control	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
(	O
Cd45	B-Protein
.	I-Protein
2	I-Protein
)	O
harboring	O
a	O
Foxp3	B-Protein
-	O
ires	O
-	O
GFP	B-Protein
allele	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
)	O
were	O
stimulated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
mAbs	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

After	O
3	O
d	O
,	O
Foxp3	B-Protein
+	O
-	O
GFP	B-Protein
+	O
cells	O
were	O
sorted	O
by	O
flow	O
cytometry	O
and	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
CD4	B-Protein
+	O
cells	O
at	O
ratios	O
of	O
1	O
:	O
4	O
,	O
1	O
:	O
2	O
,	O
and	O
1	O
:	O
1	O
.	O

The	O
cells	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
mAb	O
for	O
four	O
more	O
days	O
.	O

CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
(	O
Fig	O
.	O
6	O
A	O
)	O
.	O

CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
CD4	B-Protein
+	O
T	O
cells	O
activated	O
in	O
the	O
presence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
showed	O
a	O
clear	O
suppression	O
of	O
T	O
cell	O
proliferation	O
that	O
became	O
even	O
more	O
apparent	O
when	O
an	O
increased	O
ratio	O
of	O
FOXP3	B-Protein
+	O
/	O
CD25	B-Protein
-	O
cells	O
was	O
used	O
(	O
Fig	O
.	O
6	O
B	O
)	O
.	O

The	O
suppression	O
was	O
significantly	O
reduced	O
when	O
cells	O
from	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
were	O
used	O
,	O
demonstrating	O
that	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
induced	O
Runx	O
complexes	O
are	O
important	O
for	O
the	O
suppressive	O
activity	O
of	O
Foxp3	B-Protein
+	O
T	O
reg	O
cells	O
(	O
Fig	O
.	O
6	O
B	O
)	O
.	O

As	O
a	O
control	O
,	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
CD4	B-Protein
+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
were	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
naive	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
CD4	B-Protein
+	O
cells	O
.	O

No	O
suppression	O
could	O
be	O
observed	O
in	O
all	O
control	O
groups	O
without	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
at	O
all	O
tested	O
ratios	O
(	O
Fig	O
.	O
6	O
C	O
)	O
.	O

The	O
decreased	O
suppression	O
capacity	O
of	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
iT	O
reg	O
cells	O
was	O
unlikely	O
to	O
be	O
caused	O
by	O
decreased	O
survival	O
or	O
proliferation	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
to	B-X
culture	B-X
and	B-X
expand	B-X
B	B-X
cells	B-X
in	B-X
vitro	B-X
has	B-X
become	B-X
a	B-X
useful	B-X
tool	B-X
for	B-X
studying	B-X
human	B-X
immunity	B-X
.	B-X
A	B-X
limitation	B-X
of	B-X
current	B-X
methods	B-X
for	B-X
human	B-X
B	B-X
cell	B-X
culture	B-X
is	B-X
the	B-X
capacity	B-X
to	B-X
support	B-X
mature	B-X
B	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
developed	B-X
a	B-X
culture	B-X
method	B-X
to	B-X
support	B-X
the	B-X
efficient	B-X
activation	B-X
and	B-X
proliferation	B-X
of	B-X
naive	B-X
and	B-X
memory	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
This	B-X
culture	B-X
supports	B-X
extensive	B-X
B	B-X
cell	B-X
proliferation	B-X
,	B-X
with	B-X
∼10	B-X

Foxp3	B-Protein
+	O
and	O
Foxp3	B-Protein
-	O
cells	O
generated	O
from	O
both	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
control	O
cells	O
all	O
displayed	O
similar	O
proliferation	O
rates	O
and	O
cell	O
death	O
as	O
measured	O
by	O
CFSE	O
dilution	O
and	O
annexin	B-Protein
V	I-Protein
staining	O
,	O
respectively	O
(	O
Fig	O
.	O
S7	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
we	O
tested	O
the	O
requirement	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
for	O
the	O
development	O
of	O
the	O
suppressive	O
capacity	O
in	O
human	O
iT	O
reg	O
cells	O
.	O

We	O
isolated	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
and	O
transfected	O
them	O
with	O
a	O
combination	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
,	O
or	O
with	O
a	O
scrambled	O
control	O
siRNA	O
.	O
<EOS>	B-X
Exosomes	B-X
are	B-X
extracellular	B-X
vesicles	B-X
generated	B-X
by	B-X
all	B-X
cell	B-X
types	B-X
with	B-X
a	B-X
capacity	B-X
to	B-X
efficiently	B-X
enter	B-X
cells	B-X
across	B-X
different	B-X
biological	B-X
barriers	B-X
.	B-X
Exosomes	B-X
derived	B-X
from	B-X
clinical	B-X
grade	B-X
fibroblast-like	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
were	B-X
engineered	B-X
to	B-X
carry	B-X
siRNA	B-X
or	B-X
antisense	B-X
oligonucleotide	B-X
(	B-X
ASO	B-X
)	B-X
targeting	B-X
STAT3	B-X
(	B-X
iExo	B-X
Using	B-X
plants	B-X
for	B-X
production	B-X
of	B-X
pharmaceutically	B-X
valuable	B-X
siRNAs	B-X
may	B-X
have	B-X
significant	B-X
advantages	B-X
of	B-X
cost-effectiveness	B-X
,	B-X
scalability	B-X
and	B-X
low	B-X
risk	B-X
of	B-X
contamination	B-X
with	B-X
human	B-X
pathogens	B-X
.	B-X
If	B-X
edible	B-X
plant	B-X
species	B-X
are	B-X
genetically	B-X
engineered	B-X
to	B-X
synthesize	B-X
siRNAs	B-X
,	B-X
the	B-X
costly	B-X
stage	B-X
of	B-X
target	B-X
product	B-X
purification	B-X
may	B-X
be	B-X
omitted	B-X
.	B-X
Transgenic	B-X
lettuce	B-X
plants	B-X
were	B-X
obtained	B-X
by	B-X
Agrobacterium-mediated	B-X
transformation	B-X
with	B-X
genetic	B-X
constructs	B-X
harboring	B-X
antiPKC	B-X
and	B-X
scrambled	B-X
(	B-X
control	B-X
)	B-X
shRNA	B-X
genes	B-X
.	B-X
Plants	B-X
carrying	B-X
either	B-X
antiPKC	B-X
or	B-X
scrambled	B-X
shRNA	B-X
genes	B-X
flowered	B-X
normally	B-X
,	B-X
but	B-X
did	B-X
not	B-X
produce	B-X
seeds	B-X
.	B-X
The	B-X
described	B-X
transgenic	B-X
lettuce	B-X
plants	B-X
accumulating	B-X
antiPKC	B-X
siRNA	B-X
are	B-X
the	B-X
subject	B-X
for	B-X
animal	B-X
testing	B-X
and	B-X
can	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
raw	B-X
material	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
antihypertensive	B-X
drugs	B-X
.	B-X

Cells	O
were	O
cultured	O
under	O
T	O
reg	O
conditions	O
,	O
and	O
then	O
mixed	O
with	O
CFSE	O
-	O
labeled	O
autologous	O
CD4	B-Protein
+	O
T	O
cells	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
mAb	O
.	O

Cells	O
in	O
which	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
were	O
knocked	O
down	O
showed	O
markedly	O
lower	O
suppressive	O
activity	O
compared	O
with	O
control	O
iT	O
reg	O
cells	O
at	O
a	O
T	O
reg	O
/	O
CD4	B-Protein
+	O
T	O
responder	O
cell	O
ratio	O
of	O
1	O
:	O
20	O
,	O
but	O
not	O
when	O
the	O
T	O
reg	O
/	O
CD4	B-Protein
+	O
T	O
responder	O
cell	O
ratio	O
was	O
increased	O
to	O
1	O
:	O
5	O
(	O
Fig	O
.	O
6	O
D	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
important	O
role	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
not	O
only	O
for	O
the	O
induction	O
of	O
FOXP3	B-Protein
,	O
but	O
also	O
for	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
both	O
in	O
humans	O
and	O
in	O
mice	O
.	O
<EOS>	B-X
The	B-X
RUNX	B-X
transcription	B-X
factors	B-X
are	B-X
important	B-X
regulators	B-X
of	B-X
lineage-specific	B-X
gene	B-X
expression	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
demonstrated	B-X
that	B-X
Runx3	B-X
is	B-X
a	B-X
neurogenic	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
regulates	B-X
development	B-X
and	B-X
survival	B-X
of	B-X
proprioceptive	B-X
neurons	B-X
in	B-X
dorsal	B-X
root	B-X
ganglia	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Runx3	B-X
and	B-X
Runx1	B-X
are	B-X
highly	B-X
expressed	B-X
in	B-X
thymic	B-X
medulla	B-X
and	B-X
cortex	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
function	B-X
in	B-X
development	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
during	B-X
thymopoiesis	B-X
.	B-X
Runx3-deficient	B-X
(	B-X
Runx3	B-X
KO	B-X
)	B-X
mice	B-X
display	B-X
abnormalities	B-X
in	B-X
CD4	B-X
expression	B-X
during	B-X
lineage	B-X
decisions	B-X
and	B-X
impairment	B-X
of	B-X
CD8	B-X
T	B-X
cell	B-X
maturation	B-X
in	B-X
the	B-X
thymus	B-X
.	B-X
A	B-X
large	B-X
proportion	B-X
of	B-X
Runx3	B-X
KO	B-X
peripheral	B-X
CD8	B-X
T	B-X
cells	B-X
also	B-X
expressed	B-X
CD4	B-X
,	B-X
and	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
,	B-X
their	B-X
proliferation	B-X
ability	B-X
was	B-X
largely	B-X
reduced	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
cytotoxic	B-X
activity	B-X
of	B-X
alloimmunized	B-X
peritoneal	B-X
exudate	B-X
lymphocytes	B-X
was	B-X
significantly	B-X
lower	B-X
in	B-X
Runx3	B-X
KO	B-X
compared	B-X
with	B-X
WT	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
compound	B-X
mutant	B-X
mouse	B-X
,	B-X
null	B-X
for	B-X
Runx3	B-X
and	B-X
heterozygous	B-X
for	B-X
Runx1	B-X
(	B-X
Runx3-/-	B-X
;	B-X
Runx1+/-	B-X
)	B-X
,	B-X
all	B-X
peripheral	B-X
CD8	B-X
T	B-X
cells	B-X
also	B-X
expressed	B-X
CD4	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
single-positive	B-X
CD8+	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
The	B-X
results	B-X
provide	B-X
information	B-X
on	B-X
the	B-X
role	B-X
of	B-X
Runx3	B-X
and	B-X
Runx1	B-X
in	B-X
thymopoiesis	B-X
and	B-X
suggest	B-X
that	B-X
both	B-X
act	B-X
as	B-X
transcriptional	B-X
repressors	B-X
of	B-X
CD4	B-X
expression	B-X
during	B-X
T	B-X
cell	B-X
lineage	B-X
decisions	B-X
.	B-X

The	O
data	O
suggest	O
both	O
quantity	O
and	O
quality	O
of	O
T	O
reg	O
cells	O
are	O
hampered	O
.	O

Reduced	O
intrinsic	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
was	O
demonstrated	O
in	O
mice	O
,	O
because	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
+	O
cells	O
were	O
FACS	O
sorted	O
and	O
same	O
numbers	O
of	O
iT	O
reg	O
cells	O
are	O
included	O
in	O
control	O
experiments	O
.	O

In	O
the	O
suppression	O
experiment	O
with	O
human	O
cells	O
,	O
reduced	O
suppressive	O
activity	O
was	O
caused	O
by	O
reduced	O
FOXP3	B-Protein
expression	O
in	O
T	O
cells	O
by	O
siRNA	O
inhibition	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
.	O

This	O
study	O
demonstrates	O
that	O
RUNX	B-Protein
transcription	I-Protein
factors	I-Protein
1	I-Protein
and	O
3	B-Protein
play	O
an	O
important	O
role	O
in	O
the	O
generation	O
of	O
FOXP3	B-Protein
+	O
iT	O
reg	O
cells	O
by	O
TGF	O
-	O
beta	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
mediates	O
RUNX	B-Protein
induction	O
and	O
FOXP3	B-Protein
is	O
efficiently	O
up	O
-	O
regulated	O
by	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
in	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

There	O
are	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
proximal	O
FOXP3	B-Protein
promoter	O
.	O

One	O
binding	O
site	O
was	O
predicted	O
as	O
a	O
binding	O
site	O
for	O
RUNX2	B-Protein
.	O
<EOS>	B-X
Transcription	B-X
factor	B-X
prediction	B-X
programs	B-X
revealed	B-X
several	B-X
putative	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
LGALS3	B-X
(	B-X
Galectin-3	B-X
gene	B-X
)	B-X
promoter	B-X
region	B-X
.	B-X
Two	B-X
binding	B-X
sites	B-X
for	B-X
RUNX1	B-X
and	B-X
one	B-X
binding	B-X
site	B-X
for	B-X
RUNX2	B-X
were	B-X
identified	B-X
in	B-X
the	B-X
LGALS3	B-X
promoter	B-X
region	B-X
.	B-X
LGALS3	B-X
promoter	B-X
was	B-X
further	B-X
cloned	B-X
into	B-X
a	B-X
luciferase	B-X
reporter	B-X
,	B-X
and	B-X
the	B-X
experiments	B-X
showed	B-X
that	B-X
both	B-X
RUNX1	B-X
and	B-X
RUNX2	B-X
upregulated	B-X
LGALS3	B-X
.	B-X
Knock-down	B-X
of	B-X
either	B-X
RUNX1	B-X
or	B-X
RUNX2	B-X
by	B-X
siRNA	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
downregulation	B-X
of	B-X
Galectin-3	B-X
expression	B-X
and	B-X
decreased	B-X
cell	B-X
proliferation	B-X
in	B-X
the	B-X
HP	B-X
75	B-X
cell	B-X
line	B-X
.	B-X
Immunohistochemistry	B-X
showed	B-X
a	B-X
close	B-X
correlation	B-X
between	B-X
Galectin-3	B-X
expression	B-X
and	B-X
RUNX1/RUNX2	B-X
level	B-X
in	B-X
pituitary	B-X
tumors	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
novel	B-X
binding	B-X
target	B-X
for	B-X
RUNX1	B-X
and	B-X
RUNX2	B-X
proteins	B-X
and	B-X
suggest	B-X
that	B-X
Galectin-3	B-X
is	B-X
regulated	B-X
by	B-X
RUNX1	B-X
and	B-X
RUNX2	B-X
in	B-X
human	B-X
pituitary	B-X
tumor	B-X
cells	B-X
by	B-X
direct	B-X
binding	B-X
to	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
LGALS3	B-X
and	B-X
thus	B-X
may	B-X
contribute	B-X
to	B-X
pituitary	B-X
tumor	B-X
progression	B-X
.	B-X

Promoter	O
enzyme	O
immunoassay	O
results	O
showed	O
that	O
binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
also	O
occurred	O
at	O
this	O
site	O
(	O
as	O
well	O
as	O
at	O
the	O
other	O
two	O
)	O
,	O
which	O
were	O
initially	O
identified	O
as	O
RUNX1	O
binding	O
sites	O
.	O

This	O
finding	O
is	O
not	O
surprising	O
because	O
RUNX	B-Protein
proteins	O
bind	O
to	O
promoter	O
or	O
enhancer	O
elements	O
of	O
their	O
target	O
genes	O
via	O
the	O
runt	O
domain	O
,	O
which	O
is	O
conserved	O
between	O
members	O
of	O
the	O
RUNX	B-Protein
family	O
.	O
<EOS>	B-X
Awareness	B-X
of	B-X
these	B-X
findings	B-X
can	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
missed	B-X
or	B-X
incorrect	B-X
diagnoses	B-X
that	B-X
lead	B-X
to	B-X
poor	B-X
patient	B-X
outcomes	B-X
.	B-X
The	B-X
ability	B-X
to	B-X
recognize	B-X
the	B-X
red	B-X
flag	B-X
findings	B-X
of	B-X
serious	B-X
causes	B-X
of	B-X
low	B-X
back	B-X
pain	B-X
ensures	B-X
prompt	B-X
diagnosis	B-X
and	B-X
initiation	B-X
of	B-X
appropriate	B-X
treatment	B-X
.	B-X
This	B-X
article	B-X
highlights	B-X
the	B-X
history	B-X
and	B-X
physical	B-X
examination	B-X
findings	B-X
that	B-X
will	B-X
improve	B-X
identification	B-X
of	B-X
red	B-X
flags	B-X
associated	B-X
with	B-X
emergency	B-X
or	B-X
serious	B-X
causes	B-X
.	B-X
Pathophysiology	B-X
of	B-X
vertigo/dizziness	B-X
can	B-X
be	B-X
understood	B-X
by	B-X
eye	B-X
deviation	B-X
(	B-X
nystagmus	B-X
)	B-X
.	B-X
In	B-X
benign	B-X
paroxysmal	B-X
positional	B-X
vertigo	B-X
,	B-X
eye	B-X
deviation	B-X
of	B-X
causative	B-X
semicircular	B-X
canal	B-X
stimulation	B-X
is	B-X
directly	B-X
observed	B-X
.	B-X
In	B-X
other	B-X
peripheral	B-X
vestibular	B-X
disorders	B-X
,	B-X
eye	B-X
deviation	B-X
results	B-X
from	B-X
the	B-X
sum	B-X
of	B-X
unilateral	B-X
all	B-X
semicircular	B-X
canal	B-X
disorders	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
vertigo/dizziness	B-X
of	B-X
central	B-X
origin	B-X
,	B-X
not	B-X
only	B-X
eye	B-X
deviation	B-X
due	B-X
to	B-X
impairment	B-X
of	B-X
the	B-X
central	B-X
vestibular	B-X
pathway	B-X
but	B-X
also	B-X
deviation	B-X
due	B-X
to	B-X
disinhibition	B-X
of	B-X
the	B-X
pathway	B-X
from	B-X
the	B-X
cerebellum	B-X
is	B-X
observed	B-X
.	B-X
When	B-X
treating	B-X
vertigo/dizziness	B-X
,	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
understand	B-X
the	B-X
pathophysiology	B-X
of	B-X
the	B-X
vertigo/dizziness	B-X
,	B-X
to	B-X
set	B-X
the	B-X
treatment	B-X
target	B-X
based	B-X
on	B-X
the	B-X
pathophysiology	B-X
,	B-X
and	B-X
to	B-X
intervene	B-X
for	B-X
the	B-X
target	B-X
.	B-X

The	O
RUNX	B-Protein
protein	O
that	O
actually	O
induces	O
the	O
expression	O
of	O
FOXP3	B-Protein
might	O
therefore	O
be	O
dependent	O
on	O
the	O
availability	O
of	O
the	O
specific	O
RUNX	B-Protein
family	O
member	O
at	O
certain	O
stages	O
of	O
T	O
cell	O
development	O
.	O

RUNX	B-Protein
proteins	O
are	O
able	O
to	O
increase	O
or	O
inhibit	O
transcriptional	O
activity	O
of	O
their	O
target	O
genes	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
target	O
gene	O
(	O
Otto	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O
<EOS>	B-X
Hypertrophic	B-X
chondrocytes	B-X
are	B-X
the	B-X
master	B-X
regulators	B-X
of	B-X
endochondral	B-X
ossification	B-X
;	B-X
however	B-X
,	B-X
their	B-X
ultimate	B-X
cell	B-X
fates	B-X
cells	B-X
remain	B-X
largely	B-X
elusive	B-X
due	B-X
to	B-X
their	B-X
transient	B-X
nature	B-X
.	B-X
Historically	B-X
,	B-X
hypertrophic	B-X
chondrocytes	B-X
have	B-X
been	B-X
considered	B-X
as	B-X
the	B-X
terminal	B-X
state	B-X
of	B-X
growth	B-X
plate	B-X
chondrocytes	B-X
,	B-X
which	B-X
are	B-X
destined	B-X
to	B-X
meet	B-X
their	B-X
inevitable	B-X
demise	B-X
at	B-X
the	B-X
primary	B-X
spongiosa	B-X
.	B-X
Chondrocyte	B-X
hypertrophy	B-X
is	B-X
accompanied	B-X
by	B-X
increased	B-X
organelle	B-X
synthesis	B-X
and	B-X
rapid	B-X
intracellular	B-X
water	B-X
uptake	B-X
,	B-X
which	B-X
serve	B-X
as	B-X
the	B-X
major	B-X
drivers	B-X
of	B-X
longitudinal	B-X
bone	B-X
growth	B-X
.	B-X
This	B-X
process	B-X
is	B-X
delicately	B-X
regulated	B-X
by	B-X
major	B-X
signaling	B-X
pathways	B-X
and	B-X
their	B-X
target	B-X
genes	B-X
,	B-X
including	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
,	B-X
insulin	B-X
growth	B-X
factor-1	B-X
(	B-X
IGF-1	B-X
)	B-X
,	B-X
indian	B-X
hedgehog	B-X
(	B-X
Ihh	B-X
)	B-X
,	B-X
parathyroid	B-X
hormone-related	B-X
protein	B-X
(	B-X
PTHrP	B-X
)	B-X
,	B-X
bone	B-X
morphogenetic	B-X
proteins	B-X
(	B-X
BMPs	B-X
)	B-X
,	B-X
sex	B-X
determining	B-X
region	B-X
Y-box	B-X
9	B-X
(	B-X
Sox9	B-X
)	B-X
,	B-X
runt-related	B-X
transcription	B-X
factors	B-X
(	B-X
Runx	B-X
)	B-X
and	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptors	B-X
(	B-X
FGFRs	B-X
)	B-X
.	B-X
Hypertrophic	B-X
chondrocytes	B-X
orchestrate	B-X
endochondral	B-X
ossification	B-X
by	B-X
regulating	B-X
osteogenic-angiogenic	B-X
and	B-X
osteogenic-osteoclastic	B-X
coupling	B-X
through	B-X
the	B-X
production	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
and	B-X
matrix	B-X
metallopeptidases-9/13	B-X
(	B-X
MMP-9/13	B-X
)	B-X
.	B-X
Hypertrophic	B-X
chondrocytes	B-X
also	B-X
indirectly	B-X
regulate	B-X
resorption	B-X
of	B-X
the	B-X
cartilaginous	B-X
extracellular	B-X
matrix	B-X
,	B-X
by	B-X
controlling	B-X
formation	B-X
of	B-X
a	B-X
special	B-X
subtype	B-X
of	B-X
osteoclasts	B-X
termed	B-X
``	B-X
chondroclasts	B-X
''	B-X
.	B-X
Notably	B-X
,	B-X
hypertrophic	B-X
chondrocytes	B-X
may	B-X
possess	B-X
innate	B-X
potential	B-X
for	B-X
plasticity	B-X
,	B-X
reentering	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
differentiating	B-X
into	B-X
osteoblasts	B-X
and	B-X
other	B-X
types	B-X
of	B-X
mesenchymal	B-X
cells	B-X
in	B-X
the	B-X
marrow	B-X
space	B-X
.	B-X
We	B-X
may	B-X
be	B-X
able	B-X
to	B-X
harness	B-X
this	B-X
unique	B-X
plasticity	B-X
for	B-X
therapeutic	B-X
purposes	B-X
,	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
skeletal	B-X
abnormalities	B-X
and	B-X
injuries	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
morphological	B-X
and	B-X
molecular	B-X
properties	B-X
of	B-X
hypertrophic	B-X
chondrocytes	B-X
,	B-X
which	B-X
carry	B-X
out	B-X
important	B-X
functions	B-X
during	B-X
skeletal	B-X
growth	B-X
and	B-X
regeneration	B-X
.	B-X

Mutation	O
of	O
only	O
one	O
of	O
the	O
three	O
binding	O
sites	O
had	O
only	O
a	O
little	O
effect	O
on	O
the	O
promoter	O
activity	O
;	O
however	O
,	O
when	O
two	O
binding	O
sites	O
were	O
mutated	O
,	O
the	O
FOXP3	B-Protein
promoter	O
activity	O
dropped	O
to	O
a	O
greater	O
extent	O
.	O

The	O
most	O
striking	O
effect	O
was	O
observed	O
when	O
all	O
three	O
binding	O
sites	O
were	O
mutated	O
.	O
<EOS>	B-X
A	B-X
two-fold	B-X
stimulation	B-X
of	B-X
cell	B-X
proliferation	B-X
was	B-X
observed	B-X
after	B-X
a	B-X
culture	B-X
period	B-X
of	B-X
6	B-X
days	B-X
in	B-X
1	B-X
ng	B-X
EGF/ml	B-X
,	B-X
10	B-X
ng	B-X
TGF-alpha/ml	B-X
or	B-X
20	B-X
ng	B-X
basic	B-X
FGF/ml	B-X
.	B-X
The	B-X
synthetic	B-X
androgen	B-X
R1881	B-X
(	B-X
0.1	B-X
nM	B-X
)	B-X
stimulated	B-X
cell	B-X
proliferation	B-X
three-fold	B-X
and	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
EGF	B-X
receptors	B-X
from	B-X
11500	B-X
to	B-X
28500	B-X
sites/cell	B-X
.	B-X
TGF-beta	B-X
did	B-X
not	B-X
directly	B-X
affect	B-X
androgen-responsive	B-X
growth	B-X
but	B-X
inhibited	B-X
the	B-X
synergistic	B-X
effect	B-X
of	B-X
EGF	B-X
.	B-X
Estrogens	B-X
,	B-X
progestagens	B-X
and	B-X
antiandrogens	B-X
do	B-X
not	B-X
inhibit	B-X
androgen	B-X
responsive	B-X
growth	B-X
of	B-X
LNCaP	B-X
cells	B-X
but	B-X
have	B-X
striking	B-X
growth	B-X
stimulatory	B-X
effects	B-X
,	B-X
increase	B-X
EGF	B-X
receptor	B-X
level	B-X
and	B-X
increase	B-X
acid	B-X
phosphatase	B-X
secretion	B-X
.	B-X
It	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
that	B-X
the	B-X
stimulatory	B-X
effects	B-X
are	B-X
due	B-X
to	B-X
a	B-X
mutated	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
steroid	B-X
binding	B-X
domain	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
.	B-X

We	O
therefore	O
assume	O
that	O
these	O
binding	O
sites	O
have	O
partially	O
redundant	O
functions	O
,	O
but	O
binding	O
to	O
at	O
least	O
two	O
sites	O
seems	O
to	O
be	O
necessary	O
for	O
full	O
promoter	O
activation	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
promotes	O
or	O
inhibits	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
a	O
wide	O
array	O
of	O
different	O
cells	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
β	B-X
(	B-X
TGF-β	B-X
)	B-X
has	B-X
long	B-X
been	B-X
identified	B-X
with	B-X
its	B-X
intensive	B-X
involvement	B-X
in	B-X
early	B-X
embryonic	B-X
development	B-X
and	B-X
organogenesis	B-X
,	B-X
immune	B-X
supervision	B-X
,	B-X
tissue	B-X
repair	B-X
,	B-X
and	B-X
adult	B-X
homeostasis	B-X
.	B-X
The	B-X
role	B-X
of	B-X
TGF-β	B-X
in	B-X
fibrosis	B-X
and	B-X
cancer	B-X
is	B-X
complex	B-X
and	B-X
sometimes	B-X
even	B-X
contradictory	B-X
,	B-X
exhibiting	B-X
either	B-X
inhibitory	B-X
or	B-X
promoting	B-X
effects	B-X
depending	B-X
on	B-X
the	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
Under	B-X
pathological	B-X
conditions	B-X
,	B-X
overexpressed	B-X
TGF-β	B-X
causes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
deposition	B-X
,	B-X
cancer-associated	B-X
fibroblast	B-X
(	B-X
CAF	B-X
)	B-X
formation	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
fibrotic	B-X
disease	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
Given	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
TGF-β	B-X
and	B-X
its	B-X
downstream	B-X
molecules	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
fibrosis	B-X
and	B-X
cancers	B-X
,	B-X
therapeutics	B-X
targeting	B-X
TGF-β	B-X
signaling	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
promising	B-X
strategy	B-X
.	B-X
However	B-X
,	B-X
due	B-X
to	B-X
potential	B-X
systemic	B-X
cytotoxicity	B-X
,	B-X
the	B-X
development	B-X
of	B-X
TGF-β	B-X
therapeutics	B-X
has	B-X
lagged	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarized	B-X
the	B-X
biological	B-X
process	B-X
of	B-X
TGF-β	B-X
,	B-X
with	B-X
its	B-X
dual	B-X
role	B-X
in	B-X
fibrosis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
and	B-X
the	B-X
clinical	B-X
application	B-X
of	B-X
TGF-β-targeting	B-X
therapies	B-X
.	B-X

It	O
is	O
also	O
produced	O
in	O
activated	O
T	O
cells	O
and	O
it	O
inhibits	O
T	O
cell	O
proliferation	O
(	O
Kehrl	O
et	O
al	O
.	O
,	O
1986	O
;	O
Siegel	O
and	O
Massague	O
,	O
2003	O
)	O
.	O

It	O
was	O
shown	O
that	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
is	O
mandatory	O
for	O
the	O
maintenance	O
of	O
peripheral	O
T	O
reg	O
cells	O
and	O
their	O
expression	O
of	O
Foxp3	B-Protein
(	O
Marie	O
et	O
al	O
.	O
,	O
2005	O
;	O
Rubtsov	O
and	O
Rudensky	O
,	O
2007	O
)	O
.	O

RUNX	B-Protein
transcription	O
factors	O
are	O
targets	O
of	O
the	O
TGF	O
-	O
beta	O
superfamily	O
and	O
they	O
are	O
involved	O
in	O
the	O
TGF	O
-	O
beta	O
pathway	O
.	O

They	O
interact	O
directly	O
with	O
regulatory	O
SMADs	O
(	O
Miyazawa	O
et	O
al	O
.	O
,	O
2002	O
;	O
Ito	O
and	O
Miyazono	O
,	O
2003	O
)	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
can	O
activate	O
RUNX	B-Protein
genes	O
at	O
the	O
transcriptional	O
level	O
,	O
and	O
at	O
the	O
posttranscriptional	O
level	O
through	O
activation	O
or	O
stabilization	O
of	O
RUNX	B-Protein
proteins	O
(	O
Jin	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

It	O
was	O
shown	O
that	O
RUNX2	B-Protein
regulates	O
the	O
expression	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
type	I-Protein
I	I-Protein
receptor	I-Protein
(	O
Ji	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
suggesting	O
that	O
other	O
mechanisms	O
for	O
their	O
function	O
could	O
be	O
involved	O
.	O

The	O
fusion	O
proteins	O
RUNX1	B-Protein
-	I-Protein
EVI1	I-Protein
and	O
RUNX1	B-Protein
-	I-Protein
ETO	I-Protein
block	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
inhibition	O
of	O
leukemic	O
cell	O
growth	O
.	O

RUNX3	B-Protein
plays	O
an	O
important	O
role	O
in	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
mediated	O
growth	O
control	O
in	O
epithelial	O
cells	O
,	O
as	O
loss	O
of	O
RUNX3	B-Protein
leads	O
to	O
decreased	O
sensitivity	O
to	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
hyperproliferation	O
of	O
the	O
gastric	O
mucosa	O
(	O
Blyth	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
RUNX3	B-Protein
expression	O
is	O
more	O
dominant	O
in	O
circulating	O
human	O
T	O
reg	O
cells	O
and	O
tonsil	O
T	O
reg	O
cells	O
compared	O
with	O
RUNX1	B-Protein
.	O

This	O
could	O
be	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
cells	O
and	O
organ	O
from	O
which	O
they	O
were	O
isolated	O
.	O
<EOS>	B-X
Metastasis	B-X
frequently	B-X
develops	B-X
years	B-X
after	B-X
the	B-X
removal	B-X
of	B-X
a	B-X
primary	B-X
tumor	B-X
,	B-X
from	B-X
a	B-X
minority	B-X
of	B-X
disseminated	B-X
cancer	B-X
cells	B-X
that	B-X
survived	B-X
as	B-X
latent	B-X
entities	B-X
through	B-X
unknown	B-X
mechanisms	B-X
.	B-X
We	B-X
isolated	B-X
latency	B-X
competent	B-X
cancer	B-X
(	B-X
LCC	B-X
)	B-X
cells	B-X
from	B-X
early	B-X
stage	B-X
human	B-X
lung	B-X
and	B-X
breast	B-X
carcinoma	B-X
cell	B-X
lines	B-X
and	B-X
defined	B-X
the	B-X
mechanisms	B-X
that	B-X
suppress	B-X
outgrowth	B-X
,	B-X
support	B-X
long-term	B-X
survival	B-X
,	B-X
and	B-X
maintain	B-X
tumor-initiating	B-X
potential	B-X
in	B-X
these	B-X
cells	B-X
during	B-X
the	B-X
latent	B-X
metastasis	B-X
stage	B-X
.	B-X
LCC	B-X
cells	B-X
show	B-X
stem-cell-like	B-X
characteristics	B-X
and	B-X
express	B-X
SOX2	B-X
and	B-X
SOX9	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
essential	B-X
for	B-X
their	B-X
survival	B-X
in	B-X
host	B-X
organs	B-X
under	B-X
immune	B-X
surveillance	B-X
and	B-X
for	B-X
metastatic	B-X
outgrowth	B-X
under	B-X
permissive	B-X
conditions	B-X
.	B-X
Through	B-X
expression	B-X
of	B-X
the	B-X
WNT	B-X
inhibitor	B-X
DKK1	B-X
,	B-X
LCC	B-X
cells	B-X
self-impose	B-X
a	B-X
slow-cycling	B-X
state	B-X
with	B-X
broad	B-X
downregulation	B-X
of	B-X
ULBP	B-X
ligands	B-X
for	B-X
NK	B-X
cells	B-X
and	B-X
evasion	B-X
of	B-X
NK-cell-mediated	B-X
clearance	B-X
.	B-X
By	B-X
expressing	B-X
a	B-X
Sox-dependent	B-X
stem-like	B-X
state	B-X
and	B-X
actively	B-X
silencing	B-X
WNT	B-X
signaling	B-X
,	B-X
LCC	B-X
cells	B-X
can	B-X
enter	B-X
quiescence	B-X
and	B-X
evade	B-X
innate	B-X
immunity	B-X
to	B-X
remain	B-X
latent	B-X
for	B-X
extended	B-X
periods	B-X
.	B-X

We	O
observed	O
that	O
single	O
siRNA	O
interference	O
of	O
either	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
alone	O
shows	O
a	O
slight	O
decrease	O
in	O
Foxp3	B-Protein
+	O
T	O
reg	O
cell	O
induction	O
,	O
which	O
could	O
be	O
caused	O
by	O
redundancy	O
of	O
these	O
proteins	O
.	O

For	O
this	O
reason	O
,	O
we	O
decided	O
to	O
use	O
CbfbetaF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
.	O

Foxp3	B-Protein
induction	O
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
is	O
reduced	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
compared	O
with	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

Retinoic	O
acid	O
is	O
secreted	O
by	O
a	O
subset	O
of	O
dendritic	O
cells	O
in	O
the	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
They	B-X
act	B-X
as	B-X
professional	B-X
antigen-presenting	B-X
cells	B-X
and	B-X
are	B-X
capable	B-X
of	B-X
activating	B-X
naive	B-X
T	B-X
cells	B-X
and	B-X
stimulating	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
According	B-X
to	B-X
their	B-X
molecular	B-X
expression	B-X
,	B-X
DCs	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
several	B-X
subsets	B-X
with	B-X
different	B-X
functions	B-X
.	B-X
We	B-X
focus	B-X
on	B-X
DC	B-X
subsets	B-X
expressing	B-X
langerin	B-X
,	B-X
a	B-X
C-type	B-X
lectin	B-X
.	B-X
Langerin	B-X
expression	B-X
is	B-X
predominant	B-X
in	B-X
skin	B-X
DCs	B-X
,	B-X
but	B-X
langerin-expressing	B-X
DCs	B-X
also	B-X
exist	B-X
in	B-X
mucosal	B-X
tissue	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
immunization	B-X
and	B-X
sometimes	B-X
by	B-X
nutrient	B-X
deficiency	B-X
.	B-X
Yet	B-X
,	B-X
in	B-X
one	B-X
recent	B-X
study	B-X
,	B-X
langerin	B-X
(	B-X
+	B-X
)	B-X
DCs	B-X
were	B-X
generated	B-X
in	B-X
gut-associated	B-X
lymphoid	B-X
tissue	B-X
and	B-X
contributed	B-X
to	B-X
the	B-X
suppressive	B-X
intestinal	B-X
immune	B-X
environment	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
retinoic	B-X
acid	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
phenotypic	B-X
and	B-X
functional	B-X
characteristics	B-X
of	B-X
langerin	B-X
(	B-X
+	B-X
)	B-X
DCs	B-X
in	B-X
the	B-X
mucosal	B-X
tissues	B-X
,	B-X
especially	B-X
MLNs	B-X
.	B-X

It	O
inhibits	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
driven	O
induction	O
of	O
Th17	O
cells	O
and	O
facilitates	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
to	O
Foxp3	B-Protein
+	O
T	O
reg	O
cells	O
(	O
Mucida	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

We	O
observed	O
an	O
increased	O
number	O
of	O
Foxp3	B-Protein
+	O
cells	O
by	O
retinoic	O
acid	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
compared	O
with	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
treatment	O
alone	O
in	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
and	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
.	O

In	O
addition	O
,	O
we	O
showed	O
a	O
defective	O
in	O
vivo	O
generation	O
of	O
T	O
reg	O
cells	O
from	O
Cbfb	B-Protein
-	O
deficient	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
Rag2	B-Protein
-	O
/	O
-	O
mice	O
.	O

These	O
data	O
in	O
mice	O
confirm	O
the	O
human	O
data	O
that	O
RUNX	B-Protein
proteins	O
play	O
an	O
important	O
role	O
for	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
-	O
dependent	O
FOXP3	B-Protein
induction	O
,	O
as	O
well	O
as	O
in	O
the	O
suppressive	O
capacity	O
of	O
iT	O
reg	O
cells	O
.	O

As	O
an	O
additional	O
support	O
for	O
this	O
concept	O
,	O
the	O
overexpression	O
of	O
RUNX1	B-Protein
induced	O
increased	O
FOXP3	B-Protein
protein	O
expression	O
without	O
any	O
requirement	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
stimulation	O
in	O
human	O
primary	O
CD4	B-Protein
+	O
cells	O
.	O

In	O
both	O
human	O
and	O
mouse	O
systems	O
,	O
reduced	O
Foxp3	B-Protein
expression	O
was	O
associated	O
with	O
reduced	O
T	O
reg	O
cell	O
suppressive	O
activity	O
.	O
<EOS>	B-X
Multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
is	B-X
a	B-X
human	B-X
disease	B-X
that	B-X
results	B-X
from	B-X
autoimmune	B-X
T	B-X
cells	B-X
targeting	B-X
myelin	B-X
protein	B-X
that	B-X
is	B-X
expressed	B-X
within	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
.	B-X
In	B-X
MS	B-X
,	B-X
the	B-X
number	B-X
of	B-X
FoxP3-expressing	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
T	B-X

In	O
a	O
recent	O
study	O
,	O
the	O
role	O
of	O
Runx	B-Protein
-	O
CBFbeta	B-Protein
was	O
investigated	O
in	O
nT	O
reg	O
cell	O
development	O
in	O
the	O
thymus	O
(	O
Rudra	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

It	O
was	O
reported	O
that	O
Foxp3	B-Protein
expression	O
in	O
nT	O
reg	O
cells	O
is	O
unstable	O
in	O
the	O
absence	O
of	O
Runx	O
-	O
CBFbeta	B-Protein
complexes	O
.	O

Cbfb	B-Protein
-	O
deficient	O
nT	O
reg	O
cells	O
progressively	O
lose	O
Foxp3	B-Protein
upon	O
division	O
,	O
and	O
there	O
is	O
no	O
evidence	O
of	O
increased	O
death	O
of	O
Cbfb	B-Protein
-	O
deficient	O
nT	O
reg	O
cells	O
in	O
that	O
study	O
.	O

The	O
experiments	O
in	O
Cbfb	B-Protein
-	O
deficient	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
T	O
cells	O
in	O
mice	O
and	O
the	O
knockdown	O
experiments	O
in	O
humans	O
in	O
this	O
study	O
suggest	O
that	O
the	O
induction	O
of	O
Foxp3	B-Protein
expression	O
is	O
a	O
major	O
contributing	O
factor	O
in	O
the	O
in	O
vivo	O
conversion	O
experiment	O
.	O

Here	O
,	O
we	O
observed	O
that	O
there	O
is	O
a	O
twofold	O
increased	O
Foxp3	B-Protein
+	O
iT	O
reg	O
cell	O
generation	O
in	O
vivo	O
.	O

This	O
is	O
in	O
the	O
same	O
range	O
with	O
previously	O
published	O
studies	O
targeting	O
different	O
mechanisms	O
in	O
Foxp3	B-Protein
induction	O
(	O
Maynard	O
et	O
al	O
.	O
,	O
2007	O
;	O
Sun	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Whether	O
the	O
diminished	O
capacity	O
of	O
Cbfb	B-Protein
-	O
deficient	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
T	O
cells	O
in	O
the	O
generation	O
of	O
Foxp3	B-Protein
may	O
be	O
caused	O
by	O
peripheral	O
expansion	O
of	O
Cbfb	B-Protein
-	O
deficient	O
non	O
-	O
T	O
reg	O
cells	O
or	O
survival	O
problems	O
faced	O
by	O
Cbfb	B-Protein
-	O
deficient	O
iT	O
reg	O
cells	O
after	O
Foxp3	B-Protein
induction	O
remains	O
to	O
be	O
elucidated	O
.	O

The	O
involvement	O
of	O
RUNX	B-Protein
proteins	O
in	O
autoimmune	O
diseases	O
has	O
been	O
previously	O
suggested	O
(	O
Alarcon	O
-	O
Riquelme	O
,	O
2003	O
)	O
.	O

A	O
mutation	O
in	O
the	O
RUNX1	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
programmed	B-Protein
cell	I-Protein
death	I-Protein
1	I-Protein
gene	O
(	O
PDCD	B-Protein
-	I-Protein
1	I-Protein
)	O
has	O
been	O
implicated	O
in	O
systemic	O
lupus	O
erythematosus	O
pathogenesis	O
(	O
Prokunina	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Polymorphisms	O
that	O
alter	O
RUNX1	B-Protein
binding	O
to	O
other	O
genes	O
have	O
also	O
been	O
described	O
in	O
rheumatoid	O
arthritis	O
linkage	O
at	O
5q31	O
in	O
Japanese	O
patients	O
(	O
Tokuhiro	O
et	O
al	O
.	O
,	O
2003	O
)	O
and	O
in	O
a	O
psoriasis	O
linkage	O
at	O
17q25	O
(	O
Prokunina	O
et	O
al	O
.	O
,	O
2002	O
;	O
Helms	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

RUNX3	B-Protein
-	O
deficient	O
mice	O
spontaneously	O
develop	O
inflammatory	O
bowel	O
disease	O
and	O
hyperplastic	O
gastritis	O
-	O
like	O
lesions	O
(	O
Brenner	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

These	O
disease	O
symptoms	O
resemble	O
those	O
occurring	O
after	O
depletion	O
of	O
Foxp3	B-Protein
-	O
expressing	O
T	O
reg	O
cells	O
(	O
Sakaguchi	O
,	O
2004	O
)	O
.	O

Derepression	O
of	O
Th2	O
cytokines	O
might	O
also	O
account	O
for	O
some	O
of	O
the	O
observed	O
disease	O
symptoms	O
,	O
as	O
it	O
was	O
shown	O
that	O
T	B-Protein
-	I-Protein
bet	I-Protein
first	O
induces	O
Runx3	B-Protein
in	O
Th1	O
cells	O
and	O
then	O
partners	O
with	O
Runx3	B-Protein
to	O
direct	O
lineage	O
-	O
specific	O
gene	O
activation	O
.	O

Runx3	B-Protein
/	O
Cbfbeta	B-Protein
are	O
both	O
required	O
for	O
the	O
activation	O
of	O
the	O
Ifng	B-Protein
gene	O
and	O
silencing	O
of	O
the	O
Il4	B-Protein
gene	O
in	O
Th1	O
cells	O
(	O
Djuretic	O
et	O
al	O
.	O
,	O
2007	O
;	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Runx	B-Protein
proteins	O
also	O
play	O
an	O
essential	O
role	O
during	O
T	O
lymphocyte	O
differentiation	O
in	O
the	O
thymus	O
(	O
Taniuchi	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Runx1	B-Protein
regulates	O
the	O
transitions	O
of	O
developing	O
thymocytes	O
from	O
the	O
CD4	B-Protein
-	O
CD8	B-Protein
-	O
double	O
-	O
negative	O
stage	O
to	O
the	O
CD4	B-Protein
+	O
CD8	B-Protein
+	O
double	O
-	O
positive	O
stage	O
and	O
from	O
the	O
DP	O
stage	O
to	O
the	O
mature	O
single	O
-	O
positive	O
stage	O
(	O
Egawa	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Runx1	B-Protein
and	O
Runx3	B-Protein
deficiencies	O
caused	O
marked	O
reductions	O
in	O
mature	O
thymocytes	O
and	O
T	O
cells	O
of	O
the	O
CD4	B-Protein
+	O
helper	O
and	O
CD8	B-Protein
+	O
cytotoxic	O
T	O
cell	O
lineages	O
.	O

In	O
addition	O
,	O
inactivation	O
of	O
both	O
Runx1	B-Protein
and	O
Runx3	B-Protein
at	O
the	O
double	O
-	O
positive	O
stages	O
resulted	O
in	O
a	O
severe	O
blockage	O
in	O
the	O
development	O
of	O
CD8	B-Protein
+	O
mature	O
thymocytes	O
.	O

These	O
results	O
indicate	O
that	O
Runx	B-Protein
proteins	O
have	O
important	O
roles	O
at	O
multiple	O
stages	O
of	O
T	O
cell	O
development	O
and	O
in	O
the	O
homeostasis	O
of	O
mature	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
nT	O
reg	O
cell	O
development	O
,	O
which	O
remains	O
to	O
be	O
elucidated	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
Runx1	B-Protein
activates	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
gene	O
expression	O
in	O
conventional	O
CD4	B-Protein
+	O
T	O
cells	O
by	O
binding	O
to	O
their	O
respective	O
promoter	O
.	O

RUNX1	B-Protein
interacts	O
physically	O
with	O
Foxp3	B-Protein
protein	O
,	O
and	O
it	O
was	O
demonstrated	O
that	O
this	O
interaction	O
might	O
be	O
responsible	O
for	O
the	O
suppression	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
and	O
up	O
-	O
regulation	O
of	O
T	O
reg	O
cell	O
-	O
associated	O
molecules	O
(	O
Ono	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
Foxp3	B-Protein
also	O
influences	O
Th17	O
differentiation	O
.	O
<EOS>	B-X
T	B-X
helper	B-X
type	B-X
17	B-X
(	B-X
Th17	B-X
)	B-X
cells	B-X
and	B-X
pTreg	B-X
cells	B-X
,	B-X
which	B-X
share	B-X
a	B-X
common	B-X
precursor	B-X
cell	B-X
(	B-X
the	B-X
naïve	B-X
CD4	B-X
T	B-X
cell	B-X
)	B-X
,	B-X
require	B-X
a	B-X
common	B-X
tumor	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-β	B-X
signal	B-X
for	B-X
initial	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
terminally	B-X
differentiated	B-X
cells	B-X
fulfill	B-X
opposite	B-X
functions	B-X
:	B-X
Th17	B-X
cells	B-X
cause	B-X
autoimmunity	B-X
and	B-X
inflammation	B-X
,	B-X
whereas	B-X
Treg	B-X
cells	B-X
inhibit	B-X
these	B-X
phenomena	B-X
and	B-X
maintain	B-X
immune	B-X
homeostasis	B-X
.	B-X
Thus	B-X
,	B-X
unraveling	B-X
the	B-X
mechanisms	B-X
that	B-X
affect	B-X
the	B-X
Th17/Treg	B-X
cell	B-X
balance	B-X
is	B-X
critical	B-X
if	B-X
we	B-X
are	B-X
to	B-X
better	B-X
understand	B-X
autoimmunity	B-X
and	B-X
tolerance	B-X
.	B-X
This	B-X
review	B-X
article	B-X
summarizes	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
Th17/Treg	B-X
balance	B-X
and	B-X
its	B-X
implications	B-X
with	B-X
respect	B-X
to	B-X
autoimmune	B-X
disease	B-X
.	B-X

Specifically	O
,	O
Foxp3	B-Protein
physically	O
interacts	O
with	O
RORgammat	B-Protein
,	O
and	O
this	O
interaction	O
inhibits	O
RORgammat	B-Protein
function	O
(	O
Zhou	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

This	O
relationship	O
of	O
RORgammat	B-Protein
and	O
Foxp3	B-Protein
and	O
probably	O
yet	O
unknown	O
mechanisms	O
might	O
be	O
the	O
basis	O
of	O
the	O
observation	O
that	O
the	O
differentiation	O
of	O
Th17	O
cells	O
and	O
T	O
reg	O
cells	O
is	O
often	O
reciprocal	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Recently	O
,	O
data	O
suggests	O
that	O
Runx1	B-Protein
may	O
also	O
be	O
involved	O
in	O
regulating	O
Il17	B-Protein
transcription	O
,	O
functioning	O
in	O
complex	O
with	O
RORgammat	B-Protein
to	O
activate	O
transcription	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

The	O
Runx3	B-Protein
-	O
deficient	O
mice	O
develop	O
spontaneous	O
Th2	O
-	O
dominated	O
autoimmune	O
colitis	O
and	O
asthma	O
(	O
Brenner	O
et	O
al	O
.	O
,	O
2004	O
;	O
Fainaru	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Cbfbf	B-Protein
/	O
f	O
Cd4	B-Protein
mice	O
also	O
show	O
a	O
spontaneous	O
Th2	O
dominated	O
disease	O
,	O
with	O
increased	O
serum	O
IgA	O
,	O
IgG1	O
,	O
and	O
IgE	O
titers	O
and	O
lymphocyte	O
and	O
eosinophil	O
infiltration	O
of	O
the	O
lung	O
(	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

All	O
these	O
phenotypes	O
were	O
previously	O
attributed	O
to	O
a	O
loss	O
of	O
Th2	O
silencing	O
whereas	O
our	O
findings	O
additionally	O
suggest	O
that	O
loss	O
of	O
T	O
reg	O
function	O
plays	O
a	O
role	O
.	O

We	O
have	O
shown	O
a	O
link	O
between	O
Foxp3	B-Protein
induction	O
in	O
iT	O
reg	O
cells	O
and	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

RUNX	B-Protein
proteins	O
play	O
a	O
central	O
role	O
in	O
pathways	O
regulating	O
cell	O
growth	O
and	O
differentiation	O
,	O
and	O
their	O
interaction	O
with	O
the	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
pathway	O
is	O
of	O
particular	O
interest	O
.	O

Foxp3	B-Protein
protein	O
interacts	O
not	O
only	O
with	O
RUNX	B-Protein
proteins	O
but	O
also	O
with	O
several	O
other	O
transcriptional	O
partners	O
,	O
such	O
as	O
NFAT	O
and	O
possibly	O
NF	O
-	O
kappaB	O
;	O
with	O
histone	O
acetyl	O
transferases	O
,	O
such	O
as	O
TIP60	B-Protein
;	O
and	O
histone	O
deacetyl	O
transferase	O
(	O
HDAC	O
)	O
complexes	O
,	O
such	O
as	O
HDAC7	O
and	O
HDAC9	O
(	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
;	O
Sakaguchi	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
Foxp3	B-X
controls	B-X
the	B-X
differentiation	B-X
and	B-X
function	B-X
of	B-X
regulatory	B-X
T-cells	B-X
(	B-X
Treg	B-X
)	B-X
.	B-X
Studies	B-X
in	B-X
the	B-X
past	B-X
decades	B-X
identified	B-X
numerous	B-X
Foxp3-interacting	B-X
protein	B-X
partners	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
still	B-X
not	B-X
clear	B-X
how	B-X
Foxp3	B-X
produces	B-X
the	B-X
Treg-type	B-X
transcriptomic	B-X
landscape	B-X
through	B-X
cooperating	B-X
with	B-X
its	B-X
partners	B-X
.	B-X
Here	B-X
I	B-X
show	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
how	B-X
Foxp3	B-X
transcription	B-X
factor	B-X
complexes	B-X
regulate	B-X
the	B-X
differentiation	B-X
,	B-X
maintenance	B-X
and	B-X
functional	B-X
maturation	B-X
of	B-X
Treg	B-X
.	B-X
Importantly	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
signalling	B-X
plays	B-X
central	B-X
roles	B-X
in	B-X
Treg	B-X
differentiation	B-X
and	B-X
Foxp3-mediated	B-X
gene	B-X
regulation	B-X
.	B-X
Differentiating	B-X
Treg	B-X
will	B-X
have	B-X
recognized	B-X
their	B-X
cognate	B-X
antigens	B-X
and	B-X
received	B-X
TCR	B-X
signals	B-X
before	B-X
initiating	B-X
Foxp3	B-X
transcription	B-X
,	B-X
which	B-X
is	B-X
triggered	B-X
by	B-X
TCR-induced	B-X
transcription	B-X
factors	B-X
including	B-X
NFAT	B-X
,	B-X
AP-1	B-X
and	B-X
NF-κB	B-X
.	B-X
Once	B-X
expressed	B-X
,	B-X
Foxp3	B-X
seizes	B-X
TCR	B-X
signal-induced	B-X
transcriptional	B-X
and	B-X
epigenetic	B-X
mechanisms	B-X
through	B-X
interacting	B-X
with	B-X
AML1/Runx1	B-X
and	B-X
NFAT	B-X
.	B-X
Thus	B-X
,	B-X
Foxp3	B-X
modifies	B-X
gene	B-X
expression	B-X
dynamics	B-X
of	B-X
TCR-induced	B-X
genes	B-X
,	B-X
which	B-X
constitute	B-X
cardinal	B-X
mechanisms	B-X
for	B-X
Treg-mediated	B-X
immune	B-X
suppression	B-X
.	B-X
Next	B-X
,	B-X
I	B-X
discuss	B-X
the	B-X
following	B-X
key	B-X
topics	B-X
,	B-X
proposing	B-X
new	B-X
mechanistic	B-X
models	B-X
for	B-X
Foxp3-mediated	B-X
gene	B-X
regulation	B-X
:	B-X
(	B-X
i	B-X
)	B-X
how	B-X
Foxp3	B-X
transcription	B-X
is	B-X
induced	B-X
and	B-X
maintained	B-X
by	B-X
the	B-X
Foxp3-inducing	B-X
enhanceosome	B-X
and	B-X
the	B-X
Foxp3	B-X
autoregulatory	B-X
transcription	B-X
factor	B-X
complex	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
molecular	B-X
mechanisms	B-X
for	B-X
effector	B-X
Treg	B-X
differentiation	B-X
(	B-X
i.e	B-X
.	B-X
Treg	B-X
maturation	B-X
)	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
how	B-X
Foxp3	B-X
activates	B-X
or	B-X
represses	B-X
its	B-X
target	B-X
genes	B-X
through	B-X
recruiting	B-X
coactivators	B-X
and	B-X
corepressors	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
'decision-making	B-X
'	B-X
Foxp3-containing	B-X
transcription	B-X
factor	B-X
complex	B-X
for	B-X
Th17	B-X
and	B-X
Treg	B-X
differentiation	B-X
;	B-X
and	B-X
(	B-X
v	B-X
)	B-X
the	B-X
roles	B-X
of	B-X
post-translational	B-X
modification	B-X
in	B-X
Foxp3	B-X
regulation	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
article	B-X
provides	B-X
cutting-edge	B-X
understanding	B-X
of	B-X
molecular	B-X
biology	B-X
of	B-X
Foxp3	B-X
and	B-X
Treg	B-X
,	B-X
integrating	B-X
findings	B-X
by	B-X
biochemical	B-X
and	B-X
genomic	B-X
studies	B-X
.	B-X

NFAT	O
forms	O
a	O
complex	O
with	O
AP	B-Protein
-	I-Protein
1	I-Protein
and	O
NF	O
-	O
kappaB	O
and	O
regulates	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
CTLA4	B-Protein
in	O
conventional	O
T	O
cells	O
,	O
which	O
leads	O
to	O
the	O
activation	O
and	O
differentiation	O
to	O
effector	O
T	O
cells	O
(	O
Dolganov	O
et	O
al	O
.	O
,	O
1996	O
;	O
Hu	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
NFAT	O
-	O
AP	B-Protein
-	I-Protein
1	I-Protein
complex	O
also	O
binds	O
to	O
the	O
Foxp3	B-Protein
promoter	O
after	O
TCR	O
triggering	O
and	O
regulates	O
its	O
gene	O
expression	O
positively	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

It	O
was	O
shown	O
that	O
NFAT	O
and	O
Smad3	B-Protein
cooperate	O
to	O
induce	O
Foxp3	B-Protein
expression	O
through	O
its	O
enhancer	O
(	O
Tone	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
but	O
no	O
TGF	O
-	O
beta	O
response	O
element	O
was	O
identified	O
in	O
the	O
Foxp3	B-Protein
gene	O
or	O
in	O
the	O
surrounding	O
regions	O
.	O
<EOS>	B-X
Regionalization	B-X
,	B-X
which	B-X
emphasizes	B-X
matching	B-X
patient	B-X
needs	B-X
with	B-X
the	B-X
capabilities	B-X
of	B-X
the	B-X
hospital	B-X
in	B-X
which	B-X
care	B-X
is	B-X
provided	B-X
,	B-X
has	B-X
long	B-X
been	B-X
a	B-X
recommended	B-X
approach	B-X
to	B-X
reducing	B-X
neonatal	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
research	B-X
methods	B-X
surrounding	B-X
the	B-X
measurement	B-X
and	B-X
evaluation	B-X
of	B-X
such	B-X
programs	B-X
have	B-X
improved	B-X
,	B-X
thus	B-X
strengthening	B-X
arguments	B-X
for	B-X
implementation	B-X
of	B-X
these	B-X
strategies	B-X
.	B-X
However	B-X
,	B-X
regionalization	B-X
policies	B-X
vary	B-X
widely	B-X
across	B-X
regions	B-X
and	B-X
between	B-X
countries	B-X
,	B-X
with	B-X
potential	B-X
impacts	B-X
on	B-X
neonatal	B-X
outcomes	B-X
as	B-X
well	B-X
as	B-X
costs	B-X
of	B-X
care	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
account	B-X
for	B-X
geographic	B-X
and	B-X
other	B-X
regional	B-X
differences	B-X
when	B-X
determining	B-X
the	B-X
feasibility	B-X
of	B-X
regionalization	B-X
for	B-X
a	B-X
specific	B-X
region	B-X
,	B-X
as	B-X
certain	B-X
areas	B-X
and	B-X
populations	B-X
may	B-X
need	B-X
particular	B-X
consideration	B-X
in	B-X
order	B-X
for	B-X
regionalization	B-X
policies	B-X
to	B-X
be	B-X
successful	B-X
.	B-X

The	O
initial	O
induction	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
and	O
the	O
subsequent	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
Foxp3	B-Protein
promoter	O
that	O
we	O
showed	O
here	O
might	O
explain	O
the	O
relatively	O
late	O
induction	O
of	O
Foxp3	B-Protein
mRNA	O
that	O
peaks	O
24	O
-	O
48	O
h	O
after	O
stimulation	O
.	O

The	O
interaction	O
of	O
Foxp3	B-Protein
and	O
NFAT	O
is	O
dependent	O
on	O
their	O
cooperative	O
binding	O
to	O
DNA	O
(	O
Wu	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

RUNX1	B-Protein
alone	O
,	O
or	O
together	O
with	O
its	O
interacting	O
partners	O
p300	B-Protein
and	O
CREB	B-Protein
-	O
binding	O
protein	O
,	O
may	O
cooperate	O
with	O
the	O
NFAT	O
transcription	O
complex	O
to	O
activate	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
(	O
Sakaguchi	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
<EOS>	B-X
The	B-X
majority	B-X
of	B-X
RUNX1	B-X
mutations	B-X
in	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
are	B-X
missense	B-X
or	B-X
deletion-truncation	B-X
and	B-X
behave	B-X
as	B-X
loss-of-function	B-X
mutations	B-X
.	B-X
Following	B-X
standard	B-X
therapy	B-X
,	B-X
AML	B-X
patients	B-X
expressing	B-X
mtRUNX1	B-X
exhibit	B-X
inferior	B-X
clinical	B-X
outcome	B-X
than	B-X
those	B-X
without	B-X
mutant	B-X
RUNX1	B-X
.	B-X
Studies	B-X
presented	B-X
here	B-X
demonstrate	B-X
that	B-X
as	B-X
compared	B-X
with	B-X
AML	B-X
cells	B-X
lacking	B-X
mtRUNX1	B-X
,	B-X
their	B-X
isogenic	B-X
counterparts	B-X
harboring	B-X
mtRUNX1	B-X
display	B-X
impaired	B-X
ribosomal	B-X
biogenesis	B-X
and	B-X
differentiation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
exhibit	B-X
reduced	B-X
levels	B-X
of	B-X
wild-type	B-X
RUNX1	B-X
,	B-X
PU.1	B-X
,	B-X
and	B-X
c-Myc	B-X
.	B-X
Compared	B-X
with	B-X
AML	B-X
cells	B-X
with	B-X
only	B-X
wild-type	B-X
RUNX1	B-X
,	B-X
AML	B-X
cells	B-X
expressing	B-X
mtRUNX1	B-X
were	B-X
also	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
protein	B-X
translation	B-X
inhibitor	B-X
homoharringtonine	B-X
(	B-X
omacetaxine	B-X
)	B-X
and	B-X
BCL2	B-X
inhibitor	B-X
venetoclax	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
cotreatment	B-X
with	B-X
omacetaxine	B-X
and	B-X
venetoclax	B-X
or	B-X
BET	B-X
inhibitor	B-X
induced	B-X
synergistic	B-X
in	B-X
vitro	B-X
lethality	B-X
in	B-X
AML	B-X
expressing	B-X
mtRUNX1	B-X
.	B-X
Compared	B-X
with	B-X
each	B-X
agent	B-X
alone	B-X
,	B-X
cotreatment	B-X
with	B-X
omacetaxine	B-X
and	B-X
venetoclax	B-X
or	B-X
BET	B-X
inhibitor	B-X
also	B-X
displayed	B-X
improved	B-X
in	B-X
vivo	B-X
anti-AML	B-X
efficacy	B-X
,	B-X
associated	B-X
with	B-X
improved	B-X
survival	B-X
of	B-X
immune-depleted	B-X
mice	B-X
engrafted	B-X
with	B-X
AML	B-X
cells	B-X
harboring	B-X
mtRUNX1	B-X
.	B-X
These	B-X
findings	B-X
highlight	B-X
superior	B-X
efficacy	B-X
of	B-X
omacetaxine-based	B-X
combination	B-X
therapies	B-X
for	B-X
AML	B-X
harboring	B-X
mtRUNX1	B-X
.	B-X

Similar	O
to	O
this	O
interaction	O
,	O
NFAT	O
may	O
also	O
cooperate	O
with	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
to	O
activate	O
Foxp3	B-Protein
,	O
but	O
further	O
studies	O
are	O
necessary	O
to	O
elaborate	O
on	O
this	O
concept	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
elucidate	O
the	O
role	O
of	O
RUNX	B-Protein
proteins	O
in	O
iT	O
reg	O
cell	O
development	O
and	O
function	O
.	O

The	O
induction	O
of	O
the	O
transcription	O
factors	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
the	O
subsequent	O
up	O
-	O
regulation	O
of	O
Foxp3	B-Protein
play	O
a	O
role	O
in	O
iT	O
reg	O
cell	O
generation	O
and	O
its	O
suppressive	O
capacity	O
.	O

Mice	O
.	O
<EOS>	B-X
The	B-X
problem	B-X
of	B-X
passenger	B-X
genes	B-X
in	B-X
transgenic	B-X
mice	B-X
.	B-X
Studies	B-X
on	B-X
cryopreservation	B-X
of	B-X
embryos	B-X
and	B-X
gametes	B-X
in	B-X
mice	B-X
.	B-X
Mice	B-X
may	B-X
become	B-X
caught	B-X
in	B-X
nesting	B-X
material	B-X
.	B-X
Mice	B-X
cloned	B-X
from	B-X
cultured	B-X
stem	B-X
cells	B-X
.	B-X

CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	O
cre	B-Protein
and	O
Foxp3GFP	B-Protein
mice	O
have	O
previously	O
been	O
described	O
(	O
Bettelli	O
et	O
al	O
.	O
,	O
2006	O
;	O
Naoe	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Cd45	B-Protein
.	I-Protein
1	I-Protein
and	O
Rag2	B-Protein
-	O
/	O
-	O
mice	O
were	O
purchased	O
from	O
Jackson	O
ImmunoResearch	O
Laboratories	O
and	O
Taconic	O
,	O
respectively	O
.	O

For	O
the	O
in	O
vivo	O
Foxp3	B-Protein
conversion	O
assay	O
,	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
Cbfb	B-Protein
CD4	B-Protein
-	O
cre	B-Protein
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3	B-Protein
-	O
IRES	O
-	O
GFP	B-Protein
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	B-Protein
-	O
deficient	O
mice	O
.	O

5	O
x	O
106	O
cells	O
were	O
used	O
per	O
transfer	O
.	O
<EOS>	B-X
Various	B-X
open	B-X
and	B-X
semi-closed	B-X
methods	B-X
are	B-X
used	B-X
for	B-X
red	B-X
cell	B-X
(	B-X
RBC	B-X
)	B-X
depletion	B-X
and	B-X
hematopoietic	B-X
progenitor	B-X
cell	B-X
(	B-X
HPC	B-X
)	B-X
enrichment	B-X
of	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
with	B-X
variable	B-X
efficacy	B-X
.	B-X
A	B-X
simple	B-X
,	B-X
efficient	B-X
,	B-X
and	B-X
safe	B-X
method	B-X
using	B-X
dextran	B-X
110k	B-X
was	B-X
developed	B-X
.	B-X
Tn916	B-X
was	B-X
transferred	B-X
from	B-X
Streptococcus	B-X
faecalis	B-X
DS16C1	B-X
to	B-X
B.	B-X
anthracis	B-X
VNR-1	B-X
by	B-X
conjugation	B-X
in	B-X
a	B-X
standard	B-X
filter	B-X
mating	B-X
procedure	B-X
.	B-X
Tetracycline-resistant	B-X
(	B-X
Tcr	B-X
)	B-X
transconjugants	B-X
were	B-X
obtained	B-X
at	B-X
a	B-X
frequency	B-X
of	B-X
1.6	B-X
X	B-X
10	B-X
(	B-X
-8	B-X
)	B-X
per	B-X
donor	B-X
CFU	B-X
.	B-X
When	B-X
donor	B-X
and	B-X
recipient	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
nafcillin	B-X
before	B-X
conjugation	B-X
,	B-X
the	B-X
frequency	B-X
was	B-X
increased	B-X
nearly	B-X
10-fold	B-X
.	B-X
Nafcillin	B-X
pretreatment	B-X
of	B-X
donor	B-X
and	B-X
recipient	B-X
strains	B-X
was	B-X
used	B-X
in	B-X
all	B-X
subsequent	B-X
conjugation	B-X
experiments	B-X
.	B-X
S.faecalis	B-X
CG110	B-X
,	B-X
containing	B-X
multiple	B-X
chromosomal	B-X
insertions	B-X
of	B-X
Tn916	B-X
,	B-X
transferred	B-X
the	B-X
transposon	B-X
to	B-X
B.	B-X
anthracis	B-X
VNR-1	B-X
at	B-X
a	B-X
frequency	B-X
of	B-X
9.3	B-X
x	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
.	B-X
A	B-X
Tcr	B-X
B.	B-X
anthracis	B-X
transconjugant	B-X
,	B-X
strain	B-X
VNR-1-tet-1	B-X
,	B-X
transferred	B-X
Tn916	B-X
to	B-X
B.	B-X
anthracis	B-X
UM23-1	B-X
and	B-X
Bacillus	B-X
subtilis	B-X
BST1	B-X
at	B-X
frequencies	B-X
of	B-X
2.1	B-X
x	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
and	B-X
5.8	B-X
X	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
transfer	B-X
of	B-X
Tn916	B-X
occurred	B-X
only	B-X
on	B-X
membrane	B-X
filters	B-X
,	B-X
since	B-X
no	B-X
Tcr	B-X
transconjugants	B-X
were	B-X
obtained	B-X
when	B-X
strains	B-X
VNR-1-tet-1	B-X
and	B-X
UM23-1	B-X
were	B-X
mixed	B-X
and	B-X
incubated	B-X
in	B-X
broth	B-X
culture	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
the	B-X
Tn916-associated	B-X
tetM	B-X
gene	B-X
in	B-X
Tcr	B-X
B.	B-X
anthracis	B-X
and	B-X
B.	B-X
subtilis	B-X
transconjugants	B-X
was	B-X
confirmed	B-X
in	B-X
hybridization	B-X
experiments	B-X
by	B-X
using	B-X
a	B-X
5-kilobase-pair	B-X
DNA	B-X
fragment	B-X
containing	B-X
the	B-X
tetM	B-X
gene	B-X
as	B-X
a	B-X
probe	B-X
.	B-X
Of	B-X
3,000	B-X
B.	B-X
anthracis	B-X
UM23-1	B-X
Tcr	B-X
transconjugants	B-X
tested	B-X
,	B-X
21	B-X
were	B-X
phenylalanine	B-X
auxotrophs	B-X
and	B-X
2	B-X
were	B-X
auxotrophic	B-X
for	B-X
phenylalanine	B-X
,	B-X
tyrosine	B-X
,	B-X
and	B-X
tryptophan	B-X
.	B-X

6	O
wk	O
later	O
,	O
TCRbeta	B-Protein
+	O
CD4	B-Protein
+	O
gated	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
were	O
analyzed	O
for	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
expression	O
.	O

All	O
analyses	O
and	O
experiments	O
were	O
performed	O
on	O
animals	O
at	O
6	O
-	O
8	O
wk	O
of	O
age	O
.	O
<EOS>	B-X
At	B-X
an	B-X
age	B-X
of	B-X
14	B-X
wk	B-X
,	B-X
10	B-X
LBW-LBV	B-X
(	B-X
BiW	B-X
:	B-X
1.07	B-X
±	B-X
0.09	B-X
[	B-X
SD	B-X
]	B-X
kg	B-X
;	B-X
EBV	B-X
:	B-X
-2.52	B-X
±	B-X
3.97	B-X
g/d	B-X
,	B-X
compared	B-X
with	B-X
an	B-X
average	B-X
crossbred	B-X
pig	B-X
with	B-X
a	B-X
protein	B-X
deposition	B-X
of	B-X
165	B-X
g/d	B-X
)	B-X
,	B-X
10	B-X
LBW-HBV	B-X
(	B-X
BiW	B-X
:	B-X
1.02	B-X
±	B-X
0.13	B-X
kg	B-X
;	B-X
EBV	B-X
:	B-X
10.47	B-X
±	B-X
4.26	B-X
g/d	B-X
)	B-X
,	B-X
10	B-X
HBW-LBV	B-X
(	B-X
BiW	B-X
:	B-X
1.80	B-X
±	B-X
0.13	B-X
kg	B-X
;	B-X
EBV	B-X
:	B-X
-2.15	B-X
±	B-X
2.28	B-X
g/d	B-X
)	B-X
,	B-X
and	B-X
10	B-X
HBW-HBV	B-X
(	B-X
BiW	B-X
:	B-X
1.80	B-X
±	B-X
0.15	B-X
kg	B-X
;	B-X
EBV	B-X
:	B-X
11.18	B-X
±	B-X
3.68	B-X
g/d	B-X
)	B-X
male	B-X
growing	B-X
pigs	B-X
were	B-X
allotted	B-X
to	B-X
the	B-X
experiment	B-X
.	B-X
The	B-X
pigs	B-X
were	B-X
individually	B-X
housed	B-X
in	B-X
metabolism	B-X
cages	B-X
and	B-X
were	B-X
subjected	B-X
to	B-X
an	B-X
N	B-X
balance	B-X
study	B-X
in	B-X
two	B-X
sequential	B-X
periods	B-X
of	B-X
5	B-X
d	B-X
,	B-X
after	B-X
an	B-X
11-d	B-X
dietary	B-X
adaptation	B-X
period	B-X
.	B-X
Pigs	B-X
were	B-X
fed	B-X
2.8	B-X
times	B-X
the	B-X
energy	B-X
requirements	B-X
for	B-X
maintenance	B-X
.	B-X
Nontargeted	B-X
metabolomics	B-X
analyses	B-X
were	B-X
performed	B-X
in	B-X
urine	B-X
and	B-X
blood	B-X
plasma	B-X
samples	B-X
.	B-X

Animals	O
were	O
housed	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
at	O
the	O
animal	O
facility	O
of	O
the	O
Skirball	O
Institute	O
,	O
and	O
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
approved	O
protocols	O
for	O
the	O
New	O
York	O
University	O
Institutional	O
Animal	O
Care	O
and	O
Usage	O
Committee	O
.	O

Isolation	O
of	O
PBMCs	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
culture	O
conditions	O
.	O
<EOS>	B-X
The	B-X
thymus	B-X
,	B-X
the	B-X
primary	B-X
organ	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
αβ	B-X
T	B-X
cells	B-X
and	B-X
backbone	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
in	B-X
vertebrates	B-X
,	B-X
has	B-X
long	B-X
been	B-X
considered	B-X
as	B-X
the	B-X
only	B-X
source	B-X
of	B-X
αβT	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
thymic	B-X
involution	B-X
begins	B-X
early	B-X
in	B-X
life	B-X
leading	B-X
to	B-X
a	B-X
drastically	B-X
reduced	B-X
output	B-X
of	B-X
naïve	B-X
αβT	B-X
cells	B-X
into	B-X
the	B-X
periphery	B-X
.	B-X
γδ	B-X
T	B-X
cells	B-X
are	B-X
innate	B-X
lymphocytes	B-X
that	B-X
constitute	B-X
the	B-X
main	B-X
T-cell	B-X
subset	B-X
in	B-X
the	B-X
tissues	B-X
.	B-X
We	B-X
recently	B-X
ascribed	B-X
a	B-X
so	B-X
far	B-X
unappreciated	B-X
outstanding	B-X
function	B-X
to	B-X
a	B-X
γδ	B-X
T	B-X
cell	B-X
subset	B-X
by	B-X
showing	B-X
that	B-X
the	B-X
scarce	B-X
entity	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Vδ1	B-X
(	B-X
+	B-X
)	B-X
γδ	B-X
T	B-X
cells	B-X
can	B-X
transdifferentiate	B-X
into	B-X
αβT	B-X
cells	B-X
in	B-X
inflammatory	B-X
conditions	B-X
.	B-X
Vδ1	B-X
cells	B-X
are	B-X
positively	B-X
enriched	B-X
from	B-X
PBMCs	B-X
of	B-X
healthy	B-X
human	B-X
donors	B-X
using	B-X
magnetic	B-X
beads	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
second	B-X
step	B-X
wherein	B-X
we	B-X
target	B-X
the	B-X
scarce	B-X
fraction	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
with	B-X
a	B-X
further	B-X
magnetic	B-X
labeling	B-X
technique	B-X
.	B-X
We	B-X
then	B-X
introduce	B-X
the	B-X
technique	B-X
and	B-X
culture	B-X
condition	B-X
required	B-X
for	B-X
cloning	B-X
and	B-X
efficiently	B-X
expanding	B-X
the	B-X
cells	B-X
and	B-X
for	B-X
identification	B-X
of	B-X
the	B-X
generated	B-X
clones	B-X
by	B-X
FACS	B-X
analysis	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
detailed	B-X
protocol	B-X
for	B-X
the	B-X
purification	B-X
,	B-X
culture	B-X
and	B-X
ex	B-X
vivo	B-X
expansion	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Vδ1	B-X
(	B-X
+	B-X
)	B-X
γδ	B-X
T	B-X
cells	B-X
.	B-X

Human	O
PBMCs	O
were	O
isolated	O
by	O
Ficoll	O
(	O
Biochrom	O
)	O
density	O
gradient	O
centrifugation	O
and	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
then	O
isolated	O
using	O
the	O
Dynal	O
CD4	B-Protein
+	O
Isolation	O
kit	B-Protein
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
purity	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
initially	O
tested	O
by	O
flow	O
cytometry	O
and	O
was	O
>	O
=	O
95	O
%	O
.	O

Cells	O
were	O
stimulated	O
with	O
the	O
following	O
combination	O
of	O
mAbs	O
to	O
T	O
cell	O
surface	O
molecules	O
(	O
Meiler	O
et	O
al	O
.	O
,	O
2008	O
)	O
:	O
anti	O
-	O
CD2	B-Protein
(	O
clone	O
4B2	O
and	O
6G4	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
)	O
,	O
anti	O
-	O
CD3	B-Protein
(	O
clone	O
OKT3	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
)	O
,	O
and	O
anti	O
-	O
CD28	B-Protein
mAb	O
(	O
clone	O
B7G5	O
;	O
0	O
.	O
5	O
microg	O
/	O
ml	O
;	O
all	O
from	O
Sanquin	O
)	O
and	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
(	O
Life	O
Technologies	O
)	O
with	O
the	O
addition	O
of	O
1	O
nmol	O
/	O
liter	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
Roche	O
)	O
.	O

TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
was	O
used	O
at	O
5	O
ng	O
/	O
ml	O
,	O
if	O
not	O
stated	O
otherwise	O
.	O
<EOS>	B-X
Microtubes	B-X
(	B-X
MTs	B-X
)	B-X
,	B-X
cytoplasmic	B-X
extensions	B-X
of	B-X
glioma	B-X
cells	B-X
,	B-X
are	B-X
important	B-X
cell	B-X
communication	B-X
structures	B-X
promoting	B-X
invasion	B-X
and	B-X
treatment	B-X
resistance	B-X
through	B-X
network	B-X
formation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
identify	B-X
potential	B-X
signaling	B-X
pathways	B-X
involved	B-X
in	B-X
MT	B-X
formation	B-X
.	B-X
Epithelial	B-X
plasticity	B-X
responses	B-X
are	B-X
directed	B-X
through	B-X
cooperation	B-X
of	B-X
signaling	B-X
pathways	B-X
,	B-X
with	B-X
TGF-β	B-X
and	B-X
TGF-β-related	B-X
proteins	B-X
playing	B-X
prominent	B-X
instructive	B-X
roles	B-X
.	B-X
Epithelial-mesenchymal	B-X
transitions	B-X
(	B-X
EMTs	B-X
)	B-X
directed	B-X
by	B-X
activin-like	B-X
molecules	B-X
,	B-X
bone	B-X
morphogenetic	B-X
proteins	B-X
,	B-X
or	B-X
TGF-β	B-X
regulate	B-X
metazoan	B-X
development	B-X
and	B-X
wound	B-X
healing	B-X
and	B-X
drive	B-X
fibrosis	B-X
and	B-X
cancer	B-X
progression	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
roles	B-X
of	B-X
TGF-β	B-X
and	B-X
TGF-β-related	B-X
proteins	B-X
,	B-X
and	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
,	B-X
in	B-X
epithelial	B-X
plasticity	B-X
in	B-X
development	B-X
and	B-X
wound	B-X
healing	B-X
,	B-X
fibrosis	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X

A	O
combination	O
of	O
PMA	O
(	O
25	O
ng	O
/	O
ml	O
)	O
and	O
ionomycin	O
(	O
1	O
mg	O
/	O
ml	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
used	O
.	O

Human	O
CD4	B-Protein
+	O
CD127	B-Protein
-	O
CD25high	B-Protein
and	O
CD4	B-Protein
+	O
CD127	B-Protein
+	O
CD25neg	B-Protein
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
using	O
anti	O
-	O
CD127	B-Protein
,	O
anti	O
-	O
CD25	B-Protein
-	O
PC5	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
anti	O
-	O
CD4	B-Protein
-	O
FITC	O
antibodies	O
(	O
Dako	O
)	O
.	O

Mouse	O
naive	O
(	O
CD62Lhi44lo25	B-Protein
-	O
)	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
purified	O
by	O
flow	O
cytometry	O
and	O
activated	O
in	O
vitro	O
with	O
5	O
microg	O
/	O
ml	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
and	O
1	O
microg	O
/	O
ml	O
soluble	O
anti	O
-	O
CD28	B-Protein
antibodies	O
(	O
eBioscience	O
)	O
in	O
RPMI	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
5	O
mM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
antibiotics	O
.	O

Neutralizing	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
mAbs	O
(	O
BD	O
)	O
were	O
used	O
at	O
1	O
microg	O
/	O
ml	O
concentrations	O
when	O
indicated	O
.	O

In	O
vitro	O
T	O
cell	O
differentiation	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
play	B-X
central	B-X
roles	B-X
in	B-X
adaptive	B-X
immunity	B-X
,	B-X
driving	B-X
appropriate	B-X
immune	B-X
responses	B-X
to	B-X
invading	B-X
pathogens	B-X
of	B-X
diverse	B-X
types	B-X
.	B-X
Four	B-X
major	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
subsets	B-X
,	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
Th17	B-X
,	B-X
and	B-X
Treg	B-X
cells	B-X
are	B-X
differentiated	B-X
from	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
upon	B-X
ligation	B-X
of	B-X
their	B-X
T	B-X
cell	B-X
receptors	B-X
with	B-X
antigens	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
cytokines	B-X
they	B-X
receive	B-X
.	B-X
Th1	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
IL-12	B-X
and	B-X
IFN-γ	B-X
,	B-X
mediate	B-X
host	B-X
defense	B-X
against	B-X
intracellular	B-X
pathogens	B-X
by	B-X
exclusively	B-X
expressing	B-X
IFN-γ	B-X
.	B-X
Th2	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
IL4	B-X
,	B-X
secrete	B-X
IL-4	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-13	B-X
,	B-X
and	B-X
protect	B-X
hosts	B-X
from	B-X
helminths	B-X
.	B-X
IL-6	B-X
plus	B-X
TGF-β	B-X
induces	B-X
Th17	B-X
cells	B-X
,	B-X
another	B-X
Th	B-X
subset	B-X
identified	B-X
relatively	B-X
recently	B-X
,	B-X
express	B-X
IL-17	B-X
and	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
eradication	B-X
of	B-X
extracellular	B-X
bacteria	B-X
and	B-X
fungi	B-X
.	B-X
Treg	B-X
cells	B-X
,	B-X
which	B-X
play	B-X
central	B-X
roles	B-X
in	B-X
immune	B-X
suppression	B-X
,	B-X
are	B-X
composed	B-X
of	B-X
either	B-X
thymus-derived	B-X
Treg	B-X
cells	B-X
(	B-X
tTreg	B-X
cells	B-X
)	B-X
,	B-X
which	B-X
are	B-X
directly	B-X
developed	B-X
from	B-X
CD4-single	B-X
positive	B-X
(	B-X
CD4-SP	B-X
)	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
,	B-X
or	B-X
peripherally	B-X
derived	B-X
Treg	B-X
cells	B-X
(	B-X
pTreg	B-X
cells	B-X
)	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
by	B-X
TGF-β	B-X
plus	B-X
IL-2	B-X
from	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
Although	B-X
the	B-X
regulated	B-X
induction	B-X
of	B-X
Th	B-X
cells	B-X
results	B-X
in	B-X
proper	B-X
eradication	B-X
of	B-X
pathogens	B-X
,	B-X
their	B-X
excess	B-X
activation	B-X
results	B-X
in	B-X
various	B-X
immune-associated	B-X
diseases	B-X
.	B-X
For	B-X
example	B-X
,	B-X
aberrant	B-X
activation	B-X
of	B-X
Th1	B-X
and	B-X
Th17	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
autoimmune	B-X
diseases	B-X
,	B-X
excess	B-X
Th2	B-X
activity	B-X
causes	B-X
atopic	B-X
diseases	B-X
,	B-X
and	B-X
impaired	B-X
function	B-X
of	B-X
Treg	B-X
cells	B-X
due	B-X
to	B-X
abrogation	B-X
of	B-X
Foxp3	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
cause	B-X
fatal	B-X
inflammatory	B-X
disorders	B-X
both	B-X
in	B-X
human	B-X
and	B-X
in	B-X
mouse	B-X
.	B-X
The	B-X
methods	B-X
for	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
each	B-X
Th	B-X
subset	B-X
described	B-X
above	B-X
are	B-X
presented	B-X
here	B-X
.	B-X
We	B-X
hope	B-X
these	B-X
methods	B-X
will	B-X
facilitate	B-X
understanding	B-X
of	B-X
differentiation	B-X
and	B-X
function	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
pathogenesis	B-X
of	B-X
various	B-X
inflammatory	B-X
diseases	B-X
.	B-X

CD4	B-Protein
+	O
CD45RA	B-Protein
+	O
magnetically	O
sorted	O
(	O
CD45RO	B-Protein
depletion	O
with	O
AutoMACS	O
;	O
Miltenyi	O
Biotec	O
)	O
cells	O
were	O
stimulated	O
with	O
immobilized	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	B-Protein
(	O
1	O
microg	O
/	O
ml	O
;	O
OKT3	O
;	O
IgG1	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
microg	O
/	O
ml	O
)	O
.	O

For	O
Th1	O
differentiation	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
25	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
Th2	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
25	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
T	O
reg	O
cell	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
5	O
ng	O
/	O
ml	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O

For	O
Th17	O
conditions	O
,	O
cells	O
were	O
stimulated	O
with	O
the	O
following	O
:	O
40	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
20	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
5	O
ng	O
/	O
ml	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
20	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
23	I-Protein
(	O
Alexis	O
Biochemicals	O
Corp	O
.	O
)	O
,	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
and	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
IL	B-Protein
-	I-Protein
12	I-Protein
were	O
used	O
.	O

Proliferating	O
cells	O
were	O
expanded	O
in	O
medium	O
containing	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Despite	B-X
its	B-X
role	B-X
in	B-X
cancer	B-X
surveillance	B-X
,	B-X
adoptive	B-X
immunotherapy	B-X
using	B-X
γδ	B-X
T	B-X
cells	B-X
has	B-X
achieved	B-X
limited	B-X
efficacy	B-X
.	B-X
To	B-X
enhance	B-X
trafficking	B-X
to	B-X
bone	B-X
marrow	B-X
,	B-X
circulating	B-X
Vγ9Vδ2	B-X
T	B-X
cells	B-X
are	B-X
expanded	B-X
in	B-X
serum-free	B-X
medium	B-X
containing	B-X
TGF-β1	B-X
and	B-X
IL-2	B-X
(	B-X
γδ	B-X
[	B-X
T2	B-X
]	B-X
cells	B-X
)	B-X
or	B-X
medium	B-X
containing	B-X
IL-2	B-X
alone	B-X
(	B-X
γδ	B-X
[	B-X
2	B-X
]	B-X
cells	B-X
,	B-X
as	B-X
the	B-X
control	B-X
)	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
yield	B-X
and	B-X
viability	B-X
of	B-X
γδ	B-X
[	B-X
T2	B-X
]	B-X
cells	B-X
are	B-X
also	B-X
increased	B-X
by	B-X
TGF-β1	B-X
,	B-X
when	B-X
compared	B-X
to	B-X
γδ	B-X
[	B-X
2	B-X
]	B-X
controls	B-X
.	B-X
γδ	B-X
[	B-X
T2	B-X
]	B-X
cells	B-X
are	B-X
less	B-X
differentiated	B-X
and	B-X
yet	B-X
display	B-X
increased	B-X
cytolytic	B-X
activity	B-X
,	B-X
cytokine	B-X
release	B-X
,	B-X
and	B-X
antitumor	B-X
activity	B-X
in	B-X
several	B-X
leukemic	B-X
and	B-X
solid	B-X
tumor	B-X
models	B-X
.	B-X

The	O
cytokine	O
profile	O
of	O
these	O
cells	O
demonstrated	O
that	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
is	O
the	O
predominant	O
cytokine	O
in	O
Th1	O
cells	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
in	O
Th2	O
cells	O
,	O
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
Th17	O
cells	O
(	O
Akdis	O
et	O
al	O
.	O
,	O
2000	O
;	O
Burgler	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Immunohistochemistry	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
for	B-X
tissue-based	B-X
diagnostics	B-X
and	B-X
biomarker	B-X
detection	B-X
with	B-X
broad	B-X
worldwide	B-X
adoption	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
in	B-X
many	B-X
veterinary	B-X
laboratories	B-X
for	B-X
diagnostic	B-X
and	B-X
research	B-X
purposes	B-X
.	B-X
Next-Generation	B-X
Pathology	B-X
by	B-X
Multiplexed	B-X
Immunohistochemistry	B-X
.	B-X

Human	O
tonsils	O
were	O
obtained	O
from	O
tonsillectomy	O
samples	O
of	O
hypertrophic	O
and	O
obstructive	O
tonsils	O
without	O
a	O
current	O
infection	O
.	O

Ethical	O
permission	O
was	O
obtained	O
from	O
Cantonal	O
Ethics	O
Commission	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
patients	O
.	O
<EOS>	B-X
It	B-X
is	B-X
a	B-X
complex	B-X
genetic	B-X
condition	B-X
and	B-X
,	B-X
in	B-X
case	B-X
of	B-X
early	B-X
onset	B-X
(	B-X
EO	B-X
)	B-X
,	B-X
the	B-X
patients	B-X
manifest	B-X
a	B-X
more	B-X
severe	B-X
phenotype	B-X
,	B-X
and	B-X
an	B-X
increased	B-X
heritability	B-X
.	B-X

Paraformaldehyde	O
-	O
fixed	O
tonsil	O
cryosections	O
were	O
stained	O
with	O
unconjugated	O
rabbit	O
IgG	O
polyclonal	O
antibody	O
to	O
human	O
RUNX1	B-Protein
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
or	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
RUNX3	B-Protein
(	O
Abcam	O
)	O
.	O

After	O
a	O
washing	O
step	O
,	O
the	O
sections	O
were	O
stained	O
with	O
the	O
corresponding	O
secondary	O
antibodies	O
.	O

RUNX1	B-Protein
-	O
binding	O
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
633	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
and	O
RUNX3	B-Protein
-	O
binding	O
antibodies	O
were	O
detected	O
by	O
using	O
Alexa	O
Fluor	O
532	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG1	O
.	O

Afterward	O
,	O
the	O
sections	O
were	O
washed	O
and	O
in	O
the	O
case	O
of	O
RUNX3	B-Protein
staining	O
a	O
blocking	O
step	O
with	O
an	O
unconjugated	O
mouse	O
IgG1	O
mAb	O
was	O
used	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
stained	O
with	O
Alexa	O
Fluor	O
488	O
-	O
conjugated	O
mouse	O
IgG1	O
mAb	O
to	O
human	O
FOXP3	B-Protein
(	O
eBioscience	O
)	O
or	O
the	O
corresponding	O
isotype	O
control	O
.	O
<EOS>	B-X
We	B-X
undertook	B-X
a	B-X
meta-analysis	B-X
of	B-X
randomized	B-X
controlled	B-X
trials	B-X
to	B-X
investigate	B-X
whether	B-X
probiotic	B-X
use	B-X
during	B-X
pregnancy	B-X
and	B-X
early	B-X
life	B-X
decreases	B-X
the	B-X
incidence	B-X
of	B-X
atopic	B-X
dermatitis	B-X
and	B-X
immunoglobulin	B-X
E	B-X
(	B-X
IgE	B-X
)	B-X
-associated	B-X
atopic	B-X
dermatitis	B-X
in	B-X
infants	B-X
and	B-X
young	B-X
children	B-X
.	B-X
Antibodies	B-X
Against	B-X
SARS-CoV-2	B-X
in	B-X
Human	B-X
Breast	B-X
Milk	B-X
After	B-X
Vaccination	B-X
:	B-X
A	B-X
Systematic	B-X
Review	B-X
and	B-X
Meta-Analysis	B-X
.	B-X
28	B-X
people	B-X
without	B-X
oncological	B-X
diseases	B-X
were	B-X
examinedas	B-X
a	B-X
control	B-X
.	B-X
The	B-X
levels	B-X
of	B-X
FLC	B-X
in	B-X
blood	B-X
serum	B-X
obtained	B-X
by	B-X
immunoturbidimetry	B-X
in	B-X
Bence-Jones	B-X
myeloma	B-X
of	B-X
the	B-X
corresponding	B-X
type	B-X
were	B-X
higher	B-X
than	B-X
the	B-X
reference	B-X
levels	B-X
in	B-X
100	B-X
%	B-X
of	B-X
cases	B-X
.	B-X
The	B-X
median	B-X
level	B-X
of	B-X
κ-FLC	B-X
reached	B-X
4358	B-X
mg/l	B-X
,	B-X
λ-FLC	B-X
-	B-X
2225	B-X
mg/l	B-X
,	B-X
which	B-X
was	B-X
statistically	B-X
significantly	B-X
higher	B-X
than	B-X
the	B-X
control	B-X
levels	B-X
.	B-X
The	B-X
median	B-X
concentrations	B-X
of	B-X
IgG	B-X
,	B-X
IgA	B-X
and	B-X
IgM	B-X
in	B-X
patients	B-X
with	B-X
Bence-Jones	B-X
myeloma	B-X
were	B-X
statistically	B-X
significantly	B-X
lower	B-X
than	B-X
in	B-X
the	B-X
control	B-X
group	B-X
,	B-X
while	B-X
the	B-X
medians	B-X
of	B-X
β2-microglobulin	B-X
and	B-X
C-reactive	B-X
protein	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
the	B-X
control	B-X
.	B-X

Tissue	O
sections	O
were	O
stained	O
with	O
DAPI	O
for	O
the	O
demonstration	O
of	O
nuclei	O
and	O
mounted	O
with	O
Prolong	O
antifade	O
(	O
Invitrogen	O
)	O
.	O

Images	O
were	O
acquired	O
and	O
analyzed	O
using	O
the	O
confocal	O
microscope	O
DMI	O
4000B	O
and	O
the	O
TCS	O
SPE	O
system	O
(	O
both	O
from	O
Leica	O
)	O
.	O

In	O
vitro	O
suppression	O
assays	O
.	O
<EOS>	B-X
The	B-X
in	B-X
vitro	B-X
culture	B-X
system	B-X
outlined	B-X
in	B-X
this	B-X
chapter	B-X
allows	B-X
for	B-X
standardized	B-X
protocols	B-X
to	B-X
examine	B-X
canonical	B-X
and	B-X
adaptive	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
responses	B-X
while	B-X
interacting	B-X
with	B-X
immune	B-X
suppressor	B-X
cells	B-X
such	B-X
as	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
and	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
(	B-X
MDSC	B-X
)	B-X
.	B-X
This	B-X
approach	B-X
can	B-X
further	B-X
be	B-X
utilized	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
immune	B-X
checkpoint	B-X
inhibitors	B-X
in	B-X
vitro	B-X
and	B-X
ex	B-X
vivo	B-X
.	B-X
We	B-X
studied	B-X
in	B-X
vitro	B-X
lymphocyte	B-X
transformation	B-X
in	B-X
response	B-X
to	B-X
spherulin	B-X
,	B-X
as	B-X
extract	B-X
of	B-X
the	B-X
parasitic	B-X
phase	B-X
of	B-X
Coccidioides	B-X
immitis	B-X
,	B-X
and	B-X
the	B-X
nonspecific	B-X
mitogen	B-X
phytohemagglutinin	B-X
in	B-X
patients	B-X
with	B-X
progressive	B-X
disseminated	B-X
coccidioidomycosis	B-X
who	B-X
were	B-X
anergic	B-X
to	B-X
spherulin	B-X
and	B-X
in	B-X
healthy	B-X
skin	B-X
test-positive	B-X
and	B-X
skin	B-X
test-negative	B-X
control	B-X
subjects	B-X
.	B-X
Prolonged	B-X
incubation	B-X
of	B-X
cells	B-X
in	B-X
vitro	B-X
did	B-X
not	B-X
restore	B-X
the	B-X
hyporesponsiveness	B-X
.	B-X

Mouse	O
Foxp3	B-Protein
+	O
CD4	B-Protein
+	O
CD8	B-Protein
-	O
T	O
cells	O
were	O
FACS	O
purified	O
based	O
on	O
GFP	B-Protein
expressed	O
from	O
a	O
Foxp3	B-Protein
-	O
IRES	O
-	O
GFP	B-Protein
knock	O
-	O
in	O
allele	O
(	O
Foxp3GFP	B-Protein
)	O
.	O

Naive	O
(	O
CD62Lhi44lo25	B-Protein
-	O
)	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
effectors	O
)	O
were	O
FACS	O
-	O
purified	O
from	O
Cd45	B-Protein
.	I-Protein
1	I-Protein
mice	O
,	O
then	O
loaded	O
with	O
5	O
microM	O
CFSE	O
(	O
Invitrogen	O
)	O
.	O

Total	O
splenocytes	O
from	O
C57BL	O
/	O
6	O
mice	O
inactivated	O
with	O
50	O
microg	O
/	O
ml	O
mitomycin	O
C	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
45	O
min	O
were	O
used	O
as	O
APCs	O
.	O

A	O
total	O
of	O
4	O
x	O
105	O
CD4	B-Protein
+	O
cells	O
(	O
CFSE	O
-	O
loaded	O
CD25	B-Protein
-	O
plus	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
+	O
)	O
was	O
mixed	O
with	O
105	O
APCs	O
+	O
1	O
microg	O
/	O
ml	O
anti	O
-	O
CD3	B-Protein
mAb	O
per	O
well	O
of	O
a	O
96	O
well	O
round	O
bottom	O
plate	O
.	O

Proliferation	O
of	O
the	O
effector	O
cells	O
was	O
analyzed	O
by	O
CFSE	O
dilution	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
features	B-X
responsible	B-X
for	B-X
the	B-X
increase	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
in	B-X
gastric	B-X
cancer	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
,	B-X
during	B-X
viral	B-X
infection	B-X
,	B-X
ordered	B-X
phenotypic	B-X
and	B-X
functional	B-X
changes	B-X
occur	B-X
in	B-X
human	B-X
antigen-specific	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
analyzed	B-X
whether	B-X
a	B-X
similar	B-X
differentiation	B-X
program	B-X
is	B-X
induced	B-X
after	B-X
alloantigen	B-X
stimulation	B-X
in	B-X
vitro	B-X
.	B-X

Apoptosis	O
of	O
the	O
cells	O
was	O
investigated	O
by	O
annexin	B-Protein
V	I-Protein
staining	O
and	O
flow	O
cytometry	O
.	O
<EOS>	B-X
Cell	B-X
autophagy	B-X
reduces	B-X
the	B-X
sensitivity	B-X
of	B-X
cancer	B-X
cells	B-X
to	B-X
therapeutic	B-X
reagents	B-X
in	B-X
various	B-X
types	B-X
of	B-X
human	B-X
cancer	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
study	B-X
was	B-X
to	B-X
use	B-X
human	B-X
colorectal	B-X
cancer	B-X
HCT116	B-X
cells	B-X
to	B-X
explore	B-X
whether	B-X
inhibition	B-X
of	B-X
autophagy	B-X
by	B-X
3-Methyladenine	B-X
(	B-X
3-MA	B-X
,	B-X
an	B-X
autophagy	B-X
inhibitor	B-X
)	B-X
is	B-X
able	B-X
to	B-X
enhance	B-X
hypoxia-induced	B-X
apoptosis	B-X
in	B-X
vitro	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
LA	B-X
against	B-X
HepG2	B-X
cells	B-X
.	B-X
LA	B-X
anti-tumor	B-X
activity	B-X
was	B-X
assessed	B-X
with	B-X
the	B-X
CCK-8	B-X
,	B-X
Ki-67	B-X
,	B-X
and	B-X
immunofluorescence	B-X
staining	B-X
.	B-X
Cells	B-X
apoptotic	B-X
ratio	B-X
was	B-X
evaluated	B-X
by	B-X
Annexin	B-X
V/PI	B-X
double-staining	B-X
assay	B-X
.	B-X
JC-1	B-X
staining	B-X
was	B-X
carried	B-X
out	B-X
to	B-X
detect	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
(	B-X
ΔΨm	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Western	B-X
blot	B-X
analysis	B-X
was	B-X
used	B-X
to	B-X
analyse	B-X
the	B-X
apoptosis-associated	B-X
proteins	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
LA	B-X
significantly	B-X
suppressed	B-X
the	B-X
viability	B-X
of	B-X
HepG2	B-X
cells	B-X
.	B-X
Flow	B-X
cytometry	B-X
analysis	B-X
showed	B-X
that	B-X
LA	B-X
exhibited	B-X
a	B-X
apoptosis-inducing	B-X
effect	B-X
.	B-X
The	B-X
proteomic	B-X
study	B-X
observed	B-X
the	B-X
presence	B-X
of	B-X
apoptosis-associated	B-X
proteins	B-X
and	B-X
mitochondrial	B-X
dysfunction	B-X
in	B-X
HepG2	B-X
cells	B-X
after	B-X
LA-treatment	B-X
.	B-X

Positive	O
and	O
negative	O
control	O
gates	O
were	O
made	O
according	O
to	O
T	O
cells	O
cultured	O
only	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
without	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
stimulation	O
.	O

Human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
by	O
negative	O
selection	O
by	O
MACS	O
from	O
PBMCs	O
and	O
either	O
transfected	O
with	O
a	O
scrambled	O
siRNA	O
or	O
with	O
a	O
combination	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
.	O

Cells	O
were	O
then	O
cultured	O
under	O
iT	O
reg	O
cell	O
differentiating	O
conditions	O
and	O
mixed	O
with	O
2	O
x	O
105	O
autologous	O
irradiated	O
PBMCs	O
that	O
were	O
used	O
as	O
APCs	O
and	O
autologous	O
CFSE	O
-	O
labeled	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

T	O
reg	O
cell	O
to	O
responder	O
cell	O
ratio	O
was	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O
<EOS>	B-X
Although	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+	B-X
)	B-X
T	B-X
regulatory	B-X
cells	B-X
(	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
)	B-X
are	B-X
a	B-X
potentially	B-X
powerful	B-X
tool	B-X
in	B-X
bone	B-X
marrow	B-X
transplantation	B-X
,	B-X
a	B-X
prerequisite	B-X
for	B-X
clinical	B-X
use	B-X
is	B-X
a	B-X
cell-separation	B-X
strategy	B-X
complying	B-X
with	B-X
good	B-X
manufacturing	B-X
practice	B-X
guidelines	B-X
.	B-X
We	B-X
isolated	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
from	B-X
standard	B-X
leukapheresis	B-X
products	B-X
using	B-X
double-negative	B-X
selection	B-X
(	B-X
anti-CD8	B-X
and	B-X
anti-CD19	B-X
monoclonal	B-X
antibodies	B-X
)	B-X
followed	B-X
by	B-X
positive	B-X
selection	B-X
(	B-X
anti-CD25	B-X
monoclonal	B-X
antibody	B-X
)	B-X
.	B-X
The	B-X
final	B-X
cell	B-X
fraction	B-X
(	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+	B-X
)	B-X
)	B-X
showed	B-X
a	B-X
mean	B-X
purity	B-X
of	B-X
93.6	B-X
%	B-X
+/-	B-X
1.1	B-X
.	B-X
Recovery	B-X
efficiency	B-X
was	B-X
81.52	B-X
%	B-X
+/-	B-X
7.4	B-X
.	B-X
The	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+bright	B-X
)	B-X
cells	B-X
were	B-X
28.4	B-X
%	B-X
+/-	B-X
6.8	B-X
.	B-X
The	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+	B-X
)	B-X
fraction	B-X
contained	B-X
a	B-X
mean	B-X
of	B-X
51.9	B-X
%	B-X
+/-	B-X
15.1	B-X
FoxP3	B-X
cells	B-X
and	B-X
a	B-X
mean	B-X
of	B-X
18.9	B-X
%	B-X
+/-	B-X
11.5	B-X
CD127	B-X
cells	B-X
.	B-X
Increased	B-X
FoxP3	B-X
and	B-X
depleted	B-X
CD127	B-X
mRNAs	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
FoxP3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
were	B-X
in	B-X
line	B-X
with	B-X
flow	B-X
cytometric	B-X
results	B-X
.	B-X
In	B-X
Vbeta	B-X
spectratyping	B-X
the	B-X
complexity	B-X
scores	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
,	B-X
indicating	B-X
that	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
had	B-X
a	B-X
broad	B-X
T	B-X
cell	B-X
receptor	B-X
repertoire	B-X
.	B-X
The	B-X
inhibition	B-X
assay	B-X
showed	B-X
that	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
inhibited	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
(	B-X
mean	B-X
inhibition	B-X
percentages	B-X
:	B-X
72.4	B-X
+/-	B-X
8.9	B-X
[	B-X
ratio	B-X
of	B-X
T	B-X
responder	B-X
(	B-X
T	B-X
(	B-X
resp	B-X
)	B-X
)	B-X
to	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
,	B-X
1:2	B-X
]	B-X
;	B-X
60.8	B-X
%	B-X
+/-	B-X
20.5	B-X
(	B-X
ratio	B-X
of	B-X
T	B-X
(	B-X
resp	B-X
)	B-X
to	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
,	B-X
1:1	B-X
)	B-X
;	B-X
25.6	B-X
+/-	B-X
19.6	B-X
(	B-X
ratio	B-X
of	B-X
T	B-X
(	B-X
resp	B-X
)	B-X
to	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
,	B-X
1:0.1	B-X
)	B-X
)	B-X
.	B-X
Our	B-X
study	B-X
shows	B-X
that	B-X
negative/positive	B-X
T	B-X
(	B-X
reg	B-X
)	B-X
selection	B-X
,	B-X
performed	B-X
using	B-X
the	B-X
CliniMACS	B-X
device	B-X
and	B-X
reagents	B-X
,	B-X
enriches	B-X
significantly	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
FoxP3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
endowed	B-X
with	B-X
immunosuppressive	B-X
capacities	B-X
.	B-X
The	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
FoxP3	B-X
(	B-X
+	B-X
)	B-X
population	B-X
is	B-X
a	B-X
source	B-X
of	B-X
natural	B-X
T	B-X
(	B-X
reg	B-X
)	B-X
cells	B-X
that	B-X
are	B-X
depleted	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD25	B-X
(	B-X
-	B-X
)	B-X
reacting	B-X
clones	B-X
which	B-X
are	B-X
potentially	B-X
responsible	B-X
for	B-X
triggering	B-X
graft-versus-host	B-X
disease	B-X
(	B-X
GvHD	B-X
)	B-X
.	B-X
Cells	B-X
isolated	B-X
by	B-X
means	B-X
of	B-X
this	B-X
approach	B-X
might	B-X
be	B-X
used	B-X
in	B-X
allogeneic	B-X
haematopoietic	B-X
cell	B-X
transplantation	B-X
to	B-X
facilitate	B-X
engraftment	B-X
and	B-X
reduce	B-X
the	B-X
incidence	B-X
and	B-X
severity	B-X
of	B-X
GvHD	B-X
without	B-X
abrogating	B-X
the	B-X
potential	B-X
graft-versus-tumour	B-X
effect	B-X
.	B-X

To	O
check	O
the	O
proliferation	O
of	O
the	O
CD4	B-Protein
+	O
T	O
cells	O
without	O
suppression	O
,	O
no	O
T	O
reg	O
cells	O
were	O
added	O
in	O
a	O
control	O
group	O
.	O

Cells	O
were	O
stimulated	O
with	O
2	O
.	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
CD3	B-Protein
mAb	O
,	O
cultured	O
in	O
a	O
96	O
-	O
well	O
plate	O
and	O
the	O
proliferation	O
of	O
the	O
effector	O
cells	O
was	O
determined	O
by	O
analyzing	O
the	O
CFSE	O
dilution	O
by	O
flow	O
cytometry	O
after	O
5	O
d	O
of	O
culture	O
.	O

Gating	O
on	O
the	O
CD4	B-Protein
+	O
CFSE	O
+	O
T	O
cells	O
enabled	O
the	O
exclusion	O
of	O
APCs	O
and	O
T	O
reg	O
cells	O
.	O

Cloning	O
of	O
the	O
FOXP3	B-Protein
promoter	O
,	O
construction	O
of	O
mutant	O
FOXP3	B-Protein
promoter	O
,	O
and	O
RUNX	B-Protein
expression	O
plasmids	O
.	O

The	O
FOXP3	B-Protein
promoter	O
was	O
cloned	O
into	O
the	O
pGL3	O
basic	O
vector	O
(	O
Promega	O
Biotech	O
)	O
to	O
generate	O
pGL3	O
FOXP3	B-Protein
-	O
511	O
/	O
+	O
176	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
for	O
the	O
three	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
region	O
was	O
introduced	O
using	O
the	O
QuickChange	O
kit	O
(	O
Stratagene	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
confirmed	O
by	O
sequencing	O
the	O
DNA	O
.	O

The	O
following	O
primers	O
and	O
their	O
complementary	O
strands	O
were	O
used	O
:	O
foxp	O
runx	O
-	O
333	O
,	O
forward	O
5	O
'	O
-	O
CACTTTTGTTTTAAAAACTGTCCTTTCTCATGAGCCCTATTATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
333	O
reverse	O
5	O
'	O
-	O
GATAATAGGGCTCATGAGAAAGGACAGTTTTTAAAACAAAAGTG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
forward	O
5	O
'	O
-	O
CCTCTCACCTCTGTCCTGAGGGGAAGAAATC	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
287	O
reverse	O
5	O
'	O
-	O
GATTTCTTCCCCTCAGGACAGAGGTGAGAGG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
forward	O
5	O
'	O
-	O
GCTTCCACACCGTACAGCGTCCTTTTTCTTCTCGGTATAAAAG	O
-	O
3	O
'	O
;	O
foxp	O
runx	O
-	O
53	O
reverse	O
5	O
'	O
-	O
CTTTTATACCGAGAAGAAAAAGGACGCTGTACGGTGTGGAAGC	O
-	O
3	O
'	O
.	O

The	O
human	O
RUNX1	B-Protein
fragment	O
from	O
the	O
Addgene	O
plasmid	O
12504	O
(	O
Biggs	O
et	O
al	O
.	O
,	O
2006	O
)	O
pFlagCMV2	O
-	O
AML1B	O
was	O
sub	O
-	O
cloned	O
in	O
the	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
)	O
.	O

The	O
RUNX3	B-Protein
vector	O
pCMV	O
human	O
RUNX3	B-Protein
,	O
which	O
was	O
a	O
gift	O
from	O
K	O
.	O

Ito	O
(	O
Institute	O
of	O
Molecular	O
and	O
Cell	O
Biology	O
,	O
Proteos	O
,	O
Singapore	O
)	O
was	O
subcloned	O
into	O
pEGFPN1	O
vector	O
(	O
Clontech	O
Laboratories	O
;	O
Yamamura	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Transfections	O
and	O
reporter	O
gene	O
assays	O
.	O
<EOS>	B-X
Because	B-X
transfection	B-X
efficiency	B-X
in	B-X
such	B-X
assays	B-X
can	B-X
be	B-X
low	B-X
,	B-X
promoters	B-X
are	B-X
commonly	B-X
fused	B-X
to	B-X
heterologous	B-X
reporter	B-X
genes	B-X
that	B-X
encode	B-X
enzymes	B-X
that	B-X
can	B-X
be	B-X
quantified	B-X
using	B-X
highly	B-X
sensitive	B-X
assays	B-X
.	B-X
The	B-X
reporter	B-X
protein	B-X
's	B-X
activity	B-X
or	B-X
fluorescence	B-X
within	B-X
a	B-X
transfected	B-X
cell	B-X
population	B-X
is	B-X
approximately	B-X
proportional	B-X
to	B-X
the	B-X
steady-state	B-X
mRNA	B-X
level	B-X
.	B-X
Although	B-X
the	B-X
Escherichia	B-X
coli	B-X
lacZ	B-X
gene	B-X
,	B-X
encoding	B-X
beta-galactosidase	B-X
(	B-X
beta-gal	B-X
)	B-X
,	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
standard	B-X
reporter	B-X
for	B-X
monitoring	B-X
the	B-X
strength	B-X
of	B-X
a	B-X
promoter	B-X
or	B-X
enhancer	B-X
in	B-X
a	B-X
transient	B-X
or	B-X
stable	B-X
transfection	B-X
assay	B-X
,	B-X
it	B-X
is	B-X
predominantly	B-X
used	B-X
as	B-X
an	B-X
internal	B-X
control	B-X
during	B-X
transient	B-X
transfection	B-X
experiments	B-X
.	B-X
When	B-X
used	B-X
in	B-X
this	B-X
manner	B-X
,	B-X
cells	B-X
are	B-X
usually	B-X
transfected	B-X
with	B-X
the	B-X
control	B-X
plasmid	B-X
(	B-X
containing	B-X
a	B-X
ubiquitously	B-X
active	B-X
viral	B-X
promoter	B-X
fused	B-X
to	B-X
the	B-X
E.	B-X
coli	B-X
lacZ	B-X
gene	B-X
)	B-X
and	B-X
an	B-X
experimental	B-X
plasmid	B-X
containing	B-X
another	B-X
reporter	B-X
gene	B-X
(	B-X
e.g.	B-X
,	B-X
luciferase	B-X
or	B-X
chloramphenicol	B-X
acetyltransferase	B-X
[	B-X
CAT	B-X
]	B-X
)	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
promoter	B-X
or	B-X
enhancer	B-X
of	B-X
interest	B-X
.	B-X

T	O
cells	O
were	O
rested	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
overnight	O
.	O

3	O
.	O
5	O
microg	O
of	O
the	O
FOXP3	B-Protein
promoter	O
luciferase	B-Protein
reporter	O
vector	O
or	O
a	O
combination	O
together	O
with	O
the	O
RUNX1	B-Protein
,	O
RUNX3	B-Protein
pEGFPN1	O
vector	O
,	O
and	O
0	O
.	O
5	O
microg	O
phRL	O
-	O
TK	O
were	O
added	O
to	O
3	O
x	O
106	O
CD4	B-Protein
+	O
T	O
cells	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
using	O
the	O
program	O
U	O
-	O
15	O
.	O

After	O
a	O
24	O
-	O
h	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
and	O
stimuli	O
as	O
indicated	O
in	O
the	O
figures	O
,	O
luciferase	B-Protein
activity	O
was	O
measured	O
by	O
the	O
dual	O
luciferase	B-Protein
assay	O
system	O
(	O
Promega	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

PMA	O
/	O
ionomycin	O
was	O
used	O
to	O
stimulate	O
the	O
cells	O
,	O
because	O
the	O
transfection	O
was	O
only	O
transient	O
and	O
the	O
luciferase	B-Protein
assay	O
required	O
a	O
strong	O
and	O
fast	O
stimulation	O
of	O
the	O
cells	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
overexpression	O
of	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
on	O
FOXP3	B-Protein
protein	O
levels	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
preactivated	O
with	O
2	O
microg	O
/	O
ml	O
phytohemagglutinin	B-Protein
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
serum	O
-	O
free	O
AIM	O
-	O
V	O
medium	O
in	O
the	O
presence	O
of	O
1	O
nmol	O
/	O
liter	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
Roche	O
)	O
for	O
12	O
h	O
,	O
and	O
then	O
transfected	O
with	O
the	O
vector	O
pEGFPN1	O
containing	O
the	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
fragment	O
using	O
the	O
Nucleofector	O
system	O
(	O
Amaxa	O
Biosystems	O
)	O
and	O
the	O
program	O
T	O
-	O
23	O
.	O

FOXP3	B-Protein
expression	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
after	O
48	O
h	O
of	O
culture	O
in	O
AIM	O
-	O
V	O
medium	O
containing	O
1	O
nmol	O
/	O
liter	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

RNA	O
interference	O
.	O
<EOS>	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
is	B-X
a	B-X
biological	B-X
process	B-X
by	B-X
which	B-X
double-stranded	B-X
RNA	B-X
(	B-X
dsRNA	B-X
)	B-X
induces	B-X
sequence-specific	B-X
gene	B-X
silencing	B-X
by	B-X
targeting	B-X
mRNA	B-X
for	B-X
degradation	B-X
.	B-X
As	B-X
a	B-X
tool	B-X
for	B-X
knocking	B-X
down	B-X
the	B-X
expression	B-X
of	B-X
individual	B-X
genes	B-X
posttranscriptionally	B-X
,	B-X
RNAi	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
to	B-X
study	B-X
the	B-X
cellular	B-X
function	B-X
of	B-X
genes	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
I	B-X
describe	B-X
procedures	B-X
for	B-X
using	B-X
gene-specific	B-X
,	B-X
synthetic	B-X
,	B-X
short	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
to	B-X
induce	B-X
gene	B-X
silencing	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Potential	B-X
challenges	B-X
and	B-X
problems	B-X
associated	B-X
with	B-X
the	B-X
siRNA	B-X
technology	B-X
are	B-X
also	B-X
discussed	B-X
.	B-X

CD4	B-Protein
+	O
or	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
resuspended	O
in	O
100	O
microl	O
of	O
Nucleofector	O
solution	O
(	O
Lonza	O
)	O
and	O
electroporated	O
with	O
2	O
microM	O
siRNA	O
using	O
the	O
Nucleofector	O
technology	O
program	O
U	O
-	O
14	O
(	O
Lonza	O
)	O
.	O

Five	O
different	O
Silencer	O
or	O
Silencer	O
Select	O
Pre	O
-	O
designed	O
siRNAs	O
for	O
RUNX1	B-Protein
(	O
Applied	O
Biosystems	O
)	O
and	O
three	O
Silencer	O
Pre	O
-	O
designed	O
siRNAs	O
for	O
RUNX3	B-Protein
(	O
Applied	O
Biosystems	O
)	O
were	O
tested	O
,	O
and	O
the	O
best	O
was	O
selected	O
for	O
all	O
further	O
experiments	O
.	O

The	O
Silencer	O
Negative	O
Control	O
#	O
1	O
siRNA	O
(	O
Applied	O
Biosystems	O
)	O
was	O
used	O
for	O
normalization	O
.	O

Cells	O
were	O
then	O
left	O
unstimulated	O
or	O
were	O
stimulated	O
after	O
12	O
h	O
with	O
anti	O
-	O
CD2	B-Protein
,	O
anti	O
-	O
CD3	B-Protein
,	O
and	O
anti	O
-	O
CD28	B-Protein
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
an	B-X
important	B-X
player	B-X
in	B-X
chronic	B-X
inflammation	B-X
associated	B-X
with	B-X
heart	B-X
failure	B-X
and	B-X
tumor-induced	B-X
cachexia	B-X
.	B-X
Fibroblasts	B-X
are	B-X
salient	B-X
mediators	B-X
of	B-X
both	B-X
inflammation	B-X
and	B-X
fibrosis	B-X
.	B-X
Whereas	B-X
the	B-X
general	B-X
outcome	B-X
of	B-X
IL-6	B-X
on	B-X
the	B-X
heart	B-X
's	B-X
function	B-X
and	B-X
muscle	B-X
wasting	B-X
has	B-X
been	B-X
intensively	B-X
studied	B-X
,	B-X
the	B-X
influence	B-X
of	B-X
IL-6	B-X
on	B-X
fibroblasts	B-X
of	B-X
the	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
(	B-X
SM	B-X
)	B-X
has	B-X
not	B-X
been	B-X
analyzed	B-X
so	B-X
far	B-X
.	B-X
We	B-X
illustrate	B-X
that	B-X
SM-derived	B-X
fibroblasts	B-X
exhibit	B-X
higher	B-X
basal	B-X
mRNA	B-X
expression	B-X
of	B-X
α-SMA	B-X
,	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
(	B-X
collagen1a1/3a1/5a1	B-X
)	B-X
,	B-X
and	B-X
chemokines	B-X
(	B-X
CCL2	B-X
,	B-X
CCL7	B-X
,	B-X
and	B-X
CX3CL1	B-X
)	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
left	B-X
ventricle	B-X
(	B-X
LV	B-X
)	B-X
-derived	B-X
fibroblasts	B-X
.	B-X
IL-6	B-X
drives	B-X
the	B-X
transdifferentiation	B-X
of	B-X
fibroblasts	B-X
into	B-X
myofibroblasts	B-X
as	B-X
indicated	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
α-SMA	B-X
expression	B-X
and	B-X
upregulates	B-X
NLRP3	B-X
inflammasome	B-X
activity	B-X
in	B-X
both	B-X
LV-	B-X
and	B-X
SM-derived	B-X
fibroblasts	B-X
.	B-X
IL-6	B-X
increases	B-X
the	B-X
release	B-X
of	B-X
CCL7	B-X
to	B-X
CX3CL1	B-X
in	B-X
the	B-X
supernatant	B-X
of	B-X
SM-derived	B-X
fibroblasts	B-X
associated	B-X
with	B-X
the	B-X
attraction	B-X
of	B-X
more	B-X
pro	B-X
(	B-X
Ly6C	B-X

Cells	O
were	O
cultured	O
in	O
serum	O
-	O
free	O
AIM	B-Protein
-	I-Protein
V	I-Protein
medium	O
with	O
the	O
addition	O
of	O
1	O
nmol	O
/	O
l	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
for	O
mRNA	O
detection	O
of	O
the	O
target	O
genes	O
after	O
24	O
h	O
and	O
for	O
protein	O
detection	O
after	O
48	O
h	O
.	O
<EOS>	B-X
Oligonucleotides	B-X
offer	B-X
the	B-X
potential	B-X
to	B-X
manipulate	B-X
gene	B-X
expression	B-X
in	B-X
targeted	B-X
cells	B-X
which	B-X
might	B-X
be	B-X
exploitable	B-X
for	B-X
therapeutic	B-X
benefit	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
combining	B-X
a	B-X
phosphorothioate	B-X
oligonucleotide	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
p53	B-X
,	B-X
which	B-X
transiently	B-X
down-regulates	B-X
p53	B-X
levels	B-X
,	B-X
with	B-X
an	B-X
anthracycline	B-X
,	B-X
Idarubicin	B-X
,	B-X
on	B-X
the	B-X
growth	B-X
of	B-X
wild-type	B-X
p53	B-X
WMN	B-X
gene-expressing	B-X
lymphoma	B-X
cells	B-X
was	B-X
evaluated	B-X
.	B-X
Fluorescent	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
p53	B-X
,	B-X
was	B-X
used	B-X
to	B-X
demonstrate	B-X
oligonucleotide	B-X
uptake	B-X
and	B-X
retention	B-X
by	B-X
the	B-X
WMN	B-X
cells	B-X
.	B-X
Uptake	B-X
was	B-X
maximal	B-X
at	B-X
24	B-X
hours	B-X
and	B-X
compared	B-X
to	B-X
baseline	B-X
(	B-X
0	B-X
hours	B-X
)	B-X
increasing	B-X
apoptotic	B-X
cells	B-X
were	B-X
evident	B-X
in	B-X
WMN	B-X
cells	B-X
treated	B-X
with	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
alone	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
Idarubicin	B-X
(	B-X
0.2	B-X
nM	B-X
)	B-X
for	B-X
24	B-X
to	B-X
48	B-X
hours	B-X
.	B-X
In	B-X
cells	B-X
treated	B-X
with	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
p53	B-X
and	B-X
Idarubicin	B-X
,	B-X
truncated	B-X
p53	B-X
message	B-X
of	B-X
a	B-X
predicted	B-X
201	B-X
base	B-X
pair	B-X
length	B-X
based	B-X
on	B-X
RNAase	B-X
H	B-X
cleavage	B-X
of	B-X
the	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
p53-p53	B-X
mRNA	B-X
heteroduplex	B-X
was	B-X
detected	B-X
after	B-X
7	B-X
hours	B-X
of	B-X
incubation	B-X
.	B-X
The	B-X
message	B-X
for	B-X
p53	B-X
was	B-X
transiently	B-X
downregulated	B-X
as	B-X
detected	B-X
by	B-X
RT-PCR	B-X
analysis	B-X
at	B-X
24	B-X
hours	B-X
,	B-X
and	B-X
protein	B-X
levels	B-X
transiently	B-X
reduced	B-X
at	B-X
36	B-X
hours	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
quantitative	B-X
Western	B-X
blot	B-X
.	B-X
Corresponding	B-X
to	B-X
these	B-X
events	B-X
,	B-X
the	B-X
growth	B-X
of	B-X
WMN	B-X
cells	B-X
ceased	B-X
after	B-X
48	B-X
hours	B-X
in	B-X
the	B-X
concurrent	B-X
presence	B-X
of	B-X
OL	B-X
(	B-X
1	B-X
)	B-X
p53	B-X
and	B-X
Idarubicin	B-X
and	B-X
,	B-X
the	B-X
lymphoma	B-X
cells	B-X
were	B-X
dead	B-X
after	B-X
72	B-X
hours	B-X
.	B-X
No	B-X
reduction	B-X
in	B-X
hematopoietic	B-X
colony	B-X
forming	B-X
cell	B-X
capacity	B-X
of	B-X
similarly	B-X
treated	B-X
hematopoietic	B-X
progenitor	B-X
cells	B-X
harvested	B-X
from	B-X
cytokine-mobilized	B-X
blood	B-X
by	B-X
apheresis	B-X
was	B-X
observed	B-X
.	B-X
Therefore	B-X
,	B-X
synergistic	B-X
cytotoxicity	B-X
of	B-X
Idarubicin	B-X
for	B-X
lymphoma	B-X
cells	B-X
treated	B-X
with	B-X
an	B-X
oligonucleotide	B-X
targeting	B-X
p53	B-X
message	B-X
was	B-X
demonstrated	B-X
at	B-X
oligonucleotide	B-X
and	B-X
Idarubicin	B-X
concentrations	B-X
which	B-X
were	B-X
minimally	B-X
toxic	B-X
to	B-X
hematopoietic	B-X
progenitor	B-X
cells	B-X
.	B-X
This	B-X
approach	B-X
offers	B-X
new	B-X
opportunities	B-X
for	B-X
purging	B-X
of	B-X
lymphoma	B-X
cells	B-X
from	B-X
hematopoietic	B-X
harvests	B-X
and	B-X
systemic	B-X
lymphoma	B-X
therapy	B-X
.	B-X

RNA	O
isolation	O
and	O
cDNA	O
synthesis	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
scalable	B-X
method	B-X
for	B-X
measuring	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
following	B-X
RNAi	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
outlines	B-X
methods	B-X
to	B-X
transfect	B-X
cells	B-X
,	B-X
isolate	B-X
total	B-X
RNA	B-X
,	B-X
perform	B-X
cDNA	B-X
synthesis	B-X
,	B-X
run	B-X
qPCR	B-X
reactions	B-X
with	B-X
multiplexed	B-X
TaqMan	B-X
dual	B-X
hydrolysis	B-X
probes	B-X
,	B-X
and	B-X
analyze	B-X
the	B-X
results	B-X
from	B-X
qPCR	B-X
using	B-X
relative	B-X
quantification	B-X
(	B-X
Fleige	B-X
et	B-X
al.	B-X
,	B-X
2006	B-X
)	B-X
.	B-X
These	B-X
methods	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
relative	B-X
knockdown	B-X
of	B-X
a	B-X
set	B-X
of	B-X
siRNAs	B-X
against	B-X
a	B-X
target	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
the	B-X
most	B-X
effective	B-X
molecule	B-X
and	B-X
they	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
potency	B-X
of	B-X
a	B-X
siRNA	B-X
or	B-X
group	B-X
of	B-X
siRNAs	B-X
when	B-X
performed	B-X
over	B-X
a	B-X
range	B-X
of	B-X
doses	B-X
.	B-X
When	B-X
screening	B-X
panels	B-X
of	B-X
siRNAs	B-X
targeting	B-X
a	B-X
given	B-X
gene	B-X
,	B-X
knockdown	B-X
can	B-X
be	B-X
assessed	B-X
in	B-X
two	B-X
phases	B-X
.	B-X

RNA	O
was	O
isolated	O
using	O
the	O
RNeasy	O
Mini	O
kit	O
(	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Reverse	O
transcription	O
of	O
human	O
samples	O
was	O
performed	O
with	O
reverse	O
-	O
transcription	O
reagents	O
(	O
Fermentas	O
)	O
with	O
random	O
hexamers	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Real	O
-	O
time	O
PCR	O
.	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
is	B-X
a	B-X
technique	B-X
for	B-X
simultaneous	B-X
amplification	B-X
and	B-X
product	B-X
quantification	B-X
of	B-X
a	B-X
target	B-X
DNA	B-X
as	B-X
the	B-X
process	B-X
takes	B-X
place	B-X
in	B-X
real	B-X
time	B-X
in	B-X
a	B-X
``	B-X
closed-tube	B-X
''	B-X
system	B-X
.	B-X
The	B-X
quantification	B-X
process	B-X
employs	B-X
melting	B-X
curve	B-X
analysis	B-X
and/or	B-X
fluorescent	B-X
detection	B-X
systems	B-X
and	B-X
can	B-X
provide	B-X
amplification	B-X
and	B-X
genotyping	B-X
in	B-X
a	B-X
relatively	B-X
short	B-X
time	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
has	B-X
provided	B-X
the	B-X
necessary	B-X
analytical	B-X
performance	B-X
for	B-X
many	B-X
molecular	B-X
analyses	B-X
.	B-X
PCR-based	B-X
methods	B-X
for	B-X
SNP/mutation	B-X
detection	B-X
are	B-X
broadly	B-X
categorized	B-X
into	B-X
two	B-X
types-	B-X
(	B-X
1	B-X
)	B-X
polymorphic	B-X
or	B-X
mutant	B-X
allele-directed	B-X
specific	B-X
analysis	B-X
using	B-X
primers	B-X
matched	B-X
with	B-X
substituted	B-X
nucleotide	B-X
or	B-X
using	B-X
oligonucleotides	B-X
to	B-X
block	B-X
or	B-X
clamp	B-X
the	B-X
nontargeted	B-X
template	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
melting	B-X
curve	B-X
analysis	B-X
,	B-X
which	B-X
is	B-X
combined	B-X
with	B-X
the	B-X
real-time	B-X
PCR	B-X
techniques	B-X
using	B-X
hydrolysis	B-X
probes	B-X
,	B-X
hybridization	B-X
probes	B-X
,	B-X
or	B-X
double-stranded	B-X
DNA-binding	B-X
fluorescent	B-X
dyes	B-X
.	B-X
These	B-X
advances	B-X
include	B-X
DNA/RNA	B-X
preparation	B-X
and	B-X
subsequent	B-X
amplification	B-X
steps	B-X
,	B-X
and	B-X
miniaturization	B-X
of	B-X
PCR	B-X
instruments	B-X
such	B-X
that	B-X
testing	B-X
may	B-X
be	B-X
performed	B-X
with	B-X
relative	B-X
ease	B-X
in	B-X
clinical	B-X
laboratories	B-X
or	B-X
as	B-X
a	B-X
point-of-care	B-X
test	B-X
in	B-X
clinical	B-X
settings	B-X
.	B-X

PCR	O
primers	O
and	O
probes	O
were	O
designed	O
based	O
on	O
the	O
sequences	O
reported	O
in	O
GenBank	O
with	O
the	O
Primer	O
Express	O
software	O
version	O
1	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
as	O
follows	O
:	O
FOXP3	B-Protein
forward	O
primer	O
,	O
5	O
'	O
-	O
GAAACAGCACATTCCCAGAGTTC	O
-	O
3	O
'	O
;	O
FOXP3	B-Protein
reverse	O
primer	O
,	O
5	O
'	O
-	O
ATGGCCCAGCGGATGAG	O
-	O
3	O
'	O
;	O
EF	B-Protein
-	I-Protein
1a	I-Protein
forward	O
primer	O
,	O
5	O
'	O
-	O
CTGAACCATCCAGGCCAAAT	O
-	O
3	O
'	O
;	O
and	O
EF	B-Protein
-	I-Protein
1a	I-Protein
reverse	O
primer	O
,	O
5	O
'	O
-	O
GCCGTGTGGCAATCCAAT	O
-	O
3	O
'	O
,	O
as	O
previously	O
described	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

GATA3	B-Protein
forward	O
primer	O
,	O
5	O
'	O
-	O
GCGGGCTCTATCACAAAATGA	O
-	O
3	O
'	O
;	O
and	O
GATA3	B-Protein
reverse	O
primer	O
5	O
'	O
-	O
GCTCTCCTGGCTGCAGACAGC	O
-	O
3	O
'	O
(	O
Mantel	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
forward	O
primer	O
,	O
5	O
'	O
-	O
GATGCGCCAGGAAGTTTCAT	O
-	O
3	O
'	O
;	O
T	B-Protein
-	I-Protein
bet	I-Protein
reverse	O
primer	O
,	O
5	O
'	O
-	O
GCACAATCATCTGGGTCACATT	O
-	O
3	O
'	O
;	O
RORC2	B-Protein
forward	O
primer	O
,	O
5	O
'	O
-	O
CAGTCATGAGAACACAAATTGAAGTG	O
-	O
3	O
'	O
;	O
and	O
RORC2	B-Protein
reverse	O
primer	O
5	O
'	O
-	O
CAGGTGATAACCCCGTAGTGGAT	O
-	O
3	O
'	O
.	O

The	O
prepared	O
cDNAs	O
were	O
amplified	O
using	O
SYBR	O
green	O
PCR	O
master	O
mix	O
(	O
Fermentas	O
)	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
manufacturer	O
in	O
an	O
ABI	O
PRISM	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

RUNX1	B-Protein
and	O
RUNX3	B-Protein
mRNA	O
was	O
detected	O
by	O
using	O
TaqMan	O
Gene	O
Expression	O
Assays	O
from	O
Applied	O
Biosystems	O
and	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
using	O
TaqMan	O
master	O
mix	O
using	O
a	O
7000	O
real	O
-	O
time	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
amplification	O
of	O
the	O
housekeeping	O
gene	O
encoding	O
elongation	B-Protein
factor	I-Protein
(	I-Protein
EF	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
or	O
by	O
using	O
the	O
18S	B-Protein
rRNA	I-Protein
Gene	O
Expression	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
was	O
performed	O
to	O
allow	O
normalization	O
between	O
samples	O
.	O

Relative	O
quantification	O
and	O
calculation	O
of	O
the	O
range	O
of	O
confidence	O
was	O
performed	O
using	O
the	O
comparative	O
deltadeltaCT	O
method	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
percentage	O
of	O
FOXP3	B-Protein
mRNA	O
in	O
siRNA	O
-	O
mediated	O
RUNX	B-Protein
knockdown	O
cells	O
was	O
calculated	O
in	O
relation	O
to	O
cells	O
,	O
which	O
were	O
transfected	O
with	O
scrambled	O
control	O
siRNA	O
.	O

Arbitrary	O
units	O
show	O
the	O
2	O
-	O
(	O
deltact	O
)	O
values	O
multiplied	O
by	O
10	O
,	O
000	O
incorporating	O
the	O
ct	O
values	O
of	O
the	O
gene	O
of	O
interest	O
and	O
the	O
housekeeping	O
gene	O
.	O

Flow	O
cytometry	O
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
technology	B-X
that	B-X
provides	B-X
rapid	B-X
multi-parametric	B-X
analysis	B-X
of	B-X
single	B-X
cells	B-X
in	B-X
solution	B-X
.	B-X
Flow	B-X
cytometers	B-X
utilize	B-X
lasers	B-X
as	B-X
light	B-X
sources	B-X
to	B-X
produce	B-X
both	B-X
scattered	B-X
and	B-X
fluorescent	B-X
light	B-X
signals	B-X
that	B-X
are	B-X
read	B-X
by	B-X
detectors	B-X
such	B-X
as	B-X
photodiodes	B-X
or	B-X
photomultiplier	B-X
tubes	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
fluorescent	B-X
reagents	B-X
are	B-X
utilized	B-X
in	B-X
flow	B-X
cytometry	B-X
.	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
that	B-X
has	B-X
applications	B-X
in	B-X
immunology	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
bacteriology	B-X
,	B-X
virology	B-X
,	B-X
cancer	B-X
biology	B-X
,	B-X
and	B-X
infectious	B-X
disease	B-X
monitoring	B-X
.	B-X

For	O
analysis	O
of	O
human	O
FOXP3	B-Protein
expression	O
on	O
the	O
single	O
-	O
cell	O
level	O
,	O
cells	O
were	O
first	O
stained	O
with	O
the	O
monoclonal	O
CD4	B-Protein
mAb	O
(	O
Beckman	O
Coulter	O
)	O
,	O
and	O
after	O
fixation	O
and	O
permeabilization	O
,	O
they	O
were	O
incubated	O
with	O
anti	O
-	O
human	O
Foxp3	B-Protein
-	O
Alexa	O
Fluor	O
488	O
antibody	O
(	O
BioLegend	O
)	O
based	O
on	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
and	O
subjected	O
to	O
FACS	O
(	O
EPICS	O
XL	O
-	O
MCL	O
;	O
Beckman	O
Coulter	O
)	O
.	O

A	O
mouse	O
IgG1	O
antibody	O
(	O
BioLegend	O
)	O
was	O
used	O
as	O
an	O
isotype	O
control	O
.	O

Data	O
were	O
analyzed	O
with	O
the	O
CXP	O
software	O
(	O
Beckman	O
Coulter	O
)	O
.	O

Cells	O
were	O
cultured	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
then	O
left	O
unstimulated	O
or	O
stimulated	O
with	O
anti	O
-	O
CD2	B-Protein
/	O
-	O
CD3	B-Protein
/	O
-	O
CD28	B-Protein
mAb	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
,	B-X
using	B-X
cell	B-X
blot	B-X
analysis	B-X
,	B-X
the	B-X
association	B-X
of	B-X
gingival	B-X
tissue	B-X
mononuclear	B-X
cells	B-X
(	B-X
GTMC	B-X
)	B-X
isolated	B-X
from	B-X
lesions	B-X
displaying	B-X
histories	B-X
of	B-X
early-onset	B-X
periodontitis	B-X
(	B-X
EOP	B-X
;	B-X
typically	B-X
B-lymphocyte	B-X
dominated	B-X
)	B-X
and	B-X
gingivitis	B-X
(	B-X
typically	B-X
T-lymphocyte	B-X
dominated	B-X
)	B-X
with	B-X
the	B-X
B-cell	B-X
stimulating	B-X
cytokine	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
and	B-X
the	B-X
T-cell	B-X
stimulating	B-X
cytokine	B-X
,	B-X
IL-2	B-X
.	B-X
Cells	B-X
were	B-X
separated	B-X
into	B-X
four	B-X
aliquots	B-X
.	B-X
One	B-X
was	B-X
left	B-X
unstimulated	B-X
;	B-X
the	B-X
remainder	B-X
were	B-X
stimulated	B-X
for	B-X
2	B-X
hours	B-X
with	B-X
Porphyromonas	B-X
gingivalis	B-X
outer	B-X
membrane	B-X
protein	B-X
,	B-X
mitogen	B-X
Concanavalin	B-X
A	B-X
,	B-X
or	B-X
common	B-X
antigen	B-X
tetanus	B-X
toxoid	B-X
.	B-X
Cells	B-X
then	B-X
were	B-X
centrifuged	B-X
onto	B-X
transfer	B-X
membranes	B-X
and	B-X
incubated	B-X
in	B-X
RPMI	B-X
1640	B-X
media	B-X
for	B-X
6	B-X
hours	B-X
to	B-X
allow	B-X
absorption	B-X
of	B-X
secreted	B-X
cytokine	B-X
.	B-X
Membranes	B-X
were	B-X
treated	B-X
with	B-X
monoclonal	B-X
anti-IL-2	B-X
or	B-X
anti-IL-4	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
biotin-conjugated	B-X
second	B-X
layer	B-X
,	B-X
streptavidin-alkaline	B-X
phosphatase	B-X
and	B-X
nitro	B-X
blue	B-X
tetrazolium/5-bromo-4-chloro-indolyl-phosphate	B-X
(	B-X
NBT/BCIP	B-X
)	B-X
color	B-X
development	B-X
.	B-X
A	B-X
higher	B-X
percentage	B-X
of	B-X
GTMC	B-X
from	B-X
EOP	B-X
patients	B-X
were	B-X
IL-2+	B-X
when	B-X
stimulated	B-X
with	B-X
P.	B-X
gingivalis	B-X
compared	B-X
with	B-X
GTMC	B-X
from	B-X
GC	B-X
patients	B-X
(	B-X
20	B-X
+/-	B-X
2	B-X
%	B-X
vs.	B-X
12	B-X
+/-	B-X
2	B-X
%	B-X
,	B-X
P	B-X
<	B-X
0.003	B-X
)	B-X
.	B-X
A	B-X
higher	B-X
percentage	B-X
of	B-X
non-stimulated	B-X
GTMC	B-X
from	B-X
EOP	B-X
patients	B-X
produced	B-X
IL-4	B-X
than	B-X
from	B-X
GC	B-X
(	B-X
22	B-X
+/-	B-X
4	B-X
%	B-X
vs.	B-X
6	B-X
+/-	B-X
3	B-X
%	B-X
,	B-X
P	B-X
<	B-X
0.00007	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
when	B-X
stimulated	B-X
with	B-X
P.	B-X
gingivalis	B-X
(	B-X
22	B-X
+/-	B-X
3	B-X
%	B-X
vs.	B-X
13	B-X
+/-	B-X
2	B-X
%	B-X
,	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

Flow	O
cytometry	O
analyses	O
of	O
the	O
mouse	O
cells	O
were	O
performed	O
on	O
an	O
LSRII	O
(	O
BD	O
)	O
and	O
cell	O
sorting	O
was	O
performed	O
on	O
a	O
FACSAria	O
(	O
BD	O
)	O
.	O

All	O
antibodies	O
for	O
these	O
experiments	O
were	O
purchased	O
from	O
eBioscience	O
or	O
BD	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
introduction	B-X
of	B-X
serological	B-X
tests	B-X
for	B-X
determination	B-X
of	B-X
IgM	B-X
and	B-X
IgG	B-X
antibodies	B-X
has	B-X
become	B-X
the	B-X
main	B-X
diagnostic	B-X
tool	B-X
,	B-X
useful	B-X
for	B-X
tracking	B-X
the	B-X
spread	B-X
of	B-X
the	B-X
virus	B-X
and	B-X
for	B-X
consequently	B-X
allowing	B-X
its	B-X
containment	B-X
.	B-X
In	B-X
our	B-X
study	B-X
we	B-X
compared	B-X
point	B-X
of	B-X
care	B-X
test	B-X
(	B-X
POCT	B-X
)	B-X
lateral	B-X
flow	B-X
immunoassay	B-X
(	B-X
FIA	B-X
)	B-X
vs	B-X
automated	B-X
chemiluminescent	B-X
immunoassay	B-X
(	B-X
CLIA	B-X
)	B-X
,	B-X
in	B-X
order	B-X
to	B-X
assess	B-X
their	B-X
specificity	B-X
and	B-X
sensibility	B-X
for	B-X
COVID-19	B-X
antibodies	B-X
detection	B-X
.	B-X
This	B-X
perspective	B-X
certainly	B-X
applies	B-X
to	B-X
the	B-X
teaching	B-X
of	B-X
genetics	B-X
as	B-X
hallmarked	B-X
by	B-X
the	B-X
pea	B-X
experiments	B-X
of	B-X
Mendel	B-X
.	B-X
It	B-X
is	B-X
very	B-X
common	B-X
to	B-X
find	B-X
an	B-X
introduction	B-X
about	B-X
heredity	B-X
in	B-X
genetic	B-X
textbooks	B-X
covering	B-X
Mendel	B-X
without	B-X
mentions	B-X
of	B-X
preceding	B-X
breeding	B-X
experiments	B-X
carried	B-X
out	B-X
in	B-X
his	B-X
alma	B-X
mater	B-X
.	B-X

Western	O
blotting	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
techniques	B-X
in	B-X
molecular	B-X
biology	B-X
and	B-X
proteomics	B-X
.	B-X
Since	B-X
western	B-X
blotting	B-X
is	B-X
a	B-X
multistep	B-X
protocol	B-X
,	B-X
variations	B-X
and	B-X
errors	B-X
can	B-X
occur	B-X
at	B-X
any	B-X
step	B-X
reducing	B-X
the	B-X
reliability	B-X
and	B-X
reproducibility	B-X
of	B-X
this	B-X
technique	B-X
.	B-X
Areas	B-X
covered	B-X
:	B-X
In	B-X
this	B-X
review	B-X
,	B-X
improvements	B-X
in	B-X
different	B-X
areas	B-X
of	B-X
western	B-X
blotting	B-X
,	B-X
including	B-X
protein	B-X
transfer	B-X
and	B-X
antibody	B-X
validation	B-X
,	B-X
are	B-X
summarized	B-X
.	B-X
The	B-X
review	B-X
discusses	B-X
the	B-X
most	B-X
advanced	B-X
western	B-X
blotting	B-X
techniques	B-X
available	B-X
and	B-X
highlights	B-X
the	B-X
relationship	B-X
between	B-X
next	B-X
generation	B-X
western	B-X
blotting	B-X
techniques	B-X
and	B-X
its	B-X
clinical	B-X
relevance	B-X
.	B-X
New	B-X
methods	B-X
such	B-X
as	B-X
single	B-X
cell-resolution	B-X
western	B-X
blot	B-X
,	B-X
capillary	B-X
electrophoresis	B-X
,	B-X
DigiWest	B-X
,	B-X
automated	B-X
microfluid	B-X
western	B-X
blotting	B-X
and	B-X
microchip	B-X
electrophoresis	B-X
have	B-X
all	B-X
been	B-X
developed	B-X
to	B-X
reduce	B-X
potential	B-X
problems	B-X
associated	B-X
with	B-X
the	B-X
western	B-X
blotting	B-X
technique	B-X
.	B-X

For	O
human	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
analysis	O
on	O
the	O
protein	O
level	O
,	O
106	O
cells	O
were	O
lysed	O
and	O
loaded	O
next	O
to	O
a	O
protein	O
-	O
mass	O
ladder	O
(	O
Invitrogen	O
)	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
.	O

Unspecific	O
binding	O
was	O
blocked	O
with	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
,	O
and	O
the	O
membranes	O
were	O
subsequently	O
incubated	O
with	O
a	O
1	O
:	O
1	O
,	O
000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	B-Protein
(	O
ab11903	O
;	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	B-Protein
(	O
H	O
-	O
50	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
in	O
blocking	O
buffer	O
containing	O
3	O
%	O
milk	O
in	O
TBS	O
Tween	O
overnight	O
at	O
4degreesC	O
.	O

The	O
blots	O
were	O
developed	O
using	O
an	O
anti	O
-	O
rabbit	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
visualized	O
with	O
a	O
LAS	O
-	O
1000	O
gel	O
documentation	O
system	O
(	O
Fujifilm	O
)	O
.	O

To	O
confirm	O
sample	O
loading	O
and	O
transfer	O
membranes	O
were	O
incubated	O
in	O
stripping	O
buffer	O
and	O
reblocked	O
for	O
1	O
h	O
and	O
reprobed	O
using	O
anti	O
-	O
GAPDH	B-Protein
(	O
6C5	O
;	O
Ambion	O
)	O
and	O
developed	O
using	O
an	O
anti	O
-	O
mouse	O
IgG	O
HRP	O
-	O
labeled	O
mAb	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Pull	O
-	O
down	O
assay	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
classic	B-X
and	B-X
widely	B-X
used	B-X
methods	B-X
to	B-X
discover	B-X
or	B-X
confirm	B-X
novel	B-X
protein	B-X
interactions	B-X
in	B-X
plant	B-X
cells	B-X
is	B-X
the	B-X
pull-down	B-X
assay	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
practical	B-X
protocol	B-X
of	B-X
the	B-X
tag-based	B-X
pull-down	B-X
assay	B-X
and	B-X
discuss	B-X
solutions	B-X
to	B-X
some	B-X
common	B-X
problems	B-X
associated	B-X
with	B-X
this	B-X
assay	B-X
.	B-X
The	B-X
GST	B-X
pull-down	B-X
assay	B-X
is	B-X
an	B-X
intuitive	B-X
and	B-X
fast	B-X
in	B-X
vitro	B-X
method	B-X
for	B-X
analyzing	B-X
protein-protein	B-X
or	B-X
protein-ligand	B-X
interactions	B-X
and	B-X
is	B-X
comprised	B-X
of	B-X
a	B-X
``	B-X
bait	B-X
''	B-X
which	B-X
is	B-X
a	B-X
GST-fused	B-X
protein	B-X
expressed	B-X
in	B-X
E.	B-X
coli	B-X
host	B-X
or	B-X
a	B-X
baculovirus	B-X
expression	B-X
system	B-X
and	B-X
a	B-X
``	B-X
prey	B-X
''	B-X
which	B-X
comprises	B-X
putative	B-X
binding	B-X
partner	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
or	B-X
other	B-X
ligand	B-X
molecule	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
pull-down	B-X
assay	B-X
is	B-X
an	B-X
in	B-X
vitro	B-X
technique	B-X
used	B-X
to	B-X
detect	B-X
physical	B-X
interactions	B-X
between	B-X
two	B-X
or	B-X
more	B-X
proteins	B-X
and	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
confirming	B-X
a	B-X
predicted	B-X
protein-protein	B-X
interaction	B-X
or	B-X
identifying	B-X
novel	B-X
interacting	B-X
partners	B-X
.	B-X

HEK293T	O
cells	O
were	O
transfected	O
with	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
using	O
the	O
Lipofectamine	O
2000	O
reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Cells	O
were	O
lysed	O
by	O
sonication	O
in	O
HKMG	O
buffer	O
(	O
10	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
9	O
,	O
100	O
mM	O
KCl	O
,	O
5	O
mM	O
MgCl2	O
,	O
10	O
%	O
glycerol	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
%	O
Nonidet	O
P	O
-	O
40	O
)	O
containing	O
a	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
Diagnostics	O
)	O
.	O

The	O
cell	O
lysate	O
was	O
precleared	O
using	O
streptavidin	O
-	O
agarose	O
beads	O
(	O
GE	O
Healthcare	O
)	O
,	O
incubated	O
with	O
biotinylated	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
RUNX	O
binding	O
sites	O
,	O
and	O
polydeoxyinosinicdeoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

A	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
in	O
the	O
assay	O
.	O
<EOS>	B-X
Complementary	B-X
oligodeoxyribonucleotide	B-X
(	B-X
oligo	B-X
)	B-X
primers	B-X
and	B-X
the	B-X
polymerase	B-X
chain	B-X
reaction	B-X
are	B-X
used	B-X
to	B-X
generate	B-X
two	B-X
DNA	B-X
fragments	B-X
having	B-X
overlapping	B-X
ends	B-X
.	B-X
Using	B-X
this	B-X
technique	B-X
of	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
three	B-X
variants	B-X
of	B-X
a	B-X
mouse	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class-I	B-X
gene	B-X
have	B-X
been	B-X
generated	B-X
,	B-X
cloned	B-X
and	B-X
analyzed	B-X
.	B-X
Conjugation	B-X
of	B-X
DNA	B-X
to	B-X
proteins	B-X
is	B-X
increasingly	B-X
used	B-X
in	B-X
academia	B-X
and	B-X
industry	B-X
to	B-X
provide	B-X
proteins	B-X
with	B-X
tags	B-X
for	B-X
identification	B-X
or	B-X
handles	B-X
for	B-X
hybridization	B-X
to	B-X
other	B-X
DNA	B-X
strands	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
a	B-X
number	B-X
of	B-X
chemical	B-X
methods	B-X
that	B-X
target	B-X
conjugation	B-X
to	B-X
specific	B-X
sites	B-X
at	B-X
native	B-X
proteins	B-X
have	B-X
become	B-X
available	B-X
,	B-X
and	B-X
an	B-X
overview	B-X
of	B-X
these	B-X
methods	B-X
is	B-X
provided	B-X
in	B-X
this	B-X
Account	B-X
.	B-X
In	B-X
DPTC	B-X
,	B-X
we	B-X
target	B-X
metal	B-X
binding	B-X
sites	B-X
in	B-X
proteins	B-X
to	B-X
template	B-X
selective	B-X
covalent	B-X
conjugation	B-X
reactions	B-X
.	B-X
By	B-X
chelation	B-X
of	B-X
a	B-X
DNA-metal	B-X
complex	B-X
with	B-X
a	B-X
metal	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
protein	B-X
,	B-X
an	B-X
electrophile	B-X
on	B-X
a	B-X
second	B-X
DNA	B-X
strand	B-X
is	B-X
aligned	B-X
for	B-X
reaction	B-X
with	B-X
a	B-X
lysine	B-X
side	B-X
chain	B-X
on	B-X
the	B-X
protein	B-X
in	B-X
the	B-X
proximity	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
.	B-X
The	B-X
method	B-X
is	B-X
quite	B-X
general	B-X
because	B-X
approximately	B-X
one-third	B-X
of	B-X
all	B-X
wild-type	B-X
proteins	B-X
contain	B-X
metal-binding	B-X
sites	B-X
,	B-X
including	B-X
many	B-X
IgG	B-X
antibodies	B-X
,	B-X
and	B-X
it	B-X
is	B-X
also	B-X
applicable	B-X
to	B-X
His-tagged	B-X
proteins	B-X
.	B-X

DNA	O
-	O
bound	O
proteins	O
were	O
collected	O
with	O
streptavidin	O
-	O
agarose	O
beads	O
,	O
washed	O
with	O
HKMG	O
buffer	O
,	O
and	O
finally	O
resuspended	O
in	O
NuPAGE	O
loading	O
buffer	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
,	O
heated	O
to	O
70degreesC	O
for	O
10	O
min	O
,	O
and	O
separated	O
on	O
a	O
NuPAGE	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
gel	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
.	O

The	O
proteins	O
were	O
electroblotted	O
onto	O
a	O
PVDF	O
membrane	O
(	O
GE	O
Healthcare	O
)	O
and	O
detected	O
using	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
antibodies	O
described	O
in	O
the	O
previous	O
section	O
.	O

Promoter	O
enzyme	O
immuno	O
assay	O
.	O
<EOS>	B-X
Melanoma	B-X
is	B-X
a	B-X
model	B-X
tumor	B-X
in	B-X
immuno-oncology	B-X
.	B-X
The	B-X
inflammatory	B-X
process	B-X
also	B-X
orchestrates	B-X
the	B-X
adaptative	B-X
immunosuppression	B-X
of	B-X
tumor	B-X
cells	B-X
that	B-X
helps	B-X
them	B-X
to	B-X
evade	B-X
immune	B-X
destruction	B-X
.	B-X
CCK8	B-X
assay	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
cell	B-X
viability	B-X
;	B-X
wound-healing	B-X
assay	B-X
and	B-X
transwell	B-X
assay	B-X
were	B-X
used	B-X
to	B-X
measure	B-X
the	B-X
migration	B-X
ability	B-X
of	B-X
ATC	B-X
.	B-X
Converged	B-X
Rab37/IL-6	B-X
trafficking	B-X
and	B-X
STAT3/PD-1	B-X
transcription	B-X
axes	B-X
elicit	B-X
an	B-X
immunosuppressive	B-X
lung	B-X
tumor	B-X
microenvironment	B-X
.	B-X

As	O
performed	O
in	O
the	O
pull	O
-	O
down	O
assay	O
,	O
HEK293T	B-Protein
cells	I-Protein
were	O
transfected	O
with	O
RUNX1	B-Protein
or	O
RUNX3	B-Protein
and	O
subsequently	O
lysed	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
used	B-X
tangential	B-X
flow	B-X
filtration	B-X
(	B-X
TFF	B-X
)	B-X
to	B-X
isolate	B-X
polymeric	B-X
Hp	B-X
from	B-X
plasma	B-X
proteins	B-X
using	B-X
human	B-X
Fraction	B-X
IV	B-X
(	B-X
FIV	B-X
)	B-X
as	B-X
the	B-X
starting	B-X
material	B-X
.	B-X
After	B-X
removal	B-X
of	B-X
insoluble	B-X
material	B-X
from	B-X
a	B-X
suspension	B-X
of	B-X
FIV	B-X
paste	B-X
,	B-X
the	B-X
protein	B-X
mixture	B-X
was	B-X
clarified	B-X
on	B-X
a	B-X
0.2	B-X
μm	B-X
hollow	B-X
fiber	B-X
(	B-X
HF	B-X
)	B-X
TFF	B-X
filter	B-X
.	B-X
Because	B-X
the	B-X
chromophore	B-X
is	B-X
not	B-X
chemically	B-X
bound	B-X
to	B-X
the	B-X
protein	B-X
or	B-X
other	B-X
insoluble	B-X
material	B-X
,	B-X
it	B-X
is	B-X
not	B-X
lost	B-X
when	B-X
the	B-X
insoluble	B-X
substrate	B-X
is	B-X
removed	B-X
by	B-X
centrifugation	B-X
or	B-X
filtration	B-X
after	B-X
the	B-X
reaction	B-X
is	B-X
completed	B-X
.	B-X
The	B-X
temperature	B-X
of	B-X
-196	B-X
°C	B-X
achieved	B-X
with	B-X
the	B-X
use	B-X
of	B-X
LN2	B-X
protects	B-X
the	B-X
biological	B-X
material	B-X
from	B-X
degradation	B-X
by	B-X
proteases	B-X
and	B-X
nucleases	B-X
,	B-X
allowing	B-X
the	B-X
retrieval	B-X
of	B-X
intact	B-X
proteins	B-X
,	B-X
nucleic	B-X
acids	B-X
and	B-X
other	B-X
macromolecules	B-X
.	B-X
This	B-X
popcorn	B-X
is	B-X
then	B-X
pulverized	B-X
under	B-X
LN2	B-X
in	B-X
a	B-X
freezer	B-X
mill	B-X
to	B-X
generate	B-X
a	B-X
frozen	B-X
``	B-X
powdered	B-X
''	B-X
extract	B-X
which	B-X
is	B-X
thawed	B-X
slowly	B-X
and	B-X
clarified	B-X
by	B-X
centrifugation	B-X
to	B-X
remove	B-X
insoluble	B-X
debris	B-X
.	B-X

384	O
-	O
well	O
plates	O
,	O
precoated	O
with	O
streptavidin	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
were	O
washed	O
3	O
times	O
with	O
washing	O
buffer	O
(	O
PBS	O
and	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
.	O

Biotinylated	O
FOXP3	B-Protein
promoter	O
/	O
oligonucleotides	O
probes	O
containing	O
the	O
RUNX	O
binding	O
sites	O
were	O
added	O
(	O
1	O
pmol	O
per	O
well	O
;	O
50	O
fmol	O
/	O
microl	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Either	O
a	O
combination	O
of	O
all	O
three	O
oligonucleotides	O
containing	O
the	O
mutated	O
or	O
the	O
wild	O
-	O
type	O
binding	O
sites	O
was	O
used	O
or	O
single	O
oligonucleotides	O
were	O
used	O
in	O
the	O
assay	O
.	O
<EOS>	B-X
Complementary	B-X
oligodeoxyribonucleotide	B-X
(	B-X
oligo	B-X
)	B-X
primers	B-X
and	B-X
the	B-X
polymerase	B-X
chain	B-X
reaction	B-X
are	B-X
used	B-X
to	B-X
generate	B-X
two	B-X
DNA	B-X
fragments	B-X
having	B-X
overlapping	B-X
ends	B-X
.	B-X
Using	B-X
this	B-X
technique	B-X
of	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
three	B-X
variants	B-X
of	B-X
a	B-X
mouse	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class-I	B-X
gene	B-X
have	B-X
been	B-X
generated	B-X
,	B-X
cloned	B-X
and	B-X
analyzed	B-X
.	B-X
Aptamers	B-X
are	B-X
single	B-X
stranded	B-X
DNA	B-X
or	B-X
RNA	B-X
oligonucleotides	B-X
that	B-X
have	B-X
high	B-X
affinity	B-X
and	B-X
specificity	B-X
towards	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
target	B-X
molecules	B-X
.	B-X
Owing	B-X
to	B-X
these	B-X
indispensable	B-X
advantages	B-X
,	B-X
aptamers	B-X
have	B-X
been	B-X
implemented	B-X
as	B-X
molecular	B-X
recognition	B-X
element	B-X
as	B-X
alternative	B-X
to	B-X
antibodies	B-X
in	B-X
various	B-X
assays	B-X
for	B-X
diagnostics	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
administration	B-X
of	B-X
aptamers	B-X
in	B-X
applications	B-X
involving	B-X
assays	B-X
of	B-X
fluorescence	B-X
,	B-X
electrochemistry	B-X
,	B-X
nano-label	B-X
and	B-X
nano-constructs	B-X
are	B-X
discussed	B-X
.	B-X
Although	B-X
detection	B-X
strategies	B-X
are	B-X
different	B-X
for	B-X
various	B-X
aptamer-based	B-X
assays	B-X
,	B-X
the	B-X
core	B-X
of	B-X
the	B-X
design	B-X
strategies	B-X
is	B-X
similar	B-X
towards	B-X
reporting	B-X
the	B-X
presence	B-X
of	B-X
specific	B-X
target	B-X
binding	B-X
to	B-X
the	B-X
corresponding	B-X
aptamers	B-X
.	B-X
It	B-X
is	B-X
prognosticated	B-X
that	B-X
aptamers	B-X
will	B-X
find	B-X
even	B-X
broader	B-X
applications	B-X
with	B-X
the	B-X
development	B-X
of	B-X
new	B-X
methods	B-X
of	B-X
transducing	B-X
aptamer	B-X
target	B-X
binding	B-X
.	B-X

After	O
3	O
washing	O
steps	O
with	O
washing	O
buffer	O
,	O
the	O
nuclear	O
extract	O
was	O
added	O
(	O
concentration	O
>	O
0	O
.	O
2	O
microg	O
/	O
microl	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

The	O
lysates	O
were	O
incubated	O
with	O
10	O
microg	O
of	O
poly	O
-	O
deoxyinosinic	O
-	O
deoxycytidylic	O
acid	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

The	O
plate	O
was	O
washed	O
with	O
HKMG	O
buffer	O
and	O
incubated	O
with	O
a	O
1	O
:	O
1000	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX1	B-Protein
(	O
ab11903	O
,	O
Abcam	O
)	O
or	O
1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
RUNX3	B-Protein
(	O
H	O
-	O
50	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
at	O
4degreesC	O
for	O
2	O
h	O
.	O

After	O
three	O
washing	O
steps	O
with	O
HKMG	O
buffer	O
,	O
a	O
secondary	O
antibody	O
(	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
,	O
1	O
:	O
3	O
,	O
000	O
in	O
HKMG	O
buffer	O
,	O
Cell	O
Signaling	O
Technology	O
)	O
was	O
added	O
,	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
1	O
h	O
at	O
4degreesC	O
.	O

The	O
wells	O
were	O
washed	O
4	O
times	O
with	O
HKMG	O
buffer	O
before	O
adding	O
the	O
substrate	O
reagent	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

The	O
colorimetric	O
reaction	O
was	O
stopped	O
by	O
adding	O
2	O
M	O
H2SO4	O
.	O

Absorbance	O
at	O
450	O
nm	O
was	O
measured	O
using	O
a	O
microplate	O
reader	O
(	O
Berthold	O
Technologies	O
)	O
.	O

ChIP	O
.	O
<EOS>	B-X
Owing	B-X
to	B-X
its	B-X
digital	B-X
nature	B-X
,	B-X
ChIP-seq	B-X
has	B-X
become	B-X
the	B-X
standard	B-X
method	B-X
for	B-X
genome-wide	B-X
ChIP	B-X
analysis	B-X
.	B-X
The	B-X
densities	B-X
of	B-X
recovered	B-X
ChIP	B-X
sequence	B-X
reads	B-X
along	B-X
the	B-X
genome	B-X
are	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Although	B-X
a	B-X
relatively	B-X
small	B-X
amount	B-X
of	B-X
ChIP	B-X
DNA	B-X
is	B-X
required	B-X
for	B-X
ChIP-seq	B-X
,	B-X
the	B-X
current	B-X
sequencing	B-X
platforms	B-X
still	B-X
require	B-X
amplification	B-X
of	B-X
the	B-X
ChIP	B-X
DNA	B-X
by	B-X
ligation-mediated	B-X
PCR	B-X
(	B-X
LM-PCR	B-X
)	B-X
.	B-X
This	B-X
protocol	B-X
,	B-X
which	B-X
involves	B-X
linker	B-X
ligation	B-X
followed	B-X
by	B-X
size	B-X
selection	B-X
,	B-X
is	B-X
the	B-X
standard	B-X
ChIP-seq	B-X
protocol	B-X
using	B-X
an	B-X
Illumina	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
size-selected	B-X
ChIP	B-X
DNA	B-X
is	B-X
amplified	B-X
by	B-X
LM-PCR	B-X
and	B-X
size-selected	B-X
for	B-X
the	B-X
second	B-X
time	B-X
.	B-X
The	B-X
purified	B-X
ChIP	B-X
DNA	B-X
is	B-X
then	B-X
loaded	B-X
into	B-X
the	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
ChIP	B-X
DNA	B-X
can	B-X
also	B-X
be	B-X
processed	B-X
in	B-X
parallel	B-X
for	B-X
ChIP-chip	B-X
results	B-X
.	B-X

Human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
either	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
only	O
or	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
,	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
for	O
72	O
h	O
,	O
and	O
protein	O
-	O
DNA	O
complexes	O
were	O
fixed	O
by	O
cross	O
-	O
linking	O
with	O
formaldehyde	O
in	O
a	O
final	O
concentration	O
of	O
1	O
.	O
42	O
%	O
for	O
15	O
min	O
.	O
<EOS>	B-X
Costimulation	B-X
pathways	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
regulation	B-X
.	B-X
CD155	B-X
expressed	B-X
on	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
interacts	B-X
with	B-X
TIGIT	B-X
,	B-X
an	B-X
inhibitory	B-X
costimulatory	B-X
molecule	B-X
,	B-X
and	B-X
CD226	B-X
,	B-X
an	B-X
activating	B-X
costimulatory	B-X
molecule	B-X
,	B-X
on	B-X
T	B-X
cells	B-X
.	B-X
TIGIT	B-X
and	B-X
CD226	B-X
are	B-X
expressed	B-X
at	B-X
varying	B-X
levels	B-X
depending	B-X
on	B-X
the	B-X
T	B-X
cell	B-X
subset	B-X
and	B-X
activation	B-X
state	B-X
.	B-X
T	B-X
follicular	B-X
helper	B-X
cells	B-X
in	B-X
germinal	B-X
centers	B-X
(	B-X
GC-Tfh	B-X
)	B-X
in	B-X
human	B-X
tonsils	B-X
express	B-X
high	B-X
TIGIT	B-X
and	B-X
low	B-X
CD226	B-X
.	B-X
However	B-X
,	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
the	B-X
CD155/TIGIT/CD226	B-X
axis	B-X
in	B-X
human	B-X
Tfh	B-X
cell	B-X
biology	B-X
has	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
To	B-X
address	B-X
this	B-X
,	B-X
we	B-X
analyzed	B-X
tonsillar	B-X
CD4	B-X

Formaldehyde	O
was	O
quenched	O
with	O
125	O
mM	O
glycine	O
for	O
5	O
min	O
,	O
and	O
cells	O
were	O
subsequently	O
harvested	O
.	O

The	O
ChIP	O
assay	O
was	O
performed	O
as	O
described	O
in	O
the	O
fast	O
chromatin	O
immunoprecipitation	O
method	O
(	O
Nelson	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Cells	O
were	O
lysed	O
with	O
immunoprecipitation	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
,	O
5	O
mM	O
EDTA	O
,	O
NP	O
-	O
40	O
[	O
0	O
.	O
5	O
%	O
vol	O
/	O
vol	O
]	O
)	O
containing	O
phosphatase	O
(	O
Roche	O
)	O
and	O
protease	O
inhibitors	O
cocktails	O
(	O
Roche	O
)	O
,	O
the	O
nuclear	O
pellet	O
was	O
washed	O
,	O
the	O
chromatin	O
was	O
sheared	O
by	O
sonication	O
and	O
incubated	O
with	O
antibodies	O
for	O
RUNX1	B-Protein
(	O
H	O
-	O
65	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
RUNX3	B-Protein
(	O
H	O
-	O
50	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
CBFbeta	B-Protein
(	O
PEBP2beta	O
;	O
FL	O
-	O
182	O
X	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
and	O
as	O
controls	O
normal	O
rabbit	O
IgG	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
,	O
anti	O
-	O
human	O
RNA	B-Protein
polymerase	I-Protein
II	I-Protein
antibody	O
,	O
and	O
mouse	O
control	O
IgG	O
(	O
both	O
from	O
SA	O
Biosciences	O
)	O
.	O

The	O
cleared	O
chromatin	O
was	O
incubated	O
with	O
protein	B-Protein
A	I-Protein
agarose	O
beads	O
and	O
,	O
after	O
several	O
washing	O
steps	O
,	O
DNA	O
was	O
isolated	O
with	O
10	O
%	O
(	O
wt	O
/	O
vol	O
)	O
Chelex	O
100	O
resin	O
.	O

Samples	O
were	O
treated	O
with	O
proteinase	B-Protein
K	I-Protein
at	O
55degreesC	O
for	O
30	O
min	O
.	O

The	O
proteinase	B-Protein
K	I-Protein
was	O
then	O
inactivated	O
by	O
boiling	O
the	O
samples	O
for	O
10	O
min	O
.	O
<EOS>	B-X
After	B-X
we	B-X
inactivated	B-X
the	B-X
endogenous	B-X
lipoxygenase	B-X
(	B-X
LOX	B-X
)	B-X
activity	B-X
in	B-X
the	B-X
mash	B-X
by	B-X
mashing	B-X
at	B-X
70	B-X
degrees	B-X
C	B-X
for	B-X
30	B-X
min	B-X
,	B-X
further	B-X
incubation	B-X
with	B-X
recombinant	B-X
barley	B-X
LOX-1	B-X
stimulated	B-X
the	B-X
accumulation	B-X
of	B-X
2	B-X
(	B-X
E	B-X
)	B-X
-nonenal	B-X
;	B-X
however	B-X
,	B-X
this	B-X
effect	B-X
was	B-X
significantly	B-X
reduced	B-X
by	B-X
boiling	B-X
the	B-X
mash	B-X
sample	B-X
.	B-X
Malt	B-X
contained	B-X
fatty	B-X
acid	B-X
hydroperoxide	B-X
lyase-like	B-X
activity	B-X
(	B-X
HPL-like	B-X
activity	B-X
)	B-X
that	B-X
transformed	B-X
9-hydroperoxy-10	B-X
(	B-X
E	B-X
)	B-X
,	B-X
12	B-X
(	B-X
Z	B-X
)	B-X
-octadecadienoic	B-X
and	B-X
13-hydroperoxy-9	B-X
(	B-X
Z	B-X
)	B-X
,	B-X
11	B-X
(	B-X
E	B-X
)	B-X
-octadecadienoic	B-X
acid	B-X
into	B-X
2	B-X
(	B-X
E	B-X
)	B-X
-nonenal	B-X
and	B-X
hexanal	B-X
,	B-X
respectively	B-X
.	B-X
Proteinase	B-X
K	B-X
sensitivity	B-X
tests	B-X
showed	B-X
that	B-X
they	B-X
are	B-X
distinct	B-X
factors	B-X
.	B-X
9-HPL-like	B-X
activity	B-X
survived	B-X
through	B-X
the	B-X
mashing	B-X
at	B-X
70	B-X
degrees	B-X
C	B-X
for	B-X
30	B-X
min	B-X
but	B-X
was	B-X
inactivated	B-X
by	B-X
boiling	B-X
,	B-X
suggesting	B-X
it	B-X
will	B-X
be	B-X
the	B-X
heat-stable	B-X
enzymatic	B-X
factor	B-X
found	B-X
in	B-X
the	B-X
model	B-X
mashing	B-X
experiment	B-X
.	B-X

The	O
purified	O
DNA	O
was	O
used	O
in	O
a	O
real	O
-	O
time	O
PCR	O
reaction	O
.	O

Specific	O
primers	O
for	O
the	O
FOXP3	B-Protein
promoter	O
,	O
spanning	O
the	O
region	O
from	O
-	O
87	O
to	O
-	O
3	O
,	O
FOXP3	B-Protein
promoter	O
forward	O
primer	O
5	O
'	O
-	O
AGAGGTCTGCGGCTTCCA	O
-	O
3	O
'	O
,	O
FOXP3	B-Protein
promoter	O
reverse	O
primer	O
5	O
'	O
-	O
GGAAACTGTCACGTATCAAAAACAA	O
-	O
3	O
'	O
,	O
or	O
control	O
GAPDH	B-Protein
primer	O
(	O
SA	O
Biosciences	O
)	O
for	O
the	O
RNA	B-Protein
polymerase	I-Protein
II	I-Protein
were	O
used	O
.	O

A	O
negative	O
control	O
PCR	O
for	O
each	O
immunoprecipitation	O
using	O
IGX1A	O
negative	O
control	O
primer	O
targeting	O
ORF	O
-	O
free	O
intergenic	O
DNA	O
(	O
SA	O
Biosciences	O
)	O
was	O
used	O
.	O

The	O
fold	O
enrichment	O
in	O
site	O
occupancy	O
was	O
calculated	O
incorporating	O
IgG	O
control	O
values	O
and	O
input	O
DNA	O
values	O
using	O
the	O
ChampionChIP	O
qPCR	O
data	O
analysis	O
file	O
(	O
SA	O
Biosciences	O
)	O
.	O

Quantification	O
of	O
cytokine	O
levels	O
.	O
<EOS>	B-X
Quantification	B-X
of	B-X
cytokines	B-X
has	B-X
significant	B-X
value	B-X
in	B-X
both	B-X
clinical	B-X
medicine	B-X
and	B-X
biology	B-X
as	B-X
the	B-X
levels	B-X
provide	B-X
insights	B-X
into	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
aid	B-X
diagnosis	B-X
and	B-X
treatment	B-X
.	B-X
Factors	B-X
affecting	B-X
cytokines	B-X
quantification	B-X
in	B-X
biological	B-X
fluids	B-X
,	B-X
native	B-X
levels	B-X
in	B-X
different	B-X
body	B-X
fluids	B-X
,	B-X
sample	B-X
processing	B-X
and	B-X
storage	B-X
conditions	B-X
,	B-X
sensitivity	B-X
to	B-X
freeze-thaw	B-X
,	B-X
and	B-X
soluble	B-X
cytokine	B-X
receptors	B-X
are	B-X
discussed	B-X
.	B-X
Various	B-X
quantification	B-X
platforms	B-X
for	B-X
high-sensitivity	B-X
and	B-X
reliable	B-X
measurement	B-X
of	B-X
cytokines	B-X
in	B-X
different	B-X
scenarios	B-X
are	B-X
discussed	B-X
,	B-X
and	B-X
commercially	B-X
available	B-X
cytokine	B-X
assays	B-X
are	B-X
compared	B-X
.	B-X
A	B-X
discussion	B-X
of	B-X
challenges	B-X
in	B-X
the	B-X
development	B-X
and	B-X
advancement	B-X
of	B-X
technologies	B-X
for	B-X
cytokine	B-X
quantification	B-X
that	B-X
aim	B-X
to	B-X
achieve	B-X
real-time	B-X
multiplex	B-X
cytokine	B-X
analysis	B-X
for	B-X
point-of-care	B-X
situations	B-X
applicable	B-X
for	B-X
both	B-X
biomedical	B-X
research	B-X
and	B-X
clinical	B-X
practice	B-X
are	B-X
discussed	B-X
.	B-X

IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
secretion	O
was	O
assessed	O
using	O
fluorescent	O
bead	O
-	O
based	O
technology	O
.	O

The	O
Bio	O
-	O
Plex	O
-	O
hu	O
Cytokine	O
Panel	O
,	O
17	O
-	O
Plex	O
Group	O
1	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Fluorescent	O
signals	O
were	O
read	O
and	O
analyzed	O
using	O
the	O
Bio	O
-	O
Plex	O
200	O
System	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Online	O
supplemental	O
material	O
.	O
<EOS>	B-X
Novel	B-X
techniques	B-X
in	B-X
the	B-X
field	B-X
of	B-X
breast	B-X
imaging	B-X
may	B-X
soon	B-X
play	B-X
a	B-X
role	B-X
in	B-X
breast	B-X
cancer	B-X
screening	B-X
:	B-X
digital	B-X
breast	B-X
tomosynthesis	B-X
,	B-X
contrast	B-X
material-enhanced	B-X
spectral	B-X
mammography	B-X
,	B-X
US	B-X
(	B-X
automated	B-X
three-dimensional	B-X
breast	B-X
US	B-X
,	B-X
transmission	B-X
tomography	B-X
,	B-X
elastography	B-X
,	B-X
optoacoustic	B-X
imaging	B-X
)	B-X
,	B-X
MRI	B-X
(	B-X
abbreviated	B-X
and	B-X
ultrafast	B-X
,	B-X
diffusion-weighted	B-X
imaging	B-X
)	B-X
,	B-X
and	B-X
molecular	B-X
breast	B-X
imaging	B-X
.	B-X
To	B-X
view	B-X
the	B-X
original	B-X
version	B-X
of	B-X
this	B-X
poem	B-X
,	B-X
see	B-X
the	B-X
supplemental	B-X
material	B-X
section	B-X
of	B-X
this	B-X
article	B-X
online	B-X
.	B-X
To	B-X
view	B-X
the	B-X
original	B-X
version	B-X
of	B-X
this	B-X
poem	B-X
,	B-X
see	B-X
the	B-X
supplemental	B-X
material	B-X
section	B-X
of	B-X
this	B-X
article	B-X
online	B-X
.	B-X
Without	B-X
utilizing	B-X
radiation	B-X
,	B-X
iodinated	B-X
contrast	B-X
material	B-X
,	B-X
or	B-X
sedation	B-X
and/or	B-X
anesthesia	B-X
,	B-X
US	B-X
provides	B-X
a	B-X
means	B-X
for	B-X
quick	B-X
and	B-X
cost-effective	B-X
acquisition	B-X
of	B-X
information	B-X
,	B-X
including	B-X
the	B-X
location	B-X
,	B-X
size	B-X
,	B-X
shape	B-X
,	B-X
internal	B-X
content	B-X
,	B-X
and	B-X
vascularity	B-X
of	B-X
the	B-X
mass	B-X
.	B-X
Online	B-X
supplemental	B-X
material	B-X
is	B-X
available	B-X
for	B-X
this	B-X
article	B-X
.	B-X

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S1	O
shows	O
the	O
induction	O
of	O
RUNX1	B-Protein
,	O
RUNX3	B-Protein
,	O
and	O
FOXP3	B-Protein
mRNA	O
in	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAb	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
stimulation	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S2	O
shows	O
decreased	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
mRNA	O
and	O
protein	O
expression	O
after	O
siRNA	O
-	O
mediated	O
knockdown	O
and	O
decreased	O
FOXP3	B-Protein
expression	O
in	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
knockdown	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S3	O
shows	O
the	O
quantification	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
levels	O
in	O
control	O
siRNA	O
transfected	O
or	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
transfected	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S4	O
shows	O
the	O
putative	O
RUNX	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
core	O
promoter	O
sequence	O
of	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S5	O
shows	O
the	O
induction	O
of	O
FOXP3	B-Protein
protein	O
after	O
overexpression	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
in	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S6	O
shows	O
that	O
endogenous	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
do	O
not	O
effect	O
Foxp3	B-Protein
expression	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
CbfbF	B-Protein
/	O
F	O
control	O
mice	O
,	O
which	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
mAbs	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
in	O
the	O
absence	O
or	O
presence	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
neutralizing	O
mAbs	O
.	O
<EOS>	B-X
Airway	B-X
allergic	B-X
diseases	B-X
are	B-X
regulated	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-5	B-X
,	B-X
which	B-X
causes	B-X
infiltration	B-X
of	B-X
eosinophils	B-X
into	B-X
the	B-X
bronchial	B-X
epithelium	B-X
,	B-X
and	B-X
by	B-X
IL-4	B-X
which	B-X
increases	B-X
serum	B-X
immunoglobulin	B-X
E	B-X
(	B-X
IgE	B-X
)	B-X
production	B-X
and	B-X
promotes	B-X
CD30	B-X
expression	B-X
on	B-X
Th	B-X
cells	B-X
.	B-X
CD30	B-X
generates	B-X
a	B-X
costimulatory	B-X
signal	B-X
involved	B-X
in	B-X
apoptosis	B-X
or	B-X
cell	B-X
proliferation	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
microenvironment	B-X
.	B-X
Our	B-X
aims	B-X
were	B-X
:	B-X
(	B-X
i	B-X
)	B-X
to	B-X
analyze	B-X
if	B-X
CD4+	B-X
CD30+	B-X
T	B-X
cells	B-X
from	B-X
allergic	B-X
patients	B-X
proliferate	B-X
in	B-X
response	B-X
to	B-X
Dermatophagoides	B-X
pteronyssinus	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
if	B-X
upon	B-X
stimulation	B-X
this	B-X
cell	B-X
population	B-X
produces	B-X
IL-4	B-X
and	B-X
IL-5	B-X
.	B-X
Interleukin-12	B-X
is	B-X
a	B-X
recently	B-X
discovered	B-X
lymphokine	B-X
displaying	B-X
an	B-X
array	B-X
of	B-X
in	B-X
vitro	B-X
activities	B-X
suggesting	B-X
a	B-X
major	B-X
role	B-X
in	B-X
protective	B-X
immunity	B-X
against	B-X
infectious	B-X
agents	B-X
like	B-X
viruses	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
evidence	B-X
that	B-X
IL-12	B-X
may	B-X
also	B-X
be	B-X
implicated	B-X
in	B-X
the	B-X
selection	B-X
of	B-X
the	B-X
immunoglobulin	B-X
isotypes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
picomolar	B-X
concentrations	B-X
of	B-X
rIL-12	B-X
markedly	B-X
inhibit	B-X
the	B-X
synthesis	B-X
of	B-X
IgE	B-X
by	B-X
IL-4-stimulated	B-X
PBMC	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
IgE	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
protein	B-X
and	B-X
at	B-X
the	B-X
mRNA	B-X
levels	B-X
,	B-X
it	B-X
is	B-X
isotype	B-X
specific	B-X
,	B-X
and	B-X
it	B-X
is	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-12	B-X
mAbs	B-X
.	B-X
IL-12	B-X
may	B-X
suppress	B-X
IgE	B-X
synthesis	B-X
by	B-X
:	B-X
(	B-X
a	B-X
)	B-X
inducing	B-X
the	B-X
production	B-X
of	B-X
IFN-gamma	B-X
,	B-X
a	B-X
known	B-X
inhibitor	B-X
of	B-X
IgE	B-X
synthesis	B-X
and	B-X
(	B-X
b	B-X
)	B-X
by	B-X
a	B-X
novel	B-X
mechanism	B-X
which	B-X
is	B-X
IFN-gamma	B-X
independent	B-X
.	B-X
The	B-X
best	B-X
evidence	B-X
for	B-X
this	B-X
is	B-X
from	B-X
studies	B-X
on	B-X
IgE	B-X
synthesis	B-X
by	B-X
IL-4-plus	B-X
hydrocortisone-stimulated	B-X
umbilical	B-X
cord	B-X
blood	B-X
lymphocytes	B-X
,	B-X
which	B-X
do	B-X
not	B-X
produce	B-X
detectable	B-X
amounts	B-X
of	B-X
IFN-gamma	B-X
.	B-X
In	B-X
such	B-X
cultures	B-X
,	B-X
rIL-12	B-X
inhibits	B-X
IgE	B-X
synthesis	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
excess	B-X
of	B-X
neutralizing	B-X
anti-IFN-gamma	B-X
mAb	B-X
.	B-X

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S7	O
shows	O
similar	O
cell	O
death	O
(	O
A	O
)	O
and	O
proliferation	O
(	O
B	O
)	O
of	O
Foxp3	B-Protein
+	O
and	O
Foxp3	B-Protein
-	O
cells	O
in	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	O
cre	B-Protein
and	O
CbfbF	B-Protein
/	O
F	O
control	O
mice	O
cultures	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20090596	O
/	O
DC1	O
.	O

RUNX1	B-Protein
and	O
RUNX3	B-Protein
are	O
involved	O
in	O
the	O
induction	O
of	O
Foxp3	B-Protein
in	O
iT	O
reg	O
cells	O
.	O

(	O
A	O
)	O
RUNX1	B-Protein
,	O
RUNX3	B-Protein
,	O
and	O
FOXP3	B-Protein
mRNA	O
induction	O
in	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
alone	O
or	O
combined	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAb	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
stimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Real	O
-	O
time	O
PCR	O
of	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
48	O
h	O
of	O
culture	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
FOXP3	B-Protein
mRNA	O
induction	O
by	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
mAb	O
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
in	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
is	O
reduced	O
after	O
siRNA	O
-	O
mediated	O
RUNX1	B-Protein
/	O
3	B-Protein
knockdown	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
RNA	O
from	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	B-Protein
and	O
/	O
or	O
RUNX3	B-Protein
siRNA	O
or	O
with	O
a	O
control	O
siRNA	O
and	O
cultured	O
with	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Runt-related	B-X
transcription	B-X
factor	B-X
3	B-X
(	B-X
RUNX3	B-X
)	B-X
exerts	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
associated	B-X
with	B-X
gastric	B-X
and	B-X
other	B-X
cancers	B-X
,	B-X
including	B-X
glioma	B-X
.	B-X
However	B-X
,	B-X
how	B-X
its	B-X
anti-tumor	B-X
mechanism	B-X
in	B-X
functions	B-X
glioma	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
possible	B-X
functions	B-X
of	B-X
Runx1	B-X
and	B-X
Runx3	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
.	B-X
Both	B-X
Runx1	B-X
and	B-X
Runx3	B-X
proteins	B-X
were	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
mouse	B-X
keratinocytes	B-X
.	B-X
Proteins	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
undifferentiated	B-X
keratinocytes	B-X
but	B-X
translocated	B-X
to	B-X
the	B-X
cytoplasm	B-X
of	B-X
differentiated	B-X
cells	B-X
.	B-X
The	B-X
siRNA-mediated	B-X
inhibition	B-X
of	B-X

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
FOXP3	B-Protein
mRNA	O
is	O
down	O
-	O
regulated	O
in	O
iT	O
reg	O
cells	O
after	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
.	O

Real	O
-	O
time	O
PCR	O
for	O
FOXP3	B-Protein
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
,	O
GATA3	B-Protein
,	O
and	O
RORC2	B-Protein
from	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
or	O
with	O
scrambled	O
siRNA	O
(	O
control	O
)	O
and	O
cultured	O
under	O
iT	B-Protein
reg	I-Protein
,	O
Th1	O
,	O
Th2	O
,	O
or	O
Th17	B-Protein
-	O
driving	O
conditions	O
for	O
12	O
d	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
T-cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
making	B-X
them	B-X
an	B-X
attractive	B-X
cellular	B-X
adjuvant	B-X
for	B-X
use	B-X
in	B-X
cancer	B-X
vaccines	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
DC	B-X
is	B-X
crucial	B-X
for	B-X
directing	B-X
T	B-X
cell	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1	B-X
,	B-X
Th2	B-X
or	B-X
Th17	B-X
type	B-X
,	B-X
and	B-X
several	B-X
factors	B-X
determining	B-X
the	B-X
direction	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
polarization	B-X
.	B-X
IL-12	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
not	B-X
only	B-X
by	B-X
augmenting	B-X
the	B-X
cytotoxic	B-X
activity	B-X
of	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
and	B-X
regulating	B-X
IFN-gamma	B-X
production	B-X
,	B-X
but	B-X
also	B-X
by	B-X
the	B-X
capacity	B-X
of	B-X
IL-12	B-X
to	B-X
promote	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
cells	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
M1	B-X
and	B-X
M4	B-X
,	B-X
end	B-X
products	B-X
of	B-X
steroidal	B-X
ginseng	B-X
saponins	B-X
metabolized	B-X
in	B-X
digestive	B-X
tracts	B-X
,	B-X
as	B-X
well	B-X
as	B-X
T-cadinol	B-X
and	B-X
calamenene	B-X
can	B-X
drive	B-X
DC	B-X
maturation	B-X
from	B-X
human	B-X
monocytes	B-X
in	B-X
vitro	B-X
.	B-X
Human	B-X
monocytes	B-X
were	B-X
cultured	B-X
with	B-X
GM-CSF	B-X
and	B-X
IL-4	B-X
for	B-X
6	B-X
days	B-X
under	B-X
standard	B-X
conditions	B-X
,	B-X
followed	B-X
by	B-X
another	B-X
2	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
M1	B-X
,	B-X
M4	B-X
,	B-X
T-cadinol	B-X
or	B-X
calamenene	B-X
.	B-X
Naïve	B-X
T	B-X
cells	B-X
co-cultured	B-X
with	B-X
allogeneic	B-X
M1-primed	B-X
DC	B-X
,	B-X
M4-primed	B-X
DC	B-X
,	B-X
T-cadinol-primed	B-X
DC	B-X
or	B-X
calamenene-primed	B-X
DC	B-X
turned	B-X
into	B-X
typical	B-X
Th1	B-X
cells	B-X
,	B-X
which	B-X
produced	B-X
large	B-X
quantities	B-X
of	B-X
IFN-gamma	B-X
and	B-X
released	B-X
small	B-X
amounts	B-X
of	B-X
IL-4	B-X
depending	B-X
on	B-X
IL-12	B-X
secretion	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
M1	B-X
,	B-X
M4	B-X
,	B-X
T-cadinol	B-X
and	B-X
calamenene	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
good	B-X
factor	B-X
to	B-X
induce	B-X
DC	B-X
maturation	B-X
,	B-X
or	B-X
even	B-X
better	B-X
in	B-X
some	B-X
respect	B-X
,	B-X
for	B-X
the	B-X
use	B-X
in	B-X
clinical	B-X
DC	B-X
therapy	B-X
to	B-X
induce	B-X
strong	B-X
Th1	B-X
type	B-X
immune	B-X
responses	B-X
.	B-X

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
FOXP3	B-Protein
protein	O
induction	O
in	O
iT	O
reg	O
cells	O
is	O
reduced	O
after	O
siRNA	O
-	O
mediated	O
RUNX1	B-Protein
/	O
3	B-Protein
knockdown	O
.	O

Human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
transfected	O
with	O
RUNX1	B-Protein
and	O
/	O
or	O
RUNX3	B-Protein
siRNA	O
or	O
with	O
a	O
control	O
siRNA	O
and	O
stimulated	O
with	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Runt-related	B-X
transcription	B-X
factor	B-X
3	B-X
(	B-X
RUNX3	B-X
)	B-X
exerts	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
associated	B-X
with	B-X
gastric	B-X
and	B-X
other	B-X
cancers	B-X
,	B-X
including	B-X
glioma	B-X
.	B-X
However	B-X
,	B-X
how	B-X
its	B-X
anti-tumor	B-X
mechanism	B-X
in	B-X
functions	B-X
glioma	B-X
is	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
possible	B-X
functions	B-X
of	B-X
Runx1	B-X
and	B-X
Runx3	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
.	B-X
Both	B-X
Runx1	B-X
and	B-X
Runx3	B-X
proteins	B-X
were	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
mouse	B-X
keratinocytes	B-X
.	B-X
Proteins	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
undifferentiated	B-X
keratinocytes	B-X
but	B-X
translocated	B-X
to	B-X
the	B-X
cytoplasm	B-X
of	B-X
differentiated	B-X
cells	B-X
.	B-X
The	B-X
siRNA-mediated	B-X
inhibition	B-X
of	B-X

CD4	B-Protein
and	O
intracellular	O
FOXP3	B-Protein
analysis	O
by	O
flow	O
cytometry	O
after	O
72	O
h	O
.	O
<EOS>	B-X
Several	B-X
distinct	B-X
T	B-X
lymphocyte	B-X
subpopulations	B-X
with	B-X
immunoregulatory	B-X
activity	B-X
have	B-X
been	B-X
described	B-X
in	B-X
a	B-X
number	B-X
of	B-X
mammalian	B-X
species	B-X
.	B-X
This	B-X
study	B-X
performed	B-X
a	B-X
phenotypic	B-X
analysis	B-X
of	B-X
cells	B-X
expressing	B-X
regulatory	B-X
T	B-X
cell	B-X
(	B-X
Treg	B-X
)	B-X
markers	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
a	B-X
cohort	B-X
of	B-X
18	B-X
horses	B-X
aged	B-X
6	B-X
months	B-X
to	B-X
23	B-X
years	B-X
,	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
intracellular	B-X
and	B-X
cell	B-X
surface	B-X
markers	B-X
,	B-X
including	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
,	B-X
CD4	B-X
,	B-X
CD8	B-X
,	B-X
CD25	B-X
,	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNγ	B-X
)	B-X
and	B-X
interleukin	B-X
10	B-X
(	B-X
IL-10	B-X
)	B-X
.	B-X
In	B-X
peripheral	B-X
blood	B-X
,	B-X
a	B-X
mean	B-X
of	B-X
2.2	B-X
±	B-X
0.2	B-X
%	B-X
CD4+	B-X
and	B-X
0.5	B-X
±	B-X
0.1	B-X
%	B-X
CD8+	B-X
lymphocytes	B-X
expressed	B-X
FOXP3	B-X
.	B-X
The	B-X
mean	B-X
percentage	B-X
of	B-X
CD4+FOXP3+	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
significantly	B-X
decreased	B-X
in	B-X
horses	B-X
15	B-X
years	B-X
and	B-X
older	B-X
(	B-X
1.5	B-X
%	B-X
)	B-X
as	B-X
compared	B-X
to	B-X
horses	B-X
6	B-X
years	B-X
and	B-X
younger	B-X
(	B-X
2.7	B-X
%	B-X
)	B-X
,	B-X
but	B-X
did	B-X
not	B-X
differ	B-X
between	B-X
females	B-X
and	B-X
males	B-X
and	B-X
ponies	B-X
and	B-X
horses	B-X
.	B-X
Activation	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
by	B-X
pokeweed	B-X
mitogen	B-X
resulted	B-X
in	B-X
induction	B-X
of	B-X
CD25	B-X
and	B-X
FOXP3	B-X
expression	B-X
by	B-X
CD4+	B-X
cells	B-X
,	B-X
with	B-X
peak	B-X
expression	B-X
noted	B-X
after	B-X
48	B-X
and	B-X
72	B-X
h	B-X
in	B-X
culture	B-X
respectively	B-X
.	B-X
Activated	B-X
CD4+FOXP3+	B-X
cells	B-X
expressed	B-X
IFNγ	B-X
(	B-X
35	B-X
%	B-X
of	B-X
FOXP3+	B-X
cells	B-X
)	B-X
or	B-X
IL-10	B-X
(	B-X
9	B-X
%	B-X
FOXP3+	B-X
cells	B-X
)	B-X
.	B-X
Cell	B-X
sorting	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
FOXP3	B-X
expression	B-X
by	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
dim	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
subpopulations	B-X
.	B-X
Immediately	B-X
following	B-X
sorting	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
CD4+FOXP3+	B-X
cells	B-X
was	B-X
higher	B-X
within	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
population	B-X
(	B-X
22.7-26.3	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
dim	B-X
)	B-X
(	B-X
17	B-X
%	B-X
cells	B-X
)	B-X
but	B-X
was	B-X
similar	B-X
within	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
dim	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
cells	B-X
after	B-X
resting	B-X
in	B-X
IL-2	B-X
(	B-X
9-14	B-X
%	B-X
)	B-X
.	B-X
Fewer	B-X
than	B-X
2	B-X
%	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
population	B-X
expressed	B-X
FOXP3	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
heterogeneity	B-X
in	B-X
equine	B-X
lymphocyte	B-X
subsets	B-X
that	B-X
express	B-X
molecules	B-X
associated	B-X
with	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
CD4+FOXP3+	B-X
cells	B-X
are	B-X
likely	B-X
to	B-X
represent	B-X
natural	B-X
Tregs	B-X
,	B-X
with	B-X
CD4+FOXP3+IL-10+	B-X
cells	B-X
representing	B-X
either	B-X
activated	B-X
natural	B-X
Tregs	B-X
or	B-X
inducible	B-X
Tregs	B-X
,	B-X
and	B-X
CD4+FOXP3+IFNγ+	B-X
cells	B-X
likely	B-X
to	B-X
represent	B-X
activated	B-X
Th1	B-X
cells	B-X
.	B-X

One	O
of	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
main	B-X
theoretical	B-X
reasons	B-X
for	B-X
choosing	B-X
transport	B-X
and	B-X
grip	B-X
as	B-X
building	B-X
blocks	B-X
is	B-X
that	B-X
they	B-X
are	B-X
anatomically	B-X
independent	B-X
:	B-X
one	B-X
can	B-X
determine	B-X
for	B-X
each	B-X
muscle	B-X
,	B-X
joint	B-X
or	B-X
brain	B-X
area	B-X
whether	B-X
it	B-X
belongs	B-X
to	B-X
transport	B-X
or	B-X
grip	B-X
.	B-X
According	B-X
to	B-X
this	B-X
view	B-X
,	B-X
both	B-X
the	B-X
transport	B-X
of	B-X
the	B-X
hand	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
grip	B-X
emerge	B-X
from	B-X
the	B-X
combination	B-X
of	B-X
independent	B-X
digits	B-X
'	B-X
movements	B-X
towards	B-X
the	B-X
objects	B-X
'	B-X
surface	B-X
.	B-X
Different	B-X
synergies	B-X
are	B-X
activated	B-X
independently	B-X
,	B-X
but	B-X
a	B-X
single	B-X
muscle	B-X
can	B-X
be	B-X
part	B-X
of	B-X
several	B-X
synergies	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
we	B-X
will	B-X
present	B-X
three	B-X
types	B-X
of	B-X
experiments	B-X
that	B-X
were	B-X
designed	B-X
to	B-X
test	B-X
to	B-X
what	B-X
extent	B-X
the	B-X
individual	B-X
digits	B-X
'	B-X
movements	B-X
can	B-X
be	B-X
considered	B-X
the	B-X
building	B-X
blocks	B-X
of	B-X
the	B-X
reach-to-grasp	B-X
movement	B-X
.	B-X

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
P	O
<	O
0	O
.	O
01	O
.	O
<EOS>	B-X
The	B-X
NAb	B-X
response	B-X
was	B-X
also	B-X
assessed	B-X
in	B-X
90	B-X
individuals	B-X
who	B-X
had	B-X
received	B-X
the	B-X
complete	B-X
dose	B-X
regimen	B-X
of	B-X
BNT162b2	B-X
.	B-X
The	B-X
effectiveness	B-X
of	B-X
messenger	B-X
RNA	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
delineated	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
about	B-X
dampened	B-X
immune	B-X
responses	B-X
to	B-X
COVID-19	B-X
vaccination	B-X
among	B-X
immunocompromised	B-X
patients	B-X
,	B-X
including	B-X
people	B-X
living	B-X
with	B-X
HIV	B-X
(	B-X
PLWH	B-X
)	B-X
,	B-X
which	B-X
may	B-X
blunt	B-X
the	B-X
vaccine	B-X
's	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
protection	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
qualitative	B-X
SARS-CoV-2	B-X
vaccine	B-X
immunogenicity	B-X
among	B-X
PLWH	B-X
after	B-X
vaccination	B-X
.	B-X

RUNX1	B-Protein
and	O
RUNX3	B-Protein
expression	O
in	O
Foxp3	B-Protein
+	O
T	O
reg	O
cells	O
and	O
in	O
human	O
CD4	B-Protein
+	O
,	O
CD127	B-Protein
-	O
,	O
CD25high	B-Protein
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
P3	B-X
(	B-X
FOXP3	B-X
)	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
inducible	B-X
regulatory	B-X
T	B-X
(	B-X
iT	B-X
reg	B-X
)	B-X
cells	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
Runt-related	B-X
transcription	B-X
factors	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
induction	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
to	B-X
three	B-X
putative	B-X
RUNX	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
FOXP3	B-X
promoter	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
RUNX	B-X
cofactor	B-X
core-binding	B-X
factor-beta	B-X
(	B-X
CBFbeta	B-X
)	B-X
in	B-X
mice	B-X
and	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
suppression	B-X
of	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
reduced	B-X
expression	B-X
of	B-X
Foxp3	B-X
.	B-X
The	B-X
in	B-X
vivo	B-X
conversion	B-X
of	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
into	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
iT	B-X
reg	B-X
cells	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
adoptively	B-X
transferred	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
naive	B-X
T	B-X
cells	B-X
into	B-X
Rag2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Both	B-X
RUNX1	B-X
and	B-X
RUNX3	B-X
siRNA	B-X
silenced	B-X
human	B-X
T	B-X
reg	B-X
cells	B-X
and	B-X
Cbfb	B-X
(	B-X
F/F	B-X
)	B-X
CD4-cre	B-X
mouse	B-X
T	B-X
reg	B-X
cells	B-X
showed	B-X
diminished	B-X
suppressive	B-X
function	B-X
in	B-X
vitro	B-X
.	B-X
Circulating	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
high	B-X
)	B-X
CD127	B-X
(	B-X
-	B-X
)	B-X
T	B-X
reg	B-X
cells	B-X
significantly	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
FOXP3	B-X
,	B-X
and	B-X
TGF-beta	B-X
mRNA	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
-	B-X
)	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
FOXP3	B-X
and	B-X
RUNX3	B-X
were	B-X
colocalized	B-X
in	B-X
human	B-X
tonsil	B-X
T	B-X
reg	B-X
cells	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
Runx	B-X
transcription	B-X
factors	B-X
as	B-X
a	B-X
molecular	B-X
link	B-X
in	B-X
TGF-beta-induced	B-X
Foxp3	B-X
expression	B-X
in	B-X
iT	B-X
reg	B-X
cell	B-X
differentiation	B-X
and	B-X
function	B-X
.	B-X

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
analysis	O
of	O
CD4	B-Protein
+	O
,	O
CD127	B-Protein
-	O
,	O
and	O
CD25high	B-Protein
T	O
reg	O
cells	O
and	O
CD4	B-Protein
+	O
,	O
CD127	B-Protein
+	O
,	O
and	O
CD25neg	B-Protein
T	O
cells	O
isolated	O
from	O
human	O
peripheral	O
blood	O
showed	O
an	O
increased	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
FOXP3	B-Protein
,	O
and	O
RUNX3	B-Protein
mRNA	O
in	O
CD25	B-Protein
+	O
compared	O
with	O
CD25	B-Protein
-	O
cells	O
.	O

Bars	O
show	O
the	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
tonsil	O
sections	O
were	O
analyzed	O
by	O
confocal	O
microscopy	O
.	O

Tissue	O
sections	O
were	O
stained	O
for	O
FOXP3	B-Protein
,	O
RUNX1	B-Protein
,	O
RUNX3	B-Protein
,	O
and	O
DAPI	O
or	O
isotype	O
controls	O
.	O
<EOS>	B-X
Among	B-X
five	B-X
known	B-X
isotypes	B-X
,	B-X
IgM	B-X
and	B-X
IgD	B-X
are	B-X
the	B-X
common	B-X
B	B-X
cell	B-X
antigen	B-X
receptors	B-X
(	B-X
BCRs	B-X
)	B-X
that	B-X
are	B-X
co-expressed	B-X
in	B-X
naïve	B-X
B	B-X
cells	B-X
.	B-X
Despite	B-X
having	B-X
identical	B-X
antigen	B-X
specificity	B-X
and	B-X
being	B-X
associated	B-X
with	B-X
the	B-X
same	B-X
signaling	B-X
heterodimer	B-X
Igα/Igβ	B-X
(	B-X
CD79a/CD79b	B-X
)	B-X
,	B-X
IgM	B-X
and	B-X
IgD-BCR	B-X
isotypes	B-X
functionally	B-X
differ	B-X
from	B-X
each	B-X
other	B-X
in	B-X
the	B-X
manner	B-X
of	B-X
antigen	B-X
binding	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
isolated	B-X
nanoclusters	B-X
and	B-X
in	B-X
their	B-X
interaction	B-X
with	B-X
co-receptors	B-X
such	B-X
as	B-X
CD19	B-X
and	B-X
CXCR4	B-X
on	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
cytoskeleton	B-X
network	B-X
beneath	B-X
the	B-X
membrane	B-X
controls	B-X
the	B-X
BCR	B-X
isotype-specific	B-X
organization	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
co-receptors	B-X
.	B-X
BCR	B-X
triggering	B-X
results	B-X
in	B-X
reorganization	B-X
of	B-X
the	B-X
cytoskeleton	B-X
network	B-X
,	B-X
which	B-X
is	B-X
further	B-X
modulated	B-X
by	B-X
isotype-specific	B-X
signals	B-X
from	B-X
co-receptors	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
functional	B-X
specificity	B-X
and	B-X
nanocluster	B-X
assembly	B-X
of	B-X
BCR	B-X
isotypes	B-X
and	B-X
the	B-X
consequences	B-X
of	B-X
cross-talk	B-X
between	B-X
CXCR4	B-X
and	B-X
IgD-BCR	B-X
.	B-X

HEK	B-Protein
cells	I-Protein
RUNX1	B-Protein
-	O
transfected	O
or	O
not	O
transfected	O
served	O
as	O
additional	O
control	O
for	O
RUNX1	B-Protein
staining	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
both	B-X
upstream	B-X
regions	B-X
function	B-X
as	B-X
promoters	B-X
in	B-X
hematopoietic	B-X
(	B-X
Jurkat	B-X
)	B-X
and	B-X
nonhematopoietic	B-X
(	B-X
HEK	B-X
)	B-X
cell	B-X
lines	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
additional	B-X
control	B-X
elements	B-X
,	B-X
either	B-X
negative	B-X
or	B-X
positive	B-X
,	B-X
regulate	B-X
the	B-X
tissue-specific	B-X
expression	B-X
of	B-X
AML1	B-X
.	B-X

Data	O
shown	O
are	O
representative	O
from	O
one	O
of	O
the	O
three	O
tissue	O
samples	O
with	O
similar	O
results	O
.	O
<EOS>	B-X
We	B-X
report	B-X
on	B-X
the	B-X
analysis	B-X
of	B-X
three	B-X
human	B-X
cranial	B-X
fragments	B-X
from	B-X
a	B-X
Mousterian	B-X
context	B-X
at	B-X
the	B-X
site	B-X
of	B-X
La	B-X
Quina	B-X
(	B-X
France	B-X
)	B-X
,	B-X
which	B-X
show	B-X
anthropogenic	B-X
surface	B-X
modifications	B-X
.	B-X
Macroscopic	B-X
and	B-X
microscopic	B-X
analyses	B-X
,	B-X
including	B-X
SEM	B-X
observation	B-X
,	B-X
demonstrate	B-X
that	B-X
the	B-X
modifications	B-X
visible	B-X
on	B-X
one	B-X
of	B-X
these	B-X
fragments	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
produced	B-X
on	B-X
bone	B-X
fragments	B-X
used	B-X
experimentally	B-X
to	B-X
retouch	B-X
flakes	B-X
.	B-X
The	B-X
traces	B-X
of	B-X
utilisation	B-X
and	B-X
the	B-X
dimensions	B-X
of	B-X
this	B-X
object	B-X
are	B-X
compared	B-X
to	B-X
those	B-X
on	B-X
a	B-X
sample	B-X
of	B-X
67	B-X
bone	B-X
retouchers	B-X
found	B-X
in	B-X
the	B-X
same	B-X
excavation	B-X
area	B-X
and	B-X
layer	B-X
.	B-X
This	B-X
skull	B-X
fragment	B-X
represents	B-X
the	B-X
earliest	B-X
known	B-X
use	B-X
of	B-X
human	B-X
bone	B-X
as	B-X
a	B-X
raw	B-X
material	B-X
and	B-X
the	B-X
first	B-X
reported	B-X
use	B-X
of	B-X
human	B-X
bone	B-X
for	B-X
this	B-X
purpose	B-X
by	B-X
hominins	B-X
other	B-X
than	B-X
modern	B-X
humans	B-X
.	B-X
The	B-X
deliberate	B-X
versus	B-X
unintentional	B-X
hypotheses	B-X
for	B-X
the	B-X
unusual	B-X
choice	B-X
of	B-X
the	B-X
bone	B-X
are	B-X
presented	B-X
in	B-X
light	B-X
of	B-X
contextual	B-X
information	B-X
,	B-X
modifications	B-X
identified	B-X
on	B-X
the	B-X
two	B-X
skull	B-X
fragments	B-X
not	B-X
used	B-X
as	B-X
tools	B-X
,	B-X
and	B-X
data	B-X
on	B-X
bone	B-X
retouchers	B-X
from	B-X
the	B-X
same	B-X
layer	B-X
,	B-X
the	B-X
same	B-X
site	B-X
,	B-X
and	B-X
other	B-X
Mousterian	B-X
sites	B-X
.	B-X

Bars	O
,	O
5	O
microm	O
.	O
<EOS>	B-X
Evaluate	B-X
the	B-X
effect	B-X
of	B-X
smoke-free	B-X
legislation	B-X
on	B-X
fine	B-X
particulate	B-X
[	B-X
particulate	B-X
matter	B-X
<	B-X
2.5	B-X
microm	B-X
in	B-X
diameter	B-X
(	B-X
PM	B-X
(	B-X
2.5	B-X
)	B-X
)	B-X
]	B-X
air	B-X
pollution	B-X
levels	B-X
in	B-X
bars	B-X
in	B-X
Scotland	B-X
,	B-X
England	B-X
,	B-X
and	B-X
Wales	B-X
.	B-X
In	B-X
the	B-X
study	B-X
described	B-X
in	B-X
this	B-X
article	B-X
,	B-X
the	B-X
authors	B-X
'	B-X
objective	B-X
was	B-X
to	B-X
measure	B-X
particles	B-X
<	B-X
or	B-X
=	B-X
2.5	B-X
microm	B-X
in	B-X
aerodynamic	B-X
diameter	B-X
(	B-X
PM2.5	B-X
)	B-X
and	B-X
carbon	B-X
monoxide	B-X
(	B-X
CO	B-X
)	B-X
in	B-X
outdoor	B-X
waiting	B-X
areas	B-X
and	B-X
patios	B-X
of	B-X
restaurants	B-X
and	B-X
bars	B-X
in	B-X
downtown	B-X
Athens	B-X
,	B-X
Georgia	B-X
,	B-X
where	B-X
indoor	B-X
smoking	B-X
is	B-X
banned	B-X
.	B-X
Real-time	B-X
PM2.5	B-X
and	B-X
CO	B-X
were	B-X
monitored	B-X
on	B-X
four	B-X
summer	B-X
weekend	B-X
afternoons/evenings	B-X
in	B-X
outdoor	B-X
waiting	B-X
areas	B-X
or	B-X
patios	B-X
at	B-X
five	B-X
locations	B-X
in	B-X
Athens	B-X
.	B-X
PM2.5	B-X
levels	B-X
were	B-X
significantly	B-X
higher	B-X
than	B-X
levels	B-X
at	B-X
the	B-X
control	B-X
location	B-X
(	B-X
all	B-X
p-values	B-X
>	B-X
.001	B-X
)	B-X
.	B-X
The	B-X
results	B-X
of	B-X
the	B-X
authors	B-X
'	B-X
study	B-X
indicate	B-X
that	B-X
(	B-X
1	B-X
)	B-X
secondhand	B-X
smoke	B-X
(	B-X
SHS	B-X
)	B-X
leads	B-X
to	B-X
significant	B-X
increases	B-X
in	B-X
PM2.5	B-X
outside	B-X
of	B-X
restaurants	B-X
and	B-X
bars	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
although	B-X
CO	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
proxy	B-X
for	B-X
SHS	B-X
in	B-X
these	B-X
outdoor	B-X
environments	B-X
,	B-X
its	B-X
levels	B-X
remain	B-X
relatively	B-X
low	B-X
.	B-X

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
P	O
<	O
0	O
.	O
01	O
.	O
<EOS>	B-X
The	B-X
NAb	B-X
response	B-X
was	B-X
also	B-X
assessed	B-X
in	B-X
90	B-X
individuals	B-X
who	B-X
had	B-X
received	B-X
the	B-X
complete	B-X
dose	B-X
regimen	B-X
of	B-X
BNT162b2	B-X
.	B-X
The	B-X
effectiveness	B-X
of	B-X
messenger	B-X
RNA	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
delineated	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
about	B-X
dampened	B-X
immune	B-X
responses	B-X
to	B-X
COVID-19	B-X
vaccination	B-X
among	B-X
immunocompromised	B-X
patients	B-X
,	B-X
including	B-X
people	B-X
living	B-X
with	B-X
HIV	B-X
(	B-X
PLWH	B-X
)	B-X
,	B-X
which	B-X
may	B-X
blunt	B-X
the	B-X
vaccine	B-X
's	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
protection	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
qualitative	B-X
SARS-CoV-2	B-X
vaccine	B-X
immunogenicity	B-X
among	B-X
PLWH	B-X
after	B-X
vaccination	B-X
.	B-X

Binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
proteins	O
to	O
the	O
predicted	O
binding	O
sites	O
in	O
the	O
FOXP3	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Mutated	O
and	O
wild	O
-	O
type	O
oligonucleotides	O
are	O
shown	O
.	O
<EOS>	B-X
Ionis	B-X
Pharmaceuticals	B-X
and	B-X
Akcea	B-X
Therapeutics	B-X
have	B-X
developed	B-X
inotersen	B-X
(	B-X
Tegsedi™	B-X
)	B-X
,	B-X
an	B-X
antisense	B-X
oligonucleotide	B-X
inhibitor	B-X
of	B-X
mutant	B-X
and	B-X
wild-type	B-X
human	B-X
transthyretin	B-X
(	B-X
TTR	B-X
)	B-X
,	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
hereditary	B-X
transthyretin	B-X
amyloidosis	B-X
(	B-X
hATTR	B-X
)	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
some	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
cancer	B-X
cells	B-X
with	B-X
global	B-X
splicing	B-X
alterations	B-X
are	B-X
dependent	B-X
on	B-X
the	B-X
transcriptional	B-X
products	B-X
derived	B-X
from	B-X
wild-type	B-X
spliceosome	B-X
for	B-X
their	B-X
survival	B-X
,	B-X
which	B-X
potentially	B-X
creates	B-X
a	B-X
therapeutic	B-X
vulnerability	B-X
in	B-X
cancers	B-X
with	B-X
a	B-X
mutant	B-X
spliceosome	B-X
.	B-X
Presence	B-X
of	B-X
excess	B-X
unaltered	B-X
,	B-X
wild-type	B-X
DNA	B-X
(	B-X
wtDNA	B-X
)	B-X
providing	B-X
information	B-X
of	B-X
little	B-X
clinical	B-X
value	B-X
may	B-X
often	B-X
mask	B-X
low-level	B-X
mutations	B-X
containing	B-X
important	B-X
diagnostic	B-X
or	B-X
therapeutic	B-X
clues	B-X
.	B-X
Glycogen	B-X
storage	B-X
disease	B-X
type	B-X
II	B-X
(	B-X
GSDII	B-X
,	B-X
Pompe	B-X
disease	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
metabolic	B-X
disorder	B-X
caused	B-X
by	B-X
a	B-X
deficiency	B-X
of	B-X
acid	B-X
alpha-glucosidase	B-X
(	B-X
GAA	B-X
)	B-X
,	B-X
an	B-X
enzyme	B-X
localized	B-X
within	B-X
lysosomes	B-X
that	B-X
is	B-X
solely	B-X
responsible	B-X
for	B-X
glycogen	B-X
degradation	B-X
in	B-X
this	B-X
compartment	B-X
.	B-X
These	B-X
approaches	B-X
,	B-X
which	B-X
we	B-X
review	B-X
here	B-X
,	B-X
comprise	B-X
splicing	B-X
modification	B-X
by	B-X
antisense	B-X
oligonucleotides	B-X
,	B-X
chaperone	B-X
therapy	B-X
,	B-X
stop	B-X
codon	B-X
readthrough	B-X
therapy	B-X
,	B-X
and	B-X
the	B-X
use	B-X
of	B-X
viral	B-X
vectors	B-X
to	B-X
introduce	B-X
wild-type	B-X
genes	B-X
.	B-X

The	O
predicted	O
RUNX	O
binding	O
sites	O
are	O
accentuated	O
(	O
boxed	O
and	O
in	O
green	O
letters	O
)	O
and	O
stars	O
mark	O
mutations	O
introduced	O
into	O
the	O
binding	O
site	O
of	O
the	O
control	O
oligonucleotides	O
.	O

Nuclear	O
extracts	O
from	O
HEK293T	O
cells	O
were	O
incubated	O
with	O
biotinylated	O
oligonucleotides	O
.	O

The	O
precipitated	O
oligonucleotide	O
-	O
transcription	O
factor	O
complexes	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
identified	O
by	O
Western	O
blotting	O
with	O
anti	O
-	O
RUNX1	B-Protein
and	O
anti	O
-	O
RUNX3	B-Protein
antibodies	O
.	O

A	O
mixture	O
of	O
all	O
three	O
oligonucleotides	O
with	O
the	O
predicted	O
binding	O
sites	O
or	O
with	O
the	O
inserted	O
mutation	O
into	O
the	O
predicted	O
sites	O
was	O
used	O
.	O
<EOS>	B-X
Many	B-X
individuals	B-X
with	B-X
multiple	B-X
or	B-X
large	B-X
colorectal	B-X
adenomas	B-X
or	B-X
early-onset	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
have	B-X
no	B-X
detectable	B-X
germline	B-X
mutations	B-X
in	B-X
the	B-X
known	B-X
cancer	B-X
predisposition	B-X
genes	B-X
.	B-X
The	B-X
variants	B-X
associated	B-X
with	B-X
susceptibility	B-X
,	B-X
POLE	B-X
p.Leu424Val	B-X
and	B-X
POLD1	B-X
p.Ser478Asn	B-X
,	B-X
have	B-X
high	B-X
penetrance	B-X
,	B-X
and	B-X
POLD1	B-X
mutation	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
endometrial	B-X
cancer	B-X
predisposition	B-X
.	B-X
The	B-X
mutations	B-X
map	B-X
to	B-X
equivalent	B-X
sites	B-X
in	B-X
the	B-X
proofreading	B-X
(	B-X
exonuclease	B-X
)	B-X
domain	B-X
of	B-X
DNA	B-X
polymerases	B-X
ɛ	B-X
and	B-X
δ	B-X
and	B-X
are	B-X
predicted	B-X
to	B-X
cause	B-X
a	B-X
defect	B-X
in	B-X
the	B-X
correction	B-X
of	B-X
mispaired	B-X
bases	B-X
inserted	B-X
during	B-X
DNA	B-X
replication	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
prediction	B-X
,	B-X
the	B-X
tumors	B-X
from	B-X
mutation	B-X
carriers	B-X
were	B-X
microsatellite	B-X
stable	B-X
but	B-X
tended	B-X
to	B-X
acquire	B-X
base	B-X
substitution	B-X
mutations	B-X
,	B-X
as	B-X
confirmed	B-X
by	B-X
yeast	B-X
functional	B-X
assays	B-X
.	B-X
Further	B-X
analysis	B-X
of	B-X
published	B-X
data	B-X
showed	B-X
that	B-X
the	B-X
recently	B-X
described	B-X
group	B-X
of	B-X
hypermutant	B-X
,	B-X
microsatellite-stable	B-X
CRCs	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
somatic	B-X
POLE	B-X
mutations	B-X
affecting	B-X
the	B-X
exonuclease	B-X
domain	B-X
.	B-X

Data	O
shown	O
are	O
one	O
representative	O
of	O
three	O
independent	O
experiments	O
with	O
similar	O
results	O
.	O
<EOS>	B-X
When	B-X
fractionation	B-X
schemes	B-X
for	B-X
hypofractionation	B-X
and	B-X
stereotactic	B-X
body	B-X
radiotherapy	B-X
are	B-X
considered	B-X
,	B-X
a	B-X
reliable	B-X
cell	B-X
survival	B-X
model	B-X
at	B-X
high	B-X
dose	B-X
is	B-X
needed	B-X
for	B-X
calculating	B-X
doses	B-X
of	B-X
similar	B-X
biological	B-X
effectiveness	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
hybrid	B-X
genotypes	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
surveys	B-X
of	B-X
natural	B-X
populations	B-X
,	B-X
genetic	B-X
variation	B-X
reported	B-X
in	B-X
a	B-X
number	B-X
of	B-X
Leishmania	B-X
species	B-X
,	B-X
and	B-X
the	B-X
extant	B-X
capacity	B-X
for	B-X
genetic	B-X
exchange	B-X
demonstrated	B-X
in	B-X
laboratory	B-X
experiments	B-X
.	B-X
To	B-X
date	B-X
there	B-X
is	B-X
only	B-X
one	B-X
previous	B-X
study	B-X
on	B-X
a	B-X
natural	B-X
population	B-X
of	B-X
Leishmania	B-X
hybrids	B-X
based	B-X
on	B-X
whole-genome	B-X
sequences	B-X
.	B-X
Patterns	B-X
of	B-X
inheritance	B-X
are	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
reported	B-X
with	B-X
multiple	B-X
,	B-X
apparently	B-X
independent	B-X
,	B-X
origins	B-X
from	B-X
similar	B-X
parents	B-X
that	B-X
include	B-X
backcrossing	B-X
with	B-X
parental	B-X
types	B-X
.	B-X
Analysis	B-X
indicates	B-X
that	B-X
hybrids	B-X
are	B-X
representative	B-X
of	B-X
at	B-X
least	B-X
three	B-X
different	B-X
histories	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
recombination	B-X
is	B-X
a	B-X
significant	B-X
feature	B-X
of	B-X
natural	B-X
populations	B-X
and	B-X
contributes	B-X
to	B-X
the	B-X
growing	B-X
body	B-X
of	B-X
data	B-X
that	B-X
shows	B-X
how	B-X
recombination	B-X
,	B-X
and	B-X
gene	B-X
flow	B-X
,	B-X
shape	B-X
natural	B-X
populations	B-X
of	B-X
Leishmania	B-X
.	B-X

(	O
B	O
)	O
Promoter	O
enzyme	O
immunoassay	O
using	O
wild	O
-	O
type	O
and	O
mutated	O
oligonucleotides	O
within	O
the	O
FOXP3	B-Protein
promoter	O
.	O

Bars	O
show	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
Chromatin	O
immunoprecipitation	O
assay	O
results	O
show	O
binding	O
of	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
complexes	O
containing	O
CBFbeta	B-Protein
to	O
the	O
human	O
FOXP3	B-Protein
promoter	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
that	O
were	O
cultured	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
together	O
with	O
anti	O
-	O
CD2	B-Protein
/	O
3	B-Protein
/	O
28	B-Protein
and	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

There	O
was	O
no	O
change	O
in	O
site	O
occupancy	O
in	O
all	O
immunoprecipitations	O
when	O
IGX1A	O
negative	O
control	O
primers	O
were	O
used	O
.	O

The	O
results	O
are	O
normalized	O
to	O
input	O
and	O
isotype	O
control	O
antibody	O
.	O
<EOS>	B-X
With	B-X
the	B-X
continuous	B-X
generation	B-X
of	B-X
new	B-X
variants	B-X
of	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
the	B-X
pressure	B-X
of	B-X
epidemic	B-X
prevention	B-X
and	B-X
control	B-X
continues	B-X
to	B-X
increase	B-X
in	B-X
China	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
understand	B-X
the	B-X
epidemiological	B-X
characteristics	B-X
of	B-X
Omicron	B-X
variant	B-X
via	B-X
analyzing	B-X
the	B-X
epidemiological	B-X
characteristics	B-X
of	B-X
imported	B-X
patients	B-X
with	B-X
Omicron	B-X
in	B-X
Hunan	B-X
Province	B-X
,	B-X
and	B-X
to	B-X
provide	B-X
reference	B-X
for	B-X
preventing	B-X
and	B-X
controlling	B-X
the	B-X
imported	B-X
epidemics	B-X
.	B-X
We	B-X
have	B-X
attempted	B-X
to	B-X
identify	B-X
a	B-X
direct	B-X
role	B-X
for	B-X
mast	B-X
cell	B-X
mediators	B-X
in	B-X
the	B-X
control	B-X
of	B-X
visceral	B-X
afferent	B-X
excitability	B-X
by	B-X
examining	B-X
intracellular	B-X
electrophysiological	B-X
changes	B-X
in	B-X
vagal	B-X
neurons	B-X
after	B-X
application	B-X
of	B-X
extracts	B-X
prepared	B-X
from	B-X
purified	B-X
and	B-X
IgE-stimulated	B-X
human	B-X
lung	B-X
mast	B-X
cells	B-X
(	B-X
HLMC	B-X
)	B-X
.	B-X
HLMC	B-X
's	B-X
,	B-X
applied	B-X
by	B-X
superfusion	B-X
or	B-X
by	B-X
focal	B-X
pressure	B-X
ejection	B-X
from	B-X
micropipettes	B-X
,	B-X
reversibly	B-X
enhanced	B-X
the	B-X
excitability	B-X
of	B-X
a	B-X
subpopulation	B-X
of	B-X
rabbit	B-X
visceral	B-X
sensory	B-X
C-fiber	B-X
neurons	B-X
by	B-X
1	B-X
)	B-X
abolishing	B-X
the	B-X
slow	B-X
Ca2+-dependent	B-X
post-spike	B-X
after	B-X
hyperpolarization	B-X
that	B-X
uniquely	B-X
resides	B-X
in	B-X
these	B-X
neurons	B-X
and	B-X
controls	B-X
their	B-X
spike	B-X
frequency	B-X
,	B-X
2	B-X
)	B-X
depolarizing	B-X
the	B-X
cell	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
3	B-X
)	B-X
increasing	B-X
membrane	B-X
input	B-X
resistance	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
the	B-X
first	B-X
unambiguous	B-X
evidence	B-X
that	B-X
products	B-X
released	B-X
from	B-X
immunologically	B-X
challenged	B-X
HLMC	B-X
's	B-X
directly	B-X
affect	B-X
visceral	B-X
afferent	B-X
nerve	B-X
cell	B-X
function	B-X
.	B-X

Bars	O
show	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
experiments	O
.	O

Statistical	O
differences	O
were	O
verified	O
by	O
the	O
paired	O
Student	O
'	O
s	O
t	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
<EOS>	B-X
The	B-X
NAb	B-X
response	B-X
was	B-X
also	B-X
assessed	B-X
in	B-X
90	B-X
individuals	B-X
who	B-X
had	B-X
received	B-X
the	B-X
complete	B-X
dose	B-X
regimen	B-X
of	B-X
BNT162b2	B-X
.	B-X
The	B-X
effectiveness	B-X
of	B-X
messenger	B-X
RNA	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
delineated	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
about	B-X
dampened	B-X
immune	B-X
responses	B-X
to	B-X
COVID-19	B-X
vaccination	B-X
among	B-X
immunocompromised	B-X
patients	B-X
,	B-X
including	B-X
people	B-X
living	B-X
with	B-X
HIV	B-X
(	B-X
PLWH	B-X
)	B-X
,	B-X
which	B-X
may	B-X
blunt	B-X
the	B-X
vaccine	B-X
's	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
protection	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
qualitative	B-X
SARS-CoV-2	B-X
vaccine	B-X
immunogenicity	B-X
among	B-X
PLWH	B-X
after	B-X
vaccination	B-X
.	B-X

Regulation	O
of	O
FOXP3	B-Protein
promoter	O
activity	O
by	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
.	O

(	O
A	O
)	O
Human	O
primary	O
CD4	B-Protein
+	O
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
FOXP3	B-Protein
promoter	O
region	O
(	O
FOXP3	B-Protein
-	O
511	O
/	O
+	O
176	O
)	O
fused	O
to	O
the	O
luciferase	B-Protein
reporter	O
gene	O
together	O
with	O
a	O
GFP	B-Protein
,	O
RUNX1	B-Protein
,	O
or	O
RUNX3	B-Protein
expression	O
vector	O
.	O
<EOS>	B-X
RUNX	B-X
proteins	B-X
belong	B-X
to	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
essential	B-X
for	B-X
cellular	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
apoptosis	B-X
with	B-X
emerging	B-X
data	B-X
implicating	B-X
RUNX3	B-X
in	B-X
haematopoiesis	B-X
and	B-X
haematological	B-X
malignancies	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
RUNX3	B-X
plays	B-X
an	B-X
important	B-X
regulatory	B-X
role	B-X
in	B-X
normal	B-X
human	B-X
erythropoiesis	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
altering	B-X
RUNX3	B-X
expression	B-X
on	B-X
erythropoiesis	B-X
was	B-X
determined	B-X
by	B-X
transducing	B-X
human	B-X
CD34	B-X
The	B-X
Dsi1	B-X
locus	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
common	B-X
integration	B-X
site	B-X
for	B-X
Moloney	B-X
murine	B-X
leukemia	B-X
virus	B-X
(	B-X
MLV	B-X
)	B-X
in	B-X
rat	B-X
thymic	B-X
lymphomas	B-X
,	B-X
but	B-X
previous	B-X
efforts	B-X
to	B-X
identify	B-X
a	B-X
gene	B-X
affected	B-X
by	B-X
these	B-X
insertions	B-X
were	B-X
unsuccessful	B-X
.	B-X
We	B-X
considered	B-X
the	B-X
Runx3	B-X
gene	B-X
a	B-X
potential	B-X
candidate	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
genetic	B-X
mapping	B-X
which	B-X
showed	B-X
that	B-X
Dsi1	B-X
and	B-X
Runx3	B-X
are	B-X
closely	B-X
linked	B-X
on	B-X
mouse	B-X
chromosome	B-X
4	B-X
and	B-X
the	B-X
precedent	B-X
of	B-X
the	B-X
related	B-X
Runx2	B-X
gene	B-X
,	B-X
which	B-X
emerged	B-X
recently	B-X
as	B-X
a	B-X
Myc-collaborating	B-X
gene	B-X
activated	B-X
by	B-X
retroviral	B-X
insertion	B-X
in	B-X
thymic	B-X
lymphomas	B-X
of	B-X
CD2-MYC	B-X
mice	B-X
.	B-X
We	B-X
now	B-X
report	B-X
the	B-X
physical	B-X
mapping	B-X
of	B-X
the	B-X
Dsi1	B-X
locus	B-X
to	B-X
a	B-X
site	B-X
30	B-X
kb	B-X
upstream	B-X
of	B-X
the	B-X
distal	B-X
(	B-X
P1	B-X
)	B-X
promoter	B-X
of	B-X
the	B-X
murine	B-X
Runx3	B-X
gene	B-X
.	B-X
Comparison	B-X
with	B-X
the	B-X
syntenic	B-X
region	B-X
of	B-X
human	B-X
chromosome	B-X
1	B-X
shows	B-X
that	B-X
the	B-X
next	B-X
gene	B-X
is	B-X
over	B-X
250	B-X
kb	B-X
5	B-X
'	B-X
to	B-X
Runx3	B-X
,	B-X
suggesting	B-X
that	B-X
Runx3	B-X
may	B-X
be	B-X
the	B-X
primary	B-X
target	B-X
of	B-X
retroviral	B-X
insertions	B-X
at	B-X
Dsi1	B-X
.	B-X
Proviral	B-X
insertion	B-X
was	B-X
associated	B-X
with	B-X
very	B-X
high	B-X
levels	B-X
of	B-X
expression	B-X
of	B-X
Runx3	B-X
,	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
transcripts	B-X
arising	B-X
at	B-X
the	B-X
P1	B-X
promoter	B-X
.	B-X
These	B-X
results	B-X
confirm	B-X
that	B-X
Runx3	B-X
is	B-X
a	B-X
target	B-X
of	B-X
retroviral	B-X
insertions	B-X
at	B-X
Dsi1	B-X
and	B-X
indicate	B-X
that	B-X
Runx3	B-X
can	B-X
act	B-X
as	B-X
an	B-X
alternative	B-X
to	B-X
Runx2	B-X
as	B-X
a	B-X
Myc-collaborating	B-X
gene	B-X
in	B-X
thymic	B-X
lymphoma	B-X
.	B-X

Bars	O
show	O
the	O
mean	O
luciferase	B-Protein
activity	O
+	O
/	O
-	O
SE	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
B	O
)	O
Human	O
primary	O
CD4	B-Protein
+	O
cells	O
were	O
transfected	O
with	O
an	O
empty	O
vector	O
(	O
pGL3	O
Basic	O
)	O
,	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	B-Protein
promoter	O
region	O
(	O
FOXP3	B-Protein
-	O
511	O
/	O
+	O
176	O
)	O
fused	O
to	O
the	O
luciferase	B-Protein
reporter	O
gene	O
,	O
or	O
with	O
a	O
vector	O
containing	O
the	O
putative	O
FOXP3	B-Protein
promoter	O
region	O
(	O
FOXP3	O
-	O
511	O
/	O
+	O
176	O
)	O
with	O
single	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
or	O
with	O
the	O
combination	O
of	O
two	O
or	O
three	O
RUNX	O
binding	O
sites	O
mutated	O
(	O
53	O
,	O
287	O
,	O
or	O
333	O
)	O
fused	O
to	O
the	O
luciferase	B-Protein
reporter	O
gene	O
.	O

Bars	O
show	O
the	O
mean	O
luciferase	B-Protein
activity	O
+	O
/	O
-	O
SD	O
measured	O
as	O
arbitrary	O
light	O
units	O
of	O
three	O
independent	O
experiments	O
.	O

Diminished	O
capacity	O
of	O
Cbfb	B-Protein
-	O
deficient	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
T	O
cells	O
in	O
the	O
generation	O
of	O
Foxp3	B-Protein
+	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

(	O
A	O
)	O
FACS	O
-	O
purified	O
naive	O
CD4	B-Protein
+	O
CD8	B-Protein
-	O
T	O
cells	O
from	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
control	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
mAb	O
,	O
50	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
+	O
/	O
-	O
10	O
nM	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
and	O
increasing	O
concentrations	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

After	O
3	O
d	O
in	O
culture	O
,	O
the	O
cells	O
were	O
restimulated	O
with	O
PMA	O
+	O
ionomycin	O
,	O
and	O
then	O
analyzed	O
for	O
intracellular	O
Foxp3	B-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

One	O
of	O
five	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
Rodent	B-X
gerontology	B-X
experiments	B-X
should	B-X
be	B-X
carefully	B-X
designed	B-X
and	B-X
correctly	B-X
analyzed	B-X
so	B-X
as	B-X
to	B-X
provide	B-X
the	B-X
maximum	B-X
amount	B-X
of	B-X
information	B-X
for	B-X
the	B-X
minimum	B-X
amount	B-X
of	B-X
work	B-X
.	B-X
There	B-X
are	B-X
five	B-X
criteria	B-X
for	B-X
a	B-X
``	B-X
good	B-X
''	B-X
experimental	B-X
design	B-X
.	B-X
These	B-X
are	B-X
applicable	B-X
both	B-X
to	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
experiments	B-X
:	B-X
(	B-X
1	B-X
)	B-X
The	B-X
experiment	B-X
should	B-X
be	B-X
unbiased	B-X
so	B-X
that	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
make	B-X
a	B-X
true	B-X
comparison	B-X
between	B-X
treatment	B-X
groups	B-X
in	B-X
the	B-X
knowledge	B-X
that	B-X
no	B-X
one	B-X
group	B-X
has	B-X
a	B-X
more	B-X
favorable	B-X
``	B-X
environment	B-X
.	B-X
''	B-X
Thus	B-X
,	B-X
the	B-X
present	B-X
experiments	B-X
aimed	B-X
to	B-X
fill	B-X
this	B-X
gap	B-X
in	B-X
the	B-X
literature	B-X
.	B-X
In	B-X
Phase	B-X
2	B-X
,	B-X
target-lever	B-X
pressing	B-X
was	B-X
extinguished	B-X
,	B-X
and	B-X
alternative-lever	B-X
pressing	B-X
produced	B-X
either	B-X
five-pellet	B-X
,	B-X
one-pellet	B-X
,	B-X
or	B-X
no	B-X
alternative	B-X
reinforcement	B-X
.	B-X

(	O
B	O
)	O
Naive	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
Cbfb	B-Protein
CD4	B-Protein
-	I-Protein
cre	I-Protein
or	O
control	O
mice	O
(	O
harboring	O
a	O
Foxp3	B-Protein
-	O
IRES	O
-	O
GFP	B-Protein
allele	O
)	O
were	O
adoptively	O
transferred	O
into	O
Rag	B-Protein
-	O
deficient	O
mice	O
(	O
5	O
x	O
106	O
cells	O
per	O
transfer	O
)	O
.	O

6	O
wk	O
later	O
,	O
TCRbeta	B-Protein
+	O
CD4	B-Protein
+	O
cells	O
from	O
the	O
spleen	O
,	O
mesenteric	O
lymph	O
node	O
(	O
MLN	O
)	O
,	O
and	O
lamina	O
propria	O
of	O
the	O
small	O
intestine	O
(	O
LP	O
)	O
were	O
analyzed	O
for	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
expression	O
.	O

Results	O
from	O
one	O
of	O
four	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
and	O
control	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
with	O
same	O
findings	O
are	O
shown	O
.	O

The	O
data	O
from	O
four	O
sets	O
of	O
mice	O
is	O
shown	O
in	O
C	O
.	O

Statistical	O
analysis	O
was	O
performed	O
with	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

*	O
,	O
P	O
<	O
0	O
.	O
05	O
between	O
groups	O
.	O
<EOS>	B-X
We	B-X
aimed	B-X
at	B-X
comparing	B-X
the	B-X
vaccine-induced	B-X
humoral	B-X
and	B-X
T-cell	B-X
responses	B-X
of	B-X
these	B-X
vulnerable	B-X
patient	B-X
groups	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
Hemodialysis	B-X
(	B-X
HD	B-X
)	B-X
patients	B-X
have	B-X
a	B-X
high	B-X
prevalence	B-X
of	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
infection	B-X
and	B-X
mortality	B-X
,	B-X
but	B-X
they	B-X
may	B-X
have	B-X
a	B-X
weak	B-X
response	B-X
to	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
.	B-X
ChAdOx1	B-X
and	B-X
BNT162b2	B-X
vaccines	B-X
are	B-X
currently	B-X
commonly	B-X
used	B-X
against	B-X
coronavirus	B-X
disease	B-X
2019	B-X
worldwide	B-X
.	B-X

CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mouse	O
cells	O
and	O
iT	O
reg	O
cells	O
generated	O
from	O
human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
undergoing	O
siRNA	O
-	O
mediated	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
knock	O
down	O
show	O
a	O
diminished	O
suppressive	O
activity	O
.	O

Experimental	O
setup	O
(	O
A	O
)	O
and	O
results	O
of	O
the	O
mouse	O
suppression	O
assay	O
(	O
B	O
)	O
,	O
FACS	O
-	O
purified	O
naive	O
CD4	B-Protein
+	O
8	B-Protein
-	O
T	O
cells	O
from	O
CbfbF	B-Protein
/	O
F	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
(	O
left	O
)	O
and	O
control	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
mice	O
(	O
Cd45	B-Protein
.	I-Protein
2	I-Protein
;	O
right	O
)	O
were	O
activated	O
in	O
vitro	O
with	O
anti	O
-	O
CD3	B-Protein
/	O
28	B-Protein
mAb	O
,	O
50	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
2	O
.	O
5	O
ng	O
/	O
ml	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
.	O

After	O
3	O
d	O
,	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
+	O
cells	O
were	O
FACS	O
-	O
sorted	O
and	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
CD4	B-Protein
+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

These	O
were	O
then	O
incubated	O
with	O
inactivated	O
splenocytes	O
and	O
anti	O
-	O
CD3	B-Protein
mAb	O
.	O

After	O
a	O
further	O
4	O
d	O
,	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

(	O
C	O
)	O
As	O
a	O
control	O
,	O
CbfbF	B-Protein
/	O
+	O
CD4	B-Protein
-	I-Protein
cre	I-Protein
CD4	B-Protein
+	O
T	O
cells	O
activated	O
in	O
absence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
were	O
mixed	O
with	O
CFSE	O
-	O
loaded	O
naive	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
CD4	B-Protein
+	O
cells	O
at	O
the	O
indicated	O
ratios	O
.	O

Four	O
days	O
later	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
cells	O
were	O
analyzed	O
for	O
CFSE	O
dilution	O
.	O

The	O
median	O
division	O
number	O
(	O
of	O
the	O
naive	O
CD45	B-Protein
.	I-Protein
1	I-Protein
+	O
CD4	B-Protein
+	O
cells	O
in	O
the	O
cultures	O
containing	O
Foxp3	B-Protein
-	I-Protein
GFP	I-Protein
+	O
cells	O
)	O
is	O
indicated	O
in	O
each	O
of	O
the	O
histograms	O
.	O

One	O
of	O
three	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
summarizes	B-X
three	B-X
experiments	B-X
on	B-X
the	B-X
genetic	B-X
manipulation	B-X
of	B-X
fitness	B-X
components	B-X
involved	B-X
in	B-X
the	B-X
evolution	B-X
of	B-X
lifespan	B-X
through	B-X
the	B-X
introduction	B-X
of	B-X
an	B-X
additional	B-X
copy	B-X
of	B-X
the	B-X
gene	B-X
for	B-X
elongation	B-X
factor	B-X
EF-1	B-X
alpha	B-X
into	B-X
the	B-X
genome	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
.	B-X
It	B-X
used	B-X
inbred	B-X
stocks	B-X
;	B-X
three	B-X
treatment	B-X
and	B-X
three	B-X
control	B-X
lines	B-X
were	B-X
available	B-X
.	B-X
In	B-X
three	B-X
experiments	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
cognitive	B-X
underpinnings	B-X
of	B-X
self-serving	B-X
dishonesty	B-X
by	B-X
manipulating	B-X
cognitive	B-X
load	B-X
under	B-X
different	B-X
incentive	B-X
structures	B-X
.	B-X
This	B-X
hypothesis	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
outcome	B-X
of	B-X
two	B-X
out	B-X
of	B-X
three	B-X
experiments	B-X
.	B-X

(	O
D	O
)	O
Human	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
transfected	O
with	O
RUNX1	B-Protein
and	O
RUNX3	B-Protein
siRNA	O
and	O
cultured	O
under	O
iT	O
reg	O
differentiating	O
conditions	O
were	O
used	O
in	O
an	O
in	O
vitro	O
suppression	O
assay	O
,	O
cultured	O
together	O
with	O
autologous	O
CFSE	O
-	O
labeled	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
mAb	O
.	O

The	O
CFSE	O
dilution	O
of	O
the	O
CD4	B-Protein
+	O
T	O
cell	O
responder	O
cells	O
was	O
analyzed	O
after	O
5	O
d	O
by	O
flow	O
cytometry	O
.	O

The	O
T	O
reg	O
/	O
responder	O
CD4	B-Protein
+	O
T	O
cell	O
ratios	O
used	O
were	O
1	O
:	O
20	O
,	O
1	O
:	O
10	O
,	O
and	O
1	O
:	O
5	O
.	O

One	O
of	O
two	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
Motional	B-X
reorientation	B-X
experiments	B-X
are	B-X
extensions	B-X
of	B-X
Magic	B-X
Angle	B-X
Spinning	B-X
(	B-X
MAS	B-X
)	B-X
where	B-X
the	B-X
rotor	B-X
axis	B-X
is	B-X
changed	B-X
in	B-X
order	B-X
to	B-X
average	B-X
out	B-X
,	B-X
reintroduce	B-X
,	B-X
or	B-X
scale	B-X
anisotropic	B-X
interactions	B-X
(	B-X
e.g	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
Variable	B-X
Angle	B-X
Spinning	B-X
(	B-X
VAS	B-X
)	B-X
,	B-X
Switched	B-X
Angle	B-X
Spinning	B-X
(	B-X
SAS	B-X
)	B-X
,	B-X
and	B-X
Dynamic	B-X
Angle	B-X
Spinning	B-X
(	B-X
DAS	B-X
)	B-X
,	B-X
all	B-X
of	B-X
which	B-X
involve	B-X
spinning	B-X
at	B-X
two	B-X
or	B-X
more	B-X
different	B-X
angles	B-X
sequentially	B-X
,	B-X
either	B-X
in	B-X
successive	B-X
experiments	B-X
or	B-X
during	B-X
a	B-X
multidimensional	B-X
experiment	B-X
.	B-X
In	B-X
all	B-X
of	B-X
these	B-X
experiments	B-X
,	B-X
anisotropic	B-X
terms	B-X
in	B-X
the	B-X
Hamiltonian	B-X
are	B-X
scaled	B-X
by	B-X
changing	B-X
the	B-X
orientation	B-X
of	B-X
the	B-X
spinning	B-X
sample	B-X
relative	B-X
to	B-X
the	B-X
static	B-X
magnetic	B-X
field	B-X
.	B-X
These	B-X
experiments	B-X
vary	B-X
in	B-X
experimental	B-X
complexity	B-X
and	B-X
instrumentation	B-X
requirements	B-X
.	B-X
In	B-X
SAS	B-X
,	B-X
dipolar	B-X
couplings	B-X
and/or	B-X
chemical	B-X
shift	B-X
anisotropies	B-X
are	B-X
reintroduced	B-X
by	B-X
switching	B-X
the	B-X
sample	B-X
between	B-X
two	B-X
different	B-X
angles	B-X
,	B-X
often	B-X
0°	B-X
or	B-X
90°	B-X
and	B-X
the	B-X
magic	B-X
angle	B-X
,	B-X
yielding	B-X
a	B-X
two-dimensional	B-X
isotropic-anisotropic	B-X
correlation	B-X
spectrum	B-X
.	B-X
Although	B-X
motional	B-X
reorientation	B-X
experiments	B-X
generally	B-X
require	B-X
specialized	B-X
instrumentation	B-X
and	B-X
data	B-X
analysis	B-X
schemes	B-X
,	B-X
some	B-X
are	B-X
accessible	B-X
with	B-X
only	B-X
minor	B-X
modification	B-X
of	B-X
standard	B-X
MAS	B-X
probes	B-X
.	B-X
The	B-X
review	B-X
concludes	B-X
with	B-X
perspectives	B-X
on	B-X
how	B-X
motional	B-X
reorientation	B-X
experiments	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
current	B-X
problems	B-X
in	B-X
chemistry	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
and	B-X
materials	B-X
science	B-X
,	B-X
given	B-X
the	B-X
many	B-X
advances	B-X
in	B-X
high-field	B-X
NMR	B-X
magnets	B-X
,	B-X
fast	B-X
spinning	B-X
,	B-X
and	B-X
sample	B-X
preparation	B-X
realized	B-X
in	B-X
recent	B-X
years	B-X
.	B-X

IKKbeta	B-Protein
phosphorylation	O
regulates	O
RPS3	B-Protein
nuclear	O
translocation	O
and	O
NF	O
-	O
kappaB	O
function	O
duringEscherichia	O
coliO157	O
:	O
H7	O
infection	O

NF	O
-	O
kappaB	O
is	O
a	O
major	O
gene	O
regulator	O
in	O
immune	O
responses	O
and	O
ribosomal	B-Protein
protein	I-Protein
S3	I-Protein
(	O
RPS3	B-Protein
)	O
is	O
an	O
NF	O
-	O
kappaB	O
subunit	O
that	O
directs	O
specific	O
gene	O
transcription	O
.	O

However	O
,	O
it	O
is	O
unknown	O
how	O
RPS3	B-Protein
nuclear	O
translocation	O
is	O
regulated	O
.	O
<EOS>	B-X
Constitutive	B-X
activation	B-X
of	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
signaling	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
colorectal	B-X
carcinoma	B-X
(	B-X
CRC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
excessive	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
remain	B-X
largely	B-X
unknown	B-X
.	B-X
NF-κB	B-X
is	B-X
a	B-X
major	B-X
gene	B-X
regulator	B-X
in	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
is	B-X
an	B-X
NF-κB	B-X
subunit	B-X
that	B-X
directs	B-X
specific	B-X
gene	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
how	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
is	B-X
regulated	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
by	B-X
the	B-X
kinase	B-X
IKKβ	B-X
was	B-X
crucial	B-X
for	B-X
nuclear	B-X
localization	B-X
of	B-X
RPS3	B-X
in	B-X
response	B-X
to	B-X
activating	B-X
stimuli	B-X
.	B-X
Moreover	B-X
,	B-X
virulence	B-X
protein	B-X
NleH1	B-X
of	B-X
the	B-X
foodborne	B-X
pathogen	B-X
Escherichia	B-X
coli	B-X
strain	B-X
O157	B-X
:	B-X
H7	B-X
specifically	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
and	B-X
blocked	B-X
RPS3	B-X
function	B-X
,	B-X
thereby	B-X
promoting	B-X
bacterial	B-X
colonization	B-X
and	B-X
diarrhea	B-X
but	B-X
resulting	B-X
in	B-X
less	B-X
mortality	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet-infection	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
IKKβ-dependent	B-X
modification	B-X
of	B-X
a	B-X
specific	B-X
amino	B-X
acid	B-X
in	B-X
RPS3	B-X
promoted	B-X
specific	B-X
NF-κB	B-X
functions	B-X
that	B-X
underlie	B-X
the	B-X
molecular	B-X
pathogenetic	B-X
mechanisms	B-X
of	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
.	B-X

Here	O
we	O
report	O
that	O
IKKbeta	B-Protein
phosphorylation	O
of	O
serine	O
209	O
(	O
S209	O
)	O
was	O
crucial	O
for	O
RPS3	B-Protein
nuclear	O
localization	O
in	O
response	O
to	O
activating	O
stimuli	O
.	O

Moreover	O
,	O
the	O
foodborne	O
pathogen	O
Escherichia	O
coli	O
O157	O
:	O
H7	O
virulence	O
protein	O
NleH1	B-Protein
specifically	O
inhibited	O
RPS3	B-Protein
S209	O
phosphorylation	O
and	O
blocked	O
RPS3	B-Protein
function	O
,	O
thereby	O
promoting	O
bacterial	O
colonization	O
and	O
diarrhea	O
but	O
decreasing	O
mortality	O
in	O
a	O
gnotobiotic	O
piglet	O
infection	O
model	O
.	O

Thus	O
,	O
the	O
IKKbeta	B-Protein
-	O
dependent	O
modification	O
of	O
a	O
specific	O
amino	O
acid	O
in	O
RPS3	B-Protein
promotes	O
specific	O
NF	O
-	O
kappaB	O
functions	O
that	O
underlie	O
the	O
molecular	O
pathogenetic	O
mechanisms	O
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O
<EOS>	B-X
NF-κB	B-X
is	B-X
a	B-X
major	B-X
gene	B-X
regulator	B-X
in	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
is	B-X
an	B-X
NF-κB	B-X
subunit	B-X
that	B-X
directs	B-X
specific	B-X
gene	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
how	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
is	B-X
regulated	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
by	B-X
the	B-X
kinase	B-X
IKKβ	B-X
was	B-X
crucial	B-X
for	B-X
nuclear	B-X
localization	B-X
of	B-X
RPS3	B-X
in	B-X
response	B-X
to	B-X
activating	B-X
stimuli	B-X
.	B-X
Moreover	B-X
,	B-X
virulence	B-X
protein	B-X
NleH1	B-X
of	B-X
the	B-X
foodborne	B-X
pathogen	B-X
Escherichia	B-X
coli	B-X
strain	B-X
O157	B-X
:	B-X
H7	B-X
specifically	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
and	B-X
blocked	B-X
RPS3	B-X
function	B-X
,	B-X
thereby	B-X
promoting	B-X
bacterial	B-X
colonization	B-X
and	B-X
diarrhea	B-X
but	B-X
resulting	B-X
in	B-X
less	B-X
mortality	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet-infection	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
IKKβ-dependent	B-X
modification	B-X
of	B-X
a	B-X
specific	B-X
amino	B-X
acid	B-X
in	B-X
RPS3	B-X
promoted	B-X
specific	B-X
NF-κB	B-X
functions	B-X
that	B-X
underlie	B-X
the	B-X
molecular	B-X
pathogenetic	B-X
mechanisms	B-X
of	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
.	B-X

Nuclear	O
Factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
regulates	O
crucial	O
cellular	O
functions	O
and	O
diverse	O
stimuli	O
activate	O
this	O
pleiotropic	O
transcription	O
factor	O
,	O
which	O
in	O
turn	O
regulates	O
a	O
vast	O
array	O
of	O
genetic	O
targets1	O
-	O
3	O
.	O

The	O
best	O
-	O
known	O
mammalian	O
NF	O
-	O
kappaB	O
subunits	O
are	O
Rel	O
proteins	O
,	O
including	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
,	O
RelB	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
p50	B-Protein
,	O
and	O
p52	B-Protein
(	O
refs	O
.	O
4	O
,	O
5	O
)	O
.	O

However	O
,	O
we	O
recently	O
demonstrated	O
that	O
ribosomal	B-Protein
protein	I-Protein
S3	I-Protein
(	O
RPS3	B-Protein
)	O
is	O
a	O
key	O
non	O
-	O
Rel	B-Protein
subunit	O
of	O
certain	O
native	O
NF	O
-	O
kappaB	O
complexes6	O
.	O

RPS3	B-Protein
is	O
defined	O
as	O
a	O
"	O
specifier	O
"	O
subunit	O
of	O
NF	O
-	O
kappaB	O
,	O
because	O
it	O
facilitates	O
high	O
affinity	O
DNA	O
binding	O
thus	O
determining	O
the	O
regulatory	O
specificity	O
of	O
NF	O
-	O
kappaB	O
for	O
selected	O
target	O
genes7	O
.	O

RPS3	B-Protein
regulation	O
of	O
NF	O
-	O
kappaB	O
governs	O
key	O
physiological	O
processes	O
,	O
including	O
immunoglobulin	B-Protein
kappa	I-Protein
light	I-Protein
chain	I-Protein
gene	O
expression	O
and	O
receptor	O
editing	O
in	O
B	O
cells6	O
,	O
8	O
,	O
cytokine	O
production	O
in	O
T	O
cells6	O
,	O
and	O
in	O
host	O
defense	O
against	O
enterohemorrhagicEscherichia	O
coli	O
(	O
EHEC	O
)	O
9	O
.	O

In	O
particular	O
,	O
theE	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
certain	B-X
pro-inflammatory	B-X
pathways	B-X
,	B-X
particularly	B-X
those	B-X
associated	B-X
with	B-X
microglial	B-X
activation	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
neuroprotective	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
inflammatory	B-X
responses	B-X
,	B-X
in	B-X
particular	B-X
the	B-X
proposed	B-X
roles	B-X
of	B-X
microglia	B-X
,	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
glaucoma	B-X
.	B-X
This	B-X
article	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
this	B-X
vital	B-X
molecule	B-X
in	B-X
cell	B-X
physiology	B-X
and	B-X
detoxication	B-X
mechanisms	B-X
in	B-X
particular	B-X
.	B-X
We	B-X
show	B-X
how	B-X
a	B-X
particular	B-X
atmosphere	B-X
of	B-X
interactions	B-X
among	B-X
creative	B-X
scientists	B-X
yielded	B-X
spectacular	B-X
insights	B-X
into	B-X
how	B-X
living	B-X
things	B-X
work	B-X
.	B-X

coliO157	O
:	O
H7	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
effector	O
protein	O
NleH1	B-Protein
selectively	O
blocks	O
NF	O
-	O
kappaB	O
target	O
gene	O
transcription	O
by	O
attenuating	O
RPS3	B-Protein
nuclear	O
translocation	O
,	O
without	O
affecting	O
p65	B-Protein
localization9	O
.	O

Nonetheless	O
,	O
how	O
specific	O
NF	O
-	O
kappaB	O
activating	O
signals	O
induce	O
RPS3	B-Protein
nuclear	O
translocation	O
is	O
unknown	O
.	O
Extra	O
-	O
ribosomal	O
functions	O
have	O
been	O
ascribed	O
to	O
ribosomal	O
proteins10	O
.	O

Besides	O
binding	O
RNA	O
within	O
the	O
40S	O
ribosomal	O
subunit	O
,	O
RPS3	B-Protein
participates	O
in	O
transcription6	O
,	O
DNA	O
repair11	O
,	O
12	O
,	O
and	O
apoptosis13	O
.	O

Whether	O
or	O
not	O
RPS3	B-Protein
is	O
phosphorylated	O
had	O
been	O
controversial14	O
-	O
18	O
.	O
<EOS>	B-X
Whether	B-X
hyponatraemia	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
cancer	B-X
is	B-X
merely	B-X
a	B-X
marker	B-X
of	B-X
poor	B-X
prognosis	B-X
or	B-X
whether	B-X
its	B-X
presence	B-X
may	B-X
alter	B-X
the	B-X
patient	B-X
's	B-X
quality	B-X
of	B-X
life	B-X
remains	B-X
to	B-X
be	B-X
examined	B-X
.	B-X
Whether	B-X
to	B-X
welcome	B-X
it	B-X
or	B-X
resist	B-X
it	B-X
,	B-X
whether	B-X
to	B-X
lead	B-X
or	B-X
follow	B-X
,	B-X
or	B-X
take	B-X
a	B-X
negative	B-X
attitude	B-X
and	B-X
disrupt	B-X
the	B-X
changes	B-X
others	B-X
wish	B-X
to	B-X
make	B-X
.	B-X
To	B-X
summarize	B-X
high-quality	B-X
studies	B-X
for	B-X
10	B-X
topics	B-X
from	B-X
2018	B-X
that	B-X
have	B-X
strong	B-X
relevance	B-X
to	B-X
primary	B-X
care	B-X
practice	B-X
.	B-X

Since	O
kinase	O
cascades	O
play	O
a	O
critical	O
role	O
in	O
NF	O
-	O
kappaB	O
regulation	O
,	O
we	O
tested	O
whether	O
RPS3	B-Protein
is	O
phosphorylated	O
in	O
the	O
context	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
sought	O
to	O
identify	O
the	O
responsible	O
kinase19	O
.	O

Additionally	O
,	O
we	O
aimed	O
to	O
define	O
a	O
regulatory	O
role	O
for	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
RPS3	B-Protein
whose	O
function	O
was	O
unknown	O
.	O
Here	O
we	O
show	O
that	O
the	O
Inhibitor	B-Protein
of	I-Protein
kappaB	I-Protein
(	I-Protein
IkappaB	I-Protein
)	I-Protein
kinase	I-Protein
beta	I-Protein
(	O
IKKbeta	B-Protein
)	O
phosphorylated	O
RPS3	B-Protein
at	O
serine	O
209	O
(	O
S209	O
)	O
.	O

RPS3	B-Protein
S209	O
phosphorylation	O
enhanced	O
its	O
association	O
with	O
importin	O
-	O
alpha	O
,	O
mediating	O
RPS3	B-Protein
entry	O
into	O
the	O
karyopherin	O
pathway	O
for	O
nuclear	O
translocation	O
.	O

Furthermore	O
,	O
theE	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
interpretability	B-X
of	B-X
deep	B-X
learning	B-X
algorithms	B-X
is	B-X
still	B-X
an	B-X
ongoing	B-X
issue	B-X
.	B-X
Furthermore	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
1	B-X
microM	B-X
serotonin	B-X
and/or	B-X
dopamine	B-X
and	B-X
their	B-X
mixture	B-X
on	B-X
the	B-X
firing	B-X
activity	B-X
of	B-X
the	B-X
CGC	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
increased	B-X
dopamine	B-X
and	B-X
serotonin	B-X
levels	B-X
both	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
serotonergic	B-X
neurons	B-X
during	B-X
the	B-X
different	B-X
phases	B-X
of	B-X
feeding	B-X
.	B-X
Furthermore	B-X
,	B-X
partisans	B-X
believed	B-X
their	B-X
adversaries	B-X
were	B-X
motivated	B-X
by	B-X
an	B-X
opposition	B-X
to	B-X
the	B-X
partisans	B-X
'	B-X
own	B-X
core	B-X
values	B-X
rather	B-X
than	B-X
by	B-X
promotion	B-X
of	B-X
the	B-X
adversaries	B-X
'	B-X
core	B-X
values	B-X
.	B-X

coliNleH1	B-Protein
effector	O
specifically	O
inhibited	O
RPS3	B-Protein
S209	O
revealing	O
howE	O
.	O

coliO157	O
:	O
H7	O
inhibits	O
this	O
important	O
innate	O
immune	O
response	O
mechanism	O
.	O

RPS3	B-Protein
phosphorylation	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
activation	O
<EOS>	B-X
NF-κB	B-X
is	B-X
a	B-X
major	B-X
gene	B-X
regulator	B-X
in	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
is	B-X
an	B-X
NF-κB	B-X
subunit	B-X
that	B-X
directs	B-X
specific	B-X
gene	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
how	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
is	B-X
regulated	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
by	B-X
the	B-X
kinase	B-X
IKKβ	B-X
was	B-X
crucial	B-X
for	B-X
nuclear	B-X
localization	B-X
of	B-X
RPS3	B-X
in	B-X
response	B-X
to	B-X
activating	B-X
stimuli	B-X
.	B-X
Moreover	B-X
,	B-X
virulence	B-X
protein	B-X
NleH1	B-X
of	B-X
the	B-X
foodborne	B-X
pathogen	B-X
Escherichia	B-X
coli	B-X
strain	B-X
O157	B-X
:	B-X
H7	B-X
specifically	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
and	B-X
blocked	B-X
RPS3	B-X
function	B-X
,	B-X
thereby	B-X
promoting	B-X
bacterial	B-X
colonization	B-X
and	B-X
diarrhea	B-X
but	B-X
resulting	B-X
in	B-X
less	B-X
mortality	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet-infection	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
IKKβ-dependent	B-X
modification	B-X
of	B-X
a	B-X
specific	B-X
amino	B-X
acid	B-X
in	B-X
RPS3	B-X
promoted	B-X
specific	B-X
NF-κB	B-X
functions	B-X
that	B-X
underlie	B-X
the	B-X
molecular	B-X
pathogenetic	B-X
mechanisms	B-X
of	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
.	B-X

To	O
test	O
whether	O
RPS3	B-Protein
is	O
phosphorylated	O
during	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
performed	O
32P	O
-	O
labeling	O
experiments	O
in	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
stimulated	O
HEK	O
293T	O
cells	O
.	O

While	O
RPS3	B-Protein
was	O
scarcely	O
phosphorylated	O
in	O
unstimulated	O
cells	O
,	O
we	O
observed	O
a	O
marked	O
increase	O
in	O
32P	O
-	O
incorporation	O
after	O
TNF	O
stimulation	O
despite	O
no	O
increase	O
in	O
RPS3	B-Protein
protein	O
(	O
Fig	O
.	O
1a	O
)	O
.	O

To	O
determine	O
which	O
RPS3	B-Protein
residues	O
were	O
phosphorylated	O
,	O
we	O
immunoprecipitated	O
RPS3	B-Protein
from	O
either	O
resting	O
or	O
stimulated	O
cells	O
and	O
performed	O
immunoblotting	O
with	O
phosphorylation	O
-	O
specific	O
antibodies	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
two	B-X
clinically	B-X
used	B-X
superparamagnetic	B-X
iron	B-X
oxide	B-X
nanoparticles	B-X
(	B-X
SPIONs	B-X
)	B-X
specifically	B-X
induced	B-X
macrophage	B-X
autophagy	B-X
through	B-X
activation	B-X
of	B-X
TLR4	B-X
,	B-X
followed	B-X
by	B-X
phosphorylation	B-X
of	B-X
p38	B-X
and	B-X
nucleus	B-X
translocation	B-X
of	B-X
Nrf2	B-X
,	B-X
leading	B-X
to	B-X
upregulation	B-X
of	B-X
p62/SQSTM1	B-X
and	B-X
macrophage	B-X
scavenger	B-X
receptor	B-X
SR-AI	B-X
mRNA	B-X
expression	B-X
.	B-X
The	B-X
S6	B-X
ribosomal	B-X
protein	B-X
(	B-X
S6RP	B-X
)	B-X
is	B-X
phosphorylated	B-X
by	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
analytical	B-X
suitability	B-X
of	B-X
a	B-X
commercial	B-X
kit-based	B-X
phosphoflow	B-X
cytometry	B-X
protocol	B-X
using	B-X
whole	B-X
blood	B-X
(	B-X
WBS	B-X
)	B-X
to	B-X
measure	B-X
the	B-X
level	B-X
of	B-X
phosphorylated	B-X
S6RP	B-X
(	B-X
p-S6RP	B-X
)	B-X
in	B-X
T-cell	B-X
subsets	B-X
to	B-X
study	B-X
the	B-X
pharmacodynamic	B-X
effects	B-X
of	B-X
mTOR	B-X
inhibitors	B-X
(	B-X
mTORi	B-X
)	B-X
.	B-X
Our	B-X
poor	B-X
understanding	B-X
of	B-X
how	B-X
inflammatory	B-X
mediators	B-X
can	B-X
affect	B-X
osteoblast	B-X
behavior	B-X
led	B-X
us	B-X
to	B-X
investigate	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
α-induced	B-X
focal	B-X
adhesion	B-X
kinase	B-X
(	B-X
FAK	B-X
)	B-X
and	B-X
Src	B-X
phosphorylation	B-X
.	B-X

Both	O
TNF	O
and	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
(	O
PMA	O
+	O
I	O
)	O
stimulated	O
rapid	O
phosphorylation	O
and	O
degradaion	O
of	O
IkappaBalpha	B-Protein
within	O
5	O
min	O
which	O
was	O
accompanied	O
by	O
RPS3	B-Protein
phosphorylation	O
on	O
serine	O
residues	O
(	O
Fig	O
.	O
1b	O
and	O
data	O
not	O
shown	O
)	O
,	O
similar	O
to	O
the	O
in	O
vivo	O
labeling	O
.	O

We	O
did	O
not	O
detect	O
tyrosine	O
-	O
or	O
threonine	O
-	O
phosphorylation	O
of	O
RPS3	B-Protein
(	O
Fig	O
.	O
1b	O
)	O
.	O

RPS3	B-Protein
and	O
IKKbeta	B-Protein
interaction	O
<EOS>	B-X
NF-κB	B-X
is	B-X
a	B-X
major	B-X
gene	B-X
regulator	B-X
in	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
is	B-X
an	B-X
NF-κB	B-X
subunit	B-X
that	B-X
directs	B-X
specific	B-X
gene	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
how	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
is	B-X
regulated	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
by	B-X
the	B-X
kinase	B-X
IKKβ	B-X
was	B-X
crucial	B-X
for	B-X
nuclear	B-X
localization	B-X
of	B-X
RPS3	B-X
in	B-X
response	B-X
to	B-X
activating	B-X
stimuli	B-X
.	B-X
Moreover	B-X
,	B-X
virulence	B-X
protein	B-X
NleH1	B-X
of	B-X
the	B-X
foodborne	B-X
pathogen	B-X
Escherichia	B-X
coli	B-X
strain	B-X
O157	B-X
:	B-X
H7	B-X
specifically	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
and	B-X
blocked	B-X
RPS3	B-X
function	B-X
,	B-X
thereby	B-X
promoting	B-X
bacterial	B-X
colonization	B-X
and	B-X
diarrhea	B-X
but	B-X
resulting	B-X
in	B-X
less	B-X
mortality	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet-infection	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
IKKβ-dependent	B-X
modification	B-X
of	B-X
a	B-X
specific	B-X
amino	B-X
acid	B-X
in	B-X
RPS3	B-X
promoted	B-X
specific	B-X
NF-κB	B-X
functions	B-X
that	B-X
underlie	B-X
the	B-X
molecular	B-X
pathogenetic	B-X
mechanisms	B-X
of	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
.	B-X

The	O
activation	O
of	O
the	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
,	O
consisting	O
of	O
a	O
regulatory	O
subunit	O
IKKgamma	B-Protein
and	O
two	O
catalytic	O
subunits	O
,	O
IKKalpha	B-Protein
and	O
IKKbeta	B-Protein
,	O
is	O
critical	O
for	O
the	O
phosphorylation	O
and	O
dispatch	O
of	O
the	O
inhibitory	O
IkappaBs	O
and	O
the	O
liberation	O
of	O
NF	O
-	O
kappaB20	O
-	O
22	O
.	O

Given	O
that	O
RPS3	B-Protein
can	O
be	O
found	O
in	O
the	O
cytoplasmic	O
p65	B-Protein
-	O
p50	B-Protein
-	O
IkappaBalpha	B-Protein
inhibitory	O
complex	O
in	O
resting	O
cells6	O
,	O
we	O
hypothesized	O
that	O
activated	O
IKKbeta	B-Protein
might	O
also	O
bind	O
to	O
and	O
phosphorylate	O
RPS3	B-Protein
.	O

First	O
,	O
we	O
found	O
that	O
ectopically	O
expressed	O
IKKbeta	B-Protein
and	O
RPS3	B-Protein
interacted	O
(	O
Fig	O
.	O
1c	O
)	O
.	O

We	O
next	O
examined	O
resting	O
Jurkat	O
cells	O
and	O
detected	O
a	O
modest	O
endogenous	O
IKKbeta	B-Protein
-	O
RPS3	B-Protein
interaction	O
(	O
Fig	O
.	O
1d	O
)	O
,	O
potentially	O
accounting	O
for	O
the	O
basal	O
NF	O
-	O
kappaB	O
transcription	O
required	O
for	O
cell	O
proliferation	O
and	O
survival	O
.	O

RPS3	B-Protein
-	O
IKKbeta	B-Protein
association	O
was	O
clearly	O
augmented	O
upon	O
TNF	O
stimulation	O
,	O
peaking	O
at	O
10	O
min	O
.	O

(	O
Fig	O
.	O
1d	O
)	O
,	O
following	O
similar	O
kinetics	O
to	O
RPS3	B-Protein
serine	O
phosphorylation	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

By	O
contrast	O
,	O
there	O
was	O
no	O
detectable	O
interaction	O
between	O
RPS3	B-Protein
and	O
IKKalpha	B-Protein
(	O
Fig	O
.	O
1d	O
)	O
.	O

IKKbeta	B-Protein
is	O
required	O
for	O
RPS3	B-Protein
nuclear	O
translocation	O
<EOS>	B-X
The	B-X
enterohemorrhagic	B-X
E.	B-X
coli	B-X
NleH1	B-X
effector	B-X
prevents	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
(	B-X
ribosomal	B-X
protein	B-X
S3	B-X
)	B-X
to	B-X
inhibit	B-X
its	B-X
participation	B-X
as	B-X
a	B-X
nuclear	B-X
``	B-X
specifier	B-X
''	B-X
of	B-X
NF-κB	B-X
binding	B-X
to	B-X
target	B-X
gene	B-X
promoters	B-X
.	B-X
NleH1	B-X
binds	B-X
to	B-X
RPS3	B-X
and	B-X
inhibits	B-X
its	B-X
phosphorylation	B-X
on	B-X
Ser-209	B-X
by	B-X
IκB	B-X
kinase-β	B-X
(	B-X
IKKβ	B-X
)	B-X
.	B-X
NleH1	B-X
possesses	B-X
a	B-X
Ser/Thr	B-X
protein	B-X
kinase	B-X
activity	B-X
that	B-X
is	B-X
essential	B-X
both	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
inhibit	B-X
the	B-X
RPS3/NF-κB	B-X
pathway	B-X
and	B-X
for	B-X
full	B-X
virulence	B-X
of	B-X
the	B-X
attaching/effacing	B-X
mouse	B-X
pathogen	B-X
Citrobacter	B-X
rodentium	B-X
.	B-X
However	B-X
,	B-X
neither	B-X
RPS3	B-X
nor	B-X
IKKβ	B-X
is	B-X
a	B-X
substrate	B-X
of	B-X
NleH1	B-X
kinase	B-X
activity	B-X
.	B-X
Knockdown	B-X
of	B-X
CRKL	B-X
abundance	B-X
prevented	B-X
NleH1	B-X
from	B-X
inhibiting	B-X
RPS3	B-X
nuclear	B-X
translocation	B-X
and	B-X
NF-κB	B-X
activity	B-X
.	B-X
CRKL	B-X
residues	B-X
Tyr-198	B-X
and	B-X
Tyr-207	B-X
were	B-X
required	B-X
for	B-X
interaction	B-X
with	B-X
NleH1	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
CRKL	B-X
interaction	B-X
with	B-X
IKKβ	B-X
recruits	B-X
NleH1	B-X
to	B-X
the	B-X
IKKβ	B-X
complex	B-X
,	B-X
where	B-X
NleH1	B-X
then	B-X
inhibits	B-X
the	B-X
RPS3/NF-κB	B-X
pathway	B-X
.	B-X

To	O
examine	O
whether	O
the	O
RPS3	B-Protein
-	O
IKKbeta	B-Protein
interaction	O
is	O
required	O
for	O
RPS3	B-Protein
nuclear	O
translocation	O
,	O
we	O
knocked	O
down	O
IKKalpha	B-Protein
or	O
IKKbeta	B-Protein
expression	O
with	O
siRNAs	O
(	O
Supplementary	O
Fig	O
.	O
1	O
)	O
and	O
then	O
observed	O
stimulation	O
-	O
induced	O
RPS3	B-Protein
nuclear	O
migration	O
by	O
confocal	O
microscopy	O
.	O

Both	O
TNF	O
and	O
PMA	O
+	O
I	O
triggered	O
RPS3	B-Protein
nuclear	O
translocation	O
in	O
Jurkat	O
cells	O
transfected	O
with	O
a	O
scrambled	O
nonspecific	O
(	O
NS	O
)	O
siRNA	O
(	O
Fig	O
.	O
2a	O
)	O
6	O
.	O

RPS3	B-Protein
nuclear	O
translocation	O
was	O
only	O
slightly	O
,	O
if	O
at	O
all	O
,	O
impaired	O
by	O
IKKalpha	B-Protein
-	O
silencing	O
.	O

Conversely	O
,	O
knockdown	O
of	O
IKKbeta	B-Protein
attenuated	O
60	O
-	O
70	O
%	O
of	O
RPS3	B-Protein
nuclear	O
accumulation	O
following	O
stimulation	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

Immunoblotting	O
of	O
nuclear	O
fractions	O
confirmed	O
that	O
full	O
expression	O
of	O
IKKbeta	B-Protein
,	O
but	O
not	O
IKKalpha	B-Protein
,	O
was	O
necessary	O
for	O
activation	O
-	O
induced	O
RPS3	B-Protein
nuclear	O
translocation	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

Control	O
immunoblots	O
revealed	O
that	O
p65	B-Protein
nuclear	O
translocation	O
was	O
blocked	O
under	O
the	O
same	O
conditions	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

We	O
next	O
examined	O
the	O
nuclear	O
translocation	O
of	O
RPS3	B-Protein
in	O
cells	O
ectopically	O
expressing	O
either	O
kinase	O
-	O
dead	O
(	O
SSAA	O
)	O
or	O
constitutively	O
-	O
active	O
(	O
SSEE	O
)	O
mutant	O
IKKbeta	B-Protein
proteins	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
investigated	B-X
whether	B-X
HBoV	B-X
proteins	B-X
modulate	B-X
TNF-α-mediated	B-X
activation	B-X
of	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
HBoV	B-X
NS1	B-X
and	B-X
NS1-70	B-X
proteins	B-X
blocked	B-X
NF-κB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
TNF-α	B-X
.	B-X
Overexpression	B-X
of	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
2	B-X
(	B-X
TRAF2	B-X
)	B-X
-	B-X
,	B-X
IκB	B-X
kinase	B-X
alpha	B-X
(	B-X
IKKα	B-X
)	B-X
-	B-X
,	B-X
IκB	B-X
kinase	B-X
beta	B-X
(	B-X
IKKβ	B-X
)	B-X
-	B-X
,	B-X
constitutively	B-X
active	B-X
mutant	B-X
of	B-X
IKKβ	B-X
(	B-X
IKKβ	B-X
SS/EE	B-X
)	B-X
-	B-X
,	B-X
or	B-X
p65-induced	B-X
NF-κB	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
NS1	B-X
and	B-X
NS1-70	B-X
.	B-X
Furthermore	B-X
,	B-X
NS1	B-X
and	B-X
NS1-70	B-X
did	B-X
n't	B-X
interfere	B-X
with	B-X
TNF-α-mediated	B-X
IκBα	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
,	B-X
nor	B-X
p65	B-X
nuclear	B-X
translocation	B-X
.	B-X

As	O
expected	O
,	O
the	O
SSEE	O
,	O
but	O
not	O
SSAA	O
,	O
mutant	O
of	O
IKKbeta	B-Protein
induced	O
NF	O
-	O
kappaB	O
-	O
dependent	O
luciferase	B-Protein
reporter	O
activity	O
(	O
Fig	O
.	O
2c	O
,	O
left	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
reliability	B-X
and	B-X
validity	B-X
of	B-X
the	B-X
Short	B-X
Self-Efficacy	B-X
for	B-X
Exercise	B-X
(	B-X
SSEE	B-X
)	B-X
and	B-X
Short	B-X
Outcome	B-X
Expectations	B-X
for	B-X
Exercise	B-X
(	B-X
SOEE	B-X
)	B-X
scales	B-X
in	B-X
stroke	B-X
survivors	B-X
and	B-X
their	B-X
relationship	B-X
to	B-X
regular	B-X
exercise	B-X
.	B-X
There	B-X
was	B-X
evidence	B-X
for	B-X
internal	B-X
consistency	B-X
with	B-X
alpha	B-X
coefficients	B-X
of	B-X
.86	B-X
for	B-X
the	B-X
SSEE	B-X
and	B-X
.90	B-X
for	B-X
the	B-X
SOEE	B-X
.	B-X
R	B-X
(	B-X
2	B-X
)	B-X
values	B-X
ranged	B-X
from	B-X
.38	B-X
to	B-X
.70	B-X
in	B-X
the	B-X
SSEE	B-X
and	B-X
from	B-X
.47	B-X
to	B-X
.78	B-X
in	B-X
the	B-X
SOEE	B-X
.	B-X
Likewise	B-X
,	B-X
there	B-X
was	B-X
evidence	B-X
of	B-X
construct	B-X
validity	B-X
of	B-X
the	B-X
SSEE	B-X
and	B-X
the	B-X
SOEE	B-X
;	B-X
self-efficacy	B-X
expectations	B-X
significantly	B-X
influenced	B-X
exercise	B-X
and	B-X
accounted	B-X
for	B-X
13	B-X
%	B-X
of	B-X
the	B-X
variance	B-X
in	B-X
exercise	B-X
,	B-X
and	B-X
outcome	B-X
expectations	B-X
explained	B-X
an	B-X
additional	B-X
2	B-X
%	B-X
of	B-X
the	B-X
variance	B-X
in	B-X
exercise	B-X
,	B-X
supporting	B-X
that	B-X
the	B-X
SOEE	B-X
and	B-X
the	B-X
SSEE	B-X
are	B-X
reliable	B-X
and	B-X
valid	B-X
scales	B-X
.	B-X

Whereas	O
RPS3	B-Protein
remained	O
cytosolic	O
in	O
IKKbeta	B-Protein
(	O
SSAA	O
)	O
-	O
expressing	O
cells	O
(	O
Fig	O
.	O
2c	O
,	O
right	O
)	O
,	O
a	O
substantial	O
proportion	O
of	O
RPS3	B-Protein
translocated	O
to	O
the	O
nucleus	O
in	O
cells	O
expressing	O
IKKbeta	B-Protein
(	O
SSEE	O
)	O
(	O
Fig	O
.	O
2c	O
,	O
right	O
)	O
.	O

The	O
percentage	O
of	O
cells	O
containing	O
detectable	O
nuclear	O
RPS3	B-Protein
increased	O
5	O
-	O
fold	O
in	O
IKKbeta	B-Protein
(	O
SSEE	O
)	O
-	O
expressing	O
cells	O
,	O
but	O
not	O
in	O
IKKbeta	B-Protein
(	O
SSAA	O
)	O
-	O
expressing	O
ones	O
(	O
Fig	O
.	O
2d	O
and	O
Supplementary	O
Fig	O
.	O
2	O
)	O
.	O

Thus	O
,	O
IKKbeta	B-Protein
activity	O
is	O
necessary	O
and	O
sufficient	O
for	O
RPS3	B-Protein
nuclear	O
translocation	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
activating	O
stimuli	O
.	O

IkappaBalpha	B-Protein
degradation	O
and	O
RPS3	B-Protein
nuclear	O
translocation	O
<EOS>	B-X
The	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
strain	B-X
EDL933	B-X
carries	B-X
two	B-X
copies	B-X
of	B-X
non-locus	B-X
of	B-X
enterocyte	B-X
effacement	B-X
(	B-X
LEE	B-X
)	B-X
-encoded	B-X
protein	B-X
H	B-X
,	B-X
designated	B-X
NleH1	B-X
and	B-X
NleH2	B-X
,	B-X
both	B-X
of	B-X
which	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
complexes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
EHEC	B-X
and	B-X
EPEC	B-X
NleH	B-X
effectors	B-X
are	B-X
functionally	B-X
equivalent	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
affect	B-X
RPS3	B-X
nuclear	B-X
translocation	B-X
.	B-X
NleH1	B-X
,	B-X
but	B-X
not	B-X
NleH2	B-X
,	B-X
inhibited	B-X
NF-κB	B-X
activity	B-X
without	B-X
altering	B-X
the	B-X
kinetics	B-X
of	B-X
IκBα	B-X
phosphorylation/degradation	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
binding	B-X
RPS3	B-X
,	B-X
we	B-X
found	B-X
that	B-X
NleH1	B-X
and	B-X
NleH2	B-X
are	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
an	B-X
additional	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
E.	B-X
coli	B-X
NleH	B-X
effectors	B-X
may	B-X
regulate	B-X
the	B-X
extent	B-X
and	B-X
duration	B-X
of	B-X
NF-κB	B-X
activation	B-X
after	B-X
their	B-X
T3SS-dependent	B-X
translocation	B-X
.	B-X

Importin	O
-	O
alpha	O
regulates	O
the	O
nuclear	O
import	O
of	O
NF	O
-	O
kappaB	O
Rel	B-Protein
subunits23	O
,	O
24	O
.	O

RPS3	B-Protein
harbors	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
sequence	O
and	O
its	O
nuclear	O
translocation	O
occurs	O
in	O
parallel	O
to	O
,	O
but	O
independently	O
of	O
,	O
p65	B-Protein
translocation6	O
.	O

We	O
envisioned	O
that	O
RPS3	B-Protein
could	O
also	O
utilize	O
the	O
importin	O
-	O
alpha	O
/	O
beta	O
pathway	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
RPS3	B-Protein
association	O
with	O
importin	O
-	O
alpha	O
,	O
but	O
not	O
importin	O
-	O
beta	O
,	O
was	O
enhanced	O
in	O
TNF	O
-	O
stimulated	O
cells	O
(	O
Fig	O
.	O
3a	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
RPS3	B-Protein
binding	O
to	O
importin	O
-	O
alpha	O
is	O
essential	O
for	O
nuclear	O
translocation	O
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

Since	O
IkappaBalpha	B-Protein
degradation	O
is	O
a	O
prerequisite	O
to	O
unmask	O
the	O
NLS	O
of	O
p65	B-Protein
,	O
and	O
both	O
RPS3	B-Protein
and	O
IkappaBalpha	B-Protein
bind	O
to	O
p65	B-Protein
in	O
the	O
cytoplasmic	O
inhibitory	O
complex	O
,	O
we	O
tested	O
whether	O
IkappaBalpha	B-Protein
degradation	O
is	O
required	O
for	O
the	O
liberation	O
of	O
RPS3	B-Protein
.	O

We	O
measured	O
the	O
association	O
of	O
RPS3	B-Protein
with	O
importin	O
-	O
alpha	O
in	O
293T	O
cells	O
overexpressing	O
wild	O
-	O
type	O
IkappaBalpha	B-Protein
or	O
an	O
IkappaBalpha	B-Protein
mutant	O
(	O
SSAA	O
)	O
resistant	O
to	O
IKKbeta	B-Protein
-	O
induced	O
phosphorylation	O
and	O
degradation	O
.	O

In	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
IkappaBalpha	B-Protein
,	O
TNF	O
stimulation	O
augmented	O
the	O
interaction	O
of	O
RPS3	B-Protein
and	O
importin	O
-	O
alpha	O
to	O
a	O
similar	O
degree	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
.	O

By	O
contrast	O
,	O
we	O
observed	O
that	O
the	O
RPS3	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
was	O
abolished	O
by	O
the	O
presence	O
of	O
non	O
-	O
degradable	O
IkappaBalpha	B-Protein
(	O
Fig	O
.	O
3b	O
)	O
.	O

To	O
examine	O
whether	O
IkappaBalpha	B-Protein
is	O
the	O
only	O
cytoplasmic	O
barrier	O
precluding	O
RPS3	B-Protein
nuclear	O
translocation	O
,	O
we	O
measured	O
both	O
RPS3	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
and	O
nuclear	O
RPS3	B-Protein
after	O
reducing	O
IkappaBalpha	B-Protein
expression	O
.	O

Compared	O
with	O
nonspecific	O
siRNA	O
,	O
siRNA	B-Protein
targeting	O
of	O
IkappaBalpha	B-Protein
completely	O
depleted	O
IkappaBalpha	B-Protein
in	O
Jurkat	O
cells	O
(	O
Fig	O
.	O
3c	O
,	O
input	O
)	O
.	O

Nevertheless	O
,	O
the	O
RPS3	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
was	O
not	O
augmented	O
(	O
Fig	O
.	O
3c	O
)	O
,	O
nor	O
was	O
significant	O
nuclear	O
RPS3	B-Protein
detected	O
(	O
Fig	O
.	O
3d	O
)	O
.	O

Moreover	O
,	O
cells	O
treated	O
with	O
sodium	O
pervanadate	O
(	O
Pv	O
)	O
to	O
induce	O
IkappaBalpha	B-Protein
degradation	O
through	O
an	O
IKK	O
-	O
independent	O
mechanism25	O
-	O
27	O
did	O
not	O
show	O
increased	O
association	O
between	O
RPS3	B-Protein
and	O
importin	O
-	O
alpha	O
(	O
Fig	O
.	O
3e	O
and	O
Supplementary	O
Fig	O
.	O
3b	O
)	O
or	O
nuclear	O
accumulation	O
of	O
RPS3	B-Protein
,	O
despite	O
complete	O
IkappaBalpha	B-Protein
degradation	O
(	O
Supplementary	O
Fig	O
.	O
3c	O
)	O
.	O

We	O
further	O
examined	O
whether	O
a	O
subsequent	O
NF	O
-	O
kappaB	O
activation	O
signal	O
independently	O
promotes	O
the	O
importin	O
-	O
alpha	O
association	O
and	O
nuclear	O
transport	O
of	O
RPS3	B-Protein
after	O
IkappaBalpha	B-Protein
degradation	O
.	O

We	O
found	O
that	O
TNF	O
stimulation	O
following	O
Pv	O
treatment	O
was	O
required	O
for	O
the	O
RPS3	B-Protein
-	O
importin	O
-	O
alpha	O
association	O
,	O
comparable	O
to	O
TNF	O
stimulation	O
alone	O
(	O
Fig	O
.	O
3e	O
)	O
.	O

Thus	O
,	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
degradation	O
itself	O
is	O
required	O
but	O
not	O
sufficient	O
to	O
cause	O
RPS3	B-Protein
association	O
with	O
importin	O
-	O
alpha	O
followed	O
by	O
nuclear	O
translocation	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
NF-kappaB	B-X
mainly	B-X
occurs	B-X
via	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
-mediated	B-X
phosphorylation	B-X
of	B-X
inhibitory	B-X
molecules	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
.	B-X
Optimal	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
also	B-X
requires	B-X
phosphorylation	B-X
of	B-X
NF-kappaB	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
p65	B-X
,	B-X
within	B-X
their	B-X
transactivation	B-X
domain	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
kinases	B-X
in	B-X
response	B-X
to	B-X
distinct	B-X
stimuli	B-X
.	B-X
Whether	B-X
,	B-X
and	B-X
how	B-X
,	B-X
phosphorylation	B-X
modulates	B-X
the	B-X
function	B-X
of	B-X
other	B-X
NF-kappaB	B-X
and	B-X
IkappaB	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
B-cell	B-X
lymphoma	B-X
3	B-X
,	B-X
remains	B-X
unclear	B-X
.	B-X
Because	B-X
deregulation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
IkappaB	B-X
phosphorylations	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
chronic	B-X
inflammatory	B-X
diseases	B-X
and	B-X
cancer	B-X
,	B-X
newly	B-X
designed	B-X
drugs	B-X
targeting	B-X
these	B-X
constitutively	B-X
activated	B-X
signalling	B-X
pathways	B-X
represent	B-X
promising	B-X
therapeutic	B-X
tools	B-X
.	B-X

Rather	O
,	O
an	O
additional	O
signal	O
,	O
potentially	O
IKKbeta	B-Protein
phosphorylation	O
of	O
RPS3	B-Protein
,	O
is	O
required	O
.	O

IKKbeta	B-Protein
phosphorylates	O
RPS3	B-Protein
at	O
serine	O
209	O

Although	O
originally	O
defined	O
as	O
the	O
kinase	O
that	O
phosphorylates	O
IkappaB19	O
,	O
IKKbeta	B-Protein
also	O
phosphorylates	O
unrelated	O
substrates	O
including	O
14	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
3beta	I-Protein
and	O
Bcl10	B-Protein
,	O
which	O
lack	O
the	O
IKK	O
consensus	O
motif	O
(	O
DpSGYXpS	O
/	O
T	O
)	O
28	O
.	O

We	O
therefore	O
hypothesized	O
that	O
IKKbeta	B-Protein
could	O
directly	O
phosphorylate	O
RPS3	B-Protein
.	O

By	O
in	O
vitro	O
kinase	O
assays	O
using	O
recombinant	O
IKK	O
and	O
RPS3	B-Protein
proteins	O
,	O
we	O
observed	O
strong	O
incorporation	O
of	O
32P	O
in	O
autophosphorylatd	O
IKKalpha	B-Protein
and	O
IKKbeta	B-Protein
(	O
Fig	O
.	O
4a	O
,	O
lanes	O
2	O
-	O
7	O
)	O
as	O
well	O
as	O
phosporylated	O
GST	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	O
1	O
-	O
54	O
)	O
(	O
Supplementary	O
Fig	O
.	O
4	O
)	O
,	O
but	O
not	O
the	O
GST	B-Protein
protein	O
alone	O
(	O
Fig	O
.	O
4a	O
,	O
lanes	O
3	O
and	O
6	O
)	O
,	O
when	O
either	O
IKKalpha	B-Protein
or	O
IKKbeta	B-Protein
was	O
used	O
.	O
<EOS>	B-X
IκB	B-X
kinase	B-X
β	B-X
(	B-X
IKKβ	B-X
)	B-X
,	B-X
the	B-X
predominant	B-X
catalytic	B-X
subunit	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
,	B-X
is	B-X
required	B-X
for	B-X
canonical	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
has	B-X
been	B-X
implicated	B-X
as	B-X
the	B-X
critical	B-X
molecular	B-X
link	B-X
between	B-X
inflammation	B-X
and	B-X
cardiometabolic	B-X
diseases	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
IKKβ	B-X
has	B-X
diverse	B-X
and	B-X
unexpected	B-X
roles	B-X
in	B-X
mediating	B-X
adiposity	B-X
,	B-X
insulin	B-X
sensitivity	B-X
,	B-X
glucose	B-X
homeostasis	B-X
,	B-X
vascular	B-X
function	B-X
,	B-X
and	B-X
atherogenesis	B-X
through	B-X
complex	B-X
mechanisms	B-X
.	B-X
IKKβ	B-X
has	B-X
been	B-X
demonstrated	B-X
as	B-X
a	B-X
critical	B-X
player	B-X
in	B-X
the	B-X
development	B-X
of	B-X
cardiometabolic	B-X
diseases	B-X
and	B-X
is	B-X
implicated	B-X
as	B-X
a	B-X
promising	B-X
therapeutic	B-X
target	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
functions	B-X
of	B-X
IKKβ	B-X
in	B-X
mediating	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
cardiometabolic	B-X
diseases	B-X
.	B-X

We	O
discovered	O
that	O
GST	B-Protein
-	I-Protein
RPS3	I-Protein
could	O
be	O
phosphorylated	O
by	O
IKKbeta	B-Protein
,	O
but	O
not	O
IKKalpha	B-Protein
,	O
in	O
vitro	O
(	O
Fig	O
.	O
4a	O
,	O
compare	O
lanes	O
4	O
and	O
7	O
)	O
.	O

To	O
identify	O
the	O
RPS3	B-Protein
amino	O
acid	O
residue	O
(	O
s	O
)	O
phosphorylated	O
by	O
IKKbeta	B-Protein
,	O
we	O
performed	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
analyses	O
using	O
in	O
vitro	O
phosphorylated	O
RPS3	B-Protein
.	O

The	O
results	O
indicated	O
that	O
IKKbeta	B-Protein
phosphorylated	O
S209	O
,	O
located	O
in	O
the	O
RPS3	B-Protein
C	O
-	O
terminus	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

RPS3	B-Protein
amino	O
acid	O
sequence	O
alignment	O
revealed	O
that	O
S209	O
is	O
conserved	O
in	O
many	O
species	O
throughout	O
phylogeny	O
with	O
the	O
exception	O
of	O
Caenorhabditis	O
elegans	O
and	O
Schizosaccharomyces	O
pombe	O
,	O
two	O
organisms	O
that	O
do	O
not	O
possess	O
the	O
NF	O
-	O
kappaB	O
signal	O
pathway	O
(	O
Supplementary	O
Fig	O
.	O
5	O
)	O
.	O

To	O
verify	O
biochemically	O
that	O
S209	O
is	O
an	O
IKKbeta	B-Protein
substrate	O
,	O
we	O
performed	O
32P	O
-	O
labeling	O
in	O
vitro	O
kinase	B-Protein
assays	O
with	O
recombinant	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	B-Protein
proteins	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
protein	O
,	O
the	O
S209A	O
mutation	O
reduced	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
4c	O
)	O
.	O

There	O
might	O
be	O
alternative	O
phosphorylation	O
site	O
(	O
s	O
)	O
under	O
these	O
conditions	O
given	O
modest	O
residual	O
phosphorylated	O
RPS3	B-Protein
(	O
Fig	O
.	O
4c	O
)	O
.	O

RPS3	B-Protein
S209	O
does	O
not	O
fall	O
within	O
a	O
conventional	O
IKK	O
recognition	O
motif	O
,	O
but	O
rather	O
resides	O
in	O
a	O
sequence	O
motif	O
(	O
XXXpS	O
/	O
TXXE	O
)	O
,	O
potentially	O
recognized	O
by	O
casein	O
kinase	O
II	O
(	O
CK2	O
)	O
.	O

Although	O
IKKbeta	B-Protein
kinase	O
can	O
display	O
a	O
CK2	O
-	O
like	O
phosphorylation	O
specificity29	O
,	O
no	O
CK2	O
protein	O
was	O
detectable	O
in	O
our	O
recombinant	O
IKK	O
proteins	O
(	O
Supplementary	O
Fig	O
.	O
6	O
)	O
.	O

Thus	O
,	O
RPS3	B-Protein
S209	O
phosphorylation	O
was	O
due	O
to	O
the	O
alternate	O
specificity	O
of	O
the	O
IKKbeta	B-Protein
kinase	O
rather	O
than	O
any	O
trace	O
amount	O
of	O
CK2	O
bound	O
to	O
IKKs	O
.	O

To	O
determine	O
whether	O
S209	O
is	O
the	O
critical	O
site	O
at	O
which	O
IKKbeta	B-Protein
phosphorylates	O
RPS3	B-Protein
in	O
living	O
cells	O
,	O
we	O
transfected	O
the	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
Flag	B-Protein
-	I-Protein
RPS3	I-Protein
alone	O
,	O
or	O
together	O
with	O
IKKbeta	B-Protein
into	O
cells	O
.	O
<EOS>	B-X
Microglia-mediated	B-X
neuroinflammation	B-X
plays	B-X
a	B-X
dual	B-X
role	B-X
in	B-X
various	B-X
brain	B-X
diseases	B-X
due	B-X
to	B-X
distinct	B-X
microglial	B-X
phenotypes	B-X
,	B-X
including	B-X
deleterious	B-X
M1	B-X
and	B-X
neuroprotective	B-X
M2	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
antagonizing	B-X
PPARγ	B-X
promoted	B-X
LPS-stimulated	B-X
changes	B-X
in	B-X
polarization	B-X
from	B-X
the	B-X
M1	B-X
to	B-X
the	B-X
M2	B-X
phenotype	B-X
in	B-X
primary	B-X
microglia	B-X
.	B-X
The	B-X
LKB1	B-X
inhibitor	B-X
radicicol	B-X
or	B-X
knocking	B-X
down	B-X
LKB1	B-X
prevented	B-X
autophagy	B-X
improvement	B-X
and	B-X
the	B-X
M1-to-M2	B-X
phenotype	B-X
shift	B-X
by	B-X
T0070907	B-X
.	B-X
Simultaneously	B-X
,	B-X
we	B-X
found	B-X
that	B-X
knocking	B-X
down	B-X
PPARγ	B-X
in	B-X
BV2	B-X
microglial	B-X
cells	B-X
also	B-X
activated	B-X
LKB1-AMPK	B-X
signaling	B-X
and	B-X
inhibited	B-X
NFκB-IKKβ	B-X
activation	B-X
,	B-X
which	B-X
are	B-X
similar	B-X
to	B-X
the	B-X
effects	B-X
of	B-X
antagonizing	B-X
PPARγ	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
that	B-X
antagonizing	B-X
PPARγ	B-X
promotes	B-X
the	B-X
M1-to-M2	B-X
phenotypic	B-X
shift	B-X
in	B-X
LPS-induced	B-X
microglia	B-X
,	B-X
which	B-X
might	B-X
be	B-X
due	B-X
to	B-X
improved	B-X
autophagy	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
LKB1-AMPK	B-X
signaling	B-X
pathway	B-X
.	B-X

Indeed	O
,	O
we	O
observed	O
that	O
overexpressing	O
IKKbeta	B-Protein
enhanced	O
Flag	B-Protein
-	I-Protein
RPS3	I-Protein
phosphorylation	O
,	O
but	O
phosphorylation	O
was	O
effectively	O
eliminated	O
by	O
alanine	O
substitution	O
indicating	O
that	O
S209	O
is	O
the	O
predominant	O
target	O
site	O
for	O
IKKbeta	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
4d	O
)	O
.	O

We	O
next	O
generated	O
a	O
phospho	B-Protein
-	I-Protein
S209	I-Protein
RPS3	I-Protein
antibody	I-Protein
and	O
confirmed	O
that	O
endogenous	O
RPS3	B-Protein
was	O
phosphorylated	O
at	O
S209	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
upon	O
TNF	O
stimulation	O
(	O
Fig	O
.	O
4e	O
)	O
.	O

Thus	O
,	O
the	O
RPS3	B-Protein
C	O
-	O
terminal	O
tail	O
potentially	O
contains	O
an	O
important	O
regulatory	O
site	O
.	O

Phosphorylation	O
of	O
RPS3	B-Protein
and	O
its	O
NF	O
-	O
kappaB	O
function	O
<EOS>	B-X
NF-κB	B-X
is	B-X
a	B-X
major	B-X
gene	B-X
regulator	B-X
in	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
is	B-X
an	B-X
NF-κB	B-X
subunit	B-X
that	B-X
directs	B-X
specific	B-X
gene	B-X
transcription	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
how	B-X
nuclear	B-X
translocation	B-X
of	B-X
RPS3	B-X
is	B-X
regulated	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
by	B-X
the	B-X
kinase	B-X
IKKβ	B-X
was	B-X
crucial	B-X
for	B-X
nuclear	B-X
localization	B-X
of	B-X
RPS3	B-X
in	B-X
response	B-X
to	B-X
activating	B-X
stimuli	B-X
.	B-X
Moreover	B-X
,	B-X
virulence	B-X
protein	B-X
NleH1	B-X
of	B-X
the	B-X
foodborne	B-X
pathogen	B-X
Escherichia	B-X
coli	B-X
strain	B-X
O157	B-X
:	B-X
H7	B-X
specifically	B-X
inhibited	B-X
phosphorylation	B-X
of	B-X
RPS3	B-X
Ser209	B-X
and	B-X
blocked	B-X
RPS3	B-X
function	B-X
,	B-X
thereby	B-X
promoting	B-X
bacterial	B-X
colonization	B-X
and	B-X
diarrhea	B-X
but	B-X
resulting	B-X
in	B-X
less	B-X
mortality	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet-infection	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
IKKβ-dependent	B-X
modification	B-X
of	B-X
a	B-X
specific	B-X
amino	B-X
acid	B-X
in	B-X
RPS3	B-X
promoted	B-X
specific	B-X
NF-κB	B-X
functions	B-X
that	B-X
underlie	B-X
the	B-X
molecular	B-X
pathogenetic	B-X
mechanisms	B-X
of	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
.	B-X

We	O
next	O
examined	O
whether	O
S209	O
phosphorylation	O
plays	O
a	O
role	O
in	O
the	O
nuclear	O
translocation	O
of	O
RPS3	B-Protein
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

Subcellular	O
fractions	O
from	O
either	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	B-Protein
-	O
transfected	O
cells	O
were	O
prepared	O
and	O
blotted	O
for	O
heat	O
-	O
shock	O
protein	O
90	O
(	O
hsp90	O
)	O
,	O
a	O
cytoplasmic	O
protein	O
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
a	O
nuclear	O
protein	O
,	O
confirming	O
a	O
clean	O
separation	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

As	O
expected	O
,	O
PMA	O
+	O
I	O
stimulation	O
triggered	O
wild	O
-	O
type	O
Flag	B-Protein
-	I-Protein
RPS3	I-Protein
nuclear	O
translocation	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

However	O
,	O
RPS3	B-Protein
(	O
S209A	O
)	O
nuclear	O
translocation	O
was	O
attenuated	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

We	O
also	O
tested	O
the	O
impact	O
of	O
activating	O
NF	O
-	O
kappaB	O
by	O
overexpressing	O
IKKbeta	B-Protein
on	O
RPS3	B-Protein
nuclear	O
translocation	O
.	O

IKKbeta	B-Protein
overexpression	O
activated	O
NF	O
-	O
kappaB	O
measured	O
by	O
luciferase	B-Protein
assays	O
(	O
Supplementary	O
Fig	O
.	O
7	O
)	O
,	O
and	O
also	O
induced	O
the	O
nuclear	O
translocation	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
S209A	O
,	O
RPS3	B-Protein
(	O
Fig	O
.	O
5b	O
)	O
.	O

These	O
data	O
suggest	O
that	O
S209	O
phosphorylation	O
is	O
critical	O
for	O
the	O
NF	O
-	O
kappaB	O
activation	O
-	O
induced	O
RPS3	B-Protein
nuclear	O
translocation	O
.	O

To	O
examine	O
the	O
role	O
of	O
S209	O
phosphorylation	O
of	O
RPS3	B-Protein
to	O
its	O
NF	O
-	O
kappaB	O
function6	O
,	O
7	O
,	O
30	O
,	O
we	O
silenced	O
endogenous	O
RPS3	B-Protein
expression	O
using	O
an	O
siRNA	O
that	O
targets	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
RPS3	B-Protein
mRNA	O
,	O
followed	O
by	O
complementation	O
with	O
either	O
wild	O
-	O
type	O
or	O
S209A	O
mutant	O
RPS3	B-Protein
via	O
transfection	O
.	O

As	O
expected	O
,	O
RPS3	B-Protein
siRNA	I-Protein
severely	O
reduced	O
endogenous	O
RPS3	B-Protein
abundance	O
compared	O
to	O
NS	O
siRNA	O
,	O
but	O
did	O
not	O
affect	O
the	O
robust	O
expression	O
of	O
Flag	B-Protein
-	I-Protein
tagged	I-Protein
RPS3	I-Protein
from	O
a	O
transfected	O
construct	O
lacking	O
the	O
3	O
'	O
UTR	O
(	O
Fig	O
.	O
5c	O
)	O
.	O

We	O
also	O
found	O
that	O
RPS3	B-Protein
knockdown	O
reduced	O
TNF	O
-	O
induced	O
expression	O
of	O
an	O
Ig	O
kappaB	O
-	O
driven	O
luciferase	B-Protein
construct6	O
(	O
Fig	O
.	O
5d	O
)	O
.	O

The	O
impaired	O
luciferase	B-Protein
signal	O
caused	O
by	O
RPS3	B-Protein
deficiency	O
was	O
completely	O
restored	O
by	O
transfecting	O
wild	O
-	O
type	O
,	O
but	O
not	O
by	O
S209A	O
RPS3	B-Protein
(	O
Fig	O
.	O
5d	O
)	O
,	O
despite	O
equivalent	O
expression	O
(	O
Fig	O
.	O
5c	O
)	O
.	O

Moreover	O
,	O
the	O
failure	O
of	O
S209A	O
RPS3	O
to	O
restore	O
luciferase	O
activity	O
did	O
not	O
result	O
from	O
defective	O
translation	O
because	O
the	O
transient	O
overexpression	O
of	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
was	O
comparable	O
in	O
cells	O
complemented	O
with	O
wild	O
-	O
type	O
or	O
S029A	O
RPS3	B-Protein
(	O
Supplementary	O
Fig	O
.	O
8	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
RPS3	B-Protein
S209	O
phosphorylation	O
is	O
critical	O
for	O
NF	O
-	O
kappaB	O
activity	O
involving	O
the	O
canonical	O
Ig	O
kappaB	O
site	O
.	O

We	O
next	O
used	O
chromatin	O
immunoprecipitation	O
to	O
determine	O
whether	O
S209	O
phosphorylation	O
affects	O
RPS3	B-Protein
and	O
p65	B-Protein
recruitment	O
to	O
specific	O
kappaB	O
sites	O
in	O
intact	O
chromatin	O
during	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
RPS3	B-Protein
knockdown	O
cells	O
,	O
PMA	O
+	O
I	O
stimulated	O
the	O
recruitment	O
of	O
ectopically	O
expressed	O
,	O
Flag	O
-	O
tagged	O
wild	O
-	O
type	O
,	O
but	O
not	O
S209A	O
RPS3	B-Protein
to	O
the	O
kappaB	O
sites	O
of	O
the	O
NFKBIA	B-Protein
and	O
IL8	B-Protein
promoters	O
(	O
Fig	O
.	O
5e	O
)	O
.	O

While	O
expressing	O
RPS3	B-Protein
S209A	O
had	O
no	O
impact	O
on	O
p65	B-Protein
nuclear	O
translocation	O
,	O
it	O
substantially	O
attenuated	O
p65	B-Protein
recruitment	O
(	O
Fig	O
.	O
5e	O
)	O
.	O

Additional	O
experiments	O
revealed	O
that	O
p65	B-Protein
attraction	O
to	O
RPS3	B-Protein
-	O
independent	O
NF	O
-	O
kappaB	O
target	O
gene	O
promoters	O
such	O
as	O
CD25	B-Protein
was	O
increased	O
(	O
Supplementary	O
Fig	O
.	O
9	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
observations6	O
.	O

There	O
was	O
no	O
significant	O
Flag	B-Protein
-	I-Protein
RPS3	I-Protein
or	O
p65	B-Protein
recruitment	O
to	O
ACTB	B-Protein
promoter	O
lacking	O
kappaB	O
sites	O
(	O
Fig	O
.	O
5e	O
)	O
,	O
suggesting	O
the	O
recruitment	O
was	O
kappaB	O
site	O
-	O
specific	O
.	O

Thus	O
,	O
the	O
recruitment	O
of	O
RPS3	B-Protein
as	O
well	O
as	O
the	O
contingent	O
recruitment	O
of	O
p65	B-Protein
to	O
key	O
promoters	O
depended	O
on	O
S209	O
.	O

Interleukin	B-Protein
8	I-Protein
(	O
IL	B-Protein
-	I-Protein
8	I-Protein
)	O
secretion	O
induced	O
by	O
either	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
agonist	O
stimulation	O
or	O
PMA	O
+	O
I	O
was	O
decreased	O
as	O
a	O
consequence	O
of	O
reduced	O
RPS3	B-Protein
/	O
p65	B-Protein
recruitment	O
to	O
the	O
IL8	B-Protein
kappaB	O
sites	O
in	O
the	O
presence	O
of	O
S209A	O
mutant	O
compared	O
to	O
wild	O
-	O
type	O
RPS3	B-Protein
(	O
Supplementary	O
Fig	O
.	O
10	O
)	O
.	O

However	O
,	O
cell	O
surface	O
CD25	B-Protein
expression	O
was	O
comparable	O
between	O
the	O
wild	O
-	O
type	O
and	O
S209A	O
RPS3	B-Protein
transfected	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
11	O
)	O
.	O

Therefore	O
,	O
RPS3	B-Protein
S209	O
phosphorylation	O
by	O
IKKbeta	B-Protein
is	O
apparently	O
required	O
for	O
RPS3	B-Protein
in	O
directing	O
NF	O
-	O
kappaB	O
to	O
a	O
specific	O
subset	O
of	O
target	O
genes	O
.	O

NleH1	B-Protein
inhibits	O
RPS3	B-Protein
phosphorylation	O
in	O
vitro	O
<EOS>	B-X
The	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
strain	B-X
EDL933	B-X
carries	B-X
two	B-X
copies	B-X
of	B-X
non-locus	B-X
of	B-X
enterocyte	B-X
effacement	B-X
(	B-X
LEE	B-X
)	B-X
-encoded	B-X
protein	B-X
H	B-X
,	B-X
designated	B-X
NleH1	B-X
and	B-X
NleH2	B-X
,	B-X
both	B-X
of	B-X
which	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
complexes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
describe	B-X
significant	B-X
functional	B-X
differences	B-X
between	B-X
NleH1	B-X
and	B-X
NleH2	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
regulate	B-X
the	B-X
host	B-X
NF-κB	B-X
pathway	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
EHEC	B-X
and	B-X
EPEC	B-X
NleH	B-X
effectors	B-X
are	B-X
functionally	B-X
equivalent	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
affect	B-X
RPS3	B-X
nuclear	B-X
translocation	B-X
.	B-X
NleH1	B-X
,	B-X
but	B-X
not	B-X
NleH2	B-X
,	B-X
inhibited	B-X
NF-κB	B-X
activity	B-X
without	B-X
altering	B-X
the	B-X
kinetics	B-X
of	B-X
IκBα	B-X
phosphorylation/degradation	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
binding	B-X
RPS3	B-X
,	B-X
we	B-X
found	B-X
that	B-X
NleH1	B-X
and	B-X
NleH2	B-X
are	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
an	B-X
additional	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
E.	B-X
coli	B-X
NleH	B-X
effectors	B-X
may	B-X
regulate	B-X
the	B-X
extent	B-X
and	B-X
duration	B-X
of	B-X
NF-κB	B-X
activation	B-X
after	B-X
their	B-X
T3SS-dependent	B-X
translocation	B-X
.	B-X
Complementing	B-X
ΔnleH	B-X
with	B-X
NleH1	B-X
restored	B-X
Citrobacter	B-X
virulence	B-X
and	B-X
colonization	B-X
to	B-X
wild-type	B-X
levels	B-X
,	B-X
whereas	B-X
complementing	B-X
with	B-X
NleH2	B-X
reduced	B-X
them	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
NleH1	B-X
and	B-X
NleH2	B-X
have	B-X
pronounced	B-X
functional	B-X
differences	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
alter	B-X
host	B-X
transcriptional	B-X
responses	B-X
to	B-X
bacterial	B-X
infection	B-X
.	B-X

EHEC	O
pathogens	O
are	O
important	O
causative	O
agents	O
of	O
both	O
foodborne	O
disease	O
and	O
pediatric	O
renal	O
failure31	O
.	O

EHEC	O
utilize	O
T3SS	O
to	O
inject	O
effector	O
proteins	O
directly	O
into	O
intestinal	O
epithelial	O
cells32	O
,	O
a	O
subset	O
of	O
which	O
inhibit	O
NF	O
-	O
kappaB	O
-	O
dependent	O
innate	O
responses9	O
,	O
33	O
-	O
38	O
.	O

The	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
EDL933	O
effector	O
protein	O
NleH1	B-Protein
binds	O
to	O
and	O
attenuates	O
RPS3	B-Protein
nuclear	O
translocation	O
,	O
thus	O
impairing	O
RPS3	B-Protein
-	O
dependent	O
NF	O
-	O
kappaB	O
signaling9	O
.	O

We	O
therefore	O
hypothesized	O
that	O
NleH1	B-Protein
may	O
function	O
by	O
inhibiting	O
RPS3	B-Protein
S209	O
phosphorylation	O
.	O

As	O
expected	O
,	O
transfecting	O
increasing	O
amounts	O
of	O
NleH1	B-Protein
-	I-Protein
HA	I-Protein
plasmid	O
blocked	O
TNFalpha	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
6a	O
-	O
b	O
)	O
9	O
.	O

Remarkably	O
,	O
NleH1	B-Protein
reduced	O
both	O
TNF	B-Protein
-	O
induced	O
,	O
as	O
well	O
as	O
basal	O
RPS3	B-Protein
phosphorylation	O
to	O
roughly	O
20	O
%	O
of	O
vehicle	O
control	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Expressing	O
NleH1	B-Protein
does	O
not	O
interfere	O
with	O
either	O
TNF	B-Protein
-	O
induced	O
IKK	O
activation	O
or	O
IkappaBalpha	B-Protein
degradation	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
NleH1	B-Protein
impact	O
on	O
p65	B-Protein
nuclear	O
translocation9	O
(	O
Fig	O
.	O
6c	O
)	O
.	O
<EOS>	B-X
E.	B-X
coli	B-X
O157	B-X
carries	B-X
two	B-X
genes	B-X
encoding	B-X
the	B-X
effector	B-X
proteins	B-X
NleH1	B-X
and	B-X
NleH2	B-X
which	B-X
are	B-X
87	B-X
%	B-X
identical	B-X
.	B-X
Shigella	B-X
and	B-X
pathogenic	B-X
Escherichia	B-X
coli	B-X
possess	B-X
homologous	B-X
effector	B-X
kinases	B-X
,	B-X
OspG	B-X
and	B-X
NleH1/2	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Escherichia	B-X
coli	B-X
NleH1	B-X
and	B-X
NleH2	B-X
virulence	B-X
proteins	B-X
differentially	B-X
regulate	B-X
host	B-X
transcription	B-X
of	B-X
innate	B-X
immunity	B-X
genes	B-X
.	B-X
The	B-X
mouse	B-X
pathogen	B-X
Citrobacter	B-X
rodentium	B-X
encodes	B-X
one	B-X
NleH	B-X
protein	B-X
,	B-X
which	B-X
functions	B-X
equivalently	B-X
to	B-X
E.	B-X
coli	B-X
NleH1	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
impact	B-X
of	B-X
host	B-X
genetics	B-X
and	B-X
intestinal	B-X
inflammation	B-X
on	B-X
the	B-X
contribution	B-X
of	B-X
NleH	B-X
to	B-X
C.	B-X
rodentium	B-X
colonization	B-X
of	B-X
mice	B-X
differing	B-X
in	B-X
LPS	B-X
responsiveness	B-X
.	B-X
NleH	B-X
expression	B-X
was	B-X
detrimental	B-X
to	B-X
C.	B-X
rodentium	B-X
in	B-X
C57BL/10ScNJ	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
mount	B-X
LPS-induced	B-X
inflammatory	B-X
responses	B-X
.	B-X
This	B-X
phenotype	B-X
was	B-X
reversed	B-X
if	B-X
inflammation	B-X
was	B-X
induced	B-X
by	B-X
chemical	B-X
means	B-X
.	B-X
C.	B-X
rodentium	B-X
that	B-X
expressed	B-X
both	B-X
E.	B-X
coli	B-X
NleH1	B-X
and	B-X
NleH2	B-X
was	B-X
hypervirulent	B-X
in	B-X
C3H/HeJ	B-X
mice	B-X
.	B-X

To	O
determine	O
if	O
NleH1	B-Protein
inhibits	O
RPS3	B-Protein
phosphorylation	O
,	O
we	O
infected	O
HeLa	O
cells	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
strains	O
possessing	O
or	O
lacking	O
either	O
nleH1	B-Protein
(	O
deltanleH1	B-Protein
)	O
or	O
with	O
a	O
strain	O
lacking	O
a	O
functional	O
T3SS	O
unable	O
to	O
inject	O
NleH1	B-Protein
into	O
mammalian	O
cells	O
(	O
deltaescN	B-Protein
)	O
.	O

In	O
uninfected	O
cells	O
,	O
TNF	B-Protein
-	O
treatment	O
stimulated	O
a	O
~	O
7	O
-	O
fold	O
increase	O
in	O
RPS3	B-Protein
S209	O
phosphorylation	O
,	O
peaking	O
at	O
30	O
minutes	O
(	O
Fig	O
.	O
6d	O
)	O
.	O

By	O
contrast	O
,	O
RPS3	B-Protein
S209	O
phosphorylation	O
was	O
substantially	O
impaired	O
in	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
(	O
Fig	O
.	O
6d	O
)	O
.	O

However	O
,	O
TNF	B-Protein
-	O
induced	O
RPS3	B-Protein
S209	O
phosphorylation	O
was	O
unimpaired	O
in	O
cells	O
infected	O
with	O
either	O
deltanleH1	B-Protein
or	O
deltaescN	B-Protein
(	O
Fig	O
.	O
6d	O
)	O
.	O

We	O
showed	O
previously	O
that	O
wild	O
-	O
type	O
,	O
but	O
not	O
deltanleH1	B-Protein
or	O
deltaescN	B-Protein
E	O
.	O
coli	O
O157	O
:	O
H7	O
significantly	O
attenuated	O
TNF	B-Protein
-	O
induced	O
RPS3	B-Protein
nuclear	O
translocation9	O
.	O
<EOS>	B-X
Repeated	B-X
serial	B-X
in	B-X
vitro	B-X
passage	B-X
of	B-X
Histomonas	B-X
meleagridis	B-X
,	B-X
the	B-X
etiological	B-X
agent	B-X
of	B-X
histomoniasis	B-X
(	B-X
blackhead	B-X
)	B-X
of	B-X
turkeys	B-X
,	B-X
was	B-X
demonstrated	B-X
to	B-X
markedly	B-X
achieve	B-X
attenuation	B-X
and	B-X
reduction	B-X
of	B-X
virulence	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
original	B-X
wild-type	B-X
isolate	B-X
.	B-X
Four	B-X
experiments	B-X
were	B-X
performed	B-X
to	B-X
evaluate	B-X
the	B-X
route	B-X
(	B-X
oral	B-X
vs.	B-X
intracloacal	B-X
)	B-X
and	B-X
age	B-X
(	B-X
day-of-hatch	B-X
vs.	B-X
d	B-X
14	B-X
)	B-X
for	B-X
administration	B-X
of	B-X
attenuated	B-X
H.	B-X
meleagridis	B-X
isolates	B-X
as	B-X
vaccine	B-X
candidates	B-X
against	B-X
homologous	B-X
or	B-X
heterologous	B-X
wild-type	B-X
challenge	B-X
.	B-X
Buford	B-X
P80a	B-X
(	B-X
passage	B-X
80	B-X
,	B-X
assigned	B-X
as	B-X
isolate	B-X
lineage	B-X
``	B-X
a	B-X
''	B-X
following	B-X
repeated	B-X
passage	B-X
)	B-X
was	B-X
selected	B-X
as	B-X
the	B-X
primary	B-X
vaccine	B-X
candidate	B-X
and	B-X
was	B-X
evaluated	B-X
in	B-X
Experiments	B-X
1-3	B-X
.	B-X
Experiment	B-X
4	B-X
evaluated	B-X
selected	B-X
candidates	B-X
of	B-X
attenuated	B-X
PHL2017	B-X
(	B-X
P67	B-X
,	B-X
P129	B-X
)	B-X
and	B-X
Buford	B-X
(	B-X
P80a	B-X
,	B-X
P200a	B-X
,	B-X
P138b	B-X
,	B-X
P198c	B-X
)	B-X
strains	B-X
against	B-X
Buford	B-X
wild-type	B-X
challenge	B-X
.	B-X
As	B-X
has	B-X
been	B-X
demonstrated	B-X
previously	B-X
,	B-X
wild-type	B-X
H.	B-X
meleagridis	B-X
cultures	B-X
administered	B-X
orally	B-X
after	B-X
1	B-X
day	B-X
of	B-X
age	B-X
were	B-X
not	B-X
infective	B-X
in	B-X
the	B-X
current	B-X
studies	B-X
,	B-X
but	B-X
infection	B-X
with	B-X
wild-type	B-X
cultures	B-X
could	B-X
be	B-X
induced	B-X
orally	B-X
at	B-X
day-of-hatch	B-X
.	B-X
Intracloacal	B-X
inoculation	B-X
of	B-X
turkeys	B-X
with	B-X
the	B-X
attenuated	B-X
passaged	B-X
isolates	B-X
as	B-X
vaccine	B-X
candidates	B-X
at	B-X
d	B-X
14	B-X
was	B-X
shown	B-X
to	B-X
produce	B-X
significant	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
protection	B-X
from	B-X
mortality	B-X
,	B-X
reduction	B-X
in	B-X
body	B-X
weight	B-X
gain	B-X
,	B-X
as	B-X
well	B-X
as	B-X
reduction	B-X
in	B-X
hepatic	B-X
and	B-X
cecal	B-X
lesions	B-X
in	B-X
these	B-X
experiments	B-X
following	B-X
challenge	B-X
with	B-X
either	B-X
the	B-X
homologous	B-X
wild-type	B-X
isolate	B-X
or	B-X
from	B-X
a	B-X
wild-type	B-X
strain	B-X
obtained	B-X
years	B-X
later	B-X
from	B-X
a	B-X
geographically	B-X
disparate	B-X
area	B-X
of	B-X
the	B-X
United	B-X
States	B-X
.	B-X
Inoculation	B-X
with	B-X
the	B-X
attenuated	B-X
H.	B-X
meleagridis	B-X
isolates	B-X
at	B-X
day-of-hatch	B-X
,	B-X
either	B-X
orally	B-X
or	B-X
cloacally	B-X
,	B-X
did	B-X
not	B-X
produce	B-X
significant	B-X
protection	B-X
against	B-X
subsequent	B-X
wild-type	B-X
challenge	B-X
.	B-X
While	B-X
offering	B-X
significant	B-X
protection	B-X
with	B-X
minimal	B-X
vaccine-related	B-X
negative	B-X
effects	B-X
,	B-X
the	B-X
protection	B-X
from	B-X
cloacal	B-X
vaccine	B-X
administration	B-X
was	B-X
neither	B-X
significantly	B-X
robust	B-X
nor	B-X
encouraging	B-X
for	B-X
industry	B-X
application	B-X
using	B-X
the	B-X
methods	B-X
evaluated	B-X
in	B-X
the	B-X
present	B-X
manuscript	B-X
since	B-X
mortalities	B-X
and	B-X
lesions	B-X
were	B-X
not	B-X
completely	B-X
reduced	B-X
which	B-X
could	B-X
thereby	B-X
potentially	B-X
allow	B-X
transmission	B-X
from	B-X
residual	B-X
infection	B-X
and	B-X
shedding	B-X
within	B-X
a	B-X
flock	B-X
.	B-X

The	O
parallel	O
between	O
RPS3	B-Protein
phosphorylation	O
and	O
its	O
nuclear	O
translocation	O
during	O
E	O
.	O
coli	O
infection	O
provides	O
evidence	O
in	O
the	O
context	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
disease	O
process	O
that	O
RPS3	B-Protein
S209	O
phosphorylation	O
is	O
important	O
for	O
nuclear	O
translocation	O
.	O

Our	O
discovery	O
that	O
NleH1	B-Protein
inhibits	O
RPS3	B-Protein
S209	O
phosphorylation	O
suggested	O
that	O
it	O
should	O
also	O
blocks	O
RPS3	B-Protein
-	O
dependent	O
NF	O
-	O
kappaB	O
target	O
gene	O
transcription	O
(	O
e	O
.	O
g	O
.	O
IL8	B-Protein
,	O
NFKBIA	B-Protein
,	O
and	O
TNFAIP3	B-Protein
)	O
.	O

Indeed	O
,	O
these	O
genes	O
were	O
only	O
modestly	O
upregulated	O
in	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
,	O
but	O
significantly	O
induced	O
in	O
cells	O
infected	O
with	O
either	O
deltanleH1	B-Protein
or	O
deltaescN	B-Protein
strains	O
(	O
Fig	O
.	O
6e	O
)	O
.	O

In	O
contrast	O
,	O
deleting	O
nleH1	B-Protein
had	O
no	O
impact	O
on	O
the	O
expression	O
of	O
RPS3	O
-	O
independent	O
genes	O
,	O
including	O
CD25	B-Protein
and	O
TNFSF13B	B-Protein
(	O
Supplementary	O
Fig	O
.	O
12	O
)	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
NleH1	B-Protein
specifically	O
inhibits	O
the	O
protective	O
immune	O
response	O
by	O
directly	O
blocking	O
RPS3	B-Protein
S209	O
phosphorylation	O
and	O
thereby	O
impairing	O
critical	O
RPS3	B-Protein
-	O
dependent	O
NF	O
-	O
kappaB	O
target	O
genes	O
.	O

NleH1	B-Protein
inhibits	O
RPS3	B-Protein
S209	O
phosphorylation	O
in	O
vivo	O

We	O
previously	O
utilized	O
a	O
gnotobiotic	O
piglet	O
infection	O
model	O
to	O
determine	O
that	O
piglets	O
infected	O
with	O
deltanleH1	B-Protein
mutant	O
died	O
more	O
rapidly	O
than	O
those	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

Piglets	O
infected	O
with	O
deltanleH1	B-Protein
displayed	O
clinical	O
disease	O
consistent	O
with	O
a	O
robust	O
inflammatory	O
response	O
,	O
but	O
with	O
reduced	O
bacterial	O
colonization	O
and	O
little	O
diarrhea9	O
.	O

While	O
seemingly	O
paradoxical	O
,	O
based	O
on	O
our	O
cell	O
culture	O
data	O
(	O
Fig	O
.	O
6d	O
)	O
,	O
we	O
hypothesized	O
that	O
NleH1	B-Protein
blocked	O
RPS3	B-Protein
S209	O
phosphorylation	O
in	O
vivo	O
,	O
thereby	O
preventing	O
RPS3	B-Protein
nuclear	O
translocation	O
in	O
infected	O
piglets	O
.	O

We	O
isolated	O
piglet	O
colons	O
at	O
necropsy	O
,	O
and	O
subjected	O
them	O
to	O
immunohistochemistry	O
using	O
our	O
phospho	O
-	O
RPS3	O
antibody	O
.	O

Consistent	O
with	O
in	O
vitro	O
data	O
,	O
piglets	O
infected	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
exhibited	O
diffuse	O
and	O
low	O
intensity	O
phospho	O
-	O
RPS3	B-Protein
staining	O
,	O
whereas	O
in	O
piglets	O
infected	O
with	O
deltanleH1	B-Protein
mutant	O
,	O
phospho	O
-	O
RPS3	B-Protein
expression	O
was	O
florid	O
and	O
intense	O
(	O
Fig	O
.	O
6f	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
NleH1	B-Protein
inhibits	O
RPS3	B-Protein
S209	O
phosphorylation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
might	O
benefit	O
the	O
bacterium	O
in	O
colonization	O
and	O
transmission	O
.	O

NleH1	B-Protein
steers	O
the	O
IKKbeta	B-Protein
substrate	O
specificities	O

NleH1	B-Protein
is	O
an	O
autophosphorylated	O
serine	O
-	O
threonine	O
kinase	O
,	O
which	O
depends	O
on	O
the	O
lysine	O
159	O
(	O
K159	O
)	O
9	O
.	O

To	O
explore	O
the	O
mechanism	O
by	O
which	O
NleH1	B-Protein
inhibits	O
RPS3	B-Protein
S209	O
phosphorylation	O
,	O
we	O
first	O
performed	O
an	O
in	O
vitro	O
kinase	O
assay	O
with	O
purified	O
wild	O
-	O
type	O
His	B-Protein
-	I-Protein
NleH1	I-Protein
protein	O
and	O
a	O
mutant	O
His	B-Protein
-	I-Protein
NleH1	I-Protein
(	O
K159A	O
)	O
protein	O
,	O
confirming	O
that	O
NleH1	B-Protein
is	O
autophosphorylated	O
and	O
the	O
K159A	O
is	O
an	O
NleH1	B-Protein
kinase	O
-	O
dead	O
mutant	O
(	O
Fig	O
.	O
7a	O
)	O
.	O

To	O
examine	O
whether	O
the	O
kinase	O
activity	O
is	O
required	O
for	O
NleH1	B-Protein
to	O
inhibit	O
IKKbeta	B-Protein
phosphorlyation	O
of	O
RPS3	B-Protein
on	O
S209	O
,	O
we	O
ectopically	O
expressing	O
either	O
wild	O
-	O
type	O
or	O
K159A	O
NleH1	B-Protein
in	O
293T	O
cells	O
.	O

Wild	O
-	O
type	O
NleH1	B-Protein
expression	O
significantly	O
reduced	O
TNF	O
-	O
induced	O
RPS3	B-Protein
S209	O
phosphorylation	O
,	O
whereas	O
the	O
K159A	O
mutant	O
failed	O
to	O
do	O
so	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

Thus	O
NleH1	B-Protein
kinase	O
activity	O
is	O
required	O
to	O
protect	O
RPS3	B-Protein
from	O
IKKbeta	B-Protein
-	O
mediated	O
phosphorylation	O
.	O

Citrobacter	O
rodentium	O
is	O
a	O
mouse	O
pathogen	O
that	O
shares	O
pathogenic	O
strategies	O
with	O
E	O
.	O
coli	O
39	O
,	O
most	O
notably	O
for	O
our	O
investigation	O
,	O
C	O
.	O
rodentium	O
NleH	B-Protein
inhibited	O
RPS3	B-Protein
nuclear	O
translocation	O
and	O
RPS3	B-Protein
-	O
dependent	O
NF	O
-	O
kappaB	O
luciferase	B-Protein
activity	O
to	O
an	O
extent	O
equivalent	O
to	O
E	O
.	O
coli	O
NleH1	B-Protein
(	O
ref	O
.	O
9	O
)	O
.	O

We	O
assayed	O
RPS3	B-Protein
S209	O
phosphorylation	O
in	O
HeLa	O
cells	O
infected	O
with	O
different	O
C	O
.	O
rodentium	O
strains	O
.	O

In	O
uninfected	O
cells	O
,	O
TNF	O
-	O
treatment	O
stimulated	O
a	O
~	O
3	O
.	O
5	O
-	O
fold	O
increase	O
in	O
RPS3	B-Protein
S209	O
phosphorylation	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Such	O
augmentation	O
of	O
RPS3	B-Protein
phosphorylation	O
was	O
reduced	O
by	O
about	O
60	O
%	O
by	O
wild	O
-	O
type	O
C	O
.	O
rodentium	O
infection	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

However	O
,	O
RPS3	B-Protein
phosphorylation	O
was	O
enhanced	O
when	O
cells	O
were	O
infected	O
with	O
a	O
C	O
.	O
rodentium	O
strain	O
lacking	O
NleH	B-Protein
(	O
Fig	O
.	O
7c	O
,	O
deltanleH	B-Protein
)	O
.	O

We	O
further	O
examined	O
the	O
role	O
of	O
NleH1	B-Protein
kinase	O
activity	O
using	O
the	O
C	O
.	O
rodentium	O
deltanleH	B-Protein
strain	O
as	O
a	O
background	O
on	O
which	O
to	O
express	O
either	O
wild	O
-	O
type	O
or	O
K159A	O
E	O
.	O
coli	O
NleH1	B-Protein
.	O

Complementing	O
deltanleH	B-Protein
mutant	O
with	O
wild	O
-	O
type	O
NleH1	B-Protein
almost	O
abolished	O
TNF	B-Protein
-	O
induced	O
RPS3	B-Protein
S209	O
phosphorylation	O
whereas	O
complementing	O
with	O
K159A	O
failed	O
to	O
inhibit	O
RPS3	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
NleH1	B-Protein
kinase	O
activity	O
is	O
required	O
to	O
block	O
RPS3	B-Protein
S209	O
phosphorylation	O
.	O

We	O
next	O
examined	O
whether	O
the	O
inhibitory	O
activity	O
of	O
NleH1	B-Protein
is	O
sufficiently	O
robust	O
to	O
impair	O
the	O
strong	O
nuclear	O
translocation	O
of	O
RPS3	B-Protein
trigged	O
by	O
the	O
constitutively	O
-	O
active	O
IKKbeta	B-Protein
(	O
IKKbeta	B-Protein
[	O
SSEE	O
]	O
)	O
(	O
Fig	O
.	O
2d	O
)	O
.	O

We	O
found	O
that	O
ectopically	O
expressing	O
either	O
wild	O
-	O
type	O
or	O
SSEE	B-Protein
IKKbeta	I-Protein
proteins	O
,	O
triggered	O
more	O
RPS3	B-Protein
nuclear	O
translocation	O
than	O
the	O
kinase	O
-	O
dead	O
IKKbeta	B-Protein
(	O
SSAA	O
)	O
protein	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

RPS3	B-Protein
nuclear	O
accumulation	O
was	O
substantially	O
retarded	O
by	O
infecting	O
cells	O
with	O
wild	O
-	O
type	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

In	O
contrast	O
,	O
infecting	O
with	O
either	O
deltanleH1	B-Protein
or	O
deltaescN	B-Protein
strains	O
only	O
slightly	O
impaired	O
RPS3	B-Protein
nuclear	O
translocation	O
in	O
either	O
IKKbeta	B-Protein
-	O
or	O
IKKbeta	B-Protein
(	O
SSEE	O
)	O
-	O
expressing	O
cells	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

As	O
expected	O
,	O
E	O
.	O
coli	O
infections	O
did	O
not	O
affect	O
the	O
RPS3	B-Protein
nuclear	O
translocation	O
in	O
IKKbeta	B-Protein
(	O
SSAA	O
)	O
-	O
expressing	O
cells	O
,	O
where	O
NF	O
-	O
kappaB	O
signaling	O
was	O
low	O
(	O
Fig	O
.	O
7d	O
)	O
.	O

Thus	O
,	O
during	O
infection	O
NleH1	B-Protein
is	O
sufficiently	O
potent	O
to	O
inhibit	O
RPS3	B-Protein
nuclear	O
translocation	O
even	O
in	O
cells	O
expressing	O
constitutively	O
-	O
activated	O
IKKbeta	B-Protein
.	O

We	O
examined	O
whether	O
NleH1	B-Protein
could	O
directly	O
phosphorylate	O
IKKbeta	B-Protein
thus	O
inhibiting	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
S209	O
phosphorylation	O
.	O

We	O
performed	O
in	O
vitro	O
kinase	O
assays	O
using	O
immunoprecipitated	O
Flag	B-Protein
-	I-Protein
IKKbeta	I-Protein
(	I-Protein
K44A	I-Protein
)	I-Protein
as	O
substrate	O
and	O
recombinant	O
His	B-Protein
-	I-Protein
NleH1	I-Protein
as	O
kinase	O
,	O
so	O
that	O
IKKbeta	B-Protein
autophosphorylation	O
would	O
not	O
obscure	O
NleH1	B-Protein
-	O
induced	O
phosphorylation	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
detectable	O
32P	O
incorporation	O
in	O
IKKbeta	B-Protein
(	O
Supplementary	O
Fig	O
.	O
13	O
)	O
,	O
thus	O
ruling	O
out	O
this	O
possibility	O
.	O

We	O
then	O
tested	O
the	O
hypothesis	O
that	O
NleH1	B-Protein
could	O
alter	O
the	O
IKKbeta	B-Protein
substrate	O
specificities	O
.	O

To	O
this	O
end	O
,	O
we	O
performed	O
in	O
vitro	O
kinase	O
assays	O
using	O
both	O
CK2	O
and	O
IKK	O
substrates	O
for	O
IKKbeta	B-Protein
.	O

As	O
expected	O
,	O
IKKbeta	B-Protein
phosphorylated	O
RPS3	B-Protein
(	O
Fig	O
.	O
7e	O
,	O
lane	O
7	O
)	O
and	O
GST	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	O
1	O
-	O
54	O
)	O
protein	O
(	O
Fig	O
.	O
7e	O
,	O
lane	O
9	O
)	O
,	O
demonstrating	O
it	O
harbors	O
either	O
CK2	O
or	O
IKK	O
substrate	O
specificity	O
.	O
<EOS>	B-X
The	B-X
action	B-X
of	B-X
protein	B-X
kinases	B-X
and	B-X
protein	B-X
phosphatases	B-X
is	B-X
essential	B-X
for	B-X
multiple	B-X
physiological	B-X
responses	B-X
.	B-X
Each	B-X
protein	B-X
kinase	B-X
displays	B-X
its	B-X
own	B-X
unique	B-X
substrate	B-X
specificity	B-X
,	B-X
and	B-X
a	B-X
regulatory	B-X
mechanism	B-X
that	B-X
may	B-X
be	B-X
modulated	B-X
by	B-X
association	B-X
with	B-X
other	B-X
proteins	B-X
.	B-X
Protein	B-X
kinases	B-X
are	B-X
classified	B-X
by	B-X
the	B-X
target	B-X
amino	B-X
acid	B-X
in	B-X
their	B-X
substrates	B-X
.	B-X
Some	B-X
protein	B-X
kinases	B-X
can	B-X
phosphorylate	B-X
both	B-X
serine/threonine	B-X
,	B-X
as	B-X
well	B-X
as	B-X
tyrosine	B-X
residues	B-X
.	B-X
This	B-X
group	B-X
of	B-X
kinases	B-X
has	B-X
been	B-X
known	B-X
as	B-X
dual	B-X
specificity	B-X
kinases	B-X
.	B-X
Unlike	B-X
the	B-X
dual	B-X
specificity	B-X
kinases	B-X
,	B-X
a	B-X
heterogeneous	B-X
group	B-X
of	B-X
protein	B-X
phosphatases	B-X
are	B-X
known	B-X
as	B-X
dual-specificity	B-X
phosphatases	B-X
.	B-X
These	B-X
phosphatases	B-X
remove	B-X
phosphate	B-X
groups	B-X
from	B-X
tyrosine	B-X
and	B-X
serine/threonine	B-X
residues	B-X
on	B-X
their	B-X
substrate	B-X
.	B-X
Dual-specificity	B-X
phosphatases	B-X
are	B-X
important	B-X
signal	B-X
transduction	B-X
enzymes	B-X
that	B-X
regulate	B-X
various	B-X
cellular	B-X
processes	B-X
in	B-X
coordination	B-X
with	B-X
protein	B-X
kinases	B-X
.	B-X
The	B-X
protein	B-X
kinase-phosphoproteins	B-X
interactions	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
obesity	B-X
.	B-X
In	B-X
obesity	B-X
,	B-X
the	B-X
pro-	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
adipokines	B-X
and	B-X
cytokines	B-X
through	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mainly	B-X
involve	B-X
the	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappaB	B-X
)	B-X
and	B-X
the	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
systems	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inhibitor	B-X
of	B-X
kappaB-kinase	B-X
beta	B-X
(	B-X
IKK	B-X
beta	B-X
)	B-X
.	B-X
Impairment	B-X
of	B-X
insulin	B-X
signaling	B-X
in	B-X
obesity	B-X
is	B-X
largely	B-X
mediated	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IKKbeta	B-X
and	B-X
the	B-X
JNK	B-X
.	B-X
Additionally	B-X
,	B-X
obesity-activated	B-X
calcium/calmodulin	B-X
dependent-protein	B-X
kinase	B-X
II/p38	B-X
suppresses	B-X
insulin-induced	B-X
protein	B-X
kinase	B-X
B	B-X
phosphorylation	B-X
by	B-X
activating	B-X
the	B-X
ER	B-X
stress	B-X
effector	B-X
,	B-X
activating	B-X
transcription	B-X
factor-4	B-X
.	B-X
Obese	B-X
adults	B-X
with	B-X
vascular	B-X
endothelial	B-X
dysfunction	B-X
have	B-X
greater	B-X
endothelial	B-X
cells	B-X
activation	B-X
of	B-X
unfolded	B-X
protein	B-X
response	B-X
stress	B-X
sensors	B-X
,	B-X
RNA-dependent	B-X
protein	B-X
kinase-like	B-X
ER	B-X
eukaryotic	B-X
initiation	B-X
factor-2alpha	B-X
kinase	B-X
(	B-X
PERK	B-X
)	B-X
and	B-X
activating	B-X
transcription	B-X
factor-6	B-X
.	B-X
The	B-X
transcriptional	B-X
regulation	B-X
of	B-X
adipogenesis	B-X
in	B-X
obesity	B-X
is	B-X
influenced	B-X
by	B-X
AGC	B-X
(	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
PKG	B-X
,	B-X
PKC	B-X
)	B-X
family	B-X
signaling	B-X
kinases	B-X
.	B-X
Like	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
AMP	B-X
)	B-X
-activated	B-X
protein	B-X
kinase	B-X
(	B-X
AMPK	B-X
)	B-X
and	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
,	B-X
N-terminal	B-X
Per-ARNT-Sim	B-X
(	B-X
PAS	B-X
)	B-X
kinase	B-X
are	B-X
nutrient	B-X
responsive	B-X
protein	B-X
kinases	B-X
and	B-X
important	B-X
for	B-X
proper	B-X
regulation	B-X
of	B-X
glucose	B-X
metabolism	B-X
in	B-X
mammals	B-X
at	B-X
both	B-X
the	B-X
hormonal	B-X
and	B-X
cellular	B-X
level	B-X
.	B-X

Preincubation	O
of	O
IKKbeta	B-Protein
with	O
NleH1	B-Protein
reduced	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
phosphorylation	O
,	O
i	O
.	O
e	O
.	O
the	O
CK2	O
kinase	O
specificity	O
,	O
but	O
not	O
IKKbeta	B-Protein
-	O
mediated	O
GST	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
phosphorylation	O
,	O
i	O
.	O
e	O
.	O
the	O
IKK	O
kinase	O
specificity	O
(	O
Fig	O
.	O
7e	O
)	O
.	O

Control	O
experiments	O
revealed	O
no	O
NleH1	B-Protein
-	O
mediated	O
phosphorylation	O
or	O
autophosphorylation	O
of	O
RPS3	B-Protein
or	O
GST	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	O
Fig	O
.	O
7e	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
nleH1	B-X
and	B-X
nleH2	B-X
genes	B-X
encode	B-X
T3SS	B-X
effectors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa-light-chain-enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcriptional	B-X
complexes	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
co-localized	B-X
with	B-X
RPS3	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
but	B-X
not	B-X
in	B-X
cell	B-X
nuclei	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
both	B-X
NleH1	B-X
and	B-X
NleH2	B-X
was	B-X
required	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
RPS3	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
are	B-X
autophosphorylated	B-X
Ser/Thr	B-X
protein	B-X
kinases	B-X
,	B-X
but	B-X
their	B-X
binding	B-X
to	B-X
RPS3	B-X
is	B-X
independent	B-X
of	B-X
kinase	B-X
activity	B-X
.	B-X
NleH1	B-X
,	B-X
but	B-X
not	B-X
NleH2	B-X
,	B-X
reduced	B-X
the	B-X
nuclear	B-X
abundance	B-X
of	B-X
RPS3	B-X
without	B-X
altering	B-X
the	B-X
p50	B-X
or	B-X
p65	B-X
NF-kappaB	B-X
subunits	B-X
or	B-X
affecting	B-X
the	B-X
phosphorylation	B-X
state	B-X
or	B-X
abundance	B-X
of	B-X
the	B-X
inhibitory	B-X
NF-kappaB	B-X
chaperone	B-X
IkappaBalpha	B-X
NleH1	B-X
repressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
RPS3/NF-kappaB-dependent	B-X
reporter	B-X
plasmid	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
transcription	B-X
of	B-X
RPS3-independent	B-X
reporters	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
NleH2	B-X
stimulated	B-X
RPS3-dependent	B-X
transcription	B-X
,	B-X
as	B-X
well	B-X
as	B-X
an	B-X
AP-1-dependent	B-X
reporter	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
NleH1	B-X
(	B-X
N40-K45	B-X
)	B-X
that	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
responsible	B-X
for	B-X
the	B-X
inhibitory	B-X
activity	B-X
of	B-X
NleH1	B-X
toward	B-X
RPS3	B-X
.	B-X

Taken	O
together	O
,	O
NleH1	B-Protein
blocks	O
the	O
CK2	O
substrate	O
specificity	O
of	O
IKKbeta	B-Protein
thus	O
inhibiting	O
the	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
S209	O
phosphorylation	O
thus	O
representing	O
a	O
novel	O
strategy	O
by	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
to	O
alter	O
the	O
host	O
innate	O
immune	O
response	O
.	O

RPS3	B-Protein
was	O
previously	O
demonstrated	O
to	O
function	O
as	O
an	O
integral	O
subunit	O
conferring	O
NF	O
-	O
kappaB	O
regulatory	O
specificity6	O
.	O

Here	O
we	O
sought	O
to	O
elucidate	O
how	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
triggers	O
RPS3	B-Protein
to	O
translocate	O
and	O
participate	O
in	O
NF	O
-	O
kappaB	O
function	O
in	O
the	O
nucleus	O
.	O

We	O
demonstrate	O
that	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
S209	O
phosphorylation	O
represents	O
a	O
critical	O
determinant	O
in	O
governing	O
its	O
nuclear	O
import	O
thus	O
unveiling	O
a	O
novel	O
mechanism	O
behind	O
NF	O
-	O
kappaB	O
regulatory	O
specificity	O
.	O

IKKbeta	B-Protein
is	O
the	O
major	O
kinase	O
that	O
phosphorylates	O
IkappaBs	O
in	O
the	O
classical	O
NF	O
-	O
kappaB	O
pathway	O
,	O
leading	O
to	O
their	O
subsequent	O
degradation40	O
.	O

Strikingly	O
,	O
RPS3	B-Protein
possesses	O
not	O
any	O
consensus	O
IKK	O
motif	O
;	O
instead	O
,	O
S209	O
is	O
centered	O
in	O
a	O
consensus	O
CK2	O
motif	O
.	O

The	O
recent	O
observation	O
that	O
human	O
IKKbeta	B-Protein
displayed	O
CK2	O
-	O
like	O
phosphorylation	O
specificity29	O
coincides	O
with	O
our	O
evidence	O
that	O
recombinant	O
IKKbeta	B-Protein
,	O
but	O
not	O
IKKalpha	B-Protein
,	O
phosphorylated	O
RPS3	B-Protein
.	O

We	O
found	O
this	O
phosphorylation	O
is	O
a	O
critical	O
modulation	O
for	O
RPS3	B-Protein
nuclear	O
translocation	O
(	O
via	O
importin	O
-	O
alpha	O
)	O
and	O
engagement	O
in	O
specific	O
NF	O
-	O
kappaB	O
transcription	O
.	O

CK2	O
was	O
previously	O
shown	O
to	O
phosphorylate	O
p65	B-Protein
and	O
to	O
bind	O
to	O
and	O
phosphorylate	O
IKKbeta41	B-Protein
-	O
43	O
,	O
however	O
,	O
we	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
IKKbeta	B-Protein
-	O
bound	O
CK2	O
could	O
account	O
for	O
the	O
observed	O
RPS3	B-Protein
phosphorylation	O
because	O
no	O
CK2	O
was	O
detected	O
in	O
the	O
IKKbeta	B-Protein
preparations	O
used	O
for	O
the	O
in	O
vitro	O
kinase	O
assay	O
.	O

Because	O
RPS3	B-Protein
only	O
harbors	O
the	O
CK2	O
motif	O
and	O
not	O
a	O
traditional	O
IKK	O
motif	O
,	O
this	O
RPS3	O
regulatory	O
function	O
could	O
explain	O
why	O
IKK	O
harbors	O
the	O
alternative	O
substrate	O
phosphorylation	O
capability	O
.	O

More	O
importantly	O
,	O
our	O
study	O
has	O
elucidated	O
how	O
RPS3	B-Protein
is	O
biochemically	O
integrated	O
into	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
in	O
a	O
manner	O
that	O
is	O
pivotal	O
for	O
the	O
pathogenesis	O
of	O
foodborne	O
pathogen	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
S209	O
phosphorylation	O
is	O
a	O
critical	O
target	O
modulated	O
by	O
this	O
pathogen	O
to	O
subvert	O
host	O
NF	O
-	O
kappaB	O
signaling	O
.	O

The	O
bacterial	O
effector	O
NleH1	B-Protein
specifically	O
binds	O
to	O
RPS3	B-Protein
once	O
injected	O
into	O
host	O
cells	O
and	O
profoundly	O
suppresses	O
NF	O
-	O
kappaB	O
and	O
its	O
attendant	O
protective	O
immune	O
responses9	O
.	O

Our	O
data	O
now	O
show	O
that	O
NleH1	B-Protein
selectively	O
inhibits	O
RPS3	B-Protein
phosphorylation	O
,	O
thus	O
retarding	O
its	O
nuclear	O
translocation	O
and	O
subsequent	O
NF	O
-	O
kappaB	O
function	O
,	O
without	O
altering	O
other	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Although	O
NleH1	B-Protein
did	O
not	O
directly	O
phosphorylate	O
IKKbeta	B-Protein
,	O
its	O
kinase	O
activity	O
was	O
required	O
to	O
inhibit	O
IKKbeta	B-Protein
-	O
mediated	O
RPS3	B-Protein
S209	O
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
guides	B-X
NF-κB	B-X
subunits	B-X
to	B-X
specific	B-X
κB	B-X
sites	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
innate	B-X
response	B-X
to	B-X
bacterial	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
nleH1	B-X
and	B-X
nleH2	B-X
genes	B-X
encode	B-X
T3SS	B-X
effectors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa-light-chain-enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcriptional	B-X
complexes	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
co-localized	B-X
with	B-X
RPS3	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
but	B-X
not	B-X
in	B-X
cell	B-X
nuclei	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
both	B-X
NleH1	B-X
and	B-X
NleH2	B-X
was	B-X
required	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
RPS3	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
are	B-X
autophosphorylated	B-X
Ser/Thr	B-X
protein	B-X
kinases	B-X
,	B-X
but	B-X
their	B-X
binding	B-X
to	B-X
RPS3	B-X
is	B-X
independent	B-X
of	B-X
kinase	B-X
activity	B-X
.	B-X
NleH1	B-X
,	B-X
but	B-X
not	B-X
NleH2	B-X
,	B-X
reduced	B-X
the	B-X
nuclear	B-X
abundance	B-X
of	B-X
RPS3	B-X
without	B-X
altering	B-X
the	B-X
p50	B-X
or	B-X
p65	B-X
NF-kappaB	B-X
subunits	B-X
or	B-X
affecting	B-X
the	B-X
phosphorylation	B-X
state	B-X
or	B-X
abundance	B-X
of	B-X
the	B-X
inhibitory	B-X
NF-kappaB	B-X
chaperone	B-X
IkappaBalpha	B-X
NleH1	B-X
repressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
RPS3/NF-kappaB-dependent	B-X
reporter	B-X
plasmid	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
transcription	B-X
of	B-X
RPS3-independent	B-X
reporters	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
NleH2	B-X
stimulated	B-X
RPS3-dependent	B-X
transcription	B-X
,	B-X
as	B-X
well	B-X
as	B-X
an	B-X
AP-1-dependent	B-X
reporter	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
NleH1	B-X
(	B-X
N40-K45	B-X
)	B-X
that	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
responsible	B-X
for	B-X
the	B-X
inhibitory	B-X
activity	B-X
of	B-X
NleH1	B-X
toward	B-X
RPS3	B-X
.	B-X

Many	O
bacteria	O
pathogens	O
have	O
products	O
that	O
target	O
key	O
kinases	O
to	O
inactivate	O
them	O
in	O
host	O
cells	O
,	O
whereas	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
employed	O
NleH1	B-Protein
to	O
steer	O
the	O
substrate	O
specificity	O
of	O
IKKbeta	B-Protein
thus	O
specifically	O
fine	O
-	O
tuning	O
host	O
NF	O
-	O
kappaB	O
signaling	O
.	O

This	O
could	O
represent	O
a	O
novel	O
strategy	O
to	O
fine	O
-	O
tune	O
host	O
NF	O
-	O
kappaB	O
signaling	O
that	O
could	O
be	O
shared	O
by	O
other	O
pathogens	O
.	O

These	O
data	O
provide	O
new	O
insights	O
into	O
the	O
poorly	O
understood	O
action	O
mechanism	O
for	O
most	O
T3SS	O
effectors	O
.	O

NleH1	B-Protein
attenuates	O
the	O
transcription	O
of	O
RPS3	B-Protein
-	O
dependent	O
,	O
but	O
not	O
all	O
,	O
NF	O
-	O
kappaB	O
target	O
genes	O
,	O
in	O
particular	O
those	O
genes	O
associated	O
with	O
acute	O
proinflammatory	O
responses	O
,	O
including	O
IL8	B-Protein
and	O
TNF	O
.	O

In	O
contrast	O
,	O
NleH1	B-Protein
does	O
not	O
block	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
translocation	O
,	O
which	O
suggests	O
that	O
certain	O
p65	B-Protein
-	O
dependent	O
but	O
RPS3	B-Protein
-	O
independent	O
NF	O
-	O
kappaB	O
target	O
genes	O
might	O
thus	O
be	O
beneficial	O
for	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
to	O
replicate	O
and	O
disseminate	O
in	O
the	O
host	O
.	O
<EOS>	B-X
Enteric	B-X
bacterial	B-X
pathogens	B-X
cause	B-X
food	B-X
borne	B-X
disease	B-X
,	B-X
which	B-X
constitutes	B-X
an	B-X
enormous	B-X
economic	B-X
and	B-X
health	B-X
burden	B-X
.	B-X
Enterohemorrhagic	B-X
Escherichia	B-X
coli	B-X
(	B-X
EHEC	B-X
)	B-X
causes	B-X
a	B-X
severe	B-X
bloody	B-X
diarrhea	B-X
following	B-X
transmission	B-X
to	B-X
humans	B-X
through	B-X
various	B-X
means	B-X
,	B-X
including	B-X
contaminated	B-X
beef	B-X
and	B-X
vegetable	B-X
products	B-X
,	B-X
water	B-X
,	B-X
or	B-X
through	B-X
contact	B-X
with	B-X
animals	B-X
.	B-X
EHEC	B-X
also	B-X
causes	B-X
a	B-X
potentially	B-X
fatal	B-X
kidney	B-X
disease	B-X
(	B-X
hemolytic	B-X
uremic	B-X
syndrome	B-X
)	B-X
for	B-X
which	B-X
there	B-X
is	B-X
no	B-X
effective	B-X
treatment	B-X
or	B-X
prophylaxis	B-X
.	B-X
EHEC	B-X
and	B-X
other	B-X
enteric	B-X
pathogens	B-X
(	B-X
e.g.	B-X
,	B-X
enteropathogenic	B-X
E.	B-X
coli	B-X
(	B-X
EPEC	B-X
)	B-X
,	B-X
Salmonella	B-X
,	B-X
Shigella	B-X
,	B-X
Yersinia	B-X
)	B-X
utilize	B-X
a	B-X
type	B-X
III	B-X
secretion	B-X
system	B-X
(	B-X
T3SS	B-X
)	B-X
to	B-X
inject	B-X
virulence	B-X
proteins	B-X
(	B-X
effectors	B-X
)	B-X
into	B-X
host	B-X
cells	B-X
.	B-X
While	B-X
it	B-X
is	B-X
known	B-X
that	B-X
T3SS	B-X
effectors	B-X
subvert	B-X
host	B-X
cell	B-X
function	B-X
to	B-X
promote	B-X
diarrheal	B-X
disease	B-X
and	B-X
bacterial	B-X
transmission	B-X
,	B-X
in	B-X
many	B-X
cases	B-X
,	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
effectors	B-X
bind	B-X
to	B-X
host	B-X
proteins	B-X
and	B-X
disrupt	B-X
the	B-X
normal	B-X
function	B-X
of	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
completely	B-X
characterized	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
nleH1	B-X
and	B-X
nleH2	B-X
genes	B-X
encode	B-X
T3SS	B-X
effectors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
human	B-X
ribosomal	B-X
protein	B-X
S3	B-X
(	B-X
RPS3	B-X
)	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa-light-chain-enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NF-kappaB	B-X
)	B-X
transcriptional	B-X
complexes	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
co-localized	B-X
with	B-X
RPS3	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
but	B-X
not	B-X
in	B-X
cell	B-X
nuclei	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
both	B-X
NleH1	B-X
and	B-X
NleH2	B-X
was	B-X
required	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
RPS3	B-X
.	B-X
NleH1	B-X
and	B-X
NleH2	B-X
are	B-X
autophosphorylated	B-X
Ser/Thr	B-X
protein	B-X
kinases	B-X
,	B-X
but	B-X
their	B-X
binding	B-X
to	B-X
RPS3	B-X
is	B-X
independent	B-X
of	B-X
kinase	B-X
activity	B-X
.	B-X
NleH1	B-X
,	B-X
but	B-X
not	B-X
NleH2	B-X
,	B-X
reduced	B-X
the	B-X
nuclear	B-X
abundance	B-X
of	B-X
RPS3	B-X
without	B-X
altering	B-X
the	B-X
p50	B-X
or	B-X
p65	B-X
NF-kappaB	B-X
subunits	B-X
or	B-X
affecting	B-X
the	B-X
phosphorylation	B-X
state	B-X
or	B-X
abundance	B-X
of	B-X
the	B-X
inhibitory	B-X
NF-kappaB	B-X
chaperone	B-X
IkappaBalpha	B-X
NleH1	B-X
repressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
RPS3/NF-kappaB-dependent	B-X
reporter	B-X
plasmid	B-X
,	B-X
but	B-X
did	B-X
not	B-X
inhibit	B-X
the	B-X
transcription	B-X
of	B-X
RPS3-independent	B-X
reporters	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
NleH2	B-X
stimulated	B-X
RPS3-dependent	B-X
transcription	B-X
,	B-X
as	B-X
well	B-X
as	B-X
an	B-X
AP-1-dependent	B-X
reporter	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
region	B-X
of	B-X
NleH1	B-X
(	B-X
N40-K45	B-X
)	B-X
that	B-X
is	B-X
at	B-X
least	B-X
partially	B-X
responsible	B-X
for	B-X
the	B-X
inhibitory	B-X
activity	B-X
of	B-X
NleH1	B-X
toward	B-X
RPS3	B-X
.	B-X
Deleting	B-X
nleH1	B-X
from	B-X
E.	B-X
coli	B-X
O157	B-X
:	B-X
H7	B-X
produced	B-X
a	B-X
hypervirulent	B-X
phenotype	B-X
in	B-X
a	B-X
gnotobiotic	B-X
piglet	B-X
model	B-X
of	B-X
Shiga	B-X
toxin-producing	B-X
E.	B-X
coli	B-X
infection	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
NleH	B-X
may	B-X
disrupt	B-X
host	B-X
innate	B-X
immune	B-X
responses	B-X
by	B-X
binding	B-X
to	B-X
a	B-X
cofactor	B-X
of	B-X
host	B-X
transcriptional	B-X
complexes	B-X
.	B-X

By	O
selectively	O
inhibiting	O
RPS3	B-Protein
and	O
its	O
attendant	O
NF	O
-	O
kappaB	O
function	O
with	O
NleH1	B-Protein
,	O
the	O
pathogen	O
achieves	O
the	O
ability	O
to	O
increase	O
colonization	O
and	O
diarrhea	O
yet	O
limiting	O
the	O
mortality	O
of	O
the	O
host	O
.	O

This	O
seemingly	O
paradoxical	O
combination	O
of	O
effects	O
make	O
sense	O
when	O
one	O
considers	O
that	O
increased	O
bacterial	O
load	O
and	O
diarrhea	O
together	O
with	O
survival	O
of	O
the	O
infected	O
host	O
would	O
promote	O
the	O
spreading	O
of	O
the	O
bacteria	O
among	O
a	O
population	O
of	O
susceptible	O
individuals	O
.	O

Such	O
complex	O
and	O
paradoxical	O
pathological	O
effects	O
that	O
influence	O
the	O
spread	O
of	O
disease	O
are	O
often	O
poorly	O
understood	O
at	O
the	O
molecular	O
level	O
.	O

Our	O
data	O
elucidate	O
how	O
alterations	O
in	O
selective	O
NF	O
-	O
kappaB	O
function	O
,	O
achieved	O
by	O
impeding	O
RPS3	B-Protein
,	O
but	O
not	O
altering	O
p65	B-Protein
nuclear	O
translocation	O
,	O
can	O
influence	O
specific	O
cytokines	O
that	O
affect	O
bacterial	O
colonization	O
,	O
diarrhea	O
diseases	O
and	O
mortality	O
.	O

It	O
may	O
be	O
fruitful	O
in	O
attempting	O
to	O
understand	O
other	O
infectious	O
and	O
autoimmune	O
diseases	O
involving	O
NF	O
-	O
kappaB	O
to	O
consider	O
selective	O
effects	O
of	O
subunits	O
such	O
as	O
RPS3	B-Protein
in	O
addition	O
to	O
global	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

Cells	O
and	O
Reagents	O
<EOS>	B-X
Transfection	B-X
reagents	B-X
affect	B-X
Extracellular	B-X
Vesicle	B-X
cargo	B-X
transfer	B-X
to	B-X
recipient	B-X
cells	B-X
:	B-X
The	B-X
importance	B-X
of	B-X
appropriate	B-X
controls	B-X
in	B-X
EV	B-X
research	B-X
.	B-X

Jurkat	O
E6	O
.	O
1	O
,	O
HEK293T	O
and	O
HeLa	O
cells	O
were	O
cultured	O
in	O
RPMI	O
1640	O
and	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
2	O
mM	O
glutamine	O
,	O
and	O
100	O
U	O
/	O
ml	O
each	O
of	O
penicillin	O
and	O
streptomycin	O
,	O
respectively	O
.	O

IkappaBalpha	O
(	O
C	O
-	O
21	O
,	O
sc	O
-	O
371	O
)	O
,	O
p65	O
(	O
C	O
-	O
20	O
,	O
sc	O
-	O
372	O
)	O
,	O
and	O
phospho	O
-	O
threonine	O
(	O
H	O
-	O
2	O
,	O
sc	O
-	O
5267	O
)	O
antibodies	O
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
;	O
beta	O
-	O
actin	O
(	O
AC	O
-	O
15	O
,	O
A5441	O
)	O
,	O
Flag	O
(	O
M2	O
,	O
F3165	O
)	O
,	O
HA	O
(	O
HA	O
-	O
7	O
,	O
H3663	O
)	O
,	O
importin	O
-	O
alpha	O
(	O
IM	O
-	O
75	O
,	O
I1784	O
)	O
,	O
and	O
importin	O
-	O
beta	O
(	O
31H4	O
,	O
I2534	O
)	O
antibodies	O
were	O
from	O
Sigma	O
;	O
PARP	O
(	O
C2	O
-	O
10	O
,	O
556362	O
)	O
,	O
IKKalpha	O
(	O
B78	O
-	O
1	O
,	O
556532	O
)	O
,	O
and	O
IKKbeta	O
(	O
24	O
,	O
611254	O
)	O
antibodies	O
were	O
from	O
BD	O
Pharmingen	O
;	O
CK2alpha	O
(	O
31	O
,	O
611610	O
)	O
and	O
Hsp90	O
(	O
68	O
,	O
610418	O
)	O
antibodies	O
were	O
from	O
BD	O
Transduction	O
Laboratories	O
;	O
phospho	O
-	O
IkappaBalpha	O
(	O
5A5	O
,	O
9246S	O
)	O
and	O
phospho	O
-	O
IKKalpha	O
/	O
beta	O
(	O
16A6	O
,	O
2697S	O
)	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
;	O
phospho	O
-	O
serine	O
(	O
AB1603	O
)	O
and	O
phospho	O
-	O
tyrosine	O
(	O
4G10	O
,	O
05	O
-	O
777	O
)	O
antibodies	O
were	O
from	O
Millipore	O
.	O

The	O
rabbit	O
polyclonal	O
RPS3	O
antiserum	O
was	O
as	O
described	O
previously6	O
.	O

The	O
rabbit	O
polyclonal	O
antibody	O
specific	O
for	O
S209	O
phosphorylated	O
RPS3	O
was	O
generated	O
and	O
affinity	O
purified	O
by	O
Primm	O
Biotech	O
using	O
the	O
peptide	O
NH2	O
-	O
CKPLPDHV	O
(	O
Sp	O
)	O
IVE	O
-	O
COOH	O
.	O

Plasmid	O
Constructs	O
<EOS>	B-X
Plasmids	B-X
occupy	B-X
a	B-X
place	B-X
of	B-X
honor	B-X
in	B-X
molecular	B-X
cloning	B-X
:	B-X
They	B-X
were	B-X
used	B-X
in	B-X
the	B-X
first	B-X
recombinant	B-X
DNA	B-X
experiments	B-X
and	B-X
,	B-X
40	B-X
or	B-X
more	B-X
years	B-X
later	B-X
,	B-X
they	B-X
remain	B-X
as	B-X
the	B-X
carriage	B-X
horses	B-X
of	B-X
molecular	B-X
cloning	B-X
.	B-X
Cloning	B-X
in	B-X
plasmid	B-X
vectors	B-X
.	B-X
Gene	B-X
therapeutics	B-X
.	B-X
Plasmid	B-X
DNA	B-X
extracted	B-X
by	B-X
the	B-X
alkaline	B-X
lysis	B-X
method	B-X
was	B-X
inevitably	B-X
contaminated	B-X
with	B-X
nucleotide	B-X
fragments	B-X
.	B-X

The	O
Flag	B-Protein
-	I-Protein
IKKbeta	I-Protein
(	I-Protein
SSEE	I-Protein
)	I-Protein
,	O
Flag	B-Protein
-	I-Protein
IKKbeta	I-Protein
(	I-Protein
SSAA	I-Protein
)	I-Protein
,	O
and	O
HA	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	I-Protein
SSAA	I-Protein
)	I-Protein
constructs	O
were	O
provided	O
by	O
C	O
.	O

Wu	O
(	O
NCI	O
,	O
Bethesda	O
)	O
and	O
U	O
.	O
<EOS>	B-X
Using	B-X
whole-genome	B-X
sequencing	B-X
(	B-X
WGS	B-X
)	B-X
and	B-X
whole-exome	B-X
sequencing	B-X
(	B-X
WES	B-X
)	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
reproducibility	B-X
of	B-X
different	B-X
sample	B-X
types	B-X
with	B-X
varying	B-X
input	B-X
amount	B-X
and	B-X
tumor	B-X
purity	B-X
,	B-X
and	B-X
multiple	B-X
library	B-X
construction	B-X
protocols	B-X
,	B-X
followed	B-X
by	B-X
processing	B-X
with	B-X
nine	B-X
bioinformatics	B-X
pipelines	B-X
.	B-X
Guidelines	B-X
for	B-X
the	B-X
use	B-X
and	B-X
interpretation	B-X
of	B-X
assays	B-X
for	B-X
monitoring	B-X
autophagy	B-X
(	B-X
3rd	B-X
edition	B-X
)	B-X
.	B-X
We	B-X
applied	B-X
our	B-X
INQUSIT	B-X
pipeline	B-X
for	B-X
prioritizing	B-X
genes	B-X
as	B-X
targets	B-X
of	B-X
those	B-X
potentially	B-X
causal	B-X
variants	B-X
,	B-X
using	B-X
gene	B-X
expression	B-X
(	B-X
expression	B-X
quantitative	B-X
trait	B-X
loci	B-X
)	B-X
,	B-X
chromatin	B-X
interaction	B-X
and	B-X
functional	B-X
annotations	B-X
.	B-X
By	B-X
empirical	B-X
process	B-X
and	B-X
U-process	B-X
theories	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
the	B-X
proposed	B-X
estimator	B-X
is	B-X
consistent	B-X
and	B-X
asymptotically	B-X
normal	B-X
with	B-X
a	B-X
closed-form	B-X
consistent	B-X
variance	B-X
estimator	B-X
.	B-X

Siebenlist	O
(	O
NIAID	O
,	O
Bethesda	O
)	O
,	O
respectively	O
.	O
<EOS>	B-X
We	B-X
now	B-X
demonstrate	B-X
that	B-X
MEKK3	B-X
activates	B-X
SEK	B-X
and	B-X
MEK	B-X
,	B-X
the	B-X
known	B-X
kinases	B-X
targeting	B-X
SAPK	B-X
and	B-X
ERK	B-X
,	B-X
respectively	B-X
.	B-X

The	O
HA	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
and	O
IKKbeta	B-Protein
(	I-Protein
K44A	I-Protein
)	I-Protein
-	I-Protein
Flag	I-Protein
plasmids	O
were	O
purchased	O
from	O
Addgene44	O
,	O
45	O
.	O

The	O
Flag	B-Protein
-	I-Protein
RPS3	I-Protein
,	O
GST	B-Protein
-	I-Protein
RPS3	I-Protein
,	O
HA	B-Protein
-	I-Protein
RPS3	I-Protein
,	O
VN	B-Protein
-	I-Protein
HA	I-Protein
,	O
NleH1	B-Protein
-	I-Protein
HA	I-Protein
plasmids	O
were	O
described	O
previously6	O
,	O
9	O
.	O

The	O
point	O
mutants	O
of	O
RPS3	B-Protein
were	O
generated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
using	O
the	O
Quick	O
Change	O
Kit	O
(	O
Stratagene	O
)	O
with	O
primers	O
forward	O
5	O
'	O
-	O
CTGCCTGACCACGTGGCCATTGTGGAACCCAAA	O
-	O
3	O
'	O
and	O
reverse	O
5	O
'	O
-	O
TTTGGGTTCCACAATGGCCACGTGGTCAGGCAG	O
-	O
3	O
'	O
for	O
S209A	O
.	O

All	O
mutants	O
were	O
verified	O
by	O
DNA	O
sequencing	O
.	O
<EOS>	B-X
Eight	B-X
of	B-X
these	B-X
interactions	B-X
(	B-X
ANXA5	B-X
,	B-X
ERdj5	B-X
,	B-X
PDIA4	B-X
,	B-X
P4HB	B-X
,	B-X
PDIA6	B-X
,	B-X
RCN1	B-X
,	B-X
SDF2L1	B-X
,	B-X
and	B-X
TXNDC5	B-X
)	B-X
were	B-X
verified	B-X
at	B-X
the	B-X
western	B-X
blotting	B-X
level	B-X
.	B-X
Mutations	B-X
in	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
may	B-X
result	B-X
in	B-X
various	B-X
pathological	B-X
processes	B-X
.	B-X
Detection	B-X
of	B-X
mutant	B-X
mtDNAs	B-X
is	B-X
a	B-X
problem	B-X
for	B-X
diagnostic	B-X
practice	B-X
that	B-X
is	B-X
complicated	B-X
by	B-X
heteroplasmy	B-X
-	B-X
a	B-X
phenomenon	B-X
of	B-X
the	B-X
inferring	B-X
presence	B-X
of	B-X
at	B-X
least	B-X
two	B-X
allelic	B-X
variants	B-X
of	B-X
the	B-X
mitochondrial	B-X
genome	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
detection	B-X
of	B-X
mutations	B-X
in	B-X
heteroplasmic	B-X
mtDNA	B-X
using	B-X
up-to-date	B-X
methods	B-X
that	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
introduced	B-X
as	B-X
routine	B-X
clinical	B-X
assays	B-X
.	B-X
These	B-X
methods	B-X
can	B-X
be	B-X
used	B-X
for	B-X
detecting	B-X
mutations	B-X
in	B-X
mtDNA	B-X
to	B-X
verify	B-X
diagnosis	B-X
of	B-X
``	B-X
mitochondrial	B-X
disease	B-X
''	B-X
,	B-X
studying	B-X
dynamics	B-X
of	B-X
mutant	B-X
mtDNA	B-X
in	B-X
body	B-X
tissues	B-X
of	B-X
patients	B-X
,	B-X
as	B-X
well	B-X
as	B-X
investigating	B-X
structural	B-X
features	B-X
of	B-X
mtDNAs	B-X
.	B-X
Original	B-X
data	B-X
on	B-X
allele-specific	B-X
discrimination	B-X
of	B-X
m.11778G	B-X
>	B-X
A	B-X
mutation	B-X
by	B-X
droplet	B-X
digital	B-X
PCR	B-X
are	B-X
presented	B-X
,	B-X
which	B-X
demonstrate	B-X
an	B-X
opportunity	B-X
for	B-X
simultaneous	B-X
detection	B-X
and	B-X
quantitative	B-X
assessment	B-X
of	B-X
mutations	B-X
in	B-X
mtDNAs	B-X
.	B-X

32P	O
in	O
vivo	O
Labeling	O
<EOS>	B-X
Intracranial	B-X
injections	B-X
of	B-X
[	B-X
32P	B-X
]	B-X
orthophosphate	B-X
readily	B-X
label	B-X
a	B-X
number	B-X
of	B-X
brain	B-X
phosphoproteins	B-X
as	B-X
resolved	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
these	B-X
in	B-X
vivo	B-X
labeled	B-X
phosphoproteins	B-X
co-migrate	B-X
with	B-X
phosphoproteins	B-X
that	B-X
are	B-X
labeled	B-X
in	B-X
vitro	B-X
by	B-X
incubation	B-X
of	B-X
brain	B-X
membranes	B-X
with	B-X
[	B-X
32P	B-X
]	B-X
ATP	B-X
.	B-X
Two	B-X
of	B-X
the	B-X
major	B-X
in	B-X
vitro	B-X
labeled	B-X
phosphoproteins	B-X
with	B-X
apparent	B-X
molecular	B-X
weights	B-X
of	B-X
47,000	B-X
(	B-X
band	B-X
F1	B-X
)	B-X
and	B-X
41,000	B-X
(	B-X
band	B-X
F2	B-X
)	B-X
are	B-X
rapidly	B-X
labeled	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
electrophoretic	B-X
pattern	B-X
of	B-X
in	B-X
vivo	B-X
labeled	B-X
phosphoproteins	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
altered	B-X
by	B-X
the	B-X
method	B-X
of	B-X
sacrifice	B-X
(	B-X
focused	B-X
microwave	B-X
irradiation	B-X
,	B-X
decapitation	B-X
or	B-X
liquid	B-X
nitrogen	B-X
immersion	B-X
)	B-X
or	B-X
by	B-X
the	B-X
state	B-X
of	B-X
the	B-X
animal	B-X
at	B-X
the	B-X
time	B-X
of	B-X
labeling	B-X
(	B-X
awake	B-X
or	B-X
lightly	B-X
anesthetized	B-X
with	B-X
pentobarbital	B-X
)	B-X
.	B-X
Removal	B-X
of	B-X
phospholipids	B-X
or	B-X
polynucleotides	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
in	B-X
vivo	B-X
labeled	B-X
32P-containing	B-X
bands	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
32P-containing	B-X
bands	B-X
consist	B-X
of	B-X
phosphoester	B-X
linkages	B-X
to	B-X
serine	B-X
or	B-X
threonine	B-X
residues	B-X
.	B-X

HEK	O
293T	O
cells	O
were	O
labeled	O
with	O
2	O
mCi	O
/	O
ml	O
32P	O
-	O
orthophosphate	O
(	O
Perkin	O
Elmer	O
)	O
in	O
phosphate	O
-	O
free	O
medium	O
(	O
Invitrogen	O
)	O
for	O
2	O
h	O
.	O

Cells	O
were	O
then	O
left	O
untreated	O
or	O
treated	O
with	O
TNF	O
(	O
50	O
ng	O
/	O
ml	O
,	O
R	O
&	O
D	O
Systems	O
)	O
for	O
indicated	O
periods	O
.	O
<EOS>	B-X
Neutrophils	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
white	B-X
blood	B-X
cell	B-X
in	B-X
blood	B-X
and	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
preventing	B-X
infections	B-X
as	B-X
part	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
.	B-X
Reduction	B-X
in	B-X
neutrophils	B-X
below	B-X
an	B-X
absolute	B-X
count	B-X
of	B-X
500	B-X
cells/pL	B-X
is	B-X
termed	B-X
severe	B-X
neutropenia	B-X
or	B-X
agranulocytosis	B-X
.	B-X
Affected	B-X
patients	B-X
have	B-X
fever	B-X
,	B-X
chills	B-X
,	B-X
and	B-X
infections	B-X
;	B-X
severe	B-X
infections	B-X
left	B-X
untreated	B-X
can	B-X
result	B-X
in	B-X
death	B-X
.	B-X
Treatment	B-X
with	B-X
granulocyte	B-X
colony-stimulating	B-X
factor	B-X
can	B-X
hasten	B-X
neutrophil	B-X
recovery	B-X
.	B-X
Cumulative	B-X
data	B-X
show	B-X
that	B-X
severe	B-X
neutropenia	B-X
or	B-X
agranulocytosis	B-X
associated	B-X
with	B-X
exposure	B-X
to	B-X
nonchemotherapy	B-X
drugs	B-X
ranges	B-X
from	B-X
approximately	B-X
1.6	B-X
to	B-X
15.4	B-X
cases	B-X
per	B-X
million	B-X
population	B-X
per	B-X
year	B-X
.	B-X
Assays	B-X
used	B-X
for	B-X
detection	B-X
of	B-X
neutrophil	B-X
drug-dependent	B-X
antibodies	B-X
(	B-X
DDAbs	B-X
)	B-X
include	B-X
flow	B-X
cytometry	B-X
,	B-X
monoclonal	B-X
antibody	B-X
immobilization	B-X
of	B-X
granulocyte	B-X
antigens	B-X
,	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
,	B-X
immunoblotting	B-X
,	B-X
granulocyte	B-X
agglutination	B-X
,	B-X
and	B-X
granulocytotoxicity	B-X
.	B-X
However	B-X
,	B-X
testing	B-X
for	B-X
neutrophil	B-X
DDAbs	B-X
is	B-X
rarely	B-X
performed	B-X
owing	B-X
to	B-X
its	B-X
complexity	B-X
and	B-X
lack	B-X
of	B-X
availability	B-X
.	B-X

Cell	O
lysates	O
were	O
prepared	O
and	O
used	O
for	O
immunoprecipitations	O
with	O
RPS3	O
antibody	O
.	O

In	O
Vitro	O
Kinase	O
Assay	O
<EOS>	B-X
Kinases	B-X
are	B-X
enzymes	B-X
that	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
physiological	B-X
processes	B-X
and	B-X
their	B-X
inhibitors	B-X
have	B-X
been	B-X
found	B-X
to	B-X
exhibit	B-X
anticancer	B-X
activity	B-X
against	B-X
various	B-X
human	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
Kinase	B-X
activity	B-X
derived	B-X
from	B-X
positive	B-X
Q-column	B-X
fractions	B-X
bound	B-X
to	B-X
amylose-maltose-binding	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
-apoptin	B-X
and	B-X
could	B-X
be	B-X
eluted	B-X
with	B-X
ATP	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cofactor	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
.	B-X
Assays	B-X
are	B-X
needed	B-X
to	B-X
determine	B-X
which	B-X
inhibitor	B-X
is	B-X
most	B-X
effective	B-X
at	B-X
silencing	B-X
the	B-X
KIT	B-X
kinase	B-X
in	B-X
each	B-X
GIST	B-X
patient	B-X
.	B-X
Protein	B-X
techniques	B-X
:	B-X
immunoprecipitation	B-X
,	B-X
in	B-X
vitro	B-X
kinase	B-X
assays	B-X
,	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X

Kinase	O
-	O
active	O
recombinant	O
IKKbeta	B-Protein
and	O
IKKalpha	B-Protein
proteins	O
were	O
purchased	O
from	O
Active	O
Motif	O
and	O
Millipore	O
,	O
respectively	O
.	O

Bacterially	O
purified	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
,	O
GST	O
-	O
IkappaBalpha	O
(	O
1	O
-	O
54	O
)	O
,	O
wild	O
type	O
,	O
mutant	O
GST	B-Protein
-	I-Protein
RPS3	I-Protein
,	O
or	O
RPS3	B-Protein
proteins	O
were	O
used	O
as	O
substrates	O
.	O
<EOS>	B-X
Ubiquitin-conjugating	B-X
enzyme	B-X
E2	B-X
J1	B-X
(	B-X
UBE2J1	B-X
)	B-X
has	B-X
been	B-X
proven	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
multiple	B-X
substrate	B-X
proteins	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
UBE2J1	B-X
as	B-X
a	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
participating	B-X
in	B-X
cancer	B-X
development	B-X
and	B-X
progression	B-X
remain	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
that	B-X
UBE2J1	B-X
is	B-X
downregulated	B-X
in	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
tissues	B-X
and	B-X
cell	B-X
lines	B-X
which	B-X
are	B-X
mediated	B-X
by	B-X
DNA	B-X
hypermethylation	B-X
of	B-X
its	B-X
promoter	B-X
,	B-X
and	B-X
decreased	B-X
UBE2J1	B-X
is	B-X
associated	B-X
with	B-X
poor	B-X
prognosis	B-X
.	B-X
Functionally	B-X
,	B-X
UBE2J1	B-X
serving	B-X
as	B-X
a	B-X
suppressor	B-X
gene	B-X
inhibits	B-X
the	B-X
proliferation	B-X
and	B-X
metastasis	B-X
of	B-X
CRC	B-X
cells	B-X
.	B-X
Mechanistically	B-X
,	B-X
UBE2J1-TRIM25	B-X
,	B-X
forming	B-X
an	B-X
E2-E3	B-X
complex	B-X
,	B-X
physically	B-X
interacts	B-X
with	B-X
and	B-X
targets	B-X
RPS3	B-X
for	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
at	B-X
the	B-X
K214	B-X
residue	B-X
.	B-X
The	B-X
downregulated	B-X
RPS3	B-X
caused	B-X
by	B-X
UBE2J1	B-X
overexpression	B-X
restrains	B-X
NF-κB	B-X
translocation	B-X
into	B-X
the	B-X
nucleus	B-X
and	B-X
therefore	B-X
inactivates	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
.	B-X
Our	B-X
study	B-X
revealed	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
UBE2J1-mediated	B-X
RPS3	B-X
poly-ubiquitination	B-X
and	B-X
degradation	B-X
in	B-X
disrupting	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
,	B-X
which	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
novel	B-X
and	B-X
promising	B-X
biomarker	B-X
and	B-X
therapeutic	B-X
target	B-X
for	B-X
CRC	B-X
.	B-X

The	O
in	O
vitro	O
kinase	O
assay	O
was	O
performed	O
as	O
previously	O
described29	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
with	B-X
imatinib	B-X
mesylate	B-X
and	B-X
other	B-X
second-	B-X
and/or	B-X
third-generation	B-X
c-Abl-specific	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKIs	B-X
)	B-X
has	B-X
substantially	B-X
extended	B-X
patient	B-X
survival	B-X
.	B-X
We	B-X
performed	B-X
metabolic	B-X
analyses	B-X
on	B-X
both	B-X
stem	B-X
cell-enriched	B-X
(	B-X
CD34	B-X
MYD88	B-X
(	B-X
L265P	B-X
)	B-X
triggers	B-X
tumor-cell	B-X
growth	B-X
through	B-X
Bruton	B-X
's	B-X
tyrosine	B-X
kinase	B-X
,	B-X
a	B-X
target	B-X
of	B-X
ibrutinib	B-X
.	B-X
CXCR4	B-X
(	B-X
WHIM	B-X
)	B-X
mutations	B-X
confer	B-X
in	B-X
vitro	B-X
resistance	B-X
to	B-X
ibrutinib	B-X
.	B-X

Briefly	O
,	O
enzyme	O
(	O
100	O
ng	O
)	O
and	O
substrate	O
(	O
2	O
mug	O
)	O
were	O
co	O
-	O
incubated	O
in	O
IKK	O
reaction	O
buffer	O
(	O
25	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
8	O
.	O
0	O
]	O
,	O
50	O
mM	O
KCl	O
,	O
10	O
mM	O
MgCl2	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
Na3VO4	O
,	O
1	O
mM	O
ATP	O
)	O
or	O
NleH1	O
reaction	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
6	O
]	O
,	O
5	O
mM	O
MgCl2	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
ATP	O
)	O
with	O
0	O
.	O
5	O
muCi	O
32P	O
-	O
gamma	O
-	O
ATP	O
(	O
GE	O
Healthcare	O
)	O
added	O
at	O
37	O
degreesC	O
for	O
30	O
min	O
.	O

The	O
reactions	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
visualized	O
by	O
autoradiography	O
.	O
<EOS>	B-X
Lipopolysaccharides	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
which	B-X
constitute	B-X
the	B-X
somatic	B-X
(	B-X
O	B-X
)	B-X
antigen	B-X
of	B-X
gram-negative	B-X
bacteria	B-X
,	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
the	B-X
procedure	B-X
of	B-X
LPS	B-X
blotting	B-X
involving	B-X
the	B-X
electrophoretic	B-X
transfer	B-X
of	B-X
electrophoretically	B-X
resolved	B-X
LPS	B-X
from	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gels	B-X
to	B-X
nitrocellulose	B-X
filters	B-X
.	B-X
Immobilized	B-X
LPS	B-X
could	B-X
then	B-X
be	B-X
immunoautoradiographically	B-X
visualized	B-X
in	B-X
situ	B-X
by	B-X
reaction	B-X
with	B-X
specific	B-X
anti-LPS	B-X
antibody	B-X
and	B-X
subsequent	B-X
binding	B-X
of	B-X
radioiodinated	B-X
Staphylococcus	B-X
protein	B-X
A.	B-X
LPS	B-X
blotting	B-X
is	B-X
expected	B-X
to	B-X
provide	B-X
an	B-X
efficient	B-X
and	B-X
specific	B-X
means	B-X
of	B-X
investigating	B-X
the	B-X
LPS	B-X
(	B-X
O	B-X
)	B-X
antigens	B-X
of	B-X
gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
32P-labeled	B-X
proteins	B-X
were	B-X
resolved	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
,	B-X
the	B-X
32P	B-X
content	B-X
was	B-X
visualized	B-X
by	B-X
autoradiography	B-X
,	B-X
and	B-X
the	B-X
relative	B-X
intensities	B-X
of	B-X
specific	B-X
bands	B-X
were	B-X
quantitated	B-X
.	B-X
Heavy	B-X
and	B-X
light	B-X
chains	B-X
are	B-X
resolved	B-X
by	B-X
electrophoresis	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
.	B-X
The	B-X
electrophoretically	B-X
resolved	B-X
polypeptides	B-X
are	B-X
then	B-X
transferred	B-X
to	B-X
nitrocellulose	B-X
filters	B-X
.	B-X
Filters	B-X
containing	B-X
bound	B-X
heavy	B-X
and	B-X
light	B-X
chains	B-X
are	B-X
incubated	B-X
with	B-X
125I-labelled	B-X
anti-idiotypic	B-X
antibody	B-X
,	B-X
and	B-X
idiotype-anti-idiotype	B-X
reactivity	B-X
visualized	B-X
by	B-X
autoradiography	B-X
.	B-X
All	B-X
three	B-X
anti-idiotopic	B-X
antibodies	B-X
are	B-X
shown	B-X
to	B-X
react	B-X
with	B-X
electrophoretically	B-X
resolved	B-X
idiotype	B-X
heavy	B-X
chain	B-X
,	B-X
but	B-X
not	B-X
with	B-X
idiotype	B-X
light	B-X
chain	B-X
.	B-X

LC	O
-	O
MS	O
/	O
MS	O
Analysis	O

GST	O
or	O
GST	B-Protein
-	I-Protein
RPS3	I-Protein
was	O
incubated	O
with	O
recombinant	O
IKKbeta	B-Protein
protein	O
as	O
described	O
above	O
in	O
an	O
in	O
vitro	O
kinase	O
assay	O
reaction	O
conducted	O
without	O
32P	O
-	O
gamma	O
-	O
ATP	O
labeling	O
.	O
<EOS>	B-X
This	B-X
protocol	B-X
describes	B-X
the	B-X
purification	B-X
of	B-X
recombinant	B-X
proteins	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
,	B-X
GST-tagged	B-X
proteins	B-X
)	B-X
by	B-X
Glutathione	B-X
Affinity	B-X
purification	B-X
.	B-X
The	B-X
GST	B-X
tag	B-X
frequently	B-X
increases	B-X
the	B-X
solubility	B-X
of	B-X
the	B-X
fused	B-X
protein	B-X
of	B-X
interest	B-X
and	B-X
thus	B-X
enables	B-X
its	B-X
purification	B-X
and	B-X
subsequent	B-X
functional	B-X
characterization	B-X
.	B-X
The	B-X
GST-tagged	B-X
protein	B-X
specifically	B-X
binds	B-X
to	B-X
glutathione	B-X
immobilized	B-X
to	B-X
a	B-X
matrix	B-X
(	B-X
e.g.	B-X
,	B-X
agarose	B-X
)	B-X
and	B-X
can	B-X
be	B-X
easily	B-X
separated	B-X
from	B-X
a	B-X
cell	B-X
lysate	B-X
by	B-X
a	B-X
bind-wash-elute	B-X
procedure	B-X
.	B-X
GST-tagged	B-X
proteins	B-X
are	B-X
often	B-X
used	B-X
to	B-X
study	B-X
protein-protein	B-X
interactions	B-X
,	B-X
again	B-X
making	B-X
use	B-X
of	B-X
glutathione	B-X
affinity	B-X
in	B-X
a	B-X
procedure	B-X
called	B-X
a	B-X
GST	B-X
pull-down	B-X
assay	B-X
.	B-X
The	B-X
protocol	B-X
is	B-X
designed	B-X
to	B-X
process	B-X
200	B-X
ml	B-X
of	B-X
E.	B-X
coli	B-X
culture	B-X
expressing	B-X
intermediate	B-X
to	B-X
high	B-X
amounts	B-X
of	B-X
a	B-X
GST-tagged	B-X
protein	B-X
(	B-X
~25	B-X
mg	B-X
l	B-X
(	B-X
-1	B-X
)	B-X
)	B-X
.	B-X
The	B-X
protocol	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
purify	B-X
GST-tagged	B-X
proteins	B-X
from	B-X
other	B-X
expression	B-X
systems	B-X
,	B-X
such	B-X
as	B-X
insect	B-X
or	B-X
mammalian	B-X
cells	B-X
.	B-X
Tips	B-X
are	B-X
provided	B-X
to	B-X
aid	B-X
in	B-X
modifying	B-X
certain	B-X
steps	B-X
if	B-X
proteins	B-X
shall	B-X
be	B-X
recovered	B-X
from	B-X
alternative	B-X
expression	B-X
systems	B-X
.	B-X

The	O
reaction	O
was	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
the	O
protein	O
gel	O
was	O
stained	O
with	O
Colloidal	O
Blue	O
(	O
Invitrogen	O
)	O
.	O

The	O
corresponding	O
protein	O
fragments	O
were	O
excised	O
and	O
subjected	O
to	O
trypsin	O
digestion	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
at	O
the	O
Yale	O
Cancer	O
Center	O
Mass	O
Spectrometry	O
Resource	O
(	O
New	O
Haven	O
,	O
CT	O
)	O
.	O

RNAi	O
and	O
Transfection	O
<EOS>	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
is	B-X
a	B-X
biological	B-X
process	B-X
by	B-X
which	B-X
double-stranded	B-X
RNA	B-X
(	B-X
dsRNA	B-X
)	B-X
induces	B-X
sequence-specific	B-X
gene	B-X
silencing	B-X
by	B-X
targeting	B-X
mRNA	B-X
for	B-X
degradation	B-X
.	B-X
As	B-X
a	B-X
tool	B-X
for	B-X
knocking	B-X
down	B-X
the	B-X
expression	B-X
of	B-X
individual	B-X
genes	B-X
posttranscriptionally	B-X
,	B-X
RNAi	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
to	B-X
study	B-X
the	B-X
cellular	B-X
function	B-X
of	B-X
genes	B-X
.	B-X
We	B-X
describe	B-X
a	B-X
scalable	B-X
method	B-X
for	B-X
measuring	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
following	B-X
RNAi	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
pIRES2-EGFP	B-X
was	B-X
employed	B-X
and	B-X
a	B-X
non-target	B-X
shRNA	B-X
expressing	B-X
plasmid	B-X
was	B-X
constructed	B-X
to	B-X
simulate	B-X
overexpression	B-X
and	B-X
RNAi	B-X
(	B-X
RNA	B-X
interference	B-X
)	B-X
experiments	B-X
.	B-X
Transfection	B-X
of	B-X
pIRES2-EGFP	B-X
into	B-X
HEK293A	B-X
cells	B-X
by	B-X
cationic	B-X
lipids	B-X
VigoFect	B-X
demonstrated	B-X
that	B-X
transfection	B-X
efficiency	B-X
increased	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
with	B-X
amount	B-X
of	B-X
DNA	B-X
plasmid	B-X
used	B-X
,	B-X
and	B-X
optimal	B-X
transfection	B-X
time	B-X
and	B-X
cell	B-X
density	B-X
should	B-X
be	B-X
identified	B-X
to	B-X
reach	B-X
a	B-X
compromise	B-X
of	B-X
higher	B-X
transfection	B-X
efficiency	B-X
and	B-X
lower	B-X
toxicity	B-X
.	B-X

The	O
siRNA	O
(	O
sense	O
-	O
strand	O
sequence	O
)	O
IKKalpha	B-Protein
,	O
5	O
'	O
-	O
AUGACAGAGAAUGAUCAUGUUCUGC	O
-	O
3	O
'	O
;	O
IKKbeta	B-Protein
,	O
5	O
'	O
-	O
GCAGCAAGGAGAACAGAGGUUAAUA	O
-	O
3	O
'	O
;	O
IkappaBalpha	B-Protein
,	O
5	O
'	O
-	O
GAGCUCCGAGACUUUCGAGGAAAUA	O
-	O
3	O
'	O
;	O
RPS3	B-Protein
-	O
3	O
'	O
UTR	O
,	O
5	O
'	O
-	O
GGAUGUUGCUCUCUAAAGACC	O
-	O
3	O
'	O
(	O
Invitrogen	O
)	O
.	O

Transient	O
transfection	O
of	O
siRNA	O
and	O
DNA	O
constructs	O
into	O
Jurkat	O
cells	O
and	O
293T	O
cells	O
was	O
described	O
previously6	O
.	O

Subcellular	O
Fractionation	O
<EOS>	B-X
Subcellular	B-X
fractionation	B-X
is	B-X
usually	B-X
performed	B-X
immediately	B-X
after	B-X
tissue	B-X
dissection	B-X
because	B-X
freezing	B-X
may	B-X
fragment	B-X
cell	B-X
membranes	B-X
and	B-X
induce	B-X
organellar	B-X
cross-contamination	B-X
.	B-X
Subcellular	B-X
components	B-X
were	B-X
obtained	B-X
from	B-X
pig	B-X
platelets	B-X
,	B-X
disrupted	B-X
by	B-X
means	B-X
of	B-X
a	B-X
French	B-X
press	B-X
and	B-X
separated	B-X
into	B-X
4	B-X
primary	B-X
fractions	B-X
.	B-X
Fractionation	B-X
assays	B-X
developed	B-X
in	B-X
the	B-X
present	B-X
study	B-X
provide	B-X
a	B-X
means	B-X
to	B-X
further	B-X
dissect	B-X
the	B-X
ill-defined	B-X
post-ubiquitination	B-X
step	B-X
during	B-X
ERAD	B-X
of	B-X
polytopic	B-X
membrane	B-X
substrates	B-X
.	B-X
Fractionation	B-X
of	B-X
the	B-X
homogenate	B-X
resulted	B-X
in	B-X
a	B-X
nuclear	B-X
pellet	B-X
(	B-X
P1	B-X
)	B-X
,	B-X
a	B-X
crude	B-X
mitochondrial	B-X
pellet	B-X
(	B-X
P2	B-X
)	B-X
and	B-X
a	B-X
supernatant	B-X
(	B-X
S2	B-X
)	B-X
.	B-X

Subcellular	O
fractionation	O
was	O
performed	O
by	O
differential	O
centrifugation	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
resuspended	O
in	O
ice	O
-	O
cold	O
Buffer	O
A	O
(	O
10	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
0	O
.	O
4	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
,	O
complete	O
protease	O
inhibitor	O
cocktail	O
)	O
at	O
4	O
degreesC	O
for	O
5	O
min	O
.	O

Lysates	O
were	O
centrifuged	O
at	O
4	O
degreesC	O
,	O
500	O
x	O
g	O
for	O
3	O
min	O
,	O
and	O
supernatants	O
were	O
collected	O
as	O
cytosolic	O
fractions	O
.	O

Pellets	O
were	O
incubated	O
in	O
Buffer	O
C	O
(	O
20	O
mM	O
HEPES	O
pH7	O
.	O
9	O
,	O
420	O
mM	O
NaCl	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
25	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
PMSF	O
,	O
0	O
.	O
2	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
complete	O
protease	O
inhibitor	O
cocktail	O
)	O
at	O
4	O
degreesC	O
for	O
10	O
min	O
.	O

Supernatants	O
were	O
collected	O
as	O
nuclear	O
fractions	O
following	O
a	O
centrifuge	O
at	O
4	O
degreesC	O
,	O
13	O
,	O
800	O
x	O
g	O
for	O
10	O
min	O
.	O

Luciferase	O
Reporter	O
Gene	O
Assays	O
<EOS>	B-X
Luciferase	B-X
assays	B-X
are	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
identifying	B-X
and	B-X
characterizing	B-X
functional	B-X
variants	B-X
,	B-X
allowing	B-X
investigations	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
intracellular	B-X
signaling	B-X
,	B-X
transcription	B-X
factors	B-X
,	B-X
receptor	B-X
activity	B-X
,	B-X
and	B-X
protein	B-X
folding	B-X
.	B-X
Screening	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
the	B-X
reporter	B-X
gene	B-X
using	B-X
either	B-X
a	B-X
qualitative	B-X
or	B-X
a	B-X
quantitative	B-X
assay	B-X
,	B-X
allows	B-X
to	B-X
identify	B-X
the	B-X
regulatory	B-X
regions	B-X
of	B-X
interest	B-X
(	B-X
e.g.	B-X
,	B-X
cis-acting	B-X
elements	B-X
or	B-X
enhancer	B-X
)	B-X
in	B-X
the	B-X
promoter.Luciferase	B-X
genes	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
as	B-X
reporter	B-X
genes	B-X
for	B-X
their	B-X
sensitivity	B-X
and	B-X
efficiency	B-X
.	B-X
Reporter	B-X
gene	B-X
assays	B-X
are	B-X
versatile	B-X
and	B-X
sensitive	B-X
methods	B-X
of	B-X
assaying	B-X
numerous	B-X
targets	B-X
in	B-X
high-throughput	B-X
drug-screening	B-X
programs	B-X
.	B-X
Luciferase	B-X
based	B-X
assays	B-X
have	B-X
become	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
cloned	B-X
promoter	B-X
DNA	B-X
fragments	B-X
,	B-X
both	B-X
for	B-X
verifying	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
potential	B-X
promoter	B-X
fragment	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
in	B-X
various	B-X
cellular	B-X
contexts	B-X
,	B-X
and	B-X
for	B-X
dissecting	B-X
binding	B-X
elements	B-X
in	B-X
the	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
use	B-X
of	B-X
the	B-X
Dual-Luciferase	B-X
(	B-X
®	B-X
)	B-X
Reporter	B-X
Assay	B-X
System	B-X
created	B-X
by	B-X
Promega	B-X
(	B-X
Promega	B-X
Corporation	B-X
,	B-X
Wisconsin	B-X
,	B-X
USA	B-X
)	B-X
to	B-X
study	B-X
the	B-X
cloned	B-X
6.7	B-X
kilobases	B-X
(	B-X
kb	B-X
)	B-X
mouse	B-X
(	B-X
m	B-X
)	B-X
Tcf3	B-X
promoter	B-X
DNA	B-X
fragment	B-X
in	B-X
mouse	B-X
embryonic	B-X
derived	B-X
neural	B-X
stem	B-X
cells	B-X
(	B-X
NSC	B-X
)	B-X
.	B-X

Luciferase	O
reporter	O
gene	O
assays	O
were	O
performed	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
cotransfected	O
at	O
a	O
ratio	O
of	O
10	O
:	O
1	O
with	O
various	O
promoter	O
-	O
driven	O
firefly	O
luciferase	B-Protein
constructs	O
to	O
the	O
Renilla	O
luciferase	B-Protein
pTKRL	O
plasmid	O
,	O
together	O
with	O
indicated	O
plasmids	O
.	O

Cells	O
were	O
cultured	O
for	O
1	O
-	O
2	O
days	O
and	O
then	O
stimulated	O
in	O
triplicate	O
before	O
harvest	O
.	O
<EOS>	B-X
Rabbit	B-X
aortic	B-X
endothelial	B-X
cells	B-X
were	B-X
cultured	B-X
on	B-X
Flex	B-X
I	B-X
flexible-bottomed	B-X
culture	B-X
plates	B-X
,	B-X
and	B-X
subjected	B-X
to	B-X
load	B-X
amplitudes	B-X
of	B-X
increasing	B-X
magnitude	B-X
(	B-X
0	B-X
,	B-X
0.18	B-X
,	B-X
0.24	B-X
and	B-X
0.27	B-X
load	B-X
at	B-X
1	B-X
Hz	B-X
)	B-X
using	B-X
a	B-X
Flexercell	B-X
strain	B-X
unit	B-X
.	B-X
Cells	B-X
were	B-X
harvested	B-X
enzymatically	B-X
and	B-X
cell	B-X
numbers	B-X
determined	B-X
on	B-X
days	B-X
1	B-X
,	B-X
3	B-X
and	B-X
5	B-X
after	B-X
initiating	B-X
the	B-X
load	B-X
regimen	B-X
.	B-X
DNA	B-X
synthesis	B-X
was	B-X
quantified	B-X
after	B-X
trichloroacetic	B-X
acid	B-X
precipitation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
thymidine-labeled	B-X
cells	B-X
from	B-X
:	B-X
(	B-X
1	B-X
)	B-X
whole	B-X
culture	B-X
wells	B-X
and	B-X
(	B-X
2	B-X
)	B-X
areas	B-X
of	B-X
minimum	B-X
and	B-X
maximum	B-X
strain	B-X
in	B-X
culture	B-X
cells	B-X
.	B-X
Data	B-X
were	B-X
analyzed	B-X
using	B-X
analysis	B-X
of	B-X
variance	B-X
and	B-X
a	B-X
Tukey	B-X
's	B-X
test	B-X
(	B-X
n	B-X
=	B-X
6	B-X
observations/strain	B-X
regimen	B-X
per	B-X
day	B-X
in	B-X
triplicate	B-X
)	B-X
.	B-X
Results	B-X
from	B-X
analysis	B-X
of	B-X
endothelial	B-X
cells	B-X
in	B-X
whole	B-X
,	B-X
subconfluent	B-X
cultures	B-X
showed	B-X
that	B-X
cells	B-X
subjected	B-X
to	B-X
strains	B-X
of	B-X
0.18	B-X
had	B-X
a	B-X
decreased	B-X
rate	B-X
of	B-X
cell	B-X
division	B-X
(	B-X
76	B-X
%	B-X
of	B-X
control	B-X
)	B-X
and	B-X
DNA	B-X
synthesis	B-X
(	B-X
63	B-X
%	B-X
of	B-X
control	B-X
)	B-X
,	B-X
while	B-X
cells	B-X
subjected	B-X
to	B-X
strains	B-X
of	B-X
0.24	B-X
and	B-X
0.27	B-X
had	B-X
an	B-X
increased	B-X
rate	B-X
of	B-X
cell	B-X
division	B-X
(	B-X
108	B-X
and	B-X
83	B-X
%	B-X
increase	B-X
,	B-X
respectively	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
;	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
DNA	B-X
synthesis	B-X
(	B-X
39	B-X
and	B-X
172	B-X
%	B-X
increase	B-X
,	B-X
respectively	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
;	B-X
p	B-X
<	B-X
0.001	B-X
for	B-X
0.27	B-X
)	B-X
on	B-X
day	B-X
3	B-X
when	B-X
compared	B-X
with	B-X
control	B-X
cells	B-X
.	B-X

Lysates	O
were	O
analyzed	O
using	O
the	O
Dual	O
-	O
Luciferase	O
Kit	O
(	O
Promega	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O
(	O
ChIP	O
)	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
an	B-X
important	B-X
technique	B-X
in	B-X
the	B-X
study	B-X
of	B-X
protein-gene	B-X
interactions	B-X
.	B-X
Using	B-X
ChIP	B-X
,	B-X
DNA-protein	B-X
interactions	B-X
are	B-X
studied	B-X
within	B-X
the	B-X
context	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Although	B-X
ChIP	B-X
is	B-X
a	B-X
very	B-X
versatile	B-X
tool	B-X
,	B-X
the	B-X
procedure	B-X
requires	B-X
the	B-X
optimization	B-X
of	B-X
reaction	B-X
conditions	B-X
.	B-X
Several	B-X
modifications	B-X
to	B-X
the	B-X
original	B-X
ChIP	B-X
technique	B-X
have	B-X
been	B-X
published	B-X
to	B-X
improve	B-X
the	B-X
success	B-X
and	B-X
to	B-X
enhance	B-X
the	B-X
utility	B-X
of	B-X
this	B-X
procedure	B-X
.	B-X
This	B-X
review	B-X
addresses	B-X
the	B-X
critical	B-X
parameters	B-X
and	B-X
the	B-X
variants	B-X
of	B-X
ChiP	B-X
as	B-X
well	B-X
as	B-X
the	B-X
different	B-X
analytical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
combined	B-X
with	B-X
ChIP	B-X
to	B-X
enable	B-X
better	B-X
understanding	B-X
of	B-X
DNA-protein	B-X
interactions	B-X
in	B-X
vivo	B-X
.	B-X

ChIP	O
assays	O
was	O
performed	O
as	O
previously	O
described6	O
.	O

The	O
primers	O
used	O
to	O
amplify	O
the	O
promoter	O
region	O
adjacent	O
to	O
the	O
kappaB	O
sites	O
of	O
IL8	B-Protein
and	O
NFKBIA	B-Protein
,	O
as	O
well	O
as	O
ACTB	B-Protein
have	O
been	O
described6	O
.	O

Immunofluorescence	O
Microscopy	O
<EOS>	B-X
Immunofluorescence	B-X
microscopy	B-X
.	B-X
Immunofluorescence	B-X
microscopy	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
that	B-X
is	B-X
widely	B-X
used	B-X
by	B-X
researchers	B-X
to	B-X
assess	B-X
both	B-X
the	B-X
localization	B-X
and	B-X
endogenous	B-X
expression	B-X
levels	B-X
of	B-X
their	B-X
favorite	B-X
proteins	B-X
.	B-X
Immunofluorescence	B-X
labeling	B-X
and	B-X
microscopy	B-X
offer	B-X
a	B-X
highly	B-X
specific	B-X
means	B-X
to	B-X
visualize	B-X
proteins	B-X
or	B-X
other	B-X
molecular	B-X
species	B-X
in	B-X
a	B-X
sample	B-X
by	B-X
labeling	B-X
target	B-X
antigens	B-X
with	B-X
fluorescent	B-X
probes	B-X
.	B-X
Immunofluorescence	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
uses	B-X
antibodies	B-X
and	B-X
fluorophores	B-X
to	B-X
label	B-X
structures	B-X
inside	B-X
cells	B-X
.	B-X

Confocal	O
microscopy	O
was	O
performed	O
as	O
previously	O
described6	O
.	O

Briefly	O
,	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
and	O
then	O
Cellspin	O
mounted	O
onto	O
slides	O
.	O

The	O
fixed	O
cells	O
were	O
then	O
permeabilized	O
with	O
0	O
.	O
05	O
%	O
Triton	O
X	O
-	O
100	O
in	O
PBS	O
and	O
stained	O
with	O
FITC	O
-	O
conjugated	O
rabbit	O
anti	O
-	O
RPS3	O
antibodies	O
(	O
Primm	O
Biotech	O
)	O
,	O
or	O
AlexaFluor	O
594	O
-	O
conjugated	O
rat	O
anti	O
-	O
Flag	O
antibodies	O
(	O
BD	O
)	O
for	O
40	O
min	O
together	O
with	O
1	O
mug	O
/	O
ml	O
of	O
Hoechst	O
33342	O
(	O
Sigma	O
)	O
for	O
5	O
min	O
at	O
25	O
degreesC	O
.	O

The	O
slides	O
were	O
then	O
rinsed	O
with	O
PBS	O
three	O
times	O
and	O
cover	O
mounted	O
for	O
fluorescence	O
microscopy	O
.	O

Immunoprecipitation	O
and	O
immunoblot	O
<EOS>	B-X
Thus	B-X
,	B-X
lysosomal	B-X
turnover	B-X
of	B-X
the	B-X
autophagosomal	B-X
marker	B-X
LC3-II	B-X
reflects	B-X
starvation-induced	B-X
autophagic	B-X
activity	B-X
,	B-X
and	B-X
detecting	B-X
LC3	B-X
by	B-X
immunoblotting	B-X
or	B-X
immunofluorescence	B-X
has	B-X
become	B-X
a	B-X
reliable	B-X
method	B-X
for	B-X
monitoring	B-X
autophagy	B-X
and	B-X
autophagy-related	B-X
processes	B-X
,	B-X
including	B-X
autophagic	B-X
cell	B-X
death	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
basic	B-X
protocols	B-X
to	B-X
assay	B-X
for	B-X
endogenous	B-X
LC3-II	B-X
by	B-X
immunoblotting	B-X
,	B-X
immunoprecipitation	B-X
,	B-X
and	B-X
immunofluorescence	B-X
.	B-X
This	B-X
protocol	B-X
presents	B-X
an	B-X
optimized	B-X
co-IP	B-X
workflow	B-X
with	B-X
an	B-X
analysis	B-X
based	B-X
on	B-X
semi-quantitative	B-X
immunoblot	B-X
densitometry	B-X
to	B-X
increase	B-X
reliability	B-X
and	B-X
reproducibility	B-X
.	B-X
We	B-X
also	B-X
describe	B-X
the	B-X
protocol	B-X
for	B-X
immunoblot	B-X
analysis	B-X
of	B-X
histones	B-X
using	B-X
antibodies	B-X
against	B-X
key	B-X
histone	B-X
modifications	B-X
.	B-X

The	O
cells	O
were	O
harvested	O
and	O
lysed	O
on	O
ice	O
by	O
0	O
.	O
4	O
ml	O
of	O
the	O
modified	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
4	O
]	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
25	O
%	O
Na	O
-	O
deoxycholate	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
PMSF	O
,	O
1	O
mM	O
Na3VO4	O
,	O
1	O
mM	O
NaF	O
)	O
supplemented	O
with	O
1	O
x	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
)	O
and	O
1	O
x	O
phosphatase	O
inhibitor	O
cocktail	O
set	O
I	O
(	O
EMD	O
Biosciences	O
)	O
for	O
30	O
min	O
.	O

The	O
lysates	O
were	O
centrifuged	O
at	O
10	O
,	O
000	O
x	O
g	O
at	O
4	O
degreesC	O
for	O
10	O
min	O
to	O
remove	O
insoluble	O
material	O
.	O

After	O
normalizing	O
protein	O
concentrations	O
,	O
lysates	O
were	O
subjected	O
to	O
immunoprecipitation	O
by	O
adding	O
10	O
mg	O
/	O
ml	O
appropriate	O
antibody	O
plus	O
30	O
ml	O
of	O
protein	O
G	O
-	O
agarose	O
(	O
Roche	O
)	O
,	O
and	O
rotated	O
for	O
at	O
least	O
2	O
h	O
at	O
4degreesC	O
.	O

The	O
precipitates	O
were	O
washed	O
at	O
least	O
five	O
times	O
with	O
cold	O
lysis	O
buffer	O
followed	O
by	O
separation	O
by	O
SDS	O
-	O
PAGE	O
under	O
reduced	O
and	O
denaturing	O
conditions	O
.	O

Nitrocellulose	O
membranes	O
were	O
blocked	O
in	O
5	O
%	O
nonfat	O
milk	O
in	O
0	O
.	O
1	O
%	O
PBS	O
-	O
Tween	O
20	O
(	O
PBS	O
-	O
T	O
)	O
,	O
probed	O
with	O
specific	O
antibodies	O
as	O
described	O
previously6	O
.	O

For	O
immunoblotting	O
of	O
phosphorylated	O
proteins	O
,	O
gels	O
were	O
transferred	O
to	O
methanol	O
-	O
treated	O
polyvinylidene	O
chloride	O
membranes	O
,	O
retreated	O
with	O
methanol	O
,	O
and	O
dried	O
for	O
30	O
min	O
.	O

Blots	O
were	O
blocked	O
in	O
5	O
%	O
bovine	O
serum	O
albumin	B-Protein
in	O
0	O
.	O
1	O
%	O
Tris	O
buffered	O
saline	O
-	O
Tween	O
20	O
(	O
TBS	O
-	O
T	O
)	O
,	O
and	O
probed	O
with	O
specific	O
antibodies	O
as	O
described	O
previously46	O
.	O

Bands	O
were	O
imaged	O
by	O
the	O
Super	O
Signaling	O
system	O
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

ELISA	O
<EOS>	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
specific	B-X
and	B-X
straightforward	B-X
assays	B-X
for	B-X
detecting	B-X
biomolecules	B-X
in	B-X
research	B-X
and	B-X
clinics	B-X
.	B-X
With	B-X
advances	B-X
in	B-X
analytical	B-X
methods	B-X
,	B-X
ELISA	B-X
assay	B-X
has	B-X
been	B-X
constantly	B-X
optimized	B-X
to	B-X
improve	B-X
its	B-X
sensitivity	B-X
,	B-X
and	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
are	B-X
now	B-X
available	B-X
to	B-X
detect	B-X
various	B-X
biomarkers	B-X
.	B-X
This	B-X
chapter	B-X
provides	B-X
an	B-X
overall	B-X
summary	B-X
of	B-X
the	B-X
basic	B-X
principle	B-X
of	B-X
ELISA	B-X
,	B-X
discusses	B-X
different	B-X
components	B-X
of	B-X
ELISA	B-X
assay	B-X
,	B-X
and	B-X
clearly	B-X
outline	B-X
protocols	B-X
for	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
assays	B-X
,	B-X
including	B-X
direct	B-X
,	B-X
indirect	B-X
,	B-X
sandwich	B-X
,	B-X
competitive	B-X
,	B-X
and	B-X
nanoparticle-based	B-X
ELISA	B-X
.	B-X
These	B-X
peptide/protein	B-X
concentrations	B-X
in	B-X
biological	B-X
fluids	B-X
are	B-X
measured	B-X
using	B-X
various	B-X
methods	B-X
,	B-X
the	B-X
most	B-X
common	B-X
of	B-X
which	B-X
is	B-X
enzymatic	B-X
immunoassay	B-X
EIA/ELISA	B-X
and	B-X
which	B-X
guide	B-X
the	B-X
clinicians	B-X
in	B-X
diagnosing	B-X
and	B-X
monitoring	B-X
diseases	B-X
that	B-X
inflict	B-X
biological	B-X
systems	B-X
.	B-X
All	B-X
the	B-X
techniques	B-X
where	B-X
enzymes	B-X
are	B-X
employed	B-X
to	B-X
show	B-X
antigen-antibody	B-X
reactions	B-X
are	B-X
generally	B-X
referred	B-X
to	B-X
as	B-X
enzymatic	B-X
immunoassay	B-X
EIA/ELISA	B-X
method	B-X
.	B-X
Since	B-X
the	B-X
basic	B-X
principles	B-X
of	B-X
EIA	B-X
and	B-X
ELISA	B-X
are	B-X
the	B-X
same	B-X
.	B-X
The	B-X
main	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
present	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
historical	B-X
journey	B-X
that	B-X
had	B-X
led	B-X
to	B-X
the	B-X
invention	B-X
of	B-X
EIA/ELISA	B-X
,	B-X
an	B-X
indispensible	B-X
method	B-X
for	B-X
medical	B-X
and	B-X
research	B-X
laboratories	B-X
,	B-X
types	B-X
of	B-X
ELISA	B-X
developed	B-X
after	B-X
its	B-X
invention	B-X
[	B-X
direct	B-X
(	B-X
the	B-X
first	B-X
ELISA	B-X
method	B-X
invented	B-X
)	B-X
,	B-X
indirect	B-X
,	B-X
sandwich	B-X
and	B-X
competitive	B-X
methods	B-X
]	B-X
,	B-X
problems	B-X
encountered	B-X
during	B-X
peptide/protein	B-X
analyses	B-X
(	B-X
pre-analytical	B-X
,	B-X
analytical	B-X
and	B-X
post-analytical	B-X
)	B-X
,	B-X
rules	B-X
to	B-X
be	B-X
followed	B-X
to	B-X
prevent	B-X
these	B-X
problems	B-X
,	B-X
and	B-X
our	B-X
laboratory	B-X
experience	B-X
of	B-X
more	B-X
than	B-X
15	B-X
years	B-X
.	B-X

The	O
amount	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
present	O
in	O
supernatants	O
collected	O
from	O
Jurkat	O
cell	O
culture	O
was	O
measured	O
using	O
a	O
Human	O
Interleukin	B-Protein
-	I-Protein
8	I-Protein
ELISA	O
Ready	O
-	O
SET	O
-	O
Go	O
kit	B-Protein
(	O
eBioscience	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cell	O
Infections	O
<EOS>	B-X
Infections	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
are	B-X
among	B-X
the	B-X
most	B-X
serious	B-X
infections	B-X
Cell-to-cell	B-X
transmission	B-X
is	B-X
promoted	B-X
by	B-X
the	B-X
bacterial	B-X
surface	B-X
protein	B-X
ActA	B-X
which	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
transcriptional	B-X
activator	B-X
known	B-X
as	B-X
positive	B-X
regulatory	B-X
factor	B-X
A	B-X
.	B-X

HeLa	O
cells	O
were	O
infected	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
or	O
C	O
.	O
rodentium	O
strains	O
as	O
described	O
previously9	O
.	O

Immunohistochemistry	O
<EOS>	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
for	B-X
tissue-based	B-X
diagnostics	B-X
and	B-X
biomarker	B-X
detection	B-X
with	B-X
broad	B-X
worldwide	B-X
adoption	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
in	B-X
many	B-X
veterinary	B-X
laboratories	B-X
for	B-X
diagnostic	B-X
and	B-X
research	B-X
purposes	B-X
.	B-X
Next-Generation	B-X
Pathology	B-X
by	B-X
Multiplexed	B-X
Immunohistochemistry	B-X
.	B-X

Gnotobiotic	O
piglets	O
were	O
infected	O
with	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
strains	O
as	O
described	O
previously9	O
.	O

Spiral	O
colon	O
specimens	O
were	O
collected	O
at	O
necropsy	O
and	O
embedded	O
in	O
paraffin	O
.	O

Paraffin	O
sectioning	O
and	O
immunohistochemical	O
staining	O
using	O
phospho	O
-	O
RPS3	O
antibody	O
were	O
performed	O
by	O
Histoserv	O
Inc	O
.	O

Human	O
immunodeficiency	O
virus	O
-	O
1	O
Tat	B-Protein
activates	O
NF	O
-	O
kappaB	O
via	O
physical	O
interaction	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
is	O
a	O
master	O
regulator	O
of	O
pro	O
-	O
inflammatory	O
genes	O
and	O
is	O
upregulated	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

Mechanisms	O
underlying	O
the	O
NF	O
-	O
kappaB	O
deregulation	O
by	O
HIV	O
-	O
1	O
are	O
relevant	O
for	O
immune	O
dysfunction	O
in	O
AIDS	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

We	O
report	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
,	O
or	O
single	O
-	O
pulse	O
PMA	O
stimulation	O
,	O
the	O
HIV	O
-	O
1	O
Tat	B-Protein
transactivator	O
activated	O
NF	O
-	O
kappaB	O
by	O
hijacking	O
the	O
inhibitor	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
by	O
preventing	O
the	O
repressor	O
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O
<EOS>	B-X
The	B-X
discovery	B-X
of	B-X
broad	B-X
and	B-X
potent	B-X
HIV-1	B-X
neutralizing	B-X
antibodies	B-X
(	B-X
bNAbs	B-X
)	B-X
has	B-X
renewed	B-X
optimism	B-X
for	B-X
developing	B-X
an	B-X
effective	B-X
vaccine	B-X
against	B-X
HIV-1	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
most	B-X
bNAbs	B-X
requires	B-X
multiple	B-X
rounds	B-X
of	B-X
B	B-X
cell	B-X
receptor	B-X
affinity	B-X
maturation	B-X
,	B-X
suggesting	B-X
a	B-X
crucial	B-X
role	B-X
of	B-X
follicular	B-X
helper	B-X
T	B-X
(	B-X
Tfh	B-X
)	B-X
cells	B-X
in	B-X
their	B-X
production	B-X
.	B-X
However	B-X
,	B-X
less	B-X
than	B-X
1	B-X
%	B-X
of	B-X
HIV-infected	B-X
patients	B-X
develop	B-X
bNAbs	B-X
that	B-X
arise	B-X
late	B-X
in	B-X
the	B-X
course	B-X
of	B-X
infection	B-X
,	B-X
indicating	B-X
probable	B-X
Tfh	B-X
and	B-X
B	B-X
cell	B-X
dysfunctions	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Since	B-X
the	B-X
last	B-X
few	B-X
years	B-X
,	B-X
many	B-X
studies	B-X
have	B-X
characterized	B-X
Tfh	B-X
cells	B-X
from	B-X
lymph	B-X
nodes	B-X
and	B-X
spleen	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
and	B-X
SIV-infected	B-X
macaques	B-X
.	B-X
The	B-X
latter	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
crosstalk	B-X
and	B-X
GC	B-X
reactions	B-X
.	B-X
Meanwhile	B-X
,	B-X
advances	B-X
in	B-X
single-cell	B-X
technologies	B-X
have	B-X
made	B-X
possible	B-X
to	B-X
analyze	B-X
the	B-X
transcriptional	B-X
profiles	B-X
of	B-X
low	B-X
abundant	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
Tfh	B-X
populations	B-X
.	B-X
Using	B-X
transcriptional	B-X
signatures	B-X
,	B-X
we	B-X
review	B-X
here	B-X
the	B-X
impact	B-X
of	B-X
chronic	B-X
SIV/HIV	B-X
infection	B-X
on	B-X
Tfh	B-X
,	B-X
GC	B-X
Tfh	B-X
,	B-X
pTfh	B-X
,	B-X
and	B-X
cTfh	B-X
differentiation	B-X
and	B-X
helper	B-X
T	B-X
cell	B-X
functions	B-X
with	B-X
regard	B-X
to	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
efficient	B-X
B	B-X
cell	B-X
maturation	B-X
.	B-X
We	B-X
will	B-X
explore	B-X
some	B-X
hypothesis	B-X
to	B-X
explain	B-X
the	B-X
increased	B-X
proportion	B-X
of	B-X
Tfh	B-X
cells	B-X
reported	B-X
in	B-X
chronically	B-X
infected	B-X
individuals	B-X
and	B-X
the	B-X
impact	B-X
on	B-X
HIV	B-X
pathogenesis	B-X
.	B-X

Moreover	O
,	O
Tat	B-Protein
associated	O
with	O
the	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappaB	O
and	O
increased	O
the	O
p65	B-Protein
DNA	O
-	O
binding	O
affinity	O
and	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

The	O
arginine	O
-	O
and	O
cysteine	O
-	O
rich	O
domains	O
of	O
Tat	B-Protein
were	O
required	O
for	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
association	O
,	O
respectively	O
,	O
and	O
for	O
sustaining	O
the	O
NF	O
-	O
kappaB	O
activity	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

Among	O
an	O
array	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
Tat	B-Protein
mostly	O
activated	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
in	O
a	O
p65	B-Protein
-	O
dependent	O
manner	O
,	O
and	O
bound	O
to	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
NF	O
-	O
kappaB	O
enhancer	O
thus	O
promoting	O
the	O
recruitment	O
of	O
p65	B-Protein
with	O
displacement	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
;	O
similar	O
findings	O
were	O
obtained	O
for	O
the	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
and	O
TLR2	B-Protein
.	O

Our	O
results	O
support	O
a	O
novel	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
via	O
physical	O
interaction	O
of	O
Tat	B-Protein
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
,	O
and	O
may	O
contribute	O
to	O
further	O
insights	O
into	O
the	O
deregulation	O
of	O
the	O
inflammatory	O
response	O
by	O
HIV	O
-	O
1	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

Nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
transcription	O
factors	O
regulate	O
the	O
transcription	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
response	O
(	O
1	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
family	O
includes	O
RelA	B-Protein
/	O
p65	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
RelB	B-Protein
,	O
p50	B-Protein
and	O
p52	B-Protein
that	O
share	O
a	O
highly	O
conserved	O
300	O
-	O
amino	O
acid	O
Rel	O
homology	O
domain	O
(	O
RHD	O
)	O
for	O
homo	O
-	O
or	O
hetero	O
-	O
dimerization	O
and	O
DNA	O
-	O
binding	O
.	O
<EOS>	B-X
NPR1	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
the	B-X
defence	B-X
transcriptome	B-X
induced	B-X
by	B-X
the	B-X
plant	B-X
immune	B-X
signal	B-X
salicylic	B-X
acid	B-X
Mangiferin	B-X
is	B-X
a	B-X
glycosylated	B-X
xanthone	B-X
widely	B-X
distributed	B-X
in	B-X
nature	B-X
,	B-X
which	B-X
exhibits	B-X
wide	B-X
pharmacological	B-X
activities	B-X
,	B-X
highlighting	B-X
its	B-X
anti-cancer	B-X
properties	B-X
.	B-X
Mangiferin	B-X
interferes	B-X
with	B-X
inflammation	B-X
,	B-X
lipid	B-X
,	B-X
and	B-X
calcium	B-X
signaling	B-X
,	B-X
which	B-X
selectively	B-X
inhibits	B-X
multiple	B-X
NFkB	B-X
target	B-X
genes	B-X
as	B-X
interleukin-6	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
,	B-X
plasminogen	B-X
,	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
,	B-X
among	B-X
others	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
the	B-X
interactions	B-X
of	B-X
this	B-X
polyphenol	B-X
with	B-X
MMP-9	B-X
and	B-X
NF-κβ	B-X
are	B-X
characterized	B-X
by	B-X
using	B-X
computational	B-X
chemistry	B-X
methods	B-X
.	B-X
The	B-X
results	B-X
show	B-X
MMP-9	B-X
inhibition	B-X
by	B-X
mangiferina	B-X
is	B-X
characterized	B-X
for	B-X
the	B-X
interact	B-X
with	B-X
the	B-X
catalytic	B-X
Zn	B-X
atom	B-X
through	B-X
a	B-X
penta-coordinate	B-X
structure	B-X
.	B-X
It	B-X
is	B-X
also	B-X
demonstrated	B-X
through	B-X
a	B-X
strong	B-X
charge	B-X
transfer	B-X
established	B-X
between	B-X
mangiferin	B-X
and	B-X
Zn	B-X
in	B-X
the	B-X
QM/MM	B-X
study	B-X
.	B-X
Concerning	B-X
the	B-X
mangiferin/NF-κβ	B-X
system	B-X
,	B-X
the	B-X
92.3	B-X
%	B-X
of	B-X
interactions	B-X
between	B-X
p50	B-X
sub-unity	B-X
and	B-X
DNA	B-X
are	B-X
maintained	B-X
with	B-X
a	B-X
binding	B-X
energy	B-X
of	B-X
-	B-X
8.04	B-X
kcal/mol	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
mangiferin	B-X
blocks	B-X
the	B-X
p50-p65/DNA	B-X
interaction	B-X
resulting	B-X
in	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
functions	B-X
of	B-X
this	B-X
hetero-dimeric	B-X
member	B-X
and	B-X
suggesting	B-X
inhibition	B-X
of	B-X
the	B-X
cancer	B-X
progression	B-X
.	B-X
Experimental	B-X
results	B-X
concerning	B-X
the	B-X
anti-cancer	B-X
properties	B-X
of	B-X
mangiferin	B-X
show	B-X
that	B-X
this	B-X
natural	B-X
compound	B-X
can	B-X
inhibit	B-X
selectively	B-X
MMP-9	B-X
and	B-X
NF-ƙβ	B-X
.	B-X
Although	B-X
the	B-X
anti-tumor	B-X
properties	B-X
of	B-X
mangiferin	B-X
are	B-X
well	B-X
defined	B-X
,	B-X
its	B-X
molecular	B-X
mechanisms	B-X
of	B-X
actions	B-X
are	B-X
not	B-X
described	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
a	B-X
computational	B-X
study	B-X
is	B-X
carried	B-X
out	B-X
to	B-X
characterize	B-X
the	B-X
interactions	B-X
of	B-X
mangiferin	B-X
with	B-X
these	B-X
molecular	B-X
targets	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
corroborate	B-X
the	B-X
anti-proliferative	B-X
and	B-X
anti-apoptotic	B-X
activity	B-X
of	B-X
mangiferin	B-X
and	B-X
provide	B-X
a	B-X
depiction	B-X
of	B-X
its	B-X
mechanisms	B-X
of	B-X
action	B-X
.	B-X

The	O
transcriptional	O
activity	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
depends	O
on	O
dimer	O
composition	O
since	O
C	O
-	O
terminal	O
unrelated	O
transcriptional	O
activation	O
domains	O
are	O
present	O
exclusively	O
in	O
p65	B-Protein
,	O
RelB	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
2	O
)	O
.	O

Inhibitors	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
associate	O
with	O
the	O
NF	O
-	O
kappaB	O
complex	O
and	O
interfere	O
with	O
its	O
binding	O
to	O
DNA	O
(	O
3	O
)	O
.	O

In	O
the	O
canonical	O
pathway	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
the	O
activated	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
phosphorylates	O
IkappaB	O
at	O
specific	O
serine	O
residues	O
that	O
target	O
the	O
protein	O
to	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
,	O
which	O
releases	O
the	O
functional	O
NF	O
-	O
kappaB	O
complex	O
in	O
the	O
nucleus	O
.	O

IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
the	O
most	O
abundant	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
4	O
)	O
,	O
is	O
phosphorylated	O
by	O
IKK	O
at	O
Ser32	O
and	O
Ser36	O
(	O
5	O
)	O
,	O
and	O
subsequently	O
ubiquitylated	O
at	O
Lys21	O
and	O
Lys22	O
to	O
be	O
degraded	O
by	O
the	O
26S	O
proteasome	O
(	O
6	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
is	O
enhanced	O
by	O
phosphorylation	O
of	O
p65	B-Protein
at	O
Ser276	O
by	O
PKA	O
and	O
MSK1	B-Protein
(	O
7	O
,	O
8	O
)	O
,	O
Ser311	O
by	O
PKCzeta	B-Protein
(	O
9	O
)	O
and	O
Ser536	O
by	O
IKKalpha	B-Protein
(	O
10	O
,	O
11	O
)	O
.	O

Acetylation	O
of	O
p65	B-Protein
at	O
Lys218	O
and	O
Lys221	O
increases	O
the	O
DNA	O
binding	O
and	O
impairs	O
the	O
association	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
acetylation	O
at	O
Lys310	O
enhances	O
the	O
p65	B-Protein
transcriptional	O
activity	O
(	O
12	O
,	O
13	O
)	O
.	O

Post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
is	O
regulated	O
by	O
negative	O
feedback	O
loop	O
through	O
inhibitors	O
under	O
the	O
transcriptional	O
control	O
of	O
NF	O
-	O
kappaB	O
,	O
such	O
as	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
ubiquitin	O
-	O
editing	O
protein	O
A20	B-Protein
(	O
14	O
-	O
20	O
)	O
.	O

Deacetylation	O
of	O
p65	B-Protein
by	O
histone	B-Protein
deacetylase	I-Protein
-	I-Protein
3	I-Protein
or	O
SIRT1	B-Protein
,	O
or	O
acetylation	O
of	O
p65	B-Protein
at	O
Lys122	O
and	O
Lys123	O
down	O
-	O
regulate	O
the	O
NF	O
-	O
kappaB	O
activity	O
(	O
12	O
,	O
21	O
,	O
22	O
)	O
.	O
<EOS>	B-X
The	B-X
silent	B-X
information	B-X
regulator	B-X
sirtuin	B-X
1	B-X
(	B-X
SIRT1	B-X
)	B-X
protein	B-X
,	B-X
a	B-X
highly	B-X
conserved	B-X
NAD	B-X
Sirt1	B-X
is	B-X
the	B-X
most	B-X
prominent	B-X
and	B-X
extensively	B-X
studied	B-X
member	B-X
of	B-X
sirtuins	B-X
,	B-X
the	B-X
family	B-X
of	B-X
mammalian	B-X
class	B-X
III	B-X
histone	B-X
deacetylases	B-X
heavily	B-X
implicated	B-X
in	B-X
health	B-X
span	B-X
and	B-X
longevity	B-X
.	B-X
Although	B-X
primarily	B-X
a	B-X
nuclear	B-X
protein	B-X
,	B-X
Sirt1	B-X
's	B-X
deacetylation	B-X
of	B-X
Peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
Gamma	B-X
Coactivator-1α	B-X
(	B-X
PGC-1α	B-X
)	B-X
has	B-X
been	B-X
extensively	B-X
implicated	B-X
in	B-X
metabolic	B-X
control	B-X
and	B-X
mitochondrial	B-X
biogenesis	B-X
,	B-X
which	B-X
was	B-X
proposed	B-X
to	B-X
partially	B-X
underlie	B-X
Sirt1	B-X
's	B-X
role	B-X
in	B-X
caloric	B-X
restriction	B-X
and	B-X
impacts	B-X
on	B-X
longevity	B-X
.	B-X
The	B-X
notion	B-X
of	B-X
Sirt1	B-X
's	B-X
regulation	B-X
of	B-X
PGC-1α	B-X
activity	B-X
and	B-X
its	B-X
role	B-X
in	B-X
mitochondrial	B-X
biogenesis	B-X
has	B-X
,	B-X
however	B-X
,	B-X
been	B-X
controversial	B-X
.	B-X
I	B-X
discuss	B-X
here	B-X
evidences	B-X
for	B-X
Sirt1	B-X
's	B-X
regulation	B-X
of	B-X
mitochondrial	B-X
biogenesis	B-X
and	B-X
turnover	B-X
,	B-X
in	B-X
relation	B-X
to	B-X
PGC-1α	B-X
deacetylation	B-X
and	B-X
various	B-X
aspects	B-X
of	B-X
cellular	B-X
physiology	B-X
and	B-X
disease	B-X
.	B-X

Persistent	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
monocytes	O
,	O
macrophages	O
and	O
microglia	O
,	O
and	O
enhances	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
including	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
cell	O
adhesion	O
molecules	O
and	O
chemokines	O
(	O
23	O
-	O
25	O
)	O
.	O

Chronic	O
inflammation	O
is	O
a	O
major	O
cause	O
of	O
immune	O
and	O
neuron	O
dysfunction	O
in	O
AIDS	O
(	O
26	O
,	O
27	O
)	O
.	O

Consistently	O
,	O
non	O
-	O
human	O
primate	O
hosts	O
for	O
simian	O
immunodeficiency	O
virus	O
,	O
such	O
as	O
African	O
green	O
monkeys	O
and	O
sooty	O
mangabey	O
,	O
lack	O
aberrant	O
immune	O
activation	O
and	O
do	O
not	O
develop	O
AIDS	O
despite	O
high	O
virus	O
replication	O
(	O
28	O
,	O
29	O
)	O
.	O

Thus	O
,	O
understanding	O
the	O
mechanisms	O
of	O
NF	O
-	O
kappaB	O
deregulation	O
by	O
HIV	O
-	O
1	O
may	O
provide	O
further	O
insights	O
into	O
AIDS	O
pathogenesis	O
.	O

In	O
HIV	O
-	O
1	O
entry	O
,	O
the	O
binding	O
of	O
the	O
gp120	B-Protein
viral	O
envelope	O
to	O
CD4	B-Protein
induces	O
the	O
NF	O
-	O
kappaB	O
activity	O
by	O
activation	O
of	O
IKK	O
(	O
30	O
)	O
and	O
procaspase	B-Protein
8	I-Protein
(	O
31	O
)	O
.	O

Following	O
viral	O
integration	O
,	O
the	O
early	O
encoded	O
HIV	O
-	O
1	O
Tat	B-Protein
protein	O
interacts	O
with	O
the	O
HIV	O
-	O
1	O
RNA	O
and	O
host	O
cell	O
factors	O
to	O
sustain	O
the	O
viral	O
replication	O
.	O

Tat	B-Protein
binds	O
to	O
RNA	O
stem	O
-	O
loop	O
structures	O
generated	O
by	O
the	O
5	O
'	O
end	O
of	O
target	O
transcripts	O
,	O
including	O
the	O
HIV	O
-	O
1	O
transactivation	O
-	O
responsive	O
element	O
(	O
TAR	O
)	O
(	O
32	O
)	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
beta	I-Protein
(	O
TNFbeta	B-Protein
)	O
(	O
33	O
)	O
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
(	O
34	O
)	O
to	O
activate	O
gene	O
transcription	O
.	O

Indeed	O
,	O
Tat	B-Protein
promotes	O
the	O
transcriptional	O
initiation	O
and	O
elongation	O
by	O
interacting	O
with	O
transacting	O
factors	O
and	O
cofactors	O
,	O
such	O
as	O
Sp1	B-Protein
(	O
35	O
)	O
,	O
TFIID	B-Protein
(	O
36	O
)	O
,	O
E2F	B-Protein
-	I-Protein
4	I-Protein
(	O
37	O
)	O
,	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
(	O
38	O
)	O
,	O
cyclin	B-Protein
T1	I-Protein
/	O
CDK9	B-Protein
(	O
39	O
,	O
40	O
)	O
and	O
the	O
histone	O
acetyltransferases	O
p300	B-Protein
/	O
CBP	B-Protein
and	O
P	B-Protein
/	I-Protein
CAF	I-Protein
(	O
41	O
-	O
43	O
)	O
.	O

When	O
released	O
from	O
HIV	O
-	O
1	O
-	O
infected	O
cells	O
,	O
Tat	B-Protein
deregulates	O
the	O
cell	O
signaling	O
by	O
binding	O
to	O
cell	O
receptors	O
,	O
such	O
as	O
integrins	O
(	O
44	O
)	O
,	O
Flk1	B-Protein
/	I-Protein
KDR	I-Protein
receptor	I-Protein
(	O
45	O
)	O
and	O
chemokine	O
receptors	O
(	O
46	O
)	O
.	O

We	O
first	O
reported	O
that	O
NF	O
-	O
kappaB	O
was	O
constitutively	O
active	O
in	O
Jurkat	O
cells	O
that	O
stably	O
expressed	O
the	O
Tat	B-Protein
gene	O
(	O
47	O
)	O
.	O

Following	O
gene	O
transfection	O
or	O
protein	O
transduction	O
,	O
Tat	B-Protein
induced	O
the	O
IKK	O
activity	O
and	O
proteasomal	O
degradation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
48	O
)	O
,	O
and	O
increased	O
the	O
p65	B-Protein
transcriptional	O
activity	O
by	O
inhibiting	O
the	O
SIRT	B-Protein
-	I-Protein
1	I-Protein
-	O
mediated	O
deacetylation	O
of	O
p65	B-Protein
Lys310	O
(	O
49	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
Tat	B-Protein
modulates	O
crucial	O
enzymes	O
involved	O
in	O
NF	O
-	O
kappaB	O
signaling	O
;	O
however	O
,	O
it	O
was	O
unclear	O
how	O
Tat	B-Protein
could	O
subvert	O
the	O
negative	O
feedback	O
of	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
mainly	O
dependent	O
on	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
15	O
,	O
17	O
)	O
.	O

We	O
previously	O
found	O
that	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
binds	O
to	O
Tat	B-Protein
and	O
promotes	O
the	O
nuclear	O
export	O
of	O
the	O
viral	O
transactivator	O
(	O
50	O
,	O
51	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
Tat	B-Protein
counteracts	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
through	O
direct	O
interaction	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
,	O
which	O
enhances	O
the	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

The	O
new	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
deregulation	O
here	O
described	O
may	O
provide	O
further	O
insights	O
into	O
the	O
chronic	O
immune	O
activation	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Plasmids	O
<EOS>	B-X
Plasmids	B-X
mediate	B-X
the	B-X
horizontal	B-X
transmission	B-X
of	B-X
genetic	B-X
information	B-X
between	B-X
bacteria	B-X
,	B-X
facilitating	B-X
their	B-X
adaptation	B-X
to	B-X
multiple	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
bacteria	B-X
with	B-X
new	B-X
adaptive	B-X
tools	B-X
,	B-X
but	B-X
they	B-X
also	B-X
entail	B-X
a	B-X
metabolic	B-X
burden	B-X
that	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
selection	B-X
for	B-X
plasmid-encoded	B-X
traits	B-X
,	B-X
reduces	B-X
the	B-X
competitiveness	B-X
of	B-X
the	B-X
plasmid-carrying	B-X
clone	B-X
.	B-X
Plasmids	B-X
are	B-X
important	B-X
vehicles	B-X
for	B-X
rapid	B-X
adaptation	B-X
of	B-X
bacterial	B-X
populations	B-X
to	B-X
changing	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
various	B-X
accessory	B-X
traits	B-X
which	B-X
might	B-X
be	B-X
beneficial	B-X
under	B-X
particular	B-X
conditions	B-X
.	B-X

The	O
plasmids	O
pcDNA	O
-	O
3xHA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-Protein
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
,	I-Protein
52	I-Protein
,	I-Protein
53	I-Protein
,	I-Protein
55	I-Protein
,	I-Protein
56	I-Protein
,	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-Protein
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
and	O
pGEX	O
-	O
2T	O
-	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
,	I-Protein
52	I-Protein
,	I-Protein
53	I-Protein
,	I-Protein
55	I-Protein
,	I-Protein
56	I-Protein
,	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
were	O
previously	O
described	O
(	O
50	O
)	O
.	O

The	O
plasmids	O
pNL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
and	O
pHXB2	O
-	O
env	B-Protein
were	O
obtained	O
from	O
the	O
AIDS	O
Research	O
&	O
Reference	O
Reagent	O
Program	O
,	O
Division	O
of	O
AIDS	O
,	O
NIAID	O
,	O
NIH	O
,	O
USA	O
;	O
pkappaBluc	O
and	O
pSV	O
-	O
beta	B-Protein
-	I-Protein
Gal	I-Protein
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

The	O
plasmids	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65	I-Protein
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65deltaC	I-Protein
(	O
1	O
-	O
318	O
)	O
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65deltaN	I-Protein
(	O
122	O
-	O
551	O
)	O
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
p3xFLAG	O
-	O
CMV	O
-	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
pGEX	O
-	O
2T	O
-	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
and	O
pNL4	O
-	O
3	O
.	O
FLAG	O
-	O
Tat	B-Protein
.	O
R	O
-	O
E	O
-	O
were	O
generated	O
as	O
described	O
in	O
Supplementary	O
Data	O
.	O

Cells	O
,	O
transfection	O
,	O
treatments	O
and	O
luciferase	B-Protein
assay	O
<EOS>	B-X
To	B-X
develop	B-X
and	B-X
validate	B-X
a	B-X
novel	B-X
reporter	B-X
gene	B-X
assay	B-X
(	B-X
RGA	B-X
)	B-X
to	B-X
detect	B-X
pyrogen	B-X
,	B-X
HL60	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
an	B-X
NF-κB-RE	B-X
plasmid	B-X
containing	B-X
the	B-X
luciferase	B-X
gene	B-X
to	B-X
generate	B-X
stably	B-X
transfected	B-X
cells	B-X
.	B-X
With	B-X
the	B-X
emerging	B-X
fields	B-X
of	B-X
cancer	B-X
vaccines	B-X
and	B-X
adoptive	B-X
cell	B-X
transfer	B-X
therapies	B-X
,	B-X
there	B-X
is	B-X
an	B-X
increasing	B-X
demand	B-X
for	B-X
high-throughput	B-X
in	B-X
vitro	B-X
cytotoxicity	B-X
assays	B-X
that	B-X
efficiently	B-X
analyze	B-X
immune	B-X
effector	B-X
functions	B-X
.	B-X
The	B-X
gold	B-X
standard	B-X
(	B-X
51	B-X
)	B-X
Cr-release	B-X
assay	B-X
is	B-X
very	B-X
accurate	B-X
but	B-X
has	B-X
the	B-X
major	B-X
disadvantage	B-X
of	B-X
being	B-X
radioactive	B-X
.	B-X
We	B-X
reveal	B-X
the	B-X
development	B-X
of	B-X
a	B-X
versatile	B-X
and	B-X
nonradioactive	B-X
firefly	B-X
luciferase	B-X
in	B-X
vitro	B-X
transcribed	B-X
(	B-X
IVT	B-X
)	B-X
RNA-based	B-X
assay	B-X
.	B-X
Demonstrating	B-X
high	B-X
efficiency	B-X
,	B-X
consistency	B-X
,	B-X
and	B-X
excellent	B-X
target	B-X
cell	B-X
viability	B-X
,	B-X
our	B-X
optimized	B-X
luciferase	B-X
IVT	B-X
RNA	B-X
is	B-X
used	B-X
to	B-X
transfect	B-X
dividing	B-X
and	B-X
nondividing	B-X
primary	B-X
antigen	B-X
presenting	B-X
cells	B-X
.	B-X
Together	B-X
with	B-X
the	B-X
long-lasting	B-X
expression	B-X
and	B-X
minimal	B-X
background	B-X
,	B-X
the	B-X
direct	B-X
measurement	B-X
of	B-X
intracellular	B-X
luciferase	B-X
activity	B-X
of	B-X
living	B-X
cells	B-X
allows	B-X
for	B-X
the	B-X
monitoring	B-X
of	B-X
killing	B-X
kinetics	B-X
and	B-X
displays	B-X
paramount	B-X
sensitivity	B-X
.	B-X
The	B-X
ability	B-X
to	B-X
cotransfect	B-X
the	B-X
IVT	B-X
RNA	B-X
of	B-X
the	B-X
luciferase	B-X
reporter	B-X
and	B-X
the	B-X
antigen	B-X
of	B-X
interest	B-X
into	B-X
the	B-X
antigen	B-X
presenting	B-X
cells	B-X
and	B-X
its	B-X
simple	B-X
read-out	B-X
procedure	B-X
render	B-X
the	B-X
assay	B-X
high-throughput	B-X
in	B-X
nature	B-X
.	B-X
Results	B-X
generated	B-X
were	B-X
comparable	B-X
to	B-X
the	B-X
(	B-X
51	B-X
)	B-X
Cr	B-X
release	B-X
and	B-X
further	B-X
confirmed	B-X
the	B-X
assay	B-X
's	B-X
ability	B-X
to	B-X
measure	B-X
antibody-dependent	B-X
cell-mediated	B-X
cytotoxicity	B-X
and	B-X
complement-dependent	B-X
cytotoxicity	B-X
.	B-X
The	B-X
assay	B-X
's	B-X
combined	B-X
simplicity	B-X
,	B-X
practicality	B-X
,	B-X
and	B-X
efficiency	B-X
tailor	B-X
it	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
antigen-specific	B-X
cellular	B-X
and	B-X
humoral	B-X
effector	B-X
functions	B-X
during	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
immunotherapies	B-X
.	B-X

HeLa	O
,	O
p50	B-Protein
-	O
/	O
-	O
p65	B-Protein
-	O
/	O
-	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
(	O
52	O
)	O
and	O
293T	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
Jurkat	O
,	O
U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
cultured	O
in	O
RPMI	O
1640	O
.	O

PBMCs	O
were	O
isolated	O
as	O
previously	O
described	O
(	O
53	O
)	O
.	O
<EOS>	B-X
The	B-X
precise	B-X
role	B-X
of	B-X
cellular	B-X
autoimmune	B-X
responses	B-X
to	B-X
cardiac-specific	B-X
antigens	B-X
has	B-X
not	B-X
been	B-X
well	B-X
described	B-X
in	B-X
humans	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
the	B-X
cellular	B-X
autoimmune	B-X
response	B-X
to	B-X
cardiac	B-X
troponin	B-X
I	B-X
(	B-X
cTnI	B-X
)	B-X
,	B-X
specifically	B-X
,	B-X
the	B-X
release	B-X
of	B-X
cytokines	B-X
by	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
,	B-X
in	B-X
subjects	B-X
with	B-X
iDCM	B-X
and	B-X
healthy	B-X
control	B-X
subjects	B-X
.	B-X
PF-46396	B-X
,	B-X
a	B-X
representative	B-X
molecule	B-X
,	B-X
exhibits	B-X
antiviral	B-X
activity	B-X
against	B-X
HIV-1	B-X
laboratory	B-X
strains	B-X
and	B-X
clinical	B-X
isolates	B-X
in	B-X
T-cell	B-X
lines	B-X
and	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
.	B-X
Viral	B-X
variants	B-X
resistant	B-X
to	B-X
PF-46396	B-X
contain	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
substitution	B-X
in	B-X
HIV-1	B-X
CA	B-X
sequences	B-X
(	B-X
CAI201V	B-X
)	B-X
,	B-X
distal	B-X
to	B-X
the	B-X
CA/SP1	B-X
cleavage	B-X
site	B-X
in	B-X
the	B-X
primary	B-X
structure	B-X
,	B-X
which	B-X
we	B-X
demonstrate	B-X
is	B-X
sufficient	B-X
to	B-X
confer	B-X
significant	B-X
resistance	B-X
to	B-X
PF-46396	B-X
and	B-X
3-O-	B-X
(	B-X
3',3'-dimethylsuccinyl	B-X
)	B-X
betulinic	B-X
acid	B-X
(	B-X
DSB	B-X
)	B-X
,	B-X
a	B-X
previously	B-X
described	B-X
maturation	B-X
inhibitor	B-X
.	B-X
Conversely	B-X
,	B-X
a	B-X
single	B-X
amino	B-X
substitution	B-X
in	B-X
SP1	B-X
(	B-X
SP1A1V	B-X
)	B-X
,	B-X
which	B-X
was	B-X
previously	B-X
associated	B-X
with	B-X
DSB	B-X
in	B-X
vitro	B-X
resistance	B-X
,	B-X
was	B-X
sufficient	B-X
to	B-X
confer	B-X
resistance	B-X
to	B-X
DSB	B-X
and	B-X
PF-46396	B-X
.	B-X

Media	O
were	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
and	O
2	O
mM	O
l	O
-	O
glutamine	O
(	O
Lonza	O
Cologne	O
AG	O
,	O
Germany	O
)	O
.	O

HeLa	O
,	O
p50	B-Protein
-	O
/	O
-	O
p65	B-Protein
-	O
/	O
-	O
MEFs	O
and	O
293T	O
were	O
transfected	O
with	O
DNA	O
by	O
using	O
FuGENE	O
HD	O
(	O
Roche	O
Diagnostic	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
;	O
total	O
DNA	O
amounts	O
were	O
equalized	O
by	O
transfection	O
of	O
pRc	O
/	O
CMV	O
empty	O
vector	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
pulse	O
-	O
stimulation	O
,	O
HeLa	O
cells	O
were	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
;	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
(	O
20	O
ng	O
/	O
ml	O
)	O
for	O
5	O
min	O
,	O
or	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
;	O
Sigma	O
-	O
Aldrich	O
)	O
(	O
20	O
ng	O
/	O
ml	O
)	O
for	O
30	O
min	O
,	O
washed	O
twice	O
in	O
complete	O
culture	O
medium	O
and	O
then	O
returned	O
to	O
culture	O
.	O

For	O
luciferase	B-Protein
assays	O
,	O
pSV	O
-	O
beta	B-Protein
-	I-Protein
Gal	I-Protein
was	O
co	O
-	O
transfected	O
with	O
pkappaBluc	O
to	O
monitor	O
the	O
transfection	O
efficiency	O
.	O

Forty	O
-	O
eight	O
-	O
hour	O
post	O
-	O
transfection	O
,	O
cells	O
were	O
lysed	O
in	O
lysis	O
buffer	O
of	O
Dual	O
Light	O
Luciferase	B-Protein
System	O
(	O
Tropix	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
)	O
and	O
the	O
luciferase	B-Protein
and	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activities	O
were	O
evaluated	O
by	O
using	O
Dual	O
Light	O
Luciferase	O
System	O
(	O
Tropix	O
)	O
in	O
a	O
bioluminometer	O
(	O
Turner	O
Biosystem	O
,	O
Sunnyvale	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
ratio	O
of	O
firefly	O
luciferase	B-Protein
activity	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
was	O
expressed	O
as	O
relative	O
light	O
units	O
.	O

RNA	O
interference	O
<EOS>	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
is	B-X
a	B-X
biological	B-X
process	B-X
by	B-X
which	B-X
double-stranded	B-X
RNA	B-X
(	B-X
dsRNA	B-X
)	B-X
induces	B-X
sequence-specific	B-X
gene	B-X
silencing	B-X
by	B-X
targeting	B-X
mRNA	B-X
for	B-X
degradation	B-X
.	B-X
As	B-X
a	B-X
tool	B-X
for	B-X
knocking	B-X
down	B-X
the	B-X
expression	B-X
of	B-X
individual	B-X
genes	B-X
posttranscriptionally	B-X
,	B-X
RNAi	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
to	B-X
study	B-X
the	B-X
cellular	B-X
function	B-X
of	B-X
genes	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
I	B-X
describe	B-X
procedures	B-X
for	B-X
using	B-X
gene-specific	B-X
,	B-X
synthetic	B-X
,	B-X
short	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
to	B-X
induce	B-X
gene	B-X
silencing	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Potential	B-X
challenges	B-X
and	B-X
problems	B-X
associated	B-X
with	B-X
the	B-X
siRNA	B-X
technology	B-X
are	B-X
also	B-X
discussed	B-X
.	B-X

Jurkat	O
or	O
U937	O
cells	O
were	O
transfected	O
by	O
electroporation	O
using	O
a	O
Bio	O
-	O
Rad	O
apparatus	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
<EOS>	B-X
The	B-X
immune	B-X
response	B-X
produced	B-X
by	B-X
T	B-X
cells	B-X
is	B-X
cellular	B-X
immunity	B-X
,	B-X
which	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
anti-infection	B-X
process	B-X
of	B-X
human	B-X
body	B-X
,	B-X
and	B-X
can	B-X
participate	B-X
in	B-X
immunological	B-X
protection	B-X
and	B-X
cause	B-X
immunopathology	B-X
.	B-X
The	B-X
outcome	B-X
of	B-X
various	B-X
infectious	B-X
diseases	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
cellular	B-X
immune	B-X
function	B-X
,	B-X
especially	B-X
the	B-X
function	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Jurkat	B-X
cells	B-X
belong	B-X
to	B-X
the	B-X
human	B-X
acute	B-X
T	B-X
lymphocyte	B-X
leukemia	B-X
cell	B-X
line	B-X
.	B-X
Jurkat	B-X
cell	B-X
model	B-X
can	B-X
simulate	B-X
the	B-X
function	B-X
T	B-X
lymphocytes	B-X
,	B-X
so	B-X
it	B-X
is	B-X
widely	B-X
used	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
studies	B-X
of	B-X
T	B-X
cell	B-X
signal	B-X
transduction	B-X
,	B-X
cytokines	B-X
,	B-X
and	B-X
receptor	B-X
expression	B-X
,	B-X
and	B-X
can	B-X
provide	B-X
reference	B-X
and	B-X
guidance	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
various	B-X
infectious	B-X
diseases	B-X
and	B-X
the	B-X
research	B-X
on	B-X
their	B-X
pathogenesis	B-X
.	B-X
The	B-X
Jurkat	B-X
cell	B-X
model	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
studies	B-X
of	B-X
viral	B-X
diseases	B-X
and	B-X
atypical	B-X
pathogens	B-X
,	B-X
but	B-X
parasitic	B-X
infection	B-X
studies	B-X
using	B-X
the	B-X
Jurkat	B-X
cell	B-X
model	B-X
are	B-X
still	B-X
rare	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
advances	B-X
in	B-X
the	B-X
application	B-X
of	B-X
Jurkat	B-X
cell	B-X
model	B-X
in	B-X
the	B-X
research	B-X
on	B-X
infectious	B-X
diseases	B-X
.	B-X

Briefly	O
,	O
aliquots	O
(	O
5	O
x	O
106	O
cells	O
)	O
were	O
suspended	O
in	O
0	O
.	O
3	O
ml	O
of	O
RPMI	O
1640	O
supplemented	O
with	O
20	O
%	O
fetal	O
calf	O
serum	O
and	O
subjected	O
to	O
a	O
double	O
electrical	O
pulse	O
(	O
0	O
.	O
22	O
V	O
,	O
960	O
microF	O
)	O
in	O
the	O
presence	O
of	O
annealed	O
siRNA	O
(	O
200	O
pmol	O
)	O
;	O
electroporated	O
cells	O
were	O
washed	O
and	O
cultured	O
in	O
complete	O
medium	O
.	O

RNA	O
interference	O
was	O
performed	O
with	O
:	O
siRNA	B-Protein
Tat	I-Protein
sense	I-Protein
,	O
CUGCUUGUACCAAUUGCUAUU	O
and	O
siRNA	B-Protein
Tat	I-Protein
antisense	I-Protein
,	O
UAGCAAUUGGUACAAGCAGUU	O
;	O
siRNA	O
control	O
sense	O
,	O
CUGCUUGUCACA	O
AUUGCUAUU	O
and	O
siRNA	O
control	O
antisense	O
,	O
UAGCAAUUGUGACAAGCAGUU	O
.	O

RNA	O
interference	O
of	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
performed	O
with	O
SMART	O
pool	O
siRNA	B-Protein
p65	I-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Dharmacon	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Pseudotyped	O
virions	O
and	O
single	O
round	O
infection	O
<EOS>	B-X
However	B-X
,	B-X
these	B-X
compounds	B-X
did	B-X
not	B-X
inhibit	B-X
infection	B-X
by	B-X
single-round	B-X
infection	B-X
vesicular	B-X
stomatitis	B-X
virus	B-X
glycoprotein	B-X
G	B-X
(	B-X
VSV-G	B-X
)	B-X
-pseudotyped	B-X
viruses	B-X
,	B-X
indicating	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
early	B-X
steps	B-X
of	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
analysis	B-X
of	B-X
single-round	B-X
infection	B-X
VSV-G-pseudotyped	B-X
HIV-1	B-X
produced	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
compound	B-X
1	B-X
or	B-X
2	B-X
showed	B-X
a	B-X
complete	B-X
lack	B-X
of	B-X
infectivity	B-X
in	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
late	B-X
stages	B-X
of	B-X
the	B-X
HIV-1	B-X
life	B-X
cycle	B-X
were	B-X
affected	B-X
.	B-X
Highlighting	B-X
the	B-X
potential	B-X
therapeutic	B-X
relevance	B-X
of	B-X
fullerene	B-X
derivatives	B-X
,	B-X
these	B-X
compounds	B-X
block	B-X
infection	B-X
by	B-X
HIV-1	B-X
resistant	B-X
to	B-X
protease	B-X
and	B-X
maturation	B-X
inhibitors	B-X
.	B-X
They	B-X
are	B-X
under	B-X
continual	B-X
selection	B-X
pressure	B-X
from	B-X
the	B-X
host	B-X
antibody	B-X
response	B-X
during	B-X
chronic	B-X
infection	B-X
and	B-X
can	B-X
tolerate	B-X
adaptive	B-X
mutations	B-X
,	B-X
leading	B-X
to	B-X
great	B-X
diversity	B-X
in	B-X
a	B-X
single	B-X
host	B-X
.	B-X
Using	B-X
a	B-X
high-fidelity	B-X
,	B-X
limiting	B-X
dilution	B-X
(	B-X
``	B-X
endpoint	B-X
''	B-X
)	B-X
PCR	B-X
approach	B-X
to	B-X
amplify	B-X
single	B-X
E1/E2	B-X
cDNA	B-X
templates	B-X
,	B-X
which	B-X
can	B-X
then	B-X
generate	B-X
recombinant	B-X
model	B-X
viral	B-X
particles	B-X
using	B-X
retrovirus	B-X
packaging/reporter	B-X
constructs	B-X
.	B-X
These	B-X
retroviral	B-X
pseudoparticles	B-X
(	B-X
pseudotypes	B-X
)	B-X
facilitate	B-X
investigation	B-X
of	B-X
the	B-X
properties	B-X
of	B-X
authentic	B-X
E1/E2	B-X
glycoproteins	B-X
in	B-X
a	B-X
single-round	B-X
infection	B-X
assay	B-X
.	B-X

293T	O
cells	O
(	O
1	O
x	O
107	O
)	O
were	O
transfected	O
with	O
pNL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
or	O
pNL4	O
-	O
3	O
.	O
FLAG	O
-	O
Tat	B-Protein
.	O
R	O
-	O
E	O
-	O
(	O
10	O
microg	O
)	O
together	O
with	O
pHXB2	O
Env	B-Protein
(	O
10	O
microg	O
)	O
,	O
and	O
48	O
-	O
h	O
post	O
-	O
transfection	O
cell	O
supernatant	O
was	O
collected	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
anti	O
-	O
p24	O
antibody	O
measured	O
virion	O
concentration	O
.	O

PBMCs	O
,	O
Jurkat	O
or	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
infected	O
with	O
HXB2	O
Env	B-Protein
-	O
pseudotyped	O
virions	O
(	O
500	O
ng	O
of	O
p24	B-Protein
)	O
by	O
spinoculation	O
,	O
as	O
previously	O
described	O
(	O
50	O
)	O
.	O

Cell	O
extracts	O
,	O
western	O
blotting	O
,	O
IKK	O
activity	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
Ly	B-X
and	B-X
Te	B-X
on	B-X
NF-kappaB	B-X
signaling	B-X
in	B-X
HCT-116	B-X
colon	B-X
cancer	B-X
cells	B-X
.	B-X
DNA	B-X
binding	B-X
assays	B-X
revealed	B-X
that	B-X
combination	B-X
treatment	B-X
suppressed	B-X
both	B-X
basal	B-X
and	B-X
TNF-alpha-induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
This	B-X
suppression	B-X
correlated	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
p65	B-X
nuclear	B-X
translocation	B-X
and	B-X
IkappaB-alpha	B-X
degradation	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
change	B-X
in	B-X
IKK	B-X
expression	B-X
levels	B-X
or	B-X
inhibition	B-X
in	B-X
IkappaB-alpha	B-X
phosphorylation	B-X
suggest	B-X
the	B-X
involvement	B-X
of	B-X
an	B-X
IKK-independent	B-X
mechanism	B-X
.	B-X
Ly	B-X
and	B-X
Te	B-X
combination	B-X
was	B-X
found	B-X
to	B-X
downregulate	B-X
the	B-X
expression	B-X
of	B-X
NF-kappaB-regulated	B-X
antiapoptotic	B-X
and	B-X
proliferative	B-X
gene	B-X
products	B-X
.	B-X
Separate	B-X
treatments	B-X
and	B-X
drug	B-X
combinations	B-X
significantly	B-X
decreased	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
which	B-X
led	B-X
to	B-X
the	B-X
potentiation	B-X
of	B-X
cell	B-X
death	B-X
induced	B-X
by	B-X
the	B-X
colon	B-X
cancer	B-X
drugs	B-X
oxaliplatin	B-X
and	B-X
5-FU	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Ly	B-X
and	B-X
Te	B-X
anticancer	B-X
activities	B-X
are	B-X
partly	B-X
mediated	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
suggesting	B-X
their	B-X
use	B-X
in	B-X
combination	B-X
with	B-X
chemotherapeutic	B-X
agents	B-X
to	B-X
induce	B-X
apoptosis	B-X
.	B-X

Total	O
,	O
nuclear	O
and	O
cytosolic	O
extracts	O
were	O
performed	O
as	O
previously	O
described	O
(	O
54	O
)	O
;	O
details	O
are	O
reported	O
in	O
Supplementary	O
Data	O
.	O

Western	O
blotting	O
analysis	O
was	O
performed	O
by	O
resuspending	O
protein	O
aliquots	O
in	O
loading	O
buffer	O
(	O
125	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
6	O
.	O
8	O
,	O
5	O
%	O
SDS	O
,	O
1	O
%	O
bromophenol	O
blue	O
,	O
10	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
25	O
%	O
glycerol	O
)	O
,	O
resolved	O
on	O
12	O
%	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
polyvinylidene	O
difluoride	O
membrane	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
)	O
and	O
incubated	O
with	O
primary	O
antibodies	O
(	O
1	O
:	O
1000	O
)	O
followed	O
by	O
incubation	O
with	O
horseradish	O
-	O
peroxidase	O
-	O
linked	O
mouse	O
or	O
rabbit	O
IgG	O
(	O
1	O
:	O
2000	O
)	O
(	O
GE	O
Healthcare	O
Amersham	O
,	O
Little	O
Chalfont	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
in	O
PBS	O
containing	O
5	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Proteins	O
were	O
detected	O
by	O
chemiluminescence	O
using	O
the	O
ECL	O
System	O
(	O
GE	O
Healthcare	O
Amersham	O
)	O
.	O

Primary	O
antibodies	O
were	O
purchased	O
from	O
:	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
(	O
anti	O
-	O
HA	O
F7	O
,	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
C15	O
,	O
anti	O
-	O
Histone	O
H1	O
,	O
anti	O
-	O
Hexokinase	O
-	O
II	O
)	O
;	O
Sigma	O
-	O
Aldrich	O
(	O
anti	O
-	O
FLAG	O
M2	O
,	O
anti	O
-	O
gamma	O
-	O
Tubulin	O
)	O
;	O
Upstate	O
,	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
(	O
anti	O
-	O
p65	O
)	O
.	O

Densitometry	O
of	O
single	O
bands	O
was	O
analysed	O
by	O
ImageJ	O
software	O
package	O
(	O
NIH	O
,	O
USA	O
)	O
.	O

IKK	O
activity	O
was	O
evaluated	O
in	O
cytosolic	O
extracts	O
using	O
the	O
HTScan	O
IKK	O
kinase	O
assay	O
kit	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Binding	O
of	O
p65	B-Protein
,	O
p50	B-Protein
and	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
to	O
the	O
double	O
-	O
stranded	O
NF	O
-	O
kappaB	O
oligonucleotide	O
was	O
measured	O
using	O
NF	O
-	O
kappaB	O
Combo	O
Transcription	O
Factor	O
Assay	O
kit	O
(	O
Cayman	O
Chemical	O
Company	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O
was	O
performed	O
as	O
previously	O
described	O
(	O
55	O
)	O
;	O
details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O

In	O
vitro	O
translation	O
<EOS>	B-X
The	B-X
amplified	B-X
genes	B-X
are	B-X
used	B-X
in	B-X
transcription	B-X
and	B-X
translation	B-X
reactions	B-X
and	B-X
the	B-X
derived	B-X
radio-labeled	B-X
proteins	B-X
are	B-X
separated	B-X
by	B-X
2DE	B-X
.	B-X
In	B-X
vitro	B-X
translation	B-X
of	B-X
eukaryotic	B-X
messenger	B-X
RNA	B-X
.	B-X
In	B-X
the	B-X
present	B-X
manuscript	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
design	B-X
of	B-X
a	B-X
novel	B-X
adaptable	B-X
hybrid	B-X
in	B-X
vitro	B-X
translation	B-X
system	B-X
which	B-X
is	B-X
assembled	B-X
with	B-X
ribosomes	B-X
isolated	B-X
from	B-X
many	B-X
different	B-X
origins	B-X
.	B-X
Specialized	B-X
forms	B-X
of	B-X
control	B-X
regulate	B-X
the	B-X
translation	B-X
of	B-X
individual	B-X
mRNAs	B-X
,	B-X
and	B-X
the	B-X
factors	B-X
involved	B-X
in	B-X
these	B-X
mRNA-specific	B-X
events	B-X
are	B-X
expected	B-X
to	B-X
be	B-X
found	B-X
in	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
all	B-X
tissues	B-X
.	B-X
Consequently	B-X
,	B-X
homologous	B-X
in	B-X
vitro	B-X
translation	B-X
systems	B-X
,	B-X
prepared	B-X
from	B-X
tissues	B-X
in	B-X
which	B-X
important	B-X
regulatory	B-X
events	B-X
occur	B-X
,	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
required	B-X
to	B-X
pursue	B-X
biochemical	B-X
studies	B-X
of	B-X
the	B-X
underlying	B-X
mechanisms	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
extracts	B-X
prepared	B-X
from	B-X
Drosophila	B-X
ovaries	B-X
and	B-X
embryos	B-X
that	B-X
support	B-X
translation	B-X
of	B-X
exogenous	B-X
reporter	B-X
mRNAs	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
in	B-X
vitro	B-X
systems	B-X
should	B-X
prove	B-X
to	B-X
be	B-X
useful	B-X
in	B-X
dissecting	B-X
mechanisms	B-X
of	B-X
the	B-X
numerous	B-X
translational	B-X
control	B-X
events	B-X
shown	B-X
to	B-X
occur	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
Drosophila	B-X
development	B-X
.	B-X

HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
,	O
p65	B-Protein
and	O
Tat	B-Protein
were	O
expressed	O
under	O
the	O
T7	O
promoter	O
and	O
in	O
vitro	O
translated	O
using	O
the	O
TnT	O
quick	O
coupled	O
transcription	O
/	O
translation	O
system	O
(	O
Promega	O
)	O
,	O
as	O
previously	O
reported	O
(	O
50	O
)	O
.	O

Details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O
<EOS>	B-X
A	B-X
summary	B-X
of	B-X
the	B-X
studies	B-X
developed	B-X
using	B-X
DL	B-X
is	B-X
provided	B-X
in	B-X
the	B-X
Supplementary	B-X
Appendix	B-X
.	B-X
Then	B-X
,	B-X
the	B-X
challenges	B-X
encountered	B-X
during	B-X
the	B-X
automated	B-X
diagnosis	B-X
of	B-X
ASD	B-X
using	B-X
MRI	B-X
and	B-X
AI	B-X
techniques	B-X
are	B-X
described	B-X
in	B-X
detail	B-X
.	B-X
ChEMBL	B-X
is	B-X
a	B-X
large	B-X
,	B-X
open-access	B-X
bioactivity	B-X
database	B-X
(	B-X
https	B-X
:	B-X
//www.ebi.ac.uk/chembl	B-X
)	B-X
,	B-X
previously	B-X
described	B-X
in	B-X
the	B-X
2012	B-X
,	B-X
2014	B-X
and	B-X
2017	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
Database	B-X
Issues	B-X
.	B-X
In	B-X
the	B-X
last	B-X
two	B-X
years	B-X
,	B-X
several	B-X
important	B-X
improvements	B-X
have	B-X
been	B-X
made	B-X
to	B-X
the	B-X
database	B-X
and	B-X
are	B-X
described	B-X
here	B-X
.	B-X

Immunoprecipitation	O
assay	O
and	O
GST	B-Protein
-	O
pull	O
down	O
<EOS>	B-X
Pull-down	B-X
experiments	B-X
with	B-X
GST	B-X
fusion	B-X
proteins	B-X
attached	B-X
to	B-X
glutathione	B-X
beads	B-X
are	B-X
a	B-X
screening	B-X
technique	B-X
for	B-X
identification	B-X
of	B-X
protein-protein	B-X
interactions	B-X
.	B-X
When	B-X
coupled	B-X
with	B-X
mass	B-X
spectrometry	B-X
,	B-X
pull-downs	B-X
can	B-X
be	B-X
considered	B-X
as	B-X
the	B-X
protein-based	B-X
equivalent	B-X
of	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
.	B-X
To	B-X
improve	B-X
the	B-X
isolation	B-X
of	B-X
specific	B-X
binding	B-X
partners	B-X
,	B-X
pull-down	B-X
methods	B-X
are	B-X
described	B-X
involving	B-X
the	B-X
use	B-X
of	B-X
cross-linking	B-X
,	B-X
large-scale	B-X
tissue	B-X
lysates	B-X
,	B-X
and	B-X
spin	B-X
columns	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
detail	B-X
using	B-X
protein-protein	B-X
interaction	B-X
methods	B-X
,	B-X
including	B-X
co-immunoprecipitation	B-X
and	B-X
Glutathione-S-transferase	B-X
(	B-X
GST	B-X
)	B-X
fusion	B-X
protein	B-X
pull-down	B-X
assays	B-X
to	B-X
understand	B-X
the	B-X
molecular	B-X
interactions	B-X
of	B-X
ATM	B-X
.	B-X
These	B-X
assays	B-X
give	B-X
valuable	B-X
functional	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
ATM	B-X
,	B-X
as	B-X
they	B-X
are	B-X
easy	B-X
to	B-X
establish	B-X
within	B-X
the	B-X
laboratory	B-X
,	B-X
are	B-X
not	B-X
overly	B-X
laborious	B-X
,	B-X
and	B-X
are	B-X
easily	B-X
reproducible	B-X
.	B-X

Immunoprecipitation	O
,	O
GST	B-Protein
-	O
pull	O
down	O
,	O
and	O
production	O
of	O
GST	B-Protein
proteins	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
were	O
performed	O
as	O
previously	O
reported	O
(	O
50	O
)	O
.	O

Details	O
are	O
described	O
in	O
Supplementary	O
Data	O
.	O
<EOS>	B-X
A	B-X
summary	B-X
of	B-X
the	B-X
studies	B-X
developed	B-X
using	B-X
DL	B-X
is	B-X
provided	B-X
in	B-X
the	B-X
Supplementary	B-X
Appendix	B-X
.	B-X
Then	B-X
,	B-X
the	B-X
challenges	B-X
encountered	B-X
during	B-X
the	B-X
automated	B-X
diagnosis	B-X
of	B-X
ASD	B-X
using	B-X
MRI	B-X
and	B-X
AI	B-X
techniques	B-X
are	B-X
described	B-X
in	B-X
detail	B-X
.	B-X
ChEMBL	B-X
is	B-X
a	B-X
large	B-X
,	B-X
open-access	B-X
bioactivity	B-X
database	B-X
(	B-X
https	B-X
:	B-X
//www.ebi.ac.uk/chembl	B-X
)	B-X
,	B-X
previously	B-X
described	B-X
in	B-X
the	B-X
2012	B-X
,	B-X
2014	B-X
and	B-X
2017	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
Database	B-X
Issues	B-X
.	B-X
In	B-X
the	B-X
last	B-X
two	B-X
years	B-X
,	B-X
several	B-X
important	B-X
improvements	B-X
have	B-X
been	B-X
made	B-X
to	B-X
the	B-X
database	B-X
and	B-X
are	B-X
described	B-X
here	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
is	B-X
a	B-X
technique	B-X
for	B-X
simultaneous	B-X
amplification	B-X
and	B-X
product	B-X
quantification	B-X
of	B-X
a	B-X
target	B-X
DNA	B-X
as	B-X
the	B-X
process	B-X
takes	B-X
place	B-X
in	B-X
real	B-X
time	B-X
in	B-X
a	B-X
``	B-X
closed-tube	B-X
''	B-X
system	B-X
.	B-X
The	B-X
quantification	B-X
process	B-X
employs	B-X
melting	B-X
curve	B-X
analysis	B-X
and/or	B-X
fluorescent	B-X
detection	B-X
systems	B-X
and	B-X
can	B-X
provide	B-X
amplification	B-X
and	B-X
genotyping	B-X
in	B-X
a	B-X
relatively	B-X
short	B-X
time	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
has	B-X
provided	B-X
the	B-X
necessary	B-X
analytical	B-X
performance	B-X
for	B-X
many	B-X
molecular	B-X
analyses	B-X
.	B-X
PCR-based	B-X
methods	B-X
for	B-X
SNP/mutation	B-X
detection	B-X
are	B-X
broadly	B-X
categorized	B-X
into	B-X
two	B-X
types-	B-X
(	B-X
1	B-X
)	B-X
polymorphic	B-X
or	B-X
mutant	B-X
allele-directed	B-X
specific	B-X
analysis	B-X
using	B-X
primers	B-X
matched	B-X
with	B-X
substituted	B-X
nucleotide	B-X
or	B-X
using	B-X
oligonucleotides	B-X
to	B-X
block	B-X
or	B-X
clamp	B-X
the	B-X
nontargeted	B-X
template	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
melting	B-X
curve	B-X
analysis	B-X
,	B-X
which	B-X
is	B-X
combined	B-X
with	B-X
the	B-X
real-time	B-X
PCR	B-X
techniques	B-X
using	B-X
hydrolysis	B-X
probes	B-X
,	B-X
hybridization	B-X
probes	B-X
,	B-X
or	B-X
double-stranded	B-X
DNA-binding	B-X
fluorescent	B-X
dyes	B-X
.	B-X
These	B-X
advances	B-X
include	B-X
DNA/RNA	B-X
preparation	B-X
and	B-X
subsequent	B-X
amplification	B-X
steps	B-X
,	B-X
and	B-X
miniaturization	B-X
of	B-X
PCR	B-X
instruments	B-X
such	B-X
that	B-X
testing	B-X
may	B-X
be	B-X
performed	B-X
with	B-X
relative	B-X
ease	B-X
in	B-X
clinical	B-X
laboratories	B-X
or	B-X
as	B-X
a	B-X
point-of-care	B-X
test	B-X
in	B-X
clinical	B-X
settings	B-X
.	B-X

Total	O
RNA	O
was	O
extracted	O
from	O
cells	O
by	O
using	O
the	O
TRIzol	O
reagent	O
(	O
Invitrogen	O
)	O
;	O
RNA	O
aliquots	O
(	O
200	O
ng	O
)	O
were	O
reverse	O
transcribed	O
using	O
Random	O
Examers	O
(	O
Roche	O
)	O
and	O
Superscript	O
III	O
Reverse	O
Transcriptase	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O
<EOS>	B-X
Circulating	B-X
long	B-X
noncoding	B-X
RNAs	B-X
(	B-X
lncRNAs	B-X
)	B-X
might	B-X
serve	B-X
as	B-X
biomarkers	B-X
for	B-X
different	B-X
pathological	B-X
conditions	B-X
.	B-X
BACE1-AS	B-X
lncRNA	B-X
upregulates	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
people	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
and	B-X
might	B-X
be	B-X
detected	B-X
in	B-X
the	B-X
bloodstream	B-X
.	B-X
To	B-X
reveal	B-X
if	B-X
lncRNA	B-X
BACE1-AS	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
blood-based	B-X
biomarker	B-X
for	B-X
AD	B-X
,	B-X
we	B-X
compared	B-X
its	B-X
levels	B-X
in	B-X
plasma	B-X
and	B-X
plasma-derived	B-X
exosomes	B-X
between	B-X
AD	B-X
(	B-X
n	B-X
=	B-X
45	B-X
)	B-X
and	B-X
healthy	B-X
people	B-X
(	B-X
n	B-X
=	B-X
36	B-X
)	B-X
.	B-X
Exosomes	B-X
were	B-X
purified	B-X
from	B-X
plasma	B-X
by	B-X
Invitrogen™	B-X
Total	B-X
Exosome	B-X
Isolation	B-X
Kit	B-X
and	B-X
characterized	B-X
by	B-X
scanning	B-X
electron	B-X
microscopy	B-X
(	B-X
SEM	B-X
)	B-X
and	B-X
dynamic	B-X
light	B-X
scattering	B-X
(	B-X
DLS	B-X
)	B-X
.	B-X
Total	B-X
RNA	B-X
was	B-X
extracted	B-X
from	B-X
whole	B-X
plasma	B-X
,	B-X
and	B-X
plasma-derived	B-X
exosomes	B-X
using	B-X
TRIzol®	B-X
LS	B-X
or	B-X
TRIzol®	B-X
Reagents	B-X
respectively	B-X
were	B-X
then	B-X
reverse	B-X
transcribed	B-X
to	B-X
the	B-X
cDNA	B-X
using	B-X
PrimeScript	B-X
II	B-X
cDNA	B-X
synthesis	B-X
kit	B-X
.	B-X
The	B-X
BACE1-AS	B-X
levels	B-X
were	B-X
quantified	B-X
by	B-X
real-time	B-X
PCR	B-X
,	B-X
and	B-X
their	B-X
biomarker	B-X
potencies	B-X
were	B-X
evaluated	B-X
using	B-X
ROC	B-X
curve	B-X
analysis	B-X
.	B-X
Moreover	B-X
,	B-X
ROC	B-X
curve	B-X
analysis	B-X
revealed	B-X
that	B-X
lncRNA	B-X
BACE1-AS	B-X
may	B-X
discriminate	B-X
pre-AD	B-X
and	B-X
healthy	B-X
control	B-X
(	B-X
75	B-X
%	B-X
sensitivity	B-X
and	B-X
100	B-X
%	B-X
specificity	B-X
)	B-X
,	B-X
full-AD	B-X
and	B-X
healthy	B-X
control	B-X
(	B-X
68	B-X
%	B-X
sensitivity	B-X
and	B-X
100	B-X
%	B-X
specificity	B-X
)	B-X
,	B-X
and	B-X
pre-AD	B-X
and	B-X
full-AD	B-X
subgroups	B-X
(	B-X
78	B-X
%	B-X
sensitivity	B-X
and	B-X
100	B-X
%	B-X
specificity	B-X
)	B-X
,	B-X
highlighting	B-X
its	B-X
potential	B-X
as	B-X
a	B-X
biomarker	B-X
for	B-X
AD	B-X
development	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
the	O
iQ	O
Green	O
Super	O
mix	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
and	O
carried	O
out	O
with	O
the	O
iCycler	O
iQ	O
Real	O
-	O
Time	O
detection	O
system	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
under	O
the	O
following	O
conditions	O
:	O
95degreesC	O
,	O
1	O
min	O
;	O
(	O
94degreesC	O
,	O
10	O
s	O
;	O
60degreesC	O
,	O
30	O
s	O
)	O
x40	O
.	O

Primers	O
for	O
Tat	B-Protein
and	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
are	O
listed	O
in	O
Supplementary	O
Data	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
,	O
TLR2	B-Protein
,	O
GAPDH	B-Protein
and	O
ACTB	B-Protein
was	O
performed	O
using	O
the	O
RT2	O
profiler	O
PCR	O
Array	O
-	O
Human	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
(	O
QIAGEN	O
Sciences	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Reactions	O
were	O
carried	O
out	O
in	O
triplicate	O
,	O
and	O
gene	O
expression	O
levels	O
were	O
calculated	O
relative	O
to	O
GAPDH	B-Protein
mRNA	O
levels	O
as	O
endogenous	O
control	O
.	O

Relative	O
expression	O
was	O
calculated	O
as	O
2	O
(	O
Ct	O
gene	O
under	O
investigation	O
-	O
Ct	O
GAPDH	B-Protein
)	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
an	B-X
important	B-X
technique	B-X
in	B-X
the	B-X
study	B-X
of	B-X
protein-gene	B-X
interactions	B-X
.	B-X
The	B-X
basic	B-X
steps	B-X
in	B-X
this	B-X
technique	B-X
are	B-X
fixation	B-X
,	B-X
sonication	B-X
,	B-X
immunoprecipitation	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
the	B-X
immunoprecipitated	B-X
DNA	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
,	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
ChIP	B-X
,	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
in	B-X
vivo	B-X
interactions	B-X
of	B-X
proteins	B-X
with	B-X
specific	B-X
regions	B-X
of	B-X
genomic	B-X
DNA	B-X
.	B-X
Harvested	B-X
chromatin	B-X
is	B-X
sheared	B-X
and	B-X
subsequently	B-X
used	B-X
in	B-X
an	B-X
immunoprecipitation	B-X
incorporating	B-X
antibodies	B-X
specific	B-X
to	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
of	B-X
interest	B-X
and	B-X
thus	B-X
coprecipitating	B-X
and	B-X
enriching	B-X
the	B-X
cross-linked	B-X
,	B-X
protein-associated	B-X
DNA	B-X
.	B-X

Cells	O
were	O
fixed	O
by	O
adding	O
formaldehyde	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
at	O
the	O
final	O
concentration	O
of	O
1	O
%	O
.	O

After	O
10	O
min	O
,	O
ice	O
-	O
cold	O
PBS	O
plus	O
0	O
.	O
125	O
M	O
glycine	O
was	O
added	O
,	O
and	O
plates	O
were	O
transferred	O
on	O
ice	O
,	O
washed	O
extensively	O
with	O
PBS	O
,	O
and	O
scraped	O
.	O

After	O
centrifugation	O
,	O
cells	O
were	O
10	O
min	O
lysed	O
in	O
lysis	O
buffer	O
(	O
5	O
mM	O
PIPES	O
pH	O
8	O
.	O
0	O
,	O
85	O
mM	O
KCl	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
)	O
supplemented	O
with	O
1x	O
Complete	O
Protease	O
Inhibitor	O
(	O
Roche	O
Diagnostic	O
GmbH	O
)	O
.	O

Nuclei	O
were	O
pelletted	O
(	O
1000	O
x	O
g	O
,	O
5	O
min	O
)	O
,	O
and	O
resuspended	O
in	O
sonication	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
%	O
SDS	O
,	O
10	O
mM	O
EDTA	O
)	O
.	O

Chromatin	O
was	O
sonicated	O
using	O
Bandelin	O
Sonoplus	O
GM70	O
(	O
Bandelin	O
Electronic	O
,	O
Berlin	O
,	O
Germany	O
)	O
,	O
centrifuged	O
(	O
14	O
000	O
x	O
g	O
,	O
15	O
min	O
)	O
,	O
and	O
supernatant	O
was	O
10	O
-	O
fold	O
diluted	O
in	O
dilution	O
buffer	O
(	O
0	O
.	O
01	O
%	O
SDS	O
,	O
16	O
.	O
7	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
167	O
mM	O
NaCl	O
,	O
1	O
.	O
2	O
mM	O
EDTA	O
)	O
.	O

Samples	O
were	O
pre	O
-	O
cleared	O
by	O
3	O
-	O
h	O
incubation	O
with	O
20	O
microl	O
of	O
protein	B-Protein
G	I-Protein
agarose	O
beads	O
followed	O
by	O
incubation	O
with	O
antibodies	O
against	O
the	O
analysed	O
proteins	O
.	O

Primary	O
antibodies	O
were	O
:	O
anti	O
-	O
p65	O
(	O
sc	O
-	O
372	O
)	O
,	O
anti	O
-	O
IkappaBalpha	O
(	O
sc	O
-	O
203	O
)	O
and	O
rabbit	O
IgG	O
(	O
sc	O
-	O
2027	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
;	O
anti	O
-	O
FLAG	O
M2	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

Immunoprecipitations	O
were	O
carried	O
out	O
at	O
4degreesC	O
overnight	O
and	O
immune	O
complexes	O
were	O
collected	O
with	O
protein	B-Protein
G	I-Protein
agarose	O
beads	O
,	O
washed	O
five	O
times	O
with	O
low	O
salt	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
,	O
150	O
mM	O
NaCl	O
)	O
,	O
four	O
times	O
with	O
high	O
salt	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
,	O
500	O
mM	O
NaCl	O
)	O
,	O
once	O
with	O
TE	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
extracted	O
in	O
TE	O
buffer	O
containing	O
2	O
%	O
SDS	O
.	O

Protein	O
-	O
DNA	O
cross	O
-	O
links	O
were	O
reverted	O
by	O
heating	O
at	O
65degreesC	O
overnight	O
.	O

DNA	O
was	O
further	O
purified	O
by	O
QIAquick	O
PCR	O
purification	O
kit	O
(	O
QIAGEN	O
)	O
and	O
eluted	O
in	O
50	O
microl	O
sterile	O
distilled	O
water	O
.	O

Specific	O
enrichment	O
in	O
NF	O
-	O
kappaB	O
enhancer	O
sequences	O
was	O
measured	O
by	O
real	O
-	O
time	O
PCR	O
of	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
eluates	O
using	O
SYBR	O
GreenER	O
Master	O
Mix	O
(	O
Invitrogen	O
)	O
.	O

Reactions	O
were	O
carried	O
out	O
with	O
the	O
iCycler	O
iQ	O
Real	O
-	O
Time	O
detection	O
system	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
using	O
the	O
following	O
conditions	O
:	O
95degreesC	O
,	O
1	O
min	O
;	O
(	O
94degreesC	O
,	O
10	O
s	O
;	O
60degreesC	O
,	O
30	O
s	O
)	O
x40	O
.	O

Primers	O
used	O
for	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
GAPDH	B-Protein
and	O
ACTB	B-Protein
are	O
listed	O
in	O
Supplementary	O
Data	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
and	O
TLR2	B-Protein
were	O
performed	O
using	O
the	O
Custom	O
ChIP	O
array	O
(	O
QIAGEN	O
)	O
.	O

For	O
each	O
sample	O
,	O
values	O
were	O
normalized	O
to	O
input	O
DNA	O
and	O
reported	O
as	O
%	O
of	O
input	O
over	O
the	O
rabbit	O
IgG	O
control	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
performed	O
by	O
two	O
-	O
tail	O
unpaired	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Data	O
were	O
reported	O
as	O
means	O
+	O
/	O
-	O
SE	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
is	B-X
a	B-X
neurologic	B-X
emergency	B-X
with	B-X
potential	B-X
for	B-X
substantial	B-X
mortality	B-X
and	B-X
morbidity	B-X
.	B-X
Parenteral	B-X
benzodiazepine	B-X
is	B-X
the	B-X
established	B-X
first-line	B-X
treatment	B-X
but	B-X
fails	B-X
to	B-X
control	B-X
SE	B-X
in	B-X
about	B-X
one-third	B-X
of	B-X
patients	B-X
.	B-X
Levetiracetam	B-X
may	B-X
be	B-X
used	B-X
for	B-X
SE	B-X
that	B-X
is	B-X
refractory	B-X
to	B-X
benzodiazepine	B-X
therapy	B-X
.	B-X
The	B-X
acute	B-X
effects	B-X
of	B-X
e-cigarettes	B-X
on	B-X
arterial	B-X
pressure	B-X
and	B-X
MSNA	B-X
have	B-X
not	B-X
been	B-X
reported	B-X
:	B-X
our	B-X
purpose	B-X
was	B-X
to	B-X
clarify	B-X
this	B-X
issue	B-X
.	B-X

Differences	O
between	O
the	O
means	O
were	O
considered	O
as	O
statistically	O
significant	O
at	O
the	O
95	O
%	O
level	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Tat	B-Protein
enhances	O
the	O
NF	O
-	O
kappaB	O
activity	O
by	O
hijacking	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
inhibiting	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O

We	O
analysed	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
by	O
modulating	O
the	O
expression	O
of	O
Tat	B-Protein
with	O
RNA	O
interference	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
,	O
siRNA	O
control	O
,	O
or	O
left	O
untransfected	O
,	O
and	O
24	O
h	O
later	O
cells	O
were	O
infected	O
with	O
HXB2	O
Env	B-Protein
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
virions	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
gene	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
both	B-X
cellular	B-X
transcription	B-X
factors	B-X
and	B-X
Tat	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Tat	B-X
to	B-X
stimulate	B-X
transcriptional	B-X
elongation	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
TAR	B-X
RNA	B-X
in	B-X
conjunction	B-X
with	B-X
cyclin	B-X
T1	B-X
and	B-X
CDK9	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cellular	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
,	B-X
including	B-X
NF-kappaB	B-X
,	B-X
SP1	B-X
,	B-X
LBP	B-X
,	B-X
and	B-X
LEF	B-X
,	B-X
are	B-X
also	B-X
important	B-X
in	B-X
the	B-X
control	B-X
of	B-X
HIV-1	B-X
gene	B-X
expression	B-X
.	B-X
Although	B-X
these	B-X
factors	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
regulate	B-X
HIV-1	B-X
gene	B-X
expression	B-X
by	B-X
both	B-X
genetic	B-X
and	B-X
biochemical	B-X
analysis	B-X
,	B-X
in	B-X
most	B-X
cases	B-X
a	B-X
direct	B-X
in	B-X
vivo	B-X
demonstration	B-X
of	B-X
their	B-X
role	B-X
on	B-X
HIV-1	B-X
replication	B-X
has	B-X
not	B-X
been	B-X
established	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
efficacy	B-X
of	B-X
RNA	B-X
interference	B-X
in	B-X
mammalian	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
utilizing	B-X
small	B-X
interfering	B-X
RNAs	B-X
(	B-X
siRNAs	B-X
)	B-X
to	B-X
result	B-X
in	B-X
the	B-X
specific	B-X
degradation	B-X
of	B-X
host	B-X
mRNAs	B-X
and	B-X
decreases	B-X
the	B-X
levels	B-X
of	B-X
their	B-X
corresponding	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
whether	B-X
siRNAs	B-X
directed	B-X
against	B-X
either	B-X
HIV-1	B-X
tat	B-X
or	B-X
reverse	B-X
transcriptase	B-X
or	B-X
the	B-X
NF-kappaB	B-X
p65	B-X
subunit	B-X
could	B-X
specifically	B-X
decrease	B-X
the	B-X
levels	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
thus	B-X
alter	B-X
HIV-1	B-X
replication	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
the	B-X
specificity	B-X
of	B-X
siRNAs	B-X
for	B-X
decreasing	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
viral	B-X
and	B-X
cellular	B-X
proteins	B-X
and	B-X
inhibiting	B-X
HIV-1	B-X
replication	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
RNA	B-X
interference	B-X
is	B-X
useful	B-X
in	B-X
exploring	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
cellular	B-X
and	B-X
viral	B-X
regulatory	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
control	B-X
of	B-X
HIV-1	B-X
gene	B-X
expression	B-X
.	B-X

By	O
cytofluorimetric	O
analysis	O
,	O
~	O
40	O
%	O
of	O
cells	O
was	O
siRNA	O
-	O
transfected	O
and	O
HIV	O
-	O
1	O
-	O
infected	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O

The	O
expression	O
of	O
Tat	B-Protein
was	O
detected	O
at	O
1	O
-	O
h	O
post	O
-	O
infection	O
and	O
progressively	O
increased	O
up	O
to	O
12	O
h	O
in	O
untransfected	O
and	O
siRNA	O
control	O
-	O
transfected	O
cells	O
,	O
while	O
it	O
was	O
barely	O
detected	O
in	O
siRNA	B-Protein
Tat	I-Protein
-	O
transfected	O
cells	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
LTR	O
-	O
dependent	O
luciferase	B-Protein
expression	O
was	O
also	O
progressively	O
induced	O
at	O
1	O
-	O
to	O
12	O
-	O
h	O
post	O
-	O
infection	O
in	O
untransfected	O
and	O
siRNA	O
control	O
-	O
transfected	O
cells	O
,	O
while	O
it	O
was	O
barely	O
observed	O
in	O
siRNA	B-Protein
Tat	I-Protein
-	O
transfected	O
cells	O
,	O
as	O
expected	O
for	O
the	O
Tat	B-Protein
-	O
dependent	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
progressive	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
measured	O
by	O
p65	B-Protein
-	O
p50	B-Protein
binding	O
to	O
an	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotide	O
(	O
Figure	O
1B	O
)	O
and	O
nuclear	O
p65	B-Protein
(	O
Figure	O
1C	O
,	O
nucleus	O
)	O
,	O
was	O
observed	O
at	O
1	O
-	O
to	O
3	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	B-Protein
-	O
positive	O
(	O
no	O
siRNA	O
or	O
siRNA	O
control	O
)	O
and	O
Tat	B-Protein
-	O
negative	O
(	O
siRNA	B-Protein
Tat	I-Protein
)	O
cells	O
;	O
however	O
,	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
,	O
the	O
p65	B-Protein
DNA	O
binding	O
and	O
nuclear	O
p65	B-Protein
persisted	O
elevated	O
in	O
presence	O
of	O
Tat	B-Protein
(	O
no	O
siRNA	O
and	O
siRNA	O
control	O
)	O
,	O
while	O
they	O
dropped	O
in	O
absence	O
of	O
Tat	B-Protein
(	O
siRNA	B-Protein
Tat	I-Protein
)	O
(	O
Figure	O
1B	O
and	O
C	O
)	O
.	O

IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
degraded	O
in	O
the	O
cytosol	O
within	O
3	O
-	O
h	O
post	O
-	O
infection	O
and	O
de	O
novo	O
synthesized	O
at	O
6	O
h	O
with	O
full	O
replenishment	O
at	O
12	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	B-Protein
-	O
positive	O
and	O
Tat	B-Protein
-	O
negative	O
cells	O
(	O
Figure	O
1C	O
,	O
cytosol	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activity	O
was	O
induced	O
at	O
1	O
-	O
h	O
post	O
-	O
infection	O
,	O
and	O
decreased	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
independently	O
of	O
the	O
presence	O
of	O
Tat	B-Protein
(	O
Figure	O
1D	O
)	O
.	O

Similar	O
kinetics	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
IKK	O
activation	O
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
degradation	O
/	O
re	O
-	O
synthesis	O
were	O
observed	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
of	O
PBMCs	O
using	O
a	O
cocktail	O
of	O
Azidothymidine	O
(	O
AZT	O
)	O
and	O
Lamivudine	O
(	O
3TC	O
)	O
as	O
reverse	O
transcriptase	O
inhibitors	O
(	O
Supplementary	O
Figure	O
S2	O
)	O
.	O

These	O
results	O
indicated	O
that	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
the	O
NF	O
-	O
kappaB	O
activation	O
initially	O
correlated	O
with	O
the	O
IKK	O
activation	O
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
degradation	O
independently	O
of	O
the	O
presence	O
of	O
Tat	B-Protein
,	O
and	O
it	O
was	O
kept	O
elevated	O
in	O
presence	O
of	O
Tat	B-Protein
following	O
the	O
decay	O
of	O
the	O
IKK	O
activity	O
and	O
new	O
synthesis	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

Next	O
,	O
we	O
tested	O
the	O
single	O
action	O
of	O
Tat	B-Protein
on	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activity	O
induced	O
by	O
PMA	O
.	O

To	O
this	O
end	O
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
p3x	O
-	O
FLAG	O
-	O
Tat	B-Protein
,	O
or	O
empty	O
vector	O
,	O
stimulated	O
with	O
PMA	O
for	O
5	O
min	O
,	O
and	O
extensively	O
washed	O
to	O
avoid	O
the	O
oscillatory	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
17	O
,	O
18	O
)	O
.	O

In	O
un	O
-	O
stimulated	O
cells	O
,	O
the	O
p65	B-Protein
DNA	O
binding	O
(	O
Figure	O
2A	O
)	O
and	O
nuclear	O
p65	B-Protein
(	O
Figure	O
2B	O
,	O
nucleus	O
)	O
were	O
slightly	O
enhanced	O
by	O
Tat	B-Protein
,	O
while	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
content	O
was	O
not	O
significantly	O
affected	O
(	O
Figure	O
2B	O
,	O
cytosol	O
)	O
.	O

Transient	O
stimulation	O
with	O
PMA	O
increased	O
the	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
nuclear	O
p65	B-Protein
at	O
5	O
min	O
peaking	O
at	O
60	O
-	O
120	O
min	O
independently	O
of	O
the	O
presence	O
of	O
Tat	B-Protein
(	O
Figure	O
2A	O
and	O
B	O
)	O
;	O
however	O
,	O
while	O
the	O
p65	B-Protein
DNA	O
binding	O
and	O
nuclear	O
p65	B-Protein
persisted	O
elevated	O
at	O
240	O
-	O
min	O
post	O
-	O
treatment	O
in	O
Tat	B-Protein
-	O
positive	O
cells	O
,	O
they	O
dropped	O
in	O
Tat	B-Protein
-	O
negative	O
cells	O
(	O
Figure	O
2A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
Tat	B-Protein
bound	O
to	O
the	O
NF	O
-	O
kappaB	O
oligonucleotide	O
in	O
un	O
-	O
stimulated	O
cells	O
and	O
its	O
binding	O
increased	O
following	O
PMA	O
stimulation	O
(	O
Figure	O
2A	O
)	O
,	O
suggesting	O
that	O
the	O
viral	O
protein	O
was	O
a	O
component	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
bound	O
to	O
DNA	O
.	O

Degradation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
progressively	O
induced	O
at	O
5	O
-	O
30	O
min	O
,	O
followed	O
by	O
de	O
novo	O
synthesis	O
at	O
60	O
min	O
with	O
full	O
replenishment	O
at	O
240	O
min	O
in	O
both	O
Tat	B-Protein
-	O
positive	O
and	O
negative	O
cells	O
(	O
Figure	O
2B	O
,	O
cytosol	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activation	O
started	O
at	O
5	O
min	O
,	O
and	O
turned	O
off	O
at	O
30	O
min	O
independently	O
of	O
the	O
presence	O
of	O
Tat	B-Protein
(	O
Figure	O
2C	O
)	O
.	O

These	O
results	O
indicated	O
that	O
Tat	B-Protein
enhanced	O
the	O
NF	O
-	O
kappaB	O
activity	O
in	O
un	O
-	O
stimulated	O
and	O
PMA	O
-	O
stimulated	O
cells	O
without	O
affecting	O
the	O
IKK	O
activity	O
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
content	O
.	O

As	O
we	O
previously	O
found	O
that	O
Tat	B-Protein
binds	O
to	O
the	O
sixth	O
ankyrin	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
50	O
,	O
51	O
)	O
,	O
we	O
tested	O
whether	O
Tat	B-Protein
counteracted	O
the	O
generation	O
of	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
/	O
NF	O
-	O
kappaB	O
complex	O
.	O

To	O
this	O
end	O
,	O
the	O
association	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
with	O
p65	B-Protein
was	O
analysed	O
in	O
vivo	O
at	O
0	O
and	O
240	O
min	O
after	O
short	O
-	O
pulse	O
PMA	O
,	O
which	O
corresponded	O
to	O
the	O
time	O
of	O
un	O
-	O
stimulated	O
condition	O
and	O
post	O
-	O
activation	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
respectively	O
.	O

Coimmunoprecipitation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
with	O
p65	B-Protein
was	O
detected	O
at	O
0	O
-	O
and	O
240	O
-	O
min	O
post	O
-	O
treatment	O
in	O
Tat	B-Protein
-	O
negative	O
cells	O
(	O
Figure	O
2D	O
,	O
lanes	O
1	O
and	O
3	O
)	O
,	O
and	O
was	O
halved	O
in	O
Tat	B-Protein
-	O
positive	O
cells	O
,	O
where	O
Tat	B-Protein
coimmunoprecipitated	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Figure	O
2D	O
,	O
lanes	O
2	O
and	O
4	O
)	O
,	O
indicating	O
that	O
Tat	B-Protein
competed	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
binding	O
to	O
p65	B-Protein
.	O

Tat	B-Protein
counteracts	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
inhibition	O
of	O
p65	B-Protein
by	O
competing	O
the	O
repressor	O
binding	O

We	O
further	O
investigated	O
the	O
physical	O
interaction	O
of	O
Tat	B-Protein
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
using	O
in	O
vitro	O
translated	O
proteins	O
in	O
coimmunoprecipitation	O
assays	O
.	O

For	O
mapping	O
the	O
interaction	O
domains	O
,	O
we	O
used	O
the	O
following	O
Tat	B-Protein
mutants	O
:	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
,	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
and	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
(	O
Figure	O
3A	O
)	O
.	O

IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
coimmunoprecipitated	O
with	O
all	O
Tat	B-Protein
proteins	O
,	O
except	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
(	O
Figure	O
3B	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
arginine	O
-	O
rich	O
domain	O
of	O
Tat	B-Protein
was	O
involved	O
in	O
the	O
binding	O
to	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
which	O
was	O
consistent	O
with	O
previous	O
observations	O
(	O
50	O
,	O
51	O
)	O
.	O

Moreover	O
,	O
Tat	B-Protein
associating	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
competed	O
the	O
binding	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
to	O
p65	B-Protein
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
3C	O
,	O
lanes	O
3	O
-	O
5	O
)	O
,	O
while	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
which	O
lacked	O
the	O
binding	O
site	O
for	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
did	O
not	O
associate	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
did	O
not	O
compete	O
the	O
binding	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
to	O
p65	B-Protein
(	O
Figure	O
3C	O
,	O
lanes	O
6	O
-	O
8	O
)	O
.	O

Next	O
,	O
we	O
evaluated	O
whether	O
Tat	B-Protein
counteracted	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
inhibition	O
of	O
p65	B-Protein
binding	O
to	O
DNA	O
by	O
incubating	O
in	O
vitro	O
translated	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
proteins	O
with	O
the	O
NF	O
-	O
kappaB	O
probe	O
in	O
presence	O
or	O
absence	O
of	O
Tat	B-Protein
followed	O
by	O
EMSA	O
.	O

The	O
p65	B-Protein
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
restored	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
wild	O
-	O
type	O
Tat	B-Protein
,	O
and	O
not	O
by	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
(	O
Figure	O
3D	O
)	O
.	O

Further	O
,	O
we	O
analysed	O
the	O
Tat	B-Protein
effect	O
on	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repression	O
of	O
p65	B-Protein
transcriptional	O
activity	O
by	O
transfecting	O
p50	B-Protein
-	O
/	O
-	O
p65	B-Protein
-	O
/	O
-	O
MEFs	O
with	O
the	O
NF	O
-	O
kappaB	O
-	O
Luc	B-Protein
reporter	O
together	O
with	O
expression	O
vectors	O
of	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
in	O
presence	O
or	O
absence	O
of	O
Tat	B-Protein
.	O
<EOS>	B-X
HIV	B-X
Tat	B-X
protein	B-X
is	B-X
a	B-X
critical	B-X
protein	B-X
that	B-X
plays	B-X
multiple	B-X
roles	B-X
in	B-X
HIV	B-X
pathogenesis	B-X
.	B-X
HIV	B-X
Tat	B-X
protein	B-X
is	B-X
produced	B-X
and	B-X
released	B-X
into	B-X
the	B-X
extracellular	B-X
space	B-X
from	B-X
cells	B-X
with	B-X
active	B-X
HIV	B-X
replication	B-X
or	B-X
from	B-X
latently	B-X
HIV-infected	B-X
cells	B-X
into	B-X
neighboring	B-X
uninfected	B-X
cells	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
HIV	B-X
replication	B-X
and	B-X
viral	B-X
production	B-X
due	B-X
to	B-X
effective	B-X
ART	B-X
.	B-X
Neighboring	B-X
uninfected	B-X
and	B-X
HIV-infected	B-X
cells	B-X
can	B-X
take	B-X
up	B-X
the	B-X
released	B-X
Tat	B-X
resulting	B-X
in	B-X
the	B-X
upregulation	B-X
of	B-X
inflammatory	B-X
genes	B-X
and	B-X
activation	B-X
of	B-X
pathways	B-X
that	B-X
leads	B-X
to	B-X
cytotoxicity	B-X
observed	B-X
in	B-X
several	B-X
comorbidities	B-X
such	B-X
as	B-X
HIV	B-X
associated	B-X
neurocognitive	B-X
disorder	B-X
(	B-X
HAND	B-X
)	B-X
,	B-X
HIV	B-X
associated	B-X
cardiovascular	B-X
impairment	B-X
,	B-X
and	B-X
accelerated	B-X
aging	B-X
.	B-X
Thus	B-X
,	B-X
understanding	B-X
how	B-X
Tat	B-X
modulates	B-X
host	B-X
and	B-X
viral	B-X
response	B-X
is	B-X
important	B-X
in	B-X
designing	B-X
novel	B-X
therapeutic	B-X
approaches	B-X
to	B-X
target	B-X
the	B-X
chronic	B-X
inflammatory	B-X
effects	B-X
of	B-X
soluble	B-X
viral	B-X
proteins	B-X
in	B-X
HIV	B-X
infection	B-X
.	B-X

IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
inhibited	O
the	O
p65	B-Protein
-	O
dependent	O
expression	O
of	O
the	O
luciferase	B-Protein
gene	O
,	O
which	O
was	O
restored	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
wild	O
-	O
type	O
Tat	B-Protein
,	O
and	O
not	O
by	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
(	O
Figure	O
3E	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
Tat	B-Protein
counteracts	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repression	O
of	O
the	O
p65	B-Protein
DNA	O
-	O
binding	O
and	O
transcriptional	O
activity	O
by	O
associating	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
competing	O
the	O
repressor	O
binding	O
to	O
p65	B-Protein
.	O

Tat	B-Protein
increases	O
the	O
p65	B-Protein
affinity	O
binding	O
to	O
DNA	O
through	O
association	O
with	O
p65	B-Protein
<EOS>	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

We	O
tested	O
whether	O
Tat	B-Protein
physically	O
interacted	O
with	O
p65	B-Protein
.	O

HeLa	O
cells	O
were	O
transfected	O
with	O
the	O
expression	O
vectors	O
of	O
HA	B-Protein
-	I-Protein
p65	I-Protein
and	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
,	O
and	O
24	O
h	O
later	O
Tat	B-Protein
was	O
immunoprecipitated	O
from	O
cell	O
extracts	O
.	O

The	O
p65	B-Protein
protein	O
was	O
coimmunoprecipitated	O
with	O
wild	O
-	O
type	O
Tat	B-Protein
or	O
the	O
mutants	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
and	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
at	O
similar	O
levels	O
,	O
while	O
a	O
significant	O
decrease	O
in	O
coimmunoprecipitation	O
was	O
observed	O
for	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
(	O
Figure	O
4A	O
)	O
.	O

Consistently	O
,	O
GST	B-Protein
-	O
pull	O
down	O
of	O
in	O
vitro	O
translated	O
proteins	O
showed	O
the	O
direct	O
binding	O
of	O
p65	B-Protein
to	O
wild	O
-	O
type	O
Tat	B-Protein
,	O
or	O
the	O
mutants	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
and	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
and	O
lack	O
of	O
binding	O
to	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
indicated	O
that	O
Tat	B-Protein
associated	O
with	O
p65	B-Protein
through	O
the	O
cysteine	O
-	O
rich	O
domain	O
and	O
ruled	O
-	O
out	O
the	O
requirement	O
of	O
bridging	O
proteins	O
to	O
mediate	O
such	O
interaction	O
.	O

To	O
identify	O
the	O
p65	B-Protein
domain	O
required	O
for	O
binding	O
to	O
Tat	B-Protein
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
together	O
with	O
HA	B-Protein
-	I-Protein
p65	I-Protein
mutants	O
,	O
which	O
were	O
deleted	O
of	O
the	O
transactivation	O
domain	O
[	O
p65deltaC	B-Protein
(	I-Protein
1	I-Protein
-	I-Protein
318	I-Protein
)	I-Protein
]	O
,	O
or	O
the	O
RHD	O
[	O
p65deltaN	B-Protein
(	I-Protein
122	I-Protein
-	I-Protein
551	I-Protein
)	I-Protein
]	O
(	O
Figure	O
4C	O
)	O
.	O

Tat	B-Protein
coimmunoprecipitated	O
with	O
p65deltaC	B-Protein
(	I-Protein
1	I-Protein
-	I-Protein
318	I-Protein
)	I-Protein
,	O
and	O
not	O
with	O
p65deltaN	B-Protein
(	I-Protein
122	I-Protein
-	I-Protein
551	I-Protein
)	I-Protein
(	O
Figure	O
4D	O
)	O
,	O
indicating	O
that	O
the	O
RHD	O
of	O
p65	B-Protein
was	O
involved	O
in	O
the	O
physical	O
interaction	O
with	O
Tat	B-Protein
.	O

To	O
address	O
the	O
effect	O
of	O
Tat	B-Protein
on	O
the	O
p65	B-Protein
DNA	O
-	O
binding	O
affinity	O
,	O
purified	O
recombinant	O
p65	B-Protein
protein	O
was	O
incubated	O
with	O
32P	O
-	O
labeled	O
-	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
in	O
presence	O
or	O
absence	O
of	O
wild	O
-	O
type	O
Tat	B-Protein
or	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
,	O
and	O
p65	B-Protein
DNA	O
-	O
binding	O
was	O
analysed	O
by	O
EMSA	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
several	B-X
host	B-X
hnRNP	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
Sindbis	B-X
virus	B-X
(	B-X
SINV	B-X
)	B-X
RNAs	B-X
,	B-X
and	B-X
disrupting	B-X
the	B-X
sites	B-X
of	B-X
these	B-X
RNA-protein	B-X
interactions	B-X
results	B-X
in	B-X
decreased	B-X
viral	B-X
titers	B-X
in	B-X
tissue	B-X
culture	B-X
models	B-X
of	B-X
infection	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
primary	B-X
molecular	B-X
defect	B-X
associated	B-X
with	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
hnRNP	B-X
interactions	B-X
is	B-X
enhanced	B-X
viral	B-X
structural	B-X
protein	B-X
expression	B-X
;	B-X
however	B-X
,	B-X
the	B-X
precise	B-X
underlying	B-X
mechanisms	B-X
spurring	B-X
the	B-X
enhanced	B-X
gene	B-X
expression	B-X
remain	B-X
unknown	B-X
.	B-X
Moreover	B-X
,	B-X
our	B-X
previous	B-X
efforts	B-X
were	B-X
unable	B-X
to	B-X
functionally	B-X
dissect	B-X
whether	B-X
the	B-X
observed	B-X
phenotypes	B-X
were	B-X
due	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
hnRNP	B-X
binding	B-X
or	B-X
the	B-X
incorporation	B-X
of	B-X
polymorphisms	B-X
into	B-X
the	B-X
primary	B-X
nucleotide	B-X
sequence	B-X
of	B-X
SINV	B-X
.	B-X
To	B-X
determine	B-X
if	B-X
the	B-X
loss	B-X
of	B-X
hnRNP	B-X
binding	B-X
was	B-X
the	B-X
primary	B-X
cause	B-X
of	B-X
attenuation	B-X
or	B-X
if	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
RNA	B-X
sequence	B-X
itself	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
phenotypes	B-X
,	B-X
we	B-X
utilized	B-X
an	B-X
innovative	B-X
protein	B-X
tethering	B-X
approach	B-X
to	B-X
restore	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
hnRNP	B-X
proteins	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
native	B-X
interaction	B-X
site	B-X
.	B-X
Specifically	B-X
,	B-X
we	B-X
reconstituted	B-X
the	B-X
hnRNP	B-X
I	B-X
interaction	B-X
by	B-X
incorporating	B-X
the	B-X
20nt	B-X
bovine	B-X
immunodeficiency	B-X
virus	B-X
transactivation	B-X
RNA	B-X
response	B-X
(	B-X
BIV-TAR	B-X
)	B-X
at	B-X
the	B-X
site	B-X
of	B-X
the	B-X
native	B-X
hnRNP	B-X
I	B-X
interaction	B-X
sequence	B-X
,	B-X
which	B-X
will	B-X
bind	B-X
with	B-X
high	B-X
specificity	B-X
to	B-X
proteins	B-X
tagged	B-X
with	B-X
a	B-X
TAT	B-X
peptide	B-X
.	B-X
The	B-X
reestablishment	B-X
of	B-X
the	B-X
hnRNP	B-X
I-vRNA	B-X
interaction	B-X
via	B-X
the	B-X
BIV-TAR/TAT	B-X
tethering	B-X
approach	B-X
restored	B-X
the	B-X
phenotype	B-X
back	B-X
to	B-X
wild-type	B-X
levels	B-X
.	B-X
This	B-X
included	B-X
an	B-X
apparent	B-X
decrease	B-X
in	B-X
structural	B-X
protein	B-X
expression	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
native	B-X
primary	B-X
nucleotide	B-X
sequences	B-X
corresponding	B-X
to	B-X
the	B-X
hnRNP	B-X
I	B-X
interaction	B-X
site	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
characterization	B-X
of	B-X
the	B-X
hnRNP	B-X
I	B-X
interaction	B-X
site	B-X
elucidated	B-X
the	B-X
role	B-X
of	B-X
hnRNPs	B-X
during	B-X
viral	B-X
infection	B-X
.	B-X

Whereas	O
wild	O
-	O
type	O
Tat	B-Protein
significantly	O
increased	O
the	O
binding	O
of	O
p65	B-Protein
to	O
DNA	O
,	O
the	O
mutant	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
,	O
lacking	O
the	O
binding	O
site	O
for	O
p65	B-Protein
,	O
was	O
ineffective	O
(	O
Figure	O
4E	O
)	O
.	O

The	O
p65	B-Protein
binding	O
to	O
DNA	O
was	O
evaluated	O
by	O
competition	O
with	O
increasing	O
amounts	O
of	O
cold	O
competitor	O
NF	O
-	O
kappaB	O
oligonucleotide	O
,	O
which	O
showed	O
that	O
Tat	B-Protein
significantly	O
enhanced	O
the	O
p65	B-Protein
affinity	O
binding	O
to	O
DNA	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

Tat	B-Protein
activates	O
the	O
p65	B-Protein
-	O
dependent	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
occupies	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
and	O
promotes	O
the	O
p65	B-Protein
recruitment	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
displacement	O

We	O
analysed	O
the	O
action	O
of	O
Tat	B-Protein
on	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
in	O
vivo	O
.	O

To	O
this	O
end	O
,	O
HeLa	O
cells	O
were	O
transfected	O
with	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
,	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
or	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
and	O
48	O
h	O
later	O
the	O
expression	O
of	O
a	O
number	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
was	O
analysed	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Tat	B-Protein
significantly	O
increased	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
and	O
TLR2	B-Protein
,	O
while	O
the	O
mutants	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
and	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
were	O
ineffective	O
(	O
Figure	O
5A	O
-	O
E	O
)	O
.	O

The	O
Tat	B-Protein
-	O
dependent	O
transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
was	O
abolished	O
when	O
cells	O
were	O
transfected	O
with	O
siRNA	B-Protein
p65	I-Protein
,	O
indicating	O
that	O
the	O
Tat	B-Protein
transcriptional	O
activation	O
was	O
mediated	O
by	O
p65	B-Protein
(	O
Figure	O
5A	O
-	O
E	O
)	O
.	O

Differently	O
,	O
the	O
expression	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
independent	O
genes	O
GAPDH	B-Protein
and	O
ACTB	B-Protein
was	O
unaffected	O
by	O
wild	O
-	O
type	O
and	O
Tat	B-Protein
mutants	O
(	O
Figure	O
5F	O
and	O
G	O
)	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
requirement	O
of	O
both	O
the	O
cysteine	O
-	O
rich	O
and	O
arginine	O
-	O
rich	O
domains	O
of	O
Tat	B-Protein
to	O
enhance	O
the	O
NF	O
-	O
kappaB	O
activity	O
,	O
suggesting	O
that	O
the	O
up	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
by	O
Tat	B-Protein
might	O
occur	O
through	O
physical	O
interaction	O
of	O
the	O
viral	O
protein	O
with	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
which	O
was	O
the	O
mostly	O
activated	O
gene	O
by	O
Tat	B-Protein
,	O
encodes	O
for	O
a	O
chemokine	O
that	O
promotes	O
the	O
recruitment	O
of	O
pro	O
-	O
inflammatory	O
cells	O
(	O
56	O
)	O
.	O

Consistently	O
with	O
our	O
findings	O
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
was	O
increased	O
in	O
glial	O
cells	O
and	O
lymph	O
nodes	O
of	O
AIDS	O
patients	O
(	O
57	O
,	O
58	O
)	O
;	O
moreover	O
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
production	O
was	O
induced	O
by	O
HIV	O
-	O
1	O
infection	O
(	O
59	O
,	O
60	O
)	O
and	O
Tat	B-Protein
protein	O
(	O
57	O
,	O
61	O
,	O
62	O
)	O
.	O

The	O
transcriptional	O
regulation	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
has	O
been	O
poorly	O
characterized	O
.	O
<EOS>	B-X
NETs	B-X
are	B-X
formed	B-X
of	B-X
chromatin	B-X
and	B-X
specific	B-X
granular	B-X
proteins	B-X
and	B-X
are	B-X
released	B-X
after	B-X
execution	B-X
of	B-X
a	B-X
poorly	B-X
characterized	B-X
cell	B-X
death	B-X
pathway	B-X
.	B-X
Gene	B-X
Set	B-X
Enrichment	B-X
Analysis	B-X
demonstrated	B-X
that	B-X
these	B-X
changes	B-X
followed	B-X
a	B-X
consensus	B-X
hypoxia	B-X
transcriptional	B-X
profile	B-X
.	B-X
Multiplex	B-X
ELISA	B-X
demonstrated	B-X
that	B-X
hypoxia	B-X
could	B-X
variably	B-X
reduce	B-X
NK	B-X
cell	B-X
ability	B-X
to	B-X
release	B-X
IFNγ	B-X
,	B-X
TNFα	B-X
,	B-X
GM-CSF	B-X
,	B-X
CCL3	B-X
,	B-X
and	B-X
CCL5	B-X
following	B-X
PMA+Ionomycin	B-X
or	B-X
IL15+IL18	B-X
stimulation	B-X
,	B-X
while	B-X
it	B-X
poorly	B-X
affected	B-X
the	B-X
response	B-X
to	B-X
IL12+IL18	B-X
.	B-X

Jaspar	O
-	O
based	O
analysis	O
(	O
http	O
:	O
/	O
/	O
jaspar	O
.	O
genereg	O
.	O
net	O
/	O
)	O
predicted	O
three	O
putative	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
the	O
proximal	O
promoter	O
region	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
gene	O
:	O
NF	O
-	O
kappaB1	O
,	O
-	O
1023	O
/	O
-	O
1014	O
nucleotides	O
;	O
NF	O
-	O
kappaB2	O
,	O
-	O
661	O
/	O
-	O
652	O
nucleotides	O
;	O
NF	O
-	O
kappaB3	O
,	O
+	O
370	O
/	O
+	O
379	O
nucleotides	O
(	O
Supplementary	O
Figure	O
S3A	O
)	O
.	O

To	O
validate	O
the	O
predicted	O
NF	O
-	O
kappaB	O
binding	O
sites	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
promoter	O
,	O
we	O
stimulated	O
HeLa	O
cells	O
with	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
a	O
well	O
-	O
known	O
NF	O
-	O
kappaB	O
inducer	O
,	O
and	O
measured	O
the	O
expression	O
levels	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
real	O
-	O
time	O
PCR	O
,	O
and	O
the	O
p65	B-Protein
occupancy	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
by	O
ChIP	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
activated	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
induced	O
the	O
p65	B-Protein
recruitment	O
to	O
the	O
NF	O
-	O
kappaB1	O
site	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
without	O
affecting	O
the	O
occupancy	O
of	O
the	O
putative	O
NF	O
-	O
kappaB2	O
and	O
NF	O
-	O
kappaB3	O
sites	O
(	O
Supplementary	O
Figure	O
S3B	O
and	O
S3C	O
)	O
.	O

Tat	B-Protein
also	O
promoted	O
the	O
recruitment	O
of	O
p65	B-Protein
to	O
the	O
NF	O
-	O
kappaB1	O
site	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
while	O
it	O
did	O
not	O
affect	O
the	O
putative	O
NF	O
-	O
kappaB2	O
and	O
NF	O
-	O
kappaB3	O
sites	O
(	O
Supplementary	O
Figure	O
S3D	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
the	O
NF	O
-	O
kappaB1	O
site	O
was	O
the	O
only	O
effective	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
promoter	O
in	O
response	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
Tat	B-Protein
.	O

Similarly	O
to	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
Tat	B-Protein
increased	O
the	O
recruitment	O
of	O
p65	B-Protein
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
of	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
and	O
TLR2	B-Protein
,	O
while	O
it	O
was	O
ineffective	O
at	O
the	O
promoters	O
of	O
GAPDH	B-Protein
and	O
ACTB	B-Protein
(	O
Figure	O
5H	O
)	O
.	O

By	O
ChIP	O
,	O
Tat	B-Protein
bound	O
to	O
the	O
NF	O
-	O
kappaB	O
-	O
responsive	O
promoters	O
,	O
and	O
not	O
to	O
the	O
GAPDH	B-Protein
and	O
ACTB	B-Protein
promoters	O
,	O
with	O
loss	O
of	O
binding	O
following	O
p65	B-Protein
RNA	O
interference	O
(	O
Figure	O
5I	O
)	O
,	O
suggesting	O
that	O
Tat	B-Protein
occupancy	O
occurred	O
via	O
p65	B-Protein
interaction	O
.	O

As	O
additional	O
findings	O
,	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
chromatin	O
-	O
immunoprecipitated	O
at	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
absence	O
of	O
Tat	B-Protein
,	O
and	O
it	O
was	O
significantly	O
removed	O
in	O
presence	O
of	O
Tat	B-Protein
,	O
or	O
following	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
RNA	O
interference	O
(	O
Figure	O
5J	O
)	O
,	O
indicating	O
that	O
Tat	B-Protein
displaced	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
from	O
promoters	O
.	O

In	O
HIV	O
-	O
1	O
-	O
infected	O
monocytes	O
Tat	B-Protein
sustains	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
promotes	O
the	O
transcriptional	O
activation	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
interacting	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

We	O
next	O
analysed	O
whether	O
Tat	B-Protein
affected	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
the	O
course	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

To	O
detect	O
the	O
Tat	B-Protein
protein	O
,	O
we	O
produced	O
HXB2	O
Env	B-Protein
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
which	O
were	O
used	O
in	O
single	O
-	O
round	O
infection	O
of	O
U937	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Cells	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
,	O
siRNA	O
control	O
or	O
left	O
untransfected	O
to	O
modulate	O
the	O
Tat	B-Protein
expression	O
,	O
and	O
then	O
analysed	O
for	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
following	O
viral	O
infection	O
.	O
<EOS>	B-X
METH	B-X
and	B-X
human	B-X
immunodeficiency	B-X
virus-1	B-X
transactivator	B-X
of	B-X
transcription	B-X
(	B-X
HIV-1Tat	B-X
)	B-X
have	B-X
toxic	B-X
and	B-X
synergistic	B-X
effects	B-X
on	B-X
the	B-X
nervous	B-X
system	B-X
;	B-X
however	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
their	B-X
synergistic	B-X
effects	B-X
has	B-X
not	B-X
been	B-X
clarified	B-X
.	B-X
We	B-X
used	B-X
BV2	B-X
cells	B-X
,	B-X
primary	B-X
microglia	B-X
,	B-X
Nrf2-KO	B-X
C57BL/6J	B-X
mice	B-X
,	B-X
and	B-X
autopsied	B-X
brain	B-X
tissues	B-X
of	B-X
METH-abusing	B-X
,	B-X
HIV	B-X
infection	B-X
,	B-X
and	B-X
METH-abusing	B-X
individuals	B-X
comorbid	B-X
with	B-X
HIV	B-X
to	B-X
explore	B-X
the	B-X
regulatory	B-X
role	B-X
of	B-X
Nrf2/NQO1/HO-1	B-X
signal	B-X
pathway	B-X
on	B-X
microglia	B-X
autophagy	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
microglia	B-X
were	B-X
significantly	B-X
activated	B-X
by	B-X
METH	B-X
and	B-X
HIV-1Tat	B-X
protein	B-X
.	B-X
METH	B-X
and	B-X
HIV-1Tat	B-X
protein	B-X
combination	B-X
significantly	B-X
increase	B-X
the	B-X
autophagy-related	B-X
proteins	B-X
(	B-X
LC3-II	B-X
,	B-X
Beclin-1	B-X
,	B-X
ATG5	B-X
,	B-X
and	B-X
ATG7	B-X
)	B-X
expression	B-X
in	B-X
microglia	B-X
and	B-X
striatum	B-X
of	B-X
C57BL/6J	B-X
mice	B-X
.	B-X
After	B-X
silencing	B-X
or	B-X
knocking	B-X
out	B-X
the	B-X
Nrf2	B-X
gene	B-X
,	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
autophagy-related	B-X
proteins	B-X
were	B-X
significantly	B-X
increased	B-X
.	B-X
In	B-X
human	B-X
brain	B-X
tissue	B-X
,	B-X
microglia	B-X
were	B-X
activated	B-X
,	B-X
Nrf2	B-X
,	B-X
LC3-II	B-X
,	B-X
and	B-X
Beclin-1	B-X
expression	B-X
levels	B-X
were	B-X
raised	B-X
,	B-X
and	B-X
the	B-X
p62	B-X
expression	B-X
level	B-X
was	B-X
decreased	B-X
.	B-X
Our	B-X
results	B-X
suggested	B-X
that	B-X
METH	B-X
and	B-X
HIV	B-X
or	B-X
HIV-1Tat	B-X
synergistically	B-X
affect	B-X
autophagy	B-X
.	B-X
And	B-X
the	B-X
Nrf2	B-X
pathway	B-X
plays	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
synergistic	B-X
induction	B-X
of	B-X
microglial	B-X
autophagy	B-X
by	B-X
METH	B-X
and	B-X
HIV-1Tat	B-X
protein	B-X
.	B-X

The	O
expression	O
of	O
Tat	B-Protein
and	O
p24	B-Protein
was	O
detected	O
at	O
3	O
-	O
to	O
12	O
-	O
h	O
post	O
-	O
infection	O
,	O
while	O
it	O
was	O
barely	O
detected	O
in	O
siRNA	B-Protein
Tat	I-Protein
-	O
transfected	O
cells	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
measured	O
by	O
p65	B-Protein
DNA	O
binding	O
,	O
was	O
induced	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
in	O
both	O
Tat	B-Protein
-	O
positive	O
(	O
no	O
siRNA	O
and	O
siRNA	O
control	O
)	O
and	O
Tat	B-Protein
-	O
negative	O
cells	O
(	O
siRNA	B-Protein
Tat	I-Protein
)	O
,	O
and	O
increased	O
at	O
12	O
h	O
only	O
in	O
Tat	B-Protein
-	O
positive	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

Degradation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
observed	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
,	O
and	O
was	O
followed	O
by	O
de	O
novo	O
synthesis	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
at	O
12	O
h	O
independently	O
of	O
the	O
Tat	B-Protein
presence	O
(	O
Figure	O
6C	O
)	O
.	O

Consistently	O
,	O
the	O
IKK	O
activity	O
was	O
induced	O
at	O
3	O
-	O
h	O
post	O
-	O
infection	O
and	O
turned	O
off	O
at	O
12	O
h	O
independently	O
of	O
the	O
Tat	B-Protein
presence	O
(	O
Figure	O
6D	O
)	O
.	O

These	O
results	O
agreed	O
with	O
the	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
single	O
-	O
round	O
HIV	O
-	O
1	O
infection	O
of	O
Jurkat	O
cells	O
(	O
Figure	O
1	O
)	O
,	O
and	O
further	O
supported	O
the	O
requirement	O
of	O
viral	O
expression	O
to	O
counteract	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
HIV	O
-	O
1	O
-	O
infected	O
U937	O
cells	O
,	O
the	O
endogenous	O
Tat	B-Protein
was	O
coimmunoprecipitated	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
(	O
Figure	O
6E	O
)	O
,	O
and	O
activated	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
in	O
a	O
p65	B-Protein
-	O
dependent	O
manner	O
,	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
following	O
RNA	O
interference	O
of	O
Tat	B-Protein
or	O
p65	B-Protein
(	O
Figure	O
6F	O
)	O
.	O

Moreover	O
,	O
Tat	B-Protein
and	O
p65	B-Protein
were	O
both	O
recruited	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
while	O
the	O
p65	B-Protein
occupancy	O
was	O
abolished	O
by	O
siRNA	B-Protein
Tat	I-Protein
(	O
Figure	O
6G	O
and	O
H	O
)	O
.	O

Altogether	O
these	O
results	O
indicated	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
Tat	B-Protein
associated	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
,	O
and	O
induced	O
the	O
p65	B-Protein
-	O
dependent	O
activation	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
through	O
occupancy	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
promoter	O
and	O
increased	O
recruitment	O
of	O
p65	B-Protein
.	O

This	O
study	O
reports	O
a	O
novel	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
the	O
HIV	O
-	O
1	O
Tat	B-Protein
transactivator	O
.	O

Based	O
on	O
the	O
evidence	O
that	O
Tat	B-Protein
enhanced	O
the	O
transcriptional	O
activity	O
of	O
the	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappaB	O
(	O
49	O
,	O
63	O
,	O
64	O
)	O
,	O
and	O
physically	O
interacted	O
with	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repressor	O
(	O
50	O
,	O
51	O
)	O
,	O
we	O
investigated	O
the	O
possibility	O
that	O
Tat	B-Protein
could	O
activate	O
NF	O
-	O
kappaB	O
via	O
direct	O
interaction	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
.	O

To	O
this	O
end	O
,	O
the	O
NF	O
-	O
kappaB	O
activity	O
was	O
monitored	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
using	O
RNA	O
interference	O
to	O
silence	O
the	O
Tat	B-Protein
expression	O
.	O

By	O
this	O
approach	O
,	O
we	O
avoided	O
the	O
perpetuation	O
of	O
NF	O
-	O
kappaB	O
activation	O
signaling	O
due	O
to	O
subsequent	O
rounds	O
of	O
viral	O
entry	O
in	O
cell	O
culture	O
propagation	O
(	O
30	O
,	O
31	O
)	O
.	O

Upon	O
HIV	O
-	O
1	O
infection	O
,	O
the	O
early	O
NF	O
-	O
kappaB	O
activation	O
occurred	O
concomitantly	O
with	O
IKK	O
activation	O
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
degradation	O
in	O
the	O
absence	O
of	O
Tat	B-Protein
.	O

Soon	O
after	O
the	O
shut	O
off	O
of	O
IKK	O
activity	O
and	O
new	O
synthesis	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
the	O
NF	O
-	O
kappaB	O
activity	O
was	O
kept	O
elevated	O
in	O
the	O
presence	O
of	O
Tat	B-Protein
,	O
while	O
it	O
was	O
down	O
regulated	O
upon	O
silencing	O
of	O
the	O
Tat	B-Protein
gene	O
.	O

These	O
findings	O
indicate	O
that	O
in	O
single	O
round	O
HIV	O
-	O
1	O
infection	O
,	O
Tat	B-Protein
enhanced	O
the	O
NF	O
-	O
kappaB	O
activity	O
without	O
affecting	O
the	O
IKK	O
activity	O
and	O
the	O
half	O
-	O
life	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

Similar	O
kinetic	O
of	O
NF	O
-	O
kappaB	O
activation	O
occurred	O
upon	O
short	O
-	O
pulse	O
of	O
PMA	O
in	O
Tat	B-Protein
-	O
transfected	O
HeLa	O
cells	O
,	O
where	O
Tat	B-Protein
inhibited	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
in	O
presence	O
of	O
newly	O
synthesized	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

The	O
Tat	B-Protein
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
association	O
of	O
the	O
viral	O
protein	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
,	O
which	O
interfered	O
with	O
the	O
generation	O
of	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
/	O
p65	B-Protein
complex	O
.	O

This	O
evidence	O
demonstrated	O
that	O
Tat	B-Protein
competed	O
for	O
the	O
binding	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
to	O
p65	B-Protein
and	O
prevented	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repression	O
of	O
p65	B-Protein
.	O

As	O
additional	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
Tat	B-Protein
associated	O
with	O
p65	B-Protein
and	O
increased	O
the	O
p65	B-Protein
binding	O
affinity	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
;	O
this	O
evidence	O
was	O
obtained	O
with	O
recombinant	O
proteins	O
indicating	O
that	O
the	O
stronger	O
binding	O
of	O
p65	B-Protein
to	O
DNA	O
was	O
a	O
consequence	O
of	O
direct	O
association	O
with	O
Tat	B-Protein
,	O
which	O
likely	O
caused	O
a	O
conformational	O
change	O
of	O
p65	B-Protein
.	O

We	O
also	O
demonstrated	O
that	O
the	O
Tat	B-Protein
cysteine	O
-	O
rich	O
sequence	O
(	O
C22	O
,	O
25	O
,	O
27	O
)	O
was	O
involved	O
in	O
the	O
binding	O
to	O
the	O
RHD	O
of	O
p65	B-Protein
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Differently	O
,	O
the	O
Tat	B-Protein
arginine	O
-	O
rich	O
sequence	O
(	O
R49	O
,	O
52	O
,	O
53	O
,	O
55	O
,	O
56	O
,	O
57	O
)	O
was	O
required	O
for	O
the	O
binding	O
to	O
the	O
sixth	O
ankyrin	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
50	O
,	O
51	O
)	O
,	O
and	O
for	O
releasing	O
p65	B-Protein
from	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
inhibition	O
.	O

Altogether	O
these	O
results	O
demonstrated	O
that	O
Tat	B-Protein
abolished	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
by	O
hijacking	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repressor	O
,	O
shielding	O
p65	B-Protein
from	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
embrace	O
,	O
and	O
enforcing	O
the	O
p65	B-Protein
binding	O
to	O
DNA	O
.	O

Further	O
evidence	O
of	O
Tat	B-Protein
activation	O
of	O
NF	O
-	O
kappaB	O
showed	O
that	O
wild	O
-	O
type	O
Tat	B-Protein
,	O
and	O
not	O
the	O
Tat	B-Protein
mutants	I-Protein
lacking	O
the	O
arginine	O
-	O
or	O
cysteine	O
-	O
rich	O
domains	O
,	O
up	O
-	O
regulated	O
in	O
vivo	O
the	O
expression	O
of	O
a	O
number	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
including	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
CSF3	B-Protein
,	O
LTA	B-Protein
,	O
NFKBIA	B-Protein
and	O
TLR2	B-Protein
.	O
<EOS>	B-X
A	B-X
delay	B-X
in	B-X
HIV	B-X
production	B-X
was	B-X
consistently	B-X
observed	B-X
in	B-X
cells	B-X
expressing	B-X
a	B-X
truncated	B-X
CD4	B-X
which	B-X
lacks	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
(	B-X
CD4.401	B-X
)	B-X
compared	B-X
with	B-X
cells	B-X
expressing	B-X
the	B-X
wild	B-X
type	B-X
CD4	B-X
.	B-X
The	B-X
delay	B-X
was	B-X
much	B-X
less	B-X
in	B-X
cells	B-X
expressing	B-X
a	B-X
hybrid	B-X
CD4-CD8	B-X
molecule	B-X
(	B-X
amino	B-X
acids	B-X
1-177	B-X
of	B-X
CD4	B-X
fused	B-X
to	B-X
the	B-X
hinge	B-X
,	B-X
transmembrane	B-X
and	B-X
cytoplasmic	B-X
domains	B-X
of	B-X
CD8	B-X
)	B-X
.	B-X
Yet	B-X
the	B-X
extent	B-X
of	B-X
viral	B-X
entry	B-X
and	B-X
reverse	B-X
transcription	B-X
,	B-X
monitored	B-X
by	B-X
semi-quantitative	B-X
PCR	B-X
,	B-X
was	B-X
similar	B-X
in	B-X
each	B-X
cell	B-X
type	B-X
studied	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD4	B-X
oligomerization	B-X
by	B-X
HIV-1	B-X
induced	B-X
NF-kappa	B-X
B	B-X
translocation	B-X
in	B-X
A2.01/CD4	B-X
and	B-X
A2.01/CD4-CD8	B-X
but	B-X
not	B-X
in	B-X
A2.01/CD4.401	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
consistent	B-X
with	B-X
CAT	B-X
assay	B-X
experiments	B-X
which	B-X
provided	B-X
evidence	B-X
for	B-X
Tat-independent	B-X
NF-kappa	B-X
B	B-X
mediated	B-X
activation	B-X
of	B-X
HIV-1	B-X
LTR	B-X
promoter	B-X
after	B-X
HIV	B-X
binding	B-X
to	B-X
CD4	B-X
in	B-X
A2.01/CD4	B-X
and	B-X
A2.01/CD4-CD8	B-X
but	B-X
not	B-X
in	B-X
A2.01/CD4.401	B-X
cells	B-X
.	B-X
(	B-X
1994	B-X
,	B-X
EMBO	B-X
J.	B-X
,	B-X
13	B-X
,	B-X
774-783	B-X
)	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
a	B-X
positive	B-X
cellular	B-X
signal	B-X
initiated	B-X
following	B-X
oligomerization	B-X
of	B-X
the	B-X
CD4	B-X
by	B-X
the	B-X
virus	B-X
itself	B-X
is	B-X
involved	B-X
in	B-X
NF-kappa	B-X
B-dependent	B-X
early	B-X
HIV	B-X
transcription	B-X
in	B-X
A2.01/CD4	B-X
cells	B-X
.	B-X

By	O
ChIP	O
analysis	O
,	O
we	O
observed	O
that	O
Tat	B-Protein
increased	O
the	O
recruitment	O
of	O
p65	B-Protein
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
of	O
the	O
activated	O
genes	O
,	O
and	O
was	O
recovered	O
at	O
the	O
same	O
sites	O
.	O

RNA	O
interference	O
of	O
p65	B-Protein
abolished	O
the	O
Tat	B-Protein
occupancy	O
of	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
indicating	O
that	O
the	O
Tat	B-Protein
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
sites	O
was	O
mediated	O
by	O
p65	B-Protein
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
evidence	O
that	O
Tat	B-Protein
displaced	O
p65	B-Protein
from	O
the	O
binding	O
to	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Figures	O
2D	O
and	O
3C	O
)	O
,	O
and	O
increased	O
the	O
p65	B-Protein
DNA	O
binding	O
affinity	O
through	O
association	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

Thus	O
,	O
Tat	B-Protein
likely	O
increased	O
the	O
recruitment	O
of	O
p65	B-Protein
to	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoters	O
by	O
associating	O
with	O
p65	B-Protein
and	O
by	O
interfering	O
with	O
the	O
assembly	O
of	O
p65	B-Protein
with	O
the	O
repressor	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

Of	O
interest	O
,	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
found	O
associated	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
in	O
absence	O
of	O
Tat	B-Protein
,	O
where	O
it	O
was	O
displaced	O
in	O
presence	O
of	O
Tat	B-Protein
.	O

These	O
results	O
suggest	O
a	O
negative	O
regulatory	O
role	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
in	O
gene	O
regulation	O
through	O
occupancy	O
of	O
specific	O
promoters	O
.	O

Indeed	O
,	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
found	O
associated	O
with	O
hystone	O
deacetylases	O
at	O
the	O
hes1	B-Protein
promoter	O
,	O
from	O
where	O
it	O
was	O
removed	O
following	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
stimulation	O
causing	O
histone	O
acetylation	O
and	O
hes1	B-Protein
transcriptional	O
activation	O
(	O
65	O
)	O
.	O

A	O
similar	O
mechanism	O
of	O
gene	O
regulation	O
could	O
apply	O
to	O
the	O
NF	O
-	O
kappaB	O
-	O
dependent	O
genes	O
analysed	O
in	O
this	O
study	O
,	O
where	O
Tat	B-Protein
could	O
activate	O
the	O
gene	O
expression	O
by	O
removing	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
promoting	O
the	O
p65	B-Protein
loading	O
(	O
Figure	O
7	O
)	O
.	O

The	O
physiological	O
relevance	O
of	O
Tat	B-Protein
cross	O
talk	O
with	O
NF	O
-	O
kappaB	O
was	O
demonstrated	O
in	O
the	O
HIV	O
-	O
1	O
infection	O
of	O
human	O
monocytes	O
,	O
where	O
HIV	O
-	O
1	O
-	O
encoded	O
Tat	B-Protein
protein	O
counteracted	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
,	O
as	O
shown	O
by	O
:	O
(	O
i	O
)	O
sustained	O
NF	O
-	O
kappaB	O
activity	O
by	O
Tat	B-Protein
in	O
presence	O
of	O
newly	O
synthesized	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
;	O
(	O
ii	O
)	O
coimmunoprecipitation	O
of	O
Tat	B-Protein
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
;	O
(	O
iii	O
)	O
induction	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
dependent	O
on	O
Tat	B-Protein
and	O
p65	B-Protein
;	O
(	O
iv	O
)	O
Tat	B-Protein
occupancy	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
NF	O
-	O
kappaB	O
enhancer	O
associated	O
with	O
increased	O
recruitment	O
of	O
p65	B-Protein
.	O

This	O
study	O
supports	O
the	O
pro	O
-	O
inflammatory	O
action	O
of	O
Tat	B-Protein
through	O
physical	O
interaction	O
with	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
.	O

Several	O
inflammatory	O
cytokines	O
under	O
the	O
transcriptional	O
control	O
of	O
NF	O
-	O
kappaB	O
are	O
hyper	O
-	O
expressed	O
in	O
HIV	O
-	O
1	O
infected	O
individuals	O
,	O
including	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
66	O
,	O
67	O
)	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
(	O
68	O
)	O
,	O
and	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
57	O
-	O
62	O
,	O
69	O
-	O
71	O
)	O
.	O

In	O
the	O
case	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
Tat	B-Protein
activated	O
the	O
cytokine	O
expression	O
by	O
binding	O
to	O
the	O
TAR	O
-	O
like	O
stem	O
loop	O
of	O
the	O
5	O
'	O
transcript	O
,	O
thus	O
likely	O
promoting	O
the	O
transcriptional	O
elongation	O
(	O
33	O
,	O
37	O
,	O
47	O
)	O
.	O

Here	O
,	O
we	O
have	O
shown	O
that	O
the	O
Tat	B-Protein
-	O
dependent	O
transcriptional	O
activation	O
of	O
a	O
number	O
of	O
pro	O
-	O
inflammatory	O
genes	O
required	O
the	O
assembly	O
of	O
Tat	B-Protein
with	O
p65	B-Protein
at	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
together	O
with	O
the	O
displacement	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Figure	O
5	O
)	O
.	O

Thus	O
,	O
in	O
the	O
set	O
of	O
distinct	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
,	O
Tat	B-Protein
acted	O
as	O
a	O
component	O
of	O
the	O
transcriptional	O
initiation	O
complex	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
on	O
Tat	B-Protein
promoting	O
the	O
transcription	O
via	O
DNA	O
motifs	O
(	O
72	O
,	O
73	O
)	O
.	O

Overproduction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
is	O
considered	O
a	O
major	O
mechanism	O
of	O
immune	O
deregulation	O
(	O
26	O
)	O
and	O
neuron	O
dysfunction	O
in	O
AIDS	O
(	O
74	O
,	O
75	O
)	O
.	O

In	O
this	O
scenario	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
could	O
lead	O
to	O
a	O
therapeutic	O
strategy	O
for	O
counteracting	O
the	O
abnormal	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
HIV	O
-	O
1	O
infection	O
.	O

NF	O
-	O
kappaB	O
inhibitors	O
,	O
such	O
as	O
anti	O
-	O
oxidants	O
,	O
proteasome	O
and	O
IKK	O
inhibitors	O
,	O
significantly	O
reduced	O
the	O
HIV	O
-	O
1	O
replication	O
and	O
the	O
associated	O
inflammatory	O
response	O
(	O
76	O
,	O
77	O
)	O
;	O
however	O
,	O
these	O
NF	O
-	O
kappaB	O
inhibitors	O
acted	O
indiscriminately	O
in	O
both	O
HIV	O
-	O
1	O
-	O
infected	O
and	O
uninfected	O
cells	O
.	O

The	O
evidence	O
that	O
Tat	B-Protein
activates	O
NF	O
-	O
kappaB	O
through	O
direct	O
interaction	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
may	O
lead	O
to	O
specific	O
inhibitors	O
to	O
counteract	O
the	O
Tat	B-Protein
pro	O
-	O
inflammatory	O
action	O
.	O

Tat	B-Protein
counteracts	O
the	O
post	O
-	O
activation	O
turn	O
off	O
of	O
NF	O
-	O
kappaB	O
in	O
single	O
round	O
HIV	O
-	O
1	O
-	O
infection	O
.	O

Jurkat	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
or	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
Luc	O
.	O
R	O
-	O
E	O
-	O
virions	O
(	O
500	O
ng	O
of	O
p24	B-Protein
)	O
and	O
harvested	O
at	O
the	O
indicated	O
time	O
.	O
<EOS>	B-X
Choriocarcinoma	B-X
is	B-X
a	B-X
highly	B-X
invasive	B-X
gynaecologic	B-X
malignancy	B-X
.	B-X
Molecular	B-X
mechanism	B-X
of	B-X
metastasis	B-X
in	B-X
choriocarcinoma	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Migration	B-X
and	B-X
invasion	B-X
inhibitory	B-X
protein	B-X
(	B-X
MIIP	B-X
)	B-X
regulates	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
function	B-X
of	B-X
MIIP	B-X
in	B-X
choriocarcinoma	B-X
.	B-X

(	O
A	O
)	O
Tat	B-Protein
expression	O
was	O
measured	O
in	O
total	O
RNA	O
by	O
real	O
-	O
time	O
PCR	O
,	O
while	O
the	O
luciferase	B-Protein
activity	O
was	O
measured	O
in	O
whole	O
cell	O
extracts	O
.	O

(	O
B	O
)	O
Nuclear	O
extracts	O
(	O
10	O
microg	O
)	O
were	O
analysed	O
for	O
the	O
p65	B-Protein
and	O
p50	B-Protein
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
Assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
C	O
)	O
The	O
expression	O
of	O
p65	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
was	O
analysed	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
of	O
nuclear	O
or	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
using	O
anti	O
-	O
p65	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

Histone	O
H1	O
and	O
Hexokinase	B-Protein
II	I-Protein
were	O
detected	O
with	O
specific	O
antibodies	O
as	O
markers	O
of	O
nuclear	O
and	O
cytosolic	O
extracts	O
,	O
respectively	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
mock	O
)	O
.	O

(	O
D	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
extracts	O
(	O
100	O
microg	O
)	O
by	O
using	O
HTScan	O
IKK	O
Kinase	O
Assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

Tat	B-Protein
enhances	O
the	O
NF	O
-	O
kappaB	O
activity	O
following	O
PMA	O
stimulation	O
by	O
associating	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
counteracting	O
the	O
NF	O
-	O
kappaB	O
repression	O
.	O

HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	B-Protein
or	O
p3xFLAG	O
empty	O
vector	O
(	O
5	O
microg	O
)	O
,	O
and	O
48	O
h	O
later	O
were	O
stimulated	O
with	O
PMA	O
(	O
5	O
min	O
,	O
20	O
ng	O
/	O
ml	O
)	O
or	O
left	O
unstimulated	O
,	O
washed	O
twice	O
with	O
DMEM	O
and	O
harvested	O
at	O
the	O
indicated	O
times	O
.	O

Nuclear	O
and	O
cytosolic	O
extracts	O
were	O
prepared	O
for	O
further	O
analysis	O
.	O
<EOS>	B-X
Extracts	B-X
prepared	B-X
from	B-X
the	B-X
isolated	B-X
nuclei	B-X
of	B-X
cultured	B-X
cells	B-X
have	B-X
been	B-X
instrumental	B-X
in	B-X
dissecting	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
transcription	B-X
and	B-X
mRNA	B-X
processing	B-X
occur	B-X
.	B-X
These	B-X
extracts	B-X
are	B-X
able	B-X
to	B-X
recapitulate	B-X
accurate	B-X
transcription	B-X
initiation	B-X
and	B-X
splicing	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
has	B-X
been	B-X
useful	B-X
in	B-X
direct	B-X
functional	B-X
studies	B-X
.	B-X
This	B-X
unit	B-X
describes	B-X
the	B-X
preparation	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
cultured	B-X
cells	B-X
and	B-X
optimized	B-X
production	B-X
of	B-X
transcriptionally	B-X
active	B-X
extracts	B-X
from	B-X
HeLa	B-X
cells	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
of	B-X
total	B-X
RNA	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
single	B-X
strong	B-X
signal	B-X
of	B-X
c-fos	B-X
like	B-X
mRNA	B-X
of	B-X
1.9	B-X
Kb	B-X
during	B-X
February	B-X
and	B-X
April	B-X
.	B-X
Cytoplasmic	B-X
extracts	B-X
from	B-X
September-October	B-X
animals	B-X
bound	B-X
the	B-X
AP1	B-X
oligonucleotide	B-X
.	B-X
The	B-X
complex	B-X
was	B-X
not	B-X
available	B-X
in	B-X
the	B-X
nuclear	B-X
extracts	B-X
from	B-X
the	B-X
same	B-X
preparation	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
besides	B-X
Fos	B-X
,	B-X
Jun	B-X
products	B-X
were	B-X
also	B-X
present	B-X
.	B-X
Conversely	B-X
,	B-X
nuclear	B-X
but	B-X
not	B-X
cytosolic	B-X
binding	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
animals	B-X
collected	B-X
in	B-X
July	B-X
.	B-X

(	O
A	O
)	O
Nuclear	O
extracts	O
were	O
analysed	O
for	O
the	O
p65	B-Protein
,	O
p50	B-Protein
and	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
binding	O
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
B	O
)	O
Nuclear	O
and	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
using	O
the	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
,	O
anti	O
-	O
Histone	O
H1	O
,	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
and	O
anti	O
-	O
Hexokinase	O
-	O
II	O
antibodies	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

(	O
C	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
extracts	O
(	O
100	O
microg	O
)	O
by	O
using	O
HTScan	O
IKK	O
kinase	O
assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

(	O
D	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
or	O
without	O
p3xFLAG	O
-	O
Tat	B-Protein
(	O
5	O
microg	O
)	O
;	O
48	O
h	O
later	O
,	O
cells	O
were	O
stimulated	O
with	O
PMA	O
(	O
5	O
min	O
,	O
20	O
ng	O
/	O
ml	O
)	O
or	O
left	O
unstimulated	O
,	O
washed	O
twice	O
with	O
DMEM	O
,	O
and	O
harvested	O
after	O
240	O
min	O
.	O

Whole	O
cell	O
extracts	O
(	O
1	O
mg	O
)	O
were	O
immunoprecipitated	O
with	O
protein	B-Protein
G	I-Protein
-	O
Sepharose	O
-	O
coupled	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O

Immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

Tat	B-Protein
relieves	O
p65	B-Protein
from	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
inhibition	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
Tat	B-Protein
proteins	O
.	O

(	O
B	O
)	O
HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
(	O
5	O
microl	O
)	O
was	O
incubated	O
in	O
presence	O
or	O
absence	O
of	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
,	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
,	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
or	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
(	O
10	O
microl	O
)	O
using	O
in	O
vitro	O
translated	O
proteins	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
Tat	B-Protein
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
FLAG	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
HA	O
and	O
anti	O
-	O
FLAG	O
antibodies	O
.	O

(	O
C	O
)	O
35S	O
-	O
methionine	O
-	O
labeled	O
p65	B-Protein
(	O
5	O
microl	O
)	O
was	O
incubated	O
with	O
in	O
vitro	O
translated	O
HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
(	O
5	O
microl	O
)	O
in	O
presence	O
or	O
absence	O
of	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
or	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
(	O
5	O
,	O
10	O
or	O
20	O
microl	O
)	O
.	O

HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
was	O
immunoprecipitated	O
with	O
anti	O
-	O
HA	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
HA	O
and	O
anti	O
-	O
FLAG	O
antibodies	O
,	O
or	O
autoradiography	O
(	O
35S	O
-	O
Met	O
-	O
p65	B-Protein
)	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
lane	O
1	O
)	O
.	O

(	O
D	O
)	O
The	O
p65	B-Protein
DNA	O
binding	O
activity	O
was	O
analysed	O
by	O
EMSA	O
using	O
in	O
vitro	O
translated	O
proteins	O
.	O

32P	O
-	O
labeled	O
-	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
was	O
incubated	O
with	O
p65	B-Protein
(	O
0	O
.	O
5	O
microl	O
)	O
in	O
presence	O
or	O
absence	O
of	O
HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
(	O
1	O
microl	O
)	O
,	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
or	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
(	O
5	O
and	O
10	O
microl	O
)	O
;	O
competition	O
of	O
DNA	O
binding	O
was	O
performed	O
with	O
10	O
-	O
up	O
to	O
100	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
.	O

DNA	O
/	O
protein	O
complexes	O
were	O
run	O
on	O
6	O
%	O
PAGE	O
-	O
TBE	O
and	O
analysed	O
by	O
autoradiography	O
.	O

(	O
E	O
)	O
p50	B-Protein
-	O
/	O
-	O
p65	B-Protein
-	O
/	O
-	O
MEFs	O
(	O
3	O
x	O
105	O
cells	O
)	O
were	O
transfected	O
with	O
pkappaBLuc	O
(	O
0	O
.	O
5	O
microg	O
)	O
and	O
pSV	O
-	O
beta	B-Protein
-	I-Protein
Gal	I-Protein
(	O
0	O
.	O
1	O
microg	O
)	O
with	O
or	O
without	O
pRc	O
/	O
CMV	O
-	O
p65	B-Protein
(	O
0	O
.	O
5	O
microg	O
)	O
,	O
pCMV4	O
-	O
HA	B-Protein
-	I-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
(	O
0	O
.	O
5	O
microg	O
)	O
,	O
p3xFLAG	O
-	O
Tat	B-Protein
or	O
p3xFLAG	O
-	O
Tat	B-Protein
R	O
(	O
49	O
-	O
57	O
)	O
A	O
(	O
0	O
.	O
5	O
,	O
1	O
and	O
2	O
microg	O
)	O
.	O

The	O
luciferase	B-Protein
activity	O
was	O
measured	O
in	O
cell	O
extracts	O
48	O
-	O
h	O
post	O
-	O
transfection	O
and	O
normalized	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
.	O

Fold	O
activation	O
was	O
calculated	O
relative	O
to	O
transfection	O
of	O
the	O
pkappaBLuc	O
plasmid	O
alone	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

As	O
control	O
of	O
protein	O
expression	O
,	O
aliquots	O
of	O
cell	O
extracts	O
(	O
20	O
microg	O
)	O
were	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
HA	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
gamma	O
-	O
tubulin	O
antibodies	O
.	O

Tat	B-Protein
associates	O
with	O
p65	B-Protein
increasing	O
its	O
DNA	O
-	O
affinity	O
binding	O
.	O
<EOS>	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

(	O
A	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65	I-Protein
(	O
5	O
microg	O
)	O
in	O
presence	O
or	O
absence	O
of	O
p3xFLAG	O
-	O
Tat	B-Protein
,	O
p3xFLAG	O
-	O
Tat	B-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
p3xFLAG	O
-	O
Tat	B-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
,	O
p3xFLAG	O
-	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
or	O
p3xFLAG	O
-	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
(	O
5	O
microg	O
)	O
.	O

FLAG	B-Protein
-	I-Protein
Tat	I-Protein
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
FLAG	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
FLAG	O
or	O
anti	O
-	O
HA	O
antibodies	O
.	O

(	O
B	O
)	O
In	O
vitro	O
translated	O
p65	B-Protein
(	O
5	O
microl	O
)	O
was	O
incubated	O
with	O
GST	B-Protein
-	I-Protein
Tat	I-Protein
,	O
GST	B-Protein
-	I-Protein
Tat	I-Protein
T	I-Protein
,	I-Protein
N	I-Protein
(	I-Protein
23	I-Protein
,	I-Protein
24	I-Protein
)	I-Protein
A	I-Protein
,	O
GST	B-Protein
-	I-Protein
Tat	I-Protein
K	I-Protein
(	I-Protein
50	I-Protein
,	I-Protein
51	I-Protein
)	I-Protein
A	I-Protein
,	O
GST	B-Protein
-	I-Protein
Tat	I-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
A	I-Protein
,	O
GST	B-Protein
-	I-Protein
Tat	I-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
,	O
or	O
GST	B-Protein
(	O
5	O
microg	O
)	O
conjugated	O
with	O
Glutathione	O
-	O
Sepharose	O
.	O

Protein	O
complexes	O
were	O
recovered	O
by	O
GST	B-Protein
-	O
pull	O
down	O
,	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
,	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
or	O
anti	O
-	O
GST	O
antibodies	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
high-affinity	B-X
human	B-X
TREM2-activating	B-X
antibody	B-X
engineered	B-X
with	B-X
a	B-X
monovalent	B-X
transferrin	B-X
receptor	B-X
(	B-X
TfR	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
termed	B-X
antibody	B-X
transport	B-X
vehicle	B-X
(	B-X
ATV	B-X
)	B-X
,	B-X
to	B-X
facilitate	B-X
blood-brain	B-X
barrier	B-X
transcytosis	B-X
.	B-X
Upon	B-X
peripheral	B-X
delivery	B-X
in	B-X
mice	B-X
,	B-X
ATV	B-X
:	B-X
TREM2	B-X
showed	B-X
improved	B-X
brain	B-X
biodistribution	B-X
and	B-X
enhanced	B-X
signaling	B-X
compared	B-X
to	B-X
a	B-X
standard	B-X
anti-TREM2	B-X
antibody	B-X
.	B-X
Plumbagin	B-X
reportedly	B-X
displays	B-X
anti-inflammatory	B-X
,	B-X
anti-fibrotic	B-X
,	B-X
antioxidant	B-X
and	B-X
anthelmintic	B-X
properties	B-X
.	B-X
Plumbagin	B-X
treatment	B-X
restored	B-X
hepatic	B-X
enzymes	B-X
activity	B-X
to	B-X
nearly	B-X
normal	B-X
levels	B-X
and	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
catalase	B-X
,	B-X
SOD	B-X
,	B-X
GSH	B-X
,	B-X
total	B-X
thiol	B-X
and	B-X
GST	B-X
in	B-X
liver	B-X
tissue	B-X
homogenate	B-X
.	B-X

(	O
C	O
)	O
Schematic	O
representation	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
p65	B-Protein
proteins	O
.	O

(	O
D	O
)	O
HeLa	O
cells	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	B-Protein
(	O
5	O
microg	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65	I-Protein
,	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65deltaC	I-Protein
(	O
1	O
-	O
318	O
)	O
,	O
or	O
pRc	O
/	O
CMV	O
-	O
3xHA	B-Protein
-	I-Protein
p65deltaN	I-Protein
(	O
122	O
-	O
551	O
)	O
(	O
5	O
microg	O
)	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
HA	B-Protein
-	I-Protein
p65	I-Protein
proteins	O
were	O
immunoprecipitated	O
with	O
anti	O
-	O
HA	O
antibody	O
;	O
immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
FLAG	O
or	O
anti	O
-	O
HA	O
antibodies	O
.	O

(	O
E	O
)	O
Recombinant	O
p65	B-Protein
protein	O
(	O
100	O
ng	O
;	O
Active	O
Motif	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
was	O
20	O
min	O
incubated	O
with	O
32P	O
-	O
labeled	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
in	O
presence	O
or	O
absence	O
of	O
in	O
vitro	O
translated	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
or	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
A	I-Protein
(	O
5	O
microl	O
)	O
;	O
competitions	O
were	O
performed	O
with	O
1	O
.	O
25	O
-	O
up	O
to	O
40	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
oligonucleotide	O
.	O
<EOS>	B-X
Thrombin	B-X
is	B-X
the	B-X
central	B-X
bioregulatory	B-X
enzyme	B-X
in	B-X
hemostasis	B-X
and	B-X
is	B-X
generated	B-X
in	B-X
vascular	B-X
beds	B-X
in	B-X
which	B-X
inflammatory	B-X
responses	B-X
are	B-X
ongoing	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
thrombin	B-X
,	B-X
both	B-X
alone	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
TNF	B-X
,	B-X
on	B-X
gene	B-X
expression	B-X
in	B-X
porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
.	B-X
Thrombin	B-X
(	B-X
1-10	B-X
U/ml	B-X
)	B-X
induced	B-X
increased	B-X
mRNA	B-X
levels	B-X
of	B-X
E-selectin	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
,	B-X
IL-8	B-X
,	B-X
plasminogen	B-X
activator	B-X
inhibitor-1	B-X
,	B-X
and	B-X
IkappaB-alpha	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
mimicked	B-X
by	B-X
a	B-X
thrombin	B-X
receptor-activating	B-X
peptide	B-X
;	B-X
preincubation	B-X
of	B-X
thrombin	B-X
with	B-X
hirudin	B-X
blocked	B-X
the	B-X
induction	B-X
of	B-X
mRNA	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
increased	B-X
gene	B-X
expression	B-X
was	B-X
due	B-X
to	B-X
thrombin-specific	B-X
activity	B-X
.	B-X
Because	B-X
these	B-X
genes	B-X
are	B-X
known	B-X
to	B-X
contain	B-X
nuclear-factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
-binding	B-X
elements	B-X
in	B-X
their	B-X
promoter	B-X
region	B-X
,	B-X
we	B-X
next	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
thrombin	B-X
to	B-X
activate	B-X
this	B-X
transcription	B-X
factor	B-X
.	B-X
As	B-X
detected	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
thrombin	B-X
(	B-X
10	B-X
U/ml	B-X
)	B-X
or	B-X
thrombin	B-X
receptor-activating	B-X
peptide	B-X
(	B-X
100	B-X
microM	B-X
)	B-X
stimulated	B-X
increased	B-X
NF-kappaB-binding	B-X
activity	B-X
.	B-X
Supershift	B-X
analysis	B-X
revealed	B-X
that	B-X
these	B-X
complexes	B-X
were	B-X
comprised	B-X
principally	B-X
of	B-X
the	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
and	B-X
NF-kappaB1	B-X
(	B-X
p50	B-X
)	B-X
Rel	B-X
family	B-X
members	B-X
.	B-X
Thrombin	B-X
alone	B-X
did	B-X
not	B-X
substantively	B-X
increase	B-X
protein	B-X
levels	B-X
of	B-X
E-selectin	B-X
despite	B-X
the	B-X
increase	B-X
in	B-X
E-selectin	B-X
mRNA	B-X
levels	B-X
.	B-X
However	B-X
,	B-X
thrombin	B-X
(	B-X
3-10	B-X
U/ml	B-X
)	B-X
stimulated	B-X
a	B-X
10-fold	B-X
enhancement	B-X
in	B-X
the	B-X
ability	B-X
of	B-X
TNF	B-X
(	B-X
0.3-1.0	B-X
ng/ml	B-X
)	B-X
to	B-X
induce	B-X
E-selectin	B-X
surface	B-X
expression	B-X
.	B-X
Similar	B-X
potentiation	B-X
of	B-X
TNF-induced	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
E-selectin	B-X
transcription	B-X
by	B-X
thrombin	B-X
was	B-X
observed	B-X
in	B-X
experiments	B-X
utilizing	B-X
luciferase	B-X
reporter	B-X
constructs	B-X
expressed	B-X
in	B-X
bovine	B-X
aortic	B-X
EC	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
thrombin	B-X
to	B-X
potentiate	B-X
TNF-induced	B-X
EC	B-X
activation	B-X
thus	B-X
provides	B-X
an	B-X
important	B-X
mechanism	B-X
by	B-X
which	B-X
products	B-X
of	B-X
the	B-X
coagulation	B-X
cascade	B-X
may	B-X
enhance	B-X
cytokine-mediated	B-X
inflammatory	B-X
responses	B-X
.	B-X

DNA	O
/	O
protein	O
complexes	O
were	O
separated	O
by	O
6	O
%	O
PAGE	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
and	O
analysed	O
by	O
autoradiography	O
.	O

(	O
F	O
)	O
Densitometry	O
of	O
band	O
-	O
shifts	O
shown	O
in	O
E	O
.	O

Tat	B-Protein
activates	O
the	O
p65	B-Protein
-	O
dependent	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
by	O
occupying	O
the	O
NF	O
-	O
kappaB	O
enhancers	O
and	O
promoting	O
the	O
p65	B-Protein
recruitment	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
displacement	O
.	O

HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	B-Protein
,	O
p3xFLAG	O
-	O
Tat	B-Protein
C	I-Protein
(	I-Protein
22	I-Protein
,	I-Protein
25	I-Protein
,	I-Protein
27	I-Protein
)	I-Protein
,	O
p3xFLAG	O
-	O
Tat	B-Protein
R	I-Protein
(	I-Protein
49	I-Protein
-	I-Protein
57	I-Protein
)	I-Protein
or	O
empty	O
vector	O
(	O
10	O
microg	O
)	O
;	O
for	O
p65	B-Protein
RNA	O
interference	O
,	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	B-Protein
(	O
10	O
microg	O
)	O
and	O
siRNA	B-Protein
p65	I-Protein
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
.	O
<EOS>	B-X
A	B-X
total	B-X
of	B-X
2183	B-X
clones	B-X
derived	B-X
from	B-X
four	B-X
life	B-X
cycle	B-X
stage-specific	B-X
,	B-X
spliced-leader	B-X
cDNA	B-X
libraries	B-X
of	B-X
Leishmania	B-X
major	B-X
LV39	B-X
Neal	B-X
strain	B-X
were	B-X
randomly	B-X
picked	B-X
and	B-X
sequenced	B-X
to	B-X
generate	B-X
expressed	B-X
sequence	B-X
tags	B-X
(	B-X
ESTs	B-X
)	B-X
.	B-X
Then	B-X
1094	B-X
unique	B-X
genes	B-X
were	B-X
identified	B-X
,	B-X
with	B-X
18.2	B-X
%	B-X
having	B-X
BLAST	B-X
hits	B-X
with	B-X
known	B-X
genes/proteins	B-X
and	B-X
81.8	B-X
%	B-X
failing	B-X
to	B-X
match	B-X
genes	B-X
currently	B-X
deposited	B-X
in	B-X
public	B-X
databases	B-X
.	B-X
Approximately	B-X
250	B-X
unique	B-X
genes	B-X
were	B-X
obtained	B-X
from	B-X
a	B-X
lesion-derived	B-X
amastigote	B-X
complementary	B-X
DNA	B-X
(	B-X
cDNA	B-X
)	B-X
library	B-X
,	B-X
the	B-X
form	B-X
of	B-X
the	B-X
parasite	B-X
that	B-X
is	B-X
infective	B-X
to	B-X
the	B-X
mammalian	B-X
host	B-X
.	B-X
Polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
-amplified	B-X
ESTs	B-X
were	B-X
spotted	B-X
onto	B-X
glass	B-X
slides	B-X
,	B-X
and	B-X
DNA	B-X
microarray	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
further	B-X
approx	B-X
100	B-X
unique	B-X
cDNAs	B-X
highly	B-X
expressed	B-X
in	B-X
amastigotes	B-X
.	B-X
One	B-X
hundred	B-X
unique	B-X
,	B-X
randomly	B-X
selected	B-X
amastigote-expressed	B-X
genes	B-X
were	B-X
PCR	B-X
amplified	B-X
to	B-X
exclude	B-X
the	B-X
5'-spliced	B-X
leader	B-X
,	B-X
and	B-X
the	B-X
full-length	B-X
genes	B-X
subcloned	B-X
into	B-X
the	B-X
TOPO-TA	B-X
cloning	B-X
vector	B-X
.	B-X
The	B-X
genes	B-X
were	B-X
sequence-verified	B-X
,	B-X
excised	B-X
using	B-X
restriction	B-X
enzyme	B-X
digestion	B-X
,	B-X
and	B-X
cloned	B-X
upstream	B-X
of	B-X
the	B-X
eukaryotic	B-X
cytomegalovirus	B-X
promoter	B-X
into	B-X
the	B-X
expression	B-X
vector	B-X
pcDNA3	B-X
.	B-X
Expression	B-X
plasmids	B-X
were	B-X
sequence-verified	B-X
and	B-X
large-scale	B-X
,	B-X
endotoxin-free	B-X
plasmids	B-X
prepared	B-X
.	B-X
Then	B-X
100	B-X
microg	B-X
of	B-X
each	B-X
expression	B-X
plasmid	B-X
(	B-X
DNA	B-X
vaccine	B-X
)	B-X
was	B-X
delivered	B-X
subcutaneously	B-X
to	B-X
the	B-X
rump	B-X
of	B-X
susceptible	B-X
BALB/c	B-X
mice	B-X
,	B-X
the	B-X
mice	B-X
boosted	B-X
4	B-X
wk	B-X
later	B-X
and	B-X
then	B-X
challenged	B-X
2	B-X
wk	B-X
post-boost	B-X
with	B-X
2	B-X
x	B-X
10	B-X
(	B-X
6	B-X
)	B-X
L.	B-X
major	B-X
LV39	B-X
parasites	B-X
to	B-X
the	B-X
hind	B-X
footpad	B-X
.	B-X
Protection	B-X
was	B-X
scored	B-X
by	B-X
comparing	B-X
the	B-X
footpad	B-X
depth	B-X
of	B-X
mice	B-X
receiving	B-X
empty	B-X
vector	B-X
DNA	B-X
to	B-X
those	B-X
immunized	B-X
with	B-X
DNA	B-X
containing	B-X
L.	B-X
major	B-X
amastigote-expressed	B-X
genes	B-X
.	B-X

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
transfection	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
analysed	O
by	O
real	O
-	O
time	O
PCR	O
to	O
evaluate	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
A	O
)	O
,	O
CSF3	B-Protein
(	O
B	O
)	O
,	O
LTA	B-Protein
(	O
C	O
)	O
,	O
NFKBIA	B-Protein
(	O
D	O
)	O
,	O
TLR2	B-Protein
(	O
E	O
)	O
,	O
GAPDH	B-Protein
(	O
F	O
)	O
,	O
ACTB	B-Protein
(	O
G	O
)	O
genes	O
.	O

(	O
H	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
p3xFLAG	O
-	O
Tat	B-Protein
,	O
or	O
empty	O
vector	O
(	O
10	O
microg	O
)	O
and	O
48	O
h	O
later	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
p65	O
antibody	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O
<EOS>	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
applied	B-X
SYBR	B-X
Green	B-X
I-based	B-X
real-time	B-X
PCR	B-X
and	B-X
melting	B-X
curve	B-X
analysis	B-X
assay	B-X
for	B-X
rapid	B-X
genotyping	B-X
of	B-X
the	B-X
small	B-X
nuclear	B-X
ribonucleoprotein	B-X
polypeptide	B-X
N	B-X
(	B-X
SNRPN	B-X
)	B-X
gene	B-X
methylation	B-X
status	B-X
and	B-X
for	B-X
detecting	B-X
aberrations	B-X
in	B-X
copy	B-X
number	B-X
in	B-X
a	B-X
single	B-X
tube	B-X
.	B-X
A	B-X
single	B-X
pair	B-X
of	B-X
primers	B-X
was	B-X
designed	B-X
to	B-X
create	B-X
a	B-X
357	B-X
bp	B-X
fragment	B-X
containing	B-X
the	B-X
cytosine	B-X
phosphodiester	B-X
guanine	B-X
islands	B-X
in	B-X
the	B-X
SNRPN	B-X
promoter	B-X
and	B-X
to	B-X
amplify	B-X
both	B-X
unmethylated	B-X
and	B-X
methylated	B-X
sequences	B-X
.	B-X
Genotyping	B-X
of	B-X
SNRPN	B-X
was	B-X
performed	B-X
on	B-X
blood	B-X
samples	B-X
of	B-X
20	B-X
individuals	B-X
with	B-X
Prader-Willi	B-X
syndrome	B-X
,	B-X
3	B-X
individuals	B-X
with	B-X
Angelman	B-X
syndrome	B-X
,	B-X
and	B-X
20	B-X
unaffected	B-X
individuals	B-X
.	B-X
The	B-X
promoter	B-X
methylation	B-X
status	B-X
and	B-X
the	B-X
copy	B-X
number	B-X
changes	B-X
were	B-X
successfully	B-X
determined	B-X
and	B-X
compared	B-X
with	B-X
standard	B-X
methylation-specific	B-X
PCR	B-X
,	B-X
and	B-X
were	B-X
validated	B-X
by	B-X
multiplex	B-X
ligation-dependent	B-X
probe	B-X
amplification	B-X
.	B-X
This	B-X
single-tube	B-X
,	B-X
SYBR	B-X
Green	B-X
I	B-X
,	B-X
real-time	B-X
PCR	B-X
with	B-X
melting	B-X
curve	B-X
assay	B-X
is	B-X
rapid	B-X
,	B-X
reliable	B-X
,	B-X
sensitive	B-X
,	B-X
and	B-X
easy	B-X
to	B-X
perform	B-X
.	B-X

(	O
I	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
empty	O
vector	O
,	O
or	O
p3xFLAG	O
-	O
Tat	B-Protein
(	O
10	O
microg	O
)	O
in	O
presence	O
or	O
absence	O
of	O
siRNA	B-Protein
p65	I-Protein
,	O
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
;	O
48	O
h	O
later	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
FLAG	O
antibody	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
efficiency	B-X
of	B-X
a	B-X
targeted	B-X
siRNA	B-X
nano-delivery	B-X
system	B-X
to	B-X
silence	B-X
the	B-X
expression	B-X
of	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
,	B-X
and	B-X
to	B-X
verify	B-X
the	B-X
toxicity	B-X
of	B-X
this	B-X
delivery	B-X
system	B-X
in	B-X
MCF-7	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
most	B-X
effective	B-X
Bmi-1	B-X
siRNA	B-X
and	B-X
hTERT	B-X
siRNA	B-X
sequences	B-X
were	B-X
selected	B-X
using	B-X
RT-PCR	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
The	B-X
polyethyleneimine	B-X
(	B-X
PEI	B-X
)	B-X
/siRNA	B-X
nano-condensate	B-X
was	B-X
synthesized	B-X
using	B-X
PEI	B-X
and	B-X
modified	B-X
using	B-X
an	B-X
NGR	B-X
peptide	B-X
fragment	B-X
for	B-X
targeting	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
The	B-X
vector	B-X
morphology	B-X
,	B-X
particle	B-X
size	B-X
and	B-X
zeta	B-X
potential	B-X
were	B-X
observed	B-X
using	B-X
an	B-X
atomic	B-X
force	B-X
microscope	B-X
and	B-X
a	B-X
laser	B-X
particle	B-X
size	B-X
analyzer	B-X
.	B-X
The	B-X
MCF-7	B-X
breast	B-X
cancer	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
the	B-X
vector	B-X
,	B-X
and	B-X
cytotoxicity	B-X
was	B-X
tested	B-X
by	B-X
MTT	B-X
assays	B-X
.	B-X
The	B-X
transfection	B-X
efficiency	B-X
was	B-X
evaluated	B-X
by	B-X
qRT-PCR	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
Changes	B-X
in	B-X
gene	B-X
expression	B-X
and	B-X
apoptosis	B-X
rate	B-X
were	B-X
measured	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
The	B-X
size	B-X
of	B-X
LPN	B-X
carrier	B-X
and	B-X
the	B-X
condensate	B-X
particle	B-X
was	B-X
between	B-X
100	B-X
and	B-X
200	B-X
nm	B-X
and	B-X
the	B-X
potentials	B-X
were	B-X
close	B-X
to	B-X
neutral	B-X
.	B-X
There	B-X
was	B-X
maximum	B-X
transfection	B-X
efficiency	B-X
and	B-X
no	B-X
significant	B-X
increase	B-X
in	B-X
toxicity	B-X
at	B-X
15	B-X
pmol/L	B-X
.	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
expression	B-X
decreased	B-X
,	B-X
but	B-X
the	B-X
inhibition	B-X
rate	B-X
increased	B-X
in	B-X
the	B-X
hTERT	B-X
siRNA	B-X
group	B-X
,	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
and	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
compared	B-X
with	B-X
the	B-X
scrambled	B-X
siRNA	B-X
group	B-X
and	B-X
the	B-X
control	B-X
group	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
had	B-X
the	B-X
highest	B-X
level	B-X
of	B-X
gene	B-X
silencing	B-X
.	B-X
The	B-X
complex	B-X
,	B-X
composed	B-X
of	B-X
Lipo	B-X
,	B-X
PEI	B-X
and	B-X
siRNA	B-X
,	B-X
is	B-X
low	B-X
toxicity	B-X
and	B-X
efficient	B-X
transfection	B-X
vectors	B-X
.	B-X
The	B-X
expression	B-X
level	B-X
of	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
was	B-X
decreased	B-X
by	B-X
the	B-X
gene	B-X
silencing	B-X
of	B-X
either	B-X
Bmi-1	B-X
or	B-X
hTERT	B-X
,	B-X
but	B-X
the	B-X
effects	B-X
were	B-X
more	B-X
significant	B-X
when	B-X
both	B-X
were	B-X
silenced	B-X
simultaneously	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O
<EOS>	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
applied	B-X
SYBR	B-X
Green	B-X
I-based	B-X
real-time	B-X
PCR	B-X
and	B-X
melting	B-X
curve	B-X
analysis	B-X
assay	B-X
for	B-X
rapid	B-X
genotyping	B-X
of	B-X
the	B-X
small	B-X
nuclear	B-X
ribonucleoprotein	B-X
polypeptide	B-X
N	B-X
(	B-X
SNRPN	B-X
)	B-X
gene	B-X
methylation	B-X
status	B-X
and	B-X
for	B-X
detecting	B-X
aberrations	B-X
in	B-X
copy	B-X
number	B-X
in	B-X
a	B-X
single	B-X
tube	B-X
.	B-X
A	B-X
single	B-X
pair	B-X
of	B-X
primers	B-X
was	B-X
designed	B-X
to	B-X
create	B-X
a	B-X
357	B-X
bp	B-X
fragment	B-X
containing	B-X
the	B-X
cytosine	B-X
phosphodiester	B-X
guanine	B-X
islands	B-X
in	B-X
the	B-X
SNRPN	B-X
promoter	B-X
and	B-X
to	B-X
amplify	B-X
both	B-X
unmethylated	B-X
and	B-X
methylated	B-X
sequences	B-X
.	B-X
Genotyping	B-X
of	B-X
SNRPN	B-X
was	B-X
performed	B-X
on	B-X
blood	B-X
samples	B-X
of	B-X
20	B-X
individuals	B-X
with	B-X
Prader-Willi	B-X
syndrome	B-X
,	B-X
3	B-X
individuals	B-X
with	B-X
Angelman	B-X
syndrome	B-X
,	B-X
and	B-X
20	B-X
unaffected	B-X
individuals	B-X
.	B-X
The	B-X
promoter	B-X
methylation	B-X
status	B-X
and	B-X
the	B-X
copy	B-X
number	B-X
changes	B-X
were	B-X
successfully	B-X
determined	B-X
and	B-X
compared	B-X
with	B-X
standard	B-X
methylation-specific	B-X
PCR	B-X
,	B-X
and	B-X
were	B-X
validated	B-X
by	B-X
multiplex	B-X
ligation-dependent	B-X
probe	B-X
amplification	B-X
.	B-X
This	B-X
single-tube	B-X
,	B-X
SYBR	B-X
Green	B-X
I	B-X
,	B-X
real-time	B-X
PCR	B-X
with	B-X
melting	B-X
curve	B-X
assay	B-X
is	B-X
rapid	B-X
,	B-X
reliable	B-X
,	B-X
sensitive	B-X
,	B-X
and	B-X
easy	B-X
to	B-X
perform	B-X
.	B-X

(	O
J	O
)	O
HeLa	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
transfected	O
with	O
empty	O
vector	O
,	O
p3xFLAG	O
-	O
Tat	B-Protein
(	O
10	O
microg	O
)	O
,	O
or	O
empty	O
vector	O
plus	O
siRNA	B-Protein
IkappaB	I-Protein
-	I-Protein
alpha	I-Protein
or	O
siRNA	O
control	O
(	O
200	O
pmol	O
)	O
;	O
48	O
h	O
later	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
efficiency	B-X
of	B-X
a	B-X
targeted	B-X
siRNA	B-X
nano-delivery	B-X
system	B-X
to	B-X
silence	B-X
the	B-X
expression	B-X
of	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
,	B-X
and	B-X
to	B-X
verify	B-X
the	B-X
toxicity	B-X
of	B-X
this	B-X
delivery	B-X
system	B-X
in	B-X
MCF-7	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
most	B-X
effective	B-X
Bmi-1	B-X
siRNA	B-X
and	B-X
hTERT	B-X
siRNA	B-X
sequences	B-X
were	B-X
selected	B-X
using	B-X
RT-PCR	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
The	B-X
polyethyleneimine	B-X
(	B-X
PEI	B-X
)	B-X
/siRNA	B-X
nano-condensate	B-X
was	B-X
synthesized	B-X
using	B-X
PEI	B-X
and	B-X
modified	B-X
using	B-X
an	B-X
NGR	B-X
peptide	B-X
fragment	B-X
for	B-X
targeting	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
The	B-X
vector	B-X
morphology	B-X
,	B-X
particle	B-X
size	B-X
and	B-X
zeta	B-X
potential	B-X
were	B-X
observed	B-X
using	B-X
an	B-X
atomic	B-X
force	B-X
microscope	B-X
and	B-X
a	B-X
laser	B-X
particle	B-X
size	B-X
analyzer	B-X
.	B-X
The	B-X
MCF-7	B-X
breast	B-X
cancer	B-X
cell	B-X
line	B-X
was	B-X
transfected	B-X
with	B-X
the	B-X
vector	B-X
,	B-X
and	B-X
cytotoxicity	B-X
was	B-X
tested	B-X
by	B-X
MTT	B-X
assays	B-X
.	B-X
The	B-X
transfection	B-X
efficiency	B-X
was	B-X
evaluated	B-X
by	B-X
qRT-PCR	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
Changes	B-X
in	B-X
gene	B-X
expression	B-X
and	B-X
apoptosis	B-X
rate	B-X
were	B-X
measured	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
The	B-X
size	B-X
of	B-X
LPN	B-X
carrier	B-X
and	B-X
the	B-X
condensate	B-X
particle	B-X
was	B-X
between	B-X
100	B-X
and	B-X
200	B-X
nm	B-X
and	B-X
the	B-X
potentials	B-X
were	B-X
close	B-X
to	B-X
neutral	B-X
.	B-X
There	B-X
was	B-X
maximum	B-X
transfection	B-X
efficiency	B-X
and	B-X
no	B-X
significant	B-X
increase	B-X
in	B-X
toxicity	B-X
at	B-X
15	B-X
pmol/L	B-X
.	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
expression	B-X
decreased	B-X
,	B-X
but	B-X
the	B-X
inhibition	B-X
rate	B-X
increased	B-X
in	B-X
the	B-X
hTERT	B-X
siRNA	B-X
group	B-X
,	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
and	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
compared	B-X
with	B-X
the	B-X
scrambled	B-X
siRNA	B-X
group	B-X
and	B-X
the	B-X
control	B-X
group	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
hTERT+Bmi-1	B-X
siRNA	B-X
group	B-X
had	B-X
the	B-X
highest	B-X
level	B-X
of	B-X
gene	B-X
silencing	B-X
.	B-X
The	B-X
complex	B-X
,	B-X
composed	B-X
of	B-X
Lipo	B-X
,	B-X
PEI	B-X
and	B-X
siRNA	B-X
,	B-X
is	B-X
low	B-X
toxicity	B-X
and	B-X
efficient	B-X
transfection	B-X
vectors	B-X
.	B-X
The	B-X
expression	B-X
level	B-X
of	B-X
Bmi-1	B-X
and	B-X
hTERT	B-X
was	B-X
decreased	B-X
by	B-X
the	B-X
gene	B-X
silencing	B-X
of	B-X
either	B-X
Bmi-1	B-X
or	B-X
hTERT	B-X
,	B-X
but	B-X
the	B-X
effects	B-X
were	B-X
more	B-X
significant	B-X
when	B-X
both	B-X
were	B-X
silenced	B-X
simultaneously	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
the	O
indicated	O
promoters	O
.	O
<EOS>	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
applied	B-X
SYBR	B-X
Green	B-X
I-based	B-X
real-time	B-X
PCR	B-X
and	B-X
melting	B-X
curve	B-X
analysis	B-X
assay	B-X
for	B-X
rapid	B-X
genotyping	B-X
of	B-X
the	B-X
small	B-X
nuclear	B-X
ribonucleoprotein	B-X
polypeptide	B-X
N	B-X
(	B-X
SNRPN	B-X
)	B-X
gene	B-X
methylation	B-X
status	B-X
and	B-X
for	B-X
detecting	B-X
aberrations	B-X
in	B-X
copy	B-X
number	B-X
in	B-X
a	B-X
single	B-X
tube	B-X
.	B-X
A	B-X
single	B-X
pair	B-X
of	B-X
primers	B-X
was	B-X
designed	B-X
to	B-X
create	B-X
a	B-X
357	B-X
bp	B-X
fragment	B-X
containing	B-X
the	B-X
cytosine	B-X
phosphodiester	B-X
guanine	B-X
islands	B-X
in	B-X
the	B-X
SNRPN	B-X
promoter	B-X
and	B-X
to	B-X
amplify	B-X
both	B-X
unmethylated	B-X
and	B-X
methylated	B-X
sequences	B-X
.	B-X
Genotyping	B-X
of	B-X
SNRPN	B-X
was	B-X
performed	B-X
on	B-X
blood	B-X
samples	B-X
of	B-X
20	B-X
individuals	B-X
with	B-X
Prader-Willi	B-X
syndrome	B-X
,	B-X
3	B-X
individuals	B-X
with	B-X
Angelman	B-X
syndrome	B-X
,	B-X
and	B-X
20	B-X
unaffected	B-X
individuals	B-X
.	B-X
The	B-X
promoter	B-X
methylation	B-X
status	B-X
and	B-X
the	B-X
copy	B-X
number	B-X
changes	B-X
were	B-X
successfully	B-X
determined	B-X
and	B-X
compared	B-X
with	B-X
standard	B-X
methylation-specific	B-X
PCR	B-X
,	B-X
and	B-X
were	B-X
validated	B-X
by	B-X
multiplex	B-X
ligation-dependent	B-X
probe	B-X
amplification	B-X
.	B-X
This	B-X
single-tube	B-X
,	B-X
SYBR	B-X
Green	B-X
I	B-X
,	B-X
real-time	B-X
PCR	B-X
with	B-X
melting	B-X
curve	B-X
assay	B-X
is	B-X
rapid	B-X
,	B-X
reliable	B-X
,	B-X
sensitive	B-X
,	B-X
and	B-X
easy	B-X
to	B-X
perform	B-X
.	B-X

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

The	O
asterisks	O
indicate	O
statistically	O
significant	O
differences	O
compared	O
to	O
the	O
control	O
(	O
empty	O
vector	O
)	O
according	O
to	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
HIV	O
-	O
1	O
infection	O
Tat	B-Protein
sustains	O
the	O
NF	O
-	O
kappaB	O
activity	O
and	O
enhances	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
via	O
interaction	O
with	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
p65	B-Protein
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
and	B-X
is	B-X
upregulated	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
NF-κB	B-X
deregulation	B-X
by	B-X
HIV-1	B-X
are	B-X
relevant	B-X
for	B-X
immune	B-X
dysfunction	B-X
in	B-X
AIDS	B-X
.	B-X
We	B-X
report	B-X
that	B-X
in	B-X
single	B-X
round	B-X
HIV-1	B-X
infection	B-X
,	B-X
or	B-X
single-pulse	B-X
PMA	B-X
stimulation	B-X
,	B-X
the	B-X
HIV-1	B-X
Tat	B-X
transactivator	B-X
activated	B-X
NF-κB	B-X
by	B-X
hijacking	B-X
the	B-X
inhibitor	B-X
IκB-α	B-X
and	B-X
by	B-X
preventing	B-X
the	B-X
repressor	B-X
binding	B-X
to	B-X
the	B-X
NF-κB	B-X
complex	B-X
.	B-X
Moreover	B-X
,	B-X
Tat	B-X
associated	B-X
with	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
and	B-X
increased	B-X
the	B-X
p65	B-X
DNA-binding	B-X
affinity	B-X
and	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
arginine-	B-X
and	B-X
cysteine-rich	B-X
domains	B-X
of	B-X
Tat	B-X
were	B-X
required	B-X
for	B-X
IκB-α	B-X
and	B-X
p65	B-X
association	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
for	B-X
sustaining	B-X
the	B-X
NF-κB	B-X
activity	B-X
.	B-X
Among	B-X
an	B-X
array	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
,	B-X
Tat	B-X
mostly	B-X
activated	B-X
the	B-X
MIP-1α	B-X
expression	B-X
in	B-X
a	B-X
p65-dependent	B-X
manner	B-X
,	B-X
and	B-X
bound	B-X
to	B-X
the	B-X
MIP-1α	B-X
NF-κB	B-X
enhancer	B-X
thus	B-X
promoting	B-X
the	B-X
recruitment	B-X
of	B-X
p65	B-X
with	B-X
displacement	B-X
of	B-X
IκB-α	B-X
;	B-X
similar	B-X
findings	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
NF-κB-responsive	B-X
genes	B-X
CSF3	B-X
,	B-X
LTA	B-X
,	B-X
NFKBIA	B-X
and	B-X
TLR2	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
activation	B-X
via	B-X
physical	B-X
interaction	B-X
of	B-X
Tat	B-X
with	B-X
IκB-α	B-X
and	B-X
p65	B-X
,	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
deregulation	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
HIV-1	B-X
.	B-X

U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
,	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
.	O
R	O
-	O
E	O
-	O
virions	O
(	O
500	O
ng	O
of	O
p24	B-Protein
)	O
and	O
harvested	O
at	O
the	O
indicated	O
time	O
.	O
<EOS>	B-X
Choriocarcinoma	B-X
is	B-X
a	B-X
highly	B-X
invasive	B-X
gynaecologic	B-X
malignancy	B-X
.	B-X
Molecular	B-X
mechanism	B-X
of	B-X
metastasis	B-X
in	B-X
choriocarcinoma	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Migration	B-X
and	B-X
invasion	B-X
inhibitory	B-X
protein	B-X
(	B-X
MIIP	B-X
)	B-X
regulates	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
function	B-X
of	B-X
MIIP	B-X
in	B-X
choriocarcinoma	B-X
.	B-X

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
of	O
total	O
RNA	O
measured	O
the	O
Tat	B-Protein
expression	O
;	O
ELISA	O
measured	O
the	O
amount	O
of	O
p24	B-Protein
in	O
whole	O
cell	O
extracts	O
.	O
<EOS>	B-X
Unrepaired	B-X
mtDNA	B-X
impairs	B-X
mitochondrial	B-X
function	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
oxidative	B-X
stress	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
We	B-X
found	B-X
age-dependent	B-X
expression	B-X
of	B-X
HIV-1	B-X
viral	B-X
proteins	B-X
in	B-X
the	B-X
HIV-1	B-X
transgenic	B-X
(	B-X
HIV-1Tg	B-X
)	B-X
rat	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
also	B-X
showed	B-X
that	B-X
L-OA	B-X
osteoblasts	B-X
express	B-X
higher	B-X
levels	B-X
of	B-X
total	B-X
RANKL	B-X
compared	B-X
to	B-X
H-OA	B-X
osteoblasts	B-X
.	B-X

(	O
B	O
)	O
The	O
binding	O
of	O
p65	B-Protein
to	O
the	O
NF	O
-	O
kappaB	O
double	O
-	O
stranded	O
oligonucleotide	O
was	O
measured	O
in	O
nuclear	O
extracts	O
(	O
10	O
microg	O
)	O
using	O
the	O
NF	O
-	O
kappaB	O
Transcription	O
Factor	O
ELISA	O
assay	O
kit	O
(	O
Cayman	O
)	O
.	O

(	O
C	O
)	O
The	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
content	O
was	O
analysed	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
of	O
cytosolic	O
extracts	O
(	O
20	O
microg	O
)	O
using	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibody	O
.	O

Densitometry	O
values	O
(	O
D	O
)	O
of	O
the	O
bands	O
were	O
expressed	O
as	O
fold	O
increase	O
above	O
the	O
control	O
(	O
mock	O
)	O
.	O

(	O
D	O
)	O
IKK	O
activity	O
was	O
measured	O
in	O
cytosolic	O
cell	O
extracts	O
(	O
100	O
microg	O
)	O
using	O
HTScan	O
IKK	O
Kinase	O
Assay	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O

(	O
E	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O
<EOS>	B-X
People	B-X
with	B-X
diabetes	B-X
are	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
developing	B-X
foot	B-X
ulcers	B-X
,	B-X
which	B-X
often	B-X
become	B-X
infected	B-X
.	B-X
These	B-X
wounds	B-X
,	B-X
especially	B-X
when	B-X
infected	B-X
,	B-X
cause	B-X
substantial	B-X
morbidity	B-X
.	B-X
Wound	B-X
treatments	B-X
should	B-X
aim	B-X
to	B-X
alleviate	B-X
symptoms	B-X
,	B-X
promote	B-X
healing	B-X
,	B-X
and	B-X
avoid	B-X
adverse	B-X
outcomes	B-X
,	B-X
especially	B-X
lower	B-X
extremity	B-X
amputation	B-X
.	B-X
Topical	B-X
antimicrobial	B-X
therapy	B-X
has	B-X
been	B-X
used	B-X
on	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
,	B-X
either	B-X
as	B-X
a	B-X
treatment	B-X
for	B-X
clinically	B-X
infected	B-X
wounds	B-X
,	B-X
or	B-X
to	B-X
prevent	B-X
infection	B-X
in	B-X
clinically	B-X
uninfected	B-X
wounds	B-X
.	B-X

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
cell	O
extracts	O
(	O
1	O
mg	O
)	O
were	O
immunoprecipitated	O
with	O
protein	B-Protein
G	I-Protein
-	O
Sepharose	O
-	O
coupled	O
anti	O
-	O
FLAG	O
antibody	O
.	O

Immunocomplexes	O
were	O
separated	O
by	O
12	O
%	O
SDS	O
-	O
PAGE	O
and	O
analysed	O
by	O
western	O
blotting	O
with	O
anti	O
-	O
p65	O
,	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
IkappaB	O
-	O
alpha	O
antibodies	O
.	O

(	O
F	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
,	O
siRNA	B-Protein
p65	I-Protein
,	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O
<EOS>	B-X
Choriocarcinoma	B-X
is	B-X
a	B-X
highly	B-X
invasive	B-X
gynaecologic	B-X
malignancy	B-X
.	B-X
Molecular	B-X
mechanism	B-X
of	B-X
metastasis	B-X
in	B-X
choriocarcinoma	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Migration	B-X
and	B-X
invasion	B-X
inhibitory	B-X
protein	B-X
(	B-X
MIIP	B-X
)	B-X
regulates	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
function	B-X
of	B-X
MIIP	B-X
in	B-X
choriocarcinoma	B-X
.	B-X

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
total	O
RNA	O
was	O
analysed	O
for	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
by	O
real	O
-	O
time	O
PCR	O
.	O

(	O
G	O
and	O
H	O
)	O
U937	O
cells	O
(	O
5	O
x	O
107	O
)	O
were	O
transfected	O
with	O
siRNA	B-Protein
Tat	I-Protein
or	O
siRNA	O
control	O
(	O
2	O
nmol	O
)	O
,	O
or	O
left	O
untransfected	O
;	O
24	O
h	O
later	O
,	O
cells	O
were	O
infected	O
with	O
HXB2	O
-	O
pseudotyped	O
NL4	O
-	O
3	O
.	O
FLAG	B-Protein
-	I-Protein
Tat	I-Protein
.	O
R	O
-	O
E	O
-	O
virions	O
,	O
or	O
left	O
uninfected	O
.	O
<EOS>	B-X
Choriocarcinoma	B-X
is	B-X
a	B-X
highly	B-X
invasive	B-X
gynaecologic	B-X
malignancy	B-X
.	B-X
Molecular	B-X
mechanism	B-X
of	B-X
metastasis	B-X
in	B-X
choriocarcinoma	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Migration	B-X
and	B-X
invasion	B-X
inhibitory	B-X
protein	B-X
(	B-X
MIIP	B-X
)	B-X
regulates	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
function	B-X
of	B-X
MIIP	B-X
in	B-X
choriocarcinoma	B-X
.	B-X

Twenty	O
-	O
four	O
-	O
hour	O
post	O
-	O
infection	O
,	O
ChIP	O
was	O
performed	O
with	O
anti	O
-	O
p65	O
(	O
G	O
)	O
or	O
anti	O
-	O
FLAG	O
(	O
H	O
)	O
.	O
<EOS>	B-X
Grouper	B-X
iridovirus	B-X
(	B-X
GIV	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
genus	B-X
Ranavirus	B-X
of	B-X
the	B-X
family	B-X
Iridoviridae	B-X
;	B-X
the	B-X
genomes	B-X
of	B-X
such	B-X
viruses	B-X
contain	B-X
an	B-X
anti-apoptotic	B-X
caspase	B-X
recruitment	B-X
domain	B-X
(	B-X
CARD	B-X
)	B-X
gene	B-X
.	B-X
The	B-X
GIV-CARD	B-X
gene	B-X
encodes	B-X
a	B-X
protein	B-X
of	B-X
91	B-X
amino	B-X
acids	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
10,505	B-X
Daltons	B-X
,	B-X
and	B-X
shows	B-X
high	B-X
similarity	B-X
to	B-X
other	B-X
viral	B-X
CARD	B-X
genes	B-X
and	B-X
human	B-X
ICEBERG	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
Northern	B-X
blot	B-X
to	B-X
demonstrate	B-X
that	B-X
GIV-CARD	B-X
transcription	B-X
begins	B-X
at	B-X
4	B-X
h	B-X
post-infection	B-X
;	B-X
furthermore	B-X
,	B-X
we	B-X
report	B-X
that	B-X
its	B-X
transcription	B-X
is	B-X
completely	B-X
inhibited	B-X
by	B-X
cycloheximide	B-X
but	B-X
not	B-X
by	B-X
aphidicolin	B-X
,	B-X
indicating	B-X
that	B-X
GIV-CARD	B-X
is	B-X
an	B-X
early	B-X
gene	B-X
.	B-X
GIV-CARD-EGFP	B-X
and	B-X
GIV-CARD-FLAG	B-X
recombinant	B-X
proteins	B-X
were	B-X
observed	B-X
to	B-X
translocate	B-X
from	B-X
the	B-X
cytoplasm	B-X
into	B-X
the	B-X
nucleus	B-X
,	B-X
but	B-X
no	B-X
obvious	B-X
nuclear	B-X
localization	B-X
sequence	B-X
was	B-X
observed	B-X
within	B-X
GIV-CARD	B-X
.	B-X
RNA	B-X
interference-mediated	B-X
knockdown	B-X
of	B-X
GIV-CARD	B-X
in	B-X
GK	B-X
cells	B-X
infected	B-X
with	B-X
GIV	B-X
inhibited	B-X
expression	B-X
of	B-X
GIV-CARD	B-X
and	B-X
five	B-X
other	B-X
viral	B-X
genes	B-X
during	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
infection	B-X
,	B-X
and	B-X
also	B-X
reduced	B-X
GIV	B-X
infection	B-X
ability	B-X
.	B-X
Immunostaining	B-X
was	B-X
performed	B-X
to	B-X
show	B-X
that	B-X
apoptosis	B-X
was	B-X
effectively	B-X
inhibited	B-X
in	B-X
cells	B-X
expressing	B-X
GIV-CARD	B-X
.	B-X
HeLa	B-X
cells	B-X
irradiated	B-X
with	B-X
UV	B-X
or	B-X
treated	B-X
with	B-X
anti-Fas	B-X
antibody	B-X
will	B-X
undergo	B-X
apoptosis	B-X
through	B-X
the	B-X
intrinsic	B-X
and	B-X
extrinsic	B-X
pathways	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
over-expression	B-X
of	B-X
recombinant	B-X
GIV-CARD	B-X
protein	B-X
in	B-X
HeLa	B-X
cells	B-X
inhibited	B-X
apoptosis	B-X
induced	B-X
by	B-X
mitochondrial	B-X
and	B-X
death	B-X
receptor	B-X
signaling	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
report	B-X
that	B-X
expression	B-X
of	B-X
GIV-CARD	B-X
in	B-X
HeLa	B-X
cells	B-X
significantly	B-X
reduced	B-X
the	B-X
activities	B-X
of	B-X
caspase-8	B-X
and	B-X
-9	B-X
following	B-X
apoptosis	B-X
triggered	B-X
by	B-X
anti-Fas	B-X
antibody	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
GIV-CARD	B-X
inhibits	B-X
apoptosis	B-X
through	B-X
both	B-X
intrinsic	B-X
and	B-X
extrinsic	B-X
pathways	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
primers	O
specific	O
for	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
GAPDH	B-Protein
promoters	O
.	O

Values	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
n	O
=	O
3	O
)	O
are	O
shown	O
.	O

The	O
asterisks	O
indicate	O
statistically	O
significant	O
differences	O
compared	O
to	O
the	O
control	O
(	O
mock	O
)	O
,	O
according	O
to	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Model	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
transcriptional	O
activation	O
by	O
HIV	O
-	O
1	O
Tat	B-Protein
.	O
<EOS>	B-X
HIV-1	B-X
Tat	B-X
has	B-X
been	B-X
proposed	B-X
as	B-X
a	B-X
key	B-X
agent	B-X
in	B-X
many	B-X
AIDS-related	B-X
disorders	B-X
,	B-X
including	B-X
HIV-1-associated	B-X
neurological	B-X
diseases	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
Tat	B-X
expression	B-X
induces	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
T	B-X
lymphocytes	B-X
in	B-X
the	B-X
brains	B-X
of	B-X
Tat	B-X
transgenic	B-X
mice	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
using	B-X
this	B-X
unique	B-X
genetic	B-X
system	B-X
we	B-X
attempted	B-X
to	B-X
understand	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
Tat	B-X
expression-induced	B-X
infiltration	B-X
of	B-X
T	B-X
lymphocytes	B-X
by	B-X
examining	B-X
chemokine	B-X
expression	B-X
.	B-X
RNase	B-X
protection	B-X
assay	B-X
revealed	B-X
that	B-X
in	B-X
addition	B-X
to	B-X
CCL2	B-X
(	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
)	B-X
,	B-X
CCL3	B-X
(	B-X
macrophage	B-X
inflammatory	B-X
protein-1alpha	B-X
(	B-X
MIP-1alpha	B-X
)	B-X
)	B-X
,	B-X
CCL4	B-X
(	B-X
MIP-1beta	B-X
)	B-X
,	B-X
CCL5	B-X
(	B-X
RANTES	B-X
)	B-X
,	B-X
CXCL2	B-X
(	B-X
MIP-2	B-X
)	B-X
,	B-X
and	B-X
CXCL10	B-X
(	B-X
inducing	B-X
protein-10	B-X
)	B-X
,	B-X
XCL1	B-X
(	B-X
lymphotactin/single	B-X
C	B-X
motif-1alpha/activation-induced	B-X
,	B-X
T	B-X
cell-derived	B-X
and	B-X
chemokine-related	B-X
cytokine	B-X
)	B-X
was	B-X
identified	B-X
to	B-X
be	B-X
up-regulated	B-X
by	B-X
Tat	B-X
expression	B-X
.	B-X
XCL1	B-X
is	B-X
a	B-X
C	B-X
chemokine	B-X
and	B-X
plays	B-X
a	B-X
specific	B-X
and	B-X
important	B-X
role	B-X
in	B-X
tissue-specific	B-X
recruitment	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
further	B-X
determined	B-X
the	B-X
relationship	B-X
between	B-X
Tat	B-X
and	B-X
XCL1	B-X
expression	B-X
.	B-X
Tat-induced	B-X
XCL1	B-X
expression	B-X
was	B-X
further	B-X
confirmed	B-X
by	B-X
XCL1-specific	B-X
RT-PCR	B-X
and	B-X
ELISA	B-X
.	B-X
Combined	B-X
in	B-X
situ	B-X
hybridization	B-X
and	B-X
immunohistochemical	B-X
staining	B-X
identified	B-X
astrocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
macrophages/microglia	B-X
as	B-X
XCL1-producing	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
Using	B-X
human	B-X
astrocytes	B-X
,	B-X
U87.MG	B-X
cells	B-X
,	B-X
as	B-X
an	B-X
in	B-X
vitro	B-X
model	B-X
,	B-X
activation	B-X
of	B-X
XCL1	B-X
expression	B-X
was	B-X
positively	B-X
correlated	B-X
with	B-X
Tat	B-X
expression	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
XCL1	B-X
promoter-driven	B-X
reporter	B-X
gene	B-X
assay	B-X
showed	B-X
that	B-X
Tat-induced	B-X
XCL1	B-X
expression	B-X
occurred	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
Tat	B-X
directly	B-X
trans-activated	B-X
XCL1	B-X
expression	B-X
and	B-X
suggest	B-X
potential	B-X
roles	B-X
of	B-X
Tat-induced	B-X
XCL1	B-X
expression	B-X
in	B-X
the	B-X
CNS	B-X
infiltration	B-X
of	B-X
T	B-X
lymphocytes	B-X
during	B-X
HIV-1	B-X
infection	B-X
and	B-X
subsequent	B-X
HIV-1-induced	B-X
neurological	B-X
diseases	B-X
.	B-X

(	O
A	O
)	O
In	O
absence	O
of	O
Tat	B-Protein
,	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
occupies	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
of	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
promoter	O
and	O
likely	O
interacts	O
with	O
transcriptional	O
repressors	O
,	O
such	O
as	O
HDACs	O
(	O
65	O
)	O
,	O
to	O
inhibit	O
gene	O
transcription	O
.	O

(	O
B	O
)	O
Tat	B-Protein
activates	O
the	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
expression	O
by	O
removing	O
the	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
repressor	O
from	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
,	O
and	O
by	O
increasing	O
the	O
binding	O
of	O
p65	O
NF	O
-	O
kappaB	O
complex	O
to	O
the	O
NF	O
-	O
kappaB	O
enhancer	O
.	O

Inflammasome	O
-	O
Mediated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
Production	O
in	O
Humans	O
with	O
Cystic	O
Fibrosis	O
<EOS>	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Inflammation	O
and	O
infection	O
are	O
major	O
determinants	O
of	O
disease	O
severity	O
and	O
consequently	O
,	O
the	O
quality	O
of	O
life	O
and	O
outcome	O
for	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

Interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
is	O
a	O
key	O
inflammatory	O
mediator	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
IL-1β	B-X
release	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
elusive	B-X
.	B-X
Here	B-X
we	B-X
summarise	B-X
these	B-X
observations	B-X
and	B-X
propose	B-X
that	B-X
secretion	B-X
of	B-X
IL-1β	B-X
occurs	B-X
on	B-X
a	B-X
continuum	B-X
,	B-X
dependent	B-X
upon	B-X
stimulus	B-X
strength	B-X
and	B-X
the	B-X
extracellular	B-X
IL-1β	B-X
requirement	B-X
.	B-X
Therefore	B-X
,	B-X
therapeutic	B-X
targeting	B-X
of	B-X
inflammatory	B-X
pathways	B-X
is	B-X
suggested	B-X
to	B-X
improve	B-X
cardiovascular	B-X
outcomes	B-X
in	B-X
patients	B-X
with	B-X
cardiovascular	B-X
diseases	B-X
.	B-X
This	B-X
concept	B-X
was	B-X
recently	B-X
proven	B-X
by	B-X
CANTOS	B-X
(	B-X
Canakinumab	B-X
Anti-Inflammatory	B-X
Thrombosis	B-X
Outcomes	B-X
Study	B-X
)	B-X
,	B-X
which	B-X
demonstrated	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
the	B-X
monoclonal	B-X
IL	B-X
(	B-X
interleukin	B-X
)	B-X
-1β-neutralizing	B-X
antibody	B-X
canakinumab	B-X
.	B-X
IL-1β	B-X
and	B-X
other	B-X
IL-1	B-X
family	B-X
cytokines	B-X
are	B-X
important	B-X
vascular	B-X
and	B-X
systemic	B-X
inflammatory	B-X
mediators	B-X
,	B-X
which	B-X
contribute	B-X
to	B-X
atherogenesis	B-X
.	B-X
The	B-X
NLRP3	B-X
(	B-X
NOD	B-X
[	B-X
nucleotide	B-X
oligomerization	B-X
domain	B-X
]	B-X
-	B-X
,	B-X
LRR	B-X
[	B-X
leucine-rich	B-X
repeat	B-X
]	B-X
-	B-X
,	B-X
and	B-X
PYD	B-X
[	B-X
pyrin	B-X
domain	B-X
]	B-X
-containing	B-X
protein	B-X
3	B-X
)	B-X
inflammasome	B-X
,	B-X
an	B-X
innate	B-X
immune	B-X
signaling	B-X
complex	B-X
,	B-X
is	B-X
the	B-X
key	B-X
mediator	B-X
of	B-X
IL-1	B-X
family	B-X
cytokine	B-X
production	B-X
in	B-X
atherosclerosis	B-X
.	B-X
Consequently	B-X
,	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
contributes	B-X
to	B-X
the	B-X
vascular	B-X
inflammatory	B-X
response	B-X
driving	B-X
atherosclerosis	B-X
development	B-X
and	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
mechanisms	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
and	B-X
proinflammatory	B-X
IL-1	B-X
family	B-X
cytokine	B-X
production	B-X
in	B-X
the	B-X
context	B-X
of	B-X
atherosclerosis	B-X
and	B-X
discuss	B-X
treatment	B-X
possibilities	B-X
in	B-X
light	B-X
of	B-X
the	B-X
positive	B-X
outcomes	B-X
of	B-X
the	B-X
CANTOS	B-X
trial	B-X
.	B-X

Secretion	O
of	O
biologically	O
active	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
involves	O
inflammasome	O
-	O
mediated	O
processing	O
.	O
<EOS>	B-X
Once	B-X
activated	B-X
,	B-X
it	B-X
orchestrates	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
secreting	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
interleukin-1	B-X
(	B-X
IL-1	B-X
)	B-X
-type	B-X
cytokines	B-X
,	B-X
in	B-X
particular	B-X
IL-1beta	B-X
.	B-X
IL-1	B-X
mediates	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
vast	B-X
array	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
secondary	B-X
inflammation	B-X
.	B-X
IL-1-responsive	B-X
genes	B-X
coordinate	B-X
all	B-X
aspects	B-X
of	B-X
local	B-X
inflammation	B-X
and	B-X
also	B-X
attract	B-X
and	B-X
activate	B-X
cells	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
at	B-X
sites	B-X
of	B-X
infection	B-X
.	B-X
These	B-X
signals	B-X
activate	B-X
the	B-X
NALP3-inflammasome	B-X
pathway	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
acute	B-X
and	B-X
chronic	B-X
sterile	B-X
inflammation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
essential	B-X
components	B-X
of	B-X
the	B-X
NALP3-inflammasome	B-X
that	B-X
control	B-X
processing	B-X
and	B-X
release	B-X
of	B-X
IL-1beta	B-X
.	B-X

Little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
the	O
inflammasomes	O
in	O
CF	O
inflammatory	O
disease	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

This	O
study	O
examines	O
inflammasome	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
CF	O
bronchial	O
epithelial	O
cell	O
lines	O
and	O
human	O
patients	O
with	O
CF	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

Results	O

Bronchial	O
epithelial	O
cell	O
lines	O
were	O
found	O
to	O
produce	O
negligible	O
amounts	O
of	O
basal	O
or	O
stimulated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
compared	O
to	O
hematopoeitic	O
cells	O
and	O
they	O
did	O
not	O
significantly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O
.	O

In	O
contrast	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
both	O
CF	O
and	O
healthy	O
control	O
subjects	O
produced	O
large	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
strongly	O
upregulated	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
displayed	O
similar	O
levels	O
of	O
caspase	O
-	O
1	O
activation	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
when	O
stimulated	O
with	O
inflammasome	O
activators	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

This	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
was	O
dependent	O
on	O
NF	O
-	O
kappaB	O
activity	O
and	O
could	O
be	O
enhanced	O
by	O
priming	O
with	O
LPS	O
.	O
<EOS>	B-X
Gouty	B-X
arthritis	B-X
could	B-X
be	B-X
triggered	B-X
by	B-X
the	B-X
deposition	B-X
of	B-X
monosodium	B-X
uric	B-X
acid	B-X
(	B-X
MSU	B-X
)	B-X
crystals	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
PAL	B-X
on	B-X
LPS	B-X
plus	B-X
MSU	B-X
crystal-stimulated	B-X
gouty	B-X
arthritis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

Finally	O
,	O
chemical	O
inhibition	O
of	O
CFTR	O
activity	O
in	O
control	O
PBMCs	O
and	O
THP	O
-	O
1	O
cells	O
did	O
not	O
significantly	O
alter	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
or	O
IL	O
-	O
8	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O
<EOS>	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

Hematopoeitic	O
cells	O
appear	O
to	O
be	O
the	O
predominant	O
source	O
of	O
inflammasome	O
-	O
induced	O
pro	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
CF	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

PBMCs	O
derived	O
from	O
CF	O
subjects	O
display	O
preserved	O
inflammasome	O
activation	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
in	O
response	O
to	O
the	O
major	O
CF	O
pathogen	O
Pseudomonas	O
aeruginosa	O
.	O

However	O
,	O
our	O
data	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
increased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
CF	O
subjects	O
is	O
due	O
to	O
an	O
intrinsic	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
through	O
loss	O
of	O
CFTR	O
function	O
.	O
<EOS>	B-X
Designing	B-X
,	B-X
conducting	B-X
,	B-X
analyzing	B-X
,	B-X
reporting	B-X
,	B-X
and	B-X
interpreting	B-X
the	B-X
findings	B-X
of	B-X
a	B-X
research	B-X
study	B-X
require	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
types	B-X
and	B-X
characteristics	B-X
of	B-X
data	B-X
and	B-X
variables	B-X
.	B-X
Descriptive	B-X
statistics	B-X
are	B-X
typically	B-X
used	B-X
simply	B-X
to	B-X
calculate	B-X
,	B-X
describe	B-X
,	B-X
and	B-X
summarize	B-X
the	B-X
collected	B-X
research	B-X
data	B-X
in	B-X
a	B-X
logical	B-X
,	B-X
meaningful	B-X
,	B-X
and	B-X
efficient	B-X
way	B-X
.	B-X
Inferential	B-X
statistics	B-X
allow	B-X
researchers	B-X
to	B-X
make	B-X
a	B-X
valid	B-X
estimate	B-X
of	B-X
the	B-X
association	B-X
between	B-X
an	B-X
intervention	B-X
and	B-X
the	B-X
treatment	B-X
effect	B-X
in	B-X
a	B-X
specific	B-X
population	B-X
,	B-X
based	B-X
upon	B-X
their	B-X
randomly	B-X
collected	B-X
,	B-X
representative	B-X
sample	B-X
data	B-X
.	B-X
Categorical	B-X
data	B-X
can	B-X
be	B-X
either	B-X
dichotomous	B-X
or	B-X
polytomous	B-X
.	B-X
Dichotomous	B-X
data	B-X
have	B-X
only	B-X
2	B-X
categories	B-X
,	B-X
and	B-X
thus	B-X
are	B-X
considered	B-X
binary	B-X
.	B-X
Polytomous	B-X
data	B-X
have	B-X
more	B-X
than	B-X
2	B-X
categories	B-X
.	B-X
Unlike	B-X
dichotomous	B-X
and	B-X
polytomous	B-X
data	B-X
,	B-X
ordinal	B-X
data	B-X
are	B-X
rank	B-X
ordered	B-X
,	B-X
typically	B-X
based	B-X
on	B-X
a	B-X
numerical	B-X
scale	B-X
that	B-X
is	B-X
comprised	B-X
of	B-X
a	B-X
small	B-X
set	B-X
of	B-X
discrete	B-X
classes	B-X
or	B-X
integers	B-X
.	B-X
Continuous	B-X
data	B-X
are	B-X
measured	B-X
on	B-X
a	B-X
continuum	B-X
and	B-X
can	B-X
have	B-X
any	B-X
numeric	B-X
value	B-X
over	B-X
this	B-X
continuous	B-X
range	B-X
.	B-X
Continuous	B-X
data	B-X
can	B-X
be	B-X
meaningfully	B-X
divided	B-X
into	B-X
smaller	B-X
and	B-X
smaller	B-X
or	B-X
finer	B-X
and	B-X
finer	B-X
increments	B-X
,	B-X
depending	B-X
upon	B-X
the	B-X
precision	B-X
of	B-X
the	B-X
measurement	B-X
instrument	B-X
.	B-X
Interval	B-X
data	B-X
are	B-X
a	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
in	B-X
which	B-X
equal	B-X
intervals	B-X
represent	B-X
equal	B-X
differences	B-X
in	B-X
the	B-X
property	B-X
being	B-X
measured	B-X
.	B-X
Ratio	B-X
data	B-X
are	B-X
another	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
,	B-X
which	B-X
have	B-X
the	B-X
same	B-X
properties	B-X
as	B-X
interval	B-X
data	B-X
,	B-X
plus	B-X
a	B-X
true	B-X
definition	B-X
of	B-X
an	B-X
absolute	B-X
zero	B-X
point	B-X
,	B-X
and	B-X
the	B-X
ratios	B-X
of	B-X
the	B-X
values	B-X
on	B-X
the	B-X
measurement	B-X
scale	B-X
make	B-X
sense	B-X
.	B-X
Many	B-X
applied	B-X
inferential	B-X
statistical	B-X
tests	B-X
are	B-X
predicated	B-X
on	B-X
the	B-X
assumption	B-X
that	B-X
the	B-X
analyzed	B-X
data	B-X
follow	B-X
a	B-X
normal	B-X
distribution	B-X
.	B-X
The	B-X
histogram	B-X
and	B-X
the	B-X
Q-Q	B-X
plot	B-X
are	B-X
2	B-X
graphical	B-X
methods	B-X
to	B-X
assess	B-X
if	B-X
a	B-X
set	B-X
of	B-X
data	B-X
have	B-X
a	B-X
normal	B-X
distribution	B-X
(	B-X
display	B-X
``	B-X
normality	B-X
''	B-X
)	B-X
.	B-X
The	B-X
Shapiro-Wilk	B-X
test	B-X
and	B-X
the	B-X
Kolmogorov-Smirnov	B-X
test	B-X
are	B-X
2	B-X
well-known	B-X
and	B-X
historically	B-X
widely	B-X
applied	B-X
quantitative	B-X
methods	B-X
to	B-X
assess	B-X
for	B-X
data	B-X
normality	B-X
.	B-X
If	B-X
the	B-X
normality	B-X
test	B-X
concludes	B-X
that	B-X
the	B-X
study	B-X
data	B-X
deviate	B-X
significantly	B-X
from	B-X
a	B-X
Gaussian	B-X
distribution	B-X
,	B-X
rather	B-X
than	B-X
applying	B-X
a	B-X
less	B-X
robust	B-X
nonparametric	B-X
test	B-X
,	B-X
the	B-X
problem	B-X
can	B-X
potentially	B-X
be	B-X
remedied	B-X
by	B-X
judiciously	B-X
and	B-X
openly	B-X
:	B-X
(	B-X
1	B-X
)	B-X
performing	B-X
a	B-X
data	B-X
transformation	B-X
of	B-X
all	B-X
the	B-X
data	B-X
values	B-X
;	B-X
or	B-X
(	B-X
2	B-X
)	B-X
eliminating	B-X
any	B-X
obvious	B-X
data	B-X
outlier	B-X
(	B-X
s	B-X
)	B-X
.	B-X

Cystic	O
fibrosis	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
)	O
,	O
which	O
functions	O
as	O
a	O
chloride	O
ion	O
channel	O
.	O
<EOS>	B-X
Cystic	B-X
fibrosis	B-X
is	B-X
a	B-X
common	B-X
life-limiting	B-X
autosomal	B-X
recessive	B-X
genetic	B-X
disorder	B-X
,	B-X
with	B-X
highest	B-X
prevalence	B-X
in	B-X
Europe	B-X
,	B-X
North	B-X
America	B-X
,	B-X
and	B-X
Australia	B-X
.	B-X
The	B-X
disease	B-X
is	B-X
caused	B-X
by	B-X
mutation	B-X
of	B-X
a	B-X
gene	B-X
that	B-X
encodes	B-X
a	B-X
chloride-conducting	B-X
transmembrane	B-X
channel	B-X
called	B-X
the	B-X
cystic	B-X
fibrosis	B-X
transmembrane	B-X
conductance	B-X
regulator	B-X
(	B-X
CFTR	B-X
)	B-X
,	B-X
which	B-X
regulates	B-X
anion	B-X
transport	B-X
and	B-X
mucociliary	B-X
clearance	B-X
in	B-X
the	B-X
airways	B-X
.	B-X
Functional	B-X
failure	B-X
of	B-X
CFTR	B-X
results	B-X
in	B-X
mucus	B-X
retention	B-X
and	B-X
chronic	B-X
infection	B-X
and	B-X
subsequently	B-X
in	B-X
local	B-X
airway	B-X
inflammation	B-X
that	B-X
is	B-X
harmful	B-X
to	B-X
the	B-X
lungs	B-X
.	B-X
CFTR	B-X
dysfunction	B-X
mainly	B-X
affects	B-X
epithelial	B-X
cells	B-X
,	B-X
although	B-X
there	B-X
is	B-X
evidence	B-X
of	B-X
a	B-X
role	B-X
in	B-X
immune	B-X
cells	B-X
.	B-X
Cystic	B-X
fibrosis	B-X
affects	B-X
several	B-X
body	B-X
systems	B-X
,	B-X
and	B-X
morbidity	B-X
and	B-X
mortality	B-X
is	B-X
mostly	B-X
caused	B-X
by	B-X
bronchiectasis	B-X
,	B-X
small	B-X
airways	B-X
obstruction	B-X
,	B-X
and	B-X
progressive	B-X
respiratory	B-X
impairment	B-X
.	B-X
Important	B-X
comorbidities	B-X
caused	B-X
by	B-X
epithelial	B-X
cell	B-X
dysfunction	B-X
occur	B-X
in	B-X
the	B-X
pancreas	B-X
(	B-X
malabsorption	B-X
)	B-X
,	B-X
liver	B-X
(	B-X
biliary	B-X
cirrhosis	B-X
)	B-X
,	B-X
sweat	B-X
glands	B-X
(	B-X
heat	B-X
shock	B-X
)	B-X
,	B-X
and	B-X
vas	B-X
deferens	B-X
(	B-X
infertility	B-X
)	B-X
.	B-X
The	B-X
development	B-X
and	B-X
delivery	B-X
of	B-X
drugs	B-X
that	B-X
improve	B-X
the	B-X
clearance	B-X
of	B-X
mucus	B-X
from	B-X
the	B-X
lungs	B-X
and	B-X
treat	B-X
the	B-X
consequent	B-X
infection	B-X
,	B-X
in	B-X
combination	B-X
with	B-X
correction	B-X
of	B-X
pancreatic	B-X
insufficiency	B-X
and	B-X
undernutrition	B-X
by	B-X
multidisciplinary	B-X
teams	B-X
,	B-X
have	B-X
resulted	B-X
in	B-X
remarkable	B-X
improvements	B-X
in	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
clinical	B-X
outcomes	B-X
in	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
,	B-X
with	B-X
median	B-X
life	B-X
expectancy	B-X
now	B-X
older	B-X
than	B-X
40	B-X
years	B-X
.	B-X
Innovative	B-X
and	B-X
transformational	B-X
therapies	B-X
that	B-X
target	B-X
the	B-X
basic	B-X
defect	B-X
in	B-X
cystic	B-X
fibrosis	B-X
have	B-X
recently	B-X
been	B-X
developed	B-X
and	B-X
are	B-X
effective	B-X
in	B-X
improving	B-X
lung	B-X
function	B-X
and	B-X
reducing	B-X
pulmonary	B-X
exacerbations	B-X
.	B-X
Further	B-X
small	B-X
molecule	B-X
and	B-X
gene-based	B-X
therapies	B-X
are	B-X
being	B-X
developed	B-X
to	B-X
restore	B-X
CFTR	B-X
function	B-X
;	B-X
these	B-X
therapies	B-X
promise	B-X
to	B-X
be	B-X
disease	B-X
modifying	B-X
and	B-X
to	B-X
improve	B-X
the	B-X
lives	B-X
of	B-X
people	B-X
with	B-X
cystic	B-X
fibrosis	B-X
.	B-X

CF	O
remains	O
one	O
of	O
the	O
most	O
common	O
lethal	O
genetic	O
diseases	O
in	O
populations	O
of	O
European	O
descent	O
with	O
the	O
current	O
average	O
lifespan	O
of	O
CF	O
patients	O
approximately	O
40	O
years	O
of	O
age	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Recurrent	O
inflammatory	O
pulmonary	O
exacerbation	O
is	O
the	O
primary	O
cause	O
of	O
lung	O
disease	O
progression	O
and	O
ultimately	O
,	O
death	O
in	O
CF	O
.	O

Controlled	O
inflammation	O
is	O
important	O
for	O
fighting	O
infection	O
,	O
but	O
in	O
excess	O
,	O
it	O
becomes	O
destructive	O
to	O
host	O
cells	O
and	O
to	O
the	O
architecture	O
of	O
the	O
lungs	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

In	O
CF	O
,	O
airway	O
epithelial	O
cells	O
have	O
been	O
shown	O
to	O
produce	O
an	O
exaggerated	O
pro	O
-	O
inflammatory	O
cytokine	O
response	O
to	O
stimulation	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O
<EOS>	B-X
It	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
airway	B-X
inflammation	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
bacterial	B-X
infection	B-X
or	B-X
is	B-X
intrinsically	B-X
dysregulated	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
IL-8	B-X
secretion	B-X
and	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
primary	B-X
respiratory	B-X
epithelial	B-X
cells	B-X
cultured	B-X
from	B-X
nasal	B-X
polyps	B-X
obtained	B-X
from	B-X
CF	B-X
and	B-X
non-CF	B-X
subjects	B-X
.	B-X

It	O
is	O
unclear	O
whether	O
this	O
heightened	O
inflammatory	O
response	O
is	O
intrinsic	O
to	O
cells	O
lacking	O
CFTR	O
or	O
whether	O
it	O
is	O
a	O
result	O
of	O
chronic	O
polymicrobial	O
infection	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O
<EOS>	B-X
Of	B-X
importance	B-X
,	B-X
HCV	B-X
is	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
chronic	B-X
liver	B-X
disease	B-X
and	B-X
liver	B-X
cancer	B-X
,	B-X
especially	B-X
in	B-X
Sub-Saharan	B-X
Africa	B-X
(	B-X
SSA	B-X
)	B-X
where	B-X
the	B-X
prevalence	B-X
remains	B-X
high	B-X
but	B-X
uncertain	B-X
due	B-X
to	B-X
little	B-X
population-based	B-X
evidence	B-X
of	B-X
the	B-X
epidemic	B-X
.	B-X
Chronic	B-X
infection	B-X
with	B-X
Stenotrophomonas	B-X
maltophilia	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
independent	B-X
predictor	B-X
of	B-X
pulmonary	B-X
exacerbation	B-X
requiring	B-X
hospitalization	B-X
and	B-X
antibiotics	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
antibiotic	B-X
treatment	B-X
of	B-X
Stenotrophomonas	B-X
maltophilia	B-X
infection	B-X
in	B-X
people	B-X
with	B-X
cystic	B-X
fibrosis	B-X
is	B-X
still	B-X
unclear	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
HIV	B-X
coinfection	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
higher	B-X
incidence	B-X
of	B-X
AG-induced	B-X
hearing	B-X
loss	B-X
during	B-X
MDR-TB	B-X
treatment	B-X
is	B-X
controversial	B-X
.	B-X

Regardless	O
of	O
this	O
controversy	O
,	O
identifying	O
and	O
targeting	O
relevant	O
inflammatory	O
mediators	O
is	O
a	O
critical	O
step	O
in	O
developing	O
more	O
specific	O
therapeutic	O
approaches	O
to	O
control	O
inflammation	O
and	O
improve	O
health	O
outcomes	O
in	O
CF	O
[	O
8	O
]	O
.	O

Interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
is	O
a	O
major	O
inflammatory	O
mediator	O
.	O

Its	O
physiological	O
effects	O
are	O
diverse	O
and	O
potentially	O
important	O
to	O
the	O
pathogenesis	O
of	O
lung	O
exacerbations	O
in	O
CF	O
,	O
including	O
the	O
generation	O
of	O
fever	O
,	O
the	O
recruitment	O
of	O
inflammatory	O
effector	O
cells	O
,	O
the	O
induction	O
of	O
other	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	O
-	O
8	O
,	O
and	O
the	O
shaping	O
of	O
T	O
cell	O
responses	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

Following	O
initiation	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
cascade	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
is	O
produced	O
in	O
the	O
cytosol	O
as	O
a	O
biologically	O
inactive	O
full	O
-	O
length	O
pro	O
-	O
IL	O
-	O
1beta	O
.	O

Pro	O
-	O
IL	O
-	O
1beta	O
is	O
subsequently	O
converted	O
into	O
its	O
active	O
form	O
by	O
cytosolic	O
protein	O
complexes	O
termed	O
"	O
inflammasomes	O
.	O
"	O
Inflammasomes	O
assemble	O
in	O
response	O
to	O
certain	O
cellular	O
danger	O
signals	O
and	O
mediate	O
the	O
auto	O
-	O
activation	O
of	O
caspase	O
-	O
1	O
[	O
9	O
]	O
,	O
[	O
11	O
]	O
,	O
which	O
cleaves	O
pro	O
-	O
IL	O
-	O
1beta	O
and	O
pro	O
-	O
IL	O
-	O
18	O
into	O
their	O
biologically	O
active	O
forms	O
for	O
secretion	O
.	O

Four	O
distinct	O
inflammasomes	O
have	O
been	O
recognized	O
.	O
<EOS>	B-X
These	B-X
rare	B-X
conditions	B-X
are	B-X
collectively	B-X
named	B-X
``	B-X
hereditary	B-X
periodic	B-X
fever	B-X
syndromes	B-X
''	B-X
(	B-X
HPFS	B-X
)	B-X
,	B-X
and	B-X
protean	B-X
pathogenetic	B-X
mechanisms	B-X
combined	B-X
with	B-X
several	B-X
clinical	B-X
phenotypes	B-X
characterize	B-X
at	B-X
least	B-X
four	B-X
distinct	B-X
conditions	B-X
:	B-X
(	B-X
1	B-X
)	B-X
familial	B-X
Mediterranean	B-X
fever	B-X
,	B-X
which	B-X
is	B-X
the	B-X
prototype	B-X
and	B-X
the	B-X
most	B-X
widely	B-X
recognized	B-X
among	B-X
HPFS	B-X
,	B-X
inherited	B-X
as	B-X
an	B-X
autosomal	B-X
recessive	B-X
disorder	B-X
showing	B-X
recurrent	B-X
dysregulated	B-X
inflammatory	B-X
processes	B-X
,	B-X
caused	B-X
by	B-X
an	B-X
abnormal	B-X
interaction	B-X
between	B-X
cytoskeleton	B-X
and	B-X
inflammasome	B-X
,	B-X
a	B-X
key-signaling	B-X
platform	B-X
that	B-X
releases	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
;	B-X
(	B-X
2	B-X
)	B-X
the	B-X
group	B-X
of	B-X
cryopyrin-associated	B-X
periodic	B-X
syndrome	B-X
,	B-X
which	B-X
upsets	B-X
directly	B-X
the	B-X
production	B-X
of	B-X
IL-1β	B-X
,	B-X
with	B-X
a	B-X
dominant	B-X
pattern	B-X
of	B-X
inheritance	B-X
;	B-X
(	B-X
3	B-X
)	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
periodic	B-X
syndrome	B-X
,	B-X
which	B-X
is	B-X
an	B-X
autosomal	B-X
dominant	B-X
disorder	B-X
subverting	B-X
the	B-X
functions	B-X
and	B-X
traffic	B-X
of	B-X
a	B-X
cell	B-X
membrane	B-X
protein	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
mevalonate	B-X
kinase	B-X
deficiency	B-X
,	B-X
which	B-X
is	B-X
an	B-X
autosomal	B-X
recessive	B-X
metabolic	B-X
disorder	B-X
halting	B-X
the	B-X
biosynthesis	B-X
of	B-X
cholesterol	B-X
.	B-X

These	O
are	O
the	O
NLRP1	O
[	O
12	O
]	O
,	O
NLRP3	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
NLRC4	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
,	O
and	O
AIM2	O
inflammasomes	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
which	O
respond	O
to	O
a	O
variety	O
of	O
different	O
microbial	O
signatures	O
and	O
danger	O
signals	O
[	O
11	O
]	O
.	O

P	O
.	O
aeruginosa	O
,	O
one	O
of	O
the	O
most	O
common	O
and	O
clinically	O
relevant	O
pathogens	O
among	O
CF	O
patients	O
,	O
activates	O
the	O
NLRC4	O
inflammasome	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

Infection	O
with	O
P	O
.	O
aeruginosa	O
triggers	O
an	O
increase	O
in	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
IL	O
-	O
8	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
from	O
patients	O
with	O
CF	O
[	O
21	O
]	O
.	O

Inflammasome	O
responses	O
depend	O
on	O
NF	O
-	O
kappaB	O
signaling	O
,	O
where	O
NF	O
-	O
kappaB	O
is	O
important	O
in	O
both	O
the	O
upregulation	O
of	O
specific	O
inflammasome	O
components	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
,	O
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
expression	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
.	O

Previous	O
studies	O
support	O
a	O
role	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
the	O
pathogenesis	O
of	O
CF	O
inflammatory	O
lung	O
disease	O
.	O
<EOS>	B-X
Burkholderia	B-X
cenocepacia	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Burkholderia	B-X
cepacia	B-X
complex	B-X
(	B-X
Bcc	B-X
)	B-X
,	B-X
a	B-X
group	B-X
of	B-X
bacteria	B-X
with	B-X
members	B-X
responsible	B-X
for	B-X
causing	B-X
lung	B-X
infections	B-X
in	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
patients	B-X
.	B-X
The	B-X
most	B-X
severe	B-X
outcome	B-X
of	B-X
Bcc	B-X
infection	B-X
in	B-X
CF	B-X
patients	B-X
is	B-X
cepacia	B-X
syndrome	B-X
,	B-X
a	B-X
disease	B-X
characterized	B-X
by	B-X
necrotizing	B-X
pneumonia	B-X
with	B-X
bacteremia	B-X
and	B-X
sepsis	B-X
.	B-X
Mechanisms	B-X
underlying	B-X
the	B-X
pathogenesis	B-X
of	B-X
B.	B-X
cenocepacia	B-X
in	B-X
lung	B-X
infections	B-X
and	B-X
cepacia	B-X
syndrome	B-X
remain	B-X
to	B-X
be	B-X
uncovered	B-X
.	B-X
Inactivation	B-X
of	B-X
RhoA	B-X
by	B-X
TecA	B-X
triggers	B-X
assembly	B-X
of	B-X
the	B-X
pyrin	B-X
inflammasome	B-X
,	B-X
leading	B-X
to	B-X
secretion	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
interleukin-1β	B-X
,	B-X
from	B-X
macrophages	B-X
.	B-X
Previous	B-X
work	B-X
with	B-X
the	B-X
B.	B-X
cenocepacia	B-X
clinical	B-X
isolate	B-X
J2315	B-X
showed	B-X
that	B-X
TecA	B-X
increases	B-X
immunopathology	B-X
during	B-X
acute	B-X
lung	B-X
infection	B-X
in	B-X
C57BL/6	B-X
mice	B-X
and	B-X
suggested	B-X
that	B-X
this	B-X
effector	B-X
acts	B-X
as	B-X
a	B-X
virulence	B-X
factor	B-X
by	B-X
triggering	B-X
assembly	B-X
of	B-X
the	B-X
pyrin	B-X
inflammasome	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
extend	B-X
these	B-X
results	B-X
using	B-X
a	B-X
second	B-X
B.	B-X
cenocepacia	B-X
clinical	B-X
isolate	B-X
,	B-X
AU1054	B-X
,	B-X
to	B-X
demonstrate	B-X
that	B-X
TecA	B-X
exacerbates	B-X
weight	B-X
loss	B-X
and	B-X
lethality	B-X
during	B-X
lung	B-X
infection	B-X
in	B-X
C57BL/6	B-X
mice	B-X
and	B-X
mice	B-X
engineered	B-X
to	B-X
have	B-X
a	B-X
CF	B-X
genotype	B-X
.	B-X
Our	B-X
findings	B-X
establish	B-X
that	B-X
TecA	B-X
is	B-X
a	B-X
B.	B-X
cenocepacia	B-X
virulence	B-X
factor	B-X
that	B-X
exacerbates	B-X
lung	B-X
inflammation	B-X
,	B-X
weight	B-X
loss	B-X
,	B-X
and	B-X
lethality	B-X
in	B-X
mouse	B-X
infection	B-X
models	B-X
.	B-X

Levels	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
increased	O
in	O
BALF	O
from	O
CF	O
patients	O
with	O
infection	O
[	O
21	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
and	O
this	O
increase	O
has	O
been	O
temporally	O
associated	O
with	O
a	O
clinical	O
response	O
to	O
treatment	O
[	O
21	O
]	O
.	O

Polymorphisms	O
in	O
the	O
IL1B	B-Protein
gene	O
have	O
also	O
been	O
associated	O
with	O
varying	O
degrees	O
of	O
disease	O
severity	O
in	O
CF	O
patients	O
[	O
29	O
]	O
.	O

Murine	O
models	O
of	O
CFTR	O
dysfunction	O
have	O
exhibited	O
significant	O
increases	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
expression	O
or	O
secretion	O
in	O
macrophages	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
,	O
and	O
support	O
the	O
hypothesis	O
that	O
the	O
loss	O
of	O
CFTR	O
increases	O
NF	O
-	O
kappaB	O
activation	O
under	O
basal	O
and	O
stimulatory	O
conditions	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

Finally	O
,	O
replacement	O
of	O
chloride	O
ions	O
with	O
glutamate	O
or	O
gluconate	O
in	O
cell	O
culture	O
media	O
increases	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
response	O
to	O
NLRP3	O
stimulation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
[	O
34	O
]	O
,	O
implying	O
an	O
inhibitory	O
role	O
for	O
extracellular	O
chloride	O
in	O
NLRP3	O
activation	O
.	O
<EOS>	B-X
In	B-X
the	B-X
OB	B-X
,	B-X
DA	B-X
neurons	B-X
are	B-X
restricted	B-X
to	B-X
the	B-X
GL	B-X
,	B-X
but	B-X
using	B-X
transgenic	B-X
mice	B-X
expressing	B-X
eGFP	B-X
under	B-X
the	B-X
tyrosine	B-X
hydroxylase	B-X
(	B-X
TH	B-X
)	B-X
promoter	B-X
,	B-X
we	B-X
also	B-X
detected	B-X
the	B-X
presence	B-X
of	B-X
TH-GFP+	B-X
cells	B-X
in	B-X
the	B-X
mitral	B-X
and	B-X
external	B-X
plexiform	B-X
layers	B-X
.	B-X
Accordingly	B-X
,	B-X
TH-GFP+	B-X
cells	B-X
outside	B-X
the	B-X
GL	B-X
exhibit	B-X
functional	B-X
properties	B-X
(	B-X
appearance	B-X
of	B-X
pacemaker	B-X
currents	B-X
,	B-X
synaptic	B-X
connection	B-X
with	B-X
the	B-X
olfactory	B-X
nerve	B-X
,	B-X
intracellular	B-X
chloride	B-X
concentration	B-X
,	B-X
and	B-X
other	B-X
)	B-X
marking	B-X
a	B-X
gradient	B-X
of	B-X
maturity	B-X
toward	B-X
the	B-X
dopaminergic	B-X
phenotype	B-X
along	B-X
the	B-X
mitral-glomerular	B-X
axis	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
synaptic	B-X
contact	B-X
with	B-X
the	B-X
olfactory	B-X
nerve	B-X
is	B-X
the	B-X
key	B-X
event	B-X
allowing	B-X
these	B-X
cells	B-X
to	B-X
complete	B-X
their	B-X
differentiation	B-X
toward	B-X
the	B-X
DA	B-X
phenotype	B-X
and	B-X
to	B-X
reach	B-X
their	B-X
final	B-X
destination	B-X
.	B-X
Sodium	B-X
ions	B-X
were	B-X
found	B-X
to	B-X
have	B-X
a	B-X
biphasic	B-X
effect	B-X
;	B-X
low	B-X
concentrations	B-X
(	B-X
in	B-X
the	B-X
range	B-X
of	B-X
0.1-3	B-X
mM	B-X
)	B-X
induced	B-X
a	B-X
marked	B-X
inhibition	B-X
of	B-X
the	B-X
binding	B-X
whereas	B-X
higher	B-X
concentrations	B-X
(	B-X
10-300	B-X
mM	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
stimulation	B-X
of	B-X
binding	B-X
.	B-X
L-Cysteine	B-X
sulfinate	B-X
was	B-X
the	B-X
most	B-X
potent	B-X
inhibitor	B-X
being	B-X
3-fold	B-X
more	B-X
potent	B-X
than	B-X
L-glutamate	B-X
and	B-X
80	B-X
times	B-X
more	B-X
potent	B-X
than	B-X
L-aspartate	B-X
.	B-X
The	B-X
L-	B-X
[	B-X
3H	B-X
]	B-X
cysteine	B-X
sulfinate	B-X
uptake	B-X
increases	B-X
as	B-X
a	B-X
function	B-X
of	B-X
the	B-X
sodium	B-X
concentration	B-X
.	B-X
Chloride	B-X
and	B-X
potassium	B-X
ions	B-X
stimulate	B-X
the	B-X
uptake	B-X
.	B-X
The	B-X
decrease	B-X
or	B-X
increase	B-X
in	B-X
the	B-X
electrical	B-X
membrane	B-X
potential	B-X
(	B-X
delta	B-X
psi	B-X
)	B-X
caused	B-X
by	B-X
replacing	B-X
the	B-X
chloride	B-X
ions	B-X
by	B-X
the	B-X
sulfate	B-X
or	B-X
sulfocyanate	B-X
ions	B-X
respectively	B-X
leads	B-X
to	B-X
a	B-X
decrease	B-X
or	B-X
increase	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
uptake	B-X
.	B-X
The	B-X
length	B-X
of	B-X
the	B-X
carbon	B-X
chain	B-X
also	B-X
has	B-X
a	B-X
bearing	B-X
on	B-X
the	B-X
inhibitory	B-X
effect	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
high	B-X
affinity	B-X
system	B-X
which	B-X
may	B-X
correspond	B-X
to	B-X
the	B-X
transmitter	B-X
inactivation	B-X
.	B-X
Binding	B-X
and	B-X
uptake	B-X
sites	B-X
are	B-X
distinguishable	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
affinity	B-X
constants	B-X
,	B-X
the	B-X
ionic	B-X
and	B-X
pharmacological	B-X
effects	B-X
and	B-X
the	B-X
different	B-X
regional	B-X
distributions	B-X
in	B-X
the	B-X
brain	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
results	B-X
give	B-X
further	B-X
evidence	B-X
for	B-X
a	B-X
neurotransmitter	B-X
role	B-X
of	B-X
L-cysteine	B-X
sulfinate	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
implicate	O
the	O
involvement	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
consequently	O
,	O
the	O
inflammasomes	O
,	O
in	O
CF	O
inflammatory	O
disease	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
produce	O
significant	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
response	O
to	O
inflammasome	O
stimulation	O
<EOS>	B-X
When	B-X
compromised	B-X
,	B-X
activation	B-X
of	B-X
immune/inflammatory	B-X
responses	B-X
against	B-X
exogenous	B-X
allergens	B-X
,	B-X
microbial	B-X
substances	B-X
,	B-X
and	B-X
pollutants	B-X
might	B-X
occur	B-X
,	B-X
rendering	B-X
individuals	B-X
prone	B-X
to	B-X
develop	B-X
chronic	B-X
inflammation	B-X
as	B-X
seen	B-X
in	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X
By	B-X
putting	B-X
the	B-X
epithelial	B-X
barrier	B-X
to	B-X
the	B-X
forefront	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
airway	B-X
inflammation	B-X
,	B-X
different	B-X
approaches	B-X
to	B-X
diagnose	B-X
and	B-X
target	B-X
epithelial	B-X
barrier	B-X
defects	B-X
are	B-X
currently	B-X
being	B-X
developed	B-X
.	B-X
Using	B-X
single-cell	B-X
transcriptomics	B-X
,	B-X
novel	B-X
epithelial	B-X
cell	B-X
types	B-X
are	B-X
being	B-X
unraveled	B-X
that	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
chronicity	B-X
of	B-X
respiratory	B-X
diseases	B-X
.	B-X
We	B-X
here	B-X
review	B-X
and	B-X
discuss	B-X
the	B-X
current	B-X
understandings	B-X
of	B-X
epithelial	B-X
barrier	B-X
defects	B-X
in	B-X
type	B-X
2-driven	B-X
chronic	B-X
inflammation	B-X
of	B-X
the	B-X
upper	B-X
and	B-X
lower	B-X
airways	B-X
,	B-X
the	B-X
estimated	B-X
contribution	B-X
of	B-X
these	B-X
novel	B-X
identified	B-X
epithelial	B-X
cells	B-X
to	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
current	B-X
clinical	B-X
challenges	B-X
in	B-X
relation	B-X
to	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X

The	O
inflammasomes	O
and	O
their	O
respective	O
activators	O
examined	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Cells	O
were	O
stimulated	O
in	O
accordance	O
with	O
the	O
schedule	O
in	O
Figure	O
1	O
.	O

In	O
CF	O
,	O
airway	O
epithelial	O
cells	O
have	O
been	O
shown	O
to	O
possess	O
a	O
hyper	O
-	O
inflammatory	O
phenotype	O
and	O
produce	O
an	O
exaggerated	O
pro	O
-	O
inflammatory	O
cytokine	O
response	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

To	O
determine	O
if	O
airway	O
epithelial	O
cells	O
contribute	O
to	O
the	O
increased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
patients	O
with	O
CF	O
,	O
CF	O
and	O
control	O
bronchial	O
epithelial	O
cell	O
lines	O
were	O
stimulated	O
with	O
the	O
inflammasome	O
inducers	O
P	O
.	O
aeruginosa	O
strain	O
PAO1	O
(	O
PAO1	O
)	O
and	O
LPS	O
followed	O
by	O
ATP	O
.	O

IL	B-Protein
-	I-Protein
1beta	I-Protein
levels	O
in	O
cell	O
culture	O
supernatants	O
were	O
not	O
greatly	O
increased	O
in	O
either	O
the	O
CF	O
or	O
control	O
cell	O
lines	O
(	O
Fig	O
.	O
2a	O
-	O
d	O
)	O
,	O
although	O
a	O
small	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
was	O
detected	O
in	O
NuLi	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
cells	O
,	O
but	O
not	O
in	O
S9	O
and	O
IB3	O
-	O
1	O
cells	O
,	O
by	O
24	O
hours	O
.	O
<EOS>	B-X
With	B-X
the	B-X
TCGA	B-X
dataset	B-X
we	B-X
found	B-X
that	B-X
the	B-X
pro-inflammatory	B-X
cytokines	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
(	B-X
TNFα	B-X
)	B-X
and	B-X
interleukin	B-X
1β	B-X
(	B-X
IL-1β	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
target	B-X
pro-metastatic	B-X
chemokines	B-X
CXCL8	B-X
(	B-X
IL-8	B-X
)	B-X
,	B-X
CCL2	B-X
(	B-X
MCP-1	B-X
)	B-X
,	B-X
and	B-X
CCL5	B-X
(	B-X
RANTES	B-X
)	B-X
were	B-X
expressed	B-X
at	B-X
significantly	B-X
higher	B-X
levels	B-X
in	B-X
basal	B-X
patients	B-X
than	B-X
luminal-A	B-X
patients	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
found	B-X
that	B-X
TNFα-	B-X
or	B-X
IL-1β-stimulated	B-X
co-cultures	B-X
of	B-X
TNBC	B-X
cells	B-X
(	B-X
MDA-MB-231	B-X
,	B-X
MDA-MB-468	B-X
,	B-X
BT-549	B-X
)	B-X
with	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
expressed	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
CXCL8	B-X
compared	B-X
to	B-X
non-stimulated	B-X
co-cultures	B-X
or	B-X
each	B-X
cell	B-X
type	B-X
alone	B-X
,	B-X
with	B-X
or	B-X
without	B-X
cytokine	B-X
stimulation	B-X
.	B-X
CXCL8	B-X
was	B-X
also	B-X
up-regulated	B-X
in	B-X
TNBC	B-X
co-cultures	B-X
with	B-X
breast	B-X
cancer-associated	B-X
fibroblasts	B-X
(	B-X
CAFs	B-X
)	B-X
derived	B-X
from	B-X
patients	B-X
.	B-X
CCL2	B-X
and	B-X
CCL5	B-X
also	B-X
reached	B-X
the	B-X
highest	B-X
expression	B-X
levels	B-X
in	B-X
TNFα/IL-1β-stimulated	B-X
TNBC	B-X
:	B-X
MSC/CAF	B-X
co-cultures	B-X
.	B-X
The	B-X
elevations	B-X
in	B-X
CXCL8	B-X
and	B-X
CCL2	B-X
expression	B-X
partly	B-X
depended	B-X
on	B-X
direct	B-X
physical	B-X
contacts	B-X
between	B-X
the	B-X
tumor	B-X
cells	B-X
and	B-X
the	B-X
MSCs/CAFs	B-X
,	B-X
whereas	B-X
CCL5	B-X
up-regulation	B-X
was	B-X
entirely	B-X
dependent	B-X
on	B-X
cell-to-cell	B-X
contacts	B-X
.	B-X
Supernatants	B-X
of	B-X
TNFα-stimulated	B-X
TNBC	B-X
:	B-X
MSC	B-X
``	B-X
Contact	B-X
''	B-X
co-cultures	B-X
induced	B-X
robust	B-X
endothelial	B-X
cell	B-X
migration	B-X
and	B-X
sprouting	B-X
.	B-X
TNBC	B-X
cells	B-X
co-cultured	B-X
with	B-X
MSCs	B-X
and	B-X
TNFα	B-X
gained	B-X
migration-related	B-X
morphology	B-X
and	B-X
potent	B-X
migratory	B-X
properties	B-X
;	B-X
they	B-X
also	B-X
became	B-X
more	B-X
invasive	B-X
when	B-X
co-cultured	B-X
with	B-X
MSCs/CAFs	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
TNFα	B-X
.	B-X
Using	B-X
siRNA	B-X
to	B-X
CXCL8	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CXCL8	B-X
was	B-X
significantly	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
pro-metastatic	B-X
activities	B-X
gained	B-X
by	B-X
TNFα-stimulated	B-X
TNBC	B-X
:	B-X
MSC	B-X
``	B-X
Contact	B-X
''	B-X
co-cultures	B-X
:	B-X
angiogenesis	B-X
,	B-X
migration-related	B-X
morphology	B-X
of	B-X
the	B-X
tumor	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
cancer	B-X
cell	B-X
migration	B-X
and	B-X
invasion	B-X
.	B-X
Importantly	B-X
,	B-X
TNFα	B-X
stimulation	B-X
of	B-X
TNBC	B-X
:	B-X
MSC	B-X
``	B-X
Contact	B-X
''	B-X
co-cultures	B-X

In	O
contrast	O
,	O
these	O
airway	O
cells	O
were	O
highly	O
responsive	O
to	O
other	O
inflammatory	O
stimuli	O
,	O
such	O
as	O
recombinant	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
producing	O
large	O
quantities	O
of	O
IL	O
-	O
8	O
(	O
Fig	O
.	O
2a	O
-	O
d	O
inserts	O
)	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
significantly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
in	O
response	O
to	O
inflammasome	O
stimulation	O
<EOS>	B-X
When	B-X
compromised	B-X
,	B-X
activation	B-X
of	B-X
immune/inflammatory	B-X
responses	B-X
against	B-X
exogenous	B-X
allergens	B-X
,	B-X
microbial	B-X
substances	B-X
,	B-X
and	B-X
pollutants	B-X
might	B-X
occur	B-X
,	B-X
rendering	B-X
individuals	B-X
prone	B-X
to	B-X
develop	B-X
chronic	B-X
inflammation	B-X
as	B-X
seen	B-X
in	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X
By	B-X
putting	B-X
the	B-X
epithelial	B-X
barrier	B-X
to	B-X
the	B-X
forefront	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
airway	B-X
inflammation	B-X
,	B-X
different	B-X
approaches	B-X
to	B-X
diagnose	B-X
and	B-X
target	B-X
epithelial	B-X
barrier	B-X
defects	B-X
are	B-X
currently	B-X
being	B-X
developed	B-X
.	B-X
Using	B-X
single-cell	B-X
transcriptomics	B-X
,	B-X
novel	B-X
epithelial	B-X
cell	B-X
types	B-X
are	B-X
being	B-X
unraveled	B-X
that	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
chronicity	B-X
of	B-X
respiratory	B-X
diseases	B-X
.	B-X
We	B-X
here	B-X
review	B-X
and	B-X
discuss	B-X
the	B-X
current	B-X
understandings	B-X
of	B-X
epithelial	B-X
barrier	B-X
defects	B-X
in	B-X
type	B-X
2-driven	B-X
chronic	B-X
inflammation	B-X
of	B-X
the	B-X
upper	B-X
and	B-X
lower	B-X
airways	B-X
,	B-X
the	B-X
estimated	B-X
contribution	B-X
of	B-X
these	B-X
novel	B-X
identified	B-X
epithelial	B-X
cells	B-X
to	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
current	B-X
clinical	B-X
challenges	B-X
in	B-X
relation	B-X
to	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X

To	O
examine	O
if	O
inflammasome	O
activation	O
occurs	O
in	O
these	O
airway	O
cells	O
,	O
caspase	O
-	O
1	O
activity	O
was	O
quantified	O
by	O
flow	O
cytometry	O
.	O

There	O
was	O
no	O
significant	O
increase	O
upon	O
stimulation	O
with	O
live	O
PAO1	O
or	O
LPS	O
+	O
ATP	O
at	O
the	O
times	O
examined	O
(	O
Fig	O
.	O
3a	O
-	O
b	O
)	O
.	O

Because	O
previous	O
studies	O
have	O
indicated	O
a	O
role	O
for	O
caspase	O
-	O
1	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
through	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
signaling	O
[	O
35	O
]	O
,	O
we	O
examined	O
whether	O
chemical	O
inhibition	O
of	O
caspase	O
-	O
1	O
altered	O
NF	O
-	O
kappaB	O
-	O
dependent	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

However	O
,	O
treatment	O
with	O
the	O
caspase	O
-	O
1	O
inhibitor	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
YVAD	O
)	O
did	O
not	O
decrease	O
IL	B-Protein
-	I-Protein
6	I-Protein
secretion	O
by	O
airway	O
epithelial	O
cells	O
(	O
Fig	O
.	O
3c	O
)	O
.	O

CD14	O
positive	O
monocytes	O
from	O
CF	O
patients	O
and	O
controls	O
show	O
similar	O
increases	O
in	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
stimulation	O

Monocytes	O
were	O
identified	O
in	O
PBMC	O
populations	O
using	O
CD14	B-Protein
as	O
a	O
phenotyping	O
marker	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
subsets	B-X
of	B-X
DCs	B-X
,	B-X
identified	B-X
in	B-X
humans	B-X
,	B-X
appear	B-X
to	B-X
have	B-X
their	B-X
respective	B-X
competences	B-X
in	B-X
immune	B-X
response	B-X
modulation	B-X
.	B-X
Our	B-X
objective	B-X
is	B-X
to	B-X
purify	B-X
from	B-X
PBMC	B-X
or	B-X
to	B-X
differentiate	B-X
DC	B-X
subsets	B-X
from	B-X
monocytes	B-X
using	B-X
several	B-X
strategies	B-X
and	B-X
evaluate	B-X
their	B-X
IL10	B-X
secretion	B-X
.	B-X
To	B-X
study	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
the	B-X
affected	B-X
lower	B-X
airways	B-X
,	B-X
mixed	B-X
leukocytes	B-X
were	B-X
acquired	B-X
through	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
and	B-X
the	B-X
cell	B-X
populations	B-X
were	B-X
analyzed	B-X
on	B-X
a	B-X
single-cell	B-X
basis	B-X
by	B-X
flow	B-X
cytometry	B-X
(	B-X
FC	B-X
)	B-X
.	B-X
Using	B-X
FC	B-X
,	B-X
BAL	B-X
cells	B-X
and	B-X
PBMC	B-X
were	B-X
comprehensively	B-X
characterized	B-X
by	B-X
cell	B-X
surface	B-X
markers	B-X

CD14	O
positive	O
monocytes	O
from	O
CF	O
patients	O
and	O
healthy	O
controls	O
showed	O
a	O
significant	O
increase	O
in	O
caspase	O
-	O
1	O
activation	O
upon	O
stimulation	O
with	O
LPS	O
+	O
ATP	O
,	O
PAO1	O
,	O
and	O
LPS	O
+	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
Fig	O
.	O
4a	O
)	O
but	O
this	O
activation	O
was	O
not	O
different	O
between	O
CF	O
and	O
control	O
subjects	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
upon	O
inflammasome	O
stimulation	O
<EOS>	B-X
Growing	B-X
evidence	B-X
indicates	B-X
that	B-X
inflammasome-mediated	B-X
inflammation	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
amnestic	B-X
mild	B-X
cognitive	B-X
impairment	B-X
(	B-X
aMCI	B-X
)	B-X
and	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
Pyroptosis	B-X
induced	B-X
by	B-X
inflammasome	B-X
,	B-X
and	B-X
Gasdermin	B-X
D	B-X
(	B-X
GSDMD	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
several	B-X
neurodegenerative	B-X
disorders	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
peripheral	B-X
inflammasome	B-X
and	B-X
pyroptosis	B-X
are	B-X
activated	B-X
in	B-X
aMCI	B-X
and	B-X
AD	B-X
patients	B-X
,	B-X
influencing	B-X
on	B-X
neuroinflammation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
association	B-X
between	B-X
systemic	B-X
inflammasome-induced	B-X
pyroptosis	B-X
and	B-X
clinical	B-X
features	B-X
in	B-X
aMCI	B-X
and	B-X
AD	B-X
.	B-X

Previous	O
studies	O
have	O
shown	O
that	O
the	O
loss	O
of	O
CFTR	O
results	O
in	O
increased	O
NF	O
-	O
kappaB	O
activity	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
secretion	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

To	O
further	O
examine	O
this	O
relationship	O
,	O
PBMCs	O
from	O
CF	O
patients	O
and	O
healthy	O
adult	O
controls	O
were	O
stimulated	O
with	O
PAO1	O
,	O
LPS	O
+	O
ATP	O
,	O
and	O
LPS	O
+	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
,	O
to	O
activate	O
the	O
NLRC4	O
,	O
NLRP3	O
,	O
and	O
AIM2	O
inflammasomes	O
,	O
respectively	O
.	O

By	O
24	O
hours	O
of	O
stimulation	O
,	O
CF	O
PBMCs	O
did	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
Fig	O
.	O
5a	O
)	O
or	O
IL	O
-	O
8	O
(	O
Fig	O
.	O
5b	O
)	O
when	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
we	O
did	O
notice	O
a	O
transient	O
decrease	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
amount	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
produced	O
by	O
CF	O
cells	O
in	O
response	O
to	O
LPS	O
+	O
ATP	O
at	O
6	O
hours	O
(	O
data	O
not	O
shown	O
)	O
.	O

Stimulation	O
of	O
PBMCs	O
with	O
P	O
.	O
aeruginosa	O
that	O
lacks	O
exsA	B-Protein
(	O
PAO1deltaexsA	O
)	O
,	O
a	O
key	O
regulator	O
of	O
type	O
III	O
secretion	O
,	O
produced	O
three	O
-	O
fold	O
less	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
compared	O
to	O
the	O
parental	O
PAO1	O
strain	O
by	O
24	O
hours	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

Inflammasome	O
stimulation	O
without	O
priming	O
did	O
not	O
result	O
in	O
any	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
either	O
CF	O
or	O
control	O
PBMCs	O
.	O
<EOS>	B-X
Stimulator	B-X
of	B-X
interferon	B-X
genes	B-X
(	B-X
STING	B-X
)	B-X
contributes	B-X
to	B-X
immune	B-X
responses	B-X
against	B-X
tumors	B-X
and	B-X
may	B-X
control	B-X
viral	B-X
infection	B-X
including	B-X
SARS-CoV-2	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
airway	B-X
targeting	B-X
by	B-X
STING	B-X
activator	B-X
as	B-X
a	B-X
therapeutic	B-X
strategy	B-X
for	B-X
infection	B-X
may	B-X
enhance	B-X
lung	B-X
inflammation	B-X
with	B-X
severe	B-X
ARDS	B-X
.	B-X
STING	B-X
agonist	B-X
diABZI	B-X
induces	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
and	B-X
PANoptosis	B-X
A	B-X
,	B-X
Airway	B-X
STING	B-X
priming	B-X
induce	B-X
a	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
with	B-X
epithelial	B-X
barrier	B-X
damage	B-X
,	B-X
double-stranded	B-X
DNA	B-X
release	B-X
in	B-X
the	B-X
bronchoalvelolar	B-X
space	B-X
,	B-X
cell	B-X
death	B-X
,	B-X
NETosis	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
release	B-X
.	B-X
STING	B-X
activation	B-X
also	B-X
leads	B-X
to	B-X
NF-kB	B-X
activation	B-X
and	B-X
the	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
TNFα	B-X
and	B-X
IL-6	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
TNFR1	B-X
and	B-X
IFNAR1	B-X
signaling	B-X
pathway	B-X
results	B-X
in	B-X
ZBP1	B-X
and	B-X
RIPK3/ASC/CASP8	B-X
activation	B-X
leading	B-X
to	B-X
MLKL	B-X
phosphorylation	B-X
and	B-X
necroptosis	B-X
induction	B-X
.	B-X
Self-dsDNA	B-X
or	B-X
mtDNA	B-X
sensing	B-X
by	B-X
NLRP3	B-X
or	B-X
AIM2	B-X
induces	B-X
inflammsome	B-X
formation	B-X
leading	B-X
to	B-X
Gasdermin	B-X
D	B-X
cleavage	B-X
enabling	B-X
Gasdermin	B-X
D	B-X
pore	B-X
formation	B-X
and	B-X
the	B-X
release	B-X
mature	B-X
IL-1β	B-X
and	B-X
pyroptosis	B-X
.	B-X
A	B-X
second	B-X
signal	B-X
of	B-X
STING	B-X
activation	B-X
with	B-X
diABZI	B-X
induces	B-X
cell	B-X
death	B-X
and	B-X
the	B-X
release	B-X
of	B-X
self-DNA	B-X
which	B-X
is	B-X
sensed	B-X
by	B-X
cGAS	B-X
and	B-X
form	B-X
2	B-X
'	B-X
3'-cGAMP	B-X
leading	B-X
to	B-X
STING	B-X
hyper	B-X
activation	B-X
,	B-X
the	B-X
amplification	B-X
of	B-X
TBK1/IRF3	B-X
and	B-X
NF-kB	B-X
pathway	B-X
and	B-X
the	B-X
subsequent	B-X
production	B-X
of	B-X
IFN-I	B-X
and	B-X
inflammatory	B-X
TNFα	B-X
and	B-X
IL-6	B-X
.	B-X

Contrary	O
to	O
our	O
hypothesis	O
,	O
these	O
results	O
indicate	O
that	O
PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
display	O
increased	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
or	O
IL	B-Protein
-	I-Protein
8	I-Protein
with	O
inflammasome	O
activation	O
nor	O
do	O
they	O
suggest	O
any	O
increased	O
basal	O
or	O
induced	O
NF	O
-	O
kappaB	O
activity	O
.	O
<EOS>	B-X
The	B-X
non-canonical	B-X
NF-κB	B-X
pathway	B-X
is	B-X
an	B-X
important	B-X
arm	B-X
of	B-X
NF-κB	B-X
signaling	B-X
that	B-X
predominantly	B-X
targets	B-X
activation	B-X
of	B-X
the	B-X
p52/RelB	B-X
NF-κB	B-X
complex	B-X
.	B-X
A	B-X
central	B-X
signaling	B-X
component	B-X
of	B-X
the	B-X
non-canonical	B-X
pathway	B-X
is	B-X
NF-κB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
which	B-X
integrates	B-X
signals	B-X
from	B-X
a	B-X
subset	B-X
of	B-X
TNF	B-X
receptor	B-X
family	B-X
members	B-X
and	B-X
activates	B-X
a	B-X
downstream	B-X
kinase	B-X
,	B-X
IκB	B-X
kinase-α	B-X
(	B-X
IKKα	B-X
)	B-X
,	B-X
for	B-X
triggering	B-X
p100	B-X
phosphorylation	B-X
and	B-X
processing	B-X
.	B-X
A	B-X
unique	B-X
mechanism	B-X
of	B-X
NIK	B-X
regulation	B-X
is	B-X
through	B-X
its	B-X
fate	B-X
control	B-X
:	B-X
the	B-X
basal	B-X
level	B-X
of	B-X
NIK	B-X
is	B-X
kept	B-X
low	B-X
by	B-X
a	B-X
TRAF-cIAP	B-X
destruction	B-X
complex	B-X
and	B-X
signal-induced	B-X
non-canonical	B-X
NF-κB	B-X
signaling	B-X
involves	B-X
NIK	B-X
stabilization	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
innate	B-X
immunity	B-X
and	B-X
energy	B-X
metabolism	B-X
are	B-X
connected	B-X
together	B-X
through	B-X
an	B-X
antagonistic	B-X
crosstalk	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
signaling	B-X
pathways	B-X
.	B-X
NF-κB	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
defense	B-X
while	B-X
SIRT1	B-X
regulates	B-X
the	B-X
oxidative	B-X
respiration	B-X
and	B-X
cellular	B-X
survival	B-X
.	B-X
However	B-X
,	B-X
NF-κB	B-X
signaling	B-X
can	B-X
stimulate	B-X
glycolytic	B-X
energy	B-X
flux	B-X
during	B-X
acute	B-X
inflammation	B-X
,	B-X
whereas	B-X
SIRT1	B-X
activation	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
and	B-X
enhances	B-X
oxidative	B-X
metabolism	B-X
and	B-X
the	B-X
resolution	B-X
of	B-X
inflammation	B-X
.	B-X
SIRT1	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
directly	B-X
by	B-X
deacetylating	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
complex	B-X
.	B-X
SIRT1	B-X
stimulates	B-X
oxidative	B-X
energy	B-X
production	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
AMPK	B-X
,	B-X
PPARα	B-X
and	B-X
PGC-1α	B-X
and	B-X
simultaneously	B-X
,	B-X
these	B-X
factors	B-X
inhibit	B-X
NF-κB	B-X
signaling	B-X
and	B-X
suppress	B-X
inflammation	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
NF-κB	B-X
signaling	B-X
down-regulates	B-X
SIRT1	B-X
activity	B-X
through	B-X
the	B-X
expression	B-X
of	B-X
miR-34a	B-X
,	B-X
IFNγ	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
SIRT1	B-X
disrupts	B-X
oxidative	B-X
energy	B-X
metabolism	B-X
and	B-X
stimulates	B-X
the	B-X
NF-κB-induced	B-X
inflammatory	B-X
responses	B-X
present	B-X
in	B-X
many	B-X
chronic	B-X
metabolic	B-X
and	B-X
age-related	B-X
diseases	B-X
.	B-X
We	B-X
will	B-X
examine	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
antagonistic	B-X
signaling	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
and	B-X
describe	B-X
how	B-X
this	B-X
crosstalk	B-X
controls	B-X
inflammatory	B-X
process	B-X
and	B-X
energy	B-X
metabolism	B-X
.	B-X

These	O
results	O
are	O
consistent	O
with	O
our	O
observation	O
that	O
caspase	O
-	O
1	O
activity	O
is	O
not	O
different	O
between	O
CF	O
and	O
control	O
PBMCs	O
(	O
Fig	O
.	O
4	O
)	O
.	O
<EOS>	B-X
Inflammasome	B-X
activation	B-X
causes	B-X
the	B-X
maturation	B-X
of	B-X
caspase-1	B-X
and	B-X
activation	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
and	B-X
IL-18	B-X
,	B-X
two	B-X
proinflammatory	B-X
cytokines	B-X
involved	B-X
in	B-X
neuroimmunomodulation	B-X
,	B-X
neuroinflammation	B-X
and	B-X
neurodegeneration	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
C57BL/6	B-X
mice	B-X
with	B-X
genetic	B-X
deficiency	B-X
or	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
were	B-X
screened	B-X
for	B-X
anxiety-	B-X
and	B-X
depressive-like	B-X
behaviors	B-X
,	B-X
and	B-X
locomotion	B-X
at	B-X
baseline	B-X
and	B-X
after	B-X
chronic	B-X
stress	B-X
.	B-X
We	B-X
found	B-X
that	B-X
genetic	B-X
deficiency	B-X
of	B-X
caspase-1	B-X
decreased	B-X
depressive-	B-X
and	B-X
anxiety-like	B-X
behaviors	B-X
,	B-X
and	B-X
conversely	B-X
increased	B-X
locomotor	B-X
activity	B-X
and	B-X
skills	B-X
.	B-X
Caspase-1	B-X
deficiency	B-X
also	B-X
prevented	B-X
the	B-X
exacerbation	B-X
of	B-X
depressive-like	B-X
behaviors	B-X
following	B-X
chronic	B-X
stress	B-X
.	B-X
Furthermore	B-X
,	B-X
pharmacological	B-X
caspase-1	B-X
antagonism	B-X
with	B-X
minocycline	B-X
ameliorated	B-X
stress-induced	B-X
depressive-like	B-X
behavior	B-X
in	B-X
wild-type	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
chronic	B-X
stress	B-X
or	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
per	B-X
se	B-X
altered	B-X
the	B-X
fecal	B-X
microbiome	B-X
in	B-X
a	B-X
very	B-X
similar	B-X
manner	B-X
.	B-X
and	B-X
Blautia	B-X
spp.	B-X
,	B-X
which	B-X
are	B-X
compatible	B-X
with	B-X
beneficial	B-X
effects	B-X
of	B-X
attenuated	B-X
inflammation	B-X
and	B-X
rebalance	B-X
of	B-X
gut	B-X
microbiota	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
the	B-X
increment	B-X
in	B-X
Lachnospiracea	B-X
abundance	B-X
was	B-X
consistent	B-X
with	B-X
microbiota	B-X
changes	B-X
of	B-X
caspase-1	B-X
deficiency	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
caspase-1	B-X
inhibition	B-X
involves	B-X
the	B-X
modulation	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
stress	B-X
and	B-X
gut	B-X
microbiota	B-X
composition	B-X
,	B-X
and	B-X
establishes	B-X
the	B-X
basis	B-X
for	B-X
a	B-X
gut	B-X
microbiota-inflammasome-brain	B-X
axis	B-X
,	B-X
whereby	B-X
the	B-X
gut	B-X
microbiota	B-X
via	B-X
inflammasome	B-X
signaling	B-X
modulate	B-X
pathways	B-X
that	B-X
will	B-X
alter	B-X
brain	B-X
function	B-X
,	B-X
and	B-X
affect	B-X
depressive-	B-X
and	B-X
anxiety-like	B-X
behaviors	B-X
.	B-X

NF	O
-	O
kappaB	O
activation	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	O
-	O
8	O
responses	O
to	O
P	O
.	O
aeruginosa	O

We	O
confirmed	O
the	O
dependence	O
of	O
PAO1	O
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	O
-	O
8	O
production	O
on	O
NF	O
-	O
kappaB	O
activation	O
using	O
THP	O
-	O
1	O
cells	O
expressing	O
a	O
reporter	O
driven	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
response	O
elements	O
.	O

We	O
found	O
that	O
stimulation	O
of	O
primed	O
THP	O
-	O
1	O
reporter	O
cells	O
with	O
heat	O
-	O
killed	O
PAO1	O
produced	O
the	O
highest	O
levels	O
of	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
Fig	O
.	O
6a	O
)	O
and	O
this	O
correlated	O
with	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
but	O
negligible	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
were	O
secreted	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Stimulation	O
of	O
primed	O
THP	O
-	O
1	O
reporter	O
cells	O
with	O
live	O
PAO1	O
did	O
not	O
significantly	O
increase	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
(	O
Fig	O
.	O
6a	O
)	O
or	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
over	O
priming	O
alone	O
.	O

However	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
was	O
greatly	O
augmented	O
over	O
primed	O
cells	O
stimulated	O
with	O
heat	O
-	O
killed	O
PAO1	O
or	O
unprimed	O
cells	O
stimulated	O
with	O
live	O
PAO1	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

This	O
confirmed	O
that	O
NF	O
-	O
kappaB	O
activation	O
alone	O
is	O
not	O
sufficient	O
for	O
maximal	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
,	O
but	O
increased	O
priming	O
of	O
NF	O
-	O
kappaB	O
is	O
capable	O
of	O
augmenting	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
and	O
secretion	O
upon	O
inflammasome	O
stimulation	O
.	O
<EOS>	B-X
M1	B-X
and	B-X
M2	B-X
microglia	B-X
were	B-X
isolated	B-X
from	B-X
primary	B-X
rat	B-X
microglia	B-X
and	B-X
were	B-X
confirmed	B-X
to	B-X
secrete	B-X
pro-inflammatory	B-X
and	B-X
anti-inflammatory	B-X
factors	B-X
,	B-X
respectively	B-X
.	B-X
M1	B-X
microglial	B-X
medium	B-X
increased	B-X
astrocyte	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
factors	B-X
(	B-X
interleukin	B-X
[	B-X
IL	B-X
]	B-X
-1β	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
and	B-X
IL-6	B-X
)	B-X
,	B-X
while	B-X
M2	B-X
microglial	B-X
medium	B-X
enhanced	B-X
astrocyte	B-X
production	B-X
of	B-X
anti-inflammatory	B-X
factors	B-X
(	B-X
IL-4	B-X
and	B-X
IL-10	B-X
)	B-X
.	B-X
To	B-X
analyze	B-X
the	B-X
crosstalk	B-X
between	B-X
microglia	B-X
and	B-X
astrocytes	B-X
after	B-X
microglial	B-X
polarization	B-X
specifically	B-X
in	B-X
AD	B-X
,	B-X
we	B-X
co-cultured	B-X
astrocytes	B-X
with	B-X
medium	B-X
from	B-X
microglia	B-X
treated	B-X
with	B-X
amyloid-β	B-X
(	B-X
Aβ	B-X
)	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
other	B-X
inflammatory	B-X
substances	B-X
.	B-X
Aβ	B-X
alone	B-X
and	B-X
Aβ	B-X
combined	B-X
with	B-X
lipopolysaccharide/interferon-γ	B-X
induced	B-X
pro-inflammatory	B-X
activity	B-X
in	B-X
M1	B-X
microglia	B-X
and	B-X
astrocytes	B-X
,	B-X
whereas	B-X
IL-4/IL-13	B-X
inhibited	B-X
Aβ-induced	B-X
pro-inflammatory	B-X
activity	B-X
.	B-X

Dependency	O
of	O
these	O
responses	O
on	O
NF	O
-	O
kappaB	O
was	O
confirmed	O
by	O
pharmacologic	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
using	O
the	O
Bay11	O
-	O
7082	O
inhibitor	O
of	O
IkappaBalpha	B-Protein
phosphorylation	O
,	O
which	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6d	O
)	O
and	O
the	O
subsequent	O
production	O
of	O
IL	O
-	O
8	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
6e	O
)	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6f	O
)	O
in	O
response	O
to	O
both	O
heat	O
-	O
killed	O
and	O
live	O
PAO1	O
.	O

These	O
results	O
were	O
also	O
verified	O
in	O
CF	O
and	O
control	O
PBMCs	O
for	O
each	O
inflammasome	O
examined	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
6g	O
-	O
h	O
)	O
.	O

Overall	O
these	O
results	O
confirm	O
that	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
modulator	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
and	O
that	O
increased	O
activation	O
of	O
NF	O
-	O
kappaB	O
augments	O
inflammasome	O
-	O
mediated	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O

Bay11	O
-	O
7082	O
inhibits	O
pro	O
-	O
IL	O
-	O
1beta	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O

In	O
addition	O
to	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
Bay11	O
-	O
7082	O
can	O
also	O
directly	O
inhibit	O
the	O
NLRP3	O
inflammasome	O
[	O
38	O
]	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
inflammasome	B-X
generates	B-X
the	B-X
pro-inflammatory	B-X
cytokines	B-X
interleukin-1	B-X
beta	B-X
and	B-X
-18	B-X
,	B-X
which	B-X
are	B-X
important	B-X
mediators	B-X
of	B-X
inflammation	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
the	B-X
inflammasome	B-X
leads	B-X
to	B-X
many	B-X
inflammatory	B-X
diseases	B-X
,	B-X
including	B-X
gout	B-X
,	B-X
silicosis	B-X
,	B-X
neurodegeneration	B-X
,	B-X
and	B-X
genetically	B-X
inherited	B-X
periodic	B-X
fever	B-X
syndromes	B-X
.	B-X
Therefore	B-X
,	B-X
identification	B-X
of	B-X
small	B-X
molecule	B-X
inhibitors	B-X
that	B-X
target	B-X
the	B-X
inflammasome	B-X
is	B-X
an	B-X
important	B-X
step	B-X
toward	B-X
developing	B-X
effective	B-X
therapeutics	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
herbal	B-X
NF-kappaB	B-X
inhibitory	B-X
compound	B-X
parthenolide	B-X
inhibits	B-X
the	B-X
activity	B-X
of	B-X
multiple	B-X
inflammasomes	B-X
in	B-X
macrophages	B-X
by	B-X
directly	B-X
inhibiting	B-X
the	B-X
protease	B-X
activity	B-X
of	B-X
caspase-1	B-X
.	B-X
Additional	B-X
investigations	B-X
of	B-X
other	B-X
NF-kappaB	B-X
inhibitors	B-X
revealed	B-X
that	B-X
the	B-X
synthetic	B-X
I	B-X
kappaB	B-X
kinase-beta	B-X
inhibitor	B-X
Bay	B-X
11-7082	B-X
and	B-X
structurally	B-X
related	B-X
vinyl	B-X
sulfone	B-X
compounds	B-X
selectively	B-X
inhibit	B-X
NLRP3	B-X
inflammasome	B-X
activity	B-X
in	B-X
macrophages	B-X
independent	B-X
of	B-X
their	B-X
inhibitory	B-X
effect	B-X
on	B-X
NF-kappaB	B-X
activity	B-X
.	B-X
In	B-X
vitro	B-X
assays	B-X
of	B-X
the	B-X
effect	B-X
of	B-X
parthenolide	B-X
and	B-X
Bay	B-X
11-7082	B-X
on	B-X
the	B-X
ATPase	B-X
activity	B-X
of	B-X
NLRP3	B-X
demonstrated	B-X
that	B-X
both	B-X
compounds	B-X
inhibit	B-X
the	B-X
ATPase	B-X
activity	B-X
of	B-X
NLRP3	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
these	B-X
compounds	B-X
on	B-X
inflammasome	B-X
activity	B-X
could	B-X
be	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
their	B-X
effect	B-X
on	B-X
the	B-X
ATPase	B-X
activity	B-X
of	B-X
NLRP3	B-X
.	B-X
Our	B-X
results	B-X
thus	B-X
elucidate	B-X
the	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
therapeutic	B-X
anti-inflammatory	B-X
activity	B-X
of	B-X
parthenolide	B-X
and	B-X
identify	B-X
vinyl	B-X
sulfones	B-X
as	B-X
a	B-X
new	B-X
class	B-X
of	B-X
potential	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
NLRP3	B-X
inflammasome	B-X
.	B-X

To	O
validate	O
its	O
use	O
in	O
this	O
study	O
as	O
an	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
western	O
blots	O
for	O
pro	O
-	O
IL	O
-	O
1beta	O
were	O
performed	O
alongside	O
inhibition	O
of	O
CFTR	O
activity	O
by	O
CFTRinh172	O
in	O
response	O
to	O
PAO1	O
at	O
4	O
hours	O
after	O
stimulation	O
(	O
Fig	O
.	O
7a	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
Bay11	O
-	O
7082	O
prevents	O
production	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
whereas	O
CFTRinh172	O
does	O
not	O
seem	O
to	O
affect	O
it	O
.	O

This	O
was	O
further	O
corroborated	O
by	O
the	O
ability	O
Bay11	O
-	O
7082	O
to	O
inhibit	O
IkappaBalpha	B-Protein
degradation	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
1	O
.	O
5	O
hours	O
post	O
PAO1	O
stimulation	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

Disruption	O
of	O
CFTR	O
activity	O
does	O
not	O
increase	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
PBMCs	O
and	O
THP	O
-	O
1	O
cells	O
<EOS>	B-X
Cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
in	B-X
the	B-X
cystic	B-X
fibrosis	B-X
transmembrane	B-X
conductance	B-X
regulator	B-X
(	B-X
CFTR	B-X
)	B-X
gene	B-X
and	B-X
remains	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
life-shortening	B-X
genetic	B-X
diseases	B-X
affecting	B-X
the	B-X
lung	B-X
and	B-X
other	B-X
organs	B-X
.	B-X
CFTR	B-X
functions	B-X
as	B-X
a	B-X
cyclic	B-X
adenosine	B-X
monophosphate-dependent	B-X
anion	B-X
channel	B-X
that	B-X
transports	B-X
chloride	B-X
and	B-X
bicarbonate	B-X
across	B-X
epithelial	B-X
surfaces	B-X
,	B-X
and	B-X
disruption	B-X
of	B-X
these	B-X
ion	B-X
transport	B-X
processes	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CF	B-X
.	B-X
These	B-X
findings	B-X
provided	B-X
the	B-X
rationale	B-X
for	B-X
pharmacologic	B-X
modulation	B-X
of	B-X
ion	B-X
transport	B-X
,	B-X
either	B-X
by	B-X
targeting	B-X
mutant	B-X
CFTR	B-X
or	B-X
alternative	B-X
ion	B-X
channels	B-X
that	B-X
can	B-X
compensate	B-X
for	B-X
CFTR	B-X
dysfunction	B-X
,	B-X
as	B-X
a	B-X
promising	B-X
therapeutic	B-X
approach	B-X
.	B-X
High-throughput	B-X
screening	B-X
has	B-X
supported	B-X
the	B-X
development	B-X
of	B-X
CFTR	B-X
modulator	B-X
compounds	B-X
.	B-X
CFTR	B-X
correctors	B-X
are	B-X
designed	B-X
to	B-X
improve	B-X
defective	B-X
protein	B-X
processing	B-X
,	B-X
trafficking	B-X
,	B-X
and	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
whereas	B-X
potentiators	B-X
increase	B-X
the	B-X
activity	B-X
of	B-X
mutant	B-X
CFTR	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
The	B-X
approval	B-X
of	B-X
the	B-X
first	B-X
potentiator	B-X
ivacaftor	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
specific	B-X
CFTR	B-X
mutations	B-X
and	B-X
,	B-X
more	B-X
recently	B-X
,	B-X
the	B-X
corrector	B-X
lumacaftor	B-X
in	B-X
combination	B-X
with	B-X
ivacaftor	B-X
for	B-X
patients	B-X
homozygous	B-X
for	B-X
the	B-X
common	B-X
F508del	B-X
mutation	B-X
,	B-X
were	B-X
major	B-X
breakthroughs	B-X
on	B-X
the	B-X
path	B-X
to	B-X
causal	B-X
therapies	B-X
for	B-X
all	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X
The	B-X
present	B-X
review	B-X
focuses	B-X
on	B-X
recent	B-X
developments	B-X
and	B-X
remaining	B-X
challenges	B-X
of	B-X
CFTR-directed	B-X
therapies	B-X
,	B-X
as	B-X
well	B-X
as	B-X
modulators	B-X
of	B-X
other	B-X
ion	B-X
channels	B-X
such	B-X
as	B-X
alternative	B-X
chloride	B-X
channels	B-X
and	B-X
the	B-X
epithelial	B-X
sodium	B-X
channel	B-X
as	B-X
additional	B-X
targets	B-X
in	B-X
CF	B-X
lung	B-X
disease	B-X
.	B-X

A	O
previous	O
study	O
has	O
indicated	O
a	O
role	O
for	O
chloride	O
ion	O
concentration	O
in	O
suppression	O
of	O
NLRP3	O
inflammasome	O
activation	O
[	O
34	O
]	O
.	O

To	O
determine	O
whether	O
CFTR	O
dysfunction	O
alters	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
,	O
THP	O
-	O
1	O
cells	O
and	O
PBMCs	O
from	O
CF	O
patients	O
and	O
healthy	O
controls	O
were	O
treated	O
with	O
the	O
CFTR	O
inhibitor	O
,	O
CFTRinh172	O
,	O
prior	O
to	O
simulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
.	O

Treatment	O
with	O
CFTRinh172	O
did	O
not	O
alter	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
or	O
IL	O
-	O
8	O
production	O
in	O
control	O
subjects	O
or	O
CF	O
patients	O
(	O
Fig	O
.	O
8a	O
-	O
b	O
)	O
.	O
<EOS>	B-X
Inflammation	B-X
contributes	B-X
to	B-X
tumor	B-X
progression	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
excessive	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
.	B-X
However	B-X
,	B-X
how	B-X
their	B-X
levels	B-X
relate	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
estrogen	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
,	B-X
progesterone	B-X
receptors	B-X
(	B-X
PR	B-X
)	B-X
and	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
by	B-X
the	B-X
tumor	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Excessive	B-X
or	B-X
persistent	B-X
proinflammatory	B-X
cytokine	B-X
production	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
autoimmune	B-X
diseases	B-X
.	B-X
However	B-X
,	B-X
both	B-X
the	B-X
autonomic	B-X
nervous	B-X
system	B-X
and	B-X
innate	B-X
immune	B-X
system	B-X
are	B-X
regarded	B-X
as	B-X
systems	B-X
that	B-X
can	B-X
not	B-X
be	B-X
voluntarily	B-X
influenced	B-X
.	B-X
Healthy	B-X
volunteers	B-X
were	B-X
randomized	B-X
to	B-X
either	B-X
the	B-X
intervention	B-X
(	B-X
n	B-X
=	B-X
12	B-X
)	B-X
or	B-X
control	B-X
group	B-X
(	B-X
n	B-X
=	B-X
12	B-X
)	B-X
.	B-X
Subjects	B-X
in	B-X
the	B-X
intervention	B-X
group	B-X
were	B-X
trained	B-X
for	B-X
10	B-X
d	B-X
in	B-X
meditation	B-X
(	B-X
third	B-X
eye	B-X
meditation	B-X
)	B-X
,	B-X
breathing	B-X
techniques	B-X
(	B-X
i.a.	B-X
,	B-X
cyclic	B-X
hyperventilation	B-X
followed	B-X
by	B-X
breath	B-X
retention	B-X
)	B-X
,	B-X
and	B-X
exposure	B-X
to	B-X
cold	B-X
(	B-X
i.a.	B-X
,	B-X
immersions	B-X
in	B-X
ice	B-X
cold	B-X
water	B-X
)	B-X
.	B-X
The	B-X
control	B-X
group	B-X
was	B-X
not	B-X
trained	B-X
.	B-X
Subsequently	B-X
,	B-X
all	B-X
subjects	B-X
underwent	B-X
experimental	B-X
endotoxemia	B-X
(	B-X
i.v	B-X
.	B-X
In	B-X
the	B-X
intervention	B-X
group	B-X
,	B-X
plasma	B-X
levels	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokine	B-X
IL-10	B-X
increased	B-X
more	B-X
rapidly	B-X
after	B-X
endotoxin	B-X
administration	B-X
,	B-X
correlated	B-X
strongly	B-X
with	B-X
preceding	B-X
epinephrine	B-X
levels	B-X
,	B-X
and	B-X
were	B-X
higher	B-X
.	B-X
Levels	B-X
of	B-X
proinflammatory	B-X
mediators	B-X
TNF-α	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
IL-8	B-X
were	B-X
lower	B-X
in	B-X
the	B-X
intervention	B-X
group	B-X
and	B-X
correlated	B-X
negatively	B-X
with	B-X
IL-10	B-X
levels	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
voluntary	B-X
activation	B-X
of	B-X
the	B-X
sympathetic	B-X
nervous	B-X
system	B-X
results	B-X
in	B-X
epinephrine	B-X
release	B-X
and	B-X
subsequent	B-X
suppression	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
in	B-X
humans	B-X
in	B-X
vivo	B-X
.	B-X

Similarly	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
was	O
not	O
different	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
or	O
THP	O
-	O
1	O
reporter	O
cells	O
treated	O
with	O
CFTRinh172	O
(	O
Fig	O
.	O
8c	O
-	O
d	O
)	O
.	O
<EOS>	B-X
Caspase-1	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
NLRP3/ASC	B-X
pathway	B-X
and	B-X
inflammasomes	B-X
,	B-X
thus	B-X
triggering	B-X
pyroptosis	B-X
,	B-X
a	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
this	B-X
death	B-X
is	B-X
mediated	B-X
by	B-X
gasdermin	B-X
D	B-X
(	B-X
GSDMD	B-X
)	B-X
,	B-X
which	B-X
induces	B-X
secretion	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
and	B-X
IL-18	B-X
.	B-X
Accordingly	B-X
,	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
prevents	B-X
the	B-X
development	B-X
and	B-X
worsening	B-X
of	B-X
multiple	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
can	B-X
preserve	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
integrity	B-X
following	B-X
cerebral	B-X
infarction	B-X
.	B-X
This	B-X
study	B-X
therefore	B-X
aimed	B-X
at	B-X
understanding	B-X
the	B-X
effect	B-X
of	B-X
caspase-1	B-X
on	B-X
BBB	B-X
dysfunction	B-X
and	B-X
its	B-X
underlying	B-X
mechanisms	B-X
in	B-X
permanent	B-X
middle	B-X
cerebral	B-X
artery	B-X
occlusion	B-X
(	B-X
MCAO	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
in	B-X
rat	B-X
models	B-X
revealed	B-X
that	B-X
expression	B-X
of	B-X
caspase-1	B-X
was	B-X
upregulated	B-X
following	B-X
MCAO-induced	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
Consequently	B-X
,	B-X
pharmacologic	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
using	B-X
vx-765	B-X
ameliorated	B-X
ischemia-induced	B-X
infarction	B-X
,	B-X
neurological	B-X
deficits	B-X
,	B-X
and	B-X
neuronal	B-X
injury	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
enhanced	B-X
the	B-X
encapsulation	B-X
rate	B-X
of	B-X
pericytes	B-X
at	B-X
the	B-X
ischemic	B-X
edge	B-X
,	B-X
decreased	B-X
leakage	B-X
of	B-X
both	B-X
Evans	B-X
Blue	B-X
(	B-X
EB	B-X
)	B-X
and	B-X
matrix	B-X
metalloproteinase	B-X
(	B-X
MMP	B-X
)	B-X
proteins	B-X
,	B-X
and	B-X
upregulated	B-X
the	B-X
levels	B-X
of	B-X
tight	B-X
junctions	B-X
(	B-X
TJs	B-X
)	B-X
and	B-X
tissue	B-X
inhibitors	B-X
of	B-X
metalloproteinases	B-X
(	B-X
TIMPs	B-X
)	B-X
in	B-X
MCAO-injured	B-X
rats	B-X
.	B-X
Meanwhile	B-X
,	B-X
vx-765	B-X
blocked	B-X
the	B-X
activation	B-X
of	B-X
ischemia-induced	B-X
pyroptosis	B-X
and	B-X
reduced	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
inflammatory	B-X
factors	B-X
such	B-X
as	B-X
caspase-1	B-X
,	B-X
NLRP3	B-X
,	B-X
ASC	B-X
,	B-X
GSDMD	B-X
,	B-X
IL-1β	B-X
,	B-X
and	B-X
IL-18	B-X
.	B-X
Similarly	B-X
,	B-X
vx-765	B-X
treatment	B-X
significantly	B-X
reduced	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
inflammation-related	B-X
receptor	B-X
for	B-X
advanced	B-X
glycation	B-X
end	B-X
products	B-X
(	B-X
RAGE	B-X
)	B-X
,	B-X
high-mobility	B-X
family	B-X
box	B-X
1	B-X
(	B-X
HMGB1	B-X
)	B-X
,	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
.	B-X
Evidently	B-X
,	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
significantly	B-X
improves	B-X
ischemia-associated	B-X
BBB	B-X
permeability	B-X
and	B-X
integrity	B-X
by	B-X
suppressing	B-X
pyroptosis	B-X
activation	B-X
and	B-X
the	B-X
RAGE/MAPK	B-X
pathway	B-X
.	B-X

IL	O
-	O
8	O
(	O
Fig	O
.	O
8e	O
)	O
and	O
NF	O
-	O
kappaB	O
activity	O
(	O
Fig	O
.	O
8f	O
)	O
were	O
also	O
unchanged	O
in	O
CFTRinh172	O
-	O
treated	O
THP	O
-	O
1	O
reporter	O
cells	O
.	O

Levels	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
increased	O
in	O
the	O
BALF	O
of	O
CF	O
patients	O
but	O
the	O
cellular	O
source	O
of	O
this	O
cytokine	O
and	O
its	O
production	O
in	O
the	O
context	O
of	O
targeted	O
inflammasome	O
activation	O
are	O
still	O
unclear	O
.	O

We	O
first	O
studied	O
airway	O
epithelial	O
cells	O
due	O
to	O
their	O
role	O
in	O
barrier	O
function	O
,	O
proximity	O
to	O
infection	O
,	O
and	O
ability	O
to	O
produce	O
high	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

However	O
,	O
we	O
found	O
that	O
bronchial	O
epithelial	O
cells	O
do	O
not	O
produce	O
significant	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
do	O
not	O
show	O
a	O
significant	O
increase	O
in	O
caspase	O
-	O
1	O
activation	O
in	O
response	O
to	O
PAO1	O
and	O
LPS	O
+	O
ATP	O
,	O
in	O
comparison	O
to	O
hematopoeitic	O
mononuclear	O
cells	O
.	O
<EOS>	B-X
We	B-X
hypothesised	B-X
that	B-X
a	B-X
Type-2	B-X
cytokine	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-13	B-X
,	B-X
induces	B-X
airway	B-X
epithelial	B-X
expression	B-X
of	B-X
The	B-X
term	B-X
(	B-X
bronchial	B-X
)	B-X
asthma	B-X
describes	B-X
a	B-X
disorder	B-X
syndrome	B-X
that	B-X
comprises	B-X
several	B-X
disease	B-X
phenotypes	B-X
,	B-X
all	B-X
characterized	B-X
by	B-X
chronic	B-X
inflammation	B-X
in	B-X
the	B-X
bronchial	B-X
epithelium	B-X
,	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
subsequent	B-X
functional	B-X
consequences	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
are	B-X
not	B-X
passively	B-X
affected	B-X
by	B-X
inflammatory	B-X
mechanisms	B-X
induced	B-X
by	B-X
immunological	B-X
processes	B-X
but	B-X
rather	B-X
actively	B-X
involved	B-X
in	B-X
all	B-X
steps	B-X
of	B-X
disease	B-X
development	B-X
from	B-X
initiation	B-X
and	B-X
perpetuation	B-X
to	B-X
chronification	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
it	B-X
turned	B-X
out	B-X
that	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
show	B-X
a	B-X
high	B-X
level	B-X
of	B-X
structural	B-X
and	B-X
functional	B-X
diversity	B-X
and	B-X
plasticity	B-X
with	B-X
epigenetic	B-X
mechanisms	B-X
playing	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
processes	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
quite	B-X
reasonable	B-X
that	B-X
differential	B-X
functional	B-X
activities	B-X
of	B-X
the	B-X
bronchial	B-X
epithelium	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
different	B-X
asthma	B-X
phenotypes	B-X
and/or	B-X
stages	B-X
of	B-X
disease	B-X
.	B-X

Hematopoeitically	O
-	O
derived	O
cells	O
,	O
such	O
as	O
monocytes	O
and	O
macrophages	O
,	O
appear	O
to	O
be	O
a	O
principal	O
source	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O

CFTR	O
is	O
expressed	O
in	O
alveolar	O
macrophages	O
[	O
32	O
]	O
,	O
[	O
39	O
]	O
as	O
well	O
as	O
in	O
PBMCs	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
level	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
and	O
its	O
loss	O
is	O
frequently	O
associated	O
with	O
an	O
augmented	O
inflammatory	O
phenotype	O
.	O

Despite	O
our	O
findings	O
indicating	O
that	O
bronchial	O
epithelial	O
cells	O
when	O
grown	O
in	O
vitro	O
are	O
unlikely	O
to	O
be	O
significantly	O
involved	O
in	O
the	O
direct	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
Fig	O
.	O
2a	O
-	O
d	O
)	O
,	O
others	O
have	O
shown	O
their	O
capacity	O
to	O
respond	O
to	O
alveolar	O
macrophage	O
-	O
derived	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
to	O
amplify	O
the	O
inflammatory	O
response	O
through	O
the	O
induction	O
of	O
chemokines	O
and	O
recruitment	O
of	O
inflammatory	O
effector	O
cells	O
[	O
42	O
]	O
.	O

This	O
interaction	O
may	O
constitute	O
a	O
critical	O
component	O
to	O
effective	O
host	O
defense	O
and	O
diminishing	O
the	O
capacity	O
of	O
host	O
cells	O
to	O
respond	O
to	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
may	O
leave	O
the	O
host	O
susceptible	O
to	O
infections	O
by	O
pathogens	O
such	O
as	O
P	O
.	O
aeruginosa	O
[	O
43	O
]	O
.	O

Conversely	O
,	O
overproduction	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
can	O
also	O
play	O
a	O
key	O
role	O
in	O
chronic	O
inflammatory	O
responses	O
and	O
cause	O
damage	O
to	O
the	O
lung	O
parenchyma	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Although	O
we	O
hypothesized	O
that	O
CF	O
cells	O
would	O
secrete	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
we	O
found	O
that	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
CF	O
PBMCs	O
was	O
not	O
increased	O
upon	O
inflammasome	O
stimulation	O
as	O
compared	O
to	O
controls	O
(	O
Fig	O
.	O
5a	O
-	O
b	O
)	O
.	O

This	O
was	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
from	O
our	O
group	O
,	O
which	O
showed	O
increased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
by	O
CF	O
PBMCs	O
in	O
response	O
to	O
LPS	O
[	O
46	O
]	O
,	O
although	O
this	O
difference	O
may	O
be	O
accounted	O
for	O
by	O
technical	O
issues	O
in	O
stimulation	O
time	O
and	O
dose	O
.	O

Moreover	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
was	O
not	O
increased	O
in	O
CF	O
PBMCs	O
with	O
inflammasome	O
stimulation	O
alone	O
as	O
would	O
be	O
anticipated	O
if	O
there	O
were	O
basal	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
the	B-X
pathogenesis	B-X
of	B-X
BPD	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
caffeine	B-X
on	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
in	B-X
LPS-induced	B-X
THP-1	B-X
macrophages	B-X
and	B-X
to	B-X
explore	B-X
the	B-X
underlying	B-X
the	B-X
detailed	B-X
mechanism	B-X
.	B-X
We	B-X
found	B-X
that	B-X
caffeine	B-X
significantly	B-X
reduced	B-X
NLRP3	B-X
expression	B-X
,	B-X
ASC	B-X
speck	B-X
formation	B-X
,	B-X
and	B-X
caspase	B-X
1	B-X
cleavage	B-X
and	B-X
therefore	B-X
decreased	B-X
IL-1β	B-X
and	B-X
IL-18	B-X
secretion	B-X
in	B-X
THP-1	B-X
macrophages	B-X
.	B-X
Caffeine	B-X
also	B-X
markedly	B-X
decreased	B-X
the	B-X
phosphorylation	B-X
levels	B-X
of	B-X
MAPK	B-X
and	B-X
NF-κB	B-X
pathway	B-X
members	B-X
,	B-X
further	B-X
suppressing	B-X
the	B-X
translocation	B-X
of	B-X
NF-κB	B-X
in	B-X
THP-1	B-X
macrophages	B-X
.	B-X
Moreover	B-X
,	B-X
silencing	B-X
of	B-X
the	B-X
caffeine-antagonized	B-X
adenosine	B-X
A2a	B-X
receptor	B-X
(	B-X
A2aR	B-X
)	B-X
significantly	B-X
decreased	B-X
cleaved	B-X
caspase	B-X
1	B-X
expression	B-X
in	B-X
THP-1	B-X
macrophages	B-X
by	B-X
reducing	B-X
ROS	B-X
production	B-X
.	B-X
Given	B-X
these	B-X
findings	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
caffeine	B-X
inhibits	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
by	B-X
suppressing	B-X
MAPK/NF-κB	B-X
signaling	B-X
and	B-X
A2aR-associated	B-X
ROS	B-X
production	B-X
in	B-X
LPS-induced	B-X
THP-1	B-X
macrophages	B-X
.	B-X

Cells	O
deficient	O
in	O
CFTR	O
are	O
thought	O
to	O
exhibit	O
an	O
increased	O
basal	O
level	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
which	O
leads	O
to	O
increased	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
including	O
an	O
increased	O
availability	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
for	O
cleavage	O
and	O
secretion	O
.	O

This	O
amplification	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
was	O
shown	O
by	O
priming	O
THP	O
-	O
1	O
monocytes	O
and	O
PBMCs	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
or	O
LPS	O
prior	O
to	O
stimulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
.	O

This	O
dramatically	O
increased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
over	O
stimulation	O
with	O
live	O
P	O
.	O
aeruginosa	O
without	O
priming	O
(	O
Fig	O
.	O
6c	O
)	O
.	O

Similarly	O
,	O
if	O
CF	O
PBMCs	O
expressed	O
increased	O
basal	O
NF	O
-	O
kappaB	O
activity	O
,	O
there	O
would	O
be	O
an	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
in	O
the	O
absence	O
of	O
LPS	O
priming	O
.	O

However	O
,	O
no	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
was	O
observed	O
under	O
basal	O
or	O
primed	O
conditions	O
.	O
<EOS>	B-X
Pyroptosis	B-X
,	B-X
a	B-X
type	B-X
of	B-X
inflammatory	B-X
cell	B-X
death	B-X
,	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
inflammatory	B-X
caspase-mediated	B-X
cleavage	B-X
of	B-X
gasdermin	B-X
D	B-X
(	B-X
GSDMD	B-X
)	B-X
,	B-X
and	B-X
the	B-X
subsequent	B-X
pore	B-X
formation	B-X
on	B-X
plasma	B-X
membranes	B-X
through	B-X
which	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
and	B-X
IL-18	B-X
are	B-X
released	B-X
from	B-X
cells	B-X
.	B-X
Hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
1α	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
IL-1β	B-X
gene	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
the	B-X
metabolic	B-X
shift	B-X
towards	B-X
glycolysis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
relationships	B-X
between	B-X
pyroptosis	B-X
and	B-X
glycolysis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
between	B-X
pyroptosis	B-X
and	B-X
HIF1α	B-X
are	B-X
poorly	B-X
investigated	B-X
.	B-X
During	B-X
pyroptosis	B-X
,	B-X
HIF1α	B-X
activation	B-X
occurs	B-X
transiently	B-X
followed	B-X
by	B-X
downregulation	B-X
to	B-X
sub-basal	B-X
levels	B-X
.	B-X
HIF1α	B-X
downregulation	B-X
and	B-X
pyroptosis	B-X
are	B-X
observed	B-X
when	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
LPS	B-X
under	B-X
high	B-X
glucose	B-X
conditions	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
intracellular	B-X
levels	B-X
of	B-X
methylglyoxal	B-X
(	B-X
MGO	B-X
)	B-X
,	B-X
a	B-X
side	B-X
product	B-X
of	B-X
glycolysis	B-X
,	B-X
increase	B-X
when	B-X
cells	B-X
are	B-X
stimulated	B-X
with	B-X
LPS	B-X
under	B-X
high	B-X
glucose	B-X
conditions	B-X
.	B-X

Studies	O
investigating	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
have	O
been	O
somewhat	O
inconsistent	O
.	O

A	O
study	O
by	O
Reininger	O
et	O
al	O
.	O

[	O
43	O
]	O
provided	O
evidence	O
that	O
human	O
bronchial	O
epithelial	O
cells	O
possessing	O
the	O
deltaF508	O
CFTR	O
mutation	O
had	O
a	O
slightly	O
reduced	O
capacity	O
to	O
produce	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
lacked	O
the	O
ability	O
to	O
induce	O
an	O
early	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

Conversely	O
,	O
a	O
study	O
by	O
Kotrange	O
et	O
al	O
.	O

[	O
31	O
]	O
found	O
that	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
expressing	O
deltaF508	O
-	O
CFTR	O
produced	O
increased	O
amounts	O
of	O
IL	O
-	O
1beta	O
when	O
compared	O
to	O
macrophages	O
expressing	O
normal	O
CFTR	O
in	O
response	O
to	O
Burkholderia	O
cenocepacia	O
K56	O
-	O
2	O
.	O

The	O
differentiation	O
of	O
monocytes	O
into	O
macrophages	O
may	O
partly	O
account	O
for	O
the	O
differences	O
observed	O
with	O
the	O
study	O
by	O
Kotrange	O
.	O

Inflammasome	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
by	O
monocytes	O
and	O
PBMCs	O
does	O
differ	O
from	O
macrophages	O
[	O
47	O
]	O
,	O
[	O
48	O
]	O
,	O
[	O
49	O
]	O
and	O
macrophages	O
are	O
found	O
to	O
have	O
higher	O
expression	O
of	O
CFTR	O
over	O
monocytes	O
[	O
50	O
]	O
.	O

However	O
,	O
as	O
monocytes	O
and	O
other	O
PBMCs	O
express	O
CFTR	O
[	O
50	O
]	O
,	O
[	O
51	O
]	O
and	O
produce	O
large	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
they	O
are	O
adequate	O
models	O
to	O
examine	O
the	O
effects	O
of	O
CFTR	O
function	O
on	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
.	O

Other	O
hematopoeitic	O
cells	O
may	O
also	O
contribute	O
to	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
.	O

For	O
example	O
,	O
neutrophil	O
counts	O
can	O
be	O
significantly	O
increased	O
in	O
the	O
lungs	O
of	O
CF	O
patients	O
[	O
52	O
]	O
,	O
[	O
53	O
]	O
,	O
[	O
54	O
]	O
and	O
may	O
produce	O
mature	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
through	O
caspase	O
-	O
1	O
independent	O
mechanisms	O
[	O
55	O
]	O
.	O

The	O
role	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
inflammasome	O
activation	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
is	O
not	O
straightforward	O
.	O
<EOS>	B-X
NOD-like	B-X
receptor	B-X
protein	B-X
3	B-X
(	B-X
NLRP3	B-X
)	B-X
inflammasome	B-X
activation	B-X
occurs	B-X
in	B-X
Non-alcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
(	B-X
NAFLD	B-X
)	B-X
.	B-X
We	B-X
used	B-X
the	B-X
first	B-X
small	B-X
molecule	B-X
NLRP3	B-X
inhibitor	B-X
,	B-X
MCC950	B-X
,	B-X
to	B-X
test	B-X
whether	B-X
inflammasome	B-X
blockade	B-X
alters	B-X
inflammatory	B-X
recruitment	B-X
and	B-X
liver	B-X
fibrosis	B-X
in	B-X
two	B-X
murine	B-X
models	B-X
of	B-X
steatohepatitis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
LPS	B-X
in	B-X
hypoxia/reoxygenation	B-X
(	B-X
H/R	B-X
)	B-X
injury	B-X
in	B-X
cardiomyocytes	B-X
under	B-X
high	B-X
glucose	B-X
conditions	B-X
is	B-X
still	B-X
unclear	B-X
.	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
examine	B-X
whether	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
could	B-X
aggravate	B-X
high	B-X
glucose-	B-X
(	B-X
HG-	B-X
)	B-X
and	B-X
hypoxia/reoxygenation-	B-X
(	B-X
H/R-	B-X
)	B-X
induced	B-X
injury	B-X
by	B-X
upregulating	B-X
ROS	B-X
production	B-X
to	B-X
activate	B-X
NLRP3	B-X
inflammasome-mediated	B-X
pyroptosis	B-X
in	B-X
H9C2	B-X
cardiomyocytes	B-X
.	B-X
H9C2	B-X
cardiomyocytes	B-X
were	B-X
exposed	B-X
to	B-X
HG	B-X
(	B-X
30	B-X
mM	B-X
)	B-X
condition	B-X
with	B-X
or	B-X
without	B-X
LPS	B-X
,	B-X
along	B-X
with	B-X
caspase-1	B-X
inhibitor	B-X
(	B-X
Ac-YVAD-CMK	B-X
)	B-X
,	B-X
inflammasome	B-X
inhibitor	B-X
(	B-X
BAY11-7082	B-X
)	B-X
,	B-X
ROS	B-X
scavenger	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
or	B-X
not	B-X
for	B-X
24	B-X
h	B-X
,	B-X
then	B-X
subjected	B-X
to	B-X
4	B-X
h	B-X
of	B-X
hypoxia	B-X
followed	B-X
by	B-X
2	B-X
h	B-X
of	B-X
reoxygenation	B-X
(	B-X
H/R	B-X
)	B-X
.	B-X
The	B-X
concentrations	B-X
of	B-X
IL-1	B-X

Studies	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
production	O
of	O
pro	O
-	O
IL	O
-	O
1beta	O
and	O
inflammasome	O
components	O
such	O
as	O
NLRP3	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
IKKbeta	O
,	O
a	O
kinase	O
essential	O
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
increases	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
in	O
murine	O
macrophages	O
[	O
56	O
]	O
,	O
[	O
57	O
]	O
and	O
demonstrates	O
a	O
dual	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O

To	O
address	O
this	O
uncertainty	O
in	O
our	O
experiments	O
we	O
also	O
quantified	O
IL	O
-	O
8	O
,	O
an	O
important	O
CF	O
cytokine	O
and	O
marker	O
of	O
NF	O
-	O
kappaB	O
activation	O
[	O
58	O
]	O
,	O
and	O
found	O
no	O
differences	O
between	O
CF	O
and	O
control	O
subjects	O
.	O

Similarly	O
,	O
levels	O
of	O
intracellular	O
pro	O
-	O
IL	O
-	O
1beta	O
in	O
THP	O
-	O
1	O
cells	O
were	O
dependent	O
on	O
NF	O
-	O
kappaB	O
activity	O
and	O
did	O
not	O
increase	O
with	O
CFTRinh172	O
treatment	O
.	O

Subsequent	O
treatment	O
of	O
THP	O
-	O
1	O
cells	O
and	O
PBMCs	O
with	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
Bay11	O
-	O
7082	O
significantly	O
inhibited	O
both	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6d	O
-	O
h	O
)	O
.	O

Therefore	O
,	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	O
-	O
8	O
responses	O
observed	O
were	O
both	O
dependent	O
upon	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
The	B-X
aims	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
observe	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
microglial	B-X
cells	B-X
induced	B-X
by	B-X
oxygen-glucose	B-X
deprivation	B-X
and	B-X
reoxygenation	B-X
(	B-X
OGD/R	B-X
)	B-X
and	B-X
the	B-X
specific	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
effects	B-X
are	B-X
mediated	B-X
.	B-X
For	B-X
detecting	B-X
whether	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
increased	B-X
cell	B-X
viability	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
BV2	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
oxygen-glucose	B-X
deprivation	B-X
for	B-X
4	B-X
h	B-X
followed	B-X
by	B-X
3	B-X
h	B-X
reoxygenation	B-X
with	B-X
various	B-X
concentrations	B-X
of	B-X
drugs	B-X
(	B-X
6.25	B-X
,	B-X
12.5	B-X
,	B-X
25	B-X
,	B-X
50	B-X
,	B-X
and	B-X
100	B-X
μg/ml	B-X
)	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
IL-10	B-X
were	B-X
detected	B-X
using	B-X
a	B-X
specific	B-X
Bio-Plex	B-X
Pro™	B-X
Reagent	B-X
Kit	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
on	B-X
protein	B-X
levels	B-X
of	B-X
TLR2/4	B-X
,	B-X
MyD88	B-X
,	B-X
p-TAK1	B-X
,	B-X
p-IKKβ	B-X
,	B-X
p-IkBα	B-X
,	B-X
NF-κB	B-X
p65	B-X
,	B-X
Bcl-2	B-X
,	B-X
Bax	B-X
,	B-X
Bak	B-X
,	B-X
RIP3	B-X
,	B-X
cleaved-Caspase-3	B-X
,	B-X
cleaved	B-X
PARP-1	B-X
and	B-X
cellular	B-X
localization	B-X
of	B-X
NF-κB	B-X
p65	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
and	B-X
double-labeled	B-X
immunofluorescence	B-X
staining	B-X
,	B-X
respectively	B-X
.	B-X
OGD/R	B-X
significantly	B-X
decreased	B-X
the	B-X
cell	B-X
viability	B-X
and	B-X
increased	B-X
the	B-X
release	B-X
of	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
IL-10	B-X
,	B-X
TNF-α	B-X
in	B-X
BV2	B-X
microglia	B-X
cells	B-X
;	B-X
these	B-X
effects	B-X
were	B-X
suppressed	B-X
by	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
.	B-X
Meanwhile	B-X
,	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
also	B-X
attenuated	B-X
the	B-X
OGD/R-induced	B-X
increases	B-X
in	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
MyD88	B-X
,	B-X
Bak	B-X
,	B-X
RIP3	B-X
levels	B-X
and	B-X
reversed	B-X
cleaved	B-X
caspase-3/caspase-3	B-X
,	B-X
Bax/Bcl-2	B-X
and	B-X
cleaved	B-X
PARP-1/PARP-1	B-X
ratio	B-X
.	B-X
Furthermore	B-X
,	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
also	B-X
downregulated	B-X
p-TAK1	B-X
,	B-X
p-IkBα	B-X
,	B-X
and	B-X
p-IKKβ	B-X
and	B-X
inhibited	B-X
the	B-X
OGD/R-induced	B-X
transfer	B-X
of	B-X
NF-κB	B-X
p65	B-X
from	B-X
cytoplasm	B-X
to	B-X
nucleus	B-X
in	B-X
BV2	B-X
microglia	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
ginkgolide	B-X
and	B-X
bilobalide	B-X
can	B-X
inhibit	B-X
OGD/R-induced	B-X
production	B-X
of	B-X
inflammatory	B-X
factors	B-X
in	B-X
BV2	B-X
microglia	B-X
cells	B-X
by	B-X
regulating	B-X
the	B-X
TLRs/MyD88/NF-κB	B-X
signaling	B-X
pathways	B-X
and	B-X
attenuating	B-X
inflammatory	B-X
response	B-X
.	B-X

Priming	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
,	O
like	O
LPS	O
,	O
is	O
unable	O
to	O
induce	O
a	O
strong	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
response	O
as	O
compared	O
to	O
live	O
P	O
.	O
aeruginosa	O
(	O
Fig	O
.	O
6c	O
)	O
,	O
but	O
generated	O
greater	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activation	O
(	O
Fig	O
.	O
6a	O
)	O
and	O
IL	O
-	O
8	O
secretion	O
(	O
Fig	O
.	O
6b	O
)	O
than	O
live	O
bacteria	O
despite	O
stimulation	O
at	O
equivalent	O
MOIs	O
.	O

This	O
may	O
be	O
indicative	O
of	O
the	O
different	O
degree	O
and	O
quality	O
of	O
the	O
inflammatory	O
response	O
generated	O
by	O
live	O
as	O
opposed	O
to	O
dead	O
bacteria	O
[	O
59	O
]	O
.	O

Potential	O
shortcomings	O
of	O
these	O
experiments	O
include	O
its	O
translatability	O
to	O
lung	O
disease	O
and	O
issues	O
related	O
to	O
the	O
hypermutability	O
of	O
P	O
.	O
aeruginosa	O
during	O
the	O
evolution	O
of	O
chronic	O
infection	O
.	O

Although	O
the	O
responses	O
measured	O
in	O
peripheral	O
blood	O
cells	O
may	O
not	O
completely	O
reflect	O
the	O
responses	O
occurring	O
in	O
the	O
CF	O
lung	O
,	O
PBMCs	O
have	O
a	O
number	O
of	O
useful	O
advantages	O
:	O
(	O
i	O
)	O
PBMCs	O
are	O
not	O
subject	O
to	O
alterations	O
that	O
may	O
emerge	O
from	O
long	O
-	O
term	O
cell	O
culture	O
,	O
cloning	O
and	O
immortalization	O
,	O
and	O
(	O
ii	O
)	O
PBMCs	O
express	O
a	O
large	O
repertoire	O
of	O
innate	O
immune	O
receptors	O
and	O
secrete	O
a	O
broad	O
array	O
of	O
cytokines	O
and	O
chemokines	O
allowing	O
comprehensive	O
analysis	O
of	O
the	O
modulation	O
of	O
inflammatory	O
responses	O
by	O
CFTR	O
.	O

Consideration	O
must	O
also	O
be	O
given	O
to	O
the	O
nature	O
of	O
P	O
.	O
aeruginosa	O
infection	O
and	O
genotypic	O
changes	O
in	O
P	O
.	O
aeruginosa	O
as	O
infection	O
progresses	O
.	O

P	O
.	O
aeruginosa	O
mediates	O
inflammasome	O
activation	O
through	O
its	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
and	O
the	O
NLRC4	O
inflammasome	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O
<EOS>	B-X
The	B-X
opportunistic	B-X
pathogen	B-X
Pseudomonas	B-X
aeruginosa	B-X
utilizes	B-X
an	B-X
injectisome-type	B-X
III	B-X
secretion	B-X
system	B-X
(	B-X
injectisome-T3SS	B-X
)	B-X
to	B-X
elicit	B-X
cytotoxicity	B-X
toward	B-X
epithelial	B-X
cells	B-X
and	B-X
macrophages	B-X
.	B-X
Macrophage	B-X
killing	B-X
results	B-X
from	B-X
the	B-X
cytotoxic	B-X
properties	B-X
of	B-X
the	B-X
translocated	B-X
effector	B-X
proteins	B-X
(	B-X
ExoS	B-X
,	B-X
ExoT	B-X
,	B-X
ExoU	B-X
,	B-X
and	B-X
ExoY	B-X
)	B-X
and	B-X
inflammasome-mediated	B-X
induction	B-X
of	B-X
pyroptosis	B-X
.	B-X
Inflammasome	B-X
activation	B-X
can	B-X
occur	B-X
following	B-X
Nlrc4-mediated	B-X
recognition	B-X
of	B-X
cytosolic	B-X
translocated	B-X
flagellin	B-X
(	B-X
FliC	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
FliC	B-X
is	B-X
a	B-X
secretion	B-X
substrate	B-X
of	B-X
both	B-X
the	B-X
injectisome-	B-X
and	B-X
flagellum-associated	B-X
T3SSs	B-X
.	B-X
Molecular	B-X
analyses	B-X
indicate	B-X
that	B-X
the	B-X
first	B-X
20	B-X
amino-terminal	B-X
residues	B-X
of	B-X
FliC	B-X
are	B-X
sufficient	B-X
for	B-X
secretion	B-X
by	B-X
the	B-X
injectisome-T3SS	B-X
and	B-X
that	B-X
the	B-X
first	B-X
100	B-X
residues	B-X
are	B-X
sufficient	B-X
for	B-X
translocation	B-X
of	B-X
FliC	B-X
into	B-X
host	B-X
cells	B-X
.	B-X
Although	B-X
maximal	B-X
inflammasome	B-X
activation	B-X
requires	B-X
FliC	B-X
,	B-X
activation	B-X
can	B-X
also	B-X
occur	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
FliC	B-X
.	B-X
This	B-X
prompted	B-X
us	B-X
to	B-X
examine	B-X
whether	B-X
other	B-X
flagellar	B-X
components	B-X
might	B-X
also	B-X
be	B-X
translocated	B-X
into	B-X
cells	B-X
to	B-X
elicit	B-X
inflammasome	B-X
activation	B-X
.	B-X
Indeed	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
flagellar	B-X
cap	B-X
(	B-X
FliD	B-X
)	B-X
,	B-X
hook-associated	B-X
(	B-X
FlgK	B-X
and	B-X
FlgL	B-X
)	B-X
,	B-X
hook	B-X
(	B-X
FlgE	B-X
)	B-X
,	B-X
and	B-X
rod	B-X
(	B-X
FlgE	B-X
)	B-X
proteins	B-X
are	B-X
secretion	B-X
substrates	B-X
of	B-X
the	B-X
injectisome-T3SS	B-X
.	B-X
None	B-X
of	B-X
these	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
result	B-X
in	B-X
increased	B-X
inflammasome	B-X
activation	B-X
when	B-X
they	B-X
are	B-X
overexpressed	B-X
in	B-X
a	B-X
fliC	B-X
mutant	B-X
and	B-X
appear	B-X
to	B-X
be	B-X
translocated	B-X
into	B-X
host	B-X
cells	B-X
.	B-X
While	B-X
a	B-X
role	B-X
in	B-X
inflammasome	B-X
activation	B-X
has	B-X
been	B-X
excluded	B-X
,	B-X
these	B-X
data	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
flagellar	B-X
components	B-X
,	B-X
which	B-X
are	B-X
highly	B-X
conserved	B-X
between	B-X
different	B-X
bacterial	B-X
species	B-X
,	B-X
trigger	B-X
other	B-X
specific	B-X
host	B-X
responses	B-X
from	B-X
the	B-X
extracellular	B-X
milieu	B-X
or	B-X
contribute	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
P.	B-X
aeruginosa	B-X
.	B-X

However	O
,	O
clones	O
of	O
P	O
.	O
aeruginosa	O
established	O
during	O
chronic	O
infection	O
may	O
accumulate	O
mutations	O
in	O
virulence	O
factors	O
such	O
as	O
exsA	O
[	O
60	O
]	O
.	O

By	O
employing	O
a	O
deletion	O
mutant	O
in	O
exsA	B-Protein
,	O
the	O
key	O
regulator	O
in	O
T3SS	O
transcription	O
,	O
we	O
confirmed	O
that	O
the	O
T3SS	O
is	O
important	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
(	O
Fig	O
.	O
5a	O
-	O
b	O
)	O
,	O
and	O
that	O
depending	O
on	O
the	O
adaptation	O
in	O
type	O
III	O
secretion	O
,	O
the	O
host	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
response	O
may	O
be	O
up	O
or	O
downregulated	O
[	O
19	O
]	O
,	O
[	O
60	O
]	O
,	O
[	O
61	O
]	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
nuts	B-X
on	B-X
major	B-X
cardiovascular	B-X
disease	B-X
(	B-X
CVD	B-X
)	B-X
risk	B-X
factors	B-X
,	B-X
including	B-X
dose-responses	B-X
and	B-X
potential	B-X
heterogeneity	B-X
by	B-X
nut	B-X
type	B-X
or	B-X
phytosterol	B-X
content	B-X
,	B-X
are	B-X
not	B-X
well	B-X
established	B-X
.	B-X
Bisphenol	B-X
AF	B-X
(	B-X
BPAF	B-X
)	B-X
is	B-X
a	B-X
structural	B-X
counterpart	B-X
of	B-X
bisphenol	B-X
A	B-X
that	B-X
is	B-X
utilized	B-X
in	B-X
the	B-X
food	B-X
and	B-X
beverage	B-X
industry	B-X
.	B-X
The	B-X
present	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
mechanisms	B-X
in	B-X
BPAF-induced	B-X
neurotoxicity	B-X
in	B-X
zebrafish	B-X
embryos	B-X
.	B-X
The	B-X
BPAF	B-X
concentrations	B-X
(	B-X
0.03	B-X
,	B-X
0.1	B-X
,	B-X
0.3	B-X
,	B-X
and	B-X
1.0	B-X
µM	B-X
)	B-X
had	B-X
no	B-X
obvious	B-X
effect	B-X
on	B-X
hatching	B-X
,	B-X
mortality	B-X
,	B-X
and	B-X
body	B-X
length	B-X
of	B-X
zebrafish	B-X
larvae	B-X
,	B-X
while	B-X
curved	B-X
tail	B-X
and	B-X
pericardial	B-X
edema	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
1.0	B-X
μM	B-X
group	B-X
at	B-X
72	B-X
and	B-X
96	B-X
h	B-X
postfertilization	B-X
(	B-X
hpf	B-X
)	B-X
.	B-X
Locomotor	B-X
activity	B-X
of	B-X
the	B-X
larvae	B-X
(	B-X
at	B-X
120	B-X
hpf	B-X
)	B-X
significantly	B-X
decreased	B-X
from	B-X
dark	B-X
to	B-X
light	B-X
but	B-X
increased	B-X
from	B-X
light	B-X
to	B-X
dark	B-X
transitions	B-X
in	B-X
BPAF	B-X
groups	B-X
(	B-X
0.1	B-X
,	B-X
0.3	B-X
,	B-X
and	B-X
1.0	B-X
μM	B-X
)	B-X
.	B-X
Consistently	B-X
,	B-X
the	B-X
induced	B-X
apoptosis	B-X
significantly	B-X
up-regulated	B-X
caspase	B-X
3	B-X
at	B-X
0.3	B-X
μM	B-X
(	B-X
1.95-fold	B-X
)	B-X
and	B-X
1.0	B-X
μM	B-X
(	B-X
2.26-fold	B-X
)	B-X
and	B-X
bax	B-X
at	B-X
0.3	B-X
μM	B-X
(	B-X
1.60-fold	B-X
)	B-X
and	B-X
1.0	B-X
μM	B-X
(	B-X
1.78-fold	B-X
)	B-X
,	B-X
whereas	B-X
bcl-2	B-X
expression	B-X
was	B-X
significantly	B-X
decreased	B-X
at	B-X
0.3	B-X
μM	B-X
(	B-X
0.72-fold	B-X
)	B-X
and	B-X
1.0	B-X
μM	B-X
(	B-X
0.53-fold	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
increased	B-X
reactive	B-X
oxygen	B-X
species	B-X
concentrations	B-X
at	B-X
0.3	B-X
μM	B-X
(	B-X
27	B-X
%	B-X
)	B-X
and	B-X
1.0	B-X
μM	B-X
(	B-X
61.4	B-X
%	B-X
)	B-X
resulted	B-X
in	B-X
suppressed	B-X
superoxide	B-X
dismutase	B-X
and	B-X
catalase	B-X
activities	B-X
.	B-X
Aberrations	B-X
in	B-X
dopamine-related	B-X
genes	B-X
were	B-X
congruous	B-X
with	B-X
the	B-X
dysregulations	B-X
in	B-X
neurodevelopment	B-X
genes	B-X
(	B-X
sox11b	B-X
,	B-X
pax6a	B-X
,	B-X
syn2a	B-X
,	B-X
and	B-X
rob2	B-X
)	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
BPAF-evoked	B-X
oxidative	B-X
stress	B-X
and	B-X
apoptosis	B-X
could	B-X
translate	B-X
into	B-X
phenotypical	B-X
behavioral	B-X
and	B-X
neurodevelopmental	B-X
abnormalities	B-X
.	B-X

In	O
conclusion	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
role	O
for	O
hematopoietic	O
cells	O
,	O
not	O
airway	O
epithelial	O
cells	O
,	O
as	O
the	O
major	O
source	O
of	O
inflammasome	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
the	O
lungs	O
in	O
response	O
to	O
ATP	O
and	O
P	O
.	O
aeruginosa	O
.	O
<EOS>	B-X
To	B-X
add	B-X
insight	B-X
into	B-X
potential	B-X
response	B-X
to	B-X
mivebresib	B-X
(	B-X
ABBV-075	B-X
)	B-X
,	B-X
a	B-X
broadspectrum	B-X
BET	B-X
inhibitor	B-X
,	B-X
co-clinical	B-X
modeling	B-X
of	B-X
individual	B-X
patient	B-X
biopsies	B-X
was	B-X
conducted	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
Phase	B-X
I	B-X
trial	B-X
in	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
.	B-X
Monocytes/macrophages	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
CNS	B-X
inflammation	B-X
,	B-X
but	B-X
their	B-X
pathogenetic	B-X
role	B-X
and	B-X
migration	B-X
mechanisms	B-X
in	B-X
flavivirus	B-X
encephalitis	B-X
in	B-X
humans	B-X
are	B-X
not	B-X
well	B-X
known	B-X
.	B-X
The	B-X
data	B-X
were	B-X
analyzed	B-X
with	B-X
non-parametric	B-X
tests	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
considered	B-X
significant	B-X
.	B-X
Monocyte	B-X
CSF	B-X
count	B-X
correlated	B-X
with	B-X
other	B-X
CSF	B-X
inflammatory	B-X
parameters	B-X
,	B-X
but	B-X
not	B-X
with	B-X
the	B-X
peripheral	B-X
monocytosis	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
active	B-X
recruitment	B-X
into	B-X
CNS	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
monocytes	B-X
are	B-X
recruited	B-X
into	B-X
the	B-X
intrathecal	B-X
compartment	B-X
in	B-X
concert	B-X
with	B-X
other	B-X
leukocyte	B-X
populations	B-X
in	B-X
TBE	B-X
.	B-X

Furthermore	O
,	O
we	O
find	O
little	O
evidence	O
to	O
support	O
an	O
increased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
inflammatory	O
response	O
to	O
NF	O
-	O
kappaB	O
/	O
Inflammasome	O
stimulation	O
in	O
CF	O
patients	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
determine	O
if	O
adaptations	O
of	O
P	O
.	O
aeruginosa	O
during	O
the	O
course	O
of	O
chronic	O
lung	O
infection	O
alters	O
inflammasome	O
activation	O
,	O
and	O
whether	O
this	O
can	O
be	O
correlated	O
with	O
disease	O
severity	O
in	O
CF	O
.	O

Ethics	O
Statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
Statement	B-X
is	B-X
to	B-X
increase	B-X
awareness	B-X
of	B-X
all	B-X
stakeholders	B-X
of	B-X
science	B-X
communication	B-X
of	B-X
the	B-X
emerging	B-X
ethical	B-X
issues	B-X
in	B-X
journal	B-X
editing	B-X
and	B-X
publishing	B-X
and	B-X
initiate	B-X
a	B-X
campaign	B-X
of	B-X
upgrading	B-X
and	B-X
enforcing	B-X
related	B-X
journal	B-X
instructions	B-X
.	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
related	B-X
to	B-X
caring	B-X
theory	B-X
,	B-X
the	B-X
concepts	B-X
of	B-X
moral	B-X
accountability	B-X
and	B-X
integrity	B-X
,	B-X
and	B-X
the	B-X
documents	B-X
that	B-X
speak	B-X
of	B-X
these	B-X
values	B-X
and	B-X
concepts	B-X
in	B-X
professional	B-X
practice	B-X
(	B-X
eg	B-X
,	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
,	B-X
Nursing	B-X
's	B-X
Social	B-X
Policy	B-X
Statement	B-X
)	B-X
are	B-X
presented	B-X
in	B-X
this	B-X
article	B-X
.	B-X

Blood	O
samples	O
were	O
obtained	O
with	O
informed	O
written	O
consent	O
from	O
control	O
subjects	O
and	O
CF	O
patients	O
at	O
the	O
BC	O
Children	O
'	O
s	O
Hospital	O
.	O

Consent	O
was	O
obtained	O
for	O
children	O
by	O
their	O
parent	O
or	O
legal	O
guardian	O
.	O
<EOS>	B-X
In	B-X
Canada	B-X
,	B-X
a	B-X
majority	B-X
of	B-X
children	B-X
and	B-X
adults	B-X
are	B-X
insufficiently	B-X
active	B-X
for	B-X
health	B-X
gains	B-X
,	B-X
and	B-X
about	B-X
one	B-X
in	B-X
seven	B-X
children	B-X
and	B-X
over	B-X
20	B-X
%	B-X
of	B-X
adults	B-X
are	B-X
overweight	B-X
or	B-X
obese	B-X
.	B-X
Overweight	B-X
and	B-X
obesity	B-X
are	B-X
risk	B-X
factors	B-X
for	B-X
many	B-X
chronic	B-X
diseases	B-X
in	B-X
both	B-X
adults	B-X
and	B-X
children	B-X
and	B-X
can	B-X
result	B-X
in	B-X
lower	B-X
quality	B-X
and	B-X
quantity	B-X
of	B-X
life	B-X
.	B-X
Children	B-X
whose	B-X
parents	B-X
are	B-X
overweight	B-X
or	B-X
obese	B-X
are	B-X
more	B-X
likely	B-X
to	B-X
become	B-X
overweight	B-X
themselves	B-X
.	B-X
Thus	B-X
,	B-X
parent/child	B-X
interventions	B-X
are	B-X
important	B-X
for	B-X
reducing	B-X
obesity	B-X
and	B-X
promoting	B-X
long-term	B-X
healthy	B-X
weights	B-X
among	B-X
members	B-X
of	B-X
the	B-X
family	B-X
unit	B-X
.	B-X
Programs	B-X
using	B-X
Co-Active	B-X
coaching	B-X
have	B-X
resulted	B-X
in	B-X
positive	B-X
behaviour	B-X
changes	B-X
among	B-X
adults	B-X
with	B-X
overweight/obesity	B-X
;	B-X
however	B-X
,	B-X
little	B-X
research	B-X
has	B-X
explored	B-X
the	B-X
effects	B-X
of	B-X
Co-Active	B-X
coaching	B-X
on	B-X
parents	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
impact	B-X
on	B-X
the	B-X
family	B-X
unit	B-X
(	B-X
i.e	B-X
.	B-X
all	B-X
parents	B-X
and	B-X
children	B-X
in	B-X
the	B-X
same	B-X
household	B-X
)	B-X
.	B-X
This	B-X
protocol	B-X
paper	B-X
provides	B-X
a	B-X
detailed	B-X
methodological	B-X
account	B-X
of	B-X
a	B-X
coaching-based	B-X
program	B-X
targeting	B-X
parent	B-X
and	B-X
child	B-X
dyads	B-X
,	B-X
in	B-X
hopes	B-X
of	B-X
enhancing	B-X
health	B-X
behaviours	B-X
within	B-X
the	B-X
family	B-X
unit	B-X
.	B-X

Subjects	O
7	O
years	O
of	O
age	O
and	O
older	O
were	O
required	O
to	O
provide	O
informed	O
assent	O
as	O
well	O
.	O

Protocols	O
were	O
approved	O
by	O
the	O
Clinical	O
Research	O
Ethics	O
Board	O
(	O
H09	O
-	O
01192	O
)	O
.	O

Cell	O
Culture	O
<EOS>	B-X
Cultures	B-X
,	B-X
supposedly	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
or	B-X
mouse	B-X
,	B-X
proved	B-X
to	B-X
be	B-X
HeLa	B-X
cells	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
valuable	B-X
tools	B-X
which	B-X
is	B-X
being	B-X
applied	B-X
in	B-X
both	B-X
fundamental	B-X
and	B-X
applied	B-X
gastrointestinal	B-X
research	B-X
.	B-X
Cell	B-X
culture	B-X
-	B-X
Fact	B-X
and	B-X
fiction	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
a	B-X
well-established	B-X
standard	B-X
technique	B-X
and	B-X
a	B-X
fundamental	B-X
tool	B-X
in	B-X
biology	B-X
and	B-X
medicine	B-X
.	B-X

CF	O
(	O
IB3	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
)	O
and	O
control	O
(	O
S9	O
and	O
NuLi	O
-	O
1	O
)	O
cells	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
.	O

IB3	O
-	O
1	O
cells	O
were	O
derived	O
from	O
a	O
patient	O
expressing	O
the	O
deltaF508	O
and	O
W1282X	O
mutations	O
and	O
CuFi	O
-	O
1	O
were	O
derived	O
from	O
a	O
deltaF508	O
homozygous	O
patient	O
.	O

S9	O
cells	O
are	O
IB3	O
-	O
1	O
cells	O
that	O
have	O
been	O
transfected	O
with	O
CFTR	O
using	O
an	O
adeno	O
-	O
associated	O
viral	O
vector	O
and	O
NuLi	O
-	O
1	O
cells	O
were	O
derived	O
from	O
a	O
patient	O
possessing	O
a	O
wild	O
-	O
type	O
CFTR	O
genotype	O
.	O

THP1	O
-	O
XBlue	O
cells	O
stably	O
express	O
a	O
secreted	O
embryonic	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
reporter	O
inducible	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
(	O
Invivogen	O
)	O
.	O

Cells	O
were	O
cultured	O
as	O
recommended	O
by	O
their	O
respective	O
suppliers	O
using	O
standard	O
protocols	O
.	O

S9	O
and	O
IB3	O
-	O
1	O
cells	O
were	O
cultured	O
in	O
basal	O
LHC	O
-	O
8	O
(	O
Invitrogen	O
)	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
.	O

NuLi	O
-	O
1	O
/	O
CuFi	O
-	O
1	O
cells	O
were	O
cultured	O
in	O
BEBM	O
serum	O
-	O
free	O
medium	O
(	O
Lonza	O
)	O
with	O
supplement	O
bullet	O
kit	O
(	O
EGF	O
,	O
hydrocortisone	O
,	O
bovine	O
pituitary	O
extract	O
,	O
transferrin	B-Protein
,	O
bovine	O
insulin	B-Protein
,	O
triiodothyronine	O
,	O
epinephrine	O
,	O
retinoic	O
acid	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
.	O

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
(	O
Hyclone	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
mM	O
sodium	O
pyruvate	O
(	O
complete	O
RPMI	O
)	O
.	O

THP1	O
-	O
XBlue	O
cells	O
were	O
cultured	O
in	O
complete	O
RPMI	O
with	O
the	O
addition	O
of	O
zeocin	O
(	O
100	O
microg	O
/	O
ml	O
)	O
to	O
select	O
for	O
cells	O
expressing	O
the	O
SEAP	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
reporter	O
.	O

Prior	O
to	O
stimulation	O
,	O
bronchial	O
epithelial	O
cell	O
lines	O
were	O
plated	O
in	O
coated	O
[	O
62	O
]	O
96	O
-	O
well	O
plates	O
(	O
BD	O
Biosciences	O
)	O
at	O
3x104	O
cells	O
/	O
well	O
unless	O
indicated	O
,	O
and	O
allowed	O
to	O
adhere	O
overnight	O
.	O

Plates	O
for	O
S9	O
and	O
IB3	O
-	O
1	O
stimulations	O
were	O
coated	O
in	O
a	O
mixture	O
of	O
bovine	O
serum	B-Protein
albumin	I-Protein
(	O
100	O
microg	O
/	O
ml	O
)	O
,	O
fibronectin	O
(	O
10	O
microg	O
/	O
ml	O
)	O
,	O
and	O
bovine	O
collage	O
type	O
I	O
(	O
30	O
microg	O
/	O
ml	O
)	O
(	O
BD	O
Biosciences	O
)	O
.	O

Plates	O
for	O
NuLi	O
-	O
1	O
and	O
CuFi	O
-	O
1	O
were	O
coated	O
with	O
collagen	O
type	O
IV	O
(	O
60	O
microg	O
/	O
ml	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
.	O

PBMCs	O
were	O
plated	O
in	O
96	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
1	O
.	O
5x105	O
cells	O
/	O
well	O
in	O
200	O
microl	O
(	O
7	O
.	O
5x105	O
cells	O
/	O
mL	O
)	O
.	O

THP	O
-	O
1	O
reporter	O
cells	O
were	O
differentiated	O
into	O
a	O
macrophage	O
-	O
like	O
phenotype	O
using	O
50	O
ng	O
/	O
ml	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
for	O
24	O
hours	O
at	O
a	O
density	O
of	O
1x105	O
cells	O
/	O
well	O
in	O
200	O
microl	O
(	O
5x105	O
cells	O
/	O
ml	O
)	O
.	O

Cells	O
were	O
washed	O
with	O
PBS	O
and	O
allowed	O
to	O
rest	O
a	O
further	O
42	O
hours	O
prior	O
to	O
stimulation	O
.	O

CF	O
and	O
control	O
subject	O
PBMCs	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
systematic	B-X
review	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
previously	B-X
reported	B-X
dysregulation	B-X
of	B-X
KP	B-X
and	B-X
differences	B-X
in	B-X
its	B-X
metabolites	B-X
and	B-X
enzymes	B-X
in	B-X
patients	B-X
with	B-X
MS	B-X
compared	B-X
to	B-X
healthy	B-X
control	B-X
subjects	B-X
.	B-X
Cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
mutations	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
the	B-X
CF	B-X
transmembrane	B-X
conductance	B-X
regulator	B-X
.	B-X
It	B-X
remains	B-X
unclear	B-X
whether	B-X
the	B-X
abnormal	B-X
immune	B-X
response	B-X
in	B-X
CF	B-X
involves	B-X
extrinsic	B-X
signals	B-X
released	B-X
from	B-X
the	B-X
external	B-X
or	B-X
internal	B-X
environment	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
peripheral	B-X
immune	B-X
signatures	B-X
in	B-X
CF	B-X
and	B-X
its	B-X
association	B-X
with	B-X
clinical	B-X
phenotypes	B-X
.	B-X
Healthy	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
were	B-X
cultured	B-X
with	B-X
plasma	B-X
from	B-X
CF	B-X
probands	B-X
(	B-X
CFPs	B-X
)	B-X
or	B-X
healthy	B-X
control	B-X
subjects	B-X
(	B-X
HCs	B-X
)	B-X
followed	B-X
by	B-X
nCounter	B-X
gene	B-X
and	B-X
microRNA	B-X
(	B-X
miRNA	B-X
)	B-X
profiling	B-X
.	B-X
A	B-X
discovery	B-X
cohort	B-X
of	B-X
12	B-X
CFPs	B-X
and	B-X
12	B-X
HCs	B-X
and	B-X
a	B-X
validation	B-X
cohort	B-X
of	B-X
103	B-X
CFPs	B-X
and	B-X
31	B-X
HCs	B-X
(	B-X
our	B-X
previous	B-X
microarray	B-X
data	B-X
[	B-X
GSE71799	B-X
]	B-X
)	B-X
were	B-X
analyzed	B-X
to	B-X
characterize	B-X
the	B-X
composition	B-X
of	B-X
cultured	B-X
immune	B-X
cells	B-X
and	B-X
establish	B-X
a	B-X
miRNA‒mRNA	B-X
network	B-X
.	B-X
Significantly	B-X
differentially	B-X
expressed	B-X
genes	B-X
and	B-X
abundance	B-X
of	B-X
myeloid	B-X
cells	B-X
were	B-X
downregulated	B-X
in	B-X
PMBCs	B-X
after	B-X
culture	B-X
with	B-X
CF	B-X
plasma	B-X
(	B-X

The	O
diagnosis	O
of	O
CF	O
was	O
established	O
by	O
typical	O
clinical	O
features	O
,	O
increased	O
sweat	O
chloride	O
concentrations	O
(	O
>	O
60	O
mmol	O
/	O
l	O
)	O
,	O
and	O
detection	O
of	O
CF	O
-	O
inducing	O
mutations	O
.	O

All	O
patients	O
with	O
CF	O
were	O
clinically	O
stable	O
at	O
the	O
time	O
of	O
blood	O
donation	O
,	O
and	O
we	O
excluded	O
any	O
subjects	O
who	O
were	O
receiving	O
systemic	O
corticosteroids	O
due	O
to	O
potential	O
immunomodulatory	O
activity	O
.	O

Control	O
samples	O
were	O
provided	O
by	O
healthy	O
adult	O
volunteers	O
.	O
<EOS>	B-X
In	B-X
the	B-X
Taizhou	B-X
Longitudinal	B-X
Study	B-X
(	B-X
TZL	B-X
)	B-X
,	B-X
123,115	B-X
healthy	B-X
subjects	B-X
provided	B-X
plasma	B-X
samples	B-X
for	B-X
long-term	B-X
storage	B-X
and	B-X
were	B-X
then	B-X
monitored	B-X
for	B-X
cancer	B-X
occurrence	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
preliminary	B-X
results	B-X
of	B-X
PanSeer	B-X
,	B-X
a	B-X
noninvasive	B-X
blood	B-X
test	B-X
based	B-X
on	B-X
circulating	B-X
tumor	B-X
DNA	B-X
methylation	B-X
,	B-X
on	B-X
TZL	B-X
plasma	B-X
samples	B-X
from	B-X
605	B-X
asymptomatic	B-X
individuals	B-X
,	B-X
191	B-X
of	B-X
whom	B-X
were	B-X
later	B-X
diagnosed	B-X
with	B-X
stomach	B-X
,	B-X
esophageal	B-X
,	B-X
colorectal	B-X
,	B-X
lung	B-X
or	B-X
liver	B-X
cancer	B-X
within	B-X
four	B-X
years	B-X
of	B-X
blood	B-X
draw	B-X
.	B-X
We	B-X
also	B-X
assay	B-X
plasma	B-X
samples	B-X
from	B-X
an	B-X
additional	B-X
223	B-X
cancer	B-X
patients	B-X
,	B-X
plus	B-X
200	B-X
primary	B-X
tumor	B-X
and	B-X
normal	B-X
tissues	B-X
.	B-X
A	B-X
total	B-X
of	B-X
92	B-X
samples	B-X
were	B-X
collected	B-X
from	B-X
24	B-X
caries	B-X
patients	B-X
and	B-X
22	B-X
healthy	B-X
controls	B-X
.	B-X

In	O
previously	O
published	O
work	O
we	O
have	O
demonstrated	O
that	O
TLR	O
-	O
mediated	O
inflammatory	O
responses	O
are	O
stable	O
in	O
humans	O
from	O
birth	O
to	O
60	O
years	O
old	O
[	O
63	O
]	O
,	O
therefore	O
did	O
not	O
age	O
-	O
match	O
the	O
CF	O
patients	O
and	O
control	O
subjects	O
.	O

Peripheral	O
blood	O
was	O
collected	O
in	O
sodium	O
heparin	O
tubes	O
(	O
BD	O
Biosciences	O
)	O
and	O
PBMCs	O
were	O
isolated	O
using	O
density	O
gradient	O
centrifugation	O
on	O
Ficoll	O
-	O
Paque	O
(	O
TM	O
)	O
Plus	O
(	O
GE	O
Healthcare	O
)	O
.	O

The	O
layer	O
containing	O
PBMCs	O
was	O
isolated	O
,	O
washed	O
twice	O
in	O
PBS	O
and	O
resuspended	O
in	O
complete	O
RPMI	O
.	O

Cells	O
were	O
enumerated	O
by	O
trypan	O
blue	O
exclusion	O
using	O
the	O
Countess	O
automated	O
cell	O
counter	O
(	O
Invitrogen	O
)	O
.	O

For	O
derivation	O
of	O
macrophages	O
from	O
monocytes	O
,	O
monocytes	O
were	O
allowed	O
to	O
adhere	O
to	O
plastic	O
for	O
2	O
hours	O
in	O
RPMI	O
1640	O
after	O
which	O
non	O
-	O
adherent	O
cells	O
were	O
removed	O
.	O

Monocytes	O
were	O
allowed	O
to	O
differentiate	O
in	O
RPMI	O
1640	O
supplemented	O
with	O
10	O
%	O
human	O
AB	O
serum	O
for	O
10	O
days	O
.	O

Cell	O
stimulation	O
and	O
cytokine	O
quantification	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
methodology	B-X
for	B-X
the	B-X
enrichment	B-X
,	B-X
quantification	B-X
,	B-X
and	B-X
proteomic	B-X
and	B-X
lipidomic	B-X
analysis	B-X
of	B-X
EVs	B-X
released	B-X
from	B-X
mouse	B-X
TAMs	B-X
(	B-X
TAM-EVs	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
the	B-X
feasibility	B-X
of	B-X
direct	B-X
,	B-X
quantitative	B-X
measurement	B-X
of	B-X
cytokine	B-X
proteins	B-X
in	B-X
single	B-X
human	B-X
CD8	B-X
lymphocytes	B-X
from	B-X
fresh	B-X
peripheral	B-X
blood	B-X
of	B-X
healthy	B-X
donors	B-X
following	B-X
a	B-X
brief	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
effects	B-X
of	B-X
different	B-X
silicate-based	B-X
sealers	B-X
(	B-X
ie	B-X
,	B-X
BioRoot	B-X
RCS	B-X
[	B-X
Septodont	B-X
,	B-X
Saint	B-X
Maur	B-X
des	B-X
Fosses	B-X
,	B-X
France	B-X
]	B-X
,	B-X
ProRoot	B-X
ES	B-X
[	B-X
Dentsply	B-X
Sirona	B-X
,	B-X
York	B-X
,	B-X
PA	B-X
]	B-X
,	B-X
and	B-X
MTA	B-X
Fillapex	B-X
[	B-X
Angelus	B-X
,	B-X
Londrina	B-X
,	B-X
PR	B-X
,	B-X
Brazil	B-X
]	B-X
)	B-X
on	B-X
cytokine	B-X
production	B-X
and	B-X
viability	B-X
of	B-X
human	B-X
periodontal	B-X
ligament	B-X
stem	B-X
cells	B-X
(	B-X
PDLSCs	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
stimulation	B-X
of	B-X
cells	B-X
followed	B-X
by	B-X
surface	B-X
and	B-X
intracellular	B-X
staining	B-X
,	B-X
presented	B-X
here	B-X
,	B-X
has	B-X
the	B-X
advantage	B-X
of	B-X
detecting	B-X
the	B-X
cytokines	B-X
directly	B-X
instead	B-X
of	B-X
relying	B-X
exclusively	B-X
on	B-X
surrogate	B-X
surface	B-X
markers	B-X
which	B-X
,	B-X
although	B-X
showing	B-X
enrichment	B-X
for	B-X
the	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
are	B-X
not	B-X
specific	B-X
markers	B-X
for	B-X
the	B-X
cytokine-producing	B-X
cells	B-X
.	B-X

Bronchial	O
epithelial	O
cells	O
were	O
plated	O
and	O
allowed	O
to	O
adhere	O
overnight	O
prior	O
to	O
stimulation	O
.	O

Bronchial	O
epithelial	O
cells	O
were	O
rested	O
or	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
stimulated	O
with	O
live	O
P	O
.	O
aeruginosa	O
PAO1	O
or	O
ATP	O
for	O
the	O
times	O
indicated	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
diseases	B-X
,	B-X
asthma	B-X
affects	B-X
358	B-X
million	B-X
people	B-X
worldwide	B-X
.	B-X
Human	B-X
bronchial	B-X
epithelium	B-X
cells	B-X
(	B-X
HBEC	B-X
)	B-X
express	B-X
both	B-X
anti-inflammatory	B-X
and	B-X
activating	B-X
molecules	B-X
,	B-X
and	B-X
their	B-X
deregulated	B-X
expression	B-X
contribute	B-X
to	B-X
immune	B-X
cell	B-X
recruitment	B-X
and	B-X
activation	B-X
,	B-X
especially	B-X
platelets	B-X
(	B-X
PLT	B-X
)	B-X
particularly	B-X
involved	B-X
in	B-X
lung	B-X
tissue	B-X
inflammation	B-X
in	B-X
asthma	B-X
context	B-X
.	B-X
Previous	B-X
results	B-X
supported	B-X
that	B-X
HLA-G	B-X
dysregulation	B-X
in	B-X
lung	B-X
tissue	B-X
is	B-X
associated	B-X
with	B-X
immune	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
explored	B-X
HLA-F	B-X
transcriptional	B-X
expression	B-X
in	B-X
HBEC	B-X
;	B-X
HLA-F	B-X
total	B-X
expression	B-X
in	B-X
PBMC	B-X
and	B-X
HBEC	B-X
collected	B-X
from	B-X
healthy	B-X
individuals	B-X
at	B-X
rest	B-X
and	B-X
upon	B-X
chemical	B-X
activation	B-X
and	B-X
HLA-F	B-X
membrane	B-X
expression	B-X
in	B-X
PBMC	B-X
,	B-X
HBEC	B-X
and	B-X
PLT	B-X
collected	B-X
from	B-X
healthy	B-X
individuals	B-X
at	B-X
rest	B-X
and	B-X
upon	B-X
chemical	B-X
activation	B-X
.	B-X
We	B-X
compared	B-X
HLA-F	B-X
transcriptional	B-X
expression	B-X
in	B-X
HBEC	B-X
from	B-X
healthy	B-X
individuals	B-X
and	B-X
asthmatic	B-X
patients	B-X
and	B-X
its	B-X
surface	B-X
expression	B-X
in	B-X
HBEC	B-X
and	B-X
PLT	B-X
from	B-X
healthy	B-X
individuals	B-X
and	B-X
asthmatic	B-X
patients	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
that	B-X
HLA-F	B-X
is	B-X
expressed	B-X
by	B-X
HBEC	B-X
and	B-X
PLT	B-X
under	B-X
healthy	B-X
physiological	B-X
conditions	B-X
and	B-X
is	B-X
retained	B-X
in	B-X
cytoplasm	B-X
,	B-X
barely	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
,	B-X
as	B-X
previously	B-X
reported	B-X
in	B-X
immune	B-X
cells	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
that	B-X
HLA-F	B-X
surface	B-X
expression	B-X
is	B-X
a	B-X
ubiquitous	B-X
post-transcriptional	B-X
process	B-X
in	B-X
activated	B-X
cells	B-X
.	B-X

PBMCs	O
and	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
either	O
rested	O
or	O
primed	O
with	O
LPS	O
(	O
Invivogen	O
)	O
or	O
heat	O
-	O
killed	O
PAO1	O
overnight	O
(	O
16	O
hours	O
)	O
.	O

The	O
next	O
day	O
the	O
cells	O
were	O
challenged	O
with	O
live	O
PAO1	O
,	O
PAO1deltaexsA	O
,	O
ATP	O
(	O
Invivogen	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
Sigma	O
Aldrich	O
)	O
for	O
the	O
times	O
indicated	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O

For	O
stimulations	O
with	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
,	O
lipofectamine	O
LTX	O
was	O
used	O
at	O
a	O
1	O
:	O
1	O
(	O
w	O
:	O
v	O
)	O
ratio	O
of	O
microg	O
of	O
DNA	O
to	O
microl	O
of	O
lipofectamine	O
and	O
was	O
mixed	O
30	O
minutes	O
prior	O
to	O
stimulation	O
.	O

The	O
NF	O
-	O
kappaB	O
inhibitor	O
Bay11	O
-	O
7082	O
(	O
Invivogen	O
)	O
was	O
added	O
to	O
cultures	O
1	O
hour	O
prior	O
to	O
priming	O
.	O

If	O
no	O
priming	O
was	O
involved	O
,	O
inhibitor	O
was	O
added	O
1	O
hour	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

The	O
CFTR	O
inhibitor	O
CFTRinh172	O
(	O
Sigma	O
Aldrich	O
)	O
was	O
added	O
to	O
cultures	O
18	O
hours	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

The	O
caspase	O
-	O
1	O
inhibitor	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
Biovision	O
)	O
was	O
added	O
to	O
cultures	O
1	O
hour	O
prior	O
to	O
inflammasome	O
stimulation	O
.	O

Supernatants	O
were	O
collected	O
and	O
stored	O
at	O
-	O
20degreesC	O
.	O

Cytokines	O
released	O
into	O
supernatants	O
from	O
PBMCs	O
stimulated	O
with	O
inflammasome	O
activators	O
were	O
quantified	O
using	O
sandwich	O
ELISA	O
(	O
eBioscience	O
)	O
.	O

Immunoblotting	O
<EOS>	B-X
Immunoblotting	B-X
(	B-X
also	B-X
known	B-X
as	B-X
Western	B-X
blotting	B-X
)	B-X
combined	B-X
with	B-X
digital	B-X
image	B-X
analysis	B-X
can	B-X
be	B-X
a	B-X
reliable	B-X
method	B-X
for	B-X
analyzing	B-X
the	B-X
abundance	B-X
of	B-X
proteins	B-X
and	B-X
protein	B-X
modifications	B-X
,	B-X
but	B-X
not	B-X
every	B-X
immunoblot-analysis	B-X
combination	B-X
produces	B-X
an	B-X
accurate	B-X
result	B-X
.	B-X
Grid-Immunoblotting	B-X
is	B-X
a	B-X
fast	B-X
,	B-X
simple	B-X
,	B-X
and	B-X
efficient	B-X
method	B-X
for	B-X
simultaneously	B-X
testing	B-X
multiple	B-X
allergens	B-X
utilizing	B-X
small	B-X
amount	B-X
of	B-X
antibody	B-X
.	B-X
Immunoblotting	B-X
(	B-X
western	B-X
blotting	B-X
)	B-X
is	B-X
used	B-X
to	B-X
identify	B-X
specific	B-X
antigens	B-X
recognized	B-X
by	B-X
polyclonal	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
.	B-X
Immunoblotting	B-X
(	B-X
western	B-X
blotting	B-X
)	B-X
is	B-X
used	B-X
to	B-X
identify	B-X
specific	B-X
antigens	B-X
recognized	B-X
by	B-X
polyclonal	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
.	B-X

1x106	O
cells	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
,	O
stimulated	O
as	O
indicated	O
,	O
and	O
lysed	O
in	O
RIPA	O
buffer	O
supplemented	O
with	O
Halt	O
protease	O
and	O
phosphatase	O
inhibitor	O
cocktail	O
(	O
Thermo	O
Scientific	O
)	O
.	O

Protein	O
concentrations	O
were	O
determined	O
by	O
Bradford	O
assay	O
(	O
Thermo	O
Scientific	O
)	O
.	O
<EOS>	B-X
The	B-X
color	B-X
produced	B-X
from	B-X
this	B-X
reaction	B-X
is	B-X
stable	B-X
and	B-X
increases	B-X
in	B-X
a	B-X
proportional	B-X
manner	B-X
over	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
protein	B-X
concentrations	B-X
.	B-X
The	B-X
new	B-X
Pierce	B-X
660	B-X
nm	B-X
Protein	B-X
Assay	B-X
is	B-X
very	B-X
reproducible	B-X
,	B-X
rapid	B-X
,	B-X
and	B-X
more	B-X
linear	B-X
compared	B-X
with	B-X
the	B-X
Coomassie	B-X
dye-based	B-X
Bradford	B-X
assay	B-X
.	B-X
The	B-X
assay	B-X
reagent	B-X
is	B-X
room	B-X
temperature	B-X
stable	B-X
,	B-X
and	B-X
the	B-X
assay	B-X
is	B-X
a	B-X
simple	B-X
and	B-X
convenient	B-X
mix-and-read	B-X
format	B-X
.	B-X
The	B-X
assay	B-X
has	B-X
a	B-X
moderate	B-X
protein-to-protein	B-X
variation	B-X
and	B-X
is	B-X
compatible	B-X
with	B-X
most	B-X
detergents	B-X
,	B-X
reducing	B-X
agents	B-X
,	B-X
and	B-X
other	B-X
commonly	B-X
used	B-X
reagents	B-X
.	B-X
This	B-X
is	B-X
an	B-X
added	B-X
advantage	B-X
for	B-X
researchers	B-X
needing	B-X
to	B-X
determine	B-X
protein	B-X
concentrations	B-X
in	B-X
samples	B-X
containing	B-X
both	B-X
detergents	B-X
and	B-X
reducing	B-X
agents	B-X
.	B-X

Lysates	O
were	O
resolved	O
by	O
electrophoreses	O
on	O
10	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
and	O
transferred	O
onto	O
PVDF	O
membranes	O
(	O
Millipore	O
)	O
.	O

Blots	O
were	O
blocked	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
and	O
probed	O
overnight	O
at	O
4degreesC	O
for	O
pro	O
-	O
IL	O
-	O
1beta	O
(	O
Santa	O
Cruz	O
)	O
,	O
IkappaBalpha	B-Protein
(	O
Cell	O
Signaling	O
)	O
,	O
or	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
Cell	O
Signaling	O
)	O
.	O
<EOS>	B-X
Endothelial	B-X
cells	B-X
line	B-X
blood	B-X
vessels	B-X
and	B-X
provide	B-X
a	B-X
dynamic	B-X
interface	B-X
between	B-X
the	B-X
blood	B-X
and	B-X
tissues	B-X
.	B-X
Here	B-X
we	B-X
compare	B-X
the	B-X
signaling	B-X
networks	B-X
that	B-X
contribute	B-X
to	B-X
endothelial	B-X
permeability	B-X
and	B-X
leukocyte	B-X
transendothelial	B-X
migration	B-X
,	B-X
focusing	B-X
particularly	B-X
on	B-X
signals	B-X
mediated	B-X
by	B-X
small	B-X
GTPases	B-X
that	B-X
regulate	B-X
cell	B-X
adhesion	B-X
and	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
.	B-X
Rho	B-X
and	B-X
Rap	B-X
GTPase	B-X
signaling	B-X
is	B-X
important	B-X
for	B-X
both	B-X
processes	B-X
,	B-X
but	B-X
they	B-X
differ	B-X
in	B-X
that	B-X
signals	B-X
are	B-X
activated	B-X
locally	B-X
under	B-X
leukocytes	B-X
,	B-X
whereas	B-X
endothelial	B-X
permeability	B-X
is	B-X
a	B-X
wider	B-X
event	B-X
that	B-X
affects	B-X
the	B-X
whole	B-X
cell	B-X
.	B-X
Some	B-X
molecules	B-X
play	B-X
a	B-X
unique	B-X
role	B-X
in	B-X
one	B-X
of	B-X
the	B-X
two	B-X
processes	B-X
,	B-X
and	B-X
could	B-X
therefore	B-X
be	B-X
targeted	B-X
to	B-X
selectively	B-X
alter	B-X
either	B-X
endothelial	B-X
permeability	B-X
or	B-X
leukocyte	B-X
transendothelial	B-X
migration	B-X
.	B-X

Blots	O
were	O
subsequently	O
probed	O
with	O
fluorescently	O
-	O
labeled	O
secondary	O
antibodies	O
,	O
IRDye	O
(	O
R	O
)	O
680	O
or	O
800CW	O
(	O
LI	O
-	O
COR	O
Biosciences	O
)	O
for	O
1	O
hour	O
.	O

Both	O
blocking	O
and	O
probing	O
steps	O
were	O
carried	O
out	O
in	O
tris	O
-	O
buffered	O
saline	O
(	O
G	O
Biosciences	O
)	O
containing	O
5	O
%	O
bovine	O
serum	O
albumin	O
and	O
0	O
.	O
1	O
%	O
TWEEN	O
20	O
(	O
Calbiochem	O
)	O
.	O

Blots	O
were	O
imaged	O
on	O
a	O
LI	O
-	O
COR	O
Odyssey	O
infrared	O
imaging	O
system	O
(	O
LI	O
-	O
COR	O
Biosciences	O
)	O
and	O
quantified	O
using	O
the	O
included	O
analysis	O
software	O
.	O

Quantification	O
of	O
caspase	O
-	O
1	O
activity	O
<EOS>	B-X
(	B-X
1	B-X
)	B-X
Background	B-X
:	B-X
Monocytes	B-X
and	B-X
nucleotide-binding	B-X
oligomerization	B-X
domain-like	B-X
receptor	B-X
protein	B-X
3	B-X
(	B-X
NLRP3	B-X
)	B-X
inflammasome	B-X
orchestrate	B-X
lipid-driven	B-X
amplification	B-X
of	B-X
vascular	B-X
inflammation	B-X
promoting	B-X
the	B-X
disruption	B-X
of	B-X
the	B-X
fibrous	B-X
cap	B-X
.	B-X
(	B-X
2	B-X
)	B-X
Methods	B-X
:	B-X
The	B-X
direct	B-X
effect	B-X
of	B-X
oxLDL-activated	B-X
monocytes	B-X
in	B-X
VSMCs	B-X
co-cultured	B-X
system	B-X
was	B-X
demonstrated	B-X
via	B-X
flow	B-X
cytometry	B-X
,	B-X
qPCR	B-X
,	B-X
ELISA	B-X
,	B-X
caspase	B-X
1	B-X
,	B-X
and	B-X
pyroptosis	B-X
assay	B-X
.	B-X
Cerebral	B-X
cavernous	B-X
malformations	B-X
(	B-X
CCMs	B-X
)	B-X
are	B-X
neurovascular	B-X
lesions	B-X
caused	B-X
by	B-X
loss	B-X
of	B-X
function	B-X
mutations	B-X
in	B-X
1	B-X
of	B-X
3	B-X
genes	B-X
,	B-X
including	B-X
Pyroptosis	B-X
is	B-X
a	B-X
type	B-X
of	B-X
proinflammatory	B-X
regulated	B-X
cell	B-X
death	B-X
(	B-X
RCD	B-X
)	B-X
in	B-X
which	B-X
caspase-1	B-X
proteolytically	B-X
cleaves	B-X
gasdermin	B-X
D	B-X
(	B-X
GSDMD	B-X
)	B-X
to	B-X
yield	B-X
a	B-X
cytotoxic	B-X
pore-forming	B-X
protein	B-X
.	B-X

Bronchial	O
epithelial	O
cells	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
at	O
5x105	O
cells	O
/	O
well	O
overnight	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
stimulated	O
with	O
ATP	O
for	O
1	O
hour	O
or	O
stimulated	O
with	O
live	O
PAO1	O
for	O
3	O
hours	O
.	O

PBMCs	O
were	O
stimulated	O
the	O
same	O
day	O
as	O
blood	O
donation	O
.	O

PBMCs	O
were	O
seeded	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
a	O
density	O
of	O
4	O
.	O
5x105	O
cells	O
/	O
well	O
(	O
2	O
.	O
5x106	O
cells	O
/	O
ml	O
)	O
,	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
and	O
then	O
stimulated	O
with	O
ATP	O
for	O
1	O
hour	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
for	O
3	O
hours	O
or	O
stimulated	O
with	O
live	O
PAO1	O
for	O
3	O
hours	O
.	O
<EOS>	B-X
Poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
is	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
physio-logical	B-X
role	B-X
in	B-X
maintaining	B-X
genomic	B-X
integrity	B-X
and	B-X
in	B-X
the	B-X
repair	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
A	B-X
PARP	B-X
inhibitor	B-X
,	B-X
3	B-X
,	B-X
4-dihydro-5-	B-X
[	B-X
4-	B-X
(	B-X
1-piperidinyl	B-X
)	B-X
butoxy	B-X
]	B-X
-1	B-X
(	B-X
2H	B-X
)	B-X
-isoquinolinone	B-X
(	B-X
DPQ	B-X
;	B-X
IC50=1	B-X
microM/l	B-X
)	B-X
was	B-X
injected	B-X
i.p	B-X
.	B-X
30	B-X
min	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
MCA	B-X
occlusion	B-X
(	B-X
control	B-X
:	B-X
10	B-X
,	B-X
20	B-X
,	B-X
40	B-X
and	B-X
80	B-X
mg/kg	B-X
;	B-X
n=7	B-X
each	B-X
)	B-X
.	B-X
Twenty-four	B-X
hours	B-X
later	B-X
,	B-X
the	B-X
total	B-X
infarct	B-X
volume	B-X
was	B-X
measured	B-X
.	B-X
Regional	B-X
blood	B-X
flow	B-X
in	B-X
the	B-X
right	B-X
parietal	B-X
cortex	B-X
decreased	B-X
to	B-X
approximately	B-X
20	B-X
%	B-X
of	B-X
the	B-X
baseline	B-X
following	B-X
MCA	B-X
occlusion	B-X
in	B-X
all	B-X
groups	B-X
.	B-X
PARP	B-X
inhibition	B-X
lead	B-X
to	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
damaged	B-X
volume	B-X
in	B-X
all	B-X
treated	B-X
groups	B-X
with	B-X
the	B-X
largest	B-X
reduction	B-X
in	B-X
the	B-X
40	B-X
mg/kg	B-X
group	B-X
(	B-X
111.5+/-24	B-X
.	B-X
8	B-X
mm3	B-X
,	B-X
mean+/-SD	B-X
,	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
,	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
group	B-X
(	B-X
193.5+/-28	B-X
.	B-X
6	B-X
mm3	B-X
)	B-X
.	B-X

Caspase	O
-	O
1	O
activity	O
was	O
measured	O
using	O
FLICA	O
(	O
Immunochemistry	O
Technologies	O
)	O
,	O
a	O
cell	O
-	O
permeable	O
fluorescent	O
probe	O
(	O
FAM	O
-	O
YVAD	O
-	O
fmk	O
)	O
that	O
binds	O
active	O
caspase	O
-	O
1	O
.	O

Cells	O
were	O
incubated	O
1	O
hour	O
with	O
FLICA	O
at	O
37degreesC	O
and	O
stained	O
with	O
PE	O
-	O
Cy7	O
-	O
conjugated	O
anti	O
-	O
CD14	O
antibodies	O
(	O
eBioscience	O
)	O
to	O
identify	O
monocytes	O
.	O

The	O
gating	O
strategy	O
consisted	O
of	O
including	O
live	O
cells	O
that	O
were	O
CD14	B-Protein
positive	O
which	O
were	O
subsequently	O
analyzed	O
for	O
the	O
frequency	O
of	O
FLICA	O
positive	O
cells	O
.	O

NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
Activity	O
Assay	O
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
koreanaside	B-X
A	B-X
(	B-X
KA	B-X
)	B-X
showed	B-X
high	B-X
radical	B-X
scavenging	B-X
activity	B-X
and	B-X
suppressed	B-X
vascular	B-X
cell	B-X
adhesion	B-X
molecule	B-X
1	B-X
(	B-X
VCAM-1	B-X
)	B-X
expression	B-X
in	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
Three	B-X
transcription	B-X
factors	B-X
,	B-X
namely	B-X
NF-κB	B-X
,	B-X
NFAT	B-X
and	B-X
AP-1	B-X
,	B-X
have	B-X
a	B-X
major	B-X
role	B-X
in	B-X
inducing	B-X
the	B-X
transcriptional	B-X
program	B-X
that	B-X
is	B-X
required	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
differentiation	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
generation	B-X
of	B-X
a	B-X
triple	B-X
parameter	B-X
reporter	B-X
based	B-X
on	B-X
the	B-X
human	B-X
Jurkat	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
where	B-X
response	B-X
elements	B-X
for	B-X
NF-κB	B-X
,	B-X
NFAT	B-X
and	B-X
AP-1	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
CFP	B-X
,	B-X
eGFP	B-X
and	B-X
mCherry	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
emission	B-X
spectra	B-X
of	B-X
these	B-X
proteins	B-X
allow	B-X
simultaneous	B-X
assessment	B-X
of	B-X
NF-κB	B-X
,	B-X
NFAT	B-X
and	B-X
AP-1	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
stimulation	B-X
.	B-X
In	B-X
these	B-X
experiments	B-X
we	B-X
could	B-X
show	B-X
that	B-X
engagement	B-X
of	B-X
the	B-X
costimulatory	B-X
molecule	B-X
4-1BB	B-X
enhances	B-X
NF-κB	B-X
and	B-X
AP-1	B-X
activity	B-X
,	B-X
whereas	B-X
coinhibition	B-X
via	B-X
PD-1	B-X
or	B-X
BTLA	B-X
strongly	B-X
reduced	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
NFAT	B-X
.	B-X
Engagement	B-X
of	B-X
BTLA	B-X
significantly	B-X
inhibited	B-X
AP-1	B-X
,	B-X
whereas	B-X
PD-1	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
.	B-X
Our	B-X
triple	B-X
parameter	B-X
reporter	B-X
T	B-X
cell	B-X
line	B-X
is	B-X
an	B-X
excellent	B-X
tool	B-X
to	B-X
assess	B-X
the	B-X
effect	B-X
of	B-X
costimulatory	B-X
and	B-X
coinhibitory	B-X
receptors	B-X
on	B-X
NF-κB	B-X
,	B-X
NFAT	B-X
and	B-X
AP-1	B-X
activity	B-X
and	B-X
has	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
applications	B-X
beyond	B-X
the	B-X
evaluation	B-X
of	B-X
costimulatory	B-X
pathways	B-X
.	B-X

Supernatants	O
from	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
incubated	O
with	O
Quanti	O
-	O
Blue	O
substrate	O
(	O
Invivogen	O
)	O
at	O
37degreesC	O
and	O
allowed	O
to	O
develop	O
for	O
16	O
-	O
18	O
hours	O
.	O

Quanti	O
-	O
Blue	O
contains	O
a	O
substrate	O
for	O
alkaline	B-Protein
phosphatase	I-Protein
and	O
changes	O
in	O
the	O
amount	O
of	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
were	O
quantified	O
by	O
optical	O
density	O
(	O
lambda	O
=	O
655	O
)	O
measured	O
using	O
a	O
SpectraMax	O
384	O
Plus	O
plate	O
reader	O
and	O
SoftMax	O
Pro	O
software	O
(	O
Molecular	O
Devices	O
)	O
.	O

Bacterial	O
strains	O
<EOS>	B-X
Current	B-X
antimicrobial	B-X
treatment	B-X
regimens	B-X
were	B-X
designed	B-X
against	B-X
bacterial	B-X
strains	B-X
that	B-X
were	B-X
fully	B-X
susceptible	B-X
to	B-X
them	B-X
.	B-X
To	B-X
expand	B-X
the	B-X
useable	B-X
lifetime	B-X
of	B-X
existing	B-X
antimicrobial	B-X
drug	B-X
classes	B-X
by	B-X
modifying	B-X
treatment	B-X
regimens	B-X
,	B-X
data	B-X
are	B-X
needed	B-X
on	B-X
the	B-X
antimicrobial	B-X
pharmacodynamics	B-X
(	B-X
PD	B-X
)	B-X
against	B-X
strains	B-X
with	B-X
reduced	B-X
susceptibility	B-X
.	B-X
enterica	B-X
strains	B-X
with	B-X
varying	B-X
levels	B-X
of	B-X
acquired	B-X
resistance	B-X
.	B-X
This	B-X
study	B-X
was	B-X
focused	B-X
on	B-X
the	B-X
characterization	B-X
of	B-X
15	B-X
bacterial	B-X
strains	B-X
isolated	B-X
from	B-X
long-term	B-X
PCB-contaminated	B-X
sediment	B-X
located	B-X
at	B-X
the	B-X
Strážsky	B-X
canal	B-X
in	B-X
eastern	B-X
part	B-X
of	B-X
Slovakia	B-X
,	B-X
in	B-X
the	B-X
surroundings	B-X
of	B-X
a	B-X
former	B-X
PCB	B-X
producer	B-X
.	B-X
PCB-degrading	B-X
strains	B-X
were	B-X
isolated	B-X
and	B-X
identified	B-X
as	B-X
Microbacterium	B-X
oleivorans	B-X
,	B-X
Stenotrophomonas	B-X
maltophilia	B-X
,	B-X
Brevibacterium	B-X
sp.	B-X
,	B-X
Ochrobactrum	B-X
anthropi	B-X
,	B-X
Pseudomonas	B-X
mandelii	B-X
,	B-X
Rhodococcus	B-X
sp.	B-X
,	B-X
Achromobacter	B-X
xylosoxidans	B-X
,	B-X
Stenotrophomonas	B-X
sp.	B-X
,	B-X
Ochrobactrum	B-X
sp.	B-X
,	B-X
Pseudomonas	B-X
aeruginosa	B-X
,	B-X
and	B-X
Starkeya	B-X
novella	B-X
by	B-X
the	B-X
16S	B-X
rRNA	B-X
gene	B-X
sequence	B-X
phylogenetic	B-X
analysis	B-X
.	B-X

P	O
.	O
aeruginosa	O
laboratory	O
strains	O
PAO1	O
and	O
the	O
PAO1deltaexsA	O
mutant	O
were	O
obtained	O
from	O
Dr	O
.	O
Robert	O
Hancock	O
.	O

P	O
.	O
aeruginosa	O
strains	O
PAO1	O
and	O
PAO1deltaexsA	O
were	O
grown	O
from	O
overnight	O
cultures	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
broth	O
and	O
LB	O
+	O
streptomycin	O
(	O
150	O
microg	O
/	O
ml	O
)	O
until	O
mid	O
-	O
logarithmic	O
phase	O
.	O

Cells	O
were	O
washed	O
once	O
in	O
PBS	O
and	O
resuspended	O
in	O
PBS	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
(	O
lambda	O
=	O
600	O
nm	O
)	O
.	O

To	O
prepare	O
heat	O
-	O
killed	O
bacteria	O
,	O
live	O
PAO1	O
was	O
resuspended	O
in	O
PBS	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
and	O
heated	O
at	O
60degreesC	O
for	O
1	O
hour	O
.	O

For	O
stimulations	O
,	O
live	O
PAO1	O
was	O
resuspended	O
to	O
an	O
optical	O
density	O
of	O
0	O
.	O
5	O
in	O
PBS	O
and	O
further	O
diluted	O
in	O
culture	O
medium	O
prior	O
to	O
stimulation	O
to	O
achieve	O
the	O
desired	O
multiplicity	O
of	O
infection	O
.	O

Heat	O
-	O
killed	O
PAO1	O
was	O
added	O
in	O
a	O
volume	O
equivalent	O
to	O
that	O
used	O
to	O
achieve	O
an	O
MOI	O
of	O
1	O
for	O
live	O
PAO1	O
.	O

Statistics	O
<EOS>	B-X
Statistics	B-X
is	B-X
the	B-X
science	B-X
of	B-X
data	B-X
.	B-X
Appropriate	B-X
Statistics	B-X
for	B-X
Determining	B-X
Chance-Removed	B-X
Interpractitioner	B-X
Agreement	B-X
.	B-X
Statistics	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
diagonally	B-X
weighted	B-X
least	B-X
squares	B-X
(	B-X
cat-DWLS	B-X
)	B-X
estimator	B-X
and	B-X
with	B-X
the	B-X
unweighted	B-X
least	B-X
squares	B-X
(	B-X
cat-ULS	B-X
)	B-X
estimator	B-X
were	B-X
studied	B-X
.	B-X
This	B-X
fourth	B-X
installment	B-X
of	B-X
Explorations	B-X
in	B-X
Statistics	B-X
explores	B-X
the	B-X
bootstrap	B-X
.	B-X

All	O
graphs	O
display	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
and	O
were	O
generated	O
with	O
Prism	O
5	O
(	O
Graphpad	O
)	O
.	O

Statistical	O
significance	O
was	O
determined	O
by	O
performing	O
one	O
or	O
two	O
-	O
way	O
ANOVA	O
and	O
the	O
Bonferroni	O
post	O
-	O
test	O
where	O
applicable	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
effect	B-X
may	B-X
vary	B-X
from	B-X
one	B-X
patient	B-X
(	B-X
or	B-X
study	B-X
)	B-X
to	B-X
another	B-X
.	B-X
After	B-X
the	B-X
screening	B-X
protocol	B-X
,	B-X
a	B-X
number	B-X
of	B-X
14	B-X
studies	B-X
were	B-X
included	B-X
in	B-X
the	B-X
qualitative	B-X
analysis	B-X
,	B-X
while	B-X
seven	B-X
were	B-X
included	B-X
in	B-X
the	B-X
quantitative	B-X
one	B-X
.	B-X
The	B-X
mean	B-X
working	B-X
length	B-X
determined	B-X
by	B-X
the	B-X
electronic	B-X
apex	B-X
locator	B-X
was	B-X
11.8	B-X
mm	B-X
(	B-X
9.0-15.55	B-X
)	B-X
,	B-X
while	B-X
12.42	B-X
mm	B-X
(	B-X
11.0-13.52	B-X
)	B-X
and	B-X
12.3	B-X
mm	B-X
(	B-X
9.73-15.93	B-X
)	B-X
were	B-X
the	B-X
mean	B-X
working	B-X
length	B-X
observed	B-X
with	B-X
the	B-X
conventional	B-X
radiography	B-X
and	B-X
the	B-X
digital	B-X
radiography	B-X
,	B-X
respectively	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
classic	B-X
Snellen	B-X
acuity	B-X
,	B-X
we	B-X
simply	B-X
can	B-X
not	B-X
predict	B-X
threshold	B-X
skill	B-X
levels	B-X
of	B-X
any	B-X
one	B-X
individual	B-X
(	B-X
s	B-X
)	B-X
.	B-X

Cell	O
stimulation	O
and	O
inhibitor	O
schedule	O
.	O
<EOS>	B-X
Therapeutic	B-X
approaches	B-X
for	B-X
enhancing	B-X
incretin	B-X
action	B-X
include	B-X
degradation-resistant	B-X
GLP-1	B-X
receptor	B-X
agonists	B-X
(	B-X
incretin	B-X
mimetics	B-X
)	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
dipeptidyl	B-X
peptidase-4	B-X
(	B-X
DPP-4	B-X
)	B-X
activity	B-X
(	B-X
incretin	B-X
enhancers	B-X
)	B-X
.	B-X
Orally	B-X
administered	B-X
DPP-4	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
sitagliptin	B-X
and	B-X
vildagliptin	B-X
,	B-X
reduce	B-X
HbA1c	B-X
by	B-X
0.5-1.0	B-X
%	B-X
,	B-X
with	B-X
few	B-X
adverse	B-X
events	B-X
and	B-X
no	B-X
weight	B-X
gain	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
prior	B-X
belief	B-X
,	B-X
cancer	B-X
cells	B-X
require	B-X
oxidative	B-X
phosphorylation	B-X
(	B-X
OXPHOS	B-X
)	B-X
to	B-X
strive	B-X
,	B-X
and	B-X
exacerbated	B-X
OXPHOS	B-X
dependency	B-X
frequently	B-X
characterizes	B-X
cancer	B-X
stem	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
primary	B-X
or	B-X
acquired	B-X
resistance	B-X
against	B-X
chemotherapy	B-X
or	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
.	B-X
For	B-X
the	B-X
experimental	B-X
treatment	B-X
of	B-X
cancers	B-X
,	B-X
OXPHOS	B-X
inhibitors	B-X
can	B-X
be	B-X
advantageously	B-X
combined	B-X
with	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
,	B-X
as	B-X
well	B-X
as	B-X
with	B-X
other	B-X
strategies	B-X
to	B-X
inhibit	B-X
glycolysis	B-X
,	B-X
thereby	B-X
causing	B-X
a	B-X
lethal	B-X
energy	B-X
crisis	B-X
.	B-X
Future	B-X
studies	B-X
on	B-X
OXPHOS	B-X
inhibitors	B-X
should	B-X
elaborate	B-X
optimal	B-X
treatment	B-X
schedules	B-X
and	B-X
combination	B-X
regimens	B-X
that	B-X
stimulate-or	B-X
at	B-X
least	B-X
are	B-X
compatible	B-X
with-anticancer	B-X
immune	B-X
responses	B-X
for	B-X
long-term	B-X
tumor	B-X
control	B-X
.	B-X

Schedule	O
outlines	O
the	O
timing	O
of	O
inhibitor	O
addition	O
and	O
priming	O
in	O
relation	O
to	O
inflammasome	O
stimulation	O
(	O
t	O
=	O
0	O
)	O
for	O
THP	O
-	O
1	O
reporter	O
and	O
PBMC	O
cytokine	O
quantification	O
experiments	O
.	O

Inhibitor	O
treatments	O
and	O
stimulations	O
were	O
carried	O
out	O
as	O
described	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

Airway	O
epithelial	O
cells	O
do	O
not	O
significantly	O
contribute	O
to	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
response	O
to	O
inflammasome	O
stimuli	O
.	O
<EOS>	B-X
When	B-X
compromised	B-X
,	B-X
activation	B-X
of	B-X
immune/inflammatory	B-X
responses	B-X
against	B-X
exogenous	B-X
allergens	B-X
,	B-X
microbial	B-X
substances	B-X
,	B-X
and	B-X
pollutants	B-X
might	B-X
occur	B-X
,	B-X
rendering	B-X
individuals	B-X
prone	B-X
to	B-X
develop	B-X
chronic	B-X
inflammation	B-X
as	B-X
seen	B-X
in	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X
By	B-X
putting	B-X
the	B-X
epithelial	B-X
barrier	B-X
to	B-X
the	B-X
forefront	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
airway	B-X
inflammation	B-X
,	B-X
different	B-X
approaches	B-X
to	B-X
diagnose	B-X
and	B-X
target	B-X
epithelial	B-X
barrier	B-X
defects	B-X
are	B-X
currently	B-X
being	B-X
developed	B-X
.	B-X
Using	B-X
single-cell	B-X
transcriptomics	B-X
,	B-X
novel	B-X
epithelial	B-X
cell	B-X
types	B-X
are	B-X
being	B-X
unraveled	B-X
that	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
chronicity	B-X
of	B-X
respiratory	B-X
diseases	B-X
.	B-X
We	B-X
here	B-X
review	B-X
and	B-X
discuss	B-X
the	B-X
current	B-X
understandings	B-X
of	B-X
epithelial	B-X
barrier	B-X
defects	B-X
in	B-X
type	B-X
2-driven	B-X
chronic	B-X
inflammation	B-X
of	B-X
the	B-X
upper	B-X
and	B-X
lower	B-X
airways	B-X
,	B-X
the	B-X
estimated	B-X
contribution	B-X
of	B-X
these	B-X
novel	B-X
identified	B-X
epithelial	B-X
cells	B-X
to	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
current	B-X
clinical	B-X
challenges	B-X
in	B-X
relation	B-X
to	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
allergic	B-X
rhinitis	B-X
,	B-X
chronic	B-X
rhinosinusitis	B-X
,	B-X
and	B-X
asthma	B-X
.	B-X

Control	O
cell	O
lines	O
(	O
(	O
A	O
)	O
S9	O
,	O
(	O
C	O
)	O
NuLi	O
-	O
1	O
)	O
and	O
their	O
corresponding	O
CF	O
cell	O
lines	O
(	O
(	O
B	O
)	O
IB3	O
-	O
1	O
,	O
and	O
(	O
D	O
)	O
CuFi	O
-	O
1	O
)	O
cells	O
were	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
10	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
for	O
the	O
indicated	O
times	O
(	O
n	O
=	O
3	O
individual	O
experiments	O
)	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hours	O
where	O
appropriate	O
.	O

Cell	O
culture	O
supernatants	O
were	O
assayed	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	O
-	O
8	O
production	O
by	O
ELISA	O
.	O
<EOS>	B-X
Interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
stimulates	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
in	B-X
synovial	B-X
fluid	B-X
of	B-X
TMJ	B-X
with	B-X
internal	B-X
derangement	B-X
and	B-X
bony	B-X
changes	B-X
.	B-X
The	B-X
cranberry	B-X
(	B-X
Vaccinium	B-X
macrocarpon	B-X
)	B-X
contains	B-X
polyphenolic	B-X
compounds	B-X
that	B-X
inhibit	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
molecules	B-X
by	B-X
gingival	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
several	B-X
stimulators	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
effects	B-X
of	B-X
cranberry	B-X
components	B-X
on	B-X
IL-1β-stimulated	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
VEGF	B-X
production	B-X
by	B-X
human	B-X
TMJ	B-X
synovial	B-X
fibroblast-like	B-X
cells	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
if	B-X
bone	B-X
marrow	B-X
MSCs	B-X
obtained	B-X
from	B-X
proximal	B-X
humerus	B-X
fractures	B-X
can	B-X
be	B-X
an	B-X
alternative	B-X
source	B-X
for	B-X
obtaining	B-X
primary	B-X
cultures	B-X
of	B-X
human	B-X
MSCs	B-X
.	B-X

Insert	O
shows	O
IL	O
-	O
8	O
secretion	O
in	O
response	O
to	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
.	O

Airway	O
cells	O
do	O
not	O
strongly	O
upregulate	O
caspase	O
-	O
1	O
activity	O
in	O
response	O
to	O
inflammasome	O
stimuli	O
.	O
<EOS>	B-X
The	B-X
community	B-X
of	B-X
cells	B-X
lining	B-X
our	B-X
airways	B-X
plays	B-X
a	B-X
collaborative	B-X
role	B-X
in	B-X
the	B-X
preservation	B-X
of	B-X
immune	B-X
homeostasis	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
provides	B-X
protection	B-X
from	B-X
the	B-X
pathogens	B-X
and	B-X
pollutants	B-X
in	B-X
the	B-X
air	B-X
we	B-X
breathe	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
structural	B-X
attributes	B-X
that	B-X
provide	B-X
effective	B-X
mucociliary	B-X
clearance	B-X
of	B-X
the	B-X
lower	B-X
airspace	B-X
,	B-X
the	B-X
airway	B-X
epithelium	B-X
is	B-X
an	B-X
immunologically	B-X
active	B-X
barrier	B-X
surface	B-X
that	B-X
senses	B-X
changes	B-X
in	B-X
the	B-X
airway	B-X
environment	B-X
and	B-X
interacts	B-X
with	B-X
resident	B-X
and	B-X
recruited	B-X
immune	B-X
cells	B-X
.	B-X
There	B-X
is	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
anti-ageing	B-X
molecules	B-X
sirtuin-1	B-X
and	B-X
-6	B-X
,	B-X
which	B-X
are	B-X
regulated	B-X
by	B-X
specific	B-X
microRNAs	B-X
that	B-X
are	B-X
increased	B-X
in	B-X
COPD	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
chronic	B-X
inflammatory	B-X
response	B-X
has	B-X
been	B-X
over-simplified	B-X
in	B-X
descriptions	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
COPD	B-X
progression	B-X
.	B-X
As	B-X
a	B-X
form	B-X
of	B-X
first-line	B-X
airway	B-X
defense	B-X
,	B-X
epithelial	B-X
cells	B-X
exhibit	B-X
phenotypic	B-X
alteration	B-X
,	B-X
and	B-X
participate	B-X
in	B-X
epithelial	B-X
layer	B-X
disorganization	B-X
,	B-X
mucus	B-X
hypersecretion	B-X
,	B-X
and	B-X
extracellular	B-X
matrix	B-X
deposition	B-X
.	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
exhibit	B-X
attenuated	B-X
antigen-presenting	B-X
capacity	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
COPD	B-X
.	B-X
In	B-X
response	B-X
to	B-X
damage-associated	B-X
molecular	B-X
patterns	B-X
(	B-X
DAMPs	B-X
)	B-X
in	B-X
lung	B-X
tissue	B-X
affected	B-X
by	B-X
COPD	B-X
,	B-X
neutrophils	B-X
are	B-X
excessively	B-X
recruited	B-X
and	B-X
activated	B-X
,	B-X
where	B-X
they	B-X
promote	B-X
a	B-X
proteolytic	B-X
microenvironment	B-X
and	B-X
fibrotic	B-X
repair	B-X
in	B-X
small	B-X
airways	B-X
.	B-X
Natural	B-X
killer	B-X
T	B-X
(	B-X
NKT	B-X
)	B-X
cells	B-X
,	B-X
eosinophils	B-X
,	B-X
and	B-X
mast	B-X
cells	B-X
also	B-X
play	B-X
supplementary	B-X
roles	B-X
in	B-X
COPD	B-X
progression	B-X
;	B-X
however	B-X
,	B-X
their	B-X
cellular	B-X
activities	B-X
are	B-X
not	B-X
yet	B-X
entirely	B-X
clear	B-X
.	B-X
Overall	B-X
,	B-X
during	B-X
COPD	B-X
progression	B-X
,	B-X
``	B-X
exhausted	B-X
''	B-X
innate	B-X
immune	B-X
responses	B-X
can	B-X
be	B-X
observed	B-X
in	B-X
the	B-X
large	B-X
airways	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
enhanced	B-X
in	B-X
the	B-X
small	B-X
airways	B-X
.	B-X
Approaches	B-X
that	B-X
inhibit	B-X
the	B-X
inflammatory	B-X
cascade	B-X
,	B-X
chemotaxis	B-X
,	B-X
or	B-X
the	B-X
activation	B-X
of	B-X
inflammatory	B-X
cells	B-X
could	B-X
possibly	B-X
delay	B-X
the	B-X
progression	B-X
of	B-X
airway	B-X
remodeling	B-X
in	B-X
COPD	B-X
,	B-X
and	B-X
may	B-X
thus	B-X
have	B-X
potential	B-X
clinical	B-X
significance	B-X
.	B-X

S9	O
and	O
IB3	O
-	O
1	O
cells	O
were	O
examined	O
for	O
caspase	O
-	O
1	O
activation	O
following	O
inflammasome	O
stimulation	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
10	O
)	O
and	O
ATP	O
(	O
5	O
mM	O
)	O
.	O

Cells	O
were	O
primed	O
with	O
LPS	O
for	O
5	O
hours	O
where	O
appropriate	O
.	O

A	O
representative	O
histogram	O
of	O
%	O
caspase	O
-	O
1	O
-	O
active	O
cells	O
is	O
shown	O
in	O
(	O
A	O
)	O
and	O
the	O
averaged	O
values	O
are	O
shown	O
in	O
(	O
B	O
)	O
(	O
n	O
=	O
3	O
separate	O
experiments	O
)	O
.	O

(	O
C	O
)	O
IB3	O
-	O
1	O
cells	O
(	O
5x104	O
cells	O
/	O
well	O
)	O
were	O
pre	O
-	O
treated	O
for	O
1	O
hour	O
with	O
increasing	O
concentrations	O
of	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
10	O
-	O
30	O
microM	O
)	O
prior	O
to	O
stimulation	O
with	O
P	O
.	O
aeruginosa	O
(	O
MOI	O
=	O
50	O
)	O
.	O

Cell	O
culture	O
supernatants	O
were	O
collected	O
after	O
6	O
hours	O
and	O
assayed	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
by	O
ELISA	O
(	O
n	O
=	O
3	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
and	O
controls	O
show	O
similar	O
increases	O
in	O
caspase	O
-	O
1	O
activity	O
upon	O
inflammasome	O
activation	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
infection	B-X
are	B-X
major	B-X
determinants	B-X
of	B-X
disease	B-X
severity	B-X
and	B-X
consequently	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
.	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
inflammatory	B-X
mediator	B-X
.	B-X
Secretion	B-X
of	B-X
biologically	B-X
active	B-X
IL-1β	B-X
involves	B-X
inflammasome-mediated	B-X
processing	B-X
.	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
contribution	B-X
of	B-X
IL-1β	B-X
and	B-X
the	B-X
inflammasomes	B-X
in	B-X
CF	B-X
inflammatory	B-X
disease	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
inflammasome-mediated	B-X
IL-1β	B-X
production	B-X
in	B-X
CF	B-X
bronchial	B-X
epithelial	B-X
cell	B-X
lines	B-X
and	B-X
human	B-X
patients	B-X
with	B-X
CF	B-X
.	B-X

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
6	O
)	O
were	O
primed	O
with	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
5	O
hours	O
prior	O
to	O
stimulation	O
with	O
ATP	O
(	O
5	O
mM	O
)	O
for	O
1	O
hour	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
for	O
3	O
hours	O
.	O

PBMCs	O
were	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
strain	O
PAO1	O
for	O
3	O
hours	O
.	O

A	O
representative	O
histogram	O
of	O
the	O
%	O
caspase	O
-	O
1	O
-	O
active	O
cells	O
is	O
shown	O
in	O
(	O
A	O
)	O
with	O
the	O
averaged	O
values	O
shown	O
in	O
(	O
B	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
do	O
not	O
produce	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
peripheral	B-X
inflammasome	B-X
and	B-X
pyroptosis	B-X
are	B-X
activated	B-X
in	B-X
aMCI	B-X
and	B-X
AD	B-X
patients	B-X
,	B-X
influencing	B-X
on	B-X
neuroinflammation	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
shape	B-X
the	B-X
pattern	B-X
of	B-X
mitochondrial	B-X
respiration	B-X
in	B-X
the	B-X
blood	B-X
leukocytes	B-X
of	B-X
PD	B-X
patients	B-X
in	B-X
relation	B-X
to	B-X
both	B-X
clinical	B-X
features	B-X
and	B-X
the	B-X
profile	B-X
of	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
biomarkers	B-X
of	B-X
neurodegeneration	B-X
.	B-X
Mitochondrial	B-X
respirometry	B-X
on	B-X
the	B-X
peripheral	B-X
blood	B-X
mononucleate	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
of	B-X
16	B-X
PD	B-X
patients	B-X
and	B-X
14	B-X
controls	B-X
was	B-X
conducted	B-X
using	B-X
Seahorse	B-X
Bioscience	B-X
technology	B-X
.	B-X
In	B-X
PD	B-X
,	B-X
PBMC	B-X
mitochondrial	B-X
basal	B-X
respiration	B-X
was	B-X
normal	B-X
;	B-X
maximal	B-X
and	B-X
spare	B-X
respiratory	B-X
capacities	B-X
were	B-X
both	B-X
increased	B-X
;	B-X
and	B-X
ATP	B-X
production	B-X
was	B-X
higher	B-X
,	B-X
although	B-X
not	B-X
significantly	B-X
.	B-X
We	B-X
provided	B-X
preliminary	B-X
evidence	B-X
showing	B-X
that	B-X
mitochondrial	B-X
respiratory	B-X
activity	B-X
increases	B-X
in	B-X
the	B-X
PBMCs	B-X
of	B-X
PD	B-X
patients	B-X
,	B-X
probably	B-X
following	B-X
the	B-X
compensatory	B-X
adaptations	B-X
to	B-X
disease	B-X
progression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
bases	B-X
of	B-X
the	B-X
neuropathological	B-X
substrate	B-X
.	B-X

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
17	O
-	O
20	O
)	O
and	O
healthy	O
controls	O
(	O
n	O
=	O
15	O
-	O
19	O
)	O
were	O
primed	O
with	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
overnight	O
and	O
stimulated	O
with	O
P	O
.	O
aeruginosa	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
,	O
P	O
.	O
aeruginosa	O
PAO1	O
lacking	O
exsA	B-Protein
(	O
MOI	O
=	O
1	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
for	O
24	O
hours	O
.	O

P	O
.	O
aeruginosa	O
lacking	O
exsA	B-Protein
was	O
used	O
as	O
a	O
type	O
III	O
secretion	O
control	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
P	O
.	O
aeruginosa	O
.	O

Supernatants	O
were	O
assayed	O
for	O
(	O
A	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
(	O
B	O
)	O
IL	O
-	O
8	O
.	O

NF	O
-	O
kappaB	O
activation	O
potentiates	O
the	O
degree	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
and	O
secretion	O
upon	O
inflammasome	O
activation	O
.	O
<EOS>	B-X
Our	B-X
present	B-X
study	B-X
investigated	B-X
the	B-X
effects	B-X
and	B-X
possible	B-X
mechanism	B-X
of	B-X
a	B-X
natural	B-X
product	B-X
procyanidins	B-X
in	B-X
improving	B-X
morphine	B-X
tolerance	B-X
via	B-X
its	B-X
specific	B-X
inhibition	B-X
on	B-X
NOD-like	B-X
receptor	B-X
protein3	B-X
(	B-X
NLRP3	B-X
)	B-X
inflammasome	B-X
in	B-X
microglia	B-X
.	B-X
Recent	B-X
findings	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
NOD-like	B-X
receptor	B-X
family	B-X
,	B-X
pyrin	B-X
domain-containing	B-X
3	B-X
(	B-X
NLRP3	B-X
)	B-X
inflammasome	B-X
,	B-X
an	B-X
intracellular	B-X
multiprotein	B-X
complex	B-X
required	B-X
for	B-X
the	B-X
maturation	B-X
of	B-X
interleukin-	B-X
(	B-X
IL-	B-X
)	B-X
1β	B-X
,	B-X
may	B-X
probably	B-X
be	B-X
a	B-X
potential	B-X
target	B-X
of	B-X
HRS	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
AP	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
activation	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
and	B-X
meanwhile	B-X
assessed	B-X
the	B-X
degree	B-X
of	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammatory	B-X
cascades	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
histological	B-X
alterations	B-X
in	B-X
mice	B-X
suffering	B-X
from	B-X
cerulein-induced	B-X
AP	B-X
after	B-X
the	B-X
treatment	B-X
of	B-X
HRS	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
in	B-X
AP	B-X
mice	B-X
was	B-X
substantially	B-X
inhibited	B-X
following	B-X
the	B-X
administration	B-X
of	B-X
HRS	B-X
,	B-X
which	B-X
was	B-X
paralleled	B-X
with	B-X
the	B-X
decreased	B-X
NF-κB	B-X
activity	B-X
and	B-X
cytokines	B-X
production	B-X
,	B-X
attenuated	B-X
oxidative	B-X
stress	B-X
and	B-X
the	B-X
amelioration	B-X
of	B-X
pancreatic	B-X
tissue	B-X
damage	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
has	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
revealed	B-X
that	B-X
inhibition	B-X
of	B-X
the	B-X
activation	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
probably	B-X
contributed	B-X
to	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
HRS	B-X
in	B-X
AP	B-X
.	B-X

THP	O
-	O
1	O
reporter	O
cells	O
were	O
primed	O
overnight	O
with	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
and	O
stimulated	O
the	O
next	O
day	O
with	O
live	O
P	O
.	O
aeruginosa	O
or	O
additional	O
heat	O
-	O
killed	O
P	O
.	O
aeruginosa	O
for	O
the	O
times	O
indicated	O
.	O

Cell	O
culture	O
supernatants	O
were	O
assayed	O
for	O
(	O
A	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
,	O
(	O
B	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
C	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
(	O
n	O
=	O
3	O
-	O
6	O
experiments	O
)	O
.	O

Using	O
the	O
same	O
stimulation	O
method	O
,	O
THP	O
-	O
1	O
reporter	O
cells	O
were	O
treated	O
with	O
Bay11	O
-	O
7082	O
(	O
20	O
microM	O
)	O
for	O
1	O
hour	O
prior	O
to	O
priming	O
with	O
heat	O
-	O
killed	O
PAO1	O
or	O
live	O
PAO1	O
.	O
<EOS>	B-X
Double	B-X
Auxotrophy	B-X
to	B-X
Improve	B-X
the	B-X
Safety	B-X
of	B-X
a	B-X
Live	B-X
Anti-	B-X
Here	B-X
,	B-X
multiple	B-X
responses	B-X
of	B-X
Pseudomonas	B-X
aeruginosa	B-X
PAO1	B-X
(	B-X
PAO1	B-X
)	B-X
to	B-X
different	B-X
levels	B-X
of	B-X
polystyrene	B-X
nanoplastics	B-X
(	B-X
PS	B-X
NPs	B-X
)	B-X
exposure	B-X
were	B-X
investigated	B-X
by	B-X
physiological	B-X
experiments	B-X
,	B-X
live/dead	B-X
staining	B-X
,	B-X
redox	B-X
status	B-X
,	B-X
and	B-X
genome-wide	B-X
RNA	B-X
sequencing	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
PS	B-X
NPs	B-X
had	B-X
dual	B-X
effects	B-X
on	B-X
PAO1	B-X
,	B-X
and	B-X
different	B-X
concentrations	B-X
of	B-X
PS	B-X
NPs	B-X
demonstrated	B-X
different	B-X
effects	B-X
on	B-X
the	B-X
growth	B-X
and	B-X
metabolism	B-X
of	B-X
PAO1	B-X
.	B-X
All	B-X
levels	B-X
of	B-X
PS	B-X
NPs	B-X
had	B-X
no	B-X
obvious	B-X
biocidal	B-X
effect	B-X
on	B-X
PAO1	B-X
.	B-X
20	B-X
and	B-X
50	B-X
mg/L	B-X
of	B-X
PS	B-X
NPs	B-X
severely	B-X
inhibited	B-X
the	B-X
nitrate	B-X
reduction	B-X
,	B-X
while	B-X
0.1	B-X
mg/L	B-X
of	B-X
PS	B-X
NPs	B-X
promoted	B-X
the	B-X
denitrification	B-X
and	B-X
TCA	B-X
cycle	B-X
.	B-X
Meanwhile	B-X
,	B-X
20	B-X
and	B-X
50	B-X
mg/L	B-X
of	B-X
PS	B-X
NPs	B-X
resulted	B-X
in	B-X
intense	B-X
down-regulation	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
denitrification	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
our	B-X
results	B-X
showed	B-X
that	B-X
PS	B-X
NPs	B-X
concentrations	B-X
of	B-X
20	B-X
and	B-X
50	B-X
mg/L	B-X
exposure	B-X
substantially	B-X
up-regulated	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
for	B-X
flagellar	B-X
biosynthesis	B-X
and	B-X
biofilm	B-X
formation	B-X
to	B-X
tackle	B-X
the	B-X
stress	B-X
.	B-X

Supernatants	O
were	O
assayed	O
at	O
24	O
hours	O
for	O
(	O
D	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
,	O
(	O
E	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
F	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
(	O
n	O
=	O
3	O
-	O
5	O
)	O
.	O

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
11	O
-	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
10	O
-	O
13	O
)	O
were	O
treated	O
with	O
z	O
-	O
YVAD	O
-	O
fmk	O
(	O
20	O
microM	O
)	O
or	O
Bay11	O
-	O
7082	O
(	O
10	O
microM	O
)	O
and	O
stimulated	O
with	O
live	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
,	O
ATP	O
(	O
5	O
mM	O
)	O
,	O
or	O
Poly	O
(	O
dA	O
:	O
dT	O
)	O
(	O
1	O
microg	O
/	O
ml	O
)	O
according	O
to	O
the	O
schedule	O
in	O
Figure	O
1	O
.	O

(	O
G	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
(	O
H	O
)	O
IL	O
-	O
8	O
levels	O
were	O
measured	O
at	O
24	O
hours	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
analyze	B-X
whether	B-X
symptoms	B-X
of	B-X
discomfort	B-X
in	B-X
hydrogel	B-X
contact	B-X
lens	B-X
(	B-X
HCL	B-X
)	B-X
wearers	B-X
were	B-X
associated	B-X
with	B-X
changes	B-X
in	B-X
corneal	B-X
sensitivity	B-X
or	B-X
levels	B-X
of	B-X
tear	B-X
inflammatory	B-X
mediators	B-X
.	B-X

Statistical	O
analysis	O
was	O
performed	O
using	O
two	O
way	O
ANOVA	O
with	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

*	O
,	O
*	O
*	O
,	O
and	O
*	O
*	O
*	O
signify	O
P	O
<	O
0	O
.	O
05	O
,	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
001	O
.	O

Bay11	O
-	O
7082	O
inhibits	O
pro	O
-	O
IL	O
-	O
1beta	O
production	O
in	O
response	O
to	O
P	O
.	O
aeruginosa	O
.	O

PMA	O
-	O
differentiated	O
THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
10	O
microM	O
CFTRinh172	O
or	O
20	O
microM	O
Bay11	O
-	O
7082	O
and	O
harvested	O
after	O
(	O
A	O
)	O
4	O
hours	O
(	O
n	O
=	O
3	O
)	O
or	O
(	O
B	O
)	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
1	O
.	O
5	O
hours	O
(	O
n	O
=	O
3	O
)	O
stimulation	O
with	O
PAO1	O
.	O

One	O
representative	O
blot	O
is	O
shown	O
with	O
a	O
graph	O
of	O
the	O
averaged	O
fluorescence	O
intensity	O
values	O
over	O
3	O
experiments	O
.	O

Disruption	O
of	O
CFTR	O
activity	O
does	O
not	O
increase	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
in	O
PBMCs	O
or	O
macrophages	O
.	O
<EOS>	B-X
Inflammatory	B-X
monocytes	B-X
and	B-X
tissue-resident	B-X
macrophages	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
tissue	B-X
repair	B-X
,	B-X
regeneration	B-X
,	B-X
and	B-X
fibrosis	B-X
.	B-X
After	B-X
tissue	B-X
injury	B-X
,	B-X
monocytes	B-X
and	B-X
macrophages	B-X
undergo	B-X
marked	B-X
phenotypic	B-X
and	B-X
functional	B-X
changes	B-X
to	B-X
play	B-X
critical	B-X
roles	B-X
during	B-X
the	B-X
initiation	B-X
,	B-X
maintenance	B-X
,	B-X
and	B-X
resolution	B-X
phases	B-X
of	B-X
tissue	B-X
repair	B-X
.	B-X
Disturbances	B-X
in	B-X
macrophage	B-X
function	B-X
can	B-X
lead	B-X
to	B-X
aberrant	B-X
repair	B-X
,	B-X
such	B-X
that	B-X
uncontrolled	B-X
production	B-X
of	B-X
inflammatory	B-X
mediators	B-X
and	B-X
growth	B-X
factors	B-X
,	B-X
deficient	B-X
generation	B-X
of	B-X
anti-inflammatory	B-X
macrophages	B-X
,	B-X
or	B-X
failed	B-X
communication	B-X
between	B-X
macrophages	B-X
and	B-X
epithelial	B-X
cells	B-X
,	B-X
endothelial	B-X
cells	B-X
,	B-X
fibroblasts	B-X
,	B-X
and	B-X
stem	B-X
or	B-X
tissue	B-X
progenitor	B-X
cells	B-X
all	B-X
contribute	B-X
to	B-X
a	B-X
state	B-X
of	B-X
persistent	B-X
injury	B-X
,	B-X
and	B-X
this	B-X
could	B-X
lead	B-X
to	B-X
the	B-X
development	B-X
of	B-X
pathological	B-X
fibrosis	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
that	B-X
instruct	B-X
macrophages	B-X
to	B-X
adopt	B-X
pro-inflammatory	B-X
,	B-X
pro-wound-healing	B-X
,	B-X
pro-fibrotic	B-X
,	B-X
anti-inflammatory	B-X
,	B-X
anti-fibrotic	B-X
,	B-X
pro-resolving	B-X
,	B-X
and	B-X
tissue-regenerating	B-X
phenotypes	B-X
after	B-X
injury	B-X
,	B-X
and	B-X
we	B-X
highlight	B-X
how	B-X
some	B-X
of	B-X
these	B-X
mechanisms	B-X
and	B-X
macrophage	B-X
activation	B-X
states	B-X
could	B-X
be	B-X
exploited	B-X
therapeutically	B-X
.	B-X

PBMCs	O
from	O
CF	O
patients	O
(	O
n	O
=	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
13	O
)	O
were	O
treated	O
with	O
CFTRinh172	O
(	O
10	O
microM	O
)	O
for	O
18	O
hours	O
prior	O
to	O
stimulation	O
with	O
live	O
PAO1	O
(	O
MOI	O
=	O
1	O
)	O
.	O

(	O
A	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
(	O
B	O
)	O
IL	O
-	O
8	O
production	O
was	O
measured	O
at	O
24	O
hours	O
.	O

(	O
C	O
)	O
Monocytes	O
from	O
controls	O
(	O
n	O
=	O
3	O
)	O
were	O
differentiated	O
into	O
macrophages	O
.	O
<EOS>	B-X
What	B-X
is	B-X
the	B-X
role	B-X
of	B-X
the	B-X
programmed	B-X
cell	B-X
death-1	B-X
(	B-X
PD-1	B-X
)	B-X
/PD-1	B-X
ligand-1	B-X
(	B-X
PD-L1	B-X
)	B-X
axis	B-X
in	B-X
macrophage	B-X
polarization	B-X
during	B-X
early	B-X
pregnancy	B-X
?	B-X
Age-associated	B-X
chronic	B-X
basal	B-X
inflammation	B-X
compromises	B-X
muscle	B-X
mass	B-X
and	B-X
adaptability	B-X
,	B-X
but	B-X
exercise	B-X
training	B-X
may	B-X
exert	B-X
an	B-X
anti-inflammatory	B-X
effect	B-X
.	B-X
This	B-X
investigation	B-X
assessed	B-X
basal	B-X
and	B-X
exercise-induced	B-X
inflammation	B-X
in	B-X
three	B-X
cohorts	B-X
of	B-X
men	B-X
:	B-X
young	B-X
exercisers	B-X
[	B-X
YE	B-X
;	B-X
Macrophage	B-X
plasticity	B-X
is	B-X
critical	B-X
for	B-X
normal	B-X
tissue	B-X
repair	B-X
to	B-X
ensure	B-X
transition	B-X
from	B-X
the	B-X
inflammatory	B-X
to	B-X
the	B-X
proliferative	B-X
phase	B-X
of	B-X
healing	B-X
.	B-X
We	B-X
examined	B-X
macrophages	B-X
isolated	B-X
from	B-X
wounds	B-X
of	B-X
patients	B-X
afflicted	B-X
with	B-X
diabetes	B-X
and	B-X
of	B-X
healthy	B-X
controls	B-X
and	B-X
found	B-X
differential	B-X
expression	B-X
of	B-X
the	B-X
methyltransferase	B-X
Setdb2	B-X
.	B-X
Myeloid-specific	B-X
deletion	B-X
of	B-X
Setdb2	B-X
impaired	B-X
the	B-X
transition	B-X
of	B-X
macrophages	B-X
from	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
to	B-X
a	B-X
reparative	B-X
one	B-X
in	B-X
normal	B-X
wound	B-X
healing	B-X
.	B-X
Mechanistically	B-X
,	B-X
Setdb2	B-X
trimethylated	B-X
histone	B-X
3	B-X
at	B-X
NF-κB	B-X
binding	B-X
sites	B-X
on	B-X
inflammatory	B-X
cytokine	B-X
gene	B-X
promoters	B-X
to	B-X
suppress	B-X
transcription	B-X
.	B-X
Setdb2	B-X
expression	B-X
in	B-X
wound	B-X
macrophages	B-X
was	B-X
regulated	B-X
by	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
β	B-X
,	B-X
and	B-X
under	B-X
diabetic	B-X
conditions	B-X
,	B-X
this	B-X
IFNβ-Setdb2	B-X
axis	B-X
was	B-X
impaired	B-X
,	B-X
leading	B-X
to	B-X
a	B-X
persistent	B-X
inflammatory	B-X
macrophage	B-X
phenotype	B-X
in	B-X
diabetic	B-X
wounds	B-X
.	B-X
Setdb2	B-X
regulated	B-X
the	B-X
expression	B-X
of	B-X
xanthine	B-X
oxidase	B-X
and	B-X
thereby	B-X
the	B-X
uric	B-X
acid	B-X
(	B-X
UA	B-X
)	B-X
pathway	B-X
of	B-X
purine	B-X
catabolism	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
pharmacologic	B-X
targeting	B-X
of	B-X
Setdb2	B-X
or	B-X
the	B-X
UA	B-X
pathway	B-X
improved	B-X
healing	B-X
.	B-X
Thus	B-X
,	B-X
Setdb2	B-X
regulates	B-X
macrophage	B-X
plasticity	B-X
during	B-X
normal	B-X
and	B-X
pathologic	B-X
wound	B-X
repair	B-X
and	B-X
is	B-X
a	B-X
target	B-X
for	B-X
therapeutic	B-X
manipulation	B-X
.	B-X

Macrophages	O
were	O
treated	O
with	O
CFTRinh172	O
,	O
stimulated	O
as	O
per	O
monocytes	O
,	O
and	O
measured	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
at	O
24	O
hours	O
.	O

THP	O
-	O
1	O
reporter	O
cells	O
were	O
treated	O
with	O
CFTRinh172	O
24	O
hours	O
prior	O
to	O
stimulation	O
with	O
PAO1	O
and	O
measured	O
for	O
(	O
D	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
secretion	O
,	O
(	O
E	O
)	O
IL	O
-	O
8	O
,	O
and	O
(	O
F	O
)	O
NF	O
-	O
kappaB	O
/	O
AP	O
-	O
1	O
activity	O
at	O
24	O
hours	O
(	O
n	O
=	O
4	O
)	O
.	O

Inflammasome	O
Activators	O
.	O
<EOS>	B-X
Inflammasome	B-X
complexes	B-X
respond	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
pathogens	B-X
,	B-X
as	B-X
well	B-X
as	B-X
danger	B-X
or	B-X
homeostasis-altering	B-X
signals	B-X
;	B-X
they	B-X
can	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
development	B-X
of	B-X
autoinflammatory	B-X
conditions	B-X
and	B-X
cancer	B-X
.	B-X
Inflammasome	B-X
is	B-X
a	B-X
complex	B-X
of	B-X
multiple	B-X
proteins	B-X
found	B-X
in	B-X
cytoplasm	B-X
of	B-X
the	B-X
cells	B-X
activated	B-X
by	B-X
infectious	B-X
and/or	B-X
non-infectious	B-X
stimuli	B-X
.	B-X
Inflammasomes	B-X
are	B-X
a	B-X
class	B-X
of	B-X
cytosolic	B-X
protein	B-X
complexes	B-X
.	B-X
Inflammasome	B-X
biology	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
exciting	B-X
and	B-X
rapidly	B-X
growing	B-X
areas	B-X
in	B-X
immunology	B-X
.	B-X

